PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Burt, FJ; Rolph, MS; Rulli, NE; Mahalingam, S; Heise, MT				Burt, Felicity J.; Rolph, Micheal S.; Rulli, Nestor E.; Mahalingam, Suresh; Heise, Mark T.			Chikungunya: a re-emerging virus	LANCET			English	Article							REUNION ISLAND; INDIAN-OCEAN; ARBOVIRAL INFECTIONS; MOLECULAR DIAGNOSIS; VIRAL-INFECTIONS; RISK-FACTORS; OUTBREAK; EPIDEMIC; FEVER; SEROPREVALENCE	In the past decade, chikungunya-a virus transmitted by Aedes spp mosquitoes-has re-emerged in Africa, southern and southeastern Asia, and the Indian Ocean Islands as the cause of large outbreaks of human disease. The disease is characterised by fever, headache, myalgia, rash, and both acute and persistent arthralgia. The disease can cause severe morbidity and, since 2005, fatality. The virus is endemic to tropical regions, but the spread of Aedes albopictus into Europe and the Americas coupled with high viraemia in infected travellers returning from endemic areas increases the risk that this virus could establish itself in new endemic regions. This Seminar focuses on the re-emergence of this disease, the clinical manifestations, pathogenesis of virus-induced arthralgia, diagnostic techniques, and various treatment modalities.	[Burt, Felicity J.] Univ Free State, Fac Hlth Sci, NHLS Univ, Dept Med Microbiol & Virol, Bloemfontein, South Africa; [Rolph, Micheal S.; Rulli, Nestor E.; Mahalingam, Suresh] Griffith Univ, Inst Glyc, Gold Coast, Qld, Australia; [Rulli, Nestor E.] Univ Nacl La Plata, La Plata, Argentina; [Heise, Mark T.] Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC USA	University of the Free State; Griffith University; National University of La Plata; University of North Carolina; University of North Carolina Chapel Hill	Burt, FJ (corresponding author), Univ Free State, Fac Hlth Sci, NHLS Univ, Dept Med Microbiol & Virol, Bloemfontein, South Africa.	burtfj@ufs.ac.za	Burt, Felicity/AAB-6993-2020	Burt, Felicity/0000-0002-7238-7799; Mahalingam, Suresh/0000-0003-3141-8410				Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105; [Anonymous], OUTBREAK SPREAD CHIK; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; Arpino C, 2009, REV MED VIROL, V19, P121, DOI 10.1002/rmv.606; Bandyopadhyay D, 2008, INT J DERMATOL, V47, P1148, DOI 10.1111/j.1365-4632.2008.03817.x; Beltrame A, 2007, EMERG INFECT DIS, V13, P1264, DOI 10.3201/eid1308.070161; BLACKBURN NK, 1995, RES VIROLOGY, V146, P69, DOI 10.1016/0923-2516(96)80591-7; Borgherini G, 2008, CLIN INFECT DIS, V47, P469, DOI 10.1086/590003; Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537; Bottieau E, 2009, EUROSURVEILLANCE, V14, P2; Bouquillard E, 2009, ANN RHEUM DIS, V68, P1505, DOI 10.1136/ard.2008.097626; BRIGHTON SW, 1984, S AFR MED J, V66, P217; BRIGHTON SW, 1983, S AFR MED J, V63, P313; Briolant S, 2004, ANTIVIR RES, V61, P111, DOI 10.1016/j.antiviral.2003.09.005; Calisher C. H., 1988, The arboviruses: epidemiology and ecology. Volume I., P19; CAREY D E, 1971, Journal of the History of Medicine and Allied Sciences, V26, P243; CAREY DE, 1969, T ROY SOC TROP MED H, V63, P434, DOI 10.1016/0035-9203(69)90030-3; Cho B, 2008, J VIROL METHODS, V154, P154, DOI 10.1016/j.jviromet.2008.07.031; Couderc T, 2009, J INFECT DIS, V200, P516, DOI 10.1086/600381; D'Ortenzio E, 2009, EUROSURVEILLANCE, V14, P11; D'Ortenzio E, 2011, EMERG INFECT DIS, V17, P309, DOI 10.3201/eid1702.101056; De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049; Diallo M, 1999, AM J TROP MED HYG, V60, P281, DOI 10.4269/ajtmh.1999.60.281; ECKELS KH, 1970, APPL MICROBIOL, V19, P321, DOI 10.1128/AEM.19.2.321-325.1970; Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167; Edelman R, 2000, AM J TROP MED HYG, V62, P681, DOI 10.4269/ajtmh.2000.62.681; Edwards CJ, 2007, J CLIN VIROL, V39, P271, DOI 10.1016/j.jcv.2007.05.008; Eisenhut M, 1999, INFECTION, V27, P82, DOI 10.1007/BF02560502; Ermann J, 2007, INT J CLIN PRACT, V61, P2113, DOI 10.1111/j.1742-1241.2007.01528.x; FILIPE AR, 1973, B WORLD HEALTH ORGAN, V49, P37; FRASER JRE, 1981, AUST NZ J MED, V11, P168, DOI 10.1111/j.1445-5994.1981.tb04226.x; Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603-09; Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060; Gould LH, 2008, T ROY SOC TROP MED H, V102, P1247, DOI 10.1016/j.trstmh.2008.04.014; Guilherme JM, 1996, T ROY SOC TROP MED H, V90, P31, DOI 10.1016/S0035-9203(96)90468-X; HARRISON VR, 1971, J IMMUNOL, V107, P643; Hasebe F, 2002, J MED VIROL, V67, P370, DOI 10.1002/jmv.10085; Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255; Inamadar AC, 2008, INT J DERMATOL, V47, P154, DOI 10.1111/j.1365-4632.2008.03478.x; Jentes ES, 2010, AM J TROP MED HYG, V83, P388, DOI 10.4269/ajtmh.2010.09-0688; Johnson DF, 2008, MED J AUSTRALIA, V188, P41, DOI 10.5694/j.1326-5377.2008.tb01504.x; JOUBERT JJ, 1985, S AFR MED J, V67, P500; JUPP PG, 1981, T ROY SOC TROP MED H, V75, P15, DOI 10.1016/0035-9203(81)90005-5; Jupp PG, 1988, ARBOVIRUSES EPIDEMIO, VII, P137; Kannan M, 2009, INDIAN J MED RES, V129, P311; KASCHULA VR, 1978, J S AFR VET ASSOC, V49, P223; Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663; Kuniholm MH, 2006, AM J TROP MED HYG, V74, P1078, DOI 10.4269/ajtmh.2006.74.1078; Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104; Lahariya Chandrakant, 2006, Journal of Vector Borne Diseases, V43, P151; Lakshmi V, 2008, CLIN INFECT DIS, V46, P1436, DOI 10.1086/529444; Lam S K, 2001, Southeast Asian J Trop Med Public Health, V32, P447; Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015; Laras K, 2005, T ROY SOC TROP MED H, V99, P128, DOI 10.1016/j.trstmh.2004.03.013; Lemant J, 2008, CRIT CARE MED, V36, P2536, DOI 10.1097/CCM.0b013e318183f2d2; Leo YS, 2009, EMERG INFECT DIS, V15, P836, DOI 10.3201/eid1505.081390; Litzba N, 2008, J VIROL METHODS, V149, P175, DOI 10.1016/j.jviromet.2008.01.004; Mackenzie JS, 2001, EMERG INFECT DIS, V7, P497, DOI 10.3201/eid0707.017703; Malvy D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-200; Manimunda SP, 2010, T ROY SOC TROP MED H, V104, P392, DOI 10.1016/j.trstmh.2010.01.011; MOORE DL, 1975, ANN TROP MED PARASIT, V69, P49, DOI 10.1080/00034983.1975.11686983; Mourya DT, 2001, ACTA VIROL, V45, P305; Muthumani K, 2008, VACCINE, V26, P5128, DOI 10.1016/j.vaccine.2008.03.060; Ng LFP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004261; Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527; Panning M, 2008, EMERG INFECT DIS, V14, P416, DOI 10.3201/eid1403.070906; Panning M, 2009, J CLIN MICROBIOL, V47, P3014, DOI 10.1128/JCM.01024-09; Panning M, 2009, EMERG INFECT DIS, V15, P469, DOI 10.3201/eid1503.081104; Parida MM, 2007, J CLIN MICROBIOL, V45, P351, DOI 10.1128/JCM.01734-06; Parola P, 2006, EMERG INFECT DIS, V12, P1493, DOI 10.3201/eid1210.060610; Passi GR, 2008, INDIAN PEDIATR, V45, P240; Pastorino B, 2005, J VIROL METHODS, V124, P65, DOI 10.1016/j.jviromet.2004.11.002; Pastorino B, 2004, J MED VIROL, V74, P277, DOI 10.1002/jmv.20168; Peyrefitte CN, 2008, J MED VIROL, V80, P430, DOI 10.1002/jmv.21090; Peyrefitte CN, 2007, EMERG INFECT DIS, V13, P768, DOI 10.3201/eid1305.061500; Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X; Pistone T, 2009, J TRAVEL MED, V16, P286, DOI 10.1111/j.1708-8305.2008.00294.x; Pistone T, 2009, TRAVEL MED INFECT DI, V7, P52, DOI 10.1016/j.tmaid.2008.10.001; Powers AM, 2000, J GEN VIROL, V81, P471, DOI 10.1099/0022-1317-81-2-471; Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0; Queyriaux B, 2008, LANCET INFECT DIS, V8, P2, DOI 10.1016/S1473-3099(07)70294-3; Rampal, 2007, J Assoc Physicians India, V55, P765; RAO TR, 1971, B WORLD HEALTH ORGAN, V44, P585; Ravichandran R, 2008, J INFECT DEV COUNTR, V2, P140, DOI 10.3855/T2.2.140; Receveur M, 2010, EUROSURVEILLANCE, V15, P7; Renault P, 2007, AM J TROP MED HYG, V77, P727; Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6; Robin S, 2008, J CHILD NEUROL, V23, P1028, DOI 10.1177/0883073808314151; Robin S, 2010, EUR J PEDIATR, V169, P67, DOI 10.1007/s00431-009-0986-0; ROBINSON M C, 1955, Trans R Soc Trop Med Hyg, V49, P28, DOI [10.1016/0035-9203(57)90022-6, 10.1016/0035-9203(55)90080-8]; RODHAIN F, 1987, B SOC PATHOL EXOT, V80, P155; SARKAR JK, 1964, INDIAN J MED RES, V52, P684; Schilte C, 2010, J EXP MED, V207, P429, DOI 10.1084/jem.20090851; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; Sergon K, 2008, AM J TROP MED HYG, V78, P333, DOI 10.4269/ajtmh.2008.78.333; Sergon K, 2007, AM J TROP MED HYG, V76, P1189, DOI 10.4269/ajtmh.2007.76.1189; Shukla J, 2009, DIAGN MICR INFEC DIS, V65, P142, DOI 10.1016/j.diagmicrobio.2009.06.017; Sidwell RW, 2003, ANTIVIR RES, V57, P101, DOI 10.1016/S0166-3542(02)00203-6; Simon F, 2007, MEDICINE, V86, P123, DOI 10.1097/MD/0b013e31806010a5; Singh SS, 2008, EPIDEMIOL INFECT, V136, P1277, DOI 10.1017/S0950268807009739; Sissoko D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003066; Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389; SMEE DF, 1988, ANTIVIR RES, V10, P253, DOI 10.1016/0166-3542(88)90044-7; Soumahoro MK, 2009, PLOS ONE, V4, pA221, DOI 10.1371/journal.pone.0007800; Tandale BV, 2009, J CLIN VIROL, V46, P145, DOI 10.1016/j.jcv.2009.06.027; Thaikruea Lakkana, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P359; THIRUVENGADAM KV, 1965, INDIAN J MED RES, V53, P729; Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201; van den Bosch C, 2000, T ROY SOC TROP MED H, V94, P704, DOI 10.1016/S0035-9203(00)90240-2; Wang E, 2008, VACCINE, V26, P5030, DOI 10.1016/j.vaccine.2008.07.054; WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P253, DOI 10.1016/0035-9203(58)90084-1; Wielanek AC, 2007, NEUROLOGY, V69, P2105, DOI 10.1212/01.wnl.0000277267.07220.88; WOODRUFF AW, 1978, BRIT MED J, V1, P956, DOI 10.1136/bmj.1.6118.956; World Health Organization (WHO), GUID PREV CONTR CHIK; Yap G, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000753; Yergolkar PN, 2006, EMERG INFECT DIS, V12, P1580, DOI 10.3201/eid1210.060529	116	389	415	1	66	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					662	671		10.1016/S0140-6736(11)60281-X	http://dx.doi.org/10.1016/S0140-6736(11)60281-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22100854				2022-12-28	WOS:000300629000037
J	Chan, AT; Lippman, SM				Chan, Andrew T.; Lippman, Scott M.			Aspirin and colorectal cancer prevention in Lynch syndrome	LANCET			English	Editorial Material							RESISTANT STARCH		[Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac, Houston, TX 77030 USA; [Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Med Oncol, Houston, TX 77030 USA; [Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Chan, Andrew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol, Boston, MA USA; [Chan, Andrew T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lippman, SM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slippman@mdanderson.org	Chan, Andrew T/P-8293-2014	Chan, Andrew T/0000-0001-7284-6767	NATIONAL CANCER INSTITUTE [R01CA137178] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA137178] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Burn J, 2011, CANCER PREV RES, V4, P655, DOI 10.1158/1940-6207.CAPR-11-0106; Burn J, 2008, NEW ENGL J MED, V359, P2567, DOI 10.1056/NEJMoa0801297; Chan AT, 2005, JAMA-J AM MED ASSOC, V294, P914, DOI 10.1001/jama.294.8.914; Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Lindor NM, 2006, JAMA-J AM MED ASSOC, V296, P1507, DOI 10.1001/jama.296.12.1507; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; US Preventive Services Task Force, 2007, ANN INTERN MED, V146, P361, DOI 10.7326/0003-4819-146-5-200703060-00008; Vasen HFA, 2010, GASTROENTEROLOGY, V138, P2300, DOI 10.1053/j.gastro.2010.02.053	11	12	12	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	2011	378	9809					2051	2052		10.1016/S0140-6736(11)61216-6	http://dx.doi.org/10.1016/S0140-6736(11)61216-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865EL	22036018				2022-12-28	WOS:000298293600011
J	Becker, C; Hagmann, J; Muller, J; Koenig, D; Stegle, O; Borgwardt, K; Weigel, D				Becker, Claude; Hagmann, Joerg; Mueller, Jonas; Koenig, Daniel; Stegle, Oliver; Borgwardt, Karsten; Weigel, Detlef			Spontaneous epigenetic variation in the Arabidopsis thaliana methylome	NATURE			English	Article							DNA METHYLATION; TRANSPOSABLE ELEMENTS; SHORT READS; ALIGNMENT; PLANTS; GENES	Heritable epigenetic polymorphisms, such as differential cytosine methylation, can underlie phenotypic variation(1,2). Moreover, wild strains of the plant Arabidopsis thaliana differ in many epialleles(3,4), and these can influence the expression of nearby genes(1,2). However, to understand their role in evolution(5), it is imperative to ascertain the emergence rate and stability of epialleles, including those that are not due to structural variation. We have compared genome-wide DNA methylation among 10 A. thaliana lines, derived 30 generations ago from a common ancestor(6). Epimutations at individual positions were easily detected, and close to 30,000 cytosines in each strain were differentially methylated. In contrast, larger regions of contiguous methylation were much more stable, and the frequency of changes was in the same low range as that of DNA mutations(7). Like individual positions, the same regions were often affected by differential methylation in independent lines, with evidence for recurrent cycles of forward and reverse mutations. Transposable elements and short interfering RNAs have been causally linked to DNA methylation(8). In agreement, differentially methylated sites were farther from transposable elements and showed less association with short interfering RNA expression than invariant positions. The biased distribution and frequent reversion of epimutations have important implications for the potential contribution of sequence-independent epialleles to plant evolution.	[Becker, Claude; Hagmann, Joerg; Mueller, Jonas; Koenig, Daniel; Weigel, Detlef] Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; [Stegle, Oliver; Borgwardt, Karsten] Max Planck Inst Dev Biol, Machine Learning & Computat Biol Res Grp, D-72076 Tubingen, Germany; [Stegle, Oliver; Borgwardt, Karsten] Max Planck Inst Intelligent Syst, D-72076 Tubingen, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.	weigel@weigelworld.org	Stegle, Oliver/AAU-9177-2020; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Müller, Jonas/GQA-3371-2022; Becker, Claude/H-9011-2019; Weigel, Detlef/GSJ-0799-2022	Stegle, Oliver/0000-0002-8818-7193; Weigel, Detlef/0000-0002-2114-7963; Becker, Claude/0000-0003-3406-4670; Weigel, Detlef/0000-0002-2114-7963; Hagmann, Jorg/0000-0002-7232-3103; Koenig, Daniel/0000-0002-1037-5346; Borgwardt, Karsten/0000-0001-7221-2393	HFSP; Volkswagen Foundation; AENEAS [KBBE-2009-226477]; DFG; Max Planck Society	HFSP(Human Frontier Science Program); Volkswagen Foundation(Volkswagen); AENEAS; DFG(German Research Foundation (DFG)); Max Planck Society(Max Planck SocietyFoundation CELLEX)	We are grateful to R. Shaw for providing seeds of the mutation accumulation lines. We thank C. Lanz for help with Illumina sequencing, J. Fitz for help with the Gbrowse implementation, K. Schneeberger for help with DNA mutation analysis, D. Zilberman for providing bisulphite sequencing protocols, and R. Clark, M. Pellegrini, R. Neher and J. Paszkowski for discussion. This work was supported by an HFSP Long-Term Fellowship (D. K.), the Volkswagen Foundation (O.S.), FP7 Collaborative Project AENEAS (contract KBBE-2009-226477), a Gottfried Wilhelm Leibniz Award of the DFG, and the Max Planck Society (D.W.).	Benjamini Y, 2001, ANN STAT, V29, P1165; Cao J, 2011, NAT GENET, V43, P956, DOI 10.1038/ng.911; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745; Fahlgren N, 2010, PLANT CELL, V22, P1074, DOI 10.1105/tpc.110.073999; HOLLISTER JD, 2011, ARABIDOPSIS, V108, P2322; Kasschau KD, 2007, PLOS BIOL, V5, P479, DOI 10.1371/journal.pbio.0050057; Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109; Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lisch D, 2009, ANNU REV PLANT BIOL, V60, P43, DOI 10.1146/annurev.arplant.59.032607.092744; Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029; Lynch M, 2010, TRENDS GENET, V26, P345, DOI 10.1016/j.tig.2010.05.003; Mirouze M, 2009, NATURE, V461, P427, DOI 10.1038/nature08328; Ossowski S, 2008, GENOME RES, V18, P2024, DOI 10.1101/gr.080200.108; Ossowski S, 2010, SCIENCE, V327, P92, DOI 10.1126/science.1180677; Pagnussat GC, 2005, DEVELOPMENT, V132, P603, DOI 10.1242/dev.01595; Paszkowski J, 2011, CURR OPIN PLANT BIOL, V14, P195, DOI 10.1016/j.pbi.2011.01.002; Rangwala SH, 2006, PLOS GENET, V2, P270, DOI 10.1371/journal.pgen.0020036; Reinders J, 2009, GENE DEV, V23, P939, DOI 10.1101/gad.524609; Richards EJ, 2008, CURR OPIN GENET DEV, V18, P221, DOI 10.1016/j.gde.2008.01.014; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schneeberger K, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r98; Shaw RG, 2000, GENETICS, V155, P369; Slatkin M, 2009, GENETICS, V182, P845, DOI 10.1534/genetics.109.102798; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Teixeira FK, 2009, SCIENCE, V323, P1600, DOI 10.1126/science.1165313; Tran RK, 2005, CURR BIOL, V15, P154, DOI 10.1016/j.cub.2005.01.008; Vaughn MW, 2007, PLOS BIOL, V5, P1617, DOI 10.1371/journal.pbio.0050174; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Widman N, 2009, EPIGENETICS-US, V4, P119, DOI 10.4161/epi.4.2.8214; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zhang Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr053; Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929	35	477	495	3	182	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 8	2011	480	7376					245	U127		10.1038/nature10555	http://dx.doi.org/10.1038/nature10555			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857TR	22057020				2022-12-28	WOS:000297744200052
J	Stefanini, GG; Kalesan, B; Serruys, PW; Heg, D; Buszman, P; Linke, A; Ischinger, T; Klauss, V; Eberli, F; Wijns, W; Morice, MC; Di Mario, C; Corti, R; Antoni, D; Sohn, HY; Eerdmans, P; van Es, GA; Meier, B; Windecker, S; Juni, P				Stefanini, Giulio G.; Kalesan, Bindu; Serruys, Patrick W.; Heg, Dik; Buszman, Pawel; Linke, Axel; Ischinger, Thomas; Klauss, Volker; Eberli, Franz; Wijns, William; Morice, Marie-Claude; Di Mario, Carlo; Corti, Roberto; Antoni, Diethmar; Sohn, Hae Y.; Eerdmans, Pedro; van Es, Gerrit-Anne; Meier, Bernhard; Windecker, Stephan; Jueni, Peter			Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial	LANCET			English	Article							BARE-METAL STENTS; LARGE 2-INSTITUTIONAL COHORT; DIFFERENT COATING STRATEGIES; OFF-LABEL; THROMBOSIS; REVASCULARIZATION; METAANALYSIS; EFFICACY; RESTENOSIS; SAFETY	Background The effectiveness of durable polymer drug-eluting stents comes at the expense of delayed arterial healing and subsequent late adverse events such as stent thrombosis (ST). We report the 4 year follow-up of an assessment of biodegradable polymer-based drug-eluting stents, which aim to improve safety by avoiding the persistent inflammatory stimulus of durable polymers. Methods We did a multicentre, assessor-masked, non-inferiority trial. Between Nov 27, 2006, and May 18, 2007, patients aged 18 years or older with coronary artery disease were randomly allocated with a computer-generated sequence to receive either biodegradable polymer biolimus-eluting stents (BES) or durable polymer sirolimus-eluting stents (SES; 1: 1 ratio). The primary endpoint was a composite of cardiac death, myocardial infarction, or clinically-indicated target vessel revascularisation (TVR); patients were followed-up for 4 years. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00389220. Findings 1707 patients with 2472 lesions were randomly allocated to receive either biodegradable polymer BES (857 patients, 1257 lesions) or durable polymer SES (850 patients, 1215 lesions). At 4 years, biodegradable polymer BES were non-inferior to durable polymer SES for the primary endpoint: 160 (18.7%) patients versus 192 (22.6%) patients (rate ratios [RR] 0.81, 95% CI 0.66-1.00, p for non-inferiority <0.0001, p for superiority=0.050). The RR of definite ST was 0.62 (0.35-1.08, p=0.09), which was largely attributable to a lower risk of very late definite ST between years 1 and 4 in the BES group than in the SES group (RR 0.20, 95% CI 0.06-0.67, p=0.004). Conversely, the RR of definite ST during the first year was 0.99 (0.51-1.95; p=0.98) and the test for interaction between RR of definite ST and time was positive (p(interaction)=0.017). We recorded an interaction with time for events associated with ST but not for other events. For primary endpoint events associated with ST, the RR was 0.86 (0.41-1.80) during the first year and 0.17 (0.04-0.78) during subsequent years (p(interaction)=0.049). Interpretation Biodegradable polymer BES are non-inferior to durable polymer SES and, by reducing the risk of cardiac events associated with very late ST, might improve long-term clinical outcomes for up to 4 years compared with durable polymer SES.	[Stefanini, Giulio G.; Kalesan, Bindu; Meier, Bernhard; Windecker, Stephan] Univ Bern, Dept Cardiol, CH-3012 Bern, Switzerland; [Kalesan, Bindu; Heg, Dik; Jueni, Peter] Univ Bern, CTU Bern, CH-3012 Bern, Switzerland; [Heg, Dik; Jueni, Peter] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Serruys, Patrick W.] Erasmus Univ, Thoraxctr, Rotterdam, Netherlands; [Buszman, Pawel] Med Univ Silesia, Katowice, Poland; [Linke, Axel] Herzzentrum Leipzig, Leipzig, Germany; [Ischinger, Thomas] Kardiol Zentrum, Munich, Germany; [Klauss, Volker; Sohn, Hae Y.] Univ Hosp Munich, Dept Cardiol, Munich, Germany; [Eberli, Franz] Triemli Spital, Dept Cardiol, Zurich, Switzerland; [Wijns, William] Onze Lieve Vrouw Hosp, Dept Cardiol, Aalst, Belgium; [Di Mario, Carlo] Royal Brompton Hosp, Cardiovasc Biomed Res Unit, London SW3 6LY, England; [Corti, Roberto] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Antoni, Diethmar] Hosp Bogenhausen, Dept Cardiol, Munich, Germany; [Eerdmans, Pedro] Biosensors Europe SA, Morges, Switzerland	University of Bern; University of Bern; University of Bern; Erasmus University Rotterdam; Erasmus MC; Medical University Silesia; Heart Center Leipzig GMBH; University of Munich; Triemli Hospital; Royal Brompton Hospital; University of Zurich; University Zurich Hospital; Munchen Klinik	Windecker, S (corresponding author), Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland.	stephan.windecker@insel.ch	Juni, Peter/Q-8700-2016; Stefanini, Giulio/GZG-4754-2022; Stefanini, Giulio G/K-7406-2016; Di Mario, Carlo/K-5185-2018; Buszman, Pawel/AAX-9336-2020	Juni, Peter/0000-0002-5985-0670; Stefanini, Giulio/0000-0002-3558-6967; Stefanini, Giulio G/0000-0002-3558-6967; Di Mario, Carlo/0000-0002-4461-2055; Wijns, William/0000-0002-7267-4376; Heg, Dik/0000-0002-8766-7945; Buszman, Pawel/0000-0002-2511-4077	Biosensors Europe SA, Switzerland; Abbott; Cordis; Boston Scientific; Biosensors; Medtronic; Abbott Vascular; Johnson and Johnson; Swiss National Science Foundation [33CM30-124112]; European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology	Biosensors Europe SA, Switzerland; Abbott(Abbott Laboratories); Cordis; Boston Scientific(Boston Scientific); Biosensors; Medtronic(Medtronic); Abbott Vascular(Abbott Laboratories); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology	Biosensors Europe SA, Switzerland.; CTU Bern, which is part of the University of Bern, has a staff policy of not accepting honoraria or consultancy fees. BM has received research grants to the institution from Abbott and Cordis. SW has received research contracts to the institution from Abbott, Boston Scientific, Biosensors, Cordis, and Medtronic. PJ is an unpaid steering committee or statistical executive committee member of trials funded by Abbott Vascular, Biosensors, Medtronic, and Johnson and Johnson. FE has received an institutional grant from Biosensors and consulting fees from Cordis. WW has received institutional research grants from Biosensors and Cordis, and was co-chairman of Cordis international advisory board (until May 2011). CDM has received a research grant to the institution from Biosensors. PE is an employee of Biosensors Europe. All other authors declare that they have no conflicts of interest.; This paper was presented Transcatheter Cardiovascular Therapeutics (TCT) Congress, San Francisco, CA, USA, Nov 8, 2011. The LEADERS trial was funded by Biosensors Europe SA, Switzerland. The analysis was partly funded by a grant to SW and PJ by the Swiss National Science Foundation (grant number 33CM30-124112). GGS is the recipient of a research grant from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.	Baber U, 2011, J AM COLL CARDIOL, V58, P1569, DOI 10.1016/j.jacc.2011.06.049; Barlis P, 2010, EUR HEART J, V31, P165, DOI 10.1093/eurheartj/ehp480; Beohar N, 2007, JAMA-J AM MED ASSOC, V297, P1992, DOI 10.1001/jama.297.18.1992; Byrne RA, 2009, HEART, V95, P1489, DOI 10.1136/hrt.2009.172379; Byrne RA, 2011, J AM COLL CARDIOL, V58, P1325, DOI 10.1016/j.jacc.2011.06.027; Byrne RA, 2009, EUR HEART J, V30, P2441, DOI 10.1093/eurheartj/ehp352; Carter AJ, 2004, CARDIOVASC RES, V63, P617, DOI 10.1016/j.cardiores.2004.04.029; Cook S, 2009, CIRCULATION, V120, P391, DOI 10.1161/CIRCULATIONAHA.109.854398; *CORD, CYPHER SIR EL COR ST; *CORD, CORD ANN DISC NEVO C; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6; de Waha A, 2011, CIRC-CARDIOVASC INTE, V4, P371, DOI 10.1161/CIRCINTERVENTIONS.111.963256; Dibra A, 2007, J AM COLL CARDIOL, V49, P616, DOI 10.1016/j.jacc.2006.10.049; Finn AV, 2007, ARTERIOSCL THROM VAS, V27, P1500, DOI 10.1161/ATVBAHA.107.144220; Finn AV, 2007, CIRCULATION, V115, P2435, DOI 10.1161/CIRCULATIONAHA.107.693739; Hamilos MI, 2008, J AM COLL CARDIOL, V51, P2123, DOI 10.1016/j.jacc.2007.12.059; JENSEN L, 2010, TRANSC CARD THER M W; *JOHNS JOHNS, 3 Q 9 MONTH 2011 FIN; Joner M, 2006, J AM COLL CARDIOL, V48, P193, DOI 10.1016/j.jacc.2006.03.042; Kaiser C, 2010, NEW ENGL J MED, V363, P2310, DOI 10.1056/NEJMoa1009406; Kastrati A, 2007, NEW ENGL J MED, V356, P1030, DOI 10.1056/NEJMoa067484; Marroquin OC, 2008, NEW ENGL J MED, V358, P342, DOI 10.1056/NEJMoa0706258; Mehilli J, 2008, EUR HEART J, V29, P1975, DOI 10.1093/eurheartj/ehn253; Nakazawa G, 2008, CIRCULATION, V118, P1138, DOI 10.1161/CIRCULATIONAHA.107.762047; Park DW, 2010, J AM COLL CARDIOL, V56, P1187, DOI 10.1016/j.jacc.2010.03.086; Park KW, 2011, J AM COLL CARDIOL, V58, P1844, DOI 10.1016/j.jacc.2011.07.031; Prineas R., 1982, MINNESOTA CODE MANUA; Raber L, 2011, CIRCULATION, V123, P2819, DOI 10.1161/CIRCULATIONAHA.110.004762; Rasmussen K, 2010, LANCET, V375, P1090, DOI 10.1016/S0140-6736(10)60208-5; Silber S, 2011, LANCET, V377, P1241, DOI 10.1016/S0140-6736(11)60395-4; Smits PC, 2011, J AM COLL CARDIOL, V58, P11, DOI 10.1016/j.jacc.2011.02.023; Spaulding C, 2007, NEW ENGL J MED, V356, P989, DOI 10.1056/NEJMoa066633; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193; Stone GW, 2011, J AM COLL CARDIOL, V58, P19, DOI 10.1016/j.jacc.2011.02.022; Wenaweser P, 2008, J AM COLL CARDIOL, V52, P1134, DOI 10.1016/j.jacc.2008.07.006; Wilson GJ, 2009, CIRCULATION, V120, P141, DOI 10.1161/CIRCULATIONAHA.107.730010; Win HK, 2007, JAMA-J AM MED ASSOC, V297, P2001, DOI 10.1001/jama.297.18.2001; Windecker S, 2008, LANCET, V372, P1163, DOI 10.1016/S0140-6736(08)61244-1	40	270	278	0	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	2011	378	9807					1940	1948		10.1016/S0140-6736(11)61672-3	http://dx.doi.org/10.1016/S0140-6736(11)61672-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22075451				2022-12-28	WOS:000298136200028
J	del Alamo, JA				del Alamo, Jesus A.			Nanometre-scale electronics with III-V compound semiconductors	NATURE			English	Review							ATOMIC-LAYER-DEPOSITION; CAPACITANCE-VOLTAGE; INAS PHEMTS; TRANSISTOR; FUTURE; AL2O3; MOBILITY; MOSFETS; SIGE; GHZ	For 50 years the exponential rise in the power of electronics has been fuelled by an increase in the density of silicon complementary metal-oxide-semiconductor (CMOS) transistors and improvements to their logic performance. But silicon transistor scaling is now reaching its limits, threatening to end the microelectronics revolution. Attention is turning to a family of materials that is well placed to address this problem: group III-V compound semiconductors. The outstanding electron transport properties of these materials might be central to the development of the first nanometre-scale logic transistors.	MIT, Microsyst Technol Labs, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	del Alamo, JA (corresponding author), MIT, Microsyst Technol Labs, Cambridge, MA 02139 USA.	alamo@mit.edu	del Alamo, Jesus A./U-6515-2019	del Alamo, Jesus A./0000-0003-4003-7863	Materials, Structures and Devices FCRP Center; Intel Corporation	Materials, Structures and Devices FCRP Center; Intel Corporation(Intel Corporation)	I have enjoyed stimulating discussions with students, collaborators and colleagues. I am particularly thankful to D. Antoniadis, R. Chau, S. Datta, J. Hoyt, D. Jin, D.-H. Kim, T.-W. Kim, A. Kummel, J. Lin, M. Lundstrom, S. Oktyabrsky, M. Passlack, M. Radosavljevic, E. Vogel, N. Waldron, R. Wallace, L. Xia and P. Ye. Research on III-V CMOS transistors at my lab at MIT has been funded by the Materials, Structures and Devices FCRP Center and Intel Corporation.	BECKE H, 1965, SOLID STATE ELECTRON, V8, P813, DOI 10.1016/0038-1101(65)90074-2; Bennett BR, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2762279; Bennett BR, 2008, J CRYST GROWTH, V311, P47, DOI 10.1016/j.jcrysgro.2008.10.025; Chau R, 2007, NAT MATER, V6, P810, DOI 10.1038/nmat2014; Chen Wang, 2011, 2011 69th Annual Device Research Conference (DRC), P93, DOI 10.1109/DRC.2011.5994430; Chen YT, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3357434; Cheng CW, 2011, J APPL PHYS, V109, DOI 10.1063/1.3537915; Chin HC, 2009, IEEE ELECTR DEVICE L, V30, P805, DOI 10.1109/LED.2009.2024649; Cho MK, 2010, ICCAD-IEEE ACM INT, P694, DOI 10.1109/ICCAD.2010.5654255; del Alamo J. A., 2011, INT C COMP SEM MAN T, P17; del Alamo J.A., 2011, COMPOUND SEMICONDUCT, P1; Dewey G, 2009, INT EL DEVICES MEET, P452; Do QT, 2007, CONF P INDIUM PHOSPH, P392, DOI 10.1109/ICIPRM.2007.381206; Doyle BS, 2003, IEEE ELECTR DEVICE L, V24, P263, DOI 10.1109/LED.2003.810888; Egard M, 2010, NANO LETT, V10, P809, DOI 10.1021/nl903125m; Engel-Herbert R, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3204465; Fang H, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3537963; Ferain I, 2011, NATURE, V479, P310, DOI 10.1038/nature10676; Fiorenza JG, 2010, ECS TRANSACTIONS, V33, P963, DOI 10.1149/1.3487628; Fischetti M. V., 1989, International Electron Devices Meeting 1989. Technical Digest (Cat. No.89CH2637-7), P481, DOI 10.1109/IEDM.1989.74326; Frank DJ, 2002, IBM J RES DEV, V46, P235, DOI 10.1147/rd.462.0235; Frank MM, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1899745; Gomez L, 2010, IEEE ELECTR DEVICE L, V31, P782, DOI 10.1109/LED.2010.2050574; Hashemi P, 2008, INT EL DEVICES MEET, P865; Hinkle CL, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2883956; Hock G, 1998, ELECTRON LETT, V34, P1888, DOI 10.1049/el:19981284; Huang ML, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2146060; Hudait MK, 2007, INT EL DEVICES MEET, P625, DOI 10.1109/IEDM.2007.4419017; Hutcheson G. D., 2009, NANOERA MOORES LAW P, P11; Ishii H, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.121101; Iwai H, 2009, MICROELECTRON ENG, V86, P1520, DOI 10.1016/j.mee.2009.03.129; Jeong C, 2009, IEEE T ELECTRON DEV, V56, P2762, DOI 10.1109/TED.2009.2030844; Jin D, 2009, INT EL DEVICES MEET, P460; Khakifirooz A, 2008, IEEE T ELECTRON DEV, V55, P1391, DOI 10.1109/TED.2008.921017; Kim DH, 2009, INT EL DEVICES MEET, P805; Kim DH, 2010, IEEE ELECTR DEVICE L, V31, P806, DOI 10.1109/LED.2010.2051133; Kim DH, 2008, INT EL DEVICES MEET, P719; Kim T.-W., 2011, INT C IND PHOSPH REL; Kim T.-W., 2010, IEEE INT EL DEV M, P696; Kim TW, 2010, CONF P INDIUM PHOSPH; Ko H, 2010, NATURE, V468, P286, DOI 10.1038/nature09541; Kuhn KJ, 2010, ECS TRANSACTIONS, V33, P3, DOI 10.1149/1.3487530; Kuhn K. J., 2010, PROC INT WORKSHOP JU, P1; Leuther A., 2011, INT C IND PHOSPH REL; Li N, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2908926; Lin L, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3556619; Liu Y, 2010, FUNDAMENTALS OF III-V SEMICONDUCTOR MOSFETS, P31, DOI 10.1007/978-1-4419-1547-4_3; Liu YQ, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3504254; Milojevic M, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3054348; MIMURA T, 1978, IEEE T ELECTRON DEV, V25, P573, DOI 10.1109/T-ED.1978.19139; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; Nainani A, 2010, INT EL DEVICES MEET, DOI 10.1109/IEDM.2010.5703309; Nainani A, 2009, INT EL DEVICES MEET, P801; NAKWASKI W, 1988, J APPL PHYS, V64, P159, DOI 10.1063/1.341449; O'Connor E, 2011, J APPL PHYS, V109, DOI 10.1063/1.3533959; Ok I, 2010, FUNDAMENTALS OF III-V SEMICONDUCTOR MOSFETS, P307, DOI 10.1007/978-1-4419-1547-4_11; Oktyabrsky S, 2011, ECS TRANSACTIONS, V35, P385, DOI 10.1149/1.3569931; Passlack M, 1996, APPL PHYS LETT, V68, P1099, DOI 10.1063/1.115725; Passlack M, 1996, APPL PHYS LETT, V68, P3605, DOI 10.1063/1.116652; Passlack M, 1995, INTERNATIONAL ELECTRON DEVICES MEETING, 1995 - IEDM TECHNICAL DIGEST, P383, DOI 10.1109/IEDM.1995.499220; Passlack M, 2002, IEEE ELECTR DEVICE L, V23, P508, DOI 10.1109/LED.2002.802591; Passlack M, 2010, IEEE T ELECTRON DEV, V57, P2944, DOI 10.1109/TED.2010.2065950; Pearton SJ, 2005, PLASMA PROCESS POLYM, V2, P16, DOI 10.1002/ppap.200400035; Pillarisetty R, 2010, INT EL DEVICES MEET; Radosavljevic M, 2010, INT EL DEVICES MEET; Radosavljevic M, 2009, INT EL DEVICES MEET, P292; Radosavljevic M, 2008, INT EL DEVICES MEET, P727; Ren F, 1996, IEDM - INTERNATIONAL ELECTRON DEVICES MEETING, TECHNICAL DIGEST 1996, P943, DOI 10.1109/IEDM.1996.554137; Ren F, 1997, SOLID STATE ELECTRON, V41, P1751, DOI 10.1016/S0038-1101(97)00181-0; Scarrozza M, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3275737; Singisetti U, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3013572; Sonnet AM, 2011, MICROELECTRON ENG, V88, P1083, DOI 10.1016/j.mee.2011.03.120; Sonnet AM, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3588255; SPICER WE, 1980, J VAC SCI TECHNOL, V17, P1019, DOI 10.1116/1.570583; Suk SD, 2005, INT EL DEVICES MEET, P735; Tang CW, 2009, CONF P INDIUM PHOSPH, P136, DOI 10.1109/ICIPRM.2009.5012460; Terao R, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.054201; Theis TN, 2010, P IEEE, V98, P2005, DOI 10.1109/JPROC.2010.2066531; Trinh HD, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3467813; Umansky V, 2009, J CRYST GROWTH, V311, P1658, DOI 10.1016/j.jcrysgro.2008.09.151; Waldron N, 2010, IEEE T ELECTRON DEV, V57, P297, DOI 10.1109/TED.2009.2035031; Wang WC, 2010, J PHYS CHEM C, V114, P22610, DOI 10.1021/jp107880r; Wang WC, 2010, J APPL PHYS, V107, DOI 10.1063/1.3369540; Wu YD, 2010, J VAC SCI TECHNOL B, V28, DOI 10.1116/1.3271141; Wu YQ, 2009, INT EL DEVICES MEET, P304; Wu YQ, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3050466; Wu Y.Q., 2007, IEEE 65 DEV RES C, P117; Xia L. V. T., 2011, INT S COMP IN PRESS; Xia L, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3552963; Xu M, 2009, INT EL DEVICES MEET, P809; Xuan Y, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2217258; Ye PD, 2009, ECS TRANSACTIONS, V19, P605; Ye PD, 2003, IEEE ELECTR DEVICE L, V24, P209, DOI 10.1109/LED.2003.812144; Yokoyama M., 2010, IEDM, P46, DOI [10.1109/IEDM.2010.5703286, DOI 10.1109/IEDM.2010.5703286]	94	1314	1326	32	568	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					317	323		10.1038/nature10677	http://dx.doi.org/10.1038/nature10677			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094691				2022-12-28	WOS:000297059700031
J	Williams, E				Williams, Eric			Environmental effects of information and communications technologies	NATURE			English	Article							INDUSTRIAL ECOLOGY; ENERGY USE; CONSUMPTION; MICROCHIP; IMPACTS; INPUT	The digital revolution affects the environment on several levels. Most directly, information and communications technology (ICT) has environmental impacts through the manufacturing, operation and disposal of devices and network equipment, but it also provides ways to mitigate energy use, for example through smart buildings and teleworking. At a broader system level, ICTs influence economic growth and bring about technological and societal change. Managing the direct impacts of ICTs is more complex than just producing efficient devices, owing to the energetically expensive manufacturing process, and the increasing proliferation of devices needs to be taken into account.	Rochester Inst Technol, Golisano Inst Sustainabil, Rochester, NY 14623 USA	Rochester Institute of Technology	Williams, E (corresponding author), Rochester Inst Technol, Golisano Inst Sustainabil, Rochester, NY 14623 USA.	exwgis@rit.edu	Williams, Eric/J-4282-2012	Williams, Eric/0000-0002-6352-2928	US National Science Foundation [CBET-0731067]	US National Science Foundation(National Science Foundation (NSF))	This work was in supported in part by the US National Science Foundation via grant CBET-0731067 in the Environmental Sustainability program.	Allenby BR, 2008, J IND ECOL, V12, P267, DOI 10.1111/j.1530-9290.2008.00051.x; Audirac I, 2005, INT REGIONAL SCI REV, V28, P119, DOI 10.1177/0160017604273624; Ayres R. U., 2005, Structural Change and Economic Dynamics, V16, P181, DOI 10.1016/j.strueco.2003.10.003; Basel Action Network, 2002, EXP HARM HIGH TECH T; Basel Action Network, 2005, DIG DUMP EXP REUS AB; Baumann H., 2004, LIFE CYCLE ASSESSMEN; Boice JD, 2010, J OCCUP ENVIRON MED, V52, P1082, DOI 10.1097/JOM.0b013e3181f7e520; Boyd SB, 2010, ENVIRON RES LETT, V5, DOI 10.1088/1748-9326/5/1/014011; Boyd SB, 2009, ENVIRON SCI TECHNOL, V43, P7303, DOI 10.1021/es901514n; BUCHERT M, 2009, CRITICAL METALS SUST; Bullard C.W., 1978, RESOUR ENERGY, V1, P267, DOI DOI 10.1016/0165-0572(78)90008-7; BULLARD CW, 1975, ENERG POLICY, V3, P268, DOI 10.1016/0301-4215(75)90035-X; Carnegie Mellon University Green Design Institute, 2011, EC INP OUTP LIF CYCL; Chisholm M., 2007, REUTERS NEWS SE 0611; Deng LQ, 2011, J CLEAN PROD, V19, P1198, DOI 10.1016/j.jclepro.2011.03.004; Deng LQ, 2011, J IND ECOL, V15, P108, DOI 10.1111/j.1530-9290.2010.00306.x; Graedel T., 2009, IND ECOLOGY SUSTAINA; Greening LA, 2000, ENERG POLICY, V28, P389, DOI 10.1016/S0301-4215(00)00021-5; Greenpeace Research Laboratories, 2007, MISS CALL IPHONES HA; Grubler A., 1998, TECHNOLOGY GLOBAL CH; Hendrickson CT, 2006, ENV LIFE CYCLE ASSES; Hertwich EG, 2005, J IND ECOL, V9, P85, DOI 10.1162/1088198054084635; Hilty L.M., 2008, INFORM TECHNOLOGY SU, DOI [10.4324/9781315641980-8, DOI 10.4324/9781315641980-8]; Kawamoto K., 2001, LBNL45917; Keoleian G.A., 2000, J IND ECOL, V4, P135, DOI [DOI 10.1162/108819800569726, 10.1162/108819800569726]; Kurzweil R., 2005, SINGULARITY IS NEAR; Leontief WW, 1936, REV ECON STATISTICS, V18, P105, DOI 10.2307/1927837; Lipsey R.G., 1998, GEN PURPOSE TECHNOLO; Matthews HS, 2005, J INFRASTRUCT SYST, V11, P21, DOI 10.1061/(ASCE)1076-0342(2005)11:1(21); Meyers RJ, 2010, ENERG BUILDINGS, V42, P563, DOI 10.1016/j.enbuild.2009.10.026; Mokhtarian PL, 1998, URBAN STUD, V35, P215, DOI 10.1080/0042098984952; Mol APJ, 2006, ENVIRON PLANN C, V24, P497, DOI 10.1068/c0508j; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; Nordbrand S, 2009, OUT CONTROL E WASTE; Ok Z., 2009, P IEEE INT S SUST SY; Organisation for Economic Co-operation and Development, 2003, ICT EC GROWTH EV OEC; Roth K., 2007, ENERGY CONSUMPTION C; Shaw Susan D., 2010, Reviews on Environmental Health, V25, P261; Toxics Link, 2003, SCRAPP HIGH TECH MYT; Tsydenova O, 2011, WASTE MANAGE, V31, P45, DOI 10.1016/j.wasman.2010.08.014; US Environmental Protection Agency, 2011, EN STAR; VANENGELENBURG BCW, 1994, ENERG POLICY, V22, P648, DOI 10.1016/0301-4215(94)90058-2; Warren P., 2009, GUARDIAN        0708; Wikoff DS, 2011, HANDB ENVIRON CHEM, V16, P19, DOI 10.1007/698_2010_97; Williams E, 2004, ENVIRON SCI TECHNOL, V38, P6166, DOI 10.1021/es035152j; Williams E., 2011, THERMODYNAMICS DESTR, P190; Williams E., 2003, P 1 INT WORKSH SUST, P69; Williams ED, 2002, ENVIRON SCI TECHNOL, V36, P5504, DOI 10.1021/es025643o; Williams ED, 2004, THIN SOLID FILMS, V461, P2, DOI 10.1016/j.tsf.2004.02.049; Williams E, 2008, ENVIRON SCI TECHNOL, V42, P6446, DOI 10.1021/es702255z; Williams ED, 2009, J IND ECOL, V13, P928, DOI 10.1111/j.1530-9290.2009.00170.x; Worrell E, 1999, LBNL41724; Yu JL, 2010, ENVIRON SCI TECHNOL, V44, P3232, DOI 10.1021/es903350q	53	116	118	7	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					354	358		10.1038/nature10682	http://dx.doi.org/10.1038/nature10682			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	848OA	22094696				2022-12-28	WOS:000297059700036
J	Ovbiagele, B; Diener, HC; Yusuf, S; Martin, RH; Cotton, D; Vinisko, R; Donnan, GA; Bath, PM				Ovbiagele, Bruce; Diener, Hans-Christophe; Yusuf, Salim; Martin, Renee H.; Cotton, Daniel; Vinisko, Richard; Donnan, Geoffrey A.; Bath, Philip M.		PROFESS Investigators	Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTENDED-RELEASE DIPYRIDAMOLE; TRANSIENT ISCHEMIC ATTACK; HEALTH-CARE PROFESSIONALS; CARDIOVASCULAR OUTCOMES; HYPERTENSIVE PATIENTS; SECONDARY PREVENTION; PROGNOSTIC VALUE; TELMISARTAN; ASSOCIATION; COMBINATION	Context Recurrent stroke prevention guidelines suggest that larger reductions in systolic blood pressure (SBP) are positively associated with a greater reduction in the risk of recurrent stroke and define an SBP level of less than 120 mm Hg as normal. However, the association of SBP maintained at such levels with risk of vascular events after a recent ischemic stroke is unclear. Objective To assess the association of maintaining low-normal vs high-normal SBP levels with risk of recurrent stroke. Design, Setting, and Patients Post hoc observational analysis of a multicenter trial involving 20 330 patients (age >= 50 years) with recent non-cardioembolic ischemic stroke; patients were recruited from 695 centers in 35 countries from September 2003 through July 2006 and followed up for 2.5 years (follow-up ended on February 8, 2008). Patients were categorized based on their mean SBP level: very low-normal (<120 mm Hg), low-normal (120-<130 mm Hg), high-normal (130-<140 mm Hg), high (140-<150 mm Hg), and very high (>= 150 mm Hg). Main Outcome Measures The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Results The recurrent stroke rates were 8.0% (95% CI, 6.8%-9.2%) for the very low-normal SBP level group, 7.2% (95% CI, 6.4%-8.0%) for the low-normal SBP group, 6.8% (95% CI, 6.1%-7.4%) for the high-normal SBP group, 8.7% (95% CI, 7.9%-9.5%) for the high SBP group, and 14.1% (95% CI, 13.0%-15.2%) for the very high SBP group. Compared with patients in the high-normal SBP group, the risk of the primary outcome was higher for patients in the very low-normal SBP group (adjusted hazard ratio [AHR], 1.29; 95% CI, 1.07-1.56), in the high SBP group (AHR, 1.23; 95% CI, 1.07-1.41), and in the very high SBP group (AHR, 2.08; 95% CI, 1.83-2.37). Compared with patients in the high-normal SBP group, the risk of secondary outcome was higher for patients in the very low-normal SBP group (AHR, 1.31; 95% CI, 1.13-1.52), in the low-normal SBP group (AHR, 1.16; 95% CI, 1.03-1.31), in the high SBP group (AHR, 1.24; 95% CI, 1.11-1.39), and in the very high SBP group (AHR, 1.94; 95% CI, 1.74-2.16). Conclusion Among patients with recent non-cardioembolic ischemic stroke, SBP levels during follow-up in the very low-normal (<120 mm Hg), high (140-<150 mm Hg), or very high (>= 150 mm Hg) range were associated with increased risk of recurrent stroke.	[Ovbiagele, Bruce] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA; [Diener, Hans-Christophe] Univ Duisburg Essen, Dept Neurol, Duisburg, Germany; [Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; [Martin, Renee H.] Med Univ S Carolina, Div Biostat & Epidemiol, Dept Med, Charleston, SC USA; [Cotton, Daniel; Vinisko, Richard] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA; [Donnan, Geoffrey A.] Univ Melbourne, Natl Stroke Res Inst, Melbourne, Vic, Australia; [Bath, Philip M.] Univ Nottingham, Stroke Trials Unit, Nottingham NG7 2RD, England	University of California System; University of California San Diego; University of Duisburg Essen; McMaster University; Population Health Research Institute; Medical University of South Carolina; Boehringer Ingelheim; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Nottingham	Ovbiagele, B (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,MC 9127, San Diego, CA 92093 USA.	Ovibes@ucsd.edu	Hug, Balthasar L./G-1568-2010; Diener, Hans-Christoph/AAF-7275-2019; Bath, Philip/F-9020-2011	Donnan, Geoffrey/0000-0001-6324-3403; Yusuf, Salim/0000-0003-4776-5601; Bath, Philip/0000-0003-2734-5132	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ovbiagele reported that he was paid as a consultant by Avanir Pharmaceuticals for 1-time participation in an experts advisory meeting held in June 2011. Dr Diener reported that he receives honoraria for participation in clinical trials, for contribution to advisory boards or oral presentations, and travel expenses and accommodations from Abbott, Allergan, AstraZeneca, Bayer Vital, Bristol-Meyers Squibb, Boehringer Ingelheim, CoAxia, D-Pharm, ev3 Inc, Fresenius, GlaxoSmithKline, Janssen Cilag, Knoll, MSD (formerly Merck Sharpe Dohme), Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, sanofi-aventis, Sankyo, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth, Yamaguchi. Dr Yusuf reported that he receives grants, consulting and speaker fees, and related travel reimbursement from Boehringer Ingelheim and several other companies that manufacture antihypertensive agents and antiplatelet agents. Messrs Cotton and Vinisko reported that they are employees of Boehringer Ingelheim Pharmaceuticals Inc. Dr Bath reported that he receives honoraria for participation in clinical trials or data monitoring committees, contribution to advisory boards, or oral presentations from Boehringer Ingelheim, Lundbeck, Mitsubishi, and M's Science.	Arima H, 2006, J HYPERTENS, V24, P1201, DOI 10.1097/01.hjh.0000226212.34055.86; Bangalore S, 2011, CIRCULATION, V123, P2799, DOI 10.1161/CIRCULATIONAHA.110.016337; Benetos A, 2002, ARCH INTERN MED, V162, P577, DOI 10.1001/archinte.162.5.577; Berl T, 2005, J AM SOC NEPHROL, V16, P2170, DOI 10.1681/ASN.2004090763; Chrysant SG, 2010, AM J CARDIOL, V106, P825, DOI 10.1016/j.amjcard.2010.05.006; Cooper-DeHoff RM, 2010, JAMA-J AM MED ASSOC, V304, P61, DOI 10.1001/jama.2010.884; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Izzo JL, 2000, HYPERTENSION, V35, P1021, DOI 10.1161/01.HYP.35.5.1021; Leonardi-Bee J, 2002, STROKE, V33, P1315, DOI 10.1161/01.STR.0000014509.11540.66; Lloyd-Jones DM, 1999, HYPERTENSION, V34, P381, DOI 10.1161/01.HYP.34.3.381; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Messerli FH, 2006, ANN INTERN MED, V144, P884, DOI 10.7326/0003-4819-144-12-200606200-00005; Oates DJ, 2007, J AM GERIATR SOC, V55, P383, DOI 10.1111/j.1532-5415.2007.01069.x; Pastor-Barriuso R, 2003, ANN INTERN MED, V139, P731, DOI 10.7326/0003-4819-139-9-200311040-00007; Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15; Rastas S, 2006, J AM GERIATR SOC, V54, P912, DOI 10.1111/j.1532-5415.2006.00742.x; Reboldi G, 2011, J HYPERTENS, V29, P1253, DOI 10.1097/HJH.0b013e3283469976; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Sica DA, 2007, HYPERTENSION, V50, P287, DOI 10.1161/HYPERTENSIONAHA.107.092114; Sleight P, 2009, J HYPERTENS, V27, P1360, DOI 10.1097/HJH.0b013e32832d7370; *U BRIT COL SPS3 C, SEC PREV SMALL SUBC; *U NOTT I NEUR DIV, PREV DECL COGN STROK; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593	30	178	182	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2137	2144		10.1001/jama.2011.1650	http://dx.doi.org/10.1001/jama.2011.1650			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089721	Bronze			2022-12-28	WOS:000297013000020
J	Andersson, O; Hellstrom-Westas, L; Andersson, D; Domellof, M				Andersson, Ola; Hellstrom-Westas, Lena; Andersson, Dan; Domellof, Magnus			Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSFERRIN RECEPTOR; DEFICIENCY ANEMIA; SWEDISH INFANTS; TERM INFANTS; CHILDREN; SUPPLEMENTATION; HEMOGLOBIN; PREVALENCE; MANAGEMENT; DIAGNOSIS	Objective To investigate the effects of delayed umbilical cord clamping, compared with early clamping, on infant iron status at 4 months of age in a European setting. Design Randomised controlled trial. Setting Swedish county hospital. Participants 400 full term infants born after a low risk pregnancy. Intervention Infants were randomised to delayed umbilical cord clamping (>= 180 seconds after delivery) or early clamping (<= 10 seconds after delivery). Main outcome measures Haemoglobin and iron status at 4 months of age with the power estimate based on serum ferritin levels. Secondary outcomes included neonatal anaemia, early respiratory symptoms, polycythaemia, and need for phototherapy. Results At 4 months of age, infants showed no significant differences in haemoglobin concentration between the groups, but infants subjected to delayed cord clamping had 45% (95% confidence interval 23% to 71%) higher mean ferritin concentration (117 mu g/L v 81 mu g/L, P<0.001) and a lower prevalence of iron deficiency (1 (0.6%) v 10 (5.7%), P=0.01, relative risk reduction 0.90; number needed to treat=20 (17 to 67)). As for secondary outcomes, the delayed cord clamping group had lower prevalence of neonatal anaemia at 2 days of age (2 (1.2%) v 10 (6.3%), P=0.02, relative risk reduction 0.80, number needed to treat 20 (15 to 111)). There were no significant differences between groups in postnatal respiratory symptoms, polycythaemia, or hyperbilirubinaemia requiring phototherapy. Conclusions Delayed cord clamping, compared with early clamping, resulted in improved iron status and reduced prevalence of iron deficiency at 4 months of age, and reduced prevalence of neonatal anaemia, without demonstrable adverse effects. As iron deficiency in infants even without anaemia has been associated with impaired development, delayed cord clamping seems to benefit full term infants even in regions with a relatively low prevalence of iron deficiency anaemia.	[Andersson, Ola; Andersson, Dan] Hosp Halland, Dept Paediat, SE-30185 Halmstad, Sweden; [Andersson, Ola; Hellstrom-Westas, Lena] Uppsala Univ, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden; [Domellof, Magnus] Umea Univ, Dept Clin Sci, SE-90185 Umea, Sweden	Uppsala University; Umea University	Andersson, O (corresponding author), Hosp Halland, Dept Paediat, SE-30185 Halmstad, Sweden.	ola.k.andersson@regionhalland.se	Domellöf, Magnus/E-5307-2011; Domellöf, Magnus/AAP-9542-2021; Andersson, Ola/L-9181-2015; Andersson, Ola/L-2728-2019	Domellöf, Magnus/0000-0002-0726-7029; Andersson, Ola/0000-0002-3972-0457; Hellstrom-Westas, Lena/0000-0003-3498-6069	Regional Scientific Council of Halland; HASNA Foundation, Halmstad; HRH Crown Princess Lovisa's Foundation for Child Care, Stockholm; Framework of Positive Scientific Culture, Hospital of Halland, Halmstad	Regional Scientific Council of Halland; HASNA Foundation, Halmstad; HRH Crown Princess Lovisa's Foundation for Child Care, Stockholm; Framework of Positive Scientific Culture, Hospital of Halland, Halmstad	This study was supported by grants from the Regional Scientific Council of Halland; the HASNA Foundation, Halmstad; HRH Crown Princess Lovisa's Foundation for Child Care, Stockholm; and the Framework of Positive Scientific Culture, Hospital of Halland, Halmstad. The funders were not involved in the study design, data analysis, or manuscript preparation.	Beard J, 2007, J NUTR, V137, p524S, DOI 10.1093/jn/137.2.524S; Bramhagen AC, 1999, ACTA PAEDIATR, V88, P1333, DOI 10.1080/080352599750030031; Carlson ES, 2009, J NUTR, V139, P672, DOI 10.3945/jn.108.096354; Cernadas JMC, 2006, PEDIATRICS, V117, pE779, DOI 10.1542/peds.2005-1156; Chantry CJ, 2007, BREASTFEED MED, V2, P63, DOI 10.1089/bfm.2007.0002; Chaparro CM, 2006, LANCET, V367, P1997, DOI 10.1016/S0140-6736(06)68889-2; Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071; Dallman PR, 1977, PEDIATRICS, V16, P1111; Domellof M, 2002, J NUTR, V132, P3680, DOI 10.1093/jn/132.12.3680; Domellof M, 2001, J PEDIATR-US, V138, P679, DOI 10.1067/mpd.2001.112895; Domellof M, 2007, CURR OPIN CLIN NUTR, V10, P329, DOI 10.1097/MCO.0b013e3280523aaf; Emhamed MO, 2004, TROP DOCT, V34, P218, DOI 10.1177/004947550403400410; Fewtrell M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c5955; Geethanath R M, 1997, Indian Pediatr, V34, P103; Grajeda R, 1997, AM J CLIN NUTR, V65, P425, DOI 10.1093/ajcn/65.2.425; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; Gunnarsson BS, 2007, ACTA PAEDIATR, V96, P391, DOI 10.1111/j.1651-2227.2007.00086.x; Gupta Rajesh, 2002, Indian Pediatr, V39, P130; Hutton EK, 2007, JAMA-J AM MED ASSOC, V297, P1241, DOI 10.1001/jama.297.11.1241; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; LOZOFF B, 1987, PEDIATRICS, V79, P981; Lozoff B, 2006, NUTR REV, V64, pS34, DOI 10.1301/nr.2006.may.S34-S43; Male C, 2001, ACTA PAEDIATR, V90, P492, DOI 10.1080/080352501750197601; Malope BI, 2001, BRIT J HAEMATOL, V115, P84, DOI 10.1046/j.1365-2141.2001.03063.x; McCann JC, 2007, AM J CLIN NUTR, V85, P931, DOI 10.1093/ajcn/85.4.931; McDonald SJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004074.pub2; Mei ZG, 2005, J NUTR, V135, P1974, DOI 10.1093/jn/135.8.1974; NELLE M, 1993, AM J OBSTET GYNECOL, V169, P189, DOI 10.1016/0002-9378(93)90161-B; Pappas A, 2004, PEDIATR CLIN N AM, V51, P1063, DOI 10.1016/j.pcl.2004.03.012; Persson LA, 1998, ACTA PAEDIATR, V87, P618, DOI 10.1080/080352598750013996; Pezzullo JC, JAVASTAT 2 WAY CONTI; Pfeiffer CM, 2007, CLIN CHIM ACTA, V382, P112, DOI 10.1016/j.cca.2007.04.008; SAARINEN UM, 1977, J PEDIATR-US, V91, P875, DOI 10.1016/S0022-3476(77)80880-9; Sachdev HPS, 2005, PUBLIC HEALTH NUTR, V8, P117, DOI 10.1079/PHN2004677; SAIGAL S, 1977, BIOL NEONATE, V32, P62; Szajewska H, 2010, AM J CLIN NUTR, V91, P1684, DOI 10.3945/ajcn.2010.29191; Thane CW, 2000, PUBLIC HEALTH NUTR, V3, P433, DOI 10.1017/S1368980000000501; Thomas D, 2009, DEV NEUROPSYCHOL, V34, P196, DOI 10.1080/87565640802646767; Van Rheenen P, 2004, ANN TROP PAEDIATR, V24, P3, DOI 10.1179/027249304225013286; van Rheenen P, 2007, TROP MED INT HEALTH, V12, P603, DOI 10.1111/j.1365-3156.2007.01835.x; van Rheenen PF, 2006, BMJ-BRIT MED J, V333, P954, DOI 10.1136/bmj.39002.389236.BE; Winter C, 2007, BJOG-INT J OBSTET GY, V114, P845, DOI 10.1111/j.1471-0528.2007.01377.x; YAO AC, 1969, LANCET, V2, P505; YAO AC, 1971, PEDIATRICS, V48, P865; YAO AC, 1969, LANCET, V2, P871	46	168	180	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2011	343								d7157	10.1136/bmj.d7157	http://dx.doi.org/10.1136/bmj.d7157			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875FS	22089242	Green Published, hybrid			2022-12-28	WOS:000299016400004
J	Laville, M				Laville, Maurice			Simvastatin plus ezetimibe reduced major atherosclerotic events in patients with chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Lyon 1, F-69365 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Laville, M (corresponding author), Univ Lyon 1, F-69365 Lyon, France.							Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Weiner DE, 2007, J AM COLL CARDIOL, V50, P217, DOI 10.1016/j.jacc.2007.03.037	3	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-2	10.7326/0003-4819-155-10-201111150-02002	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084349				2022-12-28	WOS:000208885300001
J	Sacks, HS				Sacks, Henry S.			Influenza vaccination reduced cardiovascular events in patients hospitalized with an acute coronary syndrome	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sacks, HS (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.			Phrommintikul, Arintaya/0000-0003-3986-1951; Wongcharoen, Wanwarang/0000-0002-2418-329X				Ciszewski A, 2008, EUR HEART J, V29, P1350, DOI 10.1093/eurheartj/ehm581; Gurfinkel EP, 2004, EUR HEART J, V25, P25, DOI 10.1016/j.ehj.2003.10.018; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747	3	0	1	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-5	10.7326/0003-4819-155-10-201111150-02005	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084352				2022-12-28	WOS:000208885300004
J	Green, DR; Van Houten, B				Green, Douglas R.; Van Houten, Bennett			SnapShot: Mitochondrial Quality Control	CELL			English	Editorial Material							DEATH; DNA		[Green, Douglas R.] St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA; [Van Houten, Bennett] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA	St Jude Children's Research Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Green, DR (corresponding author), St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA.		Green, Douglas R/N-8083-2018; Van Houten, Bennett/K-2284-2019	Green, Douglas R/0000-0002-7332-1417; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI040646-16, R01 AI040646] Funding Source: Medline; NIGMS NIH HHS [R37 GM052735-21, R37 GM052735] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cardenas C, 2010, CELL, V142, P270, DOI 10.1016/j.cell.2010.06.007; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Green DR, 2011, MEANS END APOPTOSIS; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Leung AWC, 2008, BBA-BIOENERGETICS, V1777, P946, DOI 10.1016/j.bbabio.2008.03.009; Simsek D, 2011, NATURE, V471, P245, DOI 10.1038/nature09794; Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028	9	43	49	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4							950.e1	10.1016/j.cell.2011.10.036	http://dx.doi.org/10.1016/j.cell.2011.10.036			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078889	Green Accepted, Bronze			2022-12-28	WOS:000296902300028
J	Trivedi, NS; Ship, AN; Pinto, DS				Trivedi, Neha S.; Ship, Amy N.; Pinto, Duane S.			Update: A 43-Year-Old Man With Angina, Elevated Troponin, and Lateral ST Depression Management of Acute Coronary Syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Pinto, Duane/0000-0002-2309-8480; Trivedi, Neha/0000-0003-1006-1408				Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Pinto DS, 2010, JAMA-J AM MED ASSOC, V303, P54, DOI 10.1001/jama.2009.1870; Thomas RJ, 2010, J AM COLL CARDIOL, V56, P1159, DOI 10.1016/j.jacc.2010.06.006	4	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1911	1911		10.1001/jama.2011.1568	http://dx.doi.org/10.1001/jama.2011.1568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045768				2022-12-28	WOS:000296376200025
J	Qaseem, A; Chou, R; Humphrey, LL; Starkey, M; Shekelle, P				Qaseem, Amir; Chou, Roger; Humphrey, Linda L.; Starkey, Melissa; Shekelle, Paul		Amer Coll Phys	Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; ACUTE ISCHEMIC-STROKE; LOW-DOSE HEPARIN; FATAL PULMONARY-EMBOLISM; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; UNFRACTIONATED HEPARIN; MEDICAL PATIENTS; ACUTELY ILL	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on prophylaxis of venous thromboembolism for hospitalized nonsurgical patients (medical patients and patients with acute stroke). Methods: This guideline is based on published literature on the topic from 1950 through April 2011 that was identified by using MEDLINE, the Cochrane Library, and reference lists of pertinent randomized trials and systematic reviews to identify additional reports. Searches were limited to randomized trials and English-language publications. The primary outcome for this guideline was total mortality up to 120 days after randomization. Secondary outcomes included symptomatic deep venous thrombosis; all pulmonary embolisms; fatal pulmonary embolism; all bleeding events; major bleeding events; and, for mechanical prophylaxis, effects on skin. This guideline grades the evidence and recommendations by using the ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends assessment of the risk for thromboembolism and bleeding in medical (including stroke) patients prior to initiation of prophylaxis of venous thromboembolism (Grade: strong recommendation, moderate-quality evidence). Recommendation 2: ACP recommends pharmacologic prophylaxis with heparin or a related drug for venous thromboembolism in medical (including stroke) patients unless the assessed risk for bleeding outweighs the likely benefits (Grade: strong recommendation, moderate-quality evidence). Recommendation 3: ACP recommends against the use of mechanical prophylaxis with graduated compression stockings for prevention of venous thromboembolism (Grade: strong recommendation, moderate-quality evidence). Policy Implication: ACP does not support the application of performance measures in medical (including stroke) patients that promotes universal venous thromboembolism prophylaxis regardless of risk.	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	American College of Physicians; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Starkey, Melissa/0000-0002-5818-0265; Chou, Roger/0000-0001-9889-8610	ACP	ACP	Financial support for the development of this guideline comes exclusively from the ACP operating budget.	Alikhan R, 2004, J CLIN PATHOL, V57, P1254, DOI 10.1136/jcp.2003.013581; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Aquino JP, 1991, FRAXIPARINE; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; Cook D, 2011, NEW ENGL J MED, V364, P1305; DAHAN R, 1986, HAEMOSTASIS, V16, P159; Dennis M, 2010, ANN INTERN MED, V153, P553, DOI 10.7326/0003-4819-153-9-201011020-00280; Dennis M, 2009, LANCET, V373, P1958, DOI 10.1016/S0140-6736(09)60941-7; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; Diener HC, 2006, STROKE, V37, P139, DOI 10.1161/01.STR.0000195182.67656.ee; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025; Gardlund B, 1996, LANCET, V347, P1357; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Green D., 1998, TOP STROKE REHABIL, V5, P68; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; Hillbom M, 2002, ACTA NEUROL SCAND, V106, P84, DOI 10.1034/j.1600-0404.2002.01215.x; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Kucher N, 2005, ARCH INTERN MED, V165, P341, DOI 10.1001/archinte.165.3.341; Lacut K, 2005, NEUROLOGY, V65, P865, DOI 10.1212/01.wnl.0000176073.80532.a2; Lechler E, 1996, HAEMOSTASIS, V26, P49; Lederle FA, 2006, AM J MED, V119, P54, DOI 10.1016/j.amjmed.2005.03.049; Lederle FA, 2011, ANN INTERN MED, V155, P602, DOI 10.7326/0003-4819-155-9-201111010-00008; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; Luba Maria, 2007, Pol Arch Med Wewn, V117, P31; Mahe I, 2005, EUR J CLIN PHARMACOL, V61, P347, DOI 10.1007/s00228-005-0944-3; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; Muir KW, 2000, QJM-INT J MED, V93, P359, DOI 10.1093/qjmed/93.6.359; PRASAD BK, 1982, AGE AGEING, V11, P42, DOI 10.1093/ageing/11.1.42; PRINS MH, 1989, HAEMOSTASIS, V19, P245; Qaseem A, 2007, ANN INTERN MED, V146, P454, DOI 10.7326/0003-4819-146-6-200703200-00013; Qaseem A, 2010, ANN INTERN MED, V153, P194, DOI 10.7326/0003-4819-153-3-201008030-00010; Riess H, 2010, J THROMB HAEMOST, V8, P1209, DOI 10.1111/j.1538-7836.2010.03848.x; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Sandercock P, 1997, LANCET, V349, P1569; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Schellong SM, 2010, EXPERT OPIN PHARMACO, V11, P2953, DOI 10.1517/14656566.2010.521498; Sherman DG, 2007, LANCET, V369, P1347, DOI 10.1016/S0140-6736(07)60633-3; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; TURPIE AGG, 1987, LANCET, V1, P523; Weber C, 2008, SUPPORT CARE CANCER, V16, P847, DOI 10.1007/s00520-007-0339-3	50	181	186	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					625	U118		10.7326/0003-4819-155-9-201111010-00011	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041951				2022-12-28	WOS:000296612400007
J	Suzuki, W; Naya, Y				Suzuki, Wendy; Naya, Yuji			Two Routes for Remembering the Past	CELL			English	Editorial Material							MEMORY CONSOLIDATION; RETROGRADE-AMNESIA; FEAR MEMORY	Which brain circuits underlie retrieval of distant memories? Goshen et al. (2011) use a powerful optogenetic-based approach to reveal the critical contribution of the hippocampus to remote memory retrieval. In so doing, they provide new evidence toward resolving a long-standing debate in cognitive neuroscience.	[Suzuki, Wendy; Naya, Yuji] NYU, Ctr Neural Sci, New York, NY 10003 USA	New York University	Suzuki, W (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	ws21@nyu.edu						Bayley PJ, 2003, NEURON, V38, P135, DOI 10.1016/S0896-6273(03)00156-9; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Goshen I, 2011, CELL, V147, P678, DOI 10.1016/j.cell.2011.09.033; Kitamura T, 2009, CELL, V139, P814, DOI 10.1016/j.cell.2009.10.020; Lavenex P, 2000, HIPPOCAMPUS, V10, P420, DOI 10.1002/1098-1063(2000)10:4<420::AID-HIPO8>3.3.CO;2-X; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; RIBOT TA, 1881, DIS MEMORY; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Wiltgen BJ, 2010, CURR BIOL, V20, P1336, DOI 10.1016/j.cub.2010.06.068; Winocur G, 2011, J INT NEUROPSYCH SOC, V17, P766, DOI 10.1017/S1355617711000683	10	5	5	0	12	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					492	495		10.1016/j.cell.2011.10.005	http://dx.doi.org/10.1016/j.cell.2011.10.005			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036558	Bronze			2022-12-28	WOS:000296573700005
J	Warde, P; Mason, M; Ding, K; Kirkbride, P; Brundage, M; Cowan, R; Gospodarowicz, M; Sanders, K; Kostashuk, E; Swanson, G; Barber, J; Hiltz, A; Parmar, MKB; Sathya, J; Anderson, J; Hayter, C; Hetherington, J; Sydes, MR; Parulekar, W				Warde, Padraig; Mason, Malcolm; Ding, Keyue; Kirkbride, Peter; Brundage, Michael; Cowan, Richard; Gospodarowicz, Mary; Sanders, Karen; Kostashuk, Edmund; Swanson, Greg; Barber, Jim; Hiltz, Andrea; Parmar, Mahesh K. B.; Sathya, Jinka; Anderson, John; Hayter, Charles; Hetherington, John; Sydes, Matthew R.; Parulekar, Wendy		NCICCTG PR3 MRC UK PR07 Investigat	Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial	LANCET			English	Article							QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; CLINICAL-TRIALS; HIGH-RISK; RADIOTHERAPY; SUPPRESSION; DURATION	Background Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such patients with locally advanced prostate cancer. Methods Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-confined disease (T2) with either a prostate-specific antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL and a Gleason score of 8 or higher (n=25), were randomly assigned (done centrally with stratification and dynamic minimisation, not masked) to receive lifelong ADT and RT (65-69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes). The primary endpoint was overall survival. The results presented here are of an interim analysis planned for when two-thirds of the events for the final analysis were recorded. All efficacy analyses were done by intention to treat and were based on data from all patients. This trial is registered at controlledtrials.com as ISRCTN24991896 and Clinicaltrials.gov as NCT00002633. Results Between 1995 and 2005, 1205 patients were randomly assigned (602 in the ADT only group and 603 in the ADT and RT group); median follow-up was 6.0 years (IQR 4.4-8.0). At the time of analysis, a total of 320 patients had died, 175 in the ADT only group and 145 in the ADT and RT group. The addition of RT to ADT improved overall survival at 7 years (74%, 95% CI 70-78 vs 66%, 60-70; hazard ratio [HR] 0.77, 95% CI 0.61-0.98, p=0.033). Both toxicity and health-related quality-of-life results showed a small effect of RT on late gastrointestinal toxicity (rectal bleeding grade >3, three patients (0.5%) in the ADT only group, two (0.3%) in the ADT and RT group; diarrhoea grade >3, four patients (0.7%) vs eight (1.3%); urinary toxicity grade >3, 14 patients (2.3%) in both groups). Interpretation The benefits of combined modality treatment-ADT and RT-should be discussed with all patients with locally advanced prostate cancer.	[Warde, Padraig; Gospodarowicz, Mary] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; [Barber, Jim] Velindre Hosp, Cardiff, S Glam, Wales; [Mason, Malcolm] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales; [Ding, Keyue; Hiltz, Andrea; Parulekar, Wendy] NCIC CTG, Kingston, ON, Canada; [Brundage, Michael] Kingston Reg Canc Ctr, Kingston, ON, Canada; [Kirkbride, Peter; Anderson, John] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Kostashuk, Edmund] Fraser Valley Canc Ctr, Surrey, BC, Canada; [Swanson, Greg] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Sathya, Jinka] Dr H Bliss Murphy Canc Clin, St John, NF, Canada; [Cowan, Richard] Christie Hosp, Manchester, Lancs, England; [Sanders, Karen; Parmar, Mahesh K. B.; Sydes, Matthew R.] MRC, Clin Trials Unit, London, England; [Hetherington, John] Castle Hill Hosp, Kingston Upon Hull, N Humberside, England; [Hayter, Charles] Carlo Fidani Canc Ctr, Mississauga, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Velindre Hospital; Cardiff University; Weston Park Hospital; University of Texas System; University of Texas Health San Antonio; Christie NHS Foundation Trust; Christie Hospital; Medical Research Council Clinical Trials Unit; University of Hull	Warde, P (corresponding author), Radiat Med Program, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	padraig.warde@rmp.uhn.on.ca	cowan, richard/N-7633-2015; Sydes, Matthew/C-3373-2008; Mason, Malcolm D/H-6979-2013	cowan, richard/0000-0001-9004-8136; Sydes, Matthew/0000-0002-9323-1371; Swanson, Gregory/0000-0002-7959-1493; Kiltie, Anne/0000-0001-7208-2912; Rogers, Paul/0000-0003-2593-2595; Warde, Padraig/0000-0002-4236-0026; Eeles, Rosalind/0000-0002-3698-6241	Canadian Cancer Society Research Institute [14469]; US National Cancer Institute [CA077202]; UK Medical Research Council [G9805643]; UK National Cancer Research Network; NATIONAL CANCER INSTITUTE [U10CA077202] Funding Source: NIH RePORTER; Cancer Research UK [10588] Funding Source: researchfish; Medical Research Council [MC_U122861330] Funding Source: researchfish; MRC [MC_U122861330] Funding Source: UKRI	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Cancer Research Network; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Canadian Cancer Society Research Institute, US National Cancer Institute, and UK Medical Research Council.; This study was supported by US National Cancer Institute (grant CA077202), Canadian Cancer Society Research Institute (grant 14469), the UK Medical Research Council (grant G9805643), and the UK National Cancer Research Network.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Alibhai SMH, 2010, CURR ONCOL, V17, pS55; Alibhai SMH, 2010, J UROLOGY, V184, P918, DOI 10.1016/j.juro.2010.04.068; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095; Cella D, 2009, VALUE HEALTH, V12, P124, DOI 10.1111/j.1524-4733.2008.00409.x; Cooperberg MR, 2010, J CLIN ONCOL, V28, P1117, DOI 10.1200/JCO.2009.26.0133; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; Eastham JA, 2010, UROL ONCOL-SEMIN ORI, V28, P557, DOI 10.1016/j.urolonc.2009.12.012; Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090-4295(97)00459-7; FELLOWS GJ, 1992, BRIT J UROL, V70, P304, DOI 10.1111/j.1464-410X.1992.tb15736.x; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Horwitz EM, 2008, J CLIN ONCOL, V26, P2497, DOI 10.1200/JCO.2007.14.9021; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497; Kuban DA, 2008, INT J RADIAT ONCOL, V70, P67, DOI 10.1016/j.ijrobp.2007.06.054; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; McMullen KP, 2003, UROLOGY, V61, P391, DOI 10.1016/S0090-4295(02)02259-8; MONTI AF, 1995, RADIOTHER ONCOL, V35, P145, DOI 10.1016/0167-8140(95)01541-N; Osoba D, 2005, EUR J CANCER, V41, P280, DOI 10.1016/j.ejca.2004.10.017; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rosenthal SA, 2010, NAT REV UROL, V7, P31, DOI 10.1038/nrurol.2009.237; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2; Zietman AL, 2005, JAMA-J AM MED ASSOC, V294, P1233, DOI 10.1001/jama.294.10.1233	27	446	457	0	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	2011	378	9809					2104	2111		10.1016/S0140-6736(11)61095-7	http://dx.doi.org/10.1016/S0140-6736(11)61095-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865EL	22056152	Green Published			2022-12-28	WOS:000298293600032
J	Zambon, M				Zambon, Maria			Assessment of the burden of influenza in children	LANCET			English	Editorial Material							VACCINES		Hlth Protect Agcy, London NW9 5HT, England	Health Protection Agency	Zambon, M (corresponding author), Hlth Protect Agcy, London NW9 5HT, England.	Maria.Zambon@hpa.org.uk						Clemens J, 2010, NAT IMMUNOL, V11, P1069, DOI 10.1038/ni1210-1069; Moxon ER, 2011, LANCET, V378, P298, DOI 10.1016/S0140-6736(11)60766-6; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Ortiz JR, 2011, VACCINE, V29, P4439, DOI 10.1016/j.vaccine.2011.04.048; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; *WHO, GAP OBJ; World Health Organization, 2011, WKLY EPIDEMIOL REC, V86, P61; World Health Organization, 2006, GLOB PAND INFL ACT P; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X	11	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	2011	378	9807					1897	1898		10.1016/S0140-6736(11)61262-2	http://dx.doi.org/10.1016/S0140-6736(11)61262-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863AW	22078719				2022-12-28	WOS:000298136200011
J	Appel, LJ; Clark, JM; Yeh, HC; Wang, NY; Coughlin, JW; Daumit, G; Miller, ER; Dalcin, A; Jerome, GJ; Geller, S; Noronha, G; Pozefsky, T; Charleston, J; Reynolds, JB; Durkin, N; Rubin, RR; Louis, TA; Brancati, FL				Appel, Lawrence J.; Clark, Jeanne M.; Yeh, Hsin-Chieh; Wang, Nae-Yuh; Coughlin, Janelle W.; Daumit, Gail; Miller, Edgar R., III; Dalcin, Arlene; Jerome, Gerald J.; Geller, Steven; Noronha, Gary; Pozefsky, Thomas; Charleston, Jeanne; Reynolds, Jeffrey B.; Durkin, Nowella; Rubin, Richard R.; Louis, Thomas A.; Brancati, Frederick L.			Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-STYLE MODIFICATION; RANDOMIZED-TRIAL; BLOOD-PRESSURE; PRIMARY-CARE; HYPERTENSION PREVENTION; PHASE-II; OBESITY; REDUCTION; OVERWEIGHT; PROGRAM	BACKGROUND Obesity and its cardiovascular complications are extremely common medical problems, but evidence on how to accomplish weight loss in clinical practice is sparse. METHODS We conducted a randomized, controlled trial to examine the effects of two behavioral weight-loss interventions in 415 obese patients with at least one cardiovascular risk factor. Participants were recruited from six primary care practices; 63.6% were women, 41.0% were black, and the mean age was 54.0 years. One intervention provided patients with weight-loss support remotely - through the telephone, a study-specific Web site, and e-mail. The other intervention provided in-person support during group and individual sessions, along with the three remote means of support. There was also a control group in which weight loss was self-directed. Outcomes were compared between each intervention group and the control group and between the two intervention groups. For both interventions, primary care providers reinforced participation at routinely scheduled visits. The trial duration was 24 months. RESULTS At baseline, the mean body-mass index (the weight in kilograms divided by the square of the height in meters) for all participants was 36.6, and the mean weight was 103.8 kg. At 24 months, the mean change in weight from baseline was -0.8 kg in the control group, -4.6 kg in the group receiving remote support only (P<0.001 for the comparison with the control group), and -5.1 kg in the group receiving in-person support (P<0.001 for the comparison with the control group). The percentage of participants who lost 5% or more of their initial weight was 18.8% in the control group, 38.2% in the group receiving remote support only, and 41.4% in the group receiving in-person support. The change in weight from baseline did not differ significantly between the two intervention groups. CONCLUSIONS In two behavioral interventions, one delivered with in-person support and the other delivered remotely, without face-to-face contact between participants and weight-loss coaches, obese patients achieved and sustained clinically significant weight loss over a period of 24 months. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00783315.)	[Appel, Lawrence J.; Clark, Jeanne M.; Yeh, Hsin-Chieh; Wang, Nae-Yuh; Daumit, Gail; Miller, Edgar R., III; Brancati, Frederick L.] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21218 USA; [Appel, Lawrence J.; Clark, Jeanne M.; Yeh, Hsin-Chieh; Wang, Nae-Yuh; Daumit, Gail; Miller, Edgar R., III; Dalcin, Arlene; Jerome, Gerald J.; Noronha, Gary; Pozefsky, Thomas; Reynolds, Jeffrey B.; Durkin, Nowella; Brancati, Frederick L.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA; [Pozefsky, Thomas] Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD USA; [Coughlin, Janelle W.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Rubin, Richard R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Appel, Lawrence J.; Clark, Jeanne M.; Yeh, Hsin-Chieh; Charleston, Jeanne; Brancati, Frederick L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Wang, Nae-Yuh; Louis, Thomas A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Noronha, Gary] Johns Hopkins Community Phys, Baltimore, MD USA; [Jerome, Gerald J.] Towson Univ, Dept Kinesiol, Towson, MD USA; [Geller, Steven] Centennial Med Grp, Elkridge, MD USA; [Pozefsky, Thomas] Pk Med Associates, Lutherville Timonium, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; Towson University	Appel, LJ (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21218 USA.	lappel@jhmi.edu	Appel, Larry/GLT-2608-2022; Jerome, Gerald/R-2979-2018; Clark, Jeanne/AGG-8199-2022	Jerome, Gerald/0000-0003-0612-2626; Clark, Jeanne/0000-0003-1194-0092; Coughlin, Janelle/0000-0001-7924-5892; Wang, Nae-Yuh/0000-0001-6513-9730	National Heart, Lung, and Blood Institute [HL087085]; Prevention and Control Core of the Baltimore Diabetes Research and Training Center [P60DK079637]; National Center for Research Resources [UL1RR025005]; Healthways; Bristol-Myers Squibb; Merck; Taylor; Francis Publishing; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK079637, P30DK079637] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Prevention and Control Core of the Baltimore Diabetes Research and Training Center; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Healthways; Bristol-Myers Squibb(Bristol-Myers Squibb); Merck(Merck & Company); Taylor; Francis Publishing; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Heart, Lung, and Blood Institute (HL087085), the Prevention and Control Core of the Baltimore Diabetes Research and Training Center (P60DK079637), and the National Center for Research Resources (UL1RR025005) and by Healthways.; Dr. Louis reports receiving consulting fees from Bristol-Myers Squibb and Merck and royalties from Taylor and Francis Publishing. Johns Hopkins University has an institutional consulting agreement with Healthways. No other potential conflict of interest relevant to this article was reported.	Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Ashley JM, 2001, ARCH INTERN MED, V161, P1599, DOI 10.1001/archinte.161.13.1599; Berg AO, 2003, ANN INTERN MED, V139, P930, DOI 10.7326/0003-4819-139-11-200312020-00012; Brantley P, 2008, CLIN TRIALS, V5, P546, DOI 10.1177/1740774508096315; Digenio AG, 2009, ANN INTERN MED, V150, P255, DOI 10.7326/0003-4819-150-4-200902170-00006; DPP Res Grp, 2002, DIABETES CARE, V25, P2165; Elmer PJ, 2006, ANN INTERN MED, V144, P485, DOI 10.7326/0003-4819-144-7-200604040-00007; Ely AC, 2008, J RURAL HEALTH, V24, P125, DOI 10.1111/j.1748-0361.2008.00148.x; Finkelstein EA, 2003, HLTH AFF MILLWOOD S, pW3; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Funk K. L., 2006, HLTH PROMOT PRACT, V9, P271; HOLM S, 1979, SCAND J STAT, V6, P65; Jerome Gerald J, 2009, Obes Weight Manag, V5, P216, DOI 10.1089/obe.2009.0506; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krukowski Rebecca A, 2009, J Diabetes Sci Technol, V3, P184; Kushner RF, 2010, ARCH INTERN MED, V170, P121, DOI 10.1001/archinternmed.2009.479; Logue E, 2005, OBES RES, V13, P917, DOI 10.1038/oby.2005.106; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Tate DF, 2006, ARCH INTERN MED, V166, P1620, DOI 10.1001/archinte.166.15.1620; Tsai AG, 2009, J GEN INTERN MED, V24, P1073, DOI 10.1007/s11606-009-1042-5; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wing RR, 2010, ARCH INTERN MED, V170, P1566, DOI 10.1001/archinternmed.2010.334; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; Yeh HC, 2010, CLIN TRIALS, V7, P322, DOI 10.1177/1740774510374213	27	492	494	0	73	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2011	365	21					1959	1968		10.1056/NEJMoa1108660	http://dx.doi.org/10.1056/NEJMoa1108660			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851PF	22085317	Bronze, Green Accepted			2022-12-28	WOS:000297282600006
J	Reis, JS; Pusztai, L				Reis-Filho, Jorge S.; Pusztai, Lajos			Breast Cancer 2 Gene expression profiling in breast cancer: classification, prognostication, and prediction	LANCET			English	Article							INTERNATIONAL EXPERT CONSENSUS; POLYMERASE CHAIN-REACTION; GENOMIC GRADE INDEX; ESTROGEN-RECEPTOR; MOLECULAR CLASSIFICATION; NEOADJUVANT PACLITAXEL; ADJUVANT CHEMOTHERAPY; HISTOLOGIC GRADE; PRIMARY THERAPY; SIGNATURE	Microarray-based gene expression profiling has had a major effect on our understanding of breast cancer. Breast cancer is now perceived as a heterogeneous group of different diseases characterised by distinct molecular aberrations, rather than one disease with varying histological features and clinical behaviour. Gene expression profiling studies have shown that oestrogen-receptor (ER)-positive and ER-negative breast cancers are distinct diseases at the transcriptomic level, that additional molecular subtypes might exist within these groups, and that the prognosis of patients with ER-positive disease is largely determined by the expression of proliferation-related genes. On the basis of these principles, a molecular classification system and prognostic multigene classifiers based on microarrays or derivative technologies have been developed and are being tested in randomised clinical trials and incorporated into clinical practice. In this review, we focus on the conceptual effect and potential clinical use of the molecular classification of breast cancer, and discuss prognostic and predictive multigene predictors.	[Reis-Filho, Jorge S.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Pusztai, Lajos] Univ Texas Houston, MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Reis, JS (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.	jorge.reis-filho@icr.ac.uk	Pusztai, Lajos/AAB-2901-2019		Breakthrough Breast Cancer; NHS; Breast Cancer Research Foundation	Breakthrough Breast Cancer; NHS; Breast Cancer Research Foundation	We thank Britta Weigelt, Paul Wilkerson, and Neill Patani for critical discussions and insightful comments. We apologise to the investigators whose primary work we were unable to quote in this report due to space restrictions. JSR-F is supported by Breakthrough Breast Cancer, is one of the recipients of the 2010 Cancer Research UK Future Leaders Prize, and also acknowledges NHS funding to the NIHR Biomedical Research Centre. LP acknowledges support by grants from the Breast Cancer Research Foundation. The funding sources had no role in the writing of this paper or in the decision to submit it for publication.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; [Anonymous], 2007, LANCET ONCOL, V8, P1079, DOI 10.1016/S1470-2045(07)70346-7; Aparicio SAJR, 2010, J PATHOL, V220, P307, DOI 10.1002/path.2636; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Badve SS, 2008, J CLIN ONCOL, V26, P2473, DOI 10.1200/JCO.2007.13.6424; Baehner FL, 2010, J CLIN ONCOL, V28, P4300, DOI 10.1200/JCO.2009.24.8211; Baggerly KA, 2009, ANN APPL STAT, V3, P1309, DOI 10.1214/09-AOAS291; Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278; Bianchini G, 2010, J CLIN ONCOL, V28, P4316, DOI 10.1200/JCO.2009.27.2419; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bonnefoi H, 2011, LANCET ONCOL, V12, P116, DOI 10.1016/S1470-2045(11)70011-0; Borst P, 2010, CELL CYCLE, V9, P4836, DOI 10.4161/cc.9.24.14326; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Carlson Robert W, 2007, J Natl Compr Canc Netw, V5, P246; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Colombo PE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2890; Cuzick J, 2011, J CLIN ONCOL, DOI [10.1200/JCO.2011.37.5824, DOI 10.1200/JCO.2011.37.5824]; Dabbs DJ, 2011, J CLIN ONCOL, DOI [10.1200/JCO.2010.31.2835, DOI 10.1200/JCO.2010.31.2835]; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Desmedt C, 2011, J CLIN ONCOL, V29, P1578, DOI 10.1200/JCO.2010.31.2231; Desmedt C, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-40; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Dowsett M, 2010, J CLIN ONCOL, V28, P1829, DOI 10.1200/JCO.2009.24.4798; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Gruvberger S, 2001, CANCER RES, V61, P5979; Habel LA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1412; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Iwamoto T, 2011, J NATL CANCER I, V103, P264, DOI 10.1093/jnci/djq524; Iwamoto T, 2010, GENOME MED, V2, DOI 10.1186/gm202; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Juul N, 2010, LANCET ONCOL, V11, P358, DOI 10.1016/S1470-2045(10)70018-8; Kim C, 2010, NAT REV CLIN ONCOL, V7, P340, DOI 10.1038/nrclinonc.2010.61; Knauer M, 2010, BRIT J CANCER, V103, P1788, DOI 10.1038/sj.bjc.6605916; Knauer M, 2010, BREAST CANCER RES TR, V120, P655, DOI 10.1007/s10549-010-0814-2; Liedtke C, 2009, J CLIN ONCOL, V27, P3185, DOI 10.1200/JCO.2008.18.5934; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Ma XJ, 2008, CLIN CANCER RES, V14, P2601, DOI 10.1158/1078-0432.CCR-07-5026; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mackay A, 2011, JNCI-J NATL CANCER I, V103, P662, DOI 10.1093/jnci/djr071; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Pusztai L, 2008, J CLIN ONCOL, V26, P4679, DOI 10.1200/JCO.2008.17.2544; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Reis JS, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001329; Reyal F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2192; Simon RM, 2009, J NATL CANCER I, V101, P1446, DOI 10.1093/jnci/djp335; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Tang G, 2010, P AM SOC CLIN ONCO S, V28; Tang G, 2011, BREAST CANCER RES TR, V127, P133, DOI 10.1007/s10549-010-1331-z; Teschendorff AE, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2138; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Toussaint J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-424; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weigelt B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2734; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124	88	501	519	0	53	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2011	378	9805					1812	1823		10.1016/S0140-6736(11)61539-0	http://dx.doi.org/10.1016/S0140-6736(11)61539-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22098854				2022-12-28	WOS:000297262300026
J	Wentz, FJ; Ricciardulli, L				Wentz, Frank J.; Ricciardulli, Lucrezia			Comment on "Global Trends in Wind Speed and Wave Height"	SCIENCE			English	Editorial Material							CLIMATE; CYCLE		[Wentz, Frank J.; Ricciardulli, Lucrezia] Remote Sensing Syst, Santa Rosa, CA 95401 USA		Wentz, FJ (corresponding author), Remote Sensing Syst, 444 10th St, Santa Rosa, CA 95401 USA.	frank.wentz@remss.com						Adler RF, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010536; Allen MR, 2002, NATURE, V419, P224, DOI 10.1038/nature01092; Dai A, 2006, J CLIMATE, V19, P3589, DOI 10.1175/JCLI3816.1; Gastineau G, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047138; Gulev SK, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021040; Held IM, 2006, J CLIMATE, V19, P5686, DOI 10.1175/JCLI3990.1; Schneider T, 2010, REV GEOPHYS, V48, DOI 10.1029/2009RG000302; Stephens GL, 2008, J CLIMATE, V21, P6141, DOI 10.1175/2008JCLI2144.1; Tokinaga H, 2011, NAT GEOSCI, V4, P222, DOI [10.1038/ngeo1078, 10.1038/NGEO1078]; Tokinaga H, 2011, J CLIMATE, V24, P267, DOI 10.1175/2010JCLI3789.1; Vecchi GA, 2006, NATURE, V441, P73, DOI 10.1038/nature04744; Vecchi GA, 2007, J CLIMATE, V20, P4316, DOI 10.1175/JCLI4258.1; Wentz FJ, 2007, SCIENCE, V317, P233, DOI 10.1126/science.1140746; Young IR, 2011, SCIENCE, V332, P451, DOI 10.1126/science.1197219; Yu LS, 2007, J CLIMATE, V20, P5376, DOI 10.1175/2007JCLI1714.1	15	25	25	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					905	905		10.1126/science.1210317	http://dx.doi.org/10.1126/science.1210317			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096173				2022-12-28	WOS:000297101800027
J	Kim, K; Choi, JY; Kim, T; Cho, SH; Chung, HJ				Kim, Kinam; Choi, Jae-Young; Kim, Taek; Cho, Seong-Ho; Chung, Hyun-Jong			A role for graphene in silicon-based semiconductor devices	NATURE			English	Review							LARGE-AREA; HIGH-QUALITY; ON-CHIP; TRANSISTORS; FREQUENCY; FILMS; PHOTODETECTORS; TRANSPARENT; PHOTONICS; MODULATOR	As silicon-based electronics approach the limit of improvements to performance and capacity through dimensional scaling, attention in the semiconductor field has turned to graphene, a single layer of carbon atoms arranged in a honeycomb lattice. Its high mobility of charge carriers (electrons and holes) could lead to its use in the next generation of high-performance devices. Graphene is unlikely to replace silicon completely, however, because of the poor on/off current ratio resulting from its zero bandgap. But it could be used to improve silicon-based devices, in particular in high-speed electronics and optical modulators.	[Kim, Kinam; Choi, Jae-Young; Kim, Taek; Cho, Seong-Ho; Chung, Hyun-Jong] Samsung Elect, SAIT, Yongin 446712, Gyeonggi Do, South Korea	Samsung	Kim, K (corresponding author), Samsung Elect, SAIT, Yongin 446712, Gyeonggi Do, South Korea.	kn_kim@samsung.com	Chung, Hyun-Jong/AAJ-7950-2021	Chung, Hyun-Jong/0000-0002-8840-6296				Adam S, 2007, P NATL ACAD SCI USA, V104, P18392, DOI 10.1073/pnas.0704772104; Assefa S, 2010, IEEE J SEL TOP QUANT, V16, P1376, DOI 10.1109/JSTQE.2010.2048306; Avouris Ph., 2010, INT EL DEV M, P552; Bae S, 2010, NAT NANOTECHNOL, V5, P574, DOI [10.1038/nnano.2010.132, 10.1038/NNANO.2010.132]; Bai JW, 2010, NAT NANOTECHNOL, V5, P190, DOI [10.1038/nnano.2010.8, 10.1038/NNANO.2010.8]; Benner A., 2011, OPT IND DEV ASS WORK; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Bolotin KI, 2008, SOLID STATE COMMUN, V146, P351, DOI 10.1016/j.ssc.2008.02.024; Bolotin KI, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.096802; Bonaccorso F, 2010, NAT PHOTONICS, V4, P611, DOI [10.1038/NPHOTON.2010.186, 10.1038/nphoton.2010.186]; Brenner K, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3308482; Casiraghi C, 2007, NANO LETT, V7, P2711, DOI 10.1021/nl071168m; Chen JH, 2008, NAT NANOTECHNOL, V3, P206, DOI 10.1038/nnano.2008.58; Chen ZH, 2007, PHYSICA E, V40, P228, DOI 10.1016/j.physe.2007.06.020; Dean CR, 2010, NAT NANOTECHNOL, V5, P722, DOI 10.1038/nnano.2010.172; Deshpande A, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.205411; Eigler S, 2009, CARBON, V47, P2936, DOI 10.1016/j.carbon.2009.06.047; Emtsev KV, 2009, NAT MATER, V8, P203, DOI [10.1038/NMAT2382, 10.1038/nmat2382]; Farmer DB, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3142865; Feng NN, 2011, OPT EXPRESS, V19, P7062, DOI 10.1364/OE.19.007062; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Giovannetti G, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.026803; Green WMJ, 2007, OPT EXPRESS, V15, P17106, DOI 10.1364/OE.15.017106; Grosse K. L., 2008, NATURE NANOTECHNOL, V6, P287; Han MY, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.206805; Heersche HB, 2007, NATURE, V446, P56, DOI 10.1038/nature05555; Hofrichter J, 2010, NANO LETT, V10, P36, DOI [10.1021/nl902558x, 10.1021/nl902558X]; Hwang EH, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.186806; Ishigami M, 2007, NANO LETT, V7, P1643, DOI 10.1021/nl070613a; Ishikawa Y, 2010, IEEE PHOTONICS J, V2, P306, DOI 10.1109/JPHOT.2010.2046026; Ismach A, 2010, NANO LETT, V10, P1542, DOI 10.1021/nl9037714; Jeon I, 2011, ACS NANO, V5, P1915, DOI 10.1021/nn102916c; Kim DH, 2008, IEEE ELECTR DEVICE L, V29, P830, DOI 10.1109/LED.2008.2000794; Kim K., 2010, IEDM, P1; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Kim M, 2010, NANO LETT, V10, P1125, DOI 10.1021/nl9032318; Lai R, 2007, INT EL DEVICES MEET, P609, DOI 10.1109/IEDM.2007.4419013; LEE J, 2010, IEDM, P568, DOI DOI 10.1109/IEDM.2010.5703422; Lee S., 2007, INT EL DEV M, P568; Lee Y, 2010, NANO LETT, V10, P490, DOI 10.1021/nl903272n; Levendorf MP, 2009, NANO LETT, V9, P4479, DOI 10.1021/nl902790r; Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Liang XG, 2010, NANO LETT, V10, P2454, DOI 10.1021/nl100750v; Liao L, 2007, ELECTRON LETT, V43, P1196, DOI 10.1049/el:20072253; Liao L, 2010, NANO LETT, V10, P3952, DOI 10.1021/nl101724k; Liao L, 2010, NATURE, V467, P305, DOI 10.1038/nature09405; Lin YM, 2010, SCIENCE, V327, P662, DOI 10.1126/science.1184289; Lin YM, 2011, SCIENCE, V332, P1294, DOI 10.1126/science.1204428; Liu M, 2011, NATURE, V474, P64, DOI 10.1038/nature10067; Liu Z, 2011, NANO LETT, V11, P2032, DOI 10.1021/nl200464j; Meric I, 2010, INT EL DEVICES MEET; Meric I, 2011, NANO LETT, V11, P1093, DOI 10.1021/nl103993z; Meric I, 2008, NAT NANOTECHNOL, V3, P654, DOI 10.1038/nnano.2008.268; Meyer JC, 2007, NATURE, V446, P60, DOI 10.1038/nature05545; Miller DAB, 2009, P IEEE, V97, P1166, DOI 10.1109/JPROC.2009.2014298; Mueller T, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.245430; Mueller T, 2010, NAT PHOTONICS, V4, P297, DOI 10.1038/NPHOTON.2010.40; Nagashio K, 2009, INT EL DEVICES MEET, P527; Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Palacios T, 2010, IEEE COMMUN MAG, V48, P122, DOI 10.1109/MCOM.2010.5473873; Park J, 2010, ADV MATER, V22, P4140, DOI 10.1002/adma.201000756; Park J, 2009, NANO LETT, V9, P1742, DOI 10.1021/nl8029493; Reed GT, 2010, NAT PHOTONICS, V4, P518, DOI [10.1038/nphoton.2010.179, 10.1038/NPHOTON.2010.179]; Reina A, 2009, NANO LETT, V9, P30, DOI 10.1021/nl801827v; Robinson JA, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3549183; Russo S, 2010, PHYSICA E, V42, P677, DOI 10.1016/j.physe.2009.11.080; Schwierz F, 2011, NATURE, V472, P41, DOI 10.1038/472041a; Shacham A, 2008, IEEE T COMPUT, V57, P1246, DOI 10.1109/TC.2008.78; Shi YM, 2010, NANO LETT, V10, P4134, DOI 10.1021/nl1023707; Singisetti U, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3013572; Song L, 2010, NANO LETT, V10, P3209, DOI 10.1021/nl1022139; Tang YB, 2011, OPT EXPRESS, V19, P5811, DOI 10.1364/OE.19.005811; Vivien L, 2009, OPT EXPRESS, V17, P6252, DOI 10.1364/OE.17.006252; Wang F, 2008, SCIENCE, V320, P206, DOI 10.1126/science.1152793; Wang H, 2009, IEEE ELECTR DEVICE L, V30, P547, DOI 10.1109/LED.2009.2016443; Watts MR, 2008, 2008 5TH IEEE INTERNATIONAL CONFERENCE ON GROUP IV PHOTONICS, P4, DOI 10.1109/GROUP4.2008.4638077; Xia FN, 2011, NAT NANOTECHNOL, V6, P179, DOI [10.1038/nnano.2011.6, 10.1038/NNANO.2011.6]; Xia FN, 2010, NANO LETT, V10, P715, DOI 10.1021/nl9039636; Xia FN, 2009, NAT NANOTECHNOL, V4, P839, DOI [10.1038/nnano.2009.292, 10.1038/NNANO.2009.292]; Xia FN, 2009, NANO LETT, V9, P1039, DOI 10.1021/nl8033812; Xu QF, 2007, OPT EXPRESS, V15, P430, DOI 10.1364/OE.15.000430; Xue JM, 2011, NAT MATER, V10, P282, DOI 10.1038/NMAT2968; Yin T, 2007, OPT EXPRESS, V15, P13965, DOI 10.1364/OE.15.013965; Zhang LC, 2011, NANO RES, V4, P315, DOI 10.1007/s12274-010-0086-5; Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235	90	577	605	13	759	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					338	344		10.1038/nature10680	http://dx.doi.org/10.1038/nature10680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094694				2022-12-28	WOS:000297059700034
J	Dyer, C				Dyer, Clare			MEDICAL REGULATION Ensuring quality in primary care	BRITISH MEDICAL JOURNAL			English	Editorial Material												claredyer@aol.com						Department of Health, 2006, GOOD DOCT SAF PAT PR; Esmail A, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6392; General Medical Council, STAT MED ED PRACT 20; *HC HLTH COMM, 6 HOUS COMM HLTH COM; King's Fund, 2011, IMPR QUAL CAR GEN PR; *SHIPM INQ, REP SHIPM INQ	6	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2011	343								d7315	10.1136/bmj.d7315	http://dx.doi.org/10.1136/bmj.d7315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854LU	22089739				2022-12-28	WOS:000297497000010
J	Calvert, M; Blazeby, J; Revicki, D; Moher, D; Brundage, M				Calvert, Melanie; Blazeby, Jane; Revicki, Dennis; Moher, David; Brundage, Michael			Reporting quality of life in clinical trials: a CONSORT extension	LANCET			English	Editorial Material									[Brundage, Michael] Queens Univ, Kingston, ON K7L, Canada; [Calvert, Melanie] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England; [Blazeby, Jane] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Revicki, Dennis] United BioSource Corp, Bethesda, MD USA; [Moher, David] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Moher, David] Univ Ottawa, Ottawa, ON, Canada	Queens University - Canada; University of Birmingham; University of Bristol; United Biosource Corporation; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Brundage, M (corresponding author), Queens Univ, Kingston, ON K7L, Canada.	consortqol@contacts.bham.ac.uk; michael.brundage@krcc.on.ca	Moher, David/I-3408-2019; Calvert, Melanie/F-7055-2011	Moher, David/0000-0003-2434-4206; Calvert, Melanie/0000-0002-1856-837X	MRC [G0800808] Funding Source: UKRI; Medical Research Council [G0800808] Funding Source: Medline; Medical Research Council [UD99999939] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Brundage M, 2005, J CLIN ONCOL, V23, P6949, DOI 10.1200/JCO.2005.12.514; Brundage M, 2011, QUAL LIFE RES, V20, P979, DOI 10.1007/s11136-011-9848-0; Brundage M, 2011, QUAL LIFE RES, V20, P653, DOI 10.1007/s11136-010-9793-3; *CONSORT, CONS STAT; Curran D, 1998, STAT MED, V17, P697, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<697::AID-SIM815>3.0.CO;2-Y; Efficace F, 2003, J CLIN ONCOL, V21, P3502, DOI 10.1200/JCO.2003.12.121; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989; *INT SOC QUAL LIF, MISS STAT; Lee CW, 2000, J CLIN EPIDEMIOL, V53, P451, DOI 10.1016/S0895-4356(99)00221-8; *MED RES COUNC, MRC HUBS TRIALS METH; Staquet M, 1996, QUAL LIFE RES, V5, P496, DOI 10.1007/BF00540022; *U LIV, COMET IN	12	32	31	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	2011	378	9804					1684	1685		10.1016/S0140-6736(11)61256-7	http://dx.doi.org/10.1016/S0140-6736(11)61256-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	846LB	22078674				2022-12-28	WOS:000296899800010
J	Sime, LC; Wolff, EW				Sime, Louise C.; Wolff, Eric W.			Antarctic accumulation seasonality	NATURE			English	Letter							ICE CORE; CLIMATE	The resemblance of the orbitally filtered isotope signal from the past 340 kyr in Antarctic ice cores to Northern Hemisphere summer insolation intensity has been used to suggest that the northern hemisphere may drive orbital-scale global climate changes(1). A recent Letter(2) by Laepple et al. suggests that, contrary to this interpretation, this semblance may instead be explained by weighting the orbitally controlled Antarctic seasonal insolation cycle with a static (present-day) estimate of the seasonal cycle of accumulation. We suggest, however, that both time variability in accumulation seasonality and alternative stable seasonality can markedly alter the weighted insolation signal. This indicates that, if the last 340 kyr of Antarctic accumulation has not always looked like the estimate of precipitation and accumulation seasonality made by Laepple et al.(2), this particular accumulation weighting explanation of the Antarctic orbital-scale isotopic signal might not be robust.	[Sime, Louise C.; Wolff, Eric W.] British Antarctic Survey, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Sime, LC (corresponding author), British Antarctic Survey, Cambridge CB3 0ET, England.	lsim@bas.ac.uk	Sime, Louise/F-8058-2012; Wolff, Eric W/D-7925-2014; Wolff, Eric/AAB-1097-2021; Sime, Louise/AAX-7730-2021	Sime, Louise/0000-0002-9093-7926; Wolff, Eric W/0000-0002-5914-8531; Wolff, Eric/0000-0002-5914-8531; Sime, Louise/0000-0002-9093-7926	Natural Environment Research Council [bas0100024] Funding Source: researchfish; NERC [bas0100024] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Jouzel J, 2007, SCIENCE, V317, P793, DOI 10.1126/science.1141038; Kawamura K, 2007, NATURE, V448, P912, DOI 10.1038/nature06015; Laepple T, 2011, NATURE, V471, P91, DOI 10.1038/nature09825; Parrenin F, 2007, CLIM PAST, V3, P485, DOI 10.5194/cp-3-485-2007; Paul A, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000783; PAUL A, 2003, BOULDER DATA CONTRIB; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Sime LC, 2009, NATURE, V462, P342, DOI 10.1038/nature08564; Sime LC, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010395	9	4	5	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					E1	E2		10.1038/nature10613	http://dx.doi.org/10.1038/nature10613			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071770				2022-12-28	WOS:000298030800001
J	Burrows, MT; Schoeman, DS; Buckley, LB; Moore, P; Poloczanska, ES; Brander, KM; Brown, C; Bruno, JF; Duarte, CM; Halpern, BS; Holding, J; Kappel, CV; Kiessling, W; O'Connor, MI; Pandolfi, JM; Parmesan, C; Schwing, FB; Sydeman, WJ; Richardson, AJ				Burrows, Michael T.; Schoeman, David S.; Buckley, Lauren B.; Moore, Pippa; Poloczanska, Elvira S.; Brander, Keith M.; Brown, Chris; Bruno, John F.; Duarte, Carlos M.; Halpern, Benjamin S.; Holding, Johnna; Kappel, Carrie V.; Kiessling, Wolfgang; O'Connor, Mary I.; Pandolfi, John M.; Parmesan, Camille; Schwing, Franklin B.; Sydeman, William J.; Richardson, Anthony J.			The Pace of Shifting Climate in Marine and Terrestrial Ecosystems	SCIENCE			English	Article							LONG-TERM CHANGES; RANGE SHIFTS; GLOBAL BIODIVERSITY; SCENARIOS; PATTERNS; IMPACTS; RATES	Climate change challenges organisms to adapt or move to track changes in environments in space and time. We used two measures of thermal shifts from analyses of global temperatures over the past 50 years to describe the pace of climate change that species should track: the velocity of climate change (geographic shifts of isotherms over time) and the shift in seasonal timing of temperatures. Both measures are higher in the ocean than on land at some latitudes, despite slower ocean warming. These indices give a complex mosaic of predicted range shifts and phenology changes that deviate from simple poleward migration and earlier springs or later falls. They also emphasize potential conservation concerns, because areas of high marine biodiversity often have greater velocities of climate change and seasonal shifts.	[Burrows, Michael T.] Scottish Assoc Marine Sci, Scottish Marine Inst, Dept Ecol, Oban PA37 1QA, Argyll, Scotland; [Schoeman, David S.] Univ Ulster, Environm Sci Res Inst, Sch Environm Sci, Coleraine BT52 1SA, Londonderry, North Ireland; [Schoeman, David S.] Nelson Mandela Metropolitan Univ, Dept Zool, ZA-6031 Port Elizabeth, South Africa; [Buckley, Lauren B.; Bruno, John F.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Moore, Pippa] Aberystwyth Univ, Inst Biol Environm & Rural Sci, Aberystwyth SY23 3DA, Dyfed, Wales; [Moore, Pippa] Edith Cowan Univ, Ctr Marine Ecosyst Res, Perth, WA 6027, Australia; [Poloczanska, Elvira S.; Brown, Chris; Richardson, Anthony J.] Commonwealth Sci & Ind Res Org Marine & Atmospher, Brisbane, Qld 4001, Australia; [Brander, Keith M.] Tech Univ Denmark, Natl Inst Aquat Resources, Charlottenlund, Denmark; [Brown, Chris; Richardson, Anthony J.] Univ Queensland, Sch Biol Sci, Brisbane, Qld 4072, Australia; [Duarte, Carlos M.] Univ Western Australia, Oceans Inst, Crawley, WA 6009, Australia; [Duarte, Carlos M.; Holding, Johnna] Univ Balearic Isl, Dept Global Change Res, Inst Mediterraneo Estudios Avanzados, Consejo Super Invest Cient, Esporles 07190, Spain; [Halpern, Benjamin S.; Kappel, Carrie V.] Univ Calif Santa Barbara, Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA; [Kiessling, Wolfgang] Humboldt Univ, Museum Nat Kunde, D-10115 Berlin, Germany; [O'Connor, Mary I.] Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; [O'Connor, Mary I.] Univ British Columbia, Biodivers Res Ctr, Vancouver, BC V6T 1Z4, Canada; [Pandolfi, John M.] Univ Queensland, Australian Res Council Ctr Excellence Coral Reef, Sch Biol Sci, Brisbane, Qld 4072, Australia; [Parmesan, Camille] Univ Texas Austin, Sect Integrat Biol, Austin, TX 78712 USA; [Schwing, Franklin B.] Fisheries Serv, SW Fisheries Sci Ctr, NOAA, Pacific Grove, CA 93950 USA; [Sydeman, William J.] Farallon Inst Adv Ecosyst Res, Petaluma, CA 94975 USA; [Richardson, Anthony J.] Univ Queensland, Sch Math & Phys, Ctr Applicat Nat Resource Math, St Lucia, Qld 4072, Australia	UHI Millennium Institute; Ulster University; Nelson Mandela University; University of North Carolina; University of North Carolina Chapel Hill; Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS); Edith Cowan University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Technical University of Denmark; University of Queensland; University of Western Australia; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat de les Illes Balears; National Center for Ecological Analysis & Synthesis; University of California System; University of California Santa Barbara; Humboldt University of Berlin; Leibniz Institut fur Evolutions und Biodiversitatsforschung; University of British Columbia; University of British Columbia; University of Queensland; University of Texas System; University of Texas Austin; National Oceanic Atmospheric Admin (NOAA) - USA; University of Queensland	Burrows, MT (corresponding author), Scottish Assoc Marine Sci, Scottish Marine Inst, Dept Ecol, Oban PA37 1QA, Argyll, Scotland.	michael.burrows@sams.ac.uk	Burrows, Michael T/D-9844-2013; Moore, Pippa/H-8079-2013; Hu, Lile/E-7961-2015; Duarte Quesada, Carlos Manuel/ABD-6208-2021; poloczanska, elvira/P-5356-2014; Brander, Keith/AAN-6278-2021; Duarte, Carlos M/A-7670-2013; Moore, Pippa/HCH-3738-2022; Kiessling, Wolfgang/E-2259-2015; Richardson, Anthony J/B-3649-2010; Burrows, Michael/ABF-4844-2020; Brown, Christopher J/G-4287-2011; Parmesan, Camille/GVT-5674-2022; Buckley, Lauren/ABD-6759-2021; O'Connor, Mary I/F-2275-2010; Poloczanska, Elvira/F-4366-2014; O'Connor, Mary/R-2933-2019; Pandolfi, John M/A-3121-2009	Burrows, Michael T/0000-0003-4620-5899; Moore, Pippa/0000-0002-9889-2216; Duarte, Carlos M/0000-0002-1213-1361; Kiessling, Wolfgang/0000-0002-1088-2014; Richardson, Anthony J/0000-0002-9289-7366; Burrows, Michael/0000-0003-4620-5899; Brown, Christopher J/0000-0002-7271-4091; Buckley, Lauren/0000-0003-1315-3818; O'Connor, Mary I/0000-0001-9583-1592; Pandolfi, John M/0000-0003-3047-6694; Parmesan, Camille/0000-0002-1515-274X; Schoeman, David/0000-0003-1258-0885; Brander, Keith/0000-0001-9927-9600; Holding, Johnna M/0000-0002-7364-0055; poloczanska, elvira/0000-0001-8470-0925	National Center for Ecological Analysis and Synthesis; NSF [EF-0553768]; University of California, Santa Barbara; State of California; UK Natural Environment Research Council; Australian Research Council [DP0879365]; Future Fellowship [FT0991722]; NERC [dml010004] Funding Source: UKRI; Natural Environment Research Council [dml010004] Funding Source: researchfish	National Center for Ecological Analysis and Synthesis; NSF(National Science Foundation (NSF)); University of California, Santa Barbara(University of California System); State of California; UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Australian Research Council(Australian Research Council); Future Fellowship(Australian Research Council); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was conducted as a part of the Towards Understanding Marine Biological Impacts of Climate Change Working Group supported by the National Center for Ecological Analysis and Synthesis, a Center funded by NSF (grant no. EF-0553768); the University of California, Santa Barbara; and the State of California. M.T.B. thanks the UK Natural Environment Research Council Oceans 2025 program, J.P. thanks the Australian Research Council Centre of Excellence for Coral Reef Studies for additional support, and A.J.R. was supported by the Australian Research Council Discovery Grant DP0879365 and Future Fellowship Grant FT0991722. Data used in analyses are available from the University of East Anglia Climate Research Unit and the UK Meteorological Office Hadley Centre, with online access at the British Atmospheric Data Centre.	Ackerly DD, 2010, DIVERS DISTRIB, V16, P476, DOI 10.1111/j.1472-4642.2010.00654.x; Chen IC, 2011, SCIENCE, V333, P1024, DOI 10.1126/science.1206432; Cheung WWL, 2009, FISH FISH, V10, P235, DOI 10.1111/j.1467-2979.2008.00315.x; Colwell RK, 2008, SCIENCE, V322, P258, DOI 10.1126/science.1162547; Dulvy NK, 2008, J APPL ECOL, V45, P1029, DOI 10.1111/j.1365-2664.2008.01488.x; Helmuth B, 2006, ECOL MONOGR, V76, P461, DOI 10.1890/0012-9615(2006)076[0461:MPOTSI]2.0.CO;2; Loarie SR, 2009, NATURE, V462, P1052, DOI 10.1038/nature08649; Mieszkowska N, 2007, J MAR BIOL ASSOC UK, V87, P537, DOI 10.1017/S0025315407053799; Nye JA, 2009, MAR ECOL PROG SER, V393, P111, DOI 10.3354/meps08220; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Parmesan C, 2007, GLOBAL CHANGE BIOL, V13, P1860, DOI 10.1111/j.1365-2486.2007.01404.x; Pereira HM, 2010, SCIENCE, V330, P1496, DOI 10.1126/science.1196624; Perry AL, 2005, SCIENCE, V308, P1912, DOI 10.1126/science.1111322; Puce S, 2009, MAR ECOL-EVOL PERSP, V30, P313, DOI 10.1111/j.1439-0485.2009.00283.x; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Sorte CJB, 2010, GLOBAL ECOL BIOGEOGR, V19, P303, DOI 10.1111/j.1466-8238.2009.00519.x; Thackeray SJ, 2010, GLOBAL CHANGE BIOL, V16, P3304, DOI 10.1111/j.1365-2486.2010.02165.x; Tittensor DP, 2010, NATURE, V466, P1098, DOI 10.1038/nature09329; Trenberth KE, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P235; Williams PH, 1997, P ROY SOC B-BIOL SCI, V264, P141, DOI 10.1098/rspb.1997.0021	21	857	873	20	756	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					652	655		10.1126/science.1210288	http://dx.doi.org/10.1126/science.1210288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053045				2022-12-28	WOS:000296494700050
J	Sallet, J; Mars, RB; Noonan, MP; Andersson, JL; O'Reilly, JX; Jbabdi, S; Croxson, PL; Jenkinson, M; Miller, KL; Rushworth, MFS				Sallet, J.; Mars, R. B.; Noonan, M. P.; Andersson, J. L.; O'Reilly, J. X.; Jbabdi, S.; Croxson, P. L.; Jenkinson, M.; Miller, K. L.; Rushworth, M. F. S.			Social Network Size Affects Neural Circuits in Macaques	SCIENCE			English	Article							PREFRONTAL CORTEX; TEMPORAL CORTEX; RHESUS-MONKEYS; BRAIN; FACES	It has been suggested that variation in brain structure correlates with the sizes of individuals' social networks. Whether variation in social network size causes variation in brain structure, however, is unknown. To address this question, we neuroimaged 23 monkeys that had been living in social groups set to different sizes. Subject comparison revealed that living in larger groups caused increases in gray matter in mid-superior temporal sulcus and rostral prefrontal cortex and increased coupling of activity in frontal and temporal cortex. Social network size, therefore, contributes to changes both in brain structure and function. The changes have potential implications for an animal's success in a social context; gray matter differences in similar areas were also correlated with each animal's dominance within its social network.	[Sallet, J.; Mars, R. B.; Noonan, M. P.; Croxson, P. L.; Rushworth, M. F. S.] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Sallet, J.; Mars, R. B.; Noonan, M. P.; Andersson, J. L.; O'Reilly, J. X.; Jbabdi, S.; Jenkinson, M.; Miller, K. L.; Rushworth, M. F. S.] Univ Oxford, Oxford Ctr Funct Magnet Resonance Imaging Brain F, Oxford OX1 3UD, England; [Croxson, P. L.] Mt Sinai Sch Med, Icahn Med Inst, New York, NY 10029 USA	University of Oxford; University of Oxford; Icahn School of Medicine at Mount Sinai	Sallet, J (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	jerome.sallet@psy.ox.ac.uk	, sallet/H-9761-2019; Mars, Rogier/G-2312-2018; Mars, Rogier/GWZ-9665-2022; Jenkinson, Mark/AAC-8861-2019; Jbabdi, Saad/A-2483-2012	, sallet/0000-0002-7878-0209; Mars, Rogier/0000-0001-6302-8631; Jenkinson, Mark/0000-0001-6043-0166; Croxson, Paula/0000-0002-4649-980X; Jbabdi, Saad/0000-0003-3234-5639; O'Reilly, Jill/0000-0002-6998-455X; Rushworth, Matthew/0000-0002-5578-9884; Miller, Karla/0000-0002-2511-3189	UK Medical Research Council; Wellcome Trust; MRC [G0902373, G0700399, G0800578, G0400593, G0802459] Funding Source: UKRI; Medical Research Council [G0800578, G0400593, G0902373, G0802459, G0700399] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funded by the UK Medical Research Council and Wellcome Trust (M.P.N., K. M.). We thank C. Bergmann and Biomedical services staff for their assistance and R. Dunbar for helpful discussion.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Barbas H, 1999, J COMP NEUROL, V410, P343, DOI 10.1002/(SICI)1096-9861(19990802)410:3<343::AID-CNE1>3.0.CO;2-1; Barton RA, 2007, J EVOLUTION BIOL, V20, P1504, DOI 10.1111/j.1420-9101.2007.01330.x; Behrens TEJ, 2008, NATURE, V456, P245, DOI 10.1038/nature07538; Behrens TEJ, 2009, SCIENCE, V324, P1160, DOI 10.1126/science.1169694; Bickart KC, 2011, NAT NEUROSCI, V14, P163, DOI 10.1038/nn.2724; Dunbar RIM, 2007, SCIENCE, V317, P1344, DOI 10.1126/science.1145463; Flombaum JI, 2005, CURR BIOL, V15, P447, DOI 10.1016/j.cub.2004.12.076; Frith CD, 2007, PHILOS T R SOC B, V362, P671, DOI 10.1098/rstb.2006.2003; Fujii N, 2009, SOC NEUROSCI-UK, V4, P73, DOI 10.1080/17470910802046230; Izquierdo A, 2005, J NEUROSCI, V25, P8534, DOI 10.1523/JNEUROSCI.1232-05.2005; Kikuchi Y, 2010, J NEUROSCI, V30, P13021, DOI 10.1523/JNEUROSCI.2267-10.2010; Lerch JP, 2011, NEUROIMAGE, V54, P2086, DOI 10.1016/j.neuroimage.2010.09.086; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; Mars RB, 2011, J NEUROSCI, V31, P4087, DOI 10.1523/JNEUROSCI.5102-10.2011; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; Petrides M, 2007, J NEUROSCI, V27, P11573, DOI 10.1523/JNEUROSCI.2419-07.2007; Pinsk MA, 2009, J NEUROPHYSIOL, V101, P2581, DOI 10.1152/jn.91198.2008; Quallo MM, 2009, P NATL ACAD SCI USA, V106, P18379, DOI 10.1073/pnas.0909751106; Rudebeck PH, 2006, SCIENCE, V313, P1310, DOI 10.1126/science.1128197; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Schulke O, 2010, CURR BIOL, V20, P2207, DOI 10.1016/j.cub.2010.10.058; Seo H, 2008, PHILOS T R SOC B, V363, P3845, DOI 10.1098/rstb.2008.0158; Tsao DY, 2008, P NATL ACAD SCI USA, V105, P19514, DOI 10.1073/pnas.0809662105; Tsujimoto S, 2011, TRENDS COGN SCI, V15, P169, DOI 10.1016/j.tics.2011.02.001; Zahn R, 2007, P NATL ACAD SCI USA, V104, P6430, DOI 10.1073/pnas.0607061104; ZUMPE D, 1986, AM J PRIMATOL, V10, P291, DOI 10.1002/ajp.1350100402	29	296	299	2	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					697	700		10.1126/science.1210027	http://dx.doi.org/10.1126/science.1210027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053054				2022-12-28	WOS:000296494700062
J	Koehl, WF; Buckley, BB; Heremans, FJ; Calusine, G; Awschalom, DD				Koehl, William F.; Buckley, Bob B.; Heremans, F. Joseph; Calusine, Greg; Awschalom, David D.			Room temperature coherent control of defect spin qubits in silicon carbide	NATURE			English	Article							DIAMOND; IDENTIFICATION; STATE	Electronic spins in semiconductors have been used extensively to explore the limits of external control over quantum mechanical phenomena(1). A long-standing goal of this research has been to identify or develop robust quantum systems that can be easily manipulated, for future use in advanced information and communication technologies(2). Recently, a point defect in diamond known as the nitrogen-vacancy centre has attracted a great deal of interest because it possesses an atomic-scale electronic spin state that can be used as an individually addressable, solid-state quantum bit (qubit), even at room temperature(3). These exceptional quantum properties have motivated efforts to identify similar defects in other semiconductors, as they may offer an expanded range of functionality not available to the diamond nitrogen-vacancy centre(4). Notably, several defects in silicon carbide (SiC) have been suggested as good candidates for exploration, owing to a combination of computational predictions and magnetic resonance data(4-10). Here we demonstrate that several defect spin states in the 4H polytype of SiC (4H-SiC) can be optically addressed and coherently controlled in the time domain at temperatures ranging from 20 to 300 kelvin. Using optical and microwave techniques similar to those used with diamond nitrogen-vacancy qubits, we study the spin-1 ground state of each of four inequivalent forms of the neutral carbon-silicon divacancy, as well as a pair of defect spin states of unidentified origin. These defects are optically active near telecommunication wavelengths(11), and are found in a host material for which there already exist industrial-scale crystal growth(12) and advanced microfabrication techniques(13). In addition, they possess desirable spin coherence properties that are comparable to those of the diamond nitrogen-vacancy centre. This makes them promising candidates for various photonic, spintronic and quantum information applications that merge quantum degrees of freedom with classical electronic and optical technologies(2,14-17).	[Koehl, William F.; Buckley, Bob B.; Heremans, F. Joseph; Calusine, Greg; Awschalom, David D.] Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA.	awsch@physics.ucsb.edu	Heremans, F. Joseph/D-5555-2009		Air Force Office of Scientific Research (AFOSR); Defense Advanced Research Projects Agency (DARPA)	Air Force Office of Scientific Research (AFOSR)(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA))	We are grateful to G. D. Fuchs, A. Janotti, D. M. Toyli, C. G. Van de Walle, J. B. Varley and J. R. Weber for discussions. We thank M. E. Nowakowski for help with sample preparation. This work was supported by the Air Force Office of Scientific Research (AFOSR) and the Defense Advanced Research Projects Agency (DARPA).	Awschalom DD, 2007, NAT PHYS, V3, P153, DOI 10.1038/nphys551; Balasubramanian G, 2008, NATURE, V455, P648, DOI 10.1038/nature07278; Baranov PG, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.125203; Baranov PG, 2005, JETP LETT+, V82, P441, DOI 10.1134/1.2142873; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Carlos WE, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.235201; Carlos WE, 2003, PHYSICA B, V340, P151, DOI 10.1016/j.physb.2003.09.048; Cheung R., 2004, SILICON CARBIDE MICR; de Lange G, 2010, SCIENCE, V330, P60, DOI 10.1126/science.1192739; Gali A, 2011, PHYS STATUS SOLIDI B, V248, P1337, DOI 10.1002/pssb.201046254; Hanson R, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.161203; Hanson R, 2008, NATURE, V453, P1043, DOI 10.1038/nature07129; Jelezko F, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.076401; Ladd TD, 2010, NATURE, V464, P45, DOI 10.1038/nature08812; Liu L, 2002, MAT SCI ENG R, V37, P61, DOI 10.1016/S0927-796X(02)00008-6; Magnusson B, 2005, MATER SCI FORUM, V483, P341, DOI 10.4028/www.scientific.net/MSF.483-485.341; Maze JR, 2008, NATURE, V455, P644, DOI 10.1038/nature07279; Mizuochi N, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.235202; O'Brien JL, 2009, NAT PHOTONICS, V3, P687, DOI 10.1038/nphoton.2009.229; Powell A., 2006, INT J HIGH SPEED ELE, V16, P751; Ryu SH, 1998, IEEE T ELECTRON DEV, V45, P45, DOI 10.1109/16.658810; Saddow S.E., 2004, ADV SILICON CARBIDE; SALEH BEA, 1991, FUNDAMENTALS PHOTONI, pCH22; Son NT, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.205211; Son NT, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.055501; Son NT, 2006, PHYSICA B, V376, P334, DOI 10.1016/j.physb.2005.12.086; Stanwix PL, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.201201; VANOORT E, 1990, CHEM PHYS, V143, P131, DOI 10.1016/0301-0104(90)85013-M; Weber JR, 2010, P NATL ACAD SCI USA, V107, P8513, DOI 10.1073/pnas.1003052107; Zetterling C. M., 2002, PROCESS TECHNOLOGY S	30	506	519	8	289	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					84	U108		10.1038/nature10562	http://dx.doi.org/10.1038/nature10562			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051676				2022-12-28	WOS:000296422600036
J	Loo, VG; Bourgault, AM; Poirier, L; Lamothe, F; Michaud, S; Turgeon, N; Toye, B; Beaudoin, A; Frost, EH; Gilca, R; Brassard, P; Dendukuri, N; Beliveau, C; Oughton, M; Brukner, I; Dascal, A				Loo, Vivian G.; Bourgault, Anne-Marie; Poirier, Louise; Lamothe, Francois; Michaud, Sophie; Turgeon, Nathalie; Toye, Baldwin; Beaudoin, Axelle; Frost, Eric H.; Gilca, Rodica; Brassard, Paul; Dendukuri, Nandini; Beliveau, Claire; Oughton, Matthew; Brukner, Ivan; Dascal, Andre			Host and Pathogen Factors for Clostridium difficile Infection and Colonization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOXIN-A; ANTIBODY; RISK; STRAIN; CARRIAGE; LOCUS	Background Clostridium difficile infection is the leading cause of health care-associated diarrhea, and the bacterium can also be carried asymptomatically. The objective of this study was to identify host and bacterial factors associated with health care-associated acquisition of C. difficile infection and colonization. Methods We conducted a 15-month prospective study in six Canadian hospitals in Quebec and Ontario. Demographic information, known risk factors, potential confounding factors, and weekly stool samples or rectal swabs were collected. Pulsed-field gel electrophoresis (PFGE) was performed on C. difficile isolates to determine the genotype. Levels of serum antibodies against C. difficile toxins A and B were measured. Results A total of 4143 patients were included in the study; 117 (2.8%) and 123 (3.0%) had health care-associated C. difficile infection and colonization, respectively. Older age and use of antibiotics and proton-pump inhibitors were significantly associated with health care-associated C. difficile infection. Hospitalization in the previous 2 months; use of chemotherapy, proton-pump inhibitors, and H-2 blockers; and antibodies against toxin B were associated with health care-associated C. difficile colonization. Among patients with health care-associated C. difficile infection and those with colonization, 62.7% and 36.1%, respectively, had the North American PFGE type 1 (NAP1) strain. Conclusions In this study, health care-associated C. difficile infection and colonization were differentially associated with defined host and pathogen variables. The NAP1 strain was predominant among patients with C. difficile infection, whereas asymptomatic patients were more likely to be colonized with other strains. (Funded by the Consortium de Recherche sur le Clostridium difficile.)	[Loo, Vivian G.] McGill Univ, Ctr Hlth, Dept Microbiol, Montreal, PQ H3A 1A1, Canada; [Bourgault, Anne-Marie; Lamothe, Francois] Univ Montreal, Ctr Hosp, Montreal, PQ H3C 3J7, Canada; [Poirier, Louise; Beliveau, Claire] Univ Montreal, Hop Maison Neuve Rosemont, Montreal, PQ H3C 3J7, Canada; [Bourgault, Anne-Marie] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada; [Michaud, Sophie; Beaudoin, Axelle; Frost, Eric H.] Univ Sherbrooke, Ctr Hosp Univ CHU Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada; [Gilca, Rodica] Univ Laval, CHU Quebec Hotel Dieu Quebec, Quebec City, PQ, Canada; [Gilca, Rodica] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada; [Toye, Baldwin] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada	McGill University; Universite de Montreal; Universite de Montreal; Institut national de sante publique du Quebec (INSPQ); University of Sherbrooke; Laval University; Institut national de sante publique du Quebec (INSPQ); University of Ottawa; Ottawa Hospital Research Institute	Loo, VG (corresponding author), McGill Univ, Ctr Hlth, Dept Microbiol, 687 Pine Ave W,Rm L5-06, Montreal, PQ H3A 1A1, Canada.		Brassard, Paul/F-4079-2018; Brukner, Ivan/AAU-7504-2021; Brukner, Ivan/N-5833-2019	Brukner, Ivan/0000-0003-0225-9238; Frost, Eric/0000-0001-8958-4388	Consortium de Recherche sur le Clostridium difficile; Fonds de la Recherche en Sante du Quebec; Canadian Institutes of Health Research; Ministere de la Sante et des Services Sociaux du Quebec; Institut National de Sante Publique du Quebec; Health Canada; Centre Hospitalier de l'Universite de Montreal; McGill University Health Centre; CHU de Quebec; CHU de Sherbrooke; Merck; Pfizer Canada; Cubist Pharmaceuticals; Genome Canada	Consortium de Recherche sur le Clostridium difficile; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ministere de la Sante et des Services Sociaux du Quebec; Institut National de Sante Publique du Quebec; Health Canada; Centre Hospitalier de l'Universite de Montreal; McGill University Health Centre; CHU de Quebec; CHU de Sherbrooke; Merck(Merck & Company); Pfizer Canada(Pfizer); Cubist Pharmaceuticals; Genome Canada(Genome Canada)	Supported by the Consortium de Recherche sur le Clostridium difficile; the consortium consists of the following partners: Fonds de la Recherche en Sante du Quebec, Canadian Institutes of Health Research, Ministere de la Sante et des Services Sociaux du Quebec, Institut National de Sante Publique du Quebec, Health Canada, Centre Hospitalier de l'Universite de Montreal, McGill University Health Centre, CHU de Quebec, and CHU de Sherbrooke.; Dr. Loo reports receiving consulting fees from Merck; Dr. Turgeon, receiving lecture fees from Merck; Dr. Toye, receiving lecture fees from Pfizer Canada and owning stock in Spartan Biosciences; Dr. Oughton, receiving consulting fees from Cubist Pharmaceuticals; and Dr. Dascal, receiving grant support from and owning stock in Cepheid and receiving grant support from Genome Canada. No other potential conflict of interest relevant to this article was reported.	Alfa MJ, 2000, J CLIN MICROBIOL, V38, P2706, DOI 10.1128/JCM.38.7.2706-2714.2000; Barbut F, 1996, ARCH INTERN MED, V156, P1449, DOI 10.1001/archinte.156.13.1449; Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Bignardi GE, 1998, J HOSP INFECT, V40, P1, DOI 10.1016/S0195-6701(98)90019-6; Braun V, 1996, GENE, V181, P29, DOI 10.1016/S0378-1119(96)00398-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLABOTS CR, 1989, J CLIN MICROBIOL, V27, P2386, DOI 10.1128/JCM.27.10.2386-2387.1989; Cohen SH, 2000, J INFECT DIS, V181, P659, DOI 10.1086/315248; Dial S, 2004, CAN MED ASSOC J, V171, P33, DOI 10.1503/cmaj.1040876; Drudy D, 2007, INT J INFECT DIS, V11, P5, DOI 10.1016/j.ijid.2006.04.003; HAMMOND GA, 1995, MICROB PATHOGENESIS, V19, P203, DOI 10.1016/S0882-4010(95)90263-5; Howell MD, 2010, ARCH INTERN MED, V170, P784, DOI 10.1001/archinternmed.2010.89; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; JOHNSON S, 1992, J INFECT DIS, V166, P1287, DOI 10.1093/infdis/166.6.1287; Johnson S, 1998, CLIN INFECT DIS, V26, P1027, DOI 10.1086/520276; Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078-0432.CCR-06-1210; Kyne L, 2000, NEW ENGL J MED, V342, P390, DOI 10.1056/NEJM200002103420604; Leav BA, 2010, VACCINE, V28, P965, DOI 10.1016/j.vaccine.2009.10.144; Letourneur O, 2003, PROTEIN EXPRES PURIF, V31, P276, DOI 10.1016/S1046-5928(03)00165-7; Loo VG, 2006, NEW ENGL J MED, V354, P2200; Lyras D, 2009, NATURE, V458, P1176, DOI 10.1038/nature07822; Martin H, 2008, J CLIN MICROBIOL, V46, P2999, DOI 10.1128/JCM.02437-07; McDonald LC, 2005, INFECT CONT HOSP EP, V26, P672; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; Merrigan MM, 2009, INT J ANTIMICROB AG, V33, pS46, DOI 10.1016/S0924-8579(09)70017-2; Miller M, 2010, CLIN INFECT DIS, V50, P194, DOI 10.1086/649213; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; Shim JK, 1998, LANCET, V351, P633, DOI 10.1016/S0140-6736(97)08062-8; Tan KS, 2001, J MED MICROBIOL, V50, P613, DOI 10.1099/0022-1317-50-7-613; Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X; WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994	31	584	624	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1693	1703		10.1056/NEJMoa1012413	http://dx.doi.org/10.1056/NEJMoa1012413			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047560				2022-12-28	WOS:000296424200008
J	Beronja, S; Fuchs, E				Beronja, Slobodan; Fuchs, Elaine			A Breath of Fresh Air in Lung Regeneration	CELL			English	Editorial Material							BASAL-CELLS; STEM-CELLS; EPITHELIUM	Enhancing the ability of the lungs to regenerate following injury could revolutionize the treatment of a wide range of different diseases. In this issue, Kumar et al. (2011) and Ding et al. (2011) dissect the cellular and molecular mechanisms of murine lung regeneration following injury and provide insights into the basic biology of the organ with implications for development of future therapeutic approaches.	[Beronja, Slobodan; Fuchs, Elaine] Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10065 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10065 USA.	fuchslb@rockefeller.edu	Fuchs, Elaine/G-1565-2016	Beronja, Slobodan/0000-0002-6769-9261	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR027883-28, R37 AR027883, R01 AR027883-29, R37 AR027883-30] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ding BS, 2011, CELL, V147, P539, DOI 10.1016/j.cell.2011.10.003; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Nolen-Walston RD, 2008, AM J PHYSIOL-LUNG C, V294, pL1158, DOI 10.1152/ajplung.00298.2007; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; White AC, 2007, DEVELOPMENT, V134, P3743, DOI 10.1242/dev.004879; Yamamoto H, 2007, DEV BIOL, V308, P44, DOI 10.1016/j.ydbio.2007.04.042	10	3	3	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					481	483		10.1016/j.cell.2011.10.008	http://dx.doi.org/10.1016/j.cell.2011.10.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036554	Bronze, Green Accepted			2022-12-28	WOS:000296573700001
J	Riquelme, CA; Magida, JA; Harrison, BC; Wall, CE; Marr, TG; Secor, SM; Leinwand, LA				Riquelme, Cecilia A.; Magida, Jason A.; Harrison, Brooke C.; Wall, Christopher E.; Marr, Thomas G.; Secor, Stephen M.; Leinwand, Leslie A.			Fatty Acids Identified in the Burmese Python Promote Beneficial Cardiac Growth	SCIENCE			English	Article							GENE-EXPRESSION; MYOCYTES; HYPERTROPHY; MOLURUS; PERFORMANCE; METABOLISM; APOPTOSIS; TISSUE; HEART; MODEL	Burmese pythons display a marked increase in heart mass after a large meal. We investigated the molecular mechanisms of this physiological heart growth with the goal of applying this knowledge to the mammalian heart. We found that heart growth in pythons is characterized by myocyte hypertrophy in the absence of cell proliferation and by activation of physiological signal transduction pathways. Despite high levels of circulating lipids, the postprandial python heart does not accumulate triglycerides or fatty acids. Instead, there is robust activation of pathways of fatty acid transport and oxidation combined with increased expression and activity of superoxide dismutase, a cardioprotective enzyme. We also identified a combination of fatty acids in python plasma that promotes physiological heart growth when injected into either pythons or mice.	[Riquelme, Cecilia A.; Magida, Jason A.; Harrison, Brooke C.; Wall, Christopher E.; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; [Marr, Thomas G.] Hiberna Corp, Boulder, CO 80302 USA; [Secor, Stephen M.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA	University of Colorado System; University of Colorado Boulder; University of Alabama System; University of Alabama Tuscaloosa	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	leslie.leinwand@colorado.edu		LEINWAND, LESLIE/0000-0003-1470-4810	NIH [HL050560, 5K01AR055676]; NSF [IOS-0466139]; University of Colorado Technology Transfer Office/State of Colorado [OCG4999B]; Hiberna Corporation; American Heart Association [0725732Z]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050560, R37HL050560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR055676] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); University of Colorado Technology Transfer Office/State of Colorado; Hiberna Corporation; American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by NIH grant HL050560 (L. A. L.), NSF grant IOS-0466139 (S. M. S.), University of Colorado Technology Transfer Office/State of Colorado grant OCG4999B (L. A. L. and T. G. M.), Hiberna Corporation (T. G. M. and S. M. S.), American Heart Association fellowship 0725732Z (C. A. R.), and NIH grant 5K01AR055676 (B. C. H.). L. A. L., T. G. M., and B. C. H. are on the scientific advisory board of, and are shareholders in, Hiberna Corporation, a company that is developing drugs based on natural models of extreme metabolic regulation. C. A. R. is a shareholder in Hiberna Corporation. The authors (L. A. L., C. A. R., J.A.M., B. C. H.) and the University of Colorado have filed a patent relating to methods and compositions for inducing physiological cardiac hypertrophy. We thank S. Cozza and T. Gleason for their technical assistance.	Andersen JB, 2005, NATURE, V434, P37, DOI 10.1038/434037a; Astarita G, 2006, AM J PHYSIOL-REG I, V290, pR1407, DOI 10.1152/ajpregu.00664.2005; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Coort SLM, 2002, MOL CELL BIOCHEM, V239, P213, DOI 10.1023/A:1020539932353; deVries JE, 1997, J LIPID RES, V38, P1384; Diwan A, 2008, CIRCULATION, V117, P396, DOI 10.1161/CIRCULATIONAHA.107.727073; Fagard RH, 2001, CIRCULATION, V103, pE28; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636-10649.2004; Hickson-Bick DLM, 2000, J MOL CELL CARDIOL, V32, P511, DOI 10.1006/jmcc.1999.1098; Khan RS, 2010, CURR OPIN CLIN NUTR, V13, P145, DOI 10.1097/MCO.0b013e3283357272; Konhilas JP, 2006, CIRC RES, V98, P540, DOI 10.1161/01.RES.0000205766.97556.00; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Rossi AC, 2010, J PHYSIOL-LONDON, V588, P353, DOI 10.1113/jphysiol.2009.181008; Secor SM, 1997, PHYSIOL ZOOL, V70, P202, DOI 10.1086/639578; SECOR SM, 1995, J EXP BIOL, V198, P1313; Secor SM, 1998, NATURE, V395, P659, DOI 10.1038/27131; Secor SM, 2010, J EXP BIOL, V213, P78, DOI 10.1242/jeb.034058; Secor SM, 2008, J EXP BIOL, V211, P3767, DOI 10.1242/jeb.023754; Shimizu T, 2010, GERIATR GERONTOL INT, V10, pS70, DOI 10.1111/j.1447-0594.2010.00604.x; Sparagna GC, 2001, ANTIOXID REDOX SIGN, V3, P71, DOI 10.1089/152308601750100524; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Wall CE, 2011, PHYSIOL GENOMICS, V43, P69, DOI 10.1152/physiolgenomics.00162.2010	25	87	89	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2011	334	6055					528	531		10.1126/science.1210558	http://dx.doi.org/10.1126/science.1210558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034436	Green Accepted			2022-12-28	WOS:000296230500051
J	Muhlebach, MD; Mateo, M; Sinn, PL; Prufer, S; Uhlig, KM; Leonard, VHJ; Navaratnarajah, CK; Frenzke, M; Wong, XX; Sawatsky, B; Ramachandran, S; McCray, PB; Cichutek, K; von Messling, V; Lopez, M; Cattaneo, R				Muhlebach, Michael D.; Mateo, Mathieu; Sinn, Patrick L.; Pruefer, Steffen; Uhlig, Katharina M.; Leonard, Vincent H. J.; Navaratnarajah, Chanakha K.; Frenzke, Marie; Wong, Xiao X.; Sawatsky, Bevan; Ramachandran, Shyam; McCray, Paul B., Jr.; Cichutek, Klaus; von Messling, Veronika; Lopez, Marc; Cattaneo, Roberto			Adherens junction protein nectin-4 is the epithelial receptor for measles virus	NATURE			English	Article							ACTIVATION MOLECULE SLAM; CELLULAR RECEPTOR; V-DOMAIN; INFECTION; CELLS; MEMBER; BLIND	Measles virus is an aerosol-transmitted virus that affects more than 10 million children each year and accounts for approximately 120,000 deaths(1,2). Although it was long believed to replicate in the respiratory epithelium before disseminating, it was recently shown to infect initially macrophages and dendritic cells of the airways using signalling lymphocytic activation molecule family member 1 (SLAMF1; also called CD150) as a receptor(3-6). These cells then cross the respiratory epithelium and transport the infection to lymphatic organs where measles virus replicates vigorously(7). How and where the virus crosses back into the airways has remained unknown. On the basis of functional analyses of surface proteins preferentially expressed on virus-permissive human epithelial cell lines, here we identify nectin-4 (ref. 8; also called poliovirus-receptor-like-4 (PVRL4)) as a candidate host exit receptor. This adherens junction protein of the immunoglobulin superfamily interacts with the viral attachment protein with high affinity through its membrane-distal domain. Nectin-4 sustains measles virus entry and non-cytopathic lateral spread in well-differentiated primary human airway epithelial sheets infected basolaterally. It is downregulated in infected epithelial cells, including those of macaque tracheae. Although other viruses use receptors to enter hosts or transit through their epithelial barriers, we suggest that measles virus targets nectin-4 to emerge in the airways. Nectin-4 is a cellular marker of several types of cancer(9-11), which has implications for ongoing measles-virus-based clinical trials of oncolysis(12).	[Mateo, Mathieu; Leonard, Vincent H. J.; Navaratnarajah, Chanakha K.; Frenzke, Marie; Cattaneo, Roberto] Mayo Clin, Dept Mol Med, Rochester, MN 55902 USA; [Muhlebach, Michael D.; Pruefer, Steffen; Uhlig, Katharina M.; Cichutek, Klaus] Paul Ehrlich Inst, Div Med Biotechnol, D-63225 Langen, Germany; [Sinn, Patrick L.; Ramachandran, Shyam; McCray, Paul B., Jr.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA; [Wong, Xiao X.; Sawatsky, Bevan; von Messling, Veronika] Univ Quebec, INRS, Laval, PQ H7V 1B7, Canada; [Wong, Xiao X.; Sawatsky, Bevan; von Messling, Veronika] Univ Quebec, Inst Armand Frappier, Laval, PQ H7V 1B7, Canada; [von Messling, Veronika] Duke Univ, Singapore 169857, Singapore; [von Messling, Veronika] Natl Univ Singapore, Singapore 169857, Singapore; [Lopez, Marc] CRCM, INSERM, UMR891, F-13009 Marseille, France; [Lopez, Marc] Univ Aix Marseille, F-13009 Marseille, France	Mayo Clinic; Paul Ehrlich Institute; University of Iowa; University of Quebec; Institut national de la recherche scientifique (INRS); University of Quebec; National University of Singapore; National University of Singapore; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Cattaneo, R (corresponding author), Mayo Clin, Dept Mol Med, Rochester, MN 55902 USA.	Cattaneo.Roberto@mayo.edu	Sinn, Patrick/M-8026-2018; Navaratnarajah, Chanakha/AAB-6171-2019	Sinn, Patrick/0000-0002-9746-966X; Navaratnarajah, Chanakha/0000-0002-4513-8412; Sawatsky, Bevan/0000-0001-6908-1556; MATEO, Mathieu/0000-0001-7941-0245; Muehlebach, Michael/0000-0002-7069-5018; McCray, Paul/0000-0002-4067-577X	BMG [2510-FSB-705]; NIH [R01 AI063476, R01 CA090636]; Roy J. Carver Charitable Trust; Cell Culture Core and Cell Morphology Cores; Center for Gene Therapy for Cystic Fibrosis [NIH P30 DK-54759]; Cystic Fibrosis Foundation; CIHR [MOP-66989, CFI 9488]; INSERM; Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer; NATIONAL CANCER INSTITUTE [R01CA090636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER	BMG; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roy J. Carver Charitable Trust; Cell Culture Core and Cell Morphology Cores; Center for Gene Therapy for Cystic Fibrosis; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); CIHR(Canadian Institutes of Health Research (CIHR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank J. Bruning, A. Schnoor Cancio, A. Peterson, I. Meunier and C. Thibault for technical assistance; Y. Yanagi for Vero-hSLAM cells and p(+)MV323-EGFP; T. Stehle for soluble SLAMF1; J. Fournier and G. Kobinger for facilitating the macaque studies; and R. Konig, D. Schilling-Leiss and T. Miest for discussions. This paper is dedicated to Heinz Schaller by one of his students. This work was supported by grants BMG 2510-FSB-705 to M. D. M.; NIH R01 AI063476 and NIH R01 CA090636 to R. C.; the Roy J. Carver Charitable Trust, Cell Culture Core and Cell Morphology Cores, partially supported by the Center for Gene Therapy for Cystic Fibrosis (NIH P30 DK-54759), and the Cystic Fibrosis Foundation to P. B. M.; and CIHR MOP-66989 and CFI 9488 to V. v. M.; INSERM, Institut Paoli-Calmettes and the Ligue Nationale Contre le Cancer (label 2009-11) to M. L. X. X. W. was supported by a CIHR Master's Award.	[Anonymous], 2011, Nature, V473, P434, DOI 10.1038/473434a; Bergelson JM, 2009, CELL HOST MICROBE, V5, P517, DOI 10.1016/j.chom.2009.05.009; Brancati F, 2010, AM J HUM GENET, V87, P265, DOI 10.1016/j.ajhg.2010.07.003; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cattaneo R, 2008, NAT REV MICROBIOL, V6, P529, DOI 10.1038/nrmicro1927; Chen SY, 2011, J INFECT DIS, V203, P1517, DOI 10.1093/infdis/jir115; de Swart RL, 2007, PLOS PATHOG, V3, P1771, DOI 10.1371/journal.ppat.0030178; DeRycke MS, 2010, AM J CLIN PATHOL, V134, P835, DOI 10.1309/AJCPGXK0FR4MHIHB; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fabre-Lafay S, 2005, J BIOL CHEM, V280, P19543, DOI 10.1074/jbc.M410943200; Ferreira CSA, 2010, J VIROL, V84, P3033, DOI 10.1128/JVI.01559-09; Galanis E, 2010, CANCER RES, V70, P875, DOI 10.1158/0008-5472.CAN-09-2762; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Lemon K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001263; Leonard VHJ, 2008, J CLIN INVEST, V118, P2448, DOI 10.1172/JCI35454; Leonard VHJ, 2010, J VIROL, V84, P3413, DOI 10.1128/JVI.02304-09; Ludlow M, 2010, J GEN VIROL, V91, P971, DOI 10.1099/vir.0.016428-0; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Monto AS, 1999, CLIN INFECT DIS, V28, P200, DOI 10.1086/515113; Navaratnarajah CK, 2008, J BIOL CHEM, V283, P11763, DOI 10.1074/jbc.M800896200; Noyce RS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002240; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Tahara M, 2008, J VIROL, V82, P4630, DOI 10.1128/JVI.02691-07; Takano A, 2009, CANCER RES, V69, P6694, DOI 10.1158/0008-5472.CAN-09-0016; Takeda M, 2000, J VIROL, V74, P6643, DOI 10.1128/JVI.74.14.6643-6647.2000; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; WELSHMAN MD, 1989, VET REC, V124, P184, DOI 10.1136/vr.124.8.184	30	392	409	3	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					530	U153		10.1038/nature10639	http://dx.doi.org/10.1038/nature10639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22048310	Green Accepted			2022-12-28	WOS:000298318000062
J	Burn, J; Gerdes, AM; Macrae, F; Mecklin, JP; Moeslein, G; Olschwang, S; Eccles, D; Evans, DG; Maher, ER; Bertario, L; Bisgaard, ML; Dunlop, MG; Ho, JWC; Hodgson, SV; Lindblom, A; Lubinski, J; Morrison, PJ; Murday, V; Ramesar, R; Side, L; Scott, RJ; Thomas, HJW; Vasen, HF; Barker, G; Crawford, G; Elliott, F; Movahedi, M; Pylvanainen, K; Wijnen, JT; Fodde, R; Lynch, HT; Mathers, JC; Bishop, DT				Burn, John; Gerdes, Anne-Marie; Macrae, Finlay; Mecklin, Jukka-Pekka; Moeslein, Gabriela; Olschwang, Sylviane; Eccles, Diane; Evans, D. Gareth; Maher, Eamonn R.; Bertario, Lucio; Bisgaard, Marie-Luise; Dunlop, Malcolm G.; Ho, Judy W. C.; Hodgson, Shirley V.; Lindblom, Annika; Lubinski, Jan; Morrison, Patrick J.; Murday, Victoria; Ramesar, Raj; Side, Lucy; Scott, Rodney J.; Thomas, Huw J. W.; Vasen, Hans F.; Barker, Gail; Crawford, Gillian; Elliott, Faye; Movahedi, Mohammad; Pylvanainen, Kirsi; Wijnen, Juul T.; Fodde, Riccardo; Lynch, Henry T.; Mathers, John C.; Bishop, D. Timothy		CAPP2 Investigators	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial	LANCET			English	Article							LYNCH-SYNDROME; RESISTANT STARCH; PREVENTION; ADENOMAS; INCREASE	Background Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo. Methods In the CAPP2 randomised trial, carriers of Lynch syndrome were randomly assigned in a two-by-two factorial design to 600 mg aspirin or aspirin placebo or 30 g resistant starch or starch placebo, for up to 4 years. Randomisation was in blocks of 16 with provision for optional single-agent randomisation and extended postintervention double-blind follow-up; participants and investigators were masked to treatment allocation. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. This trial is registered, ISRCTN59521990. Results 861 participants were randomly assigned to aspirin or aspirin placebo. At a mean follow-up of 55.7 months, 48 participants had developed 53 primary colorectal cancers (18 of 427 randomly assigned to aspirin, 30 of 434 to aspirin placebo). Intention-to-treat analysis of time to first colorectal cancer showed a hazard ratio (HR) of 0.63 (95% CI 0.35-1.13, p=0.12). Poisson regression taking account of multiple primary events gave an incidence rate ratio (IRR) of 0.56 (95% CI 0.32-0.99, p=0.05). For participants completing 2 years of intervention (258 aspirin, 250 aspirin placebo), per-protocol analysis yielded an HR of 0.41 (0.19-0.86, p=0.02) and an IRR of 0.37 (0.18-0.78, p=0.008). No data for adverse events were available postintervention; during the intervention, adverse events did not differ between aspirin and placebo groups. Interpretation 600 mg aspirin per day for a mean of 25 months substantially reduced cancer incidence after 55.7 months in carriers of hereditary colorectal cancer. Further studies are needed to establish the optimum dose and duration of aspirin treatment.	[Burn, John] Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Gerdes, Anne-Marie] Rigshosp, DK-2100 Copenhagen, Denmark; [Macrae, Finlay] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Mecklin, Jukka-Pekka; Pylvanainen, Kirsi] Univ Eastern Finland, Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; [Moeslein, Gabriela] St Josefs Hosp, Bochum, Germany; [Olschwang, Sylviane] Inst Paoli Calmettes, Dept Oncol Genet, Marseille, France; [Eccles, Diane; Crawford, Gillian] Princess Anne Hosp, Clin Genet Unit, Southampton, Hants, England; [Evans, D. Gareth] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; [Maher, Eamonn R.] Univ Birmingham, Birmingham, W Midlands, England; [Bertario, Lucio] Ist Nazl Studio & Cura Tumori, Milan, Italy; [Bisgaard, Marie-Luise] Univ Copenhagen, Med Genet Clin, ICMM, Hvidovre, Denmark; [Dunlop, Malcolm G.] Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Ho, Judy W. C.] Queen Mary Hosp, Dept Surg, Hereditary GI Canc Registry, Hong Kong, Hong Kong, Peoples R China; [Hodgson, Shirley V.] St George Hosp, London, England; [Lindblom, Annika] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Lubinski, Jan] Int Hereditary Canc Ctr, Szczecin, Poland; [Morrison, Patrick J.] Queens Univ Belfast, Belfast City Hosp HSC Trust, Dept Med Genet, Belfast, Antrim, North Ireland; [Ramesar, Raj] Univ Cape Town, Div Human Genet, Observatory, South Africa; [Side, Lucy] Churchill Hosp, Dept Clin Genet, Oxford OX3 7LJ, England; [Scott, Rodney J.] John Hunter Hosp, Hunter Area Pathol Serv, New Lambton, NSW, Australia; [Thomas, Huw J. W.] Univ London Imperial Coll Sci Technol & Med, St Marks Hosp, London, England; [Vasen, Hans F.] Leiden Univ, Med Ctr, Netherlands Fdn Detect Hereditary Tumours, Leiden, Netherlands; [Vasen, Hans F.] Leiden Univ, Med Ctr, Dept Gastroenterol, Leiden, Netherlands; [Elliott, Faye; Movahedi, Mohammad; Bishop, D. Timothy] Univ Leeds, Leeds Inst Mol Med, Sect Epidemiol & Biostat, Leeds, W Yorkshire, England; [Wijnen, Juul T.] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; [Fodde, Riccardo] Erasmus Univ, Dept Pathol, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Lynch, Henry T.] Creighton Univ, Med Ctr, Dept Preventat Med & Publ Hlth, Hereditary Canc Inst, Omaha, NE USA; [Mathers, John C.] Newcastle Univ, Inst Ageing & Hlth, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England	Newcastle University - UK; Rigshospitalet; University of Copenhagen; Royal Melbourne Hospital; Central Finland Central Hospital; University of Eastern Finland; Ruhr University Bochum; UNICANCER; Institut Paoli-Calmette (IPC); University of Manchester; University of Birmingham; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Copenhagen; University of Edinburgh; University of Hong Kong; St Georges University London; Karolinska Institutet; Belfast City Hospital; Queens University Belfast; University of Cape Town; University of Oxford; John Hunter Hospital; Imperial College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Leeds; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Creighton University; Newcastle University - UK	Burn, J (corresponding author), Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	john.burn@ncl.ac.uk	Mecklin, Jukka-Pekka/AAB-5378-2020; Pylvänäinen, Kirsi/AAD-9294-2019; Gallinger, Steven/E-4575-2013; MAHER, EAMONN R/A-9507-2008; Olschwang, Sylviane/G-2716-2013; Ramesar, Raj S/I-6941-2015; Mecklin, Jukka-Pekka/AAC-9650-2019; Dunlop, Malcolm G/F-1973-2011; Movahedi, Mohammad/AAI-2476-2020; Scott, Rodney J/B-2827-2013; Evans, D Gareth/AAB-4308-2022; Fodde, Riccardo/AAW-9394-2021	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Pylvänäinen, Kirsi/0000-0003-4399-9283; MAHER, EAMONN R/0000-0002-6226-6918; Olschwang, Sylviane/0000-0001-7078-3029; Ramesar, Raj S/0000-0001-5688-1634; Dunlop, Malcolm G/0000-0002-3033-5851; Scott, Rodney J/0000-0001-7724-3404; Evans, D Gareth/0000-0002-8482-5784; Fodde, Riccardo/0000-0001-9839-4324; Eccles, Diana M/0000-0002-9935-3169; Mathers, John/0000-0003-3406-3002; Vasen, Hans/0000-0003-2682-2603; Bishop, Tim/0000-0002-8752-8785; Lubinski, Jan/0000-0003-2931-3003; Bertario, Lucio/0000-0001-5653-1431; Burn, John/0000-0002-9823-2322; Goldberg, Paul/0000-0003-1612-7519; Movahedi, Mohammad/0000-0001-6154-0121; Gerdes, Anne-Marie/0000-0002-0328-3320	European Union; Cancer Research UK [C588/A10589]; Bayer Corporation; National Starch and Chemical Co; UK Medical Research Council; Newcastle Hospitals; Cancer Council of Victoria Australia; THRIPP South Africa; Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma; Bayer Schering Pharma; International Society for Gastrointestinal Hereditary Tumours (InSiGHT); Cancer Research UK [12076, 11975, 10589] Funding Source: researchfish; Medical Research Council [G0700718B, MC_U127527198, G0900686, MC_PC_U127527198, G0100496] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10282] Funding Source: researchfish; MRC [MC_PC_U127527198, G0100496, MC_U127527198, G0900686] Funding Source: UKRI	European Union(European Commission); Cancer Research UK(Cancer Research UK); Bayer Corporation(Bayer AG); National Starch and Chemical Co; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Newcastle Hospitals; Cancer Council of Victoria Australia(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); THRIPP South Africa; Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma; Bayer Schering Pharma(Bayer AG); International Society for Gastrointestinal Hereditary Tumours (InSiGHT); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	European Union; Cancer Research UK; Bayer Corporation; National Starch and Chemical Co; UK Medical Research Council; Newcastle Hospitals trustees; Cancer Council of Victoria Australia; THRIPP South Africa; The Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma.; The CAPP2 study is an academic collaboration. Funding was initially provided by a European Union award supplemented by Programme funding in Newcastle and Leeds from Cancer Research UK (C588/A10589). Following completion of design and choice of interventions, Bayer Corporation and National Starch and Chemical Co were approached for support. Both provided free intervention including the cost of packaging and made donations to Newcastle University to help cover the cost of administration and distribution. They had no influence on design, conduct, or analysis of the study. The contracts associated with their donations required that they be given sight of the results before submission with up to 90 days for evaluation. The UK Medical Research Council (MRC) approved the trial in 2002 and became the primary funder. MRC steering and data monitoring committees were established. Financial contributions were also made to local sites by the Newcastle Hospitals trustees, Cancer Council of Victoria Australia, THRIPP South Africa, The Finnish Cancer Foundation and SIAK Switzerland. When renewal requests were declined by MRC and Cancer Research UK, follow-up analysis 2009-11 was supported by a donation from Bayer Schering Pharma to Newcastle University. CAPP2 has been made possible by all the participants who agreed to be randomised and take daily treatments for up to 4 years. Special mention must also be given to Pascale Ives (Melbourne, Australia) and Su Werner (Dusseldorf, Germany) for their exceptional recruitment achievements and to Pam Chapman, the project manager in the early stages of the CAPP2 study. Other core staff were Paul Adamson, Olive Armstrong, Julie Coaker, Jonathan Coxhead, Joanne Gascoyne, John Gilroy, Louise Lynagh, Lynn Reed, and Rachel Toes. Recruitment depended on a large number of colleagues around the world. Clinical collaborators not listed as authors are: Jan Ball, Lauren Baxter, Alex Boussioutas, Nicola Bradshaw, Carole Brewer, Mary Broughton, Barbara Bulman, Monica Castiglione, Sue Clark, Rowena Ching, Carol Chu, Susanne Cina, Jackie Cook, Carole Cummings, Rhodri Davies, Tadeusz Debniak, Celine de Moncuit, Sarah Drummond, Tony Ellis, Paulo Fidalgo, Steve Gallinger, Sheila Goff, Paul A Goldberg, Selina Goodman, Chris Harocopos, Pierre Hutter, Lisa Jeffers, Sheila Jordan, Pip Killick, Christian Krauss, Jorgen Kristensen, Caroline Langman, Julio Leite, Annelie Liljegren, Cristina Oliani, Christopher Marks, Veronique Membrez-Antonioli, Julie Miller, Tony Miles, Pedro Perez Segura, Gabriella Pichert, Elize Pietersen, Giovanni Rossi, Paola Sala, Julian Sampson, Beverly Schmocker, Joan Shaw, Allan Spigelman, Alfonso Tempesta, Mary Velthuizen, and Ian Walpole. We are also indebted to the trial steering committee (David Kerr [Chair], Sarah Perkins [MRC], Jack Cuzick, Lynn Faulds Wood, Robert Steele) and the data monitoring committee (Doug Altman [Chair], Chris Paraskeva, Wendy Atkin, Mark Hull). We are grateful to the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) for its support, since its formation in 2003, in sustaining the CAPP consortium.	Burn J, 2011, CANCER PREV RES, V4, P655, DOI 10.1158/1940-6207.CAPR-11-0106; Burn J, 2008, NEW ENGL J MED, V359, P2567, DOI 10.1056/NEJMoa0801297; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2; Liljegren A, 2008, J CLIN ONCOL, V26, P3434, DOI 10.1200/JCO.2007.13.2795; LYNCH HT, 1995, SEMIN SURG ONCOL, V11, P406, DOI 10.1002/ssu.2980110607; Mcilhatton MA, 2011, CANCER PREV RES, V4, P684, DOI 10.1158/1940-6207.CAPR-10-0319; McIlhatton NA, 2007, CANCER RES, V67, P10966, DOI 10.1158/0008-5472.CAN-07-2562; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; Vasen HFA, 2008, Z GASTROENTEROL, V46, pS41, DOI 10.1055/s-2007-963483; Vasen HFA, 2007, J MED GENET, V44, P353, DOI 10.1136/jmg.2007.048991; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X	18	648	673	1	100	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	2011	378	9809					2081	2087		10.1016/S0140-6736(11)61049-0	http://dx.doi.org/10.1016/S0140-6736(11)61049-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865EL	22036019	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000298293600029
J	Ben-Shem, A; de Loubresse, NG; Melnikov, S; Jenner, L; Yusupova, G; Yusupov, M				Ben-Shem, Adam; de Loubresse, Nicolas Garreau; Melnikov, Sergey; Jenner, Lasse; Yusupova, Gulnara; Yusupov, Marat			The Structure of the Eukaryotic Ribosome at 3.0 angstrom Resolution	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; TRANSLATION INITIATION; 80S RIBOSOME; PROTEIN-SYNTHESIS; RNA; SUBUNIT; IRES; REINITIATION; MECHANISM	Ribosomes translate genetic information encoded by messenger RNA into proteins. Many aspects of translation and its regulation are specific to eukaryotes, whose ribosomes are much larger and intricate than their bacterial counterparts. We report the crystal structure of the 80S ribosome from the yeast Saccharomyces cerevisiae-including nearly all ribosomal RNA bases and protein side chains as well as an additional protein, Stm1-at a resolution of 3.0 angstroms. This atomic model reveals the architecture of eukaryote-specific elements and their interaction with the universally conserved core, and describes all eukaryote-specific bridges between the two ribosomal subunits. It forms the structural framework for the design and analysis of experiments that explore the eukaryotic translation apparatus and the evolutionary forces that shaped it.	[Ben-Shem, Adam] Inst Genet & Biol Mol & Cellulaire, F-67400 Illkirch Graffenstaden, France; INSERM, U964, F-67400 Illkirch Graffenstaden, France; CNRS, UMR7104, F-67400 Illkirch Graffenstaden, France; Univ Strasbourg, F-67000 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ben-Shem, A (corresponding author), Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67400 Illkirch Graffenstaden, France.	adam@igbmc.fr; marat@igbmc.fr	Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013; Jenner, Lasse/H-1584-2017	Yusupov, Marat/0000-0001-5544-0597; Jenner, Lasse/0000-0003-3917-8853; Melnikov, Serguey/0000-0002-7525-9039; Ben-Shem, Adam/0000-0003-0297-8662	European Molecular Biology Organization; Human Frontier Science Program; French National Research Agency [ANR BLAN07-3_190451, ANR-07-PCVI-0015-01]; European Commission SPINE2	European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Human Frontier Science Program(Human Frontier Science Program); French National Research Agency(French National Research Agency (ANR)); European Commission SPINE2(European CommissionEuropean Commission Joint Research Centre)	We thank C. Schulze-Briese, M. Mueller, and the staff at the Swiss Light Source for advice on data collection strategy; K. Diederichs for guidance on estimating data quality; B. Seraphin and A. Urzhumtsev for invaluable discussions; M. Fournier and V. Chavant for performing mass spectrometry analysis; and S. Uge for assistance with computer facilities. Supported by a European Molecular Biology Organization long-term fellowship (A.B.-S.), the Human Frontier Science Program, French National Research Agency grants ANR BLAN07-3_190451 and ANR-07-PCVI-0015-01, and the European Commission SPINE2. Coordinates and structure factors have been deposited in the Protein Data Bank with accession codes 3U5B, 3U5C, 3U5D, 3U5E, 3U5F, 3U5G, 3U5H, and 3U5I.	Babaylova E, 2009, NUCLEIC ACIDS RES, V37, P1141, DOI 10.1093/nar/gkn1026; Balagopal V, 2011, RNA, V17, P835, DOI 10.1261/rna.2677311; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Becker T, 2009, SCIENCE, V326, P1369, DOI 10.1126/science.1178535; Ben-Shem A, 2010, SCIENCE, V330, P1203, DOI 10.1126/science.1194294; Boehringer D, 2005, STRUCTURE, V13, P1695, DOI 10.1016/j.str.2005.08.008; Bokov K, 2009, NATURE, V457, P977, DOI 10.1038/nature07749; Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jenner LB, 2010, NAT STRUCT MOL BIOL, V17, P555, DOI 10.1038/nsmb.1790; Korostelev A, 2008, CURR OPIN CHEM BIOL, V12, P674, DOI 10.1016/j.cbpa.2008.08.037; Krummel DAP, 2009, NATURE, V458, P475, DOI 10.1038/nature07851; Lecompte O, 2002, NUCLEIC ACIDS RES, V30, P5382, DOI 10.1093/nar/gkf693; Meskauskas A, 2007, MOL CELL, V25, P877, DOI 10.1016/j.molcel.2007.02.015; Nishimura T, 2005, PLANT CELL, V17, P2940, DOI 10.1105/tpc.105.036533; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; Rabl J, 2011, SCIENCE, V331, P730, DOI 10.1126/science.1198308; Rhodin MHJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020048; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Schmeing TM, 2009, NATURE, V461, P1234, DOI 10.1038/nature08403; Schuler M, 2006, NAT STRUCT MOL BIOL, V13, P1092, DOI 10.1038/nsmb1177; Sharma MR, 2010, J BIOL CHEM, V285, P4006, DOI 10.1074/jbc.M109.062299; Smith MW, 2001, MOL CELL BIOL, V21, P8264, DOI 10.1128/MCB.21.24.8264-8275.2001; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Taylor DJ, 2009, STRUCTURE, V17, P1591, DOI 10.1016/j.str.2009.09.015; Thiebeauld O, 2009, EMBO J, V28, P3171, DOI 10.1038/emboj.2009.256; Van Dyke N, 2006, J MOL BIOL, V358, P1023, DOI 10.1016/j.jmb.2006.03.018; Vila-Sanjurjo A, 2004, NAT STRUCT MOL BIOL, V11, P1054, DOI 10.1038/nsmb850; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yu YP, 2011, NUCLEIC ACIDS RES, V39, P4851, DOI 10.1093/nar/gkr045; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zhang W, 2009, SCIENCE, V325, P1014, DOI 10.1126/science.1175275	37	772	916	5	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 16	2011	334	6062					1524	1529		10.1126/science.1212642	http://dx.doi.org/10.1126/science.1212642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	862LE	22096102	Bronze			2022-12-28	WOS:000298091400045
J	Cyrklaff, M; Sanchez, CP; Kilian, N; Bisseye, C; Simpore, J; Frischknecht, F; Lanzer, M				Cyrklaff, Marek; Sanchez, Cecilia P.; Kilian, Nicole; Bisseye, Cyrille; Simpore, Jacques; Frischknecht, Friedrich; Lanzer, Michael			Hemoglobins S and C Interfere with Actin Remodeling in Plasmodium falciparum-Infected Erythrocytes	SCIENCE			English	Article							RED-CELL MEMBRANE; MAURERS CLEFTS; MALARIA; PROTEINS; BLOOD; VIRULENCE; SKELETON; REVEALS; SYSTEM	The hemoglobins S and C protect carriers from severe Plasmodium falciparum malaria. Here, we found that these hemoglobinopathies affected the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Cryoelectron tomography revealed that the parasite generated a host-derived actin cytoskeleton within the cytoplasm of wild-type red blood cells that connected the Maurer's clefts with the host cell membrane and to which transport vesicles were attached. The actin cytoskeleton and the Maurer's clefts were aberrant in erythrocytes containing hemoglobin S or C. Hemoglobin oxidation products, enriched in hemoglobin S and C erythrocytes, inhibited actin polymerization in vitro and may account for the protective role in malaria.	[Cyrklaff, Marek; Sanchez, Cecilia P.; Kilian, Nicole; Frischknecht, Friedrich; Lanzer, Michael] Univ Heidelberg, Dept Infect Dis, D-69120 Heidelberg, Germany; [Bisseye, Cyrille; Simpore, Jacques] Biomol Res Ctr Pietro Annigoni, Ouagadougou, Burkina Faso	Ruprecht Karls University Heidelberg	Cyrklaff, M (corresponding author), Univ Heidelberg, Dept Infect Dis, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	marek.cyrklaff@med.uni-heidelberg.de; michael_lanzer@med.uni-heidelberg.de	Bisseye, Cyrille/AGP-8782-2022; SIMPORE, Jacques/ABA-4873-2020; Lanzer, Michael/E-9752-2013; Bisseye, C./AFO-0118-2022	Bisseye, Cyrille/0000-0002-6888-6317; SIMPORE, Jacques/0000-0002-0415-9161; Lanzer, Michael/0000-0002-0220-6526; Frischknecht, Friedrich/0000-0002-8332-6668; Kilian, Nicole/0000-0001-7489-9782	Deutsche Forschungsgemeinschaft; Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie; Chica and Heinz Schaller Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie(Federal Ministry of Education & Research (BMBF)); Chica and Heinz Schaller Foundation	We thank S. Prior, L. Lemgruber, and D. Ouermi for technical assistance and help. We thank the Max Planck Institutes (Martinsried and Frankfurt), the European Molecular Biology Laboratory, Centre for Organismal Studies, and Bioquant (Heidelberg) for access to EM facilities. Supported by the Deutsche Forschungsgemeinschaft (research focus Host-Parasite Coevolution); the Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie, and the Chica and Heinz Schaller Foundation. M. L. and F. F. are members of the Heidelberg Excellence Cluster CellNetworks and the European Network of Excellence EVIMalaR.	Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9; An XU, 2008, BRIT J HAEMATOL, V141, P367, DOI 10.1111/j.1365-2141.2008.07091.x; ATKINSON CT, 1988, EUR J CELL BIOL, V45, P192; Cholera R, 2008, P NATL ACAD SCI USA, V105, P991, DOI 10.1073/pnas.0711401105; Cserti CM, 2007, BLOOD, V110, P2250, DOI 10.1182/blood-2007-03-077602; Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631; Farah ME, 2011, CYTOSKELETON, V68, P340, DOI 10.1002/cm.20516; Chaves MAF, 2008, HEMATOLOGY, V13, P187, DOI 10.1179/102453308X343356; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; Hanssen E, 2008, MOL MICROBIOL, V67, P703, DOI 10.1111/j.1365-2958.2007.06063.x; Hanssen E, 2010, INT J PARASITOL, V40, P123, DOI 10.1016/j.ijpara.2009.09.004; HEBBEL RP, 1991, BLOOD, V77, P214; Henrich Philipp, 2009, Biotechnology Journal, V4, P888, DOI 10.1002/biot.200900058; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hodder AN, 2009, MOL MICROBIOL, V71, P48, DOI 10.1111/j.1365-2958.2008.06508.x; JAROLIM P, 1990, BLOOD, V76, P2125; Lanzer M, 2006, INT J PARASITOL, V36, P23, DOI 10.1016/j.ijpara.2005.10.001; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LIU SC, 1984, J BIOL CHEM, V259, P1556; Maier AG, 2008, CELL, V134, P48, DOI 10.1016/j.cell.2008.04.051; Maier AG, 2009, NAT REV MICROBIOL, V7, P341, DOI 10.1038/nrmicro2110; Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556; Pasternak ND, 2009, INT J BIOCHEM CELL B, V41, P1463, DOI 10.1016/j.biocel.2008.12.012; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Schmitz S, 2005, J MOL BIOL, V349, P113, DOI 10.1016/j.jmb.2005.03.056; SHEN BW, 1984, J CELL BIOL, V99, P810, DOI 10.1083/jcb.99.3.810; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Taraschi TF, 2003, BLOOD, V102, P3420, DOI 10.1182/blood-2003-05-1448; van Ooij C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000084	29	166	168	4	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	2011	334	6060					1283	1286		10.1126/science.1213775	http://dx.doi.org/10.1126/science.1213775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HD	22075726				2022-12-28	WOS:000297553600052
J	Nguyen, D; Joshi-Datar, A; Lepine, F; Bauerle, E; Olakanmi, O; Beer, K; McKay, G; Siehnel, R; Schafhauser, J; Wang, Y; Britigan, BE; Singh, PK				Dao Nguyen; Joshi-Datar, Amruta; Lepine, Francois; Bauerle, Elizabeth; Olakanmi, Oyebode; Beer, Karlyn; McKay, Geoffrey; Siehnel, Richard; Schafhauser, James; Wang, Yun; Britigan, Bradley E.; Singh, Pradeep K.			Active Starvation Responses Mediate Antibiotic Tolerance in Biofilms and Nutrient-Limited Bacteria	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; STRINGENT RESPONSE; INFECTION; DISEASE; DAMAGE; PQS	Bacteria become highly tolerant to antibiotics when nutrients are limited. The inactivity of antibiotic targets caused by starvation-induced growth arrest is thought to be a key mechanism producing tolerance. Here we show that the antibiotic tolerance of nutrient-limited and biofilm Pseudomonas aeruginosa is mediated by active responses to starvation, rather than by the passive effects of growth arrest. The protective mechanism is controlled by the starvation-signaling stringent response (SR), and our experiments link SR-mediated tolerance to reduced levels of oxidant stress in bacterial cells. Furthermore, inactivating this protective mechanism sensitized biofilms by several orders of magnitude to four different classes of antibiotics and markedly enhanced the efficacy of antibiotic treatment in experimental infections.	[Dao Nguyen; McKay, Geoffrey; Schafhauser, James] McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; [Dao Nguyen; McKay, Geoffrey; Schafhauser, James] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3G 1A4, Canada; [Joshi-Datar, Amruta; Bauerle, Elizabeth; Beer, Karlyn; Siehnel, Richard; Singh, Pradeep K.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Joshi-Datar, Amruta; Bauerle, Elizabeth; Beer, Karlyn; Siehnel, Richard; Singh, Pradeep K.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; [Lepine, Francois] INRS Armand Frappier, Dept Microbiol, Laval, PQ H7V 1B7, Canada; [Olakanmi, Oyebode; Britigan, Bradley E.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; [Wang, Yun] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Britigan, Bradley E.] Vet Adm Med Ctr Cincinnati, Cincinnati, OH 45220 USA	McGill University; McGill University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Quebec; Institut national de la recherche scientifique (INRS); University System of Ohio; University of Cincinnati; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Nguyen, D (corresponding author), McGill Univ, Dept Med, 1650 Cedar Ave,L11-513, Montreal, PQ H3G 1A4, Canada.	dao.nguyen@mcgill.ca	Wang, Yun/E-3619-2010	Schafhauser, James/0000-0002-3979-3402; Siehnel, Richard/0000-0001-7078-5657	Burroughs Wellcome Fund; Cystic Fibrosis Foundation; Canadian Institutes for Health Research; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL102246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI101307, R56AI091714] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank M. Cashel, C. Manoil, and J. Burns for providing strains; A. Hunziker and J. Harrisson for technical assistance; and J. Penterman, J. Mougous, M. Parsek, and C. Manoil for helpful discussions. Funding was provided by the Burroughs Wellcome Fund (D.N. and P. K. S), Cystic Fibrosis Foundation (P. K. S), NIH (P. K. S), and Canadian Institutes for Health Research (D.N.).	Borriello G, 2006, ANTIMICROB AGENTS CH, V50, P382, DOI 10.1128/AAC.50.1.382-384.2006; Bredenbruch F, 2006, ENVIRON MICROBIOL, V8, P1318, DOI 10.1111/j.1462-2920.2006.01025.x; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; D'Argenio DA, 2002, J BACTERIOL, V184, P6481, DOI 10.1128/JB.184.23.6481-6489.2002; Deziel E, 2004, P NATL ACAD SCI USA, V101, P1339, DOI 10.1073/pnas.0307694100; Diggle SP, 2007, CHEM BIOL, V14, P87, DOI 10.1016/j.chembiol.2006.11.014; Dwyer DJ, 2009, CURR OPIN MICROBIOL, V12, P482, DOI 10.1016/j.mib.2009.06.018; ENG RHK, 1991, ANTIMICROB AGENTS CH, V35, P1824, DOI 10.1128/AAC.35.9.1824; Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010; Gallagher LA, 2002, J BACTERIOL, V184, P6472, DOI 10.1128/JB.184.23.6472-6480.2002; Haussler S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000166; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; MCCUNE RM, 1956, ANN NY ACAD SCI, V65, P91, DOI 10.1111/j.1749-6632.1956.tb36627.x; McDERMOTT WALSH, 1958, YALE JOUR BIOL AND MED, V30, P257; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Stewart PS, 2008, NAT REV MICROBIOL, V6, P199, DOI 10.1038/nrmicro1838; Traxler MF, 2008, MOL MICROBIOL, V68, P1128, DOI 10.1111/j.1365-2958.2008.06229.x; Vogt SL, 2011, INFECT IMMUN, V79, P4094, DOI 10.1128/IAI.00193-11; Wang XH, 2009, ANTIMICROB AGENTS CH, V53, P1395, DOI 10.1128/AAC.01087-08; Wang Y, 2008, ENVIRON SCI TECHNOL, V42, P2380, DOI 10.1021/es702290a; Warner DF, 2006, CLIN MICROBIOL REV, V19, P558, DOI 10.1128/CMR.00060-05	23	583	611	8	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					982	986		10.1126/science.1211037	http://dx.doi.org/10.1126/science.1211037			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096200	Green Accepted			2022-12-28	WOS:000297101800057
J	Bohlen, CJ; Chesler, AT; Sharif-Naeini, R; Medzihradszky, KF; Zhou, S; King, D; Sanchez, EE; Burlingame, AL; Basbaum, AI; Julius, D				Bohlen, Christopher J.; Chesler, Alexander T.; Sharif-Naeini, Reza; Medzihradszky, Katalin F.; Zhou, Sharleen; King, David; Sanchez, Elda E.; Burlingame, Alma L.; Basbaum, Allan I.; Julius, David			A heteromeric Texas coral snake toxin targets acid-sensing ion channels to produce pain	NATURE			English	Article							CAPSAICIN RECEPTOR; SENSORY NEURONS; VENOMS; MICE; CONTRIBUTES; CURRENTS; STIMULI; ASICS; TRPV1	Natural products that elicit discomfort or pain represent invaluable tools for probing molecular mechanisms underlying pain sensation(1). Plant-derived irritants have predominated in this regard, but animal venoms have also evolved to avert predators by targeting neurons and receptors whose activation produces noxious sensations(2-6). As such, venoms provide a rich and varied source of small molecule and protein pharmacophores(7,8) that can be exploited to characterize and manipulate key components of the pain-signalling pathway. With this in mind, here we perform an unbiased in vitro screen to identify snake venoms capable of activating somatosensory neurons. Venom from the Texas coral snake (Micrurus tener tener), whose bite produces intense and unremitting pain(9), excites a large cohort of sensory neurons. The purified active species (MitTx) consists of a heteromeric complex between Kunitz- and phospholipase-A2-like proteins that together function as a potent, persistent and selective agonist for acid-sensing ion channels (ASICs), showing equal or greater efficacy compared with acidic pH. MitTx is highly selective for the ASIC1 subtype at neutral pH; under more acidic conditions (pH < 6.5), MitTx massively potenti ates (>100-fold) proton-evoked activation of ASIC2a channels. These observations raise the possibility that ASIC channels function as coincidence detectors for extracellular protons and other, as yet unidentified, endogenous factors. Purified MitTx elicits robust pain-related behaviour in mice by activation of ASIC1 channels on capsaicin-sensitive nerve fibres. These findings reveal a mechanism whereby snake venoms produce pain, and highlight an unexpected contribution of ASIC1 channels to nociception.	[Bohlen, Christopher J.; Chesler, Alexander T.; Julius, David] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; [Sharif-Naeini, Reza; Basbaum, Allan I.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94158 USA; [Medzihradszky, Katalin F.; Burlingame, Alma L.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Zhou, Sharleen; King, David] Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Berkeley, CA 94720 USA; [Sanchez, Elda E.] Texas A&M Univ, Dept Chem, Kingsville, TX 78363 USA; [Sanchez, Elda E.] Texas A&M Univ, Natl Nat Toxins Res Ctr, Kingsville, TX 78363 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Texas A&M University System; Texas A&M University Kingsville; Texas A&M University System; Texas A&M University Kingsville	Julius, D (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.	david.julius@ucsf.edu	Chesler, Alexander/V-2748-2019	Chesler, Alexander/0000-0002-3131-0728; Sanchez, Elda E./0000-0001-5222-8873	Ruth Kirschstein NIH [F31NS065597]; NIH from the UCSF Cardiovascular Research Institute; Canadian Institutes of Health Research; Howard Hughes Medical Institute; NIH [NCRR P41RR001614, NCRR P40RR018300-09, NINDS R01NS065071]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614, P40RR018300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065071, F31NS065597] Funding Source: NIH RePORTER	Ruth Kirschstein NIH; NIH from the UCSF Cardiovascular Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank M. Price and M. Welsh for providing ASIC1 and ASIC3 knockout mice; Y. Kelly and J. Poblete for technical assistance; C. Williams for assisting with homology models; F. Findeisen, L. Ma and D. Minor for assistance with ITC experiments; R. Nicoll and members of the Julius laboratory for discussion and comments. This work was supported by a Ruth Kirschstein NIH predoctoral fellowship (F31NS065597 to C. B.), an NIH postdoctoral training grant from the UCSF Cardiovascular Research Institute (to A. C.), a postdoctoral fellowship from the Canadian Institutes of Health Research (to R.S.-N.), the Howard Hughes Medical Institute (K. F. M. and A. L. B.), and the NIH (NCRR P41RR001614 to A. L. B., NCRR P40RR018300-09 to E. S. and NINDS R01NS065071 to D.J.).	Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Bohlen CJ, 2010, CELL, V141, P834, DOI 10.1016/j.cell.2010.03.052; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106; CHAHL LA, 1975, PAIN, V1, P3, DOI 10.1016/0304-3959(75)90003-2; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Doley R, 2009, CELL MOL LIFE SCI, V66, P2851, DOI 10.1007/s00018-009-0050-2; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Leffler A, 2006, NEUROSCIENCE, V139, P699, DOI 10.1016/j.neuroscience.2005.12.020; Mebs D., 2002, VENOMOUS POISONOUS A; Morgan DL, 2007, SOUTH MED J, V100, P152, DOI 10.1097/01.smj.0000253596.39121.19; NISHIOKA SA, 1993, ANN TROP MED PARASIT, V87, P429, DOI 10.1080/00034983.1993.11812791; Poirot O, 2006, J PHYSIOL-LONDON, V576, P215, DOI 10.1113/jphysiol.2006.113035; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; SCHMIDT JO, 1982, ANNU REV ENTOMOL, V27, P339, DOI 10.1146/annurev.en.27.010182.002011; Siemens J, 2006, NATURE, V444, P208, DOI 10.1038/nature05285; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Yu Y, 2010, NEURON, V68, P61, DOI 10.1016/j.neuron.2010.09.001; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	30	236	245	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					410	U167		10.1038/nature10607	http://dx.doi.org/10.1038/nature10607			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094702	Green Accepted, Green Submitted			2022-12-28	WOS:000297059700048
J	Dooley, MA; Jayne, D; Ginzler, EM; Isenberg, D; Olsen, NJ; Wofsy, D; Eitner, F; Appel, GB; Contreras, G; Lisk, L; Solomons, N				Dooley, Mary Anne; Jayne, David; Ginzler, Ellen M.; Isenberg, David; Olsen, Nancy J.; Wofsy, David; Eitner, Frank; Appel, Gerald B.; Contreras, Gabriel; Lisk, Laura; Solomons, Neil		ALMS Grp	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS CYCLOPHOSPHAMIDE; INDUCTION TREATMENT; DISEASE-ACTIVITY; RENAL-DISEASE; LONG-TERM; MOFETIL; ERYTHEMATOSUS; MANAGEMENT; TRIALS; ALMS	BACKGROUND Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. METHODS We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each group, in patients who met response criteria during a 6-month induction trial. The study group underwent repeat randomization in a 1: 1 ratio. Up to 10 mg of prednisone per day or its equivalent was permitted. The primary efficacy end point was the time to treatment failure, which was defined as death, end-stage renal disease, doubling of the serum creatinine level, renal flare, or rescue therapy for lupus nephritis. Secondary assessments included the time to the individual components of treatment failure and adverse events. RESULTS A total of 227 patients were randomly assigned to maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine). Mycophenolate mofetil was superior to azathioprine with respect to the primary end point, time to treatment failure (hazard ratio, 0.44; 95% confidence interval, 0.25 to 0.77; P=0.003), and with respect to time to renal flare and time to rescue therapy (hazard ratio, <1.00; P<0.05). Observed rates of treatment failure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the azathioprine group. Adverse events, most commonly minor infections and gastrointestinal disorders, occurred in more than 95% of the patients in both groups (P=0.68). Serious adverse events occurred in 33.3% of patients in the azathioprine group and in 23.5% of those in the mycophenolate mofetil group (P=0.11), and the rate of withdrawal due to adverse events was higher with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P=0.02). CONCLUSIONS Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis who had a response to induction therapy. (Funded by Vifor Pharma [formerly Aspreva]; ALMS	[Solomons, Neil] Vifor Pharma, Clin Dept, Victoria, BC V8Z 7X8, Canada; [Dooley, Mary Anne] Univ N Carolina, Dept Med, Chapel Hill, NC USA; [Jayne, David] Addenbrookes Hosp, Renal Unit, Cambridge, England; [Lisk, Laura] Vifor Pharma, Bagshot, Surrey, England; [Ginzler, Ellen M.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Isenberg, David] UCL, Dept Med, London WC1E 6BT, England; [Olsen, Nancy J.] Penn State Milton S Hershey Med Ctr, Div Rheumatol, Hershey, PA USA; [Wofsy, David] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA USA; [Wofsy, David] Univ Calif San Francisco, Rosalind Russell Med Res Ctr, San Francisco, CA 94143 USA; [Eitner, Frank] Univ Aachen, Div Nephrol & Immunol, Rheinisch Westfal TH, D-5100 Aachen, Germany; [Appel, Gerald B.] Columbia Univ, Dept Nephrol, New York, NY USA; [Contreras, Gabriel] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA	University of North Carolina; University of North Carolina Chapel Hill; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of London; University College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; RWTH Aachen University; Columbia University; University of Miami	Solomons, N (corresponding author), Vifor Pharma, Clin Dept, 1203,4464 Markham St, Victoria, BC V8Z 7X8, Canada.	neil.solomons@viforpharma.com	Tesar, Vladimir/O-2312-2017; de Jesus Falcão Pestana Vasconcelos, Manuel/AGX-6239-2022; Mastroianni Kirsztajn, Gianna/D-9596-2013; de Jesus Falcão Pestana Vasconcelos, Manuel/E-9226-2013; ALMEIDA, FERNANDO/S-1880-2019; Lightstone, Liz/M-4331-2014; Nicholls, Kathleen/N-5002-2017	Tesar, Vladimir/0000-0001-6982-0689; de Jesus Falcão Pestana Vasconcelos, Manuel/0000-0003-1482-2024; Mastroianni Kirsztajn, Gianna/0000-0003-1317-4109; de Jesus Falcão Pestana Vasconcelos, Manuel/0000-0003-1482-2024; ALMEIDA, FERNANDO/0000-0002-9404-9707; Isenberg, David/0000-0001-9514-2455; Jayne, David/0000-0002-1712-0637; Naicker, Saraladevi/0000-0002-7058-9725; Blume, Cornelia/0000-0001-7487-4884; Lightstone, Liz/0000-0002-4603-4076; Nicholls, Kathleen/0000-0002-1297-8722	Vifor Pharma (formerly Aspreva Pharmaceuticals)	Vifor Pharma (formerly Aspreva Pharmaceuticals)	Supported by Vifor Pharma (formerly Aspreva Pharmaceuticals) as part of the Roche-Aspreva rare diseases collaboration.	Appel GB, 2009, J AM SOC NEPHROL, V20, P1103, DOI 10.1681/ASN.2008101028; Bomback AS, 2010, J AM SOC NEPHROL, V21, P2028, DOI 10.1681/ASN.2010050472; Chan TM, 2000, NEW ENGL J MED, V343, P1156, DOI 10.1056/NEJM200010193431604; Chan TM, 2005, J AM SOC NEPHROL, V16, P1076, DOI 10.1681/ASN.2004080686; Chan TM, 2005, LUPUS, V14, pS27, DOI 10.1191/0961203305lu2114oa; Contreras G, 2004, NEW ENGL J MED, V350, P971, DOI 10.1056/NEJMoa031855; Flanc RS, 2004, AM J KIDNEY DIS, V43, P197, DOI 10.1053/j.ajkd.2003.10.012; Ginzler E, 2010, ARTHRITIS RHEUM, V62, P3005; Ginzler EM, 2010, ARTHRITIS RHEUM-US, V62, P211, DOI 10.1002/art.25052; Ginzler EM, 2005, NEW ENGL J MED, V353, P2219, DOI 10.1056/NEJMoa043731; HAY EM, 1993, Q J MED, V86, P447; Houssiau FA, 2010, ANN RHEUM DIS, V69, P2083, DOI 10.1136/ard.2010.131995; Isenberg D, 2008, LUPUS, V17, P967, DOI 10.1177/0961203308095139; Isenberg D, 2010, RHEUMATOLOGY, V49, P128, DOI 10.1093/rheumatology/kep346; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Levey AS, 2008, ANN INTERN MED, V149, P519, DOI 10.7326/0003-4819-149-7-200810070-00023; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; Ong LM, 2005, NEPHROLOGY, V10, P504, DOI 10.1111/j.1440-1797.2005.00444.x; Ponticelli C, 1998, LUPUS, V7, P635, DOI 10.1191/096120398678920776; Ponticelli C, 2010, J NEPHROL, V23, P9; Sahin GM, 2008, RENAL FAILURE, V30, P865, DOI 10.1080/08860220802353843; Sinclair A, 2007, LUPUS, V16, P972, DOI 10.1177/0961203307084712; Ward MM, 2000, ARCH INTERN MED, V160, P3136, DOI 10.1001/archinte.160.20.3136; Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D	26	389	427	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1886	1895		10.1056/NEJMoa1014460	http://dx.doi.org/10.1056/NEJMoa1014460			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087680	Green Published, Bronze			2022-12-28	WOS:000297041900007
J	Nerella, N				Nerella, Nishant			A 5-item score predicted risk for warfarin-associated major hemorrhage in patients with atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Maimonides Hosp, Brooklyn, NY 11219 USA	Maimonides Medical Center	Nerella, N (corresponding author), Maimonides Hosp, Brooklyn, NY 11219 USA.							Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-13	10.7326/0003-4819-155-10-201111150-02013	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084360				2022-12-28	WOS:000208885300012
J	O'Conor, R				O'Conor, Rory			CLIMATE CHANGE Lessons from strategy game modelling climate change	BRITISH MEDICAL JOURNAL			English	Letter												rory.oconor@wdpct.nhs.uk						Godlee F., 2011, BMJ-BRIT MED J, V343, pd6789	1	0	0	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2011	343								d7379	10.1136/bmj.d7379	http://dx.doi.org/10.1136/bmj.d7379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LU	22089746				2022-12-28	WOS:000297497000017
J	Moscat, J; Diaz-Meco, MT				Moscat, Jorge; Diaz-Meco, Maria T.			Feedback on Fat: p62-mTORC1-Autophagy Connections	CELL			English	Review							AUTOPHAGY-DEFICIENT MICE; MTOR; P62; COMPLEX; OBESITY; ACTIVATION; PATHWAY; CANCER; RAPTOR	Metabolic homeostasis requires integration of multiple signals and cellular activities. Without this integration, conditions of obesity and diabetes often develop. Recent in vivo studies explore the molecular basis for metabolic homestasis, showing that p62 links autophagy and mTORC1 activation to regulate adipogenesis and energy control.	[Moscat, Jorge; Diaz-Meco, Maria T.] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Moscat, J (corresponding author), Sanford Burnham Med Res Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jmoscat@sanfordburnham.org		Diaz-Meco, Maria/0000-0003-0147-0998	NIH [R01AI072581, R01DK088107, R01CA132847, R01CA134530]; NATIONAL CANCER INSTITUTE [R01CA132847, R01CA134530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088107] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Our research is funded by grants R01AI072581 (J.M.), R01DK088107 (J.M.), R01CA132847 (J.M.), and R01CA134530 (M. T. D.-M.). We thank Maryellen Daston for editing and J. Reed for critically reading this manuscript.	Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Kaushik S, 2011, CELL METAB, V14, P173, DOI 10.1016/j.cmet.2011.06.008; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Lee SJ, 2010, CELL METAB, V12, P65, DOI 10.1016/j.cmet.2010.05.003; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Polak P, 2008, CELL METAB, V8, P399, DOI 10.1016/j.cmet.2008.09.003; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106	20	113	126	1	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					724	727		10.1016/j.cell.2011.10.021	http://dx.doi.org/10.1016/j.cell.2011.10.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078874	Green Accepted, Bronze			2022-12-28	WOS:000296902300008
J	Brook, RH				Brook, Robert H.			Can the Patient-Centered Outcomes Research Institute Become Relevant to Controlling Medical Costs and Improving Value?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH		[Brook, Robert H.] RAND Corp, Santa Monica, CA 90406 USA; [Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Brook, RH (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90406 USA.	brook@rand.org						Brook RH, 2008, JAMA-J AM MED ASSOC, V300, P211, DOI 10.1001/jama.2008.35; Brook RH, 2011, JAMA-J AM MED ASSOC, V306, P650, DOI 10.1001/jama.2011.1136; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Newhouse JP, 1993, FREE ALL LESSONS RAN; *PAT CTR OUTC RES, WORK DEF PAT CTR OUT; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X	6	19	19	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					2020	2021		10.1001/jama.2011.1621	http://dx.doi.org/10.1001/jama.2011.1621			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068994				2022-12-28	WOS:000296704300025
J	Meisel, ZF; Karlawish, J				Meisel, Zachary F.; Karlawish, Jason			Narrative vs Evidence-Based Medicine-And, Not Or	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Meisel, Zachary F.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Perelman Sch Med, Dept Med & Med Eth, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Meisel, ZF (corresponding author), Univ Penn, Perelman Sch Med, Dept Emergency Med, 3641 Locust Walk, Philadelphia, PA 19104 USA.	zfm@wharton.upenn.edu	Meisel, Zachary F/C-8631-2018	Meisel, Zachary F/0000-0001-8474-7993	NATIONAL CANCER INSTITUTE [KM1CA156715] Funding Source: NIH RePORTER; NCI NIH HHS [1KM1CA156715-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruner J. S., 1990, ACTS MEANING; Dal Cin S, 2004, RESISTANCE AND PERSUASION, P175; Hassidim A., 2008, Morbidity and Mortality Weekly Report, V57, P203; Hellerman C.Patients, 2011, PATIENTS SCI ODDS BR; Hinyard LJ, 2007, HEALTH EDUC BEHAV, V34, P777, DOI 10.1177/1090198106291963; Houston TK, 2011, ANN INTERN MED, V154, P77, DOI 10.7326/0003-4819-154-2-201101180-00004; Offit PaulA., 2008, AUTISMS FALSE PROPHE, DOI 10.7312/offi14636; Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51; Washington A Eugene, 2011, N Engl J Med, V365, pe31, DOI 10.1056/NEJMp1109407; Woolf SH, 2010, JAMA-J AM MED ASSOC, V303, P162, DOI 10.1001/jama.2009.1989	10	58	58	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					2022	2023		10.1001/jama.2011.1648	http://dx.doi.org/10.1001/jama.2011.1648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068995				2022-12-28	WOS:000296704300026
J	Tzoulaki, I; Siontis, KCM; Ioannidis, JPA				Tzoulaki, Ioanna; Siontis, Konstantinos C. M.; Ioannidis, John P. A.			Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; ATHEROSCLEROTIC VASCULAR-DISEASE; MEDICINE PRACTICE GUIDELINES; IMPROVED PREDICTION; NATIONAL ACADEMY; PUBLICATION BIAS; RISK-FACTOR; TASK-FORCE; MORTALITY	Objective To compare the reported effect sizes of cardiovascular biomarkers in datasets from observational studies with those in datasets from randomised controlled trials. Design Review of meta-analyses. Study selection Meta-analyses of emerging cardiovascular biomarkers (not part of the Framingham risk score) that included datasets from at least one observational study and at least one randomised controlled trial were identified through Medline (last update, January 2011). Data extraction Study-specific risk ratios were extracted from all identified meta-analyses and synthesised with random effects for (a) all studies, and (b) separately for observational and for randomised controlled trial populations for comparison. Results 31 eligible meta-analyses were identified. For seven major biomarkers (C reactive protein, non-HDL cholesterol, lipoprotein(a), post-load glucose, fibrinogen, B-type natriuretic peptide, and troponins), the prognostic effect was significantly stronger in datasets from observational studies than in datasets from randomised controlled trials. For five of the biomarkers the effect was less than half as strong in the randomised controlled trial datasets. Across all 31 meta-analyses, on average datasets from observational studies suggested larger prognostic effects than those from randomised controlled trials; from a random effects meta-analysis, the estimated average difference in the effect size was 24% (95% CI 7% to 40%) of the overall biomarker effect. Conclusions Cardiovascular biomarkers often have less promising results in the evidence derived from randomised controlled trials than from observational studies.	[Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Tzoulaki, Ioanna; Siontis, Konstantinos C. M.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece	Stanford University; University of Ioannina	Ioannidis, JPA (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.	jioannid@stanford.edu	Ioannidis, John P. A./G-9836-2011; Tzoulaki, Ioanna/ABE-6269-2020	Tzoulaki, Ioanna/0000-0002-4275-9328				[Anonymous], 2007, EUR J EPIDEMIOL, V22, P839, DOI 10.1007/s10654-007-9165-7; Apple FS, 2005, CLIN CHEM, V51, P810, DOI 10.1373/clinchem.2004.046292; Ballantyne C, 2007, EUR J CARDIOV PREV R, V14, P3; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Christenson RH, 2007, CLIN CHEM, V53, P545, DOI 10.1373/clinchem.2006.079749; Cleophas TJ, 2000, AM J CARDIOL, V86, P1005, DOI 10.1016/S0002-9149(00)01137-1; Danesh J, 2000, BRIT MED J, V321, P208, DOI 10.1136/bmj.321.7255.208; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Danesh J, 2001, CIRCULATION, V103, P2323; Danesh J, 2005, JAMA-J AM MED ASSOC, V294, P1799, DOI 10.1001/jama.294.14.1799; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Di Angelantonio E, 2009, CIRCULATION, V120, P2177, DOI 10.1161/CIRCULATIONAHA.109.884866; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Erqou S, 2010, J AM COLL CARDIOL, V55, P2160, DOI 10.1016/j.jacc.2009.10.080; Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063; Flores-Mateo G, 2006, AM J CLIN NUTR, V84, P762, DOI 10.1093/ajcn/84.4.762; Fox K, 2006, EUR HEART J, V27, P1341, DOI 10.1093/eurheartj/ehl001; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; Greenland P, 2010, J AM COLL CARDIOL, V56, pE50, DOI 10.1016/j.jacc.2010.09.001; Hackam DG, 2003, JAMA-J AM MED ASSOC, V290, P932, DOI 10.1001/jama.290.7.932; Hansen TW, 2011, HYPERTENSION, V57, P3, DOI 10.1161/HYPERTENSIONAHA.109.133900; Herselman M, 2010, NUTRITION, V26, P10, DOI 10.1016/j.nut.2009.07.009; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; Ioannidis JPA, 2011, JAMA-J AM MED ASSOC, V305, P2200, DOI 10.1001/jama.2011.713; Ioannidis JPA, 2009, ANN INTERN MED, V150, P139, DOI 10.7326/0003-4819-150-2-200901200-00012; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2001, BRIT MED J, V322, P879, DOI 10.1136/bmj.322.7291.879; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7; Kavvoura FK, 2007, PLOS MED, V4, P456, DOI 10.1371/journal.pmed.0040079; Kostis JB, 2004, EUR J CARDIOV PREV R, V11, P9, DOI 10.1097/01.hjr.0000114968.39211.01; Kyzas PA, 2005, JNCI-J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184; Kyzas PA, 2007, EUR J CANCER, V43, P2559, DOI 10.1016/j.ejca.2007.08.030; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Lowe GDO, 2004, EUR HEART J, V25, P252, DOI 10.1016/j.ehj.2003.11.004; Myers GL, 2009, CLIN CHEM, V55, P378, DOI 10.1373/clinchem.2008.115899; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; Ottani F, 2000, AM HEART J, V140, P917, DOI 10.1067/mhj.2000.111107; Padayachee L, 2009, ANAESTHESIA, V64, P416, DOI 10.1111/j.1365-2044.2008.05786.x; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Rennie D, 2004, JAMA-J AM MED ASSOC, V292, P1359, DOI 10.1001/jama.292.11.1359; Ridker PM, 2008, CIRCULATION, V118, P2243, DOI 10.1161/CIRCULATIONAHA.108.814251; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Riley RD, 2010, INT J EPIDEMIOL, V39, P1359, DOI 10.1093/ije/dyq129; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; Sarwar A, 2009, JACC-CARDIOVASC IMAG, V2, P675, DOI 10.1016/j.jcmg.2008.12.031; Sarwar N, 2007, EUR HEART J, V28, P2491, DOI 10.1093/eurheartj/ehm115; Sarwar N, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000278; Shah T, 2009, INT J EPIDEMIOL, V38, P217, DOI 10.1093/ije/dyn217; Smith GD, 2005, LANCET, V366, P1679, DOI 10.1016/S0140-6736(05)67676-3; Smith SC, 2006, J AM COLL CARDIOL, V47, P2130, DOI 10.1016/j.jacc.2006.04.026; Sterne JAC, 2002, STAT MED, V21, P1513, DOI 10.1002/sim.1184; Thompson A, 2006, J INTERN MED, V259, P481, DOI 10.1111/j.1365-2796.2006.01644.x; Thompson A, 2010, LANCET, V375, P1536, DOI 10.1016/S0140-6736(10)60319-4; Tzoulaki I, 2011, INT J EPIDEMIOL, V40, P1094, DOI 10.1093/ije/dyr013; Tzoulaki I, 2009, JAMA-J AM MED ASSOC, V302, P2345, DOI 10.1001/jama.2009.1757; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; Vasan RS, 2006, CIRCULATION, V113, P2335, DOI 10.1161/CIRCULATIONAHA.104.482570; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	63	45	45	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d6829	10.1136/bmj.d6829	http://dx.doi.org/10.1136/bmj.d6829			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848NH	22065657	Green Published, hybrid			2022-12-28	WOS:000297057800012
J	Lichtman, JW; Denk, W				Lichtman, Jeff W.; Denk, Winfried			The Big and the Small: Challenges of Imaging the Brain's Circuits	SCIENCE			English	Review							FIELD OPTICAL NANOSCOPY; IN-VIVO; FLUORESCENCE MICROSCOPY; CELLULAR RESOLUTION; NERVOUS-SYSTEM; ILLUMINATION MICROSCOPY; 2-PHOTON MICROSCOPY; NEURAL ACTIVITY; EVOKED ACTIVITY; VISUAL-CORTEX	The relation between the structure of the nervous system and its function is more poorly understood than the relation between structure and function in any other organ system. We explore why bridging the structure-function divide is uniquely difficult in the brain. These difficulties also explain the thrust behind the enormous amount of innovation centered on microscopy in neuroscience. We highlight some recent progress and the challenges that remain.	[Lichtman, Jeff W.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA; [Denk, Winfried] Max Planck Inst Med Res, Dept Biomed Opt, D-69120 Heidelberg, Germany	Harvard University; Max Planck Society	Lichtman, JW (corresponding author), Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.	jeff@mcb.harvard.edu; Winfried.Denk@mpimf-heidelberg.mpg.de	denk, winfried/I-6627-2012		NIH; Gatsby Charitable Foundation; Howard Hughes Medical Institute [43667]; Deutsche Forschungsgemeinschaft; Max-Planck Society	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gatsby Charitable Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Max-Planck Society(Max Planck Society)	We thank K. Briggman, H. Hess, J. Livet, M. Helmstaedter, and S. Smith for providing images and A. Karpova for commenting on the manuscript. Our own work was supported by the NIH, Gatsby Charitable Foundation, and a Collaborative Innovation Award (no. 43667) from Howard Hughes Medical Institute (J.W.L.), the Deutsche Forschungsgemeinschaft (W.D.), and the Max-Planck Society (W.D.). W.D. has provided a technology license for block-face EM to Gatan, Incorporated.	Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Bock DD, 2011, NATURE, V471, P177, DOI 10.1038/nature09802; Briggman KL, 2011, NATURE, V471, P183, DOI 10.1038/nature09818; Callaway EM, 2008, CURR OPIN NEUROBIOL, V18, P617, DOI 10.1016/j.conb.2009.03.007; Dani A, 2010, CURR OPIN NEUROBIOL, V20, P648, DOI 10.1016/j.conb.2010.07.006; Denk W, 2004, PLOS BIOL, V2, P1900, DOI 10.1371/journal.pbio.0020329; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Di Cristo G, 2004, NAT NEUROSCI, V7, P1184, DOI 10.1038/nn1334; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Dombeck DA, 2007, NEURON, V56, P43, DOI 10.1016/j.neuron.2007.08.003; Dombeck DA, 2010, NAT NEUROSCI, V13, P1433, DOI 10.1038/nn.2648; Ekstrand MI, 2008, TRENDS MOL MED, V14, P134, DOI 10.1016/j.molmed.2007.12.008; Ewald AJ, 2002, DEV DYNAM, V225, P369, DOI 10.1002/dvdy.10169; Fenno L, 2011, ANNU REV NEUROSCI, V34, P389, DOI 10.1146/annurev-neuro-061010-113817; HAMA H, NAT NEUROSCI, DOI DOI 10.1038/NN.2928; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; HELL SW, 1994, OPT LETT, V19, P780, DOI 10.1364/OL.19.000780; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Holekamp TF, 2008, NEURON, V57, P661, DOI 10.1016/j.neuron.2008.01.011; Huang B, 2009, ANNU REV BIOCHEM, V78, P993, DOI 10.1146/annurev.biochem.77.061906.092014; Huisken J, 2004, SCIENCE, V305, P1007, DOI 10.1126/science.1100035; Jain V, 2010, CURR OPIN NEUROBIOL, V20, P653, DOI 10.1016/j.conb.2010.07.004; Ji N, 2010, NAT METHODS, V7, P141, DOI 10.1038/NMETH.1411; Jung JC, 2004, J NEUROPHYSIOL, V92, P3121, DOI 10.1152/jn.00234.2004; Kim IJ, 2008, NATURE, V452, P478, DOI 10.1038/nature06739; Knott G, 2008, J NEUROSCI, V28, P2959, DOI 10.1523/JNEUROSCI.3189-07.2008; Kobat D, 2009, OPT EXPRESS, V17, P13354, DOI 10.1364/OE.17.013354; Kralj JM, 2011, SCIENCE, V333, P345, DOI 10.1126/science.1204763; Leighton S B, 1981, SCAN ELECT MICROSC, V2, P73; Lin DY, 2011, NATURE, V470, P221, DOI 10.1038/nature09736; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lu J, 2009, PLOS BIOL, V7, P265, DOI 10.1371/journal.pbio.1000032; Mank M, 2008, NAT METHODS, V5, P805, DOI 10.1038/NMETH.1243; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Micheva KD, 2010, NEURON, V68, P639, DOI 10.1016/j.neuron.2010.09.024; Mittmann W, 2011, NAT NEUROSCI, V14, P1089, DOI 10.1038/nn.2879; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOTTA PM, 1988, 8 INT S MORPH SCI LI, V295; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Rueckel M, 2006, P NATL ACAD SCI USA, V103, P17137, DOI 10.1073/pnas.0604791103; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Sawinski J, 2009, P NATL ACAD SCI USA, V106, P19557, DOI 10.1073/pnas.0903680106; Siedentopf H, 1902, ANN PHYS, V315, P1, DOI [10.1002/andp.19023150102, DOI 10.1002/ANDP.19023150102]; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Tsai PS, 2003, NEURON, V39, P27, DOI 10.1016/S0896-6273(03)00370-2; Tsien Roger Y, 2003, Harvey Lect, V99, P77; Weissman Tamily A, 2011, Cold Spring Harb Protoc, V2011, P763, DOI 10.1101/pdb.top114; Westphal V, 2008, SCIENCE, V320, P246, DOI 10.1126/science.1154228; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	51	257	259	3	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					618	623		10.1126/science.1209168	http://dx.doi.org/10.1126/science.1209168			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053041				2022-12-28	WOS:000296494700042
J	Lee, AI; Koo, S; Vaidya, A; Katz, JT; Loscalzo, J				Lee, Alfred Ian; Koo, Sophia; Vaidya, Anand; Katz, Joel T.; Loscalzo, Joseph			A Bird's-Eye View of Fever	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HISTOPLASMA-CAPSULATUM; ENDOPHTHALMITIS; MYCOSES; UPDATE; TISSUE		[Lee, Alfred Ian; Koo, Sophia; Vaidya, Anand; Katz, Joel T.; Loscalzo, Joseph] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Lee, Alfred Ian] Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Katz, JT (corresponding author), 75 Francis St, Boston, MA 02115 USA.	jkatz@partners.org	Loscalzo, Joseph/ABD-8980-2021	Koo, Sophia/0000-0002-4973-7439				CRAIG EL, 1974, ARCH OPHTHALMOL-CHIC, V91, P285; Freifeld AG, 2005, TRANSPL INFECT DIS, V7, P109, DOI 10.1111/j.1467-8365.2005.00105.x; GOLDSTEIN BG, 1983, ARCH OPHTHALMOL-CHIC, V101, P774, DOI 10.1001/archopht.1983.01040010774016; Gonzales CA, 2000, OPHTHALMOLOGY, V107, P725, DOI 10.1016/S0161-6420(99)00179-7; Kauffman CA, 2007, CLIN MICROBIOL REV, V20, P115, DOI 10.1128/CMR.00027-06; KLINTWORTH GK, 1973, ARCH OPHTHALMOL-CHIC, V90, P45, DOI 10.1001/archopht.1973.01000050047009; Koo HL, 2008, TRANSPL INFECT DIS, V10, P351, DOI 10.1111/j.1399-3062.2007.00295.x; Prasad Anita G, 2005, Curr Opin Ophthalmol, V16, P364, DOI 10.1097/01.icu.0000188321.61101.93; PULIDO JS, 1990, OPHTHALMOLOGY, V97, P217, DOI 10.1016/S0161-6420(90)32603-9; SAROSI GA, 1971, ANN INTERN MED, V75, P511, DOI 10.7326/0003-4819-75-4-511; SMITH JW, 1972, ANN INTERN MED, V76, P557, DOI 10.7326/0003-4819-76-4-557; Spetie DN, 2004, KIDNEY INT, V66, P2411, DOI 10.1111/j.1523-1755.2004.66030.x; Wheat J, 1997, CLIN INFECT DIS, V24, P1169, DOI 10.1086/513647; Wheat LJ, 2007, CLIN INFECT DIS, V45, P807, DOI 10.1086/521259	14	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1727	1732		10.1056/NEJMcps1012518	http://dx.doi.org/10.1056/NEJMcps1012518			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047564				2022-12-28	WOS:000296424200013
J	Xue, MS; Giagtzoglou, N; Bellen, HJ				Xue, Mingshan; Giagtzoglou, Nikolaos; Bellen, Hugo J.			Dueling Ca2+ Sensors in Neurotransmitter Release	CELL			English	Editorial Material							TRANSMITTER RELEASE; CENTRAL SYNAPSE; FUSION; DOC2B	Ca2+-triggered neurotransmitter release is characterized by two kinetically distinct components: a fast synchronous phase and a slow asynchronous phase. Yao et al. (2011) now report that double C2 domain (Doc2) proteins function as high-affinity Ca2+ sensors to specifically regulate the asynchronous component of neurotransmitter release.	[Giagtzoglou, Nikolaos; Bellen, Hugo J.] Baylor Coll Med, Program Dev Biol, Dept Mol & Human Genet, Houston, TX 77030 USA; [Giagtzoglou, Nikolaos; Bellen, Hugo J.] Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; [Xue, Mingshan] Univ Calif San Diego, Neurobiol Sect, Div Biol Sci, La Jolla, CA 92093 USA; [Xue, Mingshan] Univ Calif San Diego, Ctr Neural Circuits & Behav, La Jolla, CA 92093 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Bellen, HJ (corresponding author), Baylor Coll Med, Program Dev Biol, Dept Mol & Human Genet, Houston, TX 77030 USA.	hbellen@bcm.edu		Bellen, Hugo/0000-0001-5992-5989; Xue, Mingshan/0000-0003-1463-8884	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Craxton M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-37; Friedrich R, 2010, MOL NEUROBIOL, V41, P42, DOI 10.1007/s12035-009-8094-8; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; Groffen AJ, 2010, SCIENCE, V327, P1614, DOI 10.1126/science.1183765; Maximov A, 2009, SCIENCE, V323, P516, DOI 10.1126/science.1166505; Pang ZPP, 2011, NEURON, V70, P244, DOI 10.1016/j.neuron.2011.03.011; Rizo J, 2008, NAT STRUCT MOL BIOL, V15, P665, DOI 10.1038/nsmb.1450; Xue MS, 2008, P NATL ACAD SCI USA, V105, P7875, DOI 10.1073/pnas.0803012105; Yao J, 2011, CELL, V147, P666, DOI 10.1016/j.cell.2011.09.046	10	7	7	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					490	492		10.1016/j.cell.2011.10.007	http://dx.doi.org/10.1016/j.cell.2011.10.007			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036557	Green Accepted, Bronze			2022-12-28	WOS:000296573700004
J	Cernilogar, FM; Onorati, MC; Kothe, GO; Burroughs, AM; Parsi, KM; Breiling, A; Lo Sardo, F; Saxena, A; Miyoshi, K; Siomi, H; Siomi, MC; Carninci, P; Gilmour, DS; Corona, DFV; Orlando, V				Cernilogar, Filippo M.; Onorati, Maria Cristina; Kothe, Greg O.; Burroughs, A. Maxwell; Parsi, Krishna Mohan; Breiling, Achim; Lo Sardo, Federica; Saxena, Alka; Miyoshi, Keita; Siomi, Haruhiko; Siomi, Mikiko C.; Carninci, Piero; Gilmour, David S.; Corona, Davide F. V.; Orlando, Valerio			Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila	NATURE			English	Article							POLYMERASE-II; IN-VIVO; DISTINCT ROLES; SOMATIC-CELLS; HEAT-SHOCK; PATHWAY; POLYCOMB; PROTEINS; PROMOTER; RISC	RNA interference (RNAi) pathways have evolved as important modulators of gene expression that operate in the cytoplasm by degrading RNA target molecules through the activity of short (21-30 nucleotide) RNAs1-6. RNAi components have been reported to have a role in the nucleus, as they are involved in epigenetic regulation and heterochromatin formation(7-10). However, although RNAi-mediated post-transcriptional gene silencing is well documented, the mechanisms of RNAi-mediated transcriptional gene silencing and, in particular, the role of RNAi components in chromatin dynamics, especially in animal multicellular organisms, are elusive. Here we show that the key RNAi components Dicer 2 (DCR2) and Argonaute 2 (AGO2) associate with chromatin (with a strong preference for euchromatic, transcriptionally active, loci) and interact with the core transcription machinery. Notably, loss of function of DCR2 or AGO2 showed that transcriptional defects are accompanied by the perturbation of RNA polymerase II positioning on promoters. Furthermore, after heat shock, both Dcr2 and Ago2 null mutations, as well as missense mutations that compromise the RNAi activity, impaired the global dynamics of RNA polymerase II. Finally, the deep sequencing of the AGO2-associated small RNAs (AGO2 RIP-seq) revealed that AGO2 is strongly enriched in small RNAs that encompass the promoter regions and other regions of heat-shock and other genetic loci on both the sense and antisense DNA strands, but with a strong bias for the antisense strand, particularly after heat shock. Taken together, our results show that DCR2 and AGO2 are globally associated with transcriptionally active loci and may have a pivotal role in shaping the transcriptome by controlling the processivity of RNA polymerase II.	[Cernilogar, Filippo M.; Parsi, Krishna Mohan; Lo Sardo, Federica; Orlando, Valerio] IRCCS Fdn Santa Lucia, Dulbecco Telethon Inst, Epigenet & Genome Reprogramming, I-00143 Rome, Italy; [Cernilogar, Filippo M.; Parsi, Krishna Mohan] IGB ABT CNR, Dulbecco Telethon Inst, I-80131 Naples, Italy; [Onorati, Maria Cristina; Corona, Davide F. V.] Univ Palermo, Dulbecco Telethon Inst, Dipartimento STEMBIO, Sez Biol Cellulare, I-90128 Palermo, Italy; [Kothe, Greg O.; Gilmour, David S.] Penn State Univ, Ctr Eukaryot Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Burroughs, A. Maxwell; Saxena, Alka; Carninci, Piero] RIKEN Yokohama Inst, RIKEN Om Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; [Breiling, Achim] German Canc Res Ctr, DKFZ ZMBH Alliance, Div Epigenet, D-69120 Heidelberg, Germany; [Miyoshi, Keita; Siomi, Haruhiko; Siomi, Mikiko C.] Keio Univ, Sch Med, Tokyo 1608582, Japan; [Siomi, Mikiko C.] CREST, JST, Kawaguchi, Saitama 3320012, Japan	Fondazione Telethon; Dulbecco Telethon Institute (DTI); IRCCS Santa Lucia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Palermo; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; RIKEN; Helmholtz Association; German Cancer Research Center (DKFZ); Keio University; Japan Science & Technology Agency (JST)	Orlando, V (corresponding author), IRCCS Fdn Santa Lucia, Dulbecco Telethon Inst, Epigenet & Genome Reprogramming, Via Fosso di Fiorano 64, I-00143 Rome, Italy.	vorlando@dti.telethon.it	Sardo, Federica Lo/AAC-1757-2019; Carninci, Piero/K-1568-2014; Cernilogar, Filippo/AAC-3243-2021; Parsi, Krishna Mohan/AAA-4992-2019; Siomi, Haruhiko/A-7020-2015; Corona, Davide F.V./H-8467-2012	Sardo, Federica Lo/0000-0002-2912-079X; Carninci, Piero/0000-0001-7202-7243; Cernilogar, Filippo/0000-0003-2814-3436; Parsi, Krishna Mohan/0000-0002-6002-3816; Siomi, Haruhiko/0000-0001-8690-3822; Burroughs, A. Max/0000-0002-2229-8771; Breiling, Achim/0000-0002-7928-299X	National Institutes of Health [GM47477]; Deutsche Forschungsgemeinschaft [SPP 1356]; Japan Society for the Promotion of Science (JSPS) [20241047, P09745]; Council for Science and Technology Policy; NEXT Program; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency; Fondazione Telethon; Giovanni Armenise Harvard Foundation; FIRB-MIUR; Associazione Italiana Ricerca Cancro (AIRC); Human Frontier Science Program CDA; EMBO; AIRC; EU; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047477] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Council for Science and Technology Policy(Council for Science and Technology Policy (CSTP)); NEXT Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency(Core Research for Evolutional Science and Technology (CREST)); Fondazione Telethon(Fondazione TelethonEuropean Commission); Giovanni Armenise Harvard Foundation; FIRB-MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Human Frontier Science Program CDA(Human Frontier Science Program); EMBO(European Molecular Biology Organization (EMBO)); AIRC(Fondazione AIRC per la ricerca sul cancro); EU(European Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are deeply grateful to P. Macino for discussions. We also thank R. Carthew, E. Lai, Q. Liu, R. Paro, Y. Sik Lee, and J. T. Kadonaga for reagents. This work was supported by grants from the following: the National Institutes of Health (GM47477) to D. S. G.; the Deutsche Forschungsgemeinschaft (SPP 1356) to A. B.; the Japan Society for the Promotion of Science (JSPS) through the 'Funding Program for Next Generation World-Leading Researchers' (NEXT Program) (a Grant-in-Aid for Scientific Research (A) No. 20241047) and the Council for Science and Technology Policy to P. C.; the NEXT Program (a Research Grant-in-Aid to the RIKEN OSC) to K. M., M. C. S. and H. S.; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency to M. C. S.; Fondazione Telethon, the Giovanni Armenise Harvard Foundation, FIRB-MIUR, Associazione Italiana Ricerca Cancro (AIRC), the Human Frontier Science Program CDA and the EMBO Young investigator program to D. F. V. C.; Fondazione Telethon, AIRC and the EU FP6 Epigenome Network of Excellence to V.O. This work was also made possible with the contribution of the Italian Ministry of Foreign Affairs, 'Direzione Generale per la Promozione e la Cooperazione Culturale' to V.O. A. S. is supported by a JSPS fellowship (ID P09745). Sequencing was provided by the Genas service (RIKEN Omics Science Center).	Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Boehm AK, 2003, MOL CELL BIOL, V23, P7628, DOI 10.1128/MCB.23.21.7628-7637.2003; Breiling A, 2004, EMBO REP, V5, P976, DOI 10.1038/sj.embor.7400260; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Cai WL, 2008, DEVELOPMENT, V135, P2917, DOI 10.1242/dev.024927; Cartwright IL, 1999, METHOD ENZYMOL, V304, P462; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Corona DFV, 2004, METHOD ENZYMOL, V377, P70; Czech B, 2008, NATURE, V453, P798, DOI 10.1038/nature07007; de Hoon MJL, 2010, GENOME RES, V20, P257, DOI 10.1101/gr.095273.109; El-Shami M, 2007, GENE DEV, V21, P2539, DOI 10.1101/gad.451207; Ghildiyal M, 2008, SCIENCE, V320, P1077, DOI 10.1126/science.1157396; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; Hoskins RA, 2011, GENOME RES, V21, P182, DOI 10.1101/gr.112466.110; Hsu JY, 2008, GENE DEV, V22, P2353, DOI 10.1101/gad.1681808; Kavi HH, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-15; Kawamura Y, 2008, NATURE, V453, P793, DOI 10.1038/nature06938; Kawano M, 2010, BIOTECHNIQUES, V49, P751, DOI 10.2144/000113516; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Kim K, 2007, RNA, V13, P22, DOI 10.1261/rna.283207; Lee CY, 2008, MOL CELL BIOL, V28, P3290, DOI 10.1128/MCB.02224-07; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lim DH, 2008, BIOCHEM BIOPH RES CO, V371, P525, DOI 10.1016/j.bbrc.2008.04.118; Lis JT, 2007, NATURE, V450, P198, DOI 10.1038/nature06324; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Llano M, 2006, J MOL BIOL, V360, P760, DOI 10.1016/j.jmb.2006.04.073; Lupo R, 2001, MOL CELL, V7, P127, DOI 10.1016/S1097-2765(01)00161-7; Malone CD, 2009, CELL, V136, P656, DOI 10.1016/j.cell.2009.01.045; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; Mituyama T, 2009, NUCLEIC ACIDS RES, V37, pD89, DOI 10.1093/nar/gkn805; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Miyoshi K, 2009, RNA, V15, P1282, DOI 10.1261/rna.1541209; Moazed D, 2009, NATURE, V457, P413, DOI 10.1038/nature07756; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Okamura K, 2008, NATURE, V453, P803, DOI 10.1038/nature07015; Pimpinelli S., 2000, DROSOPHILA LAB MANUA, P1; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; Stock JK, 2007, NAT CELL BIOL, V9, P1428, DOI 10.1038/ncb1663; Teixeira FK, 2009, SCIENCE, V323, P1600, DOI 10.1126/science.1165313; Tweedie S, 2009, NUCLEIC ACIDS RES, V37, pD555, DOI 10.1093/nar/gkn788; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403	44	163	171	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					391	U151		10.1038/nature10492	http://dx.doi.org/10.1038/nature10492			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22056986	Green Accepted			2022-12-28	WOS:000298033000057
J	Jacobson, M; Earle, CC; Newhouse, JP				Jacobson, Mireille; Earle, Craig C.; Newhouse, Joseph P.			Geographic Variation in Physicians' Responses to a Reimbursement Change	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER		[Jacobson, Mireille] RAND Corp, Santa Monica, CA 90406 USA; [Earle, Craig C.] Canc Care Ontario, Toronto, ON, Canada; [Newhouse, Joseph P.] Harvard Univ, Sch Med, Boston, MA USA	RAND Corporation; Cancer Care Ontario; Harvard University; Harvard Medical School	Jacobson, M (corresponding author), RAND Corp, Santa Monica, CA 90406 USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022; Jacobson, Mireille/AAD-1190-2022	Jacobson, Mireille/0000-0002-4977-8783	NCI NIH HHS [R01 CA152043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA152043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1999, DARTMOUTH ATLAS HLTH; *BOARDS TRUST FED, 2011, BOARDS TRUST FED 201; Earle CC, 2002, MED CARE, V40, P75; Gross CP, 2006, JAMA-J AM MED ASSOC, V296, P2815, DOI 10.1001/jama.296.23.2815; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563	5	26	26	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	2011	365	22					2049	2052		10.1056/NEJMp1110117	http://dx.doi.org/10.1056/NEJMp1110117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854MO	22047517	Green Accepted			2022-12-28	WOS:000297499000004
J	Suga, H; Kadoshima, T; Minaguchi, M; Ohgushi, M; Soen, M; Nakano, T; Takata, N; Wataya, T; Muguruma, K; Miyoshi, H; Yonemura, S; Oiso, Y; Sasai, Y				Suga, Hidetaka; Kadoshima, Taisuke; Minaguchi, Maki; Ohgushi, Masatoshi; Soen, Mika; Nakano, Tokushige; Takata, Nozomu; Wataya, Takafumi; Muguruma, Keiko; Miyoshi, Hiroyuki; Yonemura, Shigenobu; Oiso, Yutaka; Sasai, Yoshiki			Self-formation of functional adenohypophysis in three-dimensional culture	NATURE			English	Article							PITUITARY-GLAND; RATHKES POUCH; CELL LINEAGES; DIFFERENTIATION; SPECIFICATION; INDUCTION; GROWTH; ORGANOGENESIS; MECHANISMS; EXPRESSION	The adenohypophysis (anterior pituitary) is a major centre for systemic hormones. At present, no efficient stem-cell culture for its generation is available, partly because of insufficient knowledge about how the pituitary primordium (Rathke's pouch) is induced in the embryonic head ectoderm. Here we report efficient self-formation of three-dimensional adenohypophysis tissues in an aggregate culture of mouse embryonic stem (ES) cells. ES cells were stimulated to differentiate into non-neural head ectoderm and hypothalamic neuroectoderm in adjacent layers within the aggregate, and treated with hedgehog signalling. Self-organization of Rathke's-pouch-like three-dimensional structures occurred at the interface of these two epithelia, as seen in vivo, and various endocrine cells including corticotrophs and somatotrophs were subsequently produced. The corticotrophs efficiently secreted adrenocorticotropic hormone in response to corticotrophin releasing hormone and, when grafted in vivo, these cells rescued the systemic glucocorticoid level in hypopituitary mice. Thus, functional anterior pituitary tissue self-forms in ES cell culture, recapitulating local tissue interactions.	[Suga, Hidetaka; Kadoshima, Taisuke; Minaguchi, Maki; Soen, Mika; Nakano, Tokushige; Takata, Nozomu; Wataya, Takafumi; Muguruma, Keiko; Sasai, Yoshiki] RIKEN Ctr Dev Biol, Neurogenesis & Organogenesis Grp, Kobe, Hyogo 6500047, Japan; [Suga, Hidetaka; Ohgushi, Masatoshi] RIKEN Ctr Dev Biol, Div Human Stem Cell Technol, Kobe, Hyogo 6500047, Japan; [Suga, Hidetaka; Oiso, Yutaka] Nagoya Univ, Dept Endocrinol & Diabet, Grad Sch Med, Nagoya, Aichi 4668550, Japan; [Miyoshi, Hiroyuki] RIKEN, Subteam Manipulat Cell Fate, BioResource Ctr, Tsukuba, Ibaraki 3050074, Japan; [Yonemura, Shigenobu] RIKEN Ctr Dev Biol, Electron Microscopy Lab, Kobe, Hyogo 6500047, Japan	RIKEN; RIKEN; Nagoya University; RIKEN; RIKEN	Sasai, Y (corresponding author), RIKEN Ctr Dev Biol, Neurogenesis & Organogenesis Grp, Kobe, Hyogo 6500047, Japan.	yoshikisasai@cdb.riken.jp	SUGA, HIDETAKA/I-7452-2014; Miyoshi, Hiroyuki/G-9808-2013; Takata, Nozomu/AAI-9801-2020	Takata, Nozomu/0000-0003-0171-6994; Muguruma, Keiko/0000-0002-3149-4408; Suga, Hidetaka/0000-0003-1924-7639	Ministry of Education, Culture, Sports, Science and Technology; Knowledge Cluster Initiative at Kobe; Leading Project for Realization of Regenerative Medicine; Grants-in-Aid for Scientific Research [22390188] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Knowledge Cluster Initiative at Kobe; Leading Project for Realization of Regenerative Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to H. Enomoto, R. Ladher and M. Eiraku for invaluable comments, to K. Misaki for electron microscopy analysis, and to members of the Y.S. laboratory for discussion. This work was supported by grants-in-aid from Ministry of Education, Culture, Sports, Science and Technology (Y.S., Y.O.), the Knowledge Cluster Initiative at Kobe, and the Leading Project for Realization of Regenerative Medicine (Y.S.).	Basch ML, 2006, ADV EXP MED BIOL, V589, P24; Bharti K, 2011, DEVELOPMENT, V138, P873, DOI 10.1242/dev.056465; Danjo T, 2011, J NEUROSCI, V31, P1919, DOI 10.1523/JNEUROSCI.5128-10.2011; Davis SW, 2010, MOL CELL ENDOCRINOL, V323, P4, DOI 10.1016/j.mce.2009.12.012; Davis SW, 2011, DEV BIOL, V352, P215, DOI 10.1016/j.ydbio.2011.01.010; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941; Ellsworth BS, 2008, DEV BIOL, V313, P118, DOI 10.1016/j.ydbio.2007.10.006; Ericson J, 1998, DEVELOPMENT, V125, P1005; FALCONI G, 1964, ENDOCRINOLOGY, V74, P301, DOI 10.1210/endo-74-2-301; Gleiberman AS, 1999, DEV BIOL, V213, P340, DOI 10.1006/dbio.1999.9386; HEMMING FJ, 1984, ENDOCRINOLOGY, V114, P2107, DOI 10.1210/endo-114-6-2107; Ingle DJ, 1938, AM J PHYSIOL, V124, P369, DOI 10.1152/ajplegacy.1938.124.2.369; JONES CM, 1991, DEVELOPMENT, V111, P531; Kelberman D, 2009, ENDOCR REV, V30, P790, DOI 10.1210/er.2009-0008; Kikuchi M, 2007, ANAT REC, V290, P486, DOI 10.1002/ar.20516; Kita A, 2007, MOL ENDOCRINOL, V21, P1458, DOI 10.1210/me.2007-0039; Lamolet B, 2001, CELL, V104, P849, DOI 10.1016/S0092-8674(01)00282-3; Mason I, 2007, NAT REV NEUROSCI, V8, P583, DOI 10.1038/nrn2189; Melmed S, 2011, PITUITARY, P61; Ogasawara K, 2009, ENDOCRINOLOGY, V150, P1061, DOI 10.1210/en.2008-1151; Rizzoti K, 2005, REV ENDOCR METAB DIS, V6, P161, DOI 10.1007/s11154-005-3047-7; Romero CJ, 2009, TRENDS ENDOCRIN MET, V20, P506, DOI 10.1016/j.tem.2009.06.005; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Suh H, 2002, DEVELOPMENT, V129, P329; Takuma N, 1998, DEVELOPMENT, V125, P4835; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; Treier M, 2001, DEVELOPMENT, V128, P377; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wataya T, 2008, P NATL ACAD SCI USA, V105, P11796, DOI 10.1073/pnas.0803078105; Zhao YG, 2006, MECH DEVELOP, V123, P605, DOI 10.1016/j.mod.2006.06.005; Zhu XY, 2007, PHYSIOL REV, V87, P933, DOI 10.1152/physrev.00006.2006; Zhu XY, 2006, GENE DEV, V20, P2739, DOI 10.1101/gad.1444706	33	332	352	4	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	2011	480	7375					57	U215		10.1038/nature10637	http://dx.doi.org/10.1038/nature10637			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22080957				2022-12-28	WOS:000298031900032
J	Nam, Y; Chen, C; Gregory, RI; Chou, JJ; Sliz, P				Nam, Yunsun; Chen, Casandra; Gregory, Richard I.; Chou, James J.; Sliz, Piotr			Molecular Basis for Interaction of let-7 MicroRNAs with Lin28	CELL			English	Article							GENOME-WIDE ASSOCIATION; COLD SHOCK PROTEIN; POSTTRANSCRIPTIONAL REGULATION; LIN-28; BIOGENESIS; RECOGNITION; IDENTIFICATION; MATURATION; BINDING; DROSHA	MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate gene expression. Among these, members of the let-7 miRNA family control many cell-fate determination genes to influence pluripotency, differentiation, and transformation. Lin28 is a specific, posttranscriptional inhibitor of let-7 biogenesis. We report crystal structures of mouse Lin28 in complex with sequences from let-7d, let-7-f1, and let-7g precursors. The two folded domains of Lin28 recognize two distinct regions of the RNA and are sufficient for inhibition of let-7 in vivo. We also show by NMR spectroscopy that the linker connecting the two folded domains is flexible, accommodating Lin28 binding to diverse let-7 family members. Protein-RNA complex formation imposes specific conformations on both components that could affect downstream recognition by other processing factors. Our data provide a molecular explanation for Lin28 specificity and a model for how it regulates let-7.	[Nam, Yunsun; Chen, Casandra; Gregory, Richard I.; Chou, James J.; Sliz, Piotr] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Nam, Yunsun; Chen, Casandra; Sliz, Piotr] Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; [Nam, Yunsun; Chen, Casandra; Gregory, Richard I.; Sliz, Piotr] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Sliz, P (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	piotr_sliz@hms.harvard.edu	Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; Nam, Yunsun/0000-0002-7939-8626; Sliz, Piotr/0000-0002-6522-0835	Center for Molecular and Cellular Dynamics at Harvard Medical School,; NIH [5U54GM094608]; Damon Runyon Cancer Research Foundation (DRG) [1953-07]; Charles A. King Trust N.A.; Bank of America; NATIONAL CANCER INSTITUTE [R01CA163647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094608] Funding Source: NIH RePORTER	Center for Molecular and Cellular Dynamics at Harvard Medical School,; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation (DRG); Charles A. King Trust N.A.; Bank of America; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Stephen C. Harrison for discussion and critical review of the manuscript, members of the Chou Lab for discussion about NMR experiments, Janet Iwasa for help with design of Figure 7, George Q. Daley for the pri-miR constructs for in vivo processing assays, Thomas Tuschl for Dicer expression construct, Katarzyna Szatkowski for technical assistance, and Elizabeth O'Day for participation during the early stages of the project. This work is based upon research conducted at the Advanced Photon Source (Northeastern Collaborative Access Team beamlines) and Brookhaven National Laboratory (beamline X25). This work was partially supported by Center for Molecular and Cellular Dynamics at Harvard Medical School, by NIH grant 5U54GM094608, and by postdoctoral fellowships to Y.N. from the Damon Runyon Cancer Research Foundation (DRG-# 1953-07) and the Charles A. King Trust, N.A., Bank of America, Co-Trustee. Y. N. performed experiments. C. C. provided technical assistance with experiments. R. G. provided the Lin28 clone and participated in discussions. J. C. helped with NMR spectroscopy. Y. N. and P. S. designed and interpreted experiments and prepared the manuscript.	Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Davis-Dusenbery Brandi N, 2010, Genes Cancer, V1, P1100, DOI 10.1177/1947601910396213; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; De N, 2011, METHODS MOL BIOL, V725, P107, DOI 10.1007/978-1-61779-046-1_8; Du Z, 2008, P NATL ACAD SCI USA, V105, P2391, DOI 10.1073/pnas.0711506105; Frazao C, 2006, NATURE, V443, P110, DOI 10.1038/nature05080; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jin JY, 2011, NUCLEIC ACIDS RES, V39, P3724, DOI 10.1093/nar/gkq1350; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lehrbach NJ, 2009, NAT STRUCT MOL BIOL, V16, P1016, DOI 10.1038/nsmb.1675; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Lu LG, 2009, EUR J CANCER, V45, P2212, DOI 10.1016/j.ejca.2009.05.003; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Markham NR, 2005, NUCLEIC ACIDS RES, V33, pW577, DOI 10.1093/nar/gki591; Max KEA, 2007, FEBS J, V274, P1265, DOI 10.1111/j.1742-4658.2007.05672.x; Max KEA, 2006, J MOL BIOL, V360, P702, DOI 10.1016/j.jmb.2006.05.044; Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013; Michlewski G, 2010, NAT STRUCT MOL BIOL, V17, P1011, DOI 10.1038/nsmb.1874; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Ong KK, 2009, NAT GENET, V41, P729, DOI 10.1038/ng.382; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Peng SP, 2011, STEM CELLS, V29, P496, DOI 10.1002/stem.591; Permuth-Wey J, 2011, CANCER RES, V71, P3896, DOI 10.1158/0008-5472.CAN-10-4167; Perry JRB, 2009, NAT GENET, V41, P648, DOI 10.1038/ng.386; Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Sulem P, 2009, NAT GENET, V41, P734, DOI 10.1038/ng.383; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Walker SC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng082; Wan GQ, 2010, RNA, V16, P1436, DOI 10.1261/rna.2001610; Yang DH, 2003, GENE EXPR PATTERNS, V3, P719, DOI 10.1016/S1567-133X(03)00140-6; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200; Zhang XX, 2010, NUCLEIC ACIDS RES, V38, P7689, DOI 10.1093/nar/gkq645; Zhu H, 2010, NAT GENET, V42, P626, DOI 10.1038/ng.593	53	275	293	0	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 23	2011	147	5					1080	1091		10.1016/j.cell.2011.10.020	http://dx.doi.org/10.1016/j.cell.2011.10.020			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852SA	22078496	Green Accepted, Bronze			2022-12-28	WOS:000297376600019
J	Armache, KJ; Garlick, JD; Canzio, D; Narlikar, GJ; Kingston, RE				Armache, Karim-Jean; Garlick, Joseph D.; Canzio, Daniele; Narlikar, Geeta J.; Kingston, Robert E.			Structural Basis of Silencing: Sir3 BAH Domain in Complex with a Nucleosome at 3.0 angstrom Resolution	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE H3; MATING LOCI; TELOMERIC HETEROCHROMATIN; PROTEIN INTERACTIONS; GENETIC-ANALYSIS; CORE PARTICLE; N-TERMINUS; YEAST; CHROMATIN	Gene silencing is essential for regulating cell fate in eukaryotes. Altered chromatin architectures contribute to maintaining the silenced state in a variety of species. The silent information regulator (Sir) proteins regulate mating type in Saccharomyces cerevisiae. One of these proteins, Sir3, interacts directly with the nucleosome to help generate silenced domains. We determined the crystal structure of a complex of the yeast Sir3 BAH (bromo-associated homology) domain and the nucleosome core particle at 3.0 angstrom resolution. We see multiple molecular interactions between the protein surfaces of the nucleosome and the BAH domain that explain numerous genetic mutations. These interactions are accompanied by structural rearrangements in both the nucleosome and the BAH domain. The structure explains how covalent modifications on H4K16 and H3K79 regulate formation of a silencing complex that contains the nucleosome as a central component.	[Armache, Karim-Jean; Garlick, Joseph D.; Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Armache, Karim-Jean; Garlick, Joseph D.; Kingston, Robert E.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Canzio, Daniele; Narlikar, Geeta J.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Canzio, Daniele] Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94158 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kingston@molbio.mgh.harvard.edu			NIH [GM043901]; Human Frontier Science Program; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048405, R01GM043901] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program(Human Frontier Science Program); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grant GM043901 from NIH (to R. E. K.). K-J.A. was supported in part by a fellowship from the Human Frontier Science Program. We thank the staff at Beamlines 24-IDC/E at Argonne National Laboratory, especially K. Rajashankar and F. Murphy, for excellent assistance with data collection. We thank R. Sternglanz for BAH domain constructs. We thank T. Schwartz for use of the high-throughput crystallization facility, as well as helpful discussions and critical reading of the manuscript. We thank F. Winston for critical reading of the manuscript. We thank S. Jenni and D. Kostrewa for helpful discussions; S. Tan and K. Luger for help with technical aspects of forming nucleosomes; J. Cochrane, S. Bowman, S. Miller, M. Simon, and K. Bouazoune for critical reading of the manuscript, and members of the Kingston laboratory for helpful discussions. Coordinates and structure factors have been deposited in the Protein Data Bank with accession code 3TU4.	APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Barbera AJ, 2006, SCIENCE, V311, P856, DOI 10.1126/science.1120541; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Buchberger JR, 2008, MOL CELL BIOL, V28, P6903, DOI 10.1128/MCB.01210-08; Connelly JJ, 2006, MOL CELL BIOL, V26, P3256, DOI 10.1128/MCB.26.8.3256-3265.2006; Dai JBA, 2010, GENETICS, V186, P813, DOI 10.1534/genetics.110.118489; Ehrentraut S, 2011, GENE DEV, V25, P1835, DOI 10.1101/gad.17175111; Fry CJ, 2006, MOL CELL BIOL, V26, P9045, DOI 10.1128/MCB.00248-06; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Hou ZG, 2006, PROTEIN SCI, V15, P1182, DOI 10.1110/ps.052061006; Johnson A, 2009, MOL CELL, V35, P769, DOI 10.1016/j.molcel.2009.07.030; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; King DA, 2006, J BIOL CHEM, V281, P20107, DOI 10.1074/jbc.M512588200; Kyriss MNM, 2010, MOL CELL BIOL, V30, P3503, DOI 10.1128/MCB.00290-10; Liaw H, 2006, MOL CELL BIOL, V26, P7616, DOI 10.1128/MCB.01082-06; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Liu C, 1996, GENETICS, V143, P81; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; Makde RD, 2010, NATURE, V467, P562, DOI 10.1038/nature09321; Martino F, 2009, MOL CELL, V33, P323, DOI 10.1016/j.molcel.2009.01.009; McBryant SJ, 2008, MOL CELL BIOL, V28, P3563, DOI 10.1128/MCB.01389-07; McBryant SJ, 2006, BIOCHEMISTRY-US, V45, P15941, DOI 10.1021/bi061693k; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Norris A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000301; Onishi M, 2007, MOL CELL, V28, P1015, DOI 10.1016/j.molcel.2007.12.004; Oppikofer M, 2011, EMBO J, V30, P2610, DOI 10.1038/emboj.2011.170; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Park Y, 1998, GENETICS, V150, P977; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2002, MOL BIOL CELL, V13, P2207, DOI 10.1091/mbc.E02-03-0175; Sampath V, 2009, MOL CELL BIOL, V29, P2532, DOI 10.1128/MCB.01682-08; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; Singer MS, 1998, GENETICS, V150, P613; Stone EM, 2000, GENETICS, V155, P509; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; Tanny JC, 2004, MOL CELL BIOL, V24, P6931, DOI 10.1128/MCB.24.16.6931-6946.2004; Thompson JS, 2003, GENETICS, V163, P447; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Yu Q, 2011, GENETICS, V188, P291, DOI 10.1534/genetics.111.127886	52	175	175	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					977	982		10.1126/science.1210915	http://dx.doi.org/10.1126/science.1210915			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096199	Green Accepted			2022-12-28	WOS:000297101800056
J	Lorenzen, ED; Nogues-Bravo, D; Orlando, L; Weinstock, J; Binladen, J; Marske, KA; Ugan, A; Borregaard, MK; Gilbert, MTP; Nielsen, R; Ho, SYW; Goebel, T; Graf, KE; Byers, D; Stenderup, JT; Rasmussen, M; Campos, PF; Leonard, JA; Koepfli, KP; Froese, D; Zazula, G; Stafford, TW; Aaris-Sorensen, K; Batra, P; Haywood, AM; Singarayer, JS; Valdes, PJ; Boeskorov, G; Burns, JA; Davydov, SP; Haile, J; Jenkins, DL; Kosintsev, P; Kuznetsova, T; Lai, XL; Martin, LD; McDonald, HG; Mol, D; Meldgaard, M; Munch, K; Stephan, E; Sablin, M; Sommer, RS; Sipko, T; Scott, E; Suchard, MA; Tikhonov, A; Willerslev, R; Wayne, RK; Cooper, A; Hofreiter, M; Sher, A; Shapiro, B; Rahbek, C; Willerslev, E				Lorenzen, Eline D.; Nogues-Bravo, David; Orlando, Ludovic; Weinstock, Jaco; Binladen, Jonas; Marske, Katharine A.; Ugan, Andrew; Borregaard, Michael K.; Gilbert, M. Thomas P.; Nielsen, Rasmus; Ho, Simon Y. W.; Goebel, Ted; Graf, Kelly E.; Byers, David; Stenderup, Jesper T.; Rasmussen, Morten; Campos, Paula F.; Leonard, Jennifer A.; Koepfli, Klaus-Peter; Froese, Duane; Zazula, Grant; Stafford, Thomas W., Jr.; Aaris-Sorensen, Kim; Batra, Persaram; Haywood, Alan M.; Singarayer, Joy S.; Valdes, Paul J.; Boeskorov, Gennady; Burns, James A.; Davydov, Sergey P.; Haile, James; Jenkins, Dennis L.; Kosintsev, Pavel; Kuznetsova, Tatyana; Lai, Xulong; Martin, Larry D.; McDonald, H. Gregory; Mol, Dick; Meldgaard, Morten; Munch, Kasper; Stephan, Elisabeth; Sablin, Mikhail; Sommer, Robert S.; Sipko, Taras; Scott, Eric; Suchard, Marc A.; Tikhonov, Alexei; Willerslev, Rane; Wayne, Robert K.; Cooper, Alan; Hofreiter, Michael; Sher, Andrei; Shapiro, Beth; Rahbek, Carsten; Willerslev, Eske			Species-specific responses of Late Quaternary megafauna to climate and humans	NATURE			English	Article							PLEISTOCENE; DYNAMICS; MAMMOTH; STEPPE; EXTINCTIONS; INFERENCE; PATTERNS; DECLINE; YUKON	Despite decades of research, the roles of climate and humans in driving the dramatic extinctions of large-bodied mammals during the Late Quaternary period remain contentious. Here we use ancient DNA, species distribution models and the human fossil record to elucidate how climate and humans shaped the demographic history of woolly rhinoceros, woolly mammoth, wild horse, reindeer, bison and musk ox. We show that climate has been a major driver of population change over the past 50,000 years. However, each species responds differently to the effects of climatic shifts, habitat redistribution and human encroachment. Although climate change alone can explain the extinction of some species, such as Eurasian musk ox and woolly rhinoceros, a combination of climatic and anthropogenic effects appears to be responsible for the extinction of others, including Eurasian steppe bison and wild horse. We find no genetic signature or any distinctive range dynamics distinguishing extinct from surviving species, emphasizing the challenges associated with predicting future responses of extant mammals to climate and human-mediated habitat change.	[Lorenzen, Eline D.; Orlando, Ludovic; Weinstock, Jaco; Binladen, Jonas; Gilbert, M. Thomas P.; Stenderup, Jesper T.; Rasmussen, Morten; Campos, Paula F.; Stafford, Thomas W., Jr.; Aaris-Sorensen, Kim; Haile, James; Meldgaard, Morten; Willerslev, Eske] Univ Copenhagen, Ctr GeoGenet, DK-1350 Copenhagen K, Denmark; [Nogues-Bravo, David; Marske, Katharine A.; Borregaard, Michael K.; Rahbek, Carsten] Univ Copenhagen, Dept Biol, Ctr Macroecol Evolut & Climate, DK-2100 Copenhagen O, Denmark; [Ugan, Andrew] Smithsonian Trop Res Inst, Ancon, Punama, Panama; [Nielsen, Rasmus] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Nielsen, Rasmus] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; [Nielsen, Rasmus] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen, Denmark; [Ho, Simon Y. W.] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; [Goebel, Ted; Graf, Kelly E.] Texas A&M Univ, Dept Anthropol, Ctr Study Amer 1, College Stn, TX 77843 USA; [Byers, David] Missouri State Univ, Dept Sociol & Anthropol, Springfield, MO 65807 USA; [Leonard, Jennifer A.] Uppsala Univ, Dept Evolutionary Biol, S-75236 Uppsala, Sweden; [Leonard, Jennifer A.] EBD CSIC, Conservat & Evolutionary Genet Grp, Seville 41092, Spain; [Koepfli, Klaus-Peter; Wayne, Robert K.] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA; [Koepfli, Klaus-Peter] NCI, Lab Genom Divers, Frederick, MD 21702 USA; [Froese, Duane] Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada; [Zazula, Grant] Govt Yukon, Dept Tourism & Culture, Yukon Palaeontol Program, Whitehorse, YT Y1A 2C6, Canada; [Stafford, Thomas W., Jr.] Stafford Res Inc, Lafayette, CO 80026 USA; [Batra, Persaram] Mt Holyoke Coll, Dept Earth & Environm, S Hadley, MA 01075 USA; [Haywood, Alan M.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England; [Singarayer, Joy S.; Valdes, Paul J.] Univ Bristol, Sch Geog Sci, Bristol BS8 1SS, Avon, England; [Boeskorov, Gennady] Russian Acad Sci, Siberian Branch, Diamond & Precious Met Geol Inst, Yakutsk 677891, Russia; [Burns, James A.] Royal Alberta Museum, Edmonton, AB T5N 0M6, Canada; [Burns, James A.] Manitoba Museum, Winnipeg, MB R3B 0N2, Canada; [Davydov, Sergey P.] Russian Acad Sci, Far E Branch, Pacific Inst Geog, NE Sci Stn, Chersky 678830, Russia; [Jenkins, Dennis L.] Univ Oregon, Museum Nat & Cultural Hist, Eugene, OR 97403 USA; [Kosintsev, Pavel] Russian Acad Sci, Ural Branch, Inst Plant & Anim Ecol, Ekaterinburg 620144, Russia; [Kuznetsova, Tatyana] Moscow MV Lomonosov State Univ, Moscow 119899, Russia; [Lai, Xulong] China Univ Geosci, State Key Lab Biogeol & Environm Geol, Wuhan 430074, Hubei, Peoples R China; [Martin, Larry D.] Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA; [McDonald, H. Gregory] Natl Pk Serv, Pk Museum Management Program, Ft Collins, CO 80525 USA; [Mol, Dick] Nat Hist Museum, Rotterdam, Netherlands; [Munch, Kasper] Aarhus Univ, BiRC, DK-8000 Aarhus C, Denmark; [Stephan, Elisabeth] Landesamt Denkmalpflege, Regierungsprasidium Stuttgart, D-78467 Constance, Germany; [Sablin, Mikhail; Tikhonov, Alexei] Russian Acad Sci, Inst Zool, St Petersburg 199034, Russia; [Sommer, Robert S.] Univ Kiel, Inst Nat & Resource Conservat, Dept Landscape Ecol, D-24098 Kiel, Germany; [Sipko, Taras; Sher, Andrei] Russian Acad Sci, Inst Ecol & Evolut, Moscow 119071, Russia; [Scott, Eric] San Bernardino Cty Museum, Div Geol Sci, Redlands, CA 92374 USA; [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath Genet, Los Angeles, CA 90095 USA; [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Suchard, Marc A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA; [Willerslev, Rane] Univ Oslo, Museum Cultural Hist, N-0130 Oslo, Norway; [Cooper, Alan] Univ Adelaide, Australian Ctr Ancient DNA, Adelaide, SA 5005, Australia; [Hofreiter, Michael] Univ York, Dept Biol, Area 2, York YO10 5DD, N Yorkshire, England; [Shapiro, Beth] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Ugan, Andrew] Univ Utah, Dept Anthropol, Salt Lake City, UT 84112 USA; [Ugan, Andrew] Museo Hist Nat San Rafael, Mendoza, Argentina	University of Copenhagen; University of Copenhagen; Smithsonian Institution; Smithsonian Tropical Research Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Copenhagen; University of Sydney; Texas A&M University System; Texas A&M University College Station; Missouri State University; Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alberta; Mount Holyoke College; University of Leeds; University of Bristol; Diamond & Precious Metal Geology Institute Siberian Branch of Russian Academy of Sciences; Russian Academy of Sciences; Pacific Geographical Institute of the Far Eastern Branch of the Russian Academy of Sciences; Russian Academy of Sciences; University of Oregon; Russian Academy of Sciences; Institute of Plant & Animal Ecology of the Russian Academy of Sciences; Lomonosov Moscow State University; China University of Geosciences; University of Kansas; United States Department of the Interior; Aarhus University; Russian Academy of Sciences; Zoological Institute of the Russian Academy of Sciences; University of Kiel; Russian Academy of Sciences; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Oslo; University of Adelaide; University of York - UK; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Utah System of Higher Education; University of Utah	Willerslev, E (corresponding author), Univ Copenhagen, Ctr GeoGenet, Oster Voldgade 5-7, DK-1350 Copenhagen K, Denmark.	ewillerslev@snm.ku.dk	OBRIEN, STEPHEN/ABD-1346-2020; Davydov, Sergei P./S-9906-2018; Mikhail, Sablin/K-7835-2013; Marske, Katharine/J-5962-2014; Ho, Simon YW/A-8417-2008; Koepfli, Klaus-Peter/AAT-9320-2020; Orlando, Ludovic/A-8932-2013; Munch, Kasper/A-1434-2010; Willerslev, Eske/AAA-5686-2019; Campos, Paula F/B-1634-2010; Willerslev, Eske/A-9619-2011; Campos, Paula/ABF-9898-2021; Gilbert, Marcus TP/A-8936-2013; Rahbek, Carsten/D-9372-2013; Valdes, Paul/C-4129-2013; Cooper, Alan/E-8171-2012; Nielsen, Rasmus/D-4405-2009; Lorenzen, Eline/D-1442-2012; Valdes, Paul/T-2004-2019; Tikhonov, Alexei/G-7478-2016; Boeskorov, Gennady/J-7780-2018; Rahbek, Carsten/L-1129-2013; Borregaard, Michael/B-8442-2008; Koroleva, Olga/C-1306-2012; Kuznetsova, Tatyana/J-4806-2013; Hofreiter, Michael/A-3996-2017; Leonard, Jennifer/A-7894-2010	Mikhail, Sablin/0000-0002-2773-7454; Marske, Katharine/0000-0002-9837-9367; Ho, Simon YW/0000-0002-0361-2307; Orlando, Ludovic/0000-0003-3936-1850; Munch, Kasper/0000-0003-2880-6252; Campos, Paula F/0000-0003-1285-4671; Willerslev, Eske/0000-0002-7081-6748; Gilbert, Marcus TP/0000-0002-5805-7195; Cooper, Alan/0000-0002-7738-7851; Nielsen, Rasmus/0000-0003-0513-6591; Lorenzen, Eline/0000-0002-6353-2819; Valdes, Paul/0000-0002-1902-3283; Boeskorov, Gennady/0000-0002-2360-7740; Rahbek, Carsten/0000-0003-4585-0300; Borregaard, Michael/0000-0002-8146-8435; Davydov, Sergei/0000-0003-0820-9426; Kuznetsova, Tatyana/0000-0003-4302-9607; Lai, Xulong/0000-0002-2837-0885; Hofreiter, Michael/0000-0003-0441-4705; Nogues-Bravo, David/0000-0002-4060-0153; Tikhonov, Alexei/0000-0002-7227-5797; Leonard, Jennifer/0000-0003-0291-7819; Shapiro, Beth/0000-0002-2733-7776	Leverhulme Trust [F/757/A]; McDonald Grants and Awards Fund; NSF [ARC-0909456]; Danish National Research Foundation; Lundbeck Foundation; Danish Council for Independent Research; US National Science Foundation; Directorate For Geosciences [0910272] Funding Source: National Science Foundation; Lundbeck Foundation [R9-2007-1031] Funding Source: researchfish; Natural Environment Research Council [ncas10009] Funding Source: researchfish; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003229] Funding Source: NIH RePORTER	Leverhulme Trust(Leverhulme Trust); McDonald Grants and Awards Fund; NSF(National Science Foundation (NSF)); Danish National Research Foundation(Danmarks Grundforskningsfond); Lundbeck Foundation(Lundbeckfonden); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); US National Science Foundation(National Science Foundation (NSF)); Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Lundbeck Foundation(Lundbeckfonden); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This paper is in memory of our friend and colleague Andrei Sher, who was a contributor to this study. Dr Sher died unexpectedly, but his major contributions to the field of Quaternary science will be remembered and appreciated for many years. We are grateful to A. Lister and T. Stuart for guidance and discussions. We thank T. B. Brandt, B. Hockett and A. Telka for laboratory help and samples, and L. M. R. Thrane for his work on the megafauna locality database. Data taken from the Stage 3 project were partly funded by grant F/757/A from the Leverhulme Trust, and a grant from the McDonald Grants and Awards Fund. B. S. was supported by NSF ARC-0909456. We acknowledge the Danish National Research Foundation, the Lundbeck Foundation, the Danish Council for Independent Research and the US National Science Foundation for financial support.	Alroy J, 2001, SCIENCE, V292, P1893, DOI 10.1126/science.1059342; ANDREWARTHA HG, 1954, DISTRIBUTION ABUNDAN; [Anonymous], 1965, CANADIAN WILDLIFE SE, V2; Barnes I, 2007, CURR BIOL, V17, P1072, DOI 10.1016/j.cub.2007.05.035; Barnett R, 2006, P ROY SOC B-BIOL SCI, V273, P2119, DOI 10.1098/rspb.2006.3555; Barnosky AD, 2004, SCIENCE, V306, P70, DOI 10.1126/science.1101476; Beaumont MA., 2008, SIMULATION GENETICS, P134; Borregaard MK, 2010, Q REV BIOL, V85, P3, DOI 10.1086/650265; Campos PF, 2010, P NATL ACAD SCI USA, V107, P5675, DOI 10.1073/pnas.0907189107; Debruyne R, 2008, CURR BIOL, V18, P1320, DOI 10.1016/j.cub.2008.07.061; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/mss075; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Farnell R, 2004, ARCTIC, V57, P247; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Grayson DK, 2007, J ANTHROPOL RES, V63, P185, DOI 10.3998/jar.0521004.0063.205; Guthrie RD, 2006, NATURE, V441, P207, DOI 10.1038/nature04604; Guthrie RD, 2003, NATURE, V426, P169, DOI 10.1038/nature02098; Haile J, 2009, P NATL ACAD SCI USA, V106, P22352, DOI 10.1073/pnas.0912510106; Joly K, 2011, ECOGRAPHY, V34, P345, DOI 10.1111/j.1600-0587.2010.06377.x; Koch PL, 2006, ANNU REV ECOL EVOL S, V37, P215, DOI 10.1146/annurev.ecolsys.34.011802.132415; Leader-Williams N., 1988, REINDEER S GEORGIA, P3; MacPhee Ross D.E., 1997, P169; Martin P. S., 1984, QUATERNARY EXTINCTIO, P364; Minin VN, 2008, MOL BIOL EVOL, V25, P1459, DOI 10.1093/molbev/msn090; Nogues-Bravo D, 2008, PLOS BIOL, V6, P685, DOI 10.1371/journal.pbio.0060079; Nogues-Bravo D, 2010, EVOLUTION, V64, P2442, DOI 10.1111/j.1558-5646.2010.01009.x; Pitulko VV, 2004, SCIENCE, V303, P52, DOI 10.1126/science.1085219; Reimer PJ, 2009, RADIOCARBON, V51, P1111, DOI 10.1017/S0033822200034202; Shapiro B, 2004, SCIENCE, V306, P1561, DOI 10.1126/science.1101074; SKOGLAND T, 1985, J ANIM ECOL, V54, P359, DOI 10.2307/4484; Stiller M, 2010, MOL BIOL EVOL, V27, P975, DOI 10.1093/molbev/msq083; Stuart AJ, 2004, NATURE, V431, P684, DOI 10.1038/nature02890; Stuart AJ, 2002, QUATERNARY SCI REV, V21, P1559, DOI 10.1016/S0277-3791(02)00026-4; Surovell TA, 2008, QUATERN INT, V191, P82, DOI 10.1016/j.quaint.2007.12.001; Ugan A, 2008, QUATERN INT, V191, P69, DOI 10.1016/j.quaint.2007.09.035; Vereshchagin N. K., 1971, P ZOOL INST USSR ACA, V69, P200; WILLIAMS TM, 1986, RANGIFER, V1, P19; Wilson RJ, 2004, NATURE, V432, P393, DOI 10.1038/nature03031; Zazula GD, 2003, NATURE, V423, P603, DOI 10.1038/423603a; Zazula GD, 2007, QUATERNARY SCI REV, V26, P979, DOI 10.1016/j.quascirev.2006.12.006; Zielinski GA, 1997, GEOL SOC AM BULL, V109, P547, DOI 10.1130/0016-7606(1997)109<0547:PIOTIM>2.3.CO;2	42	470	485	15	689	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					359	U195		10.1038/nature10574	http://dx.doi.org/10.1038/nature10574			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22048313	Green Accepted, Green Submitted			2022-12-28	WOS:000297059700037
J	Veevers, J				Veevers, John			GEOPHYSICS Earth's longest fossil rift-valley system	NATURE			English	Editorial Material							GAMBURTSEV SUBGLACIAL MOUNTAINS; ANTARCTIC ICE-SHEET; EVOLUTION; ZIRCONS; INDIA		Macquarie Univ, Dept Earth & Planetary Sci, Sydney, NSW 2109, Australia	Macquarie University	Veevers, J (corresponding author), Macquarie Univ, Dept Earth & Planetary Sci, Sydney, NSW 2109, Australia.	john.veevers@mq.edu.au						Bo S, 2009, NATURE, V459, P690, DOI 10.1038/nature08024; Chakraborty C, 2003, TECTONOPHYSICS, V377, P299, DOI 10.1016/j.tecto.2003.09.011; Dawson JB, 2008, GEOL SOC MEM, V33, P1, DOI 10.1144/M33.1; Ferraccioli F, 2011, NATURE, V479, P388, DOI 10.1038/nature10566; Leitchenkov G.L, 2007, ANTARCTICA KEYSTONE; Phillips G, 2009, TECTONOPHYSICS, V471, P216, DOI 10.1016/j.tecto.2009.02.012; Veevers JJ, 2008, GONDWANA RES, V14, P343, DOI 10.1016/j.gr.2007.12.006; Veevers JJ, 2008, SEDIMENT GEOL, V211, P12, DOI 10.1016/j.sedgeo.2008.08.003; Veevers JJ, 2009, GONDWANA RES, V16, P90, DOI 10.1016/j.gr.2009.02.007; Young DA, 2011, NATURE, V474, P72, DOI 10.1038/nature10114	10	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					304	306		10.1038/479304a	http://dx.doi.org/10.1038/479304a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094686				2022-12-28	WOS:000297059700027
J	Wilson, CM; Johansson, G; Pourkabirian, A; Simoen, M; Johansson, JR; Duty, T; Nori, F; Delsing, P				Wilson, C. M.; Johansson, G.; Pourkabirian, A.; Simoen, M.; Johansson, J. R.; Duty, T.; Nori, F.; Delsing, P.			Observation of the dynamical Casimir effect in a superconducting circuit	NATURE			English	Article							ELECTROMAGNETIC-FIELD; SQUEEZED STATES; RADIATION; CAVITY	One of the most surprising predictions of modern quantum theory is that the vacuum of space is not empty. In fact, quantum theory predicts that it teems with virtual particles flitting in and out of existence. Although initially a curiosity, it was quickly realized that these vacuum fluctuations had measurable consequences-for instance, producing the Lamb shift(1) of atomic spectra and modifying the magnetic moment of the electron(2). This type of renormalization due to vacuum fluctuations is now central to our understanding of nature. However, these effects provide indirect evidence for the existence of vacuum fluctuations. From early on, it was discussed whether it might be possible to more directly observe the virtual particles that compose the quantum vacuum. Forty years ago, it was suggested(3) that a mirror undergoing relativistic motion could convert virtual photons into directly observable real photons. The phenomenon, later termed the dynamical Casimir effect(4,5), has not been demonstrated previously. Here we observe the dynamical Casimir effect in a superconducting circuit consisting of a coplanar transmission line with a tunable electrical length. The rate of change of the electrical length can be made very fast (a substantial fraction of the speed of light) by modulating the inductance of a superconducting quantum interference device at high frequencies (>10 gigahertz). In addition to observing the creation of real photons, we detect two-mode squeezing in the emitted radiation, which is a signature of the quantum character of the generation process.	[Wilson, C. M.; Johansson, G.; Pourkabirian, A.; Simoen, M.; Delsing, P.] Chalmers, Dept Microtechnol & Nanosci, S-41296 Gothenburg, Sweden; [Johansson, J. R.; Nori, F.] RIKEN, Adv Sci Inst, Wako, Saitama 3510198, Japan; [Duty, T.] Univ New S Wales, Sydney, NSW 2052, Australia; [Nori, F.] Univ Michigan, Ann Arbor, MI 48109 USA	Chalmers University of Technology; RIKEN; University of New South Wales Sydney; University of Michigan System; University of Michigan	Wilson, CM (corresponding author), Chalmers, Dept Microtechnol & Nanosci, S-41296 Gothenburg, Sweden.	chris.wilson@chalmers.se	Nori, Franco/B-1222-2009; Simoen, Michaël/P-8989-2017; Wilson, Christopher/A-9676-2008; Johansson, Göran/Y-3488-2019; Duty, Timothy L/B-4747-2010; Johansson, Robert/C-6224-2008; Johansson, Göran/B-1144-2008; Pourkabirian, Arsalan/D-6639-2012; Delsing, Per/F-7288-2010	Nori, Franco/0000-0003-3682-7432; Simoen, Michaël/0000-0002-3551-7881; Johansson, Göran/0000-0001-5193-5250; Duty, Timothy L/0000-0003-1903-3745; Johansson, Robert/0000-0002-4500-5775; Johansson, Göran/0000-0001-5193-5250; Delsing, Per/0000-0002-1222-3506; Wilson, Christopher/0000-0003-2480-9229	Swedish Research Council; Wallenberg Foundation; STINT; European Research Council; NSF [0726909]; MEXT Kakenhi on Quantum Cybernetics; Australian Research Council [DP0986932, FT100100025]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Wallenberg Foundation(European Commission); STINT; European Research Council(European Research Council (ERC)European Commission); NSF(National Science Foundation (NSF)); MEXT Kakenhi on Quantum Cybernetics(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Australian Research Council(Australian Research Council)	We thank G. Milburn and V. Shumeiko for discussions, and J. Aumentado and L. Spietz for providing the shot-noise thermometer. C. M. W., P. D., G. J., A. P. and M. S. were supported by the Swedish Research Council, the Wallenberg Foundation, STINT and the European Research Council. F.N. and J. R. J. acknowledge partial support from the LPS, NSA, ARO, DARPA, AFOSR, NSF grant no. 0726909, Grant-in-Aid for Scientific Research (S), MEXT Kakenhi on Quantum Cybernetics, and the JSPS-FIRST programme. T. D. acknowledges support from STINT and the Australian Research Council (grants DP0986932 and FT100100025).	Braggio C, 2005, EUROPHYS LETT, V70, P754, DOI 10.1209/epl/i2005-10048-8; CASIMIR HBG, 1948, KON NED AKAD WET, V51, P793; CAVES CM, 1985, PHYS REV A, V31, P3068, DOI 10.1103/PhysRevA.31.3068; DALVIT DAR, 2010, FLUCTUATIONS DISSIPA; De Liberato S, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.103602; Dezael FX, 2010, EPL-EUROPHYS LETT, V89, DOI 10.1209/0295-5075/89/14001; Dodonov VV, 2010, PHYS SCRIPTA, V82, DOI 10.1088/0031-8949/82/03/038105; DODONOV VV, 1990, PHYS LETT A, V149, P225, DOI 10.1016/0375-9601(90)90333-J; DODONOV VV, 1993, PHYS REV A, V47, P4422, DOI 10.1103/PhysRevA.47.4422; FULLING SA, 1976, P ROY SOC LOND A MAT, V348, P393, DOI 10.1098/rspa.1976.0045; Greiner W, 2008, AM J PHYS, V76, P509, DOI 10.1119/1.2820395; Gunter G, 2009, NATURE, V458, P178, DOI 10.1038/nature07838; Hoi IC, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.073601; Johansson JR, 2010, PHYS REV A, V82, DOI 10.1103/PhysRevA.82.052509; Johansson JR, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.147003; Kim WJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.200402; Lambrecht A, 1996, PHYS REV LETT, V77, P615, DOI 10.1103/PhysRevLett.77.615; Lamoreaux SK, 2007, PHYS TODAY, V60, P40, DOI 10.1063/1.2711635; LOZOVIK YE, 1995, JETP LETT+, V61, P723; MOORE GT, 1970, J MATH PHYS, V11, P2679, DOI 10.1063/1.1665432; NATION PD, 2011, REV MOD PHY IN PRESS; Sandberg M, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2929367; Schutzhold R, 1998, PHYS REV A, V58, P1783, DOI 10.1103/PhysRevA.58.1783; Scully M.O., 1997, QUANTUM OPT; Spietz L, 2003, SCIENCE, V300, P1929, DOI 10.1126/science.1084647; Wilson CM, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.233907; YABLONOVITCH E, 1989, PHYS REV LETT, V62, P1742, DOI 10.1103/PhysRevLett.62.1742; YURKE B, 1984, PHYS REV A, V29, P1419, DOI 10.1103/PhysRevA.29.1419	28	633	641	5	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					376	379		10.1038/nature10561	http://dx.doi.org/10.1038/nature10561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094697	Green Submitted			2022-12-28	WOS:000297059700040
J	Mitka, M				Mitka, Mike			Evidence Fails to Support ECG Screening for Those Without Heart Disease Symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item							ELECTROCARDIOGRAPHY											Chou R, 2011, ANN INTERN MED, V155, P375, DOI 10.7326/0003-4819-155-6-201109200-00006; Lauer MS, 2011, ANN INTERN MED, V155, P395, DOI 10.7326/0003-4819-155-6-201109200-00011	2	2	2	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2080	2080		10.1001/jama.2011.1665	http://dx.doi.org/10.1001/jama.2011.1665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089708				2022-12-28	WOS:000297013000003
J	Fuchs, Y; Steller, H				Fuchs, Yaron; Steller, Hermann			Programmed Cell Death in Animal Development and Disease	CELL			English	Review							HEMATOPOIETIC STEM-CELLS; DROSOPHILA IMAGINAL DISCS; BCL-2 FAMILY-MEMBERS; LONG-TERM DEPRESSION; FIND-ME SIGNAL; NF-KAPPA-B; APOPTOTIC CELLS; CASPASE ACTIVATION; CAENORHABDITIS-ELEGANS; C-ELEGANS	Programmed cell death (PCD) plays a fundamental role in animal development and tissue homeostasis. Abnormal regulation of this process is associated with a wide variety of human diseases, including immunological and developmental disorders, neurodegeneration, and cancer. Here, we provide a brief historical overview of the field and reflect on the regulation, roles, and modes of PCD during animal development. We also discuss the function and regulation of apoptotic proteins, including caspases, the key executioners of apoptosis, and review the nonlethal functions of these proteins in diverse developmental processes, such as cell differentiation and tissue remodeling. Finally, we explore a growing body of work about the connections between apoptosis, stem cells, and cancer, focusing on how apoptotic cells release a variety of signals to communicate with their cellular environment, including factors that promote cell division, tissue regeneration, and wound healing.	[Fuchs, Yaron; Steller, Hermann] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA	Howard Hughes Medical Institute; Rockefeller University	Steller, H (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10065 USA.	steller@rockefeller.edu	qiao, zhixin/I-3408-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060124] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM060124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aballay A, 2001, P NATL ACAD SCI USA, V98, P2735, DOI 10.1073/pnas.041613098; Abdelwahid E, 2002, MICROSC RES TECHNIQ, V58, P395, DOI 10.1002/jemt.10159; Abraham MC, 2007, DEV CELL, V12, P73, DOI 10.1016/j.devcel.2006.11.012; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Arama E, 2006, EMBO J, V25, P232, DOI 10.1038/sj.emboj.7600920; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Arama E, 2007, PLOS BIOL, V5, P2745, DOI 10.1371/journal.pbio.0050251; Ardehali R, 2011, P NATL ACAD SCI USA, V108, P3282, DOI 10.1073/pnas.1019047108; Avallone B, 2002, EUR J HISTOCHEM, V46, P53; Awasaki T, 2004, CURR BIOL, V14, P668, DOI 10.1016/j.cub.2004.04.001; Bader M, 2011, CELL, V145, P371, DOI 10.1016/j.cell.2011.03.021; Bader M, 2010, DEVELOPMENT, V137, P1679, DOI 10.1242/dev.050088; Bader M, 2009, CURR OPIN CELL BIOL, V21, P878, DOI 10.1016/j.ceb.2009.09.005; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Bateup HS, 2010, CELL, V141, P750, DOI 10.1016/j.cell.2010.05.013; Ben Moshe T, 2007, HEPATOLOGY, V45, P1014, DOI 10.1002/hep.21495; Bergantinos C, 2010, DEVELOPMENT, V137, P1169, DOI 10.1242/dev.045559; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bergmann A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3145re8; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Birnbaum KD, 2008, CELL, V132, P697, DOI 10.1016/j.cell.2008.01.040; Bondar T, 2010, CELL STEM CELL, V6, P309, DOI 10.1016/j.stem.2010.03.002; Bosch M, 2005, DEV BIOL, V280, P73, DOI 10.1016/j.ydbio.2005.01.002; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Campbell CJV, 2010, BLOOD, V116, P1433, DOI 10.1182/blood-2009-12-258095; Campbell KJ, 2010, BLOOD, V116, P3197, DOI 10.1182/blood-2010-04-281071; Cathelin S, 2006, J BIOL CHEM, V281, P17779, DOI 10.1074/jbc.M600537200; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chera S, 2009, DEV CELL, V17, P279, DOI 10.1016/j.devcel.2009.07.014; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Domen J, 2003, EXP HEMATOL, V31, P631, DOI 10.1016/S0301-472X(03)00084-5; Draizen TA, 1999, J NEUROBIOL, V38, P455, DOI 10.1002/(SICI)1097-4695(199903)38:4<455::AID-NEU2>3.0.CO;2-F; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Edison N, 2012, CELL DEATH DIFFER, V19, P356, DOI 10.1038/cdd.2011.112; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Erturk-Hasdemir D, 2009, P NATL ACAD SCI USA, V106, P9779, DOI 10.1073/pnas.0812022106; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fan Y, 2008, DEV CELL, V14, P399, DOI 10.1016/j.devcel.2008.01.003; Feinstein-Rotkopf Y, 2009, APOPTOSIS, V14, P980, DOI 10.1007/s10495-009-0346-6; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; Garcia-Fernandez M, 2010, GENE DEV, V24, P2282, DOI 10.1101/gad.1970110; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Gude DR, 2008, FASEB J, V22, P2629, DOI 10.1096/fj.08-107169; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; HARDY K, 1989, DEVELOPMENT, V107, P597; HAYNIE JL, 1976, NATURE, V259, P659, DOI 10.1038/259659b0; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Huesmann GR, 2006, NEURON, V52, P1061, DOI 10.1016/j.neuron.2006.10.033; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jiao S, 2011, NEURON, V70, P758, DOI 10.1016/j.neuron.2011.04.004; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kanuka H, 2005, EMBO J, V24, P3793, DOI 10.1038/sj.emboj.7600822; Kaplan Y, 2010, DEV CELL, V19, P160, DOI 10.1016/j.devcel.2010.06.009; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kissel H, 2005, DEV CELL, V8, P353, DOI 10.1016/j.devcel.2005.01.021; Kornbluth S, 2005, J CELL SCI, V118, P1779, DOI 10.1242/jcs.02377; Koto A, 2011, CURR BIOL, V21, P278, DOI 10.1016/j.cub.2011.01.015; Kuo CT, 2006, NEURON, V51, P283, DOI 10.1016/j.neuron.2006.07.014; Kuranaga E, 2006, CELL, V126, P583, DOI 10.1016/j.cell.2006.05.048; Kuranaga E, 2011, DEVELOPMENT, V138, P1493, DOI 10.1242/dev.058958; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lemmers B, 2007, J BIOL CHEM, V282, P7416, DOI 10.1074/jbc.M606721200; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634; Li W, 2007, CELL, V129, P1215, DOI 10.1016/j.cell.2007.03.054; Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053; Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; Lohmann I, 2002, CELL, V110, P457, DOI 10.1016/S0092-8674(02)00871-1; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Mace PD, 2010, CURR OPIN CELL BIOL, V22, P828, DOI 10.1016/j.ceb.2010.08.004; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mandal PK, 2011, NAT REV MOL CELL BIO, V12, P198, DOI 10.1038/nrm3060; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Marusyk A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000324; Mendes CS, 2006, EMBO REP, V7, P933, DOI 10.1038/sj.embor.7400773; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Milyavsky M, 2010, CELL STEM CELL, V7, P186, DOI 10.1016/j.stem.2010.05.016; Miura M, 2011, DEV GROWTH DIFFER, V53, P125, DOI 10.1111/j.1440-169X.2010.01228.x; Mohrin M, 2010, CELL STEM CELL, V7, P174, DOI 10.1016/j.stem.2010.06.014; Moreno E, 2008, NAT REV CANCER, V8, P141, DOI 10.1038/nrc2252; Nagasaka A, 2010, CELL DEATH DIFFER, V17, P931, DOI 10.1038/cdd.2009.186; Nagata S, 2010, CELL, V140, P619, DOI 10.1016/j.cell.2010.02.014; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Nakaya M, 2006, J BIOL CHEM, V281, P8836, DOI 10.1074/jbc.M510972200; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Ohsawa S, 2011, DEV CELL, V20, P315, DOI 10.1016/j.devcel.2011.02.007; Okamoto H, 2006, CELL DEATH DIFFER, V13, P668, DOI 10.1038/sj.cdd.4401806; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Perez-Garijo A, 2009, DEVELOPMENT, V136, P1169, DOI 10.1242/dev.034017; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Reynaud K, 2000, MOL CELL ENDOCRINOL, V163, P101, DOI 10.1016/S0303-7207(99)00246-4; Robinow S, 1997, DEV BIOL, V190, P206, DOI 10.1006/dbio.1997.8696; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rossel M, 1999, DEVELOPMENT, V126, P5027; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rumpf S, 2011, DEVELOPMENT, V138, P1153, DOI 10.1242/dev.062703; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Ryoo HD, 2010, CURR OPIN CELL BIOL, V22, P889, DOI 10.1016/j.ceb.2010.08.022; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sandu C, 2010, J CELL BIOL, V190, P1039, DOI 10.1083/jcb.201004086; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108; Schoenmann Z, 2010, J NEUROSCI, V30, P6375, DOI 10.1523/JNEUROSCI.0922-10.2010; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schwartz HT, 2007, GENE DEV, V21, P3181, DOI 10.1101/gad.1607007; Seita J, 2010, CELL STEM CELL, V7, P145, DOI 10.1016/j.stem.2010.07.006; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shlevkov E, 2012, CELL DEATH DIFFER, V19, P451, DOI 10.1038/cdd.2011.113; Smith-Bolton RK, 2009, DEV CELL, V16, P797, DOI 10.1016/j.devcel.2009.04.015; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Srivastava M, 2007, CELL DEATH DIFFER, V14, P92, DOI 10.1038/sj.cdd.4401931; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tan Y, 2011, DEVELOPMENT, V138, P2197, DOI 10.1242/dev.058826; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Truman LA, 2008, BLOOD, V112, P5026, DOI 10.1182/blood-2008-06-162404; Tseng AS, 2007, DEV BIOL, V301, P62, DOI 10.1016/j.ydbio.2006.10.048; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang SH, 2006, BIOL REPROD, V74, P102, DOI 10.1095/biolreprod.105.045484; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Wells BS, 2006, CURR BIOL, V16, P1606, DOI 10.1016/j.cub.2006.07.046; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Williams DW, 2006, NAT NEUROSCI, V9, P1234, DOI 10.1038/nn1774; Xu DB, 2005, DEVELOPMENT, V132, P2125, DOI 10.1242/dev.01790; Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236; Yan W, 2004, P NATL ACAD SCI USA, V101, P7793, DOI 10.1073/pnas.0308025101; Yatsenko AN, 2006, HUM MOL GENET, V15, P3411, DOI 10.1093/hmg/ddl417; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299; Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zandy AJ, 2005, J BIOL CHEM, V280, P30263, DOI 10.1074/jbc.M504007200; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang YP, 2008, DEV CELL, V14, P481, DOI 10.1016/j.devcel.2008.01.018; Zhong L, 2007, DEVELOPMENT, V134, P3517, DOI 10.1242/dev.004770	188	1117	1169	12	283	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					742	758		10.1016/j.cell.2011.10.033	http://dx.doi.org/10.1016/j.cell.2011.10.033			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078876	Green Accepted, Bronze			2022-12-28	WOS:000296902300010
J	Ozawa, H; Takahashi, F; Hirose, K; Ohishi, Y; Hirao, N				Ozawa, Haruka; Takahashi, Futoshi; Hirose, Kei; Ohishi, Yasuo; Hirao, Naohisa			Phase Transition of FeO and Stratification in Earth's Outer Core	SCIENCE			English	Article							HIGH-PRESSURE; TEMPERATURES; MANTLE; IRON	Light elements such as oxygen in Earth's core influence the physical properties of the iron alloys that exist in this region. Describing the high-pressure behavior of these materials at core conditions constrains models of core structure and dynamics. From x-ray diffraction measurements of iron monoxide (FeO) at high pressure and temperature, we show that sodium chloride (NaCl)-type (B1) FeO transforms to a cesium chloride (CsCl)-type (B2) phase above 240 gigapascals at 4000 kelvin with 2% density increase. The oxygen-bearing liquid in the middle of the outer core therefore has a modified Fe-O bonding environment that, according to our numerical simulations, suppresses convection. The phase-induced stratification is seismologically invisible but strongly affects the geodynamo.	[Ozawa, Haruka; Hirose, Kei] Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Yokosuka, Kanagawa 2370061, Japan; [Ozawa, Haruka; Takahashi, Futoshi; Hirose, Kei] Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 1528551, Japan; [Ohishi, Yasuo; Hirao, Naohisa] Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan	Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Tokyo Institute of Technology; Japan Synchrotron Radiation Research Institute	Ozawa, H (corresponding author), Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, 2-15 Natsushimacho, Yokosuka, Kanagawa 2370061, Japan.	h-ozawa@jamstec.go.jp; futoshi@geo.titech.ac.jp	Takahashi, Futoshi/P-4390-2019; Hirose, Kei/C-2165-2009; Takahashi, Futoshi/D-6062-2013; Tateno, Haruka/N-7018-2014	Takahashi, Futoshi/0000-0002-7371-9783; Hirose, Kei/0000-0003-4366-7721; Takahashi, Futoshi/0000-0002-7371-9783; Tateno, Haruka/0000-0002-1173-4021				Alfe D, 2007, CONTEMP PHYS, V48, P63, DOI 10.1080/00107510701529653; Alfe D, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165118; Alfe D, 2002, EARTH PLANET SC LETT, V195, P91, DOI 10.1016/S0012-821X(01)00568-4; Badro J, 2007, EARTH PLANET SC LETT, V254, P233, DOI 10.1016/j.epsl.2006.11.025; BIRCH F, 1952, J GEOPHYS RES, V57, P227, DOI 10.1029/JZ057i002p00227; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; Brazhkin VV, 1997, HIGH PRESSURE RES, V15, P267, DOI 10.1080/08957959708240477; CHRISTENSEN UR, 1985, J GEOPHYS RES-SOLID, V90, P291, DOI 10.1029/JB090iB12p10291; FEI YW, 1994, SCIENCE, V266, P1678, DOI 10.1126/science.266.5191.1678; Fischer RA, 2011, EARTH PLANET SC LETT, V304, P496, DOI 10.1016/j.epsl.2011.02.025; Fischer RA, 2010, AM MINERAL, V95, P1473, DOI 10.2138/am.2010.3463; Hattori T, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.054203; JEANLOZ R, 1985, REV MINERAL, V14, P389; KAWAI N, 1970, JPN J APPL PHYS, V9, P31, DOI 10.1143/JJAP.9.31; Kinoshita T, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.060102; Liu LJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038130; Olson P, 2009, PHYS EARTH PLANET IN, V173, P121, DOI 10.1016/j.pepi.2008.11.010; Ozawa H, 2010, PHYS EARTH PLANET IN, V179, P157, DOI 10.1016/j.pepi.2009.11.005; ROSS M, 1985, PHYS REV B, V31, P1463, DOI 10.1103/PhysRevB.31.1463; Sata N, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB006975; SHERMAN DM, 1995, GEOPHYS RES LETT, V22, P1001, DOI 10.1029/94GL03010; Stacey F. D., 2008, PHYS EARTH; TALLON JL, 1979, PHYS LETT A, V72, P150, DOI 10.1016/0375-9601(79)90676-5; Urakawa S, 1998, GEOPHYS MONOGR SER, V101, P241, DOI 10.1029/GM101p0241; Wu ZQ, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005275; Yanagisawa T, 2010, PHYS EARTH PLANET IN, V183, P341, DOI 10.1016/j.pepi.2010.02.005	26	46	49	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					792	794		10.1126/science.1208265	http://dx.doi.org/10.1126/science.1208265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076374				2022-12-28	WOS:000296849600042
J	Jha, AK; Classen, DC				Jha, Ashish K.; Classen, David C.			Getting Moving on Patient Safety - Harnessing Electronic Data for Safer Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA; [Classen, David C.] Comp Sci Corp, Salt Lake City, UT USA; [Classen, David C.] Univ Utah, Salt Lake City, UT USA	Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Utah System of Higher Education; University of Utah	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.							[Anonymous], 2010, ADVERSE EVENTS HOSP; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Classen DC, 2011, HEALTH AFFAIR, V30, P581, DOI 10.1377/hlthaff.2011.0190; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; The Centers for Medicare & Medicaid Services: Hospital Quality Initiatives-Outcome Measures, 2011, HOSP QUAL IN OUTC ME	5	29	30	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1756	1758		10.1056/NEJMp1109398	http://dx.doi.org/10.1056/NEJMp1109398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QQ	22070474				2022-12-28	WOS:000296762800002
J	Geboes, K				Geboes, Karel			MORE SECRETS OF THE MMR SCARE Commentary: I see no convincing evidence of "enterocolitis," "colitis," or a "unique disease process"	BRITISH MEDICAL JOURNAL			English	Editorial Material									KULeuven, Dept Pathol, Louvain, Belgium	KU Leuven	Geboes, K (corresponding author), KULeuven, Dept Pathol, Louvain, Belgium.	karel.geboes@skynet.be						CORNES JS, 1965, GUT, V6, P225, DOI 10.1136/gut.6.3.225; Deer B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1127; Godlee F, 2011, BRIT MED J, V343, P7284; IACOBUZIODONOHU.CA, 2005, GASTROINTESTINAL LIV; JENKINS D, 1988, J CLIN PATHOL, V41, P72, DOI 10.1136/jcp.41.1.72; PALLONE F, 2003, INFLAMM BOWEL DIS, P85; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	7	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2011	343								d6985	10.1136/bmj.d6985	http://dx.doi.org/10.1136/bmj.d6985			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NP	22077092	Bronze			2022-12-28	WOS:000297058600013
J	Spence, D				Spence, Des			FROM THE FRONTLINE Bad medicine: adult attention-deficit/hyperactivity disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Castells X, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007813.pub2; Faraone Stephen V, 2005, J Atten Disord, V9, P384, DOI 10.1177/1087054705281478; Jasper L, ATTENTION DEFICIT DI; Lenzer J, 2008, BRIT MED J, V336, P1327, DOI 10.1136/bmj.39609.364688.DB; National Institute for Health and Clinical Excellence, ATT DEF HYP DIS DIAG; National Institute on Drug Abuse, NIDA INFOFACTS STIM; Spencer T, 2005, BIOL PSYCHIAT, V57, P456, DOI 10.1016/j.biopsych.2004.11.043	7	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d7244	10.1136/bmj.d7244	http://dx.doi.org/10.1136/bmj.d7244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NH	22065683				2022-12-28	WOS:000297057800018
J	Ho, VM; Lee, JA; Martin, KC				Ho, Victoria M.; Lee, Ji-Ann; Martin, Kelsey C.			The Cell Biology of Synaptic Plasticity	SCIENCE			English	Review							LONG-TERM POTENTIATION; DENDRITIC PROTEIN-SYNTHESIS; II MUTANT MICE; AMPA RECEPTORS; TRANSLATIONAL CONTROL; MESSENGER-RNA; CYTOPLASMIC POLYADENYLATION; DEPENDENT TRANSLATION; RECYCLING ENDOSOMES; HIPPOCAMPAL-NEURONS	Synaptic plasticity is the experience-dependent change in connectivity between neurons that is believed to underlie learning and memory. Here, we discuss the cellular and molecular processes that are altered when a neuron responds to external stimuli, and how these alterations lead to an increase or decrease in synaptic connectivity. Modification of synaptic components and changes in gene expression are necessary for many forms of plasticity. We focus on excitatory neurons in the mammalian hippocampus, one of the best-studied model systems of learning-related plasticity.	[Lee, Ji-Ann; Martin, Kelsey C.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; [Ho, Victoria M.] Univ Calif Los Angeles, Interdept Program Neurosci, Los Angeles, CA 90095 USA; [Martin, Kelsey C.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Martin, Kelsey C.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Martin, KC (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, BSRB 310,615 Charles E Young Dr S, Los Angeles, CA 90095 USA.	kcmartin@mednet.ucla.edu		Lee, Ji-Ann/0000-0002-9069-2113	NIH [R01 MH077022, R01 NS045324, T32 GM008042, T32 MH073526]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH073526, R01MH077022, R21MH069645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045324] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We apologize to those whose primary work could not be cited because of space constraints. We thank J. T. Braslow, T. J. O'Dell, and F. E. Schweizer for comments on the manuscript; J. Bourne and K. M. Harris for hippocampal electron microscopy images; and all members of the Martin lab for helpful discussions. Support comes from NIH grants R01 MH077022 and R01 NS045324 (to K.C.M.), the Medical Scientist Training Program (NIH T32 GM008042), and the Neurobehavioral Genetics Training Program (NIH grant T32 MH073526) (to V.M.H.). A glossary of terms used is included in the online (HTML) version of this article (Box 1).	Agulhon C, 2010, SCIENCE, V327, P1250, DOI 10.1126/science.1184821; Andrasfalvy BK, 2004, J PHYSIOL-LONDON, V559, P543, DOI 10.1113/jphysiol.2004.065219; Banerjee S, 2009, NEURON, V64, P871, DOI 10.1016/j.neuron.2009.11.023; Bingol B, 2006, NATURE, V441, P1144, DOI 10.1038/nature04769; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; Buard I, 2010, J NEUROSCI, V30, P8214, DOI 10.1523/JNEUROSCI.1469-10.2010; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Cesca F, 2010, PROG NEUROBIOL, V91, P313, DOI 10.1016/j.pneurobio.2010.04.006; Ch'ng TH, 2011, CURR OPIN NEUROBIOL, V21, P345, DOI 10.1016/j.conb.2011.01.011; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055; Dan Y, 2006, PHYSIOL REV, V86, P1033, DOI 10.1152/physrev.00030.2005; Delgado JY, 2007, J NEUROSCI, V27, P13210, DOI 10.1523/JNEUROSCI.3056-07.2007; Deng LB, 2011, NEURON, V69, P317, DOI 10.1016/j.neuron.2011.01.005; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Eroglu C, 2010, NATURE, V468, P223, DOI 10.1038/nature09612; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Fonseca R, 2006, NEURON, V52, P239, DOI 10.1016/j.neuron.2006.08.015; Greer PL, 2008, NEURON, V59, P846, DOI 10.1016/j.neuron.2008.09.002; Grooms SY, 2006, J NEUROSCI, V26, P8339, DOI 10.1523/JNEUROSCI.0472-06.2006; Han YY, 2011, NEURON, V69, P304, DOI 10.1016/j.neuron.2010.12.014; Heifets BD, 2009, ANNU REV PHYSIOL, V71, P283, DOI 10.1146/annurev.physiol.010908.163149; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Holtmaat A, 2009, NAT REV NEUROSCI, V10, P647, DOI 10.1038/nrn2699; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Jung MY, 2006, MOL CELL BIOL, V26, P4277, DOI 10.1128/MCB.02470-05; Kaeser PS, 2011, CELL, V144, P282, DOI 10.1016/j.cell.2010.12.029; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kiebler MA, 2006, NEURON, V51, P685, DOI 10.1016/j.neuron.2006.08.021; Kirov SA, 1999, NAT NEUROSCI, V2, P878, DOI 10.1038/13178; Lai KO, 2009, CURR OPIN NEUROBIOL, V19, P275, DOI 10.1016/j.conb.2009.04.009; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Mabb AM, 2010, ANNU REV CELL DEV BI, V26, P179, DOI 10.1146/annurev-cellbio-100109-104129; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Man HY, 2007, P NATL ACAD SCI USA, V104, P3579, DOI 10.1073/pnas.0611698104; Marsicano G, 2009, CURR TOP BEHAV NEURO, V1, P201, DOI 10.1007/978-3-540-88955-7_8; Napoli I, 2008, CELL, V134, P1042, DOI 10.1016/j.cell.2008.07.031; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Park S, 2008, NEURON, V59, P70, DOI 10.1016/j.neuron.2008.05.023; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sacktor TC, 2011, NAT REV NEUROSCI, V12, P9, DOI 10.1038/nrn2949; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Shema R, 2007, SCIENCE, V317, P951, DOI 10.1126/science.1144334; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEWARD O, 1982, J NEUROSCI, V2, P284; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tomita S, 2005, NEURON, V45, P269, DOI 10.1016/j.neuron.2005.01.009; van der Sluijs P, 2011, SEMIN CELL DEV BIOL, V22, P499, DOI 10.1016/j.semcdb.2011.06.008; Wang ZP, 2008, CELL, V135, P535, DOI 10.1016/j.cell.2008.09.057; Waung MW, 2008, NEURON, V59, P84, DOI 10.1016/j.neuron.2008.05.014; Wells DG, 2001, J NEUROSCI, V21, P9541, DOI 10.1523/JNEUROSCI.21-24-09541.2001; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	63	294	302	14	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					623	628		10.1126/science.1209236	http://dx.doi.org/10.1126/science.1209236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053042	Green Accepted			2022-12-28	WOS:000296494700043
J	Lederle, FA; Zylla, D; MacDonald, R; Wilt, TJ				Lederle, Frank A.; Zylla, Dylan; MacDonald, Roderick; Wilt, Timothy J.			Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline	ANNALS OF INTERNAL MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; LOW-MOLECULAR-WEIGHT; ACUTE ISCHEMIC-STROKE; LOW-DOSE HEPARIN; GRADUATED COMPRESSION STOCKINGS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; UNFRACTIONATED HEPARIN; ACUTELY ILL; PULMONARY-EMBOLISM	Background: Venous thromboembolism prophylaxis has been recommended for nonsurgical patients, but its effectiveness remains uncertain. Purpose: To assess the benefits and harms of prophylaxis in hospitalized adult medical patients and those with acute stroke. Data Sources: MEDLINE and the Cochrane Library from 1950 through April 2011, reference lists, and study authors. Study Selection: English-language randomized trials were included if they provided clinical outcomes and evaluated therapy with low-dose heparin or related agents or mechanical measures compared with placebo, no treatment, or other active prophylaxis in the target population. Data Extraction: Two independent investigators extracted data on study characteristics and clinical outcomes up to 120 days after randomization. The primary outcome was total mortality. Data Synthesis: In medical patients, heparin prophylaxis did not reduce total mortality but did result in fewer pulmonary embolisms (PEs) (odds ratio [OR], 0.69 [95% Cl, 0.52 to 0.90], but with evidence of publication bias) and an increase in all bleeding events (risk ratio [RR], 1.34 [Cl, 1.08 to 1.66]). Heparin prophylaxis had no statistically significant effect on any outcome in patients with acute stroke except for an increase in major bleeding events (OR, 1.66 [Cl, 1.20 to 2.28]). When trials of medical patients and those with stroke were considered together (18 studies; 36 122 patients), heparin prophylaxis reduced the incidence of PE (OR, 0.70 [Cl, 0.56 to 0.87]; absolute reduction, 3 events per 1000 patients treated [Cl, 1 to 5 events]) but increased the incidence of all bleeding (RR, 1.28 [Cl, 1.05 to 1.56]) and major bleeding events (OR, 1.61 [Cl, 1.23 to 2.10]), with an absolute increase of 9 bleeding events per 1000 patients treated (Cl, 2 to 18 events), 4 of which were major (Cl, 1 to 7 events). A reduction in total mortality approached statistical significance (RR, 0.93 [Cl, 0.86 to 1.00]; P = 0.056; absolute decrease, 6 deaths per 1000 patients treated [Cl, 0 to 11 deaths]). No statistically significant differences in clinical outcomes were observed in the 14 trials that compared unfractionated heparin with low-molecular-weight heparin. No improvements in clinical outcomes were seen in the 3 studies of mechanical prophylaxis in patients with stroke, but more patients had lower-extremity skin damage (RR, 4.02 [Cl, 2.34 to 6.91])-an increase of 39 events per 1000 patients treated (Cl, 17 to 77 events). Limitation: Non-English-language studies were not included, but these were few and small. Conclusion: Heparin prophylaxis had no significant effect on mortality, may have reduced PE in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit. No differences in benefits or harms were found according to type of heparin used. Mechanical prophylaxis provided no benefit and resulted in clinically important harm to patients with stroke. Primary Funding Source: American College of Physicians.	Minnesota Evidence Based Practice Ctr, Minneapolis, MN USA; Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Lederle, FA (corresponding author), Minneapolis Vet Affairs Med Ctr 111 O, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA.	frank.lederle@va.gov			American College of Physicians	American College of Physicians	By the American College of Physicians.	Alikhan R, 2003, BLOOD COAGUL FIBRIN, V14, P341, DOI 10.1097/00001721-200306000-00004; Aquino JP, 1990, FRAXIPARINE; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Berge E, 2000, LANCET, V355, P1205, DOI 10.1016/S0140-6736(00)02085-7; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; Bijsterveld NR, 2002, J AM COLL CARDIOL, V39, P811, DOI 10.1016/S0735-1097(01)01825-3; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Bump GM, 2009, J HOSP MED, V4, P289, DOI 10.1002/jhm.450; Carrier M, 2010, ANN INTERN MED, V152, P578, DOI 10.7326/0003-4819-152-9-201005040-00008; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; Cook D, 2011, NEW ENGL J MED, V364, P1305; DAHAN R, 1986, HAEMOSTASIS, V16, P159; DeFrances Carol J, 2007, Vital Health Stat 13, P1; Dennis M, 2010, ANN INTERN MED, V153, P553, DOI 10.7326/0003-4819-153-9-201011020-00280; Dennis M, 2009, LANCET, V373, P1958, DOI 10.1016/S0140-6736(09)60941-7; Dentali F, 2007, ANN INTERN MED, V146, P278, DOI 10.7326/0003-4819-146-4-200702200-00007; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; Diener HC, 2006, STROKE, V37, P139, DOI 10.1161/01.STR.0000195182.67656.ee; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; Gardlund B, 1996, LANCET, V347, P1357; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; GELMERS HJ, 1980, ACTA NEUROL SCAND, V61, P313; Goodman LR, 2005, RADIOLOGY, V234, P654, DOI 10.1148/radiol.2343041326; Green D., 1998, TOP STROKE REHABIL, V5, P68; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hillbom M, 2002, ACTA NEUROL SCAND, V106, P84, DOI 10.1034/j.1600-0404.2002.01215.x; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; Joint Commission, 2009, JT COMM PERSPECT, V29, P4; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KIERKEGAARD A, 1993, EUR HEART J, V14, P1365, DOI 10.1093/eurheartj/14.10.1365; King CS, 2007, CHEST, V131, P507, DOI 10.1378/chest.06-1861; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Kucher N, 2005, ARCH INTERN MED, V165, P341, DOI 10.1001/archinte.165.3.341; Lacut K, 2005, NEUROLOGY, V65, P865, DOI 10.1212/01.wnl.0000176073.80532.a2; Lechler E, 1996, HAEMOSTASIS, V26, P49; Lederle FA, 2006, AM J MED, V119, P54, DOI 10.1016/j.amjmed.2005.03.049; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Levi M, 2007, AM J RESP CRIT CARE, V176, P483, DOI 10.1164/rccm.200612-1803OC; Lowe GDO, 2003, LANCET, V362, P504, DOI 10.1016/S0140-6736(03)14149-9; Luba Maria, 2007, Pol Arch Med Wewn, V117, P31; Mahe I, 2005, EUR J CLIN PHARMACOL, V61, P347, DOI 10.1007/s00228-005-0944-3; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Muir KW, 2000, QJM-INT J MED, V93, P359, DOI 10.1093/qjmed/93.6.359; Orken DN, 2009, NEUROLOGIST, V15, P329, DOI 10.1097/NRL.0b013e3181a93bac; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; PAMBIANCO G, 1995, ARCH PHYS MED REHAB, V76, P324, DOI 10.1016/S0003-9993(95)80657-1; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; PRASAD BK, 1982, AGE AGEING, V11, P42, DOI 10.1093/ageing/11.1.42; PRINS MH, 1989, HAEMOSTASIS, V19, P245; Riess H, 2010, J THROMB HAEMOST, V8, P1209, DOI 10.1111/j.1538-7836.2010.03848.x; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Sandercock P, 1997, LANCET, V349, P1569; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Schellong SM, 2010, EXPERT OPIN PHARMACO, V11, P2953, DOI 10.1517/14656566.2010.521498; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sheldon T, 2002, BMJ-BRIT MED J, V325, P734, DOI 10.1136/bmj.325.7367.734; Sherman DG, 2007, LANCET, V369, P1347, DOI 10.1016/S0140-6736(07)60633-3; Shorr AF, 2008, CHEST, V133, P149, DOI 10.1378/chest.07-1826; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; TURPIE AGG, 1987, LANCET, V1, P523; Weber C, 2008, SUPPORT CARE CANCER, V16, P847, DOI 10.1007/s00520-007-0339-3; Wein L, 2007, ARCH INTERN MED, V167, P1476, DOI 10.1001/archinte.167.14.1476; Wille-Jorgensen P, 2005, THROMB HAEMOSTASIS, V93, P236, DOI 10.1160/TH04-09-0570	75	113	118	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					602	U91		10.7326/0003-4819-155-9-201111010-00008	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00008			27	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041949				2022-12-28	WOS:000296612400005
J	Brown, KN; Chen, S; Han, Z; Lu, CH; Tan, X; Zhang, XJ; Ding, LY; Lopez-Cruz, A; Saur, D; Anderson, SA; Huang, K; Shi, SH				Brown, Keith N.; Chen, She; Han, Zhi; Lu, Chun-Hui; Tan, Xin; Zhang, Xin-Jun; Ding, Liya; Lopez-Cruz, Alejandro; Saur, Dieter; Anderson, Stewart A.; Huang, Kun; Shi, Song-Hai			Clonal Production and Organization of Inhibitory Interneurons in the Neocortex	SCIENCE			English	Article							CORTICAL INTERNEURONS; GABAERGIC INTERNEURONS; EXCITATORY NEURONS; CEREBRAL-CORTEX; MIGRATION; CELLS; GENE; SPECIFICATION; EXPRESSION; DIVERSITY	The neocortex contains excitatory neurons and inhibitory interneurons. Clones of neocortical excitatory neurons originating from the same progenitor cell are spatially organized and contribute to the formation of functional microcircuits. In contrast, relatively little is known about the production and organization of neocortical inhibitory interneurons. We found that neocortical inhibitory interneurons were produced as spatially organized clonal units in the developing ventral telencephalon. Furthermore, clonally related interneurons did not randomly disperse but formed spatially isolated clusters in the neocortex. Individual clonal clusters consisting of interneurons expressing the same or distinct neurochemical markers exhibited clear vertical or horizontal organization. These results suggest that the lineage relationship plays a pivotal role in the organization of inhibitory interneurons in the neocortex.	[Brown, Keith N.; Chen, She; Tan, Xin; Zhang, Xin-Jun; Lopez-Cruz, Alejandro; Shi, Song-Hai] Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10065 USA; [Brown, Keith N.; Anderson, Stewart A.; Shi, Song-Hai] Weill Cornell Med Coll, Grad Program Neurosci, New York, NY 10065 USA; [Han, Zhi; Ding, Liya; Huang, Kun] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Han, Zhi; Lu, Chun-Hui] Nankai Univ, Coll Software, Tianjin 300071, Peoples R China; [Tan, Xin; Shi, Song-Hai] Weill Cornell Med Coll, Mol Biol Grad Program, New York, NY 10065 USA; [Saur, Dieter] Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; [Anderson, Stewart A.] Weill Cornell Med Coll, Dept Psychiat, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cornell University; University System of Ohio; Ohio State University; Nankai University; Cornell University; Technical University of Munich; Cornell University	Shi, SH (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Biol Program, 1275 York Ave, New York, NY 10065 USA.	shis@mskcc.org	Saur, Dieter/G-4629-2011; Huang, Kun/E-3272-2011; Saur, Dieter/O-8355-2015; Ding, Liya/B-8869-2014; Ding, Liya/HHZ-3407-2022; Zhang, Xin-Jun/O-2994-2013	Saur, Dieter/0000-0001-5874-0210; Ding, Liya/0000-0002-1209-875X; Ding, Liya/0000-0002-1209-875X; Zhang, Xin-Jun/0000-0002-0846-0584; Han, Zhi/0000-0002-5603-8433	NIH [R01DA024681, R21NS072483, R21MH083624, R01MH066912, K02MH070031]; McKnight Foundation; March of Dimes Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH070031, R01MH066912, R21MH083624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS072483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA024681] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McKnight Foundation; March of Dimes Foundation(March of Dimes); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank A. L. Joyner and M. E. Ross for comments on the manuscript; the members of the Shi laboratory for valuable discussion and input; E. C. Holland for RCAS-EGFP plasmid and advice on the production of RCAS retroviruses; F. H. Gage for providing 293 gp NIT-EGFP retrovirus packaging cell line; J. A. Kaltschmidt for R26<SUP>LSL-TVAilacZ</SUP> mice; and S. Li for technical assistance. This work was supported by grants from the NIH (R01DA024681 and R21NS072483 to S.-H.S., R21MH083624 to S.-H.S. and K.H., R01MH066912 and K02MH070031 to S.A.A.), the McKnight Foundation, and the March of Dimes Foundation (to S.-H.S.).	Ang ESBC, 2003, J NEUROSCI, V23, P5805; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Batista-Brito R, 2009, CURR TOP DEV BIOL, V87, P81, DOI 10.1016/S0070-2153(09)01203-4; Bortone D, 2009, NEURON, V62, P53, DOI 10.1016/j.neuron.2009.01.034; Butt SJB, 2008, NEURON, V59, P722, DOI 10.1016/j.neuron.2008.07.031; Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034; Corbin JG, 2001, NAT NEUROSCI, V4, P1177, DOI 10.1038/nn749; Diggle P.J., 2003, STAT ANAL SPATIAL PO; Fino E, 2011, NEURON, V69, P1188, DOI 10.1016/j.neuron.2011.02.025; Flames N, 2007, J NEUROSCI, V27, P9682, DOI 10.1523/JNEUROSCI.2750-07.2007; Fogarty M, 2007, J NEUROSCI, V27, P10935, DOI 10.1523/JNEUROSCI.1629-07.2007; Gelman DM, 2010, EUR J NEUROSCI, V31, P2136, DOI 10.1111/j.1460-9568.2010.07267.x; Gelman DM, 2009, J NEUROSCI, V29, P9380, DOI 10.1523/JNEUROSCI.0604-09.2009; Gorski JA, 2002, J NEUROSCI, V22, P6309; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Huang ZJ, 2007, NAT REV NEUROSCI, V8, P673, DOI 10.1038/nrn2188; Katzel D, 2011, NAT NEUROSCI, V14, P100, DOI 10.1038/nn.2687; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; Lavdas AA, 1996, CEREB CORTEX, V6, P490, DOI 10.1093/cercor/6.3.490; Li HD, 2008, DEV NEUROBIOL, V68, P1549, DOI 10.1002/dneu.20679; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Miyoshi G, 2007, J NEUROSCI, V27, P7786, DOI 10.1523/JNEUROSCI.1807-07.2007; Miyoshi G, 2011, CEREB CORTEX, V21, P845, DOI 10.1093/cercor/bhq155; Miyoshi G, 2010, J NEUROSCI, V30, P1582, DOI 10.1523/JNEUROSCI.4515-09.2010; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; Nobrega-Pereira S, 2008, NEURON, V59, P733, DOI 10.1016/j.neuron.2008.07.024; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; REID CB, 1995, NEURON, V15, P299, DOI 10.1016/0896-6273(95)90035-7; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Sheth AN, 1997, J COMP NEUROL, V383, P220; Sussel L, 1999, DEVELOPMENT, V126, P3359; Tanaka DH, 2009, J NEUROSCI, V29, P1300, DOI 10.1523/JNEUROSCI.5446-08.2009; Thomson AM, 2007, FRONT NEUROSCI-SWITZ, V1, P19, DOI 10.3389/neuro.01.1.1.002.2007; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0; Wonders CP, 2008, DEV BIOL, V314, P127, DOI 10.1016/j.ydbio.2007.11.018; Wonders CP, 2006, NAT REV NEUROSCI, V7, P687, DOI 10.1038/nrn1954; Xu Q, 2008, J COMP NEUROL, V506, P16, DOI 10.1002/cne.21529; Xu Q, 2010, NEURON, V65, P328, DOI 10.1016/j.neuron.2010.01.004; Yoshimura Y, 2005, NAT NEUROSCI, V8, P1552, DOI 10.1038/nn1565; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993; Yu YC, 2009, NATURE, V458, P501, DOI 10.1038/nature07722	46	110	111	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					480	486		10.1126/science.1208884	http://dx.doi.org/10.1126/science.1208884			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034427	Green Accepted			2022-12-28	WOS:000296230500038
J	Goldstone, DC; Ennis-Adeniran, V; Hedden, JJ; Groom, HCT; Rice, GI; Christodoulou, E; Walker, PA; Kelly, G; Haire, LF; Yap, MW; de Carvalho, LPS; Stoye, JP; Crow, YJ; Taylor, IA; Webb, M				Goldstone, David C.; Ennis-Adeniran, Valerie; Hedden, Joseph J.; Groom, Harriet C. T.; Rice, Gillian I.; Christodoulou, Evangelos; Walker, Philip A.; Kelly, Geoff; Haire, Lesley F.; Yap, Melvyn W.; de Carvalho, Luiz Pedro S.; Stoye, Jonathan P.; Crow, Yanick J.; Taylor, Ian A.; Webb, Michelle			HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase	NATURE			English	Article							AICARDI-GOUTIERES-SYNDROME; HUMAN DENDRITIC CELLS; REVERSE-TRANSCRIPTASE; DNTP TRIPHOSPHOHYDROLASE; INFECTION; PROTEIN; VPX; MACROPHAGE; MUTATIONS; TREX1	SAMHD1, an analogue of the murine interferon (IFN)-gamma-induced gene Mg11 (ref. 1), has recently been identified as a human immunodeficiency virus-1 (HIV-1) restriction factor that blocks early-stage virus replication in dendritic and other myeloid cells(2,3) and is the target of the lentiviral protein Vpx, which can relieve HIV-1 restriction(4-7). SAMHD1 is also associated with Aicardi-Goutieres syndrome (AGS), an inflammatory encephalopathy characterized by chronic cerebrospinal fluid lymphocytosis and elevated levels of the antiviral cytokine IFN-alpha(8). The pathology associated with AGS resembles congenital viral infection, such as transplacentally acquired HIV. Here we show that human SAMHD1 is a potent dGTP-stimulated triphosphohydrolase that converts deoxynucleoside triphosphates to the constituent deoxynucleoside and inorganic triphosphate. The crystal structure of the catalytic core of SAMHD1 reveals that the protein is dimeric and indicates a molecular basis for dGTP stimulation of catalytic activity against dNTPs. We propose that SAMHD1, which is highly expressed in dendritic cells, restricts HIV-1 replication by hydrolysing the majority of cellular dNTPs, thus inhibiting reverse transcription and viral complementary DNA (cDNA) synthesis.	[Goldstone, David C.; Ennis-Adeniran, Valerie; Hedden, Joseph J.; Christodoulou, Evangelos; Walker, Philip A.; Haire, Lesley F.; Taylor, Ian A.] MRC Natl Inst Med Res, Div Mol Struct, London NW7 1AA, England; [Groom, Harriet C. T.; Yap, Melvyn W.; Stoye, Jonathan P.] MRC Natl Inst Med Res, Div Virol, London NW7 1AA, England; [Rice, Gillian I.; Crow, Yanick J.; Webb, Michelle] Univ Manchester, Cent Manchester Fdn Trust Univ Hosp, Manchester Acad Heath Sci Ctr, Manchester M13 9PT, Lancs, England; [Kelly, Geoff] Natl Inst Med Res, MRC Biomed NMR Ctr, London NW7 1AA, England; [de Carvalho, Luiz Pedro S.] MRC Natl Inst Med Res, Div Mycobacterial Res, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research; University of Manchester; MRC National Institute for Medical Research; MRC National Institute for Medical Research	Taylor, IA (corresponding author), MRC Natl Inst Med Res, Div Mol Struct, Mill Hill, London NW7 1AA, England.	itaylor@nimr.mrc.ac.uk; Michelle.Webb@manchester.ac.uk	Crow, Yanick J/N-6120-2014; Rice, Gillian I/G-3128-2015	Crow, Yanick J/0000-0001-7211-7564; Rice, Gillian I/0000-0002-4223-0571; Sorio de Carvalho, Luiz Pedro/0000-0003-2875-4552; Christodoulou, Evangelos/0000-0001-8464-1558; Stoye, Jonathan/0000-0003-3377-323X; Webb, Michelle/0000-0002-3228-7558; Goldstone, David/0000-0003-0069-9408	UK Medical Research Council [U117565647, U117512710]; European Union [241779]; European Leukodystrophy Association; MRC [MC_U117565647, MC_U117533887, MC_U117512710, MC_UP_A253_1111] Funding Source: UKRI; Medical Research Council [MC_U117565647, MC_U117533887, MC_UP_A253_1111, MC_U117512710] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); European Leukodystrophy Association; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank S. Gamblin for comments on the manuscript and we acknowledge the Diamond Light Source for synchrotron access. This work was supported by the UK Medical Research Council, file references U117565647 (I. A. T.) and U117512710 (J.P.S.). Y.J.C. acknowledges the European Union Seventh Framework Programme (FP7/2007-2013) grant agreement number 241779 (NIMBL: http://www.NIMBL.eu/), and the European Leukodystrophy Association. Y.J.C. and M. W. acknowledge the Manchester National Institute for Health Research Biomedical Research Centre.	Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Bergamaschi A, 2009, J VIROL, V83, P4854, DOI 10.1128/JVI.00187-09; Brown PH, 2006, BIOPHYS J, V90, P4651, DOI 10.1529/biophysj.106.081372; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2; Hartman ZC, 2007, J VIROL, V81, P1796, DOI 10.1128/JVI.01936-06; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Jamburuthugoda VK, 2008, J BIOL CHEM, V283, P9206, DOI 10.1074/jbc.M710149200; Kaushik R, 2009, CELL HOST MICROBE, V6, P68, DOI 10.1016/j.chom.2009.05.022; Kennedy EM, 2010, J BIOL CHEM, V285, P39380, DOI 10.1074/jbc.M110.178582; Kondo N, 2004, J BIOCHEM, V136, P221, DOI 10.1093/jb/mvh115; Kondo N, 2007, ACTA CRYSTALLOGR D, V63, P230, DOI 10.1107/S0907444906049262; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Li N, 2000, IMMUNOL LETT, V74, P221, DOI 10.1016/S0165-2478(00)00276-5; Lindahl T, 2009, BIOCHEM SOC T, V37, P535, DOI 10.1042/BST0370535; Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prehaud C, 2005, J VIROL, V79, P12893, DOI 10.1128/JVI.79.20.12893-12904.2005; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Rice GI, 2009, NAT GENET, V41, P829, DOI 10.1038/ng.373; Rydberg B, 2002, P NATL ACAD SCI USA, V99, P16654, DOI 10.1073/pnas.262591699; SETO D, 1988, J BIOL CHEM, V263, P1494; Srivastava S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000059; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Wilson PM, 2011, NUCLEIC ACIDS RES, V39, pE112, DOI 10.1093/nar/gkr350; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Zwart Peter H., 2008, V426, P419, DOI 10.1007/978-1-60327-058-8_28	30	588	606	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					379	U134		10.1038/nature10623	http://dx.doi.org/10.1038/nature10623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22056990				2022-12-28	WOS:000298033000054
J	Maningat, P; Breslow, JL				Maningat, Patricia; Breslow, Jan L.			Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Maningat, Patricia; Breslow, Jan L.] Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Maningat, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.							Fernandez Genaro, 2011, Cleve Clin J Med, V78, P393, DOI 10.3949/ccjm.78a.10073; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; Ware JH, 2011, NEW ENGL J MED, V364, P1685, DOI 10.1056/NEJMp1103502	4	65	66	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2250	2251		10.1056/NEJMp1112023	http://dx.doi.org/10.1056/NEJMp1112023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861PN	22085320				2022-12-28	WOS:000298031800003
J	Bolli, R; Chugh, AR; D'Amario, D; Loughran, JH; Stoddard, MF; Ikram, S; Beache, GM; Wagner, SG; Leri, A; Hosoda, T; Sanada, F; Elmore, JB; Goichberg, P; Cappetta, D; Solankhi, NK; Fahsah, I; Rokosh, DG; Slaughter, MS; Kajstura, J; Anversa, P				Bolli, Roberto; Chugh, Atul R.; D'Amario, Domenico; Loughran, John H.; Stoddard, Marcus F.; Ikram, Sohail; Beache, Garth M.; Wagner, Stephen G.; Leri, Annarosa; Hosoda, Toru; Sanada, Fumihiro; Elmore, Julius B.; Goichberg, Polina; Cappetta, Donato; Solankhi, Naresh K.; Fahsah, Ibrahim; Rokosh, D. Gregg; Slaughter, Mark S.; Kajstura, Jan; Anversa, Piero			RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial (Retracted article. See vol. 393, pg. 1084, 2019)	LANCET			English	Article; Retracted Publication							REGENERATE INFARCTED MYOCARDIUM; LEFT-VENTRICULAR DYSFUNCTION; MARROW MONONUCLEAR-CELLS; CHRONIC HEART-FAILURE; PROGENITOR CELLS; FUNCTIONAL RECOVERY; TRANSPLANTATION; MULTIPOTENT; INJECTION; DISEASE	Background c-kit-positive, lineage-negative cardiac stem cells (CSCs) improve post-infarction left ventricular (LV) dysfunction when administered to animals. We under took a phase 1 trial (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO]) of autologous CSCs for the treatment of heart failure resulting from ischaemic heart disease. Methods In stage A of the SCIPIO trial, patients with post-infarction LV dysfunction (ejection fraction [EF] <= 40%) before coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B, patients were randomly assigned to the treatment or control group in a 2:3 ratio by use of a computer-generated block randomisation scheme. 1 million autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) after surgery; controls were not given any treatment. Although the study was open label, the echocardiographic analyses were masked to group assignment. The primary endpoint was short-term safety of CSCs and the secondary endpoint was efficacy. A per-protocol analysis was used. This study is registered with ClinicalTrials.gov, number NCT00474461. Findings This study is still in progress. 16 patients were assigned to the treatment group and seven to the control group; no CSC-related adverse effects were reported. In 14 CSC-treated patients who were analysed, LVEF increased from 30.3% (SE 1.9) before CSC infusion to 38.5% (2.8) at 4 months after infusion (p=0.001). By contrast, in seven control patients, during the corresponding time interval, LVEF did not change (30.1% [2.4] at 4 months after CABG vs 30.2% [2.5] at 8 months after CABG). Importantly, the salubrious effects of CSCs were even more pronounced at 1 year in eight patients (eg, LVEF increased by 12.3 ejection fraction units [2.1] vs baseline, p=0.0007). In the seven treated patients in whom cardiac MRI could be done, infarct size decreased from 32.6 g (6.3) by 7.8 g (1.7; 24%) at 4 months (p=0.004) and 9.8 g (3.5; 30%) at 1 year (p=0.04). Interpretation These initial results in patients are very encouraging. They suggest that intracoronary infusion of autologous CSCs is effective in improving LV systolic function and reducing infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies.	[Bolli, Roberto; Chugh, Atul R.; Loughran, John H.; Stoddard, Marcus F.; Ikram, Sohail; Wagner, Stephen G.; Elmore, Julius B.; Solankhi, Naresh K.; Fahsah, Ibrahim; Rokosh, D. Gregg] Univ Louisville, Div Cardiovasc Med, Louisville, KY 40202 USA; [Slaughter, Mark S.] Univ Louisville, Div Cardiothorac Surg, Louisville, KY 40202 USA; [Beache, Garth M.] Univ Louisville, Dept Radiol, Louisville, KY 40202 USA; [D'Amario, Domenico; Leri, Annarosa; Hosoda, Toru; Sanada, Fumihiro; Goichberg, Polina; Cappetta, Donato; Kajstura, Jan; Anversa, Piero] Harvard Univ, Brigham & Womens Hosp, Dept Anesthesia, Sch Med, Boston, MA 02115 USA; [D'Amario, Domenico; Leri, Annarosa; Hosoda, Toru; Sanada, Fumihiro; Goichberg, Polina; Cappetta, Donato; Kajstura, Jan; Anversa, Piero] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA; [D'Amario, Domenico; Leri, Annarosa; Hosoda, Toru; Sanada, Fumihiro; Goichberg, Polina; Cappetta, Donato; Kajstura, Jan; Anversa, Piero] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc Med, Sch Med, Boston, MA 02115 USA	University of Louisville; University of Louisville; University of Louisville; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bolli, R (corresponding author), Univ Louisville, Div Cardiovasc Med, 550 S Jackson St,Ambulatory Care Bldg,3rd Floor, Louisville, KY 40202 USA.	rbolli@louisville.edu	Bolli, Roberto/A-6870-2010; Chugh, Atul R/M-9667-2018; Rokosh, Gregg/J-2730-2013; D'Amario, Domenico/L-3603-2018; Hosoda, Toru/G-1873-2010	/0000-0003-3774-8330; Hosoda, Toru/0000-0002-7273-0630; Rokosh, Gregg/0000-0002-9214-2254	University of Louisville Research Foundation; National Institutes of Health [R37HL081737]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078825, R37HL081737, R01HL039902] Funding Source: NIH RePORTER	University of Louisville Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the University of Louisville Research Foundation and National Institutes of Health (grant R37HL081737).	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Bearzi C, 2007, P NATL ACAD SCI USA, V104, P14068, DOI 10.1073/pnas.0706760104; Beausejour CM, 2006, NATURE, V443, P404, DOI 10.1038/nature05221; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bolli R, 2006, CIRCULATION, V114, P239; British Heart Foundation, 2003, COR HEART DIS STAT; Chamuleau SAF, 2009, NETH HEART J, V17, P199, DOI 10.1007/BF03086247; D'Amario D, 2011, CIRC RES, V108, P1467, DOI 10.1161/CIRCRESAHA.111.240648; D'Amario D, 2011, CIRC RES, V108, P857, DOI 10.1161/CIRCRESAHA.111.241380; Dawn B, 2005, P NATL ACAD SCI USA, V102, P3766, DOI 10.1073/pnas.0405957102; Fischer KM, 2009, CIRCULATION, V120, P2077, DOI 10.1161/CIRCULATIONAHA.109.884403; Flett AS, 2011, JACC-CARDIOVASC IMAG, V4, P150, DOI 10.1016/j.jcmg.2010.11.015; Heusch G, 1998, PHYSIOL REV, V78, P1055, DOI 10.1152/physrev.1998.78.4.1055; Hu SS, 2011, J AM COLL CARDIOL, V57, P2409, DOI 10.1016/j.jacc.2011.01.037; Kim RJ, 2003, J CARDIOV MAGN RESON, V5, P505, DOI 10.1081/JCMR-120022267; Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102; Lorusso R, 2001, EUR J CARDIO-THORAC, V20, P937, DOI 10.1016/S1010-7940(01)00945-9; MINTZ LJ, 1980, AM J CARDIOL, V45, P210, DOI 10.1016/0002-9149(80)90637-2; Perin EC, 2011, AM HEART J, V161, P1078, DOI 10.1016/j.ahj.2011.01.028; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Rota M, 2008, CIRC RES, V103, P107, DOI 10.1161/CIRCRESAHA.108.178525; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Strauer BE, 2005, J AM COLL CARDIOL, V46, P1651, DOI 10.1016/j.jacc.2005.01.069; Strauer BE, 2010, EUR J HEART FAIL, V12, P721, DOI 10.1093/eurjhf/hfq095; Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905; The Criteria Committee of the New York Heart Association, 1994, NOMENCLATURE CRITERI, V9th, P253; Vanoverschelde JLJ, 2000, AM J CARDIOL, V85, P1432, DOI 10.1016/S0002-9149(00)00790-6; Williams AR, 2011, CIRC RES, V108, P792, DOI 10.1161/CIRCRESAHA.111.242610	31	997	1076	0	200	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2011	378	9806					1847	1857		10.1016/S0140-6736(11)61590-0	http://dx.doi.org/10.1016/S0140-6736(11)61590-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857DQ	22088800	Green Accepted, Bronze			2022-12-28	WOS:000297695800029
J	Elessi, K; Mokhallalati, M; Madbak, S				Elessi, Khamis; Mokhallalati, Mofeed; Madbak, Suhail			Evidence-based medicine comes to Gaza	LANCET			English	Editorial Material									[Elessi, Khamis; Mokhallalati, Mofeed] Islamic Univ, Fac Med, Gaza City, Occupied Palest, Israel; [Madbak, Suhail] Al Azhar Univ, Fac Med, Gaza City, Occupied Palest, Israel		Elessi, K (corresponding author), Islamic Univ, Fac Med, Gaza City, Occupied Palest, Israel.	kessi@iugaza.edu.ps						Al Barqouni LN, 2010, LANCET, V376, P68, DOI 10.1016/S0140-6736(10)60812-4; Barqouni L, 2010, INTERVENTIONS TREATI, DOI [10.1002/14651858, DOI 10.1002/14651858.CD008805]; Garner P, 1998, BRIT MED J, V317, P531; Levine R, 2008, PSYCHIAT TIMES, V25, P1; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011	7	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2011	378	9806					1834	1835		10.1016/S0140-6736(11)61513-4	http://dx.doi.org/10.1016/S0140-6736(11)61513-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857DQ	22067132				2022-12-28	WOS:000297695800013
J	Spatzal, T; Aksoyoglu, M; Zhang, LM; Andrade, SLA; Schleicher, E; Weber, S; Rees, DC; Einsle, O				Spatzal, Thomas; Aksoyoglu, Muege; Zhang, Limei; Andrade, Susana L. A.; Schleicher, Erik; Weber, Stefan; Rees, Douglas C.; Einsle, Oliver			Evidence for Interstitial Carbon in Nitrogenase FeMo Cofactor	SCIENCE			English	Article									[Spatzal, Thomas; Andrade, Susana L. A.; Einsle, Oliver] Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; [Aksoyoglu, Muege; Schleicher, Erik; Weber, Stefan] Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany; [Zhang, Limei; Rees, Douglas C.] CALTECH, Howard Hughes Med Inst, Div Chem & Chem Engn, Pasadena, CA 91125 USA; [Andrade, Susana L. A.; Einsle, Oliver] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; California Institute of Technology; Howard Hughes Medical Institute; University of Freiburg	Einsle, O (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany.	einsle@biochemie.uni-freiburg.de	Weber, Stefan/G-6164-2010; Schleicher, Erik/C-9951-2010; Andrade, Susana L. A./D-5119-2012	Andrade, Susana L. A./0000-0003-2267-8499; Einsle, Oliver/0000-0001-8722-2893; Schleicher, Erik/0000-0003-2953-050X; Kasanmascheff, Muge/0000-0002-8964-8924	Deutsche Forschungsgemeinschaft [Ei-520/7, An-676/1, IRTG 1478]; Natural Sciences and Engineering Research Council of Canada; NIH [GM45162]; HHMI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM045162] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the staff at Swiss Light Source, Villigen, Switzerland, and S. M. Consiglio for assistance with the calculations. The work was supported by Deutsche Forschungsgemeinschaft (grants Ei-520/7 to O.E., An-676/1 to S. L. A. A., and IRTG 1478), Natural Sciences and Engineering Research Council of Canada postdoctoral fellowship to L.Z., NIH (grant GM45162 to D. C. R.), and HHMI (to D. C. R.). The structural model and structure factors have been deposited with the Protein Data Bank (accession code 3U7Q).	Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Lukoyanov D, 2007, INORG CHEM, V46, P11437, DOI 10.1021/ic7018814; Rees DC, 2005, PHILOS T R SOC A, V363, P971, DOI 10.1098/rsta.2004.1539	3	613	620	13	314	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					940	940		10.1126/science.1214025	http://dx.doi.org/10.1126/science.1214025			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096190	Green Accepted			2022-12-28	WOS:000297101800045
J	Benjamin, M; Gibbs, S				Benjamin, Malvyn; Gibbs, Simon			A PATIENT'S JOURNEY Amyloidosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gibbs, Simon] UCL Med Sch, Natl Amyloidosis Ctr, London NW3 2PF, England	University of London; University College London	Gibbs, S (corresponding author), UCL Med Sch, Natl Amyloidosis Ctr, Royal Free Campus, London NW3 2PF, England.	s.gibbs@ucl.ac.uk	Gibbs, Simon/K-4974-2019						0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d6326	10.1136/bmj.d6326	http://dx.doi.org/10.1136/bmj.d6326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892DT	22088395	Bronze			2022-12-28	WOS:000300267600001
J	Chen, Y; Randerson, JT; Morton, DC; DeFries, RS; Collatz, GJ; Kasibhatla, PS; Giglio, L; Jin, YF; Marlier, ME				Chen, Yang; Randerson, James T.; Morton, Douglas C.; DeFries, Ruth S.; Collatz, G. James; Kasibhatla, Prasad S.; Giglio, Louis; Jin, Yufang; Marlier, Miriam E.			Forecasting Fire Season Severity in South America Using Sea Surface Temperature Anomalies	SCIENCE			English	Article							CLIMATE-CHANGE; AMAZON BASIN; EL-NINO; DEFORESTATION; RAINFALL; FORESTS; DROUGHT; PRODUCTS; PRECIPITATION; OSCILLATION	Fires in South America cause forest degradation and contribute to carbon emissions associated with land use change. We investigated the relationship between year-to-year changes in fire activity in South America and sea surface temperatures. We found that the Oceanic Nino Index was correlated with interannual fire activity in the eastern Amazon, whereas the Atlantic Multidecadal Oscillation index was more closely linked with fires in the southern and southwestern Amazon. Combining these two climate indices, we developed an empirical model to forecast regional fire season severity with lead times of 3 to 5 months. Our approach may contribute to the development of an early warning system for anticipating the vulnerability of Amazon forests to fires, thus enabling more effective management with benefits for climate and air quality.	[Chen, Yang; Randerson, James T.; Jin, Yufang] Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; [Morton, Douglas C.; Collatz, G. James] NASA, Goddard Space Flight Ctr, Biospher Sci Branch, Greenbelt, MD 20771 USA; [DeFries, Ruth S.] Columbia Univ, Dept Ecol Evolut & Environm Biol, New York, NY 10027 USA; [Kasibhatla, Prasad S.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; [Giglio, Louis] Univ Maryland, Dept Geog, College Pk, MD 20742 USA; [Marlier, Miriam E.] Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA	University of California System; University of California Irvine; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; Duke University; University System of Maryland; University of Maryland College Park; Columbia University	Chen, Y (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.	yang.chen@uci.edu	collatz, george j/D-5381-2012; Chen, Yang/C-6529-2008; Randerson, James/Y-2550-2019; Morton, Douglas C/D-5044-2012	Chen, Yang/0000-0002-0993-7081; Randerson, James/0000-0001-6559-7387; Kasibhatla, Prasad/0000-0003-3562-3737; Giglio, Louis/0000-0001-6312-7955	NASA [NNX08AF64G, NNX10AT83G]	NASA(National Aeronautics & Space Administration (NASA))	Supported by NASA grants NNX08AF64G and NNX10AT83G. The GFED3 carbon emissions time series is publicly available at www.globalfiredata.org.	Aragao LEOC, 2010, SCIENCE, V328, P1275, DOI 10.1126/science.1186925; Aragao LEOC, 2008, PHILOS T R SOC B, V363, P1779, DOI 10.1098/rstb.2007.0026; Cochrane MA, 2003, NATURE, V421, P913, DOI 10.1038/nature01437; Cox PM, 2008, NATURE, V453, P212, DOI 10.1038/nature06960; da Rocha HR, 2004, ECOL APPL, V14, pS22; Da Silva RR, 2008, J CLIMATE, V21, P1153, DOI 10.1175/2007JCLI1304.1; Fernandes K, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047392; Golding N, 2008, GLOBAL BIOGEOCHEM CY, V22, DOI 10.1029/2007GB003166; Justice CO, 2002, REMOTE SENS ENVIRON, V83, P244, DOI 10.1016/S0034-4257(02)00076-7; KOUSKY VE, 1984, TELLUS A, V36, P490, DOI 10.1111/j.1600-0870.1984.tb00264.x; Lee JE, 2005, P NATL ACAD SCI USA, V102, P17576, DOI 10.1073/pnas.0508785102; Lewis SL, 2011, SCIENCE, V331, P554, DOI 10.1126/science.1200807; Li WH, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006355; Los SO, 2001, J CLIMATE, V14, P1535, DOI 10.1175/1520-0442(2001)014<1535:GIVISS>2.0.CO;2; Malhi Y, 2009, P NATL ACAD SCI USA, V106, P20610, DOI 10.1073/pnas.0804619106; Marengo JA, 2008, J CLIMATE, V21, P495, DOI 10.1175/2007JCLI1600.1; Morisette JT, 2005, EARTH INTERACT, V9; Morton DC, 2008, GLOBAL CHANGE BIOL, V14, P2262, DOI 10.1111/j.1365-2486.2008.01652.x; Morton DC, 2011, REMOTE SENS ENVIRON, V115, P1706, DOI 10.1016/j.rse.2011.03.002; Nepstad D., 2004, Global Change Biology, V10, P704, DOI 10.1111/j.1529-8817.2003.00772.x; NEPSTAD DC, 1994, NATURE, V372, P666, DOI 10.1038/372666a0; Pan YD, 2011, SCIENCE, V333, P988, DOI 10.1126/science.1201609; Ronchail J, 2002, INT J CLIMATOL, V22, P1663, DOI 10.1002/joc.815; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Schroeder W, 2008, REMOTE SENS ENVIRON, V112, P2711, DOI 10.1016/j.rse.2008.01.005; SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322; Silvestrini RA, 2011, ECOL APPL, V21, P1573, DOI 10.1890/10-0827.1; Soares BS, 2006, NATURE, V440, P520, DOI 10.1038/nature04389; Trenberth KE, 1997, B AM METEOROL SOC, V78, P2771, DOI 10.1175/1520-0477(1997)078<2771:TDOENO>2.0.CO;2; Trenberth KE, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026894; van der Werf GR, 2010, ATMOS CHEM PHYS, V10, P11707, DOI 10.5194/acp-10-11707-2010; van der Werf GR, 2009, NAT GEOSCI, V2, P737, DOI 10.1038/ngeo671; Yoon JH, 2010, CLIM DYNAM, V34, P249, DOI 10.1007/s00382-009-0551-6; Zeng N, 2008, ENVIRON RES LETT, V3, DOI 10.1088/1748-9326/3/1/014002	34	157	159	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					787	791		10.1126/science.1209472	http://dx.doi.org/10.1126/science.1209472			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076373	Green Submitted			2022-12-28	WOS:000296849600041
J	Yang, LQ; Lin, CR; Liu, W; Zhang, J; Ohgi, KA; Grinstein, JD; Dorrestein, PC; Rosenfeld, MG				Yang, Liuqing; Lin, Chunru; Liu, Wen; Zhang, Jie; Ohgi, Kenneth A.; Grinstein, Jonathan D.; Dorrestein, Pieter C.; Rosenfeld, Michael G.			ncRNA- and Pc2 Methylation-Dependent Gene Relocation between Nuclear Structures Mediates Gene Activation Programs	CELL			English	Article							LONG NONCODING RNAS; HISTONE H3; LYSINE METHYLTRANSFERASE; CELL-CYCLE; PROTEIN; E2F; HETEROCHROMATIN; EXPRESSION; RECEPTOR; COMPLEXES	Although eukaryotic nuclei contain distinct architectural structures associated with noncoding RNAs (ncRNAs), their potential relationship to regulated transcriptional programs remains poorly understood. Here, we report that methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2, located in PcGs and ICGs, respectively. These ncRNAs mediate assembly of multiple corepressors/coactivators and can serve to switch mark recognition by "readers'' of the histone code. Additionally, binding of NEAT2 to unmethylated Pc2 promotes E2F1 SUMOylation, leading to activation of the growth-control gene program. These observations delineate a molecular pathway linking the actions of subnuclear structure-specific ncRNAs and nonhistone protein methylation to relocation of transcription units in the three-dimensional space of the nucleus, thus achieving coordinated gene expression programs.	[Yang, Liuqing; Lin, Chunru; Liu, Wen; Zhang, Jie; Ohgi, Kenneth A.; Grinstein, Jonathan D.; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Yang, Liuqing; Lin, Chunru; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; [Liu, Wen] Univ Calif San Diego, Sch Med, Grad Program Biol, La Jolla, CA 92093 USA; [Grinstein, Jonathan D.] Univ Calif San Diego, Sch Med, Grad Program Biomed Sci, La Jolla, CA 92093 USA; [Dorrestein, Pieter C.] Univ Calif San Diego, Sch Med, Dept Chem & Biochem, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu	Dorrestein, Pieter/ABF-2930-2020; Dorrestein, Pieter/D-5012-2012	Grinstein, Jonathan/0000-0003-2911-4506	Prostate Cancer Foundation; DoD [W81XWH-08-1-0554]; Susan G. Komen for the Cure Fellowship [KG080247];  [DK018477];  [DK74868];  [DK39949];  [CA97134];  [NS34934];  [W81XWH-08-1-0665]; NATIONAL CANCER INSTITUTE [R01CA097134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039949, R37DK039949, P01DK074868, R01DK018477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034934] Funding Source: NIH RePORTER	Prostate Cancer Foundation; DoD(United States Department of Defense); Susan G. Komen for the Cure Fellowship(Susan G. Komen Breast Cancer Foundation); ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank C. Nelson for assistance with cell culture; J. Hightower for artwork; D. Benson, M. Fisher, and R. Pardee for assistance with the manuscript; Dr. B. Tanasa for providing E2F1 target sites from previously published ChIP-Seq data; Dr. P. Sun and Dr. R. Liao for providing BJ cells and technical support for the senescence study; Dr. R. June for assistance with flow cytometry analysis; and Dr. M. Ghassemian and Wei Ting Liu for mass spectrometry analysis. Michael G. Rosenfeld is a Howard Hughes Medical Institute Investigator. This study was funded by grants from DK018477, DK74868, DK39949, CA97134, NS34934, W81XWH-08-1-0665, and the Prostate Cancer Foundation to M. G. R.; L.Y. is the recipient of a DoD Era of Hope Postdoctoral Award (W81XWH-08-1-0554); and C. L. is the recipient of a Susan G. Komen for the Cure Fellowship (KG080247).	Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; Bernstein E, 2006, MOL CELL BIOL, V26, P2560, DOI 10.1128/MCB.26.7.2560-2569.2006; Bond CS, 2009, J CELL BIOL, V186, P637, DOI 10.1083/jcb.200906113; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Czvitkovich S, 2001, MECH DEVELOP, V107, P141, DOI 10.1016/S0925-4773(01)00464-6; delaLuna S, 1996, J CELL SCI, V109, P2443; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Huang A, 2005, CANCER RES, V65, P5607, DOI 10.1158/0008-5472.CAN-05-0500; Huang J, 2008, CURR OPIN GENET DEV, V18, P152, DOI 10.1016/j.gde.2008.01.012; Huang WD, 2011, NATURE, V470, P414, DOI 10.1038/nature09703; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kerscher O, 2007, EMBO REP, V8, P550, DOI 10.1038/sj.embor.7400980; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lavrov S, 2004, METH MOL B, V247, P289; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Misteli T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000794; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Szczerbal I, 2010, CHROMOSOME RES, V18, P887, DOI 10.1007/s10577-010-9176-1; Ule J, 2005, METHODS, V37, P376, DOI 10.1016/j.ymeth.2005.07.018; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xu XJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-396; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027	50	459	487	0	57	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					773	788		10.1016/j.cell.2011.08.054	http://dx.doi.org/10.1016/j.cell.2011.08.054			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078878	Bronze, Green Accepted			2022-12-28	WOS:000296902300012
J	Mathurin, P; Moreno, C; Samuel, D; Dumortier, J; Salleron, J; Durand, F; Castel, H; Duhamel, A; Pageaux, GP; Leroy, V; Dharancy, S; Louvet, A; Boleslawski, E; Lucidi, V; Gustot, T; Francoz, C; Letoublon, C; Castaing, D; Belghiti, J; Donckier, V; Pruvot, FR; Duclos-Vallee, JC				Mathurin, Philippe; Moreno, Christophe; Samuel, Didier; Dumortier, Jerome; Salleron, Julia; Durand, Francois; Castel, Helene; Duhamel, Alain; Pageaux, Georges-Philippe; Leroy, Vincent; Dharancy, Sebastien; Louvet, Alexandre; Boleslawski, Emmanuel; Lucidi, Valerio; Gustot, Thierry; Francoz, Claire; Letoublon, Christian; Castaing, Denis; Belghiti, Jacques; Donckier, Vincent; Pruvot, Francois-Rene; Duclos-Vallee, Jean-Charles			Early Liver Transplantation for Severe Alcoholic Hepatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMULATED CONTROLS; DISEASE; CIRRHOSIS; RELAPSE; ABSTINENCE; MORTALITY; SURVIVAL; EUROPE; MODEL; SCORE	BACKGROUND A 6-month abstinence from alcohol is usually required before patients with severe alcoholic hepatitis are considered for liver transplantation. Patients whose hepatitis is not responding to medical therapy have a 6-month survival rate of approximately 30%. Since most alcoholic hepatitis deaths occur within 2 months, early liver transplantation is attractive but controversial. METHODS We selected patients from seven centers for early liver transplantation. The patients had no prior episodes of alcoholic hepatitis and had scores of 0.45 or higher according to the Lille model (which calculates scores ranging from 0 to 1, with a score >= 0.45 indicating nonresponse to medical therapy and an increased risk of death in the absence of transplantation) or rapid worsening of liver function despite medical therapy. Selected patients also had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence. Survival was compared between patients who underwent early liver transplantation and matched patients who did not. RESULTS In all, 26 patients with severe alcoholic hepatitis at high risk of death (median Lille score, 0.88) were selected and placed on the list for a liver transplant within a median of 13 days after nonresponse to medical therapy. Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected. The centers used 2.9% of available grafts for this indication. The cumulative 6-month survival rate (+/- SE) was higher among patients who received early transplantation than among those who did not (77 +/- 8% vs. 23 +/- 8%, P<0.001). This benefit of early transplantation was maintained through 2 years of follow-up (hazard ratio, 6.08; P = 0.004). Three patients resumed drinking alcohol: one at 720 days, one at 740 days, and one at 1140 days after transplantation. Conclusions Early liver transplantation can improve survival in patients with a first episode of severe alcoholic hepatitis not responding to medical therapy. (Funded by Societe Nationale Francaise de Gastroenterologie.)	[Mathurin, Philippe; Castel, Helene; Dharancy, Sebastien; Louvet, Alexandre] Ctr Hosp Univ Lille, Hop Claude Huriez, Serv Malad Appareil Digestif, Lille, France; [Mathurin, Philippe; Castel, Helene; Dharancy, Sebastien; Louvet, Alexandre] Ctr Hosp Univ Lille, INSERM, U995, Lille, France; [Boleslawski, Emmanuel; Pruvot, Francois-Rene] Ctr Hosp Univ Lille, Serv Chirurg Digest, Lille, France; [Boleslawski, Emmanuel; Pruvot, Francois-Rene] Ctr Hosp Univ Lille, Transplantat Serv, Lille, France; [Salleron, Julia; Duhamel, Alain] Ctr Hosp Univ Lille, Dept Biostat, Lille, France; [Salleron, Julia; Duhamel, Alain] Ctr Hosp Univ Lille, INSERM, EA2694, Lille, France; Univ Nord France, Lille, France; [Samuel, Didier; Castaing, Denis; Duclos-Vallee, Jean-Charles] Univ Paris 11, Hop Paul Brousse, Assistance Publ Hop Paris, Ctr Hepatobiliaire, Villejuif, France; [Samuel, Didier; Castaing, Denis; Duclos-Vallee, Jean-Charles] Univ Paris 11, INSERM, U785, Villejuif, France; [Dumortier, Jerome] Hop Edouard Herriot, Unite Transplantat Hepat, Lyon, France; [Durand, Francois; Francoz, Claire] Univ Paris 07, Hop Beaujon, INSERM, U773, Clichy, France; [Pageaux, Georges-Philippe] Hop St Eloi, Serv Hepatogastroenterol & Transplantat Hepat, Montpellier, France; [Leroy, Vincent] CHU Grenoble, Hop Albert Michallon, Serv Hepatogastroenterol, F-38043 Grenoble, France; [Leroy, Vincent] CHU Grenoble, INSERM, U823, F-38043 Grenoble, France; [Letoublon, Christian] CHU Grenoble, Serv Transplantat Hepat, F-38043 Grenoble, France; [Moreno, Christophe; Gustot, Thierry] Univ Libre Bruxelles, Erasme Hosp, Dept Gastroenterol Hepatopancreatol & Digest Onco, Brussels, Belgium; [Lucidi, Valerio; Donckier, Vincent] Univ Libre Bruxelles, Erasme Hosp, Dept Hepatobiliary Surg & Liver Transplantat, Brussels, Belgium	Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite Libre de Bruxelles; Universite Libre de Bruxelles	Mathurin, P (corresponding author), Univ Lille Nord France, Hop Claude Huriez, Serv Malad Appareil Digestif, F-59000 Lille, France.	philippe.mathurin@chru-lille.fr	Boleslawski, Emmanuel/AAB-9039-2019; Louvet, Alexandre/S-4422-2018; Mathurin, Philippe/A-9121-2018; Leroy, Vincent/L-9552-2013; Duhamel, Alain/A-4899-2013; Dharancy, Sebastien/M-4357-2018	Louvet, Alexandre/0000-0002-5293-007X; Mathurin, Philippe/0000-0003-3447-2025; Dharancy, Sebastien/0000-0002-8262-5607; BOLESLAWSKI, Emmanuel/0000-0003-3286-8608; Durand, Francois/0000-0002-0357-1090; Gustot, Thierry/0000-0002-5537-9607; Lucidi, Valerio/0000-0001-7347-9727; Francoz, Claire/0000-0001-7391-8507	Societe Nationale Francaise de Gastroenterologie; Roche; Astellas; Novartis; Janssen-Cilag; Schering-Plough; Bristol-Myers Squibb; Laboratoire Francais du Fractionnement et des Biotechnologies	Societe Nationale Francaise de Gastroenterologie; Roche(Roche Holding); Astellas(Astellas Pharmaceuticals); Novartis(Novartis); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Schering-Plough(Merck & CompanySchering Plough Corporation); Bristol-Myers Squibb(Bristol-Myers Squibb); Laboratoire Francais du Fractionnement et des Biotechnologies	Funded by Societe Nationale Francaise de Gastroenterologie.; Dr. Dharancy reports receiving consulting fees from Roche and lecture fees from Astellas and serving as a board member of Novartis. Dr. Dumortier reports receiving consulting fees, lecture fees, and grant support from Novartis and serving as a board member of Novartis; receiving lecture fees from Janssen-Cilag; receiving grant support from and serving as a board member of Astellas; receiving grant support from and serving as a board member of Roche; receiving grant support from Schering-Plough; and serving as a board member of GlaxoSmithKline. Dr. Durand reports receiving consulting fees from Astellas and consulting fees and grant support from Novartis. Dr. Leroy reports receiving lecture fees and grant support from and serving as a board member of Roche; receiving lecture fees and grant support from and serving as a board member of Bristol-Myers Squibb; receiving lecture fees and grant support from and serving as a board member of Gilead; receiving lecture fees from and serving as a board member of Merck; and serving as a board member of Janssen-Cilag. Dr. Louvet reports receiving consulting fees from Schering-Plough and Bristol-Myers Squibb. Dr. Mathurin reports receiving lecture fees and grant support from and serving as a board member of Roche; receiving lecture fees from and serving as a board member of Schering-Plough; receiving lecture fees from and serving as a board member of Bristol-Myers Squibb; receiving lecture fees from and serving as a board member of Gilead; receiving lecture fees from Bayer Healthcare; receiving grant support from and serving as a board member of Janssen-Cilag; and serving as a board member of Norgine. Dr. Pageaux reports receiving lecture fees, grant support, and reimbursement for travel expenses from Roche; receiving lecture fees from Bayer HealthCare and Gilead; receiving grant support from and serving as a board member of Astellas; and receiving grant support from Novartis. Dr. Pruvot reports receiving lecture fees and reimbursement for travel expenses from Roche. Dr. Samuel reports receiving consulting fees, lecture fees, and grant support from Roche; consulting fees and lecture fees from Schering-Plough; consulting fees from Merck; consulting fees, lecture fees, and grant support from Astellas; consulting fees, lecture fees, and grant support from Novartis; consulting fees from Janssen-Cilag; consulting fees and lecture fees from Bristol-Myers Squibb; consulting fees and lecture fees from Gilead; and consulting fees and lecture fees from Laboratoire Francais du Fractionnement et des Biotechnologies. No other potential conflicts were reported.	Bathgate AJ, 2006, LANCET, V367, P2045, DOI 10.1016/S0140-6736(06)68904-6; Benjamin M, 1994, LIVER TRANSPLANT, P113; Beresford TP, 2000, LIVER TRANSPLANT, V6, P777, DOI 10.1053/jlts.2000.19027; BIRD GLA, 1990, BRIT MED J, V301, P15, DOI 10.1136/bmj.301.6742.15; Boudjema K, 2006, LIVER TRANSPLANT, V12, P998, DOI 10.1002/lt.20765; Bravata DM, 2001, LIVER TRANSPLANT, V7, P191, DOI 10.1053/jlts.2001.22326; Burra P, 2010, AM J TRANSPLANT, V10, P138, DOI 10.1111/j.1600-6143.2009.02869.x; Burroughs AK, 2006, LANCET, V367, P225, DOI 10.1016/S0140-6736(06)68033-1; DiMartini A, 2006, LIVER TRANSPLANT, V12, P813, DOI 10.1002/lt.20688; Dunn W, 2005, HEPATOLOGY, V41, P353, DOI 10.1002/hep.20503; Dureja P, 2010, J HEPATOL, V52, P759, DOI 10.1016/j.jhep.2009.12.021; Everhart J E, 1997, Liver Transpl Surg, V3, P220, DOI 10.1053/jlts.1997.v3.ajlts0030220; Forrest EH, 2005, GUT, V54, P1174, DOI 10.1136/gut.2004.050781; Foster PF, 1997, HEPATOLOGY, V25, P1469, DOI 10.1002/hep.510250627; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; Louvet A, 2007, HEPATOLOGY, V45, P1348, DOI 10.1002/hep.21607; Louvet A, 2009, GASTROENTEROLOGY, V137, P541, DOI 10.1053/j.gastro.2009.04.062; Lucey M R, 1997, Liver Transpl Surg, V3, P628; Lucey MR, 2009, NEW ENGL J MED, V360, P2758, DOI 10.1056/NEJMra0805786; Mathurin P, 2011, GUT, V60, P255, DOI 10.1136/gut.2010.224097; McMaster P, 2000, LANCET, V355, P424; Miguet M, 2004, GASTROEN CLIN BIOL, V28, P845, DOI 10.1016/S0399-8320(04)95146-9; Neuberger J, 1998, LIVER TRANSPLANT SUR, V4, pS51; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Olthoff KM, 2004, LIVER TRANSPLANT, V10, pA6, DOI 10.1002/lt.20247; OSORIO RW, 1994, HEPATOLOGY, V20, P105, DOI 10.1016/0270-9139(94)90141-4; Pageaux GP, 1999, GUT, V45, P421, DOI 10.1136/gut.45.3.421; Pageaux GP, 2003, J HEPATOL, V38, P629, DOI 10.1016/S0168-8278(03)00088-6; POYNARD T, 1994, LANCET, V344, P502, DOI 10.1016/S0140-6736(94)91897-X; Poynard T, 1999, J HEPATOL, V30, P1130, DOI 10.1016/S0168-8278(99)80269-4; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Shawcross DL, 2010, LANCET, V376, P216, DOI 10.1016/S0140-6736(10)60487-4; Srikureja W, 2005, J HEPATOL, V42, P700, DOI 10.1016/j.jhep.2004.12.022; Surman OS, 2009, TRANSPLANTATION, V87, P1753, DOI 10.1097/TP.0b013e3181a754d4; Ubel PA, 2001, LIVER TRANSPLANT, V7, P600, DOI 10.1053/jlts.2001.25361; Yates WR, 1998, ALCOHOL CLIN EXP RES, V22, P513, DOI 10.1111/j.1530-0277.1998.tb03681.x	36	519	533	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1790	1800		10.1056/NEJMoa1105703	http://dx.doi.org/10.1056/NEJMoa1105703			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070476				2022-12-28	WOS:000296762800008
J	van Beijnum, J; van der Worp, HB; Buis, DR; Salman, RAS; Kappelle, LJ; Rinkel, GJE; van der Sprenkel, JWB; Vandertop, WP; Algra, A; Klijn, CJM				van Beijnum, Janneke; van der Worp, H. Bart; Buis, Dennis R.; Salman, Rustam Al-Shahi; Kappelle, L. Jaap; Rinkel, Gabriel J. E.; van der Sprenkel, Jan Willem Berkelbach; Vandertop, W. Peter; Algra, Ale; Klijn, Catharina J. M.			Treatment of Brain Arteriovenous Malformations A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FACTORS AFFECTING OBLITERATION; GAMMA-KNIFE RADIOSURGERY; N-BUTYL CYANOACRYLATE; TERM-FOLLOW-UP; GRADING SYSTEM; MULTIMODALITY TREATMENT; LINAC RADIOSURGERY; PREDICTIVE FACTORS; HEMORRHAGE; EMBOLIZATION	Context Outcomes following treatment of brain arteriovenous malformations (AVMs)with microsurgery, embolization, stereotactic radiosurgery (SRS), or combinations vary greatly between studies. Objectives To assess rates of case fatality, long-term risk of hemorrhage, complications, and successful obliteration of brain AVMs after interventional treatment and to assess determinants of these outcomes. Data Sources We searched PubMed and EMBASE to March 1, 2011, and hand-searched 6 journals from January 2000 until March 2011. Study Selection and Data Extraction We identified studies fulfilling predefined inclusion criteria. We used Poisson regression analyses to explore associations of patient and study characteristics with case fatality, complications, long-term risk of hemorrhage, and successful brain AVM obliteration. Data Synthesis We identified 137 observational studies including 142 cohorts, totaling 13 698 patients and 46 314 patient-years of follow-up. Case fatality was 0.68 (95% CI, 0.61-0.76) per 100 person-years overall, 1.1 (95% CI, 0.87-1.3; n=2549) after microsurgery, 0.50 (95% CI, 0.43-0.58; n=9436) after SRS, and 0.96 (95% CI, 0.67-1.4; n=1019) after embolization. Intracranial hemorrhage rates were 1.4 (95% CI, 1.3-1.5) per 100 person-years overall, 0.18 (95% CI, 0.10-0.30) after microsurgery, 1.7 (95% CI, 1.5-1.8) after SRS, and 1.7 (95% CI, 1.3-2.3) after embolization. More recent studies were associated with lower case-fatality rates (rate ratio [RR], 0.972; 95% CI, 0.955-0.989) but increased rates of hemorrhage (RR, 1.02; 95% CI, 1.00-1.03). Male sex (RR, 0.964; 95% CI, 0.945-0.984), small brain AVMs (RR, 0.988; 95% CI, 0.981-0.995), and those with strictly deep venous drainage (RR, 0.975; 95% CI, 0.960-0.990) were associated with lower case fatality. Lower hemorrhage rates were associated with male sex (RR, 0.976, 95% CI, 0.964-0.988), small brain AVMs (RR, 0.988, 95% CI, 0.980-0.996), and brain AVMs with deep venous drainage (0.982, 95% CI, 0.969-0.996). Complications leading to permanent neurological deficits or death occurred in a median 7.4% (range, 0%-40%) of patients after microsurgery, 5.1% (range, 0%-21%) after SRS, and 6.6% (range, 0%-28%) after embolization. Successful brain AVM obliteration was achieved in 96% (range, 0%-100%) of patients after microsurgery, 38% (range, 0%-75%) after SRS, and 13% (range, 0%-94%) after embolization. Conclusions Although case fatality after treatment has decreased over time, treatment of brain AVM remains associated with considerable risks and incomplete efficacy. Randomized controlled trials comparing different treatment modalities appear justified. JAMA. 2011;306(18):2011-2019	[van Beijnum, Janneke] Leiden Univ, Dept Neurosurg, Med Ctr, NL-2300 RC Leiden, Netherlands; [van der Worp, H. Bart; Buis, Dennis R.] Vrije Univ Amsterdam, Dept Neurosurg, Neurosurg Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands; [van der Worp, H. Bart; Buis, Dennis R.] Amsterdam Med Ctr, Amsterdam, Netherlands; [Salman, Rustam Al-Shahi] Univ Edinburgh, Div Clin Neurosci, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Edinburgh	van Beijnum, J (corresponding author), Leiden Univ, Dept Neurosurg, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.	j.vanbeijnum@gmail.com	Vandertop, William P./K-9288-2018; Buis, Dennis/L-3247-2019; van+Beijnum, Janneke/ACA-2245-2022; Klijn, C.J.M./E-1700-2016	Buis, Dennis/0000-0002-7411-5383; Klijn, C.J.M./0000-0002-8495-4578; Vandertop, William/0000-0001-5417-0265; Al-Shahi Salman, Rustam/0000-0002-2108-9222	Netherlands Organization for Scientific Research (NWO); Netherlands Heart Foundation [2002B138, 2010T075]; UK Medical Research Council [G108/613]; Netherlands Heart Association [2007B048]; Netherlands Organization for Health Research and Development [907-00-103]; Medical Research Council [G108/613] Funding Source: researchfish; MRC [G108/613] Funding Source: UKRI	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Heart Foundation(Netherlands Heart Foundation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Heart Association(Netherlands Heart Foundation); Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Dr van Beijnum was funded by the Netherlands Organization for Scientific Research (NWO); and by grant 2002B138 from the Netherlands Heart Foundation. Dr van der Worp is supported by grant 2010T075 from the Netherlands Heart Foundation. Dr Al-Shahi Salman was funded by grant G108/613 from the UK Medical Research Council (Clinician Scientist Fellowship). Dr Klijn was funded by grant 2007B048, the Netherlands Heart Association and by grant 907-00-103 from the Netherlands Organization for Health Research and Development.	ADELT D, 1985, ACTA NEUROCHIR, V76, P45, DOI 10.1007/BF01403828; Al-Shahi R, 2002, J NEUROL NEUROSUR PS, V73, P547, DOI 10.1136/jnnp.73.5.547; Al-Shahi R, 2005, PRACT NEUROL, V5, P194; Bhatnagar A, 2001, INT J RADIAT ONCOL, V51, P969, DOI 10.1016/S0360-3016(01)01734-5; Buis DR, 2005, INT J RADIAT ONCOL, V62, P246, DOI 10.1016/j.ijrobp.2004.12.080; Chang JH, 2000, J NEUROSURG, V93, P96, DOI 10.3171/jns.2000.93.supplement_3.0096; da Costa L, 2009, STROKE, V40, P100, DOI 10.1161/STROKEAHA.108.524678; Dorfer C, 2010, CHILD NERV SYST, V26, P681, DOI 10.1007/s00381-009-1039-8; Flickinger JC, 2002, RADIOTHER ONCOL, V63, P347, DOI 10.1016/S0167-8140(02)00103-2; Friedman WA, 2003, NEUROSURGERY, V52, P296, DOI 10.1227/01.NEU.0000043692.51385.91; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; Geibprasert S, 2010, RADIOGRAPHICS, V30, P483, DOI 10.1148/rg.302095728; Heffez DS, 1998, SURG NEUROL, V49, P373, DOI 10.1016/S0090-3019(97)00441-2; Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUBSCHMANN OR, 1987, SURG NEUROL, V27, P323, DOI 10.1016/0090-3019(87)90006-1; Kim H, 2011, ACTA NEUROCHIR SUPPL, V111, P83, DOI 10.1007/978-3-7091-0693-8_14; Kuhmonen J, 2005, ACT NEUR S, V94, P111; Lawton MT, 2010, NEUROSURGERY, V66, P702, DOI 10.1227/01.NEU.0000367555.16733.E1; Lawton MT, 2005, NEUROSURGERY, V56, P485, DOI 10.1227/01.NEU.0000153924.67360.EA; Ledezma CJ, 2006, NEUROSURGERY, V58, P602, DOI 10.1227/01.NEU.0000204103.91793.77; Liscak R, 2007, NEUROSURGERY, V60, P1005, DOI 10.1227/01.NEU.0000255474.60505.4A; Loh Y, 2010, J NEUROSURG, V113, P733, DOI 10.3171/2010.3.JNS09370; Miyawaki L, 1999, INT J RADIAT ONCOL, V44, P1089, DOI 10.1016/S0360-3016(99)00102-9; Morris Z, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3016; Natarajan SK, 2008, NEUROSURGERY, V62, P1213, DOI 10.1227/01.neu.0000333293.74986.e5; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; Pavesi G, 2009, SURG NEUROL, V72, P662, DOI 10.1016/j.surneu.2009.03.035; Pollock BE, 1998, NEUROSURGERY, V42, P1239, DOI 10.1097/00006123-199806000-00020; Pollock BE, 2002, J NEUROSURG, V96, P79, DOI 10.3171/jns.2002.96.1.0079; Pollock BE, 2008, NEUROSURGERY, V63, P239, DOI 10.1227/01.NEU.0000315861.24920.92; Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539; Ross J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003436.pub3; Schlienger M, 2000, INT J RADIAT ONCOL, V46, P1135, DOI 10.1016/S0360-3016(99)00523-4; Shin M, 2004, J NEUROSURG, V101, P18, DOI 10.3171/jns.2004.101.1.0018; SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476; Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87; Stapf C, 2004, STROKE, V35, pE195; Stapf C, 2002, CEREBROVASC DIS, V13, P43, DOI 10.1159/000047745; Starke RM, 2008, STEREOT FUNCT NEUROS, V86, P191, DOI 10.1159/000126945; Starke RM, 2009, BRIT J NEUROSURG, V23, P376, DOI 10.1080/02688690902977662; Starke RM, 2009, STROKE, V40, P2783, DOI 10.1161/STROKEAHA.108.539775; Sun DQ, 2011, INT J RADIAT ONCOL, V80, P354, DOI 10.1016/j.ijrobp.2010.01.049; Tan XX, 2011, NEUROL INDIA, V59, P199, DOI 10.4103/0028-3886.79138; van Beijnum J, 2008, STROKE, V39, P3216, DOI 10.1161/STROKEAHA.108.523662; Weber W, 2007, NEUROSURGERY, V61, P244, DOI 10.1227/01.NEU.0000255473.60505.84; Wedderburn CJ, 2008, LANCET NEUROL, V7, P223, DOI 10.1016/S1474-4422(08)70026-7; Zabel A, 2005, RADIOTHER ONCOL, V77, P105, DOI 10.1016/j.radonc.2005.04.008	48	317	319	2	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					2011	2019		10.1001/jama.2011.1632	http://dx.doi.org/10.1001/jama.2011.1632			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068993	Bronze			2022-12-28	WOS:000296704300024
J	Moore, W				Moore, Wendy			PAST CARING Backing the wrong horse	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d7187	10.1136/bmj.d7187	http://dx.doi.org/10.1136/bmj.d7187			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NH	22065676				2022-12-28	WOS:000297057800016
J	Currie, G; Fraser, K; Miller, DR; Chetty, M				Currie, Graeme; Fraser, Kimberley; Miller, David R.; Chetty, Mahendran			PICTURE QUIZ An incidental finding in a preoperative chest radiograph	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LUNG-CANCER		[Currie, Graeme; Fraser, Kimberley; Miller, David R.; Chetty, Mahendran] Aberdeen Royal Infirm, Chest Clin C, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Currie, G (corresponding author), Aberdeen Royal Infirm, Chest Clin C, Aberdeen AB25 2ZN, Scotland.	graeme.currie@nhs.net		Currie, Graeme P/0000-0002-5711-9147				Gazdar AF, 2007, J CLIN ONCOL, V25, P469, DOI 10.1200/JCO.2006.09.4623; GLAZER GM, 1985, AM J ROENTGENOL, V144, P261, DOI 10.2214/ajr.144.2.261; Lim E, 2010, THORAX, V65, P1, DOI 10.1136/thx.2010.145938; Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718; Toloza EM, 2003, CHEST, V123, p137S, DOI 10.1378/chest.123.1_suppl.137S	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2011	343								d6943	10.1136/bmj.d6943	http://dx.doi.org/10.1136/bmj.d6943			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QT	22053269				2022-12-28	WOS:000296763100007
J	Xue, T; Do, MTH; Riccio, A; Jiang, Z; Hsieh, J; Wang, HC; Merbs, SL; Welsbie, DS; Yoshioka, T; Weissgerber, P; Stolz, S; Flockerzi, V; Freichel, M; Simon, MI; Clapham, DE; Yau, KW				Xue, T.; Do, M. T. H.; Riccio, A.; Jiang, Z.; Hsieh, J.; Wang, H. C.; Merbs, S. L.; Welsbie, D. S.; Yoshioka, T.; Weissgerber, P.; Stolz, S.; Flockerzi, V.; Freichel, M.; Simon, M. I.; Clapham, D. E.; Yau, K. -W.			Melanopsin signalling in mammalian iris and retina	NATURE			English	Article							GANGLION-CELLS; DIFFERENTIAL REGULATION; PUPILLARY CONSTRICTION; LIGHT REFLEX; PHOTOTRANSDUCTION; EXPRESSION; MICE; PHOTOSENSITIVITY; LOCALIZATION; PHOTOPIGMENT	Non-mammalian vertebrates have an intrinsically photosensitive iris and thus a local pupillary light reflex (PLR). In contrast, it is thought that the PLR in mammals generally requires neuronal circuitry connecting the eye and the brain. Here we report that an intrinsic component of the PLR is in fact widespread in nocturnal and crepuscular mammals. In mouse, this intrinsic PLR requires the visual pigment melanopsin; it also requires PLC beta 4, a vertebrate homologue of the Drosophila NorpA phospholipase C which mediates rhabdomeric phototransduction. The Plcb4(-/-) genotype, in addition to removing the intrinsic PLR, also essentially eliminates the intrinsic light response of the M1 subtype of melanopsin-expressing, intrinsically photosensitive retinal ganglion cells (M1-ipRGCs), which are by far the most photosensitive ipRGC subtype and also have the largest response to light. Ablating in mouse the expression of both TRPC6 and TRPC7, members of the TRP channel superfamily, also essentially eliminated the M1-ipRGC light response but the intrinsic PLR was not affected. Thus, melanopsin signalling exists in both iris and retina, involving a PLC beta 4-mediated pathway that nonetheless diverges in the two locations.	[Xue, T.; Do, M. T. H.; Jiang, Z.; Hsieh, J.; Wang, H. C.; Yoshioka, T.; Yau, K. -W.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA; [Xue, T.; Do, M. T. H.; Jiang, Z.; Yau, K. -W.] Johns Hopkins Univ, Sch Med, Ctr Sensory Biol, Baltimore, MD 21205 USA; [Riccio, A.; Clapham, D. E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Cardiol, Boston, MA 02115 USA; [Riccio, A.; Clapham, D. E.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Hsieh, J.] Johns Hopkins Univ, BA MS Concurrent Program Neurosci, Baltimore, MD 21238 USA; [Wang, H. C.] Johns Hopkins Univ, Sch Med, Grad Program Neurosci, Baltimore, MD 21205 USA; [Merbs, S. L.; Welsbie, D. S.; Yau, K. -W.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Yoshioka, T.] Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21238 USA; [Weissgerber, P.; Stolz, S.; Flockerzi, V.; Freichel, M.] Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; [Simon, M. I.] CALTECH, Div Biol, Pasadena, CA 91125 USA	Johns Hopkins University; Johns Hopkins University; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Saarland University; California Institute of Technology	Xue, T (corresponding author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA.	txue77@gmail.com; kwyau@mail.jhmi.edu	Jiang, Zheng/A-7674-2015; Clapham, David/R-5974-2019; H, Michael Tri/A-5917-2009; Xue, Tian/G-9009-2018; Clapham, David/S-1123-2019	H, Michael Tri/0000-0001-6418-0977; Clapham, David/0000-0002-4459-9428; Hsieh, Justin/0000-0002-9701-0998; Wang, Han Chin/0000-0001-8270-6645	US NIH [EY14596]; Antonio Champalimaud Vision Award (Portugal); NATIONAL EYE INSTITUTE [R01EY014596, R37EY006837, R01EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Antonio Champalimaud Vision Award (Portugal); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank the following individuals for providing knockout mouse lines: M. Caterina (Trpv4<SUP>-/-</SUP>), J. Lem (Rho<SUP>-/-</SUP> and Gnat1<SUP>-/-</SUP>), J. C. Chen (Rho<SUP>-/-</SUP>), J. Nathans (cl, also known as cone-DTA), A. Sancar (Cry1<SUP>-/-</SUP>Cry2<SUP>-/-</SUP>) and L. Birnbaumer (Trpc1<SUP>-/-</SUP>, Trpc3<SUP>-/-</SUP> and Trpc6<SUP>-/-</SUP>). We thank D. Marshak, R. von der Heydt, X. Wang and V. Casagrande for eyes from baboon, rhesus monkey, marmoset and bush baby, respectively, and W. Li, R. Mi, B. O'Rourke, L. Pipitone, D. Ruben, D. Ryugo, L. Smale and G. Tomaselli for eyes of other animals. Experiments on bush baby were carried out in the Casagrande laboratory with help and hospitality. We also thank W. Gao for suggestions on the force transducer, F. Rieke and A. Sampath for suggestions on the design of the LED light system, P. Ala-Laurila for the method of equivalent 480-nm-photon conversion, H. Cahill for the mouse-head-anchoring method, X. Ren for help on western blots, O. Garalde and A. Chen for help in the monkey experiments, and W. W. S. Yue for help on RT-PCR. We also thank T. Shelley for fabricating all custom equipment, S. Kulason for help in data analysis, and L. Ding for mouse-genotyping support. Members of the Yau laboratory provided comments on the manuscript. This work was supported by US NIH Grant EY14596 and the Antonio Champalimaud Vision Award (Portugal) to K.-W.Y.	Allen AE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015063; Bailes HJ, 2010, CELL MOL LIFE SCI, V67, P99, DOI 10.1007/s00018-009-0155-7; BARR L, 1963, J GEN PHYSIOL, V46, P1249, DOI 10.1085/jgp.46.6.1249; BARR L, 1989, CRIT REV NEUROBIOL, V4, P325; Bellingham J, 2002, MOL BRAIN RES, V107, P128, DOI 10.1016/S0169-328X(02)00454-0; Berridge MJ, 2008, J PHYSIOL-LONDON, V586, P5047, DOI 10.1113/jphysiol.2008.160440; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; BITO LZ, 1975, COMP BIOCHEM PHYSIOL, V50, P407, DOI 10.1016/0300-9629(75)90034-1; Blanchong JA, 1999, J BIOL RHYTHM, V14, P364, DOI 10.1177/074873099129000777; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; Gomez MD, 2009, P NATL ACAD SCI USA, V106, P9081, DOI 10.1073/pnas.0900708106; Do MTH, 2009, NATURE, V457, P281, DOI 10.1038/nature07682; Do MTH, 2010, PHYSIOL REV, V90, P1547, DOI 10.1152/physrev.00013.2010; Ghosh S, 2004, NEUROSCI LETT, V370, P7, DOI 10.1016/j.neulet.2004.07.026; Gonzalez-Cobos JC, 2010, FRONT BIOSCI-LANDMRK, V15, P1023, DOI 10.2741/3660; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; Graham DM, 2008, J NEUROPHYSIOL, V99, P2522, DOI 10.1152/jn.01066.2007; Grozdanic S, 2003, CURR EYE RES, V26, P371, DOI 10.1076/ceyr.26.5.371.15439; Hankins MW, 2008, TRENDS NEUROSCI, V31, P27, DOI 10.1016/j.tins.2007.11.002; Hartwick ATE, 2007, J NEUROSCI, V27, P13468, DOI 10.1523/JNEUROSCI.3626-07.2007; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Isoldi MC, 2005, P NATL ACAD SCI USA, V102, P1217, DOI 10.1073/pnas.0409252102; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; KARGACIN GJ, 1985, J NEUROSCI, V5, P3081; Koyanagi M, 2005, CURR BIOL, V15, P1065, DOI 10.1016/j.cub.2005.04.063; LAU KC, 1992, J NEUROL SCI, V113, P70, DOI 10.1016/0022-510X(92)90267-O; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Nayak SK, 2007, CELL MOL LIFE SCI, V64, P144, DOI 10.1007/s00018-006-5581-1; Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004; Oyster CW., 1999, HUMAN EYE STRUCTURE; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; Perez-Leighton CE, 2011, EUR J NEUROSCI, V33, P856, DOI 10.1111/j.1460-9568.2010.07583.x; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; Sekaran S, 2007, J NEUROSCI, V27, P3981, DOI 10.1523/JNEUROSCI.4716-06.2007; SELIGER HH, 1962, J GEN PHYSIOL, V46, P333, DOI 10.1085/jgp.46.2.333; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Terakita A, 2008, J NEUROCHEM, V105, P883, DOI 10.1111/j.1471-4159.2007.05184.x; Tu DC, 2004, SCIENCE, V306, P129, DOI 10.1126/science.1101484; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Warren EJ, 2006, EUR J NEUROSCI, V23, P2477, DOI 10.1111/j.1460-9568.2006.04777.x; Yau KW, 2009, CELL, V139, P246, DOI 10.1016/j.cell.2009.09.029; Zhu YL, 2007, INVEST OPHTH VIS SCI, V48, P1268, DOI 10.1167/iovs.06-0925; ZUCKER R, 1978, NATURE, V274, P78, DOI 10.1038/274078a0	50	186	193	3	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2011	479	7371					67	73		10.1038/nature10567	http://dx.doi.org/10.1038/nature10567			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051675	Green Accepted			2022-12-28	WOS:000296422600033
J	Moynihan, R				Moynihan, Ray			REALITY CHECK Is journalism the drug industry's new dance partner?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					*HLTH NEWS REV, JOURN WEIGH PFIZ PFU; Institute of Medicine, 2009, CONFL INT MED RES ED; Schwartz LM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2535; Sweet M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6903	4	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2011	343								d6978	10.1136/bmj.d6978	http://dx.doi.org/10.1136/bmj.d6978			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QC	22049523				2022-12-28	WOS:000296761400006
J	Sokol, DK				Sokol, Daniel K.			ETHICS MAN Boxing, mixed martial arts, and other risky sports: is the BMA confused?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Sokol, DK (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	daniel.sokol@talk21.com						*BMA, 2009, BOX BMAS POS; *BMA, 2004, MED ETH TOD; Mill John Stuart, 2002, BASIC WRITINGS JS MI; Ngai KM, 2008, BRIT J SPORT MED, V42, P686, DOI 10.1136/bjsm.2007.044891; *WARR CREED, MMA FIGHT RUL	5	4	4	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2011	343								d6937	10.1136/bmj.d6937	http://dx.doi.org/10.1136/bmj.d6937			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844PY	22045991				2022-12-28	WOS:000296760900008
J	Pink, J; Lane, S; Pirmohamed, M; Hughes, DA				Pink, Joshua; Lane, Steven; Pirmohamed, Munir; Hughes, Dyfrig A.			Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; STROKE PREVENTION; ASPIRIN; REVERSAL; THERAPY; ANTICOAGULATION; PERSISTENCE; OUTCOMES; TRIAL	Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. Design Quantitative benefit-harm and economic analyses using a discrete event simulation model to extrapolate the findings of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study to a lifetime horizon. Setting UK National Health Service. Population Cohorts of 50 000 simulated patients at moderate to high risk of stroke with a mean baseline CHADS(2) (Congestive heart failure, Hypertension, Age >= 75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack) score of 2.1. Main outcome measures Quality adjusted life years (QALYs) gained and incremental cost per QALY of dabigatran compared with warfarin. Results Compared with warfarin, low dose and high dose dabigatran were associated with positive incremental net benefits of 0.094 (95% central range -0.083 to 0.267) and 0.146 (-0.029 to 0.322) QALYs. Positive incremental net benefits resulted for high dose dabigatran in 94% of simulations versus warfarin and in 76% of those versus low dose dabigatran. In the economic analysis, high dose dabigatran dominated the low dose, had an incremental cost effectiveness ratio of 23 pound 082 ((sic)26 700; $35 800) per QALY gained versus warfarin, and was more cost effective in patients with a baseline CHADS2 score of 3 or above. However, at centres that achieved good control of international normalised ratio, such as those in the UK, dabigatran 150 mg was not cost effective, at 42 pound 386 per QALY gained. Conclusions This analysis supports regulatory decisions that dabigatran offers a positive benefit to harm ratio when compared with warfarin. However, no subgroup for which dabigatran 110 mg offered any clinical or economic advantage over 150 mg was identified. High dose dabigatran will be cost effective only for patients at increased risk of stroke or for whom international normalised ratio is likely to be less well controlled.	[Pink, Joshua; Hughes, Dyfrig A.] Bangor Univ, Inst Med & Social Care Res, Ctr Hlth Econ & Med Evaluat, Bangor LL57 1UT, Gwynedd, Wales; [Lane, Steven] Univ Liverpool, Ctr Med Stat & Hlth Evaluat, Liverpool L69 3BX, Merseyside, England; [Pirmohamed, Munir] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Wolfson Ctr Personalised Med, Liverpool L69 3BX, Merseyside, England	Bangor University; University of Liverpool; University of Liverpool	Hughes, DA (corresponding author), Bangor Univ, Inst Med & Social Care Res, Ctr Hlth Econ & Med Evaluat, Bangor LL57 1UT, Gwynedd, Wales.	d.a.hughes@bangor.ac.uk	Hughes, Dyfrig/H-5252-2012; Pirmohamed, Munir/H-6004-2011	Hughes, Dyfrig/0000-0001-8247-7459; Pirmohamed, Munir/0000-0002-7534-7266; Pink, Joshua/0000-0002-7597-4198	Medical Research Council, as part of the North West Hub in Trial Methodological Research (NWHTMR); Medical Research Council; MRC [G0800792] Funding Source: UKRI; Medical Research Council [G0800792] Funding Source: researchfish	Medical Research Council, as part of the North West Hub in Trial Methodological Research (NWHTMR)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was funded by the Medical Research Council, as part of the North West Hub in Trial Methodological Research (NWHTMR). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: JP and DAH have support from the Medical Research Council for the submitted work; no relationships that might have an interest in the submitted work in the previous three years; no non-financial interests that may be relevant to the submitted work.	Ahrens I, 2011, THROMB HAEMOSTASIS, V105, P574, DOI 10.1160/TH10-12-0808; [Anonymous], 2008, GUID METH TECHN APPR; [Anonymous], RELY ABLE LONG TERM; Beasley BN, 2011, NEW ENGL J MED, V364, P1788, DOI 10.1056/NEJMp1103050; Boehringer Ingelheim, 2010, ADV COMM BRIEF DOC D; [British Medical Association Royal Pharmaceutical Society of Great Britain], 2010, BRIT NAT FORM, V59; Caro JJ, 2010, VALUE HEALTH, V13, P1056, DOI 10.1111/j.1524-4733.2010.00775.x; Cleland JGF, 2004, AM HEART J, V148, P157, DOI 10.1016/j.ahj.2004.03.010; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Department of Health, 2009, NHS REF COSTS 2008 0; Diabetes UK, 2010, DIAB PREV 2010; Diener HC, 2010, LANCET NEUROL, V9, P1157, DOI 10.1016/S1474-4422(10)70274-X; Drummond A, 2002, QJM-INT J MED, V95, P23, DOI 10.1093/qjmed/95.1.23; Eastern Region Public Health Observatory, 2008, MOD EST PROJ HYP LOC; European Medicines Agency, 2011, PRAD PROD INF; Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034; Ezekowitz MD, 2010, CIRCULATION, V122, P2246, DOI 10.1161/CIRCULATIONAHA.110.973735; Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005; Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93; Gallagher AM, 2008, J THROMB HAEMOST, V6, P1500, DOI 10.1111/j.1538-7836.2008.03059.x; Garrison LP, 2007, HEALTH AFFAIR, V26, P684, DOI 10.1377/hlthaff.26.3.684; Guest JF, 2010, CLIN THER, V32, P2478, DOI 10.1016/j.clinthera.2011.01.011; Hankey GJ, 2011, CIRCULATION, V123, P1436, DOI 10.1161/CIRCULATIONAHA.110.004424; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Hemingway H, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14090; Hobbs FDR, 2005, HEALTH TECHNOL ASSES, V9, P1, DOI 10.3310/hta9400; Hughes DA, 2007, CLIN PHARMACOL THER, V82, P123, DOI 10.1038/sj.clpt.6100240; Hughes D, 2007, VALUE HEALTH, V10, P498, DOI 10.1111/j.1524-4733.2007.00205.x; Jorgensen AL, 2009, PHARMACOGENET GENOM, V19, P800, DOI 10.1097/FPC.0b013e3283317ab5; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; Leontiadis GI, 2007, HEALTH TECHNOL ASSES, V11, P1; Lip GYH, 2007, LANCET, V370, P604, DOI 10.1016/S0140-6736(07)61300-2; Meckley LM, 2010, PHARMACOECONOMICS, V28, P61, DOI 10.2165/11318240-000000000-00000; National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR NAT CLIN GU; National Institute for Health and Clinical Excellence, 2006, ATR FIBR MAN ATR FIB; National Institute for Health and Clinical Excellence, 2011, ATR FIBR DAB ET APPR; Office of Health Economics, 2009, EST DIR COSTS ATR FI; Rolfe Stephen, 2010, J Pharm Pract, V23, P217, DOI 10.1177/0897190010362168; Sorensen SV, 2011, THROMB HAEMOSTASIS, V105, P908, DOI 10.1160/TH11-02-0089; Sullivan PW, 2006, MED DECIS MAKING, V26, P401, DOI 10.1177/0272989X06290496; Torgerson DJ, 1999, BRIT MED J, V319, P914, DOI 10.1136/bmj.319.7214.914; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758; Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4	48	112	115	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2011	343								d6333	10.1136/bmj.d6333	http://dx.doi.org/10.1136/bmj.d6333			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844PP	22042753	Green Published			2022-12-28	WOS:000296759900013
J	Kassaye, SG; Katzenstein, D				Kassaye, Seble G.; Katzenstein, David			The point of point-of-care testing	LANCET			English	Editorial Material							ART		[Katzenstein, David] Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA; [Kassaye, Seble G.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA	Stanford University	Katzenstein, D (corresponding author), Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.	davidkk@stanford.edu		katzenstein, david/0000-0002-8593-4560	FIC NIH HHS [U2R TW006878] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALASSANE DP, 2011, J ACQ IMMUN DEF SYND, DOI DOI 10.1097/QAI.0B013E318235B378; Faal M, 2011, JAIDS-J ACQ IMM DEF, V58, pE54, DOI 10.1097/QAI.0b013e3182303921; Jani IV, 2011, LANCET, V378, P1572, DOI 10.1016/S0140-6736(11)61052-0; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Thairu L, 2011, AIDS CARE, V23, P814, DOI 10.1080/09540121.2010.541416; Zijenah LS, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-33	9	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 29	2011	378	9802					1532	1533		10.1016/S0140-6736(11)61520-1	http://dx.doi.org/10.1016/S0140-6736(11)61520-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844SL	22035547				2022-12-28	WOS:000296767500009
J	Bernstein, R				Bernstein, Rachel			Drop that Pipette: Science by Design	CELL			English	Editorial Material								An unexpected collaboration between a synthetic biology lab at UCSF and a Palo Alto-based design firm is stirring up the way that research is conceived and conducted, by integrating innovation and "design thinking'' into the scientific method.											0	5	5	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					496	497		10.1016/j.cell.2011.10.010	http://dx.doi.org/10.1016/j.cell.2011.10.010			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036559	Bronze			2022-12-28	WOS:000296573700006
J	Solmaz, SR; Chauhan, R; Blobel, G; Melcak, I				Solmaz, Sozanne R.; Chauhan, Radha; Blobel, Guenter; Melcak, Ivo			Molecular Architecture of the Transport Channel of the Nuclear Pore Complex	CELL			English	Article							BILATERAL STRIATAL NECROSIS; COILED-COIL; P62 COMPLEX; STRUCTURAL-ANALYSIS; IMPORTIN-BETA; NUCLEOPORIN; PROTEIN; MEMBRANE; DOMAIN; GLYCOPROTEINS	The nuclear pore complex encloses a central channel for nucleocytoplasmic transport, which is thought to consist of three nucleoporins, Nup54, Nup58, and Nup62. However, the structure and composition of the channel are elusive. We determined the crystal structures of the interacting domains between these nucleoporins and pieced together the molecular architecture of the mammalian transport channel. Located in the channel midplane is a flexible Nup54, Nup58 ring that can undergo large rearrangements yielding diameter changes from similar to 20 to similar to 40 nm. Nup62 . Nup54 triple helices project alternately up and down from either side of the midplane ring and form nucleoplasmic and cytoplasmic entries. The channel consists of as many as 224 copies of the three nucleoporins, amounting to a molar mass of 12.3 MDa and contributing 256 phenylalanine-glycine repeat regions. We propose that the occupancy of these repeat regions with transport receptors modulates ring diameter and transport activity.	[Solmaz, Sozanne R.; Chauhan, Radha; Blobel, Guenter; Melcak, Ivo] Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10065 USA	Howard Hughes Medical Institute; Rockefeller University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10065 USA.	blobel@rockefeller.edu; melcaki@rockefeller.edu		Solmaz, Sozanne R/0000-0002-1703-3701	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Akey DL, 2001, BIOCHEMISTRY-US, V40, P6352, DOI 10.1021/bi002829w; Alber F, 2007, NATURE, V450, P695, DOI 10.1038/nature06405; Bailer SM, 2001, MOL CELL BIOL, V21, P7944, DOI 10.1128/MCB.21.23.7944-7955.2001; Basel-Vanagaite L, 2006, ANN NEUROL, V60, P214, DOI 10.1002/ana.20902; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808; Blobel G, 2010, COLD SH Q B, V75, P545, DOI 10.1101/sqb.2010.75.004; BUSS F, 1995, J CELL BIOL, V128, P251, DOI 10.1083/jcb.128.3.251; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; Frenkiel-Krispin D, 2010, J MOL BIOL, V395, P578, DOI 10.1016/j.jmb.2009.11.010; GALL JG, 1967, J CELL BIOL, V32, P391, DOI 10.1083/jcb.32.2.391; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hsia KC, 2007, CELL, V131, P1313, DOI 10.1016/j.cell.2007.11.038; Hu TH, 1998, GENE, V221, P245, DOI 10.1016/S0378-1119(98)00467-3; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Isgro TA, 2005, STRUCTURE, V13, P1869, DOI 10.1016/j.str.2005.09.007; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Kiseleva E, 1998, J CELL SCI, V111, P223; KITA K, 1993, J BIOCHEM-TOKYO, V113, P377, DOI 10.1093/oxfordjournals.jbchem.a124054; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lim RYH, 2007, SCIENCE, V318, P640, DOI 10.1126/science.1145980; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Meinema AC, 2011, SCIENCE, V333, P90, DOI 10.1126/science.1205741; Melcak I, 2007, SCIENCE, V315, P1729, DOI 10.1126/science.1135730; Miller BR, 2000, MOL BIOL CELL, V11, P3381, DOI 10.1091/mbc.11.10.3381; MITO T, 1986, ARCH NEUROL-CHICAGO, V43, P677, DOI 10.1001/archneur.1986.00520070035014; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schrader N, 2008, MOL CELL, V29, P46, DOI 10.1016/j.molcel.2007.10.022; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63	36	83	84	0	27	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					590	602		10.1016/j.cell.2011.09.034	http://dx.doi.org/10.1016/j.cell.2011.09.034			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036567	Bronze, Green Accepted			2022-12-28	WOS:000296573700014
J	Rosenbaum, L; Lamas, D				Rosenbaum, Lisa; Lamas, Daniela			Facing a "Slow-Motion Disaster" - The UN Meeting on Noncommunicable Diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], PREV CONTR NCDS PRIO; World Health Organization, WORLD HLTH STAT 2009	2	41	41	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2011	365	25					2345	2348		10.1056/NEJMp1112235	http://dx.doi.org/10.1056/NEJMp1112235			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	865OM	22087629				2022-12-28	WOS:000298320200011
J	Meister, S; Plouffe, DM; Kuhen, KL; Bonamy, GMC; Wu, T; Barnes, SW; Bopp, SE; Borboa, R; Bright, AT; Che, JW; Cohen, S; Dharia, NV; Gagaring, K; Gettayacamin, M; Gordon, P; Groessl, T; Kato, N; Lee, MCS; McNamara, CW; Fidock, DA; Nagle, A; Nam, TG; Richmond, W; Roland, J; Rottmann, M; Zhou, B; Froissard, P; Glynne, RJ; Mazier, D; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Zhou, YY; Chatterjee, A; Diagana, TT; Winzeler, EA				Meister, Stephan; Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Bopp, Selina E.; Borboa, Rachel; Bright, A. Taylor; Che, Jianwei; Cohen, Steve; Dharia, Neekesh V.; Gagaring, Kerstin; Gettayacamin, Montip; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; Lee, Marcus C. S.; McNamara, Case W.; Fidock, David A.; Nagle, Advait; Nam, Tae-gyu; Richmond, Wendy; Roland, Jason; Rottmann, Matthias; Zhou, Bin; Froissard, Patrick; Glynne, Richard J.; Mazier, Dominique; Sattabongkot, Jetsumon; Schultz, Peter G.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Diagana, Thierry T.; Winzeler, Elizabeth A.			Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery	SCIENCE			English	Article							METHEMOGLOBINEMIA; INFECTIONS; RESISTANCE; MUTATIONS; TARGETS	Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable. We applied a multifactorial approach to a set of >4000 commercially available compounds with previously demonstrated blood-stage activity (median inhibitory concentration < 1 micromolar) and identified chemical scaffolds with potent activity against both forms. From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compounds active against Plasmodium liver stages. The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity. The open-source chemical tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biology of exo-erythrocytic forms.	[Meister, Stephan; Bopp, Selina E.; Bright, A. Taylor; Dharia, Neekesh V.; Winzeler, Elizabeth A.] Scripps Res Inst, Dept Genet, La Jolla, CA 92037 USA; [Plouffe, David M.; Kuhen, Kelli L.; Bonamy, Ghislain M. C.; Wu, Tao; Barnes, S. Whitney; Borboa, Rachel; Che, Jianwei; Cohen, Steve; Gagaring, Kerstin; Gordon, Perry; Groessl, Todd; Kato, Nobutaka; McNamara, Case W.; Nagle, Advait; Richmond, Wendy; Roland, Jason; Zhou, Bin; Glynne, Richard J.; Tuntland, Tove; Walker, John R.; Zhou, Yingyao; Chatterjee, Arnab; Winzeler, Elizabeth A.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; [Bright, A. Taylor] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Gettayacamin, Montip] Armed Forces Res Inst Med Sci AFRIMS, Dept Vet Med, Bangkok 10400, Thailand; [Lee, Marcus C. S.; Fidock, David A.] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY 10032 USA; [Fidock, David A.] Columbia Univ, Med Ctr, Dept Med, Div Infect Dis, New York, NY 10032 USA; [Nam, Tae-gyu; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Rottmann, Matthias] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Rottmann, Matthias] Univ Basel, CH-4003 Basel, Switzerland; [Froissard, Patrick; Mazier, Dominique] INSERM, U945, Paris, France; [Froissard, Patrick; Mazier, Dominique] Univ Paris 06, UMR S 945, Paris, France; [Mazier, Dominique] Grp Hosp Pitie Salpetriere, AP HP, Serv Parasitol Mycol, F-75634 Paris, France; [Sattabongkot, Jetsumon] AFRIMS, Dept Entomol, Bangkok 10400, Thailand; [Diagana, Thierry T.] Novartis Inst Trop Dis, Singapore, Singapore; [Nam, Tae-gyu] Hanyang Univ, Coll Pharm, Ansan 426791, Gyeonggi do, South Korea; [Wu, Tao] Life Technol, Carlsbad, CA 92008 USA; [Nam, Tae-gyu] Gyeonggi Bio Ctr, Suwon 443270, Gyeonggi do, South Korea	Scripps Research Institute; Novartis; University of California System; University of California San Diego; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Columbia University; Columbia University; Scripps Research Institute; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Novartis; Hanyang University; Thermo Fisher Scientific	Winzeler, EA (corresponding author), Scripps Res Inst, Dept Genet, La Jolla, CA 92037 USA.	winzeler@scripps.edu	Dharia, Neekesh/AAC-1245-2020; Meister, Stephan/M-6608-2014; Prachumsri, Jetsumon/AAZ-7732-2021; Winzeler, Elizabeth/AAP-6752-2020	Dharia, Neekesh/0000-0001-5048-067X; Meister, Stephan/0000-0003-2436-7037; Winzeler, Elizabeth/0000-0002-4049-2113; Rottmann, Matthias/0000-0002-2207-7899; Fidock, David/0000-0001-6753-8938; Bopp, Selina/0000-0002-9412-9766; Sattabongkot, Jetsumon/0000-0002-3938-4588; Lee, Marcus/0000-0002-4973-0915; Bonamy, Ghislain/0000-0002-2826-5225	Keck Foundation; NIH [R01AI090141, R01 AI079709]; Deutsche Forschungsgemeinschaft [ME 3528/1-1]; Medicines for Malaria Venture; Wellcome Trust [WT078285]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090141, R01AI079709] Funding Source: NIH RePORTER	Keck Foundation(W.M. Keck Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Medicines for Malaria Venture; Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We wish to thank I. Sherman for helpful comments on the manuscript, members of the New York University Insectary for providing infected mosquitoes and C. Fischli for P. berghei efficacy testing. The whole genome sequencing data has been deposited at the National Center for Biotechnology Information (NCBI) Sequence Read Archive database (http://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?) with the project accession no. SRA045972.1. The microarray data has been deposited at the NCBI Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/geo/) with the accession no. GSE32485. The assay data was deposited at the ChEMBL-Neglected Tropical Disease (ChEMBL-NTD) archive (www.ebi.ac.uk/chemblntd/) with the accession nos. CHEMBL1789904, CHEMBL1789905, and CHEMBL1789906. E. A. W. is supported by the Keck Foundation and by the NIH (grant R01AI090141). S. M. was supported by Deutsche Forschungsgemeinschaft (ME 3528/1-1). Funding for M. C. S. L. and D. A. F. is provided in part by the Medicines for Malaria Venture and the NIH (grant R01 AI079709). We gratefully acknowledge translational research support (WT078285) from the Wellcome Trust and funding from the Medicines for Malaria Venture to the Genomics Institute of the Novartis Research Foundation, the Swiss Tropical and Public Health Institute, and the Novartis Institute for Tropical Diseases. All compounds disclosed are either commercially available from compound vendors (vendor identifications can be sourced from the ChEmbl database), or, if members of the imidazolopiperazine series are required, they will be provided by materials transfer agreement. A materials transfer agreement will be provided by P. Froissard and INSERM-UMR945 for requests for the HepG2-CD81-eGFP cell line.	Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814; Charman SA, 2011, P NATL ACAD SCI USA, V108, P4400, DOI 10.1073/pnas.1015762108; COHEN RJ, 1968, NEW ENGL J MED, V279, P1127, DOI 10.1056/NEJM196811212792102; Coleman MD, 1996, DRUG SAFETY, V14, P394, DOI 10.2165/00002018-199614060-00005; Crowther GJ, 2011, MOL BIOCHEM PARASIT, V175, P21, DOI 10.1016/j.molbiopara.2010.08.005; DAVIDSON DE, 1981, B WORLD HEALTH ORGAN, V59, P463; Dharia NV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r21; Dong YX, 2010, J MED CHEM, V53, P481, DOI 10.1021/jm901473s; Gagaring K., 2010, CHEMBL NTD; Gego A, 2006, ANTIMICROB AGENTS CH, V50, P1586, DOI 10.1128/AAC.50.4.1586-1589.2006; Istvan ES, 2011, P NATL ACAD SCI USA, V108, P1627, DOI 10.1073/pnas.1011560108; Jonikas MC, 2009, SCIENCE, V323, P1693, DOI 10.1126/science.1167983; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Mazier D, 2009, NAT REV DRUG DISCOV, V8, P854, DOI 10.1038/nrd2960; Nam T.-G., 2011, ACS CHEM BIOL; Painter HJ, 2007, NATURE, V446, P88, DOI 10.1038/nature05572; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225; Singh B, 2004, LANCET, V363, P1017, DOI 10.1016/S0140-6736(04)15836-4; Sweeney AW, 2004, AM J TROP MED HYG, V71, P187, DOI 10.4269/ajtmh.2004.71.2.0700187; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004; Trampuz A, 2003, CRIT CARE, V7, P315, DOI 10.1186/cc2183; Wang P, 2004, MOL BIOCHEM PARASIT, V135, P77, DOI 10.1016/j.molbiopara.2004.01.008; Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2011, GUID TREATM MAL, P194; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu T, 2011, J MED CHEM, V54, P5116, DOI 10.1021/jm2003359; Yalaoui S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000010; Yan SF, 2005, J CHEM INF MODEL, V45, P1784, DOI 10.1021/ci0502808	30	235	239	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2011	334	6061					1372	1377		10.1126/science.1211936	http://dx.doi.org/10.1126/science.1211936			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858HW	22096101	Green Accepted			2022-12-28	WOS:000297787700044
J	Hosokawa, T; Omukai, K; Yoshida, N; Yorke, HW				Hosokawa, Takashi; Omukai, Kazuyuki; Yoshida, Naoki; Yorke, Harold W.			Protostellar Feedback Halts the Growth of the First Stars in the Universe	SCIENCE			English	Article							INITIAL MASS FUNCTION; POPULATION-III; PRIMORDIAL PROTOSTARS; CDM UNIVERSE; STELLAR; ACCRETION; EVOLUTION; DISKS; NUCLEOSYNTHESIS	The first stars fundamentally transformed the early universe by emitting the first light and by producing the first heavy elements. These effects were predetermined by the mass distribution of the first stars, which is thought to have been fixed by a complex interplay of gas accretion and protostellar radiation. We performed radiation-hydrodynamics simulations that followed the growth of a primordial protostar through to the early stages as a star with thermonuclear burning. The circumstellar accretion disk was evaporated by ultraviolet radiation from the star when its mass was 43 times that of the Sun. Such massive primordial stars, in contrast to the often-postulated extremely massive stars, may help explain the fact that there are no signatures of the pair-instability supernovae in abundance patterns of metal-poor stars in our galaxy.	[Hosokawa, Takashi; Yorke, Harold W.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Hosokawa, Takashi; Omukai, Kazuyuki] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; [Yoshida, Naoki] Univ Tokyo, Todai Inst Adv Study, Inst Phys & Math Universe, Kashiwa, Chiba 2778568, Japan	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Kyoto University; University of Tokyo	Hosokawa, T (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	hosokwtk@gmail.com	Yorke, Harold/GQZ-3989-2022; YOSHIDA, NAOKI/G-4986-2014	Yoshida, Naoki/0000-0001-7925-238X; Hosokawa, Takashi/0000-0003-3127-5982	Japan Society for the Promotion of Science for Research Abroad; Ministry of Education, Science and Culture of Japan [19047004, 2168407, 21244021, 20674003]; NASA	Japan Society for the Promotion of Science for Research Abroad(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NASA(National Aeronautics & Space Administration (NASA))	We thank T. Nakamura, K. Nomoto, S. Inutsuka, and N. Turner for stimulating discussions on this topic. Comments by an anonymous referee helped improve the manuscript. T. H. appreciates the support by Fellowship of the Japan Society for the Promotion of Science for Research Abroad. The present work is supported in part by the grants-in-aid by the Ministry of Education, Science and Culture of Japan (19047004, 2168407, 21244021:KO, 20674003:NY). Portions of this research were conducted at the Jet Propulsion Laboratory, California Institute of Technology, which is supported by NASA. Data analysis was (in part) carried out on the general-purpose PC farm at Center for Computational Astrophysics (CfCA) of National Astronomical Observatory of Japan.	Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Bromm V, 2009, NATURE, V459, P49, DOI 10.1038/nature07990; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; Clark PC, 2011, SCIENCE, V331, P1040, DOI 10.1126/science.1198027; EZER D, 1971, ASTROPHYS SPACE SCI, V14, P399, DOI 10.1007/BF00653327; Frebel A, 2009, MON NOT R ASTRON SOC, V392, pL50, DOI 10.1111/j.1745-3933.2008.00587.x; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; Hosokawa T, 2009, ASTROPHYS J, V703, P1810, DOI 10.1088/0004-637X/703/2/1810; Hosokawa T, 2009, ASTROPHYS J, V691, P823, DOI 10.1088/0004-637X/691/1/823; Iwamoto N, 2005, SCIENCE, V309, P451, DOI 10.1126/science.1112997; Mckee CF, 2008, ASTROPHYS J, V681, P771, DOI 10.1086/587434; O'Shea BW, 2007, ASTROPHYS J, V654, P66, DOI 10.1086/509250; O'Shea BW, 2005, ASTROPHYS J, V628, pL5, DOI 10.1086/432683; Ohkubo T, 2009, ASTROPHYS J, V706, P1184, DOI 10.1088/0004-637X/706/2/1184; Omukai K, 1998, ASTROPHYS J, V508, P141, DOI 10.1086/306395; Omukai K, 2003, ASTROPHYS J, V589, P677, DOI 10.1086/374810; Schaerer D, 2002, ASTRON ASTROPHYS, V382, P28, DOI 10.1051/0004-6361:20011619; Tumlinson J, 2004, ASTROPHYS J, V612, P602, DOI 10.1086/422571; Turk MJ, 2009, SCIENCE, V325, P601, DOI 10.1126/science.1173540; Umeda H, 2002, ASTROPHYS J, V565, P385, DOI 10.1086/323946; Yorke HW, 1999, ASTROPHYS J, V525, P330, DOI 10.1086/307867; Yorke HW, 2002, ASTROPHYS J, V569, P846, DOI 10.1086/339264; Yorke HW, 1996, ASTRON ASTROPHYS, V315, P555; Yoshida N, 2008, SCIENCE, V321, P669, DOI 10.1126/science.1160259; Yoshida N, 2007, ASTROPHYS J, V667, pL117, DOI 10.1086/522202; Yoshida N, 2006, ASTROPHYS J, V652, P6, DOI 10.1086/507978	27	297	298	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	2011	334	6060					1250	1253		10.1126/science.1207433	http://dx.doi.org/10.1126/science.1207433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HD	22075723	Green Submitted			2022-12-28	WOS:000297553600043
J	Belenky, P; Collins, JJ				Belenky, Peter; Collins, James J.			Antioxidant Strategies to Tolerate Antibiotics	SCIENCE			English	Editorial Material							DEATH; RESISTANCE		[Belenky, Peter; Collins, James J.] Boston Univ, Howard Hughes Med Inst, Dept Biomed Chem, Boston, MA 02215 USA; [Belenky, Peter; Collins, James J.] Boston Univ, Ctr BioDynam, Boston, MA 02215 USA; [Collins, James J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Collins, James J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA	Boston University; Howard Hughes Medical Institute; Boston University; Boston University; Harvard University	Belenky, P (corresponding author), Boston Univ, Howard Hughes Med Inst, Dept Biomed Chem, Boston, MA 02215 USA.	jcollins@engc.bu.edu		Belenky, Peter/0000-0002-1682-945X	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Cabiscol Elisa, 2000, International Microbiology, V3, P3; Nguyen D, 2011, SCIENCE, V334, P982, DOI 10.1126/science.1211037; Debbia EA, 2001, MICROB DRUG RESIST, V7, P335, DOI 10.1089/10766290152773347; Dorr T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000760; Dwyer DJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100135; Gusarov I, 2009, SCIENCE, V325, P1380, DOI 10.1126/science.1175439; Imlay JA, 2008, ANNU REV BIOCHEM, V77, P755, DOI 10.1146/annurev.biochem.77.061606.161055; Kohanski MA, 2008, CELL, V135, P679, DOI 10.1016/j.cell.2008.09.038; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Kohanski MA, 2010, MOL CELL, V37, P311, DOI 10.1016/j.molcel.2010.01.003; Ristow M, 2010, EXP GERONTOL, V45, P410, DOI 10.1016/j.exger.2010.03.014; Shatalin K, 2011, SCIENCE, V334, P986, DOI 10.1126/science.1209855; Wright GD, 2005, ADV DRUG DELIVER REV, V57, P1451, DOI 10.1016/j.addr.2005.04.002	13	42	43	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					915	916		10.1126/science.1214823	http://dx.doi.org/10.1126/science.1214823			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096180				2022-12-28	WOS:000297101800036
J	Brassard, G				Brassard, Gilles			QUANTUM INFORMATION The conundrum of secure positioning	NATURE			English	Editorial Material									Univ Montreal, Dept Informat & Rech Operat, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Brassard, G (corresponding author), Univ Montreal, Dept Informat & Rech Operat, Montreal, PQ H3C 3J7, Canada.	brassard@iro.umontreal.ca	Brassard, Gilles/K-5725-2019					BEIGI S, 2011, PREPRINT; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Brands S., 1993, LNCS, P344, DOI DOI 10.1007/3-540-48285-7; Buhrman H, 2011, LECT NOTES COMPUT SC, V6841, P429, DOI 10.1007/978-3-642-22792-9_24; CHANDRAN N, 2010, PREPRINT; Chandran N, 2009, LECT NOTES COMPUT SC, V5677, P391, DOI 10.1007/978-3-642-03356-8_23; DIEKS D, 1982, PHYS LETT A, V92, P271, DOI 10.1016/0375-9601(82)90084-6; Kent A.P., 2006, U.S. patent, Patent No. [7,075,438, 7075438]; Kent A, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.022335; Kent A, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.012326; Malaney RA, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.042319; Schrodinger E, 1935, P CAMB PHILOS SOC, V31, P555, DOI 10.1017/S0305004100013554; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	14	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					307	308		10.1038/479307a	http://dx.doi.org/10.1038/479307a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	848OA	22094688				2022-12-28	WOS:000297059700029
J	Demers-Carpentier, V; Goubert, G; Masini, F; Lafleur-Lambert, R; Dong, Y; Lavoie, S; Mahieu, G; Boukouvalas, J; Gao, HL; Rasmussen, AMH; Ferrighi, L; Pan, YX; Hammer, B; McBreen, PH				Demers-Carpentier, Vincent; Goubert, Guillaume; Masini, Federico; Lafleur-Lambert, Raphael; Dong, Yi; Lavoie, Stephane; Mahieu, Gautier; Boukouvalas, John; Gao, Haili; Rasmussen, Anton M. H.; Ferrighi, Lara; Pan, Yunxiang; Hammer, Bjork; McBreen, Peter H.			Direct Observation of Molecular Preorganization for Chirality Transfer on a Catalyst Surface	SCIENCE			English	Article							ENANTIOSELECTIVE HETEROGENEOUS CATALYSIS; RECOGNITION; MODIFIERS; PLATINUM	The chemisorption of specific optically active compounds on metal surfaces can create catalytically active chirality transfer sites. However, the mechanism through which these sites bias the stereoselectivity of reactions (typically hydrogenations) is generally assumed to be so complex that continued progress in the area is uncertain. We show that the investigation of heterogeneous asymmetric induction with single-site resolution sufficient to distinguish stereochemical conformations at the submolecular level is finally accessible. A combination of scanning tunneling microscopy and density functional theory calculations reveals the stereodirecting forces governing preorganization into precise chiral modifier-substrate bimolecular surface complexes. The study shows that the chiral modifier induces prochiral switching on the surface and that different prochiral ratios prevail at different submolecular binding sites on the modifier at the reaction temperature.	[Gao, Haili; Rasmussen, Anton M. H.; Ferrighi, Lara; Pan, Yunxiang; Hammer, Bjork] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus, Denmark; [Gao, Haili; Rasmussen, Anton M. H.; Ferrighi, Lara; Pan, Yunxiang; Hammer, Bjork] Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus, Denmark; [Demers-Carpentier, Vincent; Goubert, Guillaume; Masini, Federico; Lafleur-Lambert, Raphael; Dong, Yi; Lavoie, Stephane; Mahieu, Gautier; Boukouvalas, John; McBreen, Peter H.] Univ Laval, Ctr Rech Proprietes Interfaces & Catalyse CERPIC, Quebec City, PQ G1V 0A6, Canada; [Demers-Carpentier, Vincent; Goubert, Guillaume; Masini, Federico; Lafleur-Lambert, Raphael; Dong, Yi; Lavoie, Stephane; Mahieu, Gautier; Boukouvalas, John; McBreen, Peter H.] Univ Laval, Dept Chim, Quebec City, PQ G1V 0A6, Canada	Aarhus University; Aarhus University; Laval University; Laval University	Hammer, B (corresponding author), Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus, Denmark.	hammer@phys.au.dk; peter.mcbreen@chm.ulaval.ca	Rasmussen, Anton/G-6573-2011; Ferrighi, Lara/A-5902-2009; Boukouvalas, John/C-2264-2009; ferrighi, lara/T-2088-2018; Pan, Yun-Xiang/AFP-2307-2022; Hammer, Bjork/C-3701-2013; Goubert, Guillaume/O-4547-2017	Rasmussen, Anton/0000-0001-6136-1916; ferrighi, lara/0000-0001-5221-1377; Pan, Yun-Xiang/0000-0002-7992-1544; DONG, YI/0000-0002-2205-5200; Hammer, Bjork/0000-0002-7849-6347; DONG, YI/0000-0003-1612-2793; Goubert, Guillaume/0000-0002-4325-0267	Natural Sciences and Engineering Research Council of Canada (NSERC); Fonds Quebecois de la Recherche sur la Nature et les Technologies (FQRNT) team; Canadian Foundation for Innovation (CFI); FQRNT Centre in Green Chemistry and Catalysis (CCVC); Lundbeck Foundation; Danish Research Councils; Danish Center for Scientific Computing	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Fonds Quebecois de la Recherche sur la Nature et les Technologies (FQRNT) team(FQRNT); Canadian Foundation for Innovation (CFI)(Canada Foundation for Innovation); FQRNT Centre in Green Chemistry and Catalysis (CCVC); Lundbeck Foundation(Lundbeckfonden); Danish Research Councils(Det Frie Forskningsrad (DFF)); Danish Center for Scientific Computing	This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) discovery grant, a Fonds Quebecois de la Recherche sur la Nature et les Technologies (FQRNT) team grant, Canadian Foundation for Innovation (CFI) grants, and the FQRNT Centre in Green Chemistry and Catalysis (CCVC). This work was in part supported by the Lundbeck Foundation, the Danish Research Councils, and the Danish Center for Scientific Computing. V.D.-C. acknowledges an NSERC graduate student scholarship.	Blankenburg S, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.196107; Blaser HU, 2007, ACCOUNTS CHEM RES, V40, P1348, DOI 10.1021/ar700088f; Bonello JM, 2003, J AM CHEM SOC, V125, P2723, DOI 10.1021/ja028436x; Burkholder L, 2011, J PHYS CHEM C, V115, P8790, DOI 10.1021/jp202291h; Chen Q, 2003, NAT MATER, V2, P324, DOI 10.1038/nmat878; Demers-Carpentier V, 2011, J PHYS CHEM C, V115, P1355, DOI 10.1021/jp107972u; Ernst KH, 2010, ORIGINS LIFE EVOL B, V40, P41, DOI 10.1007/s11084-009-9185-2; Forster M, 2011, TOP CATAL, V54, P13, DOI 10.1007/s11244-011-9634-9; Gellman AJ, 2010, ACS NANO, V4, P5, DOI 10.1021/nn901885n; Heitbaum M, 2006, ANGEW CHEM INT EDIT, V45, P4732, DOI 10.1002/anie.200504212; Knowles RR, 2010, P NATL ACAD SCI USA, V107, P20678, DOI 10.1073/pnas.1006402107; Kuhnle A, 2002, NATURE, V415, P891, DOI 10.1038/415891a; Kyriakou G, 2011, LANGMUIR, V27, P9687, DOI 10.1021/la200009w; Lingenfelder M, 2007, ANGEW CHEM INT EDIT, V46, P4492, DOI 10.1002/anie.200700194; NING L, 2007, ANGEW CHEM INT EDIT, V40, P7613; Orglmeister E, 2005, ADV SYNTH CATAL, V347, P78, DOI 10.1002/adsc.200404152; Trant AG, 2011, J PHYS CHEM C, V115, P1025, DOI 10.1021/jp105377p; Weigelt S, 2006, NAT MATER, V5, P112, DOI 10.1038/nmat1558; Zehnacker A, 2008, ANGEW CHEM INT EDIT, V47, P6970, DOI 10.1002/anie.200800957	19	77	77	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					776	780		10.1126/science.1208710	http://dx.doi.org/10.1126/science.1208710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076371				2022-12-28	WOS:000296849600038
J	Livio, M				Livio, Mario			Mystery of the missing text solved	NATURE			English	Editorial Material							EXTRA-GALACTIC NEBULAE		Space Telescope Sci Inst, Baltimore, MD 21218 USA	Space Telescope Science Institute	Livio, M (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	mlivio@stsci.edu						Hubble E, 1926, ASTROPHYS J, V64, P321, DOI 10.1086/143018; Hubble E, 1929, P NATL ACAD SCI USA, V15, P168, DOI 10.1073/pnas.15.3.168; Lemaitre G., 1927, ANN SOC SCI BRUX, VA47, P49; Lemaitre G., 1931, MON NOT R ASTRON SOC, V95, P483; Lemaitre G., 1931, MON NOT R ASTRON SOC, V91, P490, DOI DOI 10.1093/MNRAS/91.5.490; Reich E, 2011, NATURE; Stromberg G, 1925, ASTROPHYS J, V61, P353, DOI 10.1086/142897; 1931, ROYAL ASTRONOMICAL S, V12, P160	8	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					171	173		10.1038/479171a	http://dx.doi.org/10.1038/479171a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	861PD	22071745				2022-12-28	WOS:000298030800017
J	van Wijk, JPH; ter Braak, EWMT				van Wijk, Jeroen P. H.; ter Braak, Edith W. M. T.			Amenorrhea, Abdominal Pain, and Weight Gain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[van Wijk, Jeroen P. H.; ter Braak, Edith W. M. T.] Univ Med Ctr, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van Wijk, JPH (corresponding author), Univ Med Ctr, Utrecht, Netherlands.	j.p.h.vanwijk@umcutrecht.nl		ter Braak, Edith/0000-0002-3882-5804					0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					E39	E39		10.1056/NEJMicm1103447	http://dx.doi.org/10.1056/NEJMicm1103447			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070499				2022-12-28	WOS:000296762800012
J	Rampino, MR; Caldeira, K				Rampino, Michael R.; Caldeira, Ken			Comment on "Atmospheric PCO2 Perturbations Associated with the Central Atlantic Magmatic Province"	SCIENCE			English	Editorial Material							CARBON-DIOXIDE; BOUNDARY; METHANE; END	Schaller et al. (Research Article, 18 March 2011, p. 1404) proposed that carbon dioxide (CO2) released by the Central Atlantic Magmatic Province eruptions over periods of about 20,000 years led to substantial increases of up to 2000 parts per million (ppm) in the concentration of atmospheric carbon dioxide (Pco(2)) near the Triassic-Jurassic boundary. Use of an atmosphere-ocean model coupled to a carbon-cycle model predicts Pco(2) increases of less than 400 ppm from magmatic volatiles, with only a small climatic impact.	[Rampino, Michael R.] NYU, Dept Biol, New York, NY 10003 USA; [Rampino, Michael R.] NYU, Environm Studies Program, New York, NY 10003 USA; [Rampino, Michael R.] NASA, Goddard Inst Space Studies, New York, NY 10025 USA; [Caldeira, Ken] Carnegie Inst, Dept Global Ecol, Stanford, CA 94305 USA	New York University; New York University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Carnegie Institution for Science	Rampino, MR (corresponding author), NYU, Dept Biol, 100 Washington Sq E, New York, NY 10003 USA.	mrr1@nyu.edu	Caldeira, Ken/E-7914-2011	Caldeira, Ken/0000-0002-4591-643X				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; CALDEIRA K, 1990, GEOPHYS RES LETT, V17, P1299, DOI 10.1029/GL017i009p01299; CALDEIRA K, 1991, GEOPHYS RES LETT, V18, P987, DOI 10.1029/91GL01237; COURTILLOT V, 1986, EARTH PLANET SC LETT, V80, P361, DOI 10.1016/0012-821X(86)90118-4; Dessert C, 2001, EARTH PLANET SC LETT, V188, P459, DOI 10.1016/S0012-821X(01)00317-X; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; McElwain JC, 1999, SCIENCE, V285, P1386, DOI 10.1126/science.285.5432.1386; Schaller MF, 2011, SCIENCE, V331, P1404, DOI 10.1126/science.1199011; Self S, 2006, EARTH PLANET SC LETT, V248, P518, DOI 10.1016/j.epsl.2006.05.041; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; van de Schootbrugge B, 2007, PALAEOGEOGR PALAEOCL, V244, P126, DOI 10.1016/j.palaeo.2006.06.026	11	6	6	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056								10.1126/science.1208653	http://dx.doi.org/10.1126/science.1208653			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053029	Green Submitted			2022-12-28	WOS:000296494700029
J	Fenton, N				Fenton, Norman			Improve statistics in court	NATURE			English	Editorial Material									Univ London, London WC1E 7HU, England; [Fenton, Norman] Agena, Cambridge, England	University of London	Fenton, N (corresponding author), Univ London, London WC1E 7HU, England.	norman@eecs.qmul.ac.uk	Fenton, Norman/L-5861-2019	Fenton, Norman/0000-0003-2924-0510				Aitken C., 2004, STAT EVALUATION EVID, P26; Aitken C. G. G., 2010, FUNDAMENTALS PROBABI; Berger CEH, 2011, SCI JUSTICE, V51, P43, DOI 10.1016/j.scijus.2011.03.005; FENTON NE, AUST J LEGA IN PRESS; Fenton N, 2010, J BIOMED INFORM, V43, P485, DOI 10.1016/j.jbi.2010.02.004; Thompson WC, 2003, J FORENSIC SCI, V48, P47	6	18	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					36	37		10.1038/479036a	http://dx.doi.org/10.1038/479036a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	840FA	22051660	Bronze			2022-12-28	WOS:000296422600017
J	Bhuva, AN; Lota, HK				Bhuva, Anish N.; Lota, Harpreet K.			A 34 year old man with bilateral anterior uveitis and a rash	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SARCOIDOSIS		[Bhuva, Anish N.; Lota, Harpreet K.] Hillingdon Hosp NHS Fdn Trust, Uxbridge UB8 3NN, Middx, England		Lota, HK (corresponding author), Hillingdon Hosp NHS Fdn Trust, Uxbridge UB8 3NN, Middx, England.	harpreet.lota@hotmail.co.uk		Bhuva, Anish/0000-0001-7532-7815				Aladesanmi Oluranti A, 2004, MedGenMed, V6, P7; Antonovich DD, 2005, ARCH DERMATOL, V141, P869, DOI 10.1001/archderm.141.7.869; Boeck C, 1899, J CUTAN GENITURIN DI, V17, P743; Dempsey OJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3206; Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Kieszko R, 2007, RESP MED, V101, P645, DOI 10.1016/j.rmed.2006.06.004; Morales-Callaghan AM, 2006, J AM ACAD DERMATOL, V55, pS71, DOI 10.1016/j.jaad.2005.12.022; Newman LS, 2004, AM J RESP CRIT CARE, V170, P1324, DOI 10.1164/rccm.200402-249OC; SCADDING JG, 1961, BRIT MED J, V2, P1165, DOI 10.1136/bmj.2.5261.1165; Wells AU, 2008, THORAX, V63, DOI 10.1136/thx.2008.101691	11	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2011	343								d6831	10.1136/bmj.d6831	http://dx.doi.org/10.1136/bmj.d6831			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844PP	22042754				2022-12-28	WOS:000296759900012
J	Birch, K; Blackburn, C; Brody, L; Wallace, P				Birch, Kristi; Blackburn, Carol; Brody, Linda; Wallace, Patricia			An Online Community for Students Who Love STEM	SCIENCE			English	Editorial Material									[Birch, Kristi; Blackburn, Carol; Brody, Linda; Wallace, Patricia] Johns Hopkins Univ, Ctr Talented Youth, Baltimore, MD 21209 USA	Johns Hopkins University	Birch, K (corresponding author), Johns Hopkins Univ, Ctr Talented Youth, Baltimore, MD 21209 USA.	kbirch@jhu.edu						[Anonymous], LIVING LEARNING NEW; CAVANAGH S, 2009, ED WEEK, V9, P12; National Science Board, 2010, PREP NEXT GEN STEM I; WESTLY E, 2008, DISCOVER, V29, P37	4	0	0	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2011	334	6055					467	468		10.1126/science.1196983	http://dx.doi.org/10.1126/science.1196983			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034426	Bronze			2022-12-28	WOS:000296230500034
J	Kriks, S; Shim, JW; Piao, JH; Ganat, YM; Wakeman, DR; Xie, Z; Carrillo-Reid, L; Auyeung, G; Antonacci, C; Buch, A; Yang, LC; Beal, MF; Surmeier, DJ; Kordower, JH; Tabar, V; Studer, L				Kriks, Sonja; Shim, Jae-Won; Piao, Jinghua; Ganat, Yosif M.; Wakeman, Dustin R.; Xie, Zhong; Carrillo-Reid, Luis; Auyeung, Gordon; Antonacci, Chris; Buch, Amanda; Yang, Lichuan; Beal, M. Flint; Surmeier, D. James; Kordower, Jeffrey H.; Tabar, Viviane; Studer, Lorenz			Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease	NATURE			English	Article							STEM-CELLS; FLOOR PLATE; STRIATAL PROGENITORS; DIFFERENTIATION; TRANSPLANTATION; SPECIFICATION; DERIVATION; TISSUE; BRAIN	Human pluripotent stem cells (PSCs) are a promising source of cells for applications in regenerative medicine. Directed differentiation of PSCs into specialized cells such as spinal motoneurons(1) or midbrain dopamine (DA) neurons(2) has been achieved. However, the effective use of PSCs for cell therapy has lagged behind. Whereas mouse PSC-derived DA neurons have shown efficacy in models of Parkinson's disease(3,4), DA neurons from human PSCs generally show poor in vivo performance(5). There are also considerable safety concerns for PSCs related to their potential for teratoma formation or neural overgrowth(6,7). Here we present a novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells. Midbrain floor-plate precursors are derived from PSCs 11 days after exposure to small molecule activators of sonic hedgehog (SHH) and canonical WNT signalling. Engraftable midbrain DA neurons are obtained by day 25 and can be maintained in vitro for several months. Extensive molecular profiling, biochemical and electrophysiological data define developmental progression and confirm identity of PSC-derived midbrain DA neurons. In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. Finally, scalability is demonstrated by transplantation into parkinsonian monkeys. Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease.	[Kriks, Sonja; Shim, Jae-Won; Piao, Jinghua; Ganat, Yosif M.; Auyeung, Gordon; Antonacci, Chris; Buch, Amanda; Tabar, Viviane; Studer, Lorenz] Mem Sloan Kettering Canc Ctr, Ctr Stem Cell Biol, New York, NY 10065 USA; [Kriks, Sonja; Shim, Jae-Won; Ganat, Yosif M.; Studer, Lorenz] Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10065 USA; [Piao, Jinghua; Auyeung, Gordon; Antonacci, Chris; Buch, Amanda; Tabar, Viviane; Studer, Lorenz] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [Wakeman, Dustin R.; Kordower, Jeffrey H.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA; [Xie, Zhong; Carrillo-Reid, Luis; Surmeier, D. James] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; [Yang, Lichuan; Beal, M. Flint] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Rush University; Northwestern University; Feinberg School of Medicine; Cornell University; NewYork-Presbyterian Hospital	Studer, L (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Stem Cell Biol, 1275 York Ave, New York, NY 10065 USA.	studerl@mskcc.org	Xie, Zhong/B-6829-2011; Studer, Lorenz/ABH-1491-2021; Piao, Jinghua/A-7743-2010	Xie, Zhong/0000-0002-8348-4455; Studer, Lorenz/0000-0003-0741-7987; Carrillo-Reid, Luis/0000-0002-0511-2533; Antonacci, Christopher/0000-0002-9793-0524; Buch, Amanda M./0000-0001-5889-3495	NIH/NINDS [NS052671, P50 NS047085]; European Commission; Starr foundation; NYSTEM [C024414, C024413]; Michael T. McCarthy Foundation; Elkus Family Foundation; Consolidated Anti-Aging Foundation; Falk Medical Research Trust; NYSCF; Starr stem cell scholar fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS047085, P50NS071669, R01NS052671] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); European Commission(European CommissionEuropean Commission Joint Research Centre); Starr foundation; NYSTEM; Michael T. McCarthy Foundation; Elkus Family Foundation; Consolidated Anti-Aging Foundation; Falk Medical Research Trust; NYSCF; Starr stem cell scholar fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank K. Manova, M. Tomishima and A. Viale for excellent technical support, and R. McKay for the anti-nestin antibody. The work was supported by NIH/NINDS grant NS052671, the European Commission project NeuroStemcell, the Starr foundation and NYSTEM contract C024414 to L. S.; by NYSTEM contract C024413, the Michael T. McCarthy Foundation and the Elkus Family Foundation to V. T.; by the Consolidated Anti-Aging Foundation to J.H.K.; by NIH/NINDS grant P50 NS047085, and support from Falk Medical Research Trust to D.J.S.; J.-W.S. was supported by NYSCF (Druckenmiller fellowship) and S. K. by a Starr stem cell scholar fellowship.	Aubry L, 2008, P NATL ACAD SCI USA, V105, P16707, DOI 10.1073/pnas.0808488105; Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108; Blume SR, 2009, EXP NEUROL, V219, P208, DOI 10.1016/j.expneurol.2009.05.017; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; Elkabetz Y, 2008, GENE DEV, V22, P152, DOI 10.1101/gad.1616208; Fasano CA, 2010, CELL STEM CELL, V6, P336, DOI 10.1016/j.stem.2010.03.001; Ferrari D, 2006, EUR J NEUROSCI, V24, P1885, DOI 10.1111/j.1460-9568.2006.05093.x; Ferri ALM, 2007, DEVELOPMENT, V134, P2761, DOI 10.1242/dev.000141; Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Joksimovic M, 2009, NAT NEUROSCI, V12, P125, DOI 10.1038/nn.2243; Kim H, 2011, CELL STEM CELL, V8, P695, DOI 10.1016/j.stem.2011.04.002; Kittappa R, 2007, PLOS BIOL, V5, P2875, DOI 10.1371/journal.pbio.0050325; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lyashenko N, 2011, NAT CELL BIOL, V13, P753, DOI 10.1038/ncb2260; Muroyama Y, 2002, GENE DEV, V16, P548, DOI 10.1101/gad.937102; NEDERGAARD S, 1993, J PHYSIOL-LONDON, V466, P727; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Paxinos G., 2000, RHESUS MONKEY BRAIN; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Studer L, 1996, BRAIN RES BULL, V41, P143, DOI 10.1016/0361-9230(96)00114-1; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Tabar V, 2005, NAT BIOTECHNOL, V23, P601, DOI 10.1038/nbt1088; Tabar V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732; VanDunk C, 2011, J NEUROSCI, V31, P6457, DOI 10.1523/JNEUROSCI.5385-10.2011; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	37	1222	1275	4	347	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					547	U177		10.1038/nature10648	http://dx.doi.org/10.1038/nature10648			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22056989	Green Accepted			2022-12-28	WOS:000298318000066
J	Cooperberg, MR				Cooperberg, Matthew R.			High-risk prostate cancer: treat the prostate	LANCET			English	Editorial Material							ANDROGEN-DEPRIVATION THERAPY; RADIOTHERAPY; OUTCOMES; MEN		Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cooperberg, MR (corresponding author), Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.	mcooperberg@urology.ucsf.edu	Cooperberg, Matthew R/G-6249-2017	Cooperberg, Matthew R/0000-0003-4339-6685				Bechis SK, 2011, J CLIN ONCOL, V29, P235, DOI 10.1200/JCO.2010.30.2075; Cooperberg MR, 2010, CANCER-AM CANCER SOC, V116, P5226, DOI 10.1002/cncr.25456; Institute of Medicine, 2009, IN NAT PRIOR COMP EF, P1; Lu-Yao GL, 2008, JAMA-J AM MED ASSOC, V300, P173, DOI 10.1001/jama.300.2.173; Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348; Mohler J, 2010, J NATL COMPR CANC NE, V8, P162, DOI 10.6004/jnccn.2010.0012; Singh Jaspreet, 2010, Curr Urol Rep, V11, P139, DOI 10.1007/s11934-010-0103-y; Thompson I, 2007, J UROLOGY, V177, P2106, DOI 10.1016/j.juro.2007.03.003; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Wei JT, 2000, UROLOGY, V56, P899, DOI 10.1016/S0090-4295(00)00858-X; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2; Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209; Zelefsky MJ, 2010, J CLIN ONCOL, V28, P1508, DOI 10.1200/JCO.2009.22.2265	13	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	2011	378	9809					2056	2057		10.1016/S0140-6736(11)61254-3	http://dx.doi.org/10.1016/S0140-6736(11)61254-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865EL	22056154	Green Submitted			2022-12-28	WOS:000298293600014
J	Tran, JC; Zamdborg, L; Ahlf, DR; Lee, JE; Catherman, AD; Durbin, KR; Tipton, JD; Vellaichamy, A; Kellie, JF; Li, MX; Wu, C; Sweet, SMM; Early, BP; Siuti, N; LeDuc, RD; Compton, PD; Thomas, PM; Kelleher, NL				Tran, John C.; Zamdborg, Leonid; Ahlf, Dorothy R.; Lee, Ji Eun; Catherman, Adam D.; Durbin, Kenneth R.; Tipton, Jeremiah D.; Vellaichamy, Adaikkalam; Kellie, John F.; Li, Mingxi; Wu, Cong; Sweet, Steve M. M.; Early, Bryan P.; Siuti, Nertila; LeDuc, Richard D.; Compton, Philip D.; Thomas, Paul M.; Kelleher, Neil L.			Mapping intact protein isoforms in discovery mode using top-down proteomics	NATURE			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; CELLULAR SENESCENCE; QUANTITATIVE-ANALYSIS; LARGE-SCALE; IDENTIFICATION; TIME; ELECTROPHORESIS; DISSOCIATION; SEPARATION; PRECISE	A full description of the human proteome relies on the challenging task of detecting mature and changing forms of protein molecules in the body. Large-scale proteome analysis(1) has routinely involved digesting intact proteins followed by inferred protein identification using mass spectrometry(2). This 'bottom-up' process affords a high number of identifications (not always unique to a single gene). However, complications arise from incomplete or ambiguous(2) characterization of alternative splice forms, diverse modifications (for example, acetylation and methylation) and endogenous protein cleavages, especially when combinations of these create complex patterns of intact protein isoforms and species(3). 'Top-down' interrogation of whole proteins can overcome these problems for individual proteins(4,5), but has not been achieved on a proteome scale owing to the lack of intact protein fractionation methods that are well integrated with tandem mass spectrometry. Here we show, using a new four-dimensional separation system, identification of 1,043 gene products from human cells that are dispersed into more than 3,000 protein species created by post-translational modification (PTM), RNA splicing and proteolysis. The overall system produced greater than 20-fold increases in both separation power and proteome coverage, enabling the identification of proteins up to 105 kDa and those with up to 11 transmembrane helices. Many previously undetected isoforms of endogenous human proteins were mapped, including changes in multiply modified species in response to accelerated cellular ageing (senescence) induced by DNA damage. Integrated with the latest version of the Swiss-Prot database(6), the data provide precise correlations to individual genes and proof-of-concept for large-scale interrogation of whole protein molecules. The technology promises to improve the link between proteomics data and complex phenotypes in basic biology and disease research(7).	[Tran, John C.; Zamdborg, Leonid; Ahlf, Dorothy R.; Lee, Ji Eun; Catherman, Adam D.; Durbin, Kenneth R.; Vellaichamy, Adaikkalam; Kellie, John F.; Li, Mingxi; Wu, Cong; Sweet, Steve M. M.; Early, Bryan P.; Siuti, Nertila; Thomas, Paul M.; Kelleher, Neil L.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Tran, John C.; Zamdborg, Leonid; Ahlf, Dorothy R.; Lee, Ji Eun; Catherman, Adam D.; Durbin, Kenneth R.; Vellaichamy, Adaikkalam; Kellie, John F.; Li, Mingxi; Wu, Cong; Sweet, Steve M. M.; Early, Bryan P.; Siuti, Nertila; Thomas, Paul M.; Kelleher, Neil L.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Tran, John C.; Zamdborg, Leonid; Ahlf, Dorothy R.; Lee, Ji Eun; Catherman, Adam D.; Durbin, Kenneth R.; Vellaichamy, Adaikkalam; Kellie, John F.; Li, Mingxi; Wu, Cong; Sweet, Steve M. M.; Early, Bryan P.; Siuti, Nertila; Thomas, Paul M.; Kelleher, Neil L.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Tran, John C.; Ahlf, Dorothy R.; Catherman, Adam D.; Durbin, Kenneth R.; Tipton, Jeremiah D.; Kellie, John F.; Li, Mingxi; Sweet, Steve M. M.; Early, Bryan P.; Compton, Philip D.; Thomas, Paul M.; Kelleher, Neil L.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Tran, John C.; Ahlf, Dorothy R.; Catherman, Adam D.; Durbin, Kenneth R.; Tipton, Jeremiah D.; Kellie, John F.; Li, Mingxi; Sweet, Steve M. M.; Early, Bryan P.; Compton, Philip D.; Thomas, Paul M.; Kelleher, Neil L.] Northwestern Univ, Dept Mol Sci, Evanston, IL 60208 USA; [Tran, John C.; Ahlf, Dorothy R.; Catherman, Adam D.; Durbin, Kenneth R.; Tipton, Jeremiah D.; Kellie, John F.; Li, Mingxi; Sweet, Steve M. M.; Early, Bryan P.; Compton, Philip D.; Thomas, Paul M.; Kelleher, Neil L.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA; [Lee, Ji Eun] Korea Inst Sci & Technol, Doping Control Ctr, Seoul, South Korea; [Lee, Ji Eun] Korea Inst Sci & Technol, Ctr Theragnosis, Seoul, South Korea; [LeDuc, Richard D.] Univ Wisconsin Madison, Dept Great Lakes Bioenergy Res Ctr, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Northwestern University; Northwestern University; Northwestern University; Feinberg School of Medicine; Korea Institute of Science & Technology (KIST); Korea Institute of Science & Technology (KIST); University of Wisconsin System; University of Wisconsin Madison	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, Urbana, IL 61801 USA.	n-kelleher@northwestern.edu	Compton, Philip/A-9921-2013; Vellaichamy, Adaikkalam/GWN-0713-2022; Tran, John/AAI-2593-2020; Tran, John/E-7195-2014; Thomas, Paul M/A-6233-2011; Compton, Philip/AAK-9633-2021; Sweet, Steve/B-5528-2008	Compton, Philip/0000-0001-5212-7175; Vellaichamy, Adaikkalam/0000-0002-1740-1252; Tran, John/0000-0003-1697-9404; Tran, John/0000-0003-1697-9404; Thomas, Paul M/0000-0003-2887-4765; Compton, Philip/0000-0001-5212-7175; Sweet, Steve/0000-0002-3962-0421; LeDuc, Richard/0000-0002-6951-2923; Tipton, Jeremiah/0000-0002-3671-8239	Chicago Community Trust; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Institute on Drug Abuse [P30DA 018310]; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Institute for General Medical Sciences [GM 067193-08]; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Science Foundation [DMS 0800631]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA026672, P30DA018310] Funding Source: NIH RePORTER	Chicago Community Trust; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Institute on Drug Abuse; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Institute for General Medical Sciences; Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling through the National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank all members of the group who contributed to development of top-down mass spectrometry over the years along with several private foundations: The Searle Scholars Program, The Burroughs Wellcome Fund, The David and Lucile Packard Foundation, The Richard and Camille Dreyfus Foundation, and The Chicago Biomedical Consortium with support from The Searle Funds at The Chicago Community Trust. We further acknowledge the Department of Chemistry at the University of Illinois, the Neuroproteomics Center on Cell to Cell Signaling supported through the National Institute on Drug Abuse (P30DA 018310), the National Institute for General Medical Sciences (GM 067193-08) and the National Science Foundation (DMS 0800631), whose combined investment in basic research over the past decade made this work possible. We dedicate this work in memory of Jonathan Widom.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boyne MT, 2009, J PROTEOME RES, V8, P374, DOI 10.1021/pr800635m; Boyne MT, 2006, J PROTEOME RES, V5, P248, DOI 10.1021/pr050269n; Bunger MK, 2008, ANAL CHEM, V80, P1459, DOI 10.1021/ac7018409; Capriotti A. L., J CHROMAT A IN PRESS; Cox B, 2006, NAT PROTOC, V1, P1872, DOI 10.1038/nprot.2006.273; Duncan MW, 2010, NAT BIOTECHNOL, V28, P659, DOI 10.1038/nbt0710-659; Durbin KR, 2010, PROTEOMICS, V10, P3589, DOI 10.1002/pmic.201000177; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Ge Y, 2009, P NATL ACAD SCI USA, V106, P12658, DOI 10.1073/pnas.0813369106; Gomez SM, 2002, MOL CELL PROTEOMICS, V1, P46, DOI 10.1074/mcp.M100007-MCP200; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Horn DM, 2000, J AM SOC MASS SPECTR, V11, P320, DOI 10.1016/S1044-0305(99)00157-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeDuc RD, 2004, NUCLEIC ACIDS RES, V32, pW340, DOI 10.1093/nar/gkh447; Lee JE, 2009, J AM SOC MASS SPECTR, V20, P2183, DOI 10.1016/j.jasms.2009.08.001; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mazur MT, 2010, P NATL ACAD SCI USA, V107, P7728, DOI 10.1073/pnas.0910776107; Meng FY, 2001, NAT BIOTECHNOL, V19, P952, DOI 10.1038/nbt1001-952; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Nesvizhskii AI, 2005, MOL CELL PROTEOMICS, V4, P1419, DOI 10.1074/mcp.R500012-MCP200; Nilsson T, 2010, NAT METHODS, V7, P681, DOI 10.1038/nmeth0910-681; Papadopoulos P. M., 2001, Proceedings 2001 IEEE International Conference on Cluster Computing, P258, DOI 10.1109/CLUSTR.2001.959986; Parks BA, 2007, ANAL CHEM, V79, P7984, DOI 10.1021/ac070553t; Patrie SM, 2006, MOL CELL PROTEOMICS, V5, P14, DOI 10.1074/mcp.M500219-MCP200; Reiter L, 2009, MOL CELL PROTEOMICS, V8, P2405, DOI 10.1074/mcp.M900317-MCP200; Righetti PG, 2005, ELECTROPHORESIS, V26, P297, DOI 10.1002/elps.200406189; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Roth MJ, 2008, ANAL CHEM, V80, P2857, DOI 10.1021/ac800141g; Roth MJ, 2005, MOL CELL PROTEOMICS, V4, P1002, DOI 10.1074/mcp.M500064-MCP200; Schluter H, 2009, CHEM CENT J, V3, DOI 10.1186/1752-153X-3-11; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Service RF, 2008, SCIENCE, V321, P1758, DOI [10.1126/science.321.5897.1758, 10.1126/science.321.5897.1760]; Sgarra R, 2006, J BIOL CHEM, V281, P3764, DOI 10.1074/jbc.M510231200; Sgarra R, 2003, BIOCHEMISTRY-US, V42, P3575, DOI 10.1021/bi027338l; Soubeyrand S, 2010, MOL ONCOL, V4, P38, DOI 10.1016/j.molonc.2009.09.003; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tran JC, 2008, J PROTEOME RES, V7, P1761, DOI 10.1021/pr700677u; Tran JC, 2008, ANAL CHEM, V80, P1568, DOI 10.1021/ac702197w; Tran JC, 2009, ANAL CHEM, V81, P6201, DOI 10.1021/ac900729r; Trinkle-Mulcahy L, 2008, J CELL BIOL, V183, P223, DOI 10.1083/jcb.200805092; Vellaichamy A, 2010, ANAL CHEM, V82, P1234, DOI 10.1021/ac9021083; Wang H, 2005, MOL CELL PROTEOMICS, V4, P618, DOI 10.1074/mcp.M400126-MCP200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Yawata T, 2003, ONCOGENE, V22, P281, DOI 10.1038/sj.onc.1206143; Zamdborg L, 2007, NUCLEIC ACIDS RES, V35, pW701, DOI 10.1093/nar/gkm371	47	481	488	2	315	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 8	2011	480	7376					254	U141		10.1038/nature10575	http://dx.doi.org/10.1038/nature10575			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857TR	22037311	Green Accepted			2022-12-28	WOS:000297744200054
J	Dalla Libera, D; Colombo, B; Truci, G; Rossi, P; De Feo, D; Tiberi, S; Martinelli, V; Comi, G				Dalla Libera, Dacia; Colombo, Bruno; Truci, Giulio; Rossi, Paolo; De Feo, Donatella; Tiberi, Simon; Martinelli, Vittorio; Comi, Giancarlo			A strange case of waitress headache	LANCET			English	Editorial Material									[Dalla Libera, Dacia; Colombo, Bruno; Truci, Giulio; Rossi, Paolo; De Feo, Donatella; Martinelli, Vittorio; Comi, Giancarlo] Ist Sci San Raffaele, Inst Expt Neurol, Dept Neurol, I-20132 Milan, Italy; [Dalla Libera, Dacia; Colombo, Bruno; Truci, Giulio; Rossi, Paolo; De Feo, Donatella; Martinelli, Vittorio; Comi, Giancarlo] Univ Vita Salute San Raffaele, Milan, Italy; [Tiberi, Simon] Valtellina & Valchiavenna Sondalo Hosp, Local Hlth Unit, Sondrio, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Dalla Libera, D (corresponding author), Ist Sci San Raffaele, Inst Expt Neurol, Dept Neurol, Via Olgettina 48, I-20132 Milan, Italy.	dallalibera.dacia@hsr.it	Martinelli, Vittorio/AAN-7240-2020; Tiberi, Simon/AAU-2270-2020; Tiberi, Simon/I-2552-2019	Tiberi, Simon/0000-0002-0738-4276; Tiberi, Simon/0000-0001-9424-6551; Dalla Libera, Dacia/0000-0001-5028-4177; De Feo, Donatella/0000-0003-0121-5364				Allerberger F, 2010, CLIN MICROBIOL INFEC, V16, P16, DOI 10.1111/j.1469-0691.2009.03109.x; Calder JAM, 1997, LANCET, V350, P307, DOI 10.1016/S0140-6736(05)63384-3; Gianfranceschi MV, 2009, FOOD MICROBIOL, V26, P520, DOI 10.1016/j.fm.2009.03.003; Tyler KL, 2009, LANCET NEUROL, V8, P19, DOI 10.1016/S1474-4422(08)70279-5	4	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	2011	378	9805					1824	1824						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22098855				2022-12-28	WOS:000297262300027
J	Baek, SH; Park, J; Kim, DM; Aksyuk, VA; Das, RR; Bu, SD; Felker, DA; Lettieri, J; Vaithyanathan, V; Bharadwaja, SSN; Bassiri-Gharb, N; Chen, YB; Sun, HP; Folkman, CM; Jang, HW; Kreft, DJ; Streiffer, SK; Ramesh, R; Pan, XQ; Trolier-McKinstry, S; Schlom, DG; Rzchowski, MS; Blick, RH; Eom, CB				Baek, S. H.; Park, J.; Kim, D. M.; Aksyuk, V. A.; Das, R. R.; Bu, S. D.; Felker, D. A.; Lettieri, J.; Vaithyanathan, V.; Bharadwaja, S. S. N.; Bassiri-Gharb, N.; Chen, Y. B.; Sun, H. P.; Folkman, C. M.; Jang, H. W.; Kreft, D. J.; Streiffer, S. K.; Ramesh, R.; Pan, X. Q.; Trolier-McKinstry, S.; Schlom, D. G.; Rzchowski, M. S.; Blick, R. H.; Eom, C. B.			Giant Piezoelectricity on Si for Hyperactive MEMS	SCIENCE			English	Article							TITANATE THIN-FILMS; SINGLE-CRYSTALS; ULTRASONIC TRANSDUCERS; NANOINDENTATION; FABRICATION; DESIGN; SRTIO3	Microelectromechanical systems (MEMS) incorporating active piezoelectric layers offer integrated actuation, sensing, and transduction. The broad implementation of such active MEMS has long been constrained by the inability to integrate materials with giant piezoelectric response, such as Pb(Mg1/3Nb2/3)O-3-PbTiO3 (PMN-PT). We synthesized high-quality PMN-PT epitaxial thin films on vicinal (001) Si wafers with the use of an epitaxial (001) SrTiO3 template layer with superior piezoelectric coefficients (e(31,f) = -27 +/- 3 coulombs per square meter) and figures of merit for piezoelectric energy-harvesting systems. We have incorporated these heterostructures into microcantilevers that are actuated with extremely low drive voltage due to thin-film piezoelectric properties that rival bulk PMN-PT single crystals. These epitaxial heterostructures exhibit very large electromechanical coupling for ultrasound medical imaging, microfluidic control, mechanical sensing, and energy harvesting.	[Baek, S. H.; Kim, D. M.; Das, R. R.; Bu, S. D.; Folkman, C. M.; Jang, H. W.; Eom, C. B.] Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA; [Park, J.; Kreft, D. J.; Blick, R. H.] Univ Wisconsin, Dept Elect & Comp Engn, Madison, WI 53706 USA; [Aksyuk, V. A.; Rzchowski, M. S.] Natl Inst Stand & Technol, Ctr Nanoscale Sci & Technol, Gaithersburg, MD 20899 USA; [Felker, D. A.] Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; [Lettieri, J.; Vaithyanathan, V.; Bharadwaja, S. S. N.; Bassiri-Gharb, N.; Trolier-McKinstry, S.; Schlom, D. G.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; [Chen, Y. B.; Sun, H. P.; Pan, X. Q.] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA; [Streiffer, S. K.] Argonne Natl Lab, Ctr Nanoscale Mat, Argonne, IL 60439 USA; [Ramesh, R.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA; [Schlom, D. G.] Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA; [Schlom, D. G.] Kavli Inst Cornell Nanoscale Sci, Ithaca, NY 14853 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institute of Standards & Technology (NIST) - USA; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Michigan System; University of Michigan; United States Department of Energy (DOE); Argonne National Laboratory; University of California System; University of California Berkeley; Cornell University	Eom, CB (corresponding author), Univ Wisconsin, Dept Mat Sci & Engn, 1509 Univ Ave, Madison, WI 53706 USA.	eom@engr.wisc.edu	Bu, Sang Don/B-1576-2008; Ramesh, Ramamoorthy/ABI-4883-2020; Eom, Chang-Beom/I-5567-2014; Bassiri-Gharb, Nazanin/F-1783-2011; Jang, Ho Won/D-9866-2011; Pan, Xiaoqing/ABF-4088-2020; Rzchowski, Mark S/X-3600-2019; Trolier-McKinstry, Susan/AAD-6264-2021; Schlom, Darrell G/J-2412-2013; Park, Jonghoo/A-4342-2013; Park, Jonghoo/P-6537-2019; Blick, Robert H/M-8298-2014	Bu, Sang Don/0000-0003-4883-1308; Bassiri-Gharb, Nazanin/0000-0002-0183-5160; Jang, Ho Won/0000-0002-6952-7359; Pan, Xiaoqing/0000-0002-0965-8568; Trolier-McKinstry, Susan/0000-0002-7267-9281; Schlom, Darrell G/0000-0003-2493-6113; Park, Jonghoo/0000-0001-9163-6175; Blick, Robert H/0000-0002-3602-7702; Baek, Seung-Hyub/0000-0002-3187-6596; Aksyuk, Vladimir/0000-0002-9653-4722	NSF [ECCS-0708759, DMR-0907191, DMR-0723032]; David Lucile Packard Fellowship; National Security Science and Engineering Faculty Fellowship; Multidisciplinary University Research Initiative through the Air Force Office for Scientific Research (AFOSR) [FA9550-08-1-0337]; U.S. Department of Energy (DOE) [DE-FG02-07ER46416]; DOE, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; AFOSR [FA9550-10-1-0524]	NSF(National Science Foundation (NSF)); David Lucile Packard Fellowship(The David & Lucile Packard Foundation); National Security Science and Engineering Faculty Fellowship; Multidisciplinary University Research Initiative through the Air Force Office for Scientific Research (AFOSR)(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); U.S. Department of Energy (DOE)(United States Department of Energy (DOE)); DOE, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR))	This work was supported by the NSF under grant no. ECCS-0708759 and a David Lucile Packard Fellowship (C. B. E.). Work at Penn State was supported by a National Security Science and Engineering Faculty Fellowship. The work was partly supported by a Multidisciplinary University Research Initiative through the Air Force Office for Scientific Research (AFOSR) under grant no. FA9550-08-1-0337 (R. H. B.). Work at the Univ. of Michigan was supported by the U.S. Department of Energy (DOE) under award DE-FG02-07ER46416 and by NSF under awards DMR-0907191 and DMR-0723032 (TEM instrument). Work at Argonne National Laboratory and use of the Center for Nanoscale Materials was supported by the DOE, Office of Science, Office of Basic Energy Sciences, under contract no. DE-AC02-06CH11357. Work at Cornell was supported by AFOSR through award no. FA9550-10-1-0524. We thank N. Valanoor for helpful discussions.	Abazari M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3309706; Bu SD, 2001, APPL PHYS LETT, V79, P3482, DOI 10.1063/1.1414293; Calame F, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2472529; Cook-Chennault KA, 2008, SMART MATER STRUCT, V17, DOI 10.1088/0964-1726/17/4/043001; Delobelle P, 2006, THIN SOLID FILMS, V515, P1385, DOI 10.1016/j.tsf.2006.03.062; Dubois MA, 1998, IEEE T ULTRASON FERR, V45, P1169, DOI 10.1109/58.726440; duToit NE, 2005, INTEGR FERROELECTR, V71, P121, DOI 10.1080/10584580590964574; Elfrink R, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/9/094005; EOM CB, 1992, SCIENCE, V258, P1766, DOI 10.1126/science.258.5089.1766; Fang TH, 2003, J PHYS-CONDENS MAT, V15, P5253, DOI 10.1088/0953-8984/15/30/307; Griggio F, 2010, J APPL PHYS, V107, DOI 10.1063/1.3284945; Isarakorn D, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/5/055008; Judy JW, 2001, SMART MATER STRUCT, V10, P1115, DOI 10.1088/0964-1726/10/6/301; Kamel TM, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/10/105023; Liang Y, 2004, J APPL PHYS, V96, P3413, DOI 10.1063/1.1778214; Muralt P, 2005, IEEE T ULTRASON FERR, V52, P2276, DOI 10.1109/TUFFC.2005.1563270; Nguyen Minh D., 2011, Advances in Natural Sciences: Nanoscience & Nanotechnology, V2, DOI 10.1088/2043-6262/2/1/015005; Park SE, 1997, IEEE T ULTRASON FERR, V44, P1140, DOI 10.1109/58.655639; Park SE, 1997, J APPL PHYS, V82, P1804, DOI 10.1063/1.365983; Polcawich RG, 2000, J MATER RES, V15, P2505, DOI 10.1557/JMR.2000.0360; Polcawich RG, 2007, IEEE T MICROW THEORY, V55, P2642, DOI 10.1109/TMTT.2007.910072; Roundy S, 2005, J INTEL MAT SYST STR, V16, P809, DOI 10.1177/1045389X05054042; Sharma AK, 2000, APPL PHYS LETT, V76, P1458, DOI 10.1063/1.126063; Shepard JF, 1998, SENSOR ACTUAT A-PHYS, V71, P133, DOI 10.1016/S0924-4247(98)00161-7; Shibata K, 2008, APPL PHYS EXPRESS, V1, DOI 10.1143/APEX.1.011501; SWARTZ SL, 1982, MATER RES BULL, V17, P1245, DOI 10.1016/0025-5408(82)90159-3; Trolier-McKinstry S, 2004, J ELECTROCERAM, V12, P7, DOI 10.1023/B:JECR.0000033998.72845.51; Uchino K, 1996, PIEZOELECTRIC ACTUAT; Zhang R, 2001, J APPL PHYS, V90, P3471, DOI 10.1063/1.1390494; Zhang SJ, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2992081; Zhang ZS, 2000, MATER RES SOC SYMP P, V596, P73, DOI 10.1557/PROC-596-73	31	331	338	7	517	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					958	961		10.1126/science.1207186	http://dx.doi.org/10.1126/science.1207186			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096193				2022-12-28	WOS:000297101800050
J	Dunn, B; Kamath, H; Tarascon, JM				Dunn, Bruce; Kamath, Haresh; Tarascon, Jean-Marie			Electrical Energy Storage for the Grid: A Battery of Choices	SCIENCE			English	Review							ELECTRODE MATERIALS; LITHIUM; LI; CHALLENGES; TRANSPORT; CELLS	The increasing interest in energy storage for the grid can be attributed to multiple factors, including the capital costs of managing peak demands, the investments needed for grid reliability, and the integration of renewable energy sources. Although existing energy storage is dominated by pumped hydroelectric, there is the recognition that battery systems can offer a number of high-value opportunities, provided that lower costs can be obtained. The battery systems reviewed here include sodium-sulfur batteries that are commercially available for grid applications, redox-flow batteries that offer low cost, and lithium-ion batteries whose development for commercial electronics and electric vehicles is being applied to grid storage.	[Dunn, Bruce] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA; [Dunn, Bruce] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA; [Kamath, Haresh] Elect Power Res Inst, Palo Alto, CA 94304 USA; [Tarascon, Jean-Marie] Univ Picardie Jules Verne, Lab React Chim Solides, F-80039 Amiens, France; [Tarascon, Jean-Marie] Coll France, F-75231 Paris, France	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Electric Power Research Institute (EPRI); Picardie Universites; Universite de Picardie Jules Verne (UPJV); UDICE-French Research Universities; PSL Research University Paris; College de France	Dunn, B (corresponding author), Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA.		Tarascon, Jean-Marie/B-5952-2016; Zhang, Jingyu/E-1249-2012		Center for Molecularly Engineered Energy Materials, an Energy Frontier Research Center; U.S. Department of Energy (DOE) Office of Basic Energy Sciences [DE-SC001342]; DOE Office of Electricity	Center for Molecularly Engineered Energy Materials, an Energy Frontier Research Center; U.S. Department of Energy (DOE) Office of Basic Energy Sciences(United States Department of Energy (DOE)); DOE Office of Electricity	Support (B.D.) is from the Center for Molecularly Engineered Energy Materials, an Energy Frontier Research Center funded by the U.S. Department of Energy (DOE) Office of Basic Energy Sciences (DE-SC001342) and from the DOE Office of Electricity, Energy Storage Systems Program. The authors greatly appreciate the insightful comments provided by G. Farrington and A. Shukla. We also thank E. Lan and L. Smith for their assistance with the manuscript.	Abraham KM, 1996, J ELECTROCHEM SOC, V143, P1, DOI 10.1149/1.1836378; [Anonymous], 2007, BAS RES NEEDS EL EN; [Anonymous], 2003, EPRI DOE HDB EN STOR; [Anonymous], 2010, 20100815 SAND SAND N; Arico AS, 2005, NAT MATER, V4, P366, DOI 10.1038/nmat1368; Armand M, 2008, NATURE, V451, P652, DOI 10.1038/451652a; Barpanda P, 2010, INORG CHEM, V49, P7401, DOI 10.1021/ic100583f; BARTOLOZZI M, 1989, J POWER SOURCES, V27, P219, DOI 10.1016/0378-7753(89)80037-0; Bito A, 2005, IEEE POW EN SOC GEN; Braithwaite J. W., 2004, HDB BATTERIES; Chen HY, 2009, J AM CHEM SOC, V131, P8984, DOI 10.1021/ja9024897; de Leon CP, 2006, J POWER SOURCES, V160, P716, DOI 10.1016/j.jpowsour.2006.02.095; Debart A, 2008, ANGEW CHEM INT EDIT, V47, P4521, DOI 10.1002/anie.200705648; Doughty DH, 2010, ELECTROCHEM SOC INTE, V19, P49, DOI 10.1149/2.F05103if; Duduta M, 2011, ADV ENERGY MATER, V1, P511, DOI 10.1002/aenm.201100152; DUNN B, 1981, J APPL ELECTROCHEM, V11, P103, DOI 10.1007/BF00615328; Dustmann CH, 2004, J POWER SOURCES, V127, P85, DOI 10.1016/j.jpowsour.2003.09.039; EPRI, 2010, EL EN STOR TECHN OPT; Etacheri V, 2011, ENERG ENVIRON SCI, V4, P3243, DOI 10.1039/c1ee01598b; FARRINGTON GC, 1979, SCIENCE, V204, P1371, DOI 10.1126/science.204.4400.1371; Girishkumar G, 2010, J PHYS CHEM LETT, V1, P2193, DOI 10.1021/jz1005384; Goodenough JB, 2010, CHEM MATER, V22, P587, DOI 10.1021/cm901452z; International Energy Agency, 2010, POW GEN COAL MEAS RE; La Rosa D, 2010, CHEMSUSCHEM, V3, P1390, DOI 10.1002/cssc.201000223; Lee JS, 2011, ADV ENERGY MATER, V1, P34, DOI 10.1002/aenm.201000010; Li H, 2009, ADV MATER, V21, P4593, DOI 10.1002/adma.200901710; Lu XC, 2010, J POWER SOURCES, V195, P2431, DOI 10.1016/j.jpowsour.2009.11.120; Lu YC, 2010, J AM CHEM SOC, V132, P12170, DOI 10.1021/ja1036572; Lu YH, 2011, J MATER CHEM, V21, P10113, DOI 10.1039/c0jm04222f; Nguyen T, 2010, ELECTROCHEM SOC INTE, V19, P54, DOI 10.1149/2.F06103if; Obrovac MN, 2004, ELECTROCHEM SOLID ST, V7, pA93, DOI 10.1149/1.1652421; Ogasawara T, 2006, J AM CHEM SOC, V128, P1390, DOI 10.1021/ja056811q; Poizot P, 2000, NATURE, V407, P496, DOI 10.1038/35035045; Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297; SKYLLAS-KAZACOS M, 1986, J ELECTROCHEM SOC, V133, P1057, DOI 10.1149/1.2108706; Skyllas-Kazacos M, 2011, J ELECTROCHEM SOC, V158, pR55, DOI 10.1149/1.3599565; Soloveichik GL, 2011, ANNU REV CHEM BIOMOL, V2, P503, DOI 10.1146/annurev-chembioeng-061010-114116; Song SF, 2010, J SOLID STATE ELECTR, V14, P1735, DOI 10.1007/s10008-010-1028-6; Sudworth J., 1985, SODIUM SULFUR BATTER; Sudworth JL, 2000, MRS BULL, V25, P22, DOI 10.1557/mrs2000.14; Tarascon JM, 2010, PHILOS T R SOC A, V368, P3227, DOI 10.1098/rsta.2010.0112; Tarascon JM, 2010, CHEM MATER, V22, P724, DOI 10.1021/cm9030478; Tarascon JM, 2001, NATURE, V414, P359, DOI 10.1038/35104644; Whitacre JF, 2010, ELECTROCHEM COMMUN, V12, P463, DOI 10.1016/j.elecom.2010.01.020; Winter M, 2004, CHEM REV, V104, P4245, DOI 10.1021/cr020730k; Yamada A, 2001, J ELECTROCHEM SOC, V148, pA224, DOI 10.1149/1.1348257; Yang ZG, 2011, CHEM REV, V111, P3577, DOI 10.1021/cr100290v; YAO YFY, 1967, J INORG NUCL CHEM, V29, P2453; Zheng JP, 2008, J ELECTROCHEM SOC, V155, pA432, DOI 10.1149/1.2901961	49	9592	9833	626	11829	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					928	935		10.1126/science.1212741	http://dx.doi.org/10.1126/science.1212741			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096188				2022-12-28	WOS:000297101800043
J	Solanki, SK; Krivova, NA				Solanki, Sami K.; Krivova, Natalie A.			Analyzing Solar Cycles	SCIENCE			English	Editorial Material									[Solanki, Sami K.; Krivova, Natalie A.] Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; [Solanki, Sami K.] Kyung Hee Univ, Sch Space Res, Yongin 446701, Gyeonggi, South Korea	Max Planck Society; Kyung Hee University	Solanki, SK (corresponding author), Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany.	solanki@mps.mpg.de	Solanki, Sami K/E-2487-2013	Solanki, Sami K/0000-0002-3418-8449; Krivova, Natalie/0000-0002-1377-3067				Abreu JA, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035442; EDDY JA, 1976, SCIENCE, V192, P1189, DOI 10.1126/science.192.4245.1189; Hathaway DH, 2010, LIVING REV SOL PHYS, V7, DOI 10.12942/lrsp-2010-1; Hoyt DV, 1998, SOL PHYS, V179, P189, DOI 10.1023/A:1005007527816; Lockwood M, 2010, P ROY SOC A-MATH PHY, V466, P303, DOI 10.1098/rspa.2009.0519; Petrovay K, 2010, LIVING REV SOL PHYS, V7, DOI 10.12942/lrsp-2010-6; Solanki SK, 2004, NATURE, V431, P1084, DOI 10.1038/nature02995; Steinhilber F., 2008, ASTROPHYS SPACE SCI, V4, P1, DOI [10.5194/astra-4-1-2008, DOI 10.5194/ASTRA-4-1-2008]; Usoskin IG, 2007, ASTRON ASTROPHYS, V471, P301, DOI 10.1051/0004-6361:20077704; Vaquero JM, 2011, ASTROPHYS J LETT, V731, DOI 10.1088/2041-8205/731/2/L24	10	37	39	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					916	917		10.1126/science.1212555	http://dx.doi.org/10.1126/science.1212555			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096181				2022-12-28	WOS:000297101800037
J	Tumlinson, J; Thom, C; Werk, JK; Prochaska, JX; Tripp, TM; Weinberg, DH; Peeples, MS; O'Meara, JM; Oppenheimer, BD; Meiring, JD; Katz, NS; Dave, R; Ford, AB; Sembach, KR				Tumlinson, J.; Thom, C.; Werk, J. K.; Prochaska, J. X.; Tripp, T. M.; Weinberg, D. H.; Peeples, M. S.; O'Meara, J. M.; Oppenheimer, B. D.; Meiring, J. D.; Katz, N. S.; Dave, R.; Ford, A. B.; Sembach, K. R.			The Large, Oxygen-Rich Halos of Star-Forming Galaxies Are a Major Reservoir of Galactic Metals	SCIENCE			English	Article							ABSORPTION SYSTEMS; INTERGALACTIC MEDIUM; LOW-REDSHIFT; ULTRAVIOLET-SPECTRA; IONIZED-GAS; OUTFLOWS; OVI; ABSORBERS; EVOLUTION; VELOCITY	The circumgalactic medium (CGM) is fed by galaxy outflows and accretion of intergalactic gas, but its mass, heavy element enrichment, and relation to galaxy properties are poorly constrained by observations. In a survey of the outskirts of 42 galaxies with the Cosmic Origins Spectrograph onboard the Hubble Space Telescope, we detected ubiquitous, large (150-kiloparsec) halos of ionized oxygen surrounding star-forming galaxies; we found much less ionized oxygen around galaxies with little or no star formation. This ionized CGM contains a substantial mass of heavy elements and gas, perhaps far exceeding the reservoirs of gas in the galaxies themselves. Our data indicate that it is a basic component of nearly all star-forming galaxies that is removed or transformed during the quenching of star formation and the transition to passive evolution.	[Tumlinson, J.; Thom, C.; Sembach, K. R.] Space Telescope Sci Inst, Baltimore, MD 21218 USA; [Werk, J. K.; Prochaska, J. X.] Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Santa Cruz, CA 95064 USA; [Tripp, T. M.; Meiring, J. D.; Katz, N. S.] Univ Massachusetts, Dept Astron, Amherst, MA 01003 USA; [Weinberg, D. H.] Ohio State Univ, Dept Astron, Columbus, OH 43210 USA; [Peeples, M. S.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [O'Meara, J. M.] St Michaels Coll, Dept Chem & Phys, Colchester, VT 05439 USA; [Oppenheimer, B. D.] Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands; [Dave, R.; Ford, A. B.] Univ Arizona, Steward Observ, Tucson, AZ 85721 USA	Space Telescope Science Institute; University of California System; University of California Santa Cruz; University of Massachusetts System; University of Massachusetts Amherst; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; Leiden University; Leiden University - Excl LUMC; University of Arizona	Tumlinson, J (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	tumlinson@stsci.edu	O'Meara, John/AID-8266-2022	Dave, Romeel/0000-0003-2842-9434; Prochaska, J. Xavier/0000-0002-7738-6875; Oppenheimer, Benjamin/0000-0002-3391-2116	NASA/ESA Hubble Space Telescope [GO11598]; NASA [NAS 5-26555]; W. M. Keck Foundation; Southern California Center for Galaxy Evolution; UC Office of Research	NASA/ESA Hubble Space Telescope(National Aeronautics & Space Administration (NASA)); NASA(National Aeronautics & Space Administration (NASA)); W. M. Keck Foundation(W.M. Keck Foundation); Southern California Center for Galaxy Evolution; UC Office of Research	We thank the anonymous reviewers for constructive comments. This work is based on observations made for program GO11598 with the NASA/ESA Hubble Space Telescope, obtained at the Space Telescope Science Institute, operated by AURA under NASA contract NAS 5-26555, and at the W. M. Keck Observatory, operated as a scientific partnership of the California Institute of Technology, the University of California, and NASA. The Observatory was made possible by the generous financial support of the W. M. Keck Foundation. The Hubble data are available from the MAST archive at http://archive.stsci.edu. M. S. P. was supported by the Southern California Center for Galaxy Evolution, a multicampus research program funded by the UC Office of Research.	Asplund M, 2009, ANNU REV ASTRON ASTR, V47, P481, DOI 10.1146/annurev.astro.46.060407.145222; Bregman JN, 2005, ASTROPHYS J, V635, P1031, DOI 10.1086/497421; Bregman JN, 2007, ANNU REV ASTRON ASTR, V45, P221, DOI 10.1146/annurev.astro.45.051806.110619; Chen HW, 2010, ASTROPHYS J, V714, P1521, DOI 10.1088/0004-637X/714/2/1521; Chen HW, 2009, ASTROPHYS J, V701, P1219, DOI 10.1088/0004-637X/701/2/1219; Danforth CW, 2008, ASTROPHYS J, V679, P194, DOI 10.1086/587127; Dekel A, 2006, MON NOT R ASTRON SOC, V368, P2, DOI 10.1111/j.1365-2966.2006.10145.x; Gabor JM, 2010, MON NOT R ASTRON SOC, V407, P749, DOI 10.1111/j.1365-2966.2010.16961.x; Kauffmann G, 2003, MON NOT R ASTRON SOC, V341, P33, DOI 10.1046/j.1365-8711.2003.06291.x; Keres D, 2005, MON NOT R ASTRON SOC, V363, P2, DOI 10.1111/j.1365-2966.2005.09451.x; Lehner N, 2011, SCIENCE, V334, P955, DOI 10.1126/science.1209069; Martin CL, 2005, ASTROPHYS J, V621, P227, DOI 10.1086/427277; Oppenheimer BD, 2006, MON NOT R ASTRON SOC, V373, P1265, DOI 10.1111/j.1365-2966.2006.10989.x; Oppenheimer BD, 2010, MON NOT R ASTRON SOC, V406, P2325, DOI 10.1111/j.1365-2966.2010.16872.x; Peeples MS, 2011, MON NOT R ASTRON SOC, V417, P2962, DOI 10.1111/j.1365-2966.2011.19456.x; Putman ME, 2006, ASTROPHYS J, V645, P1164, DOI 10.1086/504509; Rupke DS, 2005, ASTROPHYS J SUPPL S, V160, P115, DOI 10.1086/432889; Schiminovich D, 2007, ASTROPHYS J SUPPL S, V173, P315, DOI 10.1086/524659; Sembach KR, 2003, ASTROPHYS J SUPPL S, V146, P165, DOI 10.1086/346231; Stewart KR, 2011, ASTROPHYS J LETT, V735, DOI 10.1088/2041-8205/735/1/L1; Stocke JT, 2006, ASTROPHYS J, V641, P217, DOI 10.1086/500386; Thom C, 2008, ASTROPHYS J, V683, P22, DOI 10.1086/587976; Thomas D, 1998, MON NOT R ASTRON SOC, V296, P119, DOI 10.1046/j.1365-8711.1998.01289.x; Tripp TM, 2000, ASTROPHYS J, V534, pL1, DOI 10.1086/312644; Tripp TM, 2008, ASTROPHYS J SUPPL S, V177, P39, DOI 10.1086/587486; Tripp TM, 2011, SCIENCE, V334, P952, DOI 10.1126/science.1209850; Veilleux S, 2005, ANNU REV ASTRON ASTR, V43, P769, DOI 10.1146/annurev.astro.43.072103.150610	32	401	401	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					948	952		10.1126/science.1209840	http://dx.doi.org/10.1126/science.1209840			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096191	Green Submitted			2022-12-28	WOS:000297101800047
J	Pillarisetty, R				Pillarisetty, Ravi			Academic and industry research progress in germanium nanodevices	NATURE			English	Review							FIELD-EFFECT TRANSISTORS; HOLE MOBILITY; GE; SILICON; PERFORMANCE; FABRICATION; MOSFETS; LAYERS	Silicon has enabled the rise of the semiconductor electronics industry, but it was not the first material used in such devices. During the 1950s, just after the birth of the transistor, solid-state devices were almost exclusively manufactured from germanium. Today, one of the key ways to improve transistor performance is to increase charge-carrier mobility within the device channel. Motivated by this, the solid-state device research community is returning to investigating the high-mobility material germanium. Germanium-based transistors have the potential to operate at high speeds with low power requirements and might therefore be used in non-silicon-based semiconductor technology in the future.	Intel Corp, Components Res Technol & Mfg Grp, Hillsboro, OR 97124 USA	Intel Corporation	Pillarisetty, R (corresponding author), Intel Corp, Components Res Technol & Mfg Grp, 5200 NE Elam Young Pkwy, Hillsboro, OR 97124 USA.	ravi.pillarisetty@intel.com						ATALLA MM, 1959, AT&T TECH J, V38, P749, DOI 10.1002/j.1538-7305.1959.tb03907.x; Bennett BR, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2762279; Caymax M, 2009, INT EL DEVICES MEET, P428; CHANG LL, 1965, PR INST ELECTR ELECT, V53, P316, DOI 10.1109/PROC.1965.3715; Chui CO, 2002, INTERNATIONAL ELECTRON DEVICES 2002 MEETING, TECHNICAL DIGEST, P437, DOI 10.1109/IEDM.2002.1175872; Currie MT, 1998, APPL PHYS LETT, V72, P1718, DOI 10.1063/1.121162; Dewey G, 2009, INT EL DEVICES MEET, P452; ENGELHARDT CM, 1994, SOLID STATE ELECTRON, V37, P949, DOI 10.1016/0038-1101(94)90333-6; Ghani T, 2003, 2003 IEEE INTERNATIONAL ELECTRON DEVICES MEETING, TECHNICAL DIGEST, P978; Gomez L, 2010, IEEE ELECTR DEVICE L, V31, P782, DOI 10.1109/LED.2010.2050574; Hashimoto T, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.066502; Houssa M, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3006320; Huang C. H., 2003, S VLSI, P119; Hudait MK, 2007, INT EL DEVICES MEET, P625, DOI 10.1109/IEDM.2007.4419017; Irisawa T, 2001, JPN J APPL PHYS 1, V40, P2694, DOI 10.1143/JJAP.40.2694; Kahng D., 1961, SEMICONDUCTOR DEVICE; Kamata Y, 2008, MATER TODAY, V11, P30, DOI 10.1016/S1369-7021(07)70350-4; KIM DH, 2006, IEDM, P837; Kita K, 2009, INT EL DEVICES MEET, P649, DOI 10.1109/IEDM.2009.5424243; Koester SJ, 2000, IEEE ELECTR DEVICE L, V21, P110, DOI 10.1109/55.823572; Krishnamohan T, 2005, 2005 SYMPOSIUM ON VLSI TECHNOLOGY, DIGEST OF TECHNICAL PAPERS, P82; Kudo M, 1997, J CRYST GROWTH, V175, P910, DOI 10.1016/S0022-0248(96)00884-6; Kuzum D, 2007, INT EL DEVICES MEET, P723, DOI 10.1109/IEDM.2007.4419048; Lee ML, 2001, APPL PHYS LETT, V79, P3344, DOI 10.1063/1.1417515; Madhavi S, 2001, J APPL PHYS, V89, P2497, DOI 10.1063/1.1334632; MARTIN SC, 1989, IEEE ELECTR DEVICE L, V10, P325, DOI 10.1109/55.29667; Mistry K, 2007, INT EL DEVICES MEET, P247, DOI 10.1109/IEDM.2007.4418914; Mitard J, 2009, 2009 SYMPOSIUM ON VLSI TECHNOLOGY, DIGEST OF TECHNICAL PAPERS, P82; Mitard J, 2008, INT EL DEVICES MEET, P873, DOI 10.1109/IEDM.2008.4796837; Moore GE, 2003, ISSCC DIG TECH PAP I, V46, P20; Nagaiah P., 2009, MATER RES SOC S P; Nakaharai S, 2003, APPL PHYS LETT, V83, P3516, DOI 10.1063/1.1622442; Ni Chleirigh C., 2007, THESIS MIT; Nicholas G, 2007, IEEE ELECTR DEVICE L, V28, P825, DOI 10.1109/LED.2007.903405; Park JS, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2435603; Pillarisetty, 2010, IEDM, P150; Radosavljevic M, 2008, INT EL DEVICES MEET, P727; Radosavljevic M., 2009, IEDM, P13, DOI [DOI 10.1109/IEDM.2009.5424361, 10.1109/IEDM.2009.5424361]; Ritenour A, 2003, 2003 IEEE INTERNATIONAL ELECTRON DEVICES MEETING, TECHNICAL DIGEST, P433; SCHIRBER JE, 1985, APPL PHYS LETT, V46, P187, DOI 10.1063/1.95678; Swaminathan S, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3313946; Taraschi G, 2004, SOLID STATE ELECTRON, V48, P1297, DOI 10.1016/j.sse.2004.01.012; Tezuka T, 2005, 2005 SYMPOSIUM ON VLSI TECHNOLOGY, DIGEST OF TECHNICAL PAPERS, P80; Wang G, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3360231; Wang G, 2010, THIN SOLID FILMS, V518, P2538, DOI 10.1016/j.tsf.2009.09.133; WANG KL, 1975, IEEE T ELECTRON DEV, VED22, P353, DOI 10.1109/T-ED.1975.18137; Wang SK, 2010, J APPL PHYS, V108, DOI 10.1063/1.3475990; Weber O, 2005, INT EL DEVICES MEET, P143; Whang SJ, 2004, IEEE INTERNATIONAL ELECTRON DEVICES MEETING 2004, TECHNICAL DIGEST, P307, DOI 10.1109/IEDM.2004.1419140; XIE YH, 1993, APPL PHYS LETT, V63, P2263, DOI 10.1063/1.110547; Xu HX, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3462301; Zhang R, 2011, S VLSI TECH, P56	52	390	398	6	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					324	328		10.1038/nature10678	http://dx.doi.org/10.1038/nature10678			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094692				2022-12-28	WOS:000297059700032
J	Punukollu, M; Harnden, A; Tulloh, R				Punukollu, Mallika; Harnden, Anthony; Tulloh, Robert			EASILY MISSED? Coarctation of the aorta in the newborn	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONGENITAL HEART-DISEASE; INFANCY; MALFORMATIONS; MANAGEMENT		[Punukollu, Mallika] Gartnavel Royal Hosp, Kershaw Unit, Glasgow G12 0XH, Lanark, Scotland; [Harnden, Anthony] Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England; [Tulloh, Robert] Univ Hosp Bristol NHS Fdn Trust, Bristol Congenital Heart Ctr, Bristol BS2 8BJ, Avon, England	Gartnavel Royal Hospital; University of Oxford; University of Bristol	Punukollu, M (corresponding author), Gartnavel Royal Hosp, Kershaw Unit, Glasgow G12 0XH, Lanark, Scotland.	mpunukollu@gmail.com		Tulloh, Robert/0000-0002-3180-6993				ABUHARB M, 1994, ARCH DIS CHILD-FETAL, V71, pF179, DOI 10.1136/fn.71.3.F179; ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; Ainsworth SB, 1999, ARCH DIS CHILD-FETAL, V80, pF43, DOI 10.1136/fn.80.1.F43; Chang RKR, 2008, ARCH PEDIAT ADOL MED, V162, P969, DOI 10.1001/archpedi.162.10.969; Crossland DS, 2004, ARCH DIS CHILD-FETAL, V89, pF325, DOI 10.1136/adc.2003.034322; de-Wahl Granelli Anne, 2009, BMJ, V338, pa3037, DOI 10.1136/bmj.a3037; Deanfield J, 2003, EUR HEART J, V24, P1035, DOI 10.1016/S0195-668X(03)00131-3; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; Gregory J, 1999, ARCH DIS CHILD, V80, pF46, DOI 10.1136/fn.80.1.F46; Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7; Ing FF, 1996, PEDIATRICS, V98, P378; Knowles R, 2005, HEALTH TECHNOL ASSES, V9, P1; Massin MM, 2006, POSTGRAD MED J, V82, P468, DOI 10.1136/pgmj.2005.044495; MENON G, 1985, ARCH DIS CHILD, V60, P1134, DOI 10.1136/adc.60.12.1134; National Institute for Health and Clinical Excellence, 2006, POSTN CAR ROUT POSTN; PRESBITERO P, 1987, BRIT HEART J, V57, P462; Rao P Syamasundar, 2005, Curr Cardiol Rep, V7, P425, DOI 10.1007/s11886-005-0060-0; Roos-Hesselink JW, 2003, HEART, V89, P1074, DOI 10.1136/heart.89.9.1074; STEWART AB, 1993, BRIT HEART J, V69, P65; Tank S, 2004, BOMBAY HOSP J, V46, P141; Turkvatan A, 2009, DIAGN INTERV RADIOL, V15, P269, DOI 10.4261/1305-3825.DIR.2434-08.1; WARD KE, 1990, PEDIATRICS, V86, P972; Warnes CA, 2008, CIRCULATION, V118, P2395, DOI [10.1161/CIRCULATIONAHA.108.190811, 10.1016/j.jacc.2008.10.001]; Wren C, 1999, ARCH DIS CHILD-FETAL, V80, pF49, DOI 10.1136/fn.80.1.F49	24	0	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2011	343								d6838	10.1136/bmj.d6838	http://dx.doi.org/10.1136/bmj.d6838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LV	22088486				2022-12-28	WOS:000297497100001
J	Oldgren, J; Alings, M; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Reilly, PA; Yang, S; Yusuf, S; Wallentin, L; Connolly, SJ				Oldgren, Jonas; Alings, Marco; Darius, Harald; Diener, Hans-Christoph; Eikelboom, John; Ezekowitz, Michael D.; Kamensky, Gabriel; Reilly, Paul A.; Yang, Sean; Yusuf, Salim; Wallentin, Lars; Connolly, Stuart J.		RE-LY Investigators	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS(2) Score: A Subgroup Analysis of the RE-LY Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ANTICOAGULATION; ANTITHROMBOTIC TREATMENT; EUROPEAN-SOCIETY; TASK-FORCE; THERAPY; GUIDELINES; MANAGEMENT; SCHEMES; ASPIRIN; EVENTS	Background: CHADS(2) is a simple, validated risk score for predicting the risk for stroke in patients with atrial fibrillation not treated with anticoagulants. There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS(2) score in patients receiving anticoagulant therapy. Objective: To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran. Design: Subgroup analysis of a randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00262600) Setting: Multinational study setting. Patients: 18 112 patients with atrial fibrillation who were receiving oral anticoagulants. Measurements: Baseline CHADS(2) score, which assigns 1 point each for congestive heart failure, hypertension, age 75 years or older, and diabetes mellitus and 2 points for stroke. Results: Distribution of CHADS(2) scores were as follows: 0 to 1-5775 patients; 2-6455 patients; and 3 to 6-5882 patients. Annual rates of the primary outcome of stroke or systemic embolism among all participants were 0.93% in patients with a CHADS(2) score of 0 to 1, 1.22% in those with a score of 2, and 2.24% in those with a score of 3 to 6. Annual rates of other outcomes among all participants with CHADS(2) scores of 0 to 1, 2, and 3 to 6, respectively, were the following: major bleeding, 2.26%, 3.11%, and 4.42%; intracranial bleeding, 0.31%, 0.40%, and 0.61%; and vascular mortality, 1.35%, 2.39%, and 3.68% (P < 0.001 for all comparisons). Rates of stroke or systemic embolism, major and intracranial bleeding, and vascular and total mortality each increased in the warfarin and dabigatran groups as CHADS(2) score increased. The rates of stroke or systemic embolism with dabigatran, 150 mg twice daily, and of intracranial bleeding with dabigatran, 150 mg or 110 mg twice daily, were lower than those with warfarin; there was no significant heterogeneity in subgroups defined by CHADS(2) scores. Limitation: These analyses were not prespecified and should be deemed exploratory. Conclusion: Higher CHADS(2) scores were associated with increased risks for stroke or systemic embolism, bleeding, and death in patients with atrial fibrillation receiving oral anticoagulants.	[Oldgren, Jonas] Uppsala Univ, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Med Sci, S-75185 Uppsala, Sweden; Working Grp Cardiovasc Res, Utrecht, Netherlands; Vivantes Klinikum Neukolln, D-12351 Berlin, Germany; Univ Duisburg Essen, Duisburg, Germany; Univ Duisburg Essen, Essen, Germany; McMaster Univ, Hamilton, ON L8L 2X2, Canada; Populat Hlth Res Inst, Hamilton, ON, Canada; Lankenau Inst Med Res, Wynnewood, PA USA; Ctr Heart, Wynnewood, PA USA; Univ Hosp Bratislava, Bratislava 82606, Slovakia; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	Uppsala University; Uppsala University; VIivantes Klinikum Neukolln; University of Duisburg Essen; University of Duisburg Essen; McMaster University; Population Health Research Institute; Lankenau Medical Center; Lankenau Institute for Medical Research; Slovak Medical University Bratislava; Boehringer Ingelheim	Oldgren, J (corresponding author), Uppsala Univ, Uppsala Clin Res Ctr, S-75185 Uppsala, Sweden.	Jonas.Oldgren@ucr.uu.se	Eikelboom, John/AAG-6117-2019; Ezekowitz, Michael/AAJ-2543-2021; Diener, Hans-Christoph/AAF-7275-2019	Eikelboom, John/0000-0003-4126-1285; Yusuf, Salim/0000-0003-4776-5601	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	Primary Funding Source: Boehringer Ingelheim.	Baruch L, 2007, STROKE, V38, P2459, DOI 10.1161/STROKEAHA.106.477133; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Crandall MA, 2009, PACE, V32, P981, DOI 10.1111/j.1540-8159.2009.02427.x; Devereaux PJ, 2001, BMJ-BRIT MED J, V323, P1218, DOI 10.1136/bmj.323.7323.1218; Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005; Fang MC, 2008, J AM COLL CARDIOL, V51, P810, DOI 10.1016/j.jacc.2007.09.065; Friberg L, 2010, EUR HEART J, V31, P967, DOI 10.1093/eurheartj/ehn599; Fuster V, 2006, EUR HEART J, V27, P1979, DOI 10.1093/eurheartj/ehl176; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gattellari M, 2008, STROKE, V39, P227, DOI 10.1161/STROKEAHA.107.495036; Gorin L, 2010, THROMB HAEMOSTASIS, V103, P833, DOI 10.1160/TH09-10-0746; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hart RG, 2008, STROKE, V39, P1901, DOI 10.1161/STROKEAHA.107.501825; Hart RG, 2007, NEUROLOGY, V69, P546; Healey JS, 2008, STROKE, V39, P1482, DOI 10.1161/STROKEAHA.107.500199; Henriksson KM, 2010, INT J CARDIOL, V141, P18, DOI 10.1016/j.ijcard.2008.11.122; Hohnloser SH, 2007, J AM COLL CARDIOL, V50, P2156, DOI 10.1016/j.jacc.2007.07.076; Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONAHA.106.653048; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lee BH, 2010, J CARDIOVASC ELECTR, V21, P501, DOI 10.1111/j.1540-8167.2009.01661.x; Nieuwlaat R, 2006, EUR HEART J, V27, P3018, DOI 10.1093/eurheartj/ehl015; Poli D, 2007, THROMB RES, V121, P347, DOI 10.1016/j.thromres.2007.05.014; Rietbrock S, 2008, AM HEART J, V156, P57, DOI 10.1016/j.ahj.2008.03.010; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Ortiz MR, 2010, CARDIOLOGY, V115, P200, DOI 10.1159/000284450; Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678; Zimetbaum PJ, 2010, AM J MED, V123, P446, DOI 10.1016/j.amjmed.2009.11.015	30	164	169	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10					660	+		10.7326/0003-4819-155-10-201111150-00004	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EI	22084332				2022-12-28	WOS:000297108000002
J	Wysocki, A; Butler, M; Shamliyan, T; Kane, RL				Wysocki, Andrea; Butler, Mary; Shamliyan, Tatyana; Kane, Robert L.			Whole-Body Vibration Therapy for Osteoporosis: State of the Science	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MINERAL DENSITY; LOW-BACK-PAIN; LOW-LEVEL; LOW-MAGNITUDE; POSTMENOPAUSAL WOMEN; MUSCLE-ACTIVITY; FRACTURE RISK; HORMONAL RESPONSES; MECHANICAL SIGNALS; EXERCISE	Clinical guidelines for osteoporosis recommend dietary and pharmacologic interventions and weight-bearing exercise to prevent bone fractures. These interventions sometimes have low adherence and can cause adverse effects. A proposed alternative or adjunctive treatment is whole-body vibration therapy (WBV), in which energy produced by a forced oscillation is transferred to an individual from a mechanical vibration platform. Whole-body vibration platforms are not approved by the U.S. Food and Drug Administration for medical purposes. This review provides a broad overview of important issues related to WBV therapy for prevention and treatment of osteoporosis. Relying on key informants and a search of the gray and published literature from January 2000 to August 2011, the investigators found that the designs of WBV platforms and protocols for their use vary widely. The optimal target population for the therapy is not defined. Although WBV has some theoretical advantages, key informants have voiced several concerns, including uncertain safety and potential consumer confusion between low-intensity vibration platforms intended for osteoporosis therapy and high-intensity platforms intended for exercise. Finally, the scant literature did not establish whether WBV therapy leads to clinically important increases in bone mineral density or reduces risk for fracture.	[Kane, Robert L.] Univ Minnesota, Sch Publ Hlth, Minnesota Evidence Based Practice Ctr, 420 Delaware St SE,MMC 197 Mayo, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kane, RL (corresponding author), Univ Minnesota, Sch Publ Hlth, Minnesota Evidence Based Practice Ctr, 420 Delaware St SE,MMC 197 Mayo, Minneapolis, MN 55455 USA.	kanex001@umn.edu	Shamliyan, Tatyana/AAU-8323-2020	Shamliyan, Tatyana/0000-0003-3584-2008	Minnesota Evidence-based Practice Center [HHSA 2 902 007 100 641]	Minnesota Evidence-based Practice Center	This project was conducted by the Minnesota Evidence-based Practice Center under contract to AHRQ (contract HHSA 2 902 007 100 641).	[Anonymous], VIBES LOW MAGNITUDE; [Anonymous], INFLUENCE VIBRATION; [Anonymous], EFFECTS WHOLE BODY V; Bemben DA, 2010, BONE, V47, P650, DOI 10.1016/j.bone.2010.06.019; Bosco C, 2000, EUR J APPL PHYSIOL, V81, P449, DOI 10.1007/s004210050067; Bruyere O, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-165; Calonge N, 2011, ANN INTERN MED, V154, P356, DOI 10.7326/0003-4819-154-5-201103010-00307; Cardinale M, 2005, BRIT J SPORT MED, V39, P585, DOI 10.1136/bjsm.2005.016857; Cardinale M., 2003, Acta Physiologica Hungarica, V90, P195, DOI 10.1556/APhysiol.90.2003.3.2; Cardinale M, 2003, J STRENGTH COND RES, V17, P621; Compston J, 2009, MATURITAS, V62, P105, DOI 10.1016/j.maturitas.2008.11.022; DANDANELL R, 1986, SCAND J WORK ENV HEA, V12, P338, DOI 10.5271/sjweh.2133; Eisman JA, 2001, LANCET, V358, P1924, DOI 10.1016/S0140-6736(01)06975-6; Erskine J, 2007, CLIN PHYSIOL FUNCT I, V27, P242, DOI 10.1111/j.1475-097X.2007.00745.x; Ezenwa B, 2008, IEEE ENG MED BIO, P4186, DOI 10.1109/IEMBS.2008.4650132; Flinn ED, 2002, AEROSPACE AM, V40, P16; Fritton JC, 1997, ANN BIOMED ENG, V25, P831, DOI 10.1007/BF02684167; Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612; Green J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4444; Gusi N, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-92; Hamdy R, 2010, SOUTH MED J, V103, P103, DOI 10.1097/SMJ.0b013e3181ca3749; Hazell TJ, 2010, J STRENGTH COND RES, V24, P1860, DOI 10.1519/JSC.0b013e3181ddf6c8; Hourigan SR, 2008, OSTEOPOROSIS INT, V19, P1077, DOI 10.1007/s00198-007-0541-7; International Organization for Standardization, 1997, MECH VIBR SHOCK EV 1; Ito M, 1997, OSTEOPOROSIS INT, V7, P120, DOI 10.1007/BF03194357; Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157; Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kerschan-Schindl K, 2001, CLIN PHYSIOL, V21, P377, DOI 10.1046/j.1365-2281.2001.00335.x; Kim SY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2938; Korpelainen R, 2006, J BONE MINER RES, V21, P772, DOI 10.1359/JBMR.060116; Lewis RD, 1998, INT J SPORT NUTR, V8, P250, DOI 10.1123/ijsn.8.3.250; Lim LS, 2009, AM J PREV MED, V36, P366, DOI 10.1016/j.amepre.2009.01.013; Lings S, 2000, INT ARCH OCC ENV HEA, V73, P290, DOI 10.1007/s004200000118; Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706; Lord SR, 1996, OSTEOPOROSIS INT, V6, P361, DOI 10.1007/BF01623009; MATOBA T, 1989, Journal of UOEH, V11, P96; Office of the Surgeon General (US), 2004, BON HLTH OST REP SUR; Park H, 2008, J BONE MINER METAB, V26, P254, DOI 10.1007/s00774-007-0819-z; Pitukcheewanont P, 2006, ENDOCRINOLOGIST, V16, P128, DOI 10.1097/01.ten.0000217885.60398.27; Pollock RD, 2010, CLIN BIOMECH, V25, P840, DOI 10.1016/j.clinbiomech.2010.05.004; Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003-4819-149-6-200809160-00007; Rauch F, 2010, J MUSCULOSKEL NEURON, V10, P193; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; Rizzoli R, 2010, BONE, V46, P294, DOI 10.1016/j.bone.2009.10.005; Roelants M, 2006, J STRENGTH COND RES, V20, P124, DOI 10.1519/R-16674.1; Ruan XY, 2008, CHINESE MED J-PEKING, V121, P1155, DOI 10.1097/00029330-200807010-00001; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2003, SPINE, V28, P2621, DOI 10.1097/01.BRS.0000102682.61791.C9; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; Russo CR, 2003, ARCH PHYS MED REHAB, V84, P1854, DOI 10.1016/S0003-9993(03)00357-5; SEIDEL H, 1988, INT ARCH OCC ENV HEA, V61, P95, DOI 10.1007/BF00381613; Semler O, 2008, CLIN REHABIL, V22, P387, DOI 10.1177/0269215507080763; Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253; Taggart H, 2002, MAYO CLIN PROC, V77, P262, DOI 10.4065/77.3.262; Tanaka SM, 2002, FASEB J, V16, P313, DOI 10.1096/fj.02-0561fje; Tiemessen IJH, 2008, OCCUP ENVIRON MED, V65, P667, DOI 10.1136/oem.2007.035147; Torvinen S, 2002, CLIN PHYSIOL FUNCT I, V22, P145, DOI 10.1046/j.1365-2281.2002.00410.x; van Duijnhoven NTL, 2010, J APPL PHYSIOL, V108, P28, DOI 10.1152/japplphysiol.00760.2009; Vela JI, 2010, J CATARACT REFR SURG, V36, P1790, DOI 10.1016/j.jcrs.2010.07.001; Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245; von Stengel S, 2011, OSTEOPOROSIS INT, V22, P317, DOI 10.1007/s00198-010-1215-4; Walker-Bone K, 2002, OCCUP MED-OXFORD, V52, P441, DOI 10.1093/occmed/52.8.441; Ward K, 2004, J BONE MINER RES, V19, P360, DOI 10.1359/JBMR.040129; Watts NB, 2008, J CLIN DENSITOM, V11, P473, DOI 10.1016/j.jocd.2008.04.003; Xie LQ, 2008, J APPL PHYSIOL, V104, P1056, DOI 10.1152/japplphysiol.00764.2007; Xie LQ, 2006, BONE, V39, P1059, DOI 10.1016/j.bone.2006.05.012	67	59	68	1	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10					680	+		10.7326/0003-4819-155-10-201111150-00006	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-00006			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EI	22084334				2022-12-28	WOS:000297108000004
J	Heath, I				Heath, Iona			LIFE AND DEATH Words are all we have	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath22@yahoo.co.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2011	343								d7166	10.1136/bmj.d7166	http://dx.doi.org/10.1136/bmj.d7166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NP	22074714				2022-12-28	WOS:000297058600015
J	Mermin, J; Ekwaru, JP; Were, W; Degerman, R; Bunnell, R; Kaharuza, F; Downing, R; Coutinho, A; Solberg, P; Alexander, LN; Tappero, J; Campbell, J; Moore, DM				Mermin, Jonathan; Ekwaru, John P.; Were, Willy; Degerman, Richard; Bunnell, Rebecca; Kaharuza, Frank; Downing, Robert; Coutinho, Alex; Solberg, Peter; Alexander, Lorraine N.; Tappero, Jordan; Campbell, James; Moore, David M.			Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							RESOURCE-LIMITED SETTINGS; SUB-SAHARAN AFRICA; HIGH-INCOME COUNTRIES; FOLLOW-UP; HIV-1-INFECTED PATIENTS; SCALING-UP; COLLABORATIVE ANALYSIS; INCREASED MORTALITY; TREATMENT PROGRAMS; DRUG-RESISTANCE	Objective To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients receiving antiretroviral therapy (ART) in Uganda. Design Randomised clinical trial Setting A home based ART programme in rural Uganda. Participants All participants were people with HIV who were members of the AIDS Support Organisation. Participants had CD4 cell counts <250 cells x 10(6)/L or World Health Organization stage 3 or 4 disease. Interventions Participants were randomised to one of three different monitoring arms: a viral load arm (clinical monitoring, quarterly CD4 counts, and viral load measurements), CD4 arm (clinical monitoring and CD4 counts), or clinical arm (clinical monitoring alone). Main outcome measures Serious morbidity (newly diagnosed AIDS defining illness) and mortality. Results 1094 participants started ART; median CD4 count at baseline was 129 cells x 106/L. Median follow-up was three years. In total, 126 participants died (12%), 148 (14%) experienced new AIDS defining illnesses, and 61(6%) experienced virological failure, defined as two consecutive viral loads >500 copies/mL occurring more than three months after the start of ART. After adjustment for age, sex, baseline CD4 count, viral load, and body mass index, the rate of new AIDS defining events or death was higher in the clinical arm than the viral load arm (adjusted hazard ratio 1.83, P=0.002) or the CD4 arm (1.49, P=0.032). There was no significant difference between the CD4 arm and the viral load arm (1.23, P=0.31). Conclusion In patients receiving ART for HIV infection in Uganda, routine laboratory monitoring is associated with improved health and survival compared with clinical monitoring alone.	[Moore, David M.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Bunnell, Rebecca] Ctr Dis Control & Prevent CDC Uganda, Global AIDS Program, Div Community Hlth, Entebbe, Uganda; [Kaharuza, Frank] Ctr Dis Control & Prevent CDC Uganda, Global AIDS Program, Epidemiol Branch, Entebbe, Uganda; [Alexander, Lorraine N.] Ctr Dis Control & Prevent CDC Uganda, Global AIDS Program, Hlth Serv, Entebbe, Uganda; [Tappero, Jordan] Ctr Dis Control & Prevent CDC Uganda, Global AIDS Program, Hlth Syst Reconstruct Off, Entebbe, Uganda; [Mermin, Jonathan; Moore, David M.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA; [Bunnell, Rebecca] CDC, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Community Hlth, Atlanta, GA 30333 USA; [Coutinho, Alex] AIDS Support Org, Kampala, Uganda; [Moore, David M.] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of British Columbia	Moore, DM (corresponding author), BC Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC, Canada.	dmoore@cfenet.ubc.ca	Mermin, Jonathan/J-9847-2012		US Centers for Disease Control and Prevention; US Agency for International Development; President's Emergency Plan for AIDS Relief; Canadian Institutes for Health Research	US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Agency for International Development(United States Agency for International Development (USAID)); President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by the US Centers for Disease Control and Prevention, the US Agency for International Development, and the President's Emergency Plan for AIDS Relief. US Centers for Disease Control and Prevention staff and other investigators were involved in the study design and implementation, data analysis, and writing of thepaper. The findings and conclusions are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: JM, JPE, WW, RD, RB, FK, RD, PS, LNA, JT, DMM had support from the US Center for Disease Control for the submitted work. AC received no direct support for this study; DMM also received support from the Canadian Institutes for Health Research through a New Investigator Award; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Bagchi S, 2007, CLIN INFECT DIS, V44, P135, DOI 10.1086/510072; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Bisson GP, 2006, AIDS, V20, P1613, DOI 10.1097/01.aids.0000238407.00874.dc; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brigido L, 2004, AIDS PATIENT CARE ST, V18, P189, DOI 10.1089/108729104323038865; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Chang LVW, 2009, JAIDS-J ACQ IMM DEF, V50, P276, DOI 10.1097/QAI.0b013e3181988375; Chen SCC, 2008, TROP MED INT HEALTH, V13, P513, DOI 10.1111/j.1365-3156.2008.02029.x; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Harries AD, 2006, LANCET, V367, P1870, DOI 10.1016/S0140-6736(06)68809-0; Hoffmann CJ, 2009, CLIN INFECT DIS, V49, P1928, DOI 10.1086/648444; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Kahn JG, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6884; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; Kamya MR, 2007, JAIDS-J ACQ IMM DEF, V46, P187, DOI 10.1097/QAI.0b013e31814278c0; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Koenig SP, 2006, BMJ-BRIT MED J, V332, P602, DOI 10.1136/bmj.332.7541.602; Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/00002030-200406003-00005; Kumarasamy N, 2004, LANCET, V364, P3, DOI 10.1016/S0140-6736(04)16605-1; Lai TL, 2006, STAT MED, V25, P1149, DOI 10.1002/sim.2357; Lohse N, 2006, CLIN INFECT DIS, V42, P136, DOI 10.1086/498515; Lundgren JD, 2008, J INFECT DIS, V197, P1145, DOI 10.1086/529523; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; MOORE D, 2006, 16 INT AIDS C TOR CA; Moore DM, 2006, JAIDS-J ACQ IMM DEF, V43, P436, DOI 10.1097/01.qai.0000243105.80393.42; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Nicastri E, 2005, J MED VIROL, V76, P153, DOI 10.1002/jmv.20352; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Reynolds SJ, 2009, ANTIVIR THER, V14, P293; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Samb B, 2007, NEW ENGL J MED, V357, P2510, DOI 10.1056/NEJMsb071889; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Tuboi SH, 2007, JAIDS-J ACQ IMM DEF, V45, P52, DOI 10.1097/QAI.0b013e318042e1c3; UNAIDS, 2010, REP GLOB AIDS EP 201; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; WHO, 2010, ANT THER HIV INF AD; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; World Health Organization, 2008, UN ACC SCAL PRIOR HI	46	91	96	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2011	343								d6792	10.1136/bmj.d6792	http://dx.doi.org/10.1136/bmj.d6792			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848NP	22074711	Green Published, hybrid			2022-12-28	WOS:000297058600003
J	Branco, T				Branco, Tiago			The Language of Dendrites	SCIENCE			English	Editorial Material									UCL, London WC1E 6BT, England	University of London; University College London	Branco, T (corresponding author), UCL, Mortimer St, London WC1E 6BT, England.	t.branco@ucl.ac.uk	Branco, Tiago/C-1503-2008					BLOOMFIELD S, 1974, BRAIN RES, V69, P115; Branco T, 2008, NEURON, V59, P475, DOI 10.1016/j.neuron.2008.07.006; Branco T, 2011, NEURON, V69, P885, DOI 10.1016/j.neuron.2011.02.006; Branco T, 2010, SCIENCE, V329, P1671, DOI 10.1126/science.1189664; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02478259; Rall W, 1964, NEURAL THEORY MODELI, P73	7	0	0	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					615	616		10.1126/science.1215079	http://dx.doi.org/10.1126/science.1215079			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053040				2022-12-28	WOS:000296494700041
J	Sorror, ML; Sandmaier, BM; Storer, BE; Franke, GN; Laport, GG; Chauncey, TR; Agura, E; Maziarz, RT; Langston, A; Hari, P; Pulsipher, MA; Bethge, W; Sahebi, F; Bruno, B; Maris, MB; Yeager, A; Petersen, FB; Vindelov, L; McSweeney, PA; Hubel, K; Mielcarek, M; Georges, GE; Niederwieser, D; Blume, KG; Maloney, DG; Storb, R				Sorror, Mohamed L.; Sandmaier, Brenda M.; Storer, Barry E.; Franke, Georg N.; Laport, Ginna G.; Chauncey, Thomas R.; Agura, Edward; Maziarz, Richard T.; Langston, Amelia; Hari, Parameswaran; Pulsipher, Michael A.; Bethge, Wolfgang; Sahebi, Firoozeh; Bruno, Benedetto; Maris, Michael B.; Yeager, Andrew; Petersen, Finn Bo; Vindelov, Lars; McSweeney, Peter A.; Huebel, Kai; Mielcarek, Marco; Georges, George E.; Niederwieser, Dietger; Blume, Karl G.; Maloney, David G.; Storb, Rainer			Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE; MARROW TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; COMORBIDITY INDEX; RISK-ASSESSMENT; FLOW-CYTOMETRY; AGE; METHOTREXATE	Context A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions. Objective To describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic HCT. Design, Setting, and Participants From 1998 to 2008, 372 patients aged 60 to 75 years were enrolled in prospective clinical HCT trials at 18 collaborating institutions using conditioning with low-dose total body irradiation alone or combined with fludarabine, 90 mg/m(2), before related (n=184) or unrelated (n=188) donor transplants. Postgrafting immunosuppression included mycophenolate mofetil and a calcineurin inhibitor. Main Outcome Measures Overall and progression-free survival were estimated by Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic graft-vs-host disease, toxicities, achievement of full donor chimerism, complete remission, relapse, and nonrelapse mortality. Hazard ratios (HRs) were estimated from Cox regression models. Results Overall, 5-year cumulative incidences of nonrelapse mortality and relapse were 27% (95% CI, 22%-32%) and 41% (95% CI, 36%-46%), respectively, leading to 5-year overall and progression-free survival of 35% (95% CI, 30%-40%) and 32% (95% CI, 27%-37%), respectively. These outcomes were not statistically significantly different when stratified by age groups. Furthermore, increasing age was not associated with increases in acute or chronic graft-vs-host disease or organ toxicities. In multivariate models, HCT-specific comorbidity index scores of 1 to 2 (HR, 1.58 [95% CI, 1.08-2.31]) and 3 or greater (HR, 1.97 [95% CI, 1.38-2.80]) were associated with worse survival compared with an HCT-specific comorbidity index score of 0 (P=.003 overall). Similarly, standard relapse risk (HR, 1.67 [95% CI, 1.10-2.54]) and high relapse risk (HR, 2.22 [95% CI, 1.43-3.43]) were associated with worse survival compared with low relapse risk (P<.001 overall). Conclusion Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively. JAMA. 2011; 306(17): 1874-1883	[Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Program, Seattle, WA 98109 USA; [Storer, Barry E.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Clin Stat Program, Seattle, WA 98109 USA; [Sorror, Mohamed L.; Sandmaier, Brenda M.; Chauncey, Thomas R.; Mielcarek, Marco; Georges, George E.; Maloney, David G.; Storb, Rainer] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA; [Storer, Barry E.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Marrow Transplant Unit, Seattle, WA USA; [Franke, Georg N.; Niederwieser, Dietger] Univ Leipzig, Dept Med, Div Hematol Oncol & Hemostaseol, Leipzig, Germany; [Laport, Ginna G.; Blume, Karl G.] Stanford Sch Med, Div Blood & Marrow Transplantat, Dept Med, Stanford, CA USA; [Agura, Edward] Baylor Univ, Hematopoiet Stem Cell Program, Sch Med, Dallas, TX USA; [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Hematopoiet Stem Cell Transplant Program, Portland, OR 97201 USA; [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Ctr Hematol Malignancies, Knight Canc Inst, Portland, OR 97201 USA; [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Sch Med, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Langston, Amelia] Emory Univ, Sch Med, Div Hematol Oncol, Atlanta, GA USA; [Langston, Amelia] Emory Univ, Bone Marrow & Stem Cell Transplant Ctr, Winship Canc Inst, Atlanta, GA 30322 USA; [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Sch Med, Milwaukee, WI 53226 USA; [Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol Blood & Marrow Transplantat, Salt Lake City, UT USA; [Pulsipher, Michael A.] Primary Childrens Med Ctr, Pediat Blood & Marrow Transplant Program, Huntsman Canc Inst, Salt Lake City, UT 84103 USA; [Bethge, Wolfgang] Univ Tubingen, Sch Med, Tubingen, Germany; [Sahebi, Firoozeh] City Hope Sch Med, Duarte, CA USA; [Bruno, Benedetto] Univ Turin, Sch Med, Turin, Italy; [Maris, Michael B.; McSweeney, Peter A.] Colorado Blood Canc Inst, Denver, CO USA; [Yeager, Andrew] Univ Arizona, Sch Med, Dept Med & Pediat, Tucson, AZ USA; [Petersen, Finn Bo] Intermt Hlth Care, Intermt Blood & Marrow Transplant Acute Leukemia, Salt Lake City, UT USA; [Petersen, Finn Bo] Univ Aarhus, Sch Med, Aarhus, Denmark; [Vindelov, Lars] Rigshosp, Hematopoiet Cell Transplantat Program, Dept Hematol, DK-2100 Copenhagen, Denmark; [McSweeney, Peter A.] Univ Colorado, Sch Med, Boulder, CO 80309 USA; [Huebel, Kai] Univ Cologne, Dept Internal Med, Sch Med, Stem Cell Transplant Program, Cologne, Germany	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Leipzig University; Stanford University; Baylor University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Emory University; Emory University; Medical College of Wisconsin; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Eberhard Karls University of Tubingen; University of Turin; University of Arizona; Intermountain Healthcare; Aarhus University; Rigshospitalet; University of Copenhagen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Cologne	Sorror, ML (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div D1 100, 1100 Fairview Ave N, Seattle, WA 98109 USA.	msorror@fhcrc.org	Franke, Georg-Nikolaus/AAB-6922-2022; Chauncey, Thomas/AAK-1331-2021	Chauncey, Thomas/0000-0003-2815-7301; Hari, Parameswaran/0000-0002-8800-297X; Bruno, Benedetto/0000-0002-7299-6770	Japanese Heath Sciences; Athersys Inc; BMT/CTN; Medac GmbH; Fresenius GmbH; Pfizer; Miltenyi Biotech GmbH; Millennium Pharmaceuticals; Danish Cancer Society; Lundbeck Foundation; Research Council of Rigshospitalet; Region of the Capital of Denmark; National Institutes of Health (NIH) [P01HL036444, P01CA078902, P01CA018029, P30CA015704, R00HL088021]; Leukemia/Lymphoma Society [7008-08]; NATIONAL CANCER INSTITUTE [P01CA078902, P30CA015704, P01CA018029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444, R00HL088021] Funding Source: NIH RePORTER	Japanese Heath Sciences; Athersys Inc; BMT/CTN; Medac GmbH; Fresenius GmbH; Pfizer(Pfizer); Miltenyi Biotech GmbH; Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Research Council of Rigshospitalet; Region of the Capital of Denmark; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia/Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sandmaier reported serving on the board of ArevaMed. Dr Franke reported receiving travel/accommodations/meeting expenses for the European Group of Blood and Marrow Transplantation 2009 meeting. Dr Maziarz reported receiving grants or grants pending (grant money to institution) from Japanese Heath Sciences, Athersys Inc, and BMT/CTN; serving on the speakers bureaus of Millennium Pharmaceuticals Inc and Genzyme Inc; receiving royalties from Springer for publication of a book; and receiving honoraria for lectures (groups change yearly; usually related to community oncology educational efforts). Dr Bethge reported serving as a consultant for Miltenyi Biotech GmbH; receiving grants or grants pending from Medac GmbH, Fresenius GmbH, Pfizer, and Miltenyi Biotech GmbH; receiving payment for lectures from Miltenyi Biotech GmbH; and receiving travel/accommodations/meeting expenses from Medac GmbH. Dr Sahebi reported receiving travel/accommodations/meeting expenses and a research fund from Millennium Pharmaceuticals. Dr Vindelov reported receiving research grants from the Danish Cancer Society, The Lundbeck Foundation, and the Research Council of Rigshospitalet and receiving a travel and research grant from the Region of the Capital of Denmark. No other authors reported disclosures.; Research for this study has been supported by grants from the National Institutes of Health (NIH) (P01HL036444, P01CA078902, P01CA018029, P30CA015704, and R00HL088021) and from the Leukemia/Lymphoma Society (7008-08).	Al-Mawali A, 2009, AM J CLIN PATHOL, V131, P16, DOI 10.1309/AJCP5TSD3DZXFLCX; [Anonymous], 2008, US CANC STAT 1999 20; [Anonymous], CANC STAT REV SEER 1; Appelbaum FR, 2006, BLOOD, V107, P3481, DOI 10.1182/blood-2005-09-3724; Baron F, 2005, J CLIN ONCOL, V23, P1993, DOI 10.1200/JCO.2005.08.136; Bottcher S, 2004, LEUKEMIA, V18, P1637, DOI 10.1038/sj.leu.2403478; Castermans E, 2011, HAEMATOL-HEMATOL J, V96, P298, DOI 10.3324/haematol.2010.029702; Couper D, 1997, STAT MED, V16, P1551, DOI 10.1002/(SICI)1097-0258(19970730)16:14<1551::AID-SIM577>3.0.CO;2-T; Estey E, 2007, BLOOD, V109, P1395, DOI 10.1182/blood-2006-05-021907; Fried LP, 1999, J CLIN EPIDEMIOL, V52, P27, DOI 10.1016/S0895-4356(98)00124-3; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Gooley TA, 2010, NEW ENGL J MED, V363, P2091, DOI 10.1056/NEJMoa1004383; Gratwohl A, 1998, LANCET, V352, P1087, DOI 10.1016/S0140-6736(98)03030-X; Kahl C, 2007, BLOOD, V110, P2744, DOI 10.1182/blood-2007-03-078592; Kantarjian H, 2010, BLOOD, V116, P4422, DOI 10.1182/blood-2010-03-276485; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Kersey JH, 2010, NEW ENGL J MED, V363, P2158, DOI 10.1056/NEJMe1010818; Lim Z, 2010, J CLIN ONCOL, V28, P405, DOI 10.1200/JCO.2009.21.8073; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; Maris M, 2003, EXP HEMATOL, V31, P941, DOI 10.1016/S0301-472X(03)00201-7; Maris MB, 2003, BLOOD, V102, P2021, DOI 10.1182/blood-2003-02-0482; McClune BL, 2010, J CLIN ONCOL, V28, P1878, DOI 10.1200/JCO.2009.25.4821; McSweeney PA, 2001, BLOOD, V97, P3390, DOI 10.1182/blood.V97.11.3390; Pasquini MC, 2010, CURRENT USE OUTCOME; Petersdorf EW, 1998, BLOOD, V92, P3515, DOI 10.1182/blood.V92.10.3515.422k49_3515_3520; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rezvani AR, 2009, BLOOD, V114, P471; Rotta M, 2010, BLOOD, V115, P1288, DOI 10.1182/blood-2009-08-240358; Smith BD, 2009, J CLIN ONCOL, V27, P2758, DOI 10.1200/JCO.2008.20.8983; Sorror ML, 2009, BIOL BLOOD MARROW TR, V15, P66, DOI 10.1016/j.bbmt.2008.12.206; Sorror ML, 2005, BIOL BLOOD MARROW TR, V11, P814, DOI 10.1016/j.bbmt.2005.05.016; Sorror ML, 2005, BIOL BLOOD MARROW TR, V11, P567, DOI 10.1016/j.bbmt.2005.03.004; Sorror ML, 2005, BLOOD, V106, P2912, DOI 10.1182/blood-2005-05-2004; Sorror ML, 2007, BLOOD, V110, P4606, DOI 10.1182/blood-2007-06-096966; Stewart BL, 2004, BLOOD, V104, P3501, DOI 10.1182/blood-2004-01-0200; Sullivan KM, 1999, HEMATOPOIETIC CELL T, P515; VOSE JM, 1992, BLOOD, V80, P2142; Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432-2277.2009.00927.x	38	206	210	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1874	1883		10.1001/jama.2011.1558	http://dx.doi.org/10.1001/jama.2011.1558			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045765	Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000296376200021
J	Pickard, G; Pan, W; Rahwan, I; Cebrian, M; Crane, R; Madan, A; Pentland, A				Pickard, Galen; Pan, Wei; Rahwan, Iyad; Cebrian, Manuel; Crane, Riley; Madan, Anmol; Pentland, Alex			Time-Critical Social Mobilization	SCIENCE			English	Article							SEARCH	The World Wide Web is commonly seen as a platform that can harness the collective abilities of large numbers of people to accomplish tasks with unprecedented speed, accuracy, and scale. To explore the Web's ability for social mobilization, the Defense Advanced Research Projects Agency (DARPA) held the DARPA Network Challenge, in which competing teams were asked to locate 10 red weather balloons placed at locations around the continental United States. Using a recursive incentive mechanism that both spread information about the task and incentivized individuals to act, our team was able to find all 10 balloons in less than 9 hours, thus winning the Challenge. We analyzed the theoretical and practical properties of this mechanism and compared it with other approaches.	[Pickard, Galen; Pan, Wei; Rahwan, Iyad; Cebrian, Manuel; Crane, Riley; Madan, Anmol; Pentland, Alex] MIT, Media Lab, Cambridge, MA 02139 USA; [Pickard, Galen] MIT, Lincoln Lab, Lexington, MA 02420 USA; [Rahwan, Iyad] Masdar Inst Sci & Technol, Comp & Informat Sci Program, Abu Dhabi 54224, U Arab Emirates	Massachusetts Institute of Technology (MIT); Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Khalifa University of Science & Technology	Pentland, A (corresponding author), MIT, Media Lab, Cambridge, MA 02139 USA.	pentland@mit.edu	Rahwan, Iyad/ABB-2422-2020	Rahwan, Iyad/0000-0002-1796-4303; Madan, Anmol/0000-0002-3300-3588	Army Research Laboratory [W911NF-09-2-0053]; Air Force Office of Scientific Research [FA9550-10-1-0122]; U.S. Air Force [FA8721-05-C-0002]; National Science Foundation [0905645]; Masdar Institute of Science and Technology [400075]; Branco Weiss Science in Society Program	Army Research Laboratory(United States Department of DefenseUS Army Research Laboratory (ARL)); Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); U.S. Air Force; National Science Foundation(National Science Foundation (NSF)); Masdar Institute of Science and Technology; Branco Weiss Science in Society Program	This research was partially sponsored by the Army Research Laboratory under cooperative agreement W911NF-09-2-0053, by the Air Force Office of Scientific Research under award FA9550-10-1-0122, by the U.S. Air Force under contract FA8721-05-C-0002, by the National Science Foundation under grant 0905645, by the Masdar Institute of Science and Technology under grant 400075, the Branco Weiss Science in Society Program, and by generous gifts from P&G, Best Buy, and Google Views. Conclusions in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the sponsors. After providing the data underlying Fig. 4, Twitter requested that Stanford University withdraw this data from public access. Please contact A.P. for information regarding use of the data on the MIT server.	Adamic L, 2005, SOC NETWORKS, V27, P187, DOI 10.1016/j.socnet.2005.01.007; [Anonymous], 2008, CROWDSOURCING WHY PO; Arrow KJ, 2008, SCIENCE, V320, P877, DOI 10.1126/science.1157679; Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459; Biyalogorsky E, 2001, MARKET SCI, V20, P82, DOI 10.1287/mksc.20.1.82.10195; Cooper S, 2010, NATURE, V466, P756, DOI 10.1038/nature09304; Defense Advanced Research Projects Agency, DARPA NETW CHALL; Defense Advanced Research Projects Agency, 2010, DARPA NETW CHALL PRO; Dodds PS, 2003, SCIENCE, V301, P827, DOI 10.1126/science.1081058; Golub B, 2010, P NATL ACAD SCI USA, V107, P10833, DOI 10.1073/pnas.1000814107; Hand E, 2010, NATURE, V465, P673, DOI 10.1038/465673a; Huberman BA, 2009, J INF SCI, V35, P758, DOI 10.1177/0165551509346786; Kleinberg J, 2005, ANN IEEE SYMP FOUND, P132, DOI 10.1109/SFCS.2005.63; Kleinberg JM, 2000, NATURE, V406, P845, DOI 10.1038/35022643; Krakow G., 2005, HAM RADIO OPERATORS; Liben-Nowell D, 2005, P NATL ACAD SCI USA, V102, P11623, DOI 10.1073/pnas.0503018102; Liben-Nowell D, 2008, P NATL ACAD SCI USA, V105, P4633, DOI 10.1073/pnas.0708471105; Iribarren JL, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.038702; Malmgren RD, 2009, SCIENCE, V325, P1696, DOI 10.1126/science.1174562; Mason W., 2010, SIGKDD EXPLORATIONS, V11, P100, DOI [DOI 10.1145/1809400.1809422, 10.1145/1600150.1600175]; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; Pontin J., 2007, NY TIMES        0325; Rosvall M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.066111; Tang JC, 2011, COMMUN ACM, V54, P78, DOI 10.1145/1924421.1924441; von Ahn L, 2006, COMPUTER, V39, P92, DOI 10.1109/MC.2006.196; Watts DJ, 2002, P NATL ACAD SCI USA, V99, P5766, DOI 10.1073/pnas.082090499; Watts DJ, 2002, SCIENCE, V296, P1302, DOI 10.1126/science.1070120; Watts DJ, 2007, HARVARD BUS REV, V85, P22; Whitworth D., 2010, BBC NEWSBEAT    0705; Yang Jaewon, 2011, P 4 ACM INT C WEB SE; Yokoo M, 2004, GAME ECON BEHAV, V46, P174, DOI 10.1016/S0899-8256(03)00045-9	31	110	114	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					509	512		10.1126/science.1205869	http://dx.doi.org/10.1126/science.1205869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034432	Green Submitted			2022-12-28	WOS:000296230500046
J	Overgaard, M; Overgaard, R				Overgaard, Morten; Overgaard, Rikke			Measurements of consciousness in the vegetative state	LANCET			English	Editorial Material							DISORDERS		[Overgaard, Morten] Aalborg Univ, CNRU, Dept Commun & Psychol, DK-9220 Aalborg, Denmark; [Overgaard, Morten] Aarhus Univ, MindLab, Hammel Neurorehabil & Res Ctr, Aarhus, Denmark; [Overgaard, Rikke] Aarhus Univ, MindLab, CNRU Ctr Funct Integrat Neurosci, Aarhus, Denmark	Aalborg University; Aarhus University; Aarhus University	Overgaard, M (corresponding author), Aalborg Univ, CNRU, Dept Commun & Psychol, DK-9220 Aalborg, Denmark.	mortover@rm.dk	Overgaard, Morten/B-3830-2010	Overgaard, Morten/0000-0002-2136-3455; Overgaard, Morten/0000-0002-1215-5355				Cooney JW, 2003, TRENDS COGN SCI, V7, P161, DOI 10.1016/S1364-6613(03)00058-5; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P238, DOI 10.1016/0010-0285(83)90010-5; Milner AD, 2008, NEUROPSYCHOLOGIA, V46, P774, DOI 10.1016/j.neuropsychologia.2007.10.005; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Overgaard M, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00164; Overgaard M, 2009, PROG BRAIN RES, V177, P11, DOI 10.1016/S0079-6123(09)17702-6; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; van Gaal S, 2012, NEUROSCIENTIST, V18, P287, DOI 10.1177/1073858411404079	10	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	2011	378	9809					2052	2054		10.1016/S0140-6736(11)61591-2	http://dx.doi.org/10.1016/S0140-6736(11)61591-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	865EL	22078856				2022-12-28	WOS:000298293600012
J	Janich, P; Pascual, G; Merlos-Suarez, A; Batlle, E; Ripperger, J; Albrecht, U; Cheng, HYM; Obrietan, K; Di Croce, L; Benitah, SA				Janich, Peggy; Pascual, Gloria; Merlos-Suarez, Anna; Batlle, Eduard; Ripperger, Juergen; Albrecht, Urs; Cheng, Hai-Ying M.; Obrietan, Karl; Di Croce, Luciano; Aznar Benitah, Salvador			The circadian molecular clock creates epidermal stem cell heterogeneity	NATURE			English	Article							HAIR FOLLICLE; EXPRESSION; NICHE; DIFFERENTIATION; PROLIFERATION; HOMEOSTASIS; POPULATION; ACTIVATION; PACEMAKER; COMPONENT	Murine epidermal stem cells undergo alternate cycles of dormancy and activation, fuelling tissue renewal. However, only a subset of stem cells becomes active during each round of morphogenesis, indicating that stem cells coexist in heterogeneous responsive states. Using a circadian-clock reporter-mouse model, here we show that the dormant hair-follicle stem cell niche contains coexisting populations of cells at opposite phases of the clock, which are differentially predisposed to respond to homeostatic cues. The core clock protein Bmal1 modulates the expression of stem cell regulatory genes in an oscillatory manner, to create populations that are either predisposed, or less prone, to activation. Disrupting this clock equilibrium, through deletion of Bmal1 (also known as Arntl) or Per1/2, resulted in a progressive accumulation or depletion of dormant stem cells, respectively. Stem cell arrhythmia also led to premature epidermal ageing, and a reduction in the development of squamous tumours. Our results indicate that the circadian clock fine-tunes the temporal behaviour of epidermal stem cells, and that its perturbation affects homeostasis and the predisposition to tumorigenesis.	[Janich, Peggy; Pascual, Gloria; Di Croce, Luciano; Aznar Benitah, Salvador] Ctr Genom Regulat, Barcelona 08003, Spain; [Janich, Peggy; Pascual, Gloria; Di Croce, Luciano; Aznar Benitah, Salvador] UPF, Barcelona 08003, Spain; [Merlos-Suarez, Anna; Batlle, Eduard] Inst Res Biomed, Barcelona 08028, Spain; [Batlle, Eduard; Di Croce, Luciano; Aznar Benitah, Salvador] ICREA, Barcelona 08010, Spain; [Ripperger, Juergen; Albrecht, Urs] Univ Fribourg, CH-1700 Fribourg, Switzerland; [Cheng, Hai-Ying M.] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; [Obrietan, Karl] Ohio State Univ, Columbus, OH 43210 USA	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Fribourg; University of Toronto; University Toronto Mississauga; University System of Ohio; Ohio State University	Benitah, SA (corresponding author), Ctr Genom Regulat, Barcelona 08003, Spain.	salvador.aznar-benitah@crg.es	Albrecht, Urs/A-9831-2011; Batlle, Eduard/K-8080-2014; Aznar-Benitah, Salvador/F-4761-2016; Angulo, Gloria Pascual/AAA-7668-2019; Di Croce, Luciano/E-7759-2015	Albrecht, Urs/0000-0002-0663-8676; Batlle, Eduard/0000-0003-2422-0326; Aznar-Benitah, Salvador/0000-0002-9059-5049; Angulo, Gloria Pascual/0000-0003-3810-6647; Di Croce, Luciano/0000-0003-3488-6228; Janich, Peggy/0000-0003-1045-7365	AICR (Association for International Cancer Research); Spanish Ministry of Health (FIS); AGAUR (Agencia de Gestio d'Ajuts Universitaris i de Recerca; Government of Cataluna); AGAUR; FIS; Worldwide Cancer Research [10-0177] Funding Source: researchfish; ICREA Funding Source: Custom	AICR (Association for International Cancer Research); Spanish Ministry of Health (FIS)(Instituto de Salud Carlos IIISpanish Government); AGAUR (Agencia de Gestio d'Ajuts Universitaris i de Recerca; Government of Cataluna)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); FIS(Instituto de Salud Carlos III); Worldwide Cancer Research; ICREA(ICREA)	We thank the AICR (Association for International Cancer Research), the Spanish Ministry of Health (FIS) and AGAUR (Agencia de Gestio d'Ajuts Universitaris i de Recerca; Government of Cataluna) for financial support. P.J. is the recipient of an AGAUR PhD Fellowship, and G. P. of a FIS fellowship. We thank D. McMahon (Vanderbilt University) for providing us with the Per1-GFP mice; E. Wagner (CNIO) for the K5-SOS mice; B. Kubler, the FACS and Genomics units of the IRB (Institute de Recerca Biomedica), the CRG (Center for Genomic Regulation) core facilities and the Animal Unit (Juan Martin Caballero) for technical support.	Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Cheng HYM, 2009, HUM MOL GENET, V18, P3110, DOI 10.1093/hmg/ddp252; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Enshell-Seijffers D, 2010, DEV CELL, V18, P633, DOI 10.1016/j.devcel.2010.01.016; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Gatfield D, 2009, GENE DEV, V23, P1313, DOI 10.1101/gad.1781009; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jensen UB, 2008, J CELL SCI, V121, P609, DOI 10.1242/jcs.025502; Kameda T, 2004, METH MOL B, V289, P29; Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Kuhlman SJ, 2000, NEUROREPORT, V11, P1479, DOI 10.1097/00001756-200005150-00023; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lin KK, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000573; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Marcheva B, 2010, NATURE, V466, P627, DOI 10.1038/nature09253; Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Morris RJ, 2004, DIFFERENTIATION, V72, P381, DOI 10.1111/j.1432-0436.2004.07208004.x; Nowak Jonathan A., 2009, V482, P215, DOI 10.1007/978-1-59745-060-7_14; Owens DM, 2003, J CELL SCI, V116, P3783, DOI 10.1242/jcs.00725; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Plikus MV, 2008, NATURE, V451, P340, DOI 10.1038/nature06457; Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738; Rogler CE, 2009, HEPATOLOGY, V50, P575, DOI 10.1002/hep.22982; Schneider MR, 2009, CURR BIOL, V19, pR132, DOI 10.1016/j.cub.2008.12.005; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Storch KF, 2007, CELL, V130, P730, DOI 10.1016/j.cell.2007.06.045; Sun FY, 2009, BIOCHEM BIOPH RES CO, V380, P660, DOI 10.1016/j.bbrc.2009.01.161; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Zhang YV, 2009, CELL STEM CELL, V5, P267, DOI 10.1016/j.stem.2009.06.004; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	48	219	227	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	2011	480	7376					209	U89		10.1038/nature10649	http://dx.doi.org/10.1038/nature10649			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857TR	22080954	Green Submitted			2022-12-28	WOS:000297744200044
J	Moreau, C; Bherer, C; Vezina, H; Jomphe, M; Labuda, D; Excoffier, L				Moreau, Claudia; Bherer, Claude; Vezina, Helene; Jomphe, Michele; Labuda, Damian; Excoffier, Laurent			Deep Human Genealogies Reveal a Selective Advantage to Be on an Expanding Wave Front	SCIENCE			English	Article							POPULATION; MUTATIONS; EXPANSION; EVOLUTION; DYNAMICS; HISTORY; LIFE	Since their origin, human populations have colonized the whole planet, but the demographic processes governing range expansions are mostly unknown. We analyzed the genealogy of more than one million individuals resulting from a range expansion in Quebec between 1686 and 1960 and reconstructed the spatial dynamics of the expansion. We find that a majority of the present Saguenay Lac-Saint-Jean population can be traced back to ancestors having lived directly on or close to the wave front. Ancestors located on the front contributed significantly more to the current gene pool than those from the range core, likely due to a 20% larger effective fertility of women on the wave front. This fitness component is heritable on the wave front and not in the core, implying that this life-history trait evolves during range expansions.	[Moreau, Claudia; Bherer, Claude; Labuda, Damian; Excoffier, Laurent] Univ Montreal, Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; [Vezina, Helene; Jomphe, Michele] Univ Quebec Chicoutimi, Projet BALSAC, Chicoutimi, PQ G7H 2B1, Canada; [Labuda, Damian] Univ Montreal, Dept Pediat, Montreal, PQ H3T 1J4, Canada; [Excoffier, Laurent] Univ Bern, Inst Ecol & Evolut, CH-3012 Bern, Switzerland; [Excoffier, Laurent] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland	Universite de Montreal; University of Quebec; University of Quebec Chicoutimi; Universite de Montreal; University of Bern; Swiss Institute of Bioinformatics	Labuda, D (corresponding author), Univ Montreal, Hop St Justine, Ctr Rech, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	damian.labuda@umontreal.ca; laurent.excoffier@iee.unibe.ch	Excoffier, Laurent/D-3498-2013	Excoffier, Laurent/0000-0002-7507-6494	Swiss NSF [3100A0-126074]; Reseau de Medecine Genetique Appliquee of the Fonds de Recherche en Sante du Quebec (FRSQ); FRSQ	Swiss NSF(Swiss National Science Foundation (SNSF)); Reseau de Medecine Genetique Appliquee of the Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); FRSQ(Fonds de la Recherche en Sante du Quebec)	We thank L. Barreiro, D. Bherer, H. Harpending, Y. Idaghdour, D. Reich, R. Shine, and M. Slatkin for their helpful comments on the manuscript. L. E. was supported by Swiss NSF grant 3100A0-126074, D. L. and H. V. by the Reseau de Medecine Genetique Appliquee of the Fonds de Recherche en Sante du Quebec (FRSQ), and C. B. was a recipient of an FRSQ studentship. The raw genealogical data used in this study are available upon request from balsac@uqac.ca.	Austerlitz F, 1998, P NATL ACAD SCI USA, V95, P15140, DOI 10.1073/pnas.95.25.15140; Bherer C, 2011, AM J PHYS ANTHROPOL, V144, P432, DOI 10.1002/ajpa.21424; Biek R, 2007, P NATL ACAD SCI USA, V104, P7993, DOI 10.1073/pnas.0700741104; Bouchard G., 1983, SAGUENAYENS INTRO HI, P125; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Charbonneau H., 2000, POPULATION HIST N AM, P99; Edmonds CA, 2004, P NATL ACAD SCI USA, V101, P975, DOI 10.1073/pnas.0308064100; Estoup A, 2010, MOL ECOL RESOUR, V10, P886, DOI 10.1111/j.1755-0998.2010.02882.x; Excoffier L, 2009, ANNU REV ECOL EVOL S, V40, P481, DOI 10.1146/annurev.ecolsys.39.110707.173414; Falconer DS, 1996, INTRO QUANTITATIVE G; Gauvreau D, 1991, HIST DUN GENOME, P145; Gibson MA, 2011, P NATL ACAD SCI USA, V108, P2200, DOI 10.1073/pnas.1010241108; Green RE, 2010, SCIENCE, V328, P710, DOI 10.1126/science.1188021; Hallatschek O, 2008, THEOR POPUL BIOL, V73, P158, DOI 10.1016/j.tpb.2007.08.008; Hallatschek O, 2007, P NATL ACAD SCI USA, V104, P19926, DOI 10.1073/pnas.0710150104; Hallatschek O, 2010, EVOLUTION, V64, P193, DOI 10.1111/j.1558-5646.2009.00809.x; Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000; Hill JK, 2011, ANNU REV ENTOMOL, V56, P143, DOI 10.1146/annurev-ento-120709-144746; Klopfstein S, 2006, MOL BIOL EVOL, V23, P482, DOI 10.1093/molbev/msj057; Lavoie TM, 2005, COMMUNITY GENET, V8, P152, DOI 10.1159/000086758; Lewontin R. C., 1965, P77; Milot E, 2011, P NATL ACAD SCI USA, V108, P17040, DOI 10.1073/pnas.1104210108; Phillips BL, 2010, ECOLOGY, V91, P1617, DOI 10.1890/09-0910.1; Prugnolle F, 2005, CURR BIOL, V15, pR159, DOI 10.1016/j.cub.2005.02.038; Pysek P, 2005, ECOSCIENCE, V12, P302, DOI 10.2980/i1195-6860-12-3-302.1; Reich D, 2010, NATURE, V468, P1053, DOI 10.1038/nature09710; Sibert A, 2002, THEOR POPUL BIOL, V62, P181, DOI 10.1006/tpbi.2002.1609; Travis JMJ, 2007, MOL BIOL EVOL, V24, P2334, DOI 10.1093/molbev/msm167; Wang S, 2007, PLOS GENET, V3, P2049, DOI 10.1371/journal.pgen.0030185	29	61	61	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	2011	334	6059					1148	1150		10.1126/science.1212880	http://dx.doi.org/10.1126/science.1212880			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852AF	22052972				2022-12-28	WOS:000297313900055
J	Raju, H; Alberg, C; Sagoo, GS; Burton, H; Behr, ER				Raju, Hariharan; Alberg, Corinna; Sagoo, Gurdeep S.; Burton, Hilary; Behr, Elijah R.			Inherited cardiomyopathies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUDDEN CARDIAC DEATH; RIGHT-VENTRICULAR CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; ANTIARRHYTHMIC-DRUGS; CLINICAL INDICATIONS; RISK STRATIFICATION; CATHETER ABLATION; DEFIBRILLATORS; PREVENTION; GUIDELINES		[Raju, Hariharan; Behr, Elijah R.] St Georges Univ London, Cardiac & Vasc Div, London SW17 0RE, England; [Alberg, Corinna; Sagoo, Gurdeep S.; Burton, Hilary] PHG Fdn, Cambridge, England	St Georges University London	Behr, ER (corresponding author), St Georges Univ London, Cardiac & Vasc Div, London SW17 0RE, England.	ebehr@sgul.ac.uk		Behr, Elijah/0000-0002-8731-2853; Sagoo, Gurdeep/0000-0003-1427-1437; Sharma, Sanjay/0000-0002-3630-6138; Raju, Hariharan/0000-0003-0000-7520	Cardiac Risk in the Young (CRY); Higher Education Funding Council for England (HEFCE); PHG Foundation; Biotronik; Boston Scientific; British Heart Foundation [FS/11/71/28918] Funding Source: researchfish	Cardiac Risk in the Young (CRY); Higher Education Funding Council for England (HEFCE)(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); PHG Foundation; Biotronik; Boston Scientific(Boston Scientific); British Heart Foundation(British Heart Foundation)	HR is supported by Cardiac Risk in the Young (CRY); EB is supported by the Higher Education Funding Council for England (HEFCE); CA, GS, and HB are supported by the PHG Foundation.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; EB has received funds for research from Biotronik and Boston Scientific.	Bos JM, 2007, CURR OPIN CARDIOL, V22, P193, DOI 10.1097/HCO.0b013e3280e1cc7f; Bowker TJ, 1995, INT J CARDIOL, V52, P241, DOI 10.1016/0167-5273(95)02495-6; Burton H, 2009, HEART HEART INHERITE; de Noronha SV, 2009, HEART, V95, P1409, DOI 10.1136/hrt.2009.168369; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Garratt CJ, 2008, HEART, V94, P502, DOI 10.1136/hrt.2007.127761; Garratt CJ, 2010, EUROPACE, V12, P1156, DOI 10.1093/europace/euq261; Hendrix A, 2011, EUROPACE, V13, P716, DOI 10.1093/europace/euq460; Hershberger RE, 2011, J AM COLL CARDIOL, V57, P1641, DOI 10.1016/j.jacc.2011.01.015; Kozeluhova M, 2011, EUROPACE, V13, P109, DOI 10.1093/europace/euq364; Mahon NG, 2005, ANN INTERN MED, V143, P108, DOI 10.7326/0003-4819-143-2-200507190-00009; Marcus FI, 2010, CIRCULATION, V121, P1533, DOI 10.1161/CIRCULATIONAHA.108.840827; Marcus GM, 2009, J AM COLL CARDIOL, V54, P609, DOI 10.1016/j.jacc.2009.04.052; Maron BJ, 2010, CIRC J, V74, P2271, DOI 10.1253/circj.CJ-10-0921; Maron Barry J., 2003, Journal of the American College of Cardiology, V42, P1687, DOI 10.1016/S0735-1097(03)00941-0; Maron BJ, 2002, J AM COLL CARDIOL, V39, P301, DOI 10.1016/S0735-1097(01)01727-2; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; Maron MS, 2010, CIRC-HEART FAIL, V3, P574, DOI 10.1161/CIRCHEARTFAILURE.109.922872; McLeod CJ, 2011, HEART RHYTHM, V8, P377, DOI 10.1016/j.hrthm.2010.11.013; Millat G, 2010, EUR J MED GENET, V53, P261, DOI 10.1016/j.ejmg.2010.07.007; Ommen SR, 2005, J AM COLL CARDIOL, V46, P470, DOI 10.1016/j.jacc.2005.02.090; Papadakis M, 2009, EUROPACE, V11, P1353, DOI 10.1093/europace/eup229; Pasotti M, 2008, J AM COLL CARDIOL, V52, P1250, DOI 10.1016/j.jacc.2008.06.044; Pinamonti B, 2011, EUR HEART J, V32, P1105, DOI 10.1093/eurheartj/ehr040; SAVAGE DD, 1978, CIRCULATION, V58, P402, DOI 10.1161/01.CIR.58.3.402; Vetter VL, 2011, AM HEART J, V161, P1000; Wichter T, 2005, HERZ, V30, P91, DOI 10.1007/s00059-005-2677-6; Wordsworth S, 2010, EUR HEART J, V31, P926, DOI 10.1093/eurheartj/ehq067; Xu TH, 2010, J AM COLL CARDIOL, V55, P587, DOI 10.1016/j.jacc.2009.11.020; Zipes DP, 2006, EUROPACE, V8, P746, DOI 10.1093/europace/eul108	30	27	27	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	2011	343								d6966	10.1136/bmj.d6966	http://dx.doi.org/10.1136/bmj.d6966			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857NC	22106372				2022-12-28	WOS:000297724200001
J	Ng, B				Ng, Bradley			Review: Cholinesterase inhibitors but not memantine increase syncope in older adults with mild cognitive impairment or dementia	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Bond Univ, Gold Coast, Qld, Australia	Bond University	Ng, B (corresponding author), Bond Univ, Gold Coast, Qld, Australia.							Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43; Hernandez RK, 2009, J AM GERIATR SOC, V57, P1997, DOI 10.1111/j.1532-5415.2009.02488.x	2	1	1	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-10	10.7326/0003-4819-155-10-201111150-02010	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084357				2022-12-28	WOS:000208885300009
J	Shultz, S; Opie, C; Atkinson, QD				Shultz, Susanne; Opie, Christopher; Atkinson, Quentin D.			Stepwise evolution of stable sociality in primates	NATURE			English	Article							CORRELATED EVOLUTION; ORGANIZATION; DISPERSAL; SELECTION; BRAIN; BIRDS	Although much attention has been focused on explaining and describing the diversity of social grouping patterns among primates(1-3), less effort has been devoted to understanding the evolutionary history of social living(4). This is partly because social behaviours do not fossilize, making it difficult to infer changes over evolutionary time. However, primate social behaviour shows strong evidence for phylogenetic inertia, permitting the use of Bayesian comparative methods to infer changes in social behaviour through time, thereby allowing us to evaluate alternative models of social evolution. Here we present a model of primate social evolution, whereby sociality progresses from solitary foraging individuals directly to large multi-male/multi-female aggregations (approximately 52 million years (Myr) ago), with pair-living (approximately 16 Myr ago) or single-male harem systems (approximately 16 Myr ago) derivative from this second stage. This model fits the data significantly better than the two widely accepted alternatives (an unstructured model implied by the socioecological hypothesis or a model that allows linear stepwise changes in social complexity through time). We also find strong support for the co-evolution of social living with a change from nocturnal to diurnal activity patterns, but not with sex-biased dispersal. This supports suggestions that social living may arise because of increased predation risk associated with diurnal activity. Sociality based on loose aggregation is followed by a second shift to stable or bonded groups. This structuring facilitates the evolution of cooperative behaviours(5) and may provide the scaffold for other distinctive anthropoid traits including coalition formation, cooperative resource defence and large brains.	[Shultz, Susanne; Opie, Christopher; Atkinson, Quentin D.] Univ Oxford, Inst Cognit & Evolutionary Anthropol, Oxford OX2 6PN, England; [Atkinson, Quentin D.] Univ Auckland, Dept Psychol, Auckland, New Zealand	University of Oxford; University of Auckland	Shultz, S (corresponding author), Univ Oxford, Inst Cognit & Evolutionary Anthropol, 64 Banbury Rd, Oxford OX2 6PN, England.	susanne.shultz@anthro.ox.ac.uk	Shultz, Susanne/C-3162-2012	Atkinson, Quentin/0000-0002-8499-7535; Shultz, Susanne/0000-0002-7135-4880; Opie, Christopher/0000-0002-3379-4703	Royal Society	Royal Society(Royal Society of London)	S.S. is supported by a Royal Society Dorothy Hodgkin Fellowship. We thank R. I. M. Dunbar for comments on the manuscript.	Arnold C, 2010, EVOL ANTHROPOL, V19, P114, DOI 10.1002/evan.20251; Barton RA, 1998, P ROY SOC B-BIOL SCI, V265, P1933, DOI 10.1098/rspb.1998.0523; Broad KD, 2006, PHILOS T R SOC B, V361, P2199, DOI 10.1098/rstb.2006.1940; Campbell CJ, 2007, PRIMATES PERSPECTIVE; Cornwallis CK, 2010, NATURE, V466, P969, DOI 10.1038/nature09335; DIFIORE A, 1994, P NATL ACAD SCI USA, V91, P9941, DOI 10.1073/pnas.91.21.9941; Dixson A.F., 1998, PRIMATE SEXUALITY CO; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Dunbar R.I.M., 1988, PRIMATE SOCIAL SYSTE; Dunbar RIM, 2000, PRIMATE MALES, P259; Elton S, 2006, J ROY ANTHROPOL INST, V12, P19, DOI 10.1111/j.1467-9655.2006.00279.x; Frank, 1998, FDN SOCIAL EVOLUTION; Freckleton RP, 2002, AM NAT, V160, P712, DOI 10.1086/343873; Gompper ME, 1997, ANIM BEHAV, V53, P781, DOI 10.1006/anbe.1996.0344; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Harmon LJ, 2008, BIOINFORMATICS, V24, P129, DOI 10.1093/bioinformatics/btm538; Hughes WOH, 2008, SCIENCE, V320, P1213, DOI 10.1126/science.1156108; Isbell LA, 1996, BEHAVIOUR, V133, P1, DOI 10.1163/156853996X00017; Jack KM, 2009, BEHAVIOUR, V146, P429, DOI 10.1163/156853909X410612; JARMAN PJ, 1974, BEHAVIOUR, V48, P215, DOI 10.1163/156853974X00345; Kappeler PM, 2002, INT J PRIMATOL, V23, P707, DOI 10.1023/A:1015520830318; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Muller AE, 2000, BIOL REV, V75, P405, DOI 10.1017/S0006323100005533; Nowak MA, 2010, NATURE, V466, P1057, DOI 10.1038/nature09205; Nunn CL, 2001, ADV PRIMATO, P159; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Pagel M, 2004, SYST BIOL, V53, P673, DOI 10.1080/10635150490522232; Pagel M, 2006, AM NAT, V167, P808, DOI 10.1086/503444; Rambaut A., 2014, TRACER V16; Schulke O, 2005, EVOL ANTHROPOL, V14, P170, DOI 10.1002/evan.20081; Shultz S, 2007, P ROY SOC B-BIOL SCI, V274, P2429, DOI 10.1098/rspb.2007.0693; Shultz S, 2010, P NATL ACAD SCI USA, V107, P21582, DOI 10.1073/pnas.1005246107; Shultz S, 2010, BIOL J LINN SOC, V100, P111, DOI 10.1111/j.1095-8312.2010.01427.x; Smuts B. B., 1987, PRIMATE SOC; Sterck EHM, 1997, BEHAV ECOL SOCIOBIOL, V41, P291, DOI 10.1007/s002650050390; Stirling DG, 2002, J EVOLUTION BIOL, V15, P277, DOI 10.1046/j.1420-9101.2002.00389.x; TERBORGH J, 1986, ANNU REV ECOL SYST, V17, P111; VANSCHAIK CP, 1983, BEHAVIOUR, V87, P120, DOI 10.1163/156853983X00147	41	210	214	2	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2011	479	7372					219	U96		10.1038/nature10601	http://dx.doi.org/10.1038/nature10601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071768				2022-12-28	WOS:000298030800040
J	Hietz, P; Turner, BL; Wanek, W; Richter, A; Nock, CA; Wright, SJ				Hietz, Peter; Turner, Benjamin L.; Wanek, Wolfgang; Richter, Andreas; Nock, Charles A.; Wright, S. Joseph			Long-Term Change in the Nitrogen Cycle of Tropical Forests	SCIENCE			English	Article							N DEPOSITION; ABUNDANCE; FOLIAR; LOSSES; TRENDS; IMPACT	Deposition of reactive nitrogen (N) from human activities has large effects on temperate forests where low natural N availability limits productivity but is not known to affect tropical forests where natural N availability is often much greater. Leaf N and the ratio of N isotopes (delta N-15) increased substantially in a moist forest in Panama between similar to 1968 and 2007, as did tree-ring delta N-15 in a dry forest in Thailand over the past century. A decade of fertilization of a nearby Panamanian forest with N caused similar increases in leaf N and delta N-15. Therefore, our results indicate regional increases in N availability due to anthropogenic N deposition. Atmospheric nitrogen dioxide measurements and increased emissions of anthropogenic reactive N over tropical land areas suggest that these changes are widespread in tropical forests.	[Hietz, Peter] Univ Nat Resources & Life Sci, Inst Bot, A-1180 Vienna, Austria; [Turner, Benjamin L.; Wright, S. Joseph] Smithsonian Trop Res Inst, Balboa, Ancon, Panama; [Wanek, Wolfgang] Univ Vienna, Dept Chem Ecol & Ecosyst Res, A-1090 Vienna, Austria; [Richter, Andreas] Univ Bremen, Inst Environm Phys, D-28359 Bremen, Germany; [Nock, Charles A.] Univ Quebec, Dept Sci Biol, Ctr Etud Foret, Montreal, PQ H3C 3P8, Canada	University of Natural Resources & Life Sciences, Vienna; Smithsonian Institution; Smithsonian Tropical Research Institute; University of Vienna; University of Bremen; University of Quebec; University of Quebec Montreal	Hietz, P (corresponding author), Univ Nat Resources & Life Sci, Inst Bot, Gregor Mendel Str 33, A-1180 Vienna, Austria.	peter.hietz@boku.ac.at	Turner, Benjamin L/E-5940-2011; Wanek, Wolfgang/E-7001-2012; Richter, Andreas/C-4971-2008; Wright, Stuart Joseph/M-3311-2013; Turner, Benjamin/AAZ-1465-2021	Turner, Benjamin L/0000-0002-6585-0722; Wanek, Wolfgang/0000-0003-2178-8258; Richter, Andreas/0000-0003-3339-212X; Wright, Stuart Joseph/0000-0003-4260-5676; Turner, Benjamin/0000-0002-6585-0722; Hietz, Peter/0000-0002-0458-6593	F. H. Levinson Fund; Austrian Science Fund [P19507-B17]	F. H. Levinson Fund; Austrian Science Fund(Austrian Science Fund (FWF))	We thank D. Agudo, T. Romero, U. Hietz-Seifert, and M. Watzka for laboratory support and the F. H. Levinson Fund and the Austrian Science Fund (grant P19507-B17) for funding. P. H. took herbarium and wood samples and analyzed the leaf, wood, and N emission data; S.J.W. provided 2007 leaves; B. L. T. analyzed 2007 leaves; W. W. analyzed herbarium leaves and wood; C. A. N. synchronized wood cores; A. R. analyzed satellite data; and P. H., B. L. T., and S.J.W. wrote the manuscript. All authors contributed to the discussion of the data. Leaf and wood data are available from P. H.; NO<INF>2</INF> satellite data are available from A.R.	Asner GP, 2001, BIOGEOCHEMISTRY, V54, P1, DOI 10.1023/A:1010653913530; Baker PJ, 2005, ECOL MONOGR, V75, P317, DOI 10.1890/04-0488; Bukata AR, 2005, ENVIRON SCI TECHNOL, V39, P7777, DOI 10.1021/es050733p; Chave J, 2008, PLOS BIOL, V6, P455, DOI 10.1371/journal.pbio.0060045; Chen Y, 2010, GLOBAL CHANGE BIOL, V16, P2024, DOI 10.1111/j.1365-2486.2009.02156.x; Corre MD, 2010, ECOLOGY, V91, P1715, DOI 10.1890/09-0274.1; Elhani S, 2005, TREE PHYSIOL, V25, P1437, DOI 10.1093/treephys/25.11.1437; Galloway JN, 2008, SCIENCE, V320, P889, DOI 10.1126/science.1136674; Galloway JN, 2004, BIOGEOCHEMISTRY, V70, P153, DOI 10.1007/s10533-004-0370-0; Hedin LO, 2009, ANNU REV ECOL EVOL S, V40, P613, DOI 10.1146/annurev.ecolsys.37.091305.110246; Hietz P, 2010, ENVIRON SCI TECHNOL, V44, P1191, DOI 10.1021/es901383g; Hogberg P, 1997, NEW PHYTOL, V137, P179, DOI 10.1046/j.1469-8137.1997.00808.x; HOGBERG P, 1993, PLANT SOIL, V157, P147, DOI 10.1007/BF02390237; Houlton BZ, 2007, P NATL ACAD SCI USA, V104, P8902, DOI 10.1073/pnas.0609935104; Kaspari M, 2008, ECOL LETT, V11, P35, DOI 10.1111/j.1461-0248.2007.01124.x; Lewis SL, 2009, ANNU REV ECOL EVOL S, V40, P529, DOI 10.1146/annurev.ecolsys.39.110707.173345; Matson PA, 1999, BIOGEOCHEMISTRY, V46, P67, DOI 10.1007/BF01007574; McLauchlan KK, 2007, P NATL ACAD SCI USA, V104, P7466, DOI 10.1073/pnas.0701779104; McLauchlan KK, 2010, NEW PHYTOL, V187, P1135, DOI 10.1111/j.1469-8137.2010.03322.x; Pardo LH, 2006, BIOGEOCHEMISTRY, V80, P143, DOI 10.1007/s10533-006-9015-9; Phoenix GK, 2006, GLOBAL CHANGE BIOL, V12, P470, DOI 10.1111/j.1365-2486.2006.01104.x; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Wassen MJ, 2005, NATURE, V437, P547, DOI 10.1038/nature03950; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; Wright SJ, 2010, ANN NY ACAD SCI, V1195, P1, DOI [10.1111/j.1749-6632.2009.05400.x, 10.1111/j.1749-6632.2010.05455.x]	25	211	221	4	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					664	666		10.1126/science.1211979	http://dx.doi.org/10.1126/science.1211979			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053047				2022-12-28	WOS:000296494700053
J	Hooper, LV				Hooper, Lora V.			You AhR What You Eat: Linking Diet and Immunity	CELL			English	Editorial Material							ARYL-HYDROCARBON RECEPTOR; DELTA T-CELLS; HOMEOSTASIS; EXPRESSION; SYSTEM	The aryl hydrocarbon receptor (AhR) is responsible for the toxic effects of environmental pollutants such as dioxin, but little is known about its normal physiological functions. Li et al. (2011) now show that specific dietary compounds present in cruciferous vegetables act through the AhR to promote intestinal immune function, revealing AhR as a critical link between diet and immunity.	[Hooper, Lora V.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Hooper, Lora V.] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hooper, LV (corresponding author), Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	lora.hooper@utsouthwestern.edu						Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; D'Souza S, 2008, INFLAMM BOWEL DIS, V14, P367, DOI 10.1002/ibd.20333; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Ismail AS, 2011, P NATL ACAD SCI USA, V108, P8743, DOI 10.1073/pnas.1019574108; Ito SJ, 2007, J CLIN INVEST, V117, P1940, DOI 10.1172/JCI31647; Kadow S, 2011, J IMMUNOL, V187, P3104, DOI 10.4049/jimmunol.1100912; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881	10	28	28	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					486	490		10.1016/j.cell.2011.10.004	http://dx.doi.org/10.1016/j.cell.2011.10.004			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036556	Bronze			2022-12-28	WOS:000296573700003
J	Shakya, R; Reid, LJ; Reczek, CR; Cole, F; Egli, D; Lin, CS; deRooij, DG; Hirsch, S; Ravi, K; Hicks, JB; Szabolcs, M; Jasin, M; Baer, R; Ludwig, T				Shakya, Reena; Reid, Latarsha J.; Reczek, Colleen R.; Cole, Francesca; Egli, Dieter; Lin, Chyuan-Sheng; deRooij, Dirk G.; Hirsch, Steffen; Ravi, Kandasamy; Hicks, James B.; Szabolcs, Matthias; Jasin, Maria; Baer, Richard; Ludwig, Thomas			BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity	SCIENCE			English	Article							BREAST-CANCER; BRCA1/BARD1 HETERODIMER; STRUCTURAL BASIS; PHOSPHOPEPTIDE RECOGNITION; BACH1 PHOSPHOPEPTIDE; MICE; TUMORIGENESIS; MUTATION; COMPLEX; IDENTIFICATION	Germline mutations of the breast cancer 1 (BRCA1) gene are a major cause of familial breast and ovarian cancer. The BRCA1 protein displays E3 ubiquitin ligase activity, and this enzymatic function is thought to be required for tumor suppression. To test this hypothesis, we generated mice that express an enzymatically defective Brca1. We found that this mutant Brca1 prevents tumor formation to the same degree as does wild-type Brca1 in three different genetically engineered mouse (GEM) models of cancer. In contrast, a mutation that ablates phosphoprotein recognition by the BRCA C terminus (BRCT) domains of BRCA1 elicits tumors in each of the three GEM models. Thus, BRCT phosphoprotein recognition, but not the E3 ligase activity, is required for BRCA1 tumor suppression.	[Shakya, Reena; Reid, Latarsha J.; Reczek, Colleen R.; Hirsch, Steffen; Baer, Richard; Ludwig, Thomas] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Shakya, Reena; Reid, Latarsha J.; Lin, Chyuan-Sheng; Hirsch, Steffen; Szabolcs, Matthias; Baer, Richard; Ludwig, Thomas] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Reczek, Colleen R.] Columbia Univ, Dept Nutr & Metab Biol, New York, NY 10032 USA; [Cole, Francesca; Jasin, Maria] Mem Sloan Kettering Canc Ctr, Dev Biol Program, New York, NY 10021 USA; [Egli, Dieter] NYSCF, New York, NY 10032 USA; [deRooij, Dirk G.] Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, NL-1105 AZ Amsterdam, Netherlands; [Ravi, Kandasamy; Hicks, James B.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Szabolcs, Matthias; Baer, Richard; Ludwig, Thomas] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center; The New York Stem Cell Foundation; University of Amsterdam; Academic Medical Center Amsterdam; Cold Spring Harbor Laboratory; Columbia University	Baer, R (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.	rb670@columbia.edu; tl54@columbia.edu	Ludwig, Thomas/Q-6484-2016; de Rooij, D.G./AAW-1195-2021	Ludwig, Thomas/0000-0003-3461-2585; Cole, Francesca/0000-0001-6391-2363	NIH [R01-CA137023, P01-CA97403, R01-HD40916]; Susan G. Komen Breast Cancer fellowship; Kirschstein National Research Service [F31-CA132626, F32-HD51392]; National Cancer Institute [T32-CA09503]; U.S. Department of Defense (DOD) [BC083089]; DOD [W81XWH04-1-0477]; Breast Cancer Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040916, F32HD051392] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA097403, F31CA132626, T32CA009503, R01CA137023] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen Breast Cancer fellowship(Susan G. Komen Breast Cancer Foundation); Kirschstein National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Defense (DOD)(United States Department of Defense); DOD(United States Department of Defense); Breast Cancer Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank X. Sun for technical assistance, V. Murty for advice, M. Wigler for discussions and encouragement, and NYSCF for access to the confocal microscope. This work was supported by NIH grants R01-CA137023 (R.B. and T.L.), P01-CA97403 (R.B. and T.L.), and R01-HD40916 (M.J.). R.S. was supported by a Susan G. Komen Breast Cancer fellowship, L.J.R. by a Kirschstein National Research Service Award fellowship (F31-CA132626), C.R.R. by fellowships from the National Cancer Institute (T32-CA09503) and U.S. Department of Defense (DOD) (BC083089), and F.C. by a Kirschstein National Research Service Award fellowship (F32-HD51392). K.R. and J.B.H. were supported by grants to M. Wigler and J.B.H. from DOD (W81XWH04-1-0477) and the Breast Cancer Research Foundation. Microarray data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) with GEO Series accession number GSE31673.	Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Reid LJ, 2008, P NATL ACAD SCI USA, V105, P20876, DOI 10.1073/pnas.0811203106; Sankaran S, 2006, CANCER RES, V66, P4100, DOI 10.1158/0008-5472.CAN-05-4430; Shakya R, 2008, P NATL ACAD SCI USA, V105, P7040, DOI 10.1073/pnas.0711032105; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Varma AK, 2005, BIOCHEMISTRY-US, V44, P10941, DOI 10.1021/bi0509651; Wijnhoven SWP, 2005, CANCER RES, V65, P8166, DOI 10.1158/0008-5472.CAN-05-1650; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu WW, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-1; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006	28	173	177	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2011	334	6055					525	528		10.1126/science.1209909	http://dx.doi.org/10.1126/science.1209909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034435	Green Accepted			2022-12-28	WOS:000296230500050
J	Rosenbaum, S				Rosenbaum, Sara			Equal Access for Medicaid Beneficiaries - The Supreme Court and the Douglas Cases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									George Washington Univ, Dept Hlth Policy, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA	George Washington University	Rosenbaum, S (corresponding author), George Washington Univ, Dept Hlth Policy, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA.							Rosenbaum S, 2011, NEW ENGL J MED, V365, P102, DOI 10.1056/NEJMp1106046	1	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2245	2247		10.1056/NEJMp1111428	http://dx.doi.org/10.1056/NEJMp1111428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	861PN	22070435				2022-12-28	WOS:000298031800001
J	Anastasiou, D; Poulogiannis, G; Asara, JM; Boxer, MB; Jiang, JK; Shen, M; Bellinger, G; Sasaki, AT; Locasale, JW; Auld, DS; Thomas, CJ; Vander Heiden, MG; Cantley, LC				Anastasiou, Dimitrios; Poulogiannis, George; Asara, John M.; Boxer, Matthew B.; Jiang, Jian-kang; Shen, Min; Bellinger, Gary; Sasaki, Atsuo T.; Locasale, Jason W.; Auld, Douglas S.; Thomas, Craig J.; Vander Heiden, Matthew G.; Cantley, Lewis C.			Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses	SCIENCE			English	Article							OXIDATIVE STRESS; TUMOR-SUPPRESSOR; CELLS; ROS; METABOLISM; CANCER; ISOFORM; PROTEIN	Control of intracellular reactive oxygen species (ROS) concentrations is critical for cancer cell survival. We show that, in human lung cancer cells, acute increases in intracellular concentrations of ROS caused inhibition of the glycolytic enzyme pyruvate kinase M2 (PKM2) through oxidation of Cys(358). This inhibition of PKM2 is required to divert glucose flux into the pentose phosphate pathway and thereby generate sufficient reducing potential for detoxification of ROS. Lung cancer cells in which endogenous PKM2 was replaced with the Cys(358) to Ser(358) oxidation-resistant mutant exhibited increased sensitivity to oxidative stress and impaired tumor formation in a xenograft model. Besides promoting metabolic changes required for proliferation, the regulatory properties of PKM2 may confer an additional advantage to cancer cells by allowing them to withstand oxidative stress.	[Anastasiou, Dimitrios; Poulogiannis, George; Asara, John M.; Bellinger, Gary; Sasaki, Atsuo T.; Locasale, Jason W.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02115 USA; [Anastasiou, Dimitrios; Poulogiannis, George; Sasaki, Atsuo T.; Locasale, Jason W.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; [Asara, John M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Boxer, Matthew B.; Jiang, Jian-kang; Shen, Min; Auld, Douglas S.; Thomas, Craig J.] NHGRI, NIH Chem Genom Ctr, NIH, Rockville, MD 20850 USA; [Bellinger, Gary; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Vander Heiden, Matthew G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); NIH National Human Genome Research Institute (NHGRI); Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Cantley, LC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02115 USA.	lewis_cantley@hms.harvard.edu	Cantley, Lewis C/D-1800-2014; Locasale, Jason W/ABE-6505-2020; Poulogiannis, George/AAY-2210-2021; Poulogiannis, George/AAE-1966-2019	Cantley, Lewis C/0000-0002-1298-7653; Locasale, Jason W/0000-0002-7766-3502; Poulogiannis, George/0000-0002-0529-8614; Thomas, Craig/0000-0001-9386-9001; Anastasiou, Dimitrios/0000-0002-1269-843X; Sasaki, Atsuo/0000-0003-2963-4501	Japanese Society for the Promotion of Science; Kanae Foundation for Research Abroad; NIH [R03MH085679, 1P30CA147882, R01-GM056203-13, P01-CA089021, P01-CA117969-04]; Burroughs Wellcome Fund; Damon Runyon Cancer Research Foundation; Smith family; Starr Cancer Consortium; Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research; National Human Genome Research Institute, NIH; NATIONAL CANCER INSTITUTE [P30CA147882, P01CA089021, P01CA117969] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIBTR000004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH085679] Funding Source: NIH RePORTER	Japanese Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kanae Foundation for Research Abroad; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Damon Runyon Cancer Research Foundation; Smith family; Starr Cancer Consortium; Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Human Genome Research Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank V. Toxavidis and J. Tigges (Beth Israel Deaconess Medical Center flow cytometry facility) for support with flow cytometry applications; X. Yang and S. Breitkopf for technical assistance with mass spectrometry; Ross Dickins and Scott Lowe (Cold Spring Harbor Laboratory) for the gift of tamoxifen-inducible Cre-expressing retroviral plasmid; and C. Benes, N. Wu, A. Shaywitz, B. Emerling, A. Saci, G. DeNicola, K. Courtney, A. Couvillon, S. Soltoff, A. Carracedo, A. Grassian, J. Brugge, and members of the Cantley lab for helpful discussions. L. C. C. is a cofounder of Agios Pharmaceuticals, a company that seeks to develop novel therapeutics that target cancer metabolism. G. P. is a Pfizer Fellow of the Life Sciences Research Foundation. A. T. S. is a Genentech Fellow and supported by the Japanese Society for the Promotion of Science and the Kanae Foundation for Research Abroad. M. G. V. H. is supported by the NIH (R03MH085679 and 1P30CA147882), the Burroughs Wellcome Fund, the Damon Runyon Cancer Research Foundation, and the Smith family. This work was supported by grants from the NIH (R01-GM056203-13, P01-CA089021, and P01-CA117969-04 to L. C. C), the Starr Cancer Consortium (L. C. C. and M. G. V. H.), the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research, and the Intramural Research Program of the National Human Genome Research Institute, NIH (M. B. B., J. J., M. S., D. S. A., and C. J. T.). We apologize to colleagues whose work we could not cite because of space limitations.	Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Boxer MB, 2010, J MED CHEM, V53, P1048, DOI 10.1021/jm901577g; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Butterfield DA, 2007, J ALZHEIMERS DIS, V12, P61; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Filosa S, 2003, BIOCHEM J, V370, P935, DOI 10.1042/BJ20021614; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011; Le Goffe C, 2002, BIOCHEM J, V364, P349, DOI 10.1042/BJ20011856; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; MAEBA P, 1968, J BIOL CHEM, V243, P448; McDonagh B, 2009, J PROTEOMICS, V72, P677, DOI 10.1016/j.jprot.2009.01.023; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004	28	780	808	3	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	2011	334	6060					1278	1283		10.1126/science.1211485	http://dx.doi.org/10.1126/science.1211485			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HD	22052977	Green Submitted, Green Accepted			2022-12-28	WOS:000297553600051
J	Kang, TW; Yevsa, T; Woller, N; Hoenicke, L; Wuestefeld, T; Dauch, D; Hohmeyer, A; Gereke, M; Rudalska, R; Potapova, A; Iken, M; Vucur, M; Weiss, S; Heikenwalder, M; Khan, S; Gil, J; Bruder, D; Manns, M; Schirmacher, P; Tacke, F; Ott, M; Luedde, T; Longerich, T; Kubicka, S; Zender, L				Kang, Tae-Won; Yevsa, Tetyana; Woller, Norman; Hoenicke, Lisa; Wuestefeld, Torsten; Dauch, Daniel; Hohmeyer, Anja; Gereke, Marcus; Rudalska, Ramona; Potapova, Anna; Iken, Marcus; Vucur, Mihael; Weiss, Siegfried; Heikenwalder, Mathias; Khan, Sadaf; Gil, Jesus; Bruder, Dunja; Manns, Michael; Schirmacher, Peter; Tacke, Frank; Ott, Michael; Luedde, Tom; Longerich, Thomas; Kubicka, Stefan; Zender, Lars			Senescence surveillance of pre-malignant hepatocytes limits liver cancer development	NATURE			English	Article							MOUSE; RAS; FIBROBLASTS; SUPPRESSION; EXPRESSION; PATHWAY; MODELS; MICE; P53	Upon the aberrant activation of oncogenes, normal cells can enter the cellular senescence program, a state of stable cell-cycle arrest, which represents an important barrier against tumour development in vivo(1). Senescent cells communicate with their environment by secreting various cytokines and growth factors, and it was reported that this 'secretory phenotype' can have pro-as well as anti-tumorigenic effects(2-5). Here we show that oncogene-induced senescence occurs in otherwise normal murine hepatocytes in vivo. Pre-malignant senescent hepatocytes secrete chemo- and cytokines and are subject to immune-mediated clearance (designated as 'senescence surveillance'), which depends on an intact CD4(+) T-cell-mediated adaptive immune response. Impaired immune surveillance of pre-malignant senescent hepatocytes results in the development of murine hepatocellular carcinomas (HCCs), thus showing that senescence surveillance is important for tumour suppression in vivo. In accordance with these observations, ras-specific Th1 lymphocytes could be detected in mice, in which oncogene-induced senescence had been triggered by hepatic expression of Nras(G12V). We also found that CD4(+) T cells require monocytes/macrophages to execute the clearance of senescent hepatocytes. Our study indicates that senescence surveillance represents an important extrinsic component of the senescence anti-tumour barrier, and illustrates how the cellular senescence program is involved in tumour immune surveillance by mounting specific immune responses against antigens expressed in pre-malignant senescent cells.	[Kang, Tae-Won; Yevsa, Tetyana; Hoenicke, Lisa; Wuestefeld, Torsten; Dauch, Daniel; Hohmeyer, Anja; Gereke, Marcus; Rudalska, Ramona; Potapova, Anna; Weiss, Siegfried; Bruder, Dunja; Zender, Lars] Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany; [Yevsa, Tetyana; Woller, Norman; Wuestefeld, Torsten; Hohmeyer, Anja; Manns, Michael; Zender, Lars] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; [Iken, Marcus; Ott, Michael] Twincore Ctr Expt & Clin Infect Res, D-30625 Hannover, Germany; [Vucur, Mihael; Tacke, Frank; Luedde, Tom] Univ Hosp Aachen, Dept Internal Med 3, D-52074 Aachen, Germany; [Heikenwalder, Mathias] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; [Heikenwalder, Mathias] Tech Univ Munich, Helmholtz Ctr Munich, Inst Virol, D-81675 Munich, Germany; [Khan, Sadaf; Gil, Jesus] Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC Clin Sci Ctr, London W12 0NN, England; [Schirmacher, Peter; Longerich, Thomas] Univ Heidelberg, Inst Pathol, D-69120 Heidelberg, Germany; [Kubicka, Stefan] Dist Hosp Reutlingen, Clin Internal Med, D-72764 Reutlingen, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; RWTH Aachen University; RWTH Aachen University Hospital; University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Imperial College London; Ruprecht Karls University Heidelberg	Zender, L (corresponding author), Helmholtz Ctr Infect Res, Inhoffenstr 7, D-38124 Braunschweig, Germany.	Lars.Zender@helmholtz-hzi.de	Kang, Tae Won/S-4864-2019; Gil, Jesus/C-7739-2012; Tacke, Frank/ABF-2212-2020; Heikenwalder, Mathias/AAA-2269-2020; Luedde, Tom/AAE-9135-2022; Woller, Norman/AAU-2803-2021	Kang, Tae Won/0000-0003-1497-8926; Gil, Jesus/0000-0002-4303-6260; Luedde, Tom/0000-0002-6288-8821; /0000-0002-2430-4397; Hoenicke, Lisa/0000-0003-0613-8337; Yevsa, Tetyana/0000-0003-0377-9198; Woller, Norman/0000-0002-4928-0117	Helmholtz Association of German Research Centres [VH-NG-424]; German Research Foundation, DFG [ZE 545/2-1, SFB/TRR77]; Wilhelm Sander Stiftung; Bear Necessities Pediatric Cancer Foundation; Federal German Ministry for Education and Research (BMBF); European Commission; MRC [MC_U120085810] Funding Source: UKRI; Medical Research Council [MC_U120085810] Funding Source: researchfish	Helmholtz Association of German Research Centres(Helmholtz Association); German Research Foundation, DFG(German Research Foundation (DFG)); Wilhelm Sander Stiftung; Bear Necessities Pediatric Cancer Foundation; Federal German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); European Commission(European CommissionEuropean Commission Joint Research Centre); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank D. Largaespada and M. Kay for providing transposon vectors and transposase encoding vectors. We thank L. Grobe, A. Rinkel, N. Struever, H. Riedesel, the team of the Helmholtz Centre for Infection Research (HZI) animal facility, M. Rothe, K. Schulze, A. Kobold, F. Heinzmann, N. Jedicke, C. Schneider, M. Pesic, H. Klimek and A. Samuels for technical assistance and assistance with animal work, and F. Alves, S. Kimmina, C. Dullin and S. Greco for assistance with flat panel-volumetric computer tomography. We thank the tissue bank of the National Center for Tumor Diseases Heidelberg for providing liver explant tissues. We thank S. Lowe, H. Tillmann, F. Greten and members of the Lowe and Zender laboratory for advice and discussions. This work was supported by the Helmholtz Association of German Research Centres (VH-NG-424 to L.Z.), the German Research Foundation, DFG (Emmy Noether Programme ZE 545/2-1 to L.Z., SFB/TRR77 and the 'Rebirth' Cluster of Excellence), the Wilhelm Sander Stiftung, the Bear Necessities Pediatric Cancer Foundation, the Federal German Ministry for Education and Research (BMBF) (ARCHES AWARD to L.Z.) and the European Commission (project 'Heptromic'). L.Z. holds an adjunct assistant Professorship with the Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA. This work is dedicated to J. Wehland.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Brown DM, 2010, CELL IMMUNOL, V262, P89, DOI 10.1016/j.cellimm.2010.02.008; Carlson CM, 2005, P NATL ACAD SCI USA, V102, P17059, DOI 10.1073/pnas.0502974102; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Frid MG, 2006, AM J PATHOL, V168, P659, DOI 10.2353/ajpath.2006.050599; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Hensel M, 2011, DTSCH ARZTEBL INT, V108, P117, DOI 10.3238/arztebl.2010.0117; HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SARMA DSR, 1986, CANCER SURV, V5, P781; Silva MT, 2010, J LEUKOCYTE BIOL, V87, P93, DOI 10.1189/jlb.0809549; Tannour-Louet M, 2002, HEPATOLOGY, V35, P1072, DOI 10.1053/jhep.2002.33164; Thomsen M, 2008, TOXICOLOGY, V246, P18, DOI 10.1016/j.tox.2007.10.017; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	21	906	929	6	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 24	2011	479	7374					547	551		10.1038/nature10599	http://dx.doi.org/10.1038/nature10599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22080947				2022-12-28	WOS:000297285600055
J	Lancaster, KM; Roemelt, M; Ettenhuber, P; Hu, YL; Ribbe, MW; Neese, F; Bergmann, U; DeBeer, S				Lancaster, Kyle M.; Roemelt, Michael; Ettenhuber, Patrick; Hu, Yilin; Ribbe, Markus W.; Neese, Frank; Bergmann, Uwe; DeBeer, Serena			X-ray Emission Spectroscopy Evidences a Central Carbon in the Nitrogenase Iron-Molybdenum Cofactor	SCIENCE			English	Article							MOFE-PROTEIN; FEMO-COFACTOR; RESTING STATE; RESOLUTION; MECHANISM; CLUSTER; SULFUR; LIGAND; ENDOR	Nitrogenase is a complex enzyme that catalyzes the reduction of dinitrogen to ammonia. Despite insight from structural and biochemical studies, its structure and mechanism await full characterization. An iron-molybdenum cofactor (FeMoco) is thought to be the site of dinitrogen reduction, but the identity of a central atom in this cofactor remains unknown. Fe K beta x-ray emission spectroscopy (XES) of intact nitrogenase MoFe protein, isolated FeMoco, and the FeMoco-deficient Delta nifB protein indicates that among the candidate atoms oxygen, nitrogen, and carbon, it is carbon that best fits the XES data. The experimental XES is supported by computational efforts, which show that oxidation and spin states do not affect the assignment of the central atom to C4-. Identification of the central atom will drive further studies on its role in catalysis.	[Hu, Yilin; Ribbe, Markus W.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; [Lancaster, Kyle M.; DeBeer, Serena] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [Roemelt, Michael; Ettenhuber, Patrick; Neese, Frank] Univ Bonn, Inst Phys & Theoret Chem, D-53115 Bonn, Germany; [Neese, Frank; DeBeer, Serena] Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany; [Bergmann, Uwe] SLAC Natl Accelerator Lab, Linac Coherent Light Source, Menlo Pk, CA 94025 USA	University of California System; University of California Irvine; Cornell University; University of Bonn; Max Planck Society; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Ribbe, MW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	mribbe@uci.edu; frank.neese@mpi-mail.mpg.de; bergmann@slac.stanford.edu; serena.debeer@mpi-mail.mpg.de	Neese, Frank/J-4959-2014; DeBeer, Serena/T-6420-2018; DeBeer, Serena/G-6718-2012	Neese, Frank/0000-0003-4691-0547; DeBeer, Serena/0000-0002-5196-3400; Roemelt, Michael/0000-0002-4780-5354	Cornell Univ.; Alfred P. Sloan Foundation; Univ. of Bonn; Max Planck Society; NIH [R01-GM 67626]; DOE, Biological and Environmental Research; NIH, National Center for Research Resources;  [SFB 813]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067626] Funding Source: NIH RePORTER	Cornell Univ.; Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Univ. of Bonn; Max Planck Society(Max Planck Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOE, Biological and Environmental Research(United States Department of Energy (DOE)); NIH, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	S.D. thanks Cornell Univ. for financial support and the Alfred P. Sloan Foundation for a fellowship; F.N. acknowledges financial support from the Univ. of Bonn, the Max Planck Society, and the SFB 813; M. W. R. thanks the NIH for funding (grant R01-GM 67626). Portions of this research were carried out at the Stanford Synchrotron Radiation Lightsource (SSRL), a U.S. Department of Energy (DOE), Basic Energy Sciences user facility. The SSRL Structural Molecular Biology program is supported by DOE, Biological and Environmental Research, and NIH, National Center for Research Resources, Biomedical Technology Program.	ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; AVERILL BA, 1973, J AM CHEM SOC, V95, P3523, DOI 10.1021/ja00792a013; Barney BM, 2009, BIOCHEMISTRY-US, V48, P9094, DOI 10.1021/bi901092z; Bergmann U, 1999, CHEM PHYS LETT, V302, P119, DOI 10.1016/S0009-2614(99)00095-0; Delgado-Jaime MU, 2011, INORG CHEM, V50, P10709, DOI 10.1021/ic201173j; Eeckhout SG, 2009, J ANAL ATOM SPECTROM, V24, P215, DOI 10.1039/b808345m; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Glatzel P, 2005, COORDIN CHEM REV, V249, P65, DOI 10.1016/j.ccr.2004.04.011; Harris TV, 2011, INORG CHEM, V50, P4811, DOI 10.1021/ic102446n; Hoffman BM, 2009, ACCOUNTS CHEM RES, V42, P609, DOI 10.1021/ar8002128; Hu YL, 2010, ACCOUNTS CHEM RES, V43, P475, DOI 10.1021/ar900254x; Lancaster KM, 2011, INORG CHEM, V50, P6767, DOI 10.1021/ic200822b; Lee HI, 1997, J AM CHEM SOC, V119, P11395, DOI 10.1021/ja971508d; Lee N, 2010, J AM CHEM SOC, V132, P9715, DOI 10.1021/ja101281e; Lukoyanov D, 2007, INORG CHEM, V46, P11437, DOI 10.1021/ic7018814; Neese F, 2006, ANGEW CHEM INT EDIT, V45, P196, DOI 10.1002/anie.200502667; NOODLEMAN L, 1981, J CHEM PHYS, V74, P5737, DOI 10.1063/1.440939; Pollock CJ, 2011, J AM CHEM SOC, V133, P5594, DOI 10.1021/ja200560z; Schmid B, 2002, SCIENCE, V296, P352, DOI 10.1126/science.1070010; Smolentsev G, 2009, J AM CHEM SOC, V131, P13161, DOI 10.1021/ja808526m; TRUE AE, 1988, J AM CHEM SOC, V110, P1935, DOI 10.1021/ja00214a045; Xiao YM, 2006, J AM CHEM SOC, V128, P7608, DOI 10.1021/ja0603655; Yoo SJ, 2000, J AM CHEM SOC, V122, P4926, DOI 10.1021/ja000254k	23	609	616	12	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					974	977		10.1126/science.1206445	http://dx.doi.org/10.1126/science.1206445			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096198	Green Accepted			2022-12-28	WOS:000297101800055
J	Nelson, CT; Gao, P; Jokisaari, JR; Heikes, C; Adamo, C; Melville, A; Baek, SH; Folkman, CM; Winchester, B; Gu, YJ; Liu, YM; Zhang, K; Wang, EG; Li, JY; Chen, LQ; Eom, CB; Schlom, DG; Pan, XQ				Nelson, Christopher T.; Gao, Peng; Jokisaari, Jacob R.; Heikes, Colin; Adamo, Carolina; Melville, Alexander; Baek, Seung-Hyub; Folkman, Chad M.; Winchester, Benjamin; Gu, Yijia; Liu, Yuanming; Zhang, Kui; Wang, Enge; Li, Jiangyu; Chen, Long-Qing; Eom, Chang-Beom; Schlom, Darrell G.; Pan, Xiaoqing			Domain Dynamics During Ferroelectric Switching	SCIENCE			English	Article							MECHANISM; NUCLEATION; CRYSTAL; FILMS	The utility of ferroelectric materials stems from the ability to nucleate and move polarized domains using an electric field. To understand the mechanisms of polarization switching, structural characterization at the nanoscale is required. We used aberration-corrected transmission electron microscopy to follow the kinetics and dynamics of ferroelectric switching at millisecond temporal and subangstrom spatial resolution in an epitaxial bilayer of an antiferromagnetic ferroelectric (BiFeO3) on a ferromagnetic electrode (La0.7Sr0.3MnO3). We observed localized nucleation events at the electrode interface, domain wall pinning on point defects, and the formation of ferroelectric domains localized to the ferroelectric and ferromagnetic interface. These results show how defects and interfaces impede full ferroelectric switching of a thin film.	[Nelson, Christopher T.; Gao, Peng; Jokisaari, Jacob R.; Zhang, Kui; Pan, Xiaoqing] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA; [Heikes, Colin; Adamo, Carolina; Melville, Alexander; Schlom, Darrell G.] Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA; [Baek, Seung-Hyub; Folkman, Chad M.; Eom, Chang-Beom] Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA; [Winchester, Benjamin; Gu, Yijia; Chen, Long-Qing] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; [Liu, Yuanming; Li, Jiangyu] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA; [Wang, Enge] Peking Univ, Sch Phys, Beijing 100871, Peoples R China; [Schlom, Darrell G.] Kavli Inst Cornell Nanoscale Sci, Ithaca, NY 14853 USA	University of Michigan System; University of Michigan; Cornell University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Washington; University of Washington Seattle; Peking University	Pan, XQ (corresponding author), Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.	panx@umich.edu	Kim, Yu Jin/A-2433-2012; Gao, Peng/AAC-8550-2019; Gao, Peng/B-4675-2012; Pan, Xiaoqing/ABF-4088-2020; Chen, LongQing/I-7536-2012; Liu, Yuanming/D-5031-2012; Eom, Chang-Beom/I-5567-2014; Li, Jiangyu/B-3191-2008; Gu, Yijia/A-6418-2013; Schlom, Darrell G/J-2412-2013	Pan, Xiaoqing/0000-0002-0965-8568; Chen, LongQing/0000-0003-3359-3781; Li, Jiangyu/0000-0003-0533-1397; Gu, Yijia/0000-0001-8036-6309; Schlom, Darrell G/0000-0003-2493-6113; , Alexander Melville/0000-0003-1158-9036; Heikes, Colin/0000-0002-8362-9175; Baek, Seung-Hyub/0000-0002-3187-6596; Gao, Peng/0000-0001-9868-2115	U.S. Department of Energy (DOE), Office of Basic Energy Sciences, Division of Materials Sciences and Engineering [DE-FG02-07ER46416]; NSF [DMR-0907191, DMR-0820404, DMR-0723032]; Cornell University by Army Research Office (ARO) [W911NF-08-2-0032]; Penn State University by the U.S. Department of Energy [DE-FG02-07ER46417]; University of Wisconsin-Madison by ARO [W911NF-10-1-0362]; University of Washington by ARO [W911NF-07-1-0410]; National Center for Electron Microscopy at Lawrence Berkeley National Laboratory under the DOE [DE-AC02-05CH11231]	U.S. Department of Energy (DOE), Office of Basic Energy Sciences, Division of Materials Sciences and Engineering(United States Department of Energy (DOE)); NSF(National Science Foundation (NSF)); Cornell University by Army Research Office (ARO); Penn State University by the U.S. Department of Energy; University of Wisconsin-Madison by ARO; University of Washington by ARO; National Center for Electron Microscopy at Lawrence Berkeley National Laboratory under the DOE	This work was supported by the U.S. Department of Energy (DOE), Office of Basic Energy Sciences, Division of Materials Sciences and Engineering, under award DE-FG02-07ER46416 and partially by NSF under awards DMR-0907191 (P. G. and K.Z.), DMR-0820404 (J.R.J.), and DMR-0723032 (aberration-corrected TEM instrument); at Cornell University by Army Research Office (ARO) grant W911NF-08-2-0032; at Penn State University by the U.S. Department of Energy under award DE-FG02-07ER46417; at the University of Wisconsin-Madison by ARO grant W911NF-10-1-0362; and at the University of Washington by ARO grant W911NF-07-1-0410. The authors also acknowledge the National Center for Electron Microscopy at Lawrence Berkeley National Laboratory for their support under the DOE grant DE-AC02-05CH11231 for user facilities. The project was conceived and directed by X. Q. P.; C.T.N., D. G. S., and X. Q. P. wrote the manuscript; TEM experiments were performed and analyzed by C.T.N. and P. G. under the guidance of X. Q. P.; BiFeO<INF>3</INF> and La<INF>0.7</INF>Sr<INF>0.3</INF>MnO<INF>3</INF> films were fabricated using molecular beam epitaxy by C. H., C. A., and A. M. under the guidance of D. G. S.; PFM experiments were performed by J.R.J. and Y.M.L. under the supervision of J.Y.L.; Hall measurements were performed by K.Z. under the supervision of X. Q. P.; sputtered films were grown by C. M. F. and S. H. B. under the supervision of C. B. E.; phase-field simulations were carried out by B. W. and Y.J.G. under the supervision of L. Q. C.; and E. G. W. participated in the modeling and analysis of interfacial properties.	AIZU K, 1969, J PHYS SOC JPN, V27, P387, DOI 10.1143/JPSJ.27.387; Baek SH, 2010, NAT MATER, V9, P309, DOI [10.1038/NMAT2703, 10.1038/nmat2703]; Balke N, 2010, ADV FUNCT MATER, V20, P3466, DOI 10.1002/adfm.201000475; Chu MW, 2004, NAT MATER, V3, P87, DOI 10.1038/nmat1057; Chu YH, 2008, NAT MATER, V7, P478, DOI 10.1038/nmat2184; Clark SJ, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2716868; Cruz MP, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.217601; Dawber M, 2005, REV MOD PHYS, V77, P1083, DOI 10.1103/RevModPhys.77.1083; de Jong MP, 2003, J APPL PHYS, V94, P7292, DOI 10.1063/1.1625081; Folkman CM, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3298362; Garcia V, 2009, NATURE, V460, P81, DOI 10.1038/nature08128; Gopalan V, 1998, J APPL PHYS, V83, P941, DOI 10.1063/1.366782; Jesse S, 2008, NAT MATER, V7, P209, DOI 10.1038/nmat2114; Jia CL, 2007, NAT MATER, V6, P64, DOI 10.1038/nmat1808; KUBEL F, 1990, ACTA CRYSTALLOGR B, V46, P698, DOI 10.1107/S0108768190006887; Kuroda A, 1996, APPL PHYS LETT, V69, P1565, DOI 10.1063/1.117031; Maksymovych P, 2009, SCIENCE, V324, P1421, DOI 10.1126/science.1171200; MERZ WJ, 1954, PHYS REV, V95, P690, DOI 10.1103/PhysRev.95.690; MULLER EW, 1955, J APPL PHYS, V26, P732, DOI 10.1063/1.1722081; Nelson CT, 2011, NANO LETT, V11, P828, DOI 10.1021/nl1041808; Pantel D, 2010, J APPL PHYS, V107, DOI 10.1063/1.3392884; Scott JF, 2007, SCIENCE, V315, P954, DOI 10.1126/science.1129564; Scott JF, 2000, APPL PHYS LETT, V76, P3801, DOI 10.1063/1.126786; SCOTT JF, 1989, SCIENCE, V246, P1400, DOI 10.1126/science.246.4936.1400; Shin YH, 2007, NATURE, V449, P881, DOI 10.1038/nature06165; Tagantsev AK, 2006, J APPL PHYS, V100, DOI 10.1063/1.2337009; Tybell T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.097601; Wu SM, 2010, NAT MATER, V9, P756, DOI [10.1038/nmat2803, 10.1038/NMAT2803]; Yuan GL, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3114993; Zhang J, 2009, J VAC SCI TECHNOL B, V27, P2012, DOI 10.1116/1.3130152; Zhao T, 2006, NAT MATER, V5, P823, DOI 10.1038/nmat1731	31	280	284	34	719	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					968	971		10.1126/science.1206980	http://dx.doi.org/10.1126/science.1206980			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096196				2022-12-28	WOS:000297101800053
J	Diringer, E				Diringer, Elliot			Letting go of Kyoto	NATURE			English	Editorial Material									[Diringer, Elliot] Ctr Climate & Energy Solut, Arlington, VA USA		Diringer, E (corresponding author), Ctr Climate & Energy Solut, Arlington, VA USA.	diringere@c2es.org							0	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					291	292		10.1038/479291a	http://dx.doi.org/10.1038/479291a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	848OA	22094672	Bronze			2022-12-28	WOS:000297059700014
J	Soper, DE; Lee, SI; Kim, JY; McDonald, AG				Soper, David E.; Lee, Susanna I.; Kim, Ji Yeon; McDonald, Anna G.			Case 35-2011: A 33-Year-Old Woman with Postpartum Leukocytosis and Gram-Positive Bacteremia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSTRIDIUM-PERFRINGENS; GENITAL-TRACT; INFECTION; SORDELLII; MICROBIOLOGY; ENDOMETRITIS; MANAGEMENT; DELIVERY; ABORTION; SEPSIS		[Soper, David E.] Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA; [Lee, Susanna I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Kim, Ji Yeon; McDonald, Anna G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Lee, Susanna I.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Kim, Ji Yeon; McDonald, Anna G.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Medical University of South Carolina; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Soper, DE (corresponding author), Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA.			Lee, Susanna I/0000-0003-2195-2943	Merck	Merck(Merck & Company)	Dr. Soper reports that his institution has received grant support from Merck. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	ACKER DB, 1985, AM J OBSTET GYNECOL, V153, P737, DOI 10.1016/0002-9378(85)90335-7; BARTLETT JG, 1978, AM J OBSTET GYNECOL, V130, P658, DOI 10.1016/0002-9378(78)90323-X; Bone RC, 1996, CLIN CHEST MED, V17, P175, DOI 10.1016/S0272-5231(05)70307-5; BUTLER HM, 1945, SURG GYNECOL OBSTET, V81, P475; Cohen AL, 2007, OBSTET GYNECOL, V110, P1027, DOI 10.1097/01.AOG.0000287291.19230.ba; DYLEWSKI J, 1989, REV INFECT DIS, V11, P470; Fischer M, 2005, NEW ENGL J MED, V353, P2352, DOI 10.1056/NEJMoa051620; GARAGIOLA DM, 1989, AM J ROENTGENOL, V153, P1239, DOI 10.2214/ajr.153.6.1239; GIBBS RS, 1982, J INFECT DIS, V145, P1, DOI 10.1093/infdis/145.1.1; Halpin TF, 2002, OBSTET GYNECOL SURV, V57, P53, DOI 10.1097/00006254-200201000-00024; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; RAMSAY AM, 1949, J OBSTET GYN BRIT EM, V56, P247; Sherman D, 1999, OBSTET GYNECOL, V94, P787, DOI 10.1016/S0029-7844(99)00421-4; SLOTNICK IJ, 1962, AM J OBSTET GYNECOL, V83, P1102, DOI 10.1016/S0002-9378(16)35947-6; Smith B, 2009, SCAND J INFECT DIS, V41, P21, DOI 10.1080/00365540802468094; SOPER DE, 1989, AM J OBSTET GYNECOL, V161, P562, DOI 10.1016/0002-9378(89)90356-6; SOPER DE, 1988, J REPROD MED, V33, P97; STEVENS DL, 1987, ANTIMICROB AGENTS CH, V31, P213, DOI 10.1128/AAC.31.2.213; STEVENS DL, 1988, J INFECT DIS, V158, P23, DOI 10.1093/infdis/158.1.23; VEATCH M, 2010, REPR HLTH 2010 ANN M; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; EARLY RECOGNITION LI	22	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1916	1924		10.1056/NEJMcpc1103564	http://dx.doi.org/10.1056/NEJMcpc1103564			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087683				2022-12-28	WOS:000297041900011
J	Nicholls, SJ; Brewer, HB; Kastelein, JJP; Krueger, KA; Wang, MD; Shao, MY; Hu, B; McErlean, E; Nissen, SE				Nicholls, Stephen J.; Brewer, H. Bryan; Kastelein, John J. P.; Krueger, Kathryn A.; Wang, Ming-Dauh; Shao, Mingyuan; Hu, Bo; McErlean, Ellen; Nissen, Steven E.			Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTER TRANSFER PROTEIN; CORONARY-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; LIPID-LEVEL MANAGEMENT; HIGH-RISK; ATHEROSCLEROSIS; TORCETRAPIB; EVENTS; PRAVASTATIN; PREVENTION	Context Interest remains high in cholesteryl ester transfer protein (CETP) inhibitors as cardioprotective agents. Few studies have documented the efficacy and safety of CETP inhibitors in combination with commonly used statins. Objective To examine the biochemical effects, safety, and tolerability of evacetrapib, as monotherapy and in combination with statins, in patients with dyslipidemia. Design, Setting, and Participants Randomized controlled trial conducted among 398 patients with elevated low-density lipoprotein cholesterol (LDL-C) or low high-density lipoprotein cholesterol (HDL-C) levels from April 2010 to January 2011 at community and academic centers in the United States and Europe. Interventions Following dietary lead-in, patients were randomly assigned to receive placebo (n=38); evacetrapib monotherapy, 30 mg/d (n=40), 100 mg/d (n=39), or 500 mg/d (n=42); or statin therapy (n=239) (simvastatin, 40 mg/d; atorvastatin, 20 mg/d; or rosuvastatin, 10 mg/d) with or without evacetrapib, 100 mg/d, for 12 weeks. Main Outcome Measures The co-primary end points were percentage changes from baseline in HDL-C and LDL-C after 12 weeks of treatment. Results The mean baseline HDL-C level was 55.1 (SD, 15.3) mg/dL and the mean baseline LDL-C level was 144.3 (SD, 26.6) mg/dL. As monotherapy, evacetrapib produced dose-dependent increases in HDL-C of 30.0 to 66.0 mg/dL (53.6% to 128.8%) compared with a decrease with placebo of -0.7 mg/dL (-3.0%; P<.001 for all compared with placebo) and decreases in LDL-C of -20.5 to -51.4 mg/dL (-13.6% to -35.9%) compared with an increase with placebo of 7.2 mg/dL (3.9%; P<.001 for all compared with placebo). In combination with statin therapy, evacetrapib, 100 mg/d, produced increases in HDL-C of 42.1 to 50.5 mg/dL (78.5% to 88.5%; P<.001 for all compared with statin monotherapy) and decreases in LDL-C of -67.1 to -75.8 mg/dL (-11.2% to -13.9%; P<.001 for all compared with statin monotherapy). Compared with evacetrapib monotherapy, the combination of statins and evacetrapib resulted in greater reductions in LDL-C (P<.001) but no greater increase in HDL-C (P=.39). Although the study was underpowered, no adverse effects were observed. Conclusions Compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C levels. The effects on cardiovascular outcomes require further investigation.	[Nicholls, Stephen J.] Cleveland Clin, Dept Cardiovasc Med, Coordinating Ctr Clin Res, Cleveland, OH 44195 USA; [Hu, Bo] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Brewer, H. Bryan] Medstar Res Inst, Washington, DC USA; [Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Krueger, Kathryn A.; Wang, Ming-Dauh] Eli Lilly, Indianapolis, IN USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Amsterdam; Academic Medical Center Amsterdam; Eli Lilly	Nicholls, SJ (corresponding author), Cleveland Clin, Dept Cardiovasc Med, Coordinating Ctr Clin Res, Mail Code JJ 65,9500 Euclid Ave, Cleveland, OH 44195 USA.	nichols1@ccf.org	Kastelein, John/AAF-7950-2020	Nicholls, Stephen/0000-0002-9668-4368	AstraZeneca; Novartis; Eli Lilly; Anthera; LipoScience; Roche; Resverlogix; Merck; Pfizer; Abbott; sanofi-aventis; Takeda; Sankyo	AstraZeneca(AstraZeneca); Novartis(Novartis); Eli Lilly(Eli Lilly); Anthera; LipoScience; Roche(Roche Holding); Resverlogix; Merck(Merck & Company); Pfizer(Pfizer); Abbott(Abbott Laboratories); sanofi-aventis(Sanofi-Aventis); Takeda(Takeda Pharmaceutical Company Ltd); Sankyo	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Nicholls reports receiving research support from AstraZeneca, Novartis, Eli Lilly, Anthera, LipoScience, Roche, and Resverlogix and receiving honoraria or serving as a consultant for AstraZeneca, Roche, Esperion, Abbott, Pfizer, Merck, Takeda, LipoScience, Omthera, Novo-Nordisk, sanofi-aventis, Atheronova, Anthera, CSL Behring, and Boehringer Ingelheim. Dr Brewer reports serving on advisory boards and receiving consulting fees and honoraria from Merck, Pfizer, Abbott, Roche, Eli Lilly, and sanofi-aventis. Dr Kastelein reports serving as a consultant for Eli Lilly, Merck, Roche, Boehringer Ingelheim, Cerenis, Novartis, Genzyme, and Isis. Drs Krueger and Wang are employees of Eli Lilly. Dr Nissen reports receiving research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and sanofi-aventis. He has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees, or any other payments from any forprofit entity are paid directly to charity so that neither income nor any tax deduction is received. No other disclosures were reported.	Barter P, 2009, AM J CARDIOL, V104, p10E, DOI 10.1016/j.amjcard.2009.09.014; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64; Bots ML, 2007, LANCET, V370, P153, DOI 10.1016/S0140-6736(07)61088-5; Brewer H Bryan Jr, 2007, Curr Cardiol Rep, V9, P486, DOI 10.1007/BF02938393; Cannon CP, 2010, NEW ENGL J MED, V363, P2406, DOI 10.1056/NEJMoa1009744; Cao GQ, 2011, J LIPID RES, V52, P2169, DOI 10.1194/jlr.M018069; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Kastelein JJP, 2007, NEW ENGL J MED, V356, P1620, DOI 10.1056/NEJMoa071359; Libby P, 2005, J AM COLL CARDIOL, V46, P1225, DOI 10.1016/j.jacc.2005.07.006; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nicholls SJ, 2008, CURR OPIN INVEST DR, V9, P950; Nicholls SJ, 2007, CLEV CLIN J MED, V74, P709, DOI 10.3949/ccjm.74.10.709; Nicholls SJ, 2008, CIRCULATION, V118, P2506, DOI 10.1161/CIRCULATIONAHA.108.790733; Niesor EJ, 2010, J LIPID RES, V51, P3443, DOI 10.1194/jlr.M008706; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; PEDERSEN TR, 1994, LANCET, V344, P1383; Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1093/eurheartj/ehr158, 10.1016/j.atherosclerosis.2011.06.012]; Ritsch A, 2010, CIRCULATION, V121, P366, DOI 10.1161/CIRCULATIONAHA.109.875013; Rittershaus CW, 2000, ARTERIOSCL THROM VAS, V20, P2106, DOI 10.1161/01.ATV.20.9.2106; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sugano M, 1998, J BIOL CHEM, V273, P5033, DOI 10.1074/jbc.273.9.5033; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Vasan RS, 2009, CIRCULATION, V120, P2414, DOI 10.1161/CIRCULATIONAHA.109.872705; Vergeer M, 2009, AM J CARDIOL, V104, p32E, DOI 10.1016/j.amjcard.2009.09.017; Yvan-Charvet L, 2007, ARTERIOSCL THROM VAS, V27, P1132, DOI 10.1161/ATVBAHA.106.138347	31	337	347	3	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2099	2109		10.1001/jama.2011.1649	http://dx.doi.org/10.1001/jama.2011.1649			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089718	Bronze			2022-12-28	WOS:000297013000016
J	Chevrier, N; Mertins, P; Artyomov, MN; Shalek, AK; Iannacone, M; Ciaccio, MF; Gat-Viks, I; Tonti, E; DeGrace, MM; Clauser, KR; Garber, M; Eisenhaure, TM; Yosef, N; Robinson, J; Sutton, A; Andersen, MS; Root, DE; von Andrian, U; Jones, RB; Park, H; Carr, SA; Regev, A; Amit, I; Hacohen, N				Chevrier, Nicolas; Mertins, Philipp; Artyomov, Maxim N.; Shalek, Alex K.; Iannacone, Matteo; Ciaccio, Mark F.; Gat-Viks, Irit; Tonti, Elena; DeGrace, Marciela M.; Clauser, Karl R.; Garber, Manuel; Eisenhaure, Thomas M.; Yosef, Nir; Robinson, Jacob; Sutton, Amy; Andersen, Mette S.; Root, David E.; von Andrian, Ulrich; Jones, Richard B.; Park, Hongkun; Carr, Steven A.; Regev, Aviv; Amit, Ido; Hacohen, Nir			Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits	CELL			English	Article							POLO-LIKE KINASES; BETA GENE-EXPRESSION; TOLL-LIKE RECEPTORS; INTERFERON-BETA; AUTOIMMUNE-DISEASES; I INTERFERON; CELLS; INHIBITORS; RESPONSES; PHOSPHORYLATION	Deciphering the signaling networks that underlie normal and disease processes remains a major challenge. Here, we report the discovery of signaling components involved in the Toll-like receptor (TLR) response of immune dendritic cells (DCs), including a previously unkown pathway shared across mammalian antiviral responses. By combining transcriptional profiling, genetic and small-molecule perturbations, and phosphoproteomics, we uncover 35 signaling regulators, including 16 known regulators, involved in TLR signaling. In particular, we find that Polo-like kinases (Plk) 2 and 4 are essential components of antiviral pathways in vitro and in vivo and activate a signaling branch involving a dozen proteins, among which is Tnfaip2, a gene associated with autoimmune diseases but whose role was unknown. Our study illustrates the power of combining systematic measurements and perturbations to elucidate complex signaling circuits and discover potential therapeutic targets.	[Chevrier, Nicolas; Mertins, Philipp; Artyomov, Maxim N.; Gat-Viks, Irit; DeGrace, Marciela M.; Clauser, Karl R.; Garber, Manuel; Eisenhaure, Thomas M.; Yosef, Nir; Root, David E.; Carr, Steven A.; Regev, Aviv; Amit, Ido; Hacohen, Nir] Broad Inst MIT& Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA; [Chevrier, Nicolas; DeGrace, Marciela M.; Eisenhaure, Thomas M.; Amit, Ido; Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA; [Chevrier, Nicolas; DeGrace, Marciela M.; Amit, Ido; Hacohen, Nir] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Chevrier, Nicolas] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA 02115 USA; [Iannacone, Matteo; Tonti, Elena; von Andrian, Ulrich] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Iannacone, Matteo; Tonti, Elena; von Andrian, Ulrich] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Artyomov, Maxim N.; Gat-Viks, Irit; Yosef, Nir; Regev, Aviv; Amit, Ido] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02142 USA; [Shalek, Alex K.; Robinson, Jacob; Sutton, Amy; Andersen, Mette S.; Park, Hongkun] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA; [Shalek, Alex K.; Robinson, Jacob; Sutton, Amy; Andersen, Mette S.; Park, Hongkun] Harvard Univ, Dept Chem Biol, Cambridge, MA 02138 USA; [Ciaccio, Mark F.; Jones, Richard B.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Shalek, Alex K.; Robinson, Jacob; Sutton, Amy; Andersen, Mette S.; Park, Hongkun] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [Ciaccio, Mark F.; Jones, Richard B.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA; [Iannacone, Matteo; Tonti, Elena] Ist Sci San Raffaele, Div Immunol Infect Dis & Transplantat, I-20132 Milan, Italy	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard University; University of Chicago; Harvard University; University of Chicago; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Amit, I (corresponding author), Broad Inst MIT& Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA.	ido.amit@weizmann.ac.il; nhacohen@partners.org	Park, Hongkun/R-9842-2019; von Andrian, Ulrich H/A-5775-2008; Iannacone, Matteo/I-8507-2018; Carr, Steven A./AAH-8366-2019; Shalek, Alex/Y-2434-2019	Park, Hongkun/0000-0001-9576-8829; Iannacone, Matteo/0000-0002-9370-2671; Shalek, Alex/0000-0001-5670-8778; Tonti, Elena/0000-0001-5002-7613; Clauser, Karl/0000-0002-1052-9456	NIH [U54 AI057159, DP2 OD002230, P50 HG006193]; Boehringer Ingelheim Fonds; Human Frontier Science Program Organization; American Physicians Fellowship for Medicine in Israel; Burroughs Wellcome Fund; Sloan Foundation; HHMI; NIH Chicago Center for Systems Biology [P50 GM081892-03]; American Cancer Society Illinois Division; NATIONAL CANCER INSTITUTE [DP1CA174427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026688] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG006193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM081892] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002230] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer Ingelheim Fonds(Boehringer Ingelheim); Human Frontier Science Program Organization(Human Frontier Science Program); American Physicians Fellowship for Medicine in Israel; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Sloan Foundation(Alfred P. Sloan Foundation); HHMI(Howard Hughes Medical Institute); NIH Chicago Center for Systems Biology; American Cancer Society Illinois Division(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the members of the Hacohen and Regev laboratories, O. Takeuchi, B. Beutler, D. Mathis, P. Anderson, L. Glimcher, and D. Bartel for valuable discussions and comments; L. Gaffney and L. Solomon for assistance with figures and artwork; and S. Gupta and the Broad Genetic Analysis Platform for microarray processing. This work was supported by NIH grant U54 AI057159, the NIH New Innovator Award DP2 OD002230 (N.H.), and NIH P50 HG006193 (A. R., N.H.); a Ph.D fellowship from the Boehringer Ingelheim Fonds (N.C.); the Human Frontier Science Program Organization and a Claire and Emanuel G. Rosenblatt Award from the American Physicians Fellowship for Medicine in Israel (I. A.); NIH Pioneer Awards (A. R., H. P.); and a Career Award at the Scientific Interface from the Burroughs Wellcome Fund, the Sloan Foundation, and HHMI (A. R.). A. R. is an investigator of the Merkin Foundation for Stem Cell Research at the Broad Institute. This work was partially supported by a pilot award from the NIH Chicago Center for Systems Biology P50 GM081892-03 to R.B.J. and an award from the American Cancer Society Illinois Division to R.B.J.	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barrat FJ, 2008, IMMUNOL REV, V223, P271, DOI 10.1111/j.1600-065X.2008.00630.x; Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13; Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chang J, 2010, EMBO J, V29, P2395, DOI 10.1038/emboj.2010.118; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Ciaccio MF, 2010, NAT METHODS, V7, P148, DOI [10.1038/nmeth.1418, 10.1038/NMETH.1418]; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Crozat K, 2007, J EXP MED, V204, P853, DOI 10.1084/jem.20062447; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fraser IDC, 2009, NAT IMMUNOL, V10, P327, DOI 10.1038/ni.1711; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Heikkinen LS, 2008, J BIOL CHEM, V283, P5719, DOI 10.1074/jbc.M707195200; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Hrincius ER, 2010, CELL MICROBIOL, V12, P831, DOI 10.1111/j.1462-5822.2010.01436.x; Iannacone M, 2010, NATURE, V465, P1079, DOI 10.1038/nature09118; Kawagoe T, 2009, NAT IMMUNOL, V10, P965, DOI 10.1038/ni.1771; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kuan AP, 1999, IMMUNOGENETICS, V49, P79, DOI 10.1007/s002510050466; Matsui K, 2006, J IMMUNOL, V177, P5785, DOI 10.4049/jimmunol.177.9.5785; Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Reizis B, 2011, ANNU REV IMMUNOL, V29, P163, DOI 10.1146/annurev-immunol-031210-101345; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Santiago-Raber ML, 2003, J EXP MED, V197, P777, DOI 10.1084/jem.20021996; Seeburg DP, 2005, ONCOGENE, V24, P292, DOI 10.1038/sj.onc.1208277; Shalek AK, 2010, P NATL ACAD SCI USA, V107, P1870, DOI 10.1073/pnas.0909350107; Sharma K, 2010, J PROTEOME RES, V9, P2539, DOI 10.1021/pr901192p; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Villen J, 2008, NAT PROTOC, V3, P1630, DOI 10.1038/nprot.2008.150; Vitour D, 2009, J BIOL CHEM, V284, P21797, DOI 10.1074/jbc.M109.018275; Wang L, 2010, IMMUNITY, V32, P518, DOI 10.1016/j.immuni.2010.03.014; Weintz G, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.29; Xiao NM, 2009, J IMMUNOL, V183, P7975, DOI 10.4049/jimmunol.0902718; Ye JQ, 2011, NAT CHEM BIOL, V7, P25, DOI 10.1038/NCHEMBIO.476; Zhang WQ, 2010, MOL BIOL CELL, V21, P2500, DOI 10.1091/mbc.E09-08-0715	45	140	149	1	30	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					853	867		10.1016/j.cell.2011.10.022	http://dx.doi.org/10.1016/j.cell.2011.10.022			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078882	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000296902300018
J	Dwyer, CA; Stevenson, DJ; Nimmo, F				Dwyer, C. A.; Stevenson, D. J.; Nimmo, F.			A long-lived lunar dynamo driven by continuous mechanical stirring	NATURE			English	Article							CORE DYNAMO; MOON; PRECESSION; MAGNETISM; EVOLUTION; HISTORY; BODY	Lunar rocks contain a record of an ancient magnetic field that seems to have persisted for more than 400 million years(1,2) and which has been attributed to a lunar dynamo(3,4). Models of conventional dynamos driven by thermal or compositional convection have had difficulty reproducing the existence and apparently long duration of the lunar dynamo(5-7). Here we investigate an alternative mechanism of dynamo generation: continuous mechanical stirring arising from the differential motion, due to Earth-driven precession of the lunar spin axis, between the solid silicate mantle and the liquid core beneath(8,9). We show that the fluid motions and the power required to drive a dynamo operating continuously for more than one billion years and generating a magnetic field that had an intensity of more than one microtesla 4.2 billion years ago(3) are readily obtained by mechanical stirring. The magnetic field is predicted to decrease with time and to shut off naturally when the Moon recedes far enough from Earth that the dissipated power is insufficient to drive a dynamo; in our nominal model, this occurred at about 48 Earth radii (2.7 billion years ago). Thus, lunar palaeomagnetic measurements may be able to constrain the poorly known early orbital evolution of the Moon. This mechanism may also be applicable to dynamos in other bodies, such as large asteroids.	[Dwyer, C. A.; Nimmo, F.] Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA; [Stevenson, D. J.] CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	University of California System; University of California Santa Cruz; California Institute of Technology	Dwyer, CA (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, 1156 High St, Santa Cruz, CA 95064 USA.	cadwyer@ucsc.edu						Bills BG, 2011, ICARUS, V213, P496, DOI 10.1016/j.icarus.2010.09.002; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; Cebron D, 2010, GEOPHYS J INT, V182, P1311, DOI 10.1111/j.1365-246X.2010.04712.x; Christensen UR, 2009, NATURE, V457, P167, DOI 10.1038/nature07626; Cisowski S. M., 1983, Journal of Geophysical Research, V88, P691, DOI 10.1029/JB088iS02p0A691; Garrick-Bethell I, 2009, SCIENCE, V323, P356, DOI 10.1126/science.1166804; GOLDREICH P, 1967, J GEOPHYS RES, V72, P3135, DOI 10.1029/JZ072i012p03135; Hood LL, 2008, ICARUS, V193, P485, DOI 10.1016/j.icarus.2007.08.023; Hood LL, 2011, ICARUS, V211, P1109, DOI 10.1016/j.icarus.2010.08.012; Konrad W, 1997, ADV SPACE RES-SERIES, V19, P1511, DOI 10.1016/S0273-1177(97)00364-5; Lawrence K, 2008, PHYS EARTH PLANET IN, V168, P71, DOI 10.1016/j.pepi.2008.05.007; Meyer J, 2011, ICARUS, V211, P921, DOI 10.1016/j.icarus.2010.09.016; Nimmo F., 2015, TREATISE GEOPHYS, P27, DOI DOI 10.1016/B978-044452748-6.00128-0; ONG L, 2010, 41 LUN PLAN SCI C; Ooe M., 1990, VARIATIONS EARTH ROT, P51; PEALE SJ, 1969, ASTRON J, V74, P483, DOI 10.1086/110825; Roberts PH, 2010, GEOPHYS ASTRO FLUID, V104, P207, DOI 10.1080/03091920903439753; Stegman DR, 2003, NATURE, V421, P143, DOI 10.1038/nature01267; Takahashi F, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL041221; Tilgner A, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1852576; WALKER JCG, 1983, EARTHS EARLIEST BIOS, P260; WARD WR, 1975, SCIENCE, V189, P377, DOI 10.1126/science.189.4200.377; WEBB DJ, 1982, GEOPHYS J ROY ASTR S, V70, P261, DOI 10.1111/j.1365-246X.1982.tb06404.x; Weber RC, 2011, SCIENCE, V331, P309, DOI 10.1126/science.1199375; Weiss BP, 2008, SCIENCE, V322, P713, DOI 10.1126/science.1162459; Wieczorek MA, 2006, REV MINERAL GEOCHEM, V60, P221, DOI 10.2138/rmg.2006.60.3; Williams GE, 2000, REV GEOPHYS, V38, P37, DOI 10.1029/1999RG900016; Williams JG, 2001, J GEOPHYS RES-PLANET, V106, P27933, DOI 10.1029/2000JE001396; YODER CF, 1981, PHILOS T R SOC A, V303, P327, DOI 10.1098/rsta.1981.0206; Zahnle K, 2007, SPACE SCI REV, V129, P35, DOI 10.1007/s11214-007-9225-z	30	106	106	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					212	U84		10.1038/nature10564	http://dx.doi.org/10.1038/nature10564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071766				2022-12-28	WOS:000298030800038
J	Rowe, IA; Mutimer, DJ				Rowe, Ian A.; Mutimer, David J.			THERAPEUTICS Protease inhibitors for treatment of genotype 1 hepatitis C virus infection	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TELAPREVIR; BOCEPREVIR		[Rowe, Ian A.; Mutimer, David J.] Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England; [Rowe, Ian A.; Mutimer, David J.] Univ Birmingham, Hepatitis Virus Res Grp C, NIHR Biomed Res Unit, Birmingham B15 2TT, W Midlands, England; [Rowe, Ian A.; Mutimer, David J.] Univ Birmingham, Liver Res Ctr, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Mutimer, DJ (corresponding author), Queen Elizabeth Hosp, Liver & Hepatobiliary Unit, Birmingham B15 2TH, W Midlands, England.	david.mutimer@uhb.nhs.uk			MRC [G0901755, G0800476] Funding Source: UKRI; Medical Research Council [G0800476, G0901755] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Manns MP, 2007, NAT REV DRUG DISCOV, V6, P991, DOI 10.1038/nrd2411; McHutchison JG, 2009, NEW ENGL J MED, V361, P580, DOI 10.1056/NEJMoa0808010; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Nash KL, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2366; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1270, DOI 10.1053/j.gastro.2007.01.041; Thompson AJV, 2009, ALIMENT PHARM THER, V29, P689, DOI 10.1111/j.1365-2036.2009.03927.x; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086	12	11	12	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 10	2011	343								d6972	10.1136/bmj.d6972	http://dx.doi.org/10.1136/bmj.d6972			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848NT	22074942				2022-12-28	WOS:000297059000008
J	Hampton, T				Hampton, Tracy			Knockout Science: Massive Mouse Project to Provide Window Into Human Diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					1968	1968		10.1001/jama.2011.1625	http://dx.doi.org/10.1001/jama.2011.1625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068986				2022-12-28	WOS:000296704300008
J	Poston, GJ; Tait, D; O'Connell, S; Bennett, A; Berendse, S				Poston, G. J.; Tait, D.; O'Connell, S.; Bennett, A.; Berendse, S.		Guideline Dev Grp	GUIDELINES Diagnosis and management of colorectal cancer: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Poston, G. J.] Aintree Univ Hosp NHS Fdn Trust, Liverpool L9 7AL, Merseyside, England; [Tait, D.] Royal Marsden Hosp, London SW3 6JJ, England; [O'Connell, S.; Bennett, A.; Berendse, S.] Natl Collaborating Ctr Canc, Cardiff CF10 3AF, S Glam, Wales	Aintree University Hospitals NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Poston, GJ (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Liverpool L9 7AL, Merseyside, England.	graeme.poston@aintree.nhs.uk	O'Connell, Susan/V-8945-2019					[Anonymous], 2007, BEV CET TREATM MET C, V118; Morris EJA, 2010, BRIT J SURG, V97, P1110, DOI 10.1002/bjs.7032; *NAT I HLTH CLIN E, 2008, CET TREATM MET COL C; *NAT I HLTH CLIN E, 2004, IMPR OUTC COL CANC N; *NAT I HLTH CLIN E, 2006, LAP SURG COL CANC RE; *NAT I HLTH CLIN E, 2010, BEV COMB OX EITH FLU; *NAT I HLTH CLIN E, 2004, GUID US CAP TEG UR M; National Institute for Health and Clinical Excellence, 2009, CET 1 LIN TREATM MET; National Institute for Health and Clinical Excellence, 2011, DIAGN MAN COL CANC; National Institute for Health and Clinical Excellence, 2005, REF SUSP CANC; *OFF NAT STAT, 2005, CANC STAT REG REG CA	11	68	68	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2011	343								d6751	10.1136/bmj.d6751	http://dx.doi.org/10.1136/bmj.d6751			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NP	22074710				2022-12-28	WOS:000297058600007
J	Surmeli, G; Akay, T; Ippolito, GC; Tucker, PW; Jessell, TM				Suermeli, Guelsen; Akay, Turgay; Ippolito, Gregory C.; Tucker, Philip W.; Jessell, Thomas M.			Patterns of Spinal Sensory-Motor Connectivity Prescribed by a Dorsoventral Positional Template	CELL			English	Article							NEURON POOL; VERTEBRATE LIMB; CHICK WINGS; HIND-LIMB; MUSCLE; SPECIFICITY; MOTONEURONS; MECHANISMS; AFFERENTS; IDENTITY	Sensory-motor circuits in the spinal cord are constructed with a fine specificity that coordinates motor behavior, but the mechanisms that direct sensory connections with their motor neuron partners remain unclear. The dorsoventral settling position of motor pools in the spinal cord is known to match the distal-to-proximal position of their muscle targets in the limb, but the significance of invariant motor neuron positioning is unknown. An analysis of sensory-motor connectivity patterns in FoxP1 mutant mice, where motor neuron position has been scrambled, shows that the final pattern of sensory-motor connections is initiated by the projection of sensory axons to discrete dorsoventral domains of the spinal cord without regard for motor neuron subtype or, indeed, the presence of motor neurons. By implication, the clustering and dorsoventral settling position of motor neuron pools serve as a determinant of the pattern of sensory input specificity and thus motor coordination.	[Suermeli, Guelsen; Akay, Turgay; Jessell, Thomas M.] Columbia Univ, Howard Hughes Med Inst, Kavli Inst Brain Sci, Dept Neurosci, New York, NY 10032 USA; [Suermeli, Guelsen; Akay, Turgay; Jessell, Thomas M.] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Ippolito, Gregory C.; Tucker, Philip W.] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; University of Texas System; University of Texas Austin	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Kavli Inst Brain Sci, Dept Neurosci, New York, NY 10032 USA.	tmj1@columbia.edu	Ippolito, Gregory C./AAR-2930-2021; Surmeli, Gulsen/AAJ-1906-2020	Ippolito, Gregory C./0000-0002-7565-7002; SURMELI, GULSEN/0000-0002-3227-0641; Akay, Turgay/0000-0002-0466-2285	Gatsby Charitable Foundation; NIH [R01-CA31534, R01-NS033245, P01-NS055923]; Marie Betzer Morrow endowment; ProjectALS/P<SUP>2</SUP>ALS; Wellcome Trust; NYSTEM; Harold and Leila Mathers Foundation; NATIONAL CANCER INSTITUTE [R01CA031534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245, R37NS033245, P01NS055923] Funding Source: NIH RePORTER	Gatsby Charitable Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Marie Betzer Morrow endowment; ProjectALS/P<SUP>2</SUP>ALS; Wellcome Trust(Wellcome TrustEuropean Commission); NYSTEM; Harold and Leila Mathers Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank George Romanes for enlightening discussions on motor neuron groupings, Jeremy Dasen for insight into FoxP function, Joriene De Noiij for help with dorsal root fills, Gert Holstege for motor pool maps, Julia Kaltschmidt for contributions to the design of sensory-motor specificity assays, Tim Machado for statistical analysis of neuronal distributions, Richard Nichols and Trevor Drew for insight into limb biomechanics, John Kelly for detective work, Kendall Doerr for a sense of place, and Ira Schieren for assistance with figures and graphics. Kaity Miao, Monica Mendelsohn, June Harriss, and Deborah Surman helped in mouse genotyping and husbandry. Silvia Arber, Richard Axel, Jeremy Dasen, Joriene de Nooij, Jennifer Morgan, Chris Henderson, John Kelly, George Mentis, Richard Nichols, Sebastian Poliak, and George Romanes provided helpful comments on the manuscript. G. S. was supported by the Gatsby Charitable Foundation, and P.W.T. by NIH grant R01-CA31534 and the Marie Betzer Morrow endowment. T.M.J. is an Investigator of the Howard Hughes Medical Institute and was supported by NIH grants R01-NS033245 and P01-NS055923, ProjectALS/P<SUP>2</SUP>ALS, The Wellcome Trust, NYSTEM, and The Harold and Leila Mathers Foundation.	Baldissera F., 1981, HDB PHYSL 1 1, V2, P509, DOI DOI 10.1002/CPHY.CP010212; Betley JN, 2009, CELL, V139, P161, DOI 10.1016/j.cell.2009.08.027; Brown A. G., 1981, ORG SPINAL CORD, DOI [10.1007/978-1-4471-1305-8, DOI 10.1007/978-1-4471-1305-8]; Burkholder TJ, 2004, J MORPHOL, V261, P118, DOI 10.1002/jmor.10233; Cooper KL, 2011, SCIENCE, V332, P1083, DOI 10.1126/science.1199499; Dasen JS, 2008, CELL, V134, P304, DOI 10.1016/j.cell.2008.06.019; Dasen JS, 2009, CURR TOP DEV BIOL, V88, P169, DOI 10.1016/S0070-2153(09)88006-X; Demireva EY, 2011, CELL, V147, P641, DOI 10.1016/j.cell.2011.09.037; Dessaud E, 2007, NATURE, V450, P717, DOI 10.1038/nature06347; ECCLES JC, 1957, J PHYSIOL-LONDON, V137, P22, DOI 10.1113/jphysiol.1957.sp005794; Feng XM, 2010, BLOOD, V115, P510, DOI 10.1182/blood-2009-07-232694; Friese A, 2009, P NATL ACAD SCI USA, V106, P13588, DOI 10.1073/pnas.0906809106; Garcia NVDM, 2008, NEURON, V57, P217, DOI 10.1016/j.neuron.2007.11.033; Gibson CL, 1999, NEUROREPORT, V10, P231, DOI 10.1097/00001756-199902050-00006; Goulding M, 2009, NAT REV NEUROSCI, V10, P507, DOI 10.1038/nrn2608; HASAN Z, 1988, ANNU REV NEUROSCI, V11, P199, DOI 10.1146/annurev.ne.11.030188.001215; Hochstim C, 2008, CELL, V133, P510, DOI 10.1016/j.cell.2008.02.046; HONGO T, 1984, PROC R SOC SER B-BIO, V221, P261, DOI 10.1098/rspb.1984.0034; Hultborn H, 2006, PROG NEUROBIOL, V78, P215, DOI 10.1016/j.pneurobio.2006.04.001; Kardon G, 2003, DEV CELL, V5, P937, DOI 10.1016/S1534-5807(03)00360-5; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; KUDO N, 1987, J PHYSIOL-LONDON, V389, P441, DOI 10.1113/jphysiol.1987.sp016665; Ladle DR, 2007, NEURON, V56, P270, DOI 10.1016/j.neuron.2007.09.026; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; Leone DP, 2008, CURR OPIN NEUROBIOL, V18, P28, DOI 10.1016/j.conb.2008.05.006; LEWIS J, 1981, J EMBRYOL EXP MORPH, V64, P211; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Maeder CI, 2011, CURR OPIN NEUROBIOL, V21, P93, DOI 10.1016/j.conb.2010.10.004; MCHANWELL S, 1981, PHILOS T ROY SOC B, V293, P477, DOI 10.1098/rstb.1981.0082; Mears SC, 1997, J NEUROSCI, V17, P3128; MENDELSON B, 1991, J NEUROSCI, V11, P1390; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NICHOLS TR, 1994, ACTA ANAT, V151, P1; NICHOLS TR, 2002, PROGR MOTOR CONTROL, P179; Pecho-Vrieseling E, 2009, NATURE, V459, P842, DOI 10.1038/nature08000; PHELAN KA, 1990, J NEUROSCI, V10, P2699; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; ROMANES G. J., 1964, PROGR BRAIN RES, V11, P93; ROMANES GJ, 1951, J COMP NEUROL, V94, P313, DOI 10.1002/cne.900940209; Romanes GJ, 1941, J ANAT, V75, P145; RONNEVI LO, 1974, BRAIN RES, V80, P335, DOI 10.1016/0006-8993(74)90696-9; Rosello-Diez A, 2011, SCIENCE, V332, P1086, DOI 10.1126/science.1199489; Rousso DL, 2008, NEURON, V59, P226, DOI 10.1016/j.neuron.2008.06.025; SEEBACH BS, 1994, J NEUROSCI, V14, P4520; Shneider NA, 2009, J NEUROSCI, V29, P4719, DOI 10.1523/JNEUROSCI.5790-08.2009; SNIDER WD, 1992, J NEUROSCI, V12, P3494; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Sperry RW, 1940, J COMP NEUROL, V73, P379, DOI 10.1002/cne.900730303; Stevens CF, 1998, CURR BIOL, V8, pR708, DOI 10.1016/S0960-9822(98)70454-3; Vanderhorst VGJM, 1997, J COMP NEUROL, V382, P46; Wang B, 2004, DEVELOPMENT, V131, P4477, DOI 10.1242/dev.01287; Wenner P, 1995, J NEUROSCI, V15, P8191; Zagoraiou L, 2009, NEURON, V64, P645, DOI 10.1016/j.neuron.2009.10.017; Zlatic M, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000135	55	115	116	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					653	665		10.1016/j.cell.2011.10.012	http://dx.doi.org/10.1016/j.cell.2011.10.012			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036571	Green Accepted, Bronze			2022-12-28	WOS:000296573700019
J	Rein, DB; Smith, BD; Wittenborn, JS; Lesesne, SB; Wagner, LD; Roblin, DW; Patel, N; Ward, JW; Weinbaum, CM				Rein, David B.; Smith, Bryce D.; Wittenborn, John S.; Lesesne, Sarah B.; Wagner, Laura D.; Roblin, Douglas W.; Patel, Nita; Ward, John W.; Weinbaum, Cindy M.			The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in US Primary Care Settings	ANNALS OF INTERNAL MEDICINE			English	Article							INJECTION-DRUG USERS; QUALITY-OF-LIFE; UNITED-STATES; VIRUS-INFECTION; ECONOMIC-EVALUATION; PEGINTERFERON ALPHA-2A; LIVER-TRANSPLANTATION; RESOURCE UTILIZATION; COMBINATION THERAPY; ANTIVIRAL TREATMENT	Background: In the United States, hepatitis C virus (HCV) infection is most prevalent among adults born from 1945 through 1965, and approximately 50% to 75% of infected adults are unaware of their infection. Objective: To estimate the cost-effectiveness of birth-cohort screening. Design: Cost-effectiveness simulation. Data Sources: National Health and Nutrition Examination Survey, U.S. Census, Medicare reimbursement schedule, and published sources. Target Population: Adults born from 1945 through 1965 with 1 or more visits to a primary care provider annually. Time Horizon: Lifetime. Perspective: Societal, health care. Intervention: One-time antibody test of 1945-1965 birth cohort. Outcome Measures: Numbers of cases that were identified and treated and that achieved a sustained viral response; liver disease and death from HCV; medical and productivity costs; quality-adjusted life-years (QALYs); incremental cost-effectiveness ratio (ICER). Results of Base-Case Analysis: Compared with the status quo, birth-cohort screening identified 808 580 additional cases of chronic HCV infection at a screening cost of $2874 per case identified. Assuming that birth-cohort screening was followed by pegylated interferon and ribavirin (PEG-IFN+R) for treated patients, screening increased QALYs by 348 800 and costs by $5.5 billion, for an ICER of $15 700 per QALY gained. Assuming that birth-cohort screening was followed by direct-acting antiviral plus PEG-IFN+R treatment for treated patients, screening increased QALYs by 532 200 and costs by $19.0 billion, for an ICER of $35 700 per QALY saved. Results of Sensitivity Analysis: The ICER of birth-cohort screening was most sensitive to sustained viral response of antiviral therapy, the cost of therapy, the discount rate, and the QALY losses assigned to disease states. Limitation: Empirical data on screening and direct-acting antiviral treatment in real-world clinical settings are scarce. Conclusion: Birth-cohort screening for HCV in primary care settings was cost-effective.	[Rein, David B.] Univ Chicago, NORC, Atlanta, GA 30305 USA; Ctr Dis Control & Prevent, RTI Int, Atlanta, GA USA; Kaiser Permanente Georgia, Atlanta, GA USA; Univ N Carolina, Chapel Hill, NC USA	University of Chicago; Centers for Disease Control & Prevention - USA; Research Triangle Institute; Kaiser Permanente; University of North Carolina; University of North Carolina Chapel Hill	Rein, DB (corresponding author), Univ Chicago, NORC, 3520 Piedmont Rd NE, Atlanta, GA 30305 USA.	rein-david@norc.org		Rein, David/0000-0002-1271-5789	Centers for Disease Control and Prevention Division of Viral Hepatitis [200-2003-02489-0007]	Centers for Disease Control and Prevention Division of Viral Hepatitis	By the Centers for Disease Control and Prevention Division of Viral Hepatitis through contract 200-2003-02489-0007.	Allen SA, 2003, ANN INTERN MED, V138, P187, DOI 10.7326/0003-4819-138-3-200302040-00010; American Medical Association, 2007, CPT 2006 CURR PROC T; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Antonucci G, 2007, AM J GASTROENTEROL, V102, P1383, DOI 10.1111/j.1572-0241.2007.01201.x; Arias Elizabeth, 2006, Natl Vital Stat Rep, V54, P1; Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Backus LI, 2007, HEPATOLOGY, V46, P37, DOI 10.1002/hep.21662; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Beech Bettina M, 2003, Semin Pediatr Infect Dis, V14, P12, DOI 10.1053/spid.2003.127212; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Bureau of Labor Statistics, 2010, HOUS DAT ANN AV 37 M; Carey WD, 2007, CLEVELAND CLIN MONOG; Cassidy C, 2010, HLTH AFFAIRS    0520; Centers for Disease Control and Prevention, 2011, EV EL ALT ANTIHCV SC; Centers for Disease Control and Prevention. National Centre for Health Statistics, 2007, NAT CTR HLTH STAT NA; Chong CAKY, 2003, AM J GASTROENTEROL, V98, P630, DOI 10.1111/j.1572-0241.2003.07332.x; Culver DH, 2000, TRANSFUSION, V40, P1176, DOI 10.1046/j.1537-2995.2000.40101176.x; Davis GL, 2003, LIVER TRANSPLANT, V9, P331, DOI 10.1053/jlts.2003.50073; Davis KL, 2011, J CLIN GASTROENTEROL, V45, pE17, DOI 10.1097/MCG.0b013e3181e12c09; Desmond CP, 2006, J VIRAL HEPATITIS, V13, P311, DOI 10.1111/j.1365-2893.2005.00685.x; Deuffic-Burban S, 2007, J VIRAL HEPATITIS, V14, P107, DOI 10.1111/j.1365-2893.2006.00785.x; Dudley T, 2006, GUT, V55, P1362, DOI 10.1136/gut.2006.094292; Englesbe MJ, 2006, AM J TRANSPLANT, V6, P2978, DOI 10.1111/j.1600-6143.2006.01575.x; Falck-Ytter Y, 2002, ANN INTERN MED, V136, P288, DOI 10.7326/0003-4819-136-4-200202190-00008; Fried MW, 2002, HEPATOLOGY, V36, pS237, DOI 10.1053/jhep.2002.36810; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Gray L, 2003, ESSENTIAL RBRVS; Grieve R, 2006, GUT, V55, P1332, DOI 10.1136/gut.2005.064774; Hagan H, 2006, PUBLIC HEALTH REP, V121, P710, DOI 10.1177/003335490612100611; Haubolt RH, 2007, 2007 US ORGAN TISSUE; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Honeycutt AA, 2007, PUBLIC HEALTH REP, V122, P55, DOI 10.1177/00333549071220S211; Innes HA, 2011, HEPATOLOGY, V54, P2281, DOI [10.1002/hep.24776, 10.1002/hep.24561]; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004; Kwiatkowski CF, 2002, ADDICTION, V97, P1289, DOI 10.1046/j.1360-0443.2002.00208.x; Maciosek MV, 2006, AM J PREV MED, V31, P52, DOI 10.1016/j.amepre.2006.03.012; Mauss S, 2005, J ANTIMICROB CHEMOTH, V56, P615, DOI 10.1093/jac/dki277; Mauss S, 2004, HEPATOLOGY, V40, P120, DOI 10.1002/hep.20279; Nainan OV, 2006, GASTROENTEROLOGY, V131, P478, DOI 10.1053/j.gastro.2006.06.007; ORTNER N, 2005, 2005 US ORGAN TISSUE; Perrillo R, 2004, J VIRAL HEPATITIS, V11, P157, DOI 10.1046/j.1365-2893.2003.00482.x; Planas R, 2004, J HEPATOL, V40, P823, DOI 10.1016/j.jhep.2004.01.005; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Rein DB, 2011, PUBLIC HEALTH REP, V126, P560, DOI 10.1177/003335491112600412; Rein DB, 2011, DIGEST LIVER DIS, V43, P66, DOI 10.1016/j.dld.2010.05.006; Roblin D, 2010, KAISER PERMANENTE GE; Salomon JA, 2003, JAMA-J AM MED ASSOC, V290, P228, DOI 10.1001/jama.290.2.228; Salomon JA, 2002, AM J EPIDEMIOL, V156, P761, DOI 10.1093/aje/kwf100; Shepherd J, 2004, Health Technol Assess, V8, piii; Shepherd J, 2004, HEALTH TECHNOL ASSES, V8, P1; Shepherd J, 2005, INT J TECHNOL ASSESS, V21, P47, DOI 10.1017/S0266462305050063; Sherman KE, 2004, ARCH INTERN MED, V164, P2377, DOI 10.1001/archinte.164.21.2377; Showstack J, 1999, JAMA-J AM MED ASSOC, V281, P1381, DOI 10.1001/jama.281.15.1381; Siebert U, 2005, GUT, V54, P172; Solomon L, 2004, J URBAN HEALTH, V81, P25, DOI 10.1093/jurban/jth085; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Thein HH, 2005, AM J GASTROENTEROL, V100, P643, DOI 10.1111/j.1572-0241.2005.40976.x; Thomas David L, 2005, Clin Liver Dis, V9, P383, DOI 10.1016/j.cld.2005.05.003; Thomas DL, 2005, CLIN LIVER DIS, V9, pvi; Thomson BJ, 2008, J VIRAL HEPATITIS, V15, P271, DOI 10.1111/j.1365-2893.2007.00941.x; Vlahov D, 2004, ADDICTION, V99, P946, DOI 10.1111/j.1360-0443.2004.00780.x; Vlahov D, 2008, SUBST USE MISUSE, V43, P413, DOI 10.1080/10826080701203013; Wasley A, 2006, J CLIN VIROL, V36, pS198, DOI 10.1016/S1386-6532(06)80618-9; Wise M, 2008, HEPATOLOGY, V47, P1128, DOI 10.1002/hep.22165; Wong JB, 2000, AM J PUBLIC HEALTH, V90, P1562, DOI 10.2105/AJPH.90.10.1562; Wong JB, 2000, AM J MED, V108, P366, DOI 10.1016/S0002-9343(00)00303-X; Wright M, 2006, HEALTH TECHNOL ASSES, V10, P1; Wright M, 2006, HEALTH TECHNOL ASSES, V10, piii; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	71	254	257	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 21	2012	156	4					263	U24		10.7326/0003-4819-156-4-201202210-00378	http://dx.doi.org/10.7326/0003-4819-156-4-201202210-00378			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	896YO	22056542	Green Accepted, Green Submitted			2022-12-28	WOS:000300607600002
J	Martucciello, G; Tripodi, R				Martucciello, Giuseppe; Tripodi, Romano			A stray bullet in the brain	LANCET			English	Editorial Material									[Martucciello, Giuseppe] Univ Genoa, Dept Pediat Sci DIPE, I-16147 Genoa, Liguria, Italy; [Tripodi, Romano] Red Cross Field Hosp, Baghdad, Iraq	University of Genoa	Martucciello, G (corresponding author), Univ Genoa, Dept Pediat Sci DIPE, Largo Gerolamo Gaslini 5, I-16147 Genoa, Liguria, Italy.	martucciello@yahoo.com	Martucciello, Giuseppe/J-6543-2018	Martucciello, Giuseppe/0000-0002-7709-8937					0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					E19	E19		10.1016/S0140-6736(11)60703-4	http://dx.doi.org/10.1016/S0140-6736(11)60703-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22100855				2022-12-28	WOS:000299316100007
J	Ionescu, AM; Riel, H				Ionescu, Adrian M.; Riel, Heike			Tunnel field-effect transistors as energy-efficient electronic switches	NATURE			English	Review							PERFORMANCE; FET; DEVICE; SPECTROSCOPY; CONDUCTANCE; IMPACT	Power dissipation is a fundamental problem for nanoelectronic circuits. Scaling the supply voltage reduces the energy needed for switching, but the field-effect transistors (FETs) in today's integrated circuits require at least 60 mV of gate voltage to increase the current by one order of magnitude at room temperature. Tunnel FETs avoid this limit by using quantum-mechanical band-to-band tunnelling, rather than thermal injection, to inject charge carriers into the device channel. Tunnel FETs based on ultrathin semiconducting films or nanowires could achieve a 100-fold power reduction over complementary metal-oxide-semiconductor (CMOS) transistors, so integrating tunnel FETs with CMOS technology could improve low-power integrated circuits.	[Ionescu, Adrian M.] Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland; [Riel, Heike] IBM Res Zurich, CH-8803 Ruschlikon, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; International Business Machines (IBM)	Ionescu, AM (corresponding author), Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland.	adrian.ionescu@epfl.ch	Ionescu, Adrian M./A-9014-2010		European Commission	European Commission(European CommissionEuropean Commission Joint Research Centre)	Some of this work was supported by the European Commission under the FP7 projects Guardian Angels for a Smarter Life and STEEPER. K. Boucart, L. De Michielis, C. Le Royer, K. Moselund, M. Bjork, H. Schmid, W. Riess and P. Solomon are particularly acknowledged for useful discussions and supporting materials.	Abele N, 2005, INT EL DEVICES MEET, P1075; Abelein U, 2006, INT CONF MICROELECTR, P127; Appenzeller J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.196805; Appenzeller J, 2005, IEEE T ELECTRON DEV, V52, P2568, DOI 10.1109/TED.2005.859654; Appenzeller J, 2008, IEEE T ELECTRON DEV, V55, P2827, DOI 10.1109/TED.2008.2008011; Asra R, 2011, IEEE T ELECTRON DEV, V58, P1855, DOI 10.1109/TED.2011.2140322; Aydin C, 2004, APPL PHYS LETT, V84, P1780, DOI 10.1063/1.1668321; BABA T, 1992, JPN J APPL PHYS 2, V31, pL455, DOI 10.1143/JJAP.31.L455; BANERJEE S, 1987, IEEE ELECTR DEVICE L, V8, P347, DOI 10.1109/EDL.1987.26655; Bernstein K, 2010, P IEEE, V98, P2169, DOI 10.1109/JPROC.2010.2066530; Bessire CD, 2011, NANO LETT, V11, P4195, DOI 10.1021/nl202103a; Bhuwalka KK, 2005, IEEE T ELECTRON DEV, V52, P1541, DOI 10.1109/TED.2005.850618; Bhuwalka KK, 2004, JPN J APPL PHYS 1, V43, P4073, DOI 10.1143/JJAP.43.4073; Bjork MT, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3499365; Boucart Kathy, 2009, Proceedings of the 39th European Solid-State Device Research Conference. ESSDERC 2009, P452, DOI 10.1109/ESSDERC.2009.5331615; Boucart K., 2009, PHD THESIS ECOLE POL; Boucart K, 2007, SOLID STATE ELECTRON, V51, P1500, DOI 10.1016/j.sse.2007.09.014; Boucart K, 2007, IEEE T ELECTRON DEV, V54, P1725, DOI 10.1109/TED.2007.899389; Boucart K, 2009, IEEE ELECTR DEVICE L, V30, P656, DOI 10.1109/LED.2009.2018127; Chang L, 2010, P IEEE, V98, P215, DOI 10.1109/JPROC.2009.2035451; Chen Fred, 2008, 2008 IEEE/ACM International Conference on Computer-Aided Design (ICCAD), P750, DOI 10.1109/ICCAD.2008.4681660; De Michielis L., IEEE DEV RE IN PRESS; Fiori G, 2009, IEEE ELECTR DEVICE L, V30, P1096, DOI 10.1109/LED.2009.2028248; Fulde M, 2008, 2008 2ND IEEE INTERNATIONAL NANOELECTRONICS CONFERENCE, VOLS 1-3, P579, DOI 10.1109/INEC.2008.4585554; Gopalakrishnan K, 2002, INTERNATIONAL ELECTRON DEVICES 2002 MEETING, TECHNICAL DIGEST, P289, DOI 10.1109/IEDM.2002.1175835; Hansch W, 2000, THIN SOLID FILMS, V369, P387, DOI 10.1016/S0040-6090(00)00896-8; Hanson S, 2008, IEEE T ELECTRON DEV, V55, P175, DOI 10.1109/TED.2007.911033; Hu C, 2008, 9 INT C SOL STAT INT, P16, DOI [10.1109/ICSICT.2008.4735116, DOI 10.1109/ICSICT.2008.4735116]; Hu CM, 2010, INT EL DEVICES MEET; Ionescu A. M., SMALL SWING SWITCHES; Kam H, 2008, INT EL DEVICES MEET, P427; KANE EO, 1959, J PHYS CHEM SOLIDS, V12, P181, DOI 10.1016/0022-3697(60)90035-4; Kim D., 2009, P INT S LOW POW EL D, P219; Knoch J, 2007, SOLID STATE ELECTRON, V51, P572, DOI 10.1016/j.sse.2007.02.001; Knoch J., 2006, DEV RES C, P153; Knoch J, 2010, IEEE ELECTR DEVICE L, V31, P305, DOI 10.1109/LED.2010.2041180; Knoch J, 2009, PROCEEDINGS OF TECHNICAL PROGRAM: 2009 INTERNATIONAL SYMPOSIUM ON VLSI TECHNOLOGY, SYSTEMS AND APPLICATIONS, P45, DOI 10.1109/VTSA.2009.5159285; Koga J, 1996, APPL PHYS LETT, V69, P1435, DOI 10.1063/1.117606; Koswatta SO, 2007, NANO LETT, V7, P1160, DOI 10.1021/nl062843f; Koswatta SO, 2010, IEEE T ELECTRON DEV, V57, P3222, DOI 10.1109/TED.2010.2079250; Koswatta SO, 2009, IEEE T ELECTRON DEV, V56, P456, DOI 10.1109/TED.2008.2011934; Krishnamohan T, 2008, INT EL DEVICES MEET, P947; Le Royer C, 2009, ULIS 2009: 10TH INTERNATIONAL CONFERENCE ON ULTIMATE INTEGRATION OF SILICON, P53, DOI 10.1109/ULIS.2009.4897537; Leonelli D., 2010, ESSDERC 2010 - 40th European Solid State Device Research Conference, P170, DOI 10.1109/ESSDERC.2010.5618408; Loh W.-Y., 2010, P EUR SOL STAT DEV R, P162; Luisier Mathieu, 2009, 2009 67th Annual Device Research Conference (DRC), P201, DOI 10.1109/DRC.2009.5354951; Luisier M, 2010, J APPL PHYS, V107, DOI 10.1063/1.3386521; Lundstrom M. S., 2006, 2006 IEEE International SOI Conference (IEEE Cat. No. 06CH37786), P1, DOI 10.1109/SOI.2006.284404; Mayer F, 2008, INT EL DEVICES MEET, P163; Mohata D, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.024105; Mookerjea S, 2009, INT EL DEVICES MEET, P316; Mookerjea S, 2010, IEEE ELECTR DEVICE L, V31, P564, DOI 10.1109/LED.2010.2045631; Mookerjea S, 2009, IEEE ELECTR DEVICE L, V30, P1102, DOI 10.1109/LED.2009.2028907; Moselund KE, 2011, IEEE T ELECTRON DEV, V58, P2911, DOI 10.1109/TED.2011.2159797; Moselund K. E., 2009, Proceedings of the 39th European Solid-State Device Research Conference. ESSDERC 2009, P448, DOI 10.1109/ESSDERC.2009.5331446; Nayfeh OM, 2008, IEEE ELECTR DEVICE L, V29, P1074, DOI 10.1109/LED.2008.2000970; Nose K., 2000, Proceedings ASP-DAC 2000. Asia and South Pacific Design Automation Conference 2000 with EDA TechnoFair 2000. (Cat. No.00EX389), P469, DOI 10.1109/ASPDAC.2000.835145; Poli S, 2008, IEEE T ELECTRON DEV, V55, P313, DOI 10.1109/TED.2007.910563; Pott V, 2010, P IEEE, V98, P2076, DOI 10.1109/JPROC.2010.2063411; QUINN JJ, 1978, SURF SCI, V73, P190, DOI 10.1016/0039-6028(78)90489-2; REDDICK WM, 1995, APPL PHYS LETT, V67, P494, DOI 10.1063/1.114547; Rusu A, 2010, INT EL DEVICES MEET; Sakurai T, 2004, IEICE T ELECTRON, VE87C, P429; Salahuddin S, 2008, NANO LETT, V8, P405, DOI 10.1021/nl071804g; Salvatore GA, 2008, INT EL DEVICES MEET, P167, DOI 10.1109/IEDM.2008.4796642; Sandow C, 2009, SOLID STATE ELECTRON, V53, P1126, DOI 10.1016/j.sse.2009.05.009; Saripalli V., 2010, 2010 68th Annual Device Research Conference (DRC 2010), P101, DOI 10.1109/DRC.2010.5551859; Schmid H., 2011, DEVICE RES C, P181, DOI [10.1109/DRC.2011.5994479, DOI 10.1109/DRC.2011.5994479]; Seabaugh AC, 2010, P IEEE, V98, P2095, DOI 10.1109/JPROC.2010.2070470; Singh J, 2010, ASIA S PACIF DES AUT, P178; Solomon P. M., 2011, 2011 69th Annual Device Research Conference (DRC), P197, DOI 10.1109/DRC.2011.5994495; Sze S. M., 1969, PHYS SEMICONDUCTOR D; Takeda E., 1988, International Electron Devices Meeting. Technical Digest (IEEE Cat. No.88CH2528-8), P402, DOI 10.1109/IEDM.1988.32841; Tomioka K, 2008, NANO LETT, V8, P3475, DOI 10.1021/nl802398j; Verhulst AS, 2008, IEEE ELECTR DEVICE L, V29, P1398, DOI 10.1109/LED.2008.2007599; Wang LQ, 2010, IEEE ELECTR DEVICE L, V31, P431, DOI 10.1109/LED.2010.2044012; Wang PF, 2004, SOLID STATE ELECTRON, V48, P2281, DOI 10.1016/j.sse.2004.04.006; Yeqing Lu, 2010, 2010 68th Annual Device Research Conference (DRC 2010), P17, DOI 10.1109/DRC.2010.5551905; ZENER C, 1934, P ROYAL SOC, V145, P523, DOI DOI 10.1098/RSPA.1934.0116; Zhang Q, 2006, IEEE ELECTR DEVICE L, V27, P297, DOI 10.1109/LED.2006.871855; Zhang YB, 2008, NAT PHYS, V4, P627, DOI 10.1038/nphys1022; Zhao H, 2011, IEEE T ELECTRON DEV, V58, P2990, DOI 10.1109/TED.2011.2159385; Zhou G., 2011, IEEE DEV RES C, P205	83	2000	2038	23	761	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					329	337		10.1038/nature10679	http://dx.doi.org/10.1038/nature10679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094693				2022-12-28	WOS:000297059700033
J	Olivera, BM; Teichert, RW				Olivera, Baldomero M.; Teichert, Russell W.			NEUROSCIENCE Chemical ecology of pain	NATURE			English	Editorial Material							ION CHANNELS		[Olivera, Baldomero M.; Teichert, Russell W.] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Olivera, BM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	olivera@biology.utah.edu	Teichert, Russell W/H-2213-2013	Teichert, Russell/0000-0002-9985-5214				Bohlen CJ, 2011, NATURE, V479, P410, DOI 10.1038/nature10607; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014	4	6	6	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					306	307		10.1038/479306a	http://dx.doi.org/10.1038/479306a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094687				2022-12-28	WOS:000297059700028
J	Rao, V				Rao, Veena			Commentary: Cultural change is essential	BRITISH MEDICAL JOURNAL			English	Editorial Material									Natl Rural Hlth Mission NRHM, Directorate Hlth & Family Welf Serv, Bangalore 560009, Karnataka, India		Rao, V (corresponding author), Natl Rural Hlth Mission NRHM, Directorate Hlth & Family Welf Serv, Bangalore 560009, Karnataka, India.	nobel_6@hotmail.com						[Anonymous], 2005, NAT FAM HLTH SURV 3; *MIN FIN, 2011, EC SURV 2011; *NAT NUTR MON BUR, 2000, TECHN REP NAT NUTR M, V20; *NAT NUTR MON BUR, REP SURV 1988 98 199; *NAT NUTR MON BUR, 2000, TECHN REP NAT NUTR M, V21; *NAT NUTR MON BUR, 2000, TECHN REP NAT NUTR M, V22; *NAT SAMPL SURV OF, 2011, 66 ROUND SURV JUL 20; Ramalingaswami V., 1996, ASIAN ENIGMA PROGR N; UNICEF, 2011, STAT WORLDS CHILDR 2	9	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 11	2011	343								d7242	10.1136/bmj.d7242	http://dx.doi.org/10.1136/bmj.d7242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NY	22080489				2022-12-28	WOS:000297059500001
J	Tsapatsis, M				Tsapatsis, Michael			Toward High-Throughput Zeolite Membranes	SCIENCE			English	Editorial Material							SEPARATION		Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Tsapatsis, M (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 151 Amundson Hall,421 Washington Ave SE, Minneapolis, MN 55455 USA.	tsapatsis@umn.edu	Tsapatsis, Michael/AAA-2527-2019					Aerts A, 2010, CHEM-EUR J, V16, P2764, DOI 10.1002/chem.200901688; Akhtar F, 2011, J MATER CHEM, V21, P8822, DOI 10.1039/c1jm10584a; Caro J, 2008, MICROPOR MESOPOR MAT, V115, P215, DOI 10.1016/j.micromeso.2008.03.008; Chmelik C, 2010, CHEM SOC REV, V39, P4864, DOI 10.1039/c0cs00100g; Choi J, 2009, SCIENCE, V325, P590, DOI 10.1126/science.1176095; Corma A, 1998, NATURE, V396, P353, DOI 10.1038/24592; Daramola MO, 2010, SEP SCI TECHNOL, V45, P21, DOI 10.1080/01496390903402141; Fan W, 2008, NAT MATER, V7, P984, DOI 10.1038/nmat2302; Koros WJ, 2004, AICHE J, V50, P2326, DOI 10.1002/aic.10330; Lee PS, 2011, J AM CHEM SOC, V133, P493, DOI 10.1021/ja107942n; Li ZJ, 2005, J PHYS CHEM B, V109, P8652, DOI 10.1021/jp0441893; Maheshwari S, 2008, J AM CHEM SOC, V130, P1507, DOI 10.1021/ja077711i; Morigami Y, 2001, SEP PURIF TECHNOL, V25, P251, DOI 10.1016/S1383-5866(01)00109-5; Na K, 2011, SCIENCE, V333, P328, DOI 10.1126/science.1204452; Snyder MA, 2007, ANGEW CHEM INT EDIT, V46, P7560, DOI 10.1002/anie.200604910; Yoon KB, 2007, ACCOUNTS CHEM RES, V40, P29, DOI 10.1021/ar000119c	16	85	91	6	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					767	768		10.1126/science.1205957	http://dx.doi.org/10.1126/science.1205957			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076367				2022-12-28	WOS:000296849600033
J	Miglis, MG				Miglis, Mitchell G.			Annie	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Miglis, MG (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.	mmiglis@bidmc.harvard.edu		Miglis, Mitchell/0000-0001-8488-0313					0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					1960	1961		10.1001/jama.2011.1627	http://dx.doi.org/10.1001/jama.2011.1627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068983				2022-12-28	WOS:000296704300001
J	Swinglehurst, D; Greenhalgh, T; Russell, J; Myall, M				Swinglehurst, Deborah; Greenhalgh, Trisha; Russell, Jill; Myall, Michelle			Receptionist input to quality and safety in repeat prescribing in UK general practice: ethnographic case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNEXPECTED INCREASED MORTALITY; MEDICATION ERRORS; ORGANIZATIONAL ROUTINES; PRIMARY-CARE; HEALTH-CARE; COLLABORATIVE WORK; IMPLEMENTATION; IMPROVEMENT; INTERVENTION; PRESCRIPTION	Objective To describe, explore, and compare organisational routines for repeat prescribing in general practice to identify contributors and barriers to safety and quality. Design Ethnographic case study. Setting Four urban UK general practices with diverse organisational characteristics using electronic patient records that supported semi-automation of repeat prescribing. Participants 395 hours of ethnographic observation of staff (25 doctors, 16 nurses, 4 healthcare assistants, 6 managers, and 56 reception or administrative staff), and 28 documents and other artefacts relating to repeat prescribing locally and nationally. Main outcome measures Potential threats to patient safety and characteristics of good practice. Methods Observation of how doctors, receptionists, and other administrative staff contributed to, and collaborated on, the repeat prescribing routine. Analysis included mapping prescribing routines, building a rich description of organisational practices, and drawing these together through narrative synthesis. This was informed by a sociological model of how organisational routines shape and are shaped by information and communications technologies. Results Repeat prescribing was a complex, technology-supported social practice requiring collaboration between clinical and administrative staff, with important implications for patient safety. More than half of requests for repeat prescriptions were classed as "exceptions" by receptionists (most commonly because the drug, dose, or timing differed from what was on the electronic repeat list). They managed these exceptions by making situated judgments that enabled them (sometimes but not always) to bridge the gap between the idealised assumptions about tasks, roles, and interactions that were built into the electronic patient record and formal protocols, and the actual repeat prescribing routine as it played out in practice. This work was creative and demanded both explicit and tacit knowledge. Clinicians were often unaware of this input and it did not feature in policy documents or previous research. Yet it was sometimes critical to getting the job done and contributed in subtle ways to safeguarding patients. Conclusion Receptionists and administrative staff make important "hidden" contributions to quality and safety in repeat prescribing in general practice, regarding themselves accountable to patients for these contributions. Studying technology-supported work routines that seem mundane, standardised, and automated, but which in reality require a high degree of local tailoring and judgment from frontline staff, opens up a new agenda for the study of patient safety.	[Swinglehurst, Deborah] Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, Natl Inst Hlth Res, London E1 2AT, England; [Myall, Michelle] WRC Res, London EC1V 0BB, England	University of London; Queen Mary University London	Swinglehurst, D (corresponding author), Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, Natl Inst Hlth Res, London E1 2AT, England.	d.swinglehurst@qmul.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Myall, Michelle/0000-0001-8733-7412; Swinglehurst, Deborah/0000-0003-1261-9268	UK Medical Research Council [07/133]; National Institute for Health Research [RDA/03/07/076]; Medical Research Council [G0600654] Funding Source: researchfish; MRC [G0600654] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by a research grant from the UK Medical Research Council (Healthcare Electronic Records in Organisations, 07/133) and a National Institute for Health Research doctoral fellowship award (RDA/03/07/076) for DS. The funders were not involved in the selection or analysis of data, or in contributing to the content of the final manuscript.	Anon, 2008, PROCEDURES SIMPLIFY; Ash JS, 2004, J AM MED INFORM ASSN, V11, P104, DOI 10.1197/jamia.M1471; *AUD COMM, 1994, PRESCR IMPR MOR RAT; Avery AJ, 2000, BRIT MED J, V321, P276, DOI 10.1136/bmj.321.7256.276; Avery Anthony J, 2005, Inform Prim Care, V13, P3; Avery AJ, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-28; AVERY T, 2010, PRESCRIBER, V21, P52, DOI DOI 10.1002/PSB.597; Barley SR, 1997, ORGAN STUD, V18, P93, DOI 10.1177/017084069701800106; Benjamin DM, 2003, J CLIN PHARMACOL, V43, P768, DOI 10.1177/0091270003254794; Berg M, 2003, INT J MED INFORM, V69, P223, DOI 10.1016/S1386-5056(02)00178-8; Chuo J, 2008, CLIN PERINATOL, V35, P119, DOI 10.1016/j.clp.2007.11.005; Cox S, 1999, QUAL HEALTH CARE, V8, P119, DOI 10.1136/qshc.8.2.119; Czarniawska B., 2008, THEORY ORG; De Smet PAGM, 2004, DRUGS, V64, P1779, DOI 10.2165/00003495-200464160-00005; Duguid P, 2002, SOCIAL LIFE INFORM; Feldman MS, 2003, IND CORP CHANGE, V12, P727, DOI 10.1093/icc/12.4.727; Feldman MS, 2000, ORGAN SCI, V11, P611, DOI 10.1287/orsc.11.6.611.12529; Garfield S, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-50; Giddens A, 1984, CONSTITUTION SOC OUT; Goffman E., 1967, INTERACTION RITUAL, P5; Green S, 1996, PROBLEMS GEN PRACTIC; Greenhalgh T, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-45; Greenhalgh T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2448; Grimsmo Anders, 2006, Tidsskr Nor Laegeforen, V126, P1740; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Harris CM, 1996, BRIT J GEN PRACT, V46, P649; Henwood F, 2003, CRIT SOC POLICY, V23, P249, DOI 10.1177/0261018303023002007; Hesselgreaves H, 2009, EDUC PRIM CARE, V20, P21, DOI 10.1080/14739879.2009.11493758; Hewitt H, 2009, BRIT J GEN PRACT, V59, P571, DOI 10.3399/bjgp09X453774; Hidle Unn, 2007, J N Y State Nurses Assoc, V38, P4; Hor SY, 2010, QUAL HEALTH RES, V20, P1091, DOI 10.1177/1049732310369232; Howard R, 2008, QUAL SAF HEALTH CARE, V17, P109, DOI 10.1136/qshc.2007.022681; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Howard-Grenville JA, 2005, ORGAN SCI, V16, P618, DOI 10.1287/orsc.1050.0150; Klein HK, 1999, MIS QUART, V23, P67, DOI 10.2307/249410; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Lee BK, 2008, INT J QUAL METH, V7, P30; Lee-Treweek G, 1998, UNDERSTANDING HLTH S; Luff P., 1992, CSCW '92. Sharing Perspectives. Proceedings of the Conference on Computer-Supported Cooperative Work, P163, DOI 10.1145/143457.143475; National Audit Office, 2007, PRESCR COSTS PRIM CA; Newby DA, 2010, MED J AUSTRALIA, V192, P192, DOI 10.5694/j.1326-5377.2010.tb03477.x; O'Malley P, 2008, CLIN NURSE SPEC, V22, P269, DOI 10.1097/01.NUR.0000325383.99717.e5; Obstfelder A, 2006, STUD HEALTH TECHNOL, V122, P626; Ormrod S, 2003, POLICY POLIT, V31, P227, DOI 10.1332/030557303765371717; Payne RA, 2011, BRIT J GEN PRACT, V61, P83, DOI 10.3399/bjgp11X556146; Pentland BT, 2005, IND CORP CHANGE, V14, P793, DOI 10.1093/icc/dth070; Pope C, 2005, MED EDUC, V39, P1180, DOI 10.1111/j.1365-2929.2005.02330.x; Redwood S, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-29; Rose G, 1982, DECIPHERING SOCIOLOG; Saastamoinen LK, 2009, J CLIN PHARM THER, V34, P261, DOI 10.1111/j.1365-2710.2008.01003.x; Saastamoinen L, 2008, PHARM WORLD SCI, V30, P605, DOI 10.1007/s11096-008-9224-5; Savage I, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-135; Schwarz H, 2002, 30 MIT PROGR SCI TEC; Sittig DF, 2006, PEDIATRICS, V118, P797, DOI 10.1542/peds.2005-3132; Smith J., 2004, BUILDING SAFER NHS P; Spencer R, 2011, CLIN RISK, V17, P39; Swinglehurst D, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-348; Taylor RJ, 1996, BRIT J GEN PRACT, V46, P640; Wagenaar H, 2004, PUBLIC ADMIN REV, V64, P643, DOI 10.1111/j.1540-6210.2004.00412.x; WEICK KE, 1993, ADMIN SCI QUART, V38, P357, DOI 10.2307/2393372; Wessell AM, 2008, AM J GERIATR PHARMAC, V6, P21, DOI 10.1016/j.amjopharm.2008.02.001; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181; Wolf Zane Robinson, 2007, Medsurg Nurs, V16, P92; Zermansky AG, 1996, BRIT J GEN PRACT, V46, P643; Zermansky AG, 2001, BRIT MED J, V323, P1340, DOI 10.1136/bmj.323.7325.1340	66	51	52	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2011	343								d6788	10.1136/bmj.d6788	http://dx.doi.org/10.1136/bmj.d6788			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QT	22053317	Green Submitted, Green Published, hybrid, Green Accepted			2022-12-28	WOS:000296763100009
J	Coradini, A; Capaccioni, F; Erard, S; Arnold, G; De Sanctis, MC; Filacchione, G; Tosi, F; Barucci, MA; Capria, MT; Ammannito, E; Grassi, D; Piccioni, G; Giuppi, S; Bellucci, G; Benkhoff, J; Bibring, JP; Blanco, A; Blecka, M; Bockelee-Morvan, D; Carraro, F; Carlson, R; Carsenty, U; Cerroni, P; Colangeli, L; Combes, M; Combi, M; Crovisier, J; Drossart, P; Encrenaz, ET; Federico, C; Fink, U; Fonti, S; Giacomini, L; Ip, WH; Jaumann, R; Kuehrt, E; Langevin, Y; Magni, G; McCord, T; Mennella, V; Mottola, S; Neukum, G; Orofino, V; Palumbo, P; Schade, U; Schmitt, B; Taylor, F; Tiphene, D; Tozzi, G				Coradini, A.; Capaccioni, F.; Erard, S.; Arnold, G.; De Sanctis, M. C.; Filacchione, G.; Tosi, F.; Barucci, M. A.; Capria, M. T.; Ammannito, E.; Grassi, D.; Piccioni, G.; Giuppi, S.; Bellucci, G.; Benkhoff, J.; Bibring, J. P.; Blanco, A.; Blecka, M.; Bockelee-Morvan, D.; Carraro, F.; Carlson, R.; Carsenty, U.; Cerroni, P.; Colangeli, L.; Combes, M.; Combi, M.; Crovisier, J.; Drossart, P.; Encrenaz, E. T.; Federico, C.; Fink, U.; Fonti, S.; Giacomini, L.; Ip, W. H.; Jaumann, R.; Kuehrt, E.; Langevin, Y.; Magni, G.; McCord, T.; Mennella, V.; Mottola, S.; Neukum, G.; Orofino, V.; Palumbo, P.; Schade, U.; Schmitt, B.; Taylor, F.; Tiphene, D.; Tozzi, G.			The Surface Composition and Temperature of Asteroid 21 Lutetia As Observed by Rosetta/VIRTIS	SCIENCE			English	Article							NEAR-INFRARED SPECTROSCOPY; ALBEDO; CHONDRITES; SIZE	The Visible, InfraRed, and Thermal Imaging Spectrometer (VIRTIS) on Rosetta obtained hyperspectral images, spectral reflectance maps, and temperature maps of the asteroid 21 Lutetia. No absorption features, of either silicates or hydrated minerals, have been detected across the observed area in the spectral range from 0.4 to 3.5 micrometers. The surface temperature reaches a maximum value of 245 kelvin and correlates well with topographic features. The thermal inertia is in the range from 20 to 30 joules meter(-2) kelvin(-1) second(-0.5), comparable to a lunarlike powdery regolith. Spectral signatures of surface alteration, resulting from space weathering, seem to be missing. Lutetia is likely a remnant of the primordial planetesimal population, unaltered by differentiation processes and composed of chondritic materials of enstatitic or carbonaceous origin, dominated by iron-poor minerals that have not suffered aqueous alteration.	[Capaccioni, F.; De Sanctis, M. C.; Filacchione, G.; Capria, M. T.; Piccioni, G.; Cerroni, P.; Magni, G.] INAF, Ist Astrofis Spaziale & Fis Cosm, I-00133 Rome, Italy; [Coradini, A.; Tosi, F.; Ammannito, E.; Grassi, D.; Giuppi, S.; Bellucci, G.; Carraro, F.; Giacomini, L.] Inst Nazl Astrofis INAF, Ist Fis Spazio Interplanetario, I-00133 Rome, Italy; [Erard, S.; Barucci, M. A.; Bockelee-Morvan, D.; Combes, M.; Crovisier, J.; Drossart, P.; Encrenaz, E. T.; Tiphene, D.] Univ Paris Diderot, Univ Paris 06, CNRS, Observ Paris,LESIA, F-92195 Meudon, France; [Arnold, G.] Inst Planetol, D-48149 Munster, Germany; [Benkhoff, J.; Colangeli, L.] European Space Agcy, European Space Res & Technol Ctr ESTEC, NL-2200 AG Noordwijk, Netherlands; [Bibring, J. P.; Langevin, Y.] CNRS, Inst Astrophys Spatiale, F-91405 Orsay, France; [Blecka, M.] Polish Acad Sci, Space Res Ctr, PL-00716 Warsaw, Poland; [Carlson, R.] NASA, Jet Prop Lab, Pasadena, CA 91109 USA; [Carsenty, U.; Jaumann, R.; Kuehrt, E.; Mottola, S.] Deutsch Zentrum Luft & Raumfahrt DLR, Inst Planetary Res, D-12489 Berlin, Germany; [Combi, M.] Univ Michigan, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA; [Federico, C.] Univ Perugia, I-06100 Perugia, Italy; [Fink, U.] Univ Arizona, Lunar Planetary Lab, Tucson, AZ 85721 USA; [Blanco, A.; Fonti, S.; Orofino, V.] Univ Lecce, Dipartimento Fis, I-73100 Lecce, Italy; [Ip, W. H.] Natl Cent Univ, Taipei, Taiwan; [McCord, T.] Bear Fight Inst, Winthrop, WA 98862 USA; [Neukum, G.] Free Univ Berlin, D-14195 Berlin, Germany; [Schmitt, B.] Univ Grenoble 1, CNRS, INSU, Inst Planetol & Astrophys Grenoble, F-38041 Grenoble, France; [Tozzi, G.] Osserv Astrofis Arcetri, I-50125 Florence, Italy; [Mennella, V.] Osservatorio Capodimonte, I-80131 Naples, Italy; [Taylor, F.] Univ Oxford, Dept Phys, Oxford OX1 2JD, England; [Palumbo, P.] Univ Napoli Parthenope, I-80133 Naples, Italy; [Schade, U.] Helmholtz Zentrum Berlin Mat & Energie, D-14109 Berlin, Germany	Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universite Paris Cite; European Space Agency; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centrum Badan Kosmicznych, Polish Academy of Sciences; Polish Academy of Sciences; Space Research Centre of the Polish Academy of Sciences; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Helmholtz Association; German Aerospace Centre (DLR); University of Michigan System; University of Michigan; University of Perugia; University of Arizona; University of Salento; National Central University; Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Institut de Planetologie et d'Astrophysique de Grenoble (IPAG); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); University of Oxford; Parthenope University Naples; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)	Capaccioni, F (corresponding author), INAF, Ist Astrofis Spaziale & Fis Cosm, I-00133 Rome, Italy.	fabrizio.capaccioni@inaf.it	Bellucci, Giancarlo/ABA-9201-2020; Drossart, Pierre/H-8670-2013; De Sanctis, Maria Cristina/G-5232-2013; Filacchione, Gianrico/S-2320-2017; Schmitt, Bernard/A-1064-2009; Piccioni, Giuseppe/T-9272-2017; Grassi, Davide/B-7916-2018; Jaumann, Ralf/N-1001-2018; Tosi, Federico/F-2321-2018; Schade, Ulrich/D-9341-2013; Combi, Michael/J-1697-2012	Bellucci, Giancarlo/0000-0003-0867-8679; De Sanctis, Maria Cristina/0000-0002-3463-4437; Filacchione, Gianrico/0000-0001-9567-0055; Schmitt, Bernard/0000-0002-1230-6627; Piccioni, Giuseppe/0000-0002-7893-6808; Grassi, Davide/0000-0003-1653-3066; Jaumann, Ralf/0000-0002-9759-6597; Tosi, Federico/0000-0003-4002-2434; Combi, Michael/0000-0002-9805-0078; Colangeli, Luigi/0000-0001-6801-9152; Tozzi, Gian Paolo/0000-0003-4775-5788; Palumbo, Pasquale/0000-0003-2323-9228; Mennella, Vito/0000-0001-9525-895X; Giuppi, Stefano/0000-0001-6900-3427; Schade, Ulrich/0000-0002-4194-2235; Erard, Stephane/0000-0002-9099-8366; Cerroni, Priscilla/0000-0003-0239-2741; Capaccioni, Fabrizio/0000-0003-1631-4314; Taylor, Fred/0000-0002-0675-9769; Blecka, Maria/0000-0002-6473-1211	Rosetta Science Operations Centre; Rosetta Mission Operations Centre; Agenzia Spaziale Italiana; Centre National d'Etudes Spatiales; Deutsches Zentrum fur Luft- und Raumfahrt	Rosetta Science Operations Centre; Rosetta Mission Operations Centre; Agenzia Spaziale Italiana(Agenzia Spaziale Italiana (ASI)); Centre National d'Etudes Spatiales(Centre National D'etudes Spatiales); Deutsches Zentrum fur Luft- und Raumfahrt(Helmholtz AssociationGerman Aerospace Centre (DLR))	The authors wish to thank L. V. Moroz for helpful comments during the revision phase and the Rosetta Science Operations Centre and the Rosetta Mission Operations Centre for their support. VIRTIS was built by a European consortium and is part of the Rosetta spacecraft, provided by the European Space Agency (ESA). We acknowledge the funding of the national space agencies: Agenzia Spaziale Italiana, Centre National d'Etudes Spatiales, Deutsches Zentrum fur Luft- und Raumfahrt. The VIRTIS calibrated data will be available through the ESA's Planetary Science Archive (PSA) Web site (www.rssd.esa.int/index.php?project=PSA&page=index) in 2011.	Ammannito E, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2349308; Barucci MA, 2008, ASTRON ASTROPHYS, V477, P665, DOI 10.1051/0004-6361:20078085; Beck P, 2010, GEOCHIM COSMOCHIM AC, V74, P4881, DOI 10.1016/j.gca.2010.05.020; Birlan M, 2006, ASTRON ASTROPHYS, V454, P677, DOI 10.1051/0004-6361:20054460; Bottke WF, 2005, ICARUS, V179, P63, DOI 10.1016/j.icarus.2005.05.017; Carvano JM, 2008, ASTRON ASTROPHYS, V479, P241, DOI 10.1051/0004-6361:20078053; Coradini A, 2007, SPACE SCI REV, V128, P529, DOI 10.1007/s11214-006-9127-5; Cremers CJ., 1973, P 4 LUN SCI C, P2459; De Sanctis MC, 2010, ICARUS, V207, P341, DOI 10.1016/j.icarus.2009.11.009; Delbo M, 2007, ICARUS, V190, P236, DOI 10.1016/j.icarus.2007.03.007; Demeo FE, 2009, ICARUS, V202, P160, DOI 10.1016/j.icarus.2009.02.005; Filacchione G, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2360786; Gaffey MJ, 2010, ICARUS, V209, P564, DOI 10.1016/j.icarus.2010.05.006; Hapke B, 2001, J GEOPHYS RES-PLANET, V106, P10039, DOI 10.1029/2000JE001338; Hemingway B. S., 1973, P LUNAR PLANET SCI C, V3, P2481; JORDA L, 2010, BAAS, V42, P1043; KEIHM SJ, 1984, ICARUS, V60, P568, DOI 10.1016/0019-1035(84)90165-9; Lagerros JSV, 1997, ASTRON ASTROPHYS, V325, P1226; Lamy PL, 2010, ASTRON ASTROPHYS, V521, DOI 10.1051/0004-6361/201014452; Lazzarin M, 2009, ASTRON ASTROPHYS, V498, P307, DOI 10.1051/0004-6361/200810184; McKay D. S., 1991, LUNAR SOURCEBOOK, P285, DOI DOI 10.1006/ICAR.1999.6165; McKay D. S., 1974, P 5 LUN SCI C, V1, P887; Moroz L. V., 2004, LUNAR PLANET SCI C, V1279; Mueller M, 2006, ASTRON ASTROPHYS, V447, P1153, DOI 10.1051/0004-6361:20053742; Nedelcu DA, 2007, ASTRON ASTROPHYS, V470, P1157, DOI 10.1051/0004-6361:20066944; Ockert-Bell ME, 2010, ICARUS, V210, P674, DOI 10.1016/j.icarus.2010.08.002; Rivkin AS, 2000, ICARUS, V145, P351, DOI 10.1006/icar.2000.6354; Shepard MK, 2010, ICARUS, V208, P221, DOI 10.1016/j.icarus.2010.01.017; Sierks H, 2011, SCIENCE, V334, P487, DOI 10.1126/science.1207325; Tedesco E. F., 1992, IRAS MINOR PLANET SU; Tholen D. J., 1989, ASTEROIDS; Vernazza P, 2009, ICARUS, V202, P477, DOI 10.1016/j.icarus.2009.03.016	32	94	95	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					492	494		10.1126/science.1204062	http://dx.doi.org/10.1126/science.1204062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034430				2022-12-28	WOS:000296230500041
J	Guruharsha, KG; Rual, JF; Zhai, B; Mintseris, J; Vaidya, P; Vaidya, N; Beekman, C; Wong, C; Rhee, DY; Cenaj, O; McKillip, E; Shah, S; Stapleton, M; Wan, KH; Yu, C; Parsa, B; Carlson, JW; Chen, X; Kapadia, B; VijayRaghavan, K; Gygi, SP; Celniker, SE; Obar, RA; Artavanis-Tsakonas, S				Guruharsha, K. G.; Rual, Jean-Francois; Zhai, Bo; Mintseris, Julian; Vaidya, Pujita; Vaidya, Namita; Beekman, Chapman; Wong, Christina; Rhee, David Y.; Cenaj, Odise; McKillip, Emily; Shah, Saumini; Stapleton, Mark; Wan, Kenneth H.; Yu, Charles; Parsa, Bayan; Carlson, Joseph W.; Chen, Xiao; Kapadia, Bhaveen; VijayRaghavan, K.; Gygi, Steven P.; Celniker, Susan E.; Obar, Robert A.; Artavanis-Tsakonas, Spyros			A Protein Complex Network of Drosophila melanogaster	CELL			English	Article							COMPREHENSIVE ANALYSIS; INTERACTION MAP; YEAST; GENE; RESOURCE; EVOLUTION; SUBUNIT; ORGANIZATION; INTERACTOME	Determining the composition of protein complexes is an essential step toward understanding the cell as an integrated system. Using coaffinity purification coupled to mass spectrometry analysis, we examined protein associations involving nearly 5,000 individual, FLAG-HA epitope-tagged Drosophila proteins. Stringent analysis of these data, based on a statistical framework designed to define individual protein-protein interactions, led to the generation of a Drosophila protein interaction map (DPiM) encompassing 556 protein complexes. The high quality of the DPiM and its usefulness as a paradigm for metazoan proteomes are apparent from the recovery of many known complexes, significant enrichment for shared functional attributes, and validation in human cells. The DPiM defines potential novel members for several important protein complexes and assigns functional links to 586 protein-coding genes lacking previous experimental annotation. The DPiM represents, to our knowledge, the largest metazoan protein complex map and provides a valuable resource for analysis of protein complex evolution.	[Guruharsha, K. G.; Rual, Jean-Francois; Zhai, Bo; Mintseris, Julian; Vaidya, Pujita; Vaidya, Namita; Beekman, Chapman; Wong, Christina; Rhee, David Y.; Cenaj, Odise; McKillip, Emily; Shah, Saumini; Gygi, Steven P.; Obar, Robert A.; Artavanis-Tsakonas, Spyros] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Wan, Kenneth H.; Yu, Charles; Parsa, Bayan; Carlson, Joseph W.; Chen, Xiao; Kapadia, Bhaveen; Celniker, Susan E.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; [VijayRaghavan, K.] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Harvard University; Harvard Medical School; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Obar, RA (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	robert_obar@hms.harvard.edu; artavanis@hms.harvard.edu	Kapadia, Bhaveen/X-4068-2019; Kuthethur, Guruharsha/Z-2605-2019	Kapadia, Bhaveen/0000-0003-1335-891X; Kuthethur, Guruharsha/0000-0001-7292-4868; Rhee, David/0000-0002-6911-4941; Rual, Jean-Francois/0000-0003-4465-8819	National Institutes of Health (NIH) [5RO1HG003616]; Deutsche Jose Carreras Leukamie-Stiftung e.V.; National Human Genome Research Institute (NHGRI) [P41HG3487]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG003487, R01HG003616] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Jose Carreras Leukamie-Stiftung e.V.; National Human Genome Research Institute (NHGRI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by a grant from the National Institutes of Health (NIH 5RO1HG003616) to S.A.-T. and a fellowship from the Deutsche Jose Carreras Leukamie-Stiftung e.V. to J.-F.R. Generation of the clone set was supported by a grant from the National Human Genome Research Institute (NHGRI P41HG3487 to S.E.C.). Special thanks to Anne-Claude Gavin, Bernhard Kuster, and Charlie Cohen, whose help was critical in the initiation of the project, as well as Gerry Rubin for help throughout. We thank Norbert Perrimon for S2R+ cells, Lucy and Peter Cherbas for help in cell culture, William Gelbart and the FlyBase team for making DPiM data available on FlyBase, and Alexey Veraksa, Ashim Mukherjee, Kadalmani Krishnan, Mathew Sowa, Dan Finley, Robin Reed, Angeliki Louvi, and members of the S.A.-T., S.E.C., S.P.G., and K.V. labs for helpful discussion and comments. We thank members of CCSB, Vidal and Harper labs, and David Hill and Eric Bennett in particular, for help with the human ORFeome collection. We also thank Manolis Kellis and Rogerio Candeias for their help.	Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Audhya A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000956; Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204; Belote JM, 2009, HEREDITY, V103, P23, DOI 10.1038/hdy.2009.23; Bennett D, 2006, J MOL BIOL, V364, P196, DOI 10.1016/j.jmb.2006.08.094; Bennett D, 2009, J MOL BIOL, V387, P518, DOI 10.1016/j.jmb.2006.08.101; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Breitkreutz A, 2010, SCIENCE, V328, P1043, DOI 10.1126/science.1176495; Cherbas L, 2011, GENOME RES, V21, P301, DOI 10.1101/gr.112961.110; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Choi H, 2011, NAT METHODS, V8, P70, DOI 10.1038/NMETH.1541; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Eng JK, 2008, J PROTEOME RES, V7, P4598, DOI 10.1021/pr800420s; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Fricke B, 2007, EMBO REP, V8, P1170, DOI 10.1038/sj.embor.7401091; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gavin AC, 2011, CURR OPIN BIOTECH, V22, P42, DOI 10.1016/j.copbio.2010.09.007; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Goshima G, 2010, CURR OPIN CELL BIOL, V22, P44, DOI 10.1016/j.ceb.2009.11.012; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graveley BR, 2011, NATURE, V471, P473, DOI 10.1038/nature09715; Guerrero C, 2008, P NATL ACAD SCI USA, V105, P13333, DOI 10.1073/pnas.0801870105; Hart GT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-236; Herold N, 2009, MOL CELL BIOL, V29, P281, DOI 10.1128/MCB.01415-08; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Hu PZ, 2009, PLOS BIOL, V7, P929, DOI 10.1371/journal.pbio.1000096; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602; Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896; Kato JY, 2009, GENES CELLS, V14, P1209, DOI 10.1111/j.1365-2443.2009.01349.x; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kuhner S, 2009, SCIENCE, V326, P1235, DOI 10.1126/science.1176343; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Michelet X, 2010, BIOL CELL, V102, P191, DOI 10.1042/BC20090145; Mintseris J, 2005, P NATL ACAD SCI USA, V102, P10930, DOI 10.1073/pnas.0502667102; Murali T, 2011, NUCLEIC ACIDS RES, V39, pD736, DOI 10.1093/nar/gkq1092; Ohtaki A, 2010, FRONT BIOSCI-LANDMRK, V15, P708, DOI 10.2741/3641; Rees JS, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002386; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stanyon CA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r96; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Sudhof TC, 2009, SCIENCE, V323, P474, DOI 10.1126/science.1161748; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tweedie S, 2009, NUCLEIC ACIDS RES, V37, pD555, DOI 10.1093/nar/gkn788; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Dam TJP, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000132; Wang XR, 2007, BIOCHEMISTRY-US, V46, P3553, DOI 10.1021/bi061994u; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Williams RD, 2004, GENE CHROMOSOME CANC, V41, P65, DOI 10.1002/gcc.20060; Wuchty S, 2004, GENOME RES, V14, P1310, DOI 10.1101/gr.2300204; Yamada T, 2009, NAT REV MOL CELL BIO, V10, P791, DOI 10.1038/nrm2787; Yu C, 2011, METHODS MOL BIOL, V723, P257, DOI 10.1007/978-1-61779-043-0_17; Yu JK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-461	65	442	449	1	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					690	703		10.1016/j.cell.2011.08.047	http://dx.doi.org/10.1016/j.cell.2011.08.047			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036573	Green Accepted, Bronze			2022-12-28	WOS:000296573700022
J	Mullen, AR; Wheaton, WW; Jin, ES; Chen, PH; Sullivan, LB; Cheng, T; Yang, YF; Linehan, WM; Chandel, NS; DeBerardinis, RJ				Mullen, Andrew R.; Wheaton, William W.; Jin, Eunsook S.; Chen, Pei-Hsuan; Sullivan, Lucas B.; Cheng, Tzuling; Yang, Youfeng; Linehan, W. Marston; Chandel, Navdeep S.; DeBerardinis, Ralph J.			Reductive carboxylation supports growth in tumour cells with defective mitochondria	NATURE			English	Article							GLUTAMINE-METABOLISM; CANCER; DEHYDROGENASE; GENE; PARAGANGLIOMA; MUTATIONS; LIVER; LINE; FLUX; ROS	Mitochondrial metabolism provides precursors to build macromolecules in growing cancer cells(1,2). In normally functioning tumour cell mitochondria, oxidative metabolism of glucose- and glutamine-derived carbon produces citrate and acetyl-coenzyme A for lipid synthesis, which is required for tumorigenesis(3). Yet some tumours harbour mutations in the citric acid cycle (CAC) or electron transport chain (ETC) that disable normal oxidative mitochondrial function(4-7), and it is unknown how cells from such tumours generate precursors for macromolecular synthesis. Here we show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This pathway uses mitochondrial and cytosolic isoforms of NADP(+)/NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of glutamine-derived citrate provides both the acetylcoenzyme A for lipid synthesis and the four-carbon intermediates needed to produce the remaining CAC metabolites and related macromolecular precursors. This reductive, glutamine-dependent pathway is the dominant mode of metabolism in rapidly growing malignant cells containing mutations in complex I or complex III of the ETC, in patient-derived renal carcinoma cells with mutations in fumarate hydratase, and in cells with normal mitochondria subjected to acute pharmacological ETC inhibition. Our findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism.	[Mullen, Andrew R.; Chen, Pei-Hsuan; Cheng, Tzuling; DeBerardinis, Ralph J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Wheaton, William W.; Sullivan, Lucas B.; Chandel, Navdeep S.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Wheaton, William W.; Sullivan, Lucas B.; Chandel, Navdeep S.] Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Jin, Eunsook S.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Jin, Eunsook S.] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Yang, Youfeng; Linehan, W. Marston] NCI, Urol Oncol Branch, Bethesda, MD 20892 USA; [DeBerardinis, Ralph J.] Univ Texas SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; [DeBerardinis, Ralph J.] Univ Texas SW Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Northwestern University; Northwestern University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	DeBerardinis, RJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.	nav@northwestern.edu; ralph.deberardinis@utsouthwestern.edu		Sullivan, Lucas/0000-0002-6745-8222	NIH [K08DK072565, R01CA157996, R01CA123067, DK078933, RR02584, 5T32GM083831, T32CA009560, T32GM008061]; Cancer Prevention and Research Institute of Texas (CPRIT) [HIRP100437]; Robert A. Welch Foundation [I1733]; LUNGevity Foundation; Consortium of Independent Lung Health Organizations; NIH, National Cancer Institute Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011043, ZIDBC011089, ZIABC011038, R01CA123067, R01CA157996, ZIABC011028, T32CA009560] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK072565, K01DK078933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM083831, T32GM008061] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); Robert A. Welch Foundation(The Welch Foundation); LUNGevity Foundation; Consortium of Independent Lung Health Organizations; NIH, National Cancer Institute Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	K. Uyeda and members of the DeBerardinis and Chandel laboratories provided critical assessment of the data, and J. Sudderth and C. Yang provided experimental assistance. We thank C. Moraes and I. F. M. de Coo for the WT 143B and CYTB 143B cell lines, I. E. Scheffler for CCL16-B2 cells and T. Yagi for CCL16-NDI1 cells. This work was supported by grants to R. J. D. from the NIH (K08DK072565 and R01CA157996), the Cancer Prevention and Research Institute of Texas (CPRIT, HIRP100437) and the Robert A. Welch Foundation (I1733); to N.S.C. from the NIH (R01CA123067), the LUNGevity Foundation and a Consortium of Independent Lung Health Organizations convened by Respiratory Health Association of Metropolitan Chicago; and to E. S. J. by an NIH grant (DK078933). The work was also supported by the Intramural Research Program of the NIH, National Cancer Institute Center for Cancer Research and by NIH grant RR02584. NIH training grants supported A. R. M. (5T32GM083831), W. W. W. (T32CA009560) and L. B. S. (T32GM008061). T. C. was supported by a CPRIT training grant.	Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Olszewski KL, 2010, NATURE, V466, P774, DOI 10.1038/nature09301; Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yang Y, 2010, CANCER GENET CYTOGEN, V196, P45, DOI 10.1016/j.cancergencyto.2009.08.018; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200	26	867	883	5	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					385	U171		10.1038/nature10642	http://dx.doi.org/10.1038/nature10642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22101431	Green Accepted			2022-12-28	WOS:000299210600047
J	Cobo, E; Cortes, J; Ribera, JM; Cardellach, F; Selva-O'Callaghan, A; Kostov, B; Garcia, L; Cirugeda, L; Altman, DG; Gonzalez, JA; Sanchez, JA; Miras, F; Urrutia, A; Fonollosa, V; Rey-Joly, C; Vilardell, M				Cobo, E.; Cortes, J.; Ribera, J. M.; Cardellach, F.; Selva-O'Callaghan, A.; Kostov, B.; Garcia, L.; Cirugeda, L.; Altman, D. G.; Gonzalez, J. A.; Sanchez, J. A.; Miras, F.; Urrutia, A.; Fonollosa, V.; Rey-Joly, C.; Vilardell, M.			Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXPLANATION; EPIDEMIOLOGY; IMPROVE	Objective To investigate the effect of an additional review based on reporting guidelines such as STROBE and CONSORT on quality of manuscripts. Design Masked randomised trial. Population Original research manuscripts submitted to the Medicina Clinica journal from May 2008 to April 2009 and considered suitable for publication. Intervention Control group: conventional peer reviews alone. Intervention group: conventional review plus an additional review looking for missing items from reporting guidelines. Outcomes Manuscript quality, assessed with a 5 point Likert scale (primary: overall quality; secondary: average quality of specific items in paper). Main analysis compared groups as allocated, after adjustment for baseline factors (analysis of covariance); sensitivity analysis compared groups as reviewed. Adherence to reviewer suggestions assessed with Likert scale. Results Of 126 consecutive papers receiving conventional review, 34 were not suitable for publication. The remaining 92 papers were allocated to receive conventional reviews alone (n=41) or additional reviews (n=51). Four papers assigned to the conventional review group deviated from protocol; they received an additional review based on reporting guidelines. We saw an improvement in manuscript quality in favour of the additional review group (comparison as allocated, 0.25, 95% confidence interval -0.05 to 0.54; as reviewed, 0.33, 0.03 to 0.63). More papers with additional reviews than with conventional reviews alone improved from baseline (22 (43%) v eight (20%), difference 23.6% (3.2% to 44.0%), number needed to treat 4.2 (from 2.3 to 31.2), relative risk 2.21 (1.10 to 4.44)). Authors in the additional review group adhered more to suggestions from conventional reviews than to those from additional reviews (average increase 0.43 Likert points (0.19 to 0.67)). Conclusions Additional reviews based on reporting guidelines improve manuscript quality, although the observed effect was smaller than hypothesised and not definitively demonstrated. Authors adhere more to suggestions from conventional reviews than to those from additional reviews, showing difficulties in adhering to high methodological standards at the latest research phases. To boost paper quality and impact, authors should be aware of future requirements of reporting guidelines at the very beginning of their study.	[Cobo, E.; Ribera, J. M.] Elsevier Barcelona, Med Clin, Dept Clin Haematol, Barcelona 08021, Spain; [Cobo, E.; Cortes, J.; Garcia, L.; Gonzalez, J. A.; Sanchez, J. A.; Miras, F.] Univ Politecn Cataluna, Barcelona, Spain; [Ribera, J. M.] Univ Autonoma Barcelona, Dept Clin Haematol, E-08193 Barcelona, Spain; [Ribera, J. M.] Hosp Badalona Germans Trias & Pujol, Dept Clin Haematol, Badalona, Spain; [Ribera, J. M.] ICO, Catalan Inst Oncol, Jose Carreras Leukaemia Res Inst, Dept Clin Haematol, Badalona, Spain; [Cardellach, F.] Univ Barcelona, Barcelona, Spain; [Cardellach, F.] Hosp Clin Barcelona, Barcelona, Spain; [Selva-O'Callaghan, A.; Fonollosa, V.; Vilardell, M.] Vall DHebron Hosp, Barcelona, Spain; [Kostov, B.] GESCLINIC, Primary Hlth Care Ctr Les Corts, Barcelona, Spain; [Cirugeda, L.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Altman, D. G.] Univ Oxford, Ctr Stat Med, Oxford, England	Reed Elsevier; Elsevier; Universitat Politecnica de Catalunya; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC); University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; University of Oxford	Cobo, E (corresponding author), Elsevier Barcelona, Med Clin, Dept Clin Haematol, Barcelona 08021, Spain.	erik.cobo@upc.edu	Gonzalez, Jose Antonio/AFP-1452-2022; Sanchez-Espigares, Jose Antonio/L-7501-2015; Cortés, Jordi/P-6563-2017; Ribera, JM/B-8181-2009; Altman, Douglas G/A-9714-2012; Cobo, Erik/H-6230-2011	Gonzalez, Jose Antonio/0000-0002-3113-4779; Sanchez-Espigares, Jose Antonio/0000-0001-8195-1913; Cortés, Jordi/0000-0002-3764-0795; Ribera, JM/0000-0003-1042-6024; Cobo, Erik/0000-0002-3534-5602; Kostov, Belchin/0000-0002-2126-3892; Cirugeda, Lourdes/0000-0003-1095-5137; Selva-O'Callaghan, Albert/0000-0003-2823-9761	"Bioestadistica para no estadisticos" learning programme; MRC [MC_qA137931] Funding Source: UKRI; Medical Research Council [MC_qA137931] Funding Source: researchfish	"Bioestadistica para no estadisticos" learning programme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf and declare that: JC, LG, LC, BK, and FM are supported by the "Bioestadistica para no estadisticos" learning programme; they have no relationships with companies that might have an interest in the submitted work in the previous 3 years; their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and they have no non-financial interests that may be relevant to the submitted work.	ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 2006, NATURE, V444, P971, DOI 10.1038/444971b; Arnau C, 2003, MED CLIN-BARCELONA, V121, P690, DOI 10.1157/13054597; Blair A, 2009, ENVIRON HEALTH PERSP, V117, P1809, DOI 10.1289/ehp.0901194; Boffetta P, 2008, JNCI-J NATL CANCER I, V100, P988, DOI 10.1093/jnci/djn191; Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; Cobo E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000332; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; EQUATOR Network, 2011, LIB HLTH RES REP; Friedberg EC, 2010, DNA REPAIR, V9, P476, DOI 10.1016/j.dnarep.2010.03.003; Garcia-Berthou Emili, 2004, BMC Med Res Methodol, V4, P13, DOI 10.1186/1471-2288-4-13; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; Jefferson T, 2007, Cochrane Database Syst Rev, pMR000016; Johnston SC, 2007, ANN NEUROL, V61, pA10, DOI 10.1002/ana.21197; Little J, 2009, EUR J EPIDEMIOL, V24, P37, DOI 10.1007/s10654-008-9302-y; McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678; Meng XL, 2009, AM STAT, V63, P202, DOI 10.1198/tast.2009.09045; Moher D, 2011, SOC CLIN TRIALS 32 A, pA79; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Plint AC, 2006, MED J AUSTRALIA, V185, P263, DOI 10.5694/j.1326-5377.2006.tb00557.x; RENNIE D, 1992, CONTROL CLIN TRIALS, V13, P443, DOI 10.1016/0197-2456(92)90201-A; Rennie D, 2003, PEER REV HLTH SCI, P1; Ross JS, 2006, JAMA-J AM MED ASSOC, V295, P1675, DOI 10.1001/jama.295.14.1675; Schroter S, 2004, BRIT MED J, V328, P673, DOI 10.1136/bmj.38023.700775.AE; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; von Elm E, 2004, BMJ-BRIT MED J, V329, P868, DOI 10.1136/bmj.329.7471.868; Young NS, 2008, PLOS MED, V5, P1418, DOI 10.1371/journal.pmed.0050201	29	163	168	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2011	343								d6783	10.1136/bmj.d6783	http://dx.doi.org/10.1136/bmj.d6783			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857ND	22108262	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000297724300003
J	Chataway, J; Miller, DH				Chataway, Jeremy; Miller, David H.			Multiple sclerosis-quenching the flames of inflammation	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; NATURAL-HISTORY; ORAL FINGOLIMOD; NATALIZUMAB		[Chataway, Jeremy; Miller, David H.] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England; [Chataway, Jeremy; Miller, David H.] UCL, Dept Neuroinflammat, Inst Neurol, London WC1N 3BG, England; [Chataway, Jeremy] Imperial Coll Healthcare NHS Trust, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London	Miller, DH (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England.	d.miller@ion.ucl.ac.uk						*ABB, 2011, BIOG ID ABB ANN POS; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Koch M, 2010, J NEUROL NEUROSUR PS, V81, P1039, DOI 10.1136/jnnp.2010.208173; O'Connor P, 2010, MULT SCLER, V16, pS41; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; *SAN, 2011, SAN REP POS TOP LIN; Scalfari A, 2010, BRAIN, V133, P1914, DOI 10.1093/brain/awq118; *TEVA PHARM IND, 2011, RES PHAS 3 BRAV TRAI	15	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	2011	378	9805					1759	1760		10.1016/S0140-6736(11)61133-1	http://dx.doi.org/10.1016/S0140-6736(11)61133-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22047970				2022-12-28	WOS:000297262300006
J	Laurance, J				Laurance, Jeremy			Profile William Seeley: brain explorer	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	2011	378	9804					1693	1693		10.1016/S0140-6736(11)61729-7	http://dx.doi.org/10.1016/S0140-6736(11)61729-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	846LB	22078676				2022-12-28	WOS:000296899800016
J	Houten, SM; Argmann, CA				Houten, Sander M.; Argmann, Carmen A.			New Driver for Lipid Synthesis	CELL			English	Editorial Material							LIVER; INSULIN; SREBP	Cholesterol regulates activation of sterol regulatory element-binding protein (SREBP) through a classic feedback loop. Walker et al. (2011) extend the regulatory inputs governing SREBP activity to include an independent loop modulated by phosphatidylcholine (PC) and cellular methylation capacity. These findings suggest a link between lipid synthesis and cellular pathways involved in methylation.	[Houten, Sander M.] Univ Amsterdam, Lab Genet Metab Dis, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; [Houten, Sander M.] Univ Amsterdam, Dept Pediat, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands; [Argmann, Carmen A.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Houten, SM (corresponding author), Univ Amsterdam, Lab Genet Metab Dis, Dept Clin Chem, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.m.houten@amc.uva.nl	Houten, Sander/Y-3599-2019	Houten, Sander/0000-0002-6167-9147				Blom HJ, 2011, J INHERIT METAB DIS, V34, P75, DOI 10.1007/s10545-010-9177-4; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Li SJ, 2010, P NATL ACAD SCI USA, V107, P3441, DOI 10.1073/pnas.0914798107; Okazaki H, 2010, J BIOL CHEM, V285, P6801, DOI 10.1074/jbc.M109.079459; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Xu Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-451	10	1	1	0	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					719	721		10.1016/j.cell.2011.10.019	http://dx.doi.org/10.1016/j.cell.2011.10.019			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078872	Bronze			2022-12-28	WOS:000296902300006
J	Mizushima, N; Komatsu, M				Mizushima, Noboru; Komatsu, Masaaki			Autophagy: Renovation of Cells and Tissues	CELL			English	Review							LIFE-SPAN EXTENSION; UBIQUITIN-PROTEASOME SYSTEM; GENOME-WIDE ASSOCIATION; PROTEIN-DEGRADATION; DEFICIENT MICE; POTENTIAL ROLE; CROHN-DISEASE; GENE ATG16L1; ATG PROTEINS; PARKIN	Autophagy is the major intracellular degradation system by which cytoplasmic materials are delivered to and degraded in the lysosome. However, the purpose of autophagy is not the simple elimination of materials, but instead, autophagy serves as a dynamic recycling system that produces new building blocks and energy for cellular renovation and homeostasis. Here we provide a multidisciplinary review of our current understanding of autophagy's role in metabolic adaptation, intracellular quality control, and renovation during development and differentiation. We also explore how recent mouse models in combination with advances in human genetics are providing key insights into how the impairment or activation of autophagy contributes to pathogenesis of diverse diseases, from neurodegenerative diseases such as Parkinson disease to inflammatory disorders such as Crohn disease.	[Mizushima, Noboru] Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Tokyo 1138519, Japan; [Komatsu, Masaaki] Tokyo Metropolitan Inst Med Sci, Prot Metab Project, Tokyo 1568506, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Metropolitan Institute of Medical Science	Mizushima, N (corresponding author), Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Tokyo 1138519, Japan.	nmizu.phy2@tmd.ac.jp; komatsu-ms@igakuken.or.jp	Komatsu, Masaaki/B-8321-2011; Mizushima, Noboru/C-3635-2009	Komatsu, Masaaki/0000-0001-7672-7722; Mizushima, Noboru/0000-0002-6258-6444	Funding Program for Next Generation World-Leading Researchers	Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We apologize to authors whose work could not be included because of space limitations. N.M. and M. K. are supported by Funding Program for Next Generation World-Leading Researchers.	Al Rawi S, 2011, SCIENCE, V334, P1144, DOI 10.1126/science.1211878; Alirezaei M, 2010, AUTOPHAGY, V6, P702, DOI 10.4161/auto.6.6.12376; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Cao DJ, 2011, P NATL ACAD SCI USA, V108, P4123, DOI 10.1073/pnas.1015081108; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Ebato C, 2008, CELL METAB, V8, P325, DOI 10.1016/j.cmet.2008.08.009; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Ezaki J, 2011, AUTOPHAGY, V7, P727, DOI 10.4161/auto.7.7.15371; Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500; Fortunato F, 2009, GASTROENTEROLOGY, V137, P350, DOI 10.1053/j.gastro.2009.04.003; Fujita N, 2009, J BIOL CHEM, V284, P32602, DOI 10.1074/jbc.M109.037671; Goode A, 2010, J CLIN PATHOL, V63, P199, DOI 10.1136/jcp.2009.064428; Grumati P, 2010, NAT MED, V16, P1313, DOI 10.1038/nm.2247; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492; Hashimoto D, 2008, J CELL BIOL, V181, P1065, DOI 10.1083/jcb.200712156; Hashimoto Y, 2009, GENES CELLS, V14, P717, DOI 10.1111/j.1365-2443.2009.01306.x; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Inoue D, 2011, BIOCHEM BIOPH RES CO, V405, P13, DOI 10.1016/j.bbrc.2010.12.092; Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Ju JS, 2009, J CELL BIOL, V187, P875, DOI 10.1083/jcb.200908115; Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kaushik S, 2011, CELL METAB, V14, P173, DOI 10.1016/j.cmet.2011.06.008; Kimura T, 2011, J AM SOC NEPHROL, V22, P902, DOI 10.1681/ASN.2010070705; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kuballa P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003391; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008; Liang CC, 2010, J BIOL CHEM, V285, P3499, DOI 10.1074/jbc.M109.072389; Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842; Malicdan MC, 2008, NEUROMUSCULAR DISORD, V18, P521, DOI 10.1016/j.nmd.2008.04.010; Mareninova OA, 2009, J CLIN INVEST, V119, P3340, DOI 10.1172/JCI38674; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Meng QY, 2011, J BIOL CHEM, V286, P32324, DOI 10.1074/jbc.M111.254417; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nishiyama J, 2007, AUTOPHAGY, V3, P591, DOI 10.4161/auto.4964; Nixon RA, 2008, AUTOPHAGY, V4, P590, DOI 10.4161/auto.6259; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x; Onodera J, 2005, J BIOL CHEM, V280, P31582, DOI 10.1074/jbc.M506736200; Orenstein SJ, 2010, SEMIN CELL DEV BIOL, V21, P719, DOI 10.1016/j.semcdb.2010.02.005; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raben N, 2010, AUTOPHAGY, V6, P1078, DOI 10.4161/auto.6.8.13378; Raben N, 2008, HUM MOL GENET, V17, P3897, DOI 10.1093/hmg/ddn292; Ravikumar B, 2010, NAT CELL BIOL, V12, P747, DOI 10.1038/ncb2078; Riley BE, 2010, J CELL BIOL, V191, P537, DOI 10.1083/jcb.201005012; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Ryoo HD, 2010, CURR OPIN CELL BIOL, V22, P889, DOI 10.1016/j.ceb.2010.08.022; Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Sanchez-Serrano I, 2006, NAT REV DRUG DISCOV, V5, P107, DOI 10.1038/nrd1959; Sato M., 2011, SCIENCE, DOI [10.1126/science.121033, DOI 10.1126/SCIENCE.121033]; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309; Sterky FH, 2011, P NATL ACAD SCI USA, V108, P12937, DOI 10.1073/pnas.1103295108; Suzuki K, 2007, GENES CELLS, V12, P209, DOI 10.1111/j.1365-2443.2007.01050.x; Suzuki SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017412; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Taneike M, 2010, AUTOPHAGY, V6, P600, DOI 10.4161/auto.6.5.11947; Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730; Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800; Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831; Toth ML, 2008, AUTOPHAGY, V4, P330, DOI 10.4161/auto.5618; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Tsukamoto S, 2008, SCIENCE, V321, P117, DOI 10.1126/science.1154822; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552; Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523	131	3700	3919	45	771	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					728	741		10.1016/j.cell.2011.10.026	http://dx.doi.org/10.1016/j.cell.2011.10.026			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078875	Bronze			2022-12-28	WOS:000296902300009
J	Nguyen-Khac, E; Thevenot, T; Piquet, MA; Benferhat, S; Goria, O; Chatelain, D; Tramier, B; Dewaele, F; Ghrib, S; Rudler, M; Carbonell, N; Tossou, H; Bental, A; Bernard-Chabert, B; Dupas, JL				Nguyen-Khac, Eric; Thevenot, Thierry; Piquet, Marie-Astrid; Benferhat, Said; Goria, Odile; Chatelain, Denis; Tramier, Blaise; Dewaele, Francois; Ghrib, Salah; Rudler, Marika; Carbonell, Nicolas; Tossou, Herve; Bental, Abdeslam; Bernard-Chabert, Brigitte; Dupas, Jean-Louis		AAH-NAC Study Grp	Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; IMPROVES LIVER-FUNCTION; SEPTIC SHOCK PATIENTS; RAT KUPFFER CELLS; RANDOMIZED-TRIAL; GLUTATHIONE DEPLETION; ENTERAL NUTRITION; TERM SURVIVAL; THERAPY; CORTICOSTEROIDS	BACKGROUND Mortality among patients with severe acute alcoholic hepatitis is high, even among those treated with glucocorticoids. We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). All patients received 4 weeks of prednisolone. The prednisolone-N-acetylcysteine group received intravenous N-acetylcysteine on day 1 (at a dose of 150, 50, and 100 mg per kilogram of body weight in 250, 500, and 1000 ml of 5% glucose solution over a period of 30 minutes, 4 hours, and 16 hours, respectively) and on days 2 through 5 (100 mg per kilogram per day in 1000 ml of 5% glucose solution). The prednisolone-only group received an infusion in 1000 ml of 5% glucose solution per day on days 1 through 5. The primary outcome was 6-month survival. Secondary outcomes included survival at 1 and 3 months, hepatitis complications, adverse events related to N-acetylcysteine use, and changes in bilirubin levels on days 7 and 14. RESULTS Mortality was not significantly lower in the prednisolone-N-acetylcysteine group than in the prednisolone-only group at 6 months (27% vs. 38%, P = 0.07). Mortality was significantly lower at 1 month (8% vs. 24%, P = 0.006) but not at 3 months (22% vs. 34%, P = 0.06). Death due to the hepatorenal syndrome was less frequent in the prednisolone-N-acetylcysteine group than in the prednisolone-only group at 6 months (9% vs. 22%, P = 0.02). In a multivariate analysis, factors associated with 6-month survival were a younger age (P<0.001), a shorter prothrombin time (P<0.001), a lower level of bilirubin at baseline (P<0.001), and a decrease in bilirubin on day 14 (P<0.001). Infections were less frequent in the prednisolone-N-acetylcysteine group than in the prednisolone-only group (P = 0.001); other side effects were similar in the two groups. CONCLUSIONS Although combination therapy with prednisolone plus N-acetylcysteine increased 1-month survival among patients with severe acute alcoholic hepatitis, 6-month survival, the primary outcome, was not improved. (Funded by Programme Hospitalier de Recherche Clinique; AAH-NAC ClinicalTrials.gov number, NCT00863785.)	[Nguyen-Khac, Eric; Dewaele, Francois; Dupas, Jean-Louis] Amiens Univ Hosp, Serv Hepatogastroenterol, F-80054 Amiens 01, France; [Chatelain, Denis] Amiens Univ Hosp, Pathol Serv, F-80054 Amiens 01, France; [Nguyen-Khac, Eric] Univ Picardy, Equipe Reg INSERM 24, Amiens, France; [Thevenot, Thierry] Besancon Univ Hosp, Serv Hepatol, Besancon, France; [Piquet, Marie-Astrid] Caen Univ Hosp, Serv Hepatogastroenterol, Caen, France; [Benferhat, Said] St Quentin Gen Hosp, Serv Hepatogastroenterol, St Quentin en Yvelines, France; [Goria, Odile] Rouen Univ Hosp, Serv Hepatogastroenterol, Rouen, France; [Tramier, Blaise] Aubagne Gen Hosp, Dept Biostat, Aubagne, France; [Ghrib, Salah] Cambrai Gen Hosp, Serv Hepatogastroenterol, Cambrai, France; [Rudler, Marika] Pitie Salpetriere Univ Hosp, Serv Hepatogastroenterol, Paris, France; [Carbonell, Nicolas] St Antoine Univ Hosp, Serv Hepatol, Paris, France; [Tossou, Herve] Beauvais Gen Hosp, Serv Hepatogastroenterol, Beauvais, France; [Bental, Abdeslam] Abbeville Gen Hosp, Serv Hepatogastroenterol, Abbeville, France; [Bernard-Chabert, Brigitte] Reims Univ Hosp, Serv Hepatogastroenterol, Reims, France	Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Universite de Franche-Comte; CHU Besancon; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Rouen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Reims	Nguyen-Khac, E (corresponding author), Amiens Univ Hosp, Serv Hepatogastroenterol, Pl Victor Pauchet, F-80054 Amiens 01, France.	nguyen-khac.eric@chu-amiens.fr	Hug, Balthasar L./G-1568-2010	betsou, fay/0000-0002-0558-4653; Thevenot, Thierry/0000-0003-3974-2784; Di Martino, Vincent/0000-0002-2022-690X	Hospitalier de Recherche Clinique; French government	Hospitalier de Recherche Clinique; French government	Funded by Programme Hospitalier de Recherche Clinique; AAH-NAC ClinicalTrials.gov number, NCT00863785.; Supported by Programme Hospitalier de Recherche Clinique, a program of the French government that supports hospital-based clinical research.	ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; CARITHERS RL, 1989, ANN INTERN MED, V110, P685, DOI 10.7326/0003-4819-110-9-685; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DAURES JP, 1991, GASTROEN CLIN BIOL, V15, P223; Dhalla S, 2007, CLIN INVEST MED, V30, P33, DOI 10.25011/cim.v30i1.447; Enomoto N, 1998, GASTROENTEROLOGY, V115, P443, DOI 10.1016/S0016-5085(98)70211-2; Hein OV, 2004, CRIT CARE, V8, pR66, DOI 10.1186/cc2426; HELMAN RA, 1971, ANN INTERN MED, V74, P311, DOI 10.7326/0003-4819-74-3-311; HIRANO T, 1992, HEPATOLOGY, V16, P1423; Holt S, 1999, LANCET, V353, P294, DOI 10.1016/S0140-6736(05)74933-3; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; Imperiale TF, 1999, AM J GASTROENTEROL, V94, P3066, DOI 10.1111/j.1572-0241.1999.03066.x; Lee WM, 2009, GASTROENTEROLOGY, V137, P856, DOI 10.1053/j.gastro.2009.06.006; Louvet A, 2009, GASTROENTEROLOGY, V137, P541, DOI 10.1053/j.gastro.2009.04.062; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; Mathurin P, 2000, HEPATOLOGY, V32, P1008, DOI 10.1053/jhep.2000.19621; Mathurin P, 2003, HEPATOLOGY, V38, P1363, DOI 10.1016/j.hep.2003.09.038; Mathurin P, 2002, J HEPATOL, V36, P480, DOI 10.1016/S0168-8278(01)00289-6; MENDENHALL CL, 1984, NEW ENGL J MED, V311, P1464, DOI 10.1056/NEJM198412063112302; Moreno C, 2010, J HEPATOL, V53, P1117, DOI 10.1016/j.jhep.2010.05.030; NeuschwanderTetri BA, 1996, BIOCHEM J, V320, P1005, DOI 10.1042/bj3201005; Nguyen-Khac E, 2008, J HEPATOL, V48, pS17, DOI 10.1016/S0168-8278(08)60040-9; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Ozaras R, 2003, WORLD J GASTROENTERO, V9, P791; Phillips M, 2006, J HEPATOL, V44, P784, DOI 10.1016/j.jhep.2005.11.039; PRESCOTT LF, 1977, LANCET, V2, P432; Rambaldi A, 2008, ALIMENT PHARM THER, V27, P1167, DOI 10.1111/j.1365-2036.2008.03685.x; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; Rank N, 2000, CRIT CARE MED, V28, P3799, DOI 10.1097/00003246-200012000-00006; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Ronis MJJ, 2005, FREE RADICAL BIO MED, V39, P619, DOI 10.1016/j.freeradbiomed.2005.04.011; Stewart S, 2007, J HEPATOL, V47, P277, DOI 10.1016/j.jhep.2007.03.027; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Wang AL, 2006, HEPATOL RES, V34, P199, DOI 10.1016/j.hepres.2005.12.005	35	225	237	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1781	1789		10.1056/NEJMoa1101214	http://dx.doi.org/10.1056/NEJMoa1101214			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070475				2022-12-28	WOS:000296762800007
J	Courchesne, E; Mouton, PR; Calhoun, ME; Semendeferi, K; Ahrens-Barbeau, C; Hallet, MJ; Barnes, CC; Pierce, K				Courchesne, Eric; Mouton, Peter R.; Calhoun, Michael E.; Semendeferi, Katerina; Ahrens-Barbeau, Clelia; Hallet, Melodie J.; Barnes, Cynthia Carter; Pierce, Karen			Neuron Number and Size in Prefrontal Cortex of Children With Autism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN OVERGROWTH; YOUNG-CHILDREN; LIFE; PATTERNS; IMPACT; LOBES; AREAS; CELLS	Context Autism often involves early brain overgrowth, including the prefrontal cortex (PFC). Although prefrontal abnormality has been theorized to underlie some autistic symptoms, the cellular defects that cause abnormal overgrowth remain unknown. Objective To investigate whether early brain overgrowth in children with autism involves excess neuron numbers in the PFC. Design, Setting, and Cases Postmortem prefrontal tissue from 7 autistic and 6 control male children aged 2 to 16 years was examined by expert anatomists who were blinded to diagnostic status. Number and size of neurons were quantified using stereological methods within the dorsolateral (DL-PFC) and mesial (M-PFC) subdivisions of the PFC. Cases were from the eastern and southeastern United States and died between 2000 and 2006. Main Outcome Measures Mean neuron number and size in the DL-PFC and M-PFC were compared between autistic and control postmortem cases. Correlations of neuron number with deviation in brain weight from normative values for age were also performed. Results Children with autism had 67% more neurons in the PFC (mean, 1.94 billion; 95% CI, 1.57-2.31) compared with control children (1.16 billion; 95% CI, 0.90-1.42; P=.002), including 79% more in DL-PFC (1.57 billion; 95% CI, 1.20-1.94 in autism cases vs 0.88 billion; 95% CI, 0.66-1.10 in controls; P=.003) and 29% more in M-PFC (0.36 billion; 95% CI, 0.33-0.40 in autism cases vs 0.28 billion; 95% CI, 0.23-0.34 in controls; P=.009). Brain weight in the autistic cases differed from normative mean weight for age by a mean of 17.6% (95% CI, 10.2%-25.0%; P=.001), while brains in controls differed by a mean of 0.2% (95% CI, -8.7% to 9.1%; P=.96). Plots of counts by weight showed autistic children had both greater total prefrontal neuron counts and brain weight for age than control children. Conclusion In this small preliminary study, brain overgrowth in males with autism involved an abnormal excess number of neurons in the PFC. JAMA. 2011;306(18):2001-2010	[Courchesne, Eric; Ahrens-Barbeau, Clelia; Hallet, Melodie J.; Barnes, Cynthia Carter; Pierce, Karen] Univ Calif San Diego, Dept Neurosci, NIH UCSD, Autism Ctr Excellence,Sch Med, La Jolla, CA 92093 USA; [Semendeferi, Katerina] Univ Calif San Diego, Dept Anthropol, La Jolla, CA 92093 USA; [Mouton, Peter R.] Univ S Florida, Sch Med, Dept Pathol & Cell Biol, Alzheimers Inst & Res Ctr, Tampa, FL 33620 USA; [Calhoun, Michael E.] Sinq Syst Inc, Silver Spring, MD USA	University of California System; University of California San Diego; University of California System; University of California San Diego; State University System of Florida; University of South Florida	Courchesne, E (corresponding author), Univ Calif San Diego, Dept Neurosci, NIH UCSD, Autism Ctr Excellence,Sch Med, La Jolla, CA 92093 USA.	ecourchesne@ucsd.edu		Semendeferi, Katerina/0000-0002-9867-9554; Calhoun, Michael/0000-0003-1342-7903	Autism Speaks; Cure Autism Now; Peter Emch Family Foundation; Simons Foundation; Thursday Club Juniors; University of California, San Diego-National Institutes of Health (UCSD-NIH) Autism Center of Excellence [P50-MH081755]; National Institute of Mental Health (NIMH) [MH076541-04]; National Institute of Child Health and Development (NICHD) Brain and Tissue Bank for Developmental Disorders [N01-HD-4-3368, N01-HD-4-3383]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036840, R44MH076541, P50MH081755] Funding Source: NIH RePORTER	Autism Speaks; Cure Autism Now; Peter Emch Family Foundation; Simons Foundation; Thursday Club Juniors; University of California, San Diego-National Institutes of Health (UCSD-NIH) Autism Center of Excellence; National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Child Health and Development (NICHD) Brain and Tissue Bank for Developmental Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by Autism Speaks, Cure Autism Now, The Peter Emch Family Foundation, the Simons Foundation, The Thursday Club Juniors, and the University of California, San Diego-National Institutes of Health (UCSD-NIH) Autism Center of Excellence (P50-MH081755) awarded to Dr Courchesne and by the National Institute of Mental Health (NIMH) (MH076541-04) awarded to Dr Mouton. Tissue was provided by the National Institute of Child Health and Development (NICHD) Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-4-3383, the Brain and Tissue Bank for Developmental Disorders, Autism Tissue Program, and direct donations to the Courchesne laboratory.	Bhardwaj RD, 2006, P NATL ACAD SCI USA, V103, P12564, DOI 10.1073/pnas.0605177103; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; Bucy PC, 1949, PRECENTRAL MOTOR COR; Carper RA, 2005, BIOL PSYCHIAT, V57, P126, DOI 10.1016/j.biopsych.2004.11.005; Carper RA, 2002, NEUROIMAGE, V16, P1038, DOI 10.1006/nimg.2002.1099; Chawarska K, 2011, ARCH GEN PSYCHIAT, V68, P1021, DOI 10.1001/archgenpsychiatry.2011.106; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Courchesne E, 2005, INT J DEV NEUROSCI, V23, P153, DOI 10.1016/j.ijdevneu.2005.01.003; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; Courchesne E, 2011, AUTISM SPECTRUM DISO; Dawson G, 2007, BIOL PSYCHIAT, V61, P458, DOI 10.1016/j.biopsych.2006.07.016; Gohlke JM, 2007, CEREB CORTEX, V17, P2433, DOI 10.1093/cercor/bhl151; Hadley JA, 2003, FORENSIC SCI INT, V133, P190, DOI 10.1016/S0379-0738(03)00069-0; Hazlett HC, 2005, ARCH GEN PSYCHIAT, V62, P1366, DOI 10.1001/archpsyc.62.12.1366; Hazlett HC, 2011, ARCH GEN PSYCHIAT, V68, P467, DOI 10.1001/archgenpsychiatry.2011.39; JENSEN EBV, 1993, J MICROSC-OXFORD, V170, P35, DOI 10.1111/j.1365-2818.1993.tb03321.x; Kanold PO, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.016.2009; Kennedy DP, 2007, BRAIN COGNITION, V64, P124, DOI 10.1016/j.bandc.2007.01.007; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Kostovic I, 2010, ACTA PAEDIATR, V99, P1119, DOI 10.1111/j.1651-2227.2010.01811.x; Larsen CC, 2006, NEUROSCIENCE, V139, P999, DOI 10.1016/j.neuroscience.2006.01.005; Mouton P.R., 2001, PRINCIPLES PRACTICES; Mouton PR, 2011, UNBIASED STEREOLOGY, P20; Mouton PR, 2010, TARGET ORGAN TOXICOL; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Rabinowicz T, 1996, J NEUROPATH EXP NEUR, V55, P320, DOI 10.1097/00005072-199603000-00007; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Redcay E, 2005, BIOL PSYCHIAT, V58, P1, DOI 10.1016/j.biopsych.2005.03.026; Redcay E, 2008, BIOL PSYCHIAT, V64, P589, DOI 10.1016/j.biopsych.2008.05.020; Samuelsen GB, 2003, CEREB CORTEX, V13, P115, DOI 10.1093/cercor/13.2.115; Santos M, 2011, BRAIN RES, V1380, P206, DOI 10.1016/j.brainres.2010.08.067; Schumann CM, 2010, J NEUROSCI, V30, P4419, DOI 10.1523/JNEUROSCI.5714-09.2010; Semendeferi K, 1997, J HUM EVOL, V32, P375, DOI 10.1006/jhev.1996.0099; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Uylings HBM, 2005, NEUROSCIENCE, V136, P715, DOI 10.1016/j.neuroscience.2005.07.048; Webb SJ, 2006, J AUTISM DEV DISORD, V36, P881, DOI 10.1007/s10803-006-0126-x; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O	39	467	487	0	71	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					2001	2010		10.1001/jama.2011.1638	http://dx.doi.org/10.1001/jama.2011.1638			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068992				2022-12-28	WOS:000296704300023
J	Danese, S; Fiocchi, C				Danese, Silvio; Fiocchi, Claudio			MEDICAL PROGRESS Ulcerative Colitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; GENOME-WIDE ASSOCIATION; QUALITY-OF-LIFE; 5-AMINOSALICYLIC ACID; MAINTAINING REMISSION; PRACTICE PARAMETERS; CROHNS-DISEASE; COLECTOMY RATE; T-CELLS		[Danese, Silvio] Ist Clin Humanitas, Dept Gastroenterol, Milan, Italy; [Fiocchi, Claudio] Cleveland Clin, Dept Gastroenterol & Hepatol, Inst Digest Dis, Cleveland, OH USA; [Fiocchi, Claudio] Cleveland Clin, Dept Pathobiol, Lerner Res Inst, Cleveland, OH USA	IRCCS Humanitas Research Hospital; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Fiocchi, C (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol NC22, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Danese, Silvio/ABH-9571-2020	Danese, Silvio/0000-0001-7341-1351	Merck Sharp Dohme; Schering Plough; AstraZeneca; Abbott Laboratories; Takeda Millennium; UCB Pharma; Ferring	Merck Sharp Dohme(Merck & Company); Schering Plough(Merck & CompanySchering Plough Corporation); AstraZeneca(AstraZeneca); Abbott Laboratories(Abbott Laboratories); Takeda Millennium; UCB Pharma(UCB Pharma SA); Ferring(Ferring Pharmaceuticals)	Dr. Danese reports receiving fees for board membership from Merck Sharp & Dohme, consulting fees from Schering Plough, AstraZeneca, Abbott Laboratories, and Takeda Millennium, and lecture fees, including fees for service on speakers' bureaus, from UCB Pharma, Ferring, and Merck Sharp & Dohme; and Dr. Fiocchi, receiving lecture fees, including fees for service on speakers' bureaus, from Merck Sharp & Dohme and Broad Medical Research Program. No other potential conflict of interest relevant to this article was reported.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Abreu MT, 2010, NAT REV IMMUNOL, V10, P215; Ahuja V, 2010, J DIGEST DIS, V11, P134, DOI 10.1111/j.1751-2980.2010.00429.x; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Aratari A, 2008, DIGEST LIVER DIS, V40, P821, DOI 10.1016/j.dld.2008.03.014; Ardizzone S, 2006, GUT, V55, P47, DOI 10.1136/gut.2005.068809; Beaugerie L, 2009, LANCET, V374, P1617, DOI 10.1016/S0140-6736(09)61302-7; Bergeron V, 2010, AM J GASTROENTEROL, V105, P2405, DOI 10.1038/ajg.2010.248; BHAGAT S, 1994, GASTROENTEROLOGY, V107, P103, DOI 10.1016/0016-5085(94)90066-3; Birrenbach T, 2004, INFLAMM BOWEL DIS, V10, P848, DOI 10.1097/00054725-200411000-00019; Bronner MP, 2008, AM J PATHOL, V173, P1853, DOI 10.2353/ajpath.2008.080250; Camilleri-Brennan J, 2003, J GASTROINTEST SURG, V7, P814, DOI 10.1016/S1091-255X(03)00103-3; Campbell S, 2005, EUR J GASTROEN HEPAT, V17, P79, DOI 10.1097/00042737-200501000-00016; Cannom RR, 2009, AM SURGEON, V75, P976; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cohen JL, 2005, DIS COLON RECTUM, V48, P1997, DOI 10.1007/s10350-005-0180-z; Collins PD, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858; Connolly MP, 2009, DIGESTION, V80, P241, DOI 10.1159/000235916; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; D'Haens G, 2007, GASTROENTEROLOGY, V132, P763, DOI 10.1053/j.gastro.2006.12.038; D'Haens GR, 2011, AM J GASTROENTEROL, V106, P199, DOI 10.1038/ajg.2010.392; DALBASIO G, 1990, DIS COLON RECTUM, V33, P394, DOI 10.1007/BF02156265; Danese S, 2004, AUTOIMMUN REV, V3, P394, DOI 10.1016/j.autrev.2004.03.002; Dendrinos K, 2008, GASTROINTEST ENDOSC, V68, P1006, DOI 10.1016/j.gie.2008.04.003; Dignass AU, 2009, CLIN GASTROENTEROL H, V7, P762, DOI 10.1016/j.cgh.2009.04.004; Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3; Duerr RH, 2007, GASTROENTEROLOGY, V132, P2045, DOI 10.1053/j.gastro.2007.03.082; Feagan BG, 2005, NEW ENGL J MED, V352, P2499, DOI 10.1056/NEJMoa042982; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Geng X, 1998, GASTROENTEROLOGY, V114, P912, DOI 10.1016/S0016-5085(98)70310-5; GIBSON P, 1995, GUT, V36, P857, DOI 10.1136/gut.36.6.857; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gionchetti P, 2005, J CLIN GASTROENTEROL, V39, P291, DOI 10.1097/01.mcg.0000155124.74548.61; Goetz M, 2007, INFLAMM BOWEL DIS, V13, P1365, DOI 10.1002/ibd.20215; Goldstein N, 2006, AM J CLIN PATHOL, V126, P365, DOI 10.1309/UAXMW3428PGNHJ3; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hanauer SB, 2005, AM J GASTROENTEROL, V100, P2478, DOI 10.1111/j.1572-0241.2005.00248.x; Hanauer SB, 2004, NAT CLIN PRACT GASTR, V1, P1, DOI 10.1038/ncpgasthep0032; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Hoie O, 2007, GASTROENTEROLOGY, V132, P507, DOI 10.1053/j.gastro.2006.11.015; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jarnerot G, 2005, GASTROENTEROLOGY, V128, P1805, DOI 10.1053/j.gastro.2005.03.003; Kamm MA, 2008, GUT, V57, P893, DOI 10.1136/gut.2007.138248; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kiesslich R, 2003, GASTROENTEROLOGY, V124, P880, DOI 10.1053/gast.2003.50146; Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727; Kornbluth A, 2010, AM J GASTROENTEROL, V105, P500, DOI 10.1038/ajg.2010.52; Korzenik JR, 2006, NAT REV DRUG DISCOV, V5, P197, DOI 10.1038/nrd1986; Kruis W, 2004, GUT, V53, P1617, DOI 10.1136/gut.2003.037747; Kugathasan S, 2008, GASTROENTEROLOGY, V135, P1038, DOI 10.1053/j.gastro.2008.08.030; Leowardi C, 2010, LANGENBECK ARCH SURG, V395, P49, DOI 10.1007/s00423-009-0479-7; Lichtenstein GR, 2010, INFLAMM BOWEL DIS, V16, P338, DOI 10.1002/ibd.20997; Linskens RK, 2002, EUR J GASTROEN HEPAT, V14, P1013, DOI 10.1097/00042737-200209000-00013; Loddenkemper C, 2009, DIGEST DIS, V27, P576, DOI 10.1159/000233301; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Lucidarme D, 1997, ALIMENT PHARM THERAP, V11, P335, DOI 10.1046/j.1365-2036.1997.126297000.x; MacDonald TT, 1995, CLIN EXP IMMUNOL, V102, P445; Mannon PJ, 2011, GUT, V60, P449, DOI 10.1136/gut.2010.226860; Marshall JK, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004115.pub2; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; Nielsen OH, 2007, NAT CLIN PRACT GASTR, V4, P160, DOI 10.1038/ncpgasthep0696; Nikolaus S, 2007, GASTROENTEROLOGY, V133, P1670, DOI 10.1053/j.gastro.2007.09.001; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Panaccione R, 2011, J CROHNS COLITIS S, V5, pS68; Pardi DS, 2009, INFLAMM BOWEL DIS, V15, P1424, DOI 10.1002/ibd.21039; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Prantera C, 2008, NAT CLIN PRACT GASTR, V5, P670, DOI 10.1038/ncpgasthep1273; Rahier JF, 2009, J CROHNS COLITIS, V3, P47, DOI 10.1016/j.crohns.2009.02.010; Reinisch W, 2011, GUT, V60, P780, DOI 10.1136/gut.2010.221127; Rex DK, 2010, ENDOSCOPY, V42, P320, DOI 10.1055/s-0029-1244067; Rodriguez SA, 2007, GASTROINTEST ENDOSC, V65, P432, DOI 10.1016/j.gie.2006.07.034; Rutgeerts P, 2006, NEW ENGL J MED, V354, P2200; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; RUTGEERTS P, 1994, GASTROENTEROLOGY, V106, P1251, DOI 10.1016/0016-5085(94)90016-7; Rutgeerts P, 2009, GASTROENTEROLOGY, V136, P1182, DOI 10.1053/j.gastro.2009.02.001; Sandborn WJ, 2009, GASTROENTEROLOGY, V137, P1250, DOI 10.1053/j.gastro.2009.06.061; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Seibold F, 1998, J CLIN IMMUNOL, V18, P153, DOI 10.1023/A:1023203118100; Seow CH, 2010, GUT, V59, P49, DOI 10.1136/gut.2009.183095; SHANAHAN F, 1993, LANCET, V342, P407, DOI 10.1016/0140-6736(93)92818-E; Solberg IC, 2009, SCAND J GASTROENTERO, V44, P431, DOI 10.1080/00365520802600961; Stange EF, 2008, J CROHNS COLITIS, V2, P1, DOI 10.1016/j.crohns.2007.11.001; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; Sutherland L, 2006, COCHRANE DB SYST REV, V2; TAKAHASHI F, 1985, J CLIN INVEST, V76, P311, DOI 10.1172/JCI111963; Thompson AI, 2011, INFLAMM BOWEL DIS, V17, P831, DOI 10.1002/ibd.21375; Timmer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000478.pub2; Travis SPL, 2008, J CROHNS COLITIS, V2, P24, DOI 10.1016/j.crohns.2007.11.002; Travis S, 2011, GUT, V60, P3, DOI 10.1136/gut.2010.216895; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Tursi A, 2010, AM J GASTROENTEROL, V105, P2218, DOI 10.1038/ajg.2010.218; van den Broek FJC, 2008, GUT, V57, P1083, DOI 10.1136/gut.2007.144097; Vermeire S, 2011, GUT, V60, P1068, DOI 10.1136/gut.2010.226548; WIKLAND M, 1990, INT J COLORECTAL DIS, V5, P49, DOI 10.1007/BF00496151; Wilks S., 1859, LONDON MED GAZETT, V2, P264; Winther KV, 2004, CLIN GASTROENTEROL H, V2, P1088, DOI 10.1016/S1542-3565(04)00543-9; Wu H, 2009, GASTROENTEROL CLIN N, V38, P651, DOI 10.1016/j.gtc.2009.07.002; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005	101	798	847	11	136	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1713	1725		10.1056/NEJMra1102942	http://dx.doi.org/10.1056/NEJMra1102942			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047562				2022-12-28	WOS:000296424200010
J	Lee, CK; Baek, BJ				Lee, Chi-Kyou; Baek, Byoung Joon			Lingual Zoster	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lee, Chi-Kyou; Baek, Byoung Joon] Soonchunhyang Univ, Sch Med, Cheonan, South Korea	Soonchunhyang University	Lee, CK (corresponding author), Soonchunhyang Univ, Sch Med, Cheonan, South Korea.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1726	1726		10.1056/NEJMicm1107466	http://dx.doi.org/10.1056/NEJMicm1107466			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047563				2022-12-28	WOS:000296424200011
J	Cassidy, J				Cassidy, Jane			LOBBY WATCH American Legislative Exchange Council	BRITISH MEDICAL JOURNAL			English	Editorial Material												janecassi2@googlemail.com						CAMPBELL J, WEDNESDAY AUGUST 12; *CHAR COMM, CHAR COMM PUBL REP I; *DIR CHECK, A MARK WERR; NEATE R, 2011, GUARDIAN        1007; NEATE R, 2011, D CAMERONS AIDE WORK; *UK PARL, REG MEMB INT	6	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2011	343								d6916	10.1136/bmj.d6916	http://dx.doi.org/10.1136/bmj.d6916			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QC	22049522				2022-12-28	WOS:000296761400007
J	Wu, J; Petralia, RS; Kurushima, H; Patel, H; Jung, MY; Volk, L; Chowdhury, S; Shepherd, JD; Dehoff, M; Li, Y; Kuhl, D; Huganir, RL; Price, DL; Scannevin, R; Troncoso, JC; Wong, PC; Worley, PF				Wu, Jing; Petralia, Ronald S.; Kurushima, Hideaki; Patel, Hiral; Jung, Mi-Young; Volk, Lenora; Chowdhury, Shoaib; Shepherd, Jason D.; Dehoff, Marlin; Li, Yueming; Kuhl, Dietmar; Huganir, Richard L.; Price, Donald L.; Scannevin, Robert; Troncoso, Juan C.; Wong, Philip C.; Worley, Paul F.			Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent beta-Amyloid Generation	CELL			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; PRECURSOR PROTEIN; CELL BIOLOGY; IN-VIVO; DEPOSITION; TRAFFICKING; PRESENILINS; FRAGMENTS	Assemblies of beta-amyloid (A beta) peptides are pathological mediators of Alzheimer's Disease (AD) and are produced by the sequential cleavages of amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase. The generation of A beta is coupled to neuronal activity, but the molecular basis is unknown. Here, we report that the immediate early gene Arc is required for activity-dependent generation of A beta. Arc is a postsynaptic protein that recruits endophilin2/3 and dynamin to early/recycling endosomes that traffic AMPA receptors to reduce synaptic strength in both Hebbian and non-Hebbian forms of plasticity. The Arc-endosome also traffics APP and BACE1, and Arc physically associates with presenilin1 (PS1) to regulate gamma-secretase trafficking and confer activity dependence. Genetic deletion of Arc reduces A beta load in a transgenic mouse model of AD. In concert with the finding that patients with AD can express anomalously high levels of Arc, we hypothesize that Arc participates in the pathogenesis of AD.	[Wu, Jing; Kurushima, Hideaki; Volk, Lenora; Chowdhury, Shoaib; Shepherd, Jason D.; Dehoff, Marlin; Huganir, Richard L.; Price, Donald L.; Wong, Philip C.; Worley, Paul F.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA; [Price, Donald L.; Troncoso, Juan C.; Worley, Paul F.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Price, Donald L.; Troncoso, Juan C.; Wong, Philip C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Volk, Lenora; Huganir, Richard L.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; [Petralia, Ronald S.] NIDCD, Lab Neurochem, NIH, Bethesda, MD 20892 USA; [Patel, Hiral; Jung, Mi-Young; Scannevin, Robert] Biogen Idec Inc, Cambridge, MA 02142 USA; [Li, Yueming] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; [Kuhl, Dietmar] Univ Med Ctr Hamburg Eppendorf UKE, Ctr Mol Neurobiol ZMNH, Inst Mol & Cellular Cognit, D-20251 Hamburg, Germany	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Biogen; Memorial Sloan Kettering Cancer Center; University of Hamburg; University Medical Center Hamburg-Eppendorf	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21205 USA.	pworley@jhmi.edu	Shepherd, Jason/N-8555-2018; Kuhl, Dietmar/A-4689-2009	Shepherd, Jason/0000-0001-7384-8289; Kuhl, Dietmar/0000-0002-4772-6701; Scannevin, Robert/0000-0002-5749-2785	NIMH [RO1 MH053608]; Johns Hopkins Alzheimer's Disease Research Center (NIH) [P50AG005146]; NIDCD; NIH [MH084020]; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH084020, R01MH053608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, ZICDC000081] Funding Source: NIH RePORTER	NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Johns Hopkins Alzheimer's Disease Research Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We would like to thank Gopal Thinakaran, Sangram Sisodia (University of Chicago), and Tong Li for critical reagents and helpful discussions. Thanks to Gay Rudow for helping with unbiased stereology. Thanks to Desheng Xu and Shi Yang for help with lentivirus packaging. Many thanks to Robert Ardiuni, Melissa Levesque, Darren Baker, and Stephan Miller from Biogen Idec for their excellent technical support on in vitro binding assay. We thank Ya-Xian Wang for help with the EM studies. We also thank Robert Malinow (University of California at San Diego) and Mike Ehlers (Duke University) for APP Sindbis virus constructs and GFP-Rab constructs. This work was supported by NIMH grant RO1 MH053608 (P.F.W.), the Johns Hopkins Alzheimer's Disease Research Center (NIH grant P50AG005146) and in part by the NIDCD Intramural Program (R.S.P.) and NIH grant MH084020.	Alberi L, 2011, NEURON, V69, P437, DOI 10.1016/j.neuron.2011.01.004; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chowdhury S, 2006, NEURON, V52, P445, DOI 10.1016/j.neuron.2006.08.033; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Cracchiolo JR, 2007, NEUROBIOL LEARN MEM, V88, P277, DOI 10.1016/j.nlm.2007.07.007; De Strooper B, 2010, ANNU REV CELL DEV BI, V26, P235, DOI 10.1146/annurev-cellbio-100109-104117; Gao M, 2010, J NEUROSCI, V30, P7168, DOI 10.1523/JNEUROSCI.1067-10.2010; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Lewis SJ, 2005, BIOORG MED CHEM LETT, V15, P373, DOI 10.1016/j.bmcl.2004.10.062; Park S, 2008, NEURON, V59, P70, DOI 10.1016/j.neuron.2008.05.023; Plath N, 2006, NEURON, V52, P437, DOI 10.1016/j.neuron.2006.08.024; Ribaut-Barassin C, 2000, SYNAPSE, V35, P96, DOI 10.1002/(SICI)1098-2396(200002)35:2<96::AID-SYN2>3.0.CO;2-0; Rosi S, 2005, J NEUROSCI, V25, P723, DOI 10.1523/JNEUROSCI.4469-04.2005; Shelton CC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-22; Shepherd JD, 2006, NEURON, V52, P475, DOI 10.1016/j.neuron.2006.08.034; Small SA, 2006, NEURON, V52, P15, DOI 10.1016/j.neuron.2006.09.001; Sperling RA, 2009, NEURON, V63, P178, DOI 10.1016/j.neuron.2009.07.003; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Tian Y, 2010, NAT STRUCT MOL BIOL, V17, P151, DOI 10.1038/nsmb.1743; Vetrivel KS, 2006, NEUROLOGY, V66, pS69, DOI 10.1212/01.wnl.0000192107.17175.39; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200	30	137	142	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					615	628		10.1016/j.cell.2011.09.036	http://dx.doi.org/10.1016/j.cell.2011.09.036			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036569	Green Accepted, Bronze			2022-12-28	WOS:000296573700016
J	Suh, J; Rivest, AJ; Nakashiba, T; Tominaga, T; Tonegawa, S				Suh, Junghyup; Rivest, Alexander J.; Nakashiba, Toshiaki; Tominaga, Takashi; Tonegawa, Susumu			Entorhinal Cortex Layer III Input to the Hippocampus Is Crucial for Temporal Association Memory	SCIENCE			English	Article							CA3 NMDA RECEPTORS; WORKING-MEMORY; SPATIAL MEMORY; PLACE CELLS; INFORMATION; NETWORK; NEURONS; RECALL	Associating temporally discontinuous elements is crucial for the formation of episodic and working memories that depend on the hippocampal-entorhinal network. However, the neural circuits subserving these associations have remained unknown. The layer III inputs of the entorhinal cortex to the hippocampus may contribute to this process. To test this hypothesis, we generated a transgenic mouse in which these inputs are specifically inhibited. The mutant mice displayed significant impairments in spatial working-memory tasks and in the encoding phase of trace fear-conditioning. These results indicate a critical role of the entorhinal cortex layer III inputs to the hippocampus in temporal association memory.	[Suh, Junghyup; Rivest, Alexander J.; Nakashiba, Toshiaki; Tonegawa, Susumu] MIT, Dept Biol, RIKEN MIT Ctr Neural Circuit Genet, Picower Inst Learning & Memory, Cambridge, MA 02139 USA; [Suh, Junghyup; Rivest, Alexander J.; Nakashiba, Toshiaki; Tonegawa, Susumu] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Tominaga, Takashi] Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Neurophysiol, Kagawa, Japan	Massachusetts Institute of Technology (MIT); Northwell Health; RIKEN; Massachusetts Institute of Technology (MIT); Tokushima Bunri University	Tonegawa, S (corresponding author), MIT, Dept Biol, RIKEN MIT Ctr Neural Circuit Genet, Picower Inst Learning & Memory, Cambridge, MA 02139 USA.	tonegawa@mit.edu	Suh, Junghyup/AAO-8265-2020; Tominaga, Takashi/C-5332-2012	Tominaga, Takashi/0000-0003-1078-7989	NIH [R01-MH078821, P50-MH58880]; RIKEN Brain Science Institute; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH078821, P50MH058880] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RIKEN Brain Science Institute; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank C. Ragion, C. Twiss, M. Pfau, M. Ragion, C. Carr, and S. Perry for technical help; N. Arzoumanian for help with manuscript preparation; and D. Buh, J. Young, and other members of the Tonegawa lab for discussion. This work was supported by NIH grants R01-MH078821 and P50-MH58880 (to S. T.) and the RIKEN Brain Science Institute.	Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Canto Cathrin B., 2008, Neural Plasticity, V2008, P1, DOI 10.1155/2008/381243; Clayton NS, 2003, NAT REV NEUROSCI, V4, P685, DOI 10.1038/nrn1180; Colgin LL, 2009, NATURE, V462, P353, DOI 10.1038/nature08573; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; Esclassan F, 2009, J NEUROSCI, V29, P8087, DOI 10.1523/JNEUROSCI.0543-09.2009; Hasselmo ME, 2006, TRENDS COGN SCI, V10, P487, DOI 10.1016/j.tics.2006.09.005; Kesner RP, 2000, CURR OPIN NEUROBIOL, V10, P260, DOI 10.1016/S0959-4388(00)00067-2; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Misane I, 2005, HIPPOCAMPUS, V15, P418, DOI 10.1002/hipo.20067; Mizuseki K, 2009, NEURON, V64, P267, DOI 10.1016/j.neuron.2009.08.037; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Nakashiba T, 2008, SCIENCE, V319, P1260, DOI 10.1126/science.1151120; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385; Nakazawa K, 2003, NEURON, V38, P305, DOI 10.1016/S0896-6273(03)00165-X; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Steffenach HA, 2005, NEURON, V45, P301, DOI 10.1016/j.neuron.2004.12.044; Tominaga T, 2000, J NEUROSCI METH, V102, P11, DOI 10.1016/S0165-0270(00)00270-3; Witter M., 2004, RAT NERVOUS SYSTEM, V3, P635, DOI [10.1016/B978-012547638-6/50022-5, DOI 10.1016/B978-012547638-6/50022-5]; Yoshida M, 2008, EUR J NEUROSCI, V28, P1116, DOI 10.1111/j.1460-9568.2008.06409.x	22	227	230	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 9	2011	334	6061					1415	1420		10.1126/science.1210125	http://dx.doi.org/10.1126/science.1210125			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858HW	22052975				2022-12-28	WOS:000297787700057
J	Goldhaber, SZ; Leizorovicz, A; Kakkar, AK; Haas, SK; Merli, G; Knabb, RM; Weitz, JI				Goldhaber, Samuel Z.; Leizorovicz, Alain; Kakkar, Ajay K.; Haas, Sylvia K.; Merli, Geno; Knabb, Robert M.; Weitz, Jeffrey I.		ADOPT Trial Investigators	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; DOUBLE-BLIND; PREVENTION; REPLACEMENT	BACKGROUND The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. METHODS In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days. The primary efficacy outcome was the 30-day composite of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of systematic bilateral compression ultrasonography on day 30. The primary safety outcome was bleeding. All efficacy and safety outcomes were independently adjudicated. RESULTS A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated for the primary efficacy outcome - 2211 in the apixaban group and 2284 in the enoxaparin group. Among the patients who could be evaluated, 2.71% in the apixaban group (60 patients) and 3.06% in the enoxaparin group (70 patients) met the criteria for the primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence interval [CI], 0.62 to 1.23; P = 0.44). By day 30, major bleeding had occurred in 0.47% of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the patients in the enoxaparin group (6 of 3217 patients) (relative risk, 2.58; 95% CI, 1.02 to 7.24; P = 0.04). CONCLUSIONS In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. Apixaban was associated with significantly more major bleeding events than was enoxaparin. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00457002.)	[Goldhaber, Samuel Z.] Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02115 USA; [Goldhaber, Samuel Z.] Harvard Univ, Sch Med, Boston, MA USA; [Leizorovicz, Alain] Univ Lyon 1, Unite Pharmacol Clin, F-69365 Lyon, France; [Kakkar, Ajay K.] UCL, Thrombosis Res Inst, London, England; [Haas, Sylvia K.] Tech Univ Munich, Inst Expt Oncol & Therapy Res, Munich, Germany; [Merli, Geno] Thomas Jefferson Univ Hosp, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Knabb, Robert M.] Bristol Myers Squibb Co, Princeton, NJ USA; [Weitz, Jeffrey I.] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Thrombosis Research Institute; University of London; University College London; Technical University of Munich; Jefferson University; Bristol-Myers Squibb; McMaster University	Goldhaber, SZ (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Dept Med, 75 Francis St, Boston, MA 02115 USA.	sgoldhaber@partners.org	Boldueva, Svetlana/AAH-3862-2019; Weitz, Jeffrey/AAD-1929-2019; Okoshi, Marina/M-7592-2019; Yusof, Zurkurnai/AAA-5893-2021; García-Morillo, José-Salvador/L-8365-2018; Guijarro, Carlos/B-3003-2008; Beyer-Westendorf, Jan/K-7569-2019; Conrad, Steven/F-3257-2015; Kaynar, Leylagul/F-6991-2013; RICHART, CRISTOBAL C/S-9158-2017; Garcia Morillo, Salvador/C-9364-2015; Zadionchenko, Vladimir/A-7445-2016; Reshetko, Olga/I-7011-2013	Boldueva, Svetlana/0000-0002-1898-084X; Weitz, Jeffrey/0000-0002-1092-7550; Okoshi, Marina/0000-0001-7728-4505; García-Morillo, José-Salvador/0000-0003-1311-5483; Guijarro, Carlos/0000-0001-8132-9366; Beyer-Westendorf, Jan/0000-0002-6983-9993; Conrad, Steven/0000-0002-4014-969X; Kaynar, Leylagul/0000-0002-2035-9462; RICHART, CRISTOBAL C/0000-0003-0852-6739; Garcia Morillo, Salvador/0000-0001-9969-1881; Zadionchenko, Vladimir/0000-0003-2377-5266; Reshetko, Olga/0000-0003-3107-7636; Harenberg, Job/0000-0003-4590-4225; SALAS PEREZ, MARCIA/0000-0002-6398-2369; Sushko, Viktor/0000-0001-6893-8642; Borris, Lars/0000-0002-0527-1518; Maignan, Maxime/0000-0002-4301-4213; Giorgi-Pierfranceschi, Matteo/0000-0002-7988-9652	Bristol-Myers Squibb; Pfizer; Boehringer Ingelheim; Daiichi Sankyo; Eisai; EKOS; Medscape; Merck; Portola; Sanofi-Aventis; Johnson Johnson; Bayer; GlaxoSmithKline; Leo Pharma; Bayer Healthcare; Isis	Bristol-Myers Squibb(Bristol-Myers Squibb); Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Daiichi Sankyo(Daiichi Sankyo Company Limited); Eisai(Eisai Co Ltd); EKOS; Medscape; Merck(Merck & Company); Portola; Sanofi-Aventis(Sanofi-Aventis); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Bayer(Bayer AG); GlaxoSmithKline(GlaxoSmithKline); Leo Pharma(LEO Pharma); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Isis	Supported by Bristol-Myers Squibb and Pfizer.; Dr. Goldhaber reports receiving consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, EKOS, Medscape, Merck, Portola, and Sanofi-Aventis and grant support through his institution from Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, EKOS, Johnson & Johnson, and Sanofi-Aventis; Dr. Leizorovicz, holding board memberships at Bayer, GlaxoSmithKline, Leo Pharma, and Sanofi-Aventis and receiving consulting fees from Bayer, Boehringer Ingelheim, and GlaxoSmithKline, grant funding through his institution from GlaxoSmithKline, lecture fees from Leo Pharma, and payment for development of educational presentations from Bayer; Dr. Kakkar, receiving consulting fees from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, GlaxoSmithKline, Pfizer, and Sanofi-Aventis, grant support through his institution from Bayer Healthcare, Boehringer Ingelheim, Eisai, Pfizer, and Sanofi-Aventis, and lecture fees from Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Pfizer, and Sanofi-Aventis; Dr. Haas, receiving consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Isis, and Sanofi-Aventis, lecture fees from Bayer and Boehringer Ingelheim, and payment for the development of educational presentations from Bayer and Bristol-Myers Squibb; Dr. Merli, receiving consulting fees and grant funding through his institution from Bayer and Sanofi-Aventis; Dr. Knabb, being an employee of Bristol-Myers Squibb and receiving stock or stock options as part of his compensation as an employee; and Dr. Weitz, receiving consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Pfizer. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2011, RIV COMP FAV EN PREV; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140-6736(08)60880-6; Lassen MR, 2010, NEW ENGL J MED, V363, P2487, DOI 10.1056/NEJMoa1006885; Lassen MR, 2010, LANCET, V375, P807, DOI 10.1016/S0140-6736(09)62125-5; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103	13	411	430	2	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	2011	365	23					2167	2177		10.1056/NEJMoa1110899	http://dx.doi.org/10.1056/NEJMoa1110899			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857PQ	22077144	Green Published			2022-12-28	WOS:000297731400002
J	Boyce, N				Boyce, Niall			Stephen Lawrie: PsySTAR trek, the next generation Profile	LANCET			English	Biographical-Item															Medical Research Council [MR/J000914/1] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	2011	378	9807					1911	1911		10.1016/S0140-6736(11)61679-6	http://dx.doi.org/10.1016/S0140-6736(11)61679-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22056153				2022-12-28	WOS:000298136200018
J	Yoo, SK; Starnes, TW; Deng, Q; Huttenlocher, A				Yoo, Sa Kan; Starnes, Taylor W.; Deng, Qing; Huttenlocher, Anna			Lyn is a redox sensor that mediates leukocyte wound attraction in vivo	NATURE			English	Article							TYROSINE KINASE; HYDROGEN-PEROXIDE; C-SRC; AUTOIMMUNE-DISEASE; CYSTEINE OXIDATION; DEFICIENT MICE; ZEBRAFISH; NEUTROPHILS; ACTIVATION; CHEMOTAXIS	Tissue wounding induces the rapid recruitment of leukocytes(1). Wounds and tumours-a type of 'unhealed wound'(2)-generate hydrogen peroxide (H2O2) through an NADPH oxidase (NOX). This extracellular H2O2 mediates recruitment of leukocytes, particularly the first responders of innate immunity, neutrophils, to injured tissue(3-6). However, the sensor that neutrophils use to detect the redox state at wounds is unknown. Here we identify the Src family kinase (SFK) Lyn as a redox sensor that mediates initial neutrophil recruitment to wounds in zebrafish larvae. Lyn activation in neutrophils is dependent on wound-derived H2O2 after tissue injury, and inhibition of Lyn attenuates neutrophil wound recruitment. Inhibition of SFKs also disrupted H2O2-mediated chemotaxis of primary human neutrophils. In vitro analysis identified a single cysteine residue, C466, as being responsible for direct oxidation-mediated activation of Lyn. Furthermore, transgenic-tissue-specific reconstitution with wild-type Lyn and a cysteine mutant revealed that Lyn C466 is important for the neutrophil wound response and downstream signalling in vivo. This is the first identification, to our knowledge, of a physiological redox sensor that mediates leukocyte wound attraction in multicellular organisms.	[Starnes, Taylor W.; Deng, Qing; Huttenlocher, Anna] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; [Yoo, Sa Kan] Univ Wisconsin, Program Cellular & Mol Biol, Madison, WI 53706 USA; [Huttenlocher, Anna] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Huttenlocher, A (corresponding author), Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA.	huttenlocher@wisc.edu	Deng, Qing/G-3923-2011; Deng, Qing/AAC-1123-2020	Deng, Qing/0000-0002-9254-9951	American Heart Association [11PRE4890041]; National Institutes of Health [GM074827, 5T32 HL07899]; UW MSTP; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL114143, T32HL007899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074827, T32GM008692] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UW MSTP; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. T. Chan for help with tissue culture work, J. M. Green and P.-Y. Lam for help with in situ hybridization, M. Shelef and S. Wernimont for drawing blood, and A. J. Wiemer for insightful discussion and critical reading of the manuscript. This work was supported by American Heart Association fellowship 11PRE4890041 (S.K.Y.), National Institutes of Health Grant GM074827 (A. H.), NIH Research Training Grant in Hematology 5T32 HL07899 (T. W. S.) and UW MSTP (T.W.S.).	Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Bienert GP, 2006, BBA-BIOMEMBRANES, V1758, P994, DOI 10.1016/j.bbamem.2006.02.015; Burgoyne JR, 2007, SCIENCE, V317, P1393, DOI 10.1126/science.1144318; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Feng Y, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000562; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; HEIT B, 2003, SCI STKE, pPL5; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Kemble DJ, 2009, P NATL ACAD SCI USA, V106, P5070, DOI 10.1073/pnas.0806117106; Klyubin IV, 1996, EUR J CELL BIOL, V70, P347; Lee YM, 2006, CELL SIGNAL, V18, P499, DOI 10.1016/j.cellsig.2005.05.025; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mathias JR, 2006, J LEUKOCYTE BIOL, V80, P1281, DOI 10.1189/jlb.0506346; Mathias JR, 2009, DEV COMP IMMUNOL, V33, P1212, DOI 10.1016/j.dci.2009.07.003; Miller EW, 2010, P NATL ACAD SCI USA, V107, P15681, DOI 10.1073/pnas.1005776107; Moreira S, 2010, CURR BIOL, V20, P464, DOI 10.1016/j.cub.2010.01.047; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Paulsen CE, 2010, ACS CHEM BIOL, V5, P47, DOI 10.1021/cb900258z; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Poole LB, 2008, CURR OPIN CHEM BIOL, V12, P18, DOI 10.1016/j.cbpa.2008.01.021; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Scapini P, 2009, IMMUNOL REV, V228, P23, DOI 10.1111/j.1600-065X.2008.00758.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tobin DM, 2010, CELL, V140, P717, DOI 10.1016/j.cell.2010.02.013; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoo SK, 2011, J LEUKOCYTE BIOL, V89, P661, DOI 10.1189/jlb.1010567; Yoo SK, 2010, DEV CELL, V18, P226, DOI 10.1016/j.devcel.2009.11.015	39	313	320	5	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	2011	480	7375					109	U278		10.1038/nature10632	http://dx.doi.org/10.1038/nature10632			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22101434	Green Accepted			2022-12-28	WOS:000298031900044
J	Misa, TJ				Misa, Thomas J.			RETROSPECTIVE Steven P. Jobs (1955-2011)	SCIENCE			English	Biographical-Item									Univ Minnesota, Charles Babbage Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Misa, TJ (corresponding author), Univ Minnesota, Charles Babbage Inst, Minneapolis, MN 55455 USA.	tmisa@umn.edu							0	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					919	919		10.1126/science.1216019	http://dx.doi.org/10.1126/science.1216019			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096183				2022-12-28	WOS:000297101800039
J	Kaufman, RJ				Kaufman, Randal J.			Beta-Cell Failure, Stress, and Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RISK		Sanford Burnham Med Res Inst, Ctr Neurosci Aging & Stem Cell Res, La Jolla, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Kaufman, RJ (corresponding author), Sanford Burnham Med Res Inst, Ctr Neurosci Aging & Stem Cell Res, La Jolla, CA USA.				NIDDK NIH HHS [R01 DK088227] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088227] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arragain S, 2010, J BIOL CHEM, V285, P28425, DOI 10.1074/jbc.M110.106831; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Wei FY, 2011, J CLIN INVEST, V121, P3598, DOI 10.1172/JCI58056	4	24	26	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1931	1933		10.1056/NEJMcibr1109442	http://dx.doi.org/10.1056/NEJMcibr1109442			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087686	Green Accepted			2022-12-28	WOS:000297041900015
J	Venema, L				Venema, Liesbeth			Silicon electronics and beyond	NATURE			English	Editorial Material														Venema, Liesbeth/0000-0002-5896-1766					0	42	43	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					309	309		10.1038/479309a	http://dx.doi.org/10.1038/479309a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094689	Bronze			2022-12-28	WOS:000297059700055
J	Hawkes, N				Hawkes, Nigel			BODY POLITIC A pair of ragged clauses: the health bill in the House of Lords	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com						2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D7099	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d7343	10.1136/bmj.d7343	http://dx.doi.org/10.1136/bmj.d7343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854LV	22088399				2022-12-28	WOS:000297497100006
J	Prasad, V; Bonow, RO				Prasad, Vinay; Bonow, Robert O.			The Cardiovascular Biomarker Conundrum Challenges and Solutions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIGH-RISK; PREDICTION; MORTALITY; EVENTS; SCORE		[Bonow, Robert O.] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bonow, RO (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Ste 1006, Chicago, IL 60611 USA.	r-bonow@northwestern.edu		Prasad, Vinayak/0000-0002-6110-8221				Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Bonow RO, 2011, NEW ENGL J MED, V364, P1617, DOI 10.1056/NEJMoa1100358; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Polonsky TS, 2010, JAMA-J AM MED ASSOC, V303, P1610, DOI 10.1001/jama.2010.461; Ray KK, 2010, ARCH INTERN MED, V170, P1024, DOI 10.1001/archinternmed.2010.182; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; SOMBERG JC, 1984, AM J CARDIOL, V54, P8; Tzoulaki I, 2009, JAMA-J AM MED ASSOC, V302, P2345, DOI 10.1001/jama.2009.1757; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	10	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2151	2152		10.1001/jama.2011.1673	http://dx.doi.org/10.1001/jama.2011.1673			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089725				2022-12-28	WOS:000297013000024
J	Frankovich, J; Longhurst, CA; Sutherland, SM				Frankovich, Jennifer; Longhurst, Christopher A.; Sutherland, Scott M.			Evidence-Based Medicine in the EMR Era	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Frankovich, Jennifer] Stanford Univ, Sch Med, Dept Pediat, Div Rheumatol, Palo Alto, CA 94304 USA; [Longhurst, Christopher A.] Stanford Univ, Sch Med, Dept Pediat, Div Syst Med, Palo Alto, CA 94304 USA; [Sutherland, Scott M.] Stanford Univ, Sch Med, Dept Pediat, Div Nephrol, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University	Frankovich, J (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Rheumatol, Palo Alto, CA 94304 USA.			Longhurst, Christopher/0000-0003-4908-6856				Gunn Paul W, 2007, AMIA Annu Symp Proc, P966; Halevy A, 2009, IEEE INTELL SYST, V24, P8, DOI 10.1109/MIS.2009.36; Lowe Henry J, 2009, AMIA Annu Symp Proc, V2009, P391; Prokosch HU, 2009, METHOD INFORM MED, V48, P38, DOI 10.3414/ME9132; Stout R, 1950, BEST FAMILIES, P71	5	104	107	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1758	1759		10.1056/NEJMp1108726	http://dx.doi.org/10.1056/NEJMp1108726			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QQ	22047518				2022-12-28	WOS:000296762800003
J	Pavey, TG; Taylor, AH; Fox, KR; Hillsdon, M; Anokye, N; Campbell, JL; Foster, C; Green, C; Moxham, T; Mutrie, N; Searle, J; Trueman, P; Taylor, RS				Pavey, T. G.; Taylor, A. H.; Fox, K. R.; Hillsdon, M.; Anokye, N.; Campbell, J. L.; Foster, C.; Green, C.; Moxham, T.; Mutrie, N.; Searle, J.; Trueman, P.; Taylor, R. S.			Effect of exercise referral schemes in primary care on physical activity and improving health outcomes: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the impact of exercise referral schemes on physical activity and health outcomes. Design Systematic review and meta-analysis. Data sources Medline, Embase, PsycINFO, Cochrane Library, ISI Web of Science, SPORTDiscus, and ongoing trial registries up to October 2009. We also checked study references. Study selection Design: randomised controlled trials or non-randomised controlled (cluster or individual) studies published in peer review journals. Population: sedentary individuals with or without medical diagnosis. Exercise referral schemes defined as: clear referrals by primary care professionals to third party service providers to increase physical activity or exercise, physical activity or exercise programmes tailored to individuals, and initial assessment and monitoring throughout programmes. Comparators: usual care, no intervention, or alternative exercise referral schemes. Results Eight randomised controlled trials met the inclusion criteria, comparing exercise referral schemes with usual care (six trials), alternative physical activity intervention (two), and an exercise referral scheme plus a self determination theory intervention (one). Compared with usual care, follow-up data for exercise referral schemes showed an increased number of participants who achieved 90-150 minutes of physical activity of at least moderate intensity per week (pooled relative risk 1.16, 95% confidence intervals 1.03 to 1.30) and a reduced level of depression (pooled standardised mean difference -0.82, -1.28 to -0.35). Evidence of a between group difference in physical activity of moderate or vigorous intensity or in other health outcomes was inconsistent at follow-up. We did not find any difference in outcomes between exercise referral schemes and the other two comparator groups. None of the included trials separately reported outcomes in individuals with specific medical diagnoses. Substantial heterogeneity in the quality and nature of the exercise referral schemes across studies might have contributed to the inconsistency in outcome findings. Conclusions Considerable uncertainty remains as to the effectiveness of exercise referral schemes for increasing physical activity, fitness, or health indicators, or whether they are an efficient use of resources for sedentary people with or without a medical diagnosis.	[Pavey, T. G.; Campbell, J. L.; Green, C.; Moxham, T.; Taylor, R. S.] Univ Exeter, Peninsula Coll Med & Dent, Exeter EX2 4SG, Devon, England; [Pavey, T. G.; Campbell, J. L.; Green, C.; Moxham, T.; Taylor, R. S.] Univ Plymouth, Exeter EX2 4SG, Devon, England; [Taylor, A. H.; Hillsdon, M.] Univ Exeter, Sch Sport & Hlth Sci, Exeter EX2 4SG, Devon, England; [Anokye, N.; Trueman, P.] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; [Fox, K. R.] Univ Bristol, Ctr Exercise Nutr & Hlth Sci, Bristol, Avon, England; [Foster, C.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Mutrie, N.] Univ Strathclyde, Sch Psychol Sci & Hlth, Strathclyde, Scotland; [Searle, J.] Fitness Ind Assoc, London, England	University of Exeter; University of Plymouth; University of Plymouth; University of Exeter; Brunel University; University of Bristol; University of Oxford; University of Strathclyde	Pavey, TG (corresponding author), Univ Exeter, Peninsula Coll Med & Dent, Exeter EX2 4SG, Devon, England.	toby.pavey@pcmd.ac.uk	Fox, Kenneth/B-5897-2014; Taylor, Adrian/GME-5077-2022; Campbell, John/A-5792-2011; Pavey, Toby/G-1299-2012; Taylor, Rod/R-9581-2019	Taylor, Adrian/0000-0003-2701-9468; Campbell, John/0000-0002-6752-3493; Pavey, Toby/0000-0002-4946-6683; Taylor, Rod/0000-0002-3043-6011; Fox, Kenneth/0000-0003-2216-4287; Anokye, Nana/0000-0003-3615-344X	National Institute for Health Research Health Technology Assessment (NIHR HTA) [08/72/01]; National Institute for Health Research [08/72/01] Funding Source: researchfish	National Institute for Health Research Health Technology Assessment (NIHR HTA); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding: This project was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme (project number 08/72/01) (www.hta.ac.uk/).	British Heart Foundation National Centre, TOOLK DES IMPL EV EX; Department of Health, 2001, EX REF SYST NAT QUAL; Department of Health, 2004, LEAST 5 WEEK EV IMP; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Fox K, 1997, BRIT J GEN PRACT, V47, P367; Gusi N, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-231; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Harrison RA, 2005, J PUBLIC HEALTH-UK, V27, P25, DOI 10.1093/pubmed/fdh197; HSE, 2009, HLTH SURV ENGL 2008; Isaacs AJ, 2007, HEALTH TECHNOL ASSES, V11, P1; Jolly K, 2009, EVALUATION BIRMINGHA; Jolly K, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-176; KHAN K, 2001, UNDERTAKING SYSTEMAT; Lamb SE, 2002, J EPIDEMIOL COMMUN H, V56, P246, DOI 10.1136/jech.56.4.246; Limb M., 2011, BMJ, V342; Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Morgan O, 2005, PUBLIC HEALTH, V119, P361, DOI 10.1016/j.puhe.2004.06.008; Munro JF, 2004, J EPIDEMIOL COMMUN H, V58, P1004, DOI 10.1136/jech.2003.014225; Murphy S., 2010, EVALUATION NATL EXER; Murphy S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-352; National Institute for Health and Clinical Excellence, 2006, RAP REV EFF ERS PROM; National Institute of Clinical Excellence, 2006, 4 COMM US METH INCR; O'Donovan G, 2010, J SPORT SCI, V28, P573, DOI 10.1080/02640411003671212; Pavey T, 2011, EFFECTIVENESS COST E; Sorensen JB, 2008, SCAND J MED SCI SPOR, V18, P288, DOI 10.1111/j.1600-0838.2008.00811.x; Sorensen JB, 2006, SCAND J PRIM HEALTH, V24, P69, DOI 10.1080/02813430600700027; Sorensen JB, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-36; Sowden SL, 2008, J EPIDEMIOL COMMUN H, V62, P835, DOI 10.1136/jech.2007.069781; Stevens W, 1998, BRIT J SPORT MED, V32, P236, DOI 10.1136/bjsm.32.3.236; Taylor AH, 2005, HEALTH PSYCHOL, V24, P11, DOI 10.1037/0278-6133.24.1.11; Taylor AH, 1998, J EPIDEMIOL COMMUN H, V52, P595, DOI 10.1136/jech.52.9.595; Taylor AH, 2003, PERSPECTIVES HLTH EX; Taylor AH, 1996, EVALUATING GP EXERCI; The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA; US Department of Health and Human Services, 2008, PHYS ACT GUID AM; Williams NH, 2007, BRIT J GEN PRACT, V57, P979, DOI 10.3399/096016407782604866	37	168	169	2	78	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d6462	10.1136/bmj.d6462	http://dx.doi.org/10.1136/bmj.d6462			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31EA	22058134	Green Accepted, Green Submitted, Green Published, hybrid			2022-12-28	WOS:000208865700001
J	Ottersen, OP; Frenk, J; Horton, R				Ottersen, Ole Petter; Frenk, Julio; Horton, Richard			The Lancet-University of Oslo Commission on Global Governance for Health, in collaboration with the Harvard Global Health Institute	LANCET			English	Editorial Material									[Ottersen, Ole Petter] Univ Oslo, N-0316 Oslo, Norway; [Frenk, Julio] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Horton, Richard] Lancet, London, England	University of Oslo; Harvard University; Harvard T.H. Chan School of Public Health	Ottersen, OP (corresponding author), Univ Oslo, N-0316 Oslo, Norway.	rektor@uio.no						Amorim C, 2007, LANCET, V369, P1373, DOI 10.1016/S0140-6736(07)60498-X; Frenk J, 2011, ROUTLEDGE HANDBOOK OF GLOBAL PUBLIC HEALTH, P11; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; Stahl T., 2006, HLTH ALL POLICIES PR, P279; STORE JG, 2010, HLTH FOREIGN POLICY; Welch Jonathan, 2003, GLOBAL HLTH CHALLENG, P67	6	31	33	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 5	2011	378	9803					1612	1613		10.1016/S0140-6736(11)61617-6	http://dx.doi.org/10.1016/S0140-6736(11)61617-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844ST	22055031				2022-12-28	WOS:000296768300011
J	Gitler, AD				Gitler, Aaron D.			Another Reason to Exercise	SCIENCE			English	Editorial Material							SPINOCEREBELLAR ATAXIA TYPE-1; CAG REPEAT; EXPANSION; DISEASE; SCA1; NEURODEGENERATION; MECHANISMS		Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Gitler, AD (corresponding author), Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	gitler@mail.med.upenn.edu		Gitler, Aaron/0000-0001-8603-1526				Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Dibble LE, 2009, J NEUROL PHYS THER, V33, P14, DOI 10.1097/NPT.0b013e3181990fcc; Duvick L, 2010, NEURON, V67, P929, DOI 10.1016/j.neuron.2010.08.022; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Fryer JD, 2011, SCIENCE, V334, P690, DOI 10.1126/science.1212673; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Rolland Y, 2008, J AM MED DIR ASSOC, V9, P390, DOI 10.1016/j.jamda.2008.02.007; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Watase K, 2007, PLOS MED, V4, P836, DOI 10.1371/journal.pmed.0040182; Zoghbi HY, 2009, J BIOL CHEM, V284, P7425, DOI 10.1074/jbc.R800041200	15	3	4	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					606	607		10.1126/science.1214714	http://dx.doi.org/10.1126/science.1214714			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053033				2022-12-28	WOS:000296494700034
J	Yartsev, MM; Witter, MP; Ulanovsky, N				Yartsev, Michael M.; Witter, Menno P.; Ulanovsky, Nachum			Grid cells without theta oscillations in the entorhinal cortex of bats	NATURE			English	Article							SPATIAL REPRESENTATION; ECHOLOCATING BATS; PATH-INTEGRATION; COGNITIVE MAP; INTERFERENCE; FREQUENCY; MODEL; RAT; PERIODICITY; HIPPOCAMPUS	Grid cells provide a neural representation of space, by discharging when an animal traverses through the vertices of a periodic hexagonal grid spanning the environment(1). Although grid cells have been characterized in detail in rats(1-6), the fundamental question of what neural dynamics give rise to the grid structure remains unresolved. Two competing classes of models were proposed: network models, based on attractor dynamics(7-9), and oscillatory interference models, which propose that interference between somatic and dendritic theta-band oscillations (4-10 Hz) in single neurons transforms a temporal oscillation into a spatially periodic grid(10-13). So far, these models could not be dissociated experimentally, because rodent grid cells always co-exist with continuous theta oscillations(4-6,14). Here we used a novel animal model, the Egyptian fruit bat(15,16), to refute the proposed causal link between grids and theta oscillations. On the basis of our previous finding from bat hippocampus, of spatially tuned place cells in the absence of continuous theta oscillations(17), we hypothesized that grid cells in bat medial entorhinal cortex might also exist without theta oscillations. Indeed, we found grid cells in bat medial entorhinal cortex that shared remarkable similarities to rodent grid cells. Notably, the grids existed in the absence of continuous theta-band oscillations, and with almost no theta modulation of grid-cell spiking-both of which are essential prerequisites of the oscillatory interference models. Our results provide a direct demonstration of grid cells in a non-rodent species. Furthermore, they strongly argue against a major class of computational models of grid cells.	[Yartsev, Michael M.; Ulanovsky, Nachum] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Witter, Menno P.] Norwegian Univ Sci & Technol, Kavli Inst Syst Neurosci, NO-7489 Trondheim, Norway; [Witter, Menno P.] Norwegian Univ Sci & Technol, Ctr Biol Memory, NO-7489 Trondheim, Norway	Weizmann Institute of Science; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Ulanovsky, N (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	nachum.ulanovsky@weizmann.ac.il		Yartsev, Michael/0000-0003-0952-2801; Ulanovsky, Nachum/0000-0001-8598-4667	Israel Science Foundation; Minerva Foundation; Lev-Zion predoctoral excellence fellowship; Norwegian Research Council; Kavli Foundation	Israel Science Foundation(Israel Science Foundation); Minerva Foundation; Lev-Zion predoctoral excellence fellowship; Norwegian Research Council(Research Council of NorwayEuropean Commission); Kavli Foundation	We thank D. Derdikman, S. Romani, M. Ahrens and Y. Cohen for comments on the manuscript, M. Melcon for initial assistance with hippocampal CA1 recordings, M. Weinberg for veterinary oversight, and R. Eilam and C. Ra'anan for histology. This study was supported by research grants from the Israel Science Foundation and Minerva Foundation to N.U., by a Lev-Zion predoctoral excellence fellowship to M. M. Y., as well as by grants from the Norwegian Research Council and the Kavli Foundation to M.P.W.	Barry C, 2007, NAT NEUROSCI, V10, P682, DOI 10.1038/nn1905; Blair HT, 2007, J NEUROSCI, V27, P3211, DOI 10.1523/JNEUROSCI.4724-06.2007; Boccara CN, 2010, NAT NEUROSCI, V13, P987, DOI 10.1038/nn.2602; Brandon MP, 2011, SCIENCE, V332, P595, DOI 10.1126/science.1201652; Burak Y, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000291; Burgess N, 2007, HIPPOCAMPUS, V17, P801, DOI 10.1002/hipo.20327; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; Deshmukh SS, 2010, J NEUROPHYSIOL, V104, P994, DOI 10.1152/jn.01141.2009; Ekstrom AD, 2005, HIPPOCAMPUS, V15, P881, DOI 10.1002/hipo.20109; Fuhs MC, 2006, J NEUROSCI, V26, P4266, DOI 10.1523/JNEUROSCI.4353-05.2006; Giocomo LM, 2007, SCIENCE, V315, P1719, DOI 10.1126/science.1139207; Hafting T, 2005, NATURE, V436, P801, DOI 10.1038/nature03721; Hafting T, 2008, NATURE, V453, P1248, DOI 10.1038/nature06957; Hansel D., 1998, METHODS NEURONAL MOD, P499; Hasselmo ME, 2007, HIPPOCAMPUS, V17, P1252, DOI 10.1002/hipo.20374; Koenig J, 2011, SCIENCE, V332, P592, DOI 10.1126/science.1201685; Langston RF, 2010, SCIENCE, V328, P1576, DOI 10.1126/science.1188210; McNaughton BL, 2006, NAT REV NEUROSCI, V7, P663, DOI 10.1038/nrn1932; Mizuseki K, 2009, NEURON, V64, P267, DOI 10.1016/j.neuron.2009.08.037; Sargolini F, 2006, SCIENCE, V312, P758, DOI 10.1126/science.1125572; Solstad T, 2008, SCIENCE, V322, P1865, DOI 10.1126/science.1166466; STEWART M, 1991, BRAIN RES, V538, P59, DOI 10.1016/0006-8993(91)90376-7; Ulanovsky N, 2008, P NATL ACAD SCI USA, V105, P8491, DOI 10.1073/pnas.0703550105; Ulanovsky N, 2007, NAT NEUROSCI, V10, P224, DOI 10.1038/nn1829; Ulanoysky N, 2011, HIPPOCAMPUS, V21, P150, DOI 10.1002/hipo.20731; Wills TJ, 2010, SCIENCE, V328, P1573, DOI 10.1126/science.1188224; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witter MP, 2000, ANN NY ACAD SCI, V911, P1; Yovel Y, 2010, SCIENCE, V327, P701, DOI 10.1126/science.1183310	30	233	235	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					103	107		10.1038/nature10583	http://dx.doi.org/10.1038/nature10583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051680				2022-12-28	WOS:000296422600040
J	Strijkers, RHW; ten Cate-Hoek, AJ; Bukkems, SFFW; Wittens, CHA				Strijkers, R. H. W.; ten Cate-Hoek, A. J.; Bukkems, S. F. F. W.; Wittens, C. H. A.			Management of deep vein thrombosis and prevention of post-thrombotic syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CATHETER-DIRECTED THROMBOLYSIS; VENOUS THROMBOSIS; D-DIMER; DETERMINANTS; COMPRESSION; LYSIS; RISK; LEG		[Strijkers, R. H. W.; Wittens, C. H. A.] Maastricht Univ, Med Ctr, Dept Vasc Surg, NL-6202 AZ Maastricht, Limburg, Netherlands; [Strijkers, R. H. W.; Wittens, C. H. A.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, NL-6202 AZ Maastricht, Limburg, Netherlands; [ten Cate-Hoek, A. J.] State Univ Limburg Hosp, Dept Internal Med, Lab Clin Thrombosis & Haemostasis, NL-6201 BX Maastricht, Netherlands; [ten Cate-Hoek, A. J.] State Univ Limburg Hosp, Dept Internal Med, Haematol Lab, NL-6201 BX Maastricht, Netherlands; [Bukkems, S. F. F. W.] VieCuri Med Ctr, Dept Physiatry, Venlo, Netherlands; [Wittens, C. H. A.] Univ Hosp RWTH Aachen, Dept Vasc Surg, Nordrhein Westfalen, Germany	Maastricht University; Maastricht University; Maastricht University; Maastricht University; VieCuri Medical Center	Wittens, CHA (corresponding author), Maastricht Univ, Med Ctr, Dept Vasc Surg, NL-6202 AZ Maastricht, Limburg, Netherlands.	c.wittens@me.com	Strijkers, R./AGR-7192-2022					Alesh I, 2007, CATHETER CARDIO INTE, V70, P143, DOI 10.1002/ccd.21079; Baldt MM, 1996, RADIOLOGY, V200, P423, DOI 10.1148/radiology.200.2.8685336; Blattler W, 2003, INT ANGIOL, V22, P393; Bulger Christopher M, 2004, Tech Vasc Interv Radiol, V7, P50, DOI 10.1053/j.tvir.2004.02.001; Buller HR, 2004, CHEST, V126, p401S, DOI 10.1378/chest.126.3_suppl.401S; Douketis JD, 2001, AM J MED, V110, P515, DOI 10.1016/S0002-9343(01)00661-1; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Grewal NK, 2010, J VASC SURG, V51, P1209, DOI 10.1016/j.jvs.2009.12.021; Hirsh J, 2008, CHEST, V133, p71S, DOI 10.1378/chest.08-0693; Kahn SR, 2008, J THROMB HAEMOST, V6, P1105, DOI 10.1111/j.1538-7836.2008.03002.x; Kahn SR, 2009, J THROMB HAEMOST, V7, P879, DOI 10.1111/j.1538-7836.2009.03294.x; Kahn SR, 2004, ARCH INTERN MED, V164, P17, DOI 10.1001/archinte.164.1.17; Kahn SR, 2008, ANN INTERN MED, V149, P698, DOI 10.7326/0003-4819-149-10-200811180-00004; Kearon C, 2003, CIRCULATION, V107, pI22, DOI 10.1161/01.CIR.0000078464.82671.78; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; Linkins LA, 2004, J THROMB HAEMOST, V2, P1256, DOI 10.1111/j.1538-7836.2004.00824.x; MEISSNER MH, 1993, J VASC SURG, V18, P596, DOI 10.1016/0741-5214(93)90069-X; Miller N, 1996, Cardiovasc Surg, V4, P505, DOI 10.1016/0967-2109(95)00148-4; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OTHIENO R, 2007, COCHRANE DB SYST REV, V3; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Prandoni P, 2007, HAEMATOLOGICA, V92, P199, DOI 10.3324/haematol.10516; Singh H, 2005, ANN VASC SURG, V19, P74, DOI 10.1007/s10016-004-0133-3; van der Velde EF, 2011, ANN FAM MED, V9, P31, DOI 10.1370/afm.1198; van Gent WB, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6045; van Langevelde K, 2010, J MAGN RESON IMAGING, V32, P1302, DOI 10.1002/jmri.22379; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153	30	25	27	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	2011	343								d5916	10.1136/bmj.d5916	http://dx.doi.org/10.1136/bmj.d5916			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844PP	22042752				2022-12-28	WOS:000296759900011
J	Waksman, R; Maluenda, G				Waksman, Ron; Maluenda, Gabriel			Polymer drug-eluting stents: is the future biodegradable?	LANCET			English	Editorial Material							CORONARY REVASCULARIZATION; BARE-METAL; OUTCOMES; METAANALYSIS		[Waksman, Ron; Maluenda, Gabriel] Washington Hosp Ctr, Washington, DC 20010 USA	MedStar Washington Hospital Center	Waksman, R (corresponding author), Washington Hosp Ctr, Washington, DC 20010 USA.	ron.waksman@medstar.net						Ahmed TAN, 2011, EUROINTERVENTION, V7, P505, DOI 10.4244/EIJV7I4A81; Byrne RA, 2011, J AM COLL CARDIOL, V58, P1325, DOI 10.1016/j.jacc.2011.06.027; de Waha A, 2011, CIRC-CARDIOVASC INTE, V4, P371, DOI 10.1161/CIRCINTERVENTIONS.111.963256; Lagerqvist B, 2007, NEW ENGL J MED, V356, P1009, DOI 10.1056/NEJMoa067722; Nakazawa G, 2008, EUROINTERVENTION, V4, P5; Nakazawa G, 2011, J AM COLL CARDIOL, V57, P1314, DOI 10.1016/j.jacc.2011.01.011; Park KW, 2011, J AM COLL CARDIOL, V58, P1844, DOI 10.1016/j.jacc.2011.07.031; Silber S, 2011, LANCET, V377, P1241, DOI 10.1016/S0140-6736(11)60395-4; Smits PC, 2011, J AM COLL CARDIOL, V58, P11, DOI 10.1016/j.jacc.2011.02.023; Stefanini GG, 2011, LANCET, V378, P1940, DOI 10.1016/S0140-6736(11)61672-3; Windecker S, 2008, LANCET, V372, P1163, DOI 10.1016/S0140-6736(08)61244-1	11	10	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2011	378	9807					1900	1902		10.1016/S0140-6736(11)61706-6	http://dx.doi.org/10.1016/S0140-6736(11)61706-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22075450				2022-12-28	WOS:000298136200013
J	Dominici, N; Ivanenko, YP; Cappellini, G; d'Avella, A; Mondi, V; Cicchese, M; Fabiano, A; Silei, T; Di Paolo, A; Giannini, C; Poppele, RE; Lacquaniti, F				Dominici, Nadia; Ivanenko, Yuri P.; Cappellini, Germana; d'Avella, Andrea; Mondi, Vito; Cicchese, Marika; Fabiano, Adele; Silei, Tiziana; Di Paolo, Ambrogio; Giannini, Carlo; Poppele, Richard E.; Lacquaniti, Francesco			Locomotor Primitives in Newborn Babies and Their Development	SCIENCE			English	Article							WALKING; COORDINATION; VERTEBRATES; PATTERNS; MODULES; HUMANS; MODEL	How rudimentary movements evolve into sophisticated ones during development remains unclear. It is often assumed that the primitive patterns of neural control are suppressed during development, replaced by entirely new patterns. Here we identified the basic patterns of lumbosacral motoneuron activity from multimuscle recordings in stepping neonates, toddlers, preschoolers, and adults. Surprisingly, we found that the two basic patterns of stepping neonates are retained through development, augmented by two new patterns first revealed in toddlers. Markedly similar patterns were observed also in the rat, cat, macaque, and guineafowl, consistent with the hypothesis that, despite substantial phylogenetic distances and morphological differences, locomotion in several animal species is built starting from common primitives, perhaps related to a common ancestral neural network.	[Dominici, Nadia; Ivanenko, Yuri P.; Cappellini, Germana; d'Avella, Andrea; Lacquaniti, Francesco] IRCCS Santa Lucia Fdn, Lab Neuromotor Physiol, I-00179 Rome, Italy; [Dominici, Nadia; Lacquaniti, Francesco] Univ Roma Tor Vergata, Ctr Space Biomed, I-00173 Rome, Italy; [Mondi, Vito; Cicchese, Marika; Fabiano, Adele; Silei, Tiziana] Univ Roma Tor Vergata, St Eugenio Hosp, Dept Pediat, I-00144 Rome, Italy; [Giannini, Carlo] St Eugenio Hosp, Neonatol Unit, I-00144 Rome, Italy; [Poppele, Richard E.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; [Lacquaniti, Francesco] Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy	IRCCS Santa Lucia; University of Rome Tor Vergata; Sant'Eugenio Hospital; University of Rome Tor Vergata; Sant'Eugenio Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Rome Tor Vergata	Lacquaniti, F (corresponding author), IRCCS Santa Lucia Fdn, Lab Neuromotor Physiol, I-00179 Rome, Italy.	lacquaniti@caspur.it	Cappellini, Germana/AAA-7754-2019; d'Avella, Andrea/K-6856-2018; Mondì, Vito/K-1161-2018; Lacquaniti, Francesco/J-9842-2016; Ivanenko, Yury/L-1599-2018	d'Avella, Andrea/0000-0002-3393-4956; Mondì, Vito/0000-0002-8473-6861; Lacquaniti, Francesco/0000-0003-0896-7315; Ivanenko, Yury/0000-0001-9363-9548; Dominici, Nadia/0000-0003-2312-915X; Cappellini, Germana/0000-0001-9110-3870	Italian Ministry of Health; Italian Ministry of University and Research; Italian Space Agency; European Union [247959, 248311]	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Italian Space Agency(Agenzia Spaziale Italiana (ASI)); European Union(European Commission)	We thank W. Gerstner, M. Molinari, P. Viviani, and M. Zago for helpful comments on earlier versions of the manuscript. This work was supported by the Italian Ministry of Health, Italian Ministry of University and Research (PRIN grant), Italian Space Agency (DCMC and CRUSOE grants), and European Union FP7-ICT programs (MINDWALKER grant 247959 and AMARSi grant 248311).	Aronov D, 2008, SCIENCE, V320, P630, DOI 10.1126/science.1155140; Bizzi E, 2008, BRAIN RES REV, V57, P125, DOI 10.1016/j.brainresrev.2007.08.004; Clark DJ, 2010, J NEUROPHYSIOL, V103, P844, DOI 10.1152/jn.00825.2009; FORSSBERG H, 1985, EXP BRAIN RES, V57, P480; Garwicz M, 2009, P NATL ACAD SCI USA, V106, P21889, DOI 10.1073/pnas.0905777106; Gerhart J, 2007, P NATL ACAD SCI USA, V104, P8582, DOI 10.1073/pnas.0701035104; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; Grillner S, 2006, NEURON, V52, P751, DOI 10.1016/j.neuron.2006.11.008; Grillner S, 2009, CURR OPIN NEUROBIOL, V19, P572, DOI 10.1016/j.conb.2009.10.011; Hart CB, 2010, J NEUROSCI, V30, P1322, DOI 10.1523/JNEUROSCI.5894-08.2010; Ivanenko YP, 2004, J PHYSIOL-LONDON, V556, P267, DOI 10.1113/jphysiol.2003.057174; Ivanenko YP, 2005, J NEUROSCI, V25, P7238, DOI 10.1523/JNEUROSCI.1327-05.2005; Kiehn O, 2011, CURR OPIN NEUROBIOL, V21, P100, DOI 10.1016/j.conb.2010.09.004; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; MUSSAIVALDI FA, 1994, P NATL ACAD SCI USA, V91, P7534, DOI 10.1073/pnas.91.16.7534; Sheynikhovich D, 2009, PSYCHOL REV, V116, P540, DOI 10.1037/a0016170; THELEN E, 1987, DEV MED CHILD NEUROL, V29, P380; Wainwright PC, 2002, CURR OPIN NEUROBIOL, V12, P691, DOI 10.1016/S0959-4388(02)00383-5; Yang JF, 1998, J PHYSIOL-LONDON, V507, P927, DOI 10.1111/j.1469-7793.1998.927bs.x	19	394	397	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					997	999		10.1126/science.1210617	http://dx.doi.org/10.1126/science.1210617			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096202				2022-12-28	WOS:000297101800061
J	Ramaswamy, S				Ramaswamy, S.			One Atom Makes All the Difference	SCIENCE			English	Editorial Material							NITROGENASE MOFE-PROTEIN; FEMO-COFACTOR; IRON PROTEIN		Inst Stem Cell Biol & Regenerat Med, Bangalore 560065, Karnataka, India	Department of Biotechnology (DBT) India; Institute for Stem Cell Biology & Regenerative Medicine - inStem	Ramaswamy, S (corresponding author), Inst Stem Cell Biol & Regenerat Med, Bangalore 560065, Karnataka, India.	ramas@ncbs.res.in	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Hu YL, 2008, BIOCHEMISTRY-US, V47, P3973, DOI 10.1021/bi7025003; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lancaster KM, 2011, SCIENCE, V334, P974, DOI 10.1126/science.1206445; Leigh GJ, 2003, SCIENCE, V301, P55, DOI 10.1126/science.1086678; ORMEJOHNSON WH, 1992, SCIENCE, V257, P1639, DOI 10.1126/science.1529351; Seefeldt LC, 2009, ANNU REV BIOCHEM, V78, P701, DOI 10.1146/annurev.biochem.78.070907.103812; Smith BE, 2002, SCIENCE, V297, P1654, DOI 10.1126/science.1076659; Spatzal T, 2011, SCIENCE, V334, P940, DOI 10.1126/science.1214025; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326; Yang TC, 2005, J AM CHEM SOC, V127, P12804, DOI 10.1021/ja0552489	12	5	5	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					914	915		10.1126/science.1215283	http://dx.doi.org/10.1126/science.1215283			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096179				2022-12-28	WOS:000297101800035
J	Ferain, I; Colinge, CA; Colinge, JP				Ferain, Isabelle; Colinge, Cynthia A.; Colinge, Jean-Pierre			Multigate transistors as the future of classical metal-oxide-semiconductor field-effect transistors	NATURE			English	Review							SOI; VOLTAGE; DESIGN; MOSFET	For more than four decades, transistors have been shrinking exponentially in size, and therefore the number of transistors in a single microelectronic chip has been increasing exponentially. Such an increase in packing density was made possible by continually shrinking the metal-oxide-semiconductor field-effect transistor (MOSFET). In the current generation of transistors, the transistor dimensions have shrunk to such an extent that the electrical characteristics of the device can be markedly degraded, making it unlikely that the exponential decrease in transistor size can continue. Recently, however, a new generation of MOSFETs, called multigate transistors, has emerged, and this multigate geometry will allow the continuing enhancement of computer performance into the next decade.	[Ferain, Isabelle; Colinge, Cynthia A.; Colinge, Jean-Pierre] Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland	University College Cork	Colinge, JP (corresponding author), Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland.	jean-pierre.colinge@tyndall.ie	Colinge, Jean-Pierre/J-5768-2017		Science Foundation Ireland [05/IN/I888, 07/IN.1/I937, 10/IN.1/I2992]; European project SQWIRE [257111]; European Community (EC) through the Network of Excellence Nano-TEC [257964]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European project SQWIRE; European Community (EC) through the Network of Excellence Nano-TEC(European CommissionEuropean Commission Joint Research Centre)	This work was supported by Science Foundation Ireland grants 05/IN/I888, 07/IN.1/I937 and 10/IN.1/I2992, the European project SQWIRE under Grant Agreement No. 257111 and the European Community (EC) Seventh Framework Program through the Network of Excellence Nano-TEC under Contract 257964. We thank N. Petkov and M. Schmidt for the electron microscopy images in Fig. 6.	Afzalian A, 2011, SOLID STATE ELECTRON, V59, P50, DOI 10.1016/j.sse.2011.01.016; Ansari L, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3478012; ARMSTRONG GA, 1991, IEEE T ELECTRON DEV, V38, P328, DOI 10.1109/16.69914; Baie X, 1995, 1995 IEEE INTERNATIONAL SOI CONFERENCE PROCEEDINGS, P66, DOI 10.1109/SOI.1995.526463; Basker VS, 2010, S VLSI TECH, P19, DOI 10.1109/VLSIT.2010.5556135; Cao SQ, 2011, MICROELECTRON RELIAB, V51, P756, DOI 10.1016/j.microrel.2010.11.013; Colinge J. P., 1990, International Electron Devices Meeting 1990. Technical Digest (Cat. No.90CH2865-4), P595, DOI 10.1109/IEDM.1990.237128; Colinge JP, 2008, INTEGR CIRCUIT SYST, P1, DOI 10.1007/978-0-387-71752-4_1; Colinge JP, 2010, NAT NANOTECHNOL, V5, P225, DOI [10.1038/nnano.2010.15, 10.1038/NNANO.2010.15]; Colinge JP, 2004, SOLID STATE ELECTRON, V48, P897, DOI 10.1016/j.sse.2003.12.020; DENNARD RH, 1974, IEEE J SOLID-ST CIRC, VSC 9, P256, DOI 10.1109/JSSC.1974.1050511; Doyle BS, 2003, IEEE ELECTR DEVICE L, V24, P263, DOI 10.1109/LED.2003.810888; Engstrom O., 2010, NANOSCALE CMOS INNOV; GROVE AS, 1967, PHYS TECHNOL       S, pCH11; Guillorn M. A., 2011, S VLSI TECH, P64; Hisamoto D., 1989, International Electron Devices Meeting 1989. Technical Digest (Cat. No.89CH2637-7), P833, DOI 10.1109/IEDM.1989.74182; Hofmann F, 2005, SOLID STATE ELECTRON, V49, P1799, DOI 10.1016/j.sse.2005.10.012; Hye Jin Cho, 2004, Device Research Conference (IEEE Cat. No.04TH8724), P209; ITRS International Technology Working Groups, 2010, ITRS 2010 UPD; Joshi RV, 2004, ESSDERC 2004: PROCEEDINGS OF THE 34TH EUROPEAN SOLID-STATE DEVICE RESEARCH CONFERENCE, P69, DOI 10.1109/ESSDER.2004.1356490; Kanemura T., 2006, INT C SIM SEM PROC D, P131; Kavalieros J. T, 2006, VLSI S, P50, DOI [DOI 10.1109/VLSIT.2006.1705211, 10.1109/VLSIT.2006.1705211]; Kuhn KJ, 2010, ASMC PROC, P241, DOI 10.1109/ASMC.2010.5551461; Lee CW, 2007, SOLID STATE ELECTRON, V51, P505, DOI 10.1016/j.sse.2006.11.013; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; Moselund KE, 2008, SOLID STATE ELECTRON, V52, P1336, DOI 10.1016/j.sse.2008.04.021; Okano K, 2005, INT EL DEVICES MEET, P739; Park J.-T., 2001, 2001 IEEE International SOI Conference. Proceedings (Cat. No.01CH37207), P115, DOI 10.1109/SOIC.2001.958013; Park JT, 2001, IEEE ELECTR DEVICE L, V22, P405, DOI 10.1109/55.936358; Salahuddin S, 2008, NANO LETT, V8, P405, DOI 10.1021/nl071804g; SEKIGAWA T, 1984, SOLID STATE ELECTRON, V27, P827, DOI 10.1016/0038-1101(84)90036-4; Skotnicki T, 2008, IEEE T ELECTRON DEV, V55, P96, DOI 10.1109/TED.2007.911338; Skotnicki T, 2010, S VLSI TECH, P153, DOI 10.1109/VLSIT.2010.5556208; Subramanian V, 2006, IEEE T ELECTRON DEV, V53, P3071, DOI 10.1109/TED.2006.885649; Suk SD, 2009, 2009 SYMPOSIUM ON VLSI TECHNOLOGY, DIGEST OF TECHNICAL PAPERS, P142; Tang X, 2000, SOLID STATE ELECTRON, V44, P2259, DOI 10.1016/S0038-1101(00)00221-5; Thijs Steven, 2010, 2010 IEEE International Conference on IC Design & Technology (ICICDT), P43, DOI 10.1109/ICICDT.2010.5510299; Wu C. C., 2011, IEEE EL DEV M, P600; Xuejue Huang, 1999, International Electron Devices Meeting 1999. Technical Digest (Cat. No.99CH36318), P67, DOI 10.1109/IEDM.1999.823848; YAN RH, 1992, IEEE T ELECTRON DEV, V39, P1704, DOI 10.1109/16.141237; Yang FL, 2002, INTERNATIONAL ELECTRON DEVICES 2002 MEETING, TECHNICAL DIGEST, P255, DOI 10.1109/IEDM.2002.1175826; Yeh C.-C., 2011, IEEE EL DEV M, P772; Zhang Q, 2006, IEEE ELECTR DEVICE L, V27, P297, DOI 10.1109/LED.2006.871855	43	621	638	32	382	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					310	316		10.1038/nature10676	http://dx.doi.org/10.1038/nature10676			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094690				2022-12-28	WOS:000297059700030
J	Wang, ZC; Saito, M; McKenna, KP; Gu, L; Tsukimoto, S; Shluger, AL; Ikuhara, Y				Wang, Zhongchang; Saito, Mitsuhiro; McKenna, Keith P.; Gu, Lin; Tsukimoto, Susumu; Shluger, Alexander L.; Ikuhara, Yuichi			Atom-resolved imaging of ordered defect superstructures at individual grain boundaries	NATURE			English	Article							MGO; SEGREGATION; SIMULATION; MICROSCOPY; RESOLUTION; ALUMINA	The ability to resolve spatially and identify chemically atoms in defects would greatly advance our understanding of the correlation between structure and property in materials(1). This is particularly important in polycrystalline materials, in which the grain boundaries have profound implications for the properties and applications of the final material(2). However, such atomic resolution is still extremely difficult to achieve, partly because grain boundaries are effective sinks for atomic defects and impurities(3-5), which may drive structural transformation of grain boundaries and consequently modify material properties(6,7). Regardless of the origin of these sinks, the interplay between defects and grain boundaries complicates our efforts to pinpoint the exact sites and chemistries of the entities present in the defective regions, thereby limiting our understanding of how specific defects mediate property changes. Here we show that the combination of advanced electron microscopy, spectroscopy and first-principles calculations can provide three-dimensional images of complex, multicomponent grain boundaries with both atomic resolution and chemical sensitivity. The high resolution of these techniques allows us to demonstrate that even for magnesium oxide, which has a simple rock-salt structure, grain boundaries can accommodate complex ordered defect superstructures that induce significant electron trapping in the bandgap of the oxide. These results offer insights into interactions between defects and grain boundaries in ceramics and demonstrate that atomic-scale analysis of complex multicomponent structures in materials is now becoming possible.	[Wang, Zhongchang; Saito, Mitsuhiro; McKenna, Keith P.; Gu, Lin; Tsukimoto, Susumu; Shluger, Alexander L.; Ikuhara, Yuichi] Tohoku Univ, Adv Inst Mat Res, World Premier Int Res Ctr, Aoba Ku, Sendai, Miyagi 9808577, Japan; [McKenna, Keith P.; Shluger, Alexander L.] UCL, Dept Phys & Astron, London WC1E 6BT, England; [McKenna, Keith P.; Shluger, Alexander L.] UCL, London Ctr Nanotechnol, London WC1E 6BT, England; [Ikuhara, Yuichi] Univ Tokyo, Inst Engn Innovat, Bunkyo Ku, Tokyo 1138656, Japan; [Ikuhara, Yuichi] Japan Fine Ceram Ctr, Nanostruct Res Lab, Atsuta Ku, Nagoya, Aichi 4568587, Japan	Tohoku University; University of London; University College London; University of London; University College London; University of Tokyo; Japan Fine Ceramics Center	Wang, ZC (corresponding author), Tohoku Univ, Adv Inst Mat Res, World Premier Int Res Ctr, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	zcwang@wpi-aimr.tohoku.ac.jp	Gu, Lin/D-9631-2011; Tsukimoto, Susumu/G-5194-2010; Saito, Mitsuhiro/A-4859-2010; Wang, Zhongchang/M-7124-2019; McKenna, Keith/A-5084-2010; Ikuhara, Yuichi/F-3066-2010; Ikuhara, Yuichi/N-1001-2015	Gu, Lin/0000-0002-7504-031X; Wang, Zhongchang/0000-0003-2141-4803; Ikuhara, Yuichi/0000-0003-3886-005X	MEXT, Japan [474]; IZUMI Science Foundation; MURATA Science Foundation; Nippon Sheet Glass Foundation;  [22760500];  [23560817];  [22740192]	MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); IZUMI Science Foundation; MURATA Science Foundation; Nippon Sheet Glass Foundation; ; ; 	This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Area "Atomic Scale Modification (474)" from MEXT, Japan. We thank T. Mizoguchi for performing electron energy-loss near-edge structure simulations and for discussions, and T. Saito and W. Zeng for experimental assistance. Z.W. acknowledges support by a Grant-in-Aid for Young Scientists (B) (grant no. 22760500) and from IZUMI Science Foundation. M. S. is grateful for a Grant-in-Aid for Scientific Research (C) (grant no. 23560817) and to MURATA Science Foundation for financial support. K. P. M. acknowledges support by a Grant-in-Aid for Young Scientists (B) (grant no. 22740192). S. T. thanks supports from the Nippon Sheet Glass Foundation. Calculations were conducted at ISSP, University of Tokyo.	Bai XM, 2010, SCIENCE, V327, P1631, DOI 10.1126/science.1183723; Barth C, 2011, ADV MATER, V23, P477, DOI 10.1002/adma.201002270; Browning ND, 1999, J AM CERAM SOC, V82, P366, DOI 10.1111/j.1551-2916.1999.tb20071.x; Buban JP, 2006, SCIENCE, V311, P212, DOI 10.1126/science.1119839; CHIANG YM, 1981, J AM CERAM SOC, V64, P385, DOI 10.1111/j.1151-2916.1981.tb09875.x; Colliex C, 2007, NATURE, V450, P622, DOI 10.1038/450622a; DAVIES JJ, 1970, J PHYS CHEM SOLIDS, V31, P2489, DOI 10.1016/0022-3697(70)90066-1; DUFFY DM, 1986, J PHYS C SOLID STATE, V19, P4393, DOI 10.1088/0022-3719/19/23/005; Findlay SD, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3265946; Harris DJ, 1996, PHILOS MAG A, V74, P407, DOI 10.1080/01418619608242151; Huang PY, 2011, NATURE, V469, P389, DOI 10.1038/nature09718; ISHIZUKA K, 1977, ACTA CRYSTALLOGR A, V33, P740, DOI 10.1107/S0567739477001879; Jia CL, 2004, SCIENCE, V303, P2001, DOI 10.1126/science.1093617; Kaiser U, 2002, NAT MATER, V1, P102, DOI 10.1038/nmat729; Kimoto K, 2007, NATURE, V450, P702, DOI 10.1038/nature06352; KINGERY WD, 1974, J AM CERAM SOC, V57, P1, DOI 10.1111/j.1151-2916.1974.tb11350.x; Kizuka T, 1998, PHILOS MAG A, V77, P413, DOI 10.1080/01418619808223761; Klie RF, 2005, NATURE, V435, P475, DOI 10.1038/nature03644; Lartigue-Korinek S, 2011, ACTA MATER, V59, P3519, DOI 10.1016/j.actamat.2011.02.025; Maiti A, 1996, PHYS REV LETT, V77, P1306, DOI 10.1103/PhysRevLett.77.1306; McKenna KP, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.224116; McKenna KP, 2008, NAT MATER, V7, P859, DOI 10.1038/nmat2289; Muller DA, 2009, NAT MATER, V8, P263, DOI [10.1038/nmat2380, 10.1038/NMAT2380]; Nellist PD, 2004, SCIENCE, V305, P1741, DOI 10.1126/science.1100965; Ortalan V, 2010, NAT NANOTECHNOL, V5, P506, DOI [10.1038/nnano.2010.92, 10.1038/NNANO.2010.92]; PENNYCOOK SJ, 1988, NATURE, V336, P565, DOI 10.1038/336565a0; Tanaka I, 2003, NAT MATER, V2, P541, DOI 10.1038/nmat939; VITEK V, 1984, SURF SCI, V144, P110, DOI 10.1016/0039-6028(84)90710-6; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Yan Y, 1998, PHYS REV LETT, V81, P3675, DOI 10.1103/PhysRevLett.81.3675	30	192	196	8	325	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					380	383		10.1038/nature10593	http://dx.doi.org/10.1038/nature10593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094698				2022-12-28	WOS:000297059700041
J	Spence, D				Spence, Des			FROM THE FRONTLINE The painful truth: deaths and misuse of prescribed drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Aggarwal VR, 2010, PAIN, V149, P354, DOI 10.1016/j.pain.2010.02.040; Aggarwal VR, 2006, INT J EPIDEMIOL, V35, P468, DOI 10.1093/ije/dyi265; [Anonymous], 2011, POL IMP PRESCR PAINK; CAVE D, 2008, NY TIMES        0614; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; OSPINA M, 2002, PREVALENCE CHRONIC P; SZALAVITZ M, 2011, TIME HEALTHLAND 0629	7	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d7403	10.1136/bmj.d7403	http://dx.doi.org/10.1136/bmj.d7403			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LV	22088400				2022-12-28	WOS:000297497100007
J	Thiruchelvam, PTR; Willicombe, M; Hakim, N; Taube, D; Papalois, V				Thiruchelvam, Paul T. R.; Willicombe, Michelle; Hakim, Nadey; Taube, David; Papalois, Vassilios			Renal transplantation	BRITISH MEDICAL JOURNAL			English	Review							DONOR KIDNEY-TRANSPLANTATION; LONG-TERM CONSEQUENCES; RECIPIENTS; SURVIVAL; COMPLICATIONS; NEPHRECTOMY; MANAGEMENT; ADVANTAGE; PREGNANCY; DIALYSIS		[Thiruchelvam, Paul T. R.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Renal & Transplant Ctr, Dept Transplant Surg, London W12 0NN, England	Imperial College London	Thiruchelvam, PTR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Renal & Transplant Ctr, Dept Transplant Surg, London W12 0NN, England.	paul.thiruchelvam@imperial.ac.uk						Abou Ayache R, 2005, TRANSPLANT P, V37, P2817, DOI 10.1016/j.transproceed.2005.05.039; Becker BN, 2006, ARCH INTERN MED, V166, P44, DOI 10.1001/archinte.166.1.44; *BRIT TRANSPL SOC, 2011, ACT BTS STAND GUID; BYRNE C, 2009, 12 UK REN REG; Chadban SJ, 2001, J AM SOC NEPHROL, V12, P394, DOI 10.1681/ASN.V122394; EBPG Expert Group on Renal Transplantation, 2002, NEPHROL DIAL TRAN S4, V17, P50; FehrmanEkholm I, 1997, TRANSPLANTATION, V64, P976, DOI 10.1097/00007890-199710150-00007; Gibbons N, 2010, NEPHROLOGY, V15, pS88, DOI 10.1111/j.1440-1797.2009.01214.x; Gill JS, 2004, TRANSPLANTATION, V78, P873, DOI 10.1097/01.TP.0000130204.80781.68; Gossmann J, 2005, AM J TRANSPLANT, V5, P2417, DOI 10.1111/j.1600-6143.2005.01037.x; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Humar A, 2005, SEMIN DIALYSIS, V18, P505, DOI 10.1111/j.1525-139X.2005.00097.x; Ibrahim HN, 2009, NEW ENGL J MED, V360, P459, DOI 10.1056/NEJMoa0804883; Innocenti GR, 2007, TRANSPLANTATION, V83, P144, DOI 10.1097/01.tp.0000250555.46539.65; Johnson RJ, 2010, TRANSPLANTATION, V89, P387, DOI 10.1097/TP.0b013e3181c9029d; Josephson MA, 2007, ADV CHRONIC KIDNEY D, V14, P156, DOI 10.1053/j.ackd.2007.01.006; Kasiske BL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013295.11876.C9; Kayler L, 2010, TRANSPL P, V42, P1413, DOI 10.1016/j.transproceed.2010.04.016; Kokkinos C, 2007, TRANSPLANTATION, V83, P1193, DOI 10.1097/01.tp.0000261710.53848.51; KUSS R, 1951, Mem Acad Chir (Paris), V77, P755; Luan FL, 2011, TRANSPLANTATION, V91, P334, DOI 10.1097/TP.0b013e318203c25f; Mange KC, 2003, NEPHROL DIAL TRANSPL, V18, P172, DOI 10.1093/ndt/18.1.172; McKay DB, 2006, NEW ENGL J MED, V354, P1281, DOI 10.1056/NEJMra050431; Moeller S, 2002, NEPHROL DIAL TRANSPL, V17, P2071, DOI 10.1093/ndt/17.12.2071; Morgan BR, 2011, CURR OPIN NEPHROL HY, V20, P605, DOI 10.1097/MNH.0b013e32834bd72b; *NHS BLOOD TRANSPL, 2011, ORG DON ACT REP 2010; *NHS BLOOD TRANSPL, 2011, ORG DON COST EFF TRA; Ojo AO, 2001, J AM SOC NEPHROL, V12, P589, DOI 10.1681/ASN.V123589; Pradel FG, 2003, AM J KIDNEY DIS, V41, P849, DOI 10.1016/S0272-6386(03)00033-7; *REN ASS, 2011, ASS POT KIDN TRANSP; Schieppati A, 2005, KIDNEY INT, V68, pS7, DOI 10.1111/j.1523-1755.2005.09801.x; Torffvit O, 1997, SCAND J UROL NEPHROL, V31, P555, DOI 10.3109/00365599709030662; UK Renal Registry, 2011, 12 UK REN REG; Weikert BC, 2008, CLIN J AM SOC NEPHRO, V3, pS76, DOI 10.2215/CJN.02900707; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303	35	25	26	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 14	2011	343								d7300	10.1136/bmj.d7300	http://dx.doi.org/10.1136/bmj.d7300			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LT	22084316				2022-12-28	WOS:000297496900001
J	Renner, SS				Renner, Susanne S.			Living Fossil Younger than Thought	SCIENCE			English	Editorial Material							CYCAD		Univ Munich, Dept Biol, D-80638 Munich, Germany	University of Munich	Renner, SS (corresponding author), Univ Munich, Dept Biol, D-80638 Munich, Germany.	renner@lrz.uni-muenchen.de						Butler RJ, 2009, BIOL REV, V84, P73, DOI 10.1111/j.1469-185X.2008.00065.x; Crisp MD, 2011, NEW PHYTOL, V192, P997, DOI 10.1111/j.1469-8137.2011.03862.x; Downie DA, 2008, MOL PHYLOGENET EVOL, V47, P102, DOI 10.1016/j.ympev.2008.01.023; Inoue JG, 2005, GENE, V349, P227, DOI 10.1016/j.gene.2005.01.008; Klavins SD, 2005, EVOL ECOL RES, V7, P479; Marler TE, 2010, AM J BOT, V97, P841, DOI 10.3732/ajb.0900251; Nagalingum NS, 2011, SCIENCE, V334, P796, DOI 10.1126/science.1209926; NORSTOG K, 1997, BIOL CYCADS; Taylor TN, 2009, PALEOBOTANY: THE BIOLOGY AND EVOLUTION OF FOSSIL PLANTS, 2ND EDITION, P1; The IUCN Red List,, IUCN RED LIST THREAT; Wang X, 2009, CHINESE SCI BULL, V54, P3116, DOI 10.1007/s11434-009-0384-z; Zachos JC, 2008, NATURE, V451, P279, DOI 10.1038/nature06588; ZHIFENG G, 1989, REV PALAEOBOT PALYNO, V60, P205, DOI 10.1016/0034-6667(89)90044-4	13	13	18	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					766	767		10.1126/science.1214649	http://dx.doi.org/10.1126/science.1214649			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076366				2022-12-28	WOS:000296849600032
J	Shearstone, JR; Pop, R; Bock, C; Boyle, P; Meissner, A; Socolovsky, M				Shearstone, Jeffrey R.; Pop, Ramona; Bock, Christoph; Boyle, Patrick; Meissner, Alexander; Socolovsky, Merav			Global DNA Demethylation During Mouse Erythropoiesis in Vivo	SCIENCE			English	Article							METHYLATION PATTERNS; CELLS; ERYTHROLEUKEMIA; MAINTENANCE	In the mammalian genome, 5'-CpG-3' dinucleotides are frequently methylated, correlating with transcriptional silencing. Genome-wide demethylation is thought to occur only twice during development, in primordial germ cells and in the pre-implantation embryo. These demethylation events are followed by de novo methylation, setting up a pattern inherited throughout development and modified only at tissue-specific loci. We studied DNA methylation in differentiating mouse erythroblasts in vivo by using genomic-scale reduced representation bisulfite sequencing (RRBS). Demethylation at the erythroid-specific beta-globin locus was coincident with global DNA demethylation at most genomic elements. Global demethylation was continuous throughout differentiation and required rapid DNA replication. Hence, DNA demethylation can occur globally during somatic cell differentiation, providing an experimental model for its study in development and disease.	[Shearstone, Jeffrey R.; Pop, Ramona; Socolovsky, Merav] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; [Shearstone, Jeffrey R.; Pop, Ramona; Socolovsky, Merav] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Bock, Christoph; Boyle, Patrick; Meissner, Alexander] Broad Inst, Cambridge, MA 02142 USA; [Bock, Christoph; Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Bock, Christoph; Meissner, Alexander] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University	Socolovsky, M (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA.	merav.socolovsky@umassmed.edu	Bock, Christoph/AAE-7618-2019	Bock, Christoph/0000-0001-6091-3088; Socolovsky, Merav/0000-0001-6747-7960; Shearstone, Jeffrey/0000-0002-6875-1826	NIH/National Heart, Lung, and Blood Institute [R01 HL084168]; American Cancer Society [RSG06-051-01]; NIH CA [T32-130807]; Diabetes Endocrinology Research Center [DK32520]; Harvard Stem Cell Institute; Pew Charitable Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Cancer Society(American Cancer Society); NIH CA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diabetes Endocrinology Research Center; Harvard Stem Cell Institute; Pew Charitable Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R. Scully, P. A. Jones, R. Jaenisch, J. Dekker, C. Peterson, and S. Akbarian for helpful discussions; D. Hidalgo for technical assistance; E. Li for Dnmt cDNAs; R. Konz, T. Giehl, and the UMass Fluorescence-Activated Cell Sorting core; and S. Baker for statistical analysis. This work was funded by NIH/National Heart, Lung, and Blood Institute R01 HL084168, American Cancer Society grant RSG06-051-01, NIH CA T32-130807, Diabetes Endocrinology Research Center grant DK32520, the Harvard Stem Cell Institute, and the Pew Charitable Trust. The RRBS analysis may be accessed at http://erythrocyte-demethylation.computational-epigenetics.org/. Affymetrix microarray expression data for the S1 and S3 subsets are deposited in the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/), GEO accession number GSE32214.	Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Dover G J, 1983, Prog Clin Biol Res, V134, P475; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Kowal-Vern A, 2000, AM J HEMATOL, V65, P5, DOI 10.1002/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; MICHALOWSKY LA, 1989, MOL CELL BIOL, V9, P885, DOI 10.1128/MCB.9.3.885; PINKUS GS, 1981, AM J PATHOL, V102, P308; Pop R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000484; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Silver L. M., 1995, MOUSE GENETICS; Singh M, 2007, EXP HEMATOL, V35, P48, DOI 10.1016/j.exphem.2006.09.001; Socolovsky M, 2007, PLOS BIOL, V5, P2296, DOI 10.1371/journal.pbio.0050252	26	117	120	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					799	802		10.1126/science.1207306	http://dx.doi.org/10.1126/science.1207306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076376	Green Accepted, Green Submitted			2022-12-28	WOS:000296849600045
J	Kahn, JG; Marseille, E; Moore, D; Bunnell, R; Were, W; Degerman, R; Tappero, JW; Ekwaru, P; Kaharuza, F; Mermin, J				Kahn, James G.; Marseille, Elliot; Moore, David; Bunnell, Rebecca; Were, Willy; Degerman, Richard; Tappero, Jordan W.; Ekwaru, Paul; Kaharuza, Frank; Mermin, Jonathan			CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study	BRITISH MEDICAL JOURNAL			English	Article							RESOURCE-LIMITED SETTINGS; POOR SETTINGS; HIV TREATMENT; AFRICA; ADHERENCE; OUTCOMES; PROGRAM; TRIAL; MODEL	Objective To examine the cost and cost effectiveness of quarterly CD4 cell count and viral load monitoring among patients taking antiretroviral therapy (ART). Design Cost effectiveness study. Setting A randomised trial in a home based ART programme in Tororo, Uganda. Participants People with HIV who were members of the AIDS Support Organisation and had CD4 cell counts <250 x 10(6) cells/L or World Health Organization stage 3 or 4 disease. Main outcome measures Outcomes calculated for the study period and projected 15 years into the future included costs, disability adjusted life years (DALYs), and incremental cost effectiveness ratios (ICER; $ per DALY averted). Cost inputs were based on the trial and other sources. Clinical inputs derived from the trial; in the base case, we assumed that point estimates reflected true differences even if non-significant. We conducted univariate and multivariate sensitivity analyses. Interventions Three monitoring strategies: clinical monitoring with quarterly CD4 cell counts and viral load measurement (clinical/CD4/viral load); clinical monitoring and quarterly CD4 counts (clinical/CD4); and clinical monitoring alone. Results With the intention to treat (ITT) results per 100 individuals starting ART, we found that clinical/CD4 monitoring compared with clinical monitoring alone increases costs by $20 458 (12 pound 780, (sic)14 707) and averts 117.3 DALYs (ICER=$174 per DALY). Clinical/CD4/viral load monitoring compared with clinical/CD4 monitoring adds $142 458, and averts 27.5 DALYs ($5181 per DALY). The superior ICER for clinical/CD4 monitoring is robust to uncertainties in input values, and that strategy is dominant (less expensive and more effective) compared with clinical/CD4/viral load monitoring in one quarter of simulations. If clinical inputs are based on the as treated analysis starting at 90 days (after laboratory monitoring was initiated), then clinical/CD4/viral load monitoring is dominated by other strategies. Conclusions Based on this trial, compared with clinical monitoring alone, monitoring of routine CD4 cell count is considerably more cost effective than additionally including routine viral load testing in the monitoring strategy and is more cost effective than ART.	[Kahn, James G.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA; [Kahn, James G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94118 USA; [Marseille, Elliot] Hlth Strategies Int, Oakland, CA USA; [Moore, David] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada; [Moore, David] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Bunnell, Rebecca] Ctr Dis Control & Prevent, CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Div Community Hlth, Entebbe, Uganda; [Tappero, Jordan W.] Ctr Dis Control & Prevent, CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Hlth Syst Reconstruct Off, Entebbe, Uganda; [Kaharuza, Frank] Ctr Dis Control & Prevent, CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Epidemiol Branch, Entebbe, Uganda; [Mermin, Jonathan] Ctr Dis Control & Prevent, CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, Div HIV AIDS Prevent, Entebbe, Uganda; [Bunnell, Rebecca] Ctr Dis Control & Prevent, Div Community Hlth, Atlanta, GA USA; [Tappero, Jordan W.] Ctr Dis Control & Prevent, Hlth Syst Reconstruct Off, Atlanta, GA USA; [Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia; B.C. Centre for Excellence in HIV/AIDS; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kahn, JG (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, 3333 Calif St,Suite 265, San Francisco, CA 94118 USA.	jgkahn@ucsf.edu	Mermin, Jonathan/J-9847-2012		US Centers for Disease Control and Prevention, Kenya; US National Institute of Drug Abuse [R01 DA15612]; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA015612, R01DA015612] Funding Source: NIH RePORTER	US Centers for Disease Control and Prevention, Kenya(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was funded by US Centers for Disease Control and Prevention, Kenya, and US National Institute of Drug Abuse (R01 DA15612). The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.	CHI BH, 2011, J ACQUIR IMMUNE 0818; Cleary Susan M, 2006, Cost Eff Resour Alloc, V4, P20, DOI 10.1186/1478-7547-4-20; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; *DIS CONTR PRIOR P, 2006, GLOB BURD DIS; Edejer T, 2003, WHO GUIDE COST EFFEC; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; Harries AD, 2006, LANCET, V367, P1870, DOI 10.1016/S0140-6736(06)68809-0; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Kimmel AD, 2010, JAIDS-J ACQ IMM DEF, V54, P258, DOI 10.1097/QAI.0b013e3181d0db97; Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/00002030-200406003-00005; Marseille E, 2009, APPL HEALTH ECON HEA, V7, P229, DOI 10.2165/11318740-000000000-00000; *MED SANS FRONT, 2007, UNT WEB ARV PRIC RED; MERMIN J, 2011, BRIT MED J, pD6792; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; *MOH UG ORC MACR, 2006, UG HIV AIDS SER BEH; Morgan M.G., 1990, UNCERTAINTY GUIDE DE; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; MURRU M, 2003, HLTH POLICY DEV J, P61; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Pitter C, 2007, JAIDS-J ACQ IMM DEF, V44, P336, DOI 10.1097/QAI.0b013e31802f12b5; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; UNAIDS, 2010, 2010 REP GLOB HIV AI; *US CENTR INT AG A, 2010, WORLD FACTB; Walensky RP, 2010, CLIN INFECT DIS, V51, P85, DOI 10.1086/653119; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; *WIK, TOR DISTR GOV; World Health Organisation (WHO), 2010, PRIOR INT HIV AIDS P	28	52	52	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	2011	343								d6884	10.1136/bmj.d6884	http://dx.doi.org/10.1136/bmj.d6884			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848NP	22074713	hybrid, Green Published			2022-12-28	WOS:000297058600004
J	Simpson, JAD; Scholefield, JH				Simpson, J. A. D.; Scholefield, J. H.			Diagnosis and management of anal intraepithelial neoplasia and anal cancer	BRITISH MEDICAL JOURNAL			English	Review							HUMAN-PAPILLOMAVIRUS; ANOGENITAL CANCER; SEXUAL PRACTICES; RADIOTHERAPY; INFECTION; CARCINOMA; CHEMOTHERAPY; POPULATION; GUIDELINES; PATHOLOGY		[Simpson, J. A. D.; Scholefield, J. H.] Univ Nottingham Hosp, Div Gastrointestinal Surg, Nottingham NG7 2UH, England	University of Nottingham	Simpson, JAD (corresponding author), Univ Nottingham Hosp, Div Gastrointestinal Surg, Queens Med Ctr Campus, Nottingham NG7 2UH, England.	alastairsimpson@hotmail.com						Ajani JA, 2010, CANCER-AM CANCER SOC, V116, P4007, DOI 10.1002/cncr.25188; Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040; Brewster DH, 2006, BRIT J CANCER, V95, P87, DOI 10.1038/sj.bjc.6603175; Carter JJ, 2001, CANCER RES, V61, P1934; CARTER PS, 1995, BRIT J SURG, V82, P473, DOI 10.1002/bjs.1800820414; Chauveinc L, 2003, BRIT J CANCER, V89, P2057, DOI 10.1038/sj.bjc.6601378; Critchlow CW, 1998, AIDS, V12, P1177, DOI 10.1097/00002030-199810000-00010; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; Edge SB, 2009, AJCC CANC STAGING MA, V7; Edgren G, 2007, LANCET ONCOL, V8, P311, DOI 10.1016/S1470-2045(07)70043-8; Glynne-Jones R, 2010, ANN ONCOL, V21, pv87, DOI 10.1093/annonc/mdq171; Hill J, 2003, Colorectal Dis, V5, P206, DOI 10.1046/j.1463-1318.2003.00482.x; Kronfli M, 2011, COLORECTAL DIS, V13, P33, DOI 10.1111/j.1463-1318.2010.02497.x; Licitra L, 2002, CRIT REV ONCOL HEMAT, V43, P77, DOI 10.1016/S1040-8428(01)00193-7; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Peiffert D, 1997, INT J RADIAT ONCOL, V39, P57, DOI 10.1016/S0360-3016(97)00316-7; Pocard M, 1998, DIS COLON RECTUM, V41, P1488, DOI 10.1007/BF02237294; Renehan AG, 2011, COLORECTAL DIS, V13, P44, DOI 10.1111/j.1463-1318.2010.02500.x; Renehan AG, 2011, COLORECTAL DIS, V13, P21, DOI 10.1111/j.1463-1318.2010.02495.x; Renehan AG, 2005, BRIT J SURG, V92, P605, DOI 10.1002/bjs.4908; Robinson D, 2009, BRIT J CANCER, V100, P527, DOI 10.1038/sj.bjc.6604871; Salmo E, 2011, COLORECTAL DIS, V13, P11, DOI 10.1111/j.1463-1318.2010.02498.x; Scholefield JH, 2011, COLORECTAL DIS, V13, P3, DOI 10.1111/j.1463-1318.2010.02494.x; Scholefield JH, 2005, BRIT J SURG, V92, P1133, DOI 10.1002/bjs.4994; SCOTT NA, 1989, BRIT J CANCER, V60, P56, DOI 10.1038/bjc.1989.219; UKCCCR AN CANC, 1996, LANCET, V348, P1049; WHO/ICO Information Centre on HPV and Cervical Cancer, 2010, HUM PAP REL CANC UK; Zbar AP, 2002, INT J COLORECTAL DIS, V17, P203, DOI 10.1007/s00384-001-0369-0	30	17	17	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 4	2011	343								d6818	10.1136/bmj.d6818	http://dx.doi.org/10.1136/bmj.d6818			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QU	22058137				2022-12-28	WOS:000296763200006
J	Jolly, K; Lewis, A; Beach, J; Denley, J; Adab, P; Deeks, JJ; Daley, A; Aveyard, P				Jolly, Kate; Lewis, Amanda; Beach, Jane; Denley, John; Adab, Peymane; Deeks, Jonathan J.; Daley, Amanda; Aveyard, Paul			Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: Lighten Up randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY QUESTIONNAIRE; SMOKING-CESSATION; STANDARD; DIET	Objective To assess the effectiveness of a range of weight management programmes in terms of weight loss. Design Eight arm randomised controlled trial. Setting Primary care trust in Birmingham, England. Participants 740 obese or overweight men and women with a comorbid disorder identified from general practice records. Interventions Weight loss programmes of 12 weeks' duration: Weight Watchers; Slimming World; Rosemary Conley; group based, dietetics led programme; general practice one to one counselling; pharmacy led one to one counselling; choice of any of the six programmes. The comparator group was provided with 12 vouchers enabling free entrance to a local leisure (fitness) centre. Main outcome measures The primary outcome was weight loss at programme end (12 weeks). Secondary outcomes were weight loss at one year, self reported physical activity, and percentage weight loss at programme end and one year. Results Follow-up data were available for 658 (88.9%) participants at programme end and 522 (70.5%) at one year. All programmes achieved significant weight loss from baseline to programme end (range 1.37 kg (general practice) to 4.43 kg (Weight Watchers)), and all except general practice and pharmacy provision resulted in significant weight loss at one year. At one year, only the Weight Watchers group had significantly greater weight loss than did the comparator group (2.5 (95% confidence interval 0.8 to 4.2) kg greater loss,). The commercial programmes achieved significantly greater weight loss than did the primary care programmes at programme end (mean difference 2.3 (1.3 to 3.4) kg). The primary care programmes were the most costly to provide. Participants allocated to the choice arm did not have better outcomes than those randomly allocated to a programme. Conclusions Commercially provided weight management services are more effective and cheaper than primary care based services led by specially trained staff, which are ineffective.	[Jolly, Kate; Lewis, Amanda; Adab, Peymane; Deeks, Jonathan J.; Daley, Amanda; Aveyard, Paul] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Beach, Jane] Nursing & Midwifery Council, London W1B 1PZ, England; [Denley, John] NHS S Birmingham, Birmingham B38 5SR, W Midlands, England	University of Birmingham	Daley, A (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England.	A.Daley@bham.ac.uk	Jolly, Kate/AAA-1341-2019; Deeks, Jon/AAV-5745-2020; Adab, Peymane/ABC-9651-2021	Jolly, Kate/0000-0002-6224-2115; Deeks, Jon/0000-0002-8850-1971; Adab, Peymane/0000-0001-9087-3945; Aveyard, Paul/0000-0002-1802-4217; Lewis, Amanda/0000-0003-0488-5347	NHS South Birmingham; National Institute for Health Research (NIHR); MRC [G0800808] Funding Source: UKRI; Medical Research Council [G0800808] Funding Source: researchfish	NHS South Birmingham; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was funded by NHS South Birmingham. PAveyard is supported by a National Institute for Health Research (NIHR) career scientist award. AD is supported by a senior research fellowship award from the NIHR. KJ was part funded by the NIHR through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, the Department of Health, NHS South Birmingham, the University of Birmingham, or the CLAHRC-BBC Steering Group. JD and JB were employed by the sponsoring organisation. Their roles are outlined above. The writing of the report and the decision to submit the article for publication rested with the authors from the University of Birmingham.	Aveyard P, 2008, BMJ-BRIT MED J, V336, P1223, DOI 10.1136/bmj.39545.852616.BE; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Burke LE, 2008, INT J OBESITY, V32, P166, DOI 10.1038/sj.ijo.0803706; Conley Rosemary, 2011, TACKL OB NHS GP REF; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Craig R, 2009, HLTH SURVEY ENGLAND; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; Gibbs HD, 2004, J HUM NUTR DIET, V17, P191, DOI 10.1111/j.1365-277X.2004.00517.x; Hardcastle S, 2008, PATIENT EDUC COUNS, V70, P31, DOI 10.1016/j.pec.2007.09.014; Heesch Kristiann C, 2010, Int J Behav Nutr Phys Act, V7, P35, DOI 10.1186/1479-5868-7-35; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Jebb SA, 2011, LANCET, V378, P1485, DOI 10.1016/S0140-6736(11)61344-5; Jolly K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-439; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kopelman P, 2007, OBES REV, V8, P13, DOI 10.1111/j.1467-789X.2007.00311.x; Lavin JH, 2006, PUBLIC HEALTH, V120, P872, DOI 10.1016/j.puhe.2006.05.008; Leverence RR, 2007, AM J PREV MED, V32, P334, DOI 10.1016/j.amepre.2006.12.008; McEwen A, 2006, ADDICT BEHAV, V31, P1650, DOI 10.1016/j.addbeh.2005.12.014; McQuigg M, 2005, EUR J CLIN NUTR, V59, pS93, DOI 10.1038/sj.ejcn.1602180; Moore H, 2003, BRIT MED J, V327, P1085, DOI 10.1136/bmj.327.7423.1085; Nanchahal K, 2009, BRIT J GEN PRACT, V59, P349, DOI 10.3399/bjgp09X420617; National Institute for Health and Clinical Excellence, 2006, OB GUID PREV ID ASS; Pagoto SL, 2011, OBESITY SILVER SPRIN; Renjilian DA, 2001, J CONSULT CLIN PSYCH, V69, P717, DOI 10.1037//0022-006X.69.4.717; Rock CL, 2007, OBESITY, V15, P939, DOI 10.1038/oby.2007.614; Ross HM, 2008, BRIT J GEN PRACT, V58, P548, DOI 10.3399/bjgp08X319710; Rzewnicki R, 2003, PUBLIC HEALTH NUTR, V6, P299, DOI 10.1079/PHN2002427; Slimming World, 2011, SLIMM SUPP INF HLTH; Truby H, 2011, BMJ-BRIT MED J, V332, P1309; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Weight Watchers, 2011, WEIGHT WATCH WORKS; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; World Health Organization, 2011, OB	33	229	230	0	59	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2011	343								d6500	10.1136/bmj.d6500	http://dx.doi.org/10.1136/bmj.d6500			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QT	22053315	hybrid, Green Published			2022-12-28	WOS:000296763100008
J	Shelton, J				Shelton, James			Scientists and the media must give a balanced view	NATURE			English	Editorial Material									US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Shelton, J (corresponding author), US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA.	jshelton@usaid.gov							0	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					7	7		10.1038/479007a	http://dx.doi.org/10.1038/479007a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	840FA	22051636	Bronze			2022-12-28	WOS:000296422600004
J	Huddle, TS; Centor, RM				Huddle, Thomas S.; Centor, Robert M.			Retainer Medicine: An Ethically Legitimate Form of Practice That Can Improve Primary Care	ANNALS OF INTERNAL MEDICINE			English	Article							CONCIERGE MEDICINE	Retainer medicine has become an important yet controversial form of primary care practice in the United States, coming under attack for its purported failure to measure up to professional ethics. Critics opine that retainer medicine obstructs professional commitments to health care access and social justice. Some ethicists urge that society should restrict or ban retainer medicine; professional organizations have yet to take a stand. The authors believe that retainer medicine is compatible with professional ethics and will more likely aid in solving the difficulties facing primary care rather than add to them. Although professional ethics should evolve to address new conditions, a condemnation of retainer medicine is warranted neither by traditional ethical precepts nor by contemporary developments in medical ethics. Any move to sanction retainer medicine under the banner of professionalism or professional ethics will be counterproductive. The primary care shortage will only get worse if physicians in retainer practice leave primary care altogether, a likely outcome of legal or professional condemnation of retainer practice.	[Huddle, Thomas S.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Huddle, TS (corresponding author), Univ Alabama Birmingham, Div Gen Internal Med, FOT 720,1530 6th Ave S, Birmingham, AL 35294 USA.	thuddle@uab.edu						Carnahan SJ, 2007, J LAW MED ETHICS, V35, P211, DOI 10.1111/j.1748-720X.2007.00125.x; DANIELS N, 1981, SOC SCI MED F-MED S, V15, P129, DOI 10.1016/0271-5392(81)90002-2; Daniels N, 2009, J MED ETHICS, V35, P36, DOI 10.1136/jme.2008.026831; Donohoe MT, 2004, VIRTUAL MENTOR, P6; O'Neill O, 2005, INT AFF, V81, P427, DOI 10.1111/j.1468-2346.2005.00459.x; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; Stillman M, 2010, ANN INTERN MED, V152, P391, DOI 10.7326/0003-4819-152-6-201003160-00009	7	10	10	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					633	U122		10.7326/0003-4819-155-9-201111010-00013	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	842PW	22041952				2022-12-28	WOS:000296612400008
J	Kumar, PA; Hu, YY; Yamamoto, Y; Hoe, NB; Wei, TS; Mu, DK; Sun, Y; Joo, LS; Dagher, R; Zielonka, EM; Wang, DY; Lim, B; Chow, VT; Crum, CP; Xian, W; McKeon, F				Kumar, Pooja A.; Hu, Yuanyu; Yamamoto, Yusuke; Hoe, Neo Boon; Wei, Tay Seok; Mu, Dakai; Sun, Yan; Joo, Lim Siew; Dagher, Rania; Zielonka, Elisabeth M.; Wang, De Yun; Lim, Bing; Chow, Vincent T.; Crum, Christopher P.; Xian, Wa; McKeon, Frank			Distal Airway Stem Cells Yield Alveoli In Vitro and during Lung Regeneration following H1N1 Influenza Infection	CELL			English	Article							RESPIRATORY-DISTRESS-SYNDROME; MOUSE MODEL; EPITHELIUM; VIRUS; MICE; REPAIR; P63; MAINTENANCE; HOMEOSTASIS; ANTIBODY	The extent of lung regeneration following catastrophic damage and the potential role of adult stem cells in such a process remains obscure. Sublethal infection of mice with an H1N1 influenza virus related to that of the 1918 pandemic triggers massive airway damage followed by apparent regeneration. We show here that p63-expressing stem cells in the bronchiolar epithelium undergo rapid proliferation after infection and radiate to interbronchiolar regions of alveolar ablation. Once there, these cells assemble into discrete, Krt5+ pods and initiate expression of markers typical of alveoli. Gene expression profiles of these pods suggest that they are intermediates in the reconstitution of the alveolar-capillary network eradicated by viral infection. The dynamics of this p63-expressing stem cell in lung regeneration mirrors our parallel finding that defined pedigrees of human distal airway stem cells assemble alveoli-like structures in vitro and suggests new therapeutic avenues to acute and chronic airway disease.	[Kumar, Pooja A.; Hu, Yuanyu; Yamamoto, Yusuke; Hoe, Neo Boon; Wei, Tay Seok; Joo, Lim Siew; Lim, Bing; McKeon, Frank] ASTAR, Genome Inst Singapore, Singapore, Singapore; [Kumar, Pooja A.] Natl Univ Singapore, Singapore Massachusetts Inst Technol Alliance, Singapore 117548, Singapore; [Wei, Tay Seok; Xian, Wa] ASTAR, Inst Med Biol, Singapore, Singapore; [Mu, Dakai; Sun, Yan; McKeon, Frank] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; [Dagher, Rania; Zielonka, Elisabeth M.] Univ Strasbourg, Inst Sci & Ingn Supramol, Strasbourg, France; [Wang, De Yun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 117595, Singapore; [Chow, Vincent T.] Natl Univ Singapore, Yong Loo Lin Sch Med, Infect Dis Program, Dept Microbiol, Singapore 117595, Singapore; [Crum, Christopher P.; Xian, Wa] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Massachusetts Institute of Technology (MIT); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Harvard University; Harvard Medical School; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National University of Singapore; National University of Singapore; Harvard University; Brigham & Women's Hospital	Xian, W (corresponding author), ASTAR, Genome Inst Singapore, Singapore, Singapore.	wa.xian@imb.a-star.edu.sg; mckeonf@gis.a-star.edu.sg	Kumar, Pooja Ashok/K-6762-2019	Kumar, Pooja/0000-0002-6589-2447; Chow, Vincent/0000-0003-2634-6213; Hu, Yuanyu/0000-0001-5457-4331	Defense Advanced Research Projects Agency (DARPA) [N66001-09-1-2121]; NIH [RC1 HL100767, RO1-GM083348, R21CA124688]; Singapore-MIT Alliance for Research and Technology; European Research Council; Agence de Nationale; Institute of Medical Biology; Genome Institute of Singapore of the Agency for Science, Technology and Research; NATIONAL CANCER INSTITUTE [R01CA083944, R21CA124688] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL100767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083348] Funding Source: NIH RePORTER	Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore-MIT Alliance for Research and Technology(Singapore-MIT Alliance for Research & Technology Centre (SMART)); European Research Council(European Research Council (ERC)European Commission); Agence de Nationale; Institute of Medical Biology(Agency for Science Technology & Research (A*STAR)); Genome Institute of Singapore of the Agency for Science, Technology and Research(Agency for Science Technology & Research (A*STAR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is dedicated to Howard Green. We thank Thomas Lufkin and Petra Kraus for their help with mouse models, Jianzhu Chen and his laboratory as well as the staff of the ABSL2 laboratory at NUS for their assistance with the viral model, and Susan and Keith Rogers for help with histology. We thank the staff of the Nikon Imaging Facility at HMS, and Graham Daniel Wright of the IMB imaging facility. We thank all the members in the Xian-McKeon laboratory for helpful discussions, and Edison Liu and Barbara Knowles for their critical review of the manuscript. We are grateful for the timely support of this work by the Defense Advanced Research Projects Agency (DARPA; Project N66001-09-1-2121), as well as the NIH (RC1 HL100767, RO1-GM083348, and R21CA124688), the Singapore-MIT Alliance for Research and Technology, the European Research Council, Agence de Nationale, the Institute of Medical Biology and the Genome Institute of Singapore of the Agency for Science, Technology and Research.	BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Belser JA, 2009, ADV VIRUS RES, V73, P55, DOI 10.1016/S0065-3527(09)73002-7; Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150; Cole BB, 2010, AM J PATHOL, V177, P362, DOI 10.2353/ajpath.2010.090870; Eaton DC, 2009, ANNU REV PHYSIOL, V71, P403, DOI 10.1146/annurev.physiol.010908.163250; Gao P, 1999, J VIROL, V73, P3184, DOI 10.1128/JVI.73.4.3184-3189.1999; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; GILLIS CN, 1982, ANNU REV PHYSIOL, V44, P269, DOI 10.1146/annurev.ph.44.030182.001413; Gubareva LV, 1998, J INFECT DIS, V178, P1592, DOI 10.1086/314515; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hoshino T, 2009, AM J RESP CELL MOL, V41, P661, DOI 10.1165/rcmb.2008-0182OC; Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324; Khimji AK, 2010, CELL SIGNAL, V22, P1615, DOI 10.1016/j.cellsig.2010.05.002; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lowy RJ, 2003, INT REV IMMUNOL, V22, P425, DOI 10.1080/08830180305216; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Matuschak George M, 2010, Mo Med, V107, P252; Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007; MORI I, 1995, MICROB PATHOGENESIS, V19, P237, DOI 10.1016/S0882-4010(95)90290-2; Nakajima N, 2012, MODERN PATHOL, V25, P1, DOI 10.1038/modpathol.2011.125; Narasaraju T, 2010, AM J RESP CELL MOL, V42, P732, DOI 10.1165/rcmb.2008-0423OC; Ramsey C, 2011, CURR OPIN CRIT CARE, V17, P64, DOI 10.1097/MCC.0b013e3283427259; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rock JR, 2010, DIS MODEL MECH, V3, P545, DOI 10.1242/dmm.006031; Sakuma T, 2006, CRIT CARE MED, V34, P676, DOI 10.1097/01.CCM.0000201403.70636.0F; Schmidt D, 1996, TOXICOL LETT, V88, P75, DOI 10.1016/0378-4274(96)03720-4; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Stripp Barry R, 2008, Proc Am Thorac Soc, V5, P328, DOI 10.1513/pats.200711-167DR; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wojcik SM, 2000, MOL CELL BIOL, V20, P5248, DOI 10.1128/MCB.20.14.5248-5255.2000; Wu SH, 2011, CURR OPIN INFECT DIS, V24, P235, DOI 10.1097/QCO.0b013e328344c0e3; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	39	374	382	0	30	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					525	538		10.1016/j.cell.2011.10.001	http://dx.doi.org/10.1016/j.cell.2011.10.001			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036562	Green Accepted, Bronze			2022-12-28	WOS:000296573700009
J	Takeda, N; Jain, R; LeBoeuf, MR; Wang, QH; Lu, MM; Epstein, JA				Takeda, Norifumi; Jain, Rajan; LeBoeuf, Matthew R.; Wang, Qiaohong; Lu, Min Min; Epstein, Jonathan A.			Interconversion Between Intestinal Stem Cell Populations in Distinct Niches	SCIENCE			English	Article							PROGENITOR CELLS; MOUSE; MARKER; HOP; IDENTIFICATION; EXPRESSION; RENEWAL; PROTEIN; CANCER; GENE	Intestinal epithelial stem cell identity and location have been the subject of substantial research. Cells in the +4 niche are slow-cycling and label-retaining, whereas a different stem cell niche located at the crypt base is occupied by crypt base columnar (CBC) cells. CBCs are distinct from +4 cells, and the relationship between them is unknown, though both give rise to all intestinal epithelial lineages. We demonstrate that Hopx, an atypical homeobox protein, is a specific marker of +4 cells. Hopx-expressing cells give rise to CBCs and all mature intestinal epithelial lineages. Conversely, CBCs can give rise to +4 Hopx-positive cells. These findings demonstrate a bidirectional lineage relationship between active and quiescent stem cells in their niches.	[Takeda, Norifumi; Jain, Rajan; LeBoeuf, Matthew R.; Wang, Qiaohong; Epstein, Jonathan A.] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Takeda, Norifumi; Jain, Rajan; Wang, Qiaohong; Lu, Min Min; Epstein, Jonathan A.] Univ Penn, Perelman Sch Med, Penn Cardiovasc Inst, Philadelphia, PA 19104 USA; [Takeda, Norifumi; Jain, Rajan; Wang, Qiaohong; Epstein, Jonathan A.] Univ Penn, Perelman Sch Med, Inst Regenerat Med, Philadelphia, PA 19104 USA; [LeBoeuf, Matthew R.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Epstein, JA (corresponding author), Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	epsteinj@mail.med.upenn.edu		TAKEDA, NORIFUMI/0000-0003-4818-3347; Epstein, Jonathan/0000-0001-8637-4465	American Heart Association [AHA 0825548D]; NIH [R01 HL071546, U01 HL100405]; Spain fund for Regenerative Medicine; W. W. Smith Endowed Chair; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL100405, R01HL071546] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spain fund for Regenerative Medicine; W. W. Smith Endowed Chair; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank the Epstein laboratory for helpful discussions; C. J. Lengner, A. Padmanabhan, N. Singh, and K. S. Zaret for critical reading of the manuscript; and the Penn Flow Cytometry core and C. Pletcher for assistance with FACS experiments. This work was supported by an American Heart Association Physician-Scientist/Postdoctoral fellowship to R. J. (AHA 0825548D) and funds from the NIH (R01 HL071546, U01 HL100405), the Spain fund for Regenerative Medicine, and W. W. Smith Endowed Chair to J.A.E.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Breault DT, 2008, P NATL ACAD SCI USA, V105, P10420, DOI 10.1073/pnas.0804800105; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; De Toni A, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-13; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1977, CELL TISSUE KINET, V10, P557, DOI 10.1111/j.1365-2184.1977.tb00312.x; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Vries RGJ, 2010, MOL ONCOL, V4, P373, DOI 10.1016/j.molonc.2010.05.001	23	512	530	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2011	334	6061					1420	1424		10.1126/science.1213214	http://dx.doi.org/10.1126/science.1213214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858HW	22075725	Green Accepted			2022-12-28	WOS:000297787700058
J	Jeanjean, A; Aubert, G				Jeanjean, Anne; Aubert, Genevieve			The art of medicine Moving pictures of Parkinson's disease	LANCET			English	Editorial Material									[Jeanjean, Anne; Aubert, Genevieve] Catholic Univ Louvain, Clin Univ St Luc, Ctr Med Sommeil, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Aubert, G (corresponding author), Catholic Univ Louvain, Clin Univ St Luc, Ctr Med Sommeil, B-1200 Brussels, Belgium.	genevieve.aubert@uclouvain.be							0	5	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	2011	378	9805					1773	1774		10.1016/S0140-6736(11)61765-0	http://dx.doi.org/10.1016/S0140-6736(11)61765-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851IS	22106466	Bronze			2022-12-28	WOS:000297262300014
J	Mitka, M				Mitka, Mike			Statin Therapy in Primary CVD Prevention Remains a Hot-button Topic for Some	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item							CHOLESTEROL											Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Green LA, 2010, ARCH INTERN MED, V170, P1007, DOI 10.1001/archinternmed.2010.168; MINDER MC, 2011, ARCH INTERN MED, V171, P1594; Ray KK, 2010, ARCH INTERN MED, V170, P1024, DOI 10.1001/archinternmed.2010.182; Redberg R, 2011, ARCH INTERN MED, V171, P619, DOI 10.1001/archinternmed.2010.465; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646	6	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2077	2078		10.1001/jama.2011.1664	http://dx.doi.org/10.1001/jama.2011.1664			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089707				2022-12-28	WOS:000297013000002
J	Piggott, BJ; Liu, J; Feng, ZY; Wescott, SA; Xu, XZS				Piggott, Beverly J.; Liu, Jie; Feng, Zhaoyang; Wescott, Seth A.; Xu, X. Z. Shawn			The Neural Circuits and Synaptic Mechanisms Underlying Motor Initiation in C. elegans	CELL			English	Article							BEHAVING CAENORHABDITIS-ELEGANS; GLR-1 GLUTAMATE-RECEPTOR; OPTICAL INTERROGATION; NEURONAL-ACTIVITY; NERVOUS-SYSTEM; HOMOLOG; SENSITIVITY; THERMOTAXIS; CHANNELS	C. elegans is widely used to dissect how neural circuits and genes generate behavior. During locomotion, worms initiate backward movement to change locomotion direction spontaneously or in response to sensory cues; however, the underlying neural circuits are not well defined. We applied a multidisciplinary approach to map neural circuits in freely behaving worms by integrating functional imaging, optogenetic interrogation, genetic manipulation, laser ablation, and electrophysiology. We found that a disinhibitory circuit and a stimulatory circuit together promote initiation of backward movement and that circuitry dynamics is differentially regulated by sensory cues. Both circuits require glutamatergic transmission but depend on distinct glutamate receptors. This dual mode of motor initiation control is found in mammals, suggesting that distantly related organisms with anatomically distinct nervous systems may adopt similar strategies for motor control. Additionally, our studies illustrate how a multidisciplinary approach facilitates dissection of circuit and synaptic mechanisms underlying behavior in a genetic model organism.	[Piggott, Beverly J.; Liu, Jie; Wescott, Seth A.; Xu, X. Z. Shawn] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Piggott, Beverly J.; Xu, X. Z. Shawn] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Feng, Zhaoyang] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Case Western Reserve University	Xu, XZS (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	shawnxu@umich.edu	Piggott, Beverly/GQH-4796-2022	liu, jie/0000-0002-1215-5814	NEI (University of Michigan); NIGMS; Pew scholar program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA022316] Funding Source: NIH RePORTER	NEI (University of Michigan)(University of Michigan SystemUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Pew scholar program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank J. Gao, W. Li, W. Zhou, and A. Ward for technical assistance; L. Looger for the G-CaMP3.0 plasmid; A. Gottschalk for ChR2 plasmid; K. Deisseroth for NpHR plasmid; J. Dent and L. Avery for avr-14 strains and plasmids; and P. Hu, A. Kumar, and B. Ye for comments on the manuscript. Some strains were obtained from the CGC and Knockout Consortiums in the USA and Japan. B. J. P. was supported by a predoctoral T32 training grant from the NEI (University of Michigan). This work was supported by grants from the NIGMS and Pew scholar program (to X.Z.S.X.).	Alkema MJ, 2005, NEURON, V46, P247, DOI 10.1016/j.neuron.2005.02.024; Ben Arous J, 2010, J NEUROSCI METH, V187, P229, DOI 10.1016/j.jneumeth.2010.01.011; Bloomfield SA, 2009, NAT REV NEUROSCI, V10, P495, DOI 10.1038/nrn2636; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Chalasani SH, 2007, NATURE, V450, P63, DOI 10.1038/nature06292; CHALFIE M, 1985, J NEUROSCI, V5, P956; Clark DA, 2006, J NEUROSCI, V26, P7444, DOI 10.1523/JNEUROSCI.1137-06.2006; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; de Bono M, 2005, ANNU REV NEUROSCI, V28, P451, DOI 10.1146/annurev.neuro.27.070203.144259; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Faumont S, 2006, J NEUROPHYSIOL, V95, P1976, DOI 10.1152/jn.01050.2005; Feng ZY, 2006, CELL, V127, P621, DOI 10.1016/j.cell.2006.09.035; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Gray JM, 2005, P NATL ACAD SCI USA, V102, P3184, DOI 10.1073/pnas.0409009101; Guo ZV, 2009, NAT METHODS, V6, P891, DOI 10.1038/nmeth.1397; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; Hilliard MA, 2005, EMBO J, V24, P63, DOI 10.1038/sj.emboj.7600493; Kang LJ, 2010, NEURON, V67, P381, DOI 10.1016/j.neuron.2010.06.032; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kerr R, 2000, NEURON, V26, P583, DOI 10.1016/S0896-6273(00)81196-4; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Leifer AM, 2011, NAT METHODS, V8, P147, DOI 10.1038/NMETH.1554; Liu J, 2010, NAT NEUROSCI, V13, P715, DOI 10.1038/nn.2540; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Nagel G, 2005, CURR BIOL, V15, P2279, DOI 10.1016/j.cub.2005.11.032; Ohnishi N, 2011, EMBO J, V30, P1376, DOI 10.1038/emboj.2011.13; PURVES D, 2008, NEUROSCIENCE, P397; Raizen DM, 2008, NATURE, V451, P569, DOI 10.1038/nature06535; Reigl M, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-25; Sporns O, 2004, PLOS BIOL, V2, P1910, DOI 10.1371/journal.pbio.0020369; Stirman JN, 2011, NAT METHODS, V8, P153, DOI 10.1038/NMETH.1555; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Ward A, 2008, NAT NEUROSCI, V11, P916, DOI 10.1038/nn.2155; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yates DM, 2003, INT J PARASITOL, V33, P1183, DOI 10.1016/S0020-7519(03)00172-3; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744; Zheng Y, 1999, NEURON, V24, P347, DOI 10.1016/S0896-6273(00)80849-1	40	163	165	2	44	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					922	933		10.1016/j.cell.2011.08.053	http://dx.doi.org/10.1016/j.cell.2011.08.053			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078887	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000296902300023
J	Watanabe, M; Cheng, K; Murayama, Y; Ueno, K; Asamizuya, T; Tanaka, K; Logothetis, N				Watanabe, Masataka; Cheng, Kang; Murayama, Yusuke; Ueno, Kenichi; Asamizuya, Takeshi; Tanaka, Keiji; Logothetis, Nikos			Attention But Not Awareness Modulates the BOLD Signal in the Human V1 During Binocular Suppression	SCIENCE			English	Article							PRIMARY VISUAL-CORTEX; PERCEPTUAL SUPPRESSION; SPATIAL ATTENTION; AWAKE MONKEY; RIVALRY; ABSENCE; DISCRIMINATION	Although recent psychophysical studies indicate that visual awareness and top-down attention are two distinct processes, it is not clear how they are neurally dissociated in the visual system. Using a two-by-two factorial functional magnetic resonance imaging design with binocular suppression, we found that the visibility or invisibility of a visual target led to only nonsignificant blood oxygenation level-dependent (BOLD) effects in the human primary visual cortex (V1). Directing attention toward and away from the target had much larger and robust effects across all study participants. The difference in the lower-level limit of BOLD activation between attention and awareness illustrates dissociated neural correlates of the two processes. Our results agree with previously reported V1 BOLD effects on attention, while they invite a reconsideration of the functional role of V1 in visual awareness.	[Watanabe, Masataka] Univ Tokyo, Sch Engn, Tokyo, Japan; [Watanabe, Masataka; Murayama, Yusuke; Logothetis, Nikos] Max Planck Inst Biol Cybernet, Tubingen, Germany; [Watanabe, Masataka; Cheng, Kang; Ueno, Kenichi; Asamizuya, Takeshi; Tanaka, Keiji] RIKEN, Brain Sci Inst, Wako, Saitama, Japan; [Logothetis, Nikos] Univ Manchester, Manchester, Lancs, England	University of Tokyo; Max Planck Society; RIKEN; University of Manchester	Watanabe, M (corresponding author), Univ Tokyo, Sch Engn, Tokyo, Japan.	watanabe@tuebingen.mpg.de	Logothetis, Nikos/U-9282-2019; Ueno, Kenichi/A-9395-2014; Tanaka, Keiji/N-5917-2015; Cheng, Kang/A-6448-2016	Tanaka, Keiji/0000-0002-1910-3427; Asamizuya, Takeshi/0000-0003-1004-6435; Watanabe, Masataka/0000-0003-0128-3690	Japanese Ministry of Education, Culture, Sports, Science and Technology [1702215]	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Japanese Ministry of Education, Culture, Sports, Science and Technology grant no. 1702215 (M.W.). We thank D. Voinescu for help with data collection and S. Tajima for early discussion and model simulation related to the project.	Braun J, 1998, PERCEPT PSYCHOPHYS, V60, P1, DOI 10.3758/BF03211915; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Gail A, 2004, CEREB CORTEX, V14, P300, DOI 10.1093/cercor/bhg129; Gandhi SP, 1999, P NATL ACAD SCI USA, V96, P3314, DOI 10.1073/pnas.96.6.3314; Kastner S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5; Koch C, 2007, TRENDS COGN SCI, V11, P16, DOI 10.1016/j.tics.2006.10.012; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; Li FF, 2002, P NATL ACAD SCI USA, V99, P9596, DOI 10.1073/pnas.092277599; Maier A, 2005, J VISION, V5, P668, DOI 10.1167/5.9.2; Maier A, 2008, NAT NEUROSCI, V11, P1193, DOI 10.1038/nn.2173; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Maruya K, 2008, J VISION, V8, DOI 10.1167/8.11.7; Maunsell JHR, 2002, PHILOS T ROY SOC B, V357, P1063, DOI 10.1098/rstb.2002.1107; Montaser-Kouhsari L, 2004, J VISION, V4, P434, DOI 10.1167/4.6.3; Naccache L, 2002, PSYCHOL SCI, V13, P416, DOI 10.1111/1467-9280.00474; Pascual-Leone A, 2001, SCIENCE, V292, P510, DOI 10.1126/science.1057099; Polonsky A, 2000, NAT NEUROSCI, V3, P1153, DOI 10.1038/80676; Reddy L, 2004, J VISION, V4, P106, DOI 10.1167/4.2.4; Reddy L, 2006, VISION RES, V46, P2336, DOI 10.1016/j.visres.2006.01.020; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; Silvanto J, 2005, CEREB CORTEX, V15, P1736, DOI 10.1093/cercor/bhi050; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; Tong F, 2001, NATURE, V411, P195, DOI 10.1038/35075583; Tsuchiya N, 2005, NAT NEUROSCI, V8, P1096, DOI 10.1038/nn1500; Watanabe T, 1998, P NATL ACAD SCI USA, V95, P11489, DOI 10.1073/pnas.95.19.11489; Weiskrantz I., 1986, BLINDSIGHT; Wilke M, 2006, P NATL ACAD SCI USA, V103, P17507, DOI 10.1073/pnas.0604673103	28	131	134	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					829	831		10.1126/science.1203161	http://dx.doi.org/10.1126/science.1203161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076381				2022-12-28	WOS:000296849600053
J	Devinsky, O				Devinsky, Orrin			CURRENT CONCEPTS Sudden, Unexpected Death in Epilepsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RISK-FACTORS; UNEXPLAINED DEATH; CARDIAC-ARRHYTHMIA; ICTAL HYPOXEMIA; CENTRAL APNEA; QT-SYNDROME; LONG-TERM; SUDEP; SEIZURE; MORTALITY		NYU Langone Sch Med, Dept Neurol, New York, NY 10016 USA	NYU Langone Medical Center	Devinsky, O (corresponding author), NYU Langone Sch Med, Dept Neurol, 223 E 34th St, New York, NY 10016 USA.	od4@nyu.edu		Devinsky, Orrin/0000-0003-0044-4632	UCB	UCB(UCB Pharma SA)	Dr. Devinsky reports providing expert testimony in legal medical proceedings regarding possible sudden, unexpected death in epilepsy and receiving lecture fees from UCB. No other potential conflict of interest relevant to this article was reported.	Annegers JF, 1997, EPILEPSIA, V38, pS9, DOI 10.1111/j.1528-1157.1997.tb06137.x; Aurlien D, 2010, EPILEPSIA S3, V51; Bateman LM, 2010, EPILEPSIA, V51, P2211, DOI 10.1111/j.1528-1167.2010.02594.x; Bateman LM, 2010, EPILEPSIA, V51, P916, DOI 10.1111/j.1528-1167.2009.02513.x; Bateman LM, 2008, BRAIN, V131, P3239, DOI 10.1093/brain/awn277; Bird JM, 1997, EPILEPSIA, V38, pS52, DOI 10.1111/j.1528-1167.1997.tb06295.x; Brotherstone R, 2010, EPILEPSIA, V51, P221, DOI 10.1111/j.1528-1167.2009.02281.x; Buchanan Gordon F., 2008, P529, DOI 10.1007/978-3-7643-8561-3_21; Camfield P, 2008, EPILEPSIA, V49, P40, DOI 10.1111/j.1528-1167.2008.01449.x; Carlson C, 2009, SEIZURE-EUR J EPILEP, V18, P225, DOI 10.1016/j.seizure.2008.08.007; DASHEIFF RM, 1991, J CLIN NEUROPHYSIOL, V8, P216, DOI 10.1097/00004691-199104000-00010; DASHEIFF RM, 1986, ARCH NEUROL-CHICAGO, V43, P194, DOI 10.1001/archneur.1986.00520020080028; Devinsky Orrin, 2004, Epilepsy Curr, V4, P43, DOI 10.1111/j.1535-7597.2004.42001.x; Donner EJ, 2001, NEUROLOGY, V57, P430, DOI 10.1212/WNL.57.3.430; Duncan JR, 2010, JAMA-J AM MED ASSOC, V303, P430, DOI 10.1001/jama.2010.45; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; Espinosa PS, 2009, NEUROLOGY, V72, P1702, DOI 10.1212/WNL.0b013e3181a55f90; Ficker DM, 1998, NEUROLOGY, V51, P1270, DOI 10.1212/WNL.51.5.1270; Gayatri NA, 2010, EPILEPSIA, V51, P777, DOI 10.1111/j.1528-1167.2009.02483.x; Gillberg C, 2010, J AUTISM DEV DISORD, V40, P352, DOI 10.1007/s10803-009-0883-4; Glasscock E, 2010, J NEUROSCI, V30, P5167, DOI 10.1523/JNEUROSCI.5591-09.2010; Hermann BP, 2002, PROG BRAIN RES, V135, P429; Hesdorffer DC, 2011, EPILEPSIA, V52, P1150, DOI 10.1111/j.1528-1167.2010.02952.x; HEWERTSON J, 1994, PEDIATRICS, V94, P148; Hitiris N, 2007, EPILEPSY BEHAV, V10, P138, DOI 10.1016/j.yebeh.2006.11.010; Johnson JN, 2009, NEUROLOGY, V72, P224, DOI 10.1212/01.wnl.0000335760.02995.ca; Johnston SC, 1997, ANN NEUROL, V42, P588, DOI 10.1002/ana.410420409; Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439; Langan Y, 2005, NEUROLOGY, V64, P1131, DOI 10.1212/01.WNL.0000156352.61328.CB; Langan Y, 2000, J NEUROL NEUROSUR PS, V68, P211, DOI 10.1136/jnnp.68.2.211; Le Gal F, 2010, EPILEPSIA, V51, P1915, DOI 10.1111/j.1528-1167.2010.02691.x; Lhatoo SD, 2010, ANN NEUROL, V68, P787, DOI 10.1002/ana.22101; Morton B, 2006, J NEUROL NEUROSUR PS, V77, P199, DOI 10.1136/jnnp.2005.066852; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x; Nei M, 2004, EPILEPSIA, V45, P338, DOI 10.1111/j.0013-9580.2004.05503.x; Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9; Nilsson L, 2003, EPILEPSIA, V44, P575, DOI 10.1046/j.1528-1157.2003.03302.x; Nilsson L, 2001, EPILEPSIA, V42, P667, DOI 10.1046/j.1528-1157.2001.22000.x; Opeskin K, 2003, SEIZURE-EUR J EPILEP, V12, P456, DOI 10.1016/S1059-1311(02)00352-7; Opeskin K, 1999, EPILEPSIA, V40, P1795, DOI 10.1111/j.1528-1157.1999.tb01600.x; PACIA SV, 1994, NEUROLOGY, V44, P1408, DOI 10.1212/WNL.44.8.1408; Persson H, 2003, EPILEPSY RES, V57, P69, DOI 10.1016/j.eplepsyres.2003.10.012; Reddy Doodipala Samba, 2010, Expert Rev Clin Pharmacol, V3, P183, DOI 10.1586/ecp.10.3; Richerson GB, 2011, EPILEPSIA, V52, P28, DOI 10.1111/j.1528-1167.2010.02908.x; Ridsdale L, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X572463; Rugg-Gunn FJ, 2004, LANCET, V364, P2212, DOI 10.1016/S0140-6736(04)17594-6; Ryvlin P, 2011, LANCET NEUROL   0919; Schuele SU, 2009, J CLIN NEUROPHYSIOL, V26, P302, DOI 10.1097/WNP.0b013e3181b7f13b; Sevcencu C, 2010, EPILEPSIA, V51, P725, DOI 10.1111/j.1528-1167.2009.02479.x; Seyal M, 2010, EPILEPSIA, V51, P1359, DOI 10.1111/j.1528-1167.2009.02518.x; Shen HY, 2010, EPILEPSIA, V51, P465, DOI 10.1111/j.1528-1167.2009.02248.x; Sillanpaa M, 2010, NEW ENGL J MED, V363, P2522, DOI 10.1056/NEJMoa0911610; So EL, 2000, EPILEPSIA, V41, P1494, DOI 10.1111/j.1528-1157.2000.tb00128.x; Sperling M, 2010, EPILEPSIA S2, V51, P320; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Surges R, 2010, NEUROLOGY, V74, P421, DOI 10.1212/WNL.0b013e3181ccc706; Surges R, 2010, EPILEPSIA, V51, P233, DOI 10.1111/j.1528-1167.2009.02330.x; Swallow RA, 2002, SEIZURE-EUR J EPILEP, V11, P446, DOI 10.1053/seiz.2002.0683; Tao JX, 2010, EPILEPSIA, V51, P2344, DOI 10.1111/j.1528-1167.2010.02719.x; Thom M, 2003, NEUROPATH APPL NEURO, V29, P132, DOI 10.1046/j.1365-2990.2003.00452.x; Thomas P, 1996, EPILEPSIES, V8, P339; Tomson T, 2005, EPILEPSIA, V46, P54, DOI 10.1111/j.1528-1167.2005.00411.x; Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3; Uteshev VV, 2010, EPILEPSY RES, V88, P183, DOI 10.1016/j.eplepsyres.2009.11.004; Walczak TS, 2001, NEUROLOGY, V56, P519, DOI 10.1212/WNL.56.4.519	66	222	227	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1801	1811		10.1056/NEJMra1010481	http://dx.doi.org/10.1056/NEJMra1010481			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070477				2022-12-28	WOS:000296762800009
J	Fortune, ES; Rodriguez, C; Li, D; Ball, GF; Coleman, MJ				Fortune, Eric S.; Rodriguez, Carlos; Li, David; Ball, Gregory F.; Coleman, Melissa J.			Neural Mechanisms for the Coordination of Duet Singing in Wrens	SCIENCE			English	Article							WHITE-CROWNED SPARROW; BLACK-BELLIED WREN; THRYOTHORUS WRENS; ZEBRA FINCHES; SONG SYSTEM; NEURONS; SELECTIVITY; HVC; REPRESENTATION; COMMUNICATION	Plain-tailed wrens (Pheugopedius euophrys) cooperate to produce a duet song in which males and females rapidly alternate singing syllables. We examined how sensory information from each wren is used to coordinate singing between individuals for the production of this cooperative behavior. Previous findings in nonduetting songbird species suggest that premotor circuits should encode each bird's own contribution to the duet. In contrast, we find that both male and female wrens encode the combined cooperative output of the pair of birds. Further, behavior and neurophysiology show that both sexes coordinate the timing of their singing based on feedback from the partner and suggest that females may lead the duet.	[Fortune, Eric S.; Li, David; Ball, Gregory F.] Johns Hopkins Univ, Dept Neurosci, Dept Psychol & Brain Sci, Baltimore, MD 21218 USA; [Fortune, Eric S.; Rodriguez, Carlos] Pontificia Univ Catolica Ecuador, Museo Zool, Quito, Ecuador; [Coleman, Melissa J.] Pitzer Coll, Claremont Mckenna Coll, WM Keck Sci Dept, Claremont, CA 91711 USA; [Coleman, Melissa J.] Scripps Coll, Claremont, CA 91711 USA	Johns Hopkins University; Pontificia Universidad Catolica del Ecuador; Claremont Colleges; Claremont Graduate School; Claremont McKenna College; Pitzer College; Claremont Colleges; Scripps College	Fortune, ES (corresponding author), Johns Hopkins Univ, Dept Neurosci, Dept Psychol & Brain Sci, 3400 N Charles St, Baltimore, MD 21218 USA.	eric.fortune@gmail.com	Rodríguez, Carlos A/H-4881-2011	Rodríguez, Carlos A/0000-0001-8077-7263; Rodriguez-Saltos, Carlos/0000-0002-3162-7645; Fortune, Eric/0000-0001-6447-5425; Ball, Gregory/0000-0002-4784-0520	Museum of Zoology (QCAZ), Pontificia Universidad Catolica del Ecuador in Quito; NSF [IOS-0817918]; Johns Hopkins University; Claremont McKenna College; Pitzer College; Scripps College	Museum of Zoology (QCAZ), Pontificia Universidad Catolica del Ecuador in Quito; NSF(National Science Foundation (NSF)); Johns Hopkins University(Johns Hopkins University); Claremont McKenna College; Pitzer College; Scripps College	This research would not have been possible without the help and support of S. Burneo, curator, Museum of Zoology (QCAZ), Pontificia Universidad Catolica del Ecuador in Quito. This project used equipment previously purchased with funds from NSF award IOS-0817918 to E. S. F. Support was also provided by the Johns Hopkins University and Claremont McKenna, Pitzer, Scripps Colleges. We thank H. Greeney, J. Simbana, R. Jarrin, A. Saa, and K. Cisneros for logistical support; N. Cowan, J. Knierim, R. Krahe, and H. Zakon for helpful discussions and feedback; and D. Margoliash for his advice and insights. Behavioral and neurophysiological data are available upon request. Animal tissues are archived in the QCAZ in Quito, Ecuador, and are available in accordance with the relevant laws and regulations of the Republic of Ecuador.	Clayton NS, 2007, PHILOS T R SOC B, V362, P507, DOI 10.1098/rstb.2006.1992; Coleman MJ, 2004, J NEUROSCI, V24, P7251, DOI 10.1523/JNEUROSCI.0947-04.2004; Crawford M.P., 1937, COMP PSYCHOL MONOGR, V14, P1; Dave AS, 2000, SCIENCE, V290, P812, DOI 10.1126/science.290.5492.812; Edwards CJ, 2002, NAT NEUROSCI, V5, P934, DOI 10.1038/nn916; FORTUNE ES, 1995, J COMP NEUROL, V360, P413, DOI 10.1002/cne.903600305; Hoare DJ, 2004, ANIM BEHAV, V67, P155, DOI 10.1016/j.anbehav.2003.04.004; Levin RN, 1996, ANIM BEHAV, V52, P1107, DOI 10.1006/anbe.1996.0258; Logue DM, 2008, ANIM BEHAV, V75, P1803, DOI 10.1016/j.anbehav.2007.10.036; Logue DM, 2007, ANIM BEHAV, V73, P105, DOI 10.1016/j.anbehav.2006.05.011; Long MA, 2008, NATURE, V456, P189, DOI 10.1038/nature07448; Long MA, 2010, NATURE, V468, P394, DOI 10.1038/nature09514; Mann NI, 2006, MOL PHYLOGENET EVOL, V40, P750, DOI 10.1016/j.ympev.2006.04.014; Mann NI, 2006, BIOL LETTERS, V2, P1, DOI 10.1098/rsbl.2005.0373; Mann NI, 2009, BEHAVIOUR, V146, P1, DOI 10.1163/156853908X390913; MARGOLIASH D, 1994, BRAIN BEHAV EVOLUT, V44, P247, DOI 10.1159/000113580; MARGOLIASH D, 1992, J NEUROSCI, V12, P4309; MARGOLIASH D, 1986, J NEUROSCI, V6, P1643; MARGOLIASH D, 1983, J NEUROSCI, V3, P1039; Mooney R, 2001, P NATL ACAD SCI USA, V98, P12778, DOI 10.1073/pnas.221453298; Mooney R, 2000, J NEUROSCI, V20, P5420, DOI 10.1523/JNEUROSCI.20-14-05420.2000; Nick TA, 2005, J NEUROBIOL, V62, P469, DOI 10.1002/neu.20115; Noe R, 2006, ANIM BEHAV, V71, P1, DOI 10.1016/j.anbehav.2005.03.037; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; Peron F, 2011, ANIM COGN, V14, P545, DOI 10.1007/s10071-011-0389-2; Prather JF, 2008, NATURE, V451, P305, DOI 10.1038/nature06492; Solis MM, 1997, J NEUROSCI, V17, P6447; Tinbergen N, 1951, STUDY INSTINCT; VU ET, 1994, J NEUROSCI, V14, P6924; Wheatcroft DJ, 2008, TRENDS ECOL EVOL, V23, P416, DOI 10.1016/j.tree.2008.04.011	30	63	64	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					666	670		10.1126/science.1209867	http://dx.doi.org/10.1126/science.1209867			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053048				2022-12-28	WOS:000296494700054
J	Ramsey, BW; Davies, J; McElvaney, NG; Tullis, E; Bell, SC; Drevinek, P; Griese, M; McKone, EF; Wainwright, CE; Konstan, MW; Moss, R; Ratjen, F; Sermet-Gaudelus, I; Rowe, SM; Dong, QM; Rodriguez, S; Yen, K; Ordonez, C; Elborn, JS				Ramsey, Bonnie W.; Davies, Jane; McElvaney, N. Gerard; Tullis, Elizabeth; Bell, Scott C.; Drevinek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia; Elborn, J. Stuart		VX08 770 102 Study Grp	A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PSEUDOMONAS-AERUGINOSA; PULMONARY-FUNCTION; IDENTIFICATION; QUESTIONNAIRE; AZITHROMYCIN; MECHANISMS; GUIDELINES; HEALTH; VX-770	Background Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis. Methods We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation. Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 hours (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 weeks. The primary end point was the estimated mean change from baseline through week 24 in the percent of predicted forced expiratory volume in 1 second (FEV1). Results The change from baseline through week 24 in the percent of predicted FEV1 was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P < 0.001). Effects on pulmonary function were noted by 2 weeks, and a significant treatment effect was maintained through week 48. Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P < 0.001). In addition, through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher numbers indicating a lower effect of symptoms on the patient's quality of life) (P < 0.001). By 48 weeks, patients treated with ivacaftor had gained, on average, 2.7 kg more weight than had patients receiving placebo (P < 0.001). The change from baseline through week 48 in the concentration of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per liter (P < 0.001). The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%). Conclusions Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks. Substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride. (Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.)	[Ramsey, Bonnie W.] Univ Washington, Dept Pediat, Seattle, WA 98105 USA; [Davies, Jane] Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, Res Biomed Res Unit, London, England; [McElvaney, N. Gerard] Beaumont Hosp, Royal Coll Surg Ireland, Beaumont, TX USA; [McKone, Edward F.; Wainwright, Claire E.] St Vincents Univ Hosp, Dublin 4, Ireland; [Ratjen, Felix] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Bell, Scott C.] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld 4032, Australia; [Bell, Scott C.; Wainwright, Claire E.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Drevinek, Pavel] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague, Czech Republic; [Griese, Matthias] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Konstan, Michael W.] Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Moss, Richard] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Tullis, Elizabeth] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Sermet-Gaudelus, Isabelle] Hop Necker Enfants Malad, Ctr Invest Clin, Paris, France; [Rowe, Steven M.] Univ Alabama Birmingham, Birmingham, AL USA; [Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia] Vertex Pharmaceut, Cambridge, MA USA; [Elborn, J. Stuart] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Ramsey, Bonnie W.] Seattle Childrens Hosp, Seattle, WA USA	University of Washington; University of Washington Seattle; Royal Brompton & Harefield NHS Foundation Trust; University College Dublin; Saint Vincent's University Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Prince Charles Hospital; University of Queensland; Charles University Prague; University of Munich; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Stanford University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Alabama System; University of Alabama Birmingham; Vertex Pharmaceuticals; Queens University Belfast; Seattle Children's Hospital	Ramsey, BW (corresponding author), Univ Washington, Dept Pediat, 4800 Sand Point Way NE,Box 5371, Seattle, WA 98105 USA.	bonnie.ramsey@seattlechildrens.org	Bell, Scott/AAJ-4298-2020; Wainwright, Claire E/G-4218-2013; Bell, Scott C/A-7241-2011; Moss, Richard B./S-9218-2019; McElvaney, Noel/A-6809-2010; Serisier, David/C-6986-2012	Bell, Scott/0000-0001-8651-7139; Wainwright, Claire E/0000-0001-8389-3809; Bell, Scott C/0000-0001-8651-7139; Moss, Richard B./0000-0003-3611-4221; Serisier, David/0000-0002-7484-7904; elborn, joseph/0000-0002-2323-442X; Boyle, Michael/0000-0002-9740-1630; Mainz, Jochen G./0000-0003-3780-7759; Davies, Jane/0000-0003-3506-1199; Fajac, Isabelle/0000-0002-1532-1486; mcelvaney, Noel/0000-0002-0152-4370; Ratjen, Felix/0000-0003-4057-6592; Konstan, Michael/0000-0002-0557-7277	Vertex Pharmaceuticals; National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield National Health Service Foundation Trust; Imperial College London; Cystic Fibrosis Foundation Therapeutic Development Center; Institute for Translational Health Sciences; National Center for Research Resources of the National Institutes of Health (NIH) [UL1 RR025014, UL1 RR024153, UL1 RR 025005]; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center; Clinical Translational Research Center [UL1-RR-024134]; NIH [UL1 RR024989, P30 DK27651, UL1 RR 025758, K23 DK075788, 5UL1 RR025777, 1UL1 RR025744]; Northern Ireland Clinical Research Network (Respiratory Medicine);  [VX08-770-102]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758, UL1RR025005, UL1RR025744, UL1RR025777, UL1RR024153, UL1RR025014, UL1RR024134, UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK089507, P30DK027651, K23DK075788] Funding Source: NIH RePORTER	Vertex Pharmaceuticals(Vertex Pharmaceuticals); National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield National Health Service Foundation Trust; Imperial College London(General Electric); Cystic Fibrosis Foundation Therapeutic Development Center; Institute for Translational Health Sciences; National Center for Research Resources of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center; Clinical Translational Research Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Northern Ireland Clinical Research Network (Respiratory Medicine); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.; Supported by Vertex Pharmaceuticals; grants from the National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London; grants from the Cystic Fibrosis Foundation Therapeutic Development Center; the Institute for Translational Health Sciences; the National Center for Research Resources of the National Institutes of Health (NIH) (UL1 RR025014 to the University of Washington, UL1 RR024153 to Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, and UL1 RR 025005 to Johns Hopkins University); the Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center (to Seattle Children's Hospital); Clinical Translational Research Center (UL1-RR-024134 to the University of Pennsylvania/Children's Hospital of Philadelphia); and the NIH (UL1 RR024989 and P30 DK27651 to Case Western Reserve University, UL1 RR 025758 to Children's Hospital Boston, K23 DK075788 and 5UL1 RR025777 to the University of Alabama at Birmingham, and 1UL1 RR025744 to Stanford University); and an infrastructure grant from Northern Ireland Clinical Research Network (Respiratory Medicine).	Accurso FJ, 2010, NEW ENGL J MED, V363, P1991, DOI 10.1056/NEJMoa0909825; Cystic Fibrosis Foundation, 2009, PAT REG 2008 ANN DAT; DURIE PR, 1989, J ROY SOC MED, V82, P11; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Farrell PM, 2008, J CYST FIBROS, V7, P450, DOI 10.1016/j.jcf.2008.03.007; Farrell PM, 2008, J PEDIATR-US, V153, pS4, DOI 10.1016/j.jpeds.2008.05.005; Flume PA, 2007, AM J RESP CRIT CARE, V176, P957, DOI 10.1164/rccm.200705-664OC; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Goss CH, 2007, J CYST FIBROS, V6, P117, DOI 10.1016/j.jcf.2006.05.012; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LeGrys VA, 2000, PEDIATR PULM, V30, P476, DOI 10.1002/1099-0496(200012)30:6<476::AID-PPUL7>3.3.CO;2-F; McKone EF, 2003, LANCET, V361, P1671, DOI 10.1016/S0140-6736(03)13368-5; Quittner AL, 2005, CHEST, V128, P2347, DOI 10.1378/chest.128.4.2347; Quittner AL, 2009, CHEST, V135, P1610, DOI 10.1378/chest.08-1190; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; Saiman L, 2010, JAMA-J AM MED ASSOC, V303, P1707, DOI 10.1001/jama.2010.563; Sanders DB, 2010, AM J RESP CRIT CARE, V182, P627, DOI 10.1164/rccm.200909-1421OC; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Welsh MJ, 2001, METABOLIC MOL BASES, P521	26	1475	1521	5	219	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1663	1672		10.1056/NEJMoa1105185	http://dx.doi.org/10.1056/NEJMoa1105185			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047557	Green Accepted, Green Published			2022-12-28	WOS:000296424200005
J	Spence, D				Spence, Des			FROM THE FRONTLINE Advance advance directives	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	2	2	1	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2011	343								d7074	10.1136/bmj.d7074	http://dx.doi.org/10.1136/bmj.d7074			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QC	22049528				2022-12-28	WOS:000296761400010
J	Xu, YM; Masuko, S; Takieddin, M; Xu, HM; Liu, RP; Jing, J; Mousa, SA; Linhardt, RJ; Liu, J				Xu, Yongmei; Masuko, Sayaka; Takieddin, Majde; Xu, Haoming; Liu, Renpeng; Jing, Juliana; Mousa, Shaker A.; Linhardt, Robert J.; Liu, Jian			Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins	SCIENCE			English	Article							ENZYMATIC-SYNTHESIS; SULFATE; ANTICOAGULANTS; WARFARIN; SULFOTRANSFERASES; OLIGOSACCHARIDES; ANTITHROMBOTICS; PENTASACCHARIDE; THROMBOLYTICS; GENERATION	Ultralow molecular weight (ULMW) heparins are sulfated glycans that are clinically used to treat thrombotic disorders. ULMW heparins range from 1500 to 3000 daltons, corresponding from 5 to 10 saccharide units. The commercial drug Arixtra (fondaparinux sodium) is a structurally homogeneous ULMW heparin pentasaccharide that is synthesized through a lengthy chemical process. Here, we report 10- and 12-step chemoenzymatic syntheses of two structurally homogeneous ULMW heparins (MW = 1778.5 and 1816.5) in 45 and 37% overall yield, respectively, starting from a simple disaccharide. These ULMW heparins display excellent in vitro anticoagulant activity and comparable pharmacokinetic properties to Arixtra, as demonstrated in a rabbit model. The chemoenzymatic approach is scalable and shows promise for a more efficient route to synthesize this important class of medicinal agent.	[Masuko, Sayaka; Linhardt, Robert J.] Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Dept Chem & Chem Biol, Troy, NY 12180 USA; [Xu, Yongmei; Xu, Haoming; Liu, Renpeng; Jing, Juliana; Liu, Jian] Univ N Carolina, Eshelman Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; [Takieddin, Majde; Mousa, Shaker A.] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Albany, NY 12208 USA; [Mousa, Shaker A.] King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia	Rensselaer Polytechnic Institute; University of North Carolina; University of North Carolina Chapel Hill; Albany College of Pharmacy & Health Sciences; King Saud University	Linhardt, RJ (corresponding author), Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Dept Chem & Chem Biol, Troy, NY 12180 USA.	linhar@rpi.edu; jian_liu@unc.edu	Liu, Renpeng/G-1625-2011; Mousa, Shaker A/A-7151-2017	Mousa, Shaker A/0000-0002-9294-015X; Xu, Haoming/0000-0002-5151-0727	National Institutes of Health [AI50050, HL094463, AI074775, HL62244, HL096972, GM38060]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL094463, R01HL096972, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050, R21AI074775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported in part by National Institutes of Health grants AI50050, HL094463, AI074775, HL62244, HL096972, and GM38060. The authors thank Q. Shi (University of North Carolina) for insightful discussion. A provisional patent application describing the chemoenzymatic synthesis of ULMW heparins has been filed with the U.S. Patent and Trademark Office (61/426,921).	Burkart MD, 2000, J ORG CHEM, V65, P5565, DOI 10.1021/jo000266o; Chen JH, 2005, J BIOL CHEM, V280, P42817, DOI 10.1074/jbc.M504338200; Chen J, 2007, CHEM BIOL, V14, P986, DOI 10.1016/j.chembiol.2007.07.015; Chen M, 2006, BIOCHEMISTRY-US, V45, P12358, DOI 10.1021/bi060844g; Guerrini M, 2008, NAT BIOTECHNOL, V26, P669, DOI 10.1038/nbt1407; Hirsh J, 2007, CIRCULATION, V116, P552, DOI 10.1161/CIRCULATIONAHA.106.685974; Hughes B, 2010, NAT REV DRUG DISCOV, V9, P1, DOI 10.1038/nrd3322; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Lindahl U, 2005, J MED CHEM, V48, P349, DOI 10.1021/jm049812m; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINHARDT RJ, 1992, BIOCHEMISTRY-US, V31, P12441, DOI 10.1021/bi00164a020; Liu HY, 2009, NAT PROD REP, V26, P313, DOI 10.1039/b819896a; Liu J, 2007, APPL MICROBIOL BIOT, V74, P263, DOI 10.1007/s00253-006-0722-x; Liu RP, 2010, J BIOL CHEM, V285, P34240, DOI 10.1074/jbc.M110.159152; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; Mackman N, 2008, NATURE, V451, P914, DOI 10.1038/nature06797; Martinez-Gonzalez J, 2010, EXPERT REV CARDIOVAS, V8, P625, DOI [10.1586/erc.10.35, 10.1586/ERC.10.35]; Mousa SA, 2010, METHODS MOL BIOL, V663, P1, DOI 10.1007/978-1-60761-803-4_1; Mousa SA, 2010, METHODS MOL BIOL, V663, P29, DOI 10.1007/978-1-60761-803-4_2; Peterson S, 2009, NAT PROD REP, V26, P610, DOI 10.1039/b803795g; Petitou M, 2004, ANGEW CHEM INT EDIT, V43, P3118, DOI 10.1002/anie.200300640; Petitou M., 1989, U.S. Patent, Patent No. [4,818,816, 4818816]; Seifert J., 2009, U. S. Patent, Patent No. [7,541,445B2, 7541445]; Sismey-Ragatz AE, 2007, J BIOL CHEM, V282, P28321, DOI 10.1074/jbc.M701599200; Tobu M, 2004, CLIN APPL THROMB-HEM, V10, P301, DOI 10.1177/107602960401000402; Wang ZY, 2010, BIOTECHNOL BIOENG, V107, P964, DOI 10.1002/bit.22898; Weitz JI, 2007, EXPERT OPIN INV DRUG, V16, P271, DOI 10.1517/13543784.16.3.271; Weitz JI, 2010, THROMB RES, V125, pS30, DOI 10.1016/S0049-3848(10)70009-8; WEITZ JI, 2005, HEMATOLOGY BASIC PRI, P2249; Xu D, 2008, NAT CHEM BIOL, V4, P200, DOI 10.1038/nchembio.66; Zhang ZQ, 2008, J AM CHEM SOC, V130, P12998, DOI 10.1021/ja8026345; Zhou XX, 2011, GLYCOBIOLOGY, V21, P771, DOI 10.1093/glycob/cwr001	32	299	317	8	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					498	501		10.1126/science.1207478	http://dx.doi.org/10.1126/science.1207478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034431	Green Accepted, Green Submitted			2022-12-28	WOS:000296230500043
J	Hawton, K; O'Connor, RC				Hawton, Keith; O'Connor, Rory C.			Self-harm in adolescence and future mental health	LANCET			English	Editorial Material							YOUNG ADULTHOOD; SCHOOLS		[Hawton, Keith] Univ Oxford, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England; [O'Connor, Rory C.] Univ Stirling, Sch Nat Sci, Suicidal Behav Res Grp, Stirling, Scotland	University of Oxford; University of Stirling	Hawton, K (corresponding author), Univ Oxford, Dept Psychiat, Ctr Suicide Res, Oxford OX3 7JX, England.	keith.hawton@psych.ox.ac.uk						De Leo D, 2004, MED J AUSTRALIA, V181, P140, DOI 10.5694/j.1326-5377.2004.tb06204.x; Donnellan MB, 2007, J PERS, V75, P237, DOI 10.1111/j.1467-6494.2007.00438.x; Fergusson DM, 2005, PSYCHOL MED, V35, P983, DOI 10.1017/S0033291704004167; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2003, J CHILD PSYCHOL PSYC, V44, P1191, DOI 10.1111/1469-7610.00200; Hawton K, 2010, EUR CHILD ADOLES PSY, V19, P513, DOI 10.1007/s00787-009-0065-0; Madge N, 2008, J CHILD PSYCHOL PSYC, V49, P667, DOI 10.1111/j.1469-7610.2008.01879.x; McMahon EM, 2010, SOC SCI MED, V71, P1300, DOI 10.1016/j.socscimed.2010.06.034; Moran P, 2012, LANCET, V379, P236, DOI 10.1016/S0140-6736(11)61141-0; O'Connor RC, 2009, SUICIDE LIFE-THREAT, V39, P364, DOI 10.1521/suli.2009.39.4.364; O'Connor RC, 2009, BRIT J PSYCHIAT, V194, P68, DOI 10.1192/bjp.bp.107.047704; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Patton GC, 2007, J AM ACAD CHILD PSY, V46, P508, DOI 10.1097/chi.0b013e31803065c7	13	18	18	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					198	199		10.1016/S0140-6736(11)61260-9	http://dx.doi.org/10.1016/S0140-6736(11)61260-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22100202				2022-12-28	WOS:000299316100013
J	Pocar, M; Bregasi, A; Passolunghi, D; Donatelli, F				Pocar, Marco; Bregasi, Alda; Passolunghi, Davide; Donatelli, Francesco			A free-floating left atrial mass	LANCET			English	Editorial Material									[Pocar, Marco; Bregasi, Alda; Passolunghi, Davide; Donatelli, Francesco] Univ Milan, MultiMed Hosp, Inst Sci, Dept Cardiovasc Sci, I-20099 Milan, Italy	University of Milan	Pocar, M (corresponding author), Univ Milan, MultiMed Hosp, Inst Sci, Dept Cardiovasc Sci, Via Milanese 300, I-20099 Milan, Italy.	marco.pocar@unimi.it	Donatelli, Francesco/G-9311-2012	Donatelli, Francesco/0000-0003-2839-0373; Pocar, Marco/0000-0003-3728-4863					0	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	2012	379	9811					152	152		10.1016/S0140-6736(11)60818-0	http://dx.doi.org/10.1016/S0140-6736(11)60818-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879GM	22056244	Bronze			2022-12-28	WOS:000299317700037
J	Al-Hadithy, N; Mordecai, SC; Papanna, MC				Al-Hadithy, Nawfal; Mordecai, Simon C.; Papanna, Madhavan C.			An injury in a child's elbow	BRITISH MEDICAL JOURNAL			English	Editorial Material							SUPRACONDYLAR FRACTURES; OPERATIVE TREATMENT; CUBITUS VARUS; HUMERUS; MANAGEMENT		[Al-Hadithy, Nawfal; Mordecai, Simon C.; Papanna, Madhavan C.] Luton & Dunstable Hosp, Luton LU4 0DZ, Beds, England		Al-Hadithy, N (corresponding author), Luton & Dunstable Hosp, Luton LU4 0DZ, Beds, England.	Nawfal@yahoo.com	Papanna, Madhavan C/ABB-8618-2020					AMIS AA, 1995, INJURY, V26, P163, DOI 10.1016/0020-1383(95)93494-3; GARTLAND JJ, 1959, SURG GYNECOL OBSTET, V109, P145; Hadlow AT, 1996, J PEDIATR ORTHOPED, V16, P104, DOI 10.1097/01241398-199601000-00021; Heal J, 2007, J Orthop Surg (Hong Kong), V15, P12; Humar R, 2001, J ORTHOP SURG, V9, P37; Jain AK, 2000, ARCH ORTHOP TRAUM SU, V120, P420, DOI 10.1007/s004029900102; LABELLE H, 1982, J PEDIATR ORTHOPED, V2, P539, DOI 10.1097/01241398-198212000-00014; MURPHY WA, 1977, RADIOLOGY, V124, P659, DOI 10.1148/124.3.659; Skaggs DL, 2008, J PEDIATR ORTHOPED, V28, P139, DOI 10.1097/BPO.0b013e3181653ac8; Skaggs DL, 1999, J BONE JOINT SURG AM, V81A, P1429, DOI 10.2106/00004623-199910000-00007; Skaggs DL, 2001, J BONE JOINT SURG AM, V83A, P735, DOI 10.2106/00004623-200105000-00013; Wilkins K, 1984, FRACTURES CHILDREN, P680; WILKINS KE, 1990, ORTHOP CLIN N AM, V21, P269	13	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2011	343								d6279	10.1136/bmj.d6279	http://dx.doi.org/10.1136/bmj.d6279			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	875FA	22108261				2022-12-28	WOS:000299014600001
J	Schaedler, TA; Jacobsen, AJ; Torrents, A; Sorensen, AE; Lian, J; Greer, JR; Valdevit, L; Carter, WB				Schaedler, T. A.; Jacobsen, A. J.; Torrents, A.; Sorensen, A. E.; Lian, J.; Greer, J. R.; Valdevit, L.; Carter, W. B.			Ultralight Metallic Microlattices	SCIENCE			English	Article							MICROSCALE TRUSS STRUCTURES; BEHAVIOR; COLLAPSE; FOAMS	Ultralight (<10 milligrams per cubic centimeter) cellular materials are desirable for thermal insulation; battery electrodes; catalyst supports; and acoustic, vibration, or shock energy damping. We present ultralight materials based on periodic hollow-tube microlattices. These materials are fabricated by starting with a template formed by self-propagating photopolymer waveguide prototyping, coating the template by electroless nickel plating, and subsequently etching away the template. The resulting metallic microlattices exhibit densities rho >= 0.9 milligram per cubic centimeter, complete recovery after compression exceeding 50% strain, and energy absorption similar to elastomers. Young's modulus E scales with density as E similar to rho(2), in contrast to the E similar to rho(3) scaling observed for ultralight aerogels and carbon nanotube foams with stochastic architecture. We attribute these properties to structural hierarchy at the nanometer, micrometer, and millimeter scales.	[Schaedler, T. A.; Jacobsen, A. J.; Sorensen, A. E.; Carter, W. B.] HRL Labs Ltd Liabil Co, Malibu, CA 90265 USA; [Torrents, A.; Valdevit, L.] Univ Calif Irvine, Dept Mech & Aerosp Engn, Irvine, CA 92697 USA; [Lian, J.; Greer, J. R.] CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA	HRL Laboratories; University of California System; University of California Irvine; California Institute of Technology	Schaedler, TA (corresponding author), HRL Labs Ltd Liabil Co, Malibu, CA 90265 USA.	taschaedler@hrl.com		Valdevit, Lorenzo/0000-0001-9525-7148	Defense Advanced Research Projects Agency [W91CRB-10-0305]	Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA))	The authors gratefully acknowledge the financial support by Defense Advanced Research Projects Agency under the Materials with Controlled Microstructural Architecture program managed by J. Goldwasser (contract no. W91CRB-10-0305) and thank J. W. Hutchinson and C. S. Roper for useful discussions. A patent application regarding the structure and formation process of the ultralight microlattices has been submitted to the U.S. Patent and Trademark Office. The polymer waveguide process has been patented (U.S. Patent 7,382,959, U.S. Patent 7,653,279, and U.S. Patent 8,017,193), but the template can be fabricated in other ways.	[Anonymous], 1999, HEXWEB HON ATTR PROP; Ashby M F, 2000, METAL FOAMS DESIGN G, P43; B. A. S. F. Corporation, 2007, MAT SAF DAT SHEET BA; Cao AY, 2005, SCIENCE, V310, P1307, DOI 10.1126/science.1118957; Chanda M., 2007, PLASTICS TECHNOLOGY; Chang SY, 2006, METALL MATER TRANS A, V37A, P2939, DOI 10.1007/s11661-006-0175-y; Deshpande VS, 2001, J MECH PHYS SOLIDS, V49, P1747, DOI 10.1016/S0022-5096(01)00010-2; Deshpande VS, 2001, INT J SOLIDS STRUCT, V38, P6275, DOI 10.1016/S0020-7683(01)00103-2; Deshpande VS, 2001, ACTA MATER, V49, P1035, DOI 10.1016/S1359-6454(00)00379-7; Gibson J.L., 1997, CELLULAR SOLIDS STRU, DOI [10.1017/cbo9781139878326, DOI 10.1017/CBO9781139878326]; GIBSON LJ, 1982, P ROY SOC LOND A MAT, V382, P43, DOI 10.1098/rspa.1982.0088; GROSS J, 1993, MAT SCI ENG A-STRUCT, V168, P235; GUINNESS BOOK OF WORLD RECORDS, 2003, GUINNESS BOOK WORLD; Jacobsen AJ, 2008, ACTA MATER, V56, P2540, DOI 10.1016/j.actamat.2008.01.051; Jacobsen AJ, 2007, ACTA MATER, V55, P6724, DOI 10.1016/j.actamat.2007.08.036; Jacobsen AJ, 2007, ADV MATER, V19, P3892, DOI 10.1002/adma.200700797; LAKES R, 1993, NATURE, V361, P511, DOI 10.1038/361511a0; Lee GF, 1998, J SOUND VIB, V211, P265, DOI 10.1006/jsvi.1997.1387; Lian J, 2011, NANO LETT, V11, P4118, DOI 10.1021/nl202475p; Ma HS, 2001, J NON-CRYST SOLIDS, V285, P216, DOI 10.1016/S0022-3093(01)00456-2; Mills NJ, 2006, CELL POLYM, V25, P293, DOI 10.1177/026248930602500502; Moner-Girona M, 1999, APPL PHYS LETT, V75, P653, DOI 10.1063/1.124471; PARK SH, 1988, J MATER SCI, V23, P1643, DOI 10.1007/BF01115703; Tappan BC, 2006, J AM CHEM SOC, V128, P6589, DOI 10.1021/ja056550k; TILLOTSON TM, 1992, J NON-CRYST SOLIDS, V145, P44, DOI 10.1016/S0022-3093(05)80427-2; Trelewicz JR, 2007, ACTA MATER, V55, P5948, DOI 10.1016/j.actamat.2007.07.020; Verdooren A, 2006, J AM CERAM SOC, V89, P3101, DOI 10.1111/j.1551-2916.2006.01225.x; Worsley MA, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3086293; Zou JH, 2010, ACS NANO, V4, P7293, DOI 10.1021/nn102246a	29	1120	1187	48	1190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					962	965		10.1126/science.1211649	http://dx.doi.org/10.1126/science.1211649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096194				2022-12-28	WOS:000297101800051
J	Giacovazzo, C				Giacovazzo, Carmelo			Herbert Hauptman (1917-2011) OBITUARY	NATURE			English	Biographical-Item									Univ Bari, Ist Cristallog, CNR, I-70126 Bari, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR); Universita degli Studi di Bari Aldo Moro	Giacovazzo, C (corresponding author), Univ Bari, Ist Cristallog, CNR, Via G Amendola 122-O, I-70126 Bari, Italy.	carmelo.giacovazzo@ic.cnr.it							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					300	300		10.1038/479300a	http://dx.doi.org/10.1038/479300a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094683	Bronze			2022-12-28	WOS:000297059700024
J	Salgo, R				Salgo, Rebekka			A 41 year old man with an itchy rash	BRITISH MEDICAL JOURNAL			English	Editorial Material							PSORIATIC-ARTHRITIS; RISK; RECOMMENDATIONS; DEPRESSION; PREVALENCE; MANAGEMENT; DISEASES; THERAPY; DRUGS		JW Goethe Univ Frankfurt, Dept Dermatol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Salgo, R (corresponding author), JW Goethe Univ Frankfurt, Dept Dermatol, D-60590 Frankfurt, Germany.	rebekka.salgo@kgu.de	Hug, Balthasar L./G-1568-2010					Basavaraj KH, 2010, INT J DERMATOL, V49, P1351, DOI 10.1111/j.1365-4632.2010.04570.x; Boehncke WH, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5666; Burden AD, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5623; Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Heiberg MS, 2007, ANN RHEUM DIS, V66, P1038, DOI 10.1136/ard.2006.064808; Kimball AB, 2008, J AM ACAD DERMATOL, V58, P1031, DOI 10.1016/j.jaad.2008.01.006; Kurd SK, 2010, ARCH DERMATOL, V146, P891, DOI 10.1001/archdermatol.2010.186; Naldi L, 2008, DERMATOLOGY, V217, P365, DOI 10.1159/000156599; Pathirana D, 2009, J EUR ACAD DERMATOL, V23, P1, DOI 10.1111/j.1468-3083.2009.03389.x; PEETERS AJ, 1992, BRIT J RHEUMATOL, V31, P502; Prodanovich S, 2009, ARCH DERMATOL, V145, P700, DOI 10.1001/archdermatol.2009.94; Qureshi AA, 2008, J RHEUMATOL, V35, P1423; Radtke MA, 2009, J EUR ACAD DERMATOL, V23, P683, DOI 10.1111/j.1468-3083.2009.03159.x; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Ritchlin CT, 2009, ANN RHEUM DIS, V68, P1387, DOI 10.1136/ard.2008.094946; Schmitt J, 2010, J EUR ACAD DERMATOL, V24, P885, DOI 10.1111/j.1468-3083.2009.03537.x; Smith CH, 2006, BMJ-BRIT MED J, V333, P380, DOI 10.1136/bmj.333.7564.380; Stern RS, 2010, J INVEST DERMATOL, V130, P917, DOI 10.1038/jid.2009.446; Van Voorhees AS, 2009, POSTGRAD MED, V121, P154, DOI 10.3810/pgm.2009.07.2040; Wakkee M, 2009, ACTA DERM-VENEREOL, V89, P476, DOI 10.2340/00015555-0688	20	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2011	343								d7320	10.1136/bmj.d7320	http://dx.doi.org/10.1136/bmj.d7320			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875FU	22094319				2022-12-28	WOS:000299016600003
J	Slatkovska, L; Alibhai, SMH; Beyene, J; Hu, HX; Demaras, A; Cheung, AM				Slatkovska, Lubomira; Alibhai, Shabbir M. H.; Beyene, Joseph; Hu, Hanxian; Demaras, Alice; Cheung, Angela M.			Effect of 12 Months of Whole-Body Vibration Therapy on Bone Density and Structure in Postmenopausal Women A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							MECHANICAL SIGNALS; LOW-LEVEL; MUSCLE STRENGTH; LOW-MAGNITUDE; FREQUENCY; OSTEOPOROSIS; RISK; HIP; MUSCULOSKELETAL; PREVENTION	Background: Although data from studies in animals demonstrated beneficial effects of whole-body vibration (WBV) therapy on bone, clinical trials in postmenopausal women showed conflicting results. Objective: To determine whether WBV improves bone density and structure. Design: A 12-month, single-center, superiority, randomized, controlled trial with 3 parallel groups. (ClinicalTrials.gov registration number: NCT00420940) Setting: Toronto General Hospital, Ontario, Canada. Participants: 202 healthy postmenopausal women with bone mineral density (BMD) T-scores between -1.0 and -2.5 who were not receiving prescription bone medications. Intervention: Participants were randomly assigned to 1 of 3 groups (1:1:1 ratio) by using a block-randomization scheme and sealed envelopes. They were asked to stand on a low-magnitude (0.3g) 90-Hz or 30-Hz WBV platform for 20 minutes daily or to serve as control participants; all participants received calcium and vitamin D. Measurements: Bone outcome assessors, who were blinded to group assignment, determined trabecular volumetric BMD and other measurements of the distal tibia and distal radius with high-resolution peripheral quantitative computed tomography and areal BMD with dual-energy x-ray absorptiometry at baseline and at 12 months. Results: 12 months of WBV therapy had no significant effect on any bone outcomes compared with no WBV therapy. For the primary outcome of tibial trabecular volumetric BMD, mean change from baseline was 0.4 mg/cm(3) (95% CI, -0.4 to 1.2 mg/cm(3)) in the 90-Hz WBV group, -0.1 mg/cm(3) (CI, -1.0 to 0.8 mg/cm(3)) in the 30-Hz WBV group, and -0.2 mg/cm(3) (CI, -1.1 to 0.6 mg/cm(3)) in the control group (P = 0.55). Changes in areal BMD at the femoral neck, total hip, and lumbar spine were also similar among the groups. Overall, low-magnitude WBV at both 90 and 30 Hz was well-tolerated. Limitations: Adherence to WBV ranged from 65% to 79%. Double-blinding was not possible. Conclusion: Whole-body vibration therapy at 0.3g and 90 or 30 Hz for 12 months did not alter BMD or bone structure in postmenopausal women who received calcium and vitamin D supplementation.	[Slatkovska, Lubomira; Alibhai, Shabbir M. H.; Beyene, Joseph; Hu, Hanxian; Demaras, Alice; Cheung, Angela M.] Mt Sinai Hosp, Univ Hlth Network, Toronto, ON M5G 1X5, Canada; [Slatkovska, Lubomira; Alibhai, Shabbir M. H.; Beyene, Joseph; Hu, Hanxian; Demaras, Alice; Cheung, Angela M.] Univ Toronto, Toronto, ON, Canada; [Slatkovska, Lubomira; Alibhai, Shabbir M. H.; Beyene, Joseph; Hu, Hanxian; Demaras, Alice; Cheung, Angela M.] McMaster Univ, Hamilton, ON L8N 3Z5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University Health Network Toronto; University of Toronto; McMaster University	Cheung, AM (corresponding author), Toronto Gen Hosp, Univ Hlth Network, 200 Elizabeth St,7 Eaton N,Room 221, Toronto, ON M5G 2C4, Canada.	angela.cheung@uhn.ca		Alibhai, Shabbir/0000-0001-7815-6046; Cheung, Angela M./0000-0001-8332-0744	Physicians' Services Incorporated Foundation [06-28]; Canadian Institutes of Health Research/Institute of Gender and Health (CIHR/IGH); University of Toronto	Physicians' Services Incorporated Foundation; Canadian Institutes of Health Research/Institute of Gender and Health (CIHR/IGH)(Canadian Institutes of Health Research (CIHR)); University of Toronto(University of Toronto)	By peer-reviewed grant 06-28 from the Physicians' Services Incorporated Foundation, a Canadian Institutes of Health Research/Institute of Gender and Health (CIHR/IGH) Doctoral Research Award (Dr. Slatkovska), and a CIHR/IGH Senior Investigator Award and the Lillian Love Chair in Women's Health at the University of Toronto (Dr. Cheung).	[Anonymous], 2006, Harv Womens Health Watch, V14, P7; Beck BR, 2010, AM J PHYS MED REHAB, V89, P997, DOI 10.1097/PHM.0b013e3181f71063; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Cheung AM, 2004, CAN MED ASSOC J, V170, P1665, DOI 10.1503/cmaj.1030757; Cheung AM, 2008, INT SOC CLIN DENS 14; Cheung AM, 2008, PLOS MED, V5, P1461, DOI 10.1371/journal.pmed.0050196; Cheung AM, 2008, JAMA-J AM MED ASSOC, V299, P1468, DOI 10.1001/jama.299.12.1468; Craven BC, EFFECTIVENESS VIBRAT; Flieger J, 1998, CALCIFIED TISSUE INT, V63, P510, DOI 10.1007/s002239900566; Garman R, 2007, J ORTHOP RES, V25, P732, DOI 10.1002/jor.20354; Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612; Griffin MJ, 1998, IND HEALTH, V36, P83, DOI 10.2486/indhealth.36.83; Gusi N, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-92; Hung A, 2011, MATURITAS, V69, P168, DOI 10.1016/j.maturitas.2011.02.016; Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157; Judex S, 2002, FASEB J, V16, P1280, DOI 10.1096/fj.01-0913fje; Judex S, 2010, J MUSCULOSKEL NEURON, V10, P3; Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014; Kiel DP, VIBES LOW MAGNITUDE; Kiiski J, 2008, J BONE MINER RES, V23, P1318, DOI [10.1359/jbmr.080315, 10.1359/JBMR.080315]; Lam T, IMPROVING LOW BONE M; Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239; Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771; Prisby RD, 2008, AGEING RES REV, V7, P319, DOI 10.1016/j.arr.2008.07.004; Qin L, 2002, ARCH PHYS MED REHAB, V83, P1355, DOI 10.1053/apmr.2002.35098; Rauch F, 2010, J MUSCULOSKEL NEURON, V10, P193; Reid I.R, 2008, PRIMER METABOLIC BON, V7, P95; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756-3282(01)00689-5; Rubin C, 2003, SPINE, V28, P2621, DOI 10.1097/01.BRS.0000102682.61791.C9; Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251; Russo CR, 2003, ARCH PHYS MED REHAB, V84, P1854, DOI 10.1016/S0003-9993(03)00357-5; Slatkovska L, 2010, OSTEOPOROSIS INT, V21, P1969, DOI 10.1007/s00198-010-1228-z; Thompson AMS, 2010, OCCUP MED-OXFORD, V60, P572, DOI 10.1093/occmed/kqq107; Verschueren SMP, 2011, J BONE MINER RES, V26, P42, DOI 10.1002/jbmr.181; Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245; Wilson HW, 1997, MED SCI SPORT EXER, V29, pS62	37	76	81	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10					668	+		10.7326/0003-4819-155-10-201111150-00005	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-00005			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EI	22084333				2022-12-28	WOS:000297108000003
J	Wang, XN; Winter, D; Ashrafi, G; Schlehe, J; Wong, YL; Selkoe, D; Rice, S; Steen, J; LaVoie, MJ; Schwarz, TL				Wang, Xinnan; Winter, Dominic; Ashrafi, Ghazaleh; Schlehe, Julia; Wong, Yao Liang; Selkoe, Dennis; Rice, Sarah; Steen, Judith; LaVoie, Matthew J.; Schwarz, Thomas L.			PINK1 and Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial Motility	CELL			English	Article							AXONAL-TRANSPORT; PINK1/PARKIN PATHWAY; DOPAMINERGIC-NEURONS; DEFICIENT MICE; DROSOPHILA; DISEASE; MUTATIONS; MITOPHAGY; INTERACTS; KINESIN	Cells keep their energy balance and avoid oxidative stress by regulating mitochondrial movement, distribution, and clearance. We report here that two Parkinson's disease proteins, the Ser/Thr kinase PINK1 and ubiquitin ligase Parkin, participate in this regulation by arresting mitochondrial movement. PINK1 phosphorylates Miro, a component of the primary motor/adaptor complex that anchors kinesin to the mitochondrial surface. The phosphorylation of Miro activates proteasomal degradation of Miro in a Parkin-dependent manner. Removal of Miro from the mitochondrion also detaches kinesin from its surface. By preventing mitochondrial movement, the PINK1/Parkin pathway may quarantine damaged mitochondria prior to their clearance. PINK1 has been shown to act upstream of Parkin, but the mechanism corresponding to this relationship has not been known. We propose that PINK1 phosphorylation of substrates triggers the subsequent action of Parkin and the proteasome.	[Wang, Xinnan; Ashrafi, Ghazaleh; Steen, Judith; Schwarz, Thomas L.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Winter, Dominic; Steen, Judith] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; [Wang, Xinnan; Schwarz, Thomas L.] Harvard Univ, Sch Med, Dept Neurobiol, Cambridge, MA 02138 USA; [Ashrafi, Ghazaleh] Harvard Univ, Dept Mol Cellular Biol, Cambridge, MA 02138 USA; [Schlehe, Julia; Selkoe, Dennis; LaVoie, Matthew J.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; [Wong, Yao Liang; Rice, Sarah] Northwestern Univ, Dept Cell & Mol Biol, Evanston, IL 60208 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard University; Harvard University; Brigham & Women's Hospital; Northwestern University	Schwarz, TL (corresponding author), Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.	thomas.schwarz@childrens.harvard.edu	Gelfand, Vladimir I/D-2545-2013; Winter, Dominic/A-2408-2014; Wang, Xinnan/B-2393-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Winter, Dominic/0000-0001-6788-6641; LaVoie, Matthew/0000-0002-2583-1578; Wong, Yao Liang/0000-0003-0298-8510	Ellison Medical Foundation; Hartman Foundation for Parkinson's Research; NIH [GM069808, NS065013, K99NS067066]; LSRF Novartis; IDDRC [P30HD18655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS065013, K99NS067066, R00NS067066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER	Ellison Medical Foundation(Lawrence Ellison Foundation); Hartman Foundation for Parkinson's Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LSRF Novartis; IDDRC; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Drs. P. Aspenstrom, A. M. Craig, M. Guo, B. Lu, R. Youle, M. Haigis, and G. Hajnoczky for reagents and S. Vasquez and Dr. M. Sahin for assistance with hippocampal cultures. This work was supported by the Ellison Medical Foundation (T. L. S.), Hartman Foundation for Parkinson's Research (T. L. S.), NIH GM069808 (T. L. S.), NIH NS065013 (M.J.L.), NIH K99NS067066 (X. W.), LSRF Novartis Fellowship (X. W.), and the proteomics, imaging, and molecular genetics cores of the IDDRC (grant number P30HD18655).	Berger AK, 2009, HUM MOL GENET, V18, P4317, DOI 10.1093/hmg/ddp384; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Deas E, 2011, HUM MOL GENET, V20, P867, DOI 10.1093/hmg/ddq526; Deng HS, 2008, P NATL ACAD SCI USA, V105, P14503, DOI 10.1073/pnas.0803998105; Exner N, 2007, J NEUROSCI, V27, P12413, DOI 10.1523/JNEUROSCI.0719-07.2007; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Frederick RL, 2007, TRAFFIC, V8, P1668, DOI 10.1111/j.1600-0854.2007.00644.x; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Gautier CA, 2008, P NATL ACAD SCI USA, V105, P11364, DOI 10.1073/pnas.0802076105; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Glater EE, 2006, J CELL BIOL, V173, P545, DOI 10.1083/jcb.200601067; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Karbowski M, 2011, CURR OPIN CELL BIOL, V23, P476, DOI 10.1016/j.ceb.2011.05.007; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; MacAskill AF, 2009, NEURON, V61, P541, DOI 10.1016/j.neuron.2009.01.030; Misko A, 2010, J NEUROSCI, V30, P4232, DOI 10.1523/JNEUROSCI.6248-09.2010; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Park JH, 2003, DEVELOPMENT, V130, P2645, DOI 10.1242/dev.00503; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; Poole AC, 2008, P NATL ACAD SCI USA, V105, P1638, DOI 10.1073/pnas.0709336105; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Pozo KBK, 2011, BBA-MOL CELL RES, V1813, P269, DOI 10.1016/j.bbamcr.2010.10.011; Saotome M, 2008, P NATL ACAD SCI USA, V105, P20728, DOI 10.1073/pnas.0808953105; Schon EA, 2011, NEURON, V70, P1033, DOI 10.1016/j.neuron.2011.06.003; Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Surmeier DJ, 2010, PROG BRAIN RES, V183, P59, DOI 10.1016/S0079-6123(10)83004-3; Twig G, 2010, AM J PHYSIOL-CELL PH, V299, pC477, DOI 10.1152/ajpcell.00427.2009; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Laar VS, 2011, HUM MOL GENET, V20, P927, DOI 10.1093/hmg/ddq531; Venderova K, 2009, HUM MOL GENET, V18, P4390, DOI 10.1093/hmg/ddp394; Vives-Bauza C, 2011, TRENDS MOL MED, V17, P158, DOI 10.1016/j.molmed.2010.11.002; Wang XN, 2009, METHOD ENZYMOL, V457, P319, DOI 10.1016/S0076-6879(09)05018-6; Wang XN, 2009, CELL, V136, P163, DOI 10.1016/j.cell.2008.11.046; Weihofen A, 2009, BIOCHEMISTRY-US, V48, P2045, DOI 10.1021/bi8019178; Whitworth AJ, 2009, J BIOENERG BIOMEMBR, V41, P499, DOI 10.1007/s10863-009-9253-3; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhou C, 2008, P NATL ACAD SCI USA, V105, P12022, DOI 10.1073/pnas.0802814105; Ziviani E, 2010, P NATL ACAD SCI USA, V107, P5018, DOI 10.1073/pnas.0913485107	47	819	843	2	125	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					893	906		10.1016/j.cell.2011.10.018	http://dx.doi.org/10.1016/j.cell.2011.10.018			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078885	Bronze, Green Accepted			2022-12-28	WOS:000296902300021
J	Wilusz, JE; Whipple, JM; Phizicky, EM; Sharp, PA				Wilusz, Jeremy E.; Whipple, Joseph M.; Phizicky, Eric M.; Sharp, Phillip A.			tRNAs Marked with CCACCA Are Targeted for Degradation	SCIENCE			English	Article							MATURE TRANSFER-RNA; RAPID TRANSFER-RNA; ADDING ENZYME; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; POLYMERIZATION; SUBSTRATE; TEMPLATE; END; NUCLEOTIDYLTRANSFERASE	The CCA-adding enzyme [ATP(CTP): tRNA nucleotidyltransferase] adds CCA to the 3' ends of transfer RNAs (tRNAs), a critical step in tRNA biogenesis that generates the amino acid attachment site. We found that the CCA-adding enzyme plays a key role in tRNA quality control by selectively marking structurally unstable tRNAs and tRNA-like small RNAs for degradation. Instead of adding CCA to the 3' ends of these transcripts, CCA-adding enzymes from all three kingdoms of life add CCACCA. In addition, hypomodified mature tRNAs are subjected to CCACCA addition as part of a rapid tRNA decay pathway in vivo. We conjecture that CCACCA addition is a universal mechanism for controlling tRNA levels and preventing errors in translation.	[Wilusz, Jeremy E.; Sharp, Phillip A.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Wilusz, Jeremy E.; Sharp, Phillip A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Whipple, Joseph M.; Phizicky, Eric M.] Univ Rochester, Sch Med, Dept Biochem & Biophys, Ctr RNA Biol, Rochester, NY 14642 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Rochester	Wilusz, JE (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	wilusz@mit.edu	Wilusz, Jeremy/AAG-4628-2020	Wilusz, Jeremy/0000-0001-6929-8755	NIH [5T32-GM068411, R01-GM34277, R01-CA133404, R01-GM52347]; Cancer Center from the National Cancer Institute [P30-CA14051]; NATIONAL CANCER INSTITUTE [R01CA133404, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277, R01GM052347, T32GM068411] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center from the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Weiner for providing CCA-adding enzyme expression plasmids; A. Leshinsky and D. Cook for performing the deep sequencing; E. Conti for providing the Rrp44 protein; O. Tam, A. Gordon, and G. Hannon for help with the deep sequencing analysis; and C. Koehrer, T. RajBhandary, P. Schimmel, D. Spector, C. Wilusz, J. Wilusz, and members of the Sharp and Phizicky laboratories for discussions and advice. J.E.W. is a fellow of the Leukemia and Lymphoma Society. Supported by NIH Training Grant in Cellular, Biochemical and Molecular Sciences 5T32-GM068411 (J.M.W.); NIH grants R01-GM34277 (P.A.S.), R01-CA133404 (P.A.S.), and R01-GM52347 (E.M.P.); and Cancer Center Support (core) Grant P30-CA14051 from the National Cancer Institute (P.A.S.).	Alexandrov A, 2006, MOL CELL, V21, P87, DOI 10.1016/j.molcel.2005.10.036; Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Betat H, 2010, CELL MOL LIFE SCI, V67, P1447, DOI 10.1007/s00018-010-0271-4; Chernyakov I, 2008, GENE DEV, V22, P1369, DOI 10.1101/gad.1654308; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; Korostelev A, 2006, CELL, V126, P1065, DOI 10.1016/j.cell.2006.08.032; Kotelawala L, 2008, RNA, V14, P158, DOI 10.1261/rna.811008; Leigh J, 2004, RNA, V10, P615, DOI 10.1261/rna.5195504; LONERGAN KM, 1993, SCIENCE, V259, P812, DOI 10.1126/science.8430334; Lorentzen E, 2008, MOL CELL, V29, P717, DOI 10.1016/j.molcel.2008.02.018; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; Pan BC, 2010, SCIENCE, V330, P937, DOI 10.1126/science.1194985; Phizicky EM, 2010, GENE DEV, V24, P1832, DOI 10.1101/gad.1956510; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; Sunwoo H, 2009, GENOME RES, V19, P347, DOI 10.1101/gr.087775.108; Thompson DM, 2009, CELL, V138, P215, DOI 10.1016/j.cell.2009.07.001; Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712; Vincent HA, 2006, J BIOL CHEM, V281, P29769, DOI 10.1074/jbc.M606744200; Whipple JM, 2011, GENE DEV, V25, P1173, DOI [10.1101/gad.2050711, 10.1101/gad.2050711.]; Wilusz JE, 2010, RNA, V16, P259, DOI 10.1261/rna.1907510; Wilusz JE, 2008, CELL, V135, P919, DOI 10.1016/j.cell.2008.10.012; Xiong Y, 2006, CURR OPIN STRUC BIOL, V16, P12, DOI 10.1016/j.sbi.2005.12.001; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Yue DX, 1996, RNA, V2, P895	28	109	116	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					817	821		10.1126/science.1213671	http://dx.doi.org/10.1126/science.1213671			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076379	Green Accepted, Green Submitted			2022-12-28	WOS:000296849600050
J	Shaw, D				Shaw, David			PERSONAL VIEW The ICMJE's definition of authorship is illogical and unethical	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Glasgow, Fac Med, Glasgow G2 3JZ, Lanark, Scotland	University of Glasgow	Shaw, D (corresponding author), Univ Glasgow, Fac Med, Glasgow G2 3JZ, Lanark, Scotland.	davidmartinshaw@gmail.com							0	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d7192	10.1136/bmj.d7192	http://dx.doi.org/10.1136/bmj.d7192			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NH	22065677	Green Accepted			2022-12-28	WOS:000297057800017
J	McGehee, MD				McGehee, Michael D.			Paradigm Shifts in Dye-Sensitized Solar Cells	SCIENCE			English	Editorial Material							EFFICIENCY		Stanford Univ, Dept Mat Sci, Stanford, CA 94305 USA	Stanford University	McGehee, MD (corresponding author), Stanford Univ, Dept Mat Sci, Stanford, CA 94305 USA.	mmcgehee@stanford.edu	McGehee, Michael/ABA-8400-2020	McGehee, Michael/0000-0001-9609-9030				Atwater HA, 2010, NAT MATER, V9, P205, DOI [10.1038/nmat2629, 10.1038/NMAT2629]; Boschloo G, 2009, ACCOUNTS CHEM RES, V42, P1819, DOI 10.1021/ar900138m; Chiba Y, 2006, JPN J APPL PHYS 2, V45, pL638, DOI 10.1143/JJAP.45.L638; Ding IK, 2011, ADV ENERGY MATER, V1, P52, DOI 10.1002/aenm.201000041; Feldt SM, 2010, J AM CHEM SOC, V132, P16714, DOI 10.1021/ja1088869; Hagfeldt A, 2010, CHEM REV, V110, P6595, DOI 10.1021/cr900356p; Hardin BE, 2009, NAT PHOTONICS, V3, P406, DOI 10.1038/NPHOTON.2009.96; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Yella A, 2011, SCIENCE, V334, P629, DOI 10.1126/science.1209688	9	54	54	0	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					607	608		10.1126/science.1212818	http://dx.doi.org/10.1126/science.1212818			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053034				2022-12-28	WOS:000296494700035
J	Woollings, T				Woollings, Tim			Ocean Effects of Blocking	SCIENCE			English	Editorial Material							NORTH-ATLANTIC OSCILLATION; CLIMATE; CIRCULATION; STREAM		Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England	University of Reading	Woollings, T (corresponding author), Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England.	t.j.woollings@reading.ac.uk		Woollings, Tim/0000-0002-5815-9079				Benedict JJ, 2004, J ATMOS SCI, V61, P121, DOI 10.1175/1520-0469(2004)061<0121:SVOTNA>2.0.CO;2; Compo GP, 2011, Q J ROY METEOR SOC, V137, P1, DOI 10.1002/qj.776; Croci-Maspoli M, 2009, MON WEATHER REV, V137, P664, DOI 10.1175/2008MWR2533.1; Czaja A, 2011, Q J ROY METEOR SOC, V137, P1095, DOI 10.1002/qj.814; Gastineau G, 2012, CLIM DYNAM, V39, P37, DOI 10.1007/s00382-011-1109-y; Hakkinen S, 2011, SCIENCE, V334, P655, DOI 10.1126/science.1205683; Knight JR, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024233; Kushnir Y, 2002, J CLIMATE, V15, P2233, DOI 10.1175/1520-0442(2002)015<2233:AGRTES>2.0.CO;2; Kwon YO, 2010, J CLIMATE, V23, P3249, DOI 10.1175/2010JCLI3343.1; Lohmann K, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039166; Matsueda M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046557; Rennert KJ, 2009, J CLIMATE, V22, P5650, DOI 10.1175/2009JCLI2669.1; Rodwell MJ, 1999, NATURE, V398, P320, DOI 10.1038/18648; Scaife AA, 2010, J CLIMATE, V23, P6143, DOI 10.1175/2010JCLI3728.1; Woollings T, 2010, Q J ROY METEOR SOC, V136, P856, DOI 10.1002/qj.625	15	12	12	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					612	613		10.1126/science.1214167	http://dx.doi.org/10.1126/science.1214167			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053038				2022-12-28	WOS:000296494700039
J	Tulsky, JA; Arnold, RM; Alexander, SC; Olsen, MK; Jeffreys, AS; Rodriguez, KL; Skinner, CS; Farrell, D; Abernethy, AP; Pollak, KI				Tulsky, James A.; Arnold, Robert M.; Alexander, Stewart C.; Olsen, Maren K.; Jeffreys, Amy S.; Rodriguez, Keri L.; Skinner, Celette Sugg; Farrell, David; Abernethy, Amy P.; Pollak, Kathryn I.			Enhancing Communication Between Oncologists and Patients With a Computer-Based Training Program A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							ADVANCED CANCER; PRIMARY-CARE; SCOPE TRIAL; SKILLS; QUALITY; PHYSICIAN; EFFICACY; MODEL; TRUST; LIFE	Background: Quality cancer care requires addressing patients' emotions, which oncologists infrequently do. Multiday courses can teach oncologists skills to handle emotion; however, such workshops are long and costly. Objective: To test whether a brief, computerized intervention improves oncologist responses to patient expressions of negative emotion. Design: Randomized, controlled, parallel-group trial stratified by site, sex, and oncologic specialty. Oncologists were randomly assigned to receive a communication lecture or the lecture plus a tailored CD-ROM. (ClinicalTrials. gov registration number: NCT00276627) Setting: Oncology clinics at a comprehensive cancer center and Veterans Affairs Medical Center in Durham, North Carolina, and a comprehensive cancer center in Pittsburgh, Pennsylvania. Participants: 48 medical, gynecologic, and radiation oncologists and 264 patients with advanced cancer. Intervention: Oncologists were randomly assigned in a 1: 1 ratio to receive an interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations. Measurements: Postintervention audio recordings were used to identify the number of empathic statements and responses to patients' expressions of negative emotion. Surveys evaluated patients' trust in their oncologists and perceptions of their oncologists' communication skills. Results: Oncologists in the intervention group used more empathic statements (relative risk, 1.9 [95% Cl, 1.1 to 3.3]; P = 0.024) and were more likely to respond to negative emotions empathically (odds ratio, 2.1 [Cl, 1.1 to 4.2]; P = 0.028) than control oncologists. Patients of intervention oncologists reported greater trust in their oncologists than did patients of control oncologists (estimated mean difference, 0.1 [Cl, 0.0 to 0.2]; P = 0.036). There was no significant difference in perceptions of communication skills. Limitations: Long-term effects were not examined. The findings may not be generalizable outside of academic medical centers. Conclusion: A brief computerized intervention improves how oncologists respond to patients' expressions of negative emotions. Primary Funding Source: National Cancer Institute.	Duke Univ, Vet Affairs Med Ctr, Durham, NC 27705 USA; People Designs, Durham, NC USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of Texas System; University of Texas Southwestern Medical Center Dallas	Tulsky, JA (corresponding author), Duke Univ, Ctr Palliat Care, Hock Plaza,Suite 1105,2424 Erwin Rd,Box 2720, Durham, NC 27705 USA.	jtulsky@duke.edu			National Cancer Institute [R01 CA100387]; NATIONAL CANCER INSTITUTE [R01CA100387] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	By grant R01 CA100387 from the National Cancer Institute.	Alexander SC, 2006, ACAD MED, V81, P1008, DOI 10.1097/01.ACM.0000242580.83851.ad; ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; Back AL, 2007, ARCH INTERN MED, V167, P453, DOI 10.1001/archinte.167.5.453; Bandura A., 1986, SOCIAL FDN THOUGHT A; Block SD, 1996, JAMA-J AM MED ASSOC, V276, P677, DOI 10.1001/jama.276.9.677; Butow P, 2008, PSYCHO-ONCOLOGY, V17, P209, DOI 10.1002/pon.1217; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Dy S, 2007, BMJ-BRIT MED J, V334, P511, DOI 10.1136/bmj.39127.653704.80; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Fischer GS, 2000, TOPICS PALLIATIVE CA; Foley KM, 2001, IMPROVING PALLIATIVE; Hedeker D., 2006, LONGITUDINAL DATA AN; Jenkins V, 2002, J CLIN ONCOL, V20, P765, DOI 10.1200/JCO.20.3.765; Koropchak CM, 2006, PALLIATIVE MED, V20, P813, DOI 10.1177/0269216306070657; Lee YY, 2009, SOC SCI MED, V68, P1060, DOI 10.1016/j.socscimed.2008.12.033; Lewin SA, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003267; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; Maguire P, 1996, EUR J CANCER, V32A, P1486, DOI 10.1016/0959-8049(96)00059-7; MAGUIRE P, 1985, BRIT MED J, V291, P1711, DOI 10.1136/bmj.291.6510.1711; Mercer SW, 2002, BRIT J GEN PRACT, V52, pS9; Meredith LS, 2001, MED CARE, V39, P349, DOI 10.1097/00005650-200104000-00006; Moore PM, 2004, COMMUNICATION SKILLS; Moss AH, 2008, CLIN J AM SOC NEPHRO, V3, P1379, DOI 10.2215/CJN.00940208; POCOCK SJ, 1979, BIOMETRICS, V35, P183, DOI 10.2307/2529944; Pollak KI, 2007, J CLIN ONCOL, V25, P5748, DOI 10.1200/JCO.2007.12.4180; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Rochon J, 1998, STAT MED, V17, P1643, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1643::AID-SIM869>3.0.CO;2-3; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; Shilling V, 2003, PSYCHO-ONCOL, V12, P599, DOI 10.1002/pon.731; Skinner CS, 2009, PATIENT EDUC COUNS, V77, P90, DOI 10.1016/j.pec.2009.02.010; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; Spiegel D, 1996, BRIT J PSYCHIAT, V168, P109, DOI 10.1192/S0007125000298486; Stark D, 2002, J CLIN ONCOL, V20, P3137, DOI 10.1200/JCO.2002.08.549; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3; Wilson KG, 2007, J CLIN ONCOL, V25, P1691, DOI 10.1200/JCO.2006.08.6801; Zabora J, 2001, PSYCHO-ONCOL, V10, P19, DOI 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6	38	175	178	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					593	U64		10.7326/0003-4819-155-9-201111010-00007	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	842PW	22041948	Green Accepted			2022-12-28	WOS:000296612400004
J	Boyce, N; Evans, G				Boyce, Niall; Evans, Gareth			The art of medicine Nothing but flowers	LANCET			English	Editorial Material									[Boyce, Niall; Evans, Gareth] The Lancet, London NW1 7BY, England		Evans, G (corresponding author), The Lancet, London NW1 7BY, England.	garethhevans@hotmail.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 29	2011	378	9802					1541	1542		10.1016/S0140-6736(11)61543-2	http://dx.doi.org/10.1016/S0140-6736(11)61543-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844SL	22043491				2022-12-28	WOS:000296767500014
J	Johansen, JP; Cain, CK; Ostroff, LE; LeDoux, JE				Johansen, Joshua P.; Cain, Christopher K.; Ostroff, Linnaea E.; LeDoux, Joseph E.			Molecular Mechanisms of Fear Learning and Memory	CELL			English	Review							LONG-TERM POTENTIATION; GATED CALCIUM-CHANNELS; BETA-ADRENERGIC-RECEPTORS; SIGNAL-REGULATED KINASE; I ADENYLYL-CYCLASE; LATERAL AMYGDALA; SYNAPTIC PLASTICITY; CONDITIONED FEAR; NEUROTROPHIC FACTOR; PROTEIN-SYNTHESIS	Pavlovian fear conditioning is a particularly useful behavioral paradigm for exploring the molecular mechanisms of learning and memory because a well-defined response to a specific environmental stimulus is produced through associative learning processes. Synaptic plasticity in the lateral nucleus of the amygdala (LA) underlies this form of associative learning. Here, we summarize the molecular mechanisms that contribute to this synaptic plasticity in the context of auditory fear conditioning, the form of fear conditioning best understood at the molecular level. We discuss the neurotransmitter systems and signaling cascades that contribute to three phases of auditory fear conditioning: acquisition, consolidation, and reconsolidation. These studies suggest that multiple intracellular signaling pathways, including those triggered by activation of Hebbian processes and neuromodulatory receptors, interact to produce neural plasticity in the LA and behavioral fear conditioning. Collectively, this body of research illustrates the power of fear conditioning as a model system for characterizing the mechanisms of learning and memory in mammals and potentially for understanding fear-related disorders, such as PTSD and phobias.	[Johansen, Joshua P.; Cain, Christopher K.; Ostroff, Linnaea E.; LeDoux, Joseph E.] NYU, Ctr Neural Sci, New York, NY 10003 USA; [Johansen, Joshua P.] RIKEN Brain Sci Inst, Lab Neural Circuitry Memory, Wako, Saitama 3510198, Japan; [Cain, Christopher K.; LeDoux, Joseph E.] Nathan S Kline Inst Psychiat Res, Emot Brain Inst, Orangeburg, NY 10962 USA	New York University; RIKEN; Nathan Kline Institute for Psychiatric Research	LeDoux, JE (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	ledoux@cns.nyu.edu	Johansen, Joshua/N-8010-2015	Johansen, Joshua/0000-0003-4240-1550; Ostroff, Linnaea/0000-0002-3348-342X; Cain, Christopher/0000-0002-3929-6094	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046516, R01MH038774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA029053] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA029053-02, R01 DA029053-01, R01 DA029053] Funding Source: Medline; NIMH NIH HHS [R01 MH038774, R01 MH038774-25, R01 MH038774-26, R01 MH046516, R01 MH046516-20, R01 MH046516-21A1] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Alberini CM, 2006, CELL MOL LIFE SCI, V63, P999, DOI 10.1007/s00018-006-6025-7; Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; Apergis-Schoute AM, 2005, J NEUROSCI, V25, P5730, DOI 10.1523/JNEUROSCI.0096-05.2005; Bailey CH, 2000, NAT REV NEUROSCI, V1, P11, DOI 10.1038/35036191; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Bailey DJ, 1999, BEHAV NEUROSCI, V113, P276, DOI 10.1037/0735-7044.113.2.276; Bauer EP, 2002, J NEUROSCI, V22, P5239, DOI 10.1523/JNEUROSCI.22-12-05239.2002; Ben Mamou C, 2006, NAT NEUROSCI, V9, P1237, DOI 10.1038/nn1778; Bergado-Acosta JR, 2008, LEARN MEMORY, V15, P163, DOI 10.1101/lm.705408; Bissiere S, 2003, NAT NEUROSCI, V6, P587, DOI 10.1038/nn1058; Blair HT, 2001, LEARN MEMORY, V8, P229, DOI 10.1101/lm.30901; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Bouton ME, 2006, BIOL PSYCHIAT, V60, P352, DOI 10.1016/j.biopsych.2005.12.015; Braga MFM, 2004, NEUROPSYCHOPHARMACOL, V29, P45, DOI 10.1038/sj.npp.1300297; Bredy TW, 2008, LEARN MEMORY, V15, P39, DOI 10.1101/lm.801108; Brenman JE, 1997, CURR OPIN NEUROBIOL, V7, P374, DOI 10.1016/S0959-4388(97)80065-7; Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; Brunet A, 2008, J PSYCHIATR RES, V42, P503, DOI 10.1016/j.jpsychires.2007.05.006; Bush DEA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00154; CAREW TJ, 1984, J NEUROSCI, V4, P1217; Chan Wan Yee Macy, 2010, Learn Mem, V17, P512, DOI 10.1101/lm.1912510; Chen FJ, 2007, NEUROSCIENCE, V144, P472, DOI 10.1016/j.neuroscience.2006.09.037; Chen ZJ, 2005, ACTA PHARMACOL SIN, V26, P1281, DOI 10.1111/j.1745-7254.2005.00224.x; Clem RL, 2010, SCIENCE, V330, P1108, DOI 10.1126/science.1195298; Cowansage Kiriana K, 2010, Curr Mol Pharmacol, V3, P12; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Day JJ, 2011, NEURON, V70, P813, DOI 10.1016/j.neuron.2011.05.019; Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Dityatev AE, 2005, NEUROSCIENTIST, V11, P75, DOI 10.1177/1073858404270857; Doyere V, 2007, NAT NEUROSCI, V10, P414, DOI 10.1038/nn1871; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Dudai Y, 2009, PHILOS T R SOC B, V364, P1255, DOI 10.1098/rstb.2008.0320; Duvarci S, 2005, EUR J NEUROSCI, V21, P283, DOI 10.1111/j.1460-9568.2004.03824.x; Duvarci S, 2008, LEARN MEMORY, V15, P747, DOI 10.1101/lm.1027208; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; ENNIS M, 1988, J NEUROSCI, V8, P3644; Faber ESL, 2008, J NEUROSCI, V28, P10803, DOI 10.1523/JNEUROSCI.1796-08.2008; Fanselow MS, 2005, ANNU REV PSYCHOL, V56, P207, DOI 10.1146/annurev.psych.56.091103.070213; Farb CR, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00162; Fourcaudot E, 2009, NAT NEUROSCI, V12, P1093, DOI 10.1038/nn.2378; Galvez R, 1996, NEUROBIOL LEARN MEM, V66, P253, DOI 10.1006/nlme.1996.0067; Gewirtz JC, 1997, NATURE, V388, P471, DOI 10.1038/41325; Glanzman DL, 2010, CURR BIOL, V20, pR31, DOI 10.1016/j.cub.2009.10.023; Goosens KA, 2000, BEHAV BRAIN RES, V114, P145, DOI 10.1016/S0166-4328(00)00224-2; Greba Q, 2001, BRAIN RES, V899, P218, DOI 10.1016/S0006-8993(01)02243-0; Guarraci FA, 1999, BRAIN RES, V827, P28, DOI 10.1016/S0006-8993(99)01291-3; Guarraci FA, 2000, BEHAV NEUROSCI, V114, P647, DOI 10.1037/0735-7044.114.3.647; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hall J, 2001, EUR J NEUROSCI, V13, P1453, DOI 10.1046/j.0953-816x.2001.01531.x; Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001; Han JH, 2007, SCIENCE, V316, P457, DOI [10.1126/science.1139438, 10.1126/science.1134697]; Han JH, 2009, SCIENCE, V323, P1492, DOI 10.1126/science.1164139; Hebb Donald O., 1949, ORG BEHAV; Helmstetter FJ, 2008, NEUROBIOL LEARN MEM, V89, P324, DOI 10.1016/j.nlm.2007.09.002; Hernandez PJ, 2008, NEUROBIOL LEARN MEM, V89, P293, DOI 10.1016/j.nlm.2007.09.010; Herry C, 2010, EUR J NEUROSCI, V31, P599, DOI 10.1111/j.1460-9568.2010.07101.x; Hoeffer CA, 2011, P NATL ACAD SCI USA, V108, P3383, DOI 10.1073/pnas.1013063108; Hu HL, 2007, CELL, V131, P160, DOI 10.1016/j.cell.2007.09.017; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Humeau Y, 2003, NATURE, V426, P841, DOI 10.1038/nature02194; Humeau Y, 2007, J NEUROSCI, V27, P10947, DOI 10.1523/JNEUROSCI.2603-07.2007; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jarome TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024349; Joels G, 2010, J NEUROSCI, V30, P15981, DOI 10.1523/JNEUROSCI.1872-10.2010; Johansen JP, 2010, P NATL ACAD SCI USA, V107, P12692, DOI 10.1073/pnas.1002418107; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kasai H, 2010, TRENDS NEUROSCI, V33, P121, DOI 10.1016/j.tins.2010.01.001; Keeley MB, 2006, LEARN MEMORY, V13, P135, DOI 10.1101/lm.86906; Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819; Kim J, 2010, J NEUROSCI, V30, P9631, DOI 10.1523/JNEUROSCI.0940-10.2010; Kim JJ, 2006, NEUROSCI BIOBEHAV R, V30, P188, DOI 10.1016/j.neubiorev.2005.06.005; Kim J, 2008, P NATL ACAD SCI USA, V105, P9087, DOI 10.1073/pnas.0803448105; Kindt M, 2009, NAT NEUROSCI, V12, P256, DOI 10.1038/nn.2271; Kwapis JL, 2009, BEHAV NEUROSCI, V123, P844, DOI 10.1037/a0016343; Lamprecht R, 2006, NEUROSCIENCE, V139, P821, DOI 10.1016/j.neuroscience.2005.12.055; Lamprecht R, 2006, NAT NEUROSCI, V9, P481, DOI 10.1038/nn1672; Lamprecht R, 2002, NEURON, V36, P727, DOI 10.1016/S0896-6273(02)01047-4; Lamprecht R, 2009, GENES BRAIN BEHAV, V8, P735, DOI 10.1111/j.1601-183X.2009.00515.x; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; Lazzaro SC, 2010, LEARN MEMORY, V17, P489, DOI 10.1101/lm.1918210; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lee HJ, 2001, NEUROSCI LETT, V303, P123, DOI 10.1016/S0304-3940(01)01733-5; Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760; Leonard SK, 2003, SYNAPSE, V50, P320, DOI 10.1002/syn.10272; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; Lin CH, 2003, J NEUROSCI, V23, P8310; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Maddox SA, 2011, LEARN MEMORY, V18, P579, DOI 10.1101/lm.2243411; Maddox SA, 2011, J NEUROSCI, V31, P7073, DOI 10.1523/JNEUROSCI.1120-11.2011; Maddox SA, 2011, LEARN MEMORY, V18, P24, DOI 10.1101/lm.1980211; Maguschak KA, 2008, NAT NEUROSCI, V11, P1319, DOI 10.1038/nn.2198; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mantzur L, 2009, NEUROBIOL LEARN MEM, V91, P85, DOI 10.1016/j.nlm.2008.09.001; Maren S, 2005, NEURON, V47, P783, DOI 10.1016/j.neuron.2005.08.009; Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; Marowsky A, 2005, NEURON, V48, P1025, DOI 10.1016/j.neuron.2005.10.029; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; McKinney BC, 2006, LEARN MEMORY, V13, P584, DOI 10.1101/lm.279006; Migues PV, 2010, NAT NEUROSCI, V13, P630, DOI 10.1038/nn.2531; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Moita MAP, 2002, NAT NEUROSCI, V5, P837, DOI 10.1038/nn901; Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975; Monsey MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019958; Morozov A, 2011, J NEUROSCI, V31, P339, DOI 10.1523/JNEUROSCI.5537-10.2011; Muller J, 1997, BEHAV NEUROSCI, V111, P683, DOI 10.1037/0735-7044.111.4.683; Muly EC, 2009, BRAIN STRUCT FUNCT, V213, P375, DOI 10.1007/s00429-009-0214-8; Muravieva EV, 2010, LEARN MEMORY, V17, P306, DOI 10.1101/lm.1794710; Myers KM, 2007, MOL PSYCHIATR, V12, P120, DOI 10.1038/sj.mp.4001939; Nader K, 1999, BEHAV NEUROSCI, V113, P891, DOI 10.1037/0735-7044.113.5.891; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Nader K, 2009, NAT REV NEUROSCI, V10, P224, DOI 10.1038/nrn2590; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nedelescu H, 2010, J COMP NEUROL, V518, P4723, DOI 10.1002/cne.22472; Ostroff LE, 2010, P NATL ACAD SCI USA, V107, P9418, DOI 10.1073/pnas.0913384107; Ota KT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011236; Ota KT, 2010, LEARN MEMORY, V17, P221, DOI 10.1101/lm.1592510; Ou LC, 2006, NEUROPSYCHOPHARMACOL, V31, P287, DOI 10.1038/sj.npp.1300830; Ou LC, 2007, MOL PHARMACOL, V72, P350, DOI 10.1124/mol.107.034934; Ou LC, 2010, NEUROBIOL LEARN MEM, V93, P372, DOI 10.1016/j.nlm.2009.12.003; Overeem KA, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/neuro.08.002.2010; Pan BX, 2008, J NEUROSCI, V28, P2089, DOI 10.1523/JNEUROSCI.5156-07.2008; Pape HC, 2010, PHYSIOL REV, V90, P419, DOI 10.1152/physrev.00037.2009; Pare D, 2002, TRENDS NEUROSCI, V25, P436, DOI 10.1016/S0166-2236(02)02243-9; Pare D, 2003, ANN NY ACAD SCI, V985, P78; Parsons RG, 2006, EUR J NEUROSCI, V23, P1853, DOI 10.1111/j.1460-9568.2006.04723.x; Parsons RG, 2006, J NEUROSCI, V26, P12977, DOI 10.1523/JNEUROSCI.4209-06.2006; Paul S, 2007, BIOL PSYCHIAT, V61, P1049, DOI 10.1016/j.biopsych.2006.08.005; Ploski JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023760; Ploski JE, 2010, J NEUROCHEM, V112, P636, DOI 10.1111/j.1471-4159.2009.06491.x; Ploski JE, 2008, J NEUROSCI, V28, P12383, DOI 10.1523/JNEUROSCI.1662-08.2008; Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7; Quirarte GL, 1998, BRAIN RES, V808, P134, DOI 10.1016/S0006-8993(98)00795-1; Quirk GJ, 2008, NEUROPSYCHOPHARMACOL, V33, P56, DOI 10.1038/sj.npp.1301555; Radley JJ, 2006, EUR J NEUROSCI, V24, P876, DOI 10.1111/j.1460-9568.2006.04962.x; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Rattiner LM, 2005, NEUROSCIENTIST, V11, P323, DOI 10.1177/1073858404272255; Rattiner LM, 2004, LEARN MEMORY, V11, P727, DOI 10.1101/lm.83304; Rattiner LM, 2004, J NEUROSCI, V24, P4796, DOI 10.1523/JNEUROSCI.5654-03.2004; Ressler KJ, 2002, J NEUROSCI, V22, P7892; Rodrigues SM, 2004, NEURON, V44, P75, DOI 10.1016/j.neuron.2004.09.014; Rodrigues SM, 2004, J NEUROSCI, V24, P3281, DOI 10.1523/JNEUROSCI.5303-03.2004; Rodrigues SM, 2001, J NEUROSCI, V21, P6889, DOI 10.1523/JNEUROSCI.21-17-06889.2001; Rodrigues SM, 2002, J NEUROSCI, V22, P5219, DOI 10.1523/JNEUROSCI.22-12-05219.2002; ROMANSKI LM, 1993, BEHAV NEUROSCI, V107, P444, DOI 10.1037/0735-7044.107.3.444; Rosenkranz JA, 2002, NATURE, V417, P282, DOI 10.1038/417282a; Rosenkranz JA, 2002, J NEUROSCI, V22, P324, DOI 10.1523/JNEUROSCI.22-01-00324.2002; Rudy JW, 2009, LEARN MEMORY, V16, P421, DOI 10.1101/lm.1444909; Rumpel S, 2005, SCIENCE, V308, P83, DOI 10.1126/science.1103944; Sacktor TC, 2008, PROG BRAIN RES, V169, P27, DOI 10.1016/S0079-6123(07)00002-7; Sah P, 2008, ANN NY ACAD SCI, V1129, P88, DOI 10.1196/annals.1417.020; Sara SJ, 2000, LEARN MEMORY, V7, P73, DOI 10.1101/lm.7.2.73; Schafe GE, 2005, EUR J NEUROSCI, V22, P201, DOI 10.1111/j.1460-9568.2005.04209.x; Schafe GE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-18-j0003.2000; Schafe GE, 2000, J NEUROSCI, V20, P8177; Schafe GE, 2001, TRENDS NEUROSCI, V24, P540, DOI 10.1016/S0166-2236(00)01969-X; Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637; Schmid S, 2006, NEUROPHARMACOLOGY, V50, P154, DOI 10.1016/j.neuropharm.2005.08.002; Schroeder BW, 2005, EUR J NEUROSCI, V22, P1775, DOI 10.1111/j.1460-9568.2005.04343.x; Schroeder BW, 2004, EUR J NEUROSCI, V20, P549, DOI 10.1111/j.1460-9568.2004.03517.x; Sejnowski TJ, 1999, NEURON, V24, P773, DOI 10.1016/S0896-6273(00)81025-9; Serrano P, 2008, PLOS BIOL, V6, P2698, DOI 10.1371/journal.pbio.0060318; Shaban H, 2006, NAT NEUROSCI, V9, P1028, DOI 10.1038/nn1732; Shinnick-Gallagher P, 2003, ANN NY ACAD SCI, V985, P135; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Siegl S, 2008, NEUROREPORT, V19, P1147, DOI 10.1097/WNR.0b013e328307f295; Sigurdsson T, 2007, NEUROPHARMACOLOGY, V52, P215, DOI 10.1016/j.neuropharm.2006.06.022; Silva AJ, 2003, J NEUROBIOL, V54, P224, DOI 10.1002/neu.10169; Soeter M, 2011, LEARN MEMORY, V18, P357, DOI 10.1101/lm.2148511; Soeter M, 2010, NEUROBIOL LEARN MEM, V94, P30, DOI 10.1016/j.nlm.2010.03.004; Sotres-Bayon F, 2006, BIOL PSYCHIAT, V60, P329, DOI 10.1016/j.biopsych.2005.10.012; Sotres-Bayon F, 2010, CURR OPIN NEUROBIOL, V20, P231, DOI 10.1016/j.conb.2010.02.005; Stork O, 2002, NEUROSCI LETT, V327, P138, DOI 10.1016/S0304-3940(02)00387-7; Stork O, 2001, LEARN MEMORY, V8, P209, DOI 10.1101/lm.39401; Sutton MA, 2006, CELL, V127, P49, DOI 10.1016/j.cell.2006.09.014; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Sweatt JD, 2003, MECH MEMORY; Szinyei C, 2007, EUR J NEUROSCI, V25, P1205, DOI 10.1111/j.1460-9568.2007.05349.x; Takeichi M, 2005, TRENDS CELL BIOL, V15, P216, DOI 10.1016/j.tcb.2005.02.002; Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090; Tronson NC, 2006, NAT NEUROSCI, V9, P167, DOI 10.1038/nn1628; Tsvetkov E, 2002, NEURON, V34, P289, DOI 10.1016/S0896-6273(02)00645-1; Tully K, 2007, P NATL ACAD SCI USA, V104, P14146, DOI 10.1073/pnas.0704621104; Tully K, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-15; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; Weisskopf MG, 1999, J NEUROSCI, V19, P10512; Wilensky AE, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0006.1999; Wiltgen BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.037.2009; Yeh SH, 2006, MOL PHARMACOL, V69, P299, DOI 10.1124/mol.105.017194; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; Yokoyama M, 2005, NEUROSCI LETT, V379, P37, DOI 10.1016/j.neulet.2004.12.047; Young AMJ, 1998, NEUROSCI LETT, V249, P49, DOI 10.1016/S0304-3940(98)00390-5; Zhou Y, 2009, NAT NEUROSCI, V12, P1438, DOI 10.1038/nn.2405	207	651	666	2	192	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					509	524		10.1016/j.cell.2011.10.009	http://dx.doi.org/10.1016/j.cell.2011.10.009			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036561	Bronze, Green Accepted			2022-12-28	WOS:000296573700008
J	Stigler, J; Ziegler, F; Gieseke, A; Gebhardt, JCM; Rief, M				Stigler, Johannes; Ziegler, Fabian; Gieseke, Anja; Gebhardt, J. Christof M.; Rief, Matthias			The Complex Folding Network of Single Calmodulin Molecules	SCIENCE			English	Article							PROTEIN; LANDSCAPE; STABILITY; DYNAMICS; REVEALS; DOMAINS; SPECTROSCOPY; SIMULATION; KINETICS; BINDING	Direct observation of the detailed conformational fluctuations of a single protein molecule en route to its folded state has so far been realized only in silico. We have used single-molecule force spectroscopy to study the folding transitions of single calmodulin molecules. High-resolution optical tweezers assays in combination with hidden Markov analysis reveal a complex network of on- and off-pathway intermediates. Cooperative and anticooperative interactions across domain boundaries can be observed directly. The folding network involves four intermediates. Two off-pathway intermediates exhibit non-native interdomain interactions and compete with the ultrafast productive folding pathway.	[Stigler, Johannes; Ziegler, Fabian; Gieseke, Anja; Gebhardt, J. Christof M.; Rief, Matthias] Tech Univ Munich, Phys Dept E22, D-85748 Garching, Germany; [Rief, Matthias] Munich Ctr Integrated Prot Sci, D-81377 Munich, Germany	Technical University of Munich; University of Munich	Rief, M (corresponding author), Tech Univ Munich, Phys Dept E22, James Franck Str, D-85748 Garching, Germany.	mrief@ph.tum.de	Gebhardt, J. Christof M./M-4851-2017	Gebhardt, J. Christof M./0000-0003-1900-600X; Stigler, Johannes/0000-0003-2472-5332	Deutsche Forschungsgemeinschaft through Institute for Advanced Study of Technische Universitat Munchen [SFB 863 A2]; International Graduate School "Materials Science of Complex Interfaces"	Deutsche Forschungsgemeinschaft through Institute for Advanced Study of Technische Universitat Munchen; International Graduate School "Materials Science of Complex Interfaces"	This work was supported by an SFB 863 A2 grant of Deutsche Forschungsgemeinschaft. M.R. acknowledges financial support through an instrument grant of the Institute for Advanced Study of Technische Universitat Munchen. J.S. was supported by the International Graduate School "Materials Science of Complex Interfaces."	Borgia MB, 2011, NATURE, V474, P662, DOI 10.1038/nature10099; Cecconi C, 2005, SCIENCE, V309, P2057, DOI 10.1126/science.1116702; Cecconi C, 2008, EUR BIOPHYS J BIOPHY, V37, P729, DOI 10.1007/s00249-007-0247-y; Chen YG, 2007, J AM CHEM SOC, V129, P2414, DOI 10.1021/ja067791a; de Messieres M, 2011, BIOPHYS J, V100, P2736, DOI 10.1016/j.bpj.2011.03.067; Dietz H, 2006, P NATL ACAD SCI USA, V103, P1244, DOI 10.1073/pnas.0509217103; Fefeu S, 2000, BIOCHEMISTRY-US, V39, P15920, DOI 10.1021/bi001772a; Freddolino PL, 2008, BIOPHYS J, V94, pL75, DOI 10.1529/biophysj.108.131565; Gebhardt JCM, 2010, P NATL ACAD SCI USA, V107, P2013, DOI 10.1073/pnas.0909854107; GUO ZY, 1995, BIOPOLYMERS, V36, P83, DOI 10.1002/bip.360360108; Junker JP, 2010, ANGEW CHEM INT EDIT, V49, P3306, DOI 10.1002/anie.200905747; Junker JP, 2009, SCIENCE, V323, P633, DOI 10.1126/science.1166191; Krebs J, 2007, N COMP BIOC, V41, P51; Lakowski TM, 2007, PROTEIN SCI, V16, P1119, DOI 10.1110/ps.072777107; Landry MP, 2009, BIOPHYS J, V97, P2128, DOI 10.1016/j.bpj.2009.07.048; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; Masino L, 2000, PROTEIN SCI, V9, P1519, DOI 10.1110/ps.9.8.1519; Nakashima K, 1999, BIOCHEMISTRY-US, V38, P98, DOI 10.1021/bi982067t; Oberhauser AF, 1999, NAT STRUCT BIOL, V6, P1025; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; Puchner EM, 2008, P NATL ACAD SCI USA, V105, P13385, DOI 10.1073/pnas.0805034105; Rabl CR, 2002, BIOPHYS CHEM, V101, P553, DOI 10.1016/S0301-4622(02)00150-3; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Schlierf M, 2004, P NATL ACAD SCI USA, V101, P7299, DOI 10.1073/pnas.0400033101; Schuler B, 2008, CURR OPIN STRUC BIOL, V18, P16, DOI 10.1016/j.sbi.2007.12.003; Shank EA, 2010, NATURE, V465, P637, DOI 10.1038/nature09021; Shaw DE, 2010, SCIENCE, V330, P341, DOI 10.1126/science.1187409; Shuman CF, 2006, J MOL BIOL, V358, P870, DOI 10.1016/j.jmb.2006.02.017; Thirumalai D, 2005, BIOCHEMISTRY-US, V44, P4957, DOI 10.1021/bi047314+; Voelz VA, 2010, J AM CHEM SOC, V132, P1526, DOI 10.1021/ja9090353; Woodside MT, 2006, SCIENCE, V314, P1001, DOI 10.1126/science.1133601; Zheng P, 2011, BIOPHYS J, V100, P1534, DOI 10.1016/j.bpj.2011.01.062	33	273	278	4	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					512	516		10.1126/science.1207598	http://dx.doi.org/10.1126/science.1207598			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034433				2022-12-28	WOS:000296230500047
J	Moran, P; Coffey, C; Romaniuk, H; Olsson, C; Borschmann, R; Carlin, JB; Patton, GC				Moran, Paul; Coffey, Carolyn; Romaniuk, Helena; Olsson, Craig; Borschmann, Rohan; Carlin, John B.; Patton, George C.			The natural history of self-harm from adolescence to young adulthood: a population-based cohort study	LANCET			English	Article							SUICIDAL-BEHAVIOR; COMMUNITY SAMPLE; RISK-FACTORS; INJURY; PREVALENCE; PREDICTORS; ENGLAND; PEOPLE; RATES; TIME	Background Knowledge about the natural history of self-harm is scarce, especially during the transition from adolescence to young adulthood, a period characterised by a sharp rise in self-inflicted deaths. From a repeated measures cohort of a representative sample, we describe the course of self-harm from middle adolescence to young adulthood. Methods A stratified, random sample of 1943 adolescents was recruited from 44 schools across the state of Victoria, Australia, between August, 1992, and January, 2008. We obtained data pertaining to self-harm from questionnaires and telephone interviews at seven waves of follow-up, commencing at mean age 15.9 years (SD 0.49) and ending at mean age 29.0 years (SD 0.59). Summary adolescent measures (waves three to six) were obtained for cannabis use, cigarette smoking, high-risk alcohol use, depression and anxiety, antisocial behaviour and parental separation or divorce. Findings 1802 participants responded in the adolescent phase, with 149 (8%) reporting self-harm, More girls (95/947 [10%]) than boys (54/855 [6%]) reported self-harm (risk ratio 1.6, 95% CI 1.2-2.2). We recorded a substantial reduction in the frequency of self-harm during late adolescence. 122 of 1652 (7%) participants who reported self-harm during adolescence reported no further self-harm in young adulthood, with a stronger continuity in girls (13/888) than boys (1/764). During adolescence, incident self-harm was independently associated with symptoms of depression and anxiety (HR 3.7, 95% CI 2.4-5.9), antisocial behaviour (1.9, 1.1-3.4), high-risk alcohol use (2.1, 1.2-3.7), cannabis use (2.4, 1.4-4.4), and cigarette smoking (1.8, 1.0-3.1). Adolescent symptoms of depression and anxiety were clearly associated with incident self-harm in young adulthood (5.9, 2.2-16). Interpretation Most self-harming behaviour in adolescents resolves spontaneously. The early detection and treatment of common mental disorders during adolescence might constitute an important and hitherto unrecognised component of suicide prevention in young adults.	[Moran, Paul; Borschmann, Rohan] Kings Coll London, Inst Psychiat, Hlth Serv, London SE5 8AF, England; [Moran, Paul; Borschmann, Rohan] Kings Coll London, Inst Psychiat, Populat Res Dept, London SE5 8AF, England; [Coffey, Carolyn; Patton, George C.] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic, Australia; [Romaniuk, Helena; Carlin, John B.] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic, Australia; [Romaniuk, Helena; Carlin, John B.; Patton, George C.] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; [Olsson, Craig] Deakin Univ, Dept Psychol, Geelong, Vic 3217, Australia	University of London; King's College London; University of London; King's College London; Murdoch Children's Research Institute; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Deakin University	Moran, P (corresponding author), Kings Coll London, Inst Psychiat, Hlth Serv, London SE5 8AF, England.	paul.moran@kcl.ac.uk	Moran, Paul A/B-1740-2010; Carlin, John B/B-3492-2012; Patton, George C/B-5246-2013; Olsson, Craig A/AAR-5057-2020; Carlin, John/AAG-4332-2020; Ribeiro, Ana Cristina/HHN-7466-2022	Moran, Paul A/0000-0002-9257-8699; Carlin, John B/0000-0002-2694-9463; Patton, George C/0000-0001-5039-8326; Olsson, Craig A/0000-0002-5927-2014; Carlin, John/0000-0002-2694-9463; Ribeiro, Ana Cristina/0000-0002-0493-8376; Borschmann, Rohan/0000-0002-0365-7775; Romaniuk, Helena/0000-0002-5801-2077	National Health and Medical Research Council, Australia; Government of Victoria, Australia	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Government of Victoria, Australia	National Health and Medical Research Council, Australia, and operational infrastructure support programme, Government of Victoria, Australia.	Beck A.T., 1974, DEV SUICIDAL INTENT; Brunner R, 2007, ARCH PEDIAT ADOL MED, V161, P641, DOI 10.1001/archpedi.161.7.641; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; Dahl RE, 2008, AM J PREV MED, V35, pS278, DOI 10.1016/j.amepre.2008.06.013; Fergusson DM, 2000, PSYCHOL MED, V30, P23, DOI 10.1017/S003329179900135X; Fortune S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-369; Haavisto A, 2005, SOC PSYCH PSYCH EPID, V40, P912, DOI 10.1007/s00127-005-0966-2; Hankin BL, 2011, PSYCHIAT RES, V186, P65, DOI 10.1016/j.psychres.2010.07.056; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2003, PSYCHOL MED, V33, P987, DOI 10.1017/S0033291703007943; Hilt LM, 2008, J EARLY ADOLESCENCE, V28, P455, DOI 10.1177/0272431608316604; Jablonska B, 2009, INT J EPIDEMIOL, V38, P1334, DOI 10.1093/ije/dyp236; Kapur N, 2006, J CLIN PSYCHIAT, V67, P1599, DOI 10.4088/JCP.v67n1016; Klonsky ED, 2007, CLIN PSYCHOL REV, V27, P226, DOI 10.1016/j.cpr.2006.08.002; Larsson B, 2008, SUICIDE LIFE-THREAT, V38, P152, DOI 10.1521/suli.2008.38.2.152; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Madge N, 2008, J CHILD PSYCHOL PSYC, V49, P667, DOI 10.1111/j.1469-7610.2008.01879.x; MOFFITT TE, 1988, AUST NZ J CRIMINOL, V21, P227, DOI 10.1177/000486588802100405; National Health and Medical Research Council, 2009, AUSTR ALC GUID HLTH; Patton GC, 2007, J AM ACAD CHILD PSY, V46, P508, DOI 10.1097/chi.0b013e31803065c7; Patton GC, 2009, LANCET, V374, P881, DOI 10.1016/S0140-6736(09)60741-8; Pirkis JE, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e388; Prinstein MJ, 2010, J ABNORM CHILD PSYCH, V38, P669, DOI 10.1007/s10802-010-9423-0; SALTER D, 1990, BRIT J CLIN PSYCHOL, V29, P361, DOI 10.1111/j.2044-8260.1990.tb00898.x; Skegg K, 2005, LANCET, V366, P1471, DOI 10.1016/S0140-6736(05)67600-3; Sourander A, 2006, J AFFECT DISORDERS, V93, P87, DOI 10.1016/j.jad.2006.02.015; Wichstrom L, 2009, ARCH SUICIDE RES, V13, P105, DOI 10.1080/13811110902834992; World Health Organization, 2016, MHGAP INT GUID MENT; Yates TM, 2008, DEV PSYCHOPATHOL, V20, P651, DOI 10.1017/S0954579408000321; Yates TM, 2008, J CONSULT CLIN PSYCH, V76, P52, DOI 10.1037/0022-006X.76.1.52; Young R, 2006, BMJ-BRIT MED J, V332, P1058, DOI 10.1136/bmj.38790.495544.7C	32	337	347	9	110	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 21	2012	379	9812					236	243		10.1016/S0140-6736(11)61141-0	http://dx.doi.org/10.1016/S0140-6736(11)61141-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879FW	22100201	Bronze			2022-12-28	WOS:000299316100038
J	Metallo, CM; Gameiro, PA; Bell, EL; Mattaini, KR; Yang, JJ; Hiller, K; Jewell, CM; Johnson, ZR; Irvine, DJ; Guarente, L; Kelleher, JK; Vander Heiden, MG; Iliopoulos, O; Stephanopoulos, G				Metallo, Christian M.; Gameiro, Paulo A.; Bell, Eric L.; Mattaini, Katherine R.; Yang, Juanjuan; Hiller, Karsten; Jewell, Christopher M.; Johnson, Zachary R.; Irvine, Darrell J.; Guarente, Leonard; Kelleher, Joanne K.; Vander Heiden, Matthew G.; Iliopoulos, Othon; Stephanopoulos, Gregory			Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia	NATURE			English	Article							FATTY-ACID SYNTHESIS; CELL-PROLIFERATION; FLUX ANALYSIS; HIF-ALPHA; GROWTH; CANCER; DEHYDROGENASE; SUPPRESSION; DISTRIBUTIONS; HYDROXYLATION	Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol(1-3). However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis(4). Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis(5), the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of alpha-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived alpha-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.	[Metallo, Christian M.; Gameiro, Paulo A.; Hiller, Karsten; Kelleher, Joanne K.; Stephanopoulos, Gregory] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Gameiro, Paulo A.] Univ Coimbra, Dept Life Sci, P-3004517 Coimbra, Portugal; [Gameiro, Paulo A.; Yang, Juanjuan; Iliopoulos, Othon] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Gameiro, Paulo A.; Yang, Juanjuan; Iliopoulos, Othon] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Bell, Eric L.; Mattaini, Katherine R.; Guarente, Leonard; Vander Heiden, Matthew G.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Mattaini, Katherine R.; Jewell, Christopher M.; Johnson, Zachary R.; Irvine, Darrell J.; Vander Heiden, Matthew G.] MIT, Koch Inst Canc Res, Cambridge, MA 02139 USA; [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; [Vander Heiden, Matthew G.] Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Universidade de Coimbra; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Stephanopoulos, G (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	iliopoul@helix.mgh.harvard.edu; gregstep@mit.edu	Bell, Eric/F-6368-2012; Gameiro, Paulo A/AAD-9324-2021; Metallo, Christian/HCH-3476-2022; damiani, chiara/R-4256-2016	Metallo, Christian/0000-0003-2404-3040; Hiller, Karsten/0000-0001-9322-5820; Gameiro, Paulo A./0000-0001-8176-4237	National Institutes of Health [R01 DK075850-01]; American Cancer Society; German Research Foundation (DFG) [HI1400]; Glenn Foundation for Medical Research; Burrough's Wellcome Fund; Smith Family; Damon Runyon Cancer Research Foundation; National Cancer Institute; Dana Farber/Harvard Cancer Center;  [R01 CA122591]; NATIONAL CANCER INSTITUTE [R01CA160458, P30CA014051, R01CA122591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075850] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); German Research Foundation (DFG)(German Research Foundation (DFG)); Glenn Foundation for Medical Research; Burrough's Wellcome Fund(Burroughs Wellcome Fund); Smith Family; Damon Runyon Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Dana Farber/Harvard Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank N. Vokes and P. Ward for discussions. We also thank S. Gross and Agios Pharmaceuticals for providing the IDH1 construct. We acknowledge support from National Institutes of Health grant R01 DK075850-01. C. M. M. is supported by a postdoctoral fellowship from the American Cancer Society. K. H. is supported by the German Research Foundation (DFG) grant HI1400. L. G. is supported by the NIH and the Glenn Foundation for Medical Research. M. G. V. H. is supported by the Burrough's Wellcome Fund, the Smith Family, the Damon Runyon Cancer Research Foundation and the National Cancer Institute. D.J.I. is an investigator of the Howard Hughes Medical Institute. O.I. is supported by R01 CA122591 and the Dana Farber/Harvard Cancer Center Kidney SPORE Grant Developmental Award.	Antoniewicz MR, 2007, METAB ENG, V9, P68, DOI 10.1016/j.ymben.2006.09.001; Antoniewicz MR, 2006, METAB ENG, V8, P324, DOI 10.1016/j.ymben.2006.01.004; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Boros LG, 2003, BLOOD, V102, P3556, DOI 10.1182/blood-2003-05-1537; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Hartong DT, 2008, NAT GENET, V40, P1230, DOI 10.1038/ng.223; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; KHARROUBI AT, 1992, AM J PHYSIOL, V263, pE667, DOI 10.1152/ajpendo.1992.263.4.E667; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Maier K, 2008, BIOTECHNOL BIOENG, V100, P355, DOI 10.1002/bit.21746; Metallo CM, 2009, J BIOTECHNOL, V144, P167, DOI 10.1016/j.jbiotec.2009.07.010; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Munger J, 2008, NAT BIOTECHNOL, V26, P1179, DOI 10.1038/nbt.1500; Noguchi Y, 2009, J BIOL CHEM, V284, P33425, DOI 10.1074/jbc.M109.049478; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sauer U, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100109; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; SIEBERT G, 1957, J BIOL CHEM, V226, P977; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200; Young JD, 2008, BIOTECHNOL BIOENG, V99, P686, DOI 10.1002/bit.21632; Zimmer M, 2004, MOL CANCER RES, V2, P89; Zimmer M, 2008, MOL CELL, V32, P838, DOI 10.1016/j.molcel.2008.12.004	40	1174	1218	19	296	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					380	U166		10.1038/nature10602	http://dx.doi.org/10.1038/nature10602			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22101433	Green Submitted, Green Accepted			2022-12-28	WOS:000299210600046
J	Cruse, D; Chennu, S; Chatelle, C; Bekinschtein, TA; Fernandez-Espejo, D; Pickard, JD; Laureys, S; Owen, AM				Cruse, Damian; Chennu, Srivas; Chatelle, Camille; Bekinschtein, Tristan A.; Fernandez-Espejo, Davinia; Pickard, John D.; Laureys, Steven; Owen, Adrian M.			Bedside detection of awareness in the vegetative state: a cohort study	LANCET			English	Article							BRAIN-COMPUTER INTERFACES; MOTOR IMAGERY; BCI; COMMUNICATION; ACCURACY	Background Patients diagnosed as vegetative have periods of wakefulness, but seem to be unaware of themselves or their environment. Although functional MRI (fMRI) studies have shown that some of these patients are consciously aware, issues of expense and accessibility preclude the use of fMRI assessment in most of these individuals. We aimed to assess bedside detection of awareness with an electroencephalography (EEG) technique in patients in the vegetative state. Methods This study was undertaken at two European centres. We recruited patients with traumatic brain injury and non-traumatic brain injury who met the Coma Recovery Scale-Revised definition of vegetative state. We developed a novel EEG task involving motor imagery to detect command-following-a universally accepted clinical indicator of awareness-in the absence of overt behaviour. Patients completed the task in which they were required to imagine movements of their right-hand and toes to command. We analysed the command-specific EEG responses of each patient for robust evidence of appropriate, consistent, and statistically reliable markers of motor imagery, similar to those noted in healthy, conscious controls. Findings We assessed 16 patients diagnosed in the vegetative state, and 12 healthy controls. Three (19%) of 16 patients could repeatedly and reliably generate appropriate EEG responses to two distinct commands, despite being behaviourally entirely unresponsive (classification accuracy 61-78%). We noted no significant relation between patients' clinical histories (age, time since injury, cause, and behavioural score) and their ability to follow commands. When separated according to cause, two (20%) of the five traumatic and one (9%) of the 11 non-traumatic patients were able to successfully complete this task. Interpretation Despite rigorous clinical assessment, many patients in the vegetative state are misdiagnosed. The EEG method that we developed is cheap, portable, widely available, and objective. It could allow the widespread use of this bedside technique for the rediagnosis of patients who behaviourally seem to be entirely vegetative, but who might have residual cognitive function and conscious awareness.	[Cruse, Damian; Fernandez-Espejo, Davinia; Owen, Adrian M.] Univ Western Ontario, Ctr Brain & Mind, London, ON N6A 5B7, Canada; [Cruse, Damian; Bekinschtein, Tristan A.; Owen, Adrian M.] Univ Cambridge, MRC, Cognit & Brain Sci Unit, Cambridge, England; [Chennu, Srivas] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Chatelle, Camille; Laureys, Steven] Univ & Univ Hosp Liege, Coma Sci Grp, Cyclotron Res Ctr, Liege, Belgium; [Chatelle, Camille; Laureys, Steven] Univ & Univ Hosp Liege, Dept Neurol, Liege, Belgium; [Pickard, John D.] Addenbrookes Hopsital, Div Acad Neurosurg, Cambridge, England	Western University (University of Western Ontario); University of Cambridge; University of Cambridge; University of Liege; University of Liege	Cruse, D (corresponding author), Univ Western Ontario, Ctr Brain & Mind, London, ON N6A 5B7, Canada.	dcruse@uwo.ca	Laureys, Steven/A-3349-2011; Owen, Adrian M/B-4997-2015; Cruse, Damian/ABA-6346-2021; Laureys, Steven/AAN-2097-2021; Fernandez-Espejo, Davinia/AAT-5481-2021	Cruse, Damian/0000-0003-4363-5981; Laureys, Steven/0000-0002-3096-3807; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Chatelle, Camille/0000-0002-7526-2107; Bekinschtein, Tristan/0000-0001-5501-8628; Chennu, Srivas/0000-0002-6840-2941	Medical Research Council; James S McDonnell Foundation; Canada Excellence Research Chairs Program; European Commission; Fonds de la Recherche Scientifique; Mind Science Foundation; Belgian French-Speaking Community Concerted Research Action; University Hospital of Liege; University of Liege; MRC [MC_U105559847, G9439390, G0600986, G0001237] Funding Source: UKRI; Medical Research Council [G9439390, G0001237, MC_U105559847, G0600986] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10327] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); James S McDonnell Foundation; Canada Excellence Research Chairs Program(Canada Research Chairs); European Commission(European CommissionEuropean Commission Joint Research Centre); Fonds de la Recherche Scientifique(Fonds de la Recherche Scientifique - FNRS); Mind Science Foundation; Belgian French-Speaking Community Concerted Research Action; University Hospital of Liege; University of Liege(University of Liege); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Medical Research Council, James S McDonnell Foundation, Canada Excellence Research Chairs Program, European Commission, Fonds de la Recherche Scientifique, Mind Science Foundation, Belgian French-Speaking Community Concerted Research Action, University Hospital of Liege, University of Liege.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; Guger C, 2003, IEEE T NEUR SYS REH, V11, P145, DOI 10.1109/TNSRE.2003.814481; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naccache L, 2006, SCIENCE, V313, P1395, DOI 10.1126/science.1132881; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pfurtscheller G, 2008, EUR J NEUROSCI, V28, P1419, DOI 10.1111/j.1460-9568.2008.06441.x; Pfurtscheller G, 2006, NEUROIMAGE, V31, P153, DOI 10.1016/j.neuroimage.2005.12.003; Pfurtscheller G, 1997, NEUROSCI LETT, V239, P65, DOI 10.1016/S0304-3940(97)00889-6; Pfurtscheller Gert, 1994, Brain Topography, V6, P269, DOI 10.1007/BF01211172; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Scholkopf B., 2002, LEARNING KERNELS; Sellers EW, 2006, CLIN NEUROPHYSIOL, V117, P538, DOI 10.1016/j.clinph.2005.06.027; Vaughan TM, 2006, IEEE T NEUR SYS REH, V14, P229, DOI 10.1109/TNSRE.2006.875577; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3	20	408	420	4	114	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 17	2011	378	9809					2088	2094		10.1016/S0140-6736(11)61224-5	http://dx.doi.org/10.1016/S0140-6736(11)61224-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865EL	22078855	Green Submitted			2022-12-28	WOS:000298293600030
J	Bari, A; Sadruddin, S; Khan, A; Khan, IU; Khan, A; Lehri, IA; Macleod, WB; Fox, MP; Thea, DM; Qazi, SA				Bari, Abdul; Sadruddin, Salim; Khan, Attaullah; Khan, Ibad ul Haque; Khan, Amanullah; Lehri, Iqbal A.; Macleod, William B.; Fox, Matthew P.; Thea, Donald M.; Qazi, Shamim A.			Community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Haripur district, Pakistan: a cluster randomised trial	LANCET			English	Article							CHILDHOOD PNEUMONIA; HEALTH-WORKERS; MORTALITY; CARE; EQUIVALENCY; COUNTRIES; KARACHI; COHORT	Background First dose oral co-trimoxazole and referral are recommended for WHO-defined severe pneumonia. Difficulties with referral compliance are reported in many low-resource settings, resulting in low access to appropriate treatment. The objective in this study was to assess whether community case management by lady health workers (LHWs) with oral amoxicillin in children with severe pneumonia was equivalent to current standard of care. Methods In Haripur district, Pakistan, 28 clusters were randomly assigned with stratification in a 1:1 ratio to intervention and control clusters by use of a computer-generated randomisation sequence. Children were included in the study if they were aged 2-59 months with WHO-defined severe pneumonia and living in the study area. In the intervention clusters, community-based LHWs provided mothers with oral amoxicillin (80-90 mg/kg per day or 375 mg twice a day for infants aged 2-11 months and 625 mg twice a day for those aged 12-59 months) with specific guidance on its use. In control clusters, LHWs gave the first dose of oral co-trimoxazole (age 2-11 months, sulfamethoxazole 200 mg plus trimethoprim 40 mg; age 12 months to 5 years, sulfamethoxazole 300 mg plus trimethoprim 60 mg) and referred the children to a health facility for standard of care. Participants, carers, and assessors were not masked to treatment assignment. The primary outcome was treatment failure by day 6. Analysis was per protocol with adjustment for clustering within groups by use of generalised estimating equations. This study is registered, number ISRCTN10618300. Findings We assigned 1995 children to treatment in 14 intervention clusters and 1477 in 14 control clusters, and we analysed 1857 and 1354 children, respectively. Cluster-adjusted treatment failure rates by day 6 were significantly reduced in the intervention clusters (165 [9%] vs 241 [18%], risk difference -8.9%, 95% CI -12.4 to -5.4). Further adjustment for baseline covariates made little difference (-7.3%, -10.1 to -4.5). Two deaths were reported in the control clusters and one in the intervention cluster. Most of the risk reduction was in the occurrence of fever and lower chest indrawing on day 3 (-6.7%, -10.0 to -3.3). Adverse events were diarrhoea (n=4) and skin rash (n=1) in the intervention clusters and diarrhoea (n=3) in the control clusters. Interpretation Community case management could result in a standardised treatment for children with severe pneumonia, reduce delay in treatment initiation, and reduce the costs for families and health-care systems.	[Bari, Abdul; Khan, Attaullah; Khan, Ibad ul Haque; Khan, Amanullah] Save Children US, Pakistan Country Off, Islamabad, Pakistan; [Sadruddin, Salim] Save Children US, Westport, CT USA; [Lehri, Iqbal A.] Natl Program Family Planning & Primary Hlth Care, Islamabad, Pakistan; [Macleod, William B.; Thea, Donald M.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA; [Macleod, William B.; Fox, Matthew P.; Thea, Donald M.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA USA; [Fox, Matthew P.] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA; [Qazi, Shamim A.] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland	Save the Children; Save the Children; Boston University; Boston University; Boston University; University of Geneva; World Health Organization	Sadruddin, S (corresponding author), Save Children, 54 Wilton Rd, Westport, CT 06880 USA.	ssadruddin@savechildren.org	Fox, Matthew/K-2004-2019	MacLeod, William/0000-0001-8003-8874; Sadruddin, Salim/0000-0001-6023-2477; Thea, Donald/0000-0002-6933-1030; Fox, Matthew/0000-0001-9887-0634	United States Agency for International Development (USAID); Department of Child and Adolescent Health and Development, WHO, Geneva, Switzerland through a USAID; National Institute of Allergy and Infectious Diseases (NIAID) [K01AI083097]; National Program of Family Planning and Primary Health Care [NPFPPHC], Khyber Pakhtoonkhawa, Pakistan; NPFPPHC, Haripur, Pakistan; NPFPPHC, Islamabad, Pakistan; District Head Quarter Hospital, Haripur; NPFPPHC, Khyber Pakhtoonkhawa; Dow Medical College, Karachi, Pakistan; Executive District Officer Health, Department of Health, Haripur; Sheikh Zaid Hospital, Lahore, Pakistan; Liaqat University of Health and Medical Sciences, Jamshoro, Sindh, Pakistan; Children's Hospital, Pakistan Institute of Medical Sciences [PIMS], Islamabad; Acute Respiratory Infection Research Cell, Children's Hospital, PIMS, Islamabad; NPFPPHC, Islamabad; District Tuberculosis Control Officer, Department of Health, Haripur; Save the Children, Haripur; Institute of Business Administration, Karachi; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI083097] Funding Source: NIH RePORTER	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); Department of Child and Adolescent Health and Development, WHO, Geneva, Switzerland through a USAID(World Health Organization); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Program of Family Planning and Primary Health Care [NPFPPHC], Khyber Pakhtoonkhawa, Pakistan; NPFPPHC, Haripur, Pakistan; NPFPPHC, Islamabad, Pakistan; District Head Quarter Hospital, Haripur; NPFPPHC, Khyber Pakhtoonkhawa; Dow Medical College, Karachi, Pakistan; Executive District Officer Health, Department of Health, Haripur; Sheikh Zaid Hospital, Lahore, Pakistan; Liaqat University of Health and Medical Sciences, Jamshoro, Sindh, Pakistan; Children's Hospital, Pakistan Institute of Medical Sciences [PIMS], Islamabad; Acute Respiratory Infection Research Cell, Children's Hospital, PIMS, Islamabad; NPFPPHC, Islamabad; District Tuberculosis Control Officer, Department of Health, Haripur; Save the Children, Haripur; Institute of Business Administration, Karachi; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	United States Agency for International Development (USAID).; The Department of Child and Adolescent Health and Development, WHO, Geneva, Switzerland, funded the study through a USAID grant. MPF was funded by the National Institute of Allergy and Infectious Diseases (NIAID, award number K01AI083097). The content of this report does not necessarily reflect the views or policies of WHO or USAID, nor does mention of trade names, commercial projects, or organisations imply endorsement by the US Government. The content is solely the responsibility of the authors and does not necessarily represent the official views or policies of NIAID, WHO, or USAID. We thank Ayaz Imran, (National Program of Family Planning and Primary Health Care [NPFPPHC], Khyber Pakhtoonkhawa, Pakistan), Farhat Yasmeen (NPFPPHC, Haripur, Pakistan), Fauzia Aqeel (NPFPPHC, Islamabad, Pakistan), Habib ur-Rehaman (District Head Quarter Hospital, Haripur), Ihsan Turabi (NPFPPHC, Khyber Pakhtoonkhawa), Inamullah Khan (NPFPPHC, Khyber Pakhtoonkhawa), Iqbal Memon (Dow Medical College, Karachi, Pakistan), Mohammad Idrees (Executive District Officer Health, Department of Health, Haripur), Sajid Maqbool (Sheikh Zaid Hospital, Lahore, Pakistan), Salma Sheikh (Liaqat University of Health and Medical Sciences, Jamshoro, Sindh, Pakistan), Tabish Hazir (Children's Hospital, Pakistan Institute of Medical Sciences [PIMS], Islamabad), Yusra Pervaiz Ashraf (Acute Respiratory Infection Research Cell, Children's Hospital, PIMS, Islamabad), Assad Hafeez (NPFPPHC, Islamabad), Baqar Hasnain Jafri (NPFPPHC, Islamabad), Saddiq ur Rehman (District Tuberculosis Control Officer, Department of Health, Haripur), Ali Asghar Khan (NPFPPHC, Islamabad), Yousaf Ayub Khan (Haripur), Rasheda Parveen (Save the Children, Haripur), and Yaseen Ahmed Meenai (Institute of Business Administration, Karachi) for their support in this study.	Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6; Addo-Yobo E, 2011, TROP MED INT HEALTH, V16, P995, DOI 10.1111/j.1365-3156.2011.02787.x; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6; *GOV PAK STAT DIV, 2000, GOV PAK CENS PUBL, V91; Haq Z, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-59; Hayes RJ, 2009, INTERD STAT, P3; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Hussain R, 1997, SOC SCI MED, V45, P991, DOI 10.1016/S0277-9536(97)00012-9; Iqbal Imran, 1997, JPMA (Journal of the Pakistan Medical Association), V47, P24; KABRA SK, 2006, COCHRANE DB SYST REV, V3, P4874; Kallander K, 2008, B WORLD HEALTH ORGAN, V86, P332, DOI 10.2471/BLT.07.049353; Marsh DR, 2008, B WORLD HEALTH ORGAN, V86, P381, DOI 10.2471/BLT.07.048462; Ministry of Health Government of Pakistan, 2008, NAT PROGR FAM PLANN; Mull D S, 1994, Med Anthropol, V15, P335; National Institute of Population Studies (NIPS) and Macro International, 2006, PAKISTAN DEMOGRAPHIC; Nizami S. Q., 1997, JPMA (Journal of the Pakistan Medical Association), V47, P29; Owais A, 2011, J PERINATOL, V31, P586, DOI 10.1038/jp.2010.191; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Rehman Gul Nayyer, 1994, JPMA (Journal of the Pakistan Medical Association), V44, P185; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; *SAV CHILDR US, 2010, END LIN SURV 2010 FI; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Siddiqi S, 2001, HEALTH POLICY PLANN, V16, P193, DOI 10.1093/heapol/16.2.193; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032; *UNICEF, 2008, COUNTD 2015 TRACK PR; *UNICEF, MAN PNEUM COMM SETT; *WHO, 1991, PROGR CONTR AC RESP; *WHO, 2000, HDB IMCI INT MAN CHI; WHO UNICEF, 2009, B WORLD HEALTH ORGAN, V86, P1; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C	34	65	65	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	2011	378	9805					1796	1803		10.1016/S0140-6736(11)61140-9	http://dx.doi.org/10.1016/S0140-6736(11)61140-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22078721	Green Accepted			2022-12-28	WOS:000297262300024
J	Grillner, S				Grillner, Sten			Human Locomotor Circuits Conform	SCIENCE			English	Editorial Material							SPINAL-CORD; CAT		Karolinska Inst, Dept Neurosci, Nobel Inst Neurophysiol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Grillner, S (corresponding author), Karolinska Inst, Dept Neurosci, Nobel Inst Neurophysiol, SE-17177 Stockholm, Sweden.	sten.grillner@ki.se						Dominici N, 2011, SCIENCE, V334, P997, DOI 10.1126/science.1210617; FORSSBERG H, 1980, ACTA PHYSIOL SCAND, V108, P269, DOI 10.1111/j.1748-1716.1980.tb06533.x; Garwicz M, 2009, P NATL ACAD SCI USA, V106, P21889, DOI 10.1073/pnas.0905777106; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; Grillner S, 2006, NEURON, V52, P751, DOI 10.1016/j.neuron.2006.11.008; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; Kiehn O, 2011, CURR OPIN NEUROBIOL, V21, P100, DOI 10.1016/j.conb.2010.09.004; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Rossignol S, 2006, PHYSIOL REV, V86, P89, DOI 10.1152/physrev.00028.2005; Stephenson-Jones M, 2011, CURR BIOL, V21, P1081, DOI 10.1016/j.cub.2011.05.001; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x	12	50	51	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					912	913		10.1126/science.1214778	http://dx.doi.org/10.1126/science.1214778			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096178				2022-12-28	WOS:000297101800034
J	Montarnal, D; Capelot, M; Tournilhac, F; Leibler, L				Montarnal, Damien; Capelot, Mathieu; Tournilhac, Francois; Leibler, Ludwik			Silica-Like Malleable Materials from Permanent Organic Networks	SCIENCE			English	Article							CROSS-LINKED POLYMERS; DYNAMIC POLYMERS; CHEMISTRY; GELATION; LIQUIDS	Permanently cross-linked materials have outstanding mechanical properties and solvent resistance, but they cannot be processed and reshaped once synthesized. Non-cross-linked polymers and those with reversible cross-links are processable, but they are soluble. We designed epoxy networks that can rearrange their topology by exchange reactions without depolymerization and showed that they are insoluble and processable. Unlike organic compounds and polymers whose viscosity varies abruptly near the glass transition, these networks show Arrhenius-like gradual viscosity variations like those of vitreous silica. Like silica, the materials can be wrought and welded to make complex objects by local heating without the use of molds. The concept of a glass made by reversible topology freezing in epoxy networks can be readily scaled up for applications and generalized to other chemistries.	[Montarnal, Damien; Capelot, Mathieu; Tournilhac, Francois; Leibler, Ludwik] Ecole Super Phys & Chim Ind Ville Paris, UMR CNRS ESPCI 7167, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Leibler, L (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, UMR CNRS ESPCI 7167, 10 Rue Vauquelin, F-75005 Paris, France.	ludwik.leibler@espci.fr	Capelot, Mathieu/I-7831-2012	Capelot, Mathieu/0000-0002-9310-8162; Montarnal, Damien/0000-0003-3246-3467	ESPCI; CNRS; Arkema	ESPCI; CNRS(Centre National de la Recherche Scientifique (CNRS)); Arkema	We gratefully acknowledge helpful discussions, with H. A. H. Meijer and A. J. Ryan on polymer processing, with K. Matyjaszewski on chemical reactions and catalysis, and with F. Krzakala and A. Maggs on glass transition. We are indebted to L. Breucker and S. Abadie for help with experiments. We acknowledge funding from ESPCI, CNRS and Arkema. The authors are declared to be inventors on three patents filed by CNRS related to the work presented here: L. Leibler, D. Montarnal, F. Tournilhac, M. Capelot, FR10.54213 (2010); FR11.50888 (2011); and FR11.50546 (2011).	Adzima BJ, 2008, MACROMOLECULES, V41, P9112, DOI 10.1021/ma801863d; Amamoto Y, 2011, ANGEW CHEM INT EDIT, V50, P1660, DOI 10.1002/anie.201003888; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; [Anonymous], 1980, VISCOELASTIC PROPERT; Chen XX, 2002, SCIENCE, V295, P1698, DOI 10.1126/science.1065879; DEAM RT, 1976, PHILOS T R SOC A, V280, P317, DOI 10.1098/rsta.1976.0001; Dyre JC, 2006, REV MOD PHYS, V78, P953, DOI 10.1103/RevModPhys.78.953; Ghosh B, 2009, SCIENCE, V323, P1458, DOI 10.1126/science.1167391; GREEN MS, 1946, J CHEM PHYS, V14, P80, DOI 10.1063/1.1724109; Higaki Y, 2006, MACROMOLECULES, V39, P2121, DOI 10.1021/ma052093g; Kloxin CJ, 2010, MACROMOLECULES, V43, P2643, DOI 10.1021/ma902596s; KUDRYAVTSEV RV, 1957, ZH OBSHCH KHIM+, V27, P1686; Lehn JM, 2005, PROG POLYM SCI, V30, P814, DOI 10.1016/j.progpolymsci.2005.06.002; LEIBLER L, 1993, J PHYS II, V3, P1581, DOI 10.1051/jp2:1993219; Maeda T, 2009, PROG POLYM SCI, V34, P581, DOI 10.1016/j.progpolymsci.2009.03.001; May C.A., 1988, EPOXY RESINS CHEM TE; Nicolay R, 2010, MACROMOLECULES, V43, P4355, DOI 10.1021/ma100378r; OTERA J, 1993, CHEM REV, V93, P1449, DOI 10.1021/cr00020a004; Park HY, 2010, MACROMOLECULES, V43, P10188, DOI 10.1021/ma1020209; PLAZEK DJ, 1971, J POLYM SCI A2, V9, P209, DOI 10.1002/pol.1971.160090202; PLAZEK DJ, 1994, J NON-CRYST SOLIDS, V172, P181, DOI 10.1016/0022-3093(94)90431-6; Reutenauer P, 2009, CHEM-EUR J, V15, P1893, DOI 10.1002/chem.200802145; Rowan SJ, 2002, ANGEW CHEM INT EDIT, V41, P898, DOI 10.1002/1521-3773(20020315)41:6<898::AID-ANIE898>3.0.CO;2-E; Rubinstein M, 1998, MACROMOLECULES, V31, P1386, DOI 10.1021/ma970617+; Scott TF, 2005, SCIENCE, V308, P1615, DOI 10.1126/science.1110505; Tanaka F., 2011, POLYM PHYS APPL MOL; URBAIN G, 1982, GEOCHIM COSMOCHIM AC, V46, P1061, DOI 10.1016/0016-7037(82)90059-X; Wojtecki RJ, 2011, NAT MATER, V10, P14, DOI [10.1038/nmat2891, 10.1038/NMAT2891]; Zhang Y, 2009, MACROMOLECULES, V42, P1906, DOI 10.1021/ma8027672	29	1492	1557	146	1603	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					965	968		10.1126/science.1212648	http://dx.doi.org/10.1126/science.1212648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096195				2022-12-28	WOS:000297101800052
J	Blendon, RJ; Kim, MK; Benson, JM				Blendon, Robert J.; Kim, Minah Kang; Benson, John M.			The Public, Political Parties, and Stem-Cell Research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Blendon, Robert J.; Kim, Minah Kang; Benson, John M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Blendon, Robert J.] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; [Kim, Minah Kang] Ewha Womans Univ, Seoul, South Korea	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Ewha Womans University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.							[Anonymous], 2010, EUR 73 1 BIOT; Cohen IG, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1105088; JAN T, 2011, BOSTON GLOBE    0807; Nisbet MC, 2005, INT J PUBLIC OPIN R, V17, P90, DOI 10.1093/ijpor/edh058	4	13	13	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1853	1856		10.1056/NEJMp1110340	http://dx.doi.org/10.1056/NEJMp1110340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848HG	22087677				2022-12-28	WOS:000297041900002
J	Vega, ME; Civic, B				Vega, Maria Elena; Civic, Brian			A Tension Bulla Mimicking Tension Pneumothorax	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Vega, Maria Elena; Civic, Brian] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Vega, ME (corresponding author), Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA.	maria.vegasanchez@tuhs.temple.edu							0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1915	1915		10.1056/NEJMicm1101918	http://dx.doi.org/10.1056/NEJMicm1101918			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087682				2022-12-28	WOS:000297041900010
J	Watanabe, K; Funaki, M				Watanabe, Kenta; Funaki, Maki			Zoster of the Tympanic Membrane	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Watanabe, Kenta; Funaki, Maki] Tokyo Metropolitan Tama Med Ctr, Tokyo, Japan		Watanabe, K (corresponding author), Tokyo Metropolitan Tama Med Ctr, Tokyo, Japan.	quentaw@aol.com							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					E40	E40		10.1056/NEJMicm1104444	http://dx.doi.org/10.1056/NEJMicm1104444			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087704				2022-12-28	WOS:000297041900001
J	Bradnock, TJ; Marven, S; Owen, A; Johnson, P; Kurinczuk, JJ; Spark, P; Draper, ES; Knight, M				Bradnock, Timothy J.; Marven, Sean; Owen, Anthony; Johnson, Paul; Kurinczuk, Jennifer J.; Spark, Patsy; Draper, Elizabeth S.; Knight, Marian		BAPS-CASS	Gastroschisis: one year outcomes from national cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPRING-LOADED SILO; RISK STRATIFICATION; PREFORMED SILO; UNITED-STATES; INFANTS; MANAGEMENT; EXPERIENCE; REDUCTION; CLOSURE; CARE	Objective To describe one year outcomes for a national cohort of infants with gastroschisis. Design Population based cohort study of all liveborn infants with gastroschisis born in the United Kingdom and Ireland from October 2006 to March 2008. Setting All 28 paediatric surgical centres in the UK and Ireland. Participants 301 infants (77%) from an original cohort of 393. Main outcome measures Duration of parenteral nutrition and stay in hospital; time to establish full enteral feeding; rates of intestinal failure, liver disease associated with intestinal failure, unplanned reoperation; case fatality. Results Compared with infants with simple gastroschisis (intact, uncompromised, continuous bowel), those with complex gastroschisis (bowel perforation, necrosis, or atresia) took longer to reach full enteral feeding (median difference 21 days, 95% confidence interval 9 to 39 days); required a longer duration of parenteral nutrition (median difference 25 days, 9 to 46 days) and a longer stay in hospital (median difference 57 days, 29 to 95 days); were more likely to develop intestinal failure (81% (25 infants) v 41% (102); relative risk 1.96, 1.56 to 2.46) and liver disease associated with intestinal failure (23% (7) v 4% (11); 5.13, 2.15 to 12.3); and were more likely to require unplanned reoperation (42% (13) v 10% (24); 4.39, 2.50 to 7.70). Compared with infants managed with primary fascial closure, those managed with preformed silos took longer to reach full enteral feeding (median difference 5 days, 1 to 9) and had an increased risk of intestinal failure (52% (50) v 32% (38); 1.61, 1.17 to 2.24). Event rates for the other outcomes were low, and there were no other significant differences between these management groups. Twelve infants died (4%). Conclusions This nationally representative study provides a benchmark against which individual centres can measure outcome and performance. Stratifying neonates with gastroschisis into simple and complex groups reliably predicts outcome at one year. There is sufficient clinical equipoise concerning the initial management strategy to embark on a multicentre randomised controlled trial comparing primary fascial closure with preformed silos in infants suitable at presentation for either treatment to determine the optimal initial management strategy and define algorithms of care.	[Kurinczuk, Jennifer J.; Knight, Marian] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; [Bradnock, Timothy J.] Royal Hosp Sick Children, Dept Paediat Surg, Glasgow G3 8SJ, Lanark, Scotland; [Marven, Sean; Owen, Anthony] Sheffield Childrens Hosp NHS Fdn Trust, Paediat Surg Unit, Sheffield, S Yorkshire, England; [Johnson, Paul] Univ Oxford, Dept Paediat Surg, Oxford OX3 7LF, England; [Draper, Elizabeth S.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England	University of Oxford; University of Glasgow; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Oxford; University of Leicester	Knight, M (corresponding author), Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England.	marian.knight@npeu.ox.ac.uk	Draper, Elizabeth S/I-6304-2018; Draper, Elizabeth/S-6874-2019; Wilkinson, David/B-7562-2011; Knight, Marian/B-6225-2009	Draper, Elizabeth S/0000-0001-9340-8176; Draper, Elizabeth/0000-0001-9340-8176; Wilkinson, David/0000-0001-5165-8230; Knight, Marian/0000-0002-1984-4575; Ong, Evelyn/0000-0002-5064-2795; Lander, Anthony/0000-0003-0503-5512; Morabito, Antonino/0000-0002-5323-3620	charity BDF Newlife; British Association of Paediatric Surgeons	charity BDF Newlife; British Association of Paediatric Surgeons	This study was funded by the charity BDF Newlife and the British Association of Paediatric Surgeons. The study funders played no part in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. All authors are independent of the funders.	Abdullah F, 2007, J PERINATOL, V27, P50, DOI 10.1038/sj.jp.7211616; ALLEN RG, 1969, J PEDIATR SURG, V4, P3, DOI 10.1016/0022-3468(69)90177-8; Allotey J, 2007, PEDIATR SURG INT, V23, P1065, DOI 10.1007/s00383-007-2004-9; Alvarez SM, 2007, J PEDIATR SURG, V42, P943, DOI 10.1016/j.jpedsurg.2007.01.026; Arnold MA, 2007, J PEDIATR SURG, V42, P1520, DOI 10.1016/j.jpedsurg.2007.04.032; Arnold MA, 2007, J PEDIATR SURG, V42, P950, DOI 10.1016/j.jpedsurg.2007.01.028; Banyard D, 2010, J PEDIATR SURG, V45, P579, DOI 10.1016/j.jpedsurg.2009.08.004; Bianchi A, 2002, J PEDIATR SURG, V37, P1334, DOI 10.1053/jpsu.2002.35003; CANIANO DA, 1990, J PEDIATR SURG, V25, P297, DOI 10.1016/0022-3468(90)90070-P; Chang DC, 2010, SURGERY, V147, P766, DOI 10.1016/j.surg.2010.01.025; Eggink BH, 2006, J PEDIATR SURG, V41, P1103, DOI 10.1016/j.jpedsurg.2006.02.008; European Surveillance of Congenital Anomalies (EUROCAT), 2001, 8 EUROCAT CENTR REG; FISCHER JD, 1995, J PEDIATR SURG, V30, P1169, DOI 10.1016/0022-3468(95)90014-4; FONKALSRUD EW, 1993, ANN SURG, V218, P742, DOI 10.1097/00000658-199312000-00007; [Intestinal Failure Working Group British Society of Paediatric Gastroenterology Hepatology and Nutrition British Association of Paediatric Surgeons], INT FAIL REC TERT MA; Islam S, 2008, CURR OPIN PEDIATR, V20, P305, DOI 10.1097/MOP.0b013e3282ffdc1e; Jager LC, 2007, PEDIATR SURG INT, V23, P731, DOI 10.1007/s00383-007-1960-4; Keys C, 2008, J PEDIATR SURG, V43, P654, DOI 10.1016/j.jpedsurg.2007.12.005; Kilby MD, 2006, BMJ-BRIT MED J, V332, P250, DOI 10.1136/bmj.332.7536.250; Knight M, 2005, BJOG-INT J OBSTET GY, V112, P263, DOI 10.1111/j.1471-0528.2005.00609.x; Knutrud O, 1979, Prog Pediatr Surg, V13, P51; Lao OB, 2010, AM J PERINAT, V27, P97, DOI 10.1055/s-0029-1241729; Laughon Matthew, 2003, J Perinatol, V23, P291, DOI 10.1038/sj.jp.7210896; Mills JA, 2010, J PERINATOL, V30, P809, DOI 10.1038/jp.2010.43; Minkes RK, 2000, J PEDIATR SURG, V35, P843, DOI 10.1053/jpsu.2000.6858; Molik KA, 2001, J PEDIATR SURG, V36, P51, DOI 10.1053/jpsu.2001.20004; Nembhard WN, 2001, TERATOLOGY, V64, P267, DOI 10.1002/tera.1073; Owen A, 2006, J PEDIATR SURG, V41, P1830, DOI 10.1016/j.jpedsurg.2006.06.048; Owen A, 2010, J PEDIATR SURG, V45, P1808, DOI 10.1016/j.jpedsurg.2010.01.036; Pastor AC, 2008, J PEDIATR SURG, V43, P1807, DOI 10.1016/j.jpedsurg.2008.04.003; Robbins J. M., 2007, Morbidity and Mortality Weekly Report, V56, P25; Schlatter M, 2003, J PEDIATR SURG, V38, P459, DOI 10.1053/jpsu.2003.50079; Skarsgard ED, 2008, J PEDIATR SURG, V43, P30, DOI 10.1016/j.jpedsurg.2007.09.011; Weinsheimer RL, 2008, J PEDIATR SURG, V43, P874, DOI 10.1016/j.jpedsurg.2007.12.030	34	105	110	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2011	343								d6749	10.1136/bmj.d6749	http://dx.doi.org/10.1136/bmj.d6749			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LU	22089731	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000297497000001
J	Tanner, M				Tanner, Michael			Review: Pregabalin and other drugs reduce pain in patients with painful diabetic neuropathy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU Med Ctr, Bellevue Hosp, New York, NY 10016 USA	Bellevue Hospital Center; New York University	Tanner, M (corresponding author), NYU Med Ctr, Bellevue Hosp, New York, NY 10016 USA.			Tanner, Michael/0000-0002-3012-8641				SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401	1	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-8	10.7326/0003-4819-155-10-201111150-02008	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084355				2022-12-28	WOS:000208885300007
J	Szijgyarto, Z; Garedew, A; Azevedo, C; Saiardi, A				Szijgyarto, Zsolt; Garedew, Assegid; Azevedo, Cristina; Saiardi, Adolfo			Influence of Inositol Pyrophosphates on Cellular Energy Dynamics	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GENE DELETION; CELLS; PYROPHOSPHORYLATION; PHOSPHORYLATION; REQUIREMENT; METABOLISM; GALACTOSE	With its high-energy phosphate bonds, adenosine triphosphate (ATP) is the main intracellular energy carrier. It also functions in most signaling pathways, as a phosphate donor or a precursor for cyclic adenosine monophosphate. We show here that inositol pyrophosphates participate in the control of intracellular ATP concentration. Yeasts devoid of inositol pyrophosphates have dysfunctional mitochondria but, paradoxically, contain four times as much ATP because of increased glycolysis. We demonstrate that inositol pyrophosphates control the activity of the major glycolytic transcription factor GCR1. Thus, inositol pyrophosphates regulate ATP concentration by altering the glycolytic/mitochondrial metabolic ratio. Metabolic reprogramming through inositol pyrophosphates is an evolutionary conserved mechanism that is also preserved in mammalian systems.	[Szijgyarto, Zsolt; Azevedo, Cristina; Saiardi, Adolfo] UCL, Med Res Council Lab Mol Cell Biol, Cell Biol Unit, London WC1E 6BT, England; [Szijgyarto, Zsolt; Azevedo, Cristina; Saiardi, Adolfo] UCL, Dept Cell & Dev Biol, London WC1E 6BT, England; [Garedew, Assegid] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Saiardi, A (corresponding author), UCL, Med Res Council Lab Mol Cell Biol, Cell Biol Unit, Gower St, London WC1E 6BT, England.	dmcbado@ucl.ac.uk	Azevedo, Cristina/Y-4296-2019	Azevedo, Cristina/0000-0002-6997-1265	Medical Research Council (MRC) [G1001704]; Human Frontier Science Program [RGP0048/2009-C]; British Heart Foundation [PG/10/72/28449]; Medical Research Council [G1001704, MC_U122680443] Funding Source: researchfish; MRC [G1001704, MC_U122680443] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Human Frontier Science Program(Human Frontier Science Program); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank R. Bhandari, A. Resnick, A. Riccio, and M. Raff for reading the manuscript and M. Bennett for his contribution in the initial phase of the project. This work was supported by the Medical Research Council (MRC) funding to the Cell Biology Unit and by a Human Frontier Science Program Grant (RGP0048/2009-C). A.G. was supported by the British Heart Foundation grant PG/10/72/28449 and MRC grant G1001704.	Azevedo C, 2009, P NATL ACAD SCI USA, V106, P21161, DOI 10.1073/pnas.0909176106; BALLWJ, 1975, J BACTERIOL, V121, P975; Barker CJ, 2009, CELL MOL LIFE SCI, V66, P3851, DOI 10.1007/s00018-009-0115-2; Bennett M, 2006, CELL MOL LIFE SCI, V63, P552, DOI 10.1007/s00018-005-5446-z; Bhandari R, 2008, P NATL ACAD SCI USA, V105, P2349, DOI 10.1073/pnas.0712227105; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Burton A, 2009, J CELL PHYSIOL, V220, P8, DOI 10.1002/jcp.21763; Chakraborty A, 2010, CELL, V143, P897, DOI 10.1016/j.cell.2010.11.032; Garedew A, 2008, J CELL SCI, V121, P3468, DOI 10.1242/jcs.034660; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Mizuno T, 2004, YEAST, V21, P851, DOI 10.1002/yea.1123; Morrison BH, 2009, ONCOGENE, V28, P2383, DOI 10.1038/onc.2009.113; Onnebo SMN, 2009, BIOCHEM J, V423, P109, DOI 10.1042/BJ20090241; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Shears SB, 2009, MOL PHARMACOL, V76, P236, DOI 10.1124/mol.109.055897; SIMS AP, 1978, J GEN MICROBIOL, V106, P277, DOI 10.1099/00221287-106-2-277; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Zeng X, 1997, GENETICS, V147, P493	23	144	155	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					802	805		10.1126/science.1211908	http://dx.doi.org/10.1126/science.1211908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076377				2022-12-28	WOS:000296849600046
J	Yu, M; Wang, CB; Kyle, AF; Jakubec, P; Dixon, DJ; Schrock, RR; Hoveyda, AH				Yu, Miao; Wang, Chenbo; Kyle, Andrew F.; Jakubec, Pavol; Dixon, Darren J.; Schrock, Richard R.; Hoveyda, Amir H.			Synthesis of macrocyclic natural products by catalyst-controlled stereoselective ring-closing metathesis	NATURE			English	Article							MICROTUBULE-STABILIZING AGENTS; ALKYNE METATHESIS; EPOTHILONE-A; MOLYBDENUM; EFFICIENT; NAKADOMARIN; COMPLEXES; ANALOGS	Many natural products contain a C=C double bond through which various other derivatives can be prepared; the stereochemical identity of the alkene can be critical to the biological activities of such molecules. Catalytic ring-closing metathesis (RCM) is a widely used method for the synthesis of large unsaturated rings(1,2); however, cyclizations often proceed without control of alkene stereochemistry(2). This shortcoming is particularly costly when the cyclization reaction is performed after a long sequence of other chemical transformations(2). Here we outline a reliable, practical and general approach for the efficient and highly stereoselective synthesis of macrocyclic alkenes by catalytic RCM; transformations deliver up to 97% of the Z isomer owing to control induced by a tungsten-based alkylidene. Utility is demonstrated through the stereoselective preparation of epothilone C (refs 3-5) and nakadomarin A (ref. 6), the previously reported syntheses of which have been marred by late-stage, non-selective RCM(7-12). The tungsten alkylidene can be manipulated in air, delivering the products in useful yields with high stereoselectivity. As a result of efficient RCM and re-incorporation of side products into the catalytic cycle with minimal alkene isomerization, desired cyclizations proceed in preference to alternative pathways, even under relatively high substrate concentration.	[Yu, Miao; Wang, Chenbo; Hoveyda, Amir H.] Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; [Kyle, Andrew F.; Jakubec, Pavol; Dixon, Darren J.] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; [Schrock, Richard R.] MIT, Dept Chem, Cambridge, MA 02139 USA	Boston College; University of Oxford; Massachusetts Institute of Technology (MIT)	Hoveyda, AH (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.	amir.hoveyda@bc.edu		Jakubec, Pavol/0000-0001-8872-3817	United States National Institutes of Health, Institute of General Medical Sciences [GM-59426]; EPSRC-GlaxoSmithKline; EPSRC; Engineering and Physical Sciences Research Council [EP/G007802/1] Funding Source: researchfish; EPSRC [EP/G007802/1] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059426] Funding Source: NIH RePORTER	United States National Institutes of Health, Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EPSRC-GlaxoSmithKline(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the United States National Institutes of Health, Institute of General Medical Sciences (grant GM-59426 to A. H. H. and R. R. S.). M. Y. is a John LaMattina graduate fellow, A. F. K. the recipient of an EPSRC-GlaxoSmithKline synthesis studentship, and P.J. an EPSRC postdoctoral fellow. D.J.D. is grateful for an EPSRC leadership fellowship. We thank S. J. Meek, S. J. Malcolmson, R. V. O'Brien, T. J. Mann and E. T. Kiesewetter for discussions; A. R. Zhugralin, S. Torker and D. L. Silverio for DFT calculations; K. Wu for experimental assistance; and Boston College for providing access to computational facilities. The X-ray facilities at Boston College are supported by the United States National Science Foundation (CHE-0923264).	Altmann KH, 2002, HELV CHIM ACTA, V85, P4086, DOI 10.1002/1522-2675(200211)85:11<4086::AID-HLCA4086>3.0.CO;2-7; BOLLAG DM, 1995, CANCER RES, V55, P2325; Coutelier O, 2006, ADV SYNTH CATAL, V348, P2038, DOI 10.1002/adsc.200606116; Furstner A, 2002, CHEM-EUR J, V8, P1856, DOI 10.1002/1521-3765(20020415)8:8<1856::AID-CHEM1856>3.0.CO;2-R; Furstner A, 2001, CHEM-EUR J, V7, P5299, DOI 10.1002/1521-3765(20011217)7:24<5299::AID-CHEM5299>3.0.CO;2-X; Furstner A, 1997, SYNTHESIS-STUTTGART, P792, DOI 10.1055/s-1997-4472; Garber SB, 2000, J AM CHEM SOC, V122, P8168, DOI 10.1021/ja001179g; Gradillas A, 2006, ANGEW CHEM INT EDIT, V45, P6086, DOI 10.1002/anie.200600641; Hofle GH, 1996, ANGEW CHEM INT EDIT, V35, P1567, DOI 10.1002/anie.199615671; Hoveyda AH, 2007, NATURE, V450, P243, DOI 10.1038/nature06351; Ibrahem I, 2009, J AM CHEM SOC, V131, P3844, DOI 10.1021/ja900097n; Jakubec P, 2009, J AM CHEM SOC, V131, P16632, DOI 10.1021/ja908399s; Jiang AJ, 2009, J AM CHEM SOC, V131, P16630, DOI 10.1021/ja908098t; Kobayashi J, 1997, J ORG CHEM, V62, P9236, DOI 10.1021/jo9715377; Kowalski RJ, 1997, J BIOL CHEM, V272, P2534; Malcolmson SJ, 2008, NATURE, V456, P933, DOI 10.1038/nature07594; Meek SJ, 2011, NATURE, V471, P461, DOI 10.1038/nature09957; Meng DF, 1997, J AM CHEM SOC, V119, P10073, DOI 10.1021/ja971946k; Nagata T, 2003, J AM CHEM SOC, V125, P7484, DOI 10.1021/ja034464j; Nicolaou KC, 1997, J AM CHEM SOC, V119, P7960, DOI 10.1021/ja971109i; Nilson MG, 2010, ORG LETT, V12, P4912, DOI 10.1021/ol102079z; Ono K, 2004, ANGEW CHEM INT EDIT, V43, P2020, DOI 10.1002/anie.200453673; Schinzer D, 1999, CHEM-EUR J, V5, P2483, DOI 10.1002/(SICI)1521-3765(19990903)5:9<2483::AID-CHEM2483>3.0.CO;2-N; Scholl M, 1999, ORG LETT, V1, P953, DOI 10.1021/ol990909q; Schrock RR, 2003, ANGEW CHEM INT EDIT, V42, P4592, DOI 10.1002/anie.200300576; Smith BJ, 2010, ANGEW CHEM INT EDIT, V49, P1599, DOI 10.1002/anie.200905732; Starks CM, 2003, J NAT PROD, V66, P1313, DOI 10.1021/np030218+; Wang YK, 2011, J AM CHEM SOC, V133, P9196, DOI 10.1021/ja202012s; Young IS, 2007, J AM CHEM SOC, V129, P1465, DOI 10.1021/ja068047t; Zhang W, 2007, ADV SYNTH CATAL, V349, P93, DOI 10.1002/adsc.200600476	30	154	178	1	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					88	93		10.1038/nature10563	http://dx.doi.org/10.1038/nature10563			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051677	Green Accepted			2022-12-28	WOS:000296422600037
J	Ding, BS; Nolan, DJ; Guo, PP; Babazadeh, AO; Cao, ZW; Rosenwaks, Z; Crystal, RG; Simons, M; Sato, TN; Worgall, S; Shido, K; Rabbany, SY; Rafii, S				Ding, Bi-Sen; Nolan, Daniel J.; Guo, Peipei; Babazadeh, Alexander O.; Cao, Zhongwei; Rosenwaks, Zev; Crystal, Ronald G.; Simons, Michael; Sato, Thomas N.; Worgall, Stefan; Shido, Koji; Rabbany, Sina Y.; Rafii, Shahin			Endothelial-Derived Angiocrine Signals Induce and Sustain Regenerative Lung Alveolarization	CELL			English	Article							MATRIX METALLOPROTEINASES; GROWTH-FACTOR; PROGENITOR CELLS; VASCULAR NICHE; SELF-RENEWAL; CROSS-TALK; VEGF-A; REPAIR; MAINTENANCE; EXPRESSION	To identify pathways involved in adult lung regeneration, we employ a unilateral pneumonectomy (PNX) model that promotes regenerative alveolarization in the remaining intact lung. We show that PNX stimulates pulmonary capillary endothelial cells (PCECs) to produce angiocrine growth factors that induce proliferation of epithelial progenitor cells supporting alveologenesis. Endothelial cells trigger expansion of cocultured epithelial cells, forming three-dimensional angiospheres reminiscent of alveolar-capillary sacs. After PNX, endothelial-specific inducible genetic ablation of Vegfr2 and Fgfr1 in mice inhibits production of MMP14, impairing alveolarization. MMP14 promotes expansion of epithelial progenitor cells by unmasking cryptic EGF-like ectodomains that activate the EGF receptor (EGFR). Consistent with this, neutralization of MMP14 impairs EGFR-mediated alveolar regeneration, whereas administration of EGF or intravascular transplantation of MMP14(+) PCECs into pneumonectomized Vegfr2/Fgfr1-deficient mice restores alveologenesis and lung inspiratory volume and compliance function. VEGFR2 and FGFR1 activation in PCECs therefore increases MMP14-dependent bioavailability of EGFR ligands to initiate and sustain alveologenesis.	[Ding, Bi-Sen; Nolan, Daniel J.; Guo, Peipei; Babazadeh, Alexander O.; Cao, Zhongwei; Crystal, Ronald G.; Worgall, Stefan; Shido, Koji; Rabbany, Sina Y.; Rafii, Shahin] Weill Cornell Med Coll, Dept Med Genet, Ansary Stem Cell Inst, Howard Hughes Med Inst, New York, NY 10065 USA; [Rosenwaks, Zev] Weill Cornell Med Coll, Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY 10065 USA; [Simons, Michael] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Sato, Thomas N.] Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300192, Japan; [Rabbany, Sina Y.] Hofstra Univ, Bioengn Program, Hempstead, NY 11549 USA	Cornell University; Howard Hughes Medical Institute; Cornell University; Yale University; Nara Institute of Science & Technology; Hofstra University	Rafii, S (corresponding author), Weill Cornell Med Coll, Dept Med Genet, Ansary Stem Cell Inst, Howard Hughes Med Inst, New York, NY 10065 USA.	srafii@med.cornell.edu	Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734	Ansary Stem Cell Institute; Howard Hughes Medical Institute; Empire State Stem Cell Board and New York State Department of Health [NYSTEM, C024180, C026438, C026878]; National Heart Lung and Blood Institute; Qatar National Priorities Research Foundation [NPRP08-663-3-140]; Anbinder and Newmans Own Foundation; Takeda Science Foundation; Uehara Memorial Foundation; JSPS;  [R01HL53793]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097797, RC2HL101846, R01HL053793, P50HL084936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [RC1AI080309] Funding Source: NIH RePORTER	Ansary Stem Cell Institute; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Empire State Stem Cell Board and New York State Department of Health; National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Qatar National Priorities Research Foundation; Anbinder and Newmans Own Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Uehara Memorial Foundation(Uehara Memorial Foundation); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	B.-S.D. is a Druckenmiller Fellow of New York Stem Cell Foundation. S. R. is supported by Ansary Stem Cell Institute; Howard Hughes Medical Institute; Empire State Stem Cell Board and New York State Department of Health grants (NYSTEM, C024180, C026438, C026878); National Heart Lung and Blood Institute; Qatar National Priorities Research Foundation NPRP08-663-3-140; and Anbinder and Newmans Own Foundation. T.N.S. is supported by Takeda Science Foundation, Uehara Memorial Foundation, JSPS (Kiban S). M. S. is supported by R01HL53793. VE-Cad-CreERT2 mice were gift from Dr. Ralf H. Adams (Max Planck Institute). SPC/CCSP-rtTA and (tetO)-cre mice were provided by Drs. Jeffrey A. Whitsett and Anne-Karina T. Perl (Cincinnati Children's Hospital Medical Centre). Fgfr1<SUP>loxP/loxP</SUP> mice were offered by Drs. Michael Simons and Masahiro Murakami (Yale University). The authors are grateful to Ms. Biin Sung for assistance in lung mechanics measurement.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Alvarez DF, 2008, AM J PHYSIOL-LUNG C, V294, pL419, DOI 10.1152/ajplung.00314.2007; Atkinson JJ, 2005, DEV DYNAM, V232, P1079, DOI 10.1002/dvdy.20267; BEERS MF, 1994, J BIOL CHEM, V269, P20318; Beers MF, 2011, J CLIN INVEST, V121, P2065, DOI 10.1172/JCI45961; Bhattacharya J, 2005, CHEST, V128, p553S, DOI 10.1016/S0012-3692(15)30979-X; Butler JM, 2010, CELL STEM CELL, V6, P251, DOI 10.1016/j.stem.2010.02.001; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cardoso WV, 2001, ANNU REV PHYSIOL, V63, P471, DOI 10.1146/annurev.physiol.63.1.471; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673; Chapman HA, 2011, ANNU REV PHYSIOL, V73, P413, DOI 10.1146/annurev-physiol-012110-142225; Chun TH, 2006, CELL, V125, P577, DOI 10.1016/j.cell.2006.02.050; COWAN MJ, 1975, AM REV RESPIR DIS, V111, P267; Del Moral PM, 2006, DEV BIOL, V290, P177, DOI 10.1016/j.ydbio.2005.11.022; DeLisser HM, 2006, J BIOL CHEM, V281, P8724, DOI 10.1074/jbc.M511798200; Ding BS, 2010, NATURE, V468, P310, DOI 10.1038/nature09493; Giordano RJ, 2008, J BIOL CHEM, V283, P29447, DOI 10.1074/jbc.M804595200; Greenlee KJ, 2007, PHYSIOL REV, V87, P69, DOI 10.1152/physrev.00022.2006; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Irie Kazuharu, 2005, Medical Molecular Morphology, V38, P43, DOI 10.1007/s00795-004-0277-9; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kobayashi H, 2010, NAT CELL BIOL, V12, P1046, DOI 10.1038/ncb2108; Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev-physiol-021909-135833; Koshikawa N, 2010, CANCER RES, V70, P6093, DOI 10.1158/0008-5472.CAN-10-0346; Kotton DN, 2008, CELL TISSUE RES, V331, P145, DOI 10.1007/s00441-007-0479-2; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Leuwerke SM, 2002, AM J PHYSIOL-LUNG C, V282, pL1272, DOI 10.1152/ajplung.00490.2001; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Liu YR, 2011, J EXP MED, V208, P1473, DOI 10.1084/jem.20102041; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762; Muzykantov Vladimir R, 2005, Expert Opin Drug Deliv, V2, P909, DOI 10.1517/17425247.2.5.909; Nolen-Walston RD, 2008, AM J PHYSIOL-LUNG C, V294, pL1158, DOI 10.1152/ajplung.00298.2007; Oblander SA, 2005, DEV BIOL, V277, P255, DOI 10.1016/j.ydbio.2004.09.033; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Sakaguchi TF, 2008, CURR BIOL, V18, P1565, DOI 10.1016/j.cub.2008.08.065; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Seandel M, 2008, P NATL ACAD SCI USA, V105, P19288, DOI 10.1073/pnas.0805980105; Shu WG, 2002, DEVELOPMENT, V129, P4831; Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872; Stratman AN, 2009, BLOOD, V114, P237, DOI 10.1182/blood-2008-12-196451; Stripp Barry R, 2008, Proc Am Thorac Soc, V5, P328, DOI 10.1513/pats.200711-167DR; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005; Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002; Warburton D, 2010, CURR TOP DEV BIOL, V90, P73, DOI 10.1016/S0070-2153(10)90003-3; White AC, 2007, DEVELOPMENT, V134, P3743, DOI 10.1242/dev.004879; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; Yamamoto H, 2007, DEV BIOL, V308, P44, DOI 10.1016/j.ydbio.2007.04.042; Yana I, 2007, J CELL SCI, V120, P1607, DOI 10.1242/jcs.000679; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	68	327	342	1	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					539	553		10.1016/j.cell.2011.10.003	http://dx.doi.org/10.1016/j.cell.2011.10.003			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036563	Green Accepted, Bronze			2022-12-28	WOS:000296573700010
J	Waggoner, SN; Cornberg, M; Selin, LK; Welsh, RM				Waggoner, Stephen N.; Cornberg, Markus; Selin, Liisa K.; Welsh, Raymond M.			Natural killer cells act as rheostats modulating antiviral T cells	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; INFECTION; RESPONSES; MICE; HLA; IDENTIFICATION; PATHOGENESIS; CHAIN	Antiviral T cells are thought to regulate whether hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections result in viral control, asymptomatic persistence or severe disease, although the reasons for these different outcomes remain unclear. Recent genetic evidence, however, has indicated a correlation between certain natural killer (NK)-cell receptors and progression of both HIV and HCV infection(1-3), implying that NK cells have a role in these T-cell-associated diseases. Although direct NK-cell-mediated lysis of virus-infected cells may contribute to antiviral defence during some virus infections-especially murine cytomegalovirus (MCMV) infections in mice and perhaps HIV in humans(4,5)-NK cells have also been suspected of having immunoregulatory functions. For instance, NK cells may indirectly regulate T-cell responses by lysing MCMV-infected antigen-presenting cells(6,7). In contrast to MCMV, lymphocytic choriomeningitis virus (LCMV) infection in mice seems to be resistant to any direct antiviral effects of NK cells(5,8). Here we examine the roles of NK cells in regulating T-cell-dependent viral persistence and immunopathology in mice infected with LCMV, an established model for HIV and HCV infections in humans. We describe a three-way interaction, whereby activated NK cells cytolytically eliminate activated CD4 T cells that affect CD8 T-cell function and exhaustion. At high virus doses, NK cells prevented fatal pathology while enabling T-cell exhaustion and viral persistence, but at medium doses NK cells paradoxically facilitated lethal T-cell-mediated pathology. Thus, NK cells can act as rheostats, regulating CD4 T-cell-mediated support for the antiviral CD8 T cells that control viral pathogenesis and persistence.	[Waggoner, Stephen N.; Selin, Liisa K.; Welsh, Raymond M.] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; [Waggoner, Stephen N.; Selin, Liisa K.; Welsh, Raymond M.] Univ Massachusetts, Sch Med, Program Immunol & Virol, Worcester, MA 01655 USA; [Cornberg, Markus] Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Hannover Medical School	Welsh, RM (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA.	Raymond.Welsh@umassmed.edu	Cornberg, Markus/AAN-6939-2021; HAMID, SHARIFAH BEE ABD/B-9749-2010	Cornberg, Markus/0000-0002-9141-8001; HAMID, SHARIFAH BEE ABD/0000-0002-5104-3938; Waggoner, Stephen/0000-0001-9658-2874; Selin, Liisa/0000-0002-6993-4333	National Institutes of Health (NIH) [AI07349, AI-17672, AI-081675, CA34461, AI46578]; German Research Foundation [CO310-2/1]; institutional Diabetes Endocrinology Research Center (DERC) [DK52530]; NATIONAL CANCER INSTITUTE [R01CA034461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI017672, R01AI081675, R01AI017672, T32AI007349, R01AI046578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052530] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation(German Research Foundation (DFG)); institutional Diabetes Endocrinology Research Center (DERC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank K. Hearn, C. Baer, J. Suschak and P. Afriyie for technical support; K. Daniels and M. Seedhom for insightful discussions; R. Taniguchi and V. Kumar for sharing unpublished observations; and H. Ducharme for mouse husbandry. We thank L. Berg for NKT tetramer, L. Lanier for anti-NKG2D blocking antibody (CX5), B. Polic for Nkg2d<SUP>-/-</SUP> mice and M. Exley for Cd1d<SUP>-/-</SUP> mice. This work was supported by National Institutes of Health (NIH) training grant AI07349 (S.N.W.) and research grants AI-17672, AI-081675, CA34461 (R. M. W.), AI46578 (L. K. S.), a German Research Foundation fellowship CO310-2/1 (M. C.) and an institutional Diabetes Endocrinology Research Center (DERC) grant DK52530. The views expressed are those of the authors and do not necessarily express the views of the NIH.	AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Alter G, 2011, NATURE, V476, P96, DOI 10.1038/nature10237; Andrews DM, 2010, J EXP MED, V207, P1333, DOI 10.1084/jem.20091193; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BUKOWSKI JF, 1984, J VIROL, V52, P119, DOI 10.1128/JVI.52.1.119-128.1984; BUKOWSKI JF, 1983, J IMMUNOL, V131, P1531; Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182; Exley MA, 2003, IMMUNOLOGY, V110, P519, DOI 10.1111/j.1365-2567.2003.01779.x; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Fuller MJ, 2004, J IMMUNOL, V172, P4204, DOI 10.4049/jimmunol.172.7.4204; Jennes W, 2006, J IMMUNOL, V177, P6588, DOI 10.4049/jimmunol.177.10.6588; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Mylin LM, 2000, J VIROL, V74, P6922, DOI 10.1128/JVI.74.15.6922-6934.2000; NAGANUMA H, 1991, INT J CANCER, V47, P527, DOI 10.1002/ijc.2910470410; Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008; Oldstone MBA, 2002, CURR TOP MICROBIOL, V263, P83; Oxenius A, 1995, EUR J IMMUNOL, V25, P3402, DOI 10.1002/eji.1830251230; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Rivas MN, 2010, J IMMUNOL, V184, P6790, DOI 10.4049/jimmunol.0902598; Robbins SH, 2007, PLOS PATHOG, V3, P1152, DOI 10.1371/journal.ppat.0030123; Soderquest K, 2011, J IMMUNOL, V186, P3304, DOI 10.4049/jimmunol.1004122; Su HC, 2001, EUR J IMMUNOL, V31, P3048, DOI 10.1002/1521-4141(2001010)31:10<3048::AID-IMMU3048>3.0.CO;2-1; van der Most RG, 1998, VIROLOGY, V240, P158, DOI 10.1006/viro.1997.8934; Waggoner SN, 2010, J CLIN INVEST, V120, P1925, DOI 10.1172/JCI41264; WELSH RM, 1991, J EXP MED, V173, P1053, DOI 10.1084/jem.173.5.1053; WELSH RM, 1986, NAT IMMUN CELL GROW, V5, P169; WELSH RM, 1978, J EXP MED, V148, P163, DOI 10.1084/jem.148.1.163; YANG H, 1985, Natural Immunity and Cell Growth Regulation, V4, P21; Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194; Zafirova B, 2009, IMMUNITY, V31, P270, DOI 10.1016/j.immuni.2009.06.017; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	36	407	417	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					394	U183		10.1038/nature10624	http://dx.doi.org/10.1038/nature10624			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22101430	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000299210600049
J	Clarke, C; Hui, E; Oliver, N; Wynne, K				Clarke, Candice; Hui, Elaine; Oliver, Nick; Wynne, Katie			An unconscious patient	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Clarke, Candice; Hui, Elaine; Oliver, Nick; Wynne, Katie] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London W12 0NN, England	Imperial College London	Wynne, K (corresponding author), Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London W12 0NN, England.	k.wynne@imperial.ac.uk	Oliver, Nick S/G-9109-2016; Wynne, Katie/P-9465-2019	Oliver, Nick S/0000-0003-3525-3633; Wynne, Katie/0000-0002-7980-3337; Clarke, Candice/0000-0001-8576-1017				Chen HF, 2010, INTERNAL MED, V49, P729, DOI 10.2169/internalmedicine.49.2965; FOSTER DW, 1983, NEW ENGL J MED, V309, P159; Kitabchi Abbas E, 2003, Diabetes Care, V26 Suppl 1, pS109; Kitabchi AE, 2001, DIABETES CARE, V24, P131, DOI 10.2337/diacare.24.1.131; Lord GM, 1993, BMJ-BRIT MED J, V307, P6912	5	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2011	343								d7266	10.1136/bmj.d7266	http://dx.doi.org/10.1136/bmj.d7266			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875FW	22102147				2022-12-28	WOS:000299016800003
J	Mokkonen, M; Kokko, H; Koskela, E; Lehtonen, J; Mappes, T; Martiskainen, H; Mills, SC				Mokkonen, Mikael; Kokko, Hanna; Koskela, Esa; Lehtonen, Jussi; Mappes, Tapio; Martiskainen, Henna; Mills, Suzanne C.			Negative Frequency-Dependent Selection of Sexually Antagonistic Alleles in Myodes glareolus	SCIENCE			English	Article							GENETIC-VARIATION; CONFLICT; FITNESS; CONSEQUENCES; DIMORPHISM; EVOLUTION	Sexually antagonistic genetic variation, where optimal values of traits are sex-dependent, is known to slow the loss of genetic variance associated with directional selection on fitness-related traits. However, sexual antagonism alone is not sufficient to maintain variation indefinitely. Selection of rare forms within the sexes can help to conserve genotypic diversity. We combined theoretical models and a field experiment with Myodes glareolus to show that negative frequency-dependent selection on male dominance maintains variation in sexually antagonistic alleles. In our experiment, high-dominance male bank voles were found to have low-fecundity sisters, and vice versa. These results show that investigations of sexually antagonistic traits should take into account the effects of social interactions on the interplay between ecology and evolution, and that investigations of genetic variation should not be conducted solely under laboratory conditions.	[Mokkonen, Mikael; Mappes, Tapio] Univ Jyvaskyla, Ctr Excellence Evolutionary Res, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland; [Kokko, Hanna; Lehtonen, Jussi] Australian Natl Univ, Ctr Excellence Biol Interact, Div Evolut Ecol & Genet, Res Sch Biol, Canberra, ACT 0200, Australia; [Koskela, Esa; Martiskainen, Henna] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland; [Lehtonen, Jussi] Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland; [Mills, Suzanne C.] Univ Perpignan, Lab Excellence CORAIL, USR CRIOBE 3278, CBETM,CNRS EPHE, F-66860 Perpignan, France	University of Jyvaskyla; Australian National University; University of Jyvaskyla; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Perpignan Via Domitia	Mokkonen, M (corresponding author), Univ Jyvaskyla, Ctr Excellence Evolutionary Res, Dept Biol & Environm Sci, Jyvaskyla 40014, Finland.	mikael.mokkonen@gmail.com	Mills, Suzanne/K-5538-2012; Kokko, Hanna/C-7861-2009; Mappes, Tapio/B-9780-2013	Mills, Suzanne/0000-0001-8948-3384; Mappes, Tapio/0000-0002-5936-7355; Lehtonen, Jussi/0000-0001-5260-1041; Kokko, Hanna/0000-0002-5772-4881	Academy of Finland [115961, 119200, 218107, 132190, 103508, 108566]; Vanamo Biological Society; Ehrnrooth Foundation; Australian Research Council; Australian National University; Finnish Cultural Foundation; Emil Aaltonen Foundation; Centre of Excellence in Evolutionary Research, University of Jyvaskyla	Academy of Finland(Academy of Finland); Vanamo Biological Society; Ehrnrooth Foundation; Australian Research Council(Australian Research Council); Australian National University(Australian National University); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Emil Aaltonen Foundation; Centre of Excellence in Evolutionary Research, University of Jyvaskyla	Supported by Academy of Finland grants 115961, 119200, and 218107 (E. K.), 132190 (T. M.), and 103508 and 108566 (S. C. M.); the Vanamo Biological Society and Ehrnrooth Foundation (M. M.); the Australian Research Council and Australian National University (H. K. and J.L.); the Finnish Cultural Foundation and Emil Aaltonen Foundation (J.L.); and the Centre of Excellence in Evolutionary Research, University of Jyvaskyla. We thank the staff of the Experimental Animal Unit and Konnevesi Research Station, University of Jyvaskyla; R. Nara and H. Pietilainen for logistical support; T. Laaksonen, V. Lummaa, and three anonymous reviewers for comments; and C. Soulsbury for statistical advice. The authors declare no conflicts of interest. All co-authors designed this study; M. M., E. K., T. M. and H. M. collected and analyzed the empirical data; J.L. analyzed theoretical results with input from all authors; and M. M. led the preparation of the manuscript with input from all co-authors. Authors after the first author are listed in alphabetical order. Data have been deposited in the Dryad Repository (doi:10.5061/dryad.6m0f6870).	Albert AYK, 2005, SCIENCE, V310, P119, DOI 10.1126/science.1115328; Arnqvist G, 2011, EVOLUTION, V65, P2111, DOI 10.1111/j.1558-5646.2011.01270.x; Arnqvist Goran, 2005, pUnpaginated; Ayala F.J., 1974, Annual Rev Ecol Syst, V5, P115, DOI 10.1146/annurev.es.05.110174.000555; Bedhomme Stephanie, 2007, P185; Bijma P, 2010, J EVOLUTION BIOL, V23, P194, DOI 10.1111/j.1420-9101.2009.01895.x; Birkhead TR, 2009, SPERM BIOLOGY: AN EVOLUTIONARY PERSPECTIVE, P1; Calisi RM, 2009, HORM BEHAV, V56, P1, DOI 10.1016/j.yhbeh.2009.02.010; Chippindale AK, 2001, P NATL ACAD SCI USA, V98, P1671, DOI 10.1073/pnas.041378098; Connallon T, 2010, EVOLUTION, V64, P1671, DOI 10.1111/j.1558-5646.2009.00934.x; Cox RM, 2009, AM NAT, V173, P176, DOI 10.1086/595841; Delcourt M, 2009, P ROY SOC B-BIOL SCI, V276, P2009, DOI 10.1098/rspb.2008.1459; Falconer DS, 1996, INTRO QUANTITATIVE G; Fedorka KM, 2004, NATURE, V429, P65, DOI 10.1038/nature02492; Foerster K, 2007, NATURE, V447, P1107, DOI 10.1038/nature05912; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; Hall MD, 2010, EVOLUTION, V64, P1697, DOI 10.1111/j.1558-5646.2009.00932.x; Kokko H, 2003, ANN ZOOL FENN, V40, P207; Kokko H, 2007, ECOL LETT, V10, P773, DOI 10.1111/j.1461-0248.2007.01086.x; Mappes T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001687; Mills SC, 2007, P ROY SOC B-BIOL SCI, V274, P143, DOI 10.1098/rspb.2006.3639; Mills SC, 2009, AM NAT, V173, P475, DOI 10.1086/597222; Mokkonen M, 2012, J ANIM ECOL, V81, P277, DOI 10.1111/j.1365-2656.2011.01903.x; Parker G.A., 1979, P123; Patten MM, 2009, BIOL LETTERS, V5, P667, DOI 10.1098/rsbl.2009.0230; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; Schroderus E, 2010, AM NAT, V176, pE90, DOI 10.1086/656264; Sinervo B, 2006, ANNU REV ECOL EVOL S, V37, P581, DOI 10.1146/annurev.ecolsys.37.091305.110128; Svensson EI, 2005, AM NAT, V165, P567, DOI 10.1086/429278; van Doorn GS, 2009, ANN NY ACAD SCI, V1168, P52, DOI 10.1111/j.1749-6632.2009.04573.x; ZUK M, 1995, P ROY SOC B-BIOL SCI, V260, P205, DOI 10.1098/rspb.1995.0081	32	60	61	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					972	974		10.1126/science.1208708	http://dx.doi.org/10.1126/science.1208708			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096197	Green Published			2022-12-28	WOS:000297101800054
J	Macnaghten, P; Owen, R				Macnaghten, Phil; Owen, Richard			Good governance for geoengineering	NATURE			English	Editorial Material									[Macnaghten, Phil] Univ Durham, Durham DH1 3HP, England; [Owen, Richard] Univ Exeter, Sch Business, Exeter EX4 4QJ, Devon, England	Durham University; University of Exeter	Macnaghten, P (corresponding author), Univ Durham, Durham DH1 3HP, England.	p.m.macnaghten@durham.ac.uk; R.J.Owen@exeter.ac.uk		Owen, Richard/0000-0002-1767-3901	ESRC [RES-077-26-0001] Funding Source: UKRI; Economic and Social Research Council [RES-077-26-0001] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		NURSE P, 2011, GUARDIAN        0908; Rayner S, 2009, MEMORANDUM DRAFT PRI; *ROYAL SOC WORK GR, 2009, GEOENG CLIM SCI GOV	3	68	68	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					293	293		10.1038/479293a	http://dx.doi.org/10.1038/479293a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	848OA	22094673				2022-12-28	WOS:000297059700015
J	Farrell, L				Farrell, Liam			THE BEST MEDICINE The sentinel	BRITISH MEDICAL JOURNAL			English	Editorial Material												drfarrell@hotmail.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d7328	10.1136/bmj.d7328	http://dx.doi.org/10.1136/bmj.d7328			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LV	22088398				2022-12-28	WOS:000297497100005
J	Farkouh, ME				Farkouh, Michael E.			Review: Lowering systolic BP to <= 135 mm Hg reduces CV events in type 2 diabetes/IFG/IGT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Farkouh, Michael E.] Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Farkouh, Michael E.] Li Ka Shing Knowledge Inst, Toronto, ON, Canada	University of Toronto; Peter Munk Cardiac Centre; University of Toronto; Li Ka Shing Knowledge Institute	Farkouh, ME (corresponding author), Peter Munk Cardiac Ctr, Toronto, ON, Canada.							Brooks MM, 2008, AM HEART J, V156, P528, DOI [10.1016/j.ahj.2008.05.015, 10.1016/j.ajh.2008.05.015]; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cooper-DeHoff RM, 2010, JAMA-J AM MED ASSOC, V304, P61, DOI 10.1001/jama.2010.884; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286	4	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-3	10.7326/0003-4819-155-10-201111150-02003	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084350				2022-12-28	WOS:000208885300002
J	Glannon, W				Glannon, Walter			Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Calgary, Calgary, AB T2N 1N4, Canada	University of Calgary	Glannon, W (corresponding author), Univ Calgary, Calgary, AB T2N 1N4, Canada.	wglannon@ucalgary.ca						Beauchamp Tom L., 2019, PRINCIPLES BIOMEDICA, V8th; FORSTER L, 2009, PATIENT REPORTED OUT; Hadjianastassiou VG, 2007, AM J TRANSPLANT, V7, P2532, DOI 10.1111/j.1600-6143.2007.01975.x; Ibrahim HN, 2009, NEW ENGL J MED, V360, P459, DOI 10.1056/NEJMoa0804883; Maple NH, 2010, J MED ETHICS, V36, P142, DOI 10.1136/jme.2009.031740; *SCI REG TRANSPL P, 2009 ANN REP SCI REG	6	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2011	343								d7179	10.1136/bmj.d7179	http://dx.doi.org/10.1136/bmj.d7179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854LU	22089243				2022-12-28	WOS:000297497000005
J	Miller, RL; Agerstrand, CL				Miller, Rachel L.; Agerstrand, Cara L.			Targeting of household air pollution: interpretation of RESPIRE	LANCET			English	Editorial Material							PARTICULATE MATTER; LUNG-FUNCTION; CHILDREN; INDOOR; PNEUMONIA; EXPOSURE		[Miller, Rachel L.; Agerstrand, Cara L.] Columbia Univ, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; [Miller, Rachel L.] Columbia Univ, Dept Pediat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Miller, RL (corresponding author), Columbia Univ, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA.	rlm14@columbia.edu						Barraza-Villarreal A, 2008, ENVIRON HEALTH PERSP, V116, P832, DOI 10.1289/ehp.10926; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; Lacasana M, 2005, EUR J EPIDEMIOL, V20, P183, DOI 10.1007/s10654-004-3005-9; Miller RL, 2007, PASSIVE SMOKING HLTH, P283; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g; Naeher LP, 2000, J EXPO ANAL ENV EPID, V10, P544, DOI 10.1038/sj.jea.7500113; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Sacks JD, 2011, ENVIRON HEALTH PERSP, V119, P446, DOI 10.1289/ehp.1002255; Smith K., 2004, COMP QUANTIFICATION, P1435; Smith KR, 2011, LANCET, V378, P1717, DOI 10.1016/S0140-6736(11)60921-5	12	0	0	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2011	378	9804					1682	1684		10.1016/S0140-6736(11)61185-9	http://dx.doi.org/10.1016/S0140-6736(11)61185-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846LB	22078673	Green Submitted			2022-12-28	WOS:000296899800009
J	Suzuki, C; Ueno, T; Nishijima, H; Haga, R; Miki, Y; Arai, A; Tomiyama, M; Baba, M				Suzuki, Chieko; Ueno, Tatsuya; Nishijima, Haruo; Haga, Rie; Miki, Yasuo; Arai, Akira; Tomiyama, Masahiko; Baba, Masayuki			Fever of unknown origin	LANCET			English	Editorial Material							ACUTE AORTIC DISSECTION; ANEURYSM		[Suzuki, Chieko; Ueno, Tatsuya; Nishijima, Haruo; Haga, Rie; Miki, Yasuo; Arai, Akira; Tomiyama, Masahiko; Baba, Masayuki] Aomori Prefectural Cent Hosp, Dept Neurol, Aomori 0308553, Japan		Suzuki, C (corresponding author), Aomori Prefectural Cent Hosp, Dept Neurol, 2-1-1 Higashi Tsukurimichi, Aomori 0308553, Japan.	chieko_murakami@med.pref.aomori.jp	MIKI, YASUO/F-5704-2013	Nishijima, Haruo/0000-0002-1065-664X				HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; MACKOWIAK PA, 1976, JAMA-J AM MED ASSOC, V236, P1725, DOI 10.1001/jama.236.15.1725; Shimada S, 2007, CIRC J, V71, P766, DOI 10.1253/circj.71.766; Suzuki T, 2009, CIRCULATION, V119, P2702, DOI 10.1161/CIRCULATIONAHA.108.833004	4	1	1	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	2011	378	9804					1756	1756		10.1016/S0140-6736(11)61547-X	http://dx.doi.org/10.1016/S0140-6736(11)61547-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846LB	22078687				2022-12-28	WOS:000296899800032
J	Ingolia, NT; Lareau, LF; Weissman, JS				Ingolia, Nicholas T.; Lareau, Liana F.; Weissman, Jonathan S.			Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes	CELL			English	Article							OPEN READING FRAMES; GENOME-WIDE ANALYSIS; MESSENGER-RNA; TRANSLATION INITIATION; GENE-EXPRESSION; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; NONCODING RNAS; HUMAN ERM; IDENTIFICATION	The ability to sequence genomes has far outstripped approaches for deciphering the information they encode. Here we present a suite of techniques, based on ribosome profiling (the deep sequencing of ribosome-protected mRNA fragments), to provide genome-wide maps of protein synthesis as well as a pulse-chase strategy for determining rates of translation elongation. We exploit the propensity of harringtonine to cause ribosomes to accumulate at sites of translation initiation together with a machine learning algorithm to define protein products systematically. Analysis of translation in mouse embryonic stem cells reveals thousands of strong pause sites and unannotated translation products. These include amino-terminal extensions and truncations and upstream open reading frames with regulatory potential, initiated at both AUG and non-AUG codons, whose translation changes after differentiation. We also define a class of short, polycistronic ribosome-associated coding RNAs (sprcRNAs) that encode small proteins. Our studies reveal an unanticipated complexity to mammalian proteomes.	[Ingolia, Nicholas T.; Weissman, Jonathan S.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Ingolia, Nicholas T.; Weissman, Jonathan S.] Calif Inst Quantitat Biosci, San Francisco, CA 94158 USA; [Lareau, Liana F.] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Stanford University	Ingolia, NT (corresponding author), Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21218 USA.	ingolia@ciwemb.edu		Weissman, Jonathan/0000-0003-2445-670X	NIH [AG10770]; Ruth L. Kirschstein NRSA [GM080853]; Damon Runyon Cancer Research Foundation [DRG-2033-09]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM080853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010770] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L. Kirschstein NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank M. Barna, S. Luo, D. Ruggero G. Schroth, P. Brown, and members of the Weissman lab including A. Frost and S. Churchman for advice and helpful discussions; C. Chu for help with sequencing; S. Rouskin for help developing the ligation protocol; G. Brar for help developing rRNA depletion; and J. Hunkapiller and J. Reiter for E14 mESCs. This investigation was supported by the NIH P01 (AG10770) and a Ruth L. Kirschstein NRSA (GM080853) (N.T.I.), the Damon Runyon Cancer Research Foundation (DRG-2033-09) (L.F.L.), and the Howard Hughes Medical Institute (J.S.W.)	Akamatsu Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001160; Alkalaeva EZ, 2006, CELL, V125, P1125, DOI 10.1016/j.cell.2006.04.035; Arava Y, 2003, P NATL ACAD SCI USA, V100, P3889, DOI 10.1073/pnas.0635171100; Atkins JF, 2010, NUCLEIC ACIDS MOL BI, V24, P1, DOI 10.1007/978-0-387-89382-2; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Brent MR, 2005, GENOME RES, V15, P1777, DOI 10.1101/gr.3866105; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; dos Reis M, 2004, NUCLEIC ACIDS RES, V32, P5036, DOI 10.1093/nar/gkh834; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111/j.1432-1033.1977.tb11256.x; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Guttman M, 2010, NAT BIOTECHNOL, V28, P503, DOI 10.1038/nbt.1633; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hamilton TL, 2006, BIOCHEM SOC T, V34, P12, DOI 10.1042/BST0340012; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hansen MB, 2002, GENOMICS, V80, P344, DOI 10.1006/geno.2002.6838; Hassan AS, 2010, GENE EXPR PATTERNS, V10, P127, DOI 10.1016/j.gep.2010.02.001; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; HUANG MT, 1975, MOL PHARMACOL, V11, P511; Hughes TA, 2006, TRENDS GENET, V22, P119, DOI 10.1016/j.tig.2006.01.001; Ingolia NT, 2010, METHOD ENZYMOL, V470, P119, DOI 10.1016/S0076-6879(10)70006-9; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; IRWIN B, 1995, J BIOL CHEM, V270, P22801, DOI 10.1074/jbc.270.39.22801; Ivanov IP, 2008, P NATL ACAD SCI USA, V105, P10079, DOI 10.1073/pnas.0801590105; Ivanov IP, 2011, NUCLEIC ACIDS RES, V39, P4220, DOI 10.1093/nar/gkr007; Joachims T., 1999, ADV KERNEL METHODS S; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Kondo T, 2010, SCIENCE, V329, P336, DOI 10.1126/science.1188158; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kraut-Cohen J, 2010, TRENDS BIOCHEM SCI, V35, P459, DOI 10.1016/j.tibs.2010.02.006; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LAZAROWITZ SG, 1977, J BIOL CHEM, V252, P7842; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Malarkannan S, 1999, IMMUNITY, V10, P681, DOI 10.1016/S1074-7613(00)80067-9; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mariappan M, 2010, NATURE, V466, P1120, DOI 10.1038/nature09296; Martin KC, 2009, CELL, V136, P719, DOI 10.1016/j.cell.2009.01.044; Medenbach J, 2011, CELL, V145, P902, DOI 10.1016/j.cell.2011.05.005; MONTE D, 1994, ONCOGENE, V9, P1397; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Namy O, 2006, NATURE, V441, P244, DOI 10.1038/nature04735; Nilsson T, 2010, NAT METHODS, V7, P681, DOI 10.1038/nmeth0910-681; Niwa H, 2009, NATURE, V460, P118, DOI 10.1038/nature08113; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Pisarev AV, 2008, EMBO J, V27, P1609, DOI 10.1038/emboj.2008.90; Robert F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005428; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sampath P, 2008, CELL STEM CELL, V2, P448, DOI 10.1016/j.stem.2008.03.013; Schneider-Poetsch T, 2010, NAT CHEM BIOL, V6, P209, DOI 10.1038/NCHEMBIO.304; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Starck SR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003460; Tanner DR, 2009, J BIOL CHEM, V284, P34809, DOI 10.1074/jbc.M109.039040; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Tremml Gabi, 2008, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01c04s5; TSCHERNE JS, 1975, ANTIMICROB AGENTS CH, V8, P479, DOI 10.1128/AAC.8.4.479; Tuller T, 2010, CELL, V141, P344, DOI 10.1016/j.cell.2010.03.031; Tupy JL, 2005, P NATL ACAD SCI USA, V102, P5495, DOI 10.1073/pnas.0501422102; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; Yanagitani K, 2011, SCIENCE, V331, P586, DOI 10.1126/science.1197142; Yanagitani K, 2009, MOL CELL, V34, P191, DOI 10.1016/j.molcel.2009.02.033; Zhang G, 2009, NAT STRUCT MOL BIOL, V16, P274, DOI 10.1038/nsmb.1554	78	1345	1383	8	277	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					789	802		10.1016/j.cell.2011.10.002	http://dx.doi.org/10.1016/j.cell.2011.10.002			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22056041	Green Accepted, Bronze			2022-12-28	WOS:000296902300013
J	Irvine, RF; Denton, RM				Irvine, Robin F.; Denton, Richard M.			Pyro-Technic Control of Metabolism	SCIENCE			English	Editorial Material							DIPHOSPHOINOSITOL POLYPHOSPHATES; INOSITOL HEXAKISPHOSPHATE; PYROPHOSPHATES; PYROPHOSPHORYLATION; TURNOVER		[Irvine, Robin F.] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; [Denton, Richard M.] Univ Bristol, Sch Biochem, Bristol BS8 1TD, Avon, England	University of Cambridge; University of Bristol	Irvine, RF (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England.	rfi20@cam.ac.uk; r.denton@bris.ac.uk	Denton, Richard/ABC-9914-2020					Azevedo C, 2009, P NATL ACAD SCI USA, V106, P21161, DOI 10.1073/pnas.0909176106; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Chakraborty A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001958; Denton RM, 2009, BBA-BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Lin HY, 2009, J BIOL CHEM, V284, P1863, DOI 10.1074/jbc.M805686200; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Mizuno T, 2004, YEAST, V21, P851, DOI 10.1002/yea.1123; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Shears SB, 2009, MOL PHARMACOL, V76, P236, DOI 10.1124/mol.109.055897; Szijgyarto Z, 2011, SCIENCE, V334, P802, DOI 10.1126/science.1211908	12	2	3	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					770	771		10.1126/science.1214727	http://dx.doi.org/10.1126/science.1214727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	845US	22076369				2022-12-28	WOS:000296849600035
J	Baker, DJ; Wijshake, T; Tchkonia, T; LeBrasseur, NK; Childs, BG; van de Sluis, B; Kirkland, JL; van Deursen, JM				Baker, Darren J.; Wijshake, Tobias; Tchkonia, Tamar; LeBrasseur, Nathan K.; Childs, Bennett G.; van de Sluis, Bart; Kirkland, James L.; van Deursen, Jan M.			Clearance of p16(Ink4a)-positive senescent cells delays ageing-associated disorders	NATURE			English	Article							TUMOR-SUPPRESSOR; BUBR1 INSUFFICIENCY; ONCOGENIC RAS; MUTANT MICE; EXPRESSION; MOUSE; FIBROBLASTS; PHENOTYPES; INHIBITOR; BIOMARKER	Advanced age is the main risk factor for most chronic diseases and functional deficits in humans, but the fundamental mechanisms that drive ageing remain largely unknown, impeding the development of interventions that might delay or prevent age-related disorders and maximize healthy lifespan. Cellular senescence, which halts the proliferation of damaged or dysfunctional cells, is an important mechanism to constrain the malignant progression of tumour cells(1,2). Senescent cells accumulate in various tissues and organs with ageing(3) and have been hypothesized to disrupt tissue structure and function because of the components they secrete(4,5). However, whether senescent cells are causally implicated in age-related dysfunction and whether their removal is beneficial has remained unknown. To address these fundamental questions, we made use of a biomarker for senescence, p16(Ink4a), to design a novel transgene, INK-ATTAC, for inducible elimination of p16(Ink4a)-positive senescent cells upon administration of a drug. Here we show that in the BubR1 progeroid mouse background, INK-ATTAC removes p16(Ink4a)-positive senescent cells upon drug treatment. In tissues-such as adipose tissue, skeletal muscle and eye-in which p16(Ink4a) contributes to the acquisition of age-related pathologies, life-long removal of p16(Ink4a)-expressing cells delayed onset of these phenotypes. Furthermore, late-life clearance attenuated progression of already established age-related disorders. These data indicate that cellular senescence is causally implicated in generating age-related phenotypes and that removal of senescent cells can prevent or delay tissue dysfunction and extend healthspan.	[Baker, Darren J.; Wijshake, Tobias; Childs, Bennett G.; van Deursen, Jan M.] Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Baker, Darren J.; Tchkonia, Tamar; LeBrasseur, Nathan K.; Kirkland, James L.; van Deursen, Jan M.] Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA; [Wijshake, Tobias; van de Sluis, Bart] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands	Mayo Clinic; Mayo Clinic; University of Groningen	van Deursen, JM (corresponding author), Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA.	vandeursen.jan@mayo.edu	Kirkland, James/F-9159-2016	Wijshake, Tobias/0000-0003-1784-2100; van de Sluis, Bart (A.J.A.)/0000-0003-3039-4365; Baker, Darren/0000-0001-9006-1939; Tchkonia, Tamar/0000-0003-4623-7145; LeBrasseur, Nathan/0000-0002-2002-0418	Ellison Medical Foundation; Noaber Foundation; Robert and Arlene Kogod Center on Aging; National Institutes of Health [CA96985, AG13925]; NATIONAL CANCER INSTITUTE [R01CA096985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG041122, R37AG013925, R01AG013925] Funding Source: NIH RePORTER	Ellison Medical Foundation(Lawrence Ellison Foundation); Noaber Foundation; Robert and Arlene Kogod Center on Aging; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank W. Zhou, D. Norris, T. Mann, U. Moedder, T. Pirtskhalava and S. Yamada for assistance; S. Khosla, T. von Zglinicki, L. Malureanu, R. Ricke and P. Galardy, and members of the J.M.v.D. laboratory for helpful discussions; and P. Scherer for the gift of the aP2-ATTAC plasmid. This work was supported by the Ellison Medical Foundation (J.M.v.D.), the Noaber Foundation (J.M.v.D. and J.L.K.), the Robert and Arlene Kogod Center on Aging, and the National Institutes of Health (CA96985, J.M.v.D. and AG13925, J.L.K.).	Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gan Q, 2008, J CELL SCI, V121, P2235, DOI 10.1242/jcs.026633; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Hartman TK, 2007, NEUROBIOL AGING, V28, P921, DOI 10.1016/j.neurobiolaging.2006.05.012; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; Kim HG, 2002, EXP CELL RES, V272, P199, DOI 10.1006/excr.2001.5420; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kirkland JL, 1996, INT J OBESITY, V20, pS102; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kulukian A, 2009, DEV CELL, V16, P105, DOI 10.1016/j.devcel.2008.11.005; LeBrasseur NK, 2009, J GERONTOL A-BIOL, V64, P940, DOI 10.1093/gerona/glp068; Li JN, 2011, BIOCHEMISTRY-US, V50, P5566, DOI 10.1021/bi200642e; Malureanu L, 2010, J CELL BIOL, V191, P313, DOI 10.1083/jcb.201003090; Malureanu LA, 2009, DEV CELL, V16, P118, DOI 10.1016/j.devcel.2008.11.004; Martinez-Fernandez A, 2009, CIRC RES, V105, P648, DOI 10.1161/CIRCRESAHA.109.203109; Matsumoto T, 2007, STROKE, V38, P1050, DOI 10.1161/01.STR.0000257967.86132.01; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200	30	2018	2134	16	326	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					232	U112		10.1038/nature10600	http://dx.doi.org/10.1038/nature10600			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22048312	Green Accepted			2022-12-28	WOS:000298030800043
J	Mueller-Cajar, O; Stotz, M; Wendler, P; Hartl, FU; Bracher, A; Hayer-Hartl, M				Mueller-Cajar, Oliver; Stotz, Mathias; Wendler, Petra; Hartl, F. Ulrich; Bracher, Andreas; Hayer-Hartl, Manajit			Structure and function of the AAA(+) protein CbbX, a red-type Rubisco activase	NATURE			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; HIGH-LEVEL EXPRESSION; FORM-I; BISPHOSPHATE CARBOXYLASE; CRYSTAL-STRUCTURE; ENCODED CBBX; CHAPERONE; VISUALIZATION; TRANSLOCATION; REFINEMENT	Ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) catalyses the fixation of atmospheric CO2 in photosynthesis, but tends to form inactive complexes with its substrate ribulose 1,5-bisphosphate (RuBP). In plants, Rubisco is reactivated by the AAA(+) (ATPases associated with various cellular activities) protein Rubisco activase (Rca), but no such protein is known for the Rubisco of red algae. Here we identify the protein CbbX as an activase of red-type Rubisco. The 3.0-angstrom crystal structure of unassembled CbbX from Rhodobacter sphaeroides revealed an AAA(+) protein architecture. Electron microscopy and biochemical analysis showed that ATP and RuBP must bind to convert CbbX into functionally active, hexameric rings. The CbbX ATPase is strongly stimulated by RuBP and Rubisco. Mutational analysis suggests that CbbX functions by transiently pulling the carboxy-terminal peptide of the Rubisco large subunit into the hexamer pore, resulting in the release of the inhibitory RuBP. Understanding Rubisco activation may facilitate efforts to improve CO2 uptake and biomass production by photosynthetic organisms.	[Mueller-Cajar, Oliver; Stotz, Mathias; Hartl, F. Ulrich; Bracher, Andreas; Hayer-Hartl, Manajit] Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; [Wendler, Petra] Univ Munich, Dept Biochem, Gene Ctr Munich, D-81377 Munich, Germany	Max Planck Society; University of Munich	Hayer-Hartl, M (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	bracher@biochem.mpg.de; mhartl@biochem.mpg.de	Hayer-Hartl, Manajit/V-8078-2017; Mueller-Cajar, Oliver/A-7237-2018; Wendler, Petra/C-9056-2014; Hartl, F. Ulrich/Y-8206-2019; Wendler, Petra/X-5799-2019	Hayer-Hartl, Manajit/0000-0001-8213-6742; Mueller-Cajar, Oliver/0000-0003-2866-5963; Wendler, Petra/0000-0002-8285-2199; 	Max Planck Institute of Biochemistry (MPIB); European Synchrotron Radiation Facility beamlines; Deutsche Forschungsgemeinschaft (DFG) [SFB 594, WE4628/1]; Korber Foundation	Max Planck Institute of Biochemistry (MPIB)(Max Planck Society); European Synchrotron Radiation Facility beamlines; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Korber Foundation	We thank S. Kaplan for providing the R. sphaeroides strain 2.4.1, S. Whitney for providing the pHue protein expression system, and R. Lange and N. Wischnewski for technical assistance. Support by the Max Planck Institute of Biochemistry (MPIB) Core Facility, the MPIB Crystallization Facility and the Joint Structural Biology Group staff at the European Synchrotron Radiation Facility beamlines is gratefully acknowledged. We thank the Deutsche Forschungsgemeinschaft (DFG) (SFB 594; DFG grant WE4628/1 to P. W.) and the Korber Foundation for financial support.	Andersson I, 2008, PLANT PHYSIOL BIOCH, V46, P275, DOI 10.1016/j.plaphy.2008.01.001; Andersson I, 2008, J EXP BOT, V59, P1555, DOI 10.1093/jxb/ern091; Badger MR, 2008, J EXP BOT, V59, P1525, DOI 10.1093/jxb/erm297; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker RT, 2005, METHOD ENZYMOL, V398, P540, DOI 10.1016/S0076-6879(05)98044-0; Bowien B, 2002, ARCH MICROBIOL, V178, P85, DOI 10.1007/s00203-002-0441-3; Catanzariti AM, 2004, PROTEIN SCI, V13, P1331, DOI 10.1110/ps.04618904; Davies JM, 2008, STRUCTURE, V16, P715, DOI 10.1016/j.str.2008.02.010; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esau BD, 1996, ARCH BIOCHEM BIOPHYS, V326, P100, DOI 10.1006/abbi.1996.0052; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Evans P.R., 1997, JOINT CCP4 ESF EACBM, V33, P22; Falkowski PG, 2004, SCIENCE, V305, P354, DOI 10.1126/science.1095964; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Fujita K, 2008, GENES GENET SYST, V83, P135, DOI 10.1266/ggs.83.135; GIBSON JL, 1979, J BACTERIOL, V140, P1023, DOI 10.1128/JB.140.3.1023-1027.1979; Gibson JL, 1997, J BACTERIOL, V179, P663, DOI 10.1128/jb.179.3.663-669.1997; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Glynn SE, 2009, CELL, V139, P744, DOI 10.1016/j.cell.2009.09.034; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hinnerwisch J, 2005, CELL, V121, P1029, DOI 10.1016/j.cell.2005.04.012; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu CM, 2010, NATURE, V463, P197, DOI 10.1038/nature08651; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; Maier UG, 2000, MOL BIOL EVOL, V17, P576, DOI 10.1093/oxfordjournals.molbev.a026337; Martin A, 2008, NAT STRUCT MOL BIOL, V15, P1147, DOI 10.1038/nsmb.1503; Massey TH, 2006, MOL CELL, V23, P457, DOI 10.1016/j.molcel.2006.06.019; Matias PM, 2006, J BIOL CHEM, V281, P38918, DOI 10.1074/jbc.M605625200; Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okano Y, 2002, FEBS LETT, V527, P33, DOI 10.1016/S0014-5793(02)03148-4; Parry MAJ, 2008, J EXP BOT, V59, P1569, DOI 10.1093/jxb/ern084; Pearce FG, 2006, BIOCHEM J, V399, P525, DOI 10.1042/BJ20060430; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; ROBINSON SP, 1989, ARCH BIOCHEM BIOPHYS, V268, P93, DOI 10.1016/0003-9861(89)90568-7; Roll-Mecak A, 2008, NATURE, V451, P363, DOI 10.1038/nature06482; Saschenbrecker S, 2007, CELL, V129, P1189, DOI 10.1016/j.cell.2007.04.025; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shaikh TR, 2008, NAT PROTOC, V3, P1941, DOI 10.1038/nprot.2008.156; Smith JM, 1999, J STRUCT BIOL, V125, P223, DOI 10.1006/jsbi.1998.4073; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Tabita FR, 2008, J EXP BOT, V59, P1515, DOI 10.1093/jxb/erm361; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VONCAEMMERER S, 1986, AUST J PLANT PHYSIOL, V13, P669, DOI 10.1071/PP9860669; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Whitney SM, 2001, PLANT J, V26, P535, DOI 10.1046/j.1365-313x.2001.01056.x	62	117	120	1	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2011	479	7372					194	U66		10.1038/nature10568	http://dx.doi.org/10.1038/nature10568			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22048315				2022-12-28	WOS:000298030800034
J	Quehenberger, O; Dennis, EA				Quehenberger, Oswald; Dennis, Edward A.			MECHANISMS OF DISEASE The Human Plasma Lipidome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TYPE-1 GAUCHER-DISEASE; CHOLINE KINASE-ACTIVITY; FREE FATTY-ACIDS; LYSOPHOSPHATIDIC ACID; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; PALMITOLEIC ACID; ORAL FINGOLIMOD; OVARIAN; CANCER		[Quehenberger, Oswald; Dennis, Edward A.] Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; [Quehenberger, Oswald] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Dennis, Edward A.] Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM069338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; [Anonymous], 1998, IS TOT FAT CONS REAL; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Bauman DR, 2009, P NATL ACAD SCI USA, V106, P16764, DOI 10.1073/pnas.0909142106; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bese T, 2010, J GYNECOL ONCOL, V21, P248, DOI 10.3802/jgo.2010.21.4.248; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; BJORKHEM I, 1987, J LIPID RES, V28, P1137; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Boomgaarden I, 2009, PROSTAG LEUKOTR ESS, V80, P185, DOI 10.1016/j.plefa.2009.02.001; Brinkmann V, 2007, PHARMACOL THERAPEUT, V115, P84, DOI 10.1016/j.pharmthera.2007.04.006; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Buczynski MW, 2009, J LIPID RES, V50, P1015, DOI 10.1194/jlr.R900004-JLR200; BURR ML, 1989, LANCET, V2, P757; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Charles MA, 1997, DIABETOLOGIA, V40, P1101, DOI 10.1007/s001250050793; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Connor WE, 1996, J LIPID RES, V37, P290; de Fost M, 2006, BLOOD, V108, P830, DOI 10.1182/blood-2005-12-5072; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; Deguchi H, 2004, J BIOL CHEM, V279, P12036, DOI 10.1074/jbc.M302531200; DeLany JP, 2000, AM J CLIN NUTR, V72, P905; Dennis EA, 2010, J BIOL CHEM, V285, P39976, DOI 10.1074/jbc.M110.182915; Dennis EA, 2009, P NATL ACAD SCI USA, V106, P2089, DOI 10.1073/pnas.0812636106; Dimopoulos N, 2006, BIOCHEM J, V399, P473, DOI 10.1042/BJ20060244; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Ervin R Bethene, 2009, Natl Health Stat Report, P1; Ewers M, 2010, EXP GERONTOL, V45, P75, DOI 10.1016/j.exger.2009.09.005; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Foster DA, 2009, BBA-MOL CELL BIOL L, V1791, P949, DOI 10.1016/j.bbalip.2009.02.009; Ginsberg HN, 2006, OBESITY, V14, p41S, DOI 10.1038/oby.2006.281; Graessler J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006261; Griffiths JR, 2002, EUR J CANCER, V38, P2085, DOI 10.1016/S0959-8049(02)00389-1; Groener JEM, 2008, BBA-MOL CELL BIOL L, V1781, P72, DOI 10.1016/j.bbalip.2007.11.004; Hammad SM, 2010, J LIPID RES, V51, P3074, DOI 10.1194/jlr.D008532; Harkewicz R, 2011, ANNU REV BIOCHEM, V80, P301, DOI 10.1146/annurev-biochem-060409-092612; Haus JM, 2009, DIABETES, V58, P337, DOI 10.2337/db08-1228; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hernando E, 2009, ONCOGENE, V28, P2425, DOI 10.1038/onc.2009.91; Hollak CEM, 1997, BRIT J HAEMATOL, V96, P470; Hopkins PN, 2003, CIRCULATION, V108, P519, DOI 10.1161/01.CIR.0000081777.17879.85; Iorio E, 2010, CANCER RES, V70, P2126, DOI 10.1158/0008-5472.CAN-09-3833; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jagannathan NR, 2001, BRIT J CANCER, V84, P1016, DOI 10.1054/bjoc.2000.1711; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kleinfeld AM, 2005, J LIPID RES, V46, P1983, DOI 10.1194/jlr.M500151-JLR200; Kotronen A, 2009, DIABETOLOGIA, V52, P684, DOI 10.1007/s00125-009-1282-2; Kris-Etherton, 2003, CIRCULATION, V107, P512, DOI 10.1161/01.CIR.0000054601.17182.B0; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Leaf A, 2001, CIRCULATION, V104, P744, DOI 10.1161/01.CIR.104.7.744; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEGASPI A, 1987, METABOLISM, V36, P958, DOI 10.1016/0026-0495(87)90132-6; Lentner C, 1981, PHYS CHEM COMPOSITIO, V3; Ley RE, 2008, SCIENCE, V322, P1188; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Maeda K, 2005, CELL METAB, V1, P107, DOI 10.1016/j.cmet.2004.12.008; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Matsuzaka T, 2007, NAT MED, V13, P1193, DOI 10.1038/nm1662; MCLENNAN PL, 1993, AM J CLIN NUTR, V57, P207, DOI 10.1093/ajcn/57.2.207; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Missmer SA, 2006, ENVIRON HEALTH PERSP, V114, P237, DOI 10.1289/ehp.8221; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Mozaffarian D, 2010, ANN INTERN MED, V153, P790, DOI 10.7326/0003-4819-153-12-201012210-00005; Mozaffarian D, 2010, AM J CLIN NUTR, V92, P1350, DOI 10.3945/ajcn.110.003970; Mulhall BP, 2002, J GASTROEN HEPATOL, V17, P1136, DOI 10.1046/j.1440-1746.2002.02881.x; Murphy PS, 2004, BRIT J CANCER, V90, P781, DOI 10.1038/sj.bjc.6601593; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; NEGENDANK W, 1992, NMR BIOMED, V5, P303, DOI 10.1002/nbm.1940050518; Nitz I, 2007, J CLIN ENDOCR METAB, V92, P3183, DOI 10.1210/jc.2006-2550; O'Brien N, 2009, J LIPID RES, V50, P2245, DOI 10.1194/jlr.M900048-JLR200; OGDEN CL, 2007, OBESITY ADULTS US NO; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Oresic M, 2011, GENOME MED, V3, DOI 10.1186/gm233; Penno A, 2010, J BIOL CHEM, V285, P11178, DOI 10.1074/jbc.M109.092973; Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; PIRNAY F, 1977, EUR J APPL PHYSIOL, V36, P247, DOI 10.1007/BF00423050; Pozlep B, 2007, EUR J GYNAECOL ONCOL, V28, P394; Quehenberger O, 2010, J LIPID RES, V51, P3299, DOI 10.1194/jlr.M009449; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Santomauro ATMG, 1999, DIABETES, V48, P1836, DOI 10.2337/diabetes.48.9.1836; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Scherer M, 2011, BBA-MOL CELL BIOL L, V1811, P68, DOI 10.1016/j.bbalip.2010.11.003; Sedlakova I, 2011, TUMOR BIOL, V32, P311, DOI 10.1007/s13277-010-0123-8; Stefan N, 2010, DIABETES CARE, V33, P405, DOI [10.2337/dc10-0002, 10.2337/dc09-0544]; Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Sysi-Aho M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015744; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Watts GF, 1996, QJM-MON J ASSOC PHYS, V89, P55, DOI 10.1093/oxfordjournals.qjmed.a030138; Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yeboah J, 2010, ARTERIOSCL THROM VAS, V30, P628, DOI 10.1161/ATVBAHA.109.199281	104	276	297	1	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1812	1823		10.1056/NEJMra1104901	http://dx.doi.org/10.1056/NEJMra1104901			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070478	Green Accepted			2022-12-28	WOS:000296762800010
J	Demireva, EY; Shapiro, LS; Jessell, TM; Zampieri, N				Demireva, Elena Y.; Shapiro, Lawrence S.; Jessell, Thomas M.; Zampieri, Niccolo			Motor Neuron Position and Topographic Order Imposed by beta- and gamma-Catenin Activities	CELL			English	Article							N-CADHERIN; SPINAL-CORD; PROTEIN INTERACTIONS; MOUSE DEVELOPMENT; CELL-ADHESION; ORGANIZATION; PLAKOGLOBIN; EXPRESSION; GENE; MICE	Neurons typically settle at positions that match the location of their synaptic targets, creating topographic maps. In the spinal cord, the organization of motor neurons into discrete clusters is linked to the location of their muscle targets, establishing a topographic map of punctate design. To define the significance of motor pool organization for neuromuscular map formation, we assessed the role of cadherin-catenin signaling in motor neuron positioning and limb muscle innervation. We find that joint inactivation of beta- and gamma-catenin scrambles motor neuron settling position in the spinal cord but fails to erode the predictive link between motor neuron transcriptional identity and muscle target. Inactivation of N-cadherin perturbs pool positioning in similar ways, albeit with reduced penetrance. These findings reveal that cadherin-catenin signaling directs motor pool patterning and imposes topographic order on an underlying identity-based neural map.	[Demireva, Elena Y.; Jessell, Thomas M.; Zampieri, Niccolo] Columbia Univ, Howard Hughes Med Inst, Kavli Inst Brain Sci, Dept Neurosci, New York, NY 10032 USA; [Shapiro, Lawrence S.; Jessell, Thomas M.] Columbia Univ, Howard Hughes Med Inst, Kavli Inst Brain Sci, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Kavli Inst Brain Sci, Dept Neurosci, New York, NY 10032 USA.	tmj1@columbia.edu	Shapiro, Lawrence/AAE-7172-2019	Zampieri, Niccolo/0000-0002-2228-9453	NINDS [RO1 NS033245]; HHMI; NIH [R01GM062270]; Wellcome Trust; G. Harold and Leila Y. Mathers Foundation; Investigator of the Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245, R37NS033245] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); HHMI(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); G. Harold and Leila Y. Mathers Foundation; Investigator of the Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors are indebted to Stephen Price for early contributions to this project. The authors thank Qiaolian Liu, Barbara Han and Ira Schieren for technical help, Susan Brenner-Morton for antibody generation, Monica Mendelsohn, Jennifer Kirkland, Barbara Han, and Susan Kales for help in the generation of conditional gamma-catenin mutant mice, Laskaro Zagoraiou and Apostolos Klinakis for DNA constructs, Corey Washington for statistical analysis, Kendall Doerr for valuable perspective, and Ira Schieren and Kathy MacArthur for help in preparing the manuscript. We are grateful to Rolf Kemler, Patricia Ruiz, Masatoshi Takeichi, Barbara Ranscht, Glenn Radice, and Makoto Taketo for mouse lines. Natalia de Marco Garcia, Sebastian Poliak, Joriene de Nooij, Jeremy Dasen, Carol Mason, Christopher Henderson, and Barbara Ranscht provided advice and helpful comments on the manuscript. E.Y.D. was supported by NINDS RO1 NS033245; N.Z. was supported by HHMI; L.S.P. was supported by NIH R01GM062270; T.M.J. was supported by grants from the NINDS RO1 NS033245, the Wellcome Trust, the G. Harold and Leila Y. Mathers Foundation, and Project A.L.S. and is an Investigator of the Howard Hughes Medical Institute.	Brault V, 2001, DEVELOPMENT, V128, P1253; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Dasen JS, 2008, CELL, V134, P304, DOI 10.1016/j.cell.2008.06.019; Dessaud E, 2007, NATURE, V450, P717, DOI 10.1038/nature06347; Garcia NVDM, 2008, NEURON, V57, P217, DOI 10.1016/j.neuron.2007.11.033; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Imai T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001776; Jossin Y, 2011, NAT NEUROSCI, V14, P697, DOI 10.1038/nn.2816; Kadowaki M, 2007, DEV BIOL, V304, P22, DOI 10.1016/j.ydbio.2006.12.014; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kostetskii I, 2005, CIRC RES, V96, P346, DOI 10.1161/01.RES.0000156274.72390.2c; Ladle DR, 2007, NEURON, V56, P270, DOI 10.1016/j.neuron.2007.09.026; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; Luo LQ, 2007, NEURON, V56, P284, DOI 10.1016/j.neuron.2007.10.014; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Machon O, 2003, NEUROSCIENCE, V122, P129, DOI 10.1016/S0306-4522(03)00519-0; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Megason SG, 2002, DEVELOPMENT, V129, P2087; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Palmesino E, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000446; Patel SD, 2006, CELL, V124, P1255, DOI 10.1016/j.cell.2005.12.046; Personius KE, 2007, P NATL ACAD SCI USA, V104, P11808, DOI 10.1073/pnas.0703357104; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Price SR, 2004, MECH DEVELOP, V121, P1103, DOI 10.1016/j.mod.2004.04.019; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; ROMANES G. J., 1964, PROGR BRAIN RES, V11, P93; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Surmeli G, 2011, CELL, V147, P653, DOI 10.1016/j.cell.2011.10.012; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Vanderhorst VGJM, 1997, J COMP NEUROL, V382, P46; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Yip YP, 2009, J COMP NEUROL, V515, P260, DOI 10.1002/cne.22044; Zelano J, 2006, EXP NEUROL, V201, P461, DOI 10.1016/j.expneurol.2006.04.026; Zhurinsky J, 2000, J CELL SCI, V113, P3127	42	62	63	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					641	652		10.1016/j.cell.2011.09.037	http://dx.doi.org/10.1016/j.cell.2011.09.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036570	Bronze, Green Accepted			2022-12-28	WOS:000296573700018
J	Lindorff-Larsen, K; Piana, S; Dror, RO; Shaw, DE				Lindorff-Larsen, Kresten; Piana, Stefano; Dror, Ron O.; Shaw, David E.			How Fast-Folding Proteins Fold	SCIENCE			English	Article							TRANSITION-STATES; PATHWAYS; MECHANISM; TOPOLOGY; RATES	An outstanding challenge in the field of molecular biology has been to understand the process by which proteins fold into their characteristic three-dimensional structures. Here, we report the results of atomic-level molecular dynamics simulations, over periods ranging between 100 mu s and 1 ms, that reveal a set of common principles underlying the folding of 12 structurally diverse proteins. In simulations conducted with a single physics-based energy function, the proteins, representing all three major structural classes, spontaneously and repeatedly fold to their experimentally determined native structures. Early in the folding process, the protein backbone adopts a nativelike topology while certain secondary structure elements and a small number of nonlocal contacts form. In most cases, folding follows a single dominant route in which elements of the native structure appear in an order highly correlated with their propensity to form in the unfolded state.	[Lindorff-Larsen, Kresten; Piana, Stefano; Dror, Ron O.; Shaw, David E.] DE Shaw Res, New York, NY 10036 USA; [Shaw, David E.] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10032 USA	D. E. Shaw Research; Columbia University	Lindorff-Larsen, K (corresponding author), DE Shaw Res, New York, NY 10036 USA.	kresten.lindorff-larsen@DEShawResearch.com; stefano.piana-agostinetti@DEShawResearch.com; david.shaw@DEShawResearch.com	Lindorff-Larsen, Kresten/K-6469-2014	Lindorff-Larsen, Kresten/0000-0002-4750-6039; Dror, Ron/0000-0002-6418-2793				Best RB, 2005, P NATL ACAD SCI USA, V102, P6732, DOI 10.1073/pnas.0408098102; Englander SW, 2007, Q REV BIOPHYS, V40, P287, DOI 10.1017/S0033583508004654; Faver JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018868; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Freddolino PL, 2010, NAT PHYS, V6, P751, DOI 10.1038/NPHYS1713; Gin BC, 2009, J MOL BIOL, V392, P1303, DOI 10.1016/j.jmb.2009.06.058; Kubelka J, 2004, CURR OPIN STRUC BIOL, V14, P76, DOI 10.1016/j.sbi.2004.01.013; Kuhlman B, 2004, CURR OPIN STRUC BIOL, V14, P89, DOI 10.1016/j.sbi.2004.01.002; Lenz P, 2009, CHEM PHYS LETT, V471, P310, DOI 10.1016/j.cplett.2009.02.054; Lindorff-Larsen K, 2005, TRENDS BIOCHEM SCI, V30, P13, DOI 10.1016/j.tibs.2004.11.008; Lindorff-Larsen K, 2004, NAT STRUCT MOL BIOL, V11, P443, DOI 10.1038/nsmb765; Modig K, 2007, FEBS LETT, V581, P4965, DOI 10.1016/j.febslet.2007.09.027; Paci E, 2005, J MOL BIOL, V352, P495, DOI 10.1016/j.jmb.2005.06.081; Pande VS, 1998, CURR OPIN STRUC BIOL, V8, P68, DOI 10.1016/S0959-440X(98)80012-2; Pandit AD, 2006, J MOL BIOL, V361, P755, DOI 10.1016/j.jmb.2006.06.041; Piana S, 2011, BIOPHYS J, V100, pL47, DOI 10.1016/j.bpj.2011.03.051; Rogen P, 2005, J PHYS-CONDENS MAT, V17, pS1523, DOI 10.1088/0953-8984/17/18/010; Settanni G, 2009, J MOL BIOL, V387, P993, DOI 10.1016/j.jmb.2009.02.014; Shah PS, 2007, J MOL BIOL, V372, P1, DOI 10.1016/j.jmb.2007.06.032; Shaw D.E., 2009, P C HIGH PERF COMP N, P1, DOI DOI 10.1145/1654059.1654126; Shaw DE, 2010, SCIENCE, V330, P341, DOI 10.1126/science.1187409; Sosnick TR, 2008, PROTEIN SCI, V17, P1308, DOI 10.1110/ps.036319.108; Sosnick TR, 2011, CURR OPIN STRUC BIOL, V21, P12, DOI 10.1016/j.sbi.2010.11.002; Wright CF, 2003, NAT STRUCT BIOL, V10, P658, DOI 10.1038/nsb947	25	1263	1276	6	536	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					517	520		10.1126/science.1208351	http://dx.doi.org/10.1126/science.1208351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034434				2022-12-28	WOS:000296230500048
J	Young, ND; Debelle, F; Oldroyd, GED; Geurts, R; Cannon, SB; Udvardi, MK; Benedito, VA; Mayer, KFX; Gouzy, J; Schoof, H; Van de Peer, Y; Proost, S; Cook, DR; Meyers, BC; Spannagl, M; Cheung, F; De Mita, S; Krishnakumar, V; Gundlach, H; Zhou, SG; Mudge, J; Bharti, AK; Murray, JD; Naoumkina, MA; Rosen, B; Silverstein, KAT; Tang, HB; Rombauts, S; Zhao, PX; Zhou, P; Barbe, V; Bardou, P; Bechner, M; Bellec, A; Berger, A; Berges, H; Bidwell, S; Bisseling, T; Choisne, N; Couloux, A; Denny, R; Deshpande, S; Dai, XB; Doyle, JJ; Dudez, AM; Farmer, AD; Fouteau, S; Franken, C; Gibelin, C; Gish, J; Goldstein, S; Gonzalez, AJ; Green, PJ; Hallab, A; Hartog, M; Hua, A; Humphray, SJ; Jeong, DH; Jing, Y; Jocker, A; Kenton, SM; Kim, DJ; Klee, K; Lai, HS; Lang, CT; Lin, SP; Macmil, SL; Magdelenat, G; Matthews, L; McCorrison, J; Monaghan, EL; Mun, JH; Najar, FZ; Nicholson, C; Noirot, C; O'Bleness, M; Paule, CR; Poulain, J; Prion, F; Qin, BF; Qu, CM; Retzel, EF; Riddle, C; Sallet, E; Samain, S; Samson, N; Sanders, I; Saurat, O; Scarpelli, C; Schiex, T; Segurens, B; Severin, AJ; Sherrier, DJ; Shi, RH; Sims, S; Singer, SR; Sinharoy, S; Sterck, L; Viollet, A; Wang, BB; Wang, KQ; Wang, MY; Wang, XH; Warfsmann, J; Weissenbach, J; White, DD; White, JD; Wiley, GB; Wincker, P; Xing, YB; Yang, LM; Yao, ZY; Ying, F; Zhai, JX; Zhou, LP; Zuber, A; Denarie, J; Dixon, RA; May, GD; Schwartz, DC; Rogers, J; Quetier, F; Town, CD; Roe, BA				Young, Nevin D.; Debelle, Frederic; Oldroyd, Giles E. D.; Geurts, Rene; Cannon, Steven B.; Udvardi, Michael K.; Benedito, Vagner A.; Mayer, Klaus F. X.; Gouzy, Jerome; Schoof, Heiko; Van de Peer, Yves; Proost, Sebastian; Cook, Douglas R.; Meyers, Blake C.; Spannagl, Manuel; Cheung, Foo; De Mita, Stephane; Krishnakumar, Vivek; Gundlach, Heidrun; Zhou, Shiguo; Mudge, Joann; Bharti, Arvind K.; Murray, Jeremy D.; Naoumkina, Marina A.; Rosen, Benjamin; Silverstein, Kevin A. T.; Tang, Haibao; Rombauts, Stephane; Zhao, Patrick X.; Zhou, Peng; Barbe, Valerie; Bardou, Philippe; Bechner, Michael; Bellec, Arnaud; Berger, Anne; Berges, Helene; Bidwell, Shelby; Bisseling, Ton; Choisne, Nathalie; Couloux, Arnaud; Denny, Roxanne; Deshpande, Shweta; Dai, Xinbin; Doyle, Jeff J.; Dudez, Anne-Marie; Farmer, Andrew D.; Fouteau, Stephanie; Franken, Carolien; Gibelin, Chrystel; Gish, John; Goldstein, Steven; Gonzalez, Alvaro J.; Green, Pamela J.; Hallab, Asis; Hartog, Marijke; Hua, Axin; Humphray, Sean J.; Jeong, Dong-Hoon; Jing, Yi; Joecker, Anika; Kenton, Steve M.; Kim, Dong-Jin; Klee, Kathrin; Lai, Hongshing; Lang, Chunting; Lin, Shaoping; Macmil, Simone L.; Magdelenat, Ghislaine; Matthews, Lucy; McCorrison, Jamison; Monaghan, Erin L.; Mun, Jeong-Hwan; Najar, Fares Z.; Nicholson, Christine; Noirot, Celine; O'Bleness, Majesta; Paule, Charles R.; Poulain, Julie; Prion, Florent; Qin, Baifang; Qu, Chunmei; Retzel, Ernest F.; Riddle, Claire; Sallet, Erika; Samain, Sylvie; Samson, Nicolas; Sanders, Iryna; Saurat, Olivier; Scarpelli, Claude; Schiex, Thomas; Segurens, Beatrice; Severin, Andrew J.; Sherrier, D. Janine; Shi, Ruihua; Sims, Sarah; Singer, Susan R.; Sinharoy, Senjuti; Sterck, Lieven; Viollet, Agnes; Wang, Bing-Bing; Wang, Keqin; Wang, Mingyi; Wang, Xiaohong; Warfsmann, Jens; Weissenbach, Jean; White, Doug D.; White, Jim D.; Wiley, Graham B.; Wincker, Patrick; Xing, Yanbo; Yang, Limei; Yao, Ziyun; Ying, Fu; Zhai, Jixian; Zhou, Liping; Zuber, Antoine; Denarie, Jean; Dixon, Richard A.; May, Gregory D.; Schwartz, David C.; Rogers, Jane; Quetier, Francis; Town, Christopher D.; Roe, Bruce A.			The Medicago genome provides insight into the evolution of rhizobial symbioses	NATURE			English	Article							FLAVONOID BIOSYNTHESIS; SIGNAL-TRANSDUCTION; GENES; ARABIDOPSIS; SEQUENCE; TRUNCATULA; DUPLICATIONS; TETRAPLOIDY; LEGUMINOSAE; EXPRESSION	Legumes (Fabaceae or Leguminosae) are unique among cultivated plants for their ability to carry out endosymbiotic nitrogen fixation with rhizobial bacteria, a process that takes place in a specialized structure known as the nodule. Legumes belong to one of the two main groups of eurosids, the Fabidae, which includes most species capable of endosymbiotic nitrogen fixation(1). Legumes comprise several evolutionary lineages derived from a common ancestor 60 million years ago (Myr ago). Papilionoids are the largest clade, dating nearly to the origin of legumes and containing most cultivated species(2). Medicago truncatula is a long-established model for the study of legume biology. Here we describe the draft sequence of the M. truncatula euchromatin based on a recently completed BAC assembly supplemented with Illumina shotgun sequence, together capturing similar to 94% of all M. truncatula genes. A whole-genome duplication (WGD) approximately 58 Myr ago had a major role in shaping the M. truncatula genome and thereby contributed to the evolution of endosymbiotic nitrogen fixation. Subsequent to the WGD, the M. truncatula genome experienced higher levels of rearrangement than two other sequenced legumes, Glycine max and Lotus japonicus. M. truncatula is a close relative of alfalfa (Medicago sativa), a widely cultivated crop with limited genomics tools and complex autotetraploid genetics. As such, the M. truncatula genome sequence provides significant opportunities to expand alfalfa's genomic toolbox.	[Young, Nevin D.; Zhou, Peng; Denny, Roxanne; Paule, Charles R.; Wang, Bing-Bing; Wang, Xiaohong] Univ Minnesota, Dept Plant Pathol, St Paul, MN 55108 USA; [Young, Nevin D.; Zhou, Peng; Denny, Roxanne; Paule, Charles R.; Wang, Bing-Bing; Wang, Xiaohong] Univ Minnesota, Dept Plant Biol, St Paul, MN 55108 USA; [Debelle, Frederic; Gouzy, Jerome; Bardou, Philippe; Dudez, Anne-Marie; Gibelin, Chrystel; Prion, Florent; Sallet, Erika; Samson, Nicolas; Saurat, Olivier; Zuber, Antoine; Denarie, Jean] INRA, LIPM, UMR441, F-31326 Castanet Tolosan, France; [Debelle, Frederic; Gouzy, Jerome; Bardou, Philippe; Dudez, Anne-Marie; Gibelin, Chrystel; Prion, Florent; Sallet, Erika; Samson, Nicolas; Saurat, Olivier; Zuber, Antoine; Denarie, Jean] CNRS, UMR2594, LIPM, F-31326 Castanet Tolosan, France; [Oldroyd, Giles E. D.; Murray, Jeremy D.] John Innes Ctr, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England; [Geurts, Rene; De Mita, Stephane; Bisseling, Ton; Franken, Carolien; Hartog, Marijke; Lang, Chunting] Wageningen Univ, Dept Plant Sci, Mol Biol Lab, NL-6708 PB Wageningen, Netherlands; [Cannon, Steven B.] ARS, USDA, Corn Insects & Crop Genet Res Unit, Ames, IA 50011 USA; [Cannon, Steven B.; Severin, Andrew J.] Iowa State Univ, Dept Agron, Ames, IA 50011 USA; [Udvardi, Michael K.; Murray, Jeremy D.; Naoumkina, Marina A.; Zhao, Patrick X.; Dai, Xinbin; Sinharoy, Senjuti; Wang, Mingyi; Dixon, Richard A.] Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73401 USA; [Benedito, Vagner A.] W Virginia Univ, Div Plant & Soil Sci, Dept Genet & Dev Biol, Morgantown, WV 26506 USA; [Mayer, Klaus F. X.; Spannagl, Manuel; Gundlach, Heidrun] Helmholtz Ctr Munich, MIPS Inst Bioinformat & Syst Biol, Neuherberg, Germany; [Schoof, Heiko] Univ Bonn, INRES Crop Bioinformat, D-53115 Bonn, Germany; [Van de Peer, Yves; Proost, Sebastian; Rombauts, Stephane; Sterck, Lieven] Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; [Cook, Douglas R.; Rosen, Benjamin; Gish, John; Kim, Dong-Jin; Mun, Jeong-Hwan] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; [Meyers, Blake C.; Green, Pamela J.; Jeong, Dong-Hoon; Sherrier, D. Janine; Zhai, Jixian] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19711 USA; [Meyers, Blake C.; Green, Pamela J.; Jeong, Dong-Hoon; Sherrier, D. Janine; Zhai, Jixian] Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19711 USA; [Cheung, Foo; Krishnakumar, Vivek; Tang, Haibao; Bidwell, Shelby; McCorrison, Jamison; Monaghan, Erin L.; Town, Christopher D.] J Craig Venter Inst, Rockville, MD 20850 USA; [Zhou, Shiguo; Bechner, Michael; Goldstein, Steven; Schwartz, David C.] Univ Wisconsin, Lab Mol & Computat Genom, Madison, WI 53706 USA; [Mudge, Joann; Bharti, Arvind K.; Farmer, Andrew D.; Retzel, Ernest F.; May, Gregory D.] Natl Ctr Genome Resources, Santa Fe, NM 87505 USA; [Silverstein, Kevin A. T.] Univ Minnesota, Biostat & Bioinformat Grp, Mason Canc Ctr, Minneapolis, MN 55455 USA; [Barbe, Valerie; Berger, Anne; Choisne, Nathalie; Couloux, Arnaud; Fouteau, Stephanie; Magdelenat, Ghislaine; Poulain, Julie; Samain, Sylvie; Scarpelli, Claude; Segurens, Beatrice; Viollet, Agnes; Weissenbach, Jean; Wincker, Patrick; Quetier, Francis] Genoscope, Ctr Natl Sequencage, F-91057 Evry, France; [Bellec, Arnaud; Berges, Helene] INRA, CNRGV, F-31326 Castanet Tolosan, France; [Bisseling, Ton] King Saud Univ, Coll Sci, Riyadh 11451, Saudi Arabia; [Deshpande, Shweta; Hua, Axin; Jing, Yi; Kenton, Steve M.; Lai, Hongshing; Lin, Shaoping; Macmil, Simone L.; Najar, Fares Z.; O'Bleness, Majesta; Qin, Baifang; Qu, Chunmei; Sanders, Iryna; Shi, Ruihua; Wang, Keqin; White, Doug D.; White, Jim D.; Wiley, Graham B.; Xing, Yanbo; Yang, Limei; Yao, Ziyun; Ying, Fu; Zhou, Liping; Roe, Bruce A.] Univ Oklahoma, Dept Chem & Biochem, Adv Ctr Genome Technol, Stephenson Res & Technol Ctr, Norman, OK 73019 USA; [Doyle, Jeff J.] Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; [Gonzalez, Alvaro J.] Univ Delaware, Dept Comp & Informat Sci, Newark, DE 19711 USA; [Gonzalez, Alvaro J.] Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19711 USA; [Hallab, Asis; Joecker, Anika; Klee, Kathrin; Warfsmann, Jens] Max Planck Inst Plant Breeding Res, D-50829 Cologne, Germany; [Humphray, Sean J.; Matthews, Lucy; Nicholson, Christine; Riddle, Claire; Sims, Sarah] Wellcome Trust Genome Campus, Cambridge CB10 1SA, England; [Kim, Dong-Jin] Int Inst Trop Agr, Ibadan, Nigeria; [Mun, Jeong-Hwan] Natl Inst Agr Biotechnol, Rural Dev Adm, Suwon 441707, South Korea; [Noirot, Celine; Schiex, Thomas] INRA, UBIA, UR875, F-31326 Castanet Tolosan, France; [Singer, Susan R.] Carleton Coll, Dept Biol, Northfield, MN 55057 USA; [Rogers, Jane] Genome Anal Ctr, Norwich NR4 7UH, Norfolk, England	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Wageningen University & Research; United States Department of Agriculture (USDA); Iowa State University; Noble Research Institute; West Virginia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bonn; Flanders Institute for Biotechnology (VIB); Ghent University; University of California System; University of California Davis; University of Delaware; University of Delaware; J. Craig Venter Institute; University of Wisconsin System; University of Wisconsin Madison; National Center for Genome Resources (NCGR); University of Minnesota System; University of Minnesota Twin Cities; CEA; UDICE-French Research Universities; Universite Paris Saclay; INRAE; King Saud University; University of Oklahoma System; University of Oklahoma - Norman; Cornell University; University of Delaware; University of Delaware; Max Planck Society; Wellcome Trust Sanger Institute; CGIAR; International Institute of Tropical Agriculture (IITA); Rural Development Administration (RDA), Republic of Korea; INRAE; Carleton College; The Genome Analysis Centre (TGAC)	Young, ND (corresponding author), Univ Minnesota, Dept Plant Pathol, St Paul, MN 55108 USA.	neviny@umn.edu	Proost, Sebastian/AAB-9845-2022; Murray, Jeremy D./F-8409-2011; Oldroyd, Giles/ABA-7501-2020; Meyers, Blake/B-6535-2012; Rombauts, Stephane M/D-7640-2014; Sinharoy, Senjuti/AAA-2572-2019; Sterck, Lieven/A-9439-2016; Schoof, Heiko/Y-7073-2018; Van de Peer, Yves/AAE-7666-2019; Rombauts, Stephane/P-2420-2019; Krishnakumar, Vivek/C-7204-2015; Udvardi, Michael/GPX-4653-2022; Bisseling, Ton/A-2421-2013; Gouzy, Jerome/AAH-4977-2020; Sherrier, D. Janine/D-6624-2017; Oldroyd, Giles/ABD-8143-2021; Mayer, Klaus FX/M-7941-2015; Zhai, Jixian/HCH-9272-2022; Tang, Haibao/A-6715-2011; Sherrier, D Janine/GNH-1971-2022; Zhou, Shiguo/B-3832-2011; Van de Peer, Yves/D-4388-2009; Quetier, Francis/J-7923-2017	Proost, Sebastian/0000-0002-6792-9442; Murray, Jeremy D./0000-0003-3000-9199; Meyers, Blake/0000-0003-3436-6097; Rombauts, Stephane M/0000-0002-3985-4981; Sinharoy, Senjuti/0000-0003-2323-2587; Sterck, Lieven/0000-0001-7116-4000; Schoof, Heiko/0000-0002-1527-3752; Van de Peer, Yves/0000-0003-4327-3730; Rombauts, Stephane/0000-0002-3985-4981; Krishnakumar, Vivek/0000-0002-5227-0200; Udvardi, Michael/0000-0001-9850-0828; Gouzy, Jerome/0000-0001-5695-4557; Sherrier, D. Janine/0000-0003-1230-0636; Oldroyd, Giles/0000-0002-5245-6355; Mayer, Klaus FX/0000-0001-6484-1077; Tang, Haibao/0000-0002-3460-8570; Zhou, Shiguo/0000-0001-7421-2506; Van de Peer, Yves/0000-0003-4327-3730; Mudge, Joann/0000-0002-2972-1640; Gundlach, Heidrun/0000-0002-6757-0943; Spannagl, Manuel/0000-0003-0701-7035; Couloux, Arnaud/0000-0003-2356-0062; Klee, Kathrin/0000-0003-2408-1282; Sallet, Erika/0000-0003-4637-473X; Cree, Simone/0000-0002-7349-422X; Poulain, Julie/0000-0002-8744-3116; BERGES, Helene/0000-0002-5492-1062; Young, Nevin/0000-0001-6463-4772; Quetier, Francis/0000-0003-4388-9287; Zhao, Patrick Xuechun/0000-0002-3460-5564; Zhai, Jixian/0000-0002-0217-0666; CHOISNE, Nathalie/0000-0001-6024-1664; Bardou, Philippe/0000-0002-0004-0251	Noble Foundation; NSF-PGRP [0321460, 0604966, 0820005, 0821966]; EU [FOOD-CT-2004-506223]; BBSRC [BBS/B/11524]; ANR [SEQMEDIC 2006-01122]; Dutch Science Organization [VIDI 864.06.007, ERA-PG FP-06.038A]; Belgian Federal Science Policy Office IUAP [P6/25]; Fund for Scientific Research Flanders; Institute for the Promotion of Innovation by Science and Technology in Flanders; Ghent University [MRP N2N]; NSF [IOS-0531408, IOS-0605251]; USDA CSREES [2006-03567]; 'Laboratoire d'Excellence' (LABEX) TULIP [ANR-10-LABX-41]; Biotechnology and Biological Sciences Research Council [BBS/E/J/00000603, BBS/B/11524, BB/G023832/1, BB/I025441/1] Funding Source: researchfish; BBSRC [BB/I025441/1, BB/G023832/1] Funding Source: UKRI; Direct For Biological Sciences [0960897] Funding Source: National Science Foundation; Division Of Integrative Organismal Systems [0820005] Funding Source: National Science Foundation	Noble Foundation; NSF-PGRP(National Science Foundation (NSF)NSF - Office of the Director (OD)); EU(European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); ANR(French National Research Agency (ANR)); Dutch Science Organization; Belgian Federal Science Policy Office IUAP(Belgian Federal Science Policy Office); Fund for Scientific Research Flanders(FWO); Institute for the Promotion of Innovation by Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Ghent University(Ghent University); NSF(National Science Foundation (NSF)); USDA CSREES(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); 'Laboratoire d'Excellence' (LABEX) TULIP; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	Funding support to N.D.Y., C. D. T. and B. A. R. from The Noble Foundation and NSF-PGRP 0321460, 0604966; to N.D.Y., J.M. and G. D. M. from NSF-PGRP 0820005; to C. D. T. from NSF-PGRP 0821966; to F. D., G.E.D.O., R. G., K. F. X. M., T. B., J. Denarie, F. Q. and J. R. from FP6 EU project GLIP/Grain Legumes FOOD-CT-2004-506223; to G.E.D.O. and J.R. from BBSRC BBS/B/11524; to F. D. and F. Q. from ANR project SEQMEDIC 2006-01122; to R. G. from the Dutch Science Organization VIDI 864.06.007, ERA-PG FP-06.038A; to Y.V.d.P. from the Belgian Federal Science Policy Office IUAP P6/25, Fund for Scientific Research Flanders, Institute for the Promotion of Innovation by Science and Technology in Flanders and Ghent University (MRP N2N); to D. R. C. from NSF IOS-0531408, IOS-0605251; to D.J.S., B. C. M. and P.J.G. from USDA CSREES 2006-03567; to J. Gouzy from 'Laboratoire d'Excellence' (LABEX) TULIP (ANR-10-LABX-41). We also acknowledge technical support from the University of Minnesota Supercomputer Institute and thank Y.W. Nam for a BamHI BAC library used by Genoscope, S. Park and M. Accerbi for RNA isolation, T. Paape for statistical consulting, and M. Harrison for supplying myc infected and control root tissues used to make small RNA libraries.	Arrighi JF, 2006, PLANT PHYSIOL, V142, P265, DOI 10.1104/pp.106.084657; Cannon SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011630; den Camp RO, 2011, SCIENCE, V331, P909, DOI 10.1126/science.1198181; Doyle JJ, 2003, PLANT PHYSIOL, V131, P900, DOI 10.1104/pp.102.018150; Freeling M, 2006, GENOME RES, V16, P805, DOI 10.1101/gr.3681406; HEGNAUER R, 1993, PHYTOCHEMISTRY, V34, P3, DOI 10.1016/S0031-9422(00)90776-3; Kato T, 2002, MOL PLANT MICROBE IN, V15, P129, DOI 10.1094/MPMI.2002.15.2.129; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kistner C, 2002, TRENDS PLANT SCI, V7, P511, DOI 10.1016/S1360-1385(02)02356-7; Kulikova O, 2001, PLANT J, V27, P49, DOI 10.1046/j.1365-313x.2001.01057.x; Lavin M, 2005, SYST BIOL, V54, P575, DOI 10.1080/10635150590947131; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Matsumoto T, 2005, NATURE, V436, P793, DOI 10.1038/nature03895; Meyers BC, 2003, PLANT CELL, V15, P809, DOI 10.1105/tpc.009308; Middleton PH, 2007, PLANT CELL, V19, P1221, DOI 10.1105/tpc.106.048264; Oldroyd GED, 2008, ANNU REV PLANT BIOL, V59, P519, DOI 10.1146/annurev.arplant.59.032607.092839; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; Pfeil BE, 2005, SYST BIOL, V54, P441, DOI 10.1080/10635150590945359; Schmutz J, 2010, NATURE, V463, P178, DOI 10.1038/nature08670; SHIRLEY BW, 1995, PLANT J, V8, P659, DOI 10.1046/j.1365-313X.1995.08050659.x; Singer SR, 2009, PLANT PHYSIOL, V151, P1041, DOI 10.1104/pp.109.144774; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; Tang HB, 2008, GENOME RES, V18, P1944, DOI 10.1101/gr.080978.108; Thomas BC, 2006, GENOME RES, V16, P934, DOI 10.1101/gr.4708406; Tuskan GA, 2006, SCIENCE, V313, P1596, DOI 10.1126/science.1128691; Van de Velde W, 2010, SCIENCE, V327, P1122, DOI 10.1126/science.1184057; Wang HC, 2009, P NATL ACAD SCI USA, V106, P3853, DOI 10.1073/pnas.0813376106; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Yang SH, 2008, MOL GENET GENOMICS, V280, P187, DOI 10.1007/s00438-008-0355-0; Zhou T, 2004, MOL GENET GENOMICS, V271, P402, DOI 10.1007/s00438-004-0990-z	30	864	977	17	430	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					520	524		10.1038/nature10625	http://dx.doi.org/10.1038/nature10625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22089132	hybrid, Green Accepted			2022-12-28	WOS:000298318000060
J	Lynch, VJ; May, G; Wagner, GP				Lynch, Vincent J.; May, Gemma; Wagner, Guenter P.			Regulatory evolution through divergence of a phosphoswitch in the transcription factor CEBPB	NATURE			English	Article							BINDING-PROTEIN-BETA; ENDOMETRIAL STROMAL CELLS; C/EBP-BETA; HOX PROTEIN; DNA-BINDING; IN-VIVO; DOMAIN; ACTIVATION; PHOSPHORYLATION; ASSOCIATION	There is an emerging consensus that gene regulation evolves through changes in cis-regulatory elements(1,2) and transcription factors(3-6). Although it is clear how nucleotide substitutions in cis-regulatory elements affect gene expression, it is not clear how amino-acid substitutions in transcription factors influence gene regulation(4-10). Here we show that amino-acid changes in the transcription factor CCAAT/enhancer binding protein-beta (CEBPB, also known as C/EBP-beta) in the stem-lineage of placental mammals changed the way it responds to cyclic AMP/protein kinase A (cAMP/PKA) signalling. By functionally analysing resurrected ancestral proteins, we identify three amino-acid substitutions in an internal regulatory domain of CEBPB that are responsible for the novel function. These amino-acid substitutions reorganize the location of key phosphorylation sites, introducing a new site and removing two ancestral sites, reversing the response of CEBPB to GSK-3 beta-mediated phosphorylation from repression to activation. We conclude that changing the response of transcription factors to signalling pathways can be an important mechanism of gene regulatory evolution.	[Lynch, Vincent J.; May, Gemma; Wagner, Guenter P.] Yale Univ, Yale Syst Biol Inst, New Haven, CT 06511 USA; [Lynch, Vincent J.; May, Gemma; Wagner, Guenter P.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06511 USA	Yale University; Yale University	Lynch, VJ (corresponding author), Yale Univ, Yale Syst Biol Inst, New Haven, CT 06511 USA.	vincent.j.lynch@yale.edu		Wagner, Gunter/0000-0002-3097-002X; Lynch, Vincent/0000-0001-5311-3824	John Templeton Foundation [12793]; Origin of Organismal Complexity	John Templeton Foundation; Origin of Organismal Complexity	This work was funded by a grant from the John Templeton Foundation, number 12793 Genetics and the Origin of Organismal Complexity; results presented here do not necessarily reflect the views of the John Templeton Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Carroll SB, 2008, CELL, V134, P25, DOI 10.1016/j.cell.2008.06.030; Chen LZ, 2010, P NATL ACAD SCI USA, V107, P10555, DOI 10.1073/pnas.1005129107; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; Friedman JR, 2004, P NATL ACAD SCI USA, V101, P12986, DOI 10.1073/pnas.0402875101; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Hsia CC, 2003, CURR OPIN GENET DEV, V13, P199, DOI 10.1016/S0959-437X(03)00017-0; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kowenz-Leutz E, 2010, EMBO J, V29, P1105, DOI 10.1038/emboj.2010.3; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee S, 2010, J BIOL CHEM, V285, P21399, DOI 10.1074/jbc.M110.128413; Lohr U, 2001, CURR BIOL, V11, P1403, DOI 10.1016/S0960-9822(01)00443-2; Lynch VJ, 2008, EVOLUTION, V62, P2131, DOI 10.1111/j.1558-5646.2008.00440.x; Lynch VJ, 2008, P NATL ACAD SCI USA, V105, P14928, DOI 10.1073/pnas.0802355105; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Prud'homme B, 2007, P NATL ACAD SCI USA, V104, P8605, DOI 10.1073/pnas.0700488104; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; Shen F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000066; Spooner CJ, 2007, MOL IMMUNOL, V44, P1384, DOI 10.1016/j.molimm.2006.05.004; Stern DL, 2008, EVOLUTION, V62, P2155, DOI 10.1111/j.1558-5646.2008.00450.x; Stern DL, 2000, EVOLUTION, V54, P1079, DOI 10.1554/0014-3820(2000)054[1079:PEDBAT]2.0.CO;2; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; Tsvetkov P, 2008, PROTEINS, V70, P1357, DOI 10.1002/prot.21614; Wagner GP, 2005, J EXP ZOOL PART B, V304B, P580, DOI 10.1002/jez.b.21074; Wagner GP, 2010, CURR BIOL, V20, pR48, DOI 10.1016/j.cub.2009.11.010; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wray GA, 2007, NAT REV GENET, V8, P206, DOI 10.1038/nrg2063; Zhao X, 2005, J BIOL CHEM, V280, P32683, DOI 10.1074/jbc.M505486200	30	68	69	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					383	U139		10.1038/nature10595	http://dx.doi.org/10.1038/nature10595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22080951				2022-12-28	WOS:000298033000055
J	Nguyen, KD; Qiu, YF; Cui, XJ; Goh, YPS; Mwangi, J; David, T; Mukundan, L; Brombacher, F; Locksley, RM; Chawla, A				Nguyen, Khoa D.; Qiu, Yifu; Cui, Xiaojin; Goh, Y. P. Sharon; Mwangi, Julia; David, Tovo; Mukundan, Lata; Brombacher, Frank; Locksley, Richard M.; Chawla, Ajay			Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis	NATURE			English	Article							INSULIN-RESISTANCE; ADIPOSE-TISSUE; LIPOLYSIS; MICE; METABOLISM	All homeotherms use thermogenesis to maintain their core body temperature, ensuring that cellular functions and physiological processes can continue in cold environments(1-3). In the prevailing model of thermogenesis, when the hypothalamus senses cold temperatures it triggers sympathetic discharge, resulting in the release of noradrenaline in brown adipose tissue and white adipose tissue(4,5). Acting via the beta(3)-adrenergic receptors, noradrenaline induces lipolysis in white adipocytes(6), whereas it stimulates the expression of thermogenic genes, such as PPAR-gamma coactivator 1a (Ppargc1a), uncoupling protein 1 (Ucp1) and acyl-CoA synthetase long-chain family member 1 (Acsl1), in brown adipocytes(7-9). However, the precise nature of all the cell types involved in this efferent loop is not well established. Here we report in mice an unexpected requirement for the interleukin-4 (IL-4)-stimulated program of alternative macrophage activation in adaptive thermogenesis. Exposure to cold temperature rapidly promoted alternative activation of adipose tissue macrophages, which secrete catecholamines to induce thermogenic gene expression in brown adipose tissue and lipolysis in white adipose tissue. Absence of alternatively activated macrophages impaired metabolic adaptations to cold, whereas administration of IL-4 increased thermogenic gene expression, fatty acid mobilization and energy expenditure, all in a macrophage dependent manner. Thus, we have discovered a role for alternatively activated macrophages in the orchestration of an important mammalian stress response, the response to cold.	[Nguyen, Khoa D.; Qiu, Yifu; Cui, Xiaojin; Goh, Y. P. Sharon; Mwangi, Julia; David, Tovo; Mukundan, Lata; Chawla, Ajay] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Nguyen, Khoa D.; Goh, Y. P. Sharon] Stanford Univ, Program Immunol, Palo Alto, CA 94305 USA; [Brombacher, Frank] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa; [Locksley, Richard M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA; [Locksley, Richard M.; Chawla, Ajay] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Locksley, Richard M.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94158 USA; [Chawla, Ajay] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Stanford University; University of Cape Town; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chawla, A (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.	ajay.chawla@ucsf.edu	DAVID, Tovo/B-5573-2013	Nguyen, Khoa/0000-0002-6720-2470; Qiu, Yifu/0000-0001-5645-3189	NIH [DK076760, HL076746, DK094641, DP1OD006415]; Larry L. Hillblom Foundation Network; Stanford Graduate Fellowship; A-STAR Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [DP1AR064158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK094641, R01DK076760, R01DK081405] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD006415] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Larry L. Hillblom Foundation Network; Stanford Graduate Fellowship(Stanford University); A-STAR Fellowship(Agency for Science Technology & Research (A*STAR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank members of the Chawla laboratory, A. Loh and C.-H. Lee for comments on the manuscript, and F. Kraemer for guidance on in vitro lipolysis assays. This work was supported by grants from the NIH (DK076760, HL076746, DK094641), Larry L. Hillblom Foundation Network Grant and an NIH Director's Pioneer Award (DP1OD006415) to A. C. Support was provided by Stanford Graduate Fellowship (K.D.N.) and A-STAR Fellowship (Y.P.G). All animal care was in accordance with Stanford University's A-PLAC and UCSF's IACUC guidelines.	Brown SW, 2003, J NEUROIMMUNOL, V135, P47, DOI 10.1016/S0165-5728(02)00435-6; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2011, J EXP BIOL, V214, P242, DOI 10.1242/jeb.050989; Ellis JM, 2010, CELL METAB, V12, P53, DOI 10.1016/j.cmet.2010.05.012; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Morrison SF, 2008, EXP PHYSIOL, V93, P773, DOI 10.1113/expphysiol.2007.041848; Nakamura K, 2008, NAT NEUROSCI, V11, P62, DOI 10.1038/nn2027; Nedergaard J, 2011, CELL METAB, V13, P238, DOI 10.1016/j.cmet.2011.02.009; Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Tseng YH, 2010, NAT REV DRUG DISCOV, V9, P465, DOI 10.1038/nrd3138; Watt MJ, 2004, AM J PHYSIOL-ENDOC M, V287, pE120, DOI 10.1152/ajpendo.00542.2003; YOSHIDA T, 1994, LIFE SCI, V54, P491, DOI 10.1016/0024-3205(94)00408-0; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	24	747	777	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	2011	480	7375					104	U272		10.1038/nature10653	http://dx.doi.org/10.1038/nature10653			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22101429	Green Accepted			2022-12-28	WOS:000298031900043
J	Yang, WW; Xia, Y; Ji, HT; Zheng, YH; Liang, J; Huang, WH; Gao, X; Aldape, K; Lu, ZM				Yang, Weiwei; Xia, Yan; Ji, Haitao; Zheng, Yanhua; Liang, Ji; Huang, Wenhua; Gao, Xiang; Aldape, Kenneth; Lu, Zhimin			Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation	NATURE			English	Article							TUMOR-CELL INVASION; PYRUVATE-KINASE M2; DOWN-REGULATION; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; CANCER METABOLISM; CARCINOMA CELLS; EXPRESSION; PROTEIN; SURVIVAL	The embryonic pyruvate kinase M2 (PKM2) isoform is highly expressed in human cancer. In contrast to the established role of PKM2 in aerobic glycolysis or the Warburg effect(1-3), its non-metabolic functions remain elusive. Here we demonstrate, in human cancer cells, that epidermal growth factor receptor (EGFR) activation induces translocation of PKM2, but not PKM1, into the nucleus, where K433 of PKM2 binds to c-Src-phosphorylated Y333 of beta-catenin. This interaction is required for both proteins to be recruited to the CCND1 promoter, leading to HDAC3 removal from the promoter, histone H3 acetylation and cyclin D1 expression. PKM2-dependent beta-catenin transactivation is instrumental in EGFR-promoted tumour cell proliferation and brain tumour development. In addition, positive correlations have been identified between c-Src activity, beta-catenin Y333 phosphorylation and PKM2 nuclear accumulation in human glioblastoma specimens. Furthermore, levels of beta-catenin phosphorylation and nuclear PKM2 have been correlated with grades of glioma malignancy and prognosis. These findings reveal that EGF induces beta-catenin transactivation via a mechanism distinct from that induced by Wnt/Wingless(4) and highlight the essential non-metabolic functions of PKM2 in EGFR-promoted beta-catenin transactivation, cell proliferation and tumorigenesis.	[Yang, Weiwei; Xia, Yan; Ji, Haitao; Zheng, Yanhua; Liang, Ji; Lu, Zhimin] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Yang, Weiwei; Xia, Yan; Ji, Haitao; Zheng, Yanhua; Liang, Ji; Lu, Zhimin] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Huang, Wenhua] Jiaxing Xinda Biotechnol Co, Jiaxing 314000, Zhejiang, Peoples R China; [Gao, Xiang] Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing 210061, Jiangsu, Peoples R China; [Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lu, Zhimin] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Lu, Zhimin] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Nanjing University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Lu, ZM (corresponding author), Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA.	zhiminlu@mdanderson.org	Ji, Haitao/B-8204-2012; Ji, Haitao/L-1615-2013; yang, zheng/HGC-7753-2022	Yang, Weiwei/0000-0002-1661-9137	National Cancer Institute [5R01CA109035, 5 P50 CA127001-03, CA16672]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP110252]; American Cancer Society [RSG-09-277-01-CSM]; University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109035, P50CA127001] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas (CPRIT); American Cancer Society(American Cancer Society); University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T. Hunter (The Salk Institute for Biological Studies) for Abl and Src knockout cells, H. Clevers (Netherlands Institute for Developmental Biology) for the pTOP-FLASH and the pFOP-FLASH, and Y. Li (Baylor College of Medicine) for a WNT1 lenti-vector. This work was supported by National Cancer Institute grants 5R01CA109035 (Z.L.), 5 P50 CA127001-03 and CA16672 (Cancer Center Support Grant); a research grant (RP110252; Z.L.) from the Cancer Prevention and Research Institute of Texas (CPRIT), an American Cancer Society Research Scholar Award RSG-09-277-01-CSM (Z.L.), and a Sister Institution Network Fund from The University of Texas MD Anderson Cancer Center (Z.L.).	Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gomez-Manzano C, 2006, CLIN CANCER RES, V12, P556, DOI 10.1158/1078-0432.CCR-05-1892; Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Le Mellay V, 2002, ADV ENZYME REGUL, V42, P317, DOI 10.1016/S0065-2571(01)00036-X; Lu ZM, 2004, CELL CYCLE, V3, P571; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; Petalidis LP, 2008, MOL CANCER THER, V7, P1013, DOI 10.1158/1535-7163.MCT-07-0177; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wykosky Jill, 2011, Chin J Cancer, V30, P5; Xia Y, 2007, MOL CELL, V25, P219, DOI 10.1016/j.molcel.2007.01.005; Yochum GS, 2007, P NATL ACAD SCI USA, V104, P3324, DOI 10.1073/pnas.0611576104	26	678	704	5	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	2011	480	7375					118	U289		10.1038/nature10598	http://dx.doi.org/10.1038/nature10598			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22056988	Green Accepted			2022-12-28	WOS:000298031900046
J	Canto, JG; Kiefe, CI; Rogers, WJ; Peterson, ED; Frederick, PD; French, WJ; Gibson, CM; Pollack, CV; Ornato, JP; Zalenski, RJ; Penney, J; Tiefenbrunn, AJ; Greenland, P				Canto, John G.; Kiefe, Catarina I.; Rogers, William J.; Peterson, Eric D.; Frederick, Paul D.; French, William J.; Gibson, C. Michael; Pollack, Charles V., Jr.; Ornato, Joseph P.; Zalenski, Robert J.; Penney, Jan; Tiefenbrunn, Alan J.; Greenland, Philip		NRMI Investigators	Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL REGISTRY; EVENTS; INDEX	Context Few studies have examined the association between the number of coronary heart disease risk factors and outcomes of acute myocardial infarction in community practice. Objective To determine the association between the number of coronary heart disease risk factors in patients with first myocardial infarction and hospital mortality. Design Observational study from the National Registry of Myocardial Infarction, 1994-2006. Patients We examined the presence and absence of 5 major traditional coronary heart disease risk factors (hypertension, smoking, dyslipidemia, diabetes, and family history of coronary heart disease) and hospital mortality among 542 008 patients with first myocardial infarction and without prior cardiovascular disease. Main Outcome Measure All-cause in-hospital mortality. Results A majority (85.6%) of patients who presented with initial myocardial infarction had at least 1 of the 5 coronary heart disease risk factors, and 14.4% had none of the 5 risk factors. Age varied inversely with the number of coronary heart disease risk factors, from a mean age of 71.5 years with 0 risk factors to 56.7 years with 5 risk factors (P for trend < .001). The total number of in-hospital deaths for all causes was 50 788. Unadjusted in-hospital mortality rates were 14.9%, 10.9%, 7.9%, 5.3%, 4.2%, and 3.6% for patients with 0, 1, 2, 3, 4, and 5 risk factors, respectively. After adjusting for age and other clinical factors, there was an inverse association between the number of coronary heart disease risk factors and hospital mortality adjusted odds ratio (1.54; 95% CI, 1.23-1.94) among individuals with 0 vs 5 risk factors. This association was consistent among several age strata and important patient subgroups. Conclusion Among patients with incident acute myocardial infarction without prior cardiovascular disease, in-hospital mortality was inversely related to the number of coronary heart disease risk factors. JAMA. 2011;306(19):2120-2127 www.jama.com	[Canto, John G.] Watson Clin LLP, Ctr Cardiovasc Prevent Res & Educ, Lakeland, FL USA; [Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Rogers, William J.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; [Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Frederick, Paul D.] ICON Late Phase & Outcomes Res, San Francisco, CA USA; [French, William J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Gibson, C. Michael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; [Pollack, Charles V., Jr.] Univ Penn, Philadelphia, PA 19104 USA; [Ornato, Joseph P.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Zalenski, Robert J.] Wayne State Univ, Sch Med, Detroit, MI USA; [Penney, Jan] Mid Michigan Hlth, Midland, MI USA; [Tiefenbrunn, Alan J.] Washington Univ, Sch Med, St Louis, MO USA; [Greenland, Philip] Northwestern Univ, Clin & Translat Sci Inst, Chicago, IL 60611 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Alabama System; University of Alabama Birmingham; Duke University; ICON plc; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania; Virginia Commonwealth University; Wayne State University; Washington University (WUSTL); Northwestern University	Canto, JG (corresponding author), Watson Clin, 1600 Lakeland Hill Blvd, Lakeland, FL 33805 USA.	jcanto@watsonclinic.com	Peterson, Eric David/ABF-5033-2021; Gibson, C. Michael/AAE-8212-2019; Greenland, Philip/ABD-5528-2021	Frederick, Paul/0000-0002-7936-5488	National Institutes of Health [U01HL 105268, U54 RR 026088]; Bristol-Myers Squibb/sanofi; Eli Lilly; Johnson Johnson; Genentech Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105268] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bristol-Myers Squibb/sanofi(Bristol-Myers Squibb); Eli Lilly(Eli Lilly); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Genentech Inc(Roche HoldingGenentech); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kiefe reports receiving partial funding from the National Institutes of Health (grants U01HL 105268 and U54 RR 026088). Dr Peterson reports receiving grants from Bristol-Myers Squibb/sanofi, Eli Lilly, and Johnson & Johnson. Mr Frederick reports being an employee of ICON Clinical Research, which received support from Genentech Inc to provide biostatistical and analytic services. Dr Gibson reports that his institution received a grant from Genentech for a research trial. Dr Pollack reports serving as a consultant and on the speakers bureau for sanofi-aventis. Dr Ornato reports being an unpaid advisory board member for ZOLL. No other disclosures were reported.	Dahabreh IJ, 2011, JAMA-J AM MED ASSOC, V305, P822, DOI 10.1001/jama.2011.163; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Roe MT, 2007, AM HEART J, V153, P507, DOI 10.1016/j.ahj.2006.12.018; Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9; Saab F, 2009, ANGIOLOGY, V60, P663, DOI 10.1177/0003319709333870; Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065; Wiviott SD, 2006, J AM COLL CARDIOL, V47, P1553, DOI 10.1016/j.jacc.2005.11.075; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	14	149	157	10	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2120	2127		10.1001/jama.2011.1654	http://dx.doi.org/10.1001/jama.2011.1654			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089719	Green Accepted, Bronze			2022-12-28	WOS:000297013000018
J	Manning, KD				Manning, Kimberly D.			Tall Buildings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Emory Univ, Sch Med, Atlanta, GA 30322 USA	Emory University	Manning, KD (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.	kdmanni@emory.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2068	2069		10.1001/jama.2011.1651	http://dx.doi.org/10.1001/jama.2011.1651			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089706				2022-12-28	WOS:000297013000001
J	Tomaselli, GF				Tomaselli, Gordon F.			Prevention of Cardiovascular Disease and Stroke Meeting the Challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Tomaselli, Gordon F.] Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Baltimore, MD 21205 USA; [Tomaselli, Gordon F.] Johns Hopkins Univ, Dept Cellular & Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Tomaselli, GF (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.	gtomase1@jhmi.edu						Ford ES, 2011, ANNU REV PUBL HEALTH, V32, P5, DOI 10.1146/annurev-publhealth-031210-101211; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; SACCO R, ACCELERATING PROGR N, DOI DOI 10.1016/S0140-6736(11)61477-3; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4	5	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2147	2148		10.1001/jama.2011.1668	http://dx.doi.org/10.1001/jama.2011.1668			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089723				2022-12-28	WOS:000297013000022
J	Khan, M; Vaes, E; Mombaerts, P				Khan, Mona; Vaes, Evelien; Mombaerts, Peter			Regulation of the Probability of Mouse Odorant Receptor Gene Choice	CELL			English	Article							OLFACTORY SENSORY NEURONS; EXPRESSION PATTERNS; MICE; EPITHELIUM; ENHANCERS; LEVEL; CIS	Each olfactory sensory neuron (OSN) in mouse chooses one of 1,200 odorant receptor (OR) genes for expression. OR genes are chosen for expression by greatly varying numbers of OSNs. The mechanisms that regulate the probability of OR gene choice remain unclear. Here, we have applied the NanoString platform of fluorescent barcodes and digital readout to measure RNA levels of 577 OR genes in a single reaction, with probes designed against coding sequences. In an inbred mouse strain with a targeted deletion in the P element, we find that this element regulates OR gene choice differentially across its cluster of 24 OR genes. Importantly, the fold changes of NanoString counts in Delta P or Delta H mice are in very close agreement with the fold changes of cell counts, determined by in situ hybridization. Thus, the P and H elements regulate the probability of OR gene choice, not OR transcript level per OSN.	[Khan, Mona; Vaes, Evelien; Mombaerts, Peter] Max Planck Inst Biophys, D-60438 Frankfurt, Germany	Max Planck Society	Mombaerts, P (corresponding author), Max Planck Inst Biophys, D-60438 Frankfurt, Germany.	peter.mombaerts@biophys.mpg.de			Max Planck Society; European Research Council	Max Planck Society(Max Planck SocietyFoundation CELLEX); European Research Council(European Research Council (ERC)European Commission)	We thank Christian Basta, Anna-Lena Hohmann, Christian Lozanoski, Bartos Machert, and Michael Marburger for expert technical assistance; Philippa Webster for comments on the manuscript; and Nathan Elliott and Jordan Moore for contributing data. Generous support was provided by the Max Planck Society and Advanced Grant ORGENECHOICE from the European Research Council to P. M. This paper is dedicated to the memory of Shou Serizawa, the discoverer of the H element.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bozza T, 2009, NEURON, V61, P220, DOI 10.1016/j.neuron.2008.11.010; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Feinstein P, 2004, CELL, V117, P833, DOI 10.1016/j.cell.2004.05.013; Fuss SH, 2007, CELL, V130, P373, DOI 10.1016/j.cell.2007.06.023; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Ishii T, 2004, J NEUROCYTOL, V33, P657, DOI 10.1007/s11068-005-3334-y; Iwema CL, 2004, J NEUROSCI, V24, P356, DOI 10.1523/JNEUROSCI.1219-03.2004; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Lee AC, 2009, CHEM SENSES, V34, P695, DOI 10.1093/chemse/bjp056; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nishizumi H, 2007, P NATL ACAD SCI USA, V104, P20067, DOI 10.1073/pnas.0706544105; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rodriguez-Gil DJ, 2010, J NEUROSCI, V30, P10067, DOI 10.1523/JNEUROSCI.1776-10.2010; Rothman A, 2005, MOL CELL NEUROSCI, V28, P535, DOI 10.1016/j.mcn.2004.11.006; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vassalli A, 2011, MOL CELL NEUROSCI, V46, P381, DOI 10.1016/j.mcn.2010.11.001; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Williams A, 2010, TRENDS GENET, V26, P188, DOI 10.1016/j.tig.2010.01.007; Xie SY, 2000, MAMM GENOME, V11, P1070, DOI 10.1007/s003350010217; Young JM, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r71; Zhang XH, 2007, GENOMICS, V89, P441, DOI 10.1016/j.ygeno.2007.01.002	33	108	110	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					907	921		10.1016/j.cell.2011.09.049	http://dx.doi.org/10.1016/j.cell.2011.09.049			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078886	Bronze			2022-12-28	WOS:000296902300022
J	Galland, C; Ghosh, Y; Steinbruck, A; Sykora, M; Hollingsworth, JA; Klimov, VI; Htoon, H				Galland, Christophe; Ghosh, Yagnaseni; Steinbrueck, Andrea; Sykora, Milan; Hollingsworth, Jennifer A.; Klimov, Victor I.; Htoon, Han			Two types of luminescence blinking revealed by spectroelectrochemistry of single quantum dots	NATURE			English	Article							SEMICONDUCTOR NANOCRYSTALS; CORE/SHELL NANOCRYSTALS; ELECTRON-TRANSFER; CDSE; FLUORESCENCE; SUPPRESSION; INTENSITY; PHOTOLUMINESCENCE; INTERMITTENCY; COMPLEXES	Photoluminescence blinking-random switching between states of high (ON) and low (OFF) emissivities-is a universal property of molecular emitters found in dyes(1), polymers(2), biological molecules(3) and artificial nanostructures such as nanocrystal quantum dots, carbon nanotubes and nanowires(4-6). For the past 15 years, colloidal nanocrystals have been used as a model system to study this phenomenon(5,6). The occurrence of OFF periods in nanocrystal emission has been commonly attributed to the presence of an additional charge(7), which leads to photoluminescence quenching by non-radiative recombination (the Auger mechanism)(8). However, this 'charging' model was recently challenged in several reports(9,10). Here we report time-resolved photoluminescence studies of individual nanocrystal quantum dots performed while electrochemically controlling the degree of their charging, with the goal of clarifying the role of charging in blinking. We find that two distinct types of blinking are possible: conventional (A-type) blinking due to charging and discharging of the nanocrystal core, in which lower photoluminescence intensities correlate with shorter photoluminescence lifetimes; and a second sort (B-type), in which large changes in the emission intensity are not accompanied by significant changes in emission dynamics. We attribute B-type blinking to charge fluctuations in the electron-accepting surface sites. When unoccupied, these sites intercept 'hot' electrons before they relax into emitting core states. Both blinking mechanisms can be electrochemically controlled and completely suppressed by application of an appropriate potential.	[Galland, Christophe; Sykora, Milan; Klimov, Victor I.; Htoon, Han] Los Alamos Natl Lab, Div Chem, Los Alamos, NM 87545 USA; [Galland, Christophe; Klimov, Victor I.; Htoon, Han] Los Alamos Natl Lab, Ctr Adv Solar Photophys, Los Alamos, NM 87545 USA; [Ghosh, Yagnaseni; Steinbrueck, Andrea; Hollingsworth, Jennifer A.; Htoon, Han] Los Alamos Natl Lab, Ctr Integrated Nanotechnol, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Klimov, VI (corresponding author), Los Alamos Natl Lab, Div Chem, POB 1663, Los Alamos, NM 87545 USA.	sykoram@lanl.gov; klimov@lanl.gov; htoon@lanl.gov	Galland, Christophe/AAX-1624-2021; Galland, Christophe/A-1075-2013; Klimov, Victor/Y-2823-2019; Htoon, Han/HGF-0637-2022; Sykora, Milan/N-5743-2019	Galland, Christophe/0000-0001-5627-0796; Galland, Christophe/0000-0001-5627-0796; Klimov, Victor/0000-0003-1158-3179; Sykora, Milan/0000-0002-1747-0709; Htoon, Han/0000-0003-3696-2896	Center for Advanced Solar Photophysics, an Energy Frontier Research Center; US Department of Energy (DOE), Office of Science, Office of Basic Energy Sciences (BES); Los Alamos National Laboratory; NIH-NIGMS [1R01GM084702-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084702] Funding Source: NIH RePORTER	Center for Advanced Solar Photophysics, an Energy Frontier Research Center; US Department of Energy (DOE), Office of Science, Office of Basic Energy Sciences (BES)(United States Department of Energy (DOE)); Los Alamos National Laboratory(United States Department of Energy (DOE)Los Alamos National Laboratory); NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	C.G. and V. I. K. acknowledge support of the Center for Advanced Solar Photophysics, an Energy Frontier Research Center funded by the US Department of Energy (DOE), Office of Science, Office of Basic Energy Sciences (BES). Y.G. and A. S. are supported by Los Alamos National Laboratory Directed Research and Development Fund. M. S., J.A.H. and H. H. are supported by NIH-NIGMS grant 1R01GM084702-01. This work was conducted, in part, at the Center for Integrated Nanotechnologies, a DOE/BES user facility.	Chen Y, 2008, J AM CHEM SOC, V130, P5026, DOI 10.1021/ja711379k; DELAIVE PJ, 1980, J AM CHEM SOC, V102, P5627, DOI 10.1021/ja00537a037; Efros AL, 1997, PHYS REV LETT, V78, P1110, DOI 10.1103/PhysRevLett.78.1110; FERNANDO D, 2009, PHYS TODAY, V6, P34; Fisher BR, 2004, J PHYS CHEM B, V108, P143, DOI 10.1021/jp035756+; Fomenko V, 2008, NANO LETT, V8, P287, DOI 10.1021/nl0726609; Frantsuzov P, 2008, NAT PHYS, V4, P519, DOI 10.1038/nphys1001; Garcia-Santamaria F, 2011, NANO LETT, V11, P687, DOI 10.1021/nl103801e; Gomez DE, 2009, ACS NANO, V3, P2281, DOI 10.1021/nn900296q; Hohng S, 2004, J AM CHEM SOC, V126, P1324, DOI 10.1021/ja039686w; Hoogenboom JP, 2007, CHEMPHYSCHEM, V8, P823, DOI 10.1002/cphc.200600783; Houtepen AJ, 2005, J PHYS CHEM B, V109, P19634, DOI 10.1021/jp053103i; Jeong S, 2005, J AM CHEM SOC, V127, P10126, DOI 10.1021/ja042591p; Jha PP, 2010, J PHYS CHEM C, V114, P21138, DOI 10.1021/jp1074626; Jha PP, 2009, ACS NANO, V3, P1011, DOI 10.1021/nn9001177; Jin SY, 2010, ACS NANO, V4, P1545, DOI 10.1021/nn901808f; JURIS A, 1988, COORDIN CHEM REV, V84, P85, DOI 10.1016/0010-8545(88)80032-8; Klimov VI, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.195324; Klimov VI, 2000, SCIENCE, V287, P1011, DOI 10.1126/science.287.5455.1011; Li JJ, 2003, J AM CHEM SOC, V125, P12567, DOI 10.1021/ja0363563; Li S, 2009, ACS NANO, V3, P1267, DOI 10.1021/nn900189f; McGuire JA, 2010, ACS NANO, V4, P6087, DOI 10.1021/nn1016296; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Park YS, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.187401; Riley EA, 2011, PHYS CHEM CHEM PHYS, V13, P1879, DOI 10.1039/c0cp01716g; Rosen S, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.157404; Tisdale WA, 2010, SCIENCE, V328, P1543, DOI 10.1126/science.1185509; Tyagi P, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3561063; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; Vela J, 2010, J BIOPHOTONICS, V3, P706, DOI 10.1002/jbio.201000058; Wang XY, 2009, NATURE, V459, P686, DOI 10.1038/nature08072; Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k; Zhang K, 2006, NANO LETT, V6, P843, DOI 10.1021/nl060483q; Zhao J, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.157403	34	584	593	15	691	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2011	479	7372					203	U75		10.1038/nature10569	http://dx.doi.org/10.1038/nature10569			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071764	Green Accepted			2022-12-28	WOS:000298030800036
J	Bjarnason, I				Bjarnason, Ingvar			MORE SECRETS OF THE MMR SCARE Commentary: We came to an overwhelming and uniform opinion that these reports do not show colitis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll Hosp London, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Bjarnason, I (corresponding author), Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.	ingvar.bjarnason@kcl.ac.uk						Deer B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1127; Godlee F, 2011, BRIT MED J, V343, P7284; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	3	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2011	343								d6979	10.1136/bmj.d6979	http://dx.doi.org/10.1136/bmj.d6979			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NP	22077091	Bronze			2022-12-28	WOS:000297058600012
J	Kinzig, AP; Perrings, C; Chapin, FS; Polasky, S; Smith, VK; Tilman, D; Turner, BL				Kinzig, A. P.; Perrings, C.; Chapin, F. S., III; Polasky, S.; Smith, V. K.; Tilman, D.; Turner, B. L., II			Paying for Ecosystem Services-Promise and Peril	SCIENCE			English	Editorial Material							ENVIRONMENTAL SERVICES; PAYMENTS; DIVERSITY; LESSONS; FORESTS		[Turner, B. L., II] Arizona State Univ, Sch Geog Sci & Urban Planning, Tempe, AZ 85287 USA; [Turner, B. L., II] Arizona State Univ, Sch Sustainabil, Tempe, AZ 85287 USA; [Kinzig, A. P.; Perrings, C.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Chapin, F. S., III] Univ Alaska Fairbanks, Dept Biol & Wildlife, Fairbanks, AK 99775 USA; [Polasky, S.] Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA; [Smith, V. K.] Arizona State Univ, WP Carey Sch Business, Tempe, AZ 85287 USA; [Tilman, D.] Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; University of Alaska System; University of Alaska Fairbanks; University of Minnesota System; University of Minnesota Twin Cities; Arizona State University; Arizona State University-Tempe; University of Minnesota System; University of Minnesota Twin Cities	Turner, BL (corresponding author), Arizona State Univ, Sch Geog Sci & Urban Planning, Tempe, AZ 85287 USA.	Billie.L.Turner@asu.edu	Polasky, Stephen/AAC-5341-2019; Chapin, F Stuart/AAZ-3931-2020; Tilman, David/ABD-5309-2021	Chapin, F Stuart/0000-0002-2558-9910; 	Division Of Behavioral and Cognitive Sci [1134890] Funding Source: National Science Foundation	Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE))		[Anonymous], 2011, FED REGISTER, V76, P208; Arriagada R, 2011, AMBIO, V40, P798, DOI 10.1007/s13280-011-0156-2; Arrow K.J, 2010, 16599 NAT BUR EC RES; Barbier EB, 2008, RESOUR ENERGY ECON, V30, P229, DOI 10.1016/j.reseneeco.2007.08.002; Barbier EB, 2010, LAND USE POLICY, V27, P98, DOI 10.1016/j.landusepol.2009.02.001; Bunker D.E., 2009, BIODIVERSITY ECOSYST; Canadell JG, 2008, SCIENCE, V320, P1456, DOI 10.1126/science.1155458; Chichilnisky G, 1998, NATURE, V391, P629, DOI 10.1038/35481; Crockett S, 2009, ECON J, V119, P1162, DOI 10.1111/j.1468-0297.2009.02254.x; Dasgupta P., 2001, HUMAN WELL BEING NAT; Demsetz H, 1967, AM ECON REV, V57, P347; Dobbs TL, 2004, REV AGR ECON, V26, P220, DOI 10.1111/j.1467-9353.2004.00172.x; Fargione J, 2008, SCIENCE, V319, P1235, DOI 10.1126/science.1152747; Ferraro PJ, 2002, LAND ECON, V78, P339, DOI 10.2307/3146894; Ferraro PJ, 2002, SCIENCE, V298, P1718, DOI 10.1126/science.1078104; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; Heal G, 2000, ECOSYSTEMS, V3, P24, DOI 10.1007/s100210000006; Horan RD, 2008, ENVIRON DEV ECON, V13, P415, DOI 10.1017/S1355770X08004269; Jorgenson DW, 2006, STUD INCOME, V66, P13; Kaul I., 1999, GLOBAL PUBLIC GOODS; Lange GM, 2007, ECOL ECON, V61, P589, DOI 10.1016/j.ecolecon.2006.09.003; Liu JG, 2008, P NATL ACAD SCI USA, V105, P9477, DOI 10.1073/pnas.0706436105; MADSEN B, 2010, OFFSET COMPENSATION; *MILL EC ASS, 2005, EC HUM WELL BEING GE; Munoz-Pina C, 2008, ECOL ECON, V65, P725, DOI 10.1016/j.ecolecon.2007.07.031; Ostfeld R. S. et al., 2008, INFECT DIS ECOLOGY E; Pagiola S, 2008, ECOL ECON, V65, P712, DOI 10.1016/j.ecolecon.2007.07.033; Pagiola S, 2007, ECOL ECON, V64, P374, DOI 10.1016/j.ecolecon.2007.04.014; Sandler T., 2004, GLOBAL COLLECTIVE AC; Stavins RN, 2003, HANDB ECON, V20, P355; Stavins RN, 1998, J ECON PERSPECT, V12, P69, DOI 10.1257/jep.12.3.69; Tilman D, 2005, J ENVIRON ECON MANAG, V49, P405, DOI 10.1016/j.jeem.2004.03.008; Turpie JK, 2008, ECOL ECON, V65, P788, DOI 10.1016/j.ecolecon.2007.12.024; Walker B, 1999, ECOSYSTEMS, V2, P95, DOI 10.1007/s100219900062; Wunder S, 2008, ENVIRON DEV ECON, V13, P279, DOI 10.1017/S1355770X08004282; Wunder S, 2008, ECOL ECON, V65, P834, DOI 10.1016/j.ecolecon.2008.03.010	36	237	260	16	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					603	604		10.1126/science.1210297	http://dx.doi.org/10.1126/science.1210297			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	841EG	22053032				2022-12-28	WOS:000296494700033
J	Maroteaux, M; Mameli, M				Maroteaux, Matthieu; Mameli, Manuel			Synaptic Switch and Social Status	SCIENCE			English	Editorial Material							DOMINANCE; PLASTICITY		[Maroteaux, Matthieu; Mameli, Manuel] Univ Paris 06, Inst Fer Moulin, INSERM UMR S 839, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Maroteaux, M (corresponding author), Univ Paris 06, Inst Fer Moulin, INSERM UMR S 839, F-75005 Paris, France.	manuel.mameli@inserm.fr		Mameli, Manuel/0000-0002-0570-6964				Bennett MR, 2000, PROG NEUROBIOL, V60, P545, DOI 10.1016/S0301-0082(99)00040-4; BLANCHARD RJ, 1988, PHYSIOL BEHAV, V43, P1, DOI 10.1016/0031-9384(88)90089-3; Cordero MI, 2007, FRONT NEUROSCI-SWITZ, V1, P175, DOI 10.3389/neuro.01.1.1.013.2007; Kessels HW, 2009, NEURON, V61, P340, DOI 10.1016/j.neuron.2009.01.015; LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Sapolsky RM, 2005, SCIENCE, V308, P648, DOI 10.1126/science.1106477; Timmer M, 2011, NEUROPSYCHOPHARMACOL, V36, P2349, DOI 10.1038/npp.2011.125; Turrigiano G, 2011, ANNU REV NEUROSCI, V34, P89, DOI 10.1146/annurev-neuro-060909-153238; van Kreveld D, 1970, Ned Tijdschr Psychol, V25, P55; Wang F, 2011, SCIENCE, V334, P693, DOI 10.1126/science.1209951	11	0	0	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					608	609		10.1126/science.1214713	http://dx.doi.org/10.1126/science.1214713			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	841EG	22053035				2022-12-28	WOS:000296494700036
J	Yella, A; Lee, HW; Tsao, HN; Yi, CY; Chandiran, AK; Nazeeruddin, MK; Diau, EWG; Yeh, CY; Zakeeruddin, SM; Gratzel, M				Yella, Aswani; Lee, Hsuan-Wei; Tsao, Hoi Nok; Yi, Chenyi; Chandiran, Aravind Kumar; Nazeeruddin, Md. Khaja; Diau, Eric Wei-Guang; Yeh, Chen-Yu; Zakeeruddin, Shaik M.; Graetzel, Michael			Porphyrin-Sensitized Solar Cells with Cobalt (II/III)-Based Redox Electrolyte Exceed 12 Percent Efficiency	SCIENCE			English	Article							CONVERSION EFFICIENCY; PHOTOVOLTAIC CELLS; TRANSFER MEDIATORS; CHARGE-TRANSPORT; TIO2 ELECTRODE; RECOMBINATION; FILMS; COMPLEXES; COUPLE; ARRAYS	The iodide/triiodide redox shuttle has limited the efficiencies accessible in dye-sensitized solar cells. Here, we report mesoscopic solar cells that incorporate a Co((II/III))tris(bipyridyl)-based redox electrolyte in conjunction with a custom synthesized donor-pi-bridge-acceptor zinc porphyrin dye as sensitizer (designated YD2-o-C8). The specific molecular design of YD2-o-C8 greatly retards the rate of interfacial back electron transfer from the conduction band of the nanocrystalline titanium dioxide film to the oxidized cobalt mediator, which enables attainment of strikingly high photovoltages approaching 1 volt. Because the YD2-o-C8 porphyrin harvests sunlight across the visible spectrum, large photocurrents are generated. Cosensitization of YD2-o-C8 with another organic dye further enhances the performance of the device, leading to a measured power conversion efficiency of 12.3% under simulated air mass 1.5 global sunlight.	[Diau, Eric Wei-Guang] Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 300, Taiwan; [Diau, Eric Wei-Guang] Natl Chiao Tung Univ, Inst Mol Sci, Hsinchu 300, Taiwan; [Yella, Aswani; Tsao, Hoi Nok; Yi, Chenyi; Chandiran, Aravind Kumar; Nazeeruddin, Md. Khaja; Zakeeruddin, Shaik M.; Graetzel, Michael] Ecole Polytech Fed Lausanne, Inst Chem Sci & Engn, Lab Photon & Interfaces, CH-1015 Lausanne, Switzerland; [Lee, Hsuan-Wei; Yeh, Chen-Yu] Natl Chung Hsing Univ, Dept Chem, Taichung 402, Taiwan; [Lee, Hsuan-Wei; Yeh, Chen-Yu] Natl Chung Hsing Univ, Ctr Nanosci & Nanotechnol, Taichung 402, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; National Chung Hsing University; National Chung Hsing University	Diau, EWG (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 300, Taiwan.	diau@mail.nctu.edu.tw; cyyeh@dragon.nchu.edu.tw; shaik.zakeer@epfl.ch; michael.graetzel@epfl.ch	Yi, Chenyi/Q-2947-2016; Nazeeruddin, Mohammad K/B-1323-2008; Yi, Chenyi/A-3476-2019; Yella, Aswani/D-9288-2014; Zakeeruddin, Mohammed/D-3244-2014	Yi, Chenyi/0000-0001-6383-7383; Nazeeruddin, Mohammad K/0000-0001-5955-4786; Yi, Chenyi/0000-0001-6383-7383; Yella, Aswani/0000-0003-4834-6505; Chandiran, Aravind Kumar/0000-0001-7857-9209; Tsao, Hoi Nok/0000-0001-6780-9873	National Science Council of Taiwan; Ministry of Education of Taiwan; European Research Council (ERC) [ARG 247404]; European community [227057]; Dayton U.S. Air force Research Laboratory; Ministry of Education, Science and Technology through the National Research Foundation of Korea [R31-2008-000-10035-0]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Education of Taiwan(Ministry of Education, Taiwan); European Research Council (ERC)(European Research Council (ERC)European Commission); European community(European Commission); Dayton U.S. Air force Research Laboratory; Ministry of Education, Science and Technology through the National Research Foundation of Korea(National Research Foundation of Korea)	E.W.-G.D. and C.Y.Y. acknowledge the financial support from the National Science Council of Taiwan and Ministry of Education of Taiwan. M.G. thanks the European Research Council (ERC) for an Advanced Research Grant (ARG 247404) funded under the "Mesolight" project. Financial support under the European community's 7th FWP for project 227057 (INNOVASOL) and under a grant from the Dayton U.S. Air force Research Laboratory is gratefully acknowledged. M.K.N. thanks World Class University program, Photovoltaic Materials, Department of Material Chemistry, Korea University, Chungnam 339-700, Korea, which is funded by the Ministry of Education, Science and Technology through the National Research Foundation of Korea (R31-2008-000-10035-0). We thank R. Humphry-Baker for fruitful discussions as well as optical measurements and M. J. M. Bonnet-Eymard from the IMT Photovoltaic Laboratory for assistance with the cell photovoltaic performance measurements.	Bai Y, 2011, CHEM COMMUN, V47, P4376, DOI 10.1039/c1cc10454c; Bessho T, 2010, ANGEW CHEM INT EDIT, V49, P6646, DOI 10.1002/anie.201002118; Borgstrom M, 2005, J PHYS CHEM B, V109, P22928, DOI 10.1021/jp054034a; Boschloo G, 2009, ACCOUNTS CHEM RES, V42, P1819, DOI 10.1021/ar900138m; Chang JC, 2005, DALTON T, P1504, DOI 10.1039/b417350c; Chen CY, 2009, ACS NANO, V3, P3103, DOI 10.1021/nn900756s; Chiba Y, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2208920; Chiba Y, 2006, JPN J APPL PHYS 2, V45, pL638, DOI 10.1143/JJAP.45.L638; Clifford JN, 2002, CHEM COMMUN, P1260, DOI 10.1039/b201855a; Clifford JN, 2011, CHEM SOC REV, V40, P1635, DOI 10.1039/b920664g; Daeneke T, 2011, NAT CHEM, V3, P211, DOI [10.1038/NCHEM.966, 10.1038/nchem.966]; Difei Z., 2011, ENV SCI, V4, P2030; Eu S, 2007, J PHYS CHEM C, V111, P3528, DOI 10.1021/jp067290b; Feldt SM, 2010, J AM CHEM SOC, V132, P16714, DOI 10.1021/ja1088869; Gregg BA, 2001, J PHYS CHEM B, V105, P1422, DOI 10.1021/jp003000u; Hagemann O, 2006, J ORG CHEM, V71, P5546, DOI 10.1021/jo060491r; Hasobe T, 2005, J AM CHEM SOC, V127, P1216, DOI 10.1021/ja047768u; Hasobe T, 2005, J PHYS CHEM B, V109, P19, DOI 10.1021/jp045246v; Hasselman GM, 2006, J PHYS CHEM B, V110, P25430, DOI 10.1021/jp064547x; Hattori S, 2005, J AM CHEM SOC, V127, P9648, DOI 10.1021/ja0506814; Hsieh CP, 2010, J MATER CHEM, V20, P1127, DOI 10.1039/b919645e; Huijser A, 2006, ADV MATER, V18, P2234, DOI 10.1002/adma.200600045; Kroon JM, 2007, PROG PHOTOVOLTAICS, V15, P1, DOI 10.1002/pip.707; Lee CW, 2009, CHEM-EUR J, V15, P1403, DOI 10.1002/chem.200801572; Li DM, 2010, ADV FUNCT MATER, V20, P3358, DOI 10.1002/adfm.201000150; Lu HP, 2009, J PHYS CHEM C, V113, P20990, DOI 10.1021/jp908100v; Lu HP, 2009, PHYS CHEM CHEM PHYS, V11, P10270, DOI 10.1039/b917271h; Mai CL, 2010, CHEM COMMUN, V46, P809, DOI 10.1039/b917316a; Nazeeruddin MK, 2005, J AM CHEM SOC, V127, P16835, DOI 10.1021/ja052467l; Nelson JJ, 2008, J PHYS CHEM C, V112, P18255, DOI 10.1021/jp806479k; Nusbaumer H, 2003, CHEM-EUR J, V9, P3756, DOI 10.1002/chem.200204577; Nusbaumer H, 2001, J PHYS CHEM B, V105, P10461, DOI 10.1021/jp012075a; O'Regan BC, 2004, J PHYS CHEM B, V108, P4342, DOI 10.1021/jp035613n; O'Regan BC, 2006, J PHYS CHEM B, V110, P17155, DOI 10.1021/jp062761f; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Sapp SA, 2002, J AM CHEM SOC, V124, P11215, DOI 10.1021/ja027355y; SIDERS P, 1981, J AM CHEM SOC, V103, P741, DOI 10.1021/ja00394a003; Snaith HJ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/42/424003; Tsao HN, 2011, CHEMSUSCHEM, V4, P591, DOI 10.1002/cssc.201100120; Wang MK, 2010, NAT CHEM, V2, P385, DOI [10.1038/NCHEM.610, 10.1038/nchem.610]; Wang ZS, 2006, CHEM MATER, V18, P2912, DOI 10.1021/cm0603102; Wei MD, 2006, J MATER CHEM, V16, P1287, DOI 10.1039/b514647j; Wu SL, 2010, ENERG ENVIRON SCI, V3, P949, DOI 10.1039/c003872p; Yu QJ, 2010, ACS NANO, V4, P6032, DOI 10.1021/nn101384e; Zeng WD, 2010, CHEM MATER, V22, P1915, DOI 10.1021/cm9036988; Zhang Z, 2008, ADV FUNCT MATER, V18, P341, DOI 10.1002/adfm.200701041	46	5287	5411	42	3495	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					629	634		10.1126/science.1209688	http://dx.doi.org/10.1126/science.1209688			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053043				2022-12-28	WOS:000296494700044
J	Di Stasi, A; Tey, SK; Dotti, G; Fujita, Y; Kennedy-Nasser, A; Martinez, C; Straathof, K; Liu, E; Durett, AG; Grilley, B; Liu, H; Cruz, CR; Savoldo, B; Gee, AP; Schindler, J; Krance, RA; Heslop, HE; Spencer, DM; Rooney, CM; Brenner, MK				Di Stasi, Antonio; Tey, Siok-Keen; Dotti, Gianpietro; Fujita, Yuriko; Kennedy-Nasser, Alana; Martinez, Caridad; Straathof, Karin; Liu, Enli; Durett, April G.; Grilley, Bambi; Liu, Hao; Cruz, Conrad R.; Savoldo, Barbara; Gee, Adrian P.; Schindler, John; Krance, Robert A.; Heslop, Helen E.; Spencer, David M.; Rooney, Cliona M.; Brenner, Malcolm K.			Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGINEERED DONOR LYMPHOCYTES; CYTOTOXIC T-LYMPHOCYTES; GRAFT-VERSUS-LEUKEMIA; SUICIDE-GENE; ADVERSE EVENT; MARROW GRAFT; TRANSPLANTATION; IMMUNOTHERAPY; DEPLETION; IMPROVE	Background Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells in case of adverse events. We devised an inducible T-cell safety switch that is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization. When exposed to a synthetic dimerizing drug, the inducible caspase 9 (iCasp9) becomes activated and leads to the rapid death of cells expressing this construct. Methods We tested the activity of our safety switch by introducing the gene into donor T cells given to enhance immune reconstitution in recipients of haploidentical stem-cell transplants. Patients received AP1903, an otherwise bioinert small-molecule dimerizing drug, if graft-versus-host disease (GVHD) developed. We measured the effects of AP1903 on GVHD and on the function and persistence of the cells containing the iCasp9 safety switch. Results Five patients between the ages of 3 and 17 years who had undergone stem-cell transplantation for relapsed acute leukemia were treated with the genetically modified T cells. The cells were detected in peripheral blood from all five patients and increased in number over time, despite their constitutive transgene expression. A single dose of dimerizing drug, given to four patients in whom GVHD developed, eliminated more than 90% of the modified T cells within 30 minutes after administration and ended the GVHD without recurrence. Conclusions The iCasp9 cell-suicide system may increase the safety of cellular therapies and expand their clinical applications. (Funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute; ClinicalTrials.gov number, NCT00710892.)	[Di Stasi, Antonio; Tey, Siok-Keen; Dotti, Gianpietro; Fujita, Yuriko; Kennedy-Nasser, Alana; Martinez, Caridad; Straathof, Karin; Liu, Enli; Durett, April G.; Grilley, Bambi; Liu, Hao; Cruz, Conrad R.; Savoldo, Barbara; Gee, Adrian P.; Krance, Robert A.; Heslop, Helen E.; Spencer, David M.; Rooney, Cliona M.; Brenner, Malcolm K.] Texas Childrens Hosp & Methodist Hosp, Ctr Cell & Gene Therapy, Baylor Coll Med, Houston, TX USA; [Schindler, John] Univ Texas Southwestern Med Sch, Dallas, TX USA	Baylor College of Medicine	Di Stasi, A (corresponding author), Texas Childrens Hosp & Methodist Hosp, Ctr Cell & Gene Therapy, Baylor Coll Med, Houston, TX USA.		Heslop, Helen/AAC-9500-2020; Tey, Siok-Keen/I-6380-2015; Rooney, Cliona/ABD-5475-2021; Wilson, Matthew H/K-3193-2013; Brenner, Malcolm/Y-2509-2019	Tey, Siok-Keen/0000-0001-9567-382X; Straathof, Karin/0000-0001-9673-8568	National Heart, Lung, and Blood Institute [U54HL08100]; National Cancer Institute [P01CA094237]; NATIONAL CANCER INSTITUTE [P30CA125123, P01CA094237, P50CA126752] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL081007] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant (U54HL08100) from the National Heart, Lung, and Blood Institute for the clinical protocol and a grant (P01CA094237) from the National Cancer Institute for the development of the caspase system.	Akatsuka Y, 1999, TISSUE ANTIGENS, V53, P122, DOI 10.1034/j.1399-0039.1999.530202.x; Amrolia PJ, 2006, BLOOD, V108, P1797, DOI 10.1182/blood-2006-02-001909; Amrolia Persis J., 2004, Blood, V104, P1605; Amrolia PJ, 2003, BLOOD, V102, P2292, DOI 10.1182/blood-2002-11-3516; Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Brentjens R, 2010, MOL THER, V18, P666, DOI 10.1038/mt.2010.31; Ciceri F, 2007, BLOOD, V109, P4698, DOI 10.1182/blood-2006-05-023416; Ciceri F, 2009, LANCET ONCOL, V10, P489, DOI 10.1016/S1470-2045(09)70074-9; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Daley GQ, 2008, CELL, V132, P544, DOI 10.1016/j.cell.2008.02.009; Donnelly MLL, 2001, J GEN VIROL, V82, P1013, DOI 10.1099/0022-1317-82-5-1013; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Kolb HJ, 2008, BLOOD, V112, P4371, DOI 10.1182/blood-2008-03-077974; Mercier-Letondal P, 2008, HUM GENE THER, V19, P937, DOI 10.1089/hum.2007.156; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Piantadosi S, 1998, CANCER CHEMOTH PHARM, V41, P429, DOI 10.1007/s002800050763; Pollok KE, 1999, HUM GENE THER, V10, P2221, DOI 10.1089/10430349950017202; Quintarelli C, 2007, BLOOD, V110, P2793, DOI 10.1182/blood-2007-02-072843; Ramos CA, 2010, STEM CELLS, V28, P1107, DOI 10.1002/stem.433; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Straathof KC, 2005, BLOOD, V105, P4247, DOI 10.1182/blood-2004-11-4564; Tey SK, 2007, BIOL BLOOD MARROW TR, V13, P913, DOI 10.1016/j.bbmt.2007.04.005; TIBERGHIEN P, 1994, BLOOD, V84, P1333; Tiberghien P, 2001, BLOOD, V97, P63, DOI 10.1182/blood.V97.1.63; Traversari C, 2007, BLOOD, V109, P4708, DOI 10.1182/blood-2006-04-015230; Williams DA, 2010, BLOOD, V116, P866, DOI 10.1182/blood-2010-05-282723; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	32	984	1118	5	139	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1673	1683		10.1056/NEJMoa1106152	http://dx.doi.org/10.1056/NEJMoa1106152			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047558	Green Accepted, Bronze			2022-12-28	WOS:000296424200006
J	Fiore, LD; D'Avolio, LW				Fiore, Louis D.; D'Avolio, Leonard William			Detours on the Road to Personalized Medicine Barriers to Biomarker Validation and Implementation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Fiore, Louis D.; D'Avolio, Leonard William] VA Boston Healthcare Syst, Cooperat Studies Program Coordinating Ctr, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Jamaica Plain, MA USA; [Fiore, Louis D.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Fiore, Louis D.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; [D'Avolio, Leonard William] Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA; [D'Avolio, Leonard William] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University; Boston University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Fiore, LD (corresponding author), Boston VA Healthcare Syst, MAVERIC, Jamaica Plain Campus,150 S Huntington Ave, Boston, MA 02130 USA.	louis.fiore@va.gov						Dana Farber Cancer Institute, 2011, ONCOMAP PROF TUM DNA; Fiore LD, 2011, CLIN TRIALS, V8, P183, DOI [10.1177/1740774510395635, 10.1177/1740774511398368]; Genomic Health&REG; Inc, ONC DX BREAST CANC A; Hunter DJ, 2007, NEW ENGL J MED, V357, P436, DOI 10.1056/NEJMp078120; Kohane IS, 2006, JAMA-J AM MED ASSOC, V296, P212, DOI 10.1001/jama.296.2.212; Partners HealthCare Center for Personalized Genetic Medicine, 2011, GEN INS SUIT; US Food and Drug Administration, 2007, GUID IND CL IN PRESS	7	16	16	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1914	1915		10.1001/jama.2011.1605	http://dx.doi.org/10.1001/jama.2011.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045770				2022-12-28	WOS:000296376200027
J	Sierks, H; Lamy, P; Barbieri, C; Koschny, D; Rickman, H; Rodrigo, R; A'Hearn, MF; Angrilli, F; Barucci, MA; Bertaux, JL; Bertini, I; Besse, S; Carry, B; Cremonese, G; Da Deppo, V; Davidsson, B; Debei, S; De Cecco, M; De Leon, J; Ferri, F; Fornasier, S; Fulle, M; Hviid, SF; Gaskell, RW; Groussin, O; Gutierrez, P; Ip, W; Jorda, L; Kaasalainen, M; Keller, HU; Knollenberg, J; Kramm, R; Kuhrt, E; Kuppers, M; Lara, L; Lazzarin, M; Leyrat, C; Moreno, JJL; Magrin, S; Marchi, S; Marzari, F; Massironi, M; Michalik, H; Moissl, R; Naletto, G; Preusker, F; Sabau, L; Sabolo, W; Scholten, F; Snodgrass, C; Thomas, N; Tubiana, C; Vernazza, P; Vincent, JB; Wenzel, KP; Andert, T; Patzold, M; Weiss, BP				Sierks, H.; Lamy, P.; Barbieri, C.; Koschny, D.; Rickman, H.; Rodrigo, R.; A'Hearn, M. F.; Angrilli, F.; Barucci, M. A.; Bertaux, J. -L.; Bertini, I.; Besse, S.; Carry, B.; Cremonese, G.; Da Deppo, V.; Davidsson, B.; Debei, S.; De Cecco, M.; De Leon, J.; Ferri, F.; Fornasier, S.; Fulle, M.; Hviid, S. F.; Gaskell, R. W.; Groussin, O.; Gutierrez, P.; Ip, W.; Jorda, L.; Kaasalainen, M.; Keller, H. U.; Knollenberg, J.; Kramm, R.; Kuehrt, E.; Kueppers, M.; Lara, L.; Lazzarin, M.; Leyrat, C.; Lopez Moreno, J. J.; Magrin, S.; Marchi, S.; Marzari, F.; Massironi, M.; Michalik, H.; Moissl, R.; Naletto, G.; Preusker, F.; Sabau, L.; Sabolo, W.; Scholten, F.; Snodgrass, C.; Thomas, N.; Tubiana, C.; Vernazza, P.; Vincent, J. -B.; Wenzel, K. -P.; Andert, T.; Paetzold, M.; Weiss, B. P.			Images of Asteroid 21 Lutetia: A Remnant Planetesimal from the Early Solar System	SCIENCE			English	Article							POROSITY; IMPACT; MORPHOLOGY; ROSETTA; CHONDRITES; DENSITY; BODIES; TARGET; GROWTH; PHOBOS	Images obtained by the Optical, Spectroscopic, and Infrared Remote Imaging System (OSIRIS) cameras onboard the Rosetta spacecraft reveal that asteroid 21 Lutetia has a complex geology and one of the highest asteroid densities measured so far, 3.4 +/- 0.3 grams per cubic centimeter. The north pole region is covered by a thick layer of regolith, which is seen to flow in major landslides associated with albedo variation. Its geologically complex surface, ancient surface age, and high density suggest that Lutetia is most likely a primordial planetesimal. This contrasts with smaller asteroids visited by previous spacecraft, which are probably shattered bodies, fragments of larger parents, or reaccumulated rubble piles.	[Sierks, H.; Hviid, S. F.; Kramm, R.; Moissl, R.; Snodgrass, C.; Tubiana, C.; Vincent, J. -B.] Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; [Lamy, P.; Groussin, O.; Jorda, L.; Vernazza, P.] CNRS, Lab Astrophys Marseille, F-13388 Marseille, France; [Lamy, P.; Groussin, O.; Jorda, L.; Vernazza, P.] Univ Aix Marseille 1, F-13388 Marseille, France; [Barbieri, C.; Lazzarin, M.; Magrin, S.] Univ Padua, Dept Astron, I-35122 Padua, Italy; [Koschny, D.; Wenzel, K. -P.] European Space Agcy, Res & Sci Support Dept, NL-2201 Noordwijk, Netherlands; [Rickman, H.; Davidsson, B.] Uppsala Univ, Dept Phys & Astron, S-75120 Uppsala, Sweden; [Rodrigo, R.; De Leon, J.; Gutierrez, P.; Lara, L.; Lopez Moreno, J. J.; Sabolo, W.] CSIC, Inst Astrofis Andalucia, E-18080 Granada, Spain; [A'Hearn, M. F.; Besse, S.] Univ Maryland, Dept Astron, College Pk, MD 20742 USA; [Angrilli, F.; Debei, S.] Univ Padua, Dept Mech Engn, I-35131 Padua, Italy; [Barucci, M. A.; Fornasier, S.; Leyrat, C.] Observ Paris, Lab Etud Spatiales & Instrumentat Astrophys, F-92195 Meudon, France; [Bertaux, J. -L.] CNRS UVSQ IPSL, LATMOS, F-78280 Guyancourt, France; [Carry, B.; Kueppers, M.; Moissl, R.] ESA, European Space Astron Ctr, Madrid, Spain; [Cremonese, G.] Osserv Astron Padova, Ist Nazl Astrofis, I-35122 Padua, Italy; [Da Deppo, V.] CNR IFN UOS Padova LUXOR, I-35131 Padua, Italy; [De Cecco, M.] Univ Trent, UNITN, I-38100 Trento, Italy; [Fulle, M.] Osserv Astron Trieste, I-34014 Trieste, Italy; [Gaskell, R. W.] Planetary Sci Inst, Tucson, AZ 85719 USA; [Ip, W.] Natl Cent Univ, Inst Space Sci, Chungli 32054, Taiwan; [Kaasalainen, M.] Tampere Univ Technol, Dept Math, FIN-33101 Tampere, Finland; [Keller, H. U.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Geophys & Extraterr Phys, D-38106 Braunschweig, Germany; [Knollenberg, J.; Kuehrt, E.; Preusker, F.; Scholten, F.] Deutsch Zentrum Luft & Raumfahrt, Inst Planetenforsch, D-12489 Berlin, Germany; [Marchi, S.] Univ Nice Sophia Antipolis, Observ Cote Azur, CNRS, F-06304 Nice, France; [Marzari, F.] Univ Padua, Dept Phys, I-35131 Padua, Italy; [Massironi, M.] Univ Padua, Dipartimento Geosci, I-35131 Padua, Italy; [Michalik, H.] Inst Datentech & Kommunikat Netze, D-38106 Braunschweig, Germany; [Naletto, G.] Univ Padua, Dept Informat Engn, I-35131 Padua, Italy; [Sabau, L.] Inst Nacl Tecn Aeroespacial, Torrejon De Ardoz 28850, Spain; [Thomas, N.] Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; [Andert, T.] Univ Bundeswehr Munchen, Inst Raumfahrttech, Neubiberg, Germany; [Paetzold, M.] Univ Cologne, Abt Planetenforsch, Rhein Inst Umweltforsch, Cologne, Germany; [Weiss, B. P.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA USA; [Rickman, H.] Polish Acad Sci, Space Res Ctr, PL-00716 Warsaw, Poland; [Barbieri, C.; Angrilli, F.; Bertini, I.; Cremonese, G.; Da Deppo, V.; Debei, S.; Ferri, F.; Marchi, S.; Marzari, F.; Massironi, M.; Naletto, G.] Univ Padua, Ctr Interdipartimentale Studi & Attivita Spaziali, I-35131 Padua, Italy; [Fornasier, S.] Univ Paris Diderot, F-75205 Paris, France	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of Padua; European Space Agency; Uppsala University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); University System of Maryland; University of Maryland College Park; University of Padua; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; European Space Agency; Istituto Nazionale Astrofisica (INAF); University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fotonica e Nanotecnologie (IFN-CNR); University of Trento; Istituto Nazionale Astrofisica (INAF); National Central University; Tampere University; Braunschweig University of Technology; Helmholtz Association; German Aerospace Centre (DLR); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; University of Padua; University of Padua; University of Padua; University of Bern; Bundeswehr University Munich; University of Cologne; Massachusetts Institute of Technology (MIT); Centrum Badan Kosmicznych, Polish Academy of Sciences; Polish Academy of Sciences; Space Research Centre of the Polish Academy of Sciences; University of Padua; UDICE-French Research Universities; Universite Paris Cite	Sierks, H (corresponding author), Max Planck Inst Sonnensyst Forsch, Max Planck Str 2, D-37191 Katlenburg Lindau, Germany.	sierks@mps.mpg.de	Moreno, Jose Juan Lopez/M-5537-2019; Lopez-Moreno, Jose Juan/C-7976-2011; Lara, Luisa M/F-5614-2012; de León, Julia/H-7569-2015; Tubiana, Cecilia/AAG-8209-2019; Da Deppo, Vania/D-2897-2012; Jorda, Laurent/AAA-1718-2021; Naletto, Giampiero/S-6329-2016; Massironi, Matteo/F-8860-2012; Rickman, Hans/X-7631-2018; Kaasalainen, Mikko/G-4236-2014; Marzari, Francesco/X-2440-2019; Gutiérrez, Pedro J/AAJ-6177-2020; Thomas, Nicolas/G-4693-2015	Moreno, Jose Juan Lopez/0000-0002-7946-2624; Lopez-Moreno, Jose Juan/0000-0002-7946-2624; Lara, Luisa M/0000-0002-7184-920X; de León, Julia/0000-0002-0696-0411; Tubiana, Cecilia/0000-0001-8475-9898; Da Deppo, Vania/0000-0001-6273-8738; Naletto, Giampiero/0000-0003-2007-3138; Rickman, Hans/0000-0002-9603-6619; Gutiérrez, Pedro J/0000-0002-7332-6269; Bertini, Ivano/0000-0002-0616-2444; JORDA, Laurent/0000-0001-8735-3308; Carry, Benoit/0000-0001-5242-3089; De Cecco, Mariolino/0000-0003-1562-0328; Vincent, Jean-Baptiste/0000-0001-6575-3079; Cremonese, Gabriele/0000-0001-9021-1140; Ferri, Francesca/0000-0003-2395-5275; Besse, Sebastien/0000-0002-1052-5439; Thomas, Nicolas/0000-0002-0146-0071; Debei, Stefano/0000-0002-6757-6616; fulle, marco/0000-0001-8435-5287; Massironi, Matteo/0000-0002-7757-8818; Snodgrass, Colin/0000-0001-9328-2905	national funding agencies of Germany (DLR); France (CNES); Italy (ASI); Spain (MEC); Sweden (SNSB); ESA Technical Directorate	national funding agencies of Germany (DLR)(Helmholtz AssociationGerman Aerospace Centre (DLR)); France (CNES)(Centre National D'etudes Spatiales); Italy (ASI)(Agenzia Spaziale Italiana (ASI)); Spain (MEC)(Spanish Government); Sweden (SNSB); ESA Technical Directorate	OSIRIS was built by a consortium of the Max-Planck-Institut fur Sonnensystemforschung, Katlenburg-Lindau, Germany; CISAS-University of Padova, Italy; the Laboratoire d'Astrophysique de Marseille, France; the Instituto de Astrofisica de Andalucia, CSIC, Granada, Spain; the Research and Scientific Support Department of the ESA, Noordwijk, Netherlands; the Instituto Nacional de Tecnica Aeroespacial, Madrid, Spain; the Universidad Politechnica de Madrid, Spain; the Department of Physics and Astronomy of Uppsala University, Sweden; and the Institut fur Datentechnik und Kommunikationsnetze der Technischen Universitat Braunschweig, Germany. The support of the national funding agencies of Germany (DLR), France (CNES), Italy (ASI), Spain (MEC), Sweden (SNSB), and the ESA Technical Directorate is gratefully acknowledged. We thank the Rosetta Science Operations Centre and the Rosetta Mission Operations Centre for the successful flyby of 21 Lutetia.	Barucci MA, 2008, ASTRON ASTROPHYS, V477, P665, DOI 10.1051/0004-6361:20078085; Barucci M. A., 2009, ROSETTA ESAS MISSION, P55; Bottke WF, 2005, ICARUS, V175, P111, DOI 10.1016/j.icarus.2004.10.026; Britt D. T., 2002, ASTEROIDS 3, VIII, P485; Carry B, 2010, ASTRON ASTROPHYS, V523, DOI 10.1051/0004-6361/201015074; Cheng A.F, 2002, NEAR EARTH ASTEROID, P351, DOI DOI 10.2514/6.1993-4089; Consolmagno GJ, 2008, CHEM ERDE-GEOCHEM, V68, P1, DOI 10.1016/j.chemer.2008.01.003; Coradini A, 2011, SCIENCE, V334, P492, DOI 10.1126/science.1204062; Elkins-Tanton LT, 2011, EARTH PLANET SC LETT, V305, P1, DOI 10.1016/j.epsl.2011.03.010; Gaskell RW, 2008, METEORIT PLANET SCI, V43, P1049, DOI 10.1111/j.1945-5100.2008.tb00692.x; Hapke B, 2002, ICARUS, V157, P523, DOI 10.1006/icar.2002.6853; Holsapple KA, 2007, ICARUS, V187, P345, DOI 10.1016/j.icarus.2006.08.029; Housen KR, 2003, ICARUS, V163, P102, DOI 10.1016/S0019-1035(03)00024-1; Kaasalainen M, 2011, INVERSE PROBL IMAG, V5, P37, DOI 10.3934/ipi.2011.5.37; Keller HU, 2007, SPACE SCI REV, V128, P433, DOI 10.1007/s11214-006-9128-4; Lazzarin M, 2010, MON NOT R ASTRON SOC, V408, P1433, DOI 10.1111/j.1365-2966.2010.17268.x; Macke RJ, 2010, METEORIT PLANET SCI, V45, P1513, DOI 10.1111/j.1945-5100.2010.01129.x; Marchi S, 2010, PLANET SPACE SCI, V58, P1116, DOI 10.1016/j.pss.2010.03.017; MARCHI S, PLANET SPACE SCI; Marchi S, 2009, ASTRON J, V137, P4936, DOI 10.1088/0004-6256/137/6/4936; MELOSH HJ, 1989, IMPACT CRATERING GEO, P84; O'Brien DP, 2006, ICARUS, V183, P79, DOI 10.1016/j.icarus.2006.02.008; Oberst J, 2010, ICARUS, V209, P230, DOI 10.1016/j.icarus.2010.03.009; Patzold M, 2011, SCIENCE, V334, P491, DOI 10.1126/science.1209389; Richardson JE, 2005, ICARUS, V179, P325, DOI 10.1016/j.icarus.2005.07.005; Sullivan R., 2002, ASTEROIDS, VIII, P331; THOMAS P, 1979, J GEOPHYS RES, V84, P8457, DOI 10.1029/JB084iB14p08457; Thomas PC, 2000, J GEOPHYS RES-PLANET, V105, P15091, DOI 10.1029/1999JE001204; Vernazza P, 2009, ICARUS, V202, P477, DOI 10.1016/j.icarus.2009.03.016; Veverka J, 2000, SCIENCE, V289, P2088, DOI 10.1126/science.289.5487.2088; Wilkison SL, 2002, ICARUS, V155, P94, DOI 10.1006/icar.2001.6751; Wunnemann K, 2006, ICARUS, V180, P514, DOI 10.1016/j.icarus.2005.10.013	34	124	126	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2011	334	6055					487	490		10.1126/science.1207325	http://dx.doi.org/10.1126/science.1207325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034428	Green Published, Green Submitted			2022-12-28	WOS:000296230500039
J	Yao, J; Gaffaney, JD; Kwon, SE; Chapman, ER				Yao, Jun; Gaffaney, Jon D.; Kwon, Sung E.; Chapman, Edwin R.			Doc2 Is a Ca2+ Sensor Required for Asynchronous Neurotransmitter Release	CELL			English	Article							DEPENDENT PHOSPHOLIPID-BINDING; CULTURED HIPPOCAMPAL-NEURONS; MEDIATED MEMBRANE-FUSION; DOUBLE C2 PROTEIN; SYNAPTOTAGMIN-I; TRANSMITTER RELEASE; SYNAPTIC-TRANSMISSION; CALCIUM SENSOR; PC12 CELLS; REVERBERATORY ACTIVITY	Synaptic transmission involves a fast synchronous phase and a slower asynchronous phase of neurotransmitter release that are regulated by distinct Ca2+ sensors. Though the Ca2+ sensor for rapid exocytosis, synaptotagmin I, has been studied in depth, the sensor for asynchronous release remains unknown. In a screen for neuronal Ca2+ sensors that respond to changes in [Ca2+] with markedly slower kinetics than synaptotagmin I, we observed that Doc2-another Ca2+, SNARE, and lipid-binding protein-operates on timescales consistent with asynchronous release. Moreover, up- and downregulation of Doc2 expression levels in hippocampal neurons increased or decreased, respectively, the slow phase of synaptic transmission. Synchronous release, when triggered by single action potentials, was unaffected by manipulation of Doc2 but was enhanced during repetitive stimulation in Doc2 knockdown neurons, potentially due to greater vesicle availability. In summary, we propose that Doc2 is a Ca2+ sensor that is kinetically tuned to regulate asynchronous neurotransmitter release.	[Yao, Jun; Gaffaney, Jon D.; Kwon, Sung E.; Chapman, Edwin R.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; [Yao, Jun; Gaffaney, Jon D.; Kwon, Sung E.; Chapman, Edwin R.] Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.	chapman@physiology.wisc.edu		Yao, Jun/0000-0002-4916-3412; Chapman, Edwin/0000-0001-9787-8140	National Institutes of Health [MH 61876]; American Heart Association [11POST5720016]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061876] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank the Chapman lab and M. B. Jackson for critical comments. This study was supported by a grant from the National Institutes of Health (MH 61876). J.Y. is supported by an American Heart Association postdoctoral fellowship (11POST5720016). E.R.C. is an Investigator of the Howard Hughes Medical Institute.	Best AR, 2009, NEURON, V62, P555, DOI 10.1016/j.neuron.2009.04.018; Bhalla A, 2005, MOL BIOL CELL, V16, P4755, DOI 10.1091/mbc.E05-04-0277; Bhalla A, 2006, NAT STRUCT MOL BIOL, V13, P323, DOI 10.1038/nsmb1076; Burgalossi A, 2010, NEURON, V68, P473, DOI 10.1016/j.neuron.2010.09.019; Chapman ER, 2008, ANNU REV BIOCHEM, V77, P615, DOI 10.1146/annurev.biochem.77.062005.101135; Chicka MC, 2008, NAT STRUCT MOL BIOL, V15, P827, DOI 10.1038/nsmb.1463; Duncan RR, 1999, J BIOL CHEM, V274, P27347, DOI 10.1074/jbc.274.39.27347; Friedrich R, 2008, J NEUROSCI, V28, P6794, DOI 10.1523/JNEUROSCI.0538-08.2008; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Gaffaney JD, 2008, J BIOL CHEM, V283, P31763, DOI 10.1074/jbc.M803355200; Galvin JE, 2006, ACTA NEUROPATHOL, V112, P665, DOI 10.1007/s00401-006-0147-8; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Groffen AJA, 2006, J NEUROCHEM, V97, P818, DOI 10.1111/j.1471-4159.2006.03755.x; Groffen AJA, 2004, J BIOL CHEM, V279, P23740, DOI 10.1074/jbc.M400731200; Groffen AJ, 2010, SCIENCE, V327, P1614, DOI 10.1126/science.1183765; Hagler DJ, 2001, J NEUROPHYSIOL, V85, P2324, DOI 10.1152/jn.2001.85.6.2324; Higashio H, 2008, J IMMUNOL, V180, P4774, DOI 10.4049/jimmunol.180.7.4774; Hjelmstad GO, 2006, J NEUROPHYSIOL, V95, P2020, DOI 10.1152/jn.01149.2005; Hui EF, 2005, P NATL ACAD SCI USA, V102, P5210, DOI 10.1073/pnas.0500941102; Hui EF, 2011, NAT STRUCT MOL BIOL, V18, P813, DOI 10.1038/nsmb.2075; Iremonger KJ, 2007, J NEUROSCI, V27, P6684, DOI 10.1523/JNEUROSCI.0934-07.2007; Johnson CP, 2010, J CELL BIOL, V191, P187, DOI 10.1083/jcb.201002089; Koh TW, 2003, TRENDS NEUROSCI, V26, P413, DOI 10.1016/S0166-2236(03)00195-4; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Korteweg N, 2000, EUR J NEUROSCI, V12, P165, DOI 10.1046/j.1460-9568.2000.00898.x; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Lau PM, 2005, P NATL ACAD SCI USA, V102, P10333, DOI 10.1073/pnas.0500717102; Lewis JL, 2001, J BIOL CHEM, V276, P15458, DOI 10.1074/jbc.M011687200; Liu HS, 2009, J NEUROSCI, V29, P7395, DOI 10.1523/JNEUROSCI.1341-09.2009; Lu T, 2000, NEURON, V26, P683, DOI 10.1016/S0896-6273(00)81204-0; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Makino H, 2009, NEURON, V64, P381, DOI 10.1016/j.neuron.2009.08.035; Maximov A, 2005, NEURON, V48, P547, DOI 10.1016/j.neuron.2005.09.006; Maximov A, 2008, P NATL ACAD SCI USA, V105, P3986, DOI 10.1073/pnas.0712372105; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; Nishiki T, 2004, J NEUROSCI, V24, P6127, DOI 10.1523/JNEUROSCI.1563-04.2004; Nishiki T, 2004, J NEUROSCI, V24, P8542, DOI 10.1523/JNEUROSCI.2545-04.2004; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Otsu Y, 2004, J NEUROSCI, V24, P420, DOI 10.1523/JNEUROSCI.4452-03.2004; Pang ZPP, 2011, NEURON, V70, P244, DOI 10.1016/j.neuron.2011.03.011; Peters JH, 2010, NEURON, V65, P657, DOI 10.1016/j.neuron.2010.02.017; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Roux I, 2006, CELL, V127, P277, DOI 10.1016/j.cell.2006.08.040; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Sato M, 2010, J NEUROCHEM, V114, P171, DOI 10.1111/j.1471-4159.2010.06739.x; Shahrezaei V, 2005, J NEUROPHYSIOL, V94, P1912, DOI 10.1152/jn.00256.2005; Sun J, 2007, NATURE, V450, P676, DOI 10.1038/nature06308; Thomson AM, 2000, PROG NEUROBIOL, V62, P159, DOI 10.1016/S0301-0082(00)00008-3; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Volman V, 2007, PHYS BIOL, V4, P91, DOI 10.1088/1478-3975/4/2/003; Wang P, 2005, MOL CELL BIOL, V25, P8693, DOI 10.1128/MCB.25.19.8693-8702.2005; Wen H, 2010, P NATL ACAD SCI USA, V107, P13906, DOI 10.1073/pnas.1008598107; Young SM, 2009, NEURON, V63, P482, DOI 10.1016/j.neuron.2009.07.028	59	138	138	1	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					666	677		10.1016/j.cell.2011.09.046	http://dx.doi.org/10.1016/j.cell.2011.09.046			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036572	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000296573700020
J	Bartels, SA; VanRooyen, MJ				Bartels, Susan A.; VanRooyen, Michael J.			Medical complications associated with earthquakes	LANCET			English	Review							POSTTRAUMATIC-STRESS-DISORDER; ACUTE-RENAL-FAILURE; PSYCHOLOGICAL TYPHOON EYE; SUDDEN CARDIAC DEATH; WENCHUAN EARTHQUAKE; MARMARA EARTHQUAKE; CRUSH SYNDROME; NATURAL DISASTER; BAM EARTHQUAKE; MENTAL-HEALTH	Major earthquakes are some of the most devastating natural disasters. The epidemiology of earthquake-related injuries and mortality is unique for these disasters. Because earthquakes frequently affect populous urban areas with poor structural standards, they often result in high death rates and mass casualties with many traumatic injuries. These injuries are highly mechanical and often multisystem, requiring intensive curative medical and surgical care at a time when the local and regional medical response capacities have been at least partly disrupted. Many patients surviving blunt and penetrating trauma and crush injuries have subsequent complications that lead to additional morbidity and mortality. Here, we review and summarise earthquake-induced injuries and medical complications affecting major organ systems.	[Bartels, Susan A.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Bartels, Susan A.; VanRooyen, Michael J.] Harvard Humanitarian Initiat, Cambridge, MA USA; [VanRooyen, Michael J.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Brigham & Women's Hospital	Bartels, SA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Emergency Med, W Clin Campus 2, Boston, MA 02215 USA.	sbartels@bidmc.harvard.edu	Bartels, Susan/Q-8756-2019	Bartels, Susan/0000-0003-2782-3480				Agaian N A, 1991, Khirurgiia (Mosk), P120; Alexander D, 1996, DISASTERS, V20, P231, DOI 10.1111/j.1467-7717.1996.tb01036.x; Ambrosioni J, 2010, INT J INFECT DIS, V14, pE16, DOI 10.1016/j.ijid.2010.02.1518; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Amundson D, 2010, ANN INTERN MED, V152, P733, DOI 10.7326/0003-4819-152-11-201006010-00215; Atef-Zafarmand A, 2003, ADV RENAL REPLACE TH, V10, P104, DOI 10.1053/jarr.2003.50015; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Bal A, 2007, EUR CHILD ADOLES PSY, V16, P449, DOI 10.1007/s00787-007-0618-z; BETTER OS, 1990, NEW ENGL J MED, V322, P825; BETTER OS, 1993, KIDNEY INT, V43, pS235; Bhattacharyya MR, 2007, PROG CARDIOVASC DIS, V49, P353, DOI 10.1016/j.pcad.2006.11.002; Bhatti SH, 2008, JCPSP-J COLL PHYSICI, V18, P22, DOI 01.2008/JCPSP.2226; Briggs SM, 2006, SURG CLIN N AM, V86, P537, DOI 10.1016/j.suc.2006.02.003; Broach J, 2010, DISASTER MED PUBLIC, V4, P116, DOI 10.1001/dmphp.4.2.116; Brown DL, 1999, AM HEART J, V137, P830, DOI 10.1016/S0002-8703(99)70406-0; Chadda RK, 2007, PREHOSP DISASTER MED, V22, P541, DOI 10.1017/S1049023X00005409; Chan CC, 2003, ANN EPIDEMIOL, V13, P502, DOI 10.1016/S1047-2797(03)00040-1; Chen Rigao, 2009, Orthopedics, V32, P322; Chen TW, 2009, SKELETAL RADIOL, V38, P1089, DOI 10.1007/s00256-009-0743-5; de Goyet CD, 2000, LANCET, V356, P762, DOI 10.1016/S0140-6736(00)02642-8; Demir T, 2010, EUR CHILD ADOLES PSY, V19, P125, DOI 10.1007/s00787-009-0048-1; Demirkiran O, 2003, EMERG MED J, V20, P247, DOI 10.1136/emj.20.3.247; Ding Yu, 2008, Zhongguo Gu Shang, V21, P742; Dong ZH, 2010, RADIOLOGY, V254, P285, DOI 10.1148/radiol.09090685; Duman H, 2003, EMERG MED J, V20, P251, DOI 10.1136/emj.20.3.251; Efstratiadis G, 2007, Hippokratia, V11, P129; Ersoy A, 2003, CLIN NEPHROL, V59, P334; Finkelstein JA, 1996, J TRAUMA, V40, P342, DOI 10.1097/00005373-199603000-00002; Floret N, 2006, EMERG INFECT DIS, V12, P543, DOI 10.3201/eid1204.051569; Gao Xin-Xue, 2009, Zhonghua Liu Xing Bing Xue Za Zhi, V30, P793; Ghodsi Seyed Mohammad, 2006, Chin J Traumatol, V9, P345; Gionis Thomas A, 2007, Am J Disaster Med, V2, P173; Gnauck KA, 2007, PREHOSP DISASTER MED, V22, P67, DOI 10.1017/S1049023X00004362; Gold LS, 2007, PREHOSP DISASTER MED, V22, P313, DOI 10.1017/S1049023X00004921; Gonzalez Dario, 2005, Crit Care Med, V33, pS34; Gunal AI, 2004, J AM SOC NEPHROL, V15, P1862, DOI 10.1097/01.asn.0000129336.09976.73; Hagh-Shenas H., 2006, Eastern Mediterranean Health Journal, V12, pS118; Hata S, 2009, CIRC J, V73, P1195, DOI 10.1253/circj.CJ-09-0305; Hatamizadeh P, 2006, AM J KIDNEY DIS, V47, P428, DOI 10.1053/j.ajkd.2005.11.019; Hosseini M, 2009, ACTA MED IRAN, P459; Hsu CC, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00022; Hu Y, 2010, WORLD J SURG, V34, P728, DOI 10.1007/s00268-010-0427-2; Huang KC, 2002, J FORMOS MED ASSOC, V101, P249; International Society of Nephrology, 2011, REN DIS REL TASK FOR; Jagodzinski NA, 2010, TRAUMA, V12, P69, DOI 10.1177/1460408610372440; Jain V, 2003, J PEDIATR SURG, V38, P663, DOI 10.1016/jpsu.2003.50178; Jia L, 2010, NEUROL INDIA, V58, P85, DOI 10.4103/0028-3886.60406; [康德英 KANG Deying], 2008, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V8, P575; Karamouzian S, 2010, ARCH IRAN MED, V13, P351, DOI 010134/AIM.0016; Kario K, 2003, HYPERTENS RES, V26, P355, DOI 10.1291/hypres.26.355; Kario K, 1998, J AM GERIATR SOC, V46, P537, DOI 10.1111/j.1532-5415.1998.tb02485.x; Kario K, 2001, AM J MED, V111, P379, DOI 10.1016/S0002-9343(01)00832-4; Kasraian L, 2010, IRAN RED CRESCENT ME, V12, P316; Keven K, 2003, SCAND J INFECT DIS, V35, P110, DOI 10.1080/0036554021000027013; Kloner RA, 2006, PROG CARDIOVASC DIS, V48, P285, DOI 10.1016/j.pcad.2005.07.001; Kokai M, 2004, PSYCHIAT CLIN NEUROS, V58, P110, DOI 10.1111/j.1440-1819.2003.01203.x; Krug EG, 1998, NEW ENGL J MED, V338, P373, DOI 10.1056/NEJM199802053380607; Kun P, 2009, DEPRESS ANXIETY, V26, P1134, DOI 10.1002/da.20612; Kuo CJ, 2003, PSYCHIAT SERV, V54, P249, DOI 10.1176/appi.ps.54.2.249; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Li S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009727; Li S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004964; Li Tao, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P415; Liang NJ, 2001, ANN EMERG MED, V38, P549, DOI 10.1067/mem.2001.118999; Ligon B Lee, 2006, Semin Pediatr Infect Dis, V17, P36, DOI 10.1053/j.spid.2006.01.002; Liu KZ, 2010, STRESS HEALTH, V26, P75, DOI 10.1002/smi.1267; Liu L, 2010, CHIN J TRAUMATOL, V13, P10, DOI 10.3760/cma.j.issn.1008-1275.2010.01.002; Liu Shi-an, 2009, Zhonghua Yufang Yixue Zazhi, V43, P380, DOI 10.3760/cma.j.issn.0253-9624.2009.05.010; Liu Yuehong, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P198; Mahue-Giangreco M, 2001, ANN EPIDEMIOL, V11, P347, DOI 10.1016/S1047-2797(01)00220-4; Malinoski DJ, 2004, CRIT CARE CLIN, V20, P171, DOI 10.1016/S0749-0704(03)00091-5; Margolin G, 2010, PROF PSYCHOL-RES PR, V41, P1, DOI 10.1037/a0018103; MICHAELSON M, 1992, WORLD J SURG, V16, P899, DOI 10.1007/BF02066989; Morgan O, 2004, REV PANAM SALUD PUBL, V15, P307, DOI 10.1590/S1020-49892004000500004; Mujeeb SA, 2007, EMERG MED J, V24, P22, DOI 10.1136/emj.2006.036848; Mulvey JM, 2008, INJURY, V39, P554, DOI 10.1016/j.injury.2007.07.025; Nadjafi I, 1997, RENAL FAILURE, V19, P655, DOI 10.3109/08860229709109031; Naghi TM, 2005, INJURY, V36, P27, DOI 10.1016/j.injury.2004.06.021; Naghii MR, 2005, REV PANAM SALUD PUBL, V18, P216, DOI 10.1590/S1020-49892005000800013; Neria Y, 2008, PSYCHOL MED, V38, P467, DOI 10.1017/S0033291707001353; Noji Eric K, 2005, Crit Care Med, V33, pS29, DOI 10.1097/01.CCM.0000151064.98207.9C; NORTH C S, 1990, Comprehensive Therapy, V16, P3; Oda J, 1997, J TRAUMA, V42, P470, DOI 10.1097/00005373-199703000-00015; Peek-Asa C, 2003, INJ PREV, V9, P62, DOI 10.1136/ip.9.1.62; Pekovic V, 2007, GENERATIONS, V31, P37; Porter Keith, 2003, Emerg Nurse, V11, P26; Quan Yi, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P549; Ran YC, 2010, SCAND J INFECT DIS, V42, P347, DOI 10.3109/00365540903510682; Rathore MFA, 2007, SPINAL CORD, V45, P658, DOI 10.1038/sj.sc.3102023; Sabzehchian M, 2006, PREHOSP DISASTER MED, V21, P336, DOI 10.1017/S1049023X00003976; Schultz CH, 1996, NEW ENGL J MED, V334, P438, DOI 10.1056/NEJM199602153340706; Sever MS, 2006, NEW ENGL J MED, V354, P1052, DOI 10.1056/NEJMra054329; Sever MS, 2004, CLIN NEPHROL, V61, P413; Sever MS, 2002, NEPHROL DIAL TRANSPL, V17, P1942, DOI 10.1093/ndt/17.11.1942; Sever MS, 2002, NEPHRON, V92, P64, DOI 10.1159/000064487; Sever MS, 2001, KIDNEY INT, V60, P1114, DOI 10.1046/j.1523-1755.2001.0600031114.x; Shinfuku Naotaka, 2002, World Psychiatry, V1, P158; Sullivan KM, 2010, DISASTERS, V34, P176, DOI 10.1111/j.1467-7717.2009.01121.x; Tanaka H, 1999, AM J EMERG MED, V17, P186, DOI 10.1016/S0735-6757(99)90059-1; Tanida N, 1996, BRIT MED J, V313, P1133, DOI 10.1136/bmj.313.7065.1133; Trauma ACOSCO, 2008, ADV TRAUM LIF SUPP P; Tsai CH, 2004, PSYCHOSOMATICS, V45, P477, DOI 10.1176/appi.psy.45.6.477; United Nations International Strategy for Disaster Reduction, 2010, EARTHQ CAUS DEADL DI; US Geological Survey, ACT VOLC PLAT TECT R; US Geological Survey, 2010, EARTHQ HAZ PROGR EAR; VanRooyen M, 2005, NEW ENGL J MED, V352, P435, DOI 10.1056/NEJMp058013; Vehid HE, 2006, TOHOKU J EXP MED, V208, P19, DOI 10.1620/tjem.208.19; Wang B, 2011, PSYCHIAT RES, V187, P392, DOI 10.1016/j.psychres.2009.07.001; Wang Hui-Yan, 2009, Zhongguo Gu Shang, V22, P910; Wang Lei, 2009, Ann Emerg Med, V54, pe10, DOI 10.1016/j.annemergmed.2009.03.028; Wang L, 2009, PSYCHOL REP, V105, P879, DOI 10.2466/PR0.105.3.879-885; Watson JT, 2007, EMERG INFECT DIS, V13, P1, DOI 10.3201/eid1301.060779; WOOD DP, 1991, AM J EMERG MED, V9, P598, DOI 10.1016/0735-6757(91)90122-Z; World Atlas, 2010, LARG CIT WORLD; Xiang B, 2009, J PEDIATR SURG, V44, P2273, DOI 10.1016/j.jpedsurg.2009.07.068; Xie Yi, 2009, Zhonghua Yi Xue Za Zhi, V89, P366; Yang Yan-Fang, 2010, Zhonghua Yu Fang Yi Xue Za Zhi, V44, P134; Yasin MA, 2009, ULUS TRAVMA ACIL CER, V15, P487; Yildiz S, 2004, GULHANE MED J, V46, P194; Yoshimura N, 1996, CHEST, V110, P759, DOI 10.1378/chest.110.3.759; Zhang XQ, 2009, AM J CARDIOL, V103, P994, DOI 10.1016/j.amjcard.2008.12.009	121	113	117	3	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	2012	379	9817					748	757		10.1016/S0140-6736(11)60887-8	http://dx.doi.org/10.1016/S0140-6736(11)60887-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	899CU	22056246				2022-12-28	WOS:000300792600031
J	Fumagalli, M; O'Meara, JM; Prochaska, JX				Fumagalli, Michele; O'Meara, John M.; Prochaska, J. Xavier			Detection of Pristine Gas Two Billion Years After the Big Bang	SCIENCE			English	Article							LYMAN LIMIT SYSTEMS; INTERGALACTIC MEDIUM; METALLICITY RELATION; STAR-FORMATION; 1ST STARS; UNIVERSE; METALS; CIV; POPULATION; ABSORPTION	In the current cosmological model, only the three lightest elements were created in the first few minutes after the Big Bang; all other elements were produced later in stars. To date, however, heavy elements have been observed in all astrophysical environments. We report the detection of two gas clouds with no discernible elements heavier than hydrogen. These systems exhibit the lowest heavy-element abundance in the early universe, and thus are potential fuel for the most metal-poor halo stars. The detection of deuterium in one system at the level predicted by primordial nucleosynthesis provides a direct confirmation of the standard cosmological model. The composition of these clouds further implies that the transport of heavy elements from galaxies to their surroundings is highly inhomogeneous.	[Fumagalli, Michele] Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; [O'Meara, John M.] St Michaels Coll, Dept Chem & Phys, Colchester, VT USA; [Prochaska, J. Xavier] Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Fumagalli, M (corresponding author), Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA.	mfumagalli@ucolick.org	O'Meara, John/AID-8266-2022; Fumagalli, Michele/K-9510-2015	Fumagalli, Michele/0000-0001-6676-3842; Prochaska, J. Xavier/0000-0002-7738-6875	Humboldt Foundation; NSF [AST0548180]; W. M. Keck Foundation	Humboldt Foundation(Alexander von Humboldt Foundation); NSF(National Science Foundation (NSF)); W. M. Keck Foundation(W.M. Keck Foundation)	We thank A. Aguirre, N. Lehner, and P. Madau for providing comments on this manuscript. We thank the Max-Planck-Institut fur Astronomie at Heidelberg for their hospitality. J.X.P. acknowledges support from the Humboldt Foundation. Support for this work came from NSF grant AST0548180. We acknowledge the use of the VPFIT program. This work is based on observations made at the W. M. Keck Observatory, which is operated as a scientific partnership among the California Institute of Technology, the University of California, and NASA. The observatory was made possible by the generous financial support of the W. M. Keck Foundation. The authors recognize and acknowledge the very significant cultural role and reverence that the summit of Mauna Kea has always had within the indigenous Hawaiian community. We are most fortunate to have the opportunity to conduct observations from this mountain. The data reported in this paper are available through the Keck Observatory Archive.	Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; D'Odorico V, 2001, ASTRON ASTROPHYS, V370, P729, DOI 10.1051/0004-6361:20010302; Dekel A, 2009, NATURE, V457, P451, DOI 10.1038/nature07648; Erb DK, 2006, ASTROPHYS J, V644, P813, DOI 10.1086/503623; Faucher-Giguere CA, 2011, MON NOT R ASTRON SOC, V412, pL118, DOI 10.1111/j.1745-3933.2011.01018.x; Ferrara A, 2000, MON NOT R ASTRON SOC, V319, P539, DOI 10.1046/j.1365-8711.2000.03857.x; Fumagalli M, 2011, MON NOT R ASTRON SOC, V418, P1796, DOI 10.1111/j.1365-2966.2011.19599.x; Hernquist L, 2003, MON NOT R ASTRON SOC, V341, P1253, DOI 10.1046/j.1365-8711.2003.06499.x; Keres D, 2005, MON NOT R ASTRON SOC, V363, P2, DOI 10.1111/j.1365-2966.2005.09451.x; Kirkman D, 2003, ASTROPHYS J SUPPL S, V149, P1, DOI 10.1086/378152; Kohler K, 2007, ASTROPHYS J, V655, P685, DOI 10.1086/510443; Komatsu E, 2011, ASTROPHYS J SUPPL S, V192, DOI 10.1088/0067-0049/192/2/18; Mackey J, 2003, ASTROPHYS J, V586, P1, DOI 10.1086/367613; O'Meara JM, 2006, ASTROPHYS J, V649, pL61, DOI 10.1086/508348; Pettini M, 2008, MON NOT R ASTRON SOC, V391, P1499, DOI 10.1111/j.1365-2966.2008.13921.x; Prochaska JX, 1999, ASTRON J, V117, P1957, DOI 10.1086/300855; Prochaska JX, 2003, ASTROPHYS J, V595, pL9, DOI 10.1086/378945; Prochter GE, 2010, ASTROPHYS J, V708, P1221, DOI 10.1088/0004-637X/708/2/1221; Romano D, 2006, MON NOT R ASTRON SOC, V369, P295, DOI 10.1111/j.1365-2966.2006.10287.x; Scannapieco E, 2005, ASTROPHYS J, V633, P1031, DOI 10.1086/444450; Schaye J, 2003, ASTROPHYS J, V596, P768, DOI 10.1086/378044; Schaye J, 2007, MON NOT R ASTRON SOC, V379, P1169, DOI 10.1111/j.1365-2966.2007.12005.x; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; Simcoe RA, 2004, ASTROPHYS J, V606, P92, DOI 10.1086/382777; Steigman G, 2007, ANNU REV NUCL PART S, V57, P463, DOI 10.1146/annurev.nucl.56.080805.140437; Wise JH, 2008, ASTROPHYS J, V685, P40, DOI 10.1086/590417; Yoshida N, 2004, ASTROPHYS J, V605, P579, DOI 10.1086/382499	29	140	140	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	2011	334	6060					1245	1249		10.1126/science.1213581	http://dx.doi.org/10.1126/science.1213581			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HD	22075722	Green Submitted			2022-12-28	WOS:000297553600042
J	Wadden, TA; Volger, S; Sarwer, DB; Vetter, ML; Tsai, AG; Berkowitz, RI; Kumanyika, S; Schmitz, KH; Diewald, LK; Barg, R; Chittams, J; Moore, RH				Wadden, Thomas A.; Volger, Sheri; Sarwer, David B.; Vetter, Marion L.; Tsai, Adam G.; Berkowitz, Robert I.; Kumanyika, Shiriki; Schmitz, Kathryn H.; Diewald, Lisa K.; Barg, Ronald; Chittams, Jesse; Moore, Renee H.			A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-STYLE INTERVENTION; WEIGHT-LOSS; OVERWEIGHT; PROGRAM; SIBUTRAMINE; REDUCTION; MAINTENANCE; PHYSICIANS; ORLISTAT; SUPPORT	BACKGROUND Calls for primary care providers (PCPs) to offer obese patients behavioral weight-loss counseling have not been accompanied by adequate guidance on how such care could be delivered. This randomized trial compared weight loss during a 2-year period in response to three lifestyle interventions, all delivered by PCPs in collaboration with auxiliary health professionals (lifestyle coaches) in their practices. METHODS We randomly assigned 390 obese adults in six primary care practices to one of three types of intervention: usual care, consisting of quarterly PCP visits that included education about weight management; brief lifestyle counseling, consisting of quarterly PCP visits combined with brief monthly sessions with lifestyle coaches who instructed participants about behavioral weight control; or enhanced brief lifestyle counseling, which provided the same care as described for the previous intervention but included meal replacements or weight-loss medication (orlistat or sibutramine), chosen by the participants in consultation with the PCPs, to potentially increase weight loss. RESULTS Of the 390 participants, 86% completed the 2-year trial, at which time, the mean (+/- SE) weight loss with usual care, brief lifestyle counseling, and enhanced brief lifestyle counseling was 1.7 +/- 0.7, 2.9 +/- 0.7, and 4.6 +/- 0.7 kg, respectively. Initial weight decreased at least 5% in 21.5%, 26.0%, and 34.9% of the participants in the three groups, respectively. Enhanced lifestyle counseling was superior to usual care on both these measures of success (P = 0.003 and P = 0.02, respectively), with no other significant differences among the groups. The benefits of enhanced lifestyle counseling remained even after participants given sibutramine were excluded from the analyses. There were no significant differences between the intervention groups in the occurrence of serious adverse events. CONCLUSIONS Enhanced weight-loss counseling helps about one third of obese patients achieve long-term, clinically meaningful weight loss. (Funded by the National Heart, Lung, and Blood Institute; POWER-UP ClinicalTrials.gov number, NCT00826774.)	[Wadden, Thomas A.; Volger, Sheri; Sarwer, David B.; Vetter, Marion L.; Berkowitz, Robert I.; Diewald, Lisa K.; Moore, Renee H.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; [Sarwer, David B.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Vetter, Marion L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Kumanyika, Shiriki; Schmitz, Kathryn H.; Chittams, Jesse; Moore, Renee H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Berkowitz, Robert I.] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat, Philadelphia, PA 19104 USA; [Barg, Ronald] Clin Care Associates, Penn Med, Philadelphia, PA USA; [Tsai, Adam G.] Univ Colorado, Div Gen Internal Med, Aurora, CO USA; [Tsai, Adam G.] Univ Colorado, Ctr Human Nutr, Aurora, CO USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Wadden, TA (corresponding author), Univ Penn, Dept Psychiat, 3535 Market St,Suite 3029, Philadelphia, PA 19104 USA.	wadden@mail.med.upenn.edu	Schmitz, Kathryn H/F-3516-2012	Schmitz, Kathryn/0000-0003-2400-2935; volger, sheri/0000-0002-1689-1173	National Heart, Lung, and Blood Institute [U01-HL087072]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087072] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant (U01-HL087072) from the National Heart, Lung, and Blood Institute.	Ackermann RT, 2008, AM J PREV MED, V35, P357, DOI 10.1016/j.amepre.2008.06.035; [Anonymous], 2008, CALORIEKING CAL FAT; Arterburn D, 2008, OBESITY, V16, P70, DOI 10.1038/oby.2007.18; Ashley JM, 2001, ARCH INTERN MED, V161, P1599, DOI 10.1001/archinte.161.13.1599; Berg AO, 2003, ANN INTERN MED, V139, P930, DOI 10.7326/0003-4819-139-11-200312020-00012; Christian JG, 2008, ARCH INTERN MED, V168, P141, DOI 10.1001/archinternmed.2007.13; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cohen M D, 1991, Fam Med, V23, P25; Curfman GD, 2010, NEW ENGL J MED, V363, P972, DOI 10.1056/NEJMe1007993; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; Digenio AG, 2009, ANN INTERN MED, V150, P255, DOI 10.7326/0003-4819-150-4-200902170-00006; Donnelly JE, 2007, INT J OBESITY, V31, P1270, DOI 10.1038/sj.ijo.0803568; Food and Drug Administration, FDA DRUG SAF COMM FD; Haapala I, 2009, PUBLIC HEALTH NUTR, V12, P2382, DOI 10.1017/S1368980009005230; Hauptman J, 2000, ARCH FAM MED, V9, P160, DOI 10.1001/archfami.9.2.160; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Heymsfield SB, 2003, INT J OBESITY, V27, P537, DOI 10.1038/sj.ijo.0802258; HOLM S, 1979, SCAND J STAT, V6, P65; James WPT, 2010, NEW ENGL J MED, V363, P905, DOI 10.1056/NEJMoa1003114; James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kumanyika S, OBESITY SIL IN PRESS; KUSHNER RF, 1995, PREV MED, V24, P546, DOI 10.1006/pmed.1995.1087; Kushner RF, 2010, ARCH INTERN MED, V170, P121, DOI 10.1001/archinternmed.2009.479; Li ZP, 2005, ANN INTERN MED, V142, P532, DOI 10.7326/0003-4819-142-7-200504050-00012; Martin PD, 2008, OBESITY, V16, P2462, DOI 10.1038/oby.2008.399; *NAT HEART LUNG BL, 2005, NIH PUBL; *NHLBI, 1998, OBES RES, V6, P464; Ockene IS, 1999, ARCH INTERN MED, V159, P725, DOI 10.1001/archinte.159.7.725; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ryan DH, 2010, ARCH INTERN MED, V170, P146, DOI 10.1001/archinternmed.2009.508; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Simkin-Silverman LR, 2008, AM J LIFESTYLE MED, V2, P296, DOI 10.1177/1559827608317287; Tate DF, 2006, ARCH INTERN MED, V166, P1620, DOI 10.1001/archinte.166.15.1620; Tsai AG, 2010, OBESITY, V18, P1614, DOI 10.1038/oby.2009.457; Tsai AG, 2009, J GEN INTERN MED, V24, P1073, DOI 10.1007/s11606-009-1042-5; Wadden TA, 2005, NEW ENGL J MED, V353, P2111, DOI 10.1056/NEJMoa050156; Wadden TA, 2006, OBESITY, V14, P737; Wing RR, 2011, DIABETES CARE, V34, P1481, DOI 10.2337/dc10-2415; Yeh HC, 2010, CLIN TRIALS, V7, P322, DOI 10.1177/1740774510374213	40	343	344	0	57	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2011	365	21					1969	1979		10.1056/NEJMoa1109220	http://dx.doi.org/10.1056/NEJMoa1109220			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851PF	22082239	Green Accepted			2022-12-28	WOS:000297282600007
J	Nicholson, T; Zehnder, D; Short, A; Ferraro, A				Nicholson, Thomas; Zehnder, Daniel; Short, Andrew; Ferraro, Alastair			CASE REPORT Problems in pregnancy	BRITISH MEDICAL JOURNAL			English	Editorial Material							GOODPASTURES-SYNDROME; KIDNEY-DISEASE; WOMEN		[Ferraro, Alastair] Nottingham Univ Hosp NHS Trust, Dept Nephrol, Nottingham NG5 1PB, England; [Nicholson, Thomas; Zehnder, Daniel; Short, Andrew] Univ Hosp Coventry & Warwickshire NHS Trust, Dept Nephrol, Coventry CV2 2DX, W Midlands, England	Nottingham University Hospital NHS Trust; University of Warwick	Ferraro, A (corresponding author), Nottingham Univ Hosp NHS Trust, Dept Nephrol, Nottingham NG5 1PB, England.	alastair.ferraro@nuh.nhs.uk						Al-Harbi Ali, 2003, Saudi J Kidney Dis Transpl, V14, P516; Barua M, 2008, CLIN J AM SOC NEPHRO, V3, P392, DOI 10.2215/CJN.04110907; BENOIT FL, 1964, AM J MED, V37, P424, DOI 10.1016/0002-9343(64)90199-8; Cardonick E, 2004, LANCET ONCOL, V5, P283, DOI 10.1016/S1470-2045(04)01466-4; Cote AM, 2008, BRIT MED J, V336, P1003, DOI 10.1136/bmj.39532.543947.BE; DAVIES HE, 2011, BRIT MED J, V342, pE947; Day C, 2008, NEPHROL DIAL TRANSPL, V23, P201, DOI 10.1093/ndt/gfm572; DEUBNER H, 1995, AM J KIDNEY DIS, V25, P330, DOI 10.1016/0272-6386(95)90016-0; Fischer MJ, 2007, ADV CHRONIC KIDNEY D, V14, P132, DOI 10.1053/j.ackd.2007.01.004; HAYSLETT JP, 1984, KIDNEY INT, V25, P579, DOI 10.1038/ki.1984.58; Hou S, 2010, AM J KIDNEY DIS, V56, P5, DOI 10.1053/j.ajkd.2010.05.002; Jayne DRW, 2007, J AM SOC NEPHROL, V18, P2180, DOI 10.1681/ASN.2007010090; Klajnbard A, 2010, CLIN CHEM LAB MED, V48, P237, DOI 10.1515/CCLM.2010.033; Lightstone L, 2008, RENAL DIS PREGNANCY, P21; LOCKWOOD CM, 1975, BRIT MED J, V2, P252, DOI 10.1136/bmj.2.5965.252; *NAT I HLTH CLIN E, 2011, 107 CG NAT I HLTH CL; NILSSEN DE, 1986, ACTA MED SCAND, V220, P489; Piccoli GB, 2010, CLIN J AM SOC NEPHRO, V5, P62, DOI 10.2215/CJN.05660809; Vasiliou DM, 2005, OBSTET GYNECOL, V106, P1196, DOI 10.1097/01.AOG.0000161061.35611.98; YANKOWITZ J, 1992, OBSTET GYNECOL, V79, P806	20	0	0	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 21	2011	343								d7239	10.1136/bmj.d7239	http://dx.doi.org/10.1136/bmj.d7239			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857NC	22106362				2022-12-28	WOS:000297724200002
J	Brodie, D; Bacchetta, M				Brodie, Daniel; Bacchetta, Matthew			Extracorporeal Membrane Oxygenation for ARDS in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; TIDAL VOLUME VENTILATION; END-EXPIRATORY PRESSURE; MECHANICAL VENTILATION; CLINICAL-TRIAL; HIGH SURVIVAL; LIFE-SUPPORT; CO2 REMOVAL	A 41-year-old woman presents with severe community-acquired pneumococcal pneumonia. Chest radiography reveals diffuse bilateral infiltrates, and hypoxemic respiratory failure develops despite appropriate antibiotic therapy. She is intubated and mechanical ventilation is initiated with a volume- and pressure-limited approach for the acute respiratory distress syndrome (ARDS). Over the ensuing 24 hours, her partial pressure of arterial oxygen (PaO(2)) decreases to 40 mm Hg, despite ventilatory support with a fraction of inspired oxygen (FIO(2)) of 1.0 and a positive end-expiratory pressure (PEEP) of 20 cm of water. She is placed in the prone position and a neuromuscular blocking agent is administered, without improvement in her PaO(2). An intensive care specialist recommends the initiation of extracorporeal membrane oxygenation (ECMO).	[Brodie, Daniel] Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA; New York Presbyterian Hosp, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital	Brodie, D (corresponding author), Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, 630 W 168th St,PH 8 E, New York, NY 10032 USA.	hdb5@columbia.edu			Maquet Cardiovascular	Maquet Cardiovascular	Dr. Brodie reports receiving consulting fees and travel expenses from Maquet Cardiovascular, being a member of its cardiovascular advisory board, and anticipating possible receipt of grant support from Maquet Cardiovascular. Dr. Bacchetta reports receiving consulting fees and travel expenses from Maquet Cardiovascular, anticipating possible receipt of grant support from Maquet Cardiovascular, and discussing with Avalon Laboratories a possible instructional video for which he would not be paid. No other potential conflict of interest relevant to the article was reported.	[Anonymous], 1999, Am J Respir Crit Care Med, V160, P2118; BARTLETT RH, 2005, ECMO EXTRACORPOREAL, P404; Beiderlinden M, 2006, INTENS CARE MED, V32, P1627, DOI 10.1007/s00134-006-0262-y; Bein T, 2006, CRIT CARE MED, V34, P1372, DOI 10.1097/01.CCM.0000215111.85483.BD; Bermudez CA, 2010, ANN THORAC SURG, V90, P991, DOI 10.1016/j.athoracsur.2010.06.017; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Brogan TV, 2009, INTENS CARE MED, V35, P2105, DOI 10.1007/s00134-009-1661-7; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Butch SH, 1996, TRANSFUSION, V36, P61, DOI 10.1046/j.1537-2995.1996.36196190517.x; Cooke CR, 2008, CRIT CARE MED, V36, P1412, DOI 10.1097/CCM.0b013e318170a375; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; Dembinski R, 2007, CRIT CARE MED, V35, P2359, DOI 10.1097/01.CCM.0000281857.87354.A5; Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee; Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/rccm.201001-0037OC, 10.1164/201001-0037OC]; Extracorporeal Life Support Organization, 2011, ECLS REG REP INT SUM; Extracorporeal Life Support Organization, 2009, PAT SPEC GUID SUPPL, P15; Florchinger B, 2008, ANN THORAC SURG, V86, P410, DOI 10.1016/j.athoracsur.2008.04.045; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Frenckner B, 2002, Minerva Anestesiol, V68, P381; Gaffney AM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5317; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemmila MR, 2004, ANN SURG, V240, P595, DOI 10.1097/01.sla.0000141159.90676.2d; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Holzgraefe B, 2010, MINERVA ANESTESIOL, V76, P1043; Jardin F, 2007, INTENS CARE MED, V33, P444, DOI 10.1007/s00134-007-0552-z; Javidfar J, 2011, ANN THORAC SURG, V91, P1763, DOI 10.1016/j.athoracsur.2011.03.002; Javidfar J, 2011, ASAIO J, V57, P203, DOI 10.1097/MAT.0b013e3182155fee; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lewandowski K, 1997, INTENS CARE MED, V23, P819, DOI 10.1007/s001340050418; Linden V, 2000, INTENS CARE MED, V26, P1630, DOI 10.1007/s001340000697; Lodato RF., 2006, PRINCIPLES PRACTICE, P965; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MATTHAY MA, 2011, AM J RESP CRIT 0511; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Miller RR, 2010, CHEST, V137, P752, DOI 10.1378/chest.09-2517; Mols G, 2000, AM J SURG, V180, P144, DOI 10.1016/S0002-9610(00)00432-3; Moran JL, 2010, CRIT CARE RESUSC, V12, P131; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; Nehra D, 2009, ARCH SURG-CHICAGO, V144, P427, DOI 10.1001/archsurg.2009.45; Netzer G, 2007, CHEST, V132, P1116, DOI 10.1378/chest.07-0145; NOAH MA, 2011, JAMA            1005; Noble DW, 2010, ANAESTHESIA, V65, P971, DOI 10.1111/j.1365-2044.2010.06507.x; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC; PARSONS PE, 2005, CRIT CARE MED, V33, P203; Patroniti N, 2011, INTENS CARE MED, V37, P1447, DOI 10.1007/s00134-011-2301-6; Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Peek GJ, 1997, CHEST, V112, P759, DOI 10.1378/chest.112.3.759; Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012; Pipeling MR, 2010, JAMA-J AM MED ASSOC, V304, P2521, DOI 10.1001/jama.2010.1752; Pranikoff T, 1997, CRIT CARE MED, V25, P28, DOI 10.1097/00003246-199701000-00008; Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rouby JJ, 2007, AM J RESP CRIT CARE, V175, P104, DOI 10.1164/rccm.200610-1564ED; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; SCHMID C, 2011, J HEART LUNG TR 0803; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; Ullrich R, 1999, ANESTHESIOLOGY, V91, P1577, DOI 10.1097/00000542-199912000-00007; VASILYEV S, 1995, CHEST, V107, P1083, DOI 10.1378/chest.107.4.1083; Wang DF, 2008, ASAIO J, V54, P606, DOI 10.1097/MAT.0b013e31818c69ab; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware Lorraine B, 2005, Crit Care Med, V33, pS217, DOI 10.1097/01.CCM.0000155788.39101.7E; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zimmermann M, 2009, CRIT CARE, V13, DOI 10.1186/cc7703; Zwischenberger JB, 2009, LANCET, V374, P1307, DOI 10.1016/S0140-6736(09)61630-5; 2010, NEW S WALES AUSTR GU, P23	79	522	564	1	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1905	1914		10.1056/NEJMct1103720	http://dx.doi.org/10.1056/NEJMct1103720			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087681				2022-12-28	WOS:000297041900009
J	Mango, SE				Mango, Susan E.			AGEING Generations of longevity	NATURE			English	Editorial Material							C. ELEGANS; COMPLEX		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Mango, SE (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	smango@mcb.harvard.edu		Mango, Susan/0000-0002-2146-3237	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM056264] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM056264-15, R37 GM056264] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bygren LO, 2001, ACTA BIOTHEOR, V49, P53, DOI 10.1023/A:1010241825519; Daxinger L, 2010, GENOME RES, V20, P1623, DOI 10.1101/gr.106138.110; Greer EL, 2011, NATURE, V479, P365, DOI 10.1038/nature10572; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Li TG, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001349; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Pferdehirt RR, 2011, GENE DEV, V25, P499, DOI 10.1101/gad.2016011; Wang MC, 2008, SCIENCE, V322, P957, DOI 10.1126/science.1162011	10	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					302	303		10.1038/479302a	http://dx.doi.org/10.1038/479302a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094684	Green Accepted			2022-12-28	WOS:000297059700025
J	Morton, JJL; McCamey, DR; Eriksson, MA; Lyon, SA				Morton, John J. L.; McCamey, Dane R.; Eriksson, Mark A.; Lyon, Stephen A.			Embracing the quantum limit in silicon computing	NATURE			English	Review							ELECTRON-SPIN-RESONANCE; SINGLE-ELECTRON; READ-OUT; TRANSPORT; ENTANGLEMENT; SPECTROSCOPY; MANIPULATION; FABRICATION; DONORS; MEMORY	Quantum computers hold the promise of massive performance enhancements across a range of applications, from cryptography and databases to revolutionary scientific simulation tools. Such computers would make use of the same quantum mechanical phenomena that pose limitations on the continued shrinking of conventional information processing devices. Many of the key requirements for quantum computing differ markedly from those of conventional computers. However, silicon, which plays a central part in conventional information processing, has many properties that make it a superb platform around which to build a quantum computer.	[Morton, John J. L.] Univ Oxford, Dept Mat, Oxford OX1 3PH, England; [Morton, John J. L.] Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England; [McCamey, Dane R.] Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia; [Eriksson, Mark A.] Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; [Lyon, Stephen A.] Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	University of Oxford; University of Oxford; University of Sydney; University of Wisconsin System; University of Wisconsin Madison; Princeton University	Morton, JJL (corresponding author), Univ Oxford, Dept Mat, Parks Rd, Oxford OX1 3PH, England.	john.morton@sjc.ox.ac.uk	Morton, John/I-3515-2013; McCamey, Dane/A-1206-2011	McCamey, Dane/0000-0001-7727-6804; Lyon, Stephen/0000-0002-4631-4190	Royal Society; St John's College, Oxford; Engineering and Physical Sciences Research Council (EPSRC) through the Centre for Advanced Electron Spin Resonance [EP/D048559/1]; Japan Science and Technology Agency (JST)-EPSRC [EP/H025952/1]; Australian Research Council [DP1093526]; Army Research Office (ARO) [W911NF-08-1-0482]; National Security Agency/Laboratory of Physical Sciences through Lawrence Berkeley National Laboratory [MOD 713106A]; National Science Foundation through the Princeton Materials Research Science and Engineering Center [DMR-0819860]; ARO through Wisconsin; Engineering and Physical Sciences Research Council [EP/I035536/1, EP/H025952/1] Funding Source: researchfish; EPSRC [EP/H025952/1, EP/I035536/1] Funding Source: UKRI	Royal Society(Royal Society of London); St John's College, Oxford; Engineering and Physical Sciences Research Council (EPSRC) through the Centre for Advanced Electron Spin Resonance(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Japan Science and Technology Agency (JST)-EPSRC(Japan Science & Technology Agency (JST)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Australian Research Council(Australian Research Council); Army Research Office (ARO); National Security Agency/Laboratory of Physical Sciences through Lawrence Berkeley National Laboratory(National Security Agency); National Science Foundation through the Princeton Materials Research Science and Engineering Center; ARO through Wisconsin; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank A. M. Tyryshkin for discussions. J.J.L.M. is supported by the Royal Society and St John's College, Oxford, and acknowledges support from the Engineering and Physical Sciences Research Council (EPSRC) through the Centre for Advanced Electron Spin Resonance (EP/D048559/1) and the Japan Science and Technology Agency (JST)-EPSRC Cooperative Program (EP/H025952/1). D. R. M. is supported by an Australian Research Council Postdoctoral Fellowship (DP1093526). M. A. E. acknowledges support from the Army Research Office (ARO) (W911NF-08-1-0482). S. A. L. acknowledges support from the National Security Agency/Laboratory of Physical Sciences through Lawrence Berkeley National Laboratory (MOD 713106A), the National Science Foundation through the Princeton Materials Research Science and Engineering Center (DMR-0819860) and the ARO through Wisconsin. We apologize to those authors whose work could not be cited owing to space limitations.	Abe E, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.121201; Andreas B, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.030801; Andresen SES, 2007, NANO LETT, V7, P2000, DOI 10.1021/nl070797t; Angus SJ, 2007, NANO LETT, V7, P2051, DOI 10.1021/nl070949k; Appelbaum I, 2007, NATURE, V447, P295, DOI 10.1038/nature05803; Berer T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2197320; Boehme C, 2002, PHYS STATUS SOLIDI B, V233, P427, DOI 10.1002/1521-3951(200210)233:3<427::AID-PSSB427>3.0.CO;2-J; Bradbury FR, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.176404; Calderon MJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.096802; Culcer D, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.205302; DEUTSCH D, 1985, P ROY SOC LOND A MAT, V400, P97, DOI 10.1098/rspa.1985.0070; DiCarlo L, 2010, NATURE, V467, P574, DOI 10.1038/nature09416; Dreher L, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.037601; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; FEHER G, 1959, PHYS REV, V114, P1219, DOI 10.1103/PhysRev.114.1219; Friesen M, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.115324; Fuechsle M, 2010, NAT NANOTECHNOL, V5, P502, DOI [10.1038/NNANO.2010.95, 10.1038/nnano.2010.95]; George RE, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.067601; GORDON JP, 1958, PHYS REV LETT, V1, P368, DOI 10.1103/PhysRevLett.1.368; Goswami S, 2007, NAT PHYS, V3, P41, DOI 10.1038/nphys475; Haran B. S., 2008, P IEEE INT EL DEV M, P1, DOI DOI 10.1109/IEDM.2008.4796769; Hayashi T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.226804; HAYES RR, 2009, LIFETIME MEASUREMENT; Hu YJ, 2007, NAT NANOTECHNOL, V2, P622, DOI 10.1038/nnano.2007.302; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Kubo Y, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.140502; Ladd TD, 2010, NATURE, V464, P45, DOI 10.1038/nature08812; Ladd TD, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.014401; Lai N. S., 2010, PAULI SPIN BLOCKADE; Lansbergen GP, 2008, NAT PHYS, V4, P656, DOI 10.1038/nphys994; Lansbergen GP, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.136602; Levy J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.147902; Lim WH, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3272858; Liu HW, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.073310; Lo CC, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2817966; Lo CC, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.207601; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Lu TM, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3127516; LYDING JW, 1994, APPL PHYS LETT, V64, P2010, DOI 10.1063/1.111722; Matsunami J, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.066602; McCamey DR, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2358928; McCamey DR, 2010, SCIENCE, V330, P1652, DOI 10.1126/science.1197931; McCamey DR, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.027601; Morello A, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.081307; Morello A, 2010, NATURE, V467, P687, DOI 10.1038/nature09392; Morley GW, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.207602; Morley GW, 2010, NAT MATER, V9, P725, DOI [10.1038/nmat2828, 10.1038/NMAT2828]; Morton J. J. L., 2010, SILICON BASED CLUSTE; Morton JJL, 2008, NATURE, V455, P1085, DOI 10.1038/nature07295; Morton JJL, 2011, ANNU REV CONDEN MA P, V2, P189, DOI 10.1146/annurev-conmatphys-062910-140514; Neeley M, 2010, NATURE, V467, P570, DOI 10.1038/nature09418; Nordberg EP, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.115331; Oskin M, 2003, CONF PROC INT SYMP C, P374, DOI 10.1109/ISCA.2003.1207015; Petta JR, 2005, SCIENCE, V309, P2180, DOI 10.1126/science.1116955; Pierre M, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3273857; Pioro-Ladriere M, 2008, NAT PHYS, V4, P776, DOI 10.1038/nphys1053; Politi A, 2008, SCIENCE, V320, P646, DOI 10.1126/science.1155441; Rokhinson LP, 2000, APPL PHYS LETT, V76, P1591, DOI 10.1063/1.126105; Ruess FJ, 2004, NANO LETT, V4, P1969, DOI 10.1021/nl048808v; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; Sakr MR, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2136436; Sarovar M, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.245302; Schenkel T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2182068; Schenkel T, 2003, J APPL PHYS, V94, P7017, DOI 10.1063/1.1622109; SCHMIDT J, 1966, CR ACAD SCI B PHYS, V263, P169; Schofield SR, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.136104; Schuster DI, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.140501; Schweiger A., 2001, PRINCIPLES PULSE ELE; Sellier H, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.206805; Shankar S, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.195323; Shin YS, 2011, SEMICOND SCI TECH, V26, DOI 10.1088/0268-1242/26/5/055004; Simmons CB, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2816331; Simmons CB, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.156804; Simmons CB, 2009, NANO LETT, V9, P3234, DOI 10.1021/nl9014974; Simmons S, 2011, NATURE, V470, P69, DOI 10.1038/nature09696; Skinner AJ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.087901; Smelyanskiy VN, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.081304; Steane AM, 1999, NATURE, V399, P124, DOI 10.1038/20127; Steger M, 2011, J APPL PHYS, V109, DOI 10.1063/1.3577614; Stegner AR, 2006, NAT PHYS, V2, P835, DOI 10.1038/nphys465; Stoneham AM, 2003, J PHYS-CONDENS MAT, V15, pL447, DOI 10.1088/0953-8984/15/27/102; Tahan C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035314; Tan KY, 2010, NANO LETT, V10, P11, DOI [10.1021/nl901635j, 10.1021/nl901635J]; Tracy LA, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3518058; Tyryshkin A. M., 2011, NATURE MAT IN PRESS; Tyryshkin AM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.126802; Tyryshkin AM, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.193207; van Beveren LHW, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2960356; Viola L, 1999, PHYS REV LETT, V82, P2417, DOI 10.1103/PhysRevLett.82.2417; Vrijen R, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012306; Weitz P, 1996, SURF SCI, V361, P542, DOI 10.1016/0039-6028(96)00465-7; Wilamowski Z, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.187203; Witzel WM, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.035322; Witzel WM, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.045218; Wu H, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.140503; Xiao M, 2004, NATURE, V430, P435, DOI 10.1038/nature02727; Xiao M, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.096801; Yang A, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.257401; Zhu XB, 2011, NATURE, V478, P221, DOI 10.1038/nature10462; Zwanenburg FA, 2009, NANO LETT, V9, P1071, DOI 10.1021/nl803440s	101	211	244	0	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					345	353		10.1038/nature10681	http://dx.doi.org/10.1038/nature10681			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094695				2022-12-28	WOS:000297059700035
J	Abrahamsen, H; Stenmark, H				Abrahamsen, Hilde; Stenmark, Harald			Growth Signaling from Inside	SCIENCE			English	Editorial Material							AMINO-ACIDS; RAG GTPASES; MTOR; MECHANISM; TARGETS; COMPLEX; CANCER; LIFE		[Abrahamsen, Hilde; Stenmark, Harald] Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway; [Abrahamsen, Hilde; Stenmark, Harald] Univ Oslo, Ctr Canc Biomed, N-0310 Oslo, Norway	University of Oslo; University of Oslo	Abrahamsen, H (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Stenmark, Harald/B-8868-2008					Bjedov I, 2011, BIOCHEM SOC T, V39, P460, DOI 10.1042/BST0390460; Bonawitz ND, 2007, CELL METAB, V5, P265, DOI 10.1016/j.cmet.2007.02.009; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	15	0	0	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					611	612		10.1126/science.1214355	http://dx.doi.org/10.1126/science.1214355			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053037				2022-12-28	WOS:000296494700038
J	Mendiburo, MJ; Padeken, J; Fulop, S; Schepers, A; Heun, P				Mendiburo, Maria Jose; Padeken, Jan; Fueloep, Stefanie; Schepers, Aloys; Heun, Patrick			Drosophila CENH3 Is Sufficient for Centromere Formation	SCIENCE			English	Article							DE-NOVO KINETOCHORE; CHROMOSOME SEGREGATION; BUDDING YEAST; CHROMATIN; NUCLEOSOMES; DNA; MODIFIERS; BYPASSES; COMPLEX	CENH3 is a centromere-specific histone H3 variant essential for kinetochore assembly. Despite its central role in centromere function, there has been no conclusive evidence supporting CENH3 as sufficient to determine centromere identity. To address this question, we artificially targeted Drosophila CENH3 (CENP-A/CID) as a CID-GFP-LacI fusion protein to stably integrated lac operator (lacO) arrays. This ectopic CID focus assembles a functional kinetochore and directs incorporation of CID molecules without the LacI-anchor, providing evidence for the self-propagation of the epigenetic mark. CID-GFP-LacI-bound extrachromosomal lacO plasmids can assemble kinetochore proteins and bind microtubules, resulting in their stable transmission for several cell generations even after eliminating CID-GFP-LacI. We conclude that CID is both necessary and sufficient to serve as an epigenetic centromere mark and nucleate heritable centromere function.	[Mendiburo, Maria Jose; Padeken, Jan; Heun, Patrick] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; [Mendiburo, Maria Jose; Padeken, Jan] Univ Freiburg, Freiburg, Germany; [Fueloep, Stefanie; Schepers, Aloys] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Dept Gene Vectors, D-81377 Munich, Germany; [Heun, Patrick] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	Max Planck Society; University of Freiburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Freiburg	Heun, P (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-79108 Freiburg, Germany.	heun@ie-freiburg.mpg.de	Padeken, Jan/AFU-6352-2022; Heun, Patrick/AAH-7390-2020	Padeken, Jan/0000-0001-6538-0946; Heun, Patrick/0000-0001-8400-1892; Mendiburo, Maria Jose/0000-0002-7840-7754; Schepers, Aloys/0000-0002-5442-5608	Deutsche Forschungsgemeinschaft [Sonderforschungsbereich (SFB) 646, SFB/TR05, Schwerpunktprogramm 1230]; Max Planck Society; Human Frontier Science Program; Excellence Initiative of the German Federal Government [EXC 294]; Excellence Initiative of the German State Government [EXC 294]; Max Planck Institute of Immunobiology and Epigenetics	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Max Planck Society(Max Planck Society); Human Frontier Science Program(Human Frontier Science Program); Excellence Initiative of the German Federal Government; Excellence Initiative of the German State Government; Max Planck Institute of Immunobiology and Epigenetics	We thank G. H. Karpen, A. Straight, T. Maresca, E. Salmon, C. Sunkel, S. Heidmann, and C. Lehner for reagents. We also thank L. Jansen for critical reading of the manuscript and the members of the Grosschedl Department, particularly S. Chlamydas for pioneering experiments and A. Olszak, H.-J. Schwarz, D. Venegas, S. Daujat, S. Saccani, and D. van Essen for reagents and helpful discussions. A. S. is supported by the Sonderforschungsbereich (SFB) 646, SFB/TR05, and Schwerpunktprogramm 1230 of the Deutsche Forschungsgemeinschaft. P. H. is funded by the Max Planck Society, the Human Frontier Science Program (Career Development Award; CDA), and the Excellence Initiative of the German Federal and State Governments (EXC 294). M.-J.M. and J.P. are grateful for an International Max Planck Research School (IMPRS) fellowship provided by the Max Planck Institute of Immunobiology and Epigenetics.	Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Black BE, 2007, MOL CELL, V25, P309, DOI 10.1016/j.molcel.2006.12.018; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Dalal Y, 2007, PLOS BIOL, V5, P1798, DOI 10.1371/journal.pbio.0050218; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Furuyama T, 2009, CELL, V138, P104, DOI 10.1016/j.cell.2009.04.049; Gascoigne KE, 2011, CELL, V145, P410, DOI 10.1016/j.cell.2011.03.031; Guse A, 2011, NATURE, V477, P354, DOI 10.1038/nature10379; Heun P, 2006, DEV CELL, V10, P303, DOI 10.1016/j.devcel.2006.01.014; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Jansen LET, 2007, J CELL BIOL, V176, P795, DOI 10.1083/jcb.200701066; Kagansky A, 2009, SCIENCE, V324, P1716, DOI 10.1126/science.1172026; Kiermaier E, 2009, NAT CELL BIOL, V11, P1109, DOI 10.1038/ncb1924; Lacefield S, 2009, NAT CELL BIOL, V11, P1116, DOI 10.1038/ncb1925; McClintock B, 1941, GENETICS, V26, P234; Nakano M, 2008, DEV CELL, V14, P507, DOI 10.1016/j.devcel.2008.02.001; Olszak AM, 2011, NAT CELL BIOL, V13, P799, DOI 10.1038/ncb2272; Pich D, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn273; Przewloka MR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000478; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; Sekulic N, 2010, NATURE, V467, P347, DOI 10.1038/nature09323; Vierstra RD, 1999, PLANT MOL BIOL, V41, P435, DOI 10.1023/A:1006323317890	25	205	207	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					686	690		10.1126/science.1206880	http://dx.doi.org/10.1126/science.1206880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053052				2022-12-28	WOS:000296494700059
J	Logothetis, CJ				Logothetis, Christopher J.			Treatment of prostate cancer metastases: more than semantics	LANCET			English	Editorial Material							BONE METASTASES		Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Logothetis, CJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	clogothe@mdanderson.org						Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078-0432.CCR-06-0269; Efstathiou E, 2011, J CLIN ONCO IN PRESS; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121; Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140-6736(11)61226-9	10	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 7	2012	379	9810					4	6		10.1016/S0140-6736(11)61540-7	http://dx.doi.org/10.1016/S0140-6736(11)61540-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873WC	22093188				2022-12-28	WOS:000298913000007
J	Choudhry, NK; Avorn, J; Glynn, RJ; Antman, EM; Schneeweiss, S; Toscano, M; Reisman, L; Fernandes, J; Spettell, C; Lee, JL; Levin, R; Brennan, T; Shrank, WH				Choudhry, Niteesh K.; Avorn, Jerry; Glynn, Robert J.; Antman, Elliott M.; Schneeweiss, Sebastian; Toscano, Michele; Reisman, Lonny; Fernandes, Joaquim; Spettell, Claire; Lee, Joy L.; Levin, Raisa; Brennan, Troyen; Shrank, William H.		Post Myocardial Infarction Free Rx	Full Coverage for Preventive Medications after Myocardial Infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICARE BENEFICIARIES; INSURANCE DESIGN; DRUG COVERAGE; HEART-DISEASE; ADHERENCE; HEALTH; MORTALITY; BENEFITS; INTERVENTIONS; ASSOCIATION	Background Adherence to medications that are prescribed after myocardial infarction is poor. Eliminating out-of-pocket costs may increase adherence and improve outcomes. Methods We enrolled patients discharged after myocardial infarction and randomly assigned their insurance-plan sponsors to full prescription coverage (1494 plan sponsors with 2845 patients) or usual prescription coverage (1486 plan sponsors with 3010 patients) for all statins, beta-blockers, angiotensin-converting-enzyme inhibitors, or angiotensin-receptor blockers. The primary outcome was the first major vascular event or revascularization. Secondary outcomes were rates of medication adherence, total major vascular events or revascularization, the first major vascular event, and health expenditures. Results Rates of adherence ranged from 35.9 to 49.0% in the usual-coverage group and were 4 to 6 percentage points higher in the full-coverage group (P<0.001 for all comparisons). There was no significant between-group difference in the primary outcome (17.6 per 100 person-years in the full-coverage group vs. 18.8 in the usual-coverage group; hazard ratio, 0.93; 95% confidence interval [CI], 0.82 to 1.04; P=0.21). The rates of total major vascular events or revascularization were significantly reduced in the full-coverage group (21.5 vs. 23.3; hazard ratio, 0.89; 95% CI, 0.90 to 0.99; P=0.03), as was the rate of the first major vascular event (11.0 vs. 12.8; hazard ratio, 0.86; 95% CI, 0.74 to 0.99; P=0.03). The elimination of copayments did not increase total spending ($66,008 for the full-coverage group and $71,778 for the usual-coverage group; relative spending, 0.89; 95% CI, 0.50 to 1.56; P=0.68). Patient costs were reduced for drugs and other services (relative spending, 0.74; 95% CI, 0.68 to 0.80; P<0.001). Conclusions The elimination of copayments for drugs prescribed after myocardial infarction did not significantly reduce rates of the trial's primary outcome. Enhanced prescription coverage improved medication adherence and rates of first major vascular events and decreased patient spending without increasing overall health costs. (Funded by Aetna and the Commonwealth Fund.)	[Choudhry, Niteesh K.; Avorn, Jerry; Glynn, Robert J.; Schneeweiss, Sebastian; Lee, Joy L.; Levin, Raisa; Shrank, William H.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA; [Glynn, Robert J.] Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02120 USA; [Antman, Elliott M.] Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02120 USA; [Choudhry, Niteesh K.; Avorn, Jerry; Glynn, Robert J.; Antman, Elliott M.; Schneeweiss, Sebastian; Lee, Joy L.; Levin, Raisa; Shrank, William H.] Harvard Univ, Sch Med, Boston, MA USA; [Toscano, Michele; Reisman, Lonny; Fernandes, Joaquim; Spettell, Claire] Aetna, Hartford, CT USA; [Brennan, Troyen] CVS Caremark, Woonsocket, RI USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	nchoudhry@partners.org	Schneeweiss, Sebastian/C-2125-2013	Schneeweiss, Sebastian/0000-0003-2575-467X; Lee, Joy/0000-0003-2589-8200	Aetna; Commonwealth Fund; Mercer Health and Benefits; CVS Caremark; Merck; AstraZeneca; Novartis; WHISCON; Pfizer; United Healthcare; Express Scripts	Aetna; Commonwealth Fund; Mercer Health and Benefits; CVS Caremark; Merck(Merck & Company); AstraZeneca(AstraZeneca); Novartis(Novartis); WHISCON; Pfizer(Pfizer); United Healthcare; Express Scripts	Supported by unrestricted research grants from Aetna and the Commonwealth Fund to Brigham and Women's Hospital.; Dr. Choudhry reports receiving consulting fees from Mercer Health and Benefits and grant support from CVS Caremark; Dr. Glynn, receiving consulting and lecture fees from Merck and grant support from AstraZeneca and Novartis; Dr. Schneeweiss, receiving consulting fees from WHISCON and grant support from Pfizer and Novartis; Ms. Toscano, Dr. Reisman, Mr. Fernandes, and Dr. Spettell, being employees of and having an equity interest in Aetna; Dr. Brennan, being an employee of, having an equity interest in, and receiving board membership fees from CVS Caremark; and Dr. Shrank, receiving consulting fees from United Healthcare and grant support from CVS Caremark and Express Scripts. No other potential conflict of interest relevant to this article was reported.	American Heart Association, GET GUID; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Chernew ME, 2008, HEALTH AFFAIR, V27, P103, DOI 10.1377/hlthaff.27.1.103; Choudhry NK, 2008, AM HEART J, V156, P31, DOI 10.1016/j.ahj.2008.03.021; Choudhry NK, 2008, CIRCULATION, V117, P1261, DOI 10.1161/CIRCULATIONAHA.107.735605; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; Choudhry NK, 2011, ARCH INTERN MED, V171, P814, DOI 10.1001/archinternmed.2010.495; Choudhry NK, 2010, HEALTH AFFAIR, V29, P1988, DOI 10.1377/hlthaff.2009.0324; Choudhry NK, 2010, HEALTH AFFAIR, V29, P1995, DOI 10.1377/hlthaff.2010.0336; Choudhry NK, 2009, AM J MANAG CARE, V15, P457; Choudhry NK, 2008, PHARMACOEPIDEM DR S, V17, P1189, DOI 10.1002/pds.1671; Fendrick AM, 2001, AM J MANAG CARE, V7, P861; Fonarow GC, 2009, AM HEART J, V157, p185e2; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Jackevicius CA, 2008, CIRCULATION, V117, P1028, DOI 10.1161/CIRCULATIONAHA.107.706820; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Lee TH, 2007, NEW ENGL J MED, V357, P1175, DOI 10.1056/NEJMp078102; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Mahoney JJ, 2005, AM J MANAG CARE, V11, pS170; Newby LK, 2006, CIRCULATION, V113, P203, DOI 10.1161/CIRCULATIONAHA.105.505636; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Owens DK, 2011, ANN INTERN MED, V154, P174, DOI 10.7326/0003-4819-154-3-201102010-00007; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; Piette JD, 2004, MED CARE, V42, P102, DOI 10.1097/01.mlr.0000108742.26446.17; Rector TS, 2004, HEALTH AFFAIR, V23, P213, DOI 10.1377/hlthaff.23.4.213; Rogers AM, 2007, AM HEART J, V154, P461, DOI 10.1016/j.ahj.2007.05.003; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Wei JL, 1989, J AM STAT ASSOC, V84, P1065; Wijeysundera HC, 2010, JAMA-J AM MED ASSOC, V303, P1841, DOI 10.1001/jama.2010.580	30	496	504	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	2011	365	22					2088	2097		10.1056/NEJMsa1107913	http://dx.doi.org/10.1056/NEJMsa1107913			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854MO	22080794				2022-12-28	WOS:000297499000009
J	Benazzi, S; Douka, K; Fornai, C; Bauer, CC; Kullmer, O; Svoboda, J; Pap, I; Mallegni, F; Bayle, P; Coquerelle, M; Condemi, S; Ronchitelli, A; Harvati, K; Weber, GW				Benazzi, Stefano; Douka, Katerina; Fornai, Cinzia; Bauer, Catherine C.; Kullmer, Ottmar; Svoboda, Jiri; Pap, Ildiko; Mallegni, Francesco; Bayle, Priscilla; Coquerelle, Michael; Condemi, Silvana; Ronchitelli, Annamaria; Harvati, Katerina; Weber, Gerhard W.			Early dispersal of modern humans in Europe and implications for Neanderthal behaviour	NATURE			English	Article							ENAMEL THICKNESS; REMAINS; GROTTE; MIDDLE; RENNE; AGE	The appearance of anatomically modern humans in Europe and the nature of the transition from the Middle to Upper Palaeolithic are matters of intense debate. Most researchers accept that before the arrival of anatomically modern humans, Neanderthals had adopted several 'transitional' technocomplexes. Two of these, the Uluzzian of southern Europe and the Chatelperronian of western Europe, are key to current interpretations regarding the timing of arrival of anatomically modern humans in the region and their potential interaction with Neanderthal populations. They are also central to current debates regarding the cognitive abilities of Neanderthals and the reasons behind their extinction(1-6). However, the actual fossil evidence associated with these assemblages is scant and fragmentary(7-10), and recent work has questioned the attribution of the Chatelperronian to Neanderthals on the basis of taphonomic mixing and lithic analysis(11,12). Here we reanalyse the deciduous molars from the Grotta del Cavallo ( southern Italy), associated with the Uluzzian and originally classified as Neanderthal(13,14). Using two independent morphometric methods based on microtomographic data, we show that the Cavallo specimens can be attributed to anatomically modern humans. The secure context of the teeth provides crucial evidence that the makers of the Uluzzian technocomplex were therefore not Neanderthals. In addition, new chronometric data for the Uluzzian layers of Grotta del Cavallo obtained from associated shell beads and included within a Bayesian age model show that the teeth must date to similar to 45,000-43,000 calendar years before present. The Cavallo human remains are therefore the oldest known European anatomically modern humans, confirming a rapid dispersal of modern humans across the continent before the Aurignacian and the disappearance of Neanderthals.	[Benazzi, Stefano; Fornai, Cinzia; Weber, Gerhard W.] Univ Vienna, Dept Anthropol, A-1090 Vienna, Austria; [Douka, Katerina] Univ Oxford, Res Lab Archaeol Hist Art, Oxford Radiocarbon Accelerator Unit, Oxford OX1 3QY, England; [Bauer, Catherine C.; Harvati, Katerina] Univ Tubingen, Dept Early Prehist & Quaternary Ecol, D-72070 Tubingen, Germany; [Kullmer, Ottmar] Senckenberg Res Inst Frankfurt, Dept Paleoanthropol & Messel Res, D-60325 Frankfurt, Germany; [Svoboda, Jiri] Acad Sci Czech Republ, Inst Archaeol, Brno 61200, Czech Republic; [Svoboda, Jiri] Masaryk Univ, Fac Sci, Dept Anthropol, Brno 60300, Czech Republic; [Pap, Ildiko] Hungarian Nat Hist Museum, Dept Anthropol, H-1083 Budapest, Hungary; [Mallegni, Francesco] Univ Pisa, Dept Biol, I-56126 Pisa, Italy; [Bayle, Priscilla] Univ Bordeaux 1, UMR PACEA 5199, F-33405 Talence, France; [Coquerelle, Michael] CSIC, Museo Nacl Ciencias Nat, Dept Paleobiol, Paleoanthropol Grp, E-28006 Madrid, Spain; [Condemi, Silvana] Fac Med Marseille, CNRS, Sect Nord, UMR 6578,EFS,Lab Anthropol Bioculturelle, F-13344 Marseille 15, France; [Ronchitelli, Annamaria] Univ Siena, Dept Environm Sci G Sarfatti, UR Prehist Ecol, I-53100 Siena, Italy; [Harvati, Katerina] Univ Tubingen, Senckenberg Ctr Human Evolut & Paleoecol, D-72070 Tubingen, Germany	University of Vienna; University of Oxford; Eberhard Karls University of Tubingen; Senckenberg Gesellschaft fur Naturforschung (SGN); Czech Academy of Sciences; Institute of Archaeology of the Czech Academy of Sciences - Brno; Masaryk University Brno; University of Pisa; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite de Bordeaux; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Siena; Eberhard Karls University of Tubingen; Senckenberg Gesellschaft fur Naturforschung (SGN)	Benazzi, S (corresponding author), Univ Vienna, Dept Anthropol, Althanstr 14, A-1090 Vienna, Austria.	stefano.benazzi@univie.ac.at	Fornai, Cinzia/AAB-6451-2020; Condemi, Silvana/ABE-2701-2021; Harvati, Katerina/A-5197-2008; Benazzi, Stefano/AAH-3923-2020; Svoboda, Jiří/H-4621-2014; Weber, Gerhard W/F-2583-2010; Douka, Katerina/L-3287-2014	Condemi, Silvana/0000-0002-6516-0879; Svoboda, Jiří/0000-0003-4256-9708; Weber, Gerhard W/0000-0002-8542-6259; Douka, Katerina/0000-0002-0558-0011; Kullmer, Ottmar/0000-0002-5929-8070; Coquerelle, Michael/0000-0001-5183-3297; Fornai, Cinzia/0000-0002-0911-0164; Benazzi, Stefano/0000-0003-4305-6920	Natural Environment Research Council (NERC) NRCF; Leverhulme Trust; NSF [01-120]; A.E.R.S. Dental Medicine Organisations GmbH [FA547013]; Fondation Fyssen; DFG [INST 37/706-1 FUGG]; NERC [NE/D014077/1]; Natural Environment Research Council [NE/D014077/1] Funding Source: researchfish	Natural Environment Research Council (NERC) NRCF(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Leverhulme Trust(Leverhulme Trust); NSF(National Science Foundation (NSF)); A.E.R.S. Dental Medicine Organisations GmbH; Fondation Fyssen; DFG(German Research Foundation (DFG)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank the Soprintendenza per i Beni Archeologici della Puglia which facilitated the excavation of Grotta del Cavallo over the years. We also thank M. A. Gorgoglionewho supported and helped in the collection of samples for <SUP>14</SUP>C dating and encouraged the collaboration with the University of Siena for the study of the archaeological remains. P. Boscato, H. Klempererova, F. Ranaldo and S. Ricci have all helped in aspects of the research and are especially thanked. We are grateful to G. Gruppioni for providing the Italian modern human sample used in this work. We thank M. Francken, B. Trautmann, I. Trautmann, H. Scherf, M. Dockner and R. Ginner for technical assistance. We thank F. L. Bookstein for suggestions on statistics. Access to the fossil specimens was made possible by the Croatian National History Museum, the French Musee National de Prehistoire, the French Museum National d'Histoire Naturelle, Paleoanthropology, Eberhard Karls Universitat Tubingen and the NESPOS Database 2011 (https://www.nespos.org/display/openspace/Home). We acknowledge the Centre de Microtomographie (Universite de Poitiers), the Vienna micro-CT Laboratory (University of Vienna), VISCOM AG Hannover, the Paleoanthropology High Resolution Computing Tomography Laboratory ( Eberhard Karls Universitat Tubingen), the European Synchrotron Radiation Facility beamline ID17, the AST-RX platform ( French Museum National d'Histoire Naturelle) and the Oxford Radiocarbon Accelerator Unit (ORAU). The authors would like to thank T. Higham and R. E. M. Hedges for their input in the radiocarbon dating part of the project, for important comments and proofreading this manuscript. The radiocarbon dating was funded by the Natural Environment Research Council (NERC) NRCF programme. K. D. is part of the Ancient Human Occupation of Britain project, funded by the Leverhulme Trust. This work was supported by the NSF 01-120 Hominid Grant 2007, A.E.R.S. Dental Medicine Organisations GmbH FA547013, the Fondation Fyssen, the DFG INST 37/706-1 FUGG and the NERC Grant (NE/D014077/1).	Bailey SE, 2006, J HUM EVOL, V50, P485, DOI 10.1016/j.jhevol.2005.11.008; Bar-Yosef O, 2010, J HUM EVOL, V59, P586, DOI 10.1016/j.jhevol.2010.06.009; Benazzi S, 2011, AM J PHYS ANTHROPOL, V144, P342, DOI 10.1002/ajpa.21409; Boscato P, 2012, QUATERN INT, V252, P90, DOI 10.1016/j.quaint.2011.03.028; Churchill SE, 2000, YEARB PHYS ANTHROPOL, V43, P61; d'Errico F, 1998, CURR ANTHROPOL, V39, pS1, DOI 10.1086/204689; d'Errico F, 2012, QUATERN INT, V259, P59, DOI 10.1016/j.quaint.2011.03.039; DICESNOLA AP, 1989, ANTHROPOLOGIE, V93, P783; Gravina B, 2005, NATURE, V438, P51, DOI 10.1038/nature04006; Harvati K, 2003, J HUM EVOL, V45, P465, DOI 10.1016/j.jhevol.2003.09.005; Higham T, 2011, ANTIQUITY, V85, P235, DOI 10.1017/S0003598X00067570; Higham T, 2010, P NATL ACAD SCI USA, V107, P20234, DOI 10.1073/pnas.1007963107; Hublin JJ, 1996, NATURE, V381, P224, DOI 10.1038/381224a0; LEVEQUE F, 1980, CR ACAD SCI D NAT, V291, P187; MARTIN L, 1985, NATURE, V314, P260, DOI 10.1038/314260a0; Mellars P, 2005, EVOL ANTHROPOL, V14, P12, DOI 10.1002/evan.20037; Mellars P, 2007, P NATL ACAD SCI USA, V104, P3657, DOI 10.1073/pnas.0608053104; Messeri P., 1976, ZEPHYRUS, V26-27, P7; Muller UC, 2011, QUATERNARY SCI REV, V30, P273, DOI 10.1016/j.quascirev.2010.11.016; Olejniczak AJ, 2008, J HUM EVOL, V55, P12, DOI 10.1016/j.jhevol.2007.11.004; Palma di Cesnola A, 1967, ANTHROPOLOGIE, V71, P249; Pinhasi R, 2011, P NATL ACAD SCI USA, V108, P8611, DOI 10.1073/pnas.1018938108; Reimer PJ, 2009, RADIOCARBON, V51, P1111, DOI 10.1017/S0033822200034202; Riel-Salvatore J, 2009, SOURCEBOOK OF PALEOLITHIC TRANSITIONS, P377, DOI 10.1007/978-0-387-76487-0_25; ROHLF FJ, 1990, SYST ZOOL, V39, P40, DOI 10.2307/2992207; Ronchitelli A., 2009, LUNGA STORIA NEANDER; SMITH BH, 1984, AM J PHYS ANTHROPOL, V63, P39, DOI 10.1002/ajpa.1330630107; Team RC., 2022, LANG ENV STAT COMP; Zilhao J, 2006, P NATL ACAD SCI USA, V103, P12643, DOI 10.1073/pnas.0605128103; Zilhao J, 2011, VERTEBR PALEOBIOL PA, P331, DOI 10.1007/978-94-007-0492-3_25	30	317	321	2	224	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2011	479	7374					525	U249		10.1038/nature10617	http://dx.doi.org/10.1038/nature10617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	851QI	22048311				2022-12-28	WOS:000297285600050
J	Molyneux, EM; Graham, SM				Molyneux, Elizabeth M.; Graham, Stephen M.			Community management of severe pneumonia in children	LANCET			English	Editorial Material							MORTALITY		[Molyneux, Elizabeth M.] Queen Elizabeth Cent Hosp, Dept Paediat, Coll Med, Blantyre, Malawi; [Graham, Stephen M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia; [Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	University of Malawi; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Molyneux, EM (corresponding author), Queen Elizabeth Cent Hosp, Dept Paediat, Coll Med, POB 360, Blantyre, Malawi.	emmolyneux@gmail.com		Graham, Stephen/0000-0003-3525-2294				BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; *GLOB HLTH TRUST J, 2004, JOINT LEARN IN HLTH; JAVENPARAST S, 2001, J PUBLIC HLTH POLICY, V32, P263; Jeena P, 2006, B WORLD HEALTH ORGAN, V84, P269; Kallander K, 2008, B WORLD HEALTH ORGAN, V86, P332, DOI 10.2471/BLT.07.049353; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; UNICEF W. H. O, 2006, PNEUM FORG KILL CHIL; *VSO, IMPR MAN SUP HLTH SU; WHO, 1991, WHO PROGR CONTR AC R	13	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	2011	378	9805					1762	1764		10.1016/S0140-6736(11)61338-X	http://dx.doi.org/10.1016/S0140-6736(11)61338-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851IS	22078720				2022-12-28	WOS:000297262300008
J	Shatalin, K; Shatalina, E; Mironov, A; Nudler, E				Shatalin, Konstantin; Shatalina, Elena; Mironov, Alexander; Nudler, Evgeny			H2S: A Universal Defense Against Antibiotics in Bacteria	SCIENCE			English	Article							NITRIC-OXIDE; HYDROGEN-PEROXIDE; SULFIDE; DEATH; IRON	Many prokaryotic species generate hydrogen sulfide (H2S) in their natural environments. However, the biochemistry and physiological role of this gas in nonsulfur bacteria remain largely unknown. Here we demonstrate that inactivation of putative cystathionine beta-synthase, cystathionine gamma-lyase, or 3-mercaptopyruvate sulfurtransferase in Bacillus anthracis, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli suppresses H2S production, rendering these pathogens highly sensitive to a multitude of antibiotics. Exogenous H2S suppresses this effect. Moreover, in bacteria that normally produce H2S and nitric oxide, these two gases act synergistically to sustain growth. The mechanism of gas-mediated antibiotic resistance relies on mitigation of oxidative stress imposed by antibiotics.	[Shatalin, Konstantin; Shatalina, Elena; Nudler, Evgeny] NYU, Dept Biochem, New York, NY 10016 USA; [Mironov, Alexander] State Res Inst Genet & Select Ind Microorganisms, Moscow 117545, Russia	New York University; National Research Centre - Kurchatov Institute; Institute of Genetics & Selection of Industrial Microorganisms	Nudler, E (corresponding author), NYU, Dept Biochem, New York, NY 10016 USA.	evgeny.nudler@nyumc.org	Mironov, Alexander/G-8531-2013	Mironov, Alexander/0000-0003-3914-1380; Nudler, Evgeny/0000-0002-8811-3071	NIH; Biogerontology Research Foundation; Dynasty Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007526] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Biogerontology Research Foundation; Dynasty Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank E. Avetissova for technical assistance, S. Mashko for materials, and members of the Nudler laboratory for valuable comments and discussion. This research was supported by the NIH Director's Pioneer Award, Biogerontology Research Foundation, and Dynasty Foundation (E.N.). Provisional patent application has been filed: U. S. Patent No. 61/438,524 "Methods for treating infections by targeting bacterial H<INF>2</INF>S-producing enzymes." by K.S. and E.N.	ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; ASAD NR, 1991, J BACTERIOL, V173, P2562, DOI 10.1128/jb.173.8.2562-2568.1991; Birren BW, 1993, PULSED FIELD GEL ELE, DOI [10.1016/B978-0-12-101290-8.50002-X, DOI 10.1016/B978-0-12-101290-8.50002-X]; Davies BW, 2009, MOL CELL, V36, P845, DOI 10.1016/j.molcel.2009.11.024; Forbes BA., 1998, BAILEY SCOTTS DIAGNO, V10; Gadalla MM, 2010, J NEUROCHEM, V113, P14, DOI 10.1111/j.1471-4159.2010.06580.x; Gusarov I, 2005, P NATL ACAD SCI USA, V102, P13855, DOI 10.1073/pnas.0504307102; Gusarov I, 2008, J BIOL CHEM, V283, P13140, DOI 10.1074/jbc.M710178200; Gusarov I, 2009, SCIENCE, V325, P1380, DOI 10.1126/science.1175439; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Kimura H, 2010, ANTIOXID REDOX SIGN, V12, P1111, DOI 10.1089/ars.2009.2919; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Kohanski MA, 2010, NAT REV MICROBIOL, V8, P423, DOI 10.1038/nrmicro2333; Lim MH, 2006, NAT CHEM BIOL, V2, P375, DOI 10.1038/nchembio794; Lima B, 2010, CIRC RES, V106, P633, DOI 10.1161/CIRCRESAHA.109.207381; Liochev SI, 1999, IUBMB LIFE, V48, P157, DOI 10.1080/152165499307161; Mustafa AK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268re2; Shatalin K, 2008, P NATL ACAD SCI USA, V105, P1009, DOI 10.1073/pnas.0710950105; Wang R, 2010, ANTIOXID REDOX SIGN, V12, P1061, DOI 10.1089/ars.2009.2938	19	455	471	15	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					986	990		10.1126/science.1209855	http://dx.doi.org/10.1126/science.1209855			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096201				2022-12-28	WOS:000297101800058
J	Tripp, TM; Meiring, JD; Prochaska, JX; Willmer, CNA; Howk, JC; Werk, JK; Jenkins, EB; Bowen, DV; Lehner, N; Sembach, KR; Thom, C; Tumlinson, J				Tripp, Todd M.; Meiring, Joseph D.; Prochaska, J. Xavier; Willmer, Christopher N. A.; Howk, J. Christopher; Werk, Jessica K.; Jenkins, Edward B.; Bowen, David V.; Lehner, Nicolas; Sembach, Kenneth R.; Thom, Christopher; Tumlinson, Jason			The Hidden Mass and Large Spatial Extent of a Post-Starburst Galaxy Outflow	SCIENCE			English	Article							ABSORPTION-LINES; GALACTIC WINDS; STAR-FORMATION; HOT GAS; FEEDBACK; SPECTRA; KINEMATICS; ABUNDANCES; EVOLUTION; UNIVERSE	Outflowing winds of multiphase plasma have been proposed to regulate the buildup of galaxies, but key aspects of these outflows have not been probed with observations. By using ultraviolet absorption spectroscopy, we show that "warm-hot" plasma at 10(5.5) kelvin contains 10 to 150 times more mass than the cold gas in a post-starburst galaxy wind. This wind extends to distances > 68 kiloparsecs, and at least some portion of it will escape. Moreover, the kinematical correlation of the cold and warm-hot phases indicates that the warm-hot plasma is related to the interaction of the cold matter with a hotter (unseen) phase at >>10(6) kelvin. Such multiphase winds can remove substantial masses and alter the evolution of post-starburst galaxies.	[Tripp, Todd M.; Meiring, Joseph D.] Univ Massachusetts, Dept Astron, Amherst, MA 01003 USA; [Prochaska, J. Xavier; Werk, Jessica K.] Univ Calif Santa Cruz, Univ Calif Observ, Lick Observ, Santa Cruz, CA 95064 USA; [Willmer, Christopher N. A.] Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; [Howk, J. Christopher; Lehner, Nicolas] Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; [Jenkins, Edward B.; Bowen, David V.] Princeton Univ Observ, Princeton, NJ 08544 USA; [Sembach, Kenneth R.; Thom, Christopher; Tumlinson, Jason] Space Telescope Sci Inst, Baltimore, MD 21218 USA	University of Massachusetts System; University of Massachusetts Amherst; University of California System; University of California Santa Cruz; University of Arizona; University of Notre Dame; Princeton University; Space Telescope Science Institute	Tripp, TM (corresponding author), Univ Massachusetts, Dept Astron, Amherst, MA 01003 USA.	tripp@astro.umass.edu	Howk, Jay/D-2577-2013; Jenkins, Edward/P-5684-2014	Jenkins, Edward/0000-0003-1892-4423; Prochaska, J. Xavier/0000-0002-7738-6875; Howk, J. Christopher/0000-0002-2591-3792; Lehner, Nicolas/0000-0001-9158-0829	NASA through the Space Telescope Science Institute [11741]; NASA [NAS5-26555, NNX08AJ44G]; NSF [AST 95-29098, 00-711098, 05-07483, 08-08133, 00-71048, 05-07428, 08-07630]; Alfred P. Sloan Foundation; U.S. Department of Energy Office of Science; Japanese Monbukagakusho; Max Planck Society	NASA through the Space Telescope Science Institute(Space Telescope Science Institute); NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF)); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); U.S. Department of Energy Office of Science(United States Department of Energy (DOE)); Japanese Monbukagakusho(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Max Planck Society(Max Planck Society)	This study has its basis in observations made with the NASA/European Space Agency Hubble Space Telescope (HST); the MMT, a joint facility operated by the Smithsonian Astrophysical Observatory and the University of Arizona; and the Large Binocular Telescope, an international collaboration among institutions in the United States, Italy, and Germany. Support for HST program number 11741 was provided by NASA through a grant from the Space Telescope Science Institute, which is operated by the Association of Universities for Research in Astronomy, Incorporated, under NASA contract NAS5-26555. Additional support was provided by NASA grant NNX08AJ44G. The DEEP2 survey was supported by NSF grants AST 95-29098, 00-711098, 05-07483, 08-08133, 00-71048, 05-07428, and 08-07630. Funding for the Sloan Digital Sky Survey has been provided by the Alfred P. Sloan Foundation, the Participating Institutions, NASA, NSF, the U.S. Department of Energy Office of Science, the Japanese Monbukagakusho, and the Max Planck Society. We thank C. Churchill for providing the archival Keck data and the referees for review comments that significantly improved this paper. We are also grateful to the Hawaiian people for graciously allowing us to conduct observations from Mauna Kea, a revered place in the culture of Hawaii. The HST data in this paper are available from the Multimission Archive at the Space Telescope Science Institute (MAST) at http://archive.stsci.edu.	Capellupo DM, 2011, MON NOT R ASTRON SOC, V413, P908, DOI 10.1111/j.1365-2966.2010.18185.x; Chen YX, 2010, ASTROPHYS J, V712, P1385, DOI 10.1088/0004-637X/712/2/1385; Ding J, 2003, ASTROPHYS J, V590, P746, DOI 10.1086/375028; Dunn JP, 2010, ASTROPHYS J, V709, P611, DOI 10.1088/0004-637X/709/2/611; Edmonds D, 2011, ASTROPHYS J, V739, DOI 10.1088/0004-637X/739/1/7; Fabian AC, 2008, NATURE, V454, P968, DOI 10.1038/nature07169; Ferland GJ, 1998, PUBL ASTRON SOC PAC, V110, P761, DOI 10.1086/316190; Grimes JP, 2009, ASTROPHYS J SUPPL S, V181, P272, DOI 10.1088/0067-0049/181/1/272; Hamann F, 1999, ANNU REV ASTRON ASTR, V37, P487, DOI 10.1146/annurev.astro.37.1.487; Hamann F, 2011, MON NOT R ASTRON SOC, V410, P1957, DOI 10.1111/j.1365-2966.2010.17575.x; Heckman TM, 2000, ASTROPHYS J SUPPL S, V129, P493, DOI 10.1086/313421; Hopkins PF, 2006, ASTROPHYS J SUPPL S, V163, P1, DOI 10.1086/499298; Keres D, 2009, MON NOT R ASTRON SOC, V396, P2332, DOI 10.1111/j.1365-2966.2009.14924.x; Kriss GA, 2011, ASTRON ASTROPHYS, V534, DOI 10.1051/0004-6361/201117123; Martin CL, 2006, ASTROPHYS J, V647, P222, DOI 10.1086/504886; Moe M, 2009, ASTROPHYS J, V706, P525, DOI 10.1088/0004-637X/706/1/525; Narayanan A, 2011, ASTROPHYS J, V730, DOI 10.1088/0004-637X/730/1/15; Oppenheimer BD, 2010, MON NOT R ASTRON SOC, V406, P2325, DOI 10.1111/j.1365-2966.2010.16872.x; Rubin KHR, 2010, ASTROPHYS J, V719, P1503, DOI 10.1088/0004-637X/719/2/1503; Savage BD, 2005, ASTROPHYS J, V626, P776, DOI 10.1086/429985; SAVAGE BD, 1991, ASTROPHYS J, V379, P245, DOI 10.1086/170498; Snyder GF, 2011, ASTROPHYS J, V741, DOI 10.1088/0004-637X/741/2/77; Tremonti C, 2009, ASTR SOC P, V419, P369; Tremonti CA, 2007, ASTROPHYS J, V663, pL77, DOI 10.1086/520083; Tripp TM, 2008, ASTROPHYS J SUPPL S, V177, P39, DOI 10.1086/587486; Tumlinson J, 2011, SCIENCE, V334, P948, DOI 10.1126/science.1209840; Veilleux S, 2005, ANNU REV ASTRON ASTR, V43, P769, DOI 10.1146/annurev.astro.43.072103.150610; VERNER DA, 1994, ASTROPHYS J, V430, P186, DOI 10.1086/174392; Willmer CNA, 2006, ASTROPHYS J, V647, P853, DOI 10.1086/505455; Zabludoff AI, 1996, ASTROPHYS J, V466, P104, DOI 10.1086/177495	34	130	130	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					952	955		10.1126/science.1209850	http://dx.doi.org/10.1126/science.1209850			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096192	Green Submitted			2022-12-28	WOS:000297101800048
J	Dalvit, DAR				Dalvit, Diego A. R.			QUANTUM PHYSICS Shaking photons out of the vacuum	NATURE			English	Editorial Material							RADIATION		Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Dalvit, DAR (corresponding author), Los Alamos Natl Lab, Div Theoret, MS B213, Los Alamos, NM 87545 USA.	dalvit@lanl.gov						Braggio C, 2005, EUROPHYS LETT, V70, P754, DOI 10.1209/epl/i2005-10048-8; CASIMIR HBG, 1948, KON NED AKAD WET, V51, P793; FULLING SA, 1976, P ROY SOC LOND A MAT, V348, P393, DOI 10.1098/rspa.1976.0045; Johansson JR, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.147003; MOORE GT, 1970, J MATH PHYS, V11, P2679, DOI 10.1063/1.1665432; Wilson CM, 2011, NATURE, V479, P376, DOI 10.1038/nature10561; YABLONOVITCH E, 1989, PHYS REV LETT, V62, P1742, DOI 10.1103/PhysRevLett.62.1742	7	4	4	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					303	304		10.1038/479303a	http://dx.doi.org/10.1038/479303a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094685				2022-12-28	WOS:000297059700026
J	Cordenonsi, M; Zanconato, F; Azzolin, L; Forcato, M; Rosato, A; Frasson, C; Inui, M; Montagner, M; Parenti, AR; Poletti, A; Daidone, MG; Dupont, S; Basso, G; Bicciato, S; Piccolo, S				Cordenonsi, Michelangelo; Zanconato, Francesca; Azzolin, Luca; Forcato, Mattia; Rosato, Antonio; Frasson, Chiara; Inui, Masafumi; Montagner, Marco; Parenti, Anna R.; Poletti, Alessandro; Daidone, Maria Grazia; Dupont, Sirio; Basso, Giuseppe; Bicciato, Silvio; Piccolo, Stefano			The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells	CELL			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; IN-VITRO PROPAGATION; TUMORIGENESIS; POLARITY; METASTASIS; PATHWAY; TUMORS	Cancer stem cells (CSCs) are proposed to drive tumor initiation and progression. Yet, our understanding of the cellular and molecular mechanisms that underlie CSC properties is limited. Here we show that the activity of TAZ, a transducer of the Hippo pathway, is required to sustain self-renewal and tumor-initiation capacities in breast CSCs. TAZ protein levels and activity are elevated in prospective CSCs and in poorly differentiated human tumors and have prognostic value. Gain of TAZ endows self-renewal capacity to non-CSCs. In epithelial cells, TAZ forms a complex with the cell-polarity determinant Scribble, and loss of Scribble- or induction of the epithelial-mesenchymal transition (EMT)disrupts the inhibitory association of TAZ with the core Hippo kinases MST and LATS. This study links the CSC concept to the Hippo pathway in breast cancer and reveals a mechanistic basis of the control of Hippo kinases by cell polarity.	[Cordenonsi, Michelangelo; Zanconato, Francesca; Azzolin, Luca; Inui, Masafumi; Montagner, Marco; Dupont, Sirio; Piccolo, Stefano] Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, I-35126 Padua, Italy; [Forcato, Mattia; Bicciato, Silvio] Univ Modena & Reggio Emilia, Dept Biomed Sci, Ctr Genome Res, I-41100 Modena, Italy; [Rosato, Antonio] Univ Padua, Dept Oncol & Surg Sci, I-35126 Padua, Italy; [Rosato, Antonio] Ist Oncol Veneto IOV, I-35126 Padua, Italy; [Frasson, Chiara; Basso, Giuseppe] Univ Padua, Dept Pediat, I-35128 Padua, Italy; [Parenti, Anna R.] Univ Padua, Sect Pathol, Dept Med Diagnost Sci & Special Therapies, I-35126 Padua, Italy; [Poletti, Alessandro] Hosp San Bassiano, Div Anat Pathol, I-36061 Bassano Del Grappa, Italy; [Daidone, Maria Grazia] Ist Nazl Tumori, Fdn IRCCS, I-20133 Milan, Italy	University of Padua; Universita di Modena e Reggio Emilia; IRCCS Istituto Oncologico Veneto (IOV); University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua; ULSS 7 Pedemontana; Ospedale San Bassiano; Fondazione IRCCS Istituto Nazionale Tumori Milan	Cordenonsi, M (corresponding author), Univ Padua, Sch Med, Dept Histol Microbiol & Med Biotechnol, Viale Colombo 3, I-35126 Padua, Italy.	michelangelo.cordenonsi@unipd.it; piccolo@bio.unipd.it	Daidone, Maria Grazia/E-9232-2017; Dupont, Sirio/AAP-8133-2021; Azzolin, Luca/K-8012-2016; Montagner, Marco/AAY-3236-2020; Rosato, Antonio/E-8626-2010; Bicciato, Silvio/C-9825-2009; Forcato, Mattia/B-7733-2015; Inui, Masafumi/GWZ-2521-2022; Cordenonsi, Michelangelo/K-7692-2016; BICCIATO, Silvio/J-4466-2019	Daidone, Maria Grazia/0000-0002-4786-1321; Azzolin, Luca/0000-0002-2425-6153; Montagner, Marco/0000-0003-3080-2138; Rosato, Antonio/0000-0002-5263-8386; Bicciato, Silvio/0000-0002-1944-7078; Forcato, Mattia/0000-0002-7383-6576; Inui, Masafumi/0000-0003-4720-007X; Cordenonsi, Michelangelo/0000-0002-8253-5724; BICCIATO, Silvio/0000-0002-1944-7078; BASSO, GIUSEPPE/0000-0002-2634-9302; PICCOLO, STEFANO/0000-0002-2037-0004; Dupont, Sirio/0000-0002-6869-1966	Italian Welfare Ministry; AIRC (Italian Association for Cancer Research)-MFAG; AIRC; Fondazione Citta della Speranza; MIUR; P.R.I.N.; AIRC-PI; University of Padua; Italian Institute of Technology; Comitato Promotore Telethon	Italian Welfare Ministry; AIRC (Italian Association for Cancer Research)-MFAG(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Citta della Speranza; MIUR(Ministry of Education, Universities and Research (MIUR)); P.R.I.N.(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC-PI(Fondazione AIRC per la ricerca sul cancro); University of Padua; Italian Institute of Technology(Istituto Italiano di Tecnologia - IIT); Comitato Promotore Telethon(Fondazione Telethon)	We thank O. Wessely for comments; S. Santner and R. A. Weinberg for cells and reagents; Vincenza Guzzardo, Vera Cappelletti, and Genesio Leo for help with clinical samples and immunohistochemistry; and L. Naldini for pMD2-VSVG vector. This work is supported by a "Young Italian Researchers'' grant of the Italian Welfare Ministry and AIRC (Italian Association for Cancer Research)-MFAG to M. C.; by AIRC interregional Pediatric Project Grant, Fondazione Citta della Speranza Grant, and MIUR and P.R.I.N. grants to G. B.; by AIRC Special Program Molecular Clinical Oncology "5 per mille'' grant to S.B.; and by AIRC-PI, AIRC Special Program Molecular Clinical Oncology "5 per mille'', University of Padua Strategic-grant, Seed-grant from Italian Institute of Technology, and Comitato Promotore Telethon grants to S.P.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang Y, 2009, CANCER RES, V69, P3795, DOI 10.1158/0008-5472.CAN-08-4596	33	894	917	1	89	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					759	772		10.1016/j.cell.2011.09.048	http://dx.doi.org/10.1016/j.cell.2011.09.048			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078877	Bronze			2022-12-28	WOS:000296902300011
J	Kane, LA; Youle, RJ				Kane, Lesley A.; Youle, Richard J.			PINK1 and Parkin Flag Miro to Direct Mitochondrial Traffic	CELL			English	Editorial Material							GTPASE	The Parkinson's disease proteins PINK1 and Parkin are proposed guardians of mitochondrial fidelity, targeting damaged mitochondria for degradation by mitophagy. In this issue of Cell, Wang et al. (2011) now show that PINK1 and Parkin also regulate mitochondrial trafficking and quarantine damaged mitochondria by severing their connection to the microtubule network.	[Kane, Lesley A.; Youle, Richard J.] NINDS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), NINDS, NIH, Bethesda, MD 20892 USA.	youle@helix.nih.gov						Deas E, 2011, BBA-MOL CELL RES, V1813, P623, DOI 10.1016/j.bbamcr.2010.08.007; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Frederick RL, 2004, J CELL BIOL, V167, P87, DOI 10.1083/jcb.200405100; Guo XF, 2005, NEURON, V47, P379, DOI 10.1016/j.neuron.2005.06.027; Kawajiri S, 2011, TRENDS PHARMACOL SCI, V32, P573, DOI 10.1016/j.tips.2011.06.001; Kornmann B, 2011, P NATL ACAD SCI USA, V108, P14151, DOI 10.1073/pnas.1111314108; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Weihofen A, 2009, BIOCHEMISTRY-US, V48, P2045, DOI 10.1021/bi8019178	9	26	26	1	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					721	723		10.1016/j.cell.2011.10.028	http://dx.doi.org/10.1016/j.cell.2011.10.028			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078873	Bronze			2022-12-28	WOS:000296902300007
J	Lee, E; Kamlet, AS; Powers, DC; Neumann, CN; Boursalian, GB; Furuya, T; Choi, DC; Hooker, JM; Ritter, T				Lee, Eunsung; Kamlet, Adam S.; Powers, David C.; Neumann, Constanze N.; Boursalian, Gregory B.; Furuya, Takeru; Choi, Daniel C.; Hooker, Jacob M.; Ritter, Tobias			A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging	SCIENCE			English	Article							REDUCTIVE ELIMINATION; RADIOSYNTHESIS; F-18	The unnatural isotope fluorine-18 (F-18) is used as a positron emitter in molecular imaging. Currently, many potentially useful F-18-labeled probe molecules are inaccessible for imaging because no fluorination chemistry is available to make them. The 110-minute half-life of F-18 requires rapid syntheses for which [F-18]fluoride is the preferred source of fluorine because of its practical access and suitable isotope enrichment. However, conventional [F-18]fluoride chemistry has been limited to nucleophilic fluorination reactions. We report the development of a palladium-based electrophilic fluorination reagent derived from fluoride and its application to the synthesis of aromatic F-18-labeled molecules via late-stage fluorination. Late-stage fluorination enables the synthesis of conventionally unavailable positron emission tomography (PET) tracers for anticipated applications in pharmaceutical development as well as preclinical and clinical PET imaging.	[Hooker, Jacob M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; [Lee, Eunsung; Kamlet, Adam S.; Powers, David C.; Neumann, Constanze N.; Boursalian, Gregory B.; Furuya, Takeru; Choi, Daniel C.; Ritter, Tobias] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Hooker, Jacob M.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Hooker, Jacob M.; Ritter, Tobias] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital	Hooker, JM (corresponding author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.	hooker@nmr.mgh.harvard.edu; ritter@chemistry.harvard.edu	Ritter, Tobias/AAJ-8703-2021; Powers, David/J-8203-2015; Ritter, Tobias/A-6244-2013; Neumann, Constanze/AAL-3918-2020; Furuya, Takeru/A-6622-2012; Lee, Eunsung/F-5308-2013; Hooker, Jacob M/P-5716-2018; Boursalian, Gregory/M-7729-2016	Powers, David/0000-0003-3717-2001; Ritter, Tobias/0000-0002-5478-0036; Neumann, Constanze/0000-0003-1004-1140; Lee, Eunsung/0000-0002-1507-098X; Hooker, Jacob M/0000-0002-9394-7708; Boursalian, Gregory/0000-0002-6644-0987; Choi, Daniel/0000-0003-3406-9113	National Institute of General Medical Sciences [GM088237]; National Institute of Biomedical Imaging and Bioengineering [EB013042]; National Center for Research Resources [1S10RR017208-01A1]; National Institute on Drug Abuse [5P30DA028800-02]; Richard and Susan Smith Family Foundation; Massachusetts Life Science Center; Harvard Catalyst; NSF [DGE0644491]; Harvard Accelerator Fund; Sloan Research Fellowship; Eli Lilly and Co.; AstraZeneca; Camille Dreyfus; Amgen; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022976, S10RR026666, S10RR017208, S10RR029495, S10RR023385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB013042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA028800] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Richard and Susan Smith Family Foundation; Massachusetts Life Science Center; Harvard Catalyst; NSF(National Science Foundation (NSF)); Harvard Accelerator Fund; Sloan Research Fellowship(Alfred P. Sloan Foundation); Eli Lilly and Co.(Eli Lilly); AstraZeneca(AstraZeneca); Camille Dreyfus; Amgen(Amgen); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by National Institute of General Medical Sciences grant GM088237, National Institute of Biomedical Imaging and Bioengineering grant EB013042, National Center for Research Resources grant 1S10RR017208-01A1, National Institute on Drug Abuse grant 5P30DA028800-02, the Richard and Susan Smith Family Foundation, the Massachusetts Life Science Center, the Harvard Catalyst, NSF Graduate Research Fellowship Program grant DGE0644491, and the Harvard Accelerator Fund. T.R. was also supported by a Sloan Research Fellowship, grants from Eli Lilly and Co. and AstraZeneca, a Camille Dreyfus Teacher-Scholar Award, and an Amgen Young Investigators Award. We thank S.-L. Zheng for x-ray crystallographic analysis. DFT computation was performed using the computer facilities at the Odyssey cluster at Harvard University. Metrical parameters for the crystal structures of compounds 1, 2, 3, 8, and S10 are available free of charge from the Cambridge Crystallographic Data Centre under reference nos. CCDC 829427, 829428, 840744, 829429, and 839058, respectively. A patent application has been filed through Harvard on methods and reagents presented in this manuscript.	Ametamey SM, 2008, CHEM REV, V108, P1501, DOI 10.1021/cr0782426; Bergman J, 1997, NUCL MED BIOL, V24, P677, DOI 10.1016/S0969-8051(97)00078-4; Brauner B. Z., 1894, Z ANORG CHEM, V7, P1; Chin FT, 2008, MOL IMAGING BIOL, V10, P82, DOI 10.1007/s11307-007-0122-3; CHRISTE KO, 1986, INORG CHEM, V25, P3721, DOI 10.1021/ic00241a001; Cotton F. A., 1990, CHEM APPL GROUP THEO; Fowler JS, 1997, ACCOUNTS CHEM RES, V30, P181, DOI 10.1021/ar960068c; Furuya T, 2008, J AM CHEM SOC, V130, P10060, DOI 10.1021/ja803187x; Furuya T, 2011, NATURE, V473, P470, DOI 10.1038/nature10108; Furuya T, 2008, ANGEW CHEM INT EDIT, V47, P5993, DOI 10.1002/anie.200802164; Furuya T, 2010, J AM CHEM SOC, V132, P3793, DOI 10.1021/ja909371t; HAIM A, 1983, PROG INORG CHEM, V30, P273, DOI 10.1002/9780470166314.ch6; Herrmann K, 2010, J NUCL MED, V51, DOI 10.2967/jnumed.108.059584; Hollingworth C, 2011, ANGEW CHEM INT EDIT, V50, P2613, DOI 10.1002/anie.201007307; Katcher MH, 2010, J AM CHEM SOC, V132, P17402, DOI 10.1021/ja109120n; Kozikowski AP, 2010, CHEMMEDCHEM, V5, P1221, DOI 10.1002/cmdc.201000186; Miller PW, 2008, ANGEW CHEM INT EDIT, V47, P8998, DOI 10.1002/anie.200800222; Noel T, 2011, ANGEW CHEM INT EDIT, V50, P8900, DOI 10.1002/anie.201104652; O'Hagan D, 2008, CHEM SOC REV, V37, P308, DOI 10.1039/b711844a; Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226; PIKE VW, 1995, J CHEM SOC CHEM COMM, P2215, DOI 10.1039/C39950002215; Pomel V, 2006, J MED CHEM, V49, P3857, DOI 10.1021/jm0601598; Stahl SS, 1998, ANGEW CHEM INT EDIT, V37, P2181, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2180::AID-ANIE2180>3.0.CO;2-A; Sun H, 2006, ANGEW CHEM INT EDIT, V45, P2720, DOI 10.1002/anie.200504555; TAUBE H, 1954, J AM CHEM SOC, V76, P2103, DOI 10.1021/ja01637a020; Teare H, 2010, ANGEW CHEM INT EDIT, V49, P6821, DOI 10.1002/anie.201002310; Toyohara J, 2009, ANN NUCL MED, V23, P301, DOI 10.1007/s12149-009-0240-x; Watson DA, 2009, SCIENCE, V325, P1661, DOI 10.1126/science.1178239; Young S., 1881, J CHEM SOC, V39, P489	29	311	323	5	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					639	642		10.1126/science.1212625	http://dx.doi.org/10.1126/science.1212625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053044	Green Accepted, Green Submitted			2022-12-28	WOS:000296494700046
J	Ehlmann, BL; Mustard, JF; Murchie, SL; Bibring, JP; Meunier, A; Fraeman, AA; Langevin, Y				Ehlmann, Bethany L.; Mustard, John F.; Murchie, Scott L.; Bibring, Jean-Pierre; Meunier, Alain; Fraeman, Abigail A.; Langevin, Yves			Subsurface water and clay mineral formation during the early history of Mars	NATURE			English	Review							HYDROTHERMAL SYSTEMS; VALLEY NETWORK; MAWRTH VALLIS; IMPACT; ROCKS; PHYLLOSILICATES; EVOLUTION; CONSTRAINTS; DIVERSITY; STABILITY	Clay minerals, recently discovered to be widespread in Mars's Noachian terrains, indicate long-duration interaction between water and rock over 3.7 billion years ago. Analysis of how they formed should indicate what environmental conditions prevailed on early Mars. If clays formed near the surface by weathering, as is common on Earth, their presence would indicate past surface conditions warmer and wetter than at present. However, available data instead indicate substantial Martian clay formation by hydrothermal groundwater circulation and a Noachian rock record dominated by evidence of subsurface waters. Cold, arid conditions with only transient surface water may have characterized Mars's surface for over 4 billion years, since the early-Noachian period, and the longest-duration aqueous, potentially habitable environments may have been in the subsurface.	[Ehlmann, Bethany L.; Bibring, Jean-Pierre; Langevin, Yves] Univ Paris 11, Inst Astrophys Spatiale, F-91405 Orsay, France; [Mustard, John F.] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Murchie, Scott L.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; [Meunier, Alain] Univ Poitiers, HydrASA, F-86022 Poitiers, France; [Fraeman, Abigail A.] Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Brown University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Universite de Poitiers; Washington University (WUSTL)	Ehlmann, BL (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	ehlmann@caltech.edu	Murchie, Scott L/E-8030-2015	Murchie, Scott L/0000-0002-1616-8751; Fraeman, Abigail/0000-0003-4017-5158				Abramov O, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002453; Abramov O, 2009, NATURE, V459, P419, DOI 10.1038/nature08015; Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; ALLEN CC, 1982, GEOPHYS RES LETT, V9, P1013, DOI 10.1029/GL009i009p01013; Altheide TS, 2010, GEOCHIM COSMOCHIM AC, V74, P6232, DOI 10.1016/j.gca.2010.08.005; Andrews-Hanna JC, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003485; [Anonymous], [No title captured]; Baldridge AM, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040069; Barnhart CJ, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2008JE003122; Bibring JP, 2006, SCIENCE, V312, P400, DOI 10.1126/science.1122659; Bishop JL, 2008, SCIENCE, V321, P830, DOI 10.1126/science.1159699; Bridges JC, 2001, SPACE SCI REV, V96, P365, DOI 10.1023/A:1011965826553; Buczkowski D., 2010, 41 LUN PLAN SCI C; Buczkowski DL, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003508; CANN JR, 1966, PHILOS TR R SOC S-A, V259, P198, DOI 10.1098/rsta.1966.0007; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; Carter J, 2010, SCIENCE, V328, P1682, DOI 10.1126/science.1189013; Chevrier V, 2007, NATURE, V448, P60, DOI 10.1038/nature05961; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; Dobrea EZN, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003351; EBERL DD, 1984, PHILOS T R SOC A, V311, P241, DOI 10.1098/rsta.1984.0026; Ehlmann BL, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL042596; Ehlmann B. L., 2011, ANALOGUE SITES MARS; Ehlmann BL, 2011, CLAY CLAY MINER, V59, P359, DOI 10.1346/CCMN.2011.0590402; Ehlmann BL, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2009JE003339; Ehlmann BL, 2008, SCIENCE, V322, P1828, DOI 10.1126/science.1164759; Fairen AG, 2010, P NATL ACAD SCI USA, V107, P12095, DOI 10.1073/pnas.1002889107; Fairen AG, 2009, NATURE, V459, P401, DOI 10.1038/nature07978; Fassett CI, 2008, ICARUS, V195, P61, DOI 10.1016/j.icarus.2007.12.009; Fraeman A. A., 2009, 40 LUN PLAN SCI C; Franzson H, 2008, J VOLCANOL GEOTH RES, V173, P217, DOI 10.1016/j.jvolgeores.2008.01.027; Frey H, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL033515; Frey M., 1999, LOW GRADE METAMORPHI; Gislason SR, 1996, AM J SCI, V296, P837, DOI 10.2475/ajs.296.8.837; Glotch TD, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044557; Grant JA, 2011, PLANET SPACE SCI, V59, P1114, DOI 10.1016/j.pss.2010.06.016; Griffith LL, 1997, J GEOPHYS RES-PLANET, V102, P9135, DOI 10.1029/96JE02939; GUGGENHEIM S, 1995, CLAY CLAY MINER, V43, P255, DOI 10.1346/CCMN.1995.0430213; Gulick VC, 1998, J GEOPHYS RES-PLANET, V103, P19365, DOI 10.1029/98JE01321; Haberle R., 1998, J GEOPHYS RES, V103, pE12; Haberle RM, 2001, J GEOPHYS RES-PLANET, V106, P23317, DOI 10.1029/2000JE001360; Halevy I, 2007, SCIENCE, V318, P1903, DOI 10.1126/science.1147039; HARDER H, 1976, CHEM GEOL, V18, P169, DOI 10.1016/0009-2541(76)90001-2; Harrison KP, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001616; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; Howard AD, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002459; Hughes A. C. G., 2011, 42 LUN PLAN SCI C; Hurowitz JA, 2007, EARTH PLANET SC LETT, V260, P432, DOI 10.1016/j.epsl.2007.05.043; Hurowitz JA, 2010, NAT GEOSCI, V3, P323, DOI 10.1038/NGEO831; Irwin RP, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002460; Johnson SS, 2008, J GEOPHYS RES-PLANET, V113, DOI 10.1029/2007JE002962; Kraft MD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018848; Kump LR, 2000, ANNU REV EARTH PL SC, V28, P611, DOI 10.1146/annurev.earth.28.1.611; Loizeau D., 2008, THESIS U PARIS SUD 1, P165; Marzo GA, 2010, ICARUS, V208, P667, DOI 10.1016/j.icarus.2010.03.013; McKeown NK, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2008JE003301; Melosh H.J, 1989, OXFORD MONOGRAPHS GE; Merriman RJ, 2005, EUR J MINERAL, V17, P7, DOI 10.1127/0935-1221/2005/0017-0007; Meunier A., 2005, CLAYS            SPR; Meunier A, 2010, ORIGINS LIFE EVOL B, V40, P253, DOI 10.1007/s11084-010-9205-2; Michalski JR, 2010, NAT GEOSCI, V3, P751, DOI [10.1038/ngeo971, 10.1038/NGEO971]; Michalski JR, 2010, ASTROBIOLOGY, V10, P687, DOI 10.1089/ast.2010.0491; Milliken RE, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL041870; Milliken RE, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038558; Milliken RE, 2010, PHILOS MAG, V90, P2293, DOI 10.1080/14786430903575132; Murchie SL, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2009JE003342; Mustard JF, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2009JE003349; Mustard J. F., 2011, 42 LUN PLAN SCI C; Mustard JF, 2008, NATURE, V454, P305, DOI 10.1038/nature07097; NESBITT HW, 1992, AM J SCI, V292, P740, DOI 10.2475/ajs.292.10.740; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; Nimmo F, 2005, ANNU REV EARTH PL SC, V33, P133, DOI 10.1146/annurev.earth.33.092203.122637; Osterloo MM, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2010JE003613; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Parmentier EM, 2007, J GEOPHYS RES-PLANET, V112, DOI 10.1029/2005JE002626; Phillips RJ, 2001, SCIENCE, V291, P2587, DOI 10.1126/science.1058701; Phillips RJ, 2011, SCIENCE, V332, P838, DOI 10.1126/science.1203091; Poulet F, 2008, ASTRON ASTROPHYS, V487, pL41, DOI 10.1051/0004-6361:200810150; Poulet F, 2005, NATURE, V438, P623, DOI 10.1038/nature04274; Rathbun JA, 2002, ICARUS, V157, P362, DOI 10.1006/icar.2002.6838; Reysenbach AL, 2002, SCIENCE, V296, P1077, DOI 10.1126/science.1072483; Roach LH, 2010, ICARUS, V206, P253, DOI 10.1016/j.icarus.2009.09.003; Rogers D., 2007, J GEOPHYS RES, V112, DOI DOI 10.1029/2006JE002727; Schwenzer SP, 2009, GEOLOGY, V37, P1091, DOI 10.1130/G30340A.1; Segura TL, 2002, SCIENCE, V298, P1977, DOI 10.1126/science.1073586; Spear F.S., 1993, MINERALOGICAL SOC AM; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; Tanaka KL, 1997, J GEOPHYS RES-PLANET, V102, P4131, DOI 10.1029/96JE02862; Taylor GJ, 2010, GEOLOGY, V38, P183, DOI 10.1130/G30470.1; Tosca NJ, 2009, EARTH PLANET SC LETT, V286, P379, DOI 10.1016/j.epsl.2009.07.004; Werner SC, 2008, ICARUS, V195, P45, DOI 10.1016/j.icarus.2007.12.008; Werner SC, 2009, ICARUS, V201, P44, DOI 10.1016/j.icarus.2008.12.019; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Wiseman SM, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003354; Wiseman SM, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035363; Wray JJ, 2011, J GEOPHYS RES-PLANET, V116, DOI 10.1029/2010JE003694; Wray JJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040734; Wray J. J., 2011, 42 LUN PLAN SCI C; Wray JJ, 2009, GEOLOGY, V37, P1043, DOI 10.1130/G30331A.1	99	545	552	4	300	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2011	479	7371					53	60		10.1038/nature10582	http://dx.doi.org/10.1038/nature10582			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051674				2022-12-28	WOS:000296422600031
J	McCall, N; Cromwell, J				McCall, Nancy; Cromwell, Jerry			Results of the Medicare Health Support Disease-Management Pilot Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE; BENEFICIARIES; QUALITY	Background In the Medicare Modernization Act of 2003, Congress required the Centers for Medicare and Medicaid Services to test the commercial disease-management model in the Medicare fee-for-service program. Methods The Medicare Health Support Pilot Program was a large, randomized study of eight commercial programs for disease management that used nurse-based call centers. We randomly assigned patients with heart failure, diabetes, or both to the intervention or to usual care (control) and compared them with the use of a difference-indifferences method to evaluate the effects of the commercial programs on the quality of clinical care, acute care utilization, and Medicare expenditures for Medicare fee-for-service beneficiaries. Results The study included 242,417 patients (163,107 in the intervention group and 79,310 in the control group). The eight commercial disease-management programs did not reduce hospital admissions or emergency room visits, as compared with usual care. We observed only 14 significant improvements in process-of-care measures out of 40 comparisons. These modest improvements came at substantial cost to the Medicare program in fees paid to the disease-management companies ($400 million), with no demonstrable savings in Medicare expenditures. Conclusions In this large study, commercial disease-management programs using nurse-based call centers achieved only modest improvements in quality-of-care measures, with no demonstrable reduction in the utilization of acute care or the costs of care.	[McCall, Nancy] RTI Int, Washington, DC 20005 USA; [Cromwell, Jerry] RTI Int, Waltham, MA USA; [Cromwell, Jerry] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA	Research Triangle Institute; Research Triangle Institute; University of Massachusetts System; University of Massachusetts Boston	McCall, N (corresponding author), RTI Int, 701 13th St NW,Suite 750, Washington, DC 20005 USA.	nmccall@rti.org						Anderson G, 2002, CHRONIC CONDITIONS M; [Anonymous], 2004, AN LIT DIS MAN; Bodenheimer Thomas, 2003, Dis Manag, V6, P63, DOI 10.1089/109350703321908441; Buntin MB, 2009, J GEN INTERN MED, V24, P649, DOI 10.1007/s11606-009-0950-8; Duncan I, 2008, POPUL HEALTH MANAG, V11, P261, DOI 10.1089/pop.2007.0015; Foote SM, 2003, HLTH AFF MILLWOOD S, pW; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; Goetzel RZ, 2005, HEALTH CARE FINANC R, V26, P1; Institute of Medicine, 2001, CROSS QUAL CHASM; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2002, JAMA-J AM MED ASSOC, V289, P2649; Knight K, 2005, AM J MANAG CARE, V11, P242; Mattke S, 2007, AM J MANAG CARE, V13, P670; Mays GP, 2007, HEALTH AFFAIR, V26, P1683, DOI 10.1377/hlthaff.26.6.1683; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Motheral Brenda R, 2011, Am J Manag Care, V17, pe10; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; RAND Corporation, 2008, EXP PAN M DIS MAN OU; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Serxner S, 2008, POPUL HEALTH MANAG, V11, P241, DOI 10.1089/pop.2008.0004; Thorpe KE, 2006, HEALTH AFFAIR, V25, pW378, DOI 10.1377/hlthaff.25.w378; Todd WE, 2001, DIS MANAGEMENT SYSTE; Vladeck BC, 2001, HEALTH AFFAIR, V20, P175, DOI 10.1377/hlthaff.20.6.175; Wagner E, 2002, CURING SYSTEM STORIE, P2; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wennberg DE, 2010, NEW ENGL J MED, V363, P1245, DOI 10.1056/NEJMsa0902321	27	87	87	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1704	1712		10.1056/NEJMsa1011785	http://dx.doi.org/10.1056/NEJMsa1011785			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	840FL	22047561	Bronze			2022-12-28	WOS:000296424200009
J	Chang, HJ				Chang, Huan J.			Indurated, Purplish Plaque on a Newborn Subcutaneous fat necrosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYPERCALCEMIA; COMPLICATIONS					tina.chang@jama-archives.org						Borgia F, 2006, J PAEDIATR CHILD H, V42, P316, DOI 10.1111/j.1440-1754.2006.00862.x; Burden AD, 1999, PEDIATR DERMATOL, V16, P384, DOI 10.1046/j.1525-1470.1999.00101.x; Mahe E, 2007, BRIT J DERMATOL, V156, P709, DOI 10.1111/j.1365-2133.2007.07782.x; Oza V, 2010, ARCH DERMATOL, V146, P882, DOI 10.1001/archdermatol.2010.176; Rapini R., 2021, PRACTICAL DERMATOPAT, V3rd; Rice AM, 1999, J PEDIATR-US, V134, P349, DOI 10.1016/S0022-3476(99)70462-2; Tran JT, 2003, PEDIATR DERMATOL, V20, P257, DOI 10.1046/j.1525-1470.2003.20315.x; Yuen NS, 2011, ARCH PEDIAT ADOL MED, V165, P563, DOI 10.1001/archpediatrics.2011.80-a	8	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1923	1924		10.1001/jama.2011.1577	http://dx.doi.org/10.1001/jama.2011.1577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045773				2022-12-28	WOS:000296376200031
J	Engels, EA; Pfeiffer, RM; Fraumeni, JF; Kasiske, BL; Israni, AK; Snyder, JJ; Wolfe, RA; Goodrich, NP; Bayakly, AR; Clarke, CA; Copeland, G; Finch, JL; Fleissner, ML; Goodman, MT; Kahn, A; Koch, L; Lynch, CF; Madeleine, MM; Pawlish, K; Rao, C; Williams, MA; Castenson, D; Curry, M; Parsons, R; Fant, G; Lin, M				Engels, Eric A.; Pfeiffer, Ruth M.; Fraumeni, Joseph F., Jr.; Kasiske, Bertram L.; Israni, Ajay K.; Snyder, Jon J.; Wolfe, Robert A.; Goodrich, Nathan P.; Bayakly, A. Rana; Clarke, Christina A.; Copeland, Glenn; Finch, Jack L.; Fleissner, Mary Lou; Goodman, Marc T.; Kahn, Amy; Koch, Lori; Lynch, Charles F.; Madeleine, Margaret M.; Pawlish, Karen; Rao, Chandrika; Williams, Melanie A.; Castenson, David; Curry, Michael; Parsons, Ruth; Fant, Gregory; Lin, Monica			Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; KIDNEY-TRANSPLANTATION; BRONCHOGENIC-CARCINOMA; LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; LUNG TRANSPLANTATION; CELL CARCINOMA; DISEASE; PEOPLE; AGENTS	Context Solid organ transplant recipients have elevated cancer risk due to immunosuppression and oncogenic viral infections. Because most prior research has concerned kidney recipients, large studies that include recipients of differing organs can inform cancer etiology. Objective To describe the overall pattern of cancer following solid organ transplantion. Design, Setting, and Participants Cohort study using linked data on solid organ transplant recipients from the US Scientific Registry of Transplant Recipients (1987-2008) and 13 state and regional cancer registries. Main Outcome Measures Standardized incidence ratios (SIRs) and excess absolute risks (EARs) assessing relative and absolute cancer risk in transplant recipients compared with the general population. Results The registry linkages yielded data on 175 732 solid organ transplants (58.4% for kidney, 21.6% for liver, 10.0% for heart, and 4.0% for lung). The overall cancer risk was elevated with 10 656 cases and an incidence of 1375 per 100 000 person-years (SIR, 2.10 [95% CI, 2.06-2.14]; EAR, 719.3 [95% CI, 693.3-745.6] per 100 000 person-years). Risk was increased for 32 different malignancies, some related to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, melanoma, thyroid and lip cancers). The most common malignancies with elevated risk were non-Hodgkin lymphoma (n=1504; incidence: 194.0 per 100 000 person-years; SIR, 7.54 [95% CI, 7.17-7.93]; EAR, 168.3 [95% CI, 158.6-178.4] per 100 000 person-years) and cancers of the lung (n=1344; incidence: 173.4 per 100 000 person-years; SIR, 1.97 [95% CI, 1.86-2.08]; EAR, 85.3 [95% CI, 76.2-94.8] per 100 000 person-years), liver (n= 930; incidence: 120.0 per 100 000 person-years; SIR, 11.56 [95% CI, 10.83-12.33]; EAR, 109.6 [95% CI, 102.0-117.6] per 100 000 person-years), and kidney (n= 752; incidence: 97.0 per 100 000 person-years; SIR, 4.65 [95% CI, 4.32-4.99]; EAR, 76.1 [95% CI, 69.3-83.3] per 100 000 person-years). Lung cancer risk was most elevated in lung recipients (SIR, 6.13 [95% CI, 5.18-7.21]) but also increased among other recipients (kidney: SIR, 1.46 [95% CI, 1.34-1.59]; liver: SIR, 1.95 [95% CI, 1.74-2.19]; and heart: SIR, 2.67 [95% CI, 2.40-2.95]). Liver cancer risk was elevated only among liver recipients (SIR, 43.83 [95% CI, 40.90-46.91]), who manifested exceptional risk in the first 6 months (SIR, 508.97 [95% CI, 474.16-545.66]) and a 2-fold excess risk for 10 to 15 years thereafter (SIR, 2.22 [95% CI, 1.57-3.04]). Among kidney recipients, kidney cancer risk was elevated (SIR, 6.66 [95% CI, 6.12-7.23]) and bimodal in onset time. Kidney cancer risk also was increased in liver recipients (SIR, 1.80 [95% CI, 1.40-2.29]) and heart recipients (SIR, 2.90 [95% CI, 2.32-3.59]). Conclusion Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have an increased risk for diverse infection-related and unrelated cancers. JAMA. 2011; 306(17): 1891-1901	[Engels, Eric A.; Pfeiffer, Ruth M.; Fraumeni, Joseph F., Jr.] NCI, Rockville, MD 20892 USA; [Kasiske, Bertram L.; Israni, Ajay K.; Snyder, Jon J.] Sci Registry Transplant Recipients, Minneapolis, MN USA; [Kasiske, Bertram L.; Israni, Ajay K.; Snyder, Jon J.] Minneapolis Med Res Fdn Inc, Minneapolis, MN USA; [Wolfe, Robert A.; Goodrich, Nathan P.] Sci Registry Transplant Recipients, Ann Arbor, MI USA; [Wolfe, Robert A.; Goodrich, Nathan P.] Arbor Res Collaborat Hlth, Ann Arbor, MI USA; [Bayakly, A. Rana] Georgia Comprehens Canc Registry, Atlanta, GA USA; [Clarke, Christina A.] Canc Prevent Inst Calif, Fremont, CA USA; [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA; [Finch, Jack L.] Colorado Cent Canc Registry, Denver, CO USA; [Fleissner, Mary Lou] Connecticut Tumor Registry, Hartford, CT USA; [Goodman, Marc T.] Univ Hawaii, Program Epidemiol, Honolulu, HI 96822 USA; [Kahn, Amy] New York State Canc Registry, Albany, NY USA; [Koch, Lori] Illinois State Canc Registry, Springfield, IL USA; [Lynch, Charles F.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA; [Madeleine, Margaret M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Pawlish, Karen] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA; [Rao, Chandrika] N Carolina Cent Canc Registry, Raleigh, NC USA; [Williams, Melanie A.] Texas Dept State Hlth Serv, Austin, TX USA; [Castenson, David; Curry, Michael; Parsons, Ruth] Informat Management Serv Inc, Rockville, MD USA; [Fant, Gregory; Lin, Monica] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Minneapolis Medical Research Foundation; Arbor Research Collaborative for Health; Cancer Prevention Institute of California; MDHHS - Michigan Department of Health & Human Services; University of Hawaii System; University of Iowa; Fred Hutchinson Cancer Center; New Jersey Department of Health & Senior Services; Texas Department of State Health Services; Information Management Services, Inc.; United States Health Resources & Service Administration (HRSA)	Engels, EA (corresponding author), NCI, 6120 Execut Blvd,EPS 7076, Rockville, MD 20892 USA.	engelse@exchange.nih.gov		Goodman, Marc/0000-0002-4839-3021	Bristol-Myers Squibb; Roche; Genzyme; American Society of Nephrology; RTI International; Arbor Research Collaborative for Health [HHSH234200537009C]; Minneapolis Medical Research Foundation [HHSH250201000018C]; Centers for Disease Control and Prevention: California [1U58 DP000807-01]; Centers for Disease Control and Prevention: Colorado [U58 DP000848-04]; Centers for Disease Control and Prevention: Georgia [5U58DP000817-05]; Centers for Disease Control and Prevention: Illinois [5658DP000805-04]; Centers for Disease Control and Prevention: Michigan [5U58DP000812-03]; Centers for Disease Control and Prevention: New Jersey [5U58/DP000808-03]; Centers for Disease Control and Prevention: NewYork [15-0351]; Centers for Disease Control and Prevention: North Carolina [U58DP000832]; Centers for Disease Control and Prevention: Texas [5U58DP000824-04]; National Cancer Institute: California [HHSN261201000036C, HHSN261201000035C, HHSN261201000034C]; National Cancer Institute: Connecticut [HHSN261201000024C]; National Cancer Institute: Hawaii [HHSN261201000037C, N01-PC35137, N01-PC-35139]; National Cancer Institute: Iowa [N01-PC35143]; National Cancer Institute: New Jersey [HHSN261200544005C ADB, N01-PC-54405]; National Cancer Institute: Seattle-Puget Sound [N01-PC-35142]; National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIACP010150] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U58DP000812, U58DP000808, U58DP000848, U58DP000807, U58DP000805, U58DP000824, U58DP000832, U58DP000817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000732] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Roche(Roche Holding); Genzyme(Sanofi-AventisGenzyme Corporation); American Society of Nephrology; RTI International; Arbor Research Collaborative for Health; Minneapolis Medical Research Foundation; Centers for Disease Control and Prevention: California; Centers for Disease Control and Prevention: Colorado; Centers for Disease Control and Prevention: Georgia; Centers for Disease Control and Prevention: Illinois; Centers for Disease Control and Prevention: Michigan; Centers for Disease Control and Prevention: New Jersey; Centers for Disease Control and Prevention: NewYork; Centers for Disease Control and Prevention: North Carolina; Centers for Disease Control and Prevention: Texas; National Cancer Institute: California; National Cancer Institute: Connecticut; National Cancer Institute: Hawaii; National Cancer Institute: Iowa; National Cancer Institute: New Jersey; National Cancer Institute: Seattle-Puget Sound; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kasiske reported that he receives grant funding from Bristol-Myers Squibb. Dr Israni reported that he receives grant funding from Bristol-Myers Squibb, Roche, and Genzyme. Dr Snyder reported that he receives consultancy fees from Genzyme for his participation on a scientific review board; research support is paid to his institution by Bristol-Myers Squibb and Genzyme; and he has received payment from the American Society of Nephrology for his work as an invited educational speaker. Mr Finch reported that consulting fees were paid to his institution by RTI International; he received travel expenses from RTI International for his work in Michigan to assist with electronic data match. No other disclosures were reported.; During most of the period in which the study was conducted, the Scientific Registry of Transplant Recipients was managed by Arbor Research Collaborative for Health (contract HHSH234200537009C). Beginning in September 2010, the Scientific Registry of Transplant Recipients was managed by Minneapolis Medical Research Foundation (contract HHSH250201000018C). The following cancer registries were supported by the National Program of Cancer Registries of the Centers for Disease Control and Prevention: California (agreement 1U58 DP000807-01), Colorado (agreement U58 DP000848-04), Georgia (agreement 5U58DP000817-05), Illinois (agreement 5658DP000805-04), Michigan (agreement 5U58DP000812-03), New Jersey (agreement 5U58/DP000808-03), NewYork (agreement 15-0351), North Carolina (agreement U58DP000832), and Texas (agreement 5U58DP000824-04). The following cancer registries were supported by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute: California (contracts HHSN261201000036C, HHSN261201000035C, and HHSN261201000034C), Connecticut (contract HHSN261201000024C), Hawaii (contracts HHSN261201000037C, N01-PC35137, and N01-PC-35139), Iowa (contract N01-PC35143), New Jersey (contract HHSN261200544005C ADB No. N01-PC-54405), and Seattle-Puget Sound (contract N01-PC-35142). Additional support was provided by California, Colorado, Connecticut, Illinois, Iowa, New Jersey, and New York (Cancer Surveillance Improvement Initiative No. 14-2491), Texas, and Washington, as well as the Fred Hutchinson Cancer Research Center. This research was supported in part by the Intramural Research Program of the National Cancer Institute.	Abrahams NA, 2004, TRANSPL P, V36, P2808, DOI 10.1016/j.transproceed.2004.10.014; Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; Andreome P, 2003, ARCH INTERN MED, V163, P1997, DOI 10.1001/archinte.163.17.1997; [Anonymous], SURVEILLANCE EPIDEMI; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Breslow NE, 1987, DESIGN ANAL COHORT S, VII; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chaturvedi AK, 2008, ANN EPIDEMIOL, V18, P230, DOI 10.1016/j.annepidem.2007.10.005; Cockfield S M, 2001, Transpl Infect Dis, V3, P70; Collett D, 2010, AM J TRANSPLANT, V10, P1889, DOI 10.1111/j.1600-6143.2010.03181.x; de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9; Dickson RP, 2006, J HEART LUNG TRANSPL, V25, P1297, DOI 10.1016/j.healun.2006.09.009; Engels EA, 2008, EXPERT REV ANTICANC, V8, P605, DOI 10.1586/14737140.8.4.605; Faull RJ, 2005, TRANSPLANTATION, V80, P193, DOI 10.1097/01.TP.0000165098.49658.F3; Goh A, 2011, AM J TRANSPLANT, V11, P86, DOI 10.1111/j.1600-6143.2010.03303.x; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Guba M, 2004, TRANSPLANTATION, V77, P1777, DOI 10.1097/01.tp.0000120181.89206.54; Harris NL, 2001, WHO CLASSIFICATION T, P264; HEINZPEER G, 1995, RADIOLOGY, V195, P667, DOI 10.1148/radiology.195.3.7753991; Hoffmann CJ, 2008, TRANSPLANTATION, V86, P784, DOI 10.1097/TP.0b013e3181837761; Kasiske BL, 2004, AM J TRANSPLANT, V4, P905, DOI 10.1111/j.1600-6143.2004.00450.x; Kasiske BL, 2000, J AM SOC NEPHROL, V11, pS1; Kyllonen L, 2000, Transpl Int, V13 Suppl 1, pS394, DOI 10.1007/s001470050369; Layman AB, 2008, JAIDS-J ACQ IMM DEF, V48, P365, DOI 10.1097/QAI.0b013e31817ae5da; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Minai OA, 2008, J THORAC ONCOL, V3, P1404, DOI 10.1097/JTO.0b013e31818e1259; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; Quinlan SC, 2011, AM J HEMATOL, V86, P206, DOI 10.1002/ajh.21911; Ritchie AJ, 2007, J HEART LUNG TRANSPL, V26, P1206, DOI 10.1016/j.healun.2007.07.017; Serraino D, 2005, BRIT J CANCER, V92, P572, DOI 10.1038/sj.bjc.6602346; Swindle P, 1998, BRIT J UROL, V81, P229; Thuluvath PJ, 2010, AM J TRANSPLANT, V10, P1003, DOI 10.1111/j.1600-6143.2010.03037.x; US Department of Health and Human Services, ORG PROC TRANSPL NET; Vajdic CM, 2006, JAMA-J AM MED ASSOC, V296, P2823, DOI 10.1001/jama.296.23.2823; Vajdic CM, 2009, INT J CANCER, V125, P1747, DOI 10.1002/ijc.24439; van Leeuwen MT, 2009, BLOOD, V114, P630, DOI 10.1182/blood-2009-02-202507; Villeneuve PJ, 2007, AM J TRANSPLANT, V7, P941, DOI 10.1111/j.1600-6143.2007.01736.x; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099	39	930	955	3	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1891	1901		10.1001/jama.2011.1592	http://dx.doi.org/10.1001/jama.2011.1592			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045767	Green Accepted			2022-12-28	WOS:000296376200023
J	Patzold, M; Andert, TP; Asmar, SW; Anderson, JD; Barriot, JP; Bird, MK; Hausler, B; Hahn, M; Tellmann, S; Sierks, H; Lamy, P; Weiss, BP				Paetzold, M.; Andert, T. P.; Asmar, S. W.; Anderson, J. D.; Barriot, J. -P.; Bird, M. K.; Haeusler, B.; Hahn, M.; Tellmann, S.; Sierks, H.; Lamy, P.; Weiss, B. P.			Asteroid 21 Lutetia: Low Mass, High Density	SCIENCE			English	Article								Asteroid 21 Lutetia was approached by the Rosetta spacecraft on 10 July 2010. The additional Doppler shift of the spacecraft radio signals imposed by 21 Lutetia's gravitational perturbation on the flyby trajectory were used to determine the mass of the asteroid. Calibrating and correcting for all Doppler contributions not associated with Lutetia, a least-squares fit to the residual frequency observations from 4 hours before to 6 hours after closest approach yields a mass of (1.700 +/- 0.017) x 10(18) kilograms. Using the volume model of Lutetia determined by the Rosetta Optical, Spectroscopic, and Infrared Remote Imaging System (OSIRIS) camera, the bulk density, an important parameter for clues to its composition and interior, is (3.4 +/- 0.3) x 10(3) kilograms per cubic meter.	[Paetzold, M.; Bird, M. K.; Hahn, M.; Tellmann, S.] Univ Cologne, Abt Planetenforsch, Rhein Inst Umweltforsch, D-50931 Cologne, Germany; [Andert, T. P.; Haeusler, B.] Univ Bundeswehr Munchen, Inst Raumfahrttech, D-85579 Neubiberg, Germany; [Asmar, S. W.; Anderson, J. D.] CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA; [Barriot, J. -P.] Univ Polynesie Francaise, F-98702 Faaa, Tahiti, France; [Bird, M. K.] Univ Bonn, Argelander Inst Astron, D-53121 Bonn, Germany; [Sierks, H.] Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; [Lamy, P.] Lab Astrophys Marseille, Marseille, France; [Weiss, B. P.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	University of Cologne; Bundeswehr University Munich; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Bonn; Max Planck Society; UDICE-French Research Universities; Aix-Marseille Universite; Massachusetts Institute of Technology (MIT)	Patzold, M (corresponding author), Univ Cologne, Abt Planetenforsch, Rhein Inst Umweltforsch, D-50931 Cologne, Germany.	martin.paetzold@uni-koeln.de	Barriot, Jean-Pierre/AAD-6709-2021	Barriot, Jean-Pierre/0000-0002-2112-9685	Deutsches Zentrum fur Luft- und Raumfahrt (DLR), Bonn [50QM1002, 50QM1004]; NASA	Deutsches Zentrum fur Luft- und Raumfahrt (DLR), Bonn(Helmholtz AssociationGerman Aerospace Centre (DLR)); NASA(National Aeronautics & Space Administration (NASA))	The Rosetta Radio Science Investigation experiment is funded by the Deutsches Zentrum fur Luft- und Raumfahrt (DLR), Bonn under grants 50QM1002 (T.P.A. and B.H.) and 50QM1004 (M.P., M.H., S.T., and M.K.B.), and under a contract with NASA (S.W.A. and J.D.A.). We thank T. Morley for valuable comments and all persons involved in Rosetta at the European Space Research and Technology Centre, European Space Operations Centre, European Space Astronomy Centre, Jet Propulsion Laboratory, and the European Space Tracking Network and Deep Space Network ground stations for their continuous support.	Andert TP, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL041829; Baer J, 2011, ASTRON J, V141, DOI 10.1088/0004-6256/141/5/143; Patzold M, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014325; Sierks H, 2011, SCIENCE, V334, P487, DOI 10.1126/science.1207325; Weiss B. P., 2011, 42 LUN PLAN SCI C WO	5	67	69	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2011	334	6055					491	492		10.1126/science.1209389	http://dx.doi.org/10.1126/science.1209389			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837UR	22034429	Green Submitted			2022-12-28	WOS:000296230500040
J	Peca, J; Ting, J; Feng, GP				Peca, Joao; Ting, Jonathan; Feng, Guoping			SnapShot: Autism and the Synapse	CELL			English	Editorial Material							BEHAVIORS		[Peca, Joao; Ting, Jonathan; Feng, Guoping] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Peca, J (corresponding author), MIT, McGovern Inst Brain Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Feng, Guoping/Y-2827-2019; Peça, João/K-7900-2013	Peça, João/0000-0003-4989-2129; Ting, Jonathan/0000-0001-8266-0392				Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; Bangash MA, 2011, CELL, V145, P758, DOI 10.1016/j.cell.2011.03.052; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Ehninger D, 2011, TRENDS MOL MED, V17, P78, DOI 10.1016/j.molmed.2010.10.002; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Peca J, 2011, NATURE, V472, P437, DOI 10.1038/nature09965; Sakai Y, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002166; Sudhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Welch JM, 2007, NATURE, V448, P894, DOI 10.1038/nature06104	10	23	25	2	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					706	706		10.1016/j.cell.2011.10.015	http://dx.doi.org/10.1016/j.cell.2011.10.015			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036574	Bronze			2022-12-28	WOS:000296573700024
J	Shen, SZ; Crowley, JL; Wang, Y; Bowring, SA; Erwin, DH; Sadler, PM; Cao, CQ; Rothman, DH; Henderson, CM; Ramezani, J; Zhang, H; Shen, YN; Wang, XD; Wang, W; Mu, L; Li, WZ; Tang, YG; Liu, XL; Liu, LJ; Zeng, Y; Jiang, YF; Jin, YG				Shen, Shu-zhong; Crowley, James L.; Wang, Yue; Bowring, Samuel A.; Erwin, Douglas H.; Sadler, Peter M.; Cao, Chang-qun; Rothman, Daniel H.; Henderson, Charles M.; Ramezani, Jahandar; Zhang, Hua; Shen, Yanan; Wang, Xiang-dong; Wang, Wei; Mu, Lin; Li, Wen-zhong; Tang, Yue-gang; Liu, Xiao-lei; Liu, Lu-jun; Zeng, Yong; Jiang, Yao-fa; Jin, Yu-gan			Calibrating the End-Permian Mass Extinction	SCIENCE			English	Article							TRIASSIC BOUNDARY; BIOTIC CRISIS; SOUTH CHINA; CARBON-CYCLE; MARINE; EVENT; RECOVERY; COAL; OCEANS; ROCKS	The end-Permian mass extinction was the most severe biodiversity crisis in Earth history. To better constrain the timing, and ultimately the causes of this event, we collected a suite of geochronologic, isotopic, and biostratigraphic data on several well-preserved sedimentary sections in South China. High-precision U-Pb dating reveals that the extinction peak occurred just before 252.28 +/- 0.08 million years ago, after a decline of 2 per mil (parts per thousand) in delta(13)C over 90,000 years, and coincided with a delta(13)C excursion of -5 parts per thousand that is estimated to have lasted <= 20,000 years. The extinction interval was less than 200,000 years and synchronous in marine and terrestrial realms; associated charcoal-rich and soot-bearing layers indicate widespread wildfires on land. A massive release of thermogenic carbon dioxide and/or methane may have caused the catastrophic extinction.	[Shen, Shu-zhong; Wang, Yue; Cao, Chang-qun; Zhang, Hua; Shen, Yanan; Wang, Xiang-dong; Wang, Wei; Mu, Lin; Li, Wen-zhong; Liu, Xiao-lei; Liu, Lu-jun; Jin, Yu-gan] Nanjing Inst Geol & Palaeontol, State Key Lab Palaeobiol & Stratig, Nanjing 210008, Peoples R China; [Crowley, James L.; Bowring, Samuel A.; Rothman, Daniel H.; Ramezani, Jahandar] MIT, Dept Earth Atmospher & Planetary Sci, Boston, MA 02130 USA; [Crowley, James L.] Boise State Univ, Dept Geosci, Boise, ID 83725 USA; [Erwin, Douglas H.] Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA; [Erwin, Douglas H.] Santa Fe Inst, Santa Fe, NM 87591 USA; [Sadler, Peter M.] Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; [Rothman, Daniel H.] MIT, Lorenz Ctr, Cambridge, MA 02139 USA; [Henderson, Charles M.] Univ Calgary, Dept Geosci, Calgary, AB T2N 1N4, Canada; [Shen, Yanan] Univ Sci & Technol China, Sch Earth & Space Sci, CAS Key Lab Crust Mantle Mat & Environm, Hefei 230026, Peoples R China; [Li, Wen-zhong] Deakin Univ, Sch Life & Environm Sci, Burwood, Vic 3125, Australia; [Tang, Yue-gang] China Univ Min & Technol, Dept Geol, Beijing 100083, Peoples R China; [Liu, Xiao-lei] Univ Bremen, D-28359 Bremen, Germany; [Zeng, Yong] China Univ Min & Technol, Sch Resources & Geosci, Xuzhou 221008, Jiangsu, Peoples R China; [Jiang, Yao-fa] Jiangsu Geol Survey Architectural Inst, Xuzhou 221116, Jiangsu, Peoples R China	Chinese Academy of Sciences; Massachusetts Institute of Technology (MIT); Idaho; Boise State University; Smithsonian Institution; Smithsonian National Museum of Natural History; The Santa Fe Institute; University of California System; University of California Riverside; Massachusetts Institute of Technology (MIT); University of Calgary; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Deakin University; China University of Mining & Technology; University of Bremen; China University of Mining & Technology	Shen, SZ (corresponding author), Nanjing Inst Geol & Palaeontol, State Key Lab Palaeobiol & Stratig, 39 E Beijing Rd, Nanjing 210008, Peoples R China.	szshen@nigpas.ac.cn; sbowring@mit.edu	WANG, Wei/H-4825-2011; Shen, Shuzhong/D-8214-2011; Shen, Yanan/L-3724-2018	Shen, Shuzhong/0000-0001-8380-0692; Shen, Yanan/0000-0001-8343-6763; Crowley, James/0000-0001-5069-0773; Sadler, Peter/0000-0002-7728-0042; Erwin, Douglas/0000-0003-2518-5614	National Natural Science Foundation of China; National Basic Research Program of China [2006CB806400, 2011CB808905]; Chinese Academy of Sciences (CAS)/State Administration of Foreign Experts Affairs of China (SAFEA); CAS [KZCX2-YW-Q08-4]; basic research program of Jiangsu Province for the Nanjing Group [BK2010022]; U.S. National Aeronautics and Space Administration (NASA) Astrobiology Institute; NASA [NNX09AM88G, NNA08CN84A]; Natural Sciences and Engineering Research Council of Canada (NSERC)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Chinese Academy of Sciences (CAS)/State Administration of Foreign Experts Affairs of China (SAFEA)(Chinese Academy of Sciences); CAS(Chinese Academy of Sciences); basic research program of Jiangsu Province for the Nanjing Group; U.S. National Aeronautics and Space Administration (NASA) Astrobiology Institute(National Aeronautics & Space Administration (NASA)); NASA(National Aeronautics & Space Administration (NASA)); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC))	This research was supported by National Natural Science Foundation of China, the National Basic Research Program of China (2006CB806400, 2011CB808905), the Chinese Academy of Sciences (CAS)/State Administration of Foreign Experts Affairs of China (SAFEA) International Partnership Program, and CAS grants KZCX2-YW-Q08-4 and BK2010022 of the basic research program of Jiangsu Province for the Nanjing Group. Further support was provided by a U.S. National Aeronautics and Space Administration (NASA) Astrobiology Institute Grant (to S. A. B. and D. H. E.), NASA Exobiology Program grant NNX09AM88G (to C. Q. C.), NASA grant NNA08CN84A (to D. H. R.), and a Discovery Grant of the Natural Sciences and Engineering Research Council of Canada (NSERC) (to C. M. H.). All data are available in the supporting online material. Author contributions: This paper is dedicated to Prof. Y. G. Jin, who initiated the China-U.S. joint research with S. A. B. and D. H. E. S. A. B., D. H. E., S.Z.S., and Y. W. wrote the paper with inputs from J.L.C., C. M. H., D. H. R., and P. M. S. All geochronologic ages were produced by S. A. B. and J.L.C. Diversity pattern analysis using CONOP was carried out by Y. W. and P. M. S. with the database established by Y. W. and S.Z.S. Biostratigraphy was analyzed by S.Z.S., C. M. H., and Y. W. Carbon isotope dynamic model based on the Meishan section was conducted by D. H. R. with the data from C. Q. C. All data from the terrestrial and transitional sections were analyzed by S.Z.S. and other coauthors of the Nanjing group. All authors joined in field work and contributed to the interpretation of the data.	Algeo TJ, 2011, PALAEOGEOGR PALAEOCL, V308, P1, DOI 10.1016/j.palaeo.2011.01.011; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Brennecka GA, 2011, P NATL ACAD SCI USA, V108, P17631, DOI 10.1073/pnas.1106039108; Cao CQ, 2009, EARTH PLANET SC LETT, V281, P188, DOI 10.1016/j.epsl.2009.02.012; de Wit MJ, 2002, J GEOL, V110, P227, DOI 10.1086/338411; Erwin D. H, 1993, GREAT PALEOZOIC CRIS; ERWIN DH, 2005, EXTINCTION; Grasby SE, 2011, NAT GEOSCI, V4, P104, DOI [10.1038/ngeo1069, 10.1038/NGEO1069]; Grice K, 2005, SCIENCE, V307, P706, DOI 10.1126/science.1104323; Holser W. T., 1988, CHEM CYCLES EVOLUTIO, P105; Huey RB, 2005, SCIENCE, V308, P398, DOI 10.1126/science.1108019; Isozaki Y, 1997, SCIENCE, V276, P235, DOI 10.1126/science.276.5310.235; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; Kamo SL, 2003, EARTH PLANET SC LETT, V214, P75, DOI 10.1016/S0012-821X(03)00347-9; Knoll AH, 2007, EARTH PLANET SC LETT, V256, P295, DOI 10.1016/j.epsl.2007.02.018; Krull ES, 2004, PALAEOGEOGR PALAEOCL, V204, P297, DOI 10.1016/S0031-0182(03)00732-6; Looy CV, 2001, P NATL ACAD SCI USA, V98, P7879, DOI 10.1073/pnas.131218098; Milkov AV, 2004, EARTH-SCI REV, V66, P183, DOI 10.1016/j.earscirev.2003.11.002; Mundil R, 2001, EARTH PLANET SC LETT, V187, P131, DOI 10.1016/S0012-821X(01)00274-6; Mundil R, 2004, SCIENCE, V305, P1760, DOI 10.1126/science.1101012; Nabbefeld B, 2010, APPL GEOCHEM, V25, P1374, DOI 10.1016/j.apgeochem.2010.06.008; Payne JL, 2004, SCIENCE, V305, P506, DOI 10.1126/science.1097023; Payne JL, 2007, GEOL SOC AM BULL, V119, P771, DOI 10.1130/B26091.1; Peng YQ, 2006, J ASIAN EARTH SCI, V28, P291, DOI 10.1016/j.jseaes.2005.10.007; RENNE PR, 1995, SCIENCE, V269, P1413, DOI 10.1126/science.269.5229.1413; Retallack GJ, 1996, GEOL SOC AM BULL, V108, P195, DOI 10.1130/0016-7606(1996)108<0195:GCGBPT>2.3.CO;2; Retallack GJ, 2008, J GEOL, V116, P1, DOI 10.1086/524120; Riccardi A, 2007, PALAEOGEOGR PALAEOCL, V248, P73, DOI 10.1016/j.palaeo.2006.11.010; Sephton MA, 2005, GEOLOGY, V33, P941, DOI 10.1130/G21784.1; Shen Shu Zhong, 2006, Palaeoworld, V15, P3, DOI 10.1016/j.palwor.2006.03.005; Shen WJ, 2011, GEOCHIM COSMOCHIM AC, V75, P1992, DOI 10.1016/j.gca.2011.01.027; Svensen H, 2009, EARTH PLANET SC LETT, V277, P490, DOI 10.1016/j.epsl.2008.11.015; Thomas BM, 2004, AUST J EARTH SCI, V51, P423, DOI 10.1111/j.1400-0952.2004.01066.x; Twitchett RJ, 2001, GEOLOGY, V29, P351, DOI 10.1130/0091-7613(2001)029<0351:RASCOM>2.0.CO;2; Visscher H, 2011, GEOLOGY, V39, P883, DOI 10.1130/G32178.1; Ward PD, 2005, SCIENCE, V307, P709, DOI 10.1126/science.1107068; Xie SC, 2007, GEOLOGY, V35, P1083, DOI 10.1130/G24224A.1; Yin HF, 2007, GLOBAL PLANET CHANGE, V55, P1, DOI 10.1016/j.gloplacha.2006.06.005	39	539	629	25	570	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 9	2011	334	6061					1367	1372		10.1126/science.1213454	http://dx.doi.org/10.1126/science.1213454			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858HW	22096103				2022-12-28	WOS:000297787700043
J	Bex, A; Haanen, J				Bex, Axel; Haanen, John			Tilting the AXIS towards therapeutic limits in renal cancer	LANCET			English	Editorial Material							CELL CARCINOMA; 2ND-LINE TREATMENT; EVEROLIMUS; SORAFENIB; SUNITINIB; EFFICACY		[Bex, Axel] Netherlands Canc Inst, Dept Surg Oncol, NL-1066 CX Amsterdam, Netherlands; [Bex, Axel] Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands; [Haanen, John] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bex, A (corresponding author), Netherlands Canc Inst, Dept Surg Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.bex@nki.nl	Haanen, John/AAD-8534-2022; Haanen, John/AAD-8578-2022	Haanen, John/0000-0001-5884-7704; 				Coppin C, 2011, BJU INT, V108, P1556, DOI 10.1111/j.1464-410X.2011.10629.x; Hoyle M, 2010, VALUE HEALTH, V13, P55, DOI 10.1111/j.1524-4733.2009.00616.x; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Norum J, 2010, J CHEMOTHERAPY, V22, P75, DOI 10.1179/joc.2010.22.2.75; Patard JJ, 2011, EUR UROL, V60, P684, DOI 10.1016/j.eururo.2011.06.017; Pitt M, 2010, HEALTH TECHNOL ASSES, V14, P41, DOI 10.3310/hta14suppl2/06; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Rini BI, 2011, JNCI-J NATL CANCER I, V103, P763, DOI 10.1093/jnci/djr128; Rini BI, 2009, J CLIN ONCOL, V27, P4462, DOI 10.1200/JCO.2008.21.7034; Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/S1470-2045(07)70285-1; Shih YCT, 2011, PHARMACOECONOMICS, V29, P331, DOI 10.2165/11586110-000000000-00000	11	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 3	2011	378	9807					1898	1900		10.1016/S0140-6736(11)61655-3	http://dx.doi.org/10.1016/S0140-6736(11)61655-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22056245				2022-12-28	WOS:000298136200012
J	Navarrete, A; van Schaik, CP; Isler, K				Navarrete, Ana; van Schaik, Carel P.; Isler, Karin			Energetics and the evolution of human brain size	NATURE			English	Article							EXPENSIVE-TISSUE HYPOTHESIS; HOMININS; MAMMALS; BIRDS; INTELLIGENCE; VERTEBRATES; METABOLISM; PRIMATES; SYSTEM; COSTS	The human brain stands out among mammals by being unusually large. The expensive-tissue hypothesis(1) explains its evolution by proposing a trade-off between the size of the brain and that of the digestive tract, which is smaller than expected for a primate of our body size. Although this hypothesis is widely accepted, empirical support so far has been equivocal. Here we test it in a sample of 100 mammalian species, including 23 primates, by analysing brain size and organ mass data. We found that, controlling for fat-free body mass, brain size is not negatively correlated with the mass of the digestive tract or any other expensive organ, thus refuting the expensive-tissue hypothesis. Nonetheless, consistent with the existence of energy trade-offs with brain size, we find that the size of brains and adipose depots are negatively correlated in mammals, indicating that encephalization and fat storage are compensatory strategies to buffer against starvation. However, these two strategies can be combined if fat storage does not unduly hamper locomotor efficiency. We propose that human encephalization was made possible by a combination of stabilization of energy inputs and a redirection of energy from locomotion, growth and reproduction.	[Navarrete, Ana; van Schaik, Carel P.; Isler, Karin] Univ Zurich, Anthropol Inst & Museum, CH-8057 Zurich, Switzerland	University of Zurich	Navarrete, A (corresponding author), Univ Zurich, Anthropol Inst & Museum, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	a.navarrete@aim.uzh.ch; kisler@aim.uzh.ch	Isler, Karin/A-9566-2008	Isler, Karin/0000-0002-2391-1523; Navarrete, Ana F./0000-0001-6020-0678	Swiss National Science Foundation [3100A0-117789]; A.H. Schultz-Stiftung; European Integrated Activities grant SYNTHESYS [HU-TAF-4916]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); A.H. Schultz-Stiftung; European Integrated Activities grant SYNTHESYS	We thank R. D. Martin and J. Wermuth for sharing the Chivers data set, J. van Woerden for sharing her endocranial volume data, and M. Genoud for sharing his revised compilation of mammalian BMR values. Specimens were provided by numerous institutions, museums and colleagues (Supplementary Information 2). We acknowledge valuable comments by L. Aiello and R. D. Martin. Financial support was provided by the Swiss National Science Foundation (grant number 3100A0-117789), the A.H. Schultz-Stiftung and the European Integrated Activities grant SYNTHESYS (grant application number HU-TAF-4916).	Aiello LC, 2001, EVOLUTIONARY ANATOMY OF THE PRIMATE CEREBRAL CORTEX, P57; Aiello LC, 2002, ANNU REV ANTHROPOL, V31, P323, DOI 10.1146/annurev.anthro.31.040402.085403; AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; [Anonymous], 2010, R LANG ENV STAT COMP; Bruhn JM, 1936, P AM ACAD ARTS SCI, V71, P259, DOI 10.2307/20023229; Burkart JM, 2009, EVOL ANTHROPOL, V18, P175, DOI 10.1002/evan.20222; Dean C, 2001, NATURE, V414, P628, DOI 10.1038/414628a; GARLAND T, 1983, AM NAT, V121, P571, DOI 10.1086/284084; Isler K, 2006, BIOL LETTERS, V2, P557, DOI 10.1098/rsbl.2006.0538; Isler K, 2006, J HUM EVOL, V51, P228, DOI 10.1016/j.jhevol.2006.03.006; Isler K, 2011, BIOESSAYS, V33, P173, DOI 10.1002/bies.201000123; Isler K, 2009, J HUM EVOL, V57, P392, DOI 10.1016/j.jhevol.2009.04.009; Isler K, 2009, BIOL LETTERS, V5, P125, DOI 10.1098/rsbl.2008.0469; Isler K, 2008, J HUM EVOL, V55, P967, DOI 10.1016/j.jhevol.2008.08.004; Jones KE, 2004, AM NAT, V164, pE20, DOI 10.1086/421334; Kaplan H, 2000, EVOL ANTHROPOL, V9, P156, DOI 10.1002/1520-6505(2000)9:4<156::AID-EVAN5>3.0.CO;2-7; Kaufman JA, 2003, CURR ANTHROPOL, V44, P705, DOI 10.1086/379258; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; Mau M., 2009, BIOSCI HYPOTHESES, V2, P205; MINK JW, 1981, AM J PHYSIOL, V241, pR203, DOI 10.1152/ajpregu.1981.241.3.R203; Orme D., 2009, CAIC COMP ANAL USING; Pfefferle AD, 2011, J HUM EVOL, V60, P205, DOI 10.1016/j.jhevol.2010.10.004; Pitts G., 1968, NATL ACAD SCI PUBL, V1598, P45; Pond C.M., 1998, FATS LIFE; Pontzer H, 2010, J HUM EVOL, V58, P492, DOI 10.1016/j.jhevol.2010.03.006; Pontzer H, 2009, J HUM EVOL, V56, P43, DOI 10.1016/j.jhevol.2008.09.001; Potts R, 1998, YEARB PHYS ANTHROPOL, V41, P93; Reader SM, 2011, PHILOS T R SOC B, V366, P1017, DOI 10.1098/rstb.2010.0342; REHKAMPER G, 1991, BRAIN BEHAV EVOLUT, V37, P125, DOI 10.1159/000114353; Santoro Sérgio, 2006, Sao Paulo Med. J., V124, P192, DOI 10.1590/S1516-31802006000400004; Sol D, 2009, BIOL LETTERS, V5, P130, DOI 10.1098/rsbl.2008.0621; van Woerden JT, 2010, AM NAT, V176, P758, DOI 10.1086/657045; Wells J., 2009, EVOLUTIONARY BIOL HU; Wrangham RW, 2009, CATCHING FIRE COOKIN; Zihlman A.L., 1984, P179	35	286	288	4	270	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	2011	480	7375					91	U252		10.1038/nature10629	http://dx.doi.org/10.1038/nature10629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	861PO	22080949	Green Accepted			2022-12-28	WOS:000298031900040
J	Yokoyama, S; Woods, SL; Boyle, GM; Aoude, LG; MacGregor, S; Zismann, V; Gartside, M; Cust, AE; Haq, R; Harland, M; Taylor, JC; Duffy, DL; Holohan, K; Dutton-Regester, K; Palmer, JM; Bonazzi, V; Stark, MS; Symmons, J; Law, MH; Schmidt, C; Lanagan, C; O'Connor, L; Holland, EA; Schmid, H; Maskiell, JA; Jetann, J; Ferguson, M; Jenkins, MA; Kefford, RF; Giles, G; Armstrong, BK; Aitken, JF; Hopper, JL; Whiteman, DC; Pharoah, PD; Easton, DF; Dunning, AM; Newton-Bishop, JA; Montgomery, GW; Martin, NG; Mann, GJ; Bishop, DT; Tsao, H; Trent, JM; Fisher, DE; Hayward, NK; Brown, KM				Yokoyama, Satoru; Woods, Susan L.; Boyle, Glen M.; Aoude, Lauren G.; MacGregor, Stuart; Zismann, Victoria; Gartside, Michael; Cust, Anne E.; Haq, Rizwan; Harland, Mark; Taylor, John C.; Duffy, David L.; Holohan, Kelly; Dutton-Regester, Ken; Palmer, Jane M.; Bonazzi, Vanessa; Stark, Mitchell S.; Symmons, Judith; Law, Matthew H.; Schmidt, Christopher; Lanagan, Cathy; O'Connor, Linda; Holland, Elizabeth A.; Schmid, Helen; Maskiell, Judith A.; Jetann, Jodie; Ferguson, Megan; Jenkins, Mark A.; Kefford, Richard F.; Giles, GrahamG.; Armstrong, Bruce K.; Aitken, Joanne F.; Hopper, John L.; Whiteman, David C.; Pharoah, Paul D.; Easton, Douglas F.; Dunning, Alison M.; Newton-Bishop, Julia A.; Montgomery, Grant W.; Martin, Nicholas G.; Mann, Graham J.; Bishop, D. Timothy; Tsao, Hensin; Trent, Jeffrey M.; Fisher, David E.; Hayward, Nicholas K.; Brown, Kevin M.			A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma	NATURE			English	Article							GENOME-WIDE ASSOCIATION; CUTANEOUS MELANOMA; PHENOTYPIC CHARACTERISTICS; TRANSCRIPTION FACTOR; GERMLINE MUTATIONS; MELANOCYTIC NEVI; SUN EXPOSURE; RISK; VARIANTS; LINKAGE	So far, two genes associated with familial melanoma have been identified, accounting for a minority of genetic risk in families. Mutations in CDKN2A account for approximately 40% of familial cases(1), and predisposing mutations in CDK4 have been reported in a very small number of melanoma kindreds(2). Here we report the whole-genome sequencing of probands from several melanoma families, which we performed in order to identify other genes associated with familial melanoma. We identify one individual carrying a novel germline variant (coding DNA sequence c. G1075A; protein sequence p. E318K; rs149617956) in the melanoma-lineage-specific oncogene microphthalmia-associated transcription factor (MITF). Although the variant co-segregated with melanoma in some but not all cases in the family, linkage analysis of 31 families subsequently identified to carry the variant generated a log of odds (lod) score of 2.7 under a dominant model, indicating E318K as a possible intermediate risk variant. Consistent with this, the E318K variant was significantly associated with melanoma in a large Australian case-control sample. Likewise, it was similarly associated in an independent case-control sample from the United Kingdom. In the Australian sample, the variant allele was significantly over-represented in cases with a family history of melanoma, multiple primary melanomas, or both. The variant allele was also associated with increased naevus count and non-blue eye colour. Functional analysis of E318K showed that MITF encoded by the variant allele had impaired sumoylation and differentially regulated several MITF targets. These data indicate that MITF is a melanoma-predisposition gene and highlight the utility of whole-genome sequencing to identify novel rare variants associated with disease susceptibility.	[Zismann, Victoria; Trent, Jeffrey M.; Brown, Kevin M.] Translat Genom Res Inst, Phoenix, AZ 85004 USA; [Yokoyama, Satoru; Haq, Rizwan; Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr,Dept Dermatol, Boston, MA 02114 USA; [Woods, Susan L.; Boyle, Glen M.; Aoude, Lauren G.; MacGregor, Stuart; Gartside, Michael; Duffy, David L.; Holohan, Kelly; Dutton-Regester, Ken; Palmer, Jane M.; Bonazzi, Vanessa; Stark, Mitchell S.; Symmons, Judith; Law, Matthew H.; Schmidt, Christopher; Lanagan, Cathy; O'Connor, Linda; Whiteman, David C.; Montgomery, Grant W.; Martin, Nicholas G.; Hayward, Nicholas K.] Queensland Inst Med Res, Brisbane, Qld 4029, Australia; [Cust, Anne E.; Armstrong, Bruce K.] Univ Sydney, Sydney Med Sch, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia; [Harland, Mark; Taylor, John C.; Newton-Bishop, Julia A.; Bishop, D. Timothy] St James Univ Hosp, Canc Res UK Clin Ctr Leeds, Leeds Inst Mol Med, Epidemiol & Biostat Sect, Leeds LS9 7TF, W Yorkshire, England; [Holland, Elizabeth A.; Schmid, Helen; Kefford, Richard F.; Mann, Graham J.] Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; [Holland, Elizabeth A.; Schmid, Helen; Kefford, Richard F.; Mann, Graham J.] Melanoma Inst Australia, Westmead, NSW 2145, Australia; [Maskiell, Judith A.; Jenkins, Mark A.; Hopper, John L.] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia; [Jetann, Jodie; Ferguson, Megan; Aitken, Joanne F.] Canc Council Queensland, Viertel Ctr Res Canc Control, Brisbane, Qld 4004, Australia; [Giles, GrahamG.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic 3053, Australia; [Pharoah, Paul D.; Easton, Douglas F.; Dunning, Alison M.] Univ Cambridge, Cambridge CB1 8RN, England; [Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA; [Brown, Kevin M.] NCI, Div Canc Epidemiol & Genet, NIH, Gaithersburg, MD 20892 USA	Translational Genomics Research Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; QIMR Berghofer Medical Research Institute; University of Sydney; Cancer Research UK; Saint James's University Hospital; University of Leeds; University of Sydney; Westmead Institute for Medical Research; Melanoma Institute Australia; University of Melbourne; Cancer Council Queensland; Cancer Council Victoria; University of Cambridge; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brown, KM (corresponding author), Translat Genom Res Inst, Phoenix, AZ 85004 USA.	brownkm2@mail.nih.gov	Law, Matthew H./AAJ-4066-2021; Armstrong, Bruce K/K-9464-2015; Yokoyama, Satoru/AAT-3254-2021; Stark, Mitchell/K-3874-2019; Aoude, Lauren/C-7484-2014; Stark, Mitchell/K-6794-2019; Stark, Mitchell S/E-3542-2010; Boyle, Glen/G-1347-2013; Martin, Nicholas/R-9235-2019; Duffy, David L/B-7392-2013; Mann, Graham J/G-4758-2014; Pharoah, Paul/V-6658-2019; Fisher, David/AAH-2878-2019; Cust, Anne/J-1797-2019; hayward, nick/AAV-8802-2020; Macgregor, Stuart/C-6442-2009; Nadeem, Sohail/I-5248-2013; Whiteman, David C/P-2728-2014; Aitken, Joanne F/C-5289-2009; hayward, nicholas k/C-1367-2015; Bonazzi, Vanessa F/R-1676-2018; Montgomery, Grant W/B-7148-2008; Jenkins, Mark/P-7803-2015; Schmidt, Christopher/A-4353-2009	Law, Matthew H./0000-0002-4303-8821; Armstrong, Bruce K/0000-0001-8940-7525; Aoude, Lauren/0000-0003-1448-3923; Stark, Mitchell/0000-0002-4510-2161; Stark, Mitchell S/0000-0002-4510-2161; Boyle, Glen/0000-0002-1385-529X; Martin, Nicholas/0000-0003-4069-8020; Duffy, David L/0000-0001-7227-632X; Mann, Graham J/0000-0003-1301-405X; Pharoah, Paul/0000-0001-8494-732X; Cust, Anne/0000-0002-5331-6370; Macgregor, Stuart/0000-0001-6731-8142; Nadeem, Sohail/0000-0002-1052-011X; Whiteman, David C/0000-0003-2563-9559; hayward, nicholas k/0000-0003-4760-1033; Bonazzi, Vanessa F/0000-0002-2574-0334; Montgomery, Grant W/0000-0002-4140-8139; Jenkins, Mark/0000-0002-8964-6160; Bishop, Tim/0000-0002-8752-8785; Yokoyama, Satoru/0000-0001-8336-486X; Aitken, Joanne Frances/0000-0001-6859-2186; Kefford, Richard/0000-0001-9251-9229; Newton-Bishop, Julia/0000-0001-9147-6802; Dutton-Regester, Ken/0000-0002-8884-6355; Jetann, Jodie/0000-0002-9760-3099; Giles, Graham/0000-0003-4946-9099; Schmidt, Christopher/0000-0002-3955-5076; Dunning, Alison Margaret/0000-0001-6651-7166; Woods, Susan/0000-0002-8955-2017	Melanoma Research Alliance; American Cancer Society [RSG-08-200-01]; National Institutes of Health (NIH) [AR043369-14, CA88363, K24CA149202, P50CA93683, R01 CA83115, CA-83115-01A2]; Doris Duke Medical Foundation; Dr Miriam and Sheldon G. Adelson Medical Research Foundation; US-Israel Binational Science Foundation; Division of Cancer Epidemiology and Genetics of the National Cancer Institute; National Health and Medical Research Council of Australia (NHMRC); Cancer Australia [1011143]; Cancer Research UK [C8216/A6129, C588/A4994, C588/A10589, C490/A11021, C8197/A10123]; NHMRC [566946, 107359, 211172, 402761, 520018]; Cancer Council New South Wales [77/00, 06/10]; Cancer Council Victoria; Cancer Council Queensland [371]; Cancer Institute NSW [10/ECF/2-06]; University of Sydney Medical Foundation; NATIONAL CANCER INSTITUTE [R01CA088363, K24CA149202, R01CA083115, F32CA009368, P50CA093683, ZIACP010201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER; Cancer Research UK [10589, 10118, 11022] Funding Source: researchfish	Melanoma Research Alliance; American Cancer Society(American Cancer Society); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Medical Foundation(Doris Duke Charitable Foundation (DDCF)); Dr Miriam and Sheldon G. Adelson Medical Research Foundation; US-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Division of Cancer Epidemiology and Genetics of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Australia; Cancer Research UK(Cancer Research UK); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council New South Wales(Cancer Council New South Wales); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council Queensland(Cancer Council Queensland); Cancer Institute NSW; University of Sydney Medical Foundation(University of Sydney); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Cancer Research UK(Cancer Research UK)	This work was supported by team science awards by the Melanoma Research Alliance (J.M.T., N.K.H., H. T. and D. E. F.), the American Cancer Society (K. M. B., RSG-08-200-01), the National Institutes of Health (NIH; D. E. F., AR043369-14; N.K.H., CA88363; H. T., K24CA149202 and P50CA93683), Doris Duke Medical Foundation (D. E. F.), Dr Miriam and Sheldon G. Adelson Medical Research Foundation (D. E. F.), US-Israel Binational Science Foundation (D. E. F.), and the Division of Cancer Epidemiology and Genetics of the National Cancer Institute (K. M. B.). N.K.H., D. L. D., S. M. and G. W. M. are supported by National Health and Medical Research Council of Australia (NHMRC) research fellowships. M. H. L. is supported by Cancer Australia grant 1011143. The collection of samples in the Leeds-based case-control study (the Melanoma Cohort Study) was funded by Cancer Research UK (Project Grant C8216/A6129 and Programme awards C588/A4994 and C588/A10589) and by the NIH (R01 CA83115). Recruitment was facilitated by the UK National Cancer Research Network. We thank S. Leake, S. Haynes, S. Waseem for Leeds case-control data collection; and H. Snowdon and C. Taylor from the Leeds Cancer Research UK Cancer Centre Genomics Facility for the genotyping of the UK samples. AMFS was supported by the NHMRC (project grants 566946, 107359, 211172 and program grant number 402761 to G.J.M. and R. F. K.); the Cancer Council New South Wales (project grant 77/00, 06/10), the Cancer Council Victoria and the Cancer Council Queensland (project grant 371); and the NIH (via RO1 grant CA-83115-01A2 to the international Melanoma Genetics Consortium-GenoMEL). The University of Cambridge SEARCH study was supported by Cancer Research UK Programme awards (C490/A11021 and C8197/A10123). A. E. C. is the recipient of an NHMRC public health postdoctoral fellowship (520018) and a Cancer Institute NSW Early Career Development Fellowship (10/ECF/2-06). B. K. A. is supported by a University of Sydney Medical Foundation Program Grant and J.L.H. is an Australia Fellow of the NHMRC. We gratefully acknowledge all of the participants, the work and dedication of the research coordinators, interviewers, examiners and data management staff, including J. Arbuckle, S. Columbus, M. Lang, H. Rodais, C. Ellis (Centre for MEGA Epidemiology); E. A. Holland, C. Agha-Hamilton, C. El Hayek, L. Morgan, J. Roland, E. Tyler, J. Barton, C. Watts and L. Porter (Westmead Institute of Cancer Research); M. Hillcoat, K. Holland, P. Saunders, J. Roberts and S. Tait (Viertel Centre for Research in Cancer Control); A. Kurien, C. Patterson, C. Thoo, S. de Zwaan, A. Sklavos, S. Manoharan, J. Cahill and S. Brennand (skin examiners).	Bataille V, 1996, BRIT J CANCER, V73, P1605, DOI 10.1038/bjc.1996.302; Baxter AJ, 2008, TWIN RES HUM GENET, V11, P183, DOI 10.1375/twin.11.2.183; Bishop DT, 2009, NAT GENET, V41, P920, DOI 10.1038/ng.411; Boyle GM, 2011, PIGM CELL MELANOMA R, V24, P525, DOI 10.1111/j.1755-148X.2011.00849.x; Brown KM, 2008, NAT GENET, V40, P838, DOI 10.1038/ng.163; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Chang YM, 2009, INT J CANCER, V124, P420, DOI 10.1002/ijc.23869; Cronin JC, 2009, PIGM CELL MELANOMA R, V22, P435, DOI 10.1111/j.1755-148X.2009.00578.x; Cust AE, 2009, AM J EPIDEMIOL, V170, P1541, DOI 10.1093/aje/kwp307; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Duffy DL, 2010, AM J HUM GENET, V87, P6, DOI 10.1016/j.ajhg.2010.05.017; Falchi M, 2009, NAT GENET, V41, P915, DOI 10.1038/ng.410; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; Goldstein AM, 2007, J MED GENET, V44, P99, DOI 10.1136/jmg.2006.043802; Gudbjartsson DF, 2008, NAT GENET, V40, P886, DOI 10.1038/ng.161; Han JL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000074; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; HOLLY EA, 1995, AM J EPIDEMIOL, V141, P934, DOI 10.1093/oxfordjournals.aje.a117360; HOLLY EA, 1995, AM J EPIDEMIOL, V141, P923, DOI 10.1093/oxfordjournals.aje.a117359; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; McGregor B, 1999, GENET EPIDEMIOL, V16, P40, DOI 10.1002/(SICI)1098-2272(1999)16:1<40::AID-GEPI4>3.3.CO;2-T; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Naldi L, 2005, ANN EPIDEMIOL, V15, P545, DOI 10.1016/j.annepidem.2004.10.005; Nan H, 2009, J INVEST DERMATOL, V129, P2250, DOI 10.1038/jid.2009.62; NANCARROW DJ, 1992, GENOMICS, V14, P939, DOI 10.1016/S0888-7543(05)80115-6; Newton-Bishop JA, 2010, CANCER EPIDEM BIOMAR, V19, P2043, DOI 10.1158/1055-9965.EPI-10-0233; Oancea E, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000146; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pooley KA, 2010, CANCER EPIDEM BIOMAR, V19, P1862, DOI 10.1158/1055-9965.EPI-10-0281; Pooley KA, 2008, CANCER EPIDEM BIOMAR, V17, P3482, DOI 10.1158/1055-9965.EPI-08-0594; Smit NPM, 2008, PHOTOCHEM PHOTOBIOL, V84, P550, DOI 10.1111/j.1751-1097.2007.00242.x; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Strauch K, 2003, AM J HUM GENET, V73, P615; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Sulem P, 2007, NAT GENET, V39, P1443, DOI 10.1038/ng.2007.13; Titus-Ernstoff L, 2005, INT J CANCER, V116, P144, DOI 10.1002/ijc.21001; Williams PF, 2011, INT J CANCER, V129, P1730, DOI 10.1002/ijc.25804; Zhu G, 2007, EUR J HUM GENET, V15, P94, DOI 10.1038/sj.ejhg.5201729; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	46	296	304	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	2011	480	7375					99	U266		10.1038/nature10630	http://dx.doi.org/10.1038/nature10630			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22080950	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000298031900042
J	Munoz, N; Herrero, R				Munoz, Nubia; Herrero, Rolando			Prevention of cervical cancer in women's hands: Mexico leads the way	LANCET			English	Editorial Material							COLLECTED VAGINAL SAMPLES; LATIN-AMERICA; ACCURACY		[Munoz, Nubia] Colombian Canc Inst, Bogota, Colombia; [Herrero, Rolando] Int Agcy Res Canc, Prevent & Implementat Grp, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Munoz, N (corresponding author), Colombian Canc Inst, Bogota, Colombia.	nubia.munoz@free.fr						Balasubramanian A, 2010, J LOW GENIT TRACT DI, V14, P185, DOI 10.1097/LGT.0b013e3181cd6d36; Belinson JL, 2012, INT J CANCER, V130, P1855, DOI 10.1002/ijc.26202; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019; Globocan WHO., 2010, GLOB 2008 GLOB PROJ; Herrero R, 2008, VACCINE, V26, pL49, DOI 10.1016/j.vaccine.2008.05.025; Lazcano-Ponce E, 2011, LANCET, V378, P1868, DOI 10.1016/S0140-6736(11)61522-5; Leinonen M, 2009, JNCI-J NATL CANCER I, V101, P1612, DOI 10.1093/jnci/djp367; Munoz N, 2008, VACCINE, V26, pL96, DOI 10.1016/j.vaccine.2008.05.062; Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9; Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562; Sowjanya AP, 2009, CANCER EPIDEM BIOMAR, V18, P1373, DOI 10.1158/1055-9965.EPI-08-1171; Ting J, 2010, INT J GYNECOL CANCER, V20, P1244, DOI 10.1111/IGC.0b013e3181f16c5f	12	6	6	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 26	2011	378	9806					1829	1831		10.1016/S0140-6736(11)61101-X	http://dx.doi.org/10.1016/S0140-6736(11)61101-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857DQ	22051738				2022-12-28	WOS:000297695800010
J	Walkey, AJ; Wiener, RS; Ghobrial, JM; Curtis, LH; Benjamin, EJ				Walkey, Allan J.; Wiener, Renda Soylemez; Ghobrial, Joanna M.; Curtis, Lesley H.; Benjamin, Emelia J.			Incident Stroke and Mortality Associated With New-Onset Atrial Fibrillation in Patients Hospitalized With Severe Sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC-STROKE; INTENSIVE-CARE-UNIT; MYOCARDIAL-INFARCTION; PULMONARY-ARTERY; ICD-9-CM CODES; RISK SCORE; INFECTION; ACCURACY; ARRHYTHMIAS; MANAGEMENT	Context New-onset atrial fibrillation (AF) has been reported in 6% to 20% of patients with severe sepsis. Chronic AF is a known risk factor for stroke and death, but the clinical significance of new-onset AF in the setting of severe sepsis is uncertain. Objective To determine the in-hospital stroke and in-hospital mortality risks associated with new-onset AF in patients with severe sepsis. Design and Setting Retrospective population-based cohort of California State Inpatient Database administrative claims data from nonfederal acute care hospitals for January 1 through December 31, 2007. Patients Data were available for 3 144 787 hospitalized adults. Severe sepsis (n=49 082 [1.56%]) was defined by validated International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 995.92. New-onset AF was defined as AF that occurred during the hospital stay, after excluding AF cases present at admission. Main Outcome Measures A priori outcome measures were in-hospital ischemic stroke (ICD-9-CM codes 433, 434, or 436) and mortality. Results Patients with severe sepsis were a mean age of 69 (SD, 16) years and 48% were women. New-onset AF occurred in 5.9% of patients with severe sepsis vs 0.65% of patients without severe sepsis (multivariable-adjusted odds ratio [OR], 6.82; 95% CI, 6.54-7.11; P < .001). Severe sepsis was present in 14% of all new-onset AF in hospitalized adults. Compared with severe sepsis patients without new-onset AF, patients with new-onset AF during severe sepsis had greater risks of in-hospital stroke (75/2896 [2.6%] vs 306/46 186 [0.6%] strokes; adjusted OR, 2.70; 95% CI, 2.05-3.57; P < .001) and in-hospital mortality (1629 [56%] vs 18 027 [39%] deaths; adjusted relative risk, 1.07; 95% CI, 1.04-1.11; P < .001). Findings were robust across 2 definitions of severe sepsis, multiple methods of addressing confounding, and multiple sensitivity analyses. Conclusion Among patients with severe sepsis, patients with new-onset AF were at increased risk of in-hospital stroke and death compared with patients with no AF and patients with preexisting AF. JAMA. 2011;306(20):2248-2255 Published online November 13, 2011. doi:10.1001/jama.2011.1615	[Walkey, Allan J.; Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Div Pulm & Crit Care Med, Boston, MA 02118 USA; [Walkey, Allan J.; Wiener, Renda Soylemez; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Benjamin, Emelia J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; [Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA; [Wiener, Renda Soylemez] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH 03756 USA; [Ghobrial, Joanna M.] Univ Washington, Sch Med, Dept Med, Div Cardiol, Seattle, WA 98195 USA; [Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA; [Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Benjamin, Emelia J.] NHLBI, Framingham, MA USA; [Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA	Boston University; Boston University; Boston University; Boston University; Dartmouth College; University of Washington; University of Washington Seattle; Duke University; Duke University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Framingham Heart Study	Walkey, AJ (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Div Pulm & Crit Care Med, R-304, Boston, MA 02118 USA.	alwalkey@bu.edu	Wiener, Renda/AAO-1557-2020; Hug, Balthasar L./G-1568-2010; Benjamin, Emelia/E-7103-2011	Wiener, Renda/0000-0001-7712-2135; Walkey, Allan/0000-0003-4685-6894; Benjamin, Emelia/0000-0003-4076-2336	Boston University Clinical Translational Research Institute [UL1RR025771]; Evans Center for Interdisciplinary Biomedical Research ARC on Atrial Fibrillation at Boston University; National Heart, Lung, and Blood Institute [1R01HL092577, 1RC1HL101056, 1R01 HL102214]; National Cancer Institute [K07 CA138772]; Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [K07CA138772] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL101056, R01HL092577, R01HL102214] Funding Source: NIH RePORTER	Boston University Clinical Translational Research Institute; Evans Center for Interdisciplinary Biomedical Research ARC on Atrial Fibrillation at Boston University; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by grant UL1RR025771 from the Boston University Clinical Translational Research Institute (Dr Walkey); by the Evans Center for Interdisciplinary Biomedical Research ARC on Atrial Fibrillation at Boston University (http://www.bumc.bu.edu/evanscenteribr/) (Drs Walkey, Curtis, and Benjamin); by National Heart, Lung, and Blood Institute grants 1R01HL092577 and 1RC1HL101056 (Dr Benjamin) and 1R01 HL102214 (Drs Curtis and Benjamin); by National Cancer Institute grant K07 CA138772 (Dr Wiener); and by the Department of Veterans Affairs (Dr Wiener).	Agency for Healthcare Research and Quality, OV STAT INP DAT SID; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2008, AM J RESP CRIT CARE, V178, P20, DOI 10.1164/rccm.200701-031OC; Arora S, 2007, ANAESTH INTENS CARE, V35, P707, DOI 10.1177/0310057X0703500508; ARTUCIO H, 1990, CRIT CARE MED, V18, P1383, DOI 10.1097/00003246-199012000-00015; Benesch C, 1997, NEUROLOGY, V49, P660, DOI 10.1212/WNL.49.3.660; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; Buch P, 2003, EUR RESPIR J, V21, P1012, DOI 10.1183/09031936.03.00051502; Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Chamberlain AM, 2011, AM J CARDIOL, V107, P85, DOI 10.1016/j.amjcard.2010.08.049; Christian SA, 2008, J CRIT CARE, V23, P532, DOI 10.1016/j.jcrc.2007.09.005; Coffey R, 2006, 200601 HCUP; Elijovich L, 2009, J STROKE CEREBROVASC, V18, P185, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.005; Elkind MSV, 2011, STROKE, V42, P1851, DOI 10.1161/STROKEAHA.110.608588; Fatema K, 2009, AM J HEMATOL, V84, P499, DOI 10.1002/ajh.21459; Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GIBBS HR, 1992, J SURG ONCOL, V50, P224, DOI 10.1002/jso.2930500405; Glance LG, 2006, HEALTH SERV RES, V41, P1413, DOI 10.1111/j.1475-6773.2006.00554.x; Glance LG, 2006, HEALTH SERV RES, V41, P231, DOI 10.1111/j.1475-6773.2005.00419.x; Glazer NL, 2007, ARCH INTERN MED, V167, P246, DOI 10.1001/archinte.167.3.246; Goldstein LB, 1998, STROKE, V29, P1602, DOI 10.1161/01.STR.29.8.1602; Goodman S, 2007, ANESTH ANALG, V104, P880, DOI 10.1213/01.ane.0000255759.41131.05; Harvey S, 2005, LANCET, V366, P472, DOI 10.1016/S0140-6736(05)67061-4; Hidalgo JD, 2004, BONE MARROW TRANSPL, V34, P615, DOI 10.1038/sj.bmt.1704623; Kreutz RP, 2005, J THROMB HAEMOST, V3, P2108, DOI 10.1111/j.1538-7836.2005.01474.x; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Meierhenrich R, 2010, CRIT CARE, V14, DOI 10.1186/cc9057; Parsons LS, 2000, P 25 ANN SAS US GROU, P1166; Poulose JT, 2009, AM J RESP CRIT CARE, V179, pA4691; Quan H, 2004, J CLIN EPIDEMIOL, V57, P366, DOI 10.1016/j.jclinepi.2003.01.002; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Salman Salam, 2008, J Intensive Care Med, V23, P178, DOI 10.1177/0885066608315838; Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; Suissa S, 2003, AM J RESP CRIT CARE, V168, P49, DOI 10.1164/rccm.200210-1231OC; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; SYRJANEN J, 1989, SCAND J INFECT DIS, V21, P285, DOI 10.3109/00365548909035698; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Winkelmayer WC, 2011, J AM SOC NEPHROL, V22, P349, DOI 10.1681/ASN.2010050459; Zeerleder S, 2005, CHEST, V128, P2864, DOI 10.1378/chest.128.4.2864; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; Zurru MC, 2009, STROKE, V40, P1986, DOI 10.1161/STROKEAHA.108.535559	46	290	300	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2011	306	20					2248	2255		10.1001/jama.2011.1615	http://dx.doi.org/10.1001/jama.2011.1615			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851GD	22081378	Green Accepted			2022-12-28	WOS:000297255500024
J	Bouchoux, C; Uhlmann, F				Bouchoux, Celine; Uhlmann, Frank			A Quantitative Model for Ordered Cdk Substrate Dephosphorylation during Mitotic Exit	CELL			English	Article							BUDDING YEAST; CELL-CYCLE; PHOSPHATASE CDC14; CHROMOSOME SEGREGATION; PROTEIN PHOSPHATASE; ANAPHASE ONSET; MITOSIS; KINASE; PHOSPHORYLATION; SEPARASE	After sister chromatid splitting at anaphase onset, exit from mitosis comprises an ordered series of events. Dephosphorylation of numerous mitotic substrates, which were phosphorylated by cyclin-dependent kinase (Cdk), is thought to bring about mitotic exit, but how temporal ordering of mitotic exit events is achieved is poorly understood. Here, we show, using budding yeast, that dephosphorylation of Cdk substrates involved in sequential mitotic exit events occurs with ordered timing. We test different models of how ordering might be achieved by modulating Cdk and Cdk-counteracting phosphatase Cdc14 activities in vivo, as well as by kinetic analysis of Cdk substrate phosphorylation and dephosphorylation in vitro. Our results suggest that the gradual change of the phosphatase to kinase ratio over the course of mitotic exit is read out by Cdk substrates that respond by dephosphorylation at distinct thresholds. This provides an example and a mechanistic explanation for a quantitative model of cell-cycle progression.	[Bouchoux, Celine; Uhlmann, Frank] Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Chromosome Segregat Lab, London WC2A 3LY, England	Cancer Research UK	Uhlmann, F (corresponding author), Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Chromosome Segregat Lab, London WC2A 3LY, England.	frank.uhlmann@cancer.org.uk		Bouchoux, Celine/0000-0001-5064-4718; Uhlmann, Frank/0000-0002-3527-6619				Coudreuse D, 2010, NATURE, V468, P1074, DOI 10.1038/nature09543; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; Drapkin BJ, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.78; Errico A, 2010, ADV ENZYME REGUL, V50, P375, DOI 10.1016/j.advenzreg.2009.12.001; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Higuchi T, 2005, NATURE, V433, P171, DOI 10.1038/nature03240; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jin FZ, 2008, P NATL ACAD SCI USA, V105, P16177, DOI 10.1073/pnas.0808719105; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Lopez-Aviles S, 2009, NATURE, V459, P592, DOI 10.1038/nature07984; Mendoza M, 2009, NAT CELL BIOL, V11, P477, DOI 10.1038/ncb1855; Mirchenko L, 2010, CURR BIOL, V20, P1396, DOI 10.1016/j.cub.2010.06.023; Mochida S, 2009, EMBO J, V28, P2777, DOI 10.1038/emboj.2009.238; Mohl DA, 2009, J CELL BIOL, V184, P527, DOI 10.1083/jcb.200812022; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nikolova N, 2008, CENT EUR J BIOL, V3, P345, DOI 10.2478/s11535-008-0035-4; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Queralt E, 2008, CURR OPIN CELL BIOL, V20, P661, DOI 10.1016/j.ceb.2008.09.003; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stern Bodo, 1996, Trends in Genetics, V12, P345, DOI 10.1016/0168-9525(96)10036-6; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang WQ, 2004, J BIOL CHEM, V279, P30459, DOI 10.1074/jbc.M402217200; Wolf F, 2006, EMBO J, V25, P2802, DOI 10.1038/sj.emboj.7601163; Woodbury EL, 2007, NAT CELL BIOL, V9, P106, DOI 10.1038/ncb1523; Wu JQ, 2009, NAT CELL BIOL, V11, P644, DOI 10.1038/ncb1871; Zhai YL, 2010, J CELL SCI, V123, P3933, DOI 10.1242/jcs.075366	43	90	91	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					803	814		10.1016/j.cell.2011.09.047	http://dx.doi.org/10.1016/j.cell.2011.09.047			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078879	Bronze			2022-12-28	WOS:000296902300014
J	Li, PP; Fan, WQ; Xu, JF; Lu, M; Yamamoto, H; Auwerx, J; Sears, DD; Talukdar, S; Oh, D; Chen, A; Bandyopadhyay, G; Scadeng, M; Ofrecio, JM; Nalbandian, S; Olefsky, JM				Li, Pingping; Fan, WuQiang; Xu, Jianfeng; Lu, Min; Yamamoto, Hiroyasu; Auwerx, Johan; Sears, Dorothy D.; Talukdar, Saswata; Oh, DaYoung; Chen, Ai; Bandyopadhyay, Gautam; Scadeng, Miriam; Ofrecio, Jachelle M.; Nalbandian, Sarah; Olefsky, Jerrold M.			Adipocyte NCoR Knockout Decreases PPAR gamma Phosphorylation and Enhances PPAR gamma Activity and Insulin Sensitivity	CELL			English	Article							ACTIVATED RECEPTOR-GAMMA; ADIPOSE-TISSUE; NUCLEAR RECEPTORS; OBESITY; INFLAMMATION; RESISTANCE; MACROPHAGES; FAT; ROSIGLITAZONE; COREGULATORS	Insulin resistance, tissue inflammation, and adipose tissue dysfunction are features of obesity and Type 2 diabetes. We generated adipocyte-specific Nuclear Receptor Corepressor (NCoR) knockout (AKO) mice to investigate the function of NCoR in adipocyte biology, glucose and insulin homeostasis. Despite increased obesity, glucose tolerance was improved in AKO mice, and clamp studies demonstrated enhanced insulin sensitivity in liver, muscle, and fat. Adipose tissue macrophage infiltration and inflammation were also decreased. PPAR gamma response genes were upregulated in adipose tissue from AKO mice and CDK5-mediated PPAR gamma ser-273 phosphorylation was reduced, creating a constitutively active PPAR gamma state. This identifies NCoR as an adaptor protein that enhances the ability of CDK5 to associate with and phosphorylate PPAR gamma. The dominant function of adipocyte NCoR is to transrepress PPAR gamma and promote PPAR gamma ser-273 phosphorylation, such that NCoR deletion leads to adipogenesis, reduced inflammation, and enhanced systemic insulin sensitivity, phenocopying the TZD-treated state.	[Li, Pingping; Fan, WuQiang; Xu, Jianfeng; Lu, Min; Sears, Dorothy D.; Talukdar, Saswata; Oh, DaYoung; Chen, Ai; Bandyopadhyay, Gautam; Ofrecio, Jachelle M.; Nalbandian, Sarah; Olefsky, Jerrold M.] Univ Calif San Diego, Div Endocrinol & Metab, Dept Med, San Diego, CA 92093 USA; [Yamamoto, Hiroyasu; Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland; [Scadeng, Miriam] Univ Calif San Diego, Dept Radiol, San Diego, CA 92098 USA	University of California System; University of California San Diego; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Div Endocrinol & Metab, Dept Med, 9500 Gilman Dr, San Diego, CA 92093 USA.	jolefsky@ucsd.edu	Li, Pingping/F-1109-2019; OH, DA YOUNG/B-2369-2008; Sears, Dorothy D/AHE-5524-2022; Auwerx, Johan/ABE-9307-2021	Li, Pingping/0000-0003-0679-270X; Sears, Dorothy D/0000-0002-9260-3540; Talukdar, Saswata/0000-0003-3042-0025; Auwerx, Johan/0000-0002-5065-5393; Scadeng, Miriam/0000-0002-9593-2956	National Institutes of Health [NIDDK DK033651, DK063491, DK 074868, DK059820]; EU [ERC-2008-AdG-23118]; Swiss National Science Foundation; Eunice Kennedy Shriver NICHD/NIH [U54 HD 012303-25]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD012303, P50HD012303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, R01DK033651, P01DK074868, T32DK007494, R37DK033651, P01DK059820] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EU(European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Eunice Kennedy Shriver NICHD/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Elizabeth J. Hansen for editorial assistance; the Flow Cytometry Resource (Dennis Young) for FACS analysis at the Rebecca and John Moores Cancer Center; and we thank the UCSD Histology Core lab for technical help with processing tissue specimens and microscope analysis. This study was funded in part by the National Institutes of Health grants NIDDK DK033651 (J.M.O.), DK063491 (J.M.O.), DK 074868 (J.M.O.), DK059820 (J. A.), and EU Ideas program (ERC-2008-AdG-23118), the Swiss National Science Foundation, and the Eunice Kennedy Shriver NICHD/NIH through a cooperative agreement U54 HD 012303-25 as part of the specialized Cooperative Centers Program in Reproduction and Infertility Research.	CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Cusi K, 2010, CURR DIABETES REP, V10, P306, DOI 10.1007/s11892-010-0122-6; Djaouti L, 2010, DIABETES-METAB RES, V26, P297, DOI 10.1002/dmrr.1081; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001; Fowler Amy M, 2004, Sci STKE, V2004, ppe51, DOI 10.1126/stke.2562004pe51; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Glass CK, 2000, GENE DEV, V14, P121; Goossens GH, 2008, PHYSIOL BEHAV, V94, P206, DOI 10.1016/j.physbeh.2007.10.010; Halberg N, 2008, ENDOCRIN METAB CLIN, V37, P753, DOI 10.1016/j.ecl.2008.07.002; Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Lessard SJ, 2007, DIABETES, V56, P1856, DOI 10.2337/db06-1065; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Lu M, 2010, MOL ENDOCRINOL, V24, P1413, DOI 10.1210/me.2009-0462; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Qatanani M, 2007, GENE DEV, V21, P1443, DOI 10.1101/gad.1550907; Qi L, 2009, CELL METAB, V9, P277, DOI 10.1016/j.cmet.2009.01.006; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Revilla Y, 2009, CRIT REV IMMUNOL, V29, P131, DOI 10.1615/CritRevImmunol.v29.i2.30; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; Sugii S, 2009, P NATL ACAD SCI USA, V106, P22504, DOI 10.1073/pnas.0912487106; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Wang YG, 2010, P NATL ACAD SCI USA, V107, P3087, DOI 10.1073/pnas.0914897107; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200	46	214	222	1	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					815	826		10.1016/j.cell.2011.09.050	http://dx.doi.org/10.1016/j.cell.2011.09.050			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078880	Green Accepted, Bronze			2022-12-28	WOS:000296902300015
J	Rodriguez, MM; Bill, E; Brennessel, WW; Holland, PL				Rodriguez, Meghan M.; Bill, Eckhard; Brennessel, William W.; Holland, Patrick L.			N-2 Reduction and Hydrogenation to Ammonia by a Molecular Iron-Potassium Complex	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HIGH-SPIN; DINITROGEN; MOSSBAUER; HYDRAZINE; MECHANISM; H-2	The most common catalyst in the Haber-Bosch process for the hydrogenation of dinitrogen (N-2) to ammonia (NH3) is an iron surface promoted with potassium cations (K+), but soluble iron complexes have neither reduced the N-N bond of N-2 to nitride (N3-) nor produced large amounts of NH3 from N-2. We report a molecular iron complex that reacts with N-2 and a potassium reductant to give a complex with two nitrides, which are bound to iron and potassium cations. The product has a Fe3N2 core, implying that three iron atoms cooperate to break the N-N triple bond through a six-electron reduction. The nitride complex reacts with acid and with H-2 to give substantial yields of N-2-derived ammonia. These reactions, although not yet catalytic, give structural and spectroscopic insight into N-2 cleavage and N-H bond-forming reactions of iron.	[Rodriguez, Meghan M.; Brennessel, William W.; Holland, Patrick L.] Univ Rochester, Dept Chem, Rochester, NY 14627 USA; [Bill, Eckhard] Max Planck Inst Bioanorgan, D-45470 Mulheim, Germany	University of Rochester; Max Planck Society	Holland, PL (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.	holland@chem.rochester.edu		Brennessel, William/0000-0001-5461-1825	NIH [GM-065313]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065313] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant from NIH (GM-065313). We thank C. Scarborough and R. Cowley for valuable discussions. Materials and methods are available as supporting material on Science Online. Crystallographic data for 2 (two independent structures with different solvents of crystallization), L<SUP>3</SUP>FeCl<INF>2</INF>, L<SUP>3</SUP>FeCl<INF>2</INF>K(18-crown-6), and [L<SUP>3</SUP>FeH]<INF>2</INF> have been deposited with the Cambridge Crystallographic Data Centre with deposition numbers CCDC 836870 to 836874.	Andres H, 2002, J AM CHEM SOC, V124, P3012, DOI 10.1021/ja012327l; Arashiba K, 2011, NAT CHEM, V3, P120, DOI 10.1038/NCHEM.906; Bennett MV, 2006, ANGEW CHEM INT EDIT, V45, P5613, DOI 10.1002/anie.200601570; Bennett MV, 2005, J AM CHEM SOC, V127, P12378, DOI 10.1021/ja052150l; Betley TA, 2004, J AM CHEM SOC, V126, P6252, DOI 10.1021/ja048713v; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; Chomitz WA, 2007, CHEM COMMUN, P4797, DOI 10.1039/b709763h; Crossland JL, 2010, COORDIN CHEM REV, V254, P1883, DOI 10.1016/j.ccr.2010.01.005; Eckert NA, 2004, INORG CHEM, V43, P3306, DOI 10.1021/ic035483x; GEORGE TA, 1995, INORG CHEM, V34, P1295, DOI 10.1021/ic00109a046; Gilbertson JD, 2005, J AM CHEM SOC, V127, P10184, DOI 10.1021/ja053030g; Hall DA, 1996, J CHEM SOC DALTON, P3539, DOI 10.1039/dt9960003539; Hazari N, 2010, CHEM SOC REV, V39, P4044, DOI 10.1039/b919680n; Hellman A, 2006, J PHYS CHEM B, V110, P17719, DOI 10.1021/jp056982h; HILLS A, 1993, J CHEM SOC DALTON, P3041, DOI 10.1039/dt9930003041; Hoffman BM, 2009, ACCOUNTS CHEM RES, V42, P609, DOI 10.1021/ar8002128; Mittasch A., 1951, GESCH AMMONIAKSYNTHE; Mortensen JJ, 1999, J CATAL, V182, P479, DOI 10.1006/jcat.1998.2364; Pool JA, 2004, NATURE, V427, P527, DOI 10.1038/nature02274; Schlogl R., 2008, HDB HETEROGENEOUS CA, V5, P2501; SCHRAUZER GN, 1976, J AM CHEM SOC, V98, P3508, DOI 10.1021/ja00428a019; Smil V, 1997, SCI AM, V277, P76, DOI 10.1038/scientificamerican0797-76; Smith JM, 2006, J AM CHEM SOC, V128, P756, DOI 10.1021/ja052707x; Smith JM, 2001, J AM CHEM SOC, V123, P9222, DOI 10.1021/ja016094+; Stoian SA, 2008, INORG CHEM, V47, P8687, DOI 10.1021/ic8004568; STRONGIN DR, 1987, J CATAL, V103, P213, DOI 10.1016/0021-9517(87)90109-6; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326	27	377	381	6	408	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					780	783		10.1126/science.1211906	http://dx.doi.org/10.1126/science.1211906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076372	Green Accepted			2022-12-28	WOS:000296849600039
J	Crocker, J				Crocker, Jennifer			The road to fraud starts with a single step	NATURE			English	Editorial Material									[Crocker, Jennifer] Ohio State Univ, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Crocker, J (corresponding author), Ohio State Univ, Columbus, OH 43210 USA.	crocker.37@osu.edu		Crocker, Jennifer/0000-0002-6590-4647				2011, NATURE, V479, P15	1	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					151	151		10.1038/479151a	http://dx.doi.org/10.1038/479151a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	861PD	22071724	Bronze			2022-12-28	WOS:000298030800006
J	Le Bars, M; Wieczorek, MA; Karatekin, O; Cebron, D; Laneuville, M				Le Bars, M.; Wieczorek, M. A.; Karatekin, O.; Cebron, D.; Laneuville, M.			An impact-driven dynamo for the early Moon	NATURE			English	Article							TIDAL INSTABILITY; ELLIPTIC INSTABILITY; MAGNETIC-FIELDS; PRECESSION; CORE; DISSIPATION; CONVECTION	The origin of lunar magnetic anomalies(1-5) remains unresolved after their discovery more than four decades ago. A commonly invoked hypothesis is that the Moon might once have possessed a thermally driven core dynamo(3), but this theory is problematical given the small size of the core and the required surface magnetic field strengths(6). An alternative hypothesis is that impact events might have amplified ambient fields near the antipodes of the largest basins(7), but many magnetic anomalies exist that are not associated with basin antipodes. Here we propose a new model for magnetic field generation, in which dynamo action comes from impact-induced changes in the Moon's rotation rate. Basin-forming impact events are energetic enough to have unlocked the Moon from synchronous rotation(8), and we demonstrate that the subsequent large-scale fluid flows in the core, excited by the tidal distortion of the core-mantle boundary(9), could have powered a lunar dynamo. Predicted surface magnetic field strengths are on the order of several microteslas, consistent with palaeomagnetic measurements(5), and the duration of these fields is sufficient to explain the central magnetic anomalies associated with several large impact basins.	[Le Bars, M.; Cebron, D.] CNRS, IRPHE, F-13384 Marseille 13, France; [Le Bars, M.; Cebron, D.] Aix Marseille Univ, F-13384 Marseille 13, France; [Wieczorek, M. A.; Laneuville, M.] Univ Paris Diderot, Inst Phys Globe Paris, F-94100 St Maur Des Fosses, France; [Karatekin, O.] Royal Observ Belgium, BE-1180 Uccle, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Universite Paris Cite	Le Bars, M (corresponding author), CNRS, IRPHE, 49 Rue F Joliot Curie,BP 146, F-13384 Marseille 13, France.	lebars@irphe.univ-mrs.fr	Cebron, David/A-9625-2014; Laneuville, Matthieu/F-8523-2010; Le Bars, Michael/M-7019-2018; Wieczorek, Mark A/G-6427-2010	Cebron, David/0000-0002-3579-8281; Laneuville, Matthieu/0000-0001-6022-0046; Le Bars, Michael/0000-0002-4884-6190; Wieczorek, Mark A/0000-0001-7007-4222	Belgian PRODEX	Belgian PRODEX	M.L.B. and D.C. acknowledge discussions with P. Le Gal and S. Le Dizes. O.K. acknowledges the support of the Belgian PRODEX programme.	Arkani-Hamed J, 2009, ICARUS, V201, P31, DOI 10.1016/j.icarus.2009.01.005; Cebron D, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3504356; Cebron D, 2010, PHYS EARTH PLANET IN, V182, P119, DOI 10.1016/j.pepi.2010.07.003; Cebron D, 2010, GEOPHYS J INT, V182, P1311, DOI 10.1111/j.1365-246X.2010.04712.x; Christensen UR, 2006, GEOPHYS J INT, V166, P97, DOI 10.1111/j.1365-246X.2006.03009.x; Christensen UR, 2009, NATURE, V457, P167, DOI 10.1038/nature07626; Christensen UR, 2004, NATURE, V429, P169, DOI 10.1038/nature02508; Cintala MJ, 1998, METEORIT PLANET SCI, V33, P889, DOI 10.1111/j.1945-5100.1998.tb01695.x; Correia ACM, 2009, ICARUS, V201, P1, DOI 10.1016/j.icarus.2008.12.034; Fuller M., 1987, GEOMAGN AERON, V2, P307; Garrick-Bethell I, 2009, SCIENCE, V323, P356, DOI 10.1126/science.1166804; Gattacceca J, 2010, EARTH PLANET SC LETT, V299, P42, DOI 10.1016/j.epsl.2010.08.011; Greenspan H. P., 1968, THEORY ROTATING FLUI; Halekas JS, 2003, METEORIT PLANET SCI, V38, P565, DOI 10.1111/j.1945-5100.2003.tb00027.x; Hood LL, 2008, ICARUS, V193, P485, DOI 10.1016/j.icarus.2007.08.023; Hood LL, 2011, ICARUS, V211, P1109, DOI 10.1016/j.icarus.2010.08.012; Kerswell RR, 2002, ANNU REV FLUID MECH, V34, P83, DOI 10.1146/annurev.fluid.34.081701.171829; Kerswell RR, 1996, J FLUID MECH, V321, P335, DOI 10.1017/S0022112096007756; Kerswell RR, 1998, GEOPHYS RES LETT, V25, P603, DOI 10.1029/98GL00237; Lacaze L, 2004, J FLUID MECH, V505, P1, DOI 10.1017/S0022112004008328; Lavorel G, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3508946; Lawrence K, 2008, PHYS EARTH PLANET IN, V168, P71, DOI 10.1016/j.pepi.2008.05.007; Le Bars M, 2010, PHYS EARTH PLANET IN, V178, P48, DOI 10.1016/j.pepi.2009.07.005; LOPER DE, 1975, PHYS EARTH PLANET IN, V11, P43, DOI 10.1016/0031-9201(75)90074-6; MALKUS WVR, 1968, SCIENCE, V160, P259, DOI 10.1126/science.160.3825.259; Meyer J, 2011, ICARUS, V211, P921, DOI 10.1016/j.icarus.2010.09.016; Peale S. J., 1977, IAU C, P87; Purucker ME, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2010JE003650; ROCHESTER MG, 1975, GEOPHYS J ROY ASTR S, V43, P661, DOI 10.1111/j.1365-246X.1975.tb06186.x; Smith DE, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043751; Stegman DR, 2003, NATURE, V421, P143, DOI 10.1038/nature01267; Tilgner A, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1852576; Wieczorek MA, 2006, REV MINERAL GEOCHEM, V60, P221, DOI 10.2138/rmg.2006.60.3; Wieczorek MA, 2009, ICARUS, V200, P358, DOI 10.1016/j.icarus.2008.12.017; Williams JG, 2001, J GEOPHYS RES-PLANET, V106, P27933, DOI 10.1029/2000JE001396; Wu CC, 2009, GEOPHYS ASTRO FLUID, V103, P467, DOI 10.1080/03091920903311788; YODER F, 1981, PHIL T R SOC LOND A, V303, P327	37	103	103	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					215	U90		10.1038/nature10565	http://dx.doi.org/10.1038/nature10565			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071767				2022-12-28	WOS:000298030800039
J	Beller, EM; Glasziou, PP; Hopewell, S; Altman, DG				Beller, Elaine M.; Glasziou, Paul P.; Hopewell, Sally; Altman, Douglas G.			Reporting of Effect Direction and Size in Abstracts of Systematic Reviews	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Beller, Elaine M.; Glasziou, Paul P.] Bond Univ, Ctr Res Evidence Based Practice, Gold Coast, Qld, Australia; [Hopewell, Sally; Altman, Douglas G.] Univ Oxford, Ctr Stat Med, Oxford, England	Bond University; University of Oxford	Beller, EM (corresponding author), Bond Univ, Ctr Res Evidence Based Practice, Gold Coast, Qld, Australia.	ebeller@bond.edu.au	Altman, Douglas G/A-9714-2012; Beller, Elaine M/E-1615-2013; Glasziou, Paul/A-7832-2008	Beller, Elaine M/0000-0002-3241-2611; Glasziou, Paul/0000-0001-7564-073X; Hopewell, Sally/0000-0002-6881-6984				[Anonymous], ABR IND MED AIM COR; Hopewell S, 2008, PLOS MED, V5, P48, DOI 10.1371/journal.pmed.0050020; Lai NM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-30; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; The Cochrane Library, COCHR COLL	6	32	32	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					1981	1982		10.1001/jama.2011.1620	http://dx.doi.org/10.1001/jama.2011.1620			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068989	Green Published			2022-12-28	WOS:000296704300020
J	Fryer, JD; Yu, P; Kang, H; Mandel-Brehm, C; Carter, AN; Crespo-Barreto, J; Gao, Y; Flora, A; Shaw, C; Orr, HT; Zoghbi, HY				Fryer, John D.; Yu, Peng; Kang, Hyojin; Mandel-Brehm, Caleigh; Carter, Angela N.; Crespo-Barreto, Juan; Gao, Yan; Flora, Adriano; Shaw, Chad; Orr, Harry T.; Zoghbi, Huda Y.			Exercise and Genetic Rescue of SCA1 via the Transcriptional Repressor Capicua	SCIENCE			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; AMYOTROPHIC-LATERAL-SCLEROSIS; MOUSE MODEL; CAG REPEAT; EXPANSION; DISEASE	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by expansion of a translated CAG repeat in Ataxin-1 (ATXN1). To determine the long-term effects of exercise, we implemented a mild exercise regimen in a mouse model of SCA1 and found a considerable improvement in survival accompanied by up-regulation of epidermal growth factor and consequential down-regulation of Capicua, which is an ATXN1 interactor. Offspring of Capicua mutant mice bred to SCA1 mice showed significant improvement of all disease phenotypes. Although polyglutamine-expanded Atxn1 caused some loss of Capicua function, further reduction of Capicua levels-either genetically or by exercise-mitigated the disease phenotypes by dampening the toxic gain of function. Thus, exercise might have long-term beneficial effects in other ataxias and neurodegenerative diseases.	[Fryer, John D.; Yu, Peng; Kang, Hyojin; Mandel-Brehm, Caleigh; Crespo-Barreto, Juan; Gao, Yan; Flora, Adriano; Shaw, Chad; Zoghbi, Huda Y.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Carter, Angela N.; Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Shaw, Chad] Baylor Coll Med, Stem Cells & Regenerat Med Ctr, Houston, TX 77030 USA; [Orr, Harry T.] Univ Minnesota, Inst Translat Neurosci, Minneapolis, MN 55455 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	hzoghbi@bcm.edu		Zoghbi, Huda/0000-0002-0700-3349; mandel-brehm, caleigh/0000-0001-7764-6529; Orr, Harry/0000-0001-6118-741X; Shaw, Chad/0000-0001-7267-5398	NIH (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center) [NS27699, NS27699-20S1-ARRA, HD24064]; NIH [1F32NS055545, NS022920, NS045667]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022920, R01NS027699, F32NS055545, R37NS022920, R37NS027699, R01NS045667, T32NS043124] Funding Source: NIH RePORTER	NIH (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	J.D.F. and H.Y.Z. conceived of the study and designed experiments. J.D.F., C. M. B., A.N.C., and Y.G. performed behavioral assays and provided input on analysis. J.D.F. and J.C.-B. performed molecular work and analysis. P.Y., H. K., and C. S. analyzed microarray data. J.D.F. and H.Y.Z. wrote the manuscript with input from J.C.-.B, A. F., and H.T.O. We are grateful to G. Schuster for the generation of mutant mice and the members of the H.Y.Z. laboratory for comments and discussions on the manuscript. This research was supported by NIH grants NS27699, NS27699-20S1-ARRA, and HD24064 (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center) to H.Y.Z.; 1F32NS055545 to J.D.F.; and NS022920 and NS045667 to H.T.O. H.Y.Z. is an investigator with the Howard Hughes Medical Institute, holds a patent on SCA1 diagnostic testing, and is on the scientific advisory board of Pfizer Neuroscience Program.	Astigarraga S, 2007, EMBO J, V26, P668, DOI 10.1038/sj.emboj.7601532; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Ilg W, 2009, NEUROLOGY, V73, P1823, DOI 10.1212/WNL.0b013e3181c33adf; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; Mahoney DJ, 2004, MUSCLE NERVE, V29, P656, DOI 10.1002/mus.20004; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Thomas PS, 2006, HUM MOL GENET, V15, P2225, DOI 10.1093/hmg/ddl148; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Vaz DV, 2008, CLIN REHABIL, V22, P234, DOI 10.1177/0269215507081578; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Zoghbi HY, 2009, J BIOL CHEM, V284, P7425, DOI 10.1074/jbc.R800041200	15	103	106	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					690	693		10.1126/science.1212673	http://dx.doi.org/10.1126/science.1212673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053053	Green Accepted			2022-12-28	WOS:000296494700060
J	Evan, AT; Kossin, JP; Chung, C; Ramanathan, V				Evan, Amato T.; Kossin, James P.; Chung, Chul 'Eddy'; Ramanathan, V.			Arabian Sea tropical cyclones intensified by emissions of black carbon and other aerosols	NATURE			English	Article							VERTICAL WIND SHEAR; INDIAN-OCEAN; CLIMATE; IMPACTS	Throughout the year, average sea surface temperatures in the Arabian Sea are warm enough to support the development of tropical cyclones(1), but the atmospheric monsoon circulation and associated strong vertical wind shear limits cyclone development and intensification, only permitting a pre-monsoon and post-monsoon period for cyclogenesis(1-4). Thus a recent increase in the intensity of tropical cyclones over the northern Indian Ocean(5) is thought to be related to the weakening of the climatological vertical wind shear(3,4). At the same time, anthropogenic emissions of aerosols have increased sixfold since the 1930s, leading to a weakening of the southwesterly lower-level and easterly upper-level winds that define the monsoonal circulation over the Arabian Sea(6-9). In principle, this aerosol-driven circulation modification could affect tropical cyclone intensity over the Arabian Sea, but so far no such linkage has been shown. Here we report an increase in the intensity of pre-monsoon Arabian Sea tropical cyclones during the period 1979-2010, and show that this change in storm strength is a consequence of a simultaneous upward trend in anthropogenic black carbon and sulphate emissions. We use a combination of observational, reanalysis and model data to demonstrate that the anomalous circulation, which is radiatively forced by these anthropogenic aerosols, reduces the basin-wide vertical wind shear, creating an environment more favourable for tropical cyclone intensification. Because most Arabian Sea tropical cyclones make landfall(1), our results suggest an additional impact on human health from regional air pollution.	[Evan, Amato T.] Univ Virginia, Charlottesville, VA 22904 USA; [Kossin, James P.] NOAA, Natl Climat Data Ctr, Asheville, NC 28801 USA; [Kossin, James P.] NOAA, Cooperat Inst Meteorol Satellite Studies, Madison, WI 53706 USA; [Chung, Chul 'Eddy'] Gwangju Inst Sci & Technol, Kwangju 500712, South Korea; [Ramanathan, V.] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of Virginia; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Gwangju Institute of Science & Technology (GIST); University of California System; University of California San Diego; Scripps Institution of Oceanography	Evan, AT (corresponding author), Univ Virginia, Charlottesville, VA 22904 USA.	ate9c@virginia.edu	Evan, Amato/GZL-2684-2022; Kossin, James/C-2022-2016	Evan, Amato/0000-0003-2812-3750; Kossin, James/0000-0003-0461-9794	National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office [NA10OAR4310136]; Korea's Research Agency for Climate Science [RACS 2010-2603]; National Science Foundation [ATM-0721142]	National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office(National Oceanic Atmospheric Admin (NOAA) - USA); Korea's Research Agency for Climate Science; National Science Foundation(National Science Foundation (NSF))	Partial funding for this work was provided by National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office (NA10OAR4310136), Korea's Research Agency for Climate Science (RACS 2010-2603) and the National Science Foundation (ATM-0721142). Data from National Centers for Environmental Prediction reanalyses 1 and 2 were provided by the NOAA/Office of Oceanic and Atmospheric Research/Earth System Research Laboratory Physical Sciences Division, Boulder, Colorado, USA, from their website (http://www.esrl.noaa.gov/psd/).	Chung CE, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006356; Chung CE, 2003, J CLIMATE, V16, P1791, DOI 10.1175/1520-0442(2003)016<1791:SAHFRI>2.0.CO;2; Chung CE, 2006, J CLIMATE, V19, P2036, DOI 10.1175/JCLI3820.1; Dash SK, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010572; DeMaria M, 1999, WEATHER FORECAST, V14, P326, DOI 10.1175/1520-0434(1999)014<0326:AUSHIP>2.0.CO;2; Dvorak V. F., 1984, 11 NOAA; Elsberry RL, 1996, MON WEATHER REV, V124, P1374, DOI 10.1175/1520-0493(1996)124<1374:VWSIOT>2.0.CO;2; Elsner JB, 2008, NATURE, V455, P92, DOI 10.1038/nature07234; Emanuel K, 2003, ANNU REV EARTH PL SC, V31, P75, DOI 10.1146/annurev.earth.31.100901.141259; EMANUEL KA, 1988, J ATMOS SCI, V45, P1143, DOI 10.1175/1520-0469(1988)045<1143:TMIOH>2.0.CO;2; Evan AT, 2011, J CLIMATE, V24, P140, DOI 10.1175/2010JCLI3611.1; Frank WM, 2001, MON WEATHER REV, V129, P2249, DOI 10.1175/1520-0493(2001)129<2249:EOVWSO>2.0.CO;2; GRAY WM, 1968, MON WEATHER REV, V96, P669, DOI 10.1175/1520-0493(1968)096<0669:GVOTOO>2.0.CO;2; Integrated assessment of black carbon and tropospheric ozone, 2011, UNEPGC26INF20 WORLD; Kanamitsu M, 2002, B AM METEOROL SOC, V83, P1631, DOI [10.1175/BAMS-83-11-1631(2002)083<1631:NAR>2.3.CO;2, 10.1175/Bams-83-11-1631]; Kiehl JT, 1998, J CLIMATE, V11, P1131, DOI 10.1175/1520-0442(1998)011<1131:TNCFAR>2.0.CO;2; Knapp KR, 2010, B AM METEOROL SOC, V91, P363, DOI 10.1175/2009BAMS2755.1; Kossin JP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028836; Kossin JP, 2009, CLIMATIC CHANGE, V97, P329, DOI 10.1007/s10584-009-9748-2; Krishna KM, 2009, GLOBAL PLANET CHANGE, V65, P12, DOI 10.1016/j.gloplacha.2008.10.007; Kumari BP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031133; Meehl GA, 2008, J CLIMATE, V21, P2869, DOI 10.1175/2007JCLI1777.1; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; Ramanathan V, 2005, P NATL ACAD SCI USA, V102, P5326, DOI 10.1073/pnas.0500656102; Rao VB, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034729; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Singh OP, 2001, CURR SCI INDIA, V80, P575; Wang C, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040114	28	109	111	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2011	479	7371					94	U119		10.1038/nature10552	http://dx.doi.org/10.1038/nature10552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051678				2022-12-28	WOS:000296422600038
J	Rougier, GW; Apesteguia, S; Gaetano, LC				Rougier, Guillermo W.; Apesteguia, Sebastian; Gaetano, Leandro C.			Highly specialized mammalian skulls from the Late Cretaceous of South America	NATURE			English	Article							ARGENTINA; PATAGONIA; SYMMETRODONTA; PHYLOGENY	Dryolestoids are an extinct mammalian group belonging to the lineage leading to modern marsupials and placentals(1,2). Dryolestoids are known by teeth and jaws from the Jurassic period of North America and Europe(2,3), but they thrived in South America up to the end of the Mesozoic era and survived to the beginnings of the Cenozoic(2,4-7). Isolated teeth and jaws from the latest Cretaceous of South America provide mounting evidence that, at least in western Gondwana, dryolestoids developed into strongly endemic groups by the Late Cretaceous(4-9). However, the lack of pre-Late Cretaceous dryolestoid remains made study of their origin and early diversification intractable. Here we describe the first mammalian remains from the early Late Cretaceous of South America, including two partial skulls and jaws of a derived dryolestoid showing dental and cranial features unknown among any other group of Mesozoic mammals, such as single-rooted molars preceded by double-rooted premolars, combined with a very long muzzle, exceedingly long canines and evidence of highly specialized masticatory musculature. On one hand, the new mammal shares derived features of dryolestoids(1-3) with forms from the Jurassic of Laurasia, whereas on the other hand, it is very specialized and highlights the endemic, diverse dryolestoid fauna from the Cretaceous of South America. Our specimens include only the second mammalian skull known for the Cretaceous of Gondwana, bridging a previous 60-million-year gap in the fossil record, and document the whole cranial morphology of a dryolestoid, revealing an unsuspected morphological and ecological diversity for non-tribosphenic mammals.	[Rougier, Guillermo W.] Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40202 USA; [Apesteguia, Sebastian] Univ Maimonides, CEBBAD Fdn Hist Nat Felix de Azara, RA-1405 Buenos Aires, DF, Argentina; [Apesteguia, Sebastian; Gaetano, Leandro C.] Consejo Nacl Invest Cient & Tecn, CONICET, Buenos Aires, DF, Argentina; [Gaetano, Leandro C.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Cs Geol, Buenos Aires, DF, Argentina	University of Louisville; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rougier, GW (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40202 USA.	grougier@louisville.edu	Apesteguía, Sebastian/F-4034-2018	Apesteguía, Sebastian/0000-0002-0414-0524	Antorchas Foundation; American Museum of Natural History; NSF [DEB 0946430, DEB 1068089, ATOL 0629959]; Jurassic Foundation; NASA; Field Museum Womens' Board	Antorchas Foundation; American Museum of Natural History; NSF(National Science Foundation (NSF)); Jurassic Foundation; NASA(National Aeronautics & Space Administration (NASA)); Field Museum Womens' Board	We thank M. Salinas, P. A. Gallina and P. J. Makovicky for finding the best specimens; the Avelas and Pincheira families for logistical support; C. Munoz and R. Barbieri from the MPCA for access to collections under their care; J. A. Gonzalez and A. Davidson for illustration and technical assistance. Field work permits and loans were facilitated by M. Solorza. C. Corbitt and J. R. Wible read an earlier version of the manuscript. Field work and research was supported by the Antorchas Foundation, American Museum of Natural History and NSF grants DEB 0946430, DEB 1068089 and ATOL 0629959 (to G. W. R.), The Jurassic Foundation (to S. A.) and NASA and Field Museum Womens' Board (to P. J. Makovicky). This is L.C.G.'s R-46 contribution to the IDEAN.	Apesteguia S, 2006, NATURE, V440, P1037, DOI 10.1038/nature04413; Apesteguia S, 2003, NATURE, V425, P609, DOI 10.1038/nature01995; Bonaparte J. F, 1986, ACT 4 C ARG PAL BIOE, V2, P63; BONAPARTE JF, 1990, NATL GEOGR RES, V6, P63; Bonaparte JF., 1994, BERLINER GEOWISS, V13, P30; Bonaparte Jose F., 1992, Ameghiniana, V29, P99; Chornogubsky L., 2011, PALAONT, V85, P1; FOX RC, 1985, J PALEONTOL, V59, P21; Gallina Pablo A., 2005, Revista del Museo Argentino de Ciencias Naturales, V7, P153; Gelfo J. N., 2001, GEODIVERSITAS, V23, P69; Gurovich Y, 2009, J MAMM EVOL, V16, P25, DOI 10.1007/s10914-008-9097-3; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Krebs Bernard, 1998, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V28, P91; Leanza HA, 2004, CRETACEOUS RES, V25, P61, DOI 10.1016/j.cretres.2003.10.005; Luo ZX, 2002, ACTA PALAEONTOL POL, V47, P1; Makovicky PJ, 2005, NATURE, V437, P1007, DOI 10.1038/nature03996; Martin Thomas, 1999, Abhandlungen der Senckenbergischen Naturforschenden Gesellschaft, V550, P1; Meng J, 2011, NATURE, V472, P181, DOI 10.1038/nature09921; Migale, 2010, PROTOMAMIFEROS MAMIF; Paez Arango N., 2008, THESIS U LOUISVILLE; Prothero D.R., 1981, Bulletin of the American Museum of Natural History, V167, P281; Rougier G. W., 2011, DINOSAURIOS PALEONTO, P195; Rougier Guillermo W., 2006, P269; Rougier GW, 2009, ACTA PALAEONTOL POL, V54, P195, DOI 10.4202/app.2006.0026; Rowe T, 2008, P NATL ACAD SCI USA, V105, P1238, DOI 10.1073/pnas.0706385105; Sigogneau-Russell D, 1998, CRETACEOUS RES, V19, P445, DOI 10.1006/cres.1998.0115; Sigogneau-Russell D, 1995, B MUSEUM NATL HIST N, V16, P291; TURNBULL W D, 1970, Fieldiana Geology, V18, P153; Wible JR, 2009, B AM MUS NAT HIST, P1, DOI 10.1206/623.1; Wilson GP, 2007, J VERTEBR PALEONTOL, V27, P521, DOI 10.1671/0272-4634(2007)27[521:LCSGFI]2.0.CO;2	30	77	84	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2011	479	7371					98	102		10.1038/nature10591	http://dx.doi.org/10.1038/nature10591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051679				2022-12-28	WOS:000296422600039
J	Dahabreh, IJ; Hadar, N; Chung, M				Dahabreh, Issa J.; Hadar, Nira; Chung, Mei			Emerging Magnetic Resonance Imaging Technologies for Musculoskeletal Imaging Under Loading Stress: Scope of the Literature	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-BACK-PAIN; LUMBAR SPINE; TIBIOFEMORAL KINEMATICS; MRI ANALYSIS; COMPUTED-TOMOGRAPHY; CANAL DIAMETER; PATELLA ALTA; FACET JOINT; UPRIGHT MRI; AXIAL LOAD	Imaging under loading stress is hypothesized to improve the diagnostic value of magnetic resonancel imaging (MRI) for musculoskeletal conditions. This article reviews 57 studies about MRI under physiologic loading stress performed in an upright or sitting position or under axial loading by using a compression device. The most commonly imaged regions were the spine (33 studies) and knee (13 studies). Most studies had a cross-sectional (n = 37) or case-control (n = 13) design and reported on anatomical measurements rather than patient-relevant end points. Studies were generally small: The median (25th, 75th percentile) number of case patients was 26 (17, 45), and the median (25th, 75th percentile) number of control participants was 13 (12, 20 for case-control studies). Fifteen of 57 studies used at least 2 imaging tests and reported on diagnostic or patient-relevant outcomes but did not report meaningful information on the relative performance of the tests. In 10 studies that included information on adverse effects, 5% to 15% of participants reported new-onset or worsening pain and neuropathy during MRI under loading stress. Overall, evidence is insufficient to support the clinical utility of MRI under loading stress for musculoskeletal conditions.	[Dahabreh, Issa J.; Hadar, Nira; Chung, Mei] Tufts Med Ctr, Ctr Clin Evidence Synth, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	Tufts Medical Center	Chung, M (corresponding author), Tufts Med Ctr, Ctr Clin Evidence Synth, Inst Clin Res & Hlth Policy Studies, 800 Washington St,Box 63, Boston, MA 02111 USA.	mchung1@tuftsmedicalcenter.org			AHRQ [290-2007-100551]	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	By contract 290-2007-100551 from the AHRQ.	Adam C, 2010, STUD HEALTH TECHNOL, V158, P38, DOI 10.3233/978-1-60750-573-0-38; Agency for Healthcare Research and Quality, 2010, TECHN BRIEF US SAF P; Ahn TJ, 2009, NEUROL MED-CHIR, V49, P242, DOI 10.2176/nmc.49.242; Altman DG, 1996, BRIT MED J, V312, P572, DOI 10.1136/bmj.312.7030.572; [Anonymous], 2007, OCCUPATIONAL MED PRA; Beastall J, 2007, SPINE, V32, P685, DOI 10.1097/01.brs.0000257578.44134.fb; Boxheimer L, 2006, RADIOLOGY, V238, P221, DOI 10.1148/radiol.2381041234; Chung M, 2011, AHRQ PUBLICATION; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; Daffner Scott D, 2009, Spine (Phila Pa 1976), V34, P2389, DOI 10.1097/BRS.0b013e3181b20054; Danielson BI, 1998, ACTA RADIOL, V39, P604, DOI 10.3109/02841859809175484; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102; Draper CE, 2009, J ORTHOP RES, V27, P571, DOI 10.1002/jor.20790; Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543; Glirtcheff SE, 2008, CLIN OBSTET GYNECOL, V51, P120, DOI 10.1097/GRF.0b013e318161e657; Hansson T, 2009, EUR SPINE J, V18, P679, DOI 10.1007/s00586-009-0919-7; Haralson RH, 2009, JAMA-J AM MED ASSOC, V302, P1586, DOI 10.1001/jama.2009.1489; Hebert LJ, 2003, J MAGN RESON IMAGING, V18, P72, DOI 10.1002/jmri.10327; Hetrick SE, 2010, J EVAL CLIN PRACT, V16, P1025, DOI 10.1111/j.1365-2753.2008.01112.x; Hiwatashi A, 2004, AM J NEURORADIOL, V25, P170; Huang KY, 2009, EUR SPINE J, V18, P1851, DOI 10.1007/s00586-009-1059-9; Juniper M, 2009, EXPERT OPIN PHARMACO, V10, P2581, DOI 10.1517/14656560903304063; Karadimas EJ, 2006, J SPINAL DISORD TECH, V19, P495, DOI 10.1097/01.bsd.0000211213.98070.c2; Kimura S, 2005, J NEUROSURG-SPINE, V2, P137, DOI 10.3171/spi.2005.2.2.0137; Kong MH, 2009, SPINE, V34, P2537, DOI 10.1097/BRS.0b013e3181b353ea; Kong MH, 2009, J NEUROSURG-SPINE, V10, P357, DOI 10.3171/2008.12.SPINE08321; Kulig K, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-8; Lee SU, 2009, PM&R, V1, P541, DOI 10.1016/j.pmrj.2009.03.014; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Logan M, 2004, AM J SPORT MED, V32, P720, DOI 10.1177/0095399703258771; Logan MC, 2004, AM J SPORT MED, V32, P984, DOI 10.1177/0363546503261702; Logan MC, 2004, AM J SPORT MED, V32, P369, DOI 10.1177/0095399703258698; Madsen R, 2008, SPINE, V33, P61, DOI 10.1097/BRS.0b013e31815e395f; Manenti G, 2003, IN VIVO, V17, P413; McGregor A, 2002, MED SCI SPORT EXER, V34, P1143, DOI 10.1097/00005768-200207000-00015; McGregor AH, 2002, BRIT J SPORT MED, V36, P214, DOI 10.1136/bjsm.36.3.214; McGregor AH, 2002, SPINE, V27, P1582, DOI 10.1097/00007632-200207150-00019; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; McWalter EJ, 2007, J BONE JOINT SURG AM, V89A, P2723, DOI 10.2106/JBJS.F.01016; MELENDEZ JC, 1993, JAMA-J AM MED ASSOC, V270, P745, DOI 10.1001/jama.270.6.745; Mitchell JM, 2008, MED CARE, V46, P460, DOI 10.1097/MLR.0b013e31815dc5ae; Miyazaki M, 2010, J SPINAL DISORD TECH, V23, P242, DOI 10.1097/BSD.0b013e3181a8123e; Morishita Y, 2008, J Orthop Surg (Hong Kong), V16, P348; Morishita Y, 2009, EUR SPINE J, V18, P877, DOI 10.1007/s00586-009-0968-y; Nath RK, 2007, MAGN RESON IMAGING, V25, P1277, DOI 10.1016/j.mri.2007.02.008; OECD, 2010, OECD HLTH DAT 2010 F; Okike K, 2011, J CLIN EPIDEMIOL, V64, P331, DOI 10.1016/j.jclinepi.2010.03.019; Patel VV, 2004, J ORTHOP RES, V22, P283, DOI 10.1016/j.orthres.2003.08.015; Perez AF, 2007, EUR J RADIOL, V62, P444, DOI 10.1016/j.ejrad.2006.12.007; Powers CM, 2008, PHYS THER, V88, P485, DOI 10.2522/ptj.20070069; Roseman M, 2011, JAMA-J AM MED ASSOC, V305, P1008, DOI 10.1001/jama.2011.257; Roudsari B, 2010, AM J ROENTGENOL, V195, P550, DOI 10.2214/AJR.10.4367; Senn SJ, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-10; Shefelbine SJ, 2006, J ORTHOP RES, V24, P1208, DOI 10.1002/jor.20139; Shellock F G, 2000, Am J Knee Surg, V13, P137; SHELLOCK FG, 1993, RADIOLOGY, V188, P575, DOI 10.1148/radiology.188.2.8327718; Siddiqui M, 2005, SPINE, V30, P2677, DOI 10.1097/01.brs.0000187878.79676.26; Siddiqui M, 2006, SPINE, V31, P2958, DOI 10.1097/01.brs.0000247797.92847.7d; Siddiqui M, 2006, J SPINAL DISORD TECH, V19, P328, DOI 10.1097/01.bsd.0000211297.52260.d5; Skelly AC., 2007, COMPREHENSIVE EVIDEN; Steiner ME, 2001, AM J SPORT MED, V29, P593, DOI 10.1177/03635465010290051201; Stewart WF, 2003, J OCCUP ENVIRON MED, V45, P1234, DOI 10.1097/01.jom.0000099999.27348.78; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Sutera R, 2010, RADIOL MED, V115, P246, DOI 10.1007/s11547-010-0534-z; Vitaz TW, 2004, SOUTH MED J, V97, P456, DOI 10.1097/00007611-200405000-00008; Vitzthum HE, 2000, J NEUROSURG, V93, P58, DOI 10.3171/spi.2000.93.1.0058; Wang YC, 2008, J FORMOS MED ASSOC, V107, P334, DOI 10.1016/S0929-6646(08)60095-9; Ward SR, 2007, J BONE JOINT SURG AM, V89A, P1749, DOI 10.2106/JBJS.F.00508; Ward SR, 2005, J BIOMECH, V38, P2415, DOI 10.1016/j.jbiomech.2004.10.010; Weiner DK, 2006, PAIN MED, V7, P143, DOI 10.1111/j.1526-4637.2006.00112.x; Weishaupt D, 2000, RADIOLOGY, V215, P247, DOI 10.1148/radiology.215.1.r00ap06247; Weishaupt D, 2003, RADIOLOGY, V226, P849, DOI 10.1148/radiol.2263011925; Wessberg P, 2006, SPINE, V31, P3039, DOI 10.1097/01.brs.0000249513.91050.80; Wildermuth S, 1998, RADIOLOGY, V207, P391, DOI 10.1148/radiology.207.2.9577486; Willen J, 1997, SPINE, V22, P2968, DOI 10.1097/00007632-199712150-00021; Willen J, 2001, SPINE, V26, P2607, DOI 10.1097/00007632-200112010-00016; Willen J, 2008, SPINE, V33, pE109, DOI 10.1097/BRS.0b013e318163f9ab; Zamani AA, 1998, JMRI-J MAGN RESON IM, V8, P1329, DOI 10.1002/jmri.1880080622; Zou J, 2008, SPINE, V33, pE140, DOI 10.1097/BRS.0b013e3181657f7e; Zou J, 2009, SPINE, V34, P2545, DOI 10.1097/BRS.0b013e3181b32998	80	21	21	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					616	U109		10.7326/0003-4819-155-9-201111010-00009	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00009			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041950				2022-12-28	WOS:000296612400006
J	Chang, HC; Paek, J; Kim, DH				Chang, Howard C.; Paek, Jennifer; Kim, Dennis H.			Natural polymorphisms in C. elegans HECW-1 E3 ligase affect pathogen avoidance behaviour	NATURE			English	Article							CAENORHABDITIS-ELEGANS; SOCIAL-BEHAVIOR; BACTERIA; PATHWAY; KINASE; HOMOLOG; SYSTEM	Heritable variation in behavioural traits generally has a complex genetic basis(1), and thus naturally occurring polymorphisms that influence behaviour have been defined only in rare instances(2,3). The isolation of wild strains of Caenorhabditis elegans has facilitated the study of natural genetic variation in this species(4) and provided insights into its diverse microbial ecology(5). C. elegans responds to bacterial infection with conserved innate immune responses(6-8) and, although lacking the immunological memory of vertebrate adaptive immunity, shows an aversive learning response to pathogenic bacteria(9). Here, we report the molecular characterization of naturally occurring coding polymorphisms in a C. elegans gene encoding a conserved HECT domain-containing E3 ubiquitin ligase, HECW-1. We show that two distinct polymorphisms in neighbouring residues of HECW-1 each affect C. elegans behavioural avoidance of a lawn of Pseudomonas aeruginosa. Neuron-specific rescue and ablation experiments and genetic interaction analysis indicate that HECW-1 functions in a pair of sensory neurons to inhibit P. aeruginosa lawn avoidance behaviour through inhibition of the neuropeptide receptor NPR-1 (ref. 10), which we have previously shown promotes P. aeruginosa lawn avoidance behaviour(11). Our data establish a molecular basis for natural variation in a C. elegans behaviour that may undergo adaptive changes in response to microbial pathogens.	[Chang, Howard C.; Paek, Jennifer; Kim, Dennis H.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kim, DH (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dhkim@mit.edu		Chang, Howard/0000-0003-4310-8890	NIH-National Center for Research Resources; NIH [GM084477]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084477] Funding Source: NIH RePORTER	NIH-National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Denning and H. R. Horvitz for the csp-1b cDNA. We thank Y. Kohara for the hecw-1 and npr-1 cDNAs. We thank J. Meisel for sequencing of hecw-1 polymorphisms. We thank D. Ma for technical advice on laser ablation. We thank T. Schwartz for expert advice with the structural modeling of HECW-1. The hecw-1(ok1347) deletion allele was generated by the C. elegans Knockout Consortium and obtained, along with other strains used in this study, from the Caenorhabditis Genetics Center (CGC), which is supported by the NIH-National Center for Research Resources. This work was supported by NIH Grant GM084477 (to D.H.K.).	Barriere A, 2005, NATURAL VARIATION PO, DOI [DOI 10.1895/WORMBOOK.1.43.1, 10.1895/wormbook.1.43.1]; Bendesky A, 2011, NATURE, V472, P313, DOI 10.1038/nature09821; BRENNER S, 1974, GENETICS, V77, P71; Chang AJ, 2006, PLOS BIOL, V4, P1588, DOI 10.1371/journal.pbio.0040274; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Felix MA, 2010, CURR BIOL, V20, pR965, DOI 10.1016/j.cub.2010.09.050; Flint J, 2009, GENOME RES, V19, P723, DOI 10.1101/gr.086660.108; Frokjaer-Jensen C, 2008, NAT GENET, V40, P1375, DOI 10.1038/ng.248; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Macosko EZ, 2009, NATURE, V458, P1171, DOI 10.1038/nature07886; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; McGrath PT, 2009, NEURON, V61, P692, DOI 10.1016/j.neuron.2009.02.012; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Nicholas HR, 2004, CURR BIOL, V14, P1256, DOI 10.1016/j.cub.2004.07.022; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Pradel E, 2007, P NATL ACAD SCI USA, V104, P2295, DOI 10.1073/pnas.0610281104; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Reddy KC, 2011, P NATL ACAD SCI USA, V108, P12887, DOI 10.1073/pnas.1108265108; Reddy KC, 2009, SCIENCE, V323, P382, DOI 10.1126/science.1166527; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Shivers RP, 2009, CELL HOST MICROBE, V6, P321, DOI 10.1016/j.chom.2009.09.001; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Tsalik EL, 2003, DEV BIOL, V263, P81, DOI 10.1016/S0012-1606(03)00447-0; Weber KP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013922; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216	30	58	64	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					525	U148		10.1038/nature10643	http://dx.doi.org/10.1038/nature10643			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22089131	Green Accepted, Green Submitted			2022-12-28	WOS:000298318000061
J	de Boer, IH; Sun, WJ; Cleary, PA; Lachin, JM; Molitch, ME; Steffes, MW; Zinman, B				de Boer, Ian H.; Sun, Wanjie; Cleary, Patricia A.; Lachin, John M.; Molitch, Mark E.; Steffes, Michael W.; Zinman, Bernard		DCCT EDIC Res Grp	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLICATIONS TRIAL; DISEASE; INTERVENTIONS; EPIDEMIOLOGY; ALBUMINURIA; NEPHROPATHY; MELLITUS; OUTCOMES	BACKGROUND An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population. METHODS In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits. RESULTS Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P = 0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventionaltherapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates. CONCLUSIONS The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.)	[de Boer, Ian H.] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA; [Sun, Wanjie; Cleary, Patricia A.; Lachin, John M.] George Washington Univ, Rockville, MD USA; [Molitch, Mark E.] Northwestern Univ, Chicago, IL 60611 USA; [Steffes, Michael W.] Univ Minnesota, Minneapolis, MN USA; [Zinman, Bernard] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Washington; University of Washington Seattle; George Washington University; Northwestern University; University of Minnesota System; University of Minnesota Twin Cities; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	de Boer, IH (corresponding author), Univ Washington, Kidney Res Inst, Box 359606,925 9th Ave, Seattle, WA 98104 USA.	deboer@u.washington.edu	van der Geest, Rob J/J-8193-2015; Bull, Shelley B/A-1920-2013; Zinman, Bernard/E-7266-2013; de Boer, Ian/GYJ-3282-2022	van der Geest, Rob J/0000-0002-9084-5597; Lachin, John/0000-0001-9838-2841; Kiss, Szilard/0000-0003-3433-8432	National Institute of Diabetes and Digestive and Kidney Diseases; Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Eye Institute, National Institute of Neurological Disorders and Stroke; General Clinical Research Center; Clinical and Translational Science Awards Program; National Center for Research Resources; Genentech through a Cooperative Research and Development Agreement; NIDDK [R01DK087726, R01DK088762, RC4DK090766]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [RC4DK090766, R01DK087726, R01DK088762] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Eye Institute, National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH National Eye Institute (NEI)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical and Translational Science Awards Program; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Genentech through a Cooperative Research and Development Agreement; NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.; Supported by contracts with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Eye Institute, National Institute of Neurological Disorders and Stroke, and the General Clinical Research Centers Program and by funding from the Clinical and Translational Science Awards Program, National Center for Research Resources, and Genentech through a Cooperative Research and Development Agreement with the NIDDK. Additional support for this study came from grants (R01DK087726, R01DK088762, and RC4DK090766) from the NIDDK. Free or discounted supplies or equipment were contributed by Abbott, Animas, Aventis, Bayer, Becton Dickinson, Can Am, Eli Lilly, LifeScan, Medtronic, MiniMed, Omron, OmniPod, Roche, and Sanofi-Aventis. These companies had no role in the design of the study or in the analysis of the data.	Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V21, P368; de Boer IH, 2011, JAMA-J AM MED ASSOC, V305, P2532, DOI 10.1001/jama.2011.861; de Boer IH, 2009, DIABETES CARE, V32, P1833, DOI 10.2337/dc09-0191; Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Finne P, 2005, JAMA-J AM MED ASSOC, V294, P1782, DOI 10.1001/jama.294.14.1782; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gray RJ, 1988, J AM STAT ASSOC, V84, p[1141, 1074]; Ismail-Beigi F, 2011, ANN INTERN MED, V154, P554, DOI 10.7326/0003-4819-154-8-201104190-00007; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; Levey AS, 2009, AM J KIDNEY DIS, V54, P205, DOI 10.1053/j.ajkd.2009.04.029; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; Molitch ME, 2010, DIABETES CARE, V33, P1536, DOI 10.2337/dc09-1098; Nathan DM, 2009, ARCH INTERN MED, V169, P1307, DOI 10.1001/archinternmed.2009.193; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Ninomiya T, 2009, J AM SOC NEPHROL, V20, P1813, DOI 10.1681/ASN.2008121270; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Steffes M, 2005, CLIN CHEM, V51, P753, DOI 10.1373/clinchem.2004.042143; Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; WISEMAN MJ, 1987, KIDNEY INT, V31, P1012, DOI 10.1038/ki.1987.100	27	372	374	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2011	365	25					2366	2376		10.1056/NEJMoa1111732	http://dx.doi.org/10.1056/NEJMoa1111732			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	865OM	22077236	Green Accepted, Green Published			2022-12-28	WOS:000298320200003
J	Kamat, SS; Williams, HJ; Raushel, FM				Kamat, Siddhesh S.; Williams, Howard J.; Raushel, Frank M.			Intermediates in the transformation of phosphonates to phosphate by bacteria	NATURE			English	Article							PYRUVATE FORMATE-LYASE; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; DEGRADATION; IDENTIFICATION; METABOLISM; CLEAVAGE; 14-GENE; OPERON	Phosphorus is an essential element for all known forms of life. In living systems, phosphorus is an integral component of nucleic acids, carbohydrates and phospholipids, where it is incorporated as a derivative of phosphate. However, most Gram-negative bacteria have the capability to use phosphonates as a nutritional source of phosphorus under conditions of phosphate starvation(1). In these organisms, methylphosphonate is converted to phosphate and methane. In a formal sense, this transformation is a hydrolytic cleavage of a carbon-phosphorus (C-P) bond, but a general enzymatic mechanism for the activation and conversion of alkylphosphonates to phosphate and an alkane has not been elucidated despite much effort for more than two decades. The actual mechanism for C-P bond cleavage is likely to be a radical-based transformation(2). In Escherichia coli, the catalytic machinery for the C-P lyase reaction has been localized to the phn gene cluster(1). This operon consists of the 14 genes phnC, phnD, ... , phnP. Genetic and biochemical experiments have demonstrated that the genes phnG, phnH, ... , phnM encode proteins that are essential for the conversion of phosphonates to phosphate and that the proteins encoded by the other genes in the operon have auxiliary functions(1,3-6). There are no functional annotations for any of the seven proteins considered essential for C-P bond cleavage. Here we show that methylphosphonate reacts with MgATP to form alpha-D-ribose-1-methylphosphonate-5-triphosphate (RPnTP) and adenine. The triphosphate moiety of RPnTP is hydrolysed to pyrophosphate and alpha-D-ribose-1-methylphosphonate-5-phosphate (PRPn). The C-P bond of PRPn is subsequently cleaved in a radical-based reaction producing alpha-D-ribose-1,2-cyclic-phosphate-5-phosphate and methane in the presence of S-adenosyl-L-methionine. Substantial quantities of phosphonates are produced worldwide for industrial processes, detergents, herbicides and pharmaceuticals(7-9). Our elucidation of the chemical steps for the biodegradation of alkylphosphonates shows how these compounds can be metabolized and recycled to phosphate.	[Kamat, Siddhesh S.; Williams, Howard J.; Raushel, Frank M.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, POB 30012, College Stn, TX 77843 USA.	raushel@tamu.edu	Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089; Kamat, Siddhesh/0000-0001-6132-7574	National Institutes of Health [GM93342, GM71790]; Robert A. Welch Foundation [A-840]; National Science Foundation [0840464]; Division Of Chemistry [0840464] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM071790, U54GM093342] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); National Science Foundation(National Science Foundation (NSF)); Division Of Chemistry(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Barondeau and his laboratory for use of the anaerobic chamber and for advice on the assembly of Fe-S clusters in radical SAM enzymes. We also thank C. Xu for help with some of the <SUP>31</SUP>P NMR spectra and S. Burrows for help with cloning phnI and phnH. This work was supported in part by the National Institutes of Health (GM93342, GM71790) and the Robert A. Welch Foundation (A-840). The cryoprobe for the NMR spectrometer was purchased with funds from the National Science Foundation (0840464)	AHN YH, 1992, J AM CHEM SOC, V114, P7953, DOI 10.1021/ja00046a075; AVILA LZ, 1991, BIOORG MED CHEM LETT, V1, P51, DOI 10.1016/S0960-894X(01)81089-1; Buis JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P288, DOI 10.1016/j.abb.2004.09.028; Chatterjee A, 2008, NAT CHEM BIOL, V4, P758, DOI 10.1038/nchembio.121; Errey JC, 2006, BIOCHEMISTRY-US, V45, P3033, DOI 10.1021/bi052297p; Frey PA, 2008, CRIT REV BIOCHEM MOL, V43, P63, DOI [10.1080/10409230701829169, 10.1080/10409230701829169 ]; FROST JW, 1987, J AM CHEM SOC, V109, P2166, DOI 10.1021/ja00241a039; Hall RS, 2011, BIOCHEMISTRY-US, V50, P5077, DOI 10.1021/bi200483k; Hove-Jensen B, 2003, J BACTERIOL, V185, P2793, DOI 10.1128/JB.185.9.2793-2801.2003; Hove-Jensen B, 2011, J AM CHEM SOC, V133, P3617, DOI 10.1021/ja1102713; Jochimsen B, 2011, P NATL ACAD SCI USA, V108, P11393, DOI 10.1073/pnas.1104922108; Kamat SS, 2011, BIOCHEMISTRY-US, V50, P1917, DOI 10.1021/bi101788n; Kononova SV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P184, DOI 10.1023/A:1014409929875; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; LaVallie E. R., 1994, CURR PROTOC MOL BIOL, V28, P5; Maynes JT, 2000, J BACTERIOL, V182, P4658, DOI 10.1128/JB.182.16.4658-4660.2000; McGlynn SE, 2010, J BACTERIOL, V192, P595, DOI 10.1128/JB.01125-09; METCALF WW, 1993, J BACTERIOL, V175, P3430, DOI 10.1128/jb.175.11.3430-3442.1993; METCALF WW, 1993, GENE, V129, P27, DOI 10.1016/0378-1119(93)90692-V; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Parker GF, 1999, J BACTERIOL, V181, P389, DOI 10.1128/JB.181.2.389-395.1999; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; Ternan NG, 1998, WORLD J MICROB BIOT, V14, P635, DOI 10.1023/A:1008848401799; Thauer RK, 2008, ANN NY ACAD SCI, V1125, P158, DOI 10.1196/annals.1419.000; White AK, 2007, ANNU REV MICROBIOL, V61, P379, DOI 10.1146/annurev.micro.61.080706.093357; Zhang Y, 2010, NATURE, V465, P891, DOI 10.1038/nature09138	26	83	93	8	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					570	573		10.1038/nature10622	http://dx.doi.org/10.1038/nature10622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22089136	Green Accepted			2022-12-28	WOS:000298318000071
J	Fawzi, NL; Ying, JF; Ghirlando, R; Torchia, DA; Clore, GM				Fawzi, Nicolas L.; Ying, Jinfa; Ghirlando, Rodolfo; Torchia, Dennis A.; Clore, G. Marius			Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed by solution NMR	NATURE			English	Article							ALZHEIMERS-DISEASE; EXPERIMENTAL CONSTRAINTS; CHEMICAL-EXCHANGE; FIBRIL FORMATION; PROTEIN; OLIGOMERS; MECHANISM; STATE; A-BETA(1-40); AGGREGATION	Exchange dynamics between molecules free in solution and bound to the surface of a large supramolecular structure, a polymer, a membrane or solid support are important in many phenomena in biology and materials science. Here we present a novel and generally applicable solution NMR technique, known as dark-state exchange saturation transfer (DEST), to probe such exchange phenomena with atomic resolution. This is illustrated by the exchange reaction between amyloid-beta (A beta) monomers and polydisperse, NMR-invisible ('dark') protofibrils, a process of significant interest because the accumulation of toxic, aggregated forms of A beta, from small oligomers to very large assemblies, has been implicated in the aetiology of Alzheimer's disease(1-6). The (15)N-DEST experiment imprints with single-residue-resolution dynamic information on the protofibril-bound species in the form of (15)N transverse relaxation rates ((15)N-R(2)) and exchange kinetics between monomers and protofibrils onto the easily observed two-dimensional (1)H-(15)N correlation spectrum of the monomer. The exchanging species on the protofibril surface comprise an ensemble of sparsely populated states where each residue is either tethered to (through other residues) or in direct contact with the surface. The first eight residues exist predominantly in a mobile tethered state, whereas the largely hydrophobic central region and part of the carboxy (C)-terminal hydrophobic region are in direct contact with the protofibril surface for a significant proportion of the time. The C-terminal residues of both A beta 40 and A beta 42 display lower affinity for the protofibril surface, indicating that they are likely to be surface exposed rather than buried as in structures of A beta fibrils(7-10), and might therefore comprise the critical nucleus for fibril formation(11,12). The (15)N-R(2)(tethered) values, however, are significantly larger for the C-terminal residues of A beta 42 than A beta 40, which might explain the former's higher propensity for rapid aggregation and fibril formation(13,14).	[Fawzi, Nicolas L.; Ying, Jinfa; Clore, G. Marius] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; [Ghirlando, Rodolfo] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; [Torchia, Dennis A.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.	mariusc@mail.nih.gov	Fawzi, Nicolas L/E-2555-2013; Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Fawzi, Nicolas L/0000-0001-5483-0577; Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health; Office of the Director of the National Institutes of Health; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK033007, ZIADK029023] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Office of the Director of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R. Tycko for discussions, D. Baber, D. Garrett and M. Cai for NMR technical assistance, F. Shewmaker for performing dot blots, and W. Qiang, B. Chen and K. Thurber for assistance with atomic force microscopy and electron microscopy imaging. This work was supported by the intramural program of the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health and the AIDS Targeted Antiviral Program of the Office of the Director of the National Institutes of Health (to G.M.C.).	Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799; Carulla N, 2005, NATURE, V436, P554, DOI 10.1038/nature03986; Carulla N, 2010, ACCOUNTS CHEM RES, V43, P1072, DOI 10.1021/ar9002784; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fawzi NL, 2010, J AM CHEM SOC, V132, P9948, DOI 10.1021/ja1048253; Fawzi NL, 2007, J MOL BIOL, V365, P535, DOI 10.1016/j.jmb.2006.10.011; Fukumoto H, 2010, FASEB J, V24, P2716, DOI 10.1096/fj.09-150359; Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200; Hansen DF, 2009, J AM CHEM SOC, V131, P12745, DOI 10.1021/ja903897e; Helgstrand M, 2000, J BIOMOL NMR, V18, P49, DOI 10.1023/A:1008309220156; Hou LM, 2004, J AM CHEM SOC, V126, P1992, DOI 10.1021/ja036813f; Ishima R, 2006, J BIOMOL NMR, V34, P209, DOI 10.1007/s10858-005-6226-7; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Lashuel HA, 2006, Q REV BIOPHYS, V39, P167, DOI 10.1017/S0033583506004422; Lee J, 2011, NAT CHEM BIOL, V7, P602, DOI [10.1038/nchembio.624, 10.1038/NCHEMBIO.624]; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Mastrangelo IA, 2006, J MOL BIOL, V358, P106, DOI 10.1016/j.jmb.2006.01.042; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; Paravastu AK, 2008, P NATL ACAD SCI USA, V105, P18349, DOI 10.1073/pnas.0806270105; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Pimplikar SW, 2009, INT J BIOCHEM CELL B, V41, P1261, DOI 10.1016/j.biocel.2008.12.015; Powers ET, 2008, BIOPHYS J, V94, P379, DOI 10.1529/biophysj.107.117168; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Riek R, 2001, EUR J BIOCHEM, V268, P5930, DOI 10.1046/j.0014-2956.2001.02537.x; Ruschak AM, 2010, NATURE, V467, P868, DOI 10.1038/nature09444; Scheidt HA, 2011, ANGEW CHEM INT EDIT, V50, P2837, DOI 10.1002/anie.201007265; SKLENAR V, 1987, J MAGN RESON, V73, P375, DOI 10.1016/0022-2364(87)90214-9; Sugase K, 2007, NATURE, V447, P1021, DOI 10.1038/nature05858; Teplow DB, 2006, ACCOUNTS CHEM RES, V39, P635, DOI 10.1021/ar050063s; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Yan YL, 2006, J MOL BIOL, V364, P853, DOI 10.1016/j.jmb.2006.09.046	32	307	306	4	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 8	2011	480	7376					268	U161		10.1038/nature10577	http://dx.doi.org/10.1038/nature10577			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857TR	22037310	Green Accepted			2022-12-28	WOS:000297744200057
J	Heusch, G				Heusch, Gerd			SCIPIO brings new momentum to cardiac cell therapy	LANCET			English	Editorial Material							REGENERATE INFARCTED MYOCARDIUM; BONE-MARROW-CELLS; STEM-CELLS; INTRACORONARY; MYOCYTES		Univ Klinikum Essen, Inst Pathophysiol, D-45122 Essen, Germany	University of Duisburg Essen	Heusch, G (corresponding author), Univ Klinikum Essen, Inst Pathophysiol, D-45122 Essen, Germany.	gerd.heusch@uk-essen.de	Heusch, Gerd/ABE-6675-2020					Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0; Dawn B, 2005, P NATL ACAD SCI USA, V102, P3766, DOI 10.1073/pnas.0405957102; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Heusch G, 2008, CIRCULATION, V118, P1915, DOI 10.1161/CIRCULATIONAHA.108.805242; Janssens SP, 2011, EUR HEART J, V32, P1697, DOI 10.1093/eurheartj/ehq513; Malliaras K, 2011, BRIT MED BULL, V98, P161, DOI 10.1093/bmb/ldr018; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Sanganalmath SK, 2011, BASIC RES CARDIOL, V106, P709, DOI 10.1007/s00395-011-0183-y; Strauer BE, 2001, DEUT MED WOCHENSCHR, V126, P932, DOI 10.1055/s-2001-16579-1; Strauer BE, 2011, J AM COLL CARDIOL, V58, P1095, DOI 10.1016/j.jacc.2011.06.016	13	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 26	2011	378	9806					1827	1828		10.1016/S0140-6736(11)61648-6	http://dx.doi.org/10.1016/S0140-6736(11)61648-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857DQ	22088799				2022-12-28	WOS:000297695800008
J	Macke, E; Magalhaes, S; Bach, F; Olivieri, I				Macke, Emilie; Magalhaes, Sara; Bach, Fabien; Olivieri, Isabelle			Experimental Evolution of Reduced Sex Ratio Adjustment Under Local Mate Competition	SCIENCE			English	Article							MITE TETRANYCHUS-URTICAE; SPIDER-MITES; FIG WASPS; PHENOTYPIC PLASTICITY; SELECTION; ALLOCATION; DENSITY	Theory predicts that local mate competition (LMC) favors the evolution of female-biased sex ratios. Empirical support of this prediction is indirect and comes from comparative studies or from studies showing that individuals can adjust their offspring sex ratio in response to varying LMC intensities. Replicate lines from a population of the spider mite Tetranychus urticae were selected under three LMC intensities for up to 54 generations. Within each selection regime, the final sex ratio matched theoretical predictions. Furthermore, the ability of individuals to adjust their offspring sex ratio diminished in females evolving under strict LMC, but not in females evolving under relaxed LMC levels. These results provide direct experimental evidence for the evolutionary process by which LMC modifies sex-allocation strategies and suggest that evolution under strict and constant LMC may lead to a loss of phenotypic plasticity.	[Macke, Emilie; Bach, Fabien; Olivieri, Isabelle] Univ Montpellier 2, UMR 5554, Inst Sci Evolut, F-34095 Montpellier 05, France; [Magalhaes, Sara] Univ Lisbon, Fac Ciencias, Ctr Biol Ambiental, P-1749016 Lisbon, Portugal	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Universidade de Lisboa	Macke, E (corresponding author), Univ Montpellier 2, UMR 5554, Inst Sci Evolut, Pl Eugene Bataillon, F-34095 Montpellier 05, France.	emilie.macke@univ-montp2.fr; snmagalhaes@fc.ul.pt; isabelle.olivieri@univ-montp2.fr	S., Magalhaes/B-9673-2012; Olivieri, Isabelle/E-5872-2016	S., Magalhaes/0000-0002-8609-7768; Macke, Emilie/0000-0002-5257-4968	University of Montpellier 2; Agence Nationale de la Recherche; Institut Universitaire de France; CNRS	University of Montpellier 2; Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut Universitaire de France; CNRS(Centre National de la Recherche Scientifique (CNRS))	We thank D. Bonte, D. Bourguet, P. David, M. Egas, B. Facon, A. Janssen, G. Martin, Y. Michalakis, M. Navajas, C. Parmesan, M.-J. Perrot-Minot, A. Rivero, F. Vala, and S. West for useful discussion and comments. We particularly thank E. A. Herre for useful suggestions during the revision process of the manuscript. M. Weill kindly tested for the presence of Wolbachia and Cardinium in our base population. D. Carbonell provided technical help by growing plant material. F. Bach was supported by The University of Montpellier 2. The research was supported by Agence Nationale de la Recherche contract "GENEVOLSPE" and Institut Universitaire de France to I.O. and a Programme International de Cooperation Scientifique (PICS 2010-2012) from CNRS to I.O. and S. M. This is publication ISEM-2011-129 from The Institut des Sciences de l'Evolution, Montpellier. Data and SAS script files are available as supporting online material.	CHARNOV E L, 1982; COLWELL RK, 1981, NATURE, V290, P401, DOI 10.1038/290401a0; DeWitt TJ, 1998, TRENDS ECOL EVOL, V13, P77, DOI 10.1016/S0169-5347(97)01274-3; Fellowes MDE, 1999, BEHAV ECOL SOCIOBIOL, V46, P95, DOI 10.1007/s002650050597; Fisher R.A., 1930, GENETICAL THEORY NAT; FRANK SA, 1985, EVOLUTION, V39, P949, DOI 10.1111/j.1558-5646.1985.tb00440.x; Greeff JM, 2011, EVOLUTION, V65, P203, DOI 10.1111/j.1558-5646.2010.01116.x; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hardy I.C.W, 2002, SEX RATIOS CONCEPTS; HERRE EA, 1987, NATURE, V329, P627, DOI 10.1038/329627a0; HERRE EA, 1985, SCIENCE, V228, P896, DOI 10.1126/science.228.4701.896; MITCHELL R, 1972, ENTOMOL EXP APPL, V15, P299, DOI 10.1007/BF00428294; Nagelkerke CJ, 1998, J EVOLUTION BIOL, V11, P649, DOI 10.1007/s000360050112; Orzack S. H., 1992, EVOLUTION DIVERSITY, P477; Roeder C, 1996, J EVOLUTION BIOL, V9, P143, DOI 10.1046/j.1420-9101.1996.9020143.x; ROEDER CM, 1992, CAN J ZOOL, V70, P1965, DOI 10.1139/z92-266; Sato Y, 2007, ECOL ENTOMOL, V32, P597, DOI 10.1111/j.1365-2311.2007.00908.x; Sultan SE, 2002, AM NAT, V160, P271, DOI 10.1086/341015; TAYLOR PD, 1980, J THEOR BIOL, V86, P409, DOI 10.1016/0022-5193(80)90342-2; Tien N. A., 2010, THESIS U AMSTERDAM; Vala F, 2003, AM NAT, V161, P254, DOI 10.1086/345856; VIA S, 1985, EVOLUTION, V39, P505, DOI 10.1111/j.1558-5646.1985.tb00391.x; West S., 2009, SEX ALLOCATION; West SA, 1998, EVOLUTION, V52, P475, DOI 10.1111/j.1558-5646.1998.tb01647.x; West SA, 2000, SCIENCE, V290, P288, DOI 10.1126/science.290.5490.288; WRENSCH DL, 1978, ENVIRON ENTOMOL, V7, P499, DOI 10.1093/ee/7.4.499; YOUNG SSY, 1986, ENTOMOL EXP APPL, V40, P53, DOI 10.1007/BF00187023	27	57	59	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 25	2011	334	6059					1127	1129		10.1126/science.1212177	http://dx.doi.org/10.1126/science.1212177			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852AF	22052976				2022-12-28	WOS:000297313900049
J	Peterson, ED; Gaziano, JM				Peterson, Eric D.; Gaziano, J. Michael			Cardiology in 2011-Amazing Opportunities, Huge Challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												peter016@mc.duke.edu; jmgaziano@partners.org	Peterson, Eric David/ABF-5033-2021					Canto JG, 2011, JAMA-J AM MED ASSOC, V306, P2120, DOI 10.1001/jama.2011.1654; Lauer MS, 2011, JAMA-J AM MED ASSOC, V306, P2145, DOI 10.1001/jama.2011.1669; Mack MJ, 2011, JAMA-J AM MED ASSOC, V306, P2149, DOI 10.1001/jama.2011.1675; Nicholls SJ, 2011, JAMA-J AM MED ASSOC, V306, P2099, DOI 10.1001/jama.2011.1649; Ovbiagele B, 2011, JAMA-J AM MED ASSOC, V306, P2137, DOI 10.1001/jama.2011.1650; Prasad V, 2011, JAMA-J AM MED ASSOC, V306, P2151, DOI 10.1001/jama.2011.1673; Shreibati JB, 2011, JAMA-J AM MED ASSOC, V306, P2128, DOI 10.1001/jama.2011.1652; Tomaselli GF, 2011, JAMA-J AM MED ASSOC, V306, P2147, DOI 10.1001/jama.2011.1668; Traverse JH, 2011, JAMA-J AM MED ASSOC, V306, P2110, DOI 10.1001/jama.2011.1670	9	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2158	2159		10.1001/jama.2011.1691	http://dx.doi.org/10.1001/jama.2011.1691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089727				2022-12-28	WOS:000297013000027
J	Canfield, SE				Canfield, Steven E.			Adding short-term androgen-deprivation therapy to radiotherapy improved survival in localized prostate cancer	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Texas Med Sch Houston, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Canfield, SE (corresponding author), Univ Texas Med Sch Houston, Houston, TX 77030 USA.							Bannuru RR, 2011, ANN INTERN MED, V155, P171, DOI 10.7326/0003-4819-155-3-201108020-00347; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283	2	1	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-7	10.7326/0003-4819-155-10-201111150-02007	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084354				2022-12-28	WOS:000208885300006
J	Cruz-Migoni, A; Hautbergue, GM; Artymiuk, PJ; Baker, PJ; Bokori-Brown, M; Chang, CT; Dickman, MJ; Essex-Lopresti, A; Harding, SV; Mahadi, NM; Marshall, LE; Mobbs, GW; Mohamed, R; Nathan, S; Ngugi, SA; Ong, C; Ooi, WF; Partridge, LJ; Phillips, HL; Raih, MF; Ruzheinikov, S; Sarkar-Tyson, M; Sedelnikova, SE; Smither, SJ; Tan, P; Titball, RW; Wilson, SA; Rice, DW				Cruz-Migoni, Abimael; Hautbergue, Guillaume M.; Artymiuk, Peter J.; Baker, Patrick J.; Bokori-Brown, Monika; Chang, Chung-Te; Dickman, Mark J.; Essex-Lopresti, Angela; Harding, Sarah V.; Mahadi, Nor Muhammad; Marshall, Laura E.; Mobbs, George W.; Mohamed, Rahmah; Nathan, Sheila; Ngugi, Sarah A.; Ong, Catherine; Ooi, Wen Fong; Partridge, Lynda J.; Phillips, Helen L.; Raih, M. Firdaus; Ruzheinikov, Sergei; Sarkar-Tyson, Mitali; Sedelnikova, Svetlana E.; Smither, Sophie J.; Tan, Patrick; Titball, Richard W.; Wilson, Stuart A.; Rice, David W.			A Burkholderia pseudomallei Toxin Inhibits Helicase Activity of Translation Factor eIF4A	SCIENCE			English	Article							INITIATION; RNA; DEAMIDATION; MELIOIDOSIS; ACTIVATION; GLUTAMINE; COMPLEX; FAMILY; RHO	The structure of BPSL1549, a protein of unknown function from Burkholderia pseudomallei, reveals a similarity to Escherichia coli cytotoxic necrotizing factor 1. We found that BPSL1549 acted as a potent cytotoxin against eukaryotic cells and was lethal when administered to mice. Expression levels of bpsl1549 correlate with conditions expected to promote or suppress pathogenicity. BPSL1549 promotes deamidation of glutamine-339 of the translation initiation factor eIF4A, abolishing its helicase activity and inhibiting translation. We propose to name BPSL1549 Burkholderia lethal factor 1.	[Cruz-Migoni, Abimael; Hautbergue, Guillaume M.; Artymiuk, Peter J.; Baker, Patrick J.; Chang, Chung-Te; Mobbs, George W.; Partridge, Lynda J.; Ruzheinikov, Sergei; Sedelnikova, Svetlana E.; Wilson, Stuart A.; Rice, David W.] Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; [Bokori-Brown, Monika; Titball, Richard W.] Univ Exeter, Coll Life & Environm Sci, Exeter EX4 4QD, Devon, England; [Dickman, Mark J.; Phillips, Helen L.] Univ Sheffield, Dept Chem & Biol Engn, Chem Engn Life Sci Interface Inst, Sheffield S1 3JD, S Yorkshire, England; [Essex-Lopresti, Angela; Harding, Sarah V.; Marshall, Laura E.; Ngugi, Sarah A.; Sarkar-Tyson, Mitali; Smither, Sophie J.] Def Sci & Technol Lab, Salisbury SP4 OJQ, Wilts, England; [Mahadi, Nor Muhammad; Mohamed, Rahmah; Nathan, Sheila] Malaysia Genome Inst, Kajang 43000, Selangor DE, Malaysia; [Mohamed, Rahmah; Nathan, Sheila; Raih, M. Firdaus] Univ Kebangsaan Malaysia, Fac Sci & Technol, Sch Biosci & Biotechnol, Bangi 43600, Selangor DE, Malaysia; [Ong, Catherine] Def Med & Environm Res Inst, DSO Natl Labs, Singapore 117510, Singapore; [Ooi, Wen Fong; Tan, Patrick] Genome Inst Singapore, Singapore 138672, Singapore	University of Sheffield; University of Exeter; University of Sheffield; Defence Science & Technology Laboratory; Universiti Kebangsaan Malaysia; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Wilson, SA (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	stuart.wilson@sheffield.ac.uk; d.rice@sheffield.ac.uk	Firdaus-Raih, Mohd/H-3286-2019; Bokori-Brown, Monika/Y-2302-2019; Nathan, Sheila/C-1182-2011; Firdaus-Raih, Mohd/A-9217-2011	Firdaus-Raih, Mohd/0000-0003-4275-4663; Nathan, Sheila/0000-0002-2132-2346; Firdaus-Raih, Mohd/0000-0003-4275-4663; Smither, Sophie/0000-0002-7835-3581; Cruz Migoni, Abimael/0000-0001-5937-4101; Baker, Patrick/0000-0003-1995-5643; wilson, stuart/0000-0003-3073-258X; Sarkar-Tyson, Mitali/0000-0002-6764-8499; Ruzheinikov, Sergey/0000-0002-3219-5004; Dickman, Mark/0000-0002-9236-0788; Chang, Chung-Te/0000-0002-4792-1646	Biotechnology and Biological Sciences Research Council; Ministry of Science, Technology and Innovation, Government of Malaysia [07-05-16-MGI-GMB08]; British Council PMI-2 Initiative; Consejo Nacional de Ciencia y Tecnologia; Ministry of Defense (UK); Engineering and Physical Sciences Research Council; Wellcome Trust [WT085162AIA]; BBSRC [BB/D524975/1, BB/E025293/1, BB/D011795/1] Funding Source: UKRI; EPSRC [EP/E036252/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D524975/1, BB/E025293/1, BB/D011795/1] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/E036252/1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ministry of Science, Technology and Innovation, Government of Malaysia(Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia); British Council PMI-2 Initiative; Consejo Nacional de Ciencia y Tecnologia(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Ministry of Defense (UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank S. Morley for providing translation factor antibodies, G. Flatau for samples of CNF1-C, C. Hellen for the eIF4B vector, A. Goldman and M. Ashe for helpful suggestions, F. Salguero (Veterinary Laboratories Agency) and C. Taylor ( Defence Science and Technology Laboratory) for histopathology analysis, and DSO National Laboratories, Singapore, for human sera. S. A. W. and M.J.D. acknowledge Biotechnology and Biological Sciences Research Council support. R. M., S.N., N.M.M., M. F. R., and D. W. R. acknowledge the Ministry of Science, Technology and Innovation, Government of Malaysia ( grant 07-05-16-MGI-GMB08) for support and the British Council PMI-2 Initiative. A. C.-M. thanks Consejo Nacional de Ciencia y Tecnologia for scholarship funding; M.S.-T. acknowledges Ministry of Defense (UK) support; M.J.D. acknowledges Engineering and Physical Sciences Research Council support; and R. W. T. acknowledges Wellcome Trust support ( grant WT085162AIA). We acknowledge the European Synchrotron Radiation Facility and Diamond Synchrotron for beamtime and thank C. Mueller-Dieckmann and R. Flaig for assistance with stations ID29 and I04. Atomic coordinates and structure factors have been deposited in the Protein Data Bank under accession codes 3TU8 and 3TUA. A patent application has been filed on the therapeutic use of the toxin and eIF4A mutants.	Andersen CBF, 2006, SCIENCE, V313, P1968, DOI 10.1126/science.1131981; Buetow L, 2001, NAT STRUCT BIOL, V8, P584, DOI 10.1038/89610; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Cui JX, 2010, SCIENCE, V329, P1215, DOI 10.1126/science.1193844; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; Marintchev A, 2009, CELL, V136, P447, DOI 10.1016/j.cell.2009.01.014; Mokas S, 2009, MOL BIOL CELL, V20, P2673, DOI 10.1091/mbc.E08-10-1061; Ngauy V, 2005, J CLIN MICROBIOL, V43, P970, DOI 10.1128/JCM.43.2.970-972.2005; Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Sengoku T, 2006, CELL, V125, P287, DOI 10.1016/j.cell.2006.01.054; Spriggs KA, 2009, MOL CELL BIOL, V29, P1565, DOI 10.1128/MCB.01283-08; Stone R, 2007, SCIENCE, V317, P1022, DOI 10.1126/science.317.5841.1022; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385	16	75	80	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					821	824		10.1126/science.1211915	http://dx.doi.org/10.1126/science.1211915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076380	Green Accepted			2022-12-28	WOS:000296849600051
J	Yamamoto, H; Williams, EG; Mouchiroud, L; Canto, C; Fan, WW; Downes, M; Heligon, C; Barish, GD; Desvergne, B; Evans, RM; Schoonjans, K; Auwerx, J				Yamamoto, Hiroyasu; Williams, Evan G.; Mouchiroud, Laurent; Canto, Carles; Fan, Weiwei; Downes, Michael; Heligon, Christophe; Barish, Grant D.; Desvergne, Beatrice; Evans, Ronald M.; Schoonjans, Kristina; Auwerx, Johan			NCoR1 Is a Conserved Physiological Modulator of Muscle Mass and Oxidative Function	CELL			English	Article							NUCLEAR RECEPTOR COREPRESSOR; SKELETAL-MUSCLE; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; CO-REPRESSOR; ERR-ALPHA; MEF2; CELL; SIRT1; SPECIFICITY	Transcriptional coregulators control the activity of many transcription factors and are thought to have wide-ranging effects on gene expression patterns. We show here that muscle-specific loss of nuclear receptor corepressor 1 (NCoR1) in mice leads to enhanced exercise endurance due to an increase of both muscle mass and of mitochondrial number and activity. The activation of selected transcription factors that control muscle function, such as MEF2, PPAR beta/delta, and ERRs, underpins these phenotypic alterations. NCoR1 levels are decreased in conditions that require fat oxidation, resetting transcriptional programs to boost oxidative metabolism. Knockdown of gei-8, the sole C. elegans NCoR homolog, also robustly increased muscle mitochondria and respiration, suggesting conservation of NCoR1 function. Collectively, our data suggest that NCoR1 plays an adaptive role in muscle physiology and that interference with NCoR1 action could be used to improve muscle function.	[Yamamoto, Hiroyasu; Williams, Evan G.; Mouchiroud, Laurent; Canto, Carles; Schoonjans, Kristina; Auwerx, Johan] Ecole Polytech Fed Lausanne EPFL, Lab Integrat & Syst Physiol LISP, CH-1015 Lausanne, Switzerland; [Fan, Weiwei; Downes, Michael; Barish, Grant D.; Evans, Ronald M.] Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; [Heligon, Christophe; Desvergne, Beatrice] Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Howard Hughes Medical Institute; Salk Institute; University of Lausanne	Auwerx, J (corresponding author), Ecole Polytech Fed Lausanne EPFL, Lab Integrat & Syst Physiol LISP, CH-1015 Lausanne, Switzerland.	admin.auwerx@epfl.ch	Auwerx, Johan/ABE-9307-2021; Williams, Evan/M-7539-2017; Frank, Viki/GXZ-9902-2022; Evans, Ronald/AAF-4001-2019; Desvergne, Beatrice/C-8892-2016	Williams, Evan/0000-0002-9746-376X; Evans, Ronald/0000-0002-9986-5965; Schoonjans, Kristina/0000-0003-1247-4265; Desvergne, Beatrice/0000-0001-5483-288X; Auwerx, Johan/0000-0002-5065-5393; HELIGON, Christophe/0000-0001-7557-3565; Canto, Carles/0000-0002-5167-7922	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation; NIH [DK059820, DK062434, 1K08HL092298, HD027183, DK057978]; EU [ERC-2008-AdG-23118]; Helmsley Charitable Trust; Glenn Foundation; Howard Hughes Medical Institute (HHMI); FRM; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105278, K08HL092298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434, R37DK057978, P01DK059820] Funding Source: NIH RePORTER	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EU(European Commission); Helmsley Charitable Trust; Glenn Foundation; Howard Hughes Medical Institute (HHMI)(Howard Hughes Medical Institute); FRM(Fondation pour la Recherche Medicale); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge M. Lazar (University of Pennsylvania, Philadelphia), A. Kralli (Scripps Research Institute, San Diego), J.-S. Annicotte and L. Fajas (Institut de Genetique Moleculaire de Montpellier, France), A. Lusis (University of California, Los Angeles), K. Schughart (Helmholtz Zentrum, Hannover, Germany), R. Williams (University of Tennessee Health Science Center, Memphis), and the Caenorhabditis Genetics Center (CGC) for generous sharing of research reagents and data. We thank N. Messadeq (Institut Clinique de la Souris, Strasbourg, France) for EM analysis and the Center for PhenoGenomics (CPG) at the EPFL for help with mouse phenotyping. This work was supported by the Ecole Polytechnique Federale de Lausanne, Swiss National Science Foundation, NIH (DK059820 to J.A., DK062434 to R.M.E., 1K08HL092298 to G.D.B., HD027183 to R.M.E., and DK057978 to R.M.E.), the EU ideas program (ERC-2008-AdG-23118), the Helmsley Charitable Trust, the Glenn Foundation, and the Howard Hughes Medical Institute (HHMI). H.Y. was supported by an FRM fellowship. R.M.E. is an Investigator of the HHMI and the March of Dimes Chair in Molecular and Developmental Biology. J.A. is the Nestle Chair in Energy Metabolism. We thank the members of the Auwerx lab and R. Williams for discussions.	Alaynick WA, 2008, MITOCHONDRION, V8, P329, DOI 10.1016/j.mito.2008.02.001; Alberts R, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-61; Alenghat T, 2008, NATURE, V456, P997, DOI 10.1038/nature07541; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Argmann CA, 2005, CELL METAB, V2, P349, DOI 10.1016/j.cmet.2005.11.002; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Champy MF, 2008, MAMM GENOME, V19, P318, DOI 10.1007/s00335-008-9107-z; Champy MF, 2004, MAMM GENOME, V15, P768, DOI 10.1007/s00335-004-2393-1; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001; Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Houtkooper RH, 2011, SCI REP-UK, V1, DOI 10.1038/srep00134; Houtkooper RH, 2010, CELL, V142, P9, DOI 10.1016/j.cell.2010.06.029; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Kiens B, 1998, AM J PHYSIOL-ENDOC M, V275, pE332, DOI 10.1152/ajpendo.1998.275.2.E332; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; Narkar VA, 2011, CELL METAB, V13, P283, DOI 10.1016/j.cmet.2011.01.019; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; Nofsinger RR, 2008, P NATL ACAD SCI USA, V105, P20021, DOI 10.1073/pnas.0811012105; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Storlien L, 2004, P NUTR SOC, V63, P363, DOI 10.1079/PNS2004349; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; van Nas A, 2010, GENETICS, V185, P1059, DOI 10.1534/genetics.110.116087; Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang Y, 2006, J BIOL CHEM, V281, P39897, DOI 10.1074/jbc.M608657200; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	57	177	183	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					827	839		10.1016/j.cell.2011.10.017	http://dx.doi.org/10.1016/j.cell.2011.10.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078881	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000296902300016
J	Cash, SS; Larvie, M; Dalmau, J				Cash, Sydney S.; Larvie, Mykol; Dalmau, Josep			Case 34-2011: A 75-Year-Old Man with Memory Loss and Partial Seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; POTASSIUM CHANNEL ANTIBODY; LIMBIC ENCEPHALITIS; LGI1; MUTATIONS		[Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Larvie, Mykol] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Cash, Sydney S.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Larvie, Mykol] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Dalmau, Josep] Univ Penn, Dept Neurol, Div Neurooncol, Hosp Univ Penn, Philadelphia, PA 19104 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine	Cash, SS (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.			Dalmau, Josep/0000-0001-5856-2813				Bataller L, 2010, NEUROLOGY, V74, P265, DOI 10.1212/WNL.0b013e3181cb3e52; Bien CG, 2007, NEUROLOGY, V69, P1236, DOI 10.1212/01.wnl.0000276946.08412.ef; Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Ebersole J.S., 2003, CURRENT PRACTICE CLI, P610; Fukata Y, 2010, P NATL ACAD SCI USA, V107, P3799, DOI 10.1073/pnas.0914537107; Graus F, 2004, J NEUROL NEUROSUR PS, V75, P1135, DOI 10.1136/jnnp.2003.034447; Gu WL, 2002, ANN NEUROL, V52, P364, DOI 10.1002/ana.10280; Hess KR, 2004, CANCER, V101, P2293, DOI 10.1002/cncr.20621; Kalachikov S, 2002, NAT GENET, V30, P335, DOI 10.1038/ng832; Lai MZ, 2010, LANCET NEUROL, V9, P776, DOI 10.1016/S1474-4422(10)70137-X; MARSAN CA, 1970, EPILEPSIA, V11, P361, DOI 10.1111/j.1528-1157.1970.tb03903.x; Morante-Redolat JM, 2002, HUM MOL GENET, V11, P1119, DOI 10.1093/hmg/11.9.1119; Poza JJ, 1999, ANN NEUROL, V45, P182, DOI 10.1002/1531-8249(199902)45:2<182::AID-ANA8>3.0.CO;2-G; Soeder BM, 2009, J NEUROL NEUROSUR PS, V80, P894, DOI 10.1136/jnnp.2008.165860; Thieben MJ, 2004, NEUROLOGY, V62, P1177, DOI 10.1212/01.WNL.0000122648.19196.02; Tuzun E, 2007, NEUROLOGIST, V13, P261, DOI 10.1097/NRL.0b013e31813e34a5; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Yu YE, 2010, HUM MOL GENET, V19, P1702, DOI 10.1093/hmg/ddq047; Zhou YD, 2009, NAT MED, V15, P1208, DOI 10.1038/nm.2019	19	11	11	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1825	1833		10.1056/NEJMcpc1100924	http://dx.doi.org/10.1056/NEJMcpc1100924			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070480				2022-12-28	WOS:000296762800013
J	Bershad, SV				Bershad, Susan V.			Atopic Dermatitis (Eczema)	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ALLERGIC SENSITIZATION; STAPHYLOCOCCUS-AUREUS; TACROLIMUS OINTMENT; DIAGNOSTIC-CRITERIA; UNITED-STATES; MANAGEMENT; GUIDELINES; SEVERITY; PRURITUS; CHILDREN											Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Berger TG, 2006, J AM ACAD DERMATOL, V54, P818, DOI 10.1016/j.jaad.2006.01.054; Meduri NB, 2007, PHOTODERMATOL PHOTO, V23, P106, DOI 10.1111/j.1600-0781.2007.00291.x; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Bos JD, 2010, EXP DERMATOL, V19, P325, DOI 10.1111/j.1600-0625.2009.01024.x; Boyce JA, 2011, J AM ACAD DERMATOL, V64, P175, DOI [10.1016/j.jaad.2010.11.020, 10.1016/j.nutres.2011.01.001]; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P613, DOI 10.1016/S0190-9622(94)70225-X; Ernst Edzard, 2002, Am J Clin Dermatol, V3, P341, DOI 10.2165/00128071-200203050-00006; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; Green C, 2004, HEALTH TECHNOL ASSES, V8, P1; Grimalt R, 2007, DERMATOLOGY, V214, P61, DOI 10.1159/000096915; HANFIN JM, 1980, ACTA DERM-VENEREOL, V92, P44; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HON KL, 2010, J ALLERGY CLIN IMMUN, V125, P4; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; IRVINE AD, 2011, N ENGL J MED; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Lee JH, 2007, J EUR ACAD DERMATOL, V21, P1360, DOI 10.1111/j.1468-3083.2007.02277.x; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Mancini AJ, 2008, PEDIATR DERMATOL, V25, P1, DOI 10.1111/j.1525-1470.2007.00572.x; Msika P, 2008, PEDIATR DERMATOL, V25, P606, DOI 10.1111/j.1525-1470.2008.00783.x; NA JI, 2010, DERMATOLOG TREAT, V21, P23; Novak N, 2007, ADV EXP MED BIOL, V601, P97; Paller AS, 2005, J AM ACAD DERMATOL, V52, P810, DOI 10.1016/j.jaad.2004.12.038; Reitamo S, 2004, BRIT J DERMATOL, V150, P554, DOI 10.1046/j.1365-2133.2004.05782.x; Ricci G, 2009, AM J CLIN DERMATOL, V10, P287, DOI 10.2165/11310760-000000000-00000; Saeki H, 2009, J DERMATOL, V36, P563, DOI 10.1111/j.1346-8138.2009.00706.x; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Su JC, 1997, ARCH DIS CHILD, V76, P159, DOI 10.1136/adc.76.2.159; Sugarman JL, 2009, J DRUGS DERMATOL, V8, P1106; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thygarajan A, 2008, CURR OPIN PEDIATR, V20, P698, DOI 10.1097/MOP.0b013e3283154f88; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Wahn U, 2008, PEDIAT ALLERG IMM-UK, V19, P332, DOI 10.1111/j.1399-3038.2007.00643.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Yang YW, 2009, BRIT J DERMATOL, V161, P373, DOI 10.1111/j.1365-2133.2009.09049.x; ZHANG W, 2004, COCHRANE DATABASE S; Zirngibl A, 2002, PEDIAT ALLERG IMM-UK, V13, P394, DOI 10.1034/j.1399-3038.2002.01110.x	47	8	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9								10.7326/0003-4819-155-9-201111010-01005	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-01005			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041966				2022-12-28	WOS:000296612400017
J	Mega, JL; Braunwald, E; Wiviott, SD; Bassand, JP; Bhatt, DL; Bode, C; Burton, P; Cohen, M; Cook-Bruns, N; Fox, KAA; Goto, S; Murphy, SA; Plotnikov, AN; Schneider, D; Sun, X; Verheugt, FWA; Gibson, CM				Mega, Jessica L.; Braunwald, Eugene; Wiviott, Stephen D.; Bassand, Jean-Pierre; Bhatt, Deepak L.; Bode, Christoph; Burton, Paul; Cohen, Marc; Cook-Bruns, Nancy; Fox, Keith A. A.; Goto, Shinya; Murphy, Sabina A.; Plotnikov, Alexei N.; Schneider, David; Sun, Xiang; Verheugt, Freek W. A.; Gibson, C. Michael		ATLAS ACS 2-TIMI 51 Investigators	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR XA INHIBITOR; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY; ENOXAPARIN; PLACEBO; THROMBOPROPHYLAXIS; APIXABAN; EVENTS; SAFETY	BACKGROUND Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke. RESULTS Rivaroxaban significantly reduced the primary efficacy end point, as compared with placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P=0.008), with significant improvement for both the twice-daily 2.5-mg dose (9.1% vs. 10.7%, P=0.02) and the twice-daily 5-mg dose (8.8% vs. 10.7%, P=0.03). The twice-daily 2.5-mg dose of rivaroxaban reduced the rates of death from cardiovascular causes (2.7% vs. 4.1%, P=0.002) and from any cause (2.9% vs. 4.5%, P=0.002), a survival benefit that was not seen with the twice-daily 5-mg dose. As compared with placebo, rivaroxaban increased the rates of major bleeding not related to coronary-artery bypass grafting (2.1% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.2%, P=0.009), without a significant increase in fatal bleeding (0.3% vs. 0.2%, P=0.66) or other adverse events. The twice-daily 2.5-mg dose resulted in fewer fatal bleeding events than the twice-daily 5-mg dose (0.1% vs. 0.4%, P=0.04). CONCLUSIONS In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but riot the risk of fatal bleeding. (Funded by Johnson & Johnson and Bayer Healthcare 7 ATLAS ACS 2-TIMI 51 ClinicalTrials.gov number, NCT00809965.)	[Mega, Jessica L.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Mega, Jessica L.; Braunwald, Eugene; Wiviott, Stephen D.; Bhatt, Deepak L.; Murphy, Sabina A.; Gibson, C. Michael] Harvard Univ, Sch Med, Boston, MA USA; [Bhatt, Deepak L.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Bassand, Jean-Pierre] Univ Hosp Jean Minjoz, Dept Cardiol, Besancon, France; [Bode, Christoph] Univ Hosp Freiburg, Freiburg, Germany; [Cook-Bruns, Nancy] Bayer Healthcare, Wuppertal, Germany; [Burton, Paul; Plotnikov, Alexei N.; Sun, Xiang] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA; [Cohen, Marc] Newark Beth Israel Med Ctr, Newark, NJ USA; [Fox, Keith A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Fox, Keith A. A.] Royal Infirm, Edinburgh, Midlothian, Scotland; [Goto, Shinya] Tokai Univ, Sch Med, Tokyo 151, Japan; [Schneider, David] Univ Vermont Fletcher Allen Hlth Care, Burlington, VT USA; [Verheugt, Freek W. A.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Universite de Franche-Comte; CHU Besancon; University of Freiburg; Bayer AG; Bayer Healthcare Pharmaceuticals; Johnson & Johnson; Johnson & Johnson USA; Newark Beth Israel Medical Center; University of Edinburgh; Royal Infirmary of Edinburgh; Tokai University; University of Vermont; University of Vermont Medical Center; Radboud University Nijmegen	Mega, JL (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	jmega@partners.org	Khokhlov, Alexander L./E-2765-2017; sharma, kamal/AAG-7271-2019; Benedek, Imre/E-7052-2017; Benedek, Theodora/F-6353-2016; Libis, Roman/O-9193-2015; Colquhoun, David M/F-9078-2013; Goto, Shinya/AAU-6045-2020; Walters, Darren/A-7069-2011; Yusof, Zurkurnai/AAA-5893-2021; Wiviott, Stephen/HIK-2534-2022; Fox, keith A A/I-3742-2013; Mirolyubova, Olga/C-8376-2018; Braun-Dullaeus, Ruediger C/G-1844-2013; Boldueva, Svetlana/AAH-3862-2019; Verheugt, F.W.A./H-8105-2014; Urina-Triana, Miguel A/H-2605-2016; Ponikowski, Piotr/O-6454-2015; Kubica, Jacek/D-6906-2014; Gibson, C. Michael/AAE-8212-2019; Ramshev, Konstantin/GYU-1641-2022; Arkhipov, Mikhail V/Q-2316-2015; Neskovic, Aleksandar/P-5204-2015	Khokhlov, Alexander L./0000-0002-0032-0341; sharma, kamal/0000-0001-5866-2566; Benedek, Imre/0000-0003-0051-4047; Benedek, Theodora/0000-0001-8326-1537; Libis, Roman/0000-0003-0130-990X; Goto, Shinya/0000-0002-6821-1504; Mirolyubova, Olga/0000-0003-4562-8398; Braun-Dullaeus, Ruediger C/0000-0003-3888-6532; Boldueva, Svetlana/0000-0002-1898-084X; Urina-Triana, Miguel A/0000-0001-6003-4622; Ponikowski, Piotr/0000-0002-3391-7064; Kubica, Jacek/0000-0001-8250-754X; Ramshev, Konstantin/0000-0002-6978-6641; Arkhipov, Mikhail V/0000-0002-7924-7668; Macin, Stella/0000-0002-1869-5918; Welsh, Robert/0000-0003-2613-9142; Neskovic, Aleksandar/0000-0001-8617-966X; ELBAZ, Meyer/0000-0002-3520-7883; Alonso, Joaquin J/0000-0003-4360-5897; Townend, Jonathan/0000-0002-5881-5806; Van de Werf, Frans/0000-0001-9479-7767; Fox, Keith/0000-0002-0140-2752; Ghezzi, Fabio/0000-0003-3949-5410; Sanmartin-Fernandez, Marcelo/0000-0001-5469-4579; Lanas, Fernando/0000-0003-3595-9759	Johnson Johnson; Bayer Healthcare; AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Sanofi-Aventis; Bristol-Myers Squibb/Sanofi-Aventis; Daiichi Sankyo; Eli Lilly; Arena; Bayer; Ortho McNeil; Merck Schering Plough; Merck/Schering-Plough; GlaxoSmithKline; Iroko; Eisai; Ethicon; Medtronic; Medicines Company; Boehringer Ingelheim; Lilly; Bristol-Myers Squibb/Pfizer; Otsuka; Asteras; Medtronics Japan; Mochida; Pfizer; Takeda; Tanabe Mitsubishi; Amarin; Regado Bioscience; Bayer Pharmaceuticals; Symetis; Archemix; Biogen IDEC; Genentech; Ischemix; Medicure; Portola Pharmaceuticals; Grants-in-Aid for Scientific Research [21390244] Funding Source: KAKEN	Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck(Merck & Company); Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb/Sanofi-Aventis(Sanofi-AventisBristol-Myers Squibb); Daiichi Sankyo(Daiichi Sankyo Company Limited); Eli Lilly(Eli Lilly); Arena(Australian Renewable Energy Agency (ARENA)); Bayer(Bayer AG); Ortho McNeil; Merck Schering Plough(Merck & CompanySchering Plough Corporation); Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); GlaxoSmithKline(GlaxoSmithKline); Iroko; Eisai(Eisai Co Ltd); Ethicon; Medtronic(Medtronic); Medicines Company; Boehringer Ingelheim(Boehringer Ingelheim); Lilly(Eli Lilly); Bristol-Myers Squibb/Pfizer(Bristol-Myers SquibbPfizer); Otsuka(Otsuka Pharmaceutical); Asteras; Medtronics Japan; Mochida; Pfizer(Pfizer); Takeda(Takeda Pharmaceutical Company Ltd); Tanabe Mitsubishi; Amarin; Regado Bioscience; Bayer Pharmaceuticals(Bayer AG); Symetis; Archemix; Biogen IDEC(Biogen); Genentech(Roche HoldingGenentech); Ischemix; Medicure; Portola Pharmaceuticals; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Johnson & Johnson and Bayer Healthcare.; Dr. Mega reports receiving consulting fees from AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Merck, Novartis, and Sanofi-Aventis, grant support through her institution from Bristol-Myers Squibb/Sanofi-Aventis, Daiichi Sankyo, and Eli Lilly, and research supplies from Accumetrics and Nanosphere; Dr. Braunwald, receiving grant support through his institution from Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, and Sanofi-Aventis; Dr. Wiviott, receiving consulting fees from Arena, AstraZeneca, Bayer, Bristol-Myers Squibb, and Ortho McNeil, grant support through his institution from Daiichi Sankyo, Eli Lilly, and Merck Schering Plough, and lecture fees from AstraZeneca, Eli Lilly, Daiichi Sankyo, Merck/Schering-Plough, and Novartis; Dr. Bassand, receiving lecture fees from Bayer, AstraZeneca, GlaxoSmithKline, and Iroko and having an equity interest in GlaxoSmithKline and Sanofi-Aventis; Dr. Bhatt, receiving grant support through his institution from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, and the Medicines Company, support from Duke Clinical Research Institute for serving as a steering committee member and national coordinator for the APPRAISE-2 trial, and being an unfunded research collaborator with PLx Pharma and Takeda; Dr. Bode, receiving consulting fees from AstraZeneca, Boehringer Ingelheim, Merck, and Sanofi-Aventis and lecture fees from AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Novartis, and Sanofi-Aventis; Dr. Burton, being employed by and having an equity interest in Johnson & Johnson; Dr. Cohen, holding a board membership at Janssen Pharmaceuticals; Dr. Cook-Bruns, being employed by and having an equity interest in Bayer Healthcare; Dr. Fox, receiving consulting fees from AstraZeneca, Bristol-Myers Squibb/Pfizer, and Eli Lilly, grant support through his institution from Eli Lilly, lecture fees from Eli Lilly, and support for travel, accommodations, and meeting expenses from Boehringer Ingelheim; Dr. Goto, holding board memberships at Bristol-Myers Squibb and Sanofi Aventis and receiving consulting fees from Eisai, grant support through his institution from Boehringer Ingelheim, Eisai, Daiichi Sankyo, Otsuka, and Sanofi-Aventis, lecture fees from Asteras, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Medtronics Japan, Merck, Mochida, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Takeda, and Tanabe Mitsubishi, and payment for the development of educational presentations from Bayer and Sanofi Aventis; Ms. Murphy, receiving consulting fees from Amarin and Eli Lilly; Dr. Plotnikov, being employed by and having an equity interest in Johnson & Johnson; Dr. Schneider, receiving consulting fees from AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Regado Bioscience, Sanofi-Aventis, and the Medicines Company and grant support through his institution from Bayer Pharmaceuticals, Bristol-Myers Squibb, Johnson & Johnson, Sanofi-Aventis, and the Medicines Company; Dr. Sun, being employed by and having an equity interest in Johnson & Johnson; Dr. Verheugt, receiving consulting fees from AstraZeneca, Bayer, Daiichi Sankyo, and Symetis, lecture fees from AstraZeneca, Bayer, and Daiichi Sankyo, and royalties from Elsevier and Nature Group; and Dr.; Gibson, receiving consulting fees directly and through his institution from Bayer, Johnson & Johnson, and Ortho McNeil, directly from Archemix, Bayer Healthcare, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, GlaxoSmithKline, Ischemix, Johnson & Johnson, Medicure, Merck/Schering-Plough, Ortho McNeil, Portla Pharmaceuticals, Sanofi-Aventis, and the Medicines Company, receiving grant support through his institution from Bristol-Myers Squibb, lecture fees from Daiichi Sankyo, Eli Lilly, and the Medicines Company, and support for the development of educational presentations from Daiichi Sankyo and Eli Lilly. No other potential conflict of interest relevant to this article was reported.	Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819; Alexander JH, 2009, CIRCULATION, V119, P2877, DOI 10.1161/CIRCULATIONAHA.108.832139; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Eikelboom JW, 2006, CIRCULATION, V114, P774, DOI 10.1161/CIRCULATIONAHA.106.612812; Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056/NEJMoa0800374; Gibson CM, 2011, AM HEART J, V161, P815, DOI 10.1016/j.ahj.2011.01.026; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140-6736(08)60880-6; Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056/NEJMoa076016; Mega JL, 2009, LANCET, V374, P29, DOI 10.1016/S0140-6736(09)60738-8; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; Oldgren J, 2011, EUR HEART J     0507; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Rothberg MB, 2005, ANN INTERN MED, V143, P241, DOI 10.7326/0003-4819-143-4-200508160-00005; Steg PG, 2011, EUR HEART J, V32, P2541, DOI 10.1093/eurheartj/ehr334; Turpie AGG, 2009, LANCET, V373, P1673, DOI 10.1016/S0140-6736(09)60734-0; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	22	1382	1468	1	149	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	2012	366	1					9	19		10.1056/NEJMoa1112277	http://dx.doi.org/10.1056/NEJMoa1112277			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XY	22077192	Green Published			2022-12-28	WOS:000299968800003
J	Connolly, SJ; Camm, AJ; Halperin, JL; Joyner, C; Alings, M; Amerena, J; Atar, D; Avezum, A; Blomstroem, P; Borggrefe, M; Budaj, A; Chen, SA; Ching, CK; Commerford, P; Dans, A; Davy, JM; Delacretaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Heidbuchel, H; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsanyi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Xavier, D; Zhu, J; Zhu, JR; Baret-Cormel, L; Weinling, E; Staiger, C; Yusuf, S; Chrolavicius, S; Afzal, R; Hohnloser, SH				Connolly, Stuart J.; Camm, A. John; Halperin, Jonathan L.; Joyner, Campbell; Alings, Marco; Amerena, John; Atar, Dan; Avezum, Alvaro; Blomstroem, Per; Borggrefe, Martin; Budaj, Andrzej; Chen, Shih-Ann; Ching, Chi Keong; Commerford, Patrick; Dans, Antonio; Davy, Jean-Marc; Delacretaz, Etienne; Di Pasquale, Giuseppe; Diaz, Rafael; Dorian, Paul; Flaker, Greg; Golitsyn, Sergey; Gonzalez-Hermosillo, Antonio; Granger, Christopher B.; Heidbuechel, Hein; Kautzner, Josef; Kim, June Soo; Lanas, Fernando; Lewis, Basil S.; Merino, Jose L.; Morillo, Carlos; Murin, Jan; Narasimhan, Calambur; Paolasso, Ernesto; Parkhomenko, Alexander; Peters, Nicholas S.; Sim, Kui-Hian; Stiles, Martin K.; Tanomsup, Supachai; Toivonen, Lauri; Tomcsanyi, Janos; Torp-Pedersen, Christian; Tse, Hung-Fat; Vardas, Panos; Vinereanu, Dragos; Xavier, Denis; Zhu, Jun; Zhu, Jun-Ren; Baret-Cormel, Lydie; Weinling, Estelle; Staiger, Christoph; Yusuf, Salim; Chrolavicius, Susan; Afzal, Rizwan; Hohnloser, Stefan H.		PALLAS Investigators	Dronedarone in High-Risk Permanent Atrial Fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMIODARONE-LIKE AGENT; FOLLOW-UP; SR-33589; HEART; ADRENOCEPTOR; ARRHYTHMIAS; MORTALITY	BACKGROUND Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. METHODS We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. RESULTS After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). CONCLUSIONS Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.)	[Connolly, Stuart J.; Morillo, Carlos; Yusuf, Salim; Chrolavicius, Susan; Afzal, Rizwan] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Camm, A. John] St Georges Univ, London, England; [Halperin, Jonathan L.] Mt Sinai Med Ctr, New York, NY 10029 USA; [Joyner, Campbell] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Alings, Marco] Amphia Hosp, Breda, Netherlands; [Atar, Dan] Oslo Univ Hosp, Oslo, Norway; [Avezum, Alvaro] Estudios Clin Latinoamer, Sao Paulo, Brazil; [Blomstroem, Per] Univ Uppsala Hosp, Uppsala, Sweden; [Borggrefe, Martin] Univ Med Ctr Mannheim, Mannheim, Germany; [Budaj, Andrzej] Grochowski Hosp, Warsaw, Poland; [Chen, Shih-Ann] Vet Gen Hosp, Taipei, Taiwan; [Ching, Chi Keong] Natl Heart Ctr, Singapore, Singapore; [Commerford, Patrick] Univ Cape Town, ZA-7925 Cape Town, South Africa; [Dans, Antonio] Philippine Gen Hosp, Manila, Philippines; [Davy, Jean-Marc] Hop Arnaud de Villeneuve, CHU Montpellier, Montpellier, France; [Delacretaz, Etienne] Univ Bern, Inselspital, Univ Klin, CH-3010 Bern, Switzerland; [Di Pasquale, Giuseppe] Maggiore Hosp, Bologna, Italy; [Diaz, Rafael] Estudios Clin Latino Amer, Rosario, Argentina; [Dorian, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Flaker, Greg] Univ Missouri, Columbia, MO 65211 USA; [Golitsyn, Sergey] Russian Cardiol Res & Prod Ctr, Moscow, Russia; [Gonzalez-Hermosillo, Antonio] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico; [Granger, Christopher B.] Duke Univ, Med Ctr, Durham, NC USA; [Heidbuechel, Hein] Univ Hosp Gasthuisberg, Louvain, Belgium; [Kautzner, Josef] Inst Clin & Expt Med, Prague, Czech Republic; [Kim, June Soo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Lanas, Fernando] Univ La Frontera, Temuco, Chile; [Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Merino, Jose L.] Univ La Paz, Madrid, Spain; [Murin, Jan] Univ Hosp Bratislava, Bratislava, Slovakia; [Narasimhan, Calambur] CARE Hosp, Hyderabad, Andhra Pradesh, India; [Paolasso, Ernesto] Inst Invest Clin Rosario, Rosario, Santa Fe, Argentina; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Peters, Nicholas S.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; [Sim, Kui-Hian] Sarawak Gen Hosp, Kuching, Malaysia; [Stiles, Martin K.] Waikato Hosp, Hamilton, New Zealand; [Stiles, Martin K.] Univ Auckland, Hamilton, New Zealand; [Tanomsup, Supachai] Ramathibodi Hosp, Bangkok, Thailand; [Toivonen, Lauri] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Tomcsanyi, Janos] St John God Hosp, Budapest, Hungary; [Torp-Pedersen, Christian] Univ Copenhagen, Hellerup, Denmark; [Tse, Hung-Fat] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; [Vardas, Panos] Univ Crete, Sch Med, Iraklion, Greece; [Vinereanu, Dragos] Emergency Clin Univ Hosp, Bucharest, Romania; [Xavier, Denis] St Johns Med Coll, Bangalore, Karnataka, India; [Zhu, Jun-Ren] Zhongshan Hosp, Shanghai, Peoples R China; [Baret-Cormel, Lydie; Weinling, Estelle; Staiger, Christoph] Sanofi Aventis, Chilly Mazarin, France; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany	McMaster University; Population Health Research Institute; St Georges University London; Icahn School of Medicine at Mount Sinai; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Amphia Hospital; University of Oslo; Uppsala University; Uppsala University Hospital; Ruprecht Karls University Heidelberg; Centre of Postgraduate Medical Education - Poland; National Heart Centre Singapore; University of Cape Town; University of the Philippines System; University of the Philippines Manila; Universite de Montpellier; CHU de Montpellier; University of Bern; University Hospital of Bern; AUSL di Bologna; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Missouri System; University of Missouri Columbia; National Medical Research Center of Cardiology; National Institute of Cardiology - Mexico; Duke University; KU Leuven; University Hospital Leuven; Institute for Clinical & Experimental Medicine (IKEM); Sungkyunkwan University (SKKU); Samsung Medical Center; Universidad de La Frontera; Clalit Health Services; Carmel Medical Center; Slovak Medical University Bratislava; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; Imperial College London; Waikato Hospital; University of Auckland; Mahidol University; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; University of Hong Kong; University of Crete; St. John's National Academy of Health Sciences; St. John's Medical College; Fudan University; Sanofi-Aventis; Goethe University Frankfurt	Connolly, SJ (corresponding author), Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	connostu@phri.ca	Vardas, Panos/AAP-5694-2021; Gizatulina, Tatiana P. P./H-1774-2019; Colquhoun, David M/F-9078-2013; Heidbuchel, Hein/C-2331-2019; Yuri, Shubik/S-7054-2017; Golitsyn, Sergey/ABH-2143-2020; Popov, Sergey/F-1751-2014; Granger, Christopher B/D-3458-2014; Avezum, Alvaro AA/K-6137-2016; Tse, Hung-Fat/C-4426-2009; Shvarts, Yury Григорьевич/AAB-4929-2022; Heidbuchel, Hein/AAU-2711-2021; vardas, panos/ABF-7144-2020; Avezum, Alvaro/AAP-7687-2020; Halperin, Jonathan/AAJ-4721-2020; Schwartz, Peter J/J-4267-2016; Lanas, Fernando/AAE-8842-2022; Gislason, Gunnar/B-7561-2009; Ching, Chi Keong/AAR-8968-2021; Widimsky, Petr/P-8088-2016; Gizatulina, Tatiana/ABB-6100-2021; Vardas, Panos/AAD-5219-2022; Fitilev, Sergey/AAG-2814-2021; Yakushin, Sergey/N-4165-2013; Kozhukhov, Sergey/E-6498-2018; Reis, Gilmar/I-4500-2013; Popov, Sergey/F-1751-2014; Kyto, Ville/D-7971-2014	Gizatulina, Tatiana P. P./0000-0003-4472-8821; Heidbuchel, Hein/0000-0001-9301-8127; Yuri, Shubik/0000-0002-8736-1575; Golitsyn, Sergey/0000-0001-9913-9974; Popov, Sergey/0000-0002-9050-4493; Granger, Christopher B/0000-0002-0045-3291; Avezum, Alvaro AA/0000-0002-3073-6890; Tse, Hung-Fat/0000-0002-9578-7808; Shvarts, Yury Григорьевич/0000-0002-5205-7311; Heidbuchel, Hein/0000-0001-9301-8127; Halperin, Jonathan/0000-0002-8318-5471; Schwartz, Peter J/0000-0003-0367-1048; Gislason, Gunnar/0000-0002-0548-402X; Widimsky, Petr/0000-0001-5686-7752; Fitilev, Sergey/0000-0001-8395-419X; Lanas, Fernando/0000-0003-3595-9759; Pella, Daniel/0000-0001-9999-6271; Yakushin, Sergey/0000-0001-7202-742X; Gulizia, Michele Massimo/0000-0003-1513-7125; Zimmermann, Sergio/0000-0002-9444-9209; Zaborska, Beata/0000-0001-5513-8371; Shalaev, Sergei/0000-0003-2724-4016; Merino, Jose Luis/0000-0002-1737-1903; Lyamina, Nadezhda/0000-0001-6939-3234; Yusuf, Salim/0000-0003-4776-5601; Kozhukhov, Sergey/0000-0002-7973-7894; Reis, Gilmar/0000-0002-4847-1034; Popov, Sergey/0000-0002-1607-1482; Tirschwell, David/0000-0002-8059-2901; Kyto, Ville/0000-0002-4521-1093; Katz, Amos/0000-0003-0422-934X	Sanofi-Aventis; British Heart Foundation [RG/10/11/28457] Funding Source: researchfish	Sanofi-Aventis(Sanofi-Aventis); British Heart Foundation(British Heart Foundation)	Supported by Sanofi-Aventis.	[Anonymous], 1989, NEW ENGL J MED, V321, P406; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; CHATELAIN P, 1995, BRIT J PHARMACOL, V116, P1949, DOI 10.1111/j.1476-5381.1995.tb16397.x; Connolly SJ, 2009, CIRCULATION, V120, P1174, DOI 10.1161/CIRCULATIONAHA.109.875252; Davy JM, 2008, AM HEART J, V156, DOI 10.1016/j.ahj.2008.06.010; Djandjighian L, 2000, J CARDIOVASC PHARM, V36, P376, DOI 10.1097/00005344-200009000-00014; FINANCE O, 1995, J CARDIOVASC PHARM, V26, P570, DOI 10.1097/00005344-199510000-00010; HODEIGE D, 1995, EUR J PHARMACOL, V279, P25, DOI 10.1016/0014-2999(95)00130-D; Hohnloser SH, 2011, NEW ENGL J MED, V364, P1481; Hohnloser SH, 2010, EUR HEART J, V31, P1717, DOI 10.1093/eurheartj/ehq113; Kato T, 2004, CIRC J, V68, P568, DOI 10.1253/circj.68.568; Kober L, 2008, NEW ENGL J MED, V358, P2678, DOI 10.1056/NEJMoa0800456; Kober L, 2010, NEW ENGL J MED, V363, P1384; LEGRAND V, 1985, DRUGS, V29, P54, DOI 10.2165/00003495-198500294-00011; Levine TB, 2010, CARDIOVASC DRUG THER, V24, P449, DOI 10.1007/s10557-010-6251-y; MANNING AS, 1995, J CARDIOVASC PHARM, V26, P453, DOI 10.1097/00005344-199509000-00016; Nieuwlaat R, 2011, EUR HEART J, V32, P618; Nieuwlaat R, 2008, EUR HEART J, V29, P1181, DOI 10.1093/eurheartj/ehn139; Page RL, 2011, AM J CARDIOL, V107, P1019, DOI 10.1016/j.amjcard.2010.11.028; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P871, DOI 10.1001/jama.289.7.871; Singh BN, 2007, NEW ENGL J MED, V357, P987, DOI 10.1056/NEJMoa054686; Thomas D, 2003, BRIT J PHARMACOL, V140, P996, DOI 10.1038/sj.bjp.0705502; Varro A, 2001, BRIT J PHARMACOL, V133, P625, DOI 10.1038/sj.bjp.0704106; Waldo, 1996, LANCET, V348, P416; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Zareba KM, 2006, DRUG TODAY, V42, P75, DOI 10.1358/dot.2006.42.2.925346	26	425	443	2	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2268	2276		10.1056/NEJMoa1109867	http://dx.doi.org/10.1056/NEJMoa1109867			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861PN	22082198	Green Published, Bronze			2022-12-28	WOS:000298031800007
J	Fujii, MS; Portegies Zwart, S				Fujii, Michiko S.; Portegies Zwart, Simon			The Origin of OB Runaway Stars	SCIENCE			English	Article							MASSIVE STAR; 30 DORADUS; CLUSTER R136; BINARY; EVOLUTION; NEBULA	About 20% of all massive stars in the Milky Way have unusually high velocities, the origin of which has puzzled astronomers for half a century. We argue that these velocities originate from strong gravitational interactions between single stars and binaries in the centers of star clusters. The ejecting binary forms naturally during the collapse of a young (less than or similar to 1 milion years old) star cluster. This model replicates the key characteristics of OB runaways in our galaxy, and it explains the presence of runaway stars of greater than or similar to 100 solar masses (M-circle dot) around young star clusters, such as R136 and Westerlund 2. The high proportion and the distributions in mass and velocity of runaways in the Milky Way are reproduced if the majority of massive stars are born in dense and relatively low-mass (5000 to 10,000 M-circle dot) clusters.	[Fujii, Michiko S.; Portegies Zwart, Simon] Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands; [Fujii, Michiko S.] Kagoshima Univ, Grad Sch Sci & Engn, Kagoshima 8900065, Japan	Leiden University; Leiden University - Excl LUMC; Kagoshima University	Portegies Zwart, S (corresponding author), Leiden Univ, Leiden Observ, POB 9513, NL-2300 RA Leiden, Netherlands.	spz@strw.leidenuniv.nl	Fujii, Michiko/ABA-5972-2020	Fujii, Michiko/0000-0002-6465-2978	Japan Society for the Promotion of Science for Young Scientists; Netherlands Research Council NWO [639.073.803, 614.061.608]; Netherlands Research School for Astronomy	Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Netherlands Research Council NWO(Netherlands Organization for Scientific Research (NWO)); Netherlands Research School for Astronomy	We thank B. Brandl, A. Brown, A. Gurkan, K. Nitadori, and H. Sana for discussions and the anonymous referees for their constructive criticism. This work was supported by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists and the Netherlands Research Council NWO [grants VICI (639.073.803), AMUSE (614.061.608), and Little Green Machine] and by the Netherlands Research School for Astronomy. The simulation software is available at http://amusecode.org and the data can be found at http://initialconditions.org.	Andersen M, 2009, ASTROPHYS J, V707, P1347, DOI 10.1088/0004-637X/707/2/1347; Bestenlehner JM, 2011, ASTRON ASTROPHYS, V530, DOI 10.1051/0004-6361/201117043; BLAAUW A, 1954, ASTROPHYS J, V119, P625, DOI 10.1086/145866; Blaauw A., 1961, BAN, V15, P265; Chene A.-N., 2011, IAU SYMP P SERIES, V272, P497; Evans CJ, 2010, ASTROPHYS J LETT, V715, pL74, DOI 10.1088/2041-8205/715/2/L74; Fregeau JM, 2004, MON NOT R ASTRON SOC, V352, P1, DOI 10.1111/j.1365-2966.2004.07914.x; Fregeau JM, 2002, ASTROPHYS J, V570, P171, DOI 10.1086/339576; Fujii M, 2008, ASTROPHYS J, V686, P1082, DOI 10.1086/591483; GIES DR, 1986, ASTROPHYS J SUPPL S, V61, P419, DOI 10.1086/191118; Gvaramadze VV, 2010, ASTRON ASTROPHYS, V519, DOI 10.1051/0004-6361/201014871; Gvaramadze VV, 2011, MON NOT R ASTRON SOC, V410, P304, DOI 10.1111/j.1365-2966.2010.17446.x; HEGGIE DC, 1975, MON NOT R ASTRON SOC, V173, P729, DOI 10.1093/mnras/173.3.729; LEONARD PJT, 1988, ASTRON J, V96, P222, DOI 10.1086/114804; Maiz-Apellaniz J., 2005, COMPLETE MULTIPLICIT; MAKINO J, 1991, ASTROPHYS J, V383, P181, DOI 10.1086/170774; Mason BD, 2009, ASTRON J, V137, P3358, DOI 10.1088/0004-6256/137/2/3358; Massey P, 2002, ASTROPHYS J, V565, P982, DOI 10.1086/324783; Moffat A. F. J., 2008, IAU S, P119; Nelan EP, 2004, ASTRON J, V128, P323, DOI 10.1086/420716; Ortolani S, 2008, NEW ASTRON, V13, P508, DOI 10.1016/j.newast.2008.01.008; Piatti AE, 1998, ASTRON ASTROPHYS SUP, V127, P423, DOI 10.1051/aas:1998111; Portegies Zwart S, 2007, MON NOT R ASTRON SOC, V378, pL29, DOI 10.1111/j.1745-3933.2007.00313.x; Portegies Zwart S, 2010, ANNU REV ASTRON ASTR, V48, P431, DOI 10.1146/annurev-astro-081309-130834; Sana H, 2010, ASTRON ASTROPHYS, V515, DOI 10.1051/0004-6361/200913688; Schnurr O, 2008, MON NOT R ASTRON SOC, V389, pL38, DOI 10.1111/j.1745-3933.2008.00517.x; Schnurr O, 2009, MON NOT R ASTRON SOC, V395, P823, DOI 10.1111/j.1365-2966.2009.14437.x; Tanikawa A, 2009, PUBL ASTRON SOC JPN, V61, P721, DOI 10.1093/pasj/61.4.721; Taylor WD, 2011, ASTRON ASTROPHYS, V530, DOI 10.1051/0004-6361/201116785; Townsley LK, 2006, ASTRON J, V131, P2164, DOI 10.1086/500535; van der Hucht KA, 2007, ASTR SOC P, V367, P159; Zwart SFP, 2000, ASTROPHYS J, V528, pL17, DOI 10.1086/312422	32	112	112	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2011	334	6061					1380	1383		10.1126/science.1211927	http://dx.doi.org/10.1126/science.1211927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858HW	22096104	Green Submitted			2022-12-28	WOS:000297787700046
J	Mega, JL; Hochholzer, W; Frelinger, AL; Kluk, MJ; Angiolillo, DJ; Kereiakes, DJ; Isserman, S; Rogers, WJ; Ruff, CT; Contant, C; Pencina, MJ; Scirica, BM; Longtine, JA; Michelson, AD; Sabatine, MS				Mega, Jessica L.; Hochholzer, Willibald; Frelinger, Andrew L., III; Kluk, Michael J.; Angiolillo, Dominick J.; Kereiakes, Dean J.; Isserman, Steven; Rogers, William J.; Ruff, Christian T.; Contant, Charles; Pencina, Michael J.; Scirica, Benjamin M.; Longtine, Janina A.; Michelson, Alan D.; Sabatine, Marc S.			Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS CORONARY INTERVENTION; MAINTENANCE-DOSE CLOPIDOGREL; ST-SEGMENT ELEVATION; CLINICAL-OUTCOMES; GENETIC POLYMORPHISMS; MYOCARDIAL-INFARCTION; ACTIVE METABOLITE; HEALTHY-SUBJECTS; CONTROLLED TRIAL; 150 MG/DAY	Context Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Objective To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes. Design, Setting, and Patients ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011. Interventions Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily. Main Outcome Measures Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y(12) assays) and adverse events. Results With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y(12) reaction units[PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASPPRI decreasing to 48.9%(95% CI, 44.6%-53.2%) and PRU to 127.5(95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (>= 230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg(P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8). Conclusion Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.	[Mega, Jessica L.; Ruff, Christian T.; Scirica, Benjamin M.; Sabatine, Marc S.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; [Mega, Jessica L.; Ruff, Christian T.; Scirica, Benjamin M.; Sabatine, Marc S.] Harvard Univ, Sch Med, Boston, MA USA; [Hochholzer, Willibald] Herz Zentrum Bad Krozingen, Bad Krozingen, Germany; [Frelinger, Andrew L., III; Michelson, Alan D.] Childrens Hosp Boston, Ctr Platelet Res Studies, Boston, MA USA; [Kluk, Michael J.; Longtine, Janina A.] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, Dept Pathol, Boston, MA 02115 USA; [Angiolillo, Dominick J.] Univ Florida, Coll Med, Jacksonville, FL USA; [Kereiakes, Dean J.] Childrens Hosp, Heart & Vasc Ctr, Cincinnati, OH 45229 USA; [Isserman, Steven] Clin Trials Amer, Hickory, NC USA; [Rogers, William J.] Univ Alabama, Birmingham Med Ctr, Tuscaloosa, AL 35487 USA; [Pencina, Michael J.] Harvard Clin Res Inst, Boston, MA USA; [Pencina, Michael J.] Boston Univ, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; State University System of Florida; University of Florida; Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Tuscaloosa; Harvard University; Harvard Medical School; Boston University	Mega, JL (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.	jmega@partners.org	Michelson, Alan/ABE-8487-2021; Sabatine, Marc/AAJ-6751-2020	Michelson, Alan/0000-0002-1746-4819; Sabatine, Marc/0000-0002-0691-3359; Pencina, Michael/0000-0001-5798-8855; Frelinger, Andrew/0000-0002-6871-7441	Bristol-Myers Squibb/sanofi-aventis; Eli Lilly; Daiichi Sankyo; Johnson Johnson/Bayer; Nanosphere; GL Synthesis; Takeda; Medicines Company; Portola; Accumetrics; Schering-Plough; AstraZeneca; Eisai; Johnson Johnson; GlaxoSmithKline; Otsuka; James and Esther King Biomedical Research Grant; Merck; Bristol-Myers Squibb; Bayer Healthcare; Gilead; sanofi-aventis; National Institutes of Health [K99/R00 HL098461]; German Heart Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL098461] Funding Source: NIH RePORTER	Bristol-Myers Squibb/sanofi-aventis(Sanofi-AventisBristol-Myers Squibb); Eli Lilly(Eli Lilly); Daiichi Sankyo(Daiichi Sankyo Company Limited); Johnson Johnson/Bayer(Johnson & JohnsonJohnson & Johnson USABayer AG); Nanosphere; GL Synthesis; Takeda(Takeda Pharmaceutical Company Ltd); Medicines Company; Portola; Accumetrics; Schering-Plough(Merck & CompanySchering Plough Corporation); AstraZeneca(AstraZeneca); Eisai(Eisai Co Ltd); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); GlaxoSmithKline(GlaxoSmithKline); Otsuka(Otsuka Pharmaceutical); James and Esther King Biomedical Research Grant; Merck(Merck & Company); Bristol-Myers Squibb(Bristol-Myers Squibb); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Gilead(Gilead Sciences); sanofi-aventis(Sanofi-Aventis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Heart Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mega reported receiving research grants from Bristol-Myers Squibb/sanofi-aventis, Eli Lilly, Daiichi Sankyo, and Johnson & Johnson/Bayer, and other research support from Nanosphere and Accumetrics and serving on consultant/advisory boards for Bristol-Myers Squibb, sanofi-aventis, AstraZeneca, Bayer, Novartis, and Merck. Dr Hochholzer reported serving on a consultant/advisory board for sanofi-aventis. Dr Frelinger reported receiving research grants from Bristol-Myers Squibb/sanofi-aventis, Eli Lilly, Daiichi Sankyo, GL Synthesis, and Takeda and serving on a consultant/advisory board for Eli Lilly. Dr Angiolillo reported receiving research grants from Eli Lilly, Daiichi Sankyo, The Medicines Company, Portola, Accumetrics, Schering-Plough, AstraZeneca, Eisai, Johnson & Johnson, Bristol-Myers Squibb/sanofi-aventis, GlaxoSmithKline, and Otsuka; other research support from a James and Esther King Biomedical Research Grant; and honoraria for lectures from Bristol-Myers Squibb, sanofi-aventis, Eli Lilly, and Daiichi Sankyo and serving on consultant/advisory boards for The Medicines Company, Portola, Novartis, Medicure, Accumetrics, Arena Pharmaceuticals, Merck, Evolva, Bristol-Myers Squibb, sanofi-aventis, Eli Lilly, Daiichi Sankyo, Abbott Vascular, and AstraZeneca. Dr Ruff reported receiving a research grant from Bristol-Myers Squibb/sanofi-aventis and Merck and serving on consultant/advisory boards for Daiichi Sankyo, Beckman Coulter, and Alere. Dr Scirica reported receiving research grants from AstraZeneca, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer Healthcare, Gilead, and Daiichi Sankyo and serving on consultant/advisory boards for Gilead and AstraZeneca. Dr Michelson reported receiving research grants from Bristol-Myers Squibb/sanofi-aventis, Eli Lilly, Daiichi Sankyo, GL Synthesis, and Takeda and serving on a consultant/advisory board for Eli Lilly. Dr Sabatine reported receiving research grants from AstraZeneca, Bristol-Myers Squibb/sanofi-aventis joint venture, Daiichi Sankyo, sanofi-aventis, and Schering-Plough and other research support from Nanosphere and serving on consultant/advisory boards for AstraZeneca, Bristol-Myers Squibb/sanofi-aventis, Daiichi Sankyo/Eli Lilly, Eli Lilly, and sanofi-aventis. No other disclosures were reported.; The ELEVATE-TIMI 56 trial was funded by an investigator-initiated grant from Bristol-Myers Squibb/sanofi-aventis. Research supplies were provided by Accumetrics and Nanosphere. Dr Mega is supported in part by grant K99/R00 HL098461 from the National Institutes of Health. Dr Hochholzer is supported in part by the German Heart Foundation.	Aleil B, 2008, JACC-CARDIOVASC INTE, V1, P631, DOI 10.1016/j.jcin.2008.09.004; Alexopoulos D, 2011, JACC-CARDIOVASC INTE, V4, P403, DOI 10.1016/j.jcin.2010.12.011; Angiolillo DJ, 2011, JACC-CARDIOVASC INTE, V4, P411, DOI 10.1016/j.jcin.2011.03.001; Barker CM, 2010, JACC-CARDIOVASC INTE, V3, P1001, DOI 10.1016/j.jcin.2010.07.012; Bliden KP, 2011, AM HEART J, V162, P160, DOI 10.1016/j.ahj.2010.11.025; Bonello L, 2008, J AM COLL CARDIOL, V51, P1404, DOI 10.1016/j.jacc.2007.12.044; Bonello L, 2010, J AM COLL CARDIOL, V56, P919, DOI 10.1016/j.jacc.2010.04.047; Brandt JT, 2007, J THROMB HAEMOST, V5, P2429, DOI 10.1111/j.1538-7836.2007.02775.x; Brar SS, 2011, J AM COLL CARDIOL, V58, P1945, DOI 10.1016/j.jacc.2011.06.059; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; Collet JP, 2011, JACC-CARDIOVASC INTE, V4, P392, DOI 10.1016/j.jcin.2011.03.002; Jeong YH, 2010, JACC-CARDIOVASC INTE, V3, P731, DOI 10.1016/j.jcin.2010.05.007; Mega JL, 2010, JAMA-J AM MED ASSOC, V304, P1821, DOI 10.1001/jama.2010.1543; Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949; Michelson AD, 2009, EUR HEART J, V30, P1753, DOI 10.1093/eurheartj/ehp159; Parodi G, 2011, JAMA-J AM MED ASSOC, V306, P1215, DOI 10.1001/jama.2011.1332; Pena A, 2009, CIRCULATION, V119, P2854, DOI 10.1161/CIRCULATIONAHA.108.857722; Price MJ, 2011, CIRCULATION, V124, P1132, DOI 10.1161/CIRCULATIONAHA.111.029165; Price MJ, 2011, JAMA-J AM MED ASSOC, V305, P1097, DOI 10.1001/jama.2011.290; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simon T, 2011, CLIN PHARMACOL THER, V90, P287, DOI 10.1038/clpt.2011.127; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056; U.S. Food and Drug Administration, GUID IND STAT APPR E; Umemura K, 2008, J THROMB HAEMOST, V6, P1439, DOI 10.1111/j.1538-7836.2008.03050.x; Wallentin L, 2010, LANCET, V376, P1320, DOI 10.1016/S0140-6736(10)61274-3; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, CIRCULATION, V116, P2923, DOI 10.1161/CIRCULATIONAHA.107.740324; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yusuf S, 2001, NEW ENGL J MED, V345, P494	31	275	299	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2011	306	20					2221	2228		10.1001/jama.2011.1703	http://dx.doi.org/10.1001/jama.2011.1703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851GD	22088980	Bronze			2022-12-28	WOS:000297255500021
J	Giraldeau, LA				Giraldeau, Luc-Alain			When More Is More	SCIENCE			English	Editorial Material							EUROPEAN STARLINGS; CONTEXT; INFORMATION; CHOICE		Univ Quebec Montreal, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Giraldeau, LA (corresponding author), Univ Quebec Montreal, Dept Sci Biol, Case Postale 8888,Succursale Ctr Ville, Montreal, PQ H3C 3P8, Canada.	giraldeau.luc-alain@uqam.ca	McKinnon, Ross Allan/B-9340-2009	McKinnon, Ross Allan/0000-0002-3725-793X				Bateson M, 2003, P ROY SOC B-BIOL SCI, V270, P1271, DOI 10.1098/rspb.2003.2365; Danchin E, 2004, SCIENCE, V305, P487, DOI 10.1126/science.1098254; Freidin E, 2011, SCIENCE, V334, P1000, DOI 10.1126/science.1209626; Giraldeau LA, 2008, ADV STUD BEHAV, V38, P59, DOI 10.1016/S0065-3454(08)00002-8; Goldstein DG, 2002, PSYCHOL REV, V109, P75, DOI 10.1037//0033-295X.109.1.75; McNamara JM, 2009, TRENDS ECOL EVOL, V24, P670, DOI 10.1016/j.tree.2009.05.011; Pompilio L, 2010, P NATL ACAD SCI USA, V107, P508, DOI 10.1073/pnas.0907250107; Rieucau G, 2011, PHILOS T R SOC B, V366, P949, DOI 10.1098/rstb.2010.0325; SIMONSON I, 1992, J MARKETING RES, V29, P281, DOI 10.2307/3172740; Stephens D.W., 1986, pi; TEMPLETON JJ, 1995, BEHAV ECOL, V6, P65, DOI 10.1093/beheco/6.1.65	11	0	0	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					910	911		10.1126/science.1214777	http://dx.doi.org/10.1126/science.1214777			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	849CA	22096176				2022-12-28	WOS:000297101800032
J	Gogotsi, Y; Simon, P				Gogotsi, Y.; Simon, P.			True Performance Metrics in Electrochemical Energy Storage	SCIENCE			English	Editorial Material									[Gogotsi, Y.] Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; [Gogotsi, Y.] Drexel Univ, AJ Drexel Nanotechnol Inst, Philadelphia, PA 19104 USA; [Simon, P.] Univ Toulouse 3, CNRS, UMR 5085, CIRIMAT, F-31062 Toulouse, France	Drexel University; Drexel University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National Polytechnique de Toulouse	Gogotsi, Y (corresponding author), Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.	gogotsi@drexel.edu; simon@chimie.ups-tlse.fr	Gogotsi, Yury/B-2167-2008; SIMON, Patrice/N-6777-2016	Gogotsi, Yury/0000-0001-9423-4032; SIMON, Patrice/0000-0002-0461-8268				Armand M, 2008, NATURE, V451, P652, DOI 10.1038/451652a; Chmiola J, 2010, SCIENCE, V328, P480, DOI 10.1126/science.1184126; Duduta M, 2011, ADV ENERGY MATER, V1, P511, DOI 10.1002/aenm.201100152; Liu CG, 2010, NANO LETT, V10, P4863, DOI 10.1021/nl102661q; Miller JR, 2008, ELECTROCHEM SOC INTE, V17, P53; Miller JR, 2008, SCIENCE, V321, P651, DOI 10.1126/science.1158736; Portet C, 2008, ELECTROCHIM ACTA, V53, P7675, DOI 10.1016/j.electacta.2008.05.019; Yang ZG, 2011, CHEM REV, V111, P3577, DOI 10.1021/cr100290v	8	1840	1883	21	896	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					917	918		10.1126/science.1213003	http://dx.doi.org/10.1126/science.1213003			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096182	Green Submitted			2022-12-28	WOS:000297101800038
J	Knigge, C; Coe, MJ; Podsiadlowski, P				Knigge, Christian; Coe, Malcolm J.; Podsiadlowski, Philipp			Two populations of X-ray pulsars produced by two types of supernova	NATURE			English	Article							SMALL-MAGELLANIC-CLOUD; ELECTRON-CAPTURE SUPERNOVAE; STAR-FORMATION HISTORY; CORE-COLLAPSE; BINARIES; EVOLUTION; SPIN; PERIODS	Two types of supernova are thought to produce the overwhelming majority of neutron stars in the Universe(1). The first type, iron-core-collapse supernovae, occurs when a high-mass star develops a degenerate iron core that exceeds the Chandrasekhar limit(2). The second type, electron-capture supernovae, is associated with the collapse of a lower-mass oxygen-neon-magnesium core as it loses pressure support owing to the sudden capture of electrons by neon and/or magnesium nuclei(3,4). It has hitherto been impossible to identify the two distinct families of neutron stars produced in these formation channels. Here we report that a large, well-known class of neutron-star-hosting X-ray pulsars is actually composed of two distinct subpopulations with different characteristic spin periods, orbital periods and orbital eccentricities. This class, the Be/X-ray binaries, contains neutron stars that accrete material from a more massive companion star(5). The two subpopulations are most probably associated with the two distinct types of neutron-star-forming supernova, with electron-capture supernovae preferentially producing systems with short spin periods, short orbital periods and low eccentricities. Intriguingly, the split between the two subpopulations is clearest in the distribution of the logarithm of spin period, a result that had not been predicted and which still remains to be explained.	[Knigge, Christian; Coe, Malcolm J.] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Podsiadlowski, Philipp] Univ Oxford, Dept Phys, Oxford OX1 3RH, England	University of Southampton; University of Oxford	Knigge, C (corresponding author), Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England.	c.knigge@soton.ac.uk		Coe, Malcolm/0000-0002-0763-8547; Knigge, Christian/0000-0002-1116-2553	UK Science and Technology Facilities Council; Science and Technology Facilities Council [ST/H002456/1, ST/G003084/1] Funding Source: researchfish; STFC [ST/H002456/1, ST/G003084/1] Funding Source: UKRI	UK Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	Research support for this project was provided by the UK Science and Technology Facilities Council. We would like to thank T. Maccarone and T. Linden for discussions.	Antoniou V, 2010, ASTROPHYS J LETT, V716, pL140, DOI 10.1088/2041-8205/716/2/L140; ASHMAN KM, 1994, ASTRON J, V108, P2348, DOI 10.1086/117248; Coe MJ, 2010, MON NOT R ASTRON SOC, V401, P252, DOI 10.1111/j.1365-2966.2009.15631.x; Coe MJ, 2005, MON NOT R ASTRON SOC, V358, P1379, DOI 10.1111/j.1365-2966.2005.08857.x; Coe MJ, 2005, MON NOT R ASTRON SOC, V356, P502, DOI 10.1111/j.1365-2966.2004.08467.x; CORBET RHD, 1984, ASTRON ASTROPHYS, V141, P91; DEJAGER C, 1988, ASTRON ASTROPHYS SUP, V72, P259; Haberl F, 2004, ASTRON ASTROPHYS, V414, P667, DOI 10.1051/0004-6361:20031654; Harris J, 2004, ASTRON J, V127, P1531, DOI 10.1086/381953; Heger A, 2003, ASTROPHYS J, V591, P288, DOI 10.1086/375341; LEE U, 1991, MON NOT R ASTRON SOC, V250, P432, DOI 10.1093/mnras/250.2.432; Li XD, 1996, ASTRON ASTROPHYS, V314, pL13; Linden T, 2009, ASTROPHYS J, V699, P1573, DOI 10.1088/0004-637X/699/2/1573; LIU QZ, 2003, P IAU S, V214, P215; NOMOTO K, 1984, ASTROPHYS J, V277, P791, DOI 10.1086/161749; NOMOTO KI, 1987, ASTROPHYS J, V322, P206, DOI 10.1086/165716; Podsiadlowski P, 2005, MON NOT R ASTRON SOC, V361, P1243, DOI 10.1111/j.1365-2966.2005.09253.x; Poelarends AJT, 2008, ASTROPHYS J, V675, P614, DOI 10.1086/520872; Reig P, 2011, ASTROPHYS SPACE SCI, V332, P1, DOI 10.1007/s10509-010-0575-8; Schwab J, 2010, ASTROPHYS J, V719, P722, DOI 10.1088/0004-637X/719/1/722; TOUT CA, 1991, MON NOT R ASTRON SOC, V253, P9, DOI 10.1093/mnras/253.1.9; van den Heuvel EPJ, 2004, ESA SPEC PUBL, V552, P185; WATERS LBFM, 1989, ASTRON ASTROPHYS, V223, P196; Woosley S, 2005, NAT PHYS, V1, P147, DOI 10.1038/nphys172	25	75	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					372	375		10.1038/nature10529	http://dx.doi.org/10.1038/nature10529			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22080948	Green Submitted, Green Accepted			2022-12-28	WOS:000297059700039
J	Kuehn, BM				Kuehn, Bridget M.			Environmental Pollutants Tied to Atherosclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																		Lind PM, 2012, ENVIRON HEALTH PERSP, V120, P38, DOI 10.1289/ehp.1103563	1	4	4	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2081	2081		10.1001/jama.2011.1666	http://dx.doi.org/10.1001/jama.2011.1666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089709				2022-12-28	WOS:000297013000004
J	Shreibati, JB; Baker, LC; Hlatky, MA				Shreibati, Jacqueline Baras; Baker, Laurence C.; Hlatky, Mark A.			Association of Coronary CT Angiography or Stress Testing With Subsequent Utilization and Spending Among Medicare Beneficiaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; FRACTIONAL FLOW RESERVE; ACUTE CHEST-PAIN; DIAGNOSTIC PERFORMANCE; ARTERY-DISEASE; UNITED-STATES; OUTCOMES; TRIAGE; TRENDS	Context Coronary computed tomography angiography (CCTA) is a new noninvasive diagnostic test for coronary artery disease (CAD), but its association with subsequent clinical management has not been established. Objective To compare utilization and spending associated with functional (stress testing) and anatomical (CCTA) noninvasive cardiac testing in a Medicare population. Design, Setting, and Patients Retrospective, observational cohort study using claims data from a 20% random sample of 2005-2008 Medicare fee-for-service beneficiaries 66 years or older with no claims for CAD in the preceding year, who received nonemergent, noninvasive testing for CAD (n=282 830). Main Outcome Measures Cardiac catheterization, coronary revascularization, acute myocardial infarction, all-cause mortality, and total and CAD-related Medicare spending over 180 days of follow-up. Results Compared with stress myocardial perfusion scintigraphy (MPS), CCTA was associated with an increased likelihood of subsequent cardiac catheterization (22.9% vs 12.1%; adjusted odds ratio [AOR], 2.19 [95% CI, 2.08 to 2.32]; P<.001), percutaneous coronary intervention (7.8% vs 3.4%; AOR, 2.49 [2.28 to 2.72]; P<.001), and coronary artery bypass graft surgery (3.7% vs 1.3%; AOR, 3.00 [2.63 to 3.41]; P<.001). CCTA was also associated with higher total health care spending ($4200 [$3193 to $5267]; P<.001), which was almost entirely attributable to payments for any claims for CAD ($4007 [$3256 to $4835]; P<.001). Compared with MPS, there was lower associated spending with stress echocardiography (-$4981 [-$4991 to -$4969]; P<.001) and exercise electrocardiography (-$7449 [-$7452 to -$7444]; P<.001). At 180 days, CCTA was associated with a similar likelihood of all-cause mortality (1.05% vs 1.28%; AOR, 1.11 [0.88 to 1.38]; P=.32) and a slightly lower likelihood of hospitalization for acute myocardial infarction (0.19% vs 0.43%; AOR, 0.60 [0.37 to 0.98]; P=.04). Conclusion Medicare beneficiaries who underwent CCTA in a nonacute setting were more likely to undergo subsequent invasive cardiac procedures and have higher CAD-related spending than patients who underwent stress testing. JAMA. 2011;306(19):2128-2136 www.jama.com	[Shreibati, Jacqueline Baras; Baker, Laurence C.; Hlatky, Mark A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Hlatky, MA (corresponding author), Stanford Univ, Sch Med, HRP Redwood Bldg,Room T150,259 Campus Dr, Stanford, CA 94305 USA.	hlatky@stanford.edu		Baras Shreibati, Jacqueline/0000-0002-1410-9432; Hlatky, Mark/0000-0003-4686-9441; Baker, Laurence/0000-0001-5032-794X	American Heart Association, Dallas, Texas	American Heart Association, Dallas, Texas(American Heart Association)	This study was funded by the American Heart Association, Dallas, Texas.	[Anonymous], MED PHYS FEE SCHED; Baim D.S., 2006, GROSSMANS CARDIAC CA, V7th, P215; Budoff MJ, 2008, J AM COLL CARDIOL, V52, P1724, DOI 10.1016/j.jacc.2008.07.031; *DARTM MED SCH CTR, 1996, DARTM ATL HLTH CAR; Fischer JJ, 2002, AM J CARDIOL, V90, P210, DOI 10.1016/S0002-9149(02)02456-6; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Goehler A, 2011, AM J ROENTGENOL, V196, P853, DOI 10.2214/AJR.10.4962; Hoffmann U, 2009, J AM COLL CARDIOL, V53, P1642, DOI 10.1016/j.jacc.2009.01.052; Ko DT, 2007, CIRCULATION, V115, P196, DOI 10.1161/CIRCULATIONAHA.106.657601; Ladapo JA, 2008, AM J ROENTGENOL, V191, P455, DOI 10.2214/AJR.07.3611; Lansky AJ, 2010, CIRC-CARDIOVASC INTE, V3, P602, DOI 10.1161/CIRCINTERVENTIONS.110.959080; Lin GA, 2008, JAMA-J AM MED ASSOC, V300, P1765, DOI 10.1001/jama.300.15.1765; Lucas F L, 1999, Eff Clin Pract, V2, P71; Lucas FL, 2008, CIRCULATION, V118, P2797, DOI 10.1161/CIRCULATIONAHA.108.789446; Lucas FL, 2006, CIRCULATION, V113, P374, DOI 10.1161/CIRCULATIONAHA.105.560433; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; McEvoy JW, 2011, ARCH INTERN MED, V171, P1260, DOI 10.1001/archinternmed.2011.204; Meijboom WB, 2008, J AM COLL CARDIOL, V52, P636, DOI 10.1016/j.jacc.2008.05.024; Meijboom WB, 2008, J AM COLL CARDIOL, V52, P2135, DOI 10.1016/j.jacc.2008.08.058; Miller JM, 2008, NEW ENGL J MED, V359, P2324, DOI 10.1056/NEJMoa0806576; Min JK, 2008, RADIOLOGY, V249, P62, DOI 10.1148/radiol.2483071453; Min JK, 2010, J AM COLL CARDIOL, V55, P957, DOI 10.1016/j.jacc.2009.08.087; Mowatt G, 2008, HEALTH TECHNOL ASSES, V12, P1; Nallamothu BK, 2007, AM J CARDIOL, V99, P749, DOI 10.1016/j.amjcard.2006.10.029; Nielsen LH, 2011, INT J CARDIOVAS IMAG, V27, P813, DOI 10.1007/s10554-010-9737-6; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Shaw LJ, 2010, JACC-CARDIOVASC IMAG, V3, P789, DOI 10.1016/j.jcmg.2010.05.004; Stein PD, 2008, AM J MED, V121, P715, DOI 10.1016/j.amjmed.2008.02.039; Stukel TA, 2005, JAMA-J AM MED ASSOC, V293, P1329, DOI 10.1001/jama.293.11.1329; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333	31	150	153	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2128	2136		10.1001/jama.2011.1652	http://dx.doi.org/10.1001/jama.2011.1652			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089720	Bronze			2022-12-28	WOS:000297013000019
J	Power, C; Rasko, JEJ				Power, Carl; Rasko, John E. J.			Promises and Challenges of Stem Cell Research for Regenerative Medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEMATOPOIETIC STEM; HUMAN FIBROBLASTS; NUCLEAR TRANSFER; THERAPY; TRANSPLANTATION; EXPANSION; CULTURE; LINES; DIFFERENTIATION; PLURIPOTENCY	In recent years, stem cells have generated increasing excitement, with frequent claims that they are revolutionizing medicine. For those not directly involved in stem cell research, however, it can be difficult to separate fact from fiction or realistic expectation from wishful thinking. This article aims to provide internists with a clear and concise introduction to the field. While recounting some scientific and medical milestones, the authors discuss the 3 main varieties of stem cells-adult, embryonic, and induced pluripotent-comparing their advantages and disadvantages for clinical medicine. The authors have sought to avoid the moral and political debates surrounding stem cell research, focusing instead on scientific and medical issues.	Univ Sydney, Centenary Inst, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Sydney, NSW, Australia	University of Sydney; Centenary Institute; University of Sydney	Rasko, JEJ (corresponding author), Centenary Inst, Locked Bag 6, Newtown, NSW 2042, Australia.	j.rasko@cenint.org	Rasko, John EJ/F-5754-2013	rasko, John/0000-0003-2975-807X	Cure The Future (Cell and Gene Trust); Brocher Foundation	Cure The Future (Cell and Gene Trust); Brocher Foundation	The authors thank Cure The Future (Cell and Gene Trust) and the Brocher Foundation for support. The figures were produced using Servier Medical Art (www.servier.com).	Allison M, 2009, NAT BIOTECHNOL, V27, P966, DOI 10.1038/nbt1109-966; [Anonymous], 2011, PHASE 1 SAFETY STUDY; [Anonymous], PHASE 1 2 OPEN LABEL; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Bernardo ME, 2009, ANN NY ACAD SCI, V1176, P101, DOI 10.1111/j.1749-6632.2009.04607.x; Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x; BRENNER MK, 1994, ANN NY ACAD SCI, V716, P204, DOI 10.1111/j.1749-6632.1994.tb21713.x; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; Cyranoski D, 2008, NATURE, V452, P406, DOI 10.1038/452406a; Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Feng Q, 2010, STEM CELLS, V28, P704, DOI 10.1002/stem.321; French AJ, 2008, STEM CELLS, V26, P485, DOI 10.1634/stemcells.2007-0252; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Grayson WL, 2009, SEMIN CELL DEV BIOL, V20, P665, DOI 10.1016/j.semcdb.2008.12.008; Green H, 2008, BIOESSAYS, V30, P897, DOI 10.1002/bies.20797; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Holst J, 2010, NAT BIOTECHNOL, V28, P1123, DOI 10.1038/nbt.1687; HOROWITZ MM, 1990, BLOOD, V75, P555; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Li H, 2007, CANCER RES, V67, P10889, DOI 10.1158/0008-5472.CAN-07-2665; Li JY, 2008, TRENDS NEUROSCI, V31, P146, DOI 10.1016/j.tins.2007.12.001; Li JY, 2009, CLONING STEM CELLS, V11, P39, DOI 10.1089/clo.2008.0041; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Menendez P, 2006, CYTOTHERAPY, V8, P530, DOI 10.1080/14653240601026654; Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554; Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566; Nakatsuji N, 2008, NAT BIOTECHNOL, V26, P739, DOI 10.1038/nbt0708-739; Neuman T., 2009, OPEN STEM CELL J, V1, P20, DOI DOI 10.2174/1876893800901010020; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Power C, 2008, ANN INTERN MED, V149, P421, DOI 10.7326/0003-4819-149-6-200809160-00009; Power C, 2011, ANN INTERN MED, V155, P114, DOI 10.7326/0003-4819-155-2-201107190-00007; Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62; Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955; Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129; Seydoux G, 2006, CELL, V127, P891, DOI 10.1016/j.cell.2006.11.016; Sharp J, 2010, STEM CELLS, V28, P152, DOI 10.1002/stem.245; Sieburg HB, 2011, P NATL ACAD SCI USA, V108, P4370, DOI 10.1073/pnas.1011414108; Szabo E, 2010, NATURE, V468, P521, DOI 10.1038/nature09591; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0; Thomas ED, 2005, INT J HEMATOL, V81, P89, DOI 10.1532/IJH97.04197; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tolar J, 2010, STEM CELLS, V28, P1446, DOI 10.1002/stem.459; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Vaughan William, 2009, P23, DOI [10.1007/978-0-387-78580-6_2, 10.1007/978-0-387-78590-6_2]; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Yu JY, 2008, GENE DEV, V22, P1987, DOI 10.1101/gad.1689808; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	62	11	11	1	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10					706	713		10.7326/0003-4819-155-10-201111150-00010	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EI	22084335				2022-12-28	WOS:000297108000007
J	Mahowald, N				Mahowald, Natalie			Aerosol Indirect Effect on Biogeochemical Cycles and Climate	SCIENCE			English	Article							NITROGEN DEPOSITION; DESERT DUST; ATMOSPHERIC NITROGEN; CARBON STORAGE; IMPACT; MODEL; CO2; SEQUESTRATION; LIMITATION; FEEDBACKS	The net effect of anthropogenic aerosols on climate is usually considered the sum of the direct radiative effect of anthropogenic aerosols, plus the indirect effect of these aerosols through aerosol-cloud interactions. However, an additional impact of aerosols on a longer time scale is their indirect effect on climate through biogeochemical feedbacks, largely due to changes in the atmospheric concentration of CO2. Aerosols can affect land and ocean biogeochemical cycles by physical forcing or by adding nutrients and pollutants to ecosystems. The net biogeochemical effect of aerosols is estimated to be equivalent to a radiative forcing of -0.5 +/- 0.4 watts per square meter, which suggests that reaching lower carbon targets will be even costlier than previously estimated.	Cornell Univ, Dept Earth & Atmospher Sci, Atkinson Ctr Sustainable Future, Ithaca, NY 14850 USA	Cornell University	Mahowald, N (corresponding author), Cornell Univ, Dept Earth & Atmospher Sci, Atkinson Ctr Sustainable Future, Ithaca, NY 14850 USA.		Mahowald, Natalie M/D-8388-2013	Mahowald, Natalie M/0000-0002-2873-997X	NSF [078369, 0832782, 0932946, 1021613, 1049033]; NASA [NNG06G127G]; Atkinson Center for Sustainable Future; Directorate For Geosciences [1003509, 0932946] Funding Source: National Science Foundation; Division Of Computer and Network Systems [0832782] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); NASA(National Aeronautics & Space Administration (NASA)); Atkinson Center for Sustainable Future; Directorate For Geosciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO)); Division Of Computer and Network Systems(National Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE))	This work was supported by grants from NSF (078369, 0832782, 0932946, 1021613, 1049033), NASA (NNG06G127G), and the Atkinson Center for Sustainable Future. Discussions with C. Goodale, P. Hess, and D. Miller contributed to this paper. Comments by R. Scanza and two anonymous reviewers improved the paper.	Andreae MO, 2005, NATURE, V435, P1187, DOI 10.1038/nature03671; Clarke L., 2007, SCENARIOS GREENHOUSE; Doney SC, 2007, P NATL ACAD SCI USA, V104, P14580, DOI 10.1073/pnas.0702218104; Duce RA, 2008, SCIENCE, V320, P893, DOI 10.1126/science.1150369; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Feng Y, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2005JD006404; Forster P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Friedlingstein P, 2008, NATURE, V451, P297, DOI 10.1038/nature06593; Fung IY, 2005, P NATL ACAD SCI USA, V102, P11201, DOI 10.1073/pnas.0504949102; Hijoka Y., 2008, GLOBAL ENV ENG, V13, P97; Holland EA, 1997, J GEOPHYS RES-ATMOS, V102, P15849, DOI 10.1029/96JD03164; Jickells TD, 2005, SCIENCE, V308, P67, DOI 10.1126/science.1105959; Jones CD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016867; Krishnamurthy A, 2010, J GEOPHYS RES-BIOGEO, V115, DOI 10.1029/2009JG001115; LeBauer DS, 2008, ECOLOGY, V89, P371, DOI 10.1890/06-2057.1; Likens GE, 2010, FRONT ECOL ENVIRON, V8, pE1, DOI 10.1890/090132; Magnani F, 2007, NATURE, V447, P848, DOI 10.1038/nature05847; Mahowald N, 2011, BIOGEOSCIENCES, V8, P387, DOI 10.5194/bg-8-387-2011; Mahowald NM, 2010, ATMOS CHEM PHYS, V10, P10875, DOI 10.5194/acp-10-10875-2010; Mahowald N, 2008, GLOBAL BIOGEOCHEM CY, V22, DOI 10.1029/2008GB003240; Mahowald NM, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2005GB002541; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; Matsuoka Y, 2006, ENERGY J, V3, P343; Melillo J.M., 1983, MAJOR BIOGEOCHEMICAL; Melillo J.M., 1983, MAJOR BIOGEOCHEMICAL; Mercado LM, 2009, NATURE, V458, P1014, DOI 10.1038/nature07949; Nadelhoffer KJ, 1999, NATURE, V398, P145, DOI 10.1038/18205; Paytan A, 2009, P NATL ACAD SCI USA, V106, P4601, DOI 10.1073/pnas.0811486106; Phillips OL, 2009, SCIENCE, V323, P1344, DOI 10.1126/science.1164033; Reay DS, 2008, NAT GEOSCI, V1, P430, DOI 10.1038/ngeo230; Riahi K, 2007, TECHNOL FORECAST SOC, V74, P887, DOI 10.1016/j.techfore.2006.05.026; Rosenfeld D, 2008, SCIENCE, V321, P1309, DOI 10.1126/science.1160606; Schindler DW, 1981, ATMOSPHERE BIOSPHERE; Smith SJ, 2006, ENERG J, P373; Stevens B, 2009, NATURE, V461, P607, DOI 10.1038/nature08281; Thomas RQ, 2010, NAT GEOSCI, V3, P13, DOI 10.1038/NGEO721; Thornton PE, 2009, BIOGEOSCIENCES, V6, P2099, DOI 10.5194/bg-6-2099-2009; Townsend AR, 1996, ECOL APPL, V6, P806, DOI 10.2307/2269486; van Vuuren DP, 2007, CLIMATIC CHANGE, V81, P119, DOI 10.1007/s10584-006-9172-9; VITOUSEK PM, 1984, ECOLOGY, V65, P285, DOI 10.2307/1939481; Wise M, 2009, SCIENCE, V324, P1183, DOI 10.1126/science.1168475; ZAEHLE S, 2010, GLOBAL BIOGEOCHEM CY, V24, DOI DOI 10.1029/2009GB003521	43	287	296	10	330	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					794	796		10.1126/science.1207374	http://dx.doi.org/10.1126/science.1207374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076375				2022-12-28	WOS:000296849600043
J	Kleinman, A				Kleinman, Arthur			The art of medicine A search for wisdom	LANCET			English	Editorial Material									Harvard Univ, Cambridge, MA 02138 USA	Harvard University	Kleinman, A (corresponding author), Harvard Univ, William James Hall Room 330, Cambridge, MA 02138 USA.	kleinman@wjh.harvard.edu						BANVILLE J, 2011, NEW YORK REV BO 1027; James William, 2010, HEART W JAMES; Kleinman Arthur, 2006, WHAT REALLY MATTERS; Richardson Robert D., 2006, W JAMES MAELSTROM AM	4	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 5	2011	378	9803					1621	1622		10.1016/S0140-6736(11)61688-7	http://dx.doi.org/10.1016/S0140-6736(11)61688-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844ST	22066140	Green Submitted			2022-12-28	WOS:000296768300017
J	Shin, SC; Kim, SH; You, H; Kim, B; Kim, AC; Lee, KA; Yoon, JH; Ryu, JH; Lee, WJ				Shin, Seung Chul; Kim, Sung-Hee; You, Hyejin; Kim, Boram; Kim, Aeri C.; Lee, Kyung-Ah; Yoon, Joo-Heon; Ryu, Ji-Hwan; Lee, Won-Jae			Drosophila Microbiome Modulates Host Developmental and Metabolic Homeostasis via Insulin Signaling	SCIENCE			English	Article							INNATE IMMUNE HOMEOSTASIS; LIFE-SPAN; BACTERIAL MUTUALISM; GUT MICROBIOME; RECEPTOR; COMMENSAL; FLIES; ABLATION; HOMOLOG; GROWTH	The symbiotic microbiota profoundly affect many aspects of host physiology; however, the molecular mechanisms underlying host-microbe cross-talk are largely unknown. Here, we show that the pyrroloquinoline quinone-dependent alcohol dehydrogenase (PQQ-ADH) activity of a commensal bacterium, Acetobacter pomorum, modulates insulin/insulin-like growth factor signaling (IIS) in Drosophila to regulate host homeostatic programs controlling developmental rate, body size, energy metabolism, and intestinal stem cell activity. Germ-free animals monoassociated with PQQ-ADH mutant bacteria displayed severe deregulation of developmental and metabolic homeostasis. Importantly, these defects were reversed by enhancing host IIS or by supplementing the diet with acetic acid, the metabolic product of PQQ-ADH.	[Shin, Seung Chul; Kim, Sung-Hee; You, Hyejin; Kim, Boram; Kim, Aeri C.; Lee, Kyung-Ah; Lee, Won-Jae] Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; [Shin, Seung Chul; Kim, Sung-Hee; You, Hyejin; Kim, Boram; Kim, Aeri C.; Lee, Kyung-Ah; Lee, Won-Jae] Natl Creat Res Initiat Ctr Symbiosyst, Seoul 151742, South Korea; [You, Hyejin; Kim, Boram; Kim, Aeri C.] Ewha Womans Univ, Dept Bioinspired Sci, Seoul 120750, South Korea; [You, Hyejin; Kim, Boram; Kim, Aeri C.] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea; [Shin, Seung Chul; Yoon, Joo-Heon; Ryu, Ji-Hwan] Yonsei Univ, Coll Med, Res Ctr Human Nat Def Syst, Seoul, South Korea	Seoul National University (SNU); Ewha Womans University; Ewha Womans University; Yonsei University; Yonsei University Health System	Lee, WJ (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	lwj@snu.ac.kr	rchnds, rchnds/D-7595-2016; Yoon, Joo-Heon/E-5781-2016	Yoon, Joo-Heon/0000-0003-2404-7156	National Creative Research Initiative Program; BK 21 program; Basic Science Research Program [2011-0001168]; Gwangju Institute of Science and Technology of the Ministry of Science and Technology Korea	National Creative Research Initiative Program(Ministry of Science & Technology (MOST), Republic of Korea); BK 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Basic Science Research Program; Gwangju Institute of Science and Technology of the Ministry of Science and Technology Korea	This work was supported by the National Creative Research Initiative Program (to W.-J.L.), the BK 21 program, the Basic Science Research Program (2011-0001168, to J.-H.R. and J.-H.Y.), and a Gwangju Institute of Science and Technology-Systems Biology grant (2011) of the Ministry of Science and Technology Korea. We thank D. Daffonchio and K. Matsushita for helpful comments on Acetobacter. The A. pomorum draft genome sequence is deposited in DNA Data Bank of Japan/European Molecular Biology Laboratory/GenBank with accession no. AEUP01000000.	Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bae YS, 2010, TRENDS IMMUNOL, V31, P278, DOI 10.1016/j.it.2010.05.003; Baker KD, 2007, CELL METAB, V6, P257, DOI 10.1016/j.cmet.2007.09.002; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009; Crotti E, 2009, ENVIRON MICROBIOL, V11, P3252, DOI 10.1111/j.1462-2920.2009.02048.x; Edgar BA, 2006, NAT REV GENET, V7, P907, DOI 10.1038/nrg1989; Favia G, 2007, P NATL ACAD SCI USA, V104, P9047, DOI 10.1073/pnas.0610451104; Johnston CS, 2010, ANN NUTR METAB, V56, P74, DOI 10.1159/000272133; Koropatnick TA, 2004, SCIENCE, V306, P1186, DOI 10.1126/science.1102218; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Ren C, 2007, CELL METAB, V6, P144, DOI 10.1016/j.cmet.2007.06.006; Roh SW, 2008, APPL ENVIRON MICROB, V74, P6171, DOI 10.1128/AEM.00301-08; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Ryu JH, 2008, SCIENCE, V319, P777, DOI 10.1126/science.1149357; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Wong CNA, 2011, ENVIRON MICROBIOL, V13, P1889, DOI 10.1111/j.1462-2920.2011.02511.x; Yakushi T, 2010, APPL MICROBIOL BIOT, V86, P1257, DOI 10.1007/s00253-010-2529-z	25	592	635	13	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					670	674		10.1126/science.1212782	http://dx.doi.org/10.1126/science.1212782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053049				2022-12-28	WOS:000296494700055
J	Mordecai, S; Al-Hadithy, N				Mordecai, Simon; Al-Hadithy, Nawfal			PICTURE QUIZ Management of ankle fractures	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RULES		[Mordecai, Simon] Salisbury Dist Hosp, Salisbury SP2 8BJ, Wilts, England; [Al-Hadithy, Nawfal] UCL, London, England	Salisbury District Hospital; University of London; University College London	Mordecai, S (corresponding author), Salisbury Dist Hosp, Salisbury SP2 8BJ, Wilts, England.	simon_mordecai@yahoo.com						Bouillon B, 2004, UNFALLCHIRURG, V107, P844, DOI 10.1007/s00113-004-0847-2; Danis R, 1949, THEORIE PRATIQUE OST; Davenport M, 2011, EMEDICINE; HARPER MC, 1989, FOOT ANKLE, V10, P156, DOI 10.1177/107110078901000308; Iskyan K, 2010, EMEDICINE; LAUGEHANSEN N, 1950, ARCH SURG-CHICAGO, V60, P957, DOI 10.1001/archsurg.1950.01250010980011; Makwana NK, 2001, J BONE JOINT SURG BR, V83B, P525, DOI 10.1302/0301-620X.83B4.11522; MICHELSON JD, 1995, J BONE JOINT SURG AM, V77A, P142, DOI 10.2106/00004623-199501000-00020; RAMSEY PL, 1976, J BONE JOINT SURG AM, V58, P356, DOI 10.2106/00004623-197658030-00010; ROBERTSON GSM, 1990, ANN ROY COLL SURG, V72, P99; Srinivasan CMS, 2001, INJURY, V32, P559, DOI 10.1016/S0020-1383(01)00034-1; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Weber BG, 1972, VERLETZUNGEN OBEREN; Whittle AP., 2008, CAMPBELLS OPERATIVE, P3085	15	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2011	343								d5204	10.1136/bmj.d5204	http://dx.doi.org/10.1136/bmj.d5204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840DB	22039272				2022-12-28	WOS:000296417400001
J	Polymenidou, M; Cleveland, DW				Polymenidou, Magdalini; Cleveland, Don W.			The Seeds of Neurodegeneration: Prion-like Spreading in ALS	CELL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; MUTANT SUPEROXIDE-DISMUTASE; CEREBRAL BETA-AMYLOIDOSIS; MOTOR-NEURON DISEASE; BINDING PROTEIN 43; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; MESSENGER-RNA; INCLUSION FORMATION	Misfolded proteins accumulating in several neurodegenerative diseases (including Alzheimer, Parkinson, and Huntington diseases) can cause aggregation of their native counterparts through a mechanism similar to the infectious prion protein's induction of a pathogenic conformation onto its cellular isoform. Evidence for such a prion-like mechanism has now spread to the main misfolded proteins, SOD1 and TDP-43, implicated in amyotrophic lateral sclerosis (ALS). The major neurodegenerative diseases may therefore have mechanistic parallels for non-cell-autonomous spread of disease within the nervous system.	[Polymenidou, Magdalini; Cleveland, Don W.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Polymenidou, Magdalini; Cleveland, Don W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Cleveland, Don/AAN-9783-2021; Polymenidou, Magdalini/D-2254-2014	Cleveland, Don/0000-0002-1934-3682	international Human Frontier Science Program Organization; National Institute of Neurological Disorders and Stroke [K99NS075216, R37NS27036]; Ludwig Institute for Cancer Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036, K99NS075216] Funding Source: NIH RePORTER	international Human Frontier Science Program Organization(Human Frontier Science Program); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Ludwig Institute for Cancer Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The authors thank all members of the Cleveland lab for discussions. M.P. was the recipient of a long-term fellowship from the international Human Frontier Science Program Organization. The authors receive support from the National Institute of Neurological Disorders and Stroke-K99NS075216 to M.P. and R37NS27036 to D.W.C. D.W.C. receives salary support from the Ludwig Institute for Cancer Research.	Aguzzi A, 2008, ANNU REV PATHOL-MECH, V3, P11, DOI 10.1146/annurev.pathmechdis.3.121806.154326; Aguzzi A, 2009, NEURON, V64, P783, DOI 10.1016/j.neuron.2009.12.016; Aguzzi A, 2009, NATURE, V459, P924, DOI 10.1038/459924a; Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694; Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Ayala YM, 2011, EMBO J, V30, P277, DOI 10.1038/emboj.2010.310; BAKER HF, 1994, MOL NEUROBIOL, V8, P25, DOI 10.1007/BF02778005; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660; Braak H, 2003, J NEURAL TRANSM, V110, P517, DOI 10.1007/s00702-002-0808-2; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chia R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010627; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Colombrita C, 2009, J NEUROCHEM, V111, P1051, DOI 10.1111/j.1471-4159.2009.06383.x; Cushman M, 2010, J CELL SCI, V123, P1191, DOI 10.1242/jcs.051672; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Deng HX, 2010, ANN NEUROL, V67, P739, DOI 10.1002/ana.22051; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; Deng YP, 2004, J CHEM NEUROANAT, V27, P143, DOI 10.1016/j.jchemneu.2004.02.005; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Di Giorgio FP, 2008, CELL STEM CELL, V3, P637, DOI 10.1016/j.stem.2008.09.017; Doi H, 2008, J BIOL CHEM, V283, P6489, DOI 10.1074/jbc.M705306200; Doi H, 2010, NEUROSCI RES, V66, P131, DOI 10.1016/j.neures.2009.10.004; Dormann D, 2010, EMBO J, V29, P2841, DOI 10.1038/emboj.2010.143; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Eisele YS, 2009, P NATL ACAD SCI USA, V106, P12926, DOI 10.1073/pnas.0903200106; Elden AC, 2010, NATURE, V466, P1069, DOI 10.1038/nature09320; Forsberg K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011552; Frost B, 2009, J BIOL CHEM, V284, P3546, DOI 10.1074/jbc.M805627200; Fuentealba RA, 2010, J BIOL CHEM, V285, P26304, DOI 10.1074/jbc.M110.125039; Fujita K, 2008, ACTA NEUROPATHOL, V116, P439, DOI 10.1007/s00401-008-0415-x; Furukawa Y, 2011, J BIOL CHEM, V286, P18664, DOI 10.1074/jbc.M111.231209; Furukawa Y, 2009, J NEUROSCI, V29, P5153, DOI 10.1523/JNEUROSCI.0783-09.2009; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Gitcho MA, 2008, ANN NEUROL, V63, P535, DOI 10.1002/ana.21344; Grad LI, 2011, P NATL ACAD SCI USA, V108, P16398, DOI 10.1073/pnas.1102645108; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Guo WR, 2011, NAT STRUCT MOL BIOL, V18, P822, DOI 10.1038/nsmb.2053; Haidet-Phillips AM, 2011, NAT BIOTECHNOL, V29, P824, DOI 10.1038/nbt.1957; Hansen C, 2011, J CLIN INVEST, V121, P715, DOI 10.1172/JCI43366; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Huang C, 2010, INT J BIOL SCI, V6, P396; Igaz LM, 2008, AM J PATHOL, V173, P182, DOI 10.2353/ajpath.2008.080003; Igaz LM, 2011, J CLIN INVEST, V121, P726, DOI 10.1172/JCI44867; Ilieva H, 2009, J CELL BIOL, V187, P761, DOI 10.1083/jcb.200908164; Ito D, 2011, ANN NEUROL, V69, P152, DOI 10.1002/ana.22246; Jaarsma D, 2008, J NEUROSCI, V28, P2075, DOI 10.1523/JNEUROSCI.5258-07.2008; Johnson BS, 2009, J BIOL CHEM, V284, P20329, DOI 10.1074/jbc.M109.010264; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kane MD, 2000, J NEUROSCI, V20, P3606, DOI 10.1523/JNEUROSCI.20-10-03606.2000; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kerman A, 2010, ACTA NEUROPATHOL, V119, P335, DOI 10.1007/s00401-010-0646-5; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Kril JJ, 2011, J MOL NEUROSCI, V45, P379, DOI 10.1007/s12031-011-9528-0; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Liu-Yesucevitz L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013250; Mahal SP, 2007, P NATL ACAD SCI USA, V104, P20908, DOI 10.1073/pnas.0710054104; Marchetto MCN, 2008, CELL STEM CELL, V3, P649, DOI 10.1016/j.stem.2008.10.001; McDonald KK, 2011, HUM MOL GENET, V20, P1400, DOI 10.1093/hmg/ddr021; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Mougenot AL, 2012, NEUROBIOL AGING, V33, P2225, DOI 10.1016/j.neurobiolaging.2011.06.022; Munch C, 2011, P NATL ACAD SCI USA, V108, P3548, DOI 10.1073/pnas.1017275108; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nonaka T, 2010, J BIOL CHEM, V285, P34885, DOI 10.1074/jbc.M110.148460; Papadeas ST, 2011, P NATL ACAD SCI USA, V108, P17803, DOI 10.1073/pnas.1103141108; Pesiridis GS, 2011, J BIOL CHEM, V286, P18845, DOI 10.1074/jbc.M111.231118; Polymenidou M, 2011, NAT NEUROSCI, V14, P459, DOI 10.1038/nn.2779; Prudencio M, 2009, HUM MOL GENET, V18, P3217, DOI 10.1093/hmg/ddp260; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Ravits J, 2007, NEUROLOGY, V68, P1576, DOI 10.1212/01.wnl.0000261045.57095.56; Ravits J, 2007, NEUROLOGY, V68, P1571, DOI 10.1212/01.wnl.0000260965.20021.47; Ren PH, 2009, NAT CELL BIOL, V11, P219, DOI 10.1038/ncb1830; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schwab C, 2008, J NEUROPATH EXP NEUR, V67, P1159, DOI 10.1097/NEN.0b013e31818e8951; Shorter J, 2005, NAT REV GENET, V6, P435, DOI 10.1038/nrg1616; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Si K, 2010, CELL, V140, P421, DOI 10.1016/j.cell.2010.01.008; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Sun ZH, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000614; Thal DR, 2008, ACTA NEUROPATHOL, V115, P599, DOI 10.1007/s00401-008-0366-2; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Urushitani M, 2006, NAT NEUROSCI, V9, P108, DOI 10.1038/nn1603; Van Deerlin VM, 2008, LANCET NEUROL, V7, P409, DOI 10.1016/S1474-4422(08)70071-1; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942; Voigt A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012247; Volpicelli-Daley LA, 2011, NEURON, V72, P57, DOI 10.1016/j.neuron.2011.08.033; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; Wang IF, 2008, J NEUROCHEM, V105, P797, DOI 10.1111/j.1471-4159.2007.05190.x; Woulfe J, 2010, BRAIN PATHOL, V20, P589, DOI 10.1111/j.1750-3639.2009.00337.x; Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047; Yokoseki A, 2008, ANN NEUROL, V63, P538, DOI 10.1002/ana.21392	103	260	265	1	59	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					498	508		10.1016/j.cell.2011.10.011	http://dx.doi.org/10.1016/j.cell.2011.10.011			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036560	Green Accepted, Bronze			2022-12-28	WOS:000296573700007
J	Mackelprang, R; Waldrop, MP; DeAngelis, KM; David, MM; Chavarria, KL; Blazewicz, SJ; Rubin, EM; Jansson, JK				Mackelprang, Rachel; Waldrop, Mark P.; DeAngelis, Kristen M.; David, Maude M.; Chavarria, Krystle L.; Blazewicz, Steven J.; Rubin, Edward M.; Jansson, Janet K.			Metagenomic analysis of a permafrost microbial community reveals a rapid response to thaw	NATURE			English	Article							BACTERIAL COMMUNITY; R-PACKAGE; DIVERSITY; CARBON; SOIL; RNA; DISCOVERY; ALIGNMENT; SEARCH; GENES	Permafrost contains an estimated 1672 Pg carbon (C), an amount roughly equivalent to the total currently contained within land plants and the atmosphere(1-3). This reservoir of C is vulnerable to decomposition as rising global temperatures cause the permafrost to thaw(2). During thaw, trapped organic matter may become more accessible for microbial degradation and result in greenhouse gas emissions(4,5). Despite recent advances in the use of molecular tools to study permafrost microbial communities(6-9), their response to thaw remains unclear. Here we use deep metagenomic sequencing to determine the impact of thaw on microbial phylogenetic and functional genes, and relate these data to measurements of methane emissions. Metagenomics, the direct sequencing of DNA from the environment, allows the examination of whole biochemical pathways and associated processes, as opposed to individual pieces of the metabolic puzzle. Our metagenome analyses reveal that during transition from a frozen to a thawed state there are rapid shifts in many microbial, phylogenetic and functional gene abundances and pathways. After one week of incubation at 5 degrees C, permafrost metagenomes converge to be more similar to each other than while they are frozen. We find that multiple genes involved in cycling of C and nitrogen shift rapidly during thaw. We also construct the first draft genome from a complex soil metagenome, which corresponds to a novel methanogen. Methane previously accumulated in permafrost is released during thaw and subsequently consumed by methanotrophic bacteria. Together these data point towards the importance of rapid cycling of methane and nitrogen in thawing permafrost.	[Mackelprang, Rachel; Rubin, Edward M.; Jansson, Janet K.] US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; [Mackelprang, Rachel] Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA; [Waldrop, Mark P.] US Geol Survey, Menlo Pk, CA 94025 USA; [DeAngelis, Kristen M.; David, Maude M.; Chavarria, Krystle L.; Jansson, Janet K.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Earth Sci, Berkeley, CA 94720 USA; [Blazewicz, Steven J.] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Rubin, Edward M.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Genom Div, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; California State University System; California State University Northridge; United States Department of the Interior; United States Geological Survey; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Jansson, JK (corresponding author), US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA.	jrjansson@lbl.gov	Jansson, Janet/H-5478-2018	Jansson, Janet/0000-0002-5487-4315; Waldrop, Mark/0000-0003-1829-7140; David, Maude/0000-0003-1561-418X; DeAngelis, Kristen/0000-0002-5585-4551; Blazewicz, Steven/0000-0001-7517-1750	Office of Science of the US Department of Energy [DE-AC02-05CH11231]; Venture Capital; United States Geological Survey	Office of Science of the US Department of Energy(United States Department of Energy (DOE)); Venture Capital; United States Geological Survey(United States Geological Survey)	The work conducted by the Lawrence Berkeley National Laboratory Earth Sciences Division (Laboratory Directed Research Development) and the Joint Genome Institute was supported in part by the Office of Science of the US Department of Energy under Contract no. DE-AC02-05CH11231. This study was also supported by the Venture Capital and Yukon River Basin project of the United States Geological Survey. We acknowledge the technical support by the Joint Genome Institute production team. We thank A. Sczyrba, R. Egan and S. Canon for discussions and advice.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 2010, R LANG ENV STAT COMP; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blow MJ, 2008, GENOME RES, V18, P1347, DOI 10.1101/gr.076091.108; Brodie E, 2002, MICROB ECOL, V44, P260, DOI 10.1007/s00248-002-2012-1; Chu HY, 2010, ENVIRON MICROBIOL, V12, P2998, DOI 10.1111/j.1462-2920.2010.02277.x; David MM, 2008, J MICROBIOL METH, V73, P73, DOI 10.1016/j.mimet.2008.01.001; DeAngelis KM, 2009, ISME J, V3, P168, DOI 10.1038/ismej.2008.103; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ferry JG, 2010, ANNU REV MICROBIOL, V64, P453, DOI 10.1146/annurev.micro.112408.134051; Griffiths RI, 2000, APPL ENVIRON MICROB, V66, P5488, DOI 10.1128/AEM.66.12.5488-5491.2000; Hamady M, 2010, ISME J, V4, P17, DOI 10.1038/ismej.2009.97; Hansen AA, 2007, ENVIRON MICROBIOL, V9, P2870, DOI 10.1111/j.1462-2920.2007.01403.x; Hess M, 2011, SCIENCE, V331, P463, DOI 10.1126/science.1200387; Huson DH, 2007, GENOME RES, V17, P377, DOI 10.1101/gr.5969107; Johnson SS, 2007, P NATL ACAD SCI USA, V104, P14401, DOI 10.1073/pnas.0706787104; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kristiansson E, 2009, BIOINFORMATICS, V25, P2737, DOI 10.1093/bioinformatics/btp508; Kunin V, 2010, OPEN J, V1, P1; Kunin V, 2010, ENVIRON MICROBIOL, V12, P118, DOI 10.1111/j.1462-2920.2009.02051.x; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Markowitz VM, 2008, NUCLEIC ACIDS RES, V36, pD534, DOI 10.1093/nar/gkm869; MURRAY PA, 1984, NATURE, V312, P284, DOI 10.1038/312284a0; Oksanen J., 2016, R PACKAG; Osterkamp TE, 2007, J GEOPHYS RES-EARTH, V112, DOI 10.1029/2006JF000578; Prater JL, 2007, GLOBAL BIOGEOCHEM CY, V21, DOI 10.1029/2006GB002866; Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Rivkina E, 2007, FEMS MICROBIOL ECOL, V61, P1, DOI 10.1111/j.1574-6941.2007.00315.x; Sakai S, 2008, INT J SYST EVOL MICR, V58, P929, DOI 10.1099/ijs.0.65571-0; Schuur EAG, 2008, BIOSCIENCE, V58, P701, DOI 10.1641/B580807; Steven B, 2008, ENVIRON MICROBIOL, V10, P3388, DOI 10.1111/j.1462-2920.2008.01746.x; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Talavera G, 2007, SYST BIOL, V56, P564, DOI 10.1080/10635150701472164; Tarnocai C, 2009, GLOBAL BIOGEOCHEM CY, V23, DOI 10.1029/2008GB003327; Trotsenko YA, 2005, FEMS MICROBIOL ECOL, V53, P15, DOI 10.1016/j.femsec.2005.02.010; Waldrop MP, 2010, GLOBAL CHANGE BIOL, V16, P2543, DOI 10.1111/j.1365-2486.2009.02141.x; White JR, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000352; Williams R, 2006, NAT METHODS, V3, P545, DOI 10.1038/NMETH896; Wu M, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r151; Yergeau E, 2010, ISME J, V4, P1206, DOI 10.1038/ismej.2010.41; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107; Zimov SA, 2006, SCIENCE, V312, P1612, DOI 10.1126/science.1128908	44	465	490	32	746	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					368	U120		10.1038/nature10576	http://dx.doi.org/10.1038/nature10576			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22056985	Green Submitted			2022-12-28	WOS:000298033000051
J	Zielke, N; Kim, KJ; Tran, V; Shibutani, ST; Bravo, MJ; Nagarajan, S; van Straaten, M; Woods, B; von Dassow, G; Rottig, C; Lehner, CF; Grewal, SS; Duronio, RJ; Edgar, BA				Zielke, Norman; Kim, Kerry J.; Vuong Tran; Shibutani, Shusaku T.; Bravo, Maria-Jose; Nagarajan, Sabarish; van Straaten, Monique; Woods, Brigitte; von Dassow, George; Rottig, Carmen; Lehner, Christian F.; Grewal, Savraj S.; Duronio, Robert J.; Edgar, Bruce A.			Control of Drosophila endocycles by E2F and CRL4(CDT2)	NATURE			English	Article							DEPENDENT KINASE INHIBITOR; CYCLIN-E; CELL-PROLIFERATION; S-PHASE; DNA-REPLICATION; TRANSCRIPTIONAL PROGRAM; ENDOREPLICATION CYCLES; DEVELOPMENTAL CONTROL; PROGRESSION; EXPRESSION	Endocycles are variant cell cycles comprised of DNA synthesis (S)- and gap (G)-phases but lacking mitosis(1,2). Such cycles facilitate post-mitotic growth in many invertebrate and plant cells, and are so ubiquitous that they may account for up to half the world's biomass(3,4). DNA replication in endocycling Drosophila cells is triggered by cyclin E/cyclin dependent kinase 2 (CYCE/CDK2), but this kinase must be inactivated during each G-phase to allow the assembly of pre-Replication Complexes (preRCs) for the next S-phase(5,6). How CYCE/CDK2 is periodically silenced to allow re-replication has not been established. Here, using genetic tests in parallel with computational modelling, we show that the endocycles of Drosophila are driven by a molecular oscillator in which the E2F1 transcription factor promotes CycE expression and S-phase initiation, S-phase then activates the CRL4(CDT2) ubiquitin ligase, and this in turn mediates the destruction of E2F1 (ref. 7). We propose that it is the transient loss of E2F1 during S phases that creates the window of low Cdk activity required for preRC formation. In support of this model overexpressed E2F1 accelerated endocycling, whereas a stabilized variant of E2F1 blocked endocycling by de-regulating target genes, including CycE, as well as Cdk1 and mitotic cyclins. Moreover, we find that altering cell growth by changing nutrition or target of rapamycin (TOR) signalling impacts E2F1 translation, thereby making endocycle progression growth-dependent. Many of the regulatory interactions essential to this novel cell cycle oscillator are conserved in animals and plants(1,2,8), indicating that elements of this mechanism act in most growth-dependent cell cycles.	[Zielke, Norman; van Straaten, Monique; Edgar, Bruce A.] Univ Heidelberg ZMBH Alliance, Zentrum Mol Biol, German Canc Res Ctr DKFZ, D-69120 Heidelberg, Germany; [Zielke, Norman; Vuong Tran; Bravo, Maria-Jose; Woods, Brigitte; Edgar, Bruce A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Kim, Kerry J.; von Dassow, George] Univ Washington, Friday Harbor Labs, Ctr Cell Dynam, Friday Harbor, WA 98250 USA; [Shibutani, Shusaku T.; Duronio, Robert J.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Nagarajan, Sabarish; Grewal, Savraj S.] Univ Calgary, Clark H Smith Brain Tumor Ctr, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Nagarajan, Sabarish; Grewal, Savraj S.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Rottig, Carmen; Lehner, Christian F.] Univ Zurich, Inst Mol & Life Sci IMLS, CH-8057 Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Fred Hutchinson Cancer Center; University of Washington; University of North Carolina; University of North Carolina Chapel Hill; University of Calgary; University of Calgary; University of Zurich	Edgar, BA (corresponding author), Univ Heidelberg ZMBH Alliance, Zentrum Mol Biol, German Canc Res Ctr DKFZ, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	b.edgar@dkfz.de		van Straaten, Monique/0000-0003-1100-8676; Duronio, Robert/0000-0001-6469-6965	NIH [GM51186, GM57859]; DAAD; NIGMS [5 P50 GM66050]; NSF [MCB0090835]; DFG [LE987/5-1]; CIHR [MOP-86622]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057859, R01GM051186, P50GM066050] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NSF(National Science Foundation (NSF)); DFG(German Research Foundation (DFG)); CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by NIH GM51186 to B. A. E., a DAAD fellowship to N.Z., NIGMS 5 P50 GM66050 and NSF MCB0090835 to G. v. D. and K.J.K, DFG LE987/5-1 to C. F. L., CIHR MOP-86622 to S. G., and NIH GM57859 to R.J.D. We thank Y. Liu for help with statistics.	Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Britton JS, 1998, DEVELOPMENT, V125, P2149; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Frolov MV, 2005, MOL CELL BIOL, V25, P3027, DOI 10.1128/MCB.25.8.3027-3039.2005; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; HAMMOND MP, 1985, CHROMOSOMA, V91, P279, DOI 10.1007/BF00328223; Heriche JK, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-9; Hong A, 2007, EMBO J, V26, P2071, DOI 10.1038/sj.emboj.7601648; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Kosman D, 2004, SCIENCE, V305, P846, DOI 10.1126/science.1099247; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lane ME, 2000, GENETICS, V155, P233; Lilly MA, 2005, ONCOGENE, V24, P2765, DOI 10.1038/sj.onc.1208610; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; Maqbool SB, 2010, J CELL SCI, V123, P4095, DOI 10.1242/jcs.064519; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Narbonne-Reveau K, 2008, DEVELOPMENT, V135, P1451, DOI 10.1242/dev.016295; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; Roodbarkelari F, 2010, P NATL ACAD SCI USA, V107, P15275, DOI 10.1073/pnas.1006941107; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Shibutani ST, 2008, DEV CELL, V15, P890, DOI 10.1016/j.devcel.2008.10.003; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Sugimoto-Shirasu K, 2003, CURR OPIN PLANT BIOL, V6, P544, DOI 10.1016/j.pbi.2003.09.009; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Van Gilst MR, 2005, P NATL ACAD SCI USA, V102, P13496, DOI 10.1073/pnas.0506234102; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Weng L, 2003, EMBO J, V22, P3865, DOI 10.1093/emboj/cdg373; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Xin SJ, 2002, DEVELOPMENT, V129, P1345; Zielke N, 2008, GENE DEV, V22, P1690, DOI 10.1101/gad.469108	45	102	104	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 1	2011	480	7375					123	U296		10.1038/nature10579	http://dx.doi.org/10.1038/nature10579			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PO	22037307	Green Accepted, Green Submitted			2022-12-28	WOS:000298031900047
J	Morrow, M; Waters, J; Morris, E				Morrow, Monica; Waters, Janet; Morris, Elizabeth			Breast Cancer 1 MRI for breast cancer screening, diagnosis, and treatment	LANCET			English	Article							SURGICAL ADJUVANT BREAST; HIGH FAMILIAL RISK; CONTRALATERAL BREAST; NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE MRI; TUMOR RESPONSE; CONSERVING SURGERY; ESTROGEN-RECEPTOR; MUTATION CARRIERS; WOMEN	MRI is used widely both for screening women who are at increased risk of breast cancer and for treatment selection. Prospective studies confirm that MRI screening of women with known or suspected genetic mutation results in a higher sensitivity for cancer detection than does mammography. However, survival data are not available. In women with breast cancer, MRI detects cancer not identified with other types of screening. In two randomised trials, this increased sensitivity did not translate into improved selection of surgical treatment or a reduction in the number of operations. Data for longer-term outcomes such as ipsilateral breast tumour recurrence rates and contralateral breast cancer incidence are scarce, but to date do not show clear benefit for MRI. MRI is better than other methods of assessing the response to neoadjuvant chemotherapy, and is helpful in identifying the primary tumour in patients who present with axillary adenopathy.	[Morrow, Monica] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA; [Waters, Janet] Mem Sloan Kettering Canc Ctr, Med Lib, New York, NY 10065 USA; [Morris, Elizabeth] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Morrow, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA.	morrowm@mskcc.org	Giger, Maryellen/AAH-1908-2021	Morris, Elizabeth/0000-0001-5069-0992				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Abe O, 2005, LANCET, V366, P2087; Allen LR, 2010, ANN SURG ONCOL, V17, P2395, DOI 10.1245/s10434-010-1000-9; Anderson SJ, 2009, J CLIN ONCOL, V27, P2466, DOI 10.1200/JCO.2008.19.8424; Balu-Maestro C, 2002, BREAST CANCER RES TR, V72, P145, DOI 10.1023/A:1014856713942; Bartella L, 2007, RADIOLOGY, V245, P80, DOI 10.1148/radiol.2451061639; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Bhattacharyya M, 2008, BRIT J CANCER, V98, P289, DOI 10.1038/sj.bjc.6604171; Bleicher RJ, 2009, J AM COLL SURGEONS, V209, P180, DOI 10.1016/j.jamcollsurg.2009.04.010; Bloom S, 2010, MAGN RESON IMAGING C, V18, P277, DOI 10.1016/j.mric.2010.02.007; Blue Cross Blue Shield Association (BCBS), 2011, BREAST MRI MAN PAT L, V2, P2011; Bollet MA, 2007, INT J RADIAT ONCOL, V69, P13, DOI 10.1016/j.ijrobp.2007.02.020; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Brennan ME, 2009, J CLIN ONCOL, V27, P5640, DOI 10.1200/JCO.2008.21.5756; Chen JH, 2008, CANCER-AM CANCER SOC, V112, P17, DOI 10.1002/cncr.23130; de Bresser J, 2010, EJSO-EUR J SURG ONC, V36, P114, DOI 10.1016/j.ejso.2009.09.007; Douek M, 2005, NAT CLIN PRACT ONCOL, V2, P128, DOI 10.1038/ncponc0105; Fischer U, 2004, EUR RADIOL, V14, P1725, DOI 10.1007/s00330-004-2351-z; Fisher B, 1996, J CLIN ONCOL, V14, P1982, DOI 10.1200/JCO.1996.14.7.1982; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Giuliano AE, 2010, ANN SURG, V252, P426, DOI 10.1097/SLA.0b013e3181f08f32; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Gotzsche PC, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001877.pub4; Griebsch I, 2006, BRIT J CANCER, V95, P801, DOI 10.1038/sj.bjc.6603356; Hagen AI, 2007, BREAST, V16, P367, DOI 10.1016/j.breast.2007.01.006; Henderson TO, 2010, ANN INTERN MED, V152, P444, DOI 10.7326/0003-4819-152-7-201004060-00009; Houssami N, 2008, J CLIN ONCOL, V26, P3248, DOI 10.1200/JCO.2007.15.2108; Hwang N, 2009, ANN SURG ONCOL, V16, P3000, DOI 10.1245/s10434-009-0607-1; Julius T, 2005, EJSO-EUR J SURG ONC, V31, P1129, DOI 10.1016/j.ejso.2005.03.004; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Kuhl CK, 2007, LANCET, V370, P485, DOI 10.1016/S0140-6736(07)61232-X; Kuhl CK, 2005, J CLIN ONCOL, V23, P8469, DOI 10.1200/JCO.2004.00.4960; Kyndi M, 2008, J CLIN ONCOL, V26, P1419, DOI 10.1200/JCO.2007.14.5565; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Lehman CD, 2005, J SURG ONCOL, V92, P9, DOI 10.1002/jso.20350; Lehman CD, 2007, NEW ENGL J MED, V356, P1295, DOI 10.1056/NEJMoa065447; Mamounas EP, 2010, J CLIN ONCOL, V28, P1677, DOI 10.1200/JCO.2009.23.7610; Mann RM, 2010, BREAST CANCER RES TR, V119, P415, DOI 10.1007/s10549-009-0616-6; McGhan LJ, 2010, ANN SURG ONCOL, V17, pS255, DOI 10.1245/s10434-010-1266-y; Mieog JSD, 2007, BRIT J SURG, V94, P1189, DOI 10.1002/bjs.5894; Millar EKA, 2009, J CLIN ONCOL, V27, P4701, DOI 10.1200/JCO.2008.21.7075; Moon HG, 2009, ANN ONCOL, V20, P636, DOI 10.1093/annonc/mdn683; Morrow M, 2009, JAMA-J AM MED ASSOC, V302, P1551, DOI 10.1001/jama.2009.1450; Nichols HB, 2011, J CLIN ONCOL, V29, P1564, DOI 10.1200/JCO.2010.32.7395; Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7; Pediconi F, 2007, RADIOLOGY, V243, P670, DOI 10.1148/radiol.2433060838; Pengel KE, 2009, BREAST CANCER RES TR, V116, P161, DOI 10.1007/s10549-008-0182-3; Peters NHGM, 2011, EUR J CANCER, V47, P879, DOI 10.1016/j.ejca.2010.11.035; Pisano ED, 2005, NEW ENGL J MED, V353, P1773, DOI 10.1056/NEJMoa052911; Port ER, 2007, ANN SURG ONCOL, V14, P1051, DOI 10.1245/s10434-006-9195-5; Sardanelli F, 2004, AM J ROENTGENOL, V183, P1149, DOI 10.2214/ajr.183.4.1831149; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; Segara D, 2007, J SURG ONCOL, V96, P474, DOI 10.1002/jso.20856; Solin LJ, 2008, J CLIN ONCOL, V26, P386, DOI 10.1200/JCO.2006.09.5448; Turnbull L, 2010, LANCET, V375, P563, DOI 10.1016/S0140-6736(09)62070-5; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Warner E, 2008, ANN INTERN MED, V148, P671, DOI 10.7326/0003-4819-148-9-200805060-00007; Warren RML, 2004, BRIT J CANCER, V90, P1349, DOI 10.1038/sj.bjc.6601710; Yeh E, 2005, AM J ROENTGENOL, V184, P868, DOI 10.2214/ajr.184.3.01840868; Yuan Y, 2010, AM J ROENTGENOL, V195, P260, DOI 10.2214/AJR.09.3908	62	239	250	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2011	378	9805					1804	1811		10.1016/S0140-6736(11)61350-0	http://dx.doi.org/10.1016/S0140-6736(11)61350-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22098853				2022-12-28	WOS:000297262300025
J	Cabrol, JC				Cabrol, Jean-Clement			War, Drought, Malnutrition, Measles - A Report from Somalia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Doctors Borders Med Sans Frontieres, Geneva, Switzerland	Doctors Without Borders	Cabrol, JC (corresponding author), Doctors Borders Med Sans Frontieres, Geneva, Switzerland.							Alberti KP, 2010, INT HEALTH, V2, P65, DOI 10.1016/j.inhe.2009.12.009; [Anonymous], WHO VACC PREV DIS MO; Isanaka S, 2010, PEDIATRICS, V126, pE442, DOI 10.1542/peds.2009-2814; *UN CHILDR FUND, 2011, VACC CAMP CHILDR UND; World Health Organization, 2009, RESP COVID 19 HLTH S	5	8	8	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1856	1858		10.1056/NEJMp1111238	http://dx.doi.org/10.1056/NEJMp1111238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848HG	22087678				2022-12-28	WOS:000297041900003
J	Juonala, M; Magnussen, CG; Berenson, GS; Venn, A; Burns, TL; Sabin, MA; Srinivasan, SR; Daniels, SR; Davis, PH; Chen, W; Sun, C; Cheung, M; Viikari, JSA; Dwyer, T; Raitakari, OT				Juonala, Markus; Magnussen, Costan G.; Berenson, Gerald S.; Venn, Alison; Burns, Trudy L.; Sabin, Matthew A.; Srinivasan, Sathanur R.; Daniels, Stephen R.; Davis, Patricia H.; Chen, Wei; Sun, Cong; Cheung, Michael; Viikari, Jorma S. A.; Dwyer, Terence; Raitakari, Olli T.			Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; INTIMA-MEDIA THICKNESS; DYSLIPIDEMIA CLASSIFICATIONS; YOUNG FINNS; FOLLOW-UP; OVERWEIGHT; OBESITY; ASSOCIATION; CHILDREN; TRENDS	BACKGROUND Obesity in childhood is associated with increased cardiovascular risk. It is uncertain whether this risk is attenuated in persons who are overweight or obese as children but not obese as adults. METHODS We analyzed data from four prospective cohort studies that measured childhood and adult body-mass index (BMI, the weight in kilograms divided by the square of the height in meters). The mean length of follow-up was 23 years. To define high adiposity status, international age-specific and sex-specific BMI cutoff points for overweight and obesity were used for children, and a BMI cutoff point of 30 was used for adults. RESULTS Data were available for 6328 subjects. Subjects with consistently high adiposity status from childhood to adulthood, as compared with persons who had a normal BMI as children and were nonobese as adults, had an increased risk of type 2 diabetes (relative risk, 5.4; 95% confidence interval [CI], 3.4 to 8.5), hypertension (relative risk, 2.7; 95% CI, 2.2 to 3.3), elevated low-density lipoprotein cholesterol levels (relative risk, 1.8; 95% CI, 1.4 to 2.3), reduced high-density lipoprotein cholesterol levels (relative risk, 2.1; 95% CI, 1.8 to 2.5), elevated triglyceride levels (relative risk, 3.0; 95% CI, 2.4 to 3.8), and carotid-artery atherosclerosis (increased intima-media thickness of the carotid artery) (relative risk, 1.7; 95% CI, 1.4 to 2.2) (P <= 0.002 for all comparisons). Persons who were overweight or obese during childhood but were nonobese as adults had risks of the outcomes that were similar to those of persons who had a normal BMI consistently from childhood to adulthood (P>0.20 for all comparisons). CONCLUSIONS Overweight or obese children who were obese as adults had increased risks of type 2 diabetes, hypertension, dyslipidemia, and carotid-artery atherosclerosis. The risks of these outcomes among overweight or obese children who became nonobese by adulthood were similar to those among persons who were never obese. (Funded by the Academy of Finland and others.)	[Juonala, Markus] Turku Univ Hosp, Dept Med, FIN-20520 Turku, Finland; [Juonala, Markus; Magnussen, Costan G.; Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, FIN-20520 Turku, Finland; [Juonala, Markus; Viikari, Jorma S. A.] Univ Turku, Dept Med, FIN-20520 Turku, Finland; [Raitakari, Olli T.] Univ Turku, Dept Clin Physiol, FIN-20520 Turku, Finland; [Magnussen, Costan G.; Venn, Alison] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; [Sabin, Matthew A.; Sun, Cong; Cheung, Michael] Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Melbourne, Vic, Australia; [Magnussen, Costan G.; Sabin, Matthew A.; Sun, Cong; Cheung, Michael; Dwyer, Terence] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Berenson, Gerald S.; Srinivasan, Sathanur R.; Chen, Wei] Tulane Univ, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70118 USA; [Davis, Patricia H.] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA USA; [Burns, Trudy L.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Daniels, Stephen R.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Daniels, Stephen R.] Hlth Sci Ctr, Aurora, CO USA	University of Turku; University of Turku; University of Turku; University of Turku; University of Tasmania; Menzies Institute for Medical Research; Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Tulane University; University of Iowa; University of Iowa; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Juonala, M (corresponding author), Turku Univ Hosp, Dept Med, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	mataju@utu.fi; olli.raitakari@utu.fi	Sabin, Matthew/B-3539-2012; Raitakari, Olli/AAQ-7389-2021; Magnussen, Costan/AAA-8260-2020; Magnussen, Costan G/J-7177-2014; Venn, Alison J/J-2803-2013	Sabin, Matthew/0000-0002-1828-7404; Magnussen, Costan G/0000-0002-6238-5730; Juonala, Markus/0000-0001-9498-364X	Academy of Finland [121584, 126925, 124282, 129378]; Social Insurance Institution of Finland; Turku University Foundation; Special Federal Grants for University Hospitals; Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research; Orion-Farmos Research Foundation; Finnish Cultural Foundation; Commonwealth Departments of Sport, Recreation and Tourism, and Health; National Heart Foundation; Commonwealth Schools Commission; Victorian Government; National Health and Medical Research Council [APP1012201]; National Institute on Aging [AG-16592]; National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) [HL-38844]; American Heart Association; National Heart, Lung, and Blood Institute [HL-14230, HL-54730]; NIH [RR-00059]; Pfizer; Merck; AstraZeneca; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061857, U01HL038844, P50HL014230, R01HL038844, R01HL054730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016592] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); Social Insurance Institution of Finland; Turku University Foundation; Special Federal Grants for University Hospitals; Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research; Orion-Farmos Research Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Commonwealth Departments of Sport, Recreation and Tourism, and Health; National Heart Foundation(National Heart Foundation of Australia); Commonwealth Schools Commission; Victorian Government; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); Merck(Merck & Company); AstraZeneca(AstraZeneca); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	These analyses were supported by funding from the individual studies. The Cardiovascular Risk in Young Finns Study was supported by grants from the Academy of Finland (121584, 126925, 124282, 129378), the Social Insurance Institution of Finland, the Turku University Foundation, Special Federal Grants for University Hospitals, the Juho Vainio Foundation, Paavo Nurmi Foundation, the Finnish Foundation of Cardiovascular Research, Orion-Farmos Research Foundation, and the Finnish Cultural Foundation. The Childhood Determinants of Adult Health study was supported at baseline by the Commonwealth Departments of Sport, Recreation and Tourism, and Health; the National Heart Foundation; and the Commonwealth Schools Commission and at follow-up by the National Health and Medical Research Council, the Heart Foundation, the Tasmanian Community Fund, and Veolia Environmental Services; authors from the Murdoch Children's Research Institute are supported by the Victorian Government Operational Infrastructure Support Program; Dr. Sabin is supported through a National Health and Medical Research Council Health Professional Training Fellowship (APP1012201). The Bogalusa Heart Study was supported by grants from the National Institute on Aging (AG-16592) and the National Heart, Lung, and Blood Institute (HL-38844) of the National Institutes of Health (NIH) and from the American Heart Association. The Muscatine Study was supported by grants from the National Heart, Lung, and Blood Institute (HL-14230 and HL-54730), and the General Clinical Research Centers Program (RR-00059) of the NIH.; Dr. Sabin reports receiving lecture fees from Pfizer; Dr. Daniels, receiving consulting fees from Merck; and Dr. Viikari, receiving lecture fees from Merck, AstraZeneca, and Pfizer. No other potential conflict of interest relevant to this article was reported.	[Anonymous], JAMA; August GP, 2008, J CLIN ENDOCR METAB, V93, P4576, DOI 10.1210/jc.2007-2458; Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515; Barker DJP, 2005, NEW ENGL J MED, V353, P1802, DOI 10.1056/NEJMoa044160; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Cleland VJ, 2009, AM J EPIDEMIOL, V170, P1069, DOI 10.1093/aje/kwp271; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Daniels SR, 2009, CIRCULATION, V119, P2114, DOI 10.1161/CIRCULATIONAHA.109.192215; Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Franks PW, 2010, NEW ENGL J MED, V362, P485, DOI 10.1056/NEJMoa0904130; Freedman DS, 2009, PEDIATRICS, V123, P750, DOI 10.1542/peds.2008-1284; Gregg EW, 2005, JAMA-J AM MED ASSOC, V294, P182; Gregg EW, 2005, JAMA-J AM MED ASSOC, V293, P1868, DOI 10.1001/jama.293.15.1868; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111; LAUER RM, 1984, CIRCULATION, V69, P242, DOI 10.1161/01.CIR.69.2.242; Li SX, 2003, JAMA-J AM MED ASSOC, V290, P2271, DOI 10.1001/jama.290.17.2271; Magnussen CG, 2008, CIRCULATION, V117, P32, DOI 10.1161/CIRCULATIONAHA.107.718981; Magnussen CG, 2009, J AM COLL CARDIOL, V53, P860, DOI 10.1016/j.jacc.2008.09.061; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; PETTIGREW HM, 1986, BIOMETRIKA, V73, P425; Raitakari OT, 2008, INT J EPIDEMIOL, V37, P1220, DOI 10.1093/ije/dym225; Raitakari OT, 2003, JAMA-J AM MED ASSOC, V290, P2277, DOI 10.1001/jama.290.17.2277; Schubert Christine M, 2009, J Pediatr, V155, DOI 10.1016/j.jpeds.2009.04.048; Singh AS, 2008, OBES REV, V9, P474, DOI 10.1111/j.1467-789X.2008.00475.x; Skyler JS, 2002, DIABETES-METAB RES, V18, pS21, DOI 10.1002/dmrr.289; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; Yeung EH, 2010, DIABETES CARE, V33, P1364, DOI 10.2337/dc10-0100	32	979	1019	5	110	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1876	1885		10.1056/NEJMoa1010112	http://dx.doi.org/10.1056/NEJMoa1010112			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22087679				2022-12-28	WOS:000297041900006
J	Du, JT; Zhou, YY; Su, XY; Yu, JJ; Khan, S; Jiang, H; Kim, J; Woo, J; Kim, JH; Choi, BH; He, B; Chen, W; Zhang, S; Cerione, RA; Auwerx, J; Hao, Q; Lin, HN				Du, Jintang; Zhou, Yeyun; Su, Xiaoyang; Yu, Jiu Jiu; Khan, Saba; Jiang, Hong; Kim, Jungwoo; Woo, Jimin; Kim, Jun Huyn; Choi, Brian Hyun; He, Bin; Chen, Wei; Zhang, Sheng; Cerione, Richard A.; Auwerx, Johan; Hao, Quan; Lin, Hening			Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase	SCIENCE			English	Article							STRUCTURAL BASIS; MALONYL-COA; DEACETYLASES; MECHANISM; INSIGHTS; ACETYLATION; INHIBITION; SIRTUINS; PEPTIDE; CELLS	Silent information regulator 2 (Sir2) proteins (sirtuins) are nicotinamide adenine dinucleotide-dependent deacetylases that regulate important biological processes. Mammals have seven sirtuins, Sirt1 to Sirt7. Four of them (Sirt4 to Sirt7) have no detectable or very weak deacetylase activity. We found that Sirt5 is an efficient protein lysine desuccinylase and demalonylase in vitro. The preference for succinyl and malonyl groups was explained by the presence of an arginine residue (Arg(105)) and tyrosine residue (Tyr(102)) in the acyl pocket of Sirt5. Several mammalian proteins were identified with mass spectrometry to have succinyl or malonyl lysine modifications. Deletion of Sirt5 in mice appeared to increase the level of succinylation on carbamoyl phosphate synthase 1, which is a known target of Sirt5. Thus, protein lysine succinylation may represent a posttranslational modification that can be reversed by Sirt5 in vivo.	[Zhou, Yeyun; Hao, Quan] Cornell Univ, Cornell High Energy Synchrotron Source, MacCHESS, Ithaca, NY 14853 USA; [Du, Jintang; Su, Xiaoyang; Khan, Saba; Jiang, Hong; Kim, Jungwoo; Woo, Jimin; Kim, Jun Huyn; Choi, Brian Hyun; He, Bin; Cerione, Richard A.; Lin, Hening] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [Yu, Jiu Jiu; Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland; [Chen, Wei; Zhang, Sheng] Cornell Univ, Prote & Mass Spectrometry Core Facil, Ithaca, NY 14853 USA; [Cerione, Richard A.] Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; [Hao, Quan] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	Cornell University; Cornell University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Cornell University; Cornell University; University of Hong Kong	Hao, Q (corresponding author), Cornell Univ, Cornell High Energy Synchrotron Source, MacCHESS, Ithaca, NY 14853 USA.	qhao@hku.hk; hl379@cornell.edu	Auwerx, Johan/ABE-9307-2021; Su, Xiaoyang/B-3398-2008; Su, Xiaoyang/Q-4884-2018; Hao, Quan/C-4304-2009; Yu, Jiujiu/H-7181-2013	Hao, Quan/0000-0002-9642-0514; Su, Xiaoyang/0000-0001-8081-1396; Auwerx, Johan/0000-0002-5065-5393; Kim, Jungwoo/0000-0002-5215-2044	Dreyfus Foundation; NIH [R01GM086703, RR01646]; Hong Kong [GRF766510]; NIH PPG [DK58920]; European Union [ERC-2008-AdG-23118]; Ecole Polytechnique Federale de Lausanne; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086703] Funding Source: NIH RePORTER	Dreyfus Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hong Kong; NIH PPG(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission); Ecole Polytechnique Federale de Lausanne; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported in part by Dreyfus Foundation (H.L.); grants NIH R01GM086703 (H.L.), Hong Kong GRF766510 (Q.H.), NIH RR01646 (R.A.C. and Q.H.), and NIH PPG DK58920 (J.A.); the European Union Ideas program (sirtuins; ERC-2008-AdG-23118 to J.A.); and the Ecole Polytechnique Federale de Lausanne (J.A.). Atomic coordinates and structure factors were deposited in the Protein Data Bank (accession codes 3RIG and 3RIY).	Cosgrove MS, 2006, BIOCHEMISTRY-US, V45, P7511, DOI 10.1021/bi0526332; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gao L, 2007, J CHROMATOGR B, V853, P303, DOI 10.1016/j.jchromb.2007.03.029; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Hawse WF, 2008, STRUCTURE, V16, P1368, DOI 10.1016/j.str.2008.05.015; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imai S, 2010, TRENDS PHARMACOL SCI, V31, P212, DOI 10.1016/j.tips.2010.02.003; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Rosen R, 2004, FEBS LETT, V577, P386, DOI 10.1016/j.febslet.2004.10.037; Saggerson D, 2008, ANNU REV NUTR, V28, P253, DOI 10.1146/annurev.nutr.28.061807.155434; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schuetz A, 2007, STRUCTURE, V15, P377, DOI 10.1016/j.str.2007.02.002; Smith BC, 2006, BIOCHEMISTRY-US, V45, P272, DOI 10.1021/bi052014t; Smith BC, 2007, BIOCHEMISTRY-US, V46, P14478, DOI 10.1021/bi7013294; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687; Zhang ZH, 2011, NAT CHEM BIOL, V7, P58, DOI 10.1038/NCHEMBIO.495; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	25	893	934	7	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					806	809		10.1126/science.1207861	http://dx.doi.org/10.1126/science.1207861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076378	Green Submitted, Green Accepted			2022-12-28	WOS:000296849600047
J	Geballe, TR; Najarro, F; Figer, DF; Schlegelmilch, BW; de la Fuente, D				Geballe, T. R.; Najarro, F.; Figer, D. F.; Schlegelmilch, B. W.; de la Fuente, D.			Infrared diffuse interstellar bands in the Galactic Centre region	NATURE			English	Article							FIELD STARS; CLOUDS; SPECTROSCOPY; QUINTUPLET; FEATURES; H-3(+); DUST	The spectrum of any star viewed through a sufficient quantity of diffuse interstellar material reveals a number of absorption features collectively called 'diffuse interstellar bands' (DIBs). The first DIBs were reported about 90 years ago(1), and currently well over 500 are known(2). None of them has been convincingly identified with any specific element or molecule, although recent studies suggest that the DIB carriers are polyatomic molecules containing carbon(3-5). Most of the DIBs currently known are at visible and very near-infrared wavelengths, with only two previously known at wavelengths beyond one micrometre (10,000 angstroms), the longer of which is at 1.318 micrometres (ref. 6). Here we report 13 diffuse interstellar bands in the 1.5-1.8 micrometre interval on high-extinction sightlines towards stars in the Galactic Centre. We argue that they originate almost entirely in the Galactic Centre region, a considerably warmer and harsher environment than where DIBs have been observed previously. The relative strengths of these DIBs towards the Galactic Centre and the Cygnus OB2 diffuse cloud are consistent with their strengths scaling mainly with the extinction by diffuse material.	[Geballe, T. R.] Gemini Observ, Hilo, HI 96720 USA; [Najarro, F.; de la Fuente, D.] Ctr Astrobiol CSIC INTA, Torrejon De Ardoz 28850, Spain; [Figer, D. F.] Rochester Inst Technol, Ctr Detectors, Rochester, NY 14623 USA; [Schlegelmilch, B. W.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Rochester Institute of Technology; University of California System; University of California Los Angeles	Geballe, TR (corresponding author), Gemini Observ, 670 N Aohoku Pl, Hilo, HI 96720 USA.	tgeballe@gemini.edu	de la Fuente, Diego/L-2853-2017; Najarro, Francisco/G-7288-2015	de la Fuente, Diego/0000-0002-6193-7345; Najarro, Francisco/0000-0002-9124-0039	Spanish Ministerio de Ciencia e Innovacion	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	This Letter is based on observations obtained at the Gemini Observatory, which is operated by the Association of Universities for Research in Astronomy, Inc., under a cooperative agreement with the NSF on behalf of the Gemini partnership: the National Science Foundation (US), the Science and Technology Facilities Council (UK), the National Research Council (Canada), CONICYT (Chile), the Australian Research Council (Australia), Ministerio da Ciencia e Tecnologia (Brazil) and Ministerio de Ciencia, Tecnologia e Innovacion Productiva (Argentina). This work was supported by the Spanish Ministerio de Ciencia e Innovacion. We thank A. Lenorzer for reductions of the H-band spectra of the Cygnus OB2 stars, and B. J. McCall and T. Oka for reviewing a preliminary version of the manuscript.	BROMAGE GE, 1973, ASTRON ASTROPHYS, V26, P17; Cox NLJ, 2011, EAS PUBLICATIONS, V46, P349, DOI 10.1051/eas/1146036; Draine B.T., 2011, PHYS INTERSTELLAR IN; Figer DF, 1999, ASTROPHYS J, V514, P202, DOI 10.1086/306931; Goto M, 2008, ASTROPHYS J, V688, P306, DOI 10.1086/591657; Heger M. L, 1922, LICK OBSERVATORY B, V10, P146; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; Hobbs LM, 2009, ASTROPHYS J, V705, P32, DOI 10.1088/0004-637X/705/1/32; HUMPHREYS RM, 1978, ASTROPHYS J SUPPL S, V38, P309, DOI 10.1086/190578; Indriolo N, 2007, ASTROPHYS J, V671, P1736, DOI 10.1086/523036; JOBLIN C, 1990, NATURE, V346, P729, DOI 10.1038/346729a0; Muno MP, 2006, ASTROPHYS J, V638, P183, DOI 10.1086/498701; NAGATA T, 1990, ASTROPHYS J, V351, P83, DOI 10.1086/168446; Oka T, 2005, ASTROPHYS J, V632, P882, DOI 10.1086/432679; Oka T, 2011, SCIENCE, V331, P293, DOI 10.1126/science.1200144; PENDLETON YJ, 1994, ASTROPHYS J, V437, P683, DOI 10.1086/175031; RAWLINGS M, 2011, IAU S, V280; Rawlings MG, 2003, MON NOT R ASTRON SOC, V341, P1121, DOI 10.1046/j.1365-8711.2003.06389.x; Snow TP, 2006, ANNU REV ASTRON ASTR, V44, P367, DOI 10.1146/annurev.astro.43.072103.150624; Whittet DCB, 1997, ASTROPHYS J, V490, P729, DOI 10.1086/304914	20	62	62	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					200	202		10.1038/nature10527	http://dx.doi.org/10.1038/nature10527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22048316	Green Submitted			2022-12-28	WOS:000298030800035
J	Shah, BR; Cowper, PA; O'Brien, SM; Jensen, N; Patel, MR; Douglas, PS; Peterson, ED				Shah, Bimal R.; Cowper, Patricia A.; O'Brien, Sean M.; Jensen, Neil; Patel, Manesh R.; Douglas, Pamela S.; Peterson, Eric D.			Association Between Physician Billing and Cardiac Stress Testing Patterns Following Coronary Revascularization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-NUCLEAR-CARDIOLOGY; APPROPRIATENESS CRITERIA; COMPUTED-TOMOGRAPHY; IONIZING-RADIATION; RADIOLOGY; COMMITTEE; COSTS	Context The degree to which financial factors may influence use of cardiac stress imaging procedures is unknown. Objective To examine the association of physician billing and nuclear stress and stress echocardiography testing following coronary revascularization. Design, Setting, and Patients Using data from a national health insurance carrier, 17 847 patients were identified between November 1, 2004, and June 30, 2007, who had coronary revascularization and an index cardiac outpatient visit more than 90 days following the procedure. Based on overall billings, physicians were classified as billing for both technical (practice/equipment) and professional (supervision/interpretation) fees, professional fees only, or not billing for either. Logistic regression models were used to evaluate the association between physician billing and use of stress testing, after adjusting for patient and other physician factors. Main Outcome Measures Incidence of nuclear and echocardiographic stress tests within 30 days of an index cardiac-related outpatient visit. Results The overall cumulative incidence of nuclear or echocardiography stress testing within 30 days of the index cardiac-related outpatient visit following revascularization was 12.2% (95% CI, 11.8%-12.7%). The cumulative incidence of nuclear stress testing was 12.6% (95% CI, 12.0%-13.2%), 8.8% (95% CI, 7.5%-10.2%), and 5.0% (95% CI, 4.4%-5.7%) among physicians who billed for technical and professional fees, professional fees only, or neither, respectively. For stress echocardiography, the cumulative incidence of testing was 2.8% (95% CI, 2.5%-3.2%), 1.4% (95% CI, 1.0%-1.9%), and 0.4% (95% CI, 0.3%-0.6%) among physicians who billed for the technical and professional fees, professional fees only, or neither, respectively. Adjusted odds ratios (ORs) of nuclear stress testing among patients treated by physicians who billed for technical and professional fees and professional fees only were 2.3 (95% CI, 1.8-2.9) and 1.6 (95% CI, 1.2-2.1), respectively, compared with those patients treated by physicians who did not bill for testing (P < .001). The adjusted OR of stress echocardiography testing among patients treated by physicians billing for both or professional fees only were 12.8 (95% CI, 7.6-21.6) and 7.1 (95% CI, 4.0-12.9), respectively, compared with patients treated by physicians who did not bill for testing (P < .001). Conclusion Nuclear stress testing and stress echocardiography testing following revascularization were more frequent among patients treated by physicians who billed for technical fees, professional fees, or both compared with those treated by physicians who did not bill for these services. JAMA. 2011;306(18):1993-2000	[Shah, Bimal R.; Cowper, Patricia A.; O'Brien, Sean M.; Patel, Manesh R.; Douglas, Pamela S.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC 27705 USA; [Shah, Bimal R.; Cowper, Patricia A.; O'Brien, Sean M.; Patel, Manesh R.; Douglas, Pamela S.; Peterson, Eric D.] Duke Univ, Med Ctr, Div Cardiovasc Med, Durham, NC USA; [Jensen, Neil] United Healthcare, Minnetonka, MN USA	Duke University; Duke University; UnitedHealth Group Incorporated	Shah, BR (corresponding author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.	bimal.shah@duke.edu	O'Brien, Sean/H-6268-2013; Peterson, Eric David/ABF-5033-2021; Patel, Manesh/AAC-5385-2019	Douglas, Pamela/0000-0001-9876-4049	Agency for Healthcare Research and Quality; National Heart, Lung, and Blood Institute; Johnson Johnson; Eli Lilly; United Healthcare	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Eli Lilly(Eli Lilly); United Healthcare	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shah reported receiving grants from the Agency for Healthcare Research and Quality and being a consultant to Cast-light. Mr Jensen is employed by United Healthcare. Dr Patel reported being a consultant for Bayer Healthcare, Genzyme, Ortho-McNeil, and Janssen; and receiving grants from the National Heart, Lung, and Blood Institute, the Agency for Healthcare Research and Quality, and Johnson & Johnson. Dr Peterson reported receiving research grants from Eli Lilly and Johnson & Johnson. No other disclosures were reported.; This work was funded by United Healthcare.	[Anonymous], MEDPAC MARCH 2010 RE; [Anonymous], MEDPAC JUN 2009 REP; Douglas PS, 2011, J AM COLL CARDIOL, V57, P1126, DOI 10.1016/j.jacc.2010.11.002; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Fowles J B, 1995, Health Care Financ Rev, V16, P189; Gazelle GS, 2007, RADIOLOGY, V245, P517, DOI 10.1148/radiol.2452070193; Gerber TC, 2009, CIRCULATION, V119, P1056, DOI 10.1161/CIRCULATIONAHA.108.191650; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Hendel RC, 2006, J AM COLL CARDIOL, V48, P1475, DOI 10.1016/j.jacc.2006.07.003; Hendel RC, 2010, J AM COLL CARDIOL, V55, P156, DOI 10.1016/j.jacc.2009.11.004; Hendel RC, 2009, CIRCULATION, V119, pE561, DOI 10.1161/CIRCULATIONAHA.109.192519; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; Hillman BJ, 2010, HEALTH AFFAIR, V29, P2231, DOI 10.1377/hlthaff.2010.1019; Hollingsworth JM, 2010, J UROLOGY, V184, P2480, DOI 10.1016/j.juro.2010.08.030; Hughes DR, 2010, HEALTH AFFAIR, V29, P2244, DOI 10.1377/hlthaff.2010.0413; Lentine KL, 2009, CLIN J AM SOC NEPHRO, V4, P1213, DOI 10.2215/CJN.00670109; Levin David C, 2009, J Am Coll Radiol, V6, P437, DOI 10.1016/j.jacr.2008.12.015; Levin David C, 2008, J Am Coll Radiol, V5, P806, DOI 10.1016/j.jacr.2008.01.025; Mehta R, 2008, J NUCL CARDIOL, V15, P337, DOI 10.1016/j.nuclcard.2007.10.010	19	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					1993	2000		10.1001/jama.2011.1604	http://dx.doi.org/10.1001/jama.2011.1604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	843VT	22068991	Bronze			2022-12-28	WOS:000296704300022
J	Leissinger, C; Gringeri, A; Antmen, B; Berntorp, E; Biasoli, C; Carpenter, S; Cortesi, P; Jo, HJ; Kavakli, K; Lassila, R; Morfini, M; Negrier, C; Rocino, A; Schramm, W; Serban, M; Uscatescu, MV; Windyga, J; Zulfikar, B; Mantovani, L				Leissinger, Cindy; Gringeri, Alessandro; Antmen, Bulent; Berntorp, Erik; Biasoli, Chiara; Carpenter, Shannon; Cortesi, Paolo; Jo, Hyejin; Kavakli, Kaan; Lassila, Riitta; Morfini, Massimo; Negrier, Claude; Rocino, Angiola; Schramm, Wolfgang; Serban, Margit; Uscatescu, Marusia Valentina; Windyga, Jerzy; Zulfikar, Bulent; Mantovani, Lorenzo			Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; TERM FEIBA PROPHYLAXIS; FACTOR-VIII; INTRACRANIAL HEMORRHAGE; CLINICAL-TRIAL; POPULATION; BENEFITS; THERAPY; BLEEDS; BOYS	Background Patients with severe hemophilia A and factor VIII inhibitors are at increased risk for serious bleeding complications and progression to end-stage joint disease. Effective strategies to prevent bleeding in such patients have not yet been established. Methods We enrolled patients with hemophilia A who were older than 2 years of age, had high-titer inhibitors, and used concentrates known as bypassing agents for bleeding in a prospective, randomized, crossover study comparing 6 months of anti-inhibitor coagulant complex (AICC), infused prophylactically at a target dose of 85 U per kilogram of body weight (+/- 15%) on 3 nonconsecutive days per week, with 6 months of on-demand therapy (AICC at a target dose of 85 U per kilogram [+/- 15%] used for bleeding episodes). The two treatment periods were separated by a 3-month washout period, during which patients received on-demand therapy for bleeding. The primary outcome was the number of bleeding episodes during each 6-month treatment period. Results Thirty-four patients underwent randomization; 26 patients completed both treatment periods and could be evaluated per protocol for the efficacy analysis. As compared with on-demand therapy, prophylaxis was associated with a 62% reduction in all bleeding episodes (P < 0.001), a 61% reduction in hemarthroses (P < 0.001), and a 72% reduction in target-joint bleeding (>= 3 hemarthroses in a single joint during a 6-month treatment period) (P < 0.001). Thirty-three randomly assigned patients received at least one infusion of the study drug and were evaluated for safety. One patient had an allergic reaction to the study drug. Conclusions AICC prophylaxis at the dosage evaluated significantly and safely decreased the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors. (Funded by Baxter BioScience; Pro-FEIBA ClinicalTrials.gov number, NCT00221195.)	[Leissinger, Cindy] Tulane Univ, Sch Med, Louisiana Ctr Bleeding & Clotting Disorders, New Orleans, LA 70112 USA; [Gringeri, Alessandro] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Med & Med Specialties, Milan, Italy; [Gringeri, Alessandro] Univ Milan, Milan, Italy; [Biasoli, Chiara] Bufalini Hosp, Hemophilia Ctr, Cesena, Italy; [Cortesi, Paolo; Mantovani, Lorenzo] Univ Milano Bicocca, Res Ctr Publ Hlth, Monza, Italy; [Morfini, Massimo] Azienda Univ, Careggi Hosp, Florence, Italy; [Rocino, Angiola] San Giovanni Bosco Hosp, Hemophilia & Thrombosis Ctr, Naples, Italy; [Mantovani, Lorenzo] Univ Naples Federico II, CIRFF Ctr Pharmacoecon, Naples, Italy; [Antmen, Bulent] Cukurova Univ, Adana, Turkey; [Kavakli, Kaan] Univ Ege, Childrens Hosp, Izmir, Turkey; [Zulfikar, Bulent] Istanbul Univ, Istanbul, Turkey; [Berntorp, Erik] Lund Univ, Malmo Univ Hosp, Malmo Ctr Thrombosis & Hemostasis, Malmo, Sweden; [Carpenter, Shannon] Univ Missouri, Kansas City Sch Med, Kansas City, MO USA; [Jo, Hyejin] Quintiles, Rockville, MD USA; [Lassila, Riitta] Univ Helsinki, Cent Hosp, Div Coagulat Disorders, Helsinki, Finland; [Negrier, Claude] Univ Lyon 1, Hemophilia Treatment Ctr, Hop Edouard Herriot, Lyon, France; [Schramm, Wolfgang] Univ Munich, Munich, Germany; [Serban, Margit] Emergency Clin Children, Timisoara, Romania; [Uscatescu, Marusia Valentina] Fundeni Clin Inst Ctr Hematol & Bone Marrow Trans, Bucharest, Romania; [Windyga, Jerzy] Inst Hematol & Transfus Med, Warsaw, Poland	Tulane University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milano-Bicocca; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Naples Federico II; Cukurova University; Ege University; Istanbul University; Lund University; Skane University Hospital; University of Missouri System; University of Missouri Kansas City; IQVIA; University of Helsinki; Helsinki University Central Hospital; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Munich; Institutul Clinic Fundeni	Leissinger, C (corresponding author), Tulane Univ, Sch Med, Louisiana Ctr Bleeding & Clotting Disorders, 1430 Tulane Ave, New Orleans, LA 70112 USA.	cleissi@tulane.edu	Selerski, Marcin/A-7594-2012; Windyga, Jerzy/AAC-8830-2020; Bulent Zulfikar, zulfikar b/AAD-8080-2020; Mantovani, Lorenzo Giovanni/AAC-4263-2021; Serban, M/ABY-4391-2022; Cortesi, Paolo Angelo/AAD-7926-2020	Windyga, Jerzy/0000-0001-7877-4784; Cortesi, Paolo Angelo/0000-0001-5241-4473; Negrier, Claude/0000-0003-3569-0366; Chamouard, Valerie/0000-0002-4443-1609; Mantovani, Lorenzo Giovanni/0000-0003-3866-8199	Baxter BioScience; Baxter; Novo Nordisk; Bayer; Pfizer	Baxter BioScience; Baxter; Novo Nordisk(Novo Nordisk); Bayer(Bayer AG); Pfizer(Pfizer)	Supported by a research grant from Baxter BioScience.; Dr. Leissinger reports serving on advisory boards and receiving lecture fees from Baxter and Novo Nordisk, and receiving grant support from Baxter and fees for the development of educational presentations from Novo Nordisk; Dr. Gringeri, serving on advisory boards for and receiving lecture fees and travel fees from Baxter; Dr. Berntorp, serving on advisory boards for and receiving lecture fees and grant support from Baxter; Dr. Carpenter, receiving grant support from Baxter; Ms. Jo, receiving consulting fees from Baxter; Dr. Kavakli, receiving grant support, lecture fees, and travel expenses from Baxter and Novo Nordisk; Dr. Lassila, providing expert testimony for Baxter and Novo Nordisk and receiving lecture fees and travel expenses from Baxter; Dr. Negrier, serving on advisory boards for and receiving consulting fees, grant support, lecture fees, and fees for development of educational presentations from Baxter; Dr. Rocino, serving on advisory boards for Baxter and receiving consulting fees from Baxter, Novo Nordisk, Bayer, and Pfizer, and receiving lecture fees from Baxter, Novo Nordisk, and Bayer; Dr. Schramm, serving on advisory boards for Wyeth and Pfizer; Dr. Uscatescu, serving on advisory boards for and receiving consulting fees from Baxter; Dr. Zulfikar, receiving consulting fees from Baxter; and Dr Windyga, serving on advisory boards and receiving consulting fees from Baxter. No other potential conflict of interest relevant to this article was reported.	ALEDORT LM, 1994, J INTERN MED, V236, P391, DOI 10.1111/j.1365-2796.1994.tb00815.x; Antunes SV, 2003, HAEMOPHILIA, V9, P573, DOI 10.1046/j.1365-2516.2003.00789.x; Astermark J, 2007, BLOOD, V109, P546, DOI 10.1182/blood-2006-04-017988; Bohn RL, 2004, HAEMOPHILIA, V10, P63, DOI 10.1046/j.1365-2516.2003.00849.x; Brackmann HH, 2000, VOX SANG, V78, P187; Darby SC, 2004, J THROMB HAEMOST, V2, P1047, DOI 10.1046/j.1538-7836.2004.00710.x; Dimichele D, 2002, HAEMOPHILIA, V8, P280, DOI 10.1046/j.1365-2516.2002.00626.x; Ettingshausen CE, 2010, HAEMOPHILIA, V16, P90, DOI 10.1111/j.1365-2516.2009.02116.x; Gringeri A, 2011, J THROMB HAEMOST, V9, P700, DOI 10.1111/j.1538-7836.2011.04214.x; Gringeri A, 2003, BLOOD, V102, P2358, DOI 10.1182/blood-2003-03-0941; Hilgartner MW, 2003, HAEMOPHILIA, V9, P261, DOI 10.1046/j.1365-2516.2003.00771.x; Ho AYL, 2000, DRUGS, V60, P547, DOI 10.2165/00003495-200060030-00003; Jimenez-Yuste V, 2009, HAEMOPHILIA, V15, P203, DOI 10.1111/j.1365-2516.2008.01915.x; Konkle BA, 2007, J THROMB HAEMOST, V5, P1904, DOI 10.1111/j.1538-7836.2007.02663.x; Leissinger CA, 2007, HAEMOPHILIA, V13, P249, DOI 10.1111/j.1365-2516.2007.01442.x; Leissinger CA, 2004, AM J HEMATOL, V77, P187, DOI 10.1002/ajh.20162; Ljung RCR, 2008, BRIT J HAEMATOL, V140, P378, DOI 10.1111/j.1365-2141.2007.06949.x; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659; MARTINOWITZ U, 1986, NEUROSURGERY, V18, P538, DOI 10.1227/00006123-198605000-00004; Nuss R, 2001, AM J HEMATOL, V68, P37, DOI 10.1002/ajh.1146; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Revel-Vilk S, 2004, J PEDIATR-US, V144, P490, DOI 10.1016/j.jpeds.2003.12.016; Scalone L, 2006, HAEMOPHILIA, V12, P154, DOI 10.1111/j.1365-2516.2006.01204.x; Traivaree C, 2007, HAEMOPHILIA, V13, P552, DOI 10.1111/j.1365-2516.2007.01545.x; Valentino LA, 2006, HAEMOPHILIA, V12, P541, DOI 10.1111/j.1365-2516.2006.01318.x; Valentino LA, 2010, HAEMOPHILIA, V16, P263, DOI 10.1111/j.1365-2516.2009.02126.x; Valentino LA, 2009, HAEMOPHILIA, V15, P733, DOI 10.1111/j.1365-2516.2009.01980.x	30	169	171	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1684	1692		10.1056/NEJMoa1104435	http://dx.doi.org/10.1056/NEJMoa1104435			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047559	Green Published			2022-12-28	WOS:000296424200007
J	Black, ME				Black, Mary E.			THE BIGGER PICTURE How to spot a "spamnal"	BRITISH MEDICAL JOURNAL			English	Editorial Material												drmaryblack@gmail.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2011	343								d7077	10.1136/bmj.d7077	http://dx.doi.org/10.1136/bmj.d7077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844PY	22045992				2022-12-28	WOS:000296760900009
J	Mullen, AC; Orlando, DA; Newman, JJ; Loven, J; Kumar, RM; Bilodeau, S; Reddy, J; Guenther, MG; DeKoter, RP; Young, RA				Mullen, Alan C.; Orlando, David A.; Newman, Jamie J.; Loven, Jakob; Kumar, Roshan M.; Bilodeau, Steve; Reddy, Jessica; Guenther, Matthew G.; DeKoter, Rodney P.; Young, Richard A.			Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-beta Signaling	CELL			English	Article							EMBRYONIC STEM-CELLS; REGULATORY CIRCUITRY; MAINTAINS PLURIPOTENCY; HISTONE MODIFICATIONS; GENE-EXPRESSION; SELF-RENEWAL; C-MYC; SMAD; PATHWAYS; FIBROBLASTS	Transforming growth factor beta (TGF-beta) signaling, mediated through the transcription factors Smad2 and Smad3 (Smad2/3), directs different responses in different cell types. Here we report that Smad3 co-occupies the genome with cell-type-specific master transcription factors. Thus, Smad3 occupies the genome with Oct4 in embryonic stem cells (ESCs), Myod1 in myotubes, and PU.1 in pro-B cells. We find that these master transcription factors are required for Smad3 occupancy and that TGF-beta signaling largely affects the genes bound by the master transcription factors. Furthermore, we show that induction of Myod1 in nonmuscle cells is sufficient to redirect Smad3 to Myod1 sites. We conclude that cell-type-specific master transcription factors determine the genes bound by Smad2/3 and are thus responsible for orchestrating the cell-type-specific effects of TGF-beta signaling.	[Mullen, Alan C.; Orlando, David A.; Newman, Jamie J.; Loven, Jakob; Kumar, Roshan M.; Bilodeau, Steve; Reddy, Jessica; Guenther, Matthew G.; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Mullen, Alan C.] Harvard Univ, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA; [Newman, Jamie J.; Reddy, Jessica; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [DeKoter, Rodney P.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Western University (University of Western Ontario)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012; DeKoter, Rodney/A-9415-2009	Young, Richard A/0000-0001-8855-8647; DeKoter, Rodney/0000-0002-9201-1983; Mullen, Alan/0000-0002-4096-3106; Bilodeau, Steve/0000-0002-9799-3832	American Gastroenterological Association; NIH [DK090122, HG002668]; Canadian Institutes of Health Research; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK090122] Funding Source: NIH RePORTER	American Gastroenterological Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to M.S.H. Ko for the gift of ES[MC1R(20)]:tetMyod1 cells, D. Wotton for the gift of Smad2/3 antibody, and H. Singh for providing the 38B9 cells with permission from N. Rosenberg. We thank T. Lee and L. Lawton for helpful discussions; J. Love, J-A. Kwon, V. Dhanapal, S. Gupta, and T. Volkert for Illumina sequencing and microarray preparation; G. Frampton and B. Yuan for help with computational analysis; and T. DiCesare for help with graphics. We also thank A. Blais for assistance with siRNA transfection. This work was supported by fellowships from the American Gastroenterological Association and NIH grant DK090122 (A.C.M.), the Canadian Institutes of Health Research (S.B.), and NIH grant HG002668 (R.A.Y.).	BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dejosez M, 2010, GENE DEV, V24, P1479, DOI 10.1101/gad.1935210; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Germain S, 2000, GENE DEV, V14, P435; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Guasconi V, 2009, TRENDS CELL BIOL, V19, P286, DOI 10.1016/j.tcb.2009.03.002; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Ludwig TE, 2006, NAT METHODS, V3, P637, DOI 10.1038/NMETH902; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Natoli G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000224; Nishiyama A, 2009, CELL STEM CELL, V5, P420, DOI 10.1016/j.stem.2009.07.012; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Nutt SL, 2007, IMMUNITY, V26, P715, DOI 10.1016/j.immuni.2007.05.010; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Seoane J, 2004, CANCER BIOL THER, V3, P226, DOI 10.4161/cbt.3.2.717; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874; Trompouki E, 2011, CELL, V147, P577, DOI 10.1016/j.cell.2011.09.044; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; Vallier L, 2009, DEVELOPMENT, V136, P1339, DOI 10.1242/dev.033951; Wandzioch E, 2009, SCIENCE, V324, P1707, DOI 10.1126/science.1174497; Xu RH, 2008, CELL STEM CELL, V3, P196, DOI 10.1016/j.stem.2008.07.001; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	62	421	429	1	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					565	576		10.1016/j.cell.2011.08.050	http://dx.doi.org/10.1016/j.cell.2011.08.050			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036565	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000296573700012
J	Sarkar, A; Hochedlinger, K				Sarkar, Abby; Hochedlinger, Konrad			A Gutsy Way to Grow: Intestinal Stem Cells as Nutrient Sensors	CELL			English	Editorial Material							BEHAVIOR	Adult tissues can rapidly and reversibly change size to adapt to environmental and behavioral influences. In this issue, O'Brien et al. (2011) demonstrate that fly intestinal stem cells alter their division patterns in response to food availability to drive organ growth.	[Sarkar, Abby; Hochedlinger, Konrad] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; [Sarkar, Abby; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Sarkar, Abby; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Sarkar, Abby; Hochedlinger, Konrad] Ctr Regenerat Med, Boston, MA 02114 USA; [Sarkar, Abby; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University	Hochedlinger, K (corresponding author), Harvard Univ, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.	khochedlinger@helix.mgh.harvard.edu		Sarkar, Abby/0000-0001-6101-1721				Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Chell JM, 2010, CELL, V143, P1161, DOI 10.1016/j.cell.2010.12.007; Jasper H, 2010, CELL METAB, V12, P561, DOI 10.1016/j.cmet.2010.11.010; Losick VP, 2011, DEV CELL, V21, P159, DOI 10.1016/j.devcel.2011.06.018; McLeod CJ, 2010, CURR BIOL, V20, P2100, DOI 10.1016/j.cub.2010.10.038; O'Brien LE, 2011, CELL, V147, P603, DOI 10.1016/j.cell.2011.08.048; Piersma T, 1997, TRENDS ECOL EVOL, V12, P134, DOI 10.1016/S0169-5347(97)01003-3; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867; WINESETT DE, 1995, AM J PHYSIOL-GASTR L, V268, pG631, DOI 10.1152/ajpgi.1995.268.4.G631	10	2	2	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					483	486		10.1016/j.cell.2011.10.006	http://dx.doi.org/10.1016/j.cell.2011.10.006			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036555	Bronze			2022-12-28	WOS:000296573700002
J	Sun, F; Park, KK; Belin, S; Wang, DQ; Lu, T; Chen, G; Zhang, K; Yeung, CC; Feng, GP; Yankner, BA; He, ZG				Sun, Fang; Park, Kevin K.; Belin, Stephane; Wang, Dongqing; Lu, Tao; Chen, Gang; Zhang, Kang; Yeung, Cecil; Feng, Guoping; Yankner, Bruce A.; He, Zhigang			Sustained axon regeneration induced by co-deletion of PTEN and SOCS3	NATURE			English	Article							MYELIN-ASSOCIATED INHIBITOR; CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCER; GROWTH; REQUIRES; CNS; TRANSCRIPTION-3; ACTIVATION; SUPPRESSOR; EXPRESSION	A formidable challenge in neural repair in the adult central nervous system (CNS) is the long distances that regenerating axons often need to travel in order to reconnect with their targets. Thus, a sustained capacity for axon regeneration is critical for achieving functional restoration. Although deletion of either phosphatase and tensin homologue (PTEN), a negative regulator of mammalian target of rapamycin (mTOR), or suppressor of cytokine signalling 3 (SOCS3), a negative regulator of Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, in adult retinal ganglion cells (RGCs) individually promoted significant optic nerve regeneration, such regrowth tapered off around 2 weeks after the crush injury(1,2). Here we show that, remarkably, simultaneous deletion of both PTEN and SOCS3 enables robust and sustained axon regeneration. We further show that PTEN and SOCS3 regulate two independent pathways that act synergistically to promote enhanced axon regeneration. Gene expression analyses suggest that double deletion not only results in the induction of many growth-related genes, but also allows RGCs to maintain the expression of a repertoire of genes at the physiological level after injury. Our results reveal concurrent activation of mTOR and STAT3 pathways as key for sustaining long-distance axon regeneration in adult CNS, a crucial step towards functional recovery.	[Sun, Fang; Belin, Stephane; Chen, Gang; Yeung, Cecil; He, Zhigang] Harvard Univ, Childrens Hosp, FM Kirby Neurobiol Ctr, Sch Med, Boston, MA 02115 USA; [Sun, Fang; Belin, Stephane; Chen, Gang; Yeung, Cecil; He, Zhigang] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Park, Kevin K.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Wang, Dongqing; Feng, Guoping] MIT, Dept Brain & Cognit Sci, McGovern Inst Brain Res, Cambridge, MA 02139 USA; [Lu, Tao; Yankner, Bruce A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of Miami; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of California System; University of California San Diego	He, ZG (corresponding author), Harvard Univ, Childrens Hosp, FM Kirby Neurobiol Ctr, Sch Med, 300 Longwood Ave, Boston, MA 02115 USA.	Zhigang.he@childrens.harvard.edu	Feng, Guoping/Y-2827-2019; Zhang, Kang/Y-2740-2019	Zhang, Kang/0000-0002-4549-1697; Belin, Stephane/0000-0001-7074-6885	Wings for Life; Miami Project to Cure Paralysis; NEI; NATIONAL EYE INSTITUTE [R01EY021342, R01EY018660, R01EY021374, R01EY021526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [DP1AG044161] Funding Source: NIH RePORTER	Wings for Life; Miami Project to Cure Paralysis; NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank M. Curry and C. Wang for technical support, H. Sasaki and F. Wang for providing Stat3<SUP>f/f</SUP> and Rosa-lox-STOP-lox-Tomato mice, J. Gray, M. Hemberg, J. Choi, J. Ngai and W. Wang for advice on microarray and data analysis, and J. Gray, X. He, T. Schwarz, F. Wang, W. Wang and C. Woolf for reading the manuscript. This study was supported by grants from Wings for Life (to F. S.), Miami Project to Cure Paralysis (to K. K. P.) and NEI (to Z.H.).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Abe N, 2010, J BIOL CHEM, V285, P28034, DOI 10.1074/jbc.M110.125336; Bareyre FM, 2011, P NATL ACAD SCI USA, V108, P6282, DOI 10.1073/pnas.1015239108; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fasnacht N, 2008, SEMIN CELL DEV BIOL, V19, P379, DOI 10.1016/j.semcdb.2008.07.001; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Filbin MT, 2006, PHILOS T R SOC B, V361, P1565, DOI 10.1098/rstb.2006.1885; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hannila SS, 2008, EXP NEUROL, V209, P321, DOI 10.1016/j.expneurol.2007.06.020; Hanz S, 2006, J NEUROCHEM, V99, P13, DOI 10.1111/j.1471-4159.2006.04089.x; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Hoffman PN, 2010, EXP NEUROL, V223, P11, DOI 10.1016/j.expneurol.2009.09.006; Joset P, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-22; Junghans D, 2005, CURR OPIN CELL BIOL, V17, P446, DOI 10.1016/j.ceb.2005.08.008; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Low K, 2008, J NEUROSCI, V28, P1099, DOI 10.1523/JNEUROSCI.4906-07.2008; Miao T, 2006, J NEUROSCI, V26, P9512, DOI 10.1523/JNEUROSCI.2160-06.2006; Moore DL, 2009, SCIENCE, V326, P298, DOI 10.1126/science.1175737; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nix P, 2011, P NATL ACAD SCI USA, V108, P10738, DOI 10.1073/pnas.1104830108; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Park KK, 2010, EXP NEUROL, V223, P45, DOI 10.1016/j.expneurol.2009.12.032; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Winzeler AM, 2011, J NEUROSCI, V31, P6481, DOI 10.1523/JNEUROSCI.3004-10.2011	30	485	502	2	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					372	U125		10.1038/nature10594	http://dx.doi.org/10.1038/nature10594			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22056987	Green Accepted, Green Submitted			2022-12-28	WOS:000298033000052
J	Chabner, BA				Chabner, Bruce A.			Drug Shortages - A Critical Challenge for the Generic-Drug Market	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Chabner, BA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.		Mendoza, Elvia/A-9361-2012					[Anonymous], 2008, REUTERS         0515; Centers for Medicare and Medicaid Services, MEDICARE B; Food and Drug Adminstration, DRUG SHORT; 2011, PHARM BLOG      0613	4	70	72	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	2011	365	23					2147	2149		10.1056/NEJMp1112633	http://dx.doi.org/10.1056/NEJMp1112633			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857PQ	22040167				2022-12-28	WOS:000297731400013
J	Otten, MH; Prince, FHM; Armbrust, W; ten Cate, R; Hoppenreijs, EPAH; Twilt, M; Koopman-Keemink, Y; Gorter, SL; Dolman, KM; Swart, JF; van den Berg, JM; Wulffraat, NM; van Rossum, MAJ; van Suijlekom-Smit, LWA				Otten, Marieke H.; Prince, Femke H. M.; Armbrust, Wineke; ten Cate, Rebecca; Hoppenreijs, Esther P. A. H.; Twilt, Marinka; Koopman-Keemink, Yvonne; Gorter, Simone L.; Dolman, Koert M.; Swart, Joost F.; van den Berg, J. Merlijn; Wulffraat, Nico M.; van Rossum, Marion A. J.; van Suijlekom-Smit, Lisette W. A.			Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; RHEUMATOID-ARTHRITIS; ANTAGONIST ANAKINRA; PREDICTORS; REGISTER; SAFETY; REMISSION; THERAPY; METHOTREXATE; EFFICACY	Context Since the introduction of biologic therapies, the pharmacological treatment approach for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive disease as a realistic goal. Objective To determine the response to therapy after initiation of etanercept therapy among patients with JIA and to examine the association between baseline factors and response to etanercept treatment. Design, Setting, and Patients The Arthritis and Biologicals in Children Register, an ongoing prospective observational study since 1999, includes all Dutch JIA patients who used biologic agents. All biologically naive patients who started etanercept before October 2009 were included, with follow-up data to January 2011. Among the 262 patients, 185 (71%) were female, 46 (18%) had systemic-onset, and the median age at initiation of etanercept treatment was 12.4 years. Main Outcome Measures Excellent response (inactive disease or discontinuation earlier due to disease remission), intermediate response (more than 50% improvement from baseline, but no inactive disease), and poor response (less than 50% improvement from baseline or discontinuation earlier due to ineffectiveness or intolerance) evaluated 15 months after initiation of etanercept. Results At 15 months after treatment initiation, 85 patients (32%) were considered excellent responders; 92 (36%), intermediate responders; and 85 (32%), poor responders. Compared with an intermediate or poor response, an excellent response was associated with lower baseline disability score (range, 0-3 points, with 0 being the best score; adjusted odds ratio [OR] per point increase, 0.49; 95% CI, 0.33-0.74); fewer disease-modifying antirheumatic drugs (DMARD) (including methotrexate) used before initiating etanercept (adjusted OR per DMARD used, 0.64; 95% CI, 0.43-0.95), and younger age at onset (adjusted OR per year increase, 0.92; 95% CI, 0.84-0.99). Compared with an intermediate or excellent response, a poor response was associated with systemic JIA (adjusted OR systemic vs nonsystemic categories, 2.92; 95% CI, 1.26-6.80), and female sex (adjusted OR female vs male, 2.16; 95% CI, 1.12-4.18). Within the first 15 months of etanercept treatment, 119 patients experienced 1 or more infectious, noninfectious, or serious adverse events, including 37 among those with an excellent response, 36 with an intermediate response, and 46 with a poor response. Within the first 15 months of treatment, 61 patients discontinued etanercept treatment, including 4 with an excellent response, 0 with an intermediate response, and 57 with a poor response. In a secondary analysis of 262 patients with a median follow-up of 35.6 months after initiation of etanercept, a range of 37% to 49% of patients reached inactive disease. The mean adherence to etanercept was 49.2 months (95% CI, 46.4-52.0) for patients with an excellent response after 15 months, 47.5 months (95% CI, 44.9-50.1) for patients with an intermediate response, and 17.4 months (95% CI, 13.6-21.2) for patients with a poor response. Conclusions Among patients with JIA who initiated treatment with etanercept, one-third achieved an excellent response, one-third an intermediate response, and one-third a poor response to therapy. Achievement of an excellent response was associated with low baseline disability scores, DMARDs used before initiating etanercept, and younger age at onset of JIA. Achievement of a poor treatment response was associated with systemic JIA and female sex. JAMA. 2011;306(21):2340-2347 Published online November 6, 2011. doi:10.1001/jama.2011.1671	[Otten, Marieke H.; Prince, Femke H. M.; Twilt, Marinka; van Suijlekom-Smit, Lisette W. A.] Sophia Childrens Univ Hosp, Dept Pediat Pediat Rheumatol, Erasmus Med Ctr, NL-3000 CB Rotterdam, Netherlands; [Armbrust, Wineke] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pediat Rheumatol, Groningen, Netherlands; [ten Cate, Rebecca; Twilt, Marinka] Leiden Univ, Med Ctr, Dept Pediat Pediat Rheumatol, NL-2300 RA Leiden, Netherlands; [Hoppenreijs, Esther P. A. H.] St Maartenskliniek, Dept Pediat Pediat Rheumatol, Groningen, Netherlands; [Hoppenreijs, Esther P. A. H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Koopman-Keemink, Yvonne] Hagaziekenhuis Juliana Childrens Hosp, Dept Pediat, The Hague, Netherlands; [Gorter, Simone L.] Acad Hosp Maastricht, Subdiv Rheumatol, Dept Internal Med, Maastricht, Netherlands; [Dolman, Koert M.] St Lucas Andreas Hosp, Dept Pediat Pediat Rheumatol, Amsterdam, Netherlands; [Dolman, Koert M.; van den Berg, J. Merlijn; van Rossum, Marion A. J.] Reade Inst, Amsterdam, Netherlands; [van den Berg, J. Merlijn; van Rossum, Marion A. J.] Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Pediat Rheumatol, Amsterdam, Netherlands; [Swart, Joost F.; Wulffraat, Nico M.] Utrecht MC Wilhelmina Childrens Hosp, Dept Pediat Pediat Rheumatol, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; University of Groningen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Sint Maartens Clinic; Radboud University Nijmegen; Haga Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); Sint Lucas Andreas Hospital; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	Otten, MH (corresponding author), Sophia Childrens Univ Hosp, Dept Pediat, Erasmus Med Ctr, Sp 1546,POB 2060, NL-3000 CB Rotterdam, Netherlands.	m.otten@erasmusmc.nl	Wulffraat, Nico M/AAE-8929-2020; Swart, Joost/AFF-8988-2022; Hoppenreijs, E.P.A.H./L-4392-2015	Wulffraat, Nico M/0000-0001-9548-5562; van den Berg, J.Merlijn/0000-0001-9431-5457	Pfizer; Roche; Abbott; Bristol-Myers Squibb; Novartis; Tevapharma; Dutch Board of Health Insurances; Dutch Arthritis Association	Pfizer(Pfizer); Roche(Roche Holding); Abbott(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb); Novartis(Novartis); Tevapharma(Teva Pharmaceutical Industries); Dutch Board of Health Insurances; Dutch Arthritis Association	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Otten reported receiving travel grants from Pfizer (formerly Wyeth), and support for consultancy from Roche. Dr Prince reported receiving consultancy fees from Roche, travel grants from Pfizer (formerly Wyeth), and grants for her thesis from Abbott, Bristol-Myers Squibb, Novartis, Tevapharma, and Pfizer (formerly Wyeth). Dr ten Cate reported receiving research grants, support for travel, and consultancy from Pfizer (formerly Wyeth). Dr Wulffraat reported receiving honoraria for lectures from Novartis. Dr van Suijlekom-Smit reported receiving grants from the Dutch Board of Health Insurances, Pfizer (formerly Wyeth), and Abbott; consulting fees from Pfizer (formerly Wyeth), Roche, and Novartis; and support for travel to meetings from Pfizer; research grants from the Dutch Arthritis Association; and travel expenses from Bristol-Myers Squibb. No other financial disclosures were reported.	Albers HM, 2009, ARTHRIT RHEUM-ARTHR, V61, P46, DOI 10.1002/art.24087; Atzeni F, 2009, AUTOIMMUN REV, V8, P431, DOI 10.1016/j.autrev.2009.01.005; Beukelman T, 2011, ARTHRIT CARE RES, V63, P465, DOI 10.1002/acr.20460; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; Hetland ML, 2010, ARTHRITIS RHEUM-US, V62, P22, DOI 10.1002/art.27227; Horneff G, 2004, ANN RHEUM DIS, V63, P1638, DOI 10.1136/ard.2003.014886; Hyrich KL, 2006, RHEUMATOLOGY, V45, P1558, DOI 10.1093/rheumatology/kel149; Iwamoto N, 2009, MOD RHEUMATOL, V19, P488, DOI 10.1007/s10165-009-0187-8; Kristensen LE, 2008, RHEUMATOLOGY, V47, P495, DOI 10.1093/rheumatology/ken002; Lovell DJ, 2008, ARTHRITIS RHEUM-US, V58, P1496, DOI 10.1002/art.23427; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Mancarella L, 2007, J RHEUMATOL, V34, P1670; Nigrovic PA, 2011, ARTHRITIS RHEUM-US, V63, P545, DOI 10.1002/art.30128; Prince FHM, 2008, RHEUMATOLOGY, V47, P1413, DOI 10.1093/rheumatology/ken245; Prince FHM, 2009, ANN RHEUM DIS, V68, P1228, DOI 10.1136/ard.2008.101030; Prince FHM, 2009, ANN RHEUM DIS, V68, P635, DOI 10.1136/ard.2007.087411; Quartier P, 2011, ANN RHEUM DIS, V70, P747, DOI 10.1136/ard.2010.134254; Remesal A, 2010, J RHEUMATOL, V37, P1970, DOI 10.3899/jrheum.100219; Southwood TR, 2011, RHEUMATOLOGY, V50, P189, DOI 10.1093/rheumatology/keq308; Swart JF, 2010, EXPERT OPIN BIOL TH, V10, P1743, DOI 10.1517/14712598.2010.532785; Tynjala P, 2009, ANN RHEUM DIS, V68, P552, DOI 10.1136/ard.2007.087130; van Rossum MAJ, 2007, ANN RHEUM DIS, V66, P1518, DOI 10.1136/ard.2006.064717; Vilca I, 2010, ANN RHEUM DIS, V69, P1479, DOI 10.1136/ard.2009.120840; Wallace CA, 2004, J RHEUMATOL, V31, P2290	24	94	104	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2011	306	21					2340	2347		10.1001/jama.2011.1671	http://dx.doi.org/10.1001/jama.2011.1671			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856YH	22056397	Bronze			2022-12-28	WOS:000297680300019
J	Baillie, JK; Barnett, MW; Upton, KR; Gerhardt, DJ; Richmond, TA; De Sapio, F; Brennan, P; Rizzu, P; Smith, S; Fell, M; Talbot, RT; Gustincich, S; Freeman, TC; Mattick, JS; Hume, DA; Heutink, P; Carninci, P; Jeddeloh, JA; Faulkner, GJ				Baillie, J. Kenneth; Barnett, Mark W.; Upton, Kyle R.; Gerhardt, Daniel J.; Richmond, Todd A.; De Sapio, Fioravante; Brennan, Paul; Rizzu, Patrizia; Smith, Sarah; Fell, Mark; Talbot, Richard T.; Gustincich, Stefano; Freeman, Thomas C.; Mattick, John S.; Hume, David A.; Heutink, Peter; Carninci, Piero; Jeddeloh, Jeffrey A.; Faulkner, Geoffrey J.			Somatic retrotransposition alters the genetic landscape of the human brain	NATURE			English	Article							L1 RETROTRANSPOSITION; HUMAN GENOME; LINE-1 RETROTRANSPOSITION; MOBILE ELEMENTS; CELLS; EVOLUTION; ENDONUCLEASE; DISRUPTION; MOSAICISM; INSERTION	Retrotransposons are mobile genetic elements that use a germline 'copy-and-paste' mechanism to spread throughout metazoan genomes(1). At least 50 per cent of the human genome is derived from retrotransposons, with three active families (L1, Alu and SVA) associated with insertional mutagenesis and disease(2,3). Epigenetic and post-transcriptional suppression block retrotransposition in somatic cells(4,5), excluding early embryo development and some malignancies(6,7). Recent reports of L1 expression(8,9) and copy number variation(10,11) in the human brain suggest that L1 mobilization may also occur during later development. However, the corresponding integration sites have not been mapped. Here we apply a high-throughput method to identify numerous L1, Alu and SVA germline mutations, as well as 7,743 putative somatic L1 insertions, in the hippocampus and caudate nucleus of three individuals. Surprisingly, we also found 13,692 somatic Alu insertions and 1,350 SVA insertions. Our results demonstrate that retrotransposons mobilize to protein-coding genes differentially expressed and active in the brain. Thus, somatic genome mosaicism driven by retrotransposition may reshape the genetic circuitry that underpins normal and abnormal neurobiological processes.	[Baillie, J. Kenneth; Barnett, Mark W.; Upton, Kyle R.; De Sapio, Fioravante; Smith, Sarah; Fell, Mark; Talbot, Richard T.; Freeman, Thomas C.; Hume, David A.; Faulkner, Geoffrey J.] Univ Edinburgh, Roslin Inst, Div Genet & Genom, Edinburgh EH25 9RG, Midlothian, Scotland; [Baillie, J. Kenneth; Barnett, Mark W.; Upton, Kyle R.; De Sapio, Fioravante; Smith, Sarah; Fell, Mark; Talbot, Richard T.; Freeman, Thomas C.; Hume, David A.; Faulkner, Geoffrey J.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH25 9RG, Midlothian, Scotland; [Gerhardt, Daniel J.; Richmond, Todd A.; Jeddeloh, Jeffrey A.] Roche NimbleGen Inc, Madison, WI 53719 USA; [Brennan, Paul] Western Gen Hosp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XR, Midlothian, Scotland; [Rizzu, Patrizia; Heutink, Peter] Vrije Univ Amsterdam Med Ctr, Sect Med Genom, Dept Clin Genet, NL-1081 BT Amsterdam, Netherlands; [Gustincich, Stefano] Int Sch Adv Studies SISSA, Neurobiol Sect, I-34136 Trieste, Italy; [Mattick, John S.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Carninci, Piero] RIKEN Yokohama Inst, Om Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh; Roche Holding; University of Edinburgh; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; International School for Advanced Studies (SISSA); University of Queensland; RIKEN	Faulkner, GJ (corresponding author), Univ Edinburgh, Roslin Inst, Div Genet & Genom, Edinburgh EH25 9RG, Midlothian, Scotland.	faulknergj@gmail.com	Hume, David A/C-7695-2013; Baillie, John Kenneth/F-3124-2011; Carninci, Piero/K-1568-2014; Faulkner, Geoffrey J/M-3168-2014; Mattick, John/ABH-6130-2020; Baillie, Kenneth/AEK-6650-2022; Mattick, John S/I-7789-2012; Upton, Kyle R./M-4772-2014	Baillie, John Kenneth/0000-0001-5258-793X; Carninci, Piero/0000-0001-7202-7243; Faulkner, Geoffrey J/0000-0001-5769-4494; Mattick, John/0000-0002-7680-7527; Baillie, Kenneth/0000-0001-5258-793X; Mattick, John S/0000-0002-7680-7527; Upton, Kyle R./0000-0003-1101-8081; Heutink, Peter/0000-0001-5218-1737; Hume, David/0000-0002-2615-1478; Gustincich, Stefano/0000-0002-2749-2514; Freeman, Thomas/0000-0001-5235-8483; Brennan, Paul/0000-0002-7347-830X	Wellcome Trust [090385/Z/09/Z]; Institute Strategic Programme Grant; British BBSRC [BB/H005935/1]; Australian NHMRC [575585]; BBSRC [BBS/E/D/05191130, BB/H005935/1, BBS/E/D/05191131] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/D/05191130, BBS/E/D/05191131, BB/H005935/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Institute Strategic Programme Grant; British BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	J.K.B. is supported by a Wellcome Trust Clinical Fellowship (090385/Z/09/Z) through the Edinburgh Clinical Academic Track. G.J.F. is funded by an Institute Strategic Programme Grant and a New Investigator Award from the British BBSRC (BB/H005935/1) and a C. J. Martin Overseas Based Biomedical Fellowship from the Australian NHMRC (575585). Human brain tissues were provided by the Netherlands Brain Bank to P. H. with ethical consent for them to be used as described in the study.	Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Belancio VP, 2010, NUCLEIC ACIDS RES, V38, P3909, DOI 10.1093/nar/gkq132; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640; Cost GJ, 2001, NUCLEIC ACIDS RES, V29, P573, DOI 10.1093/nar/29.2.573; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing AD, 2010, GENOME RES, V20, P1262, DOI 10.1101/gr.106419.110; Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368; Feschotte C, 2008, NAT REV GENET, V9, P397, DOI 10.1038/nrg2337; Garcia-Perez JL, 2010, NATURE, V466, P769, DOI 10.1038/nature09209; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Huang CRL, 2010, CELL, V141, P1171, DOI 10.1016/j.cell.2010.05.026; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Mattick JS, 2010, BIOESSAYS, V32, P548, DOI 10.1002/bies.201000028; MIKI Y, 1992, CANCER RES, V52, P643; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; Muotri AR, 2010, NATURE, V468, P443, DOI 10.1038/nature09544; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Singer T, 2010, TRENDS NEUROSCI, V33, P345, DOI 10.1016/j.tins.2010.04.001; Slager RE, 2003, NAT GENET, V33, P466, DOI 10.1038/ng1126; Wang JX, 2006, HUM MUTAT, V27, P323, DOI 10.1002/humu.20307; Xing JC, 2009, GENOME RES, V19, P1516, DOI 10.1101/gr.091827.109; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141	30	480	489	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 24	2011	479	7374					534	537		10.1038/nature10531	http://dx.doi.org/10.1038/nature10531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22037309	Green Accepted			2022-12-28	WOS:000297285600052
J	Kappos, L; Li, D; Calabresi, PA; O'Connor, P; Bar-Or, A; Barkhof, F; Yin, M; Leppert, D; Glanzman, R; Tinbergen, J; Hauser, SL				Kappos, Ludwig; Li, David; Calabresi, Peter A.; O'Connor, Paul; Bar-Or, Amit; Barkhof, Frederik; Yin, Ming; Leppert, David; Glanzman, Robert; Tinbergen, Jeroen; Hauser, Stephen L.			Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial	LANCET			English	Article							RHEUMATOID-ARTHRITIS; ORAL FINGOLIMOD; B-CELLS; CEREBROSPINAL-FLUID; DOUBLE-BLIND; T-CELLS; RITUXIMAB; EFFICACY; ANTIBODY; DISEASE	Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. Methods We did a multicentre, randomised, parallel, double-blind, placebo-controlled study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1:1:1) via an interactive voice response system to receive either placebo, low-dose (600 mg) or high-dose (2000 mg) ocrelizumab in two doses on days 1 and 15, or intramuscular interferon beta-1a (30 mu g) once a week. The randomisation list was not disclosed to the study centres, monitors, project statisticians or to the project team at Roche. All groups were double blinded to group assignment, except the interferon beta-1a group who were rater masked. At week 24, patients in the initial placebo, 600 mg ocrelizumab, and interferon beta-1a groups received ocrelizumab 600 mg; the 2000 mg group received 1000 mg. Our primary endpoint was the total number of gadolinium-enhancing lesions (GEL) and T1-weighted MRI at weeks 12, 16, 20, and 24. Analyses were done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00676715. Findings 218 (99%) of the 220 randomised patients received at least one dose of ocrelizumab, 204 (93%) completed 24 weeks of the study and 196 (89%) completed 48 weeks. In the intention-to-treat population of 218 patients, at week 24, the number of gadolinium-enhancing lesions was 89% (95% CI 68-97; p<0.0001) lower in the 600 mg ocrelizumab group than in the placebo group, and 96% (89-99; p<0.0001) lower in the 2000 mg group. In exploratory analyses, both 600 mg and 2000 mg ocrelizumab groups were better than interferon beta-1a for GEL reduction. We noted serious adverse events in two of 54 (4%; 95% CI 3.0-4.4) patients in the placebo group, one of 55 (2%; 1.3-2.3) in the 600 mg ocrelizumab group, three of 55 (5%; 4.6-6.3) in the 2000 mg group, and two of 54 (4%; 3.0-4.4) in the interferon beta-1a group. Interpretation The similarly pronounced effects of B-cell depletion with both ocrelizumab doses on MRI and relapse-related outcomes support a role for B-cells in disease pathogenesis and warrant further assessment in large, long-term trials.	[Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Li, David] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Calabresi, Peter A.] Johns Hopkins Univ, Baltimore, MD USA; [O'Connor, Paul] Univ Toronto, Toronto, ON, Canada; [Bar-Or, Amit] McGill Univ, Montreal, PQ, Canada; [Barkhof, Frederik] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Yin, Ming] Genentech Inc, San Francisco, CA 94080 USA; [Leppert, David; Glanzman, Robert; Tinbergen, Jeroen] F Hoffmann La Roche Ltd, Basel, Switzerland; [Hauser, Stephen L.] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Basel; University of British Columbia; Johns Hopkins University; University of Toronto; McGill University; Vrije Universiteit Amsterdam; Roche Holding; Genentech; Roche Holding; University of California System; University of California San Francisco	Kappos, L (corresponding author), Univ Basel Hosp, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland.	lkappos@uhbs.ch	Bar-Or, Amit/AIC-1416-2022; Calabrese, Massimiliano/I-6195-2012; Barkhof, Frederik/AAJ-6226-2020; Hauser, Stephen L/J-2978-2016; Calabresi, Peter A./AAF-2288-2019	Barkhof, Frederik/0000-0003-3543-3706; 	F Hoffmann-La Roche Ltd; Biogen Idec Inc.; Acorda Therapeutics through the University Hospital Basel; Actelion Pharmaceuticals Ltd; Advancell; Allozyne; Barofold; Bayer Health Care Pharmaceuticals; Bayer Schering Pharma; Bayhill; Biogen Idec; BioMarin; Boehringer Ingelheim; CSL Behring; Geneuro; Genmab; GlaxoSmithKline; Glenmark; Merck Serono; MediciNova; Novartis; Sanofi-Aventis; Santhera Pharmaceuticals; Shire Plc; Roche; Teva; UCB; Wyeth; Swiss MS Society; Swiss National Research Foundation; Europen Union; Gianni Rubato; Novartis Foundations; Canadian Institute of Health Research; Multiple Sclerosis Society of Canada; Serono; Biogen-IDEC; Genentech; Abbott Labs; Vertex; Actelion; BioMS; Cognosci; Daiichi Sankyo; EMD Serono; Lilly; Opexa; Warburg Pincus; Merck-Serono; Genzyme Corp; Eurpean Charcot Foundation; Lundbeck; Medicinova Inc; Jansen Alzheimer Immunotherapy; Novo Nordisk; GE medical systems	F Hoffmann-La Roche Ltd(Hoffmann-La Roche); Biogen Idec Inc.(Biogen); Acorda Therapeutics through the University Hospital Basel; Actelion Pharmaceuticals Ltd; Advancell; Allozyne; Barofold; Bayer Health Care Pharmaceuticals(Bayer AGBayer Healthcare Pharmaceuticals); Bayer Schering Pharma(Bayer AG); Bayhill; Biogen Idec(Biogen); BioMarin; Boehringer Ingelheim(Boehringer Ingelheim); CSL Behring; Geneuro(General Electric); Genmab(Genmab); GlaxoSmithKline(GlaxoSmithKline); Glenmark; Merck Serono(Merck & Company); MediciNova; Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Santhera Pharmaceuticals; Shire Plc; Roche(Roche Holding); Teva(Teva Pharmaceutical Industries); UCB(UCB Pharma SA); Wyeth(Wyeth); Swiss MS Society; Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); Europen Union; Gianni Rubato; Novartis Foundations; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Multiple Sclerosis Society of Canada; Serono(Merck & Company); Biogen-IDEC(Biogen); Genentech(Roche HoldingGenentech); Abbott Labs(Abbott Laboratories); Vertex(Vertex Pharmaceuticals); Actelion; BioMS; Cognosci; Daiichi Sankyo(Daiichi Sankyo Company Limited); EMD Serono; Lilly(Eli Lilly); Opexa; Warburg Pincus; Merck-Serono(Merck & Company); Genzyme Corp(Sanofi-AventisGenzyme Corporation); Eurpean Charcot Foundation; Lundbeck(Lundbeck Corporation); Medicinova Inc; Jansen Alzheimer Immunotherapy; Novo Nordisk(Novo Nordisk); GE medical systems(General Electric)	F Hoffmann-La Roche Ltd, Biogen Idec Inc.; LK has received grant support through the University Hospital Basel from Acorda Therapeutics, Actelion Pharmaceuticals Ltd, Advancell, Allozyne, Barofold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, Boehringer Ingelheim, CSL Behring, Geneuro, Genmab, GlaxoSmithKline, Glenmark, Merck Serono, MediciNova, Novartis, Sanofi-Aventis, Santhera Pharmaceuticals, Shire Plc, Roche, Teva, UCB, Wyeth, the Swiss MS Society, the Swiss National Research Foundation, Europen Union, Gianni Rubato, Roche, and Novartis Foundations. DL has received research funding from the Canadian Institute of Health Research and Multiple Sclerosis Society of Canada; he is the Director of the UBC MS/MRI Research Group, which has been contracted to do central analysis of MRI scans for therapeutic trials with Angiotech, Bayer, Berlex-Schering, Bio-MS, Boehringer-Ingelheim, Centocor, Daiichi Sankyo, Genentech, Hoffmann-LaRoche, Merck-Serono, Perceptives, Schering-Plough, Teva Neurosciences, Sanofi-Aventis, and Transition Therapeutics. DL has been a consultant for Genzyme and Novartis. PO'[C has received fees for consultancy from Novartis, Teva, Serono, Biogen-IDEC, Genentech, and Abbott Labs; grant support from Novartis, Biogen-IDEC, Teva, Serono, Genentech, Vertex and Bayer; consultancy fees or research support for trials of multiple sclerosis from Actelion, Bayer, Biogen Idec, BioMS, Cognosci, Daiichi Sankyo, EMD Serono, Genentech, Genmab, Lilly, Novartis, Opexa, Roche, Sanofi-Aventis, Teva, and Warburg Pincus. AB-O has received personal compensation for consulting, serving on scientific advisory boards or speaking activities from Bayer, Bayhill Therapeutics, Berlex, Biogen-IDEC, BioMS, Diogenix, Eli-Lilly, Genentech, GSK, Guthy-Jackson/GGF, Merck-Serono, Novartis, Ono Pharmacia, Roche, Sanofi-Aventis, Teva Neuroscience, and Wyeth. FB has received compensation for consultancy, committee membership or lecture fees from Bayer Schering Pharma, Merck-Serono, Sanofi-Aventis, Genzyme Corp, Novartis, Biogen-IDEC, Eurpean Charcot Foundation, Lundbeck, Roche, UCB, Medicinova Inc, Jansen Alzheimer Immunotherapy, Novo Nordisk, GE medical systems. MY, DLe, RG, and JT are employees and stockholders of Roche. SH has received consulting income from Pfizer, Novartis, Receptos, Roche, and BioMarin.	[Anonymous], 2003, OCR DAT FIL; Bar-Or A, 2010, ANN NEUROL, V67, P452, DOI 10.1002/ana.21939; Bettelli E, 2006, J CLIN INVEST, V116, P2393, DOI 10.1172/JCI28334; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Corcione A, 2005, AUTOIMMUN REV, V4, P549, DOI 10.1016/j.autrev.2005.04.012; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; Duddy M, 2006, Int MS J, V13, P84; Duddy M, 2007, J IMMUNOL, V178, P6092, DOI 10.4049/jimmunol.178.10.6092; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Emery P, 2010, AM COLL RHEUM ASS RH, P414; Furuzawa-Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2652, DOI 10.1002/art.23732; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kappos L, 2011, LANCET NEUROL, V10, P745, DOI 10.1016/S1474-4422(11)70149-1; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Meinl E, 2006, ANN NEUROL, V59, P880, DOI 10.1002/ana.20890; Monson NL, 2005, ARCH NEUROL-CHICAGO, V62, P258, DOI 10.1001/archneur.62.2.258; Morschhauser F, 2007, 49 ASH ANN M EXP ATL, P645; Nessler S, 2007, BRAIN, V130, P2186, DOI 10.1093/brain/awm105; Oksenberg JR, 2008, NAT REV GENET, V9, P516, DOI 10.1038/nrg2395; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Vallerskog T, 2007, CLIN IMMUNOL, V122, P62, DOI 10.1016/j.clim.2006.08.016	30	498	541	0	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2011	378	9805					1779	1787		10.1016/S0140-6736(11)61649-8	http://dx.doi.org/10.1016/S0140-6736(11)61649-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851IS	22047971				2022-12-28	WOS:000297262300022
J	Klinge, S; Voigts-Hoffmann, F; Leibundgut, M; Arpagaus, S; Ban, N				Klinge, Sebastian; Voigts-Hoffmann, Felix; Leibundgut, Marc; Arpagaus, Sofia; Ban, Nenad			Crystal Structure of the Eukaryotic 60S Ribosomal Subunit in Complex with Initiation Factor 6	SCIENCE			English	Article							SHWACHMAN-DIAMOND SYNDROME; TRANSFER-RNA; CYCLOHEXIMIDE RESISTANCE; TRANSLATION ELONGATION; BLACKFAN ANEMIA; MESSENGER-RNA; 80S RIBOSOME; EXIT TUNNEL; PROTEIN; YEAST	Protein synthesis in all organisms is catalyzed by ribosomes. In comparison to their prokaryotic counterparts, eukaryotic ribosomes are considerably larger and are subject to more complex regulation. The large ribosomal subunit (60S) catalyzes peptide bond formation and contains the nascent polypeptide exit tunnel. We present the structure of the 60S ribosomal subunit from Tetrahymena thermophila in complex with eukaryotic initiation factor 6 (eIF6), cocrystallized with the antibiotic cycloheximide (a eukaryotic-specific inhibitor of protein synthesis), at a resolution of 3.5 angstroms. The structure illustrates the complex functional architecture of the eukaryotic 60S subunit, which comprises an intricate network of interactions between eukaryotic-specific ribosomal protein features and RNA expansion segments. It reveals the roles of eukaryotic ribosomal protein elements in the stabilization of the active site and the extent of eukaryotic-specific differences in other functional regions of the subunit. Furthermore, it elucidates the molecular basis of the interaction with eIF6 and provides a structural framework for further studies of ribosome-associated diseases and the role of the 60S subunit in the initiation of protein synthesis.	[Klinge, Sebastian; Voigts-Hoffmann, Felix; Leibundgut, Marc; Arpagaus, Sofia; Ban, Nenad] ETH, Inst Mol Biol & Biophys, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ban, N (corresponding author), ETH, Inst Mol Biol & Biophys, CH-8092 Zurich, Switzerland.	ban@mol.biol.ethz.ch			Swiss National Science Foundation (SNSF); National Center of Excellence in Research (NCCR) of the SNSF; European Research Council [250071]; European Community; EMBO; Human Frontier Science Program fellowships	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); National Center of Excellence in Research (NCCR) of the SNSF(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission); European Community(European Commission); EMBO(European Molecular Biology Organization (EMBO)); Human Frontier Science Program fellowships	All data were collected at the Swiss Light Source (SLS, Paul Scherrer Institut, Villigen). We thank T. Tomizaki, M. Muller, V. Olieric, G. Pompidor, and A. Pauluhn for their outstanding support at the SLS; J. Rabl for advice on cell growth and ribosome purification as well as a clone of eIF6; T. Maier for advice on data collection; T. Bucher for the preparation of crystals; J. Erzberger and T. Bucher for critically reading the manuscript; and all members of the Ban laboratory for suggestions and discussions. Supported by the Swiss National Science Foundation (SNSF), the National Center of Excellence in Research (NCCR) Structural Biology program of the SNSF, and European Research Council grant 250071 under the European Community's Seventh Framework Programme (N.B.) and by EMBO and Human Frontier Science Program fellowships (S. K.). Coordinates and structure factors have been deposited in the Protein Data Bank (accession codes for molecule 1: 4A1E and 4A18; molecule 2, 4A17 and 4A19; molecule 3, 4A1A and 4A1B; molecule 4, 4A1C and 4A1D). ETH Zurich has filed a patent application to use the crystals and the coordinates of the 60S ribosomal subunit for developing compounds that can interfere with eukaryotic translation.	Armache JP, 2010, P NATL ACAD SCI USA, V107, P19748, DOI 10.1073/pnas.1009999107; Armache JP, 2010, P NATL ACAD SCI USA, V107, P19754, DOI 10.1073/pnas.1010005107; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Ben-Shem A, 2010, SCIENCE, V330, P1203, DOI 10.1126/science.1194294; Benelli D, 2009, NUCLEIC ACIDS RES, V37, P256, DOI 10.1093/nar/gkn959; Bingel-Erlenmeyer R, 2008, NATURE, V452, P108, DOI 10.1038/nature06683; Bulkley D, 2010, P NATL ACAD SCI USA, V107, P17158, DOI 10.1073/pnas.1008685107; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chao JA, 2004, STRUCTURE, V12, P1165, DOI 10.1016/j.str.2004.04.023; DeLabre ML, 2002, BBA-GENE STRUCT EXPR, V1574, P255, DOI 10.1016/S0167-4781(01)00372-4; Finch AJ, 2011, GENE DEV, V25, P917, DOI 10.1101/gad.623011; FRIED HM, 1982, NUCLEIC ACIDS RES, V10, P3133, DOI 10.1093/nar/10.10.3133; Gartmann M, 2010, J BIOL CHEM, V285, P14848, DOI 10.1074/jbc.C109.096057; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Groft CM, 2000, NAT STRUCT BIOL, V7, P1156; Gurel G, 2009, ANTIMICROB AGENTS CH, V53, P5010, DOI 10.1128/AAC.00817-09; Halic M, 2005, NAT STRUCT MOL BIOL, V12, P467, DOI 10.1038/nsmb933; Hartzoulakis B, 2007, BIOORG MED CHEM LETT, V17, P3953, DOI 10.1016/j.bmcl.2007.04.095; Houmani JL, 2009, J VIROL, V83, P9844, DOI 10.1128/JVI.01014-09; Johnson AW, 2011, GENE DEV, V25, P898, DOI 10.1101/gad.2053011; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; Kirn-Safran CB, 2007, DEV DYNAM, V236, P447, DOI 10.1002/dvdy.21046; Kondrashov N, 2011, CELL, V145, P383, DOI 10.1016/j.cell.2011.03.028; Kramer G, 2009, NAT STRUCT MOL BIOL, V16, P589, DOI 10.1038/nsmb.1614; Lacombe T, 2009, MOL MICROBIOL, V72, P69, DOI 10.1111/j.1365-2958.2009.06622.x; Lawrence MG, 2008, J BACTERIOL, V190, P5862, DOI 10.1128/JB.00632-08; Li L, 2006, NATURE, V443, P302, DOI 10.1038/nature05151; Lo KY, 2010, MOL CELL, V39, P196, DOI 10.1016/j.molcel.2010.06.018; Macias S, 2008, MOL CELL, V30, P732, DOI 10.1016/j.molcel.2008.05.002; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Moore JB, 2010, HAEMATOL-HEMATOL J, V95, P57, DOI 10.3324/haematol.2009.012450; Nakao A, 2004, NUCLEIC ACIDS RES, V32, pD168, DOI 10.1093/nar/gkh004; Panse VG, 2010, TRENDS BIOCHEM SCI, V35, P260, DOI 10.1016/j.tibs.2010.01.001; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Petry S, 2005, CELL, V123, P1255, DOI 10.1016/j.cell.2005.09.039; Rabl J, 2011, SCIENCE, V331, P730, DOI 10.1126/science.1198308; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Schmeing TM, 2009, NATURE, V461, P1234, DOI 10.1038/nature08403; Schmeing TM, 2003, RNA, V9, P1345, DOI 10.1261/rna.5120503; Schneider-Poetsch T, 2010, NAT CHEM BIOL, V6, P209, DOI 10.1038/NCHEMBIO.304; Schroeder SJ, 2007, ANTIMICROB AGENTS CH, V51, P4462, DOI 10.1128/AAC.00455-07; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Stevens DR, 2001, MOL GEN GENET, V264, P790, DOI 10.1007/s004380000368; Strunk BS, 2009, RNA, V15, P2083, DOI 10.1261/rna.1792109; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yonath A, 2005, ANNU REV BIOCHEM, V74, P649, DOI 10.1146/annurev.biochem.74.082803.133130; Zaman S, 2007, MOL MICROBIOL, V66, P1039, DOI 10.1111/j.1365-2958.2007.05975.x; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307	50	262	289	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					941	948		10.1126/science.1211204	http://dx.doi.org/10.1126/science.1211204			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22052974				2022-12-28	WOS:000297101800046
J	Freedman, SB; Parkin, PC; Willan, AR; Schuh, S				Freedman, Stephen B.; Parkin, Patricia C.; Willan, Andrew R.; Schuh, Suzanne			Rapid versus standard intravenous rehydration in paediatric gastroenteritis: pragmatic blinded randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LACTATED RINGERS SOLUTION; EMERGENCY-DEPARTMENT; DEHYDRATION SCALE; ORAL ONDANSETRON; NORMAL SALINE; CHILDREN; MYOCARDITIS; VALIDATION; MANAGEMENT; HYDRATION	Objective To determine if rapid rather than standard intravenous rehydration results in improved hydration and clinical outcomes when administered to children with gastroenteritis. Design Single centre, two arm, parallel randomised pragmatic controlled trial. Blocked randomisation stratified by site. Participants, caregivers, outcome assessors, investigators, and statisticians were blinded to the treatment assignment. Setting Paediatric emergency department in a tertiary care centre in Toronto, Canada. Participants 226 children aged 3 months to 11 years; complete follow-up was obtained on 223 (99%). Eligible children were aged over 90 days, had a diagnosis of dehydration secondary to gastroenteritis, had not responded to oral rehydration, and had been prescribed intravenous rehydration. Children were excluded if they weighed less than 5 kg or more than 33 kg, required fluid restriction, had a suspected surgical condition, or had an insurmountable language barrier. Children were also excluded if they had a history of a chronic systemic disease, abdominal surgery, bilious or bloody vomit, hypotension, or hypoglycaemia or hyperglycaemia. Interventions Rapid (60 mL/kg) or standard (20 mL/kg) rehydration with 0.9% saline over an hour; subsequent fluids administered according to protocol. Main outcome measures Primary outcome: clinical rehydration, assessed with a validated scale, two hours after the start of treatment. Secondary outcomes: prolonged treatment, mean clinical dehydration scores over the four hour study period, time to discharge, repeat visits to emergency department, adequate oral intake, and physician's comfort with discharge. Data from all randomised patients were included in an intention to treat analysis. Results 114 patients were randomised to rapid rehydration and 112 to standard. One child was withdrawn because of severe hyponatraemia at baseline. There was no evidence of a difference between the rapid and standard rehydration groups in the proportions of participants who were rehydrated at two hours (41/114 (36%) v 33/112 (30%); difference 6.5% (95% confidence interval -5.7% to 18.7%; P=0.32). The results did not change after adjustment for weight, baseline dehydration score, and baseline pH (odds ratio 1.8, 0.90 to 3.5; P=0.10). The rates of prolonged treatment were similar (52% rapid v 43% standard; difference 8.9%, 21% to -5%; P=0.19). Although dehydration scores were similar throughout the study period (P=0.96), the median time to discharge was longer in the rapid group (6.3 v 5.0 hours; P=0.03). Conclusions There are no relevant clinical benefits from the administration of rapid rather than standard intravenous rehydration to haemodynamically stable children deemed to require intravenous rehydration.	[Freedman, Stephen B.; Schuh, Suzanne] Hosp Sick Children, Div Paediat Emergency Med, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.] Hosp Sick Children, Di Paediat Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.; Parkin, Patricia C.; Willan, Andrew R.; Schuh, Suzanne] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.; Parkin, Patricia C.; Schuh, Suzanne] Univ Toronto, Dept Paediat, Fac Med, Toronto, ON M5S 1A1, Canada; [Parkin, Patricia C.] Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada; [Parkin, Patricia C.] Hosp Sick Children, Paediat Outcomes Res Team, Toronto, ON M5G 1X8, Canada; [Willan, Andrew R.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Freedman, SB (corresponding author), Hosp Sick Children, Div Paediat Emergency Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	stephen.freedman@sickkids.ca	Freedman, Stephen/H-9102-2012	Freedman, Stephen/0000-0003-2319-6192	The Physicians' Services Incorporated Foundation; The Hospital for Sick Children Foundation	The Physicians' Services Incorporated Foundation; The Hospital for Sick Children Foundation	This study was supported by a grant from The Physicians' Services Incorporated Foundation. The Paediatric Outcomes Research Team (PCP) is funded by The Hospital for Sick Children Foundation. The study sponsors played no role in study design or data collection, analysis, and interpretation or in the writing of the article and the decision to submit it for publication; all researcher activities were independent of the funding source; and the research team had full and unrestricted access to all the data.	Alam NH, 2009, J PEDIATR GASTR NUTR, V48, P318, DOI 10.1097/MPG.0b013e318180af27; Bailey B, 2010, ACAD EMERG MED, V17, P583, DOI 10.1111/j.1553-2712.2010.00767.x; Bender BJ, 2004, PEDIATR EMERG CARE, V20, P215, DOI 10.1097/01.pec.0000121239.99242.49; Chang YJ, 2006, PEDIATR EMERG CARE, V22, P439, DOI 10.1097/01.pec.0000221346.64991.e7; Cheng A, 2011, PAED CHILD HEALT-CAN, V16, P177, DOI 10.1093/pch/16.3.177; DeCamp LR, 2008, ARCH PEDIAT ADOL MED, V162, P858, DOI 10.1001/archpedi.162.9.858; Freedman SB, 2006, NEW ENGL J MED, V354, P1698, DOI 10.1056/NEJMoa055119; Freedman SB, 2007, PEDIATRICS, V120, P1278, DOI 10.1542/peds.2007-1073; Freedman SB, 2011, ACAD EMERG MED, V18, P38, DOI 10.1111/j.1553-2712.2010.00960.x; Friedman AL, 2005, KIDNEY INT, V67, P380, DOI 10.1111/j.1523-1755.2005.00092.x; Friedman LM, 1998, FUNDAMENTALS CLIN TR, P94; Frifdman JN, 2004, J PEDIATR-US, V145, P201, DOI 10.1016/j.jpeds.2004.05.035; Gharahbaghian L, 2008, CAN J EMERG MED, V10, P488; Goldman RD, 2008, PEDIATRICS, V122, P545, DOI 10.1542/peds.2007-3141; Gorelick M, 2002, RAPID INTRAVENOUS RE; Guarino A, 2008, J PEDIATR GASTR NUTR, V46, pS81, DOI 10.1097/MPG.0b013e31816f7b16; Holliday MA, 1999, PEDIATR NEPHROL, V13, P292, DOI 10.1007/s004670050611; Hoorn EJ, 2004, PEDIATRICS, V113, P1279, DOI 10.1542/peds.113.5.1279; Juca CA, 2005, ANN TROP PAEDIATR, V25, P253, DOI 10.1179/146532805X72395; Kanaan U, 2003, CLIN PEDIATR, V42, P421, DOI 10.1177/000992280304200506; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Levy JA, 2007, ACAD EMERG MED, V14, P324, DOI 10.1197/j.aem.2006.10.098; Maitland K, 2011, N ENGL J MED; MOINEUA G, 1990, Pediatric Emergency Care, V6, P186, DOI 10.1097/00006565-199009000-00005; Myburgh JA, 2011, N ENG J MED; Nager AL, 2002, PEDIATRICS, V109, P566, DOI 10.1542/peds.109.4.566; Nager AL, 2010, TINTINALLIS EMERGENC, P971; Nager AL, 2010, AM J EMERG MED, V28, P123, DOI 10.1016/j.ajem.2008.09.046; National Collaborating Centre for Women's and Children's Health, 2009, DIARRH VOM CAUS GAST; National Patient Safety Agency, 2007, NPSA200722; Neville KA, 2006, ARCH DIS CHILD, V91, P226, DOI 10.1136/adc.2005.084103; Parkin PC, 2010, CLIN PEDIATR, V49, P235, DOI 10.1177/0009922809336670; Pawlowicz Malgorzata, 2008, Pediatr Endocrinol Diabetes Metab, V14, P7; RAHMAN O, 1988, J PEDIATR-US, V113, P654, DOI 10.1016/S0022-3476(88)80374-3; Reeves JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e62; Reid SR, 1996, ANN EMERG MED, V28, P318, DOI 10.1016/S0196-0644(96)70032-X; Shaw KN, 2010, TXB PEDIAT EMERGENCY, P206; Spandorfer PR, 2005, PEDIATRICS, V115, P295, DOI 10.1542/peds.2004-0245; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Sunoto, 1990, Paediatr Indones, V30, P154; Waters JH, 2001, ANESTH ANALG, V93, P817, DOI 10.1097/00000539-200110000-00004; Williams EL, 1999, ANESTH ANALG, V88, P999, DOI 10.1097/00000539-199905000-00006	44	26	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2011	343								d6976	10.1136/bmj.d6976	http://dx.doi.org/10.1136/bmj.d6976			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875FU	22094316	Green Published, hybrid			2022-12-28	WOS:000299016600007
J	Lee, X; Goulden, ML; Hollinger, DY; Barr, A; Black, TA; Bohrer, G; Bracho, R; Drake, B; Goldstein, A; Gu, LH; Katul, G; Kolb, T; Law, BE; Margolis, H; Meyers, T; Monson, R; Munger, W; Oren, R; Kyaw, TPU; Richardson, AD; Schmid, HP; Staebler, R; Wofsy, S; Zhao, L				Lee, Xuhui; Goulden, Michael L.; Hollinger, David Y.; Barr, Alan; Black, T. Andrew; Bohrer, Gil; Bracho, Rosvel; Drake, Bert; Goldstein, Allen; Gu, Lianhong; Katul, Gabriel; Kolb, Thomas; Law, Beverly E.; Margolis, Hank; Meyers, Tilden; Monson, Russell; Munger, William; Oren, Ram; Kyaw Tha Paw U; Richardson, Andrew D.; Schmid, Hans Peter; Staebler, Ralf; Wofsy, Steven; Zhao, Lei			Observed increase in local cooling effect of deforestation at higher latitudes	NATURE			English	Article							LAND-USE; CLIMATE; VEGETATION; FOREST; ENERGY; WATER	Deforestation in mid-to high latitudes is hypothesized to have the potential to cool the Earth's surface by altering biophysical processes(1-3). In climate models of continental-scale land clearing, the cooling is triggered by increases in surface albedo and is reinforced by a land albedo-sea ice feedback(4,5). This feedback is crucial in the model predictions; without it other biophysical processes may overwhelm the albedo effect to generate warming instead(5). Ongoing land-use activities, such as land management for climate mitigation, are occurring at local scales (hectares) presumably too small to generate the feedback, and it is not known whether the intrinsic biophysical mechanism on its own can change the surface temperature in a consistent manner(6,7). Nor has the effect of deforestation on climate been demonstrated over large areas from direct observations. Here we show that surface air temperature is lower in open land than in nearby forested land. The effect is 0.85 +/- 0.44 K (mean +/- one standard deviation) northwards of 45 degrees N and 0.21 +/- 0.53 K southwards. Below 35 degrees N there is weak evidence that deforestation leads to warming. Results are based on comparisons of temperature at forested eddy covariance towers in the USA and Canada and, as a proxy for small areas of cleared land, nearby surface weather stations. Night-time temperature changes unrelated to changes in surface albedo are an important contributor to the overall cooling effect. The observed latitudinal dependence is consistent with theoretical expectation of changes in energy loss from convection and radiation across latitudes in both the daytime and night-time phase of the diurnal cycle, the latter of which remains uncertain in climate models(8).	[Lee, Xuhui; Zhao, Lei] Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; [Goulden, Michael L.] Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; [Hollinger, David Y.] US Forest Serv, USDA, No Res Stn, Durham, NH 03824 USA; [Barr, Alan] Environm Canada, Div Climate Res, Saskatoon, SK S7N 3H5, Canada; [Black, T. Andrew] Univ British Columbia, Fac Land & Food Syst, Vancouver, BC V6T 1Z4, Canada; [Bohrer, Gil] Ohio State Univ, Dept Civil & Environm Engn & Geodet Sci, Columbus, OH 43210 USA; [Bracho, Rosvel] Univ Florida, Sch Forest Resources & Conservat, Gainesville, FL 32611 USA; [Drake, Bert] Smithsonian Environm Res Ctr, Edgewater, MD 21037 USA; [Goldstein, Allen] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Gu, Lianhong] Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA; [Katul, Gabriel; Oren, Ram] Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; [Kolb, Thomas] No Arizona Univ, Sch Forestry, Flagstaff, AZ 86011 USA; [Law, Beverly E.] Oregon State Univ, Coll Forestry, Corvallis, OR 97331 USA; [Margolis, Hank] Univ Laval, Fac Foresterie Geog & Geomat, Ctr Etud Foret, Quebec City, PQ G1V 0A6, Canada; [Meyers, Tilden] NOAA ARL ATDD, Oak Ridge, TN 37830 USA; [Monson, Russell] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; [Munger, William; Wofsy, Steven] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Kyaw Tha Paw U] Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA; [Richardson, Andrew D.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; [Schmid, Hans Peter] Karlsruhe Inst Technol, Inst Meteorol & Climate Res, D-82467 Garmisch Partenkirchen, Germany; [Staebler, Ralf] Environm Canada, Proc Res Sect, Toronto, ON M3H 5T4, Canada	Yale University; University of California System; University of California Irvine; United States Department of Agriculture (USDA); United States Forest Service; Environment & Climate Change Canada; University of British Columbia; University System of Ohio; Ohio State University; State University System of Florida; University of Florida; Smithsonian Institution; Smithsonian Environmental Research Center; University of California System; University of California Berkeley; United States Department of Energy (DOE); Oak Ridge National Laboratory; Duke University; Northern Arizona University; Oregon State University; Laval University; National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; Harvard University; University of California System; University of California Davis; Harvard University; Helmholtz Association; Karlsruhe Institute of Technology; Environment & Climate Change Canada	Lee, X (corresponding author), Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA.	xuhui.lee@yale.edu	Goldstein, Allen H/A-6857-2011; Hollinger, David Y/G-7185-2012; Barr, Alan/H-9939-2014; Oren, Ram/AAC-5326-2019; Bohrer, Gil/A-9731-2008; Goulden, Michael L/B-9934-2008; Zhao, Lei/S-1855-2019; Barr, Alan George/AAX-2129-2020; Law, Beverly Elizabeth/G-3882-2010; Gu, Lianhong/H-8241-2014; Schmid, Hans Peter E/I-1224-2012; Schmid, Hans Peter/AAP-4450-2021; Katul, Gabriel G/A-7210-2008; Munger, J William/H-4502-2013; Meyers, Tilden/C-6633-2016; Richardson, Andrew/F-5691-2011	Goldstein, Allen H/0000-0003-4014-4896; Oren, Ram/0000-0002-5654-1733; Bohrer, Gil/0000-0002-9209-9540; Zhao, Lei/0000-0002-6481-3786; Law, Beverly Elizabeth/0000-0002-1605-1203; Gu, Lianhong/0000-0001-5756-8738; Schmid, Hans Peter E/0000-0001-9076-4466; Schmid, Hans Peter/0000-0001-9076-4466; Katul, Gabriel G/0000-0001-9768-3693; Munger, J William/0000-0002-1042-8452; Meyers, Tilden/0000-0002-0726-4258; Richardson, Andrew/0000-0002-0148-6714; Staebler, Ralf/0000-0002-6372-0414; Barr, Alan/0000-0003-2717-218X; Goulden, Michael/0000-0002-9379-3948	US Department of Energy; Yale University Climate and Energy Institute	US Department of Energy(United States Department of Energy (DOE)); Yale University Climate and Energy Institute	The data collection and analysis were supported in part by grants from the US Department of Energy and by a Yale University Climate and Energy Institute grant. We thank D. Fitzjarrald and R. Sakai for providing the data for the KM77 tropical site and C. von Randow for providing the friction velocity data for FLUXNET cluster e.	Anderson RG, 2011, J GEOPHYS RES-BIOGEO, V116, DOI 10.1029/2010JG001476; Bala G, 2007, P NATL ACAD SCI USA, V104, P6550, DOI 10.1073/pnas.0608998104; Baldocchi D, 2001, B AM METEOROL SOC, V82, P2415, DOI 10.1175/1520-0477(2001)082<2415:FANTTS>2.3.CO;2; Betts AK, 1997, J GEOPHYS RES-ATMOS, V102, P28901, DOI 10.1029/96JD03876; Betts RA, 2000, NATURE, V408, P187, DOI 10.1038/35041545; Betts RA, 2007, AGR FOREST METEOROL, V142, P216, DOI 10.1016/j.agrformet.2006.08.021; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; Bonan GB, 2008, SCIENCE, V320, P1444, DOI 10.1126/science.1155121; Davin EL, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029678; Davin EL, 2010, J CLIMATE, V23, P97, DOI 10.1175/2009JCLI3102.1; Douville H, 1996, CLIM DYNAM, V13, P57, DOI 10.1007/s003820050153; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Goulden ML, 2006, GLOBAL CHANGE BIOL, V12, P2146, DOI 10.1111/j.1365-2486.2006.01251.x; Goulden Michael L., 2004, Ecological Applications, V14, pS42; Juang JY, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031296; Lerner J., 1984, CLIMATE PROCESSES CL, V29, P130, DOI 10.1029/GM029p0130; Mahrt L, 2000, BOUND-LAY METEOROL, V96, P33, DOI 10.1023/A:1002482332477; Mesinger F, 2006, B AM METEOROL SOC, V87, P343, DOI 10.1175/BAMS-87-3-343; PIELKE RA, 1990, LANDSCAPE ECOL, V4, P133, DOI 10.1007/BF00132857; Pielke RA, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008229; Rotenberg E, 2010, SCIENCE, V327, P451, DOI 10.1126/science.1179998; Sakai RK, 2004, GLOBAL CHANGE BIOL, V10, P895, DOI 10.1111/j.1529-8817.2003.00773.x; Snyder PK, 2004, CLIM DYNAM, V23, P279, DOI 10.1007/s00382-004-0430-0; Stoy PC, 2006, GLOBAL CHANGE BIOL, V12, P2115, DOI 10.1111/j.1365-2486.2006.01244.x; Swann AL, 2010, P NATL ACAD SCI USA, V107, P1295, DOI 10.1073/pnas.0913846107; von Randow C, 2004, THEOR APPL CLIMATOL, V78, P5, DOI 10.1007/s00704-004-0041-z; Wild M, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028031; Zha T, 2009, GLOBAL CHANGE BIOL, V15, P1475, DOI 10.1111/j.1365-2486.2008.01817.x; Zhou LM, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036141	29	404	430	24	314	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					384	387		10.1038/nature10588	http://dx.doi.org/10.1038/nature10588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094699	Green Published			2022-12-28	WOS:000297059700042
J	Mack, MJ; Holmes, DR				Mack, Michael J.; Holmes, David R., Jr.			Rational Dispersion for the Introduction of Transcatheter Valve Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OF-CARDIOLOGY FOUNDATION; THORACIC SURGEONS; SOCIETY		[Mack, Michael J.] Soc Thorac Surg, Plano, TX 75093 USA; [Holmes, David R., Jr.] Amer Coll Cardiol, Minneapolis, MN USA	Society of Thoracic Surgeons	Mack, MJ (corresponding author), Soc Thorac Surg, 1100 Allied Dr, Plano, TX 75093 USA.	michael.mack@baylorhealth.edu						Holmes DR, 2011, J AM COLL CARDIOL, V58, P445, DOI 10.1016/j.jacc.2011.05.007; Holmes DR, 2011, ANN THORAC SURG, V92, P380, DOI 10.1016/j.athoracsur.2011.05.067; Leon MB, 2010, NEW ENGL J MED, V363, P1597, DOI 10.1056/NEJMoa1008232; US Food and Drug Administration, 2011, 2011 M MAT CIRC SYST	4	31	32	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2149	2150		10.1001/jama.2011.1675	http://dx.doi.org/10.1001/jama.2011.1675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089724				2022-12-28	WOS:000297013000023
J	Hirsch, C				Hirsch, Calvin			Systematic pain management reduced agitation in nursing home residents with dementia	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis	Hirsch, C (corresponding author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.			Husebo, Bettina Sandgathe/0000-0002-6037-2864				Cohen-Mansfield J, 2001, AM J GERIAT PSYCHIAT, V9, P361, DOI 10.1176/appi.ajgp.9.4.361; Husebo BS, 2010, SCAND J CARING SCI, V24, P380, DOI 10.1111/j.1471-6712.2009.00710.x; Kovach CR, 2006, J GERONTOL NURS, V32, P18, DOI 10.3928/00989134-20060401-05; Zwakhalen SMG, 2009, EUR J PAIN, V13, P89, DOI 10.1016/j.ejpain.2008.02.009	4	1	1	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-9	10.7326/0003-4819-155-10-201111150-02009	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084356				2022-12-28	WOS:000208885300008
J	Bhattacharya, A; Baker, NE				Bhattacharya, Abhishek; Baker, Nicholas E.			A Network of Broadly Expressed HLH Genes Regulates Tissue-Specific Cell Fates	CELL			English	Article							MORPHOGENETIC FURROW PROGRESSION; SENSORY ORGAN DEVELOPMENT; ACHAETE-SCUTE COMPLEX; LOOP-HELIX PROTEINS; PRONEURAL GENE; DNA-BINDING; DROSOPHILA EYE; NEGATIVE REGULATOR; EXTRAMACROCHAETAE; DAUGHTERLESS	Spatial and temporal expression of specific basic-helix-loop-helix (bHLH) transcription factors defines many types of cellular differentiation. We find that a distinct mechanism regulates the much broader expression of the heterodimer partners of these specific factors and impinges on differentiation. In Drosophila, a cross-interacting regulatory network links expression of the E protein Daughterless (Da), which heterodimerizes with bHLH proteins to activate them, with expression of the Id protein Extramacrochaetae (Emc), which antagonizes bHLH proteins. Coupled transcriptional feedback loops maintain the widespread Emc expression that restrains Da expression, opposing bHLH-dependent differentiation while enhancing growth and cell survival. Where extracellular signals repress emc, Da expression can increase. This defines regions of proneural ectoderm independently from the proneural bHLH genes. Similar regulation is found in multiple Drosophila tissues and in mammalian cells and therefore is likely to be a conserved general feature of developmental regulation by HLH proteins.	[Bhattacharya, Abhishek; Baker, Nicholas E.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Baker, Nicholas E.] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; [Baker, Nicholas E.] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Baker, NE (corresponding author), Albert Einstein Coll Med, Dept Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	nicholas.baker@einstein.yu.edu		Bhattacharya, Abhishek/0000-0002-4456-054X	NIH [GM47892]; Research to Prevent Blindness; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047892] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was enabled by the gift of polyclonal anti-Emc antibody by Yuh-Nung Jan. We also thank Claire Cronmiller for monoclonal anti-Da antibody, Konrad Basler and Christos Delidakis for strains and other reagents, Matthew Scharff and Richard Chahwan for help with HEK293T cell culture, Model System Genomics for embryo injections, John Fullard and David Lubensky for advice, and Hannes Buelow, Claude Desplan, Scott Emmons, Andreas Jenny, Richard Mann, Ertugrul Ozbudak, Julie Secombe, Jessica Treisman, and Lan-Hsin Wang for comments on the manuscript. This work was supported by grant GM47892 from the NIH and by an Unrestricted Grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences. Confocal microscopy was performed at the AIF, AECOM. Data in this paper are from a thesis to be submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy in the Graduate Division of Biomedical Sciences, Albert Einstein College of Medicine, Yeshiva University, USA.	Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Baker NE, 2009, DEV BIOL, V335, P356, DOI 10.1016/j.ydbio.2009.09.008; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; Bhattacharya A, 2009, DEV BIOL, V327, P288, DOI 10.1016/j.ydbio.2008.11.037; Boos MD, 2007, J EXP MED, V204, P1119, DOI 10.1084/jem.20061959; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; Brown NL, 1996, DEV BIOL, V179, P65, DOI 10.1006/dbio.1996.0241; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; Cadigan KM, 2002, DEVELOPMENT, V129, P3393; Campuzano S, 2001, ONCOGENE, V20, P8299, DOI 10.1038/sj.onc.1205162; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; Curtiss J, 2000, DEVELOPMENT, V127, P1325; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Domingos PM, 2004, DEV BIOL, V273, P121, DOI 10.1016/j.ydbio.2004.05.026; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Firth LC, 2006, METHOD ENZYMOL, V407, P711, DOI 10.1016/S0076-6879(05)07056-4; Garcia-Bellido A, 2009, GENETICS, V182, P631, DOI 10.1534/genetics.109.104083; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Giagtzoglou N, 2003, DEVELOPMENT, V130, P259, DOI 10.1242/dev.00206; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Gomez-Skarmeta J, 2003, NAT REV NEUROSCI, V4, P587, DOI 10.1038/nrn1142; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Greenwood S, 1999, DEVELOPMENT, V126, P5795; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Heng JIT, 2003, BIOESSAYS, V25, P709, DOI 10.1002/bies.10299; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Huang ML, 2000, NEURON, V25, P57, DOI 10.1016/S0896-6273(00)80871-5; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; Lee EC, 1996, MOL CELL BIOL, V16, P1179; Lee SH, 2011, MOL CANCER RES, V9, P782, DOI 10.1158/1541-7786.MCR-10-0535; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Melicharek D, 2008, GENETICS, V180, P2095, DOI 10.1534/genetics.108.093302; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Ozaki Y, 2005, J BIOCHEM, V137, P659, DOI 10.1093/jb/mvi084; Pi HW, 2004, P NATL ACAD SCI USA, V101, P8378, DOI 10.1073/pnas.0306010101; Roignant JY, 2009, INT J DEV BIOL, V53, P795, DOI 10.1387/ijdb.072483jr; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Schotte R, 2010, J IMMUNOL, V184, P6670, DOI 10.4049/jimmunol.0901508; Schwartz R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI 10.1073/pnas.0603728103; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Shoval O, 2010, CELL, V143, P326, DOI 10.1016/j.cell.2010.09.050; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; Smith JE, 2001, DEVELOPMENT, V128, P4705; Suel GM, 2006, NATURE, V440, P545, DOI 10.1038/nature04588; Sun Y, 1998, DEVELOPMENT, V125, P3731; VAESSIN H, 1994, DEVELOPMENT, V120, P935; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; Villa-Cuesta E, 2003, GENETICS, V163, P1403; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; White NM, 2000, DEVELOPMENT, V127, P1681; Wildonger J, 2005, DEV BIOL, V286, P507, DOI 10.1016/j.ydbio.2005.08.026; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223	75	59	63	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					881	892		10.1016/j.cell.2011.08.055	http://dx.doi.org/10.1016/j.cell.2011.08.055			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078884	Green Accepted, Bronze			2022-12-28	WOS:000296902300020
J	Powers, WJ; Clarke, WR; Grubb, RL; Videen, TO; Adams, HP; Derdeyn, CP				Powers, William J.; Clarke, William R.; Grubb, Robert L., Jr.; Videen, Tom O.; Adams, Harold P., Jr.; Derdeyn, Colin P.		COSS Investigators	Extracranial-Intracranial Bypass Surgery for Stroke Prevention in Hemodynamic Cerebral Ischemia The Carotid Occlusion Surgery Study Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; ARTERY OCCLUSION; ACETAZOLAMIDE; THROMBOLYSIS; REACTIVITY; PROGNOSIS; DISEASES; SCALE	Context Patients with symptomatic atherosclerotic internal carotid artery occlusion (AICAO) and hemodynamic cerebral ischemia are at high risk for subsequent stroke when treated medically. Objective To test the hypothesis that extracranial-intracranial (EC-IC) bypass surgery, added to best medical therapy, reduces subsequent ipsilateral ischemic stroke in patients with recently symptomatic AICAO and hemodynamic cerebral ischemia. Design Parallel-group, randomized, open-label, blinded-adjudication clinical treatment trial conducted from 2002 to 2010. Setting Forty-nine clinical centers and 18 positron emission tomography (PET) centers in the United States and Canada. The majority were academic medical centers. Participants Patients with arteriographically confirmed AICAO causing hemispheric symptoms within 120 days and hemodynamic cerebral ischemia identified by ipsilateral increased oxygen extraction fraction measured by PET. Of 195 patients who were randomized, 97 were randomized to receive surgery and 98 to no surgery. Follow-up for the primary end point until occurrence, 2 years, or termination of trial was 99% complete. No participant withdrew because of adverse events. Interventions Anastomosis of superficial temporal artery branch to a middle cerebral artery cortical branch for the surgical group. Antithrombotic therapy and risk factor intervention were recommended for all participants. Main Outcome Measure For all participants who were assigned to surgery and received surgery, the combination of (1) all stroke and death from surgery through 30 days after surgery and (2) ipsilateral ischemic stroke within 2 years of randomization. For the nonsurgical group and participants assigned to surgery who did not receive surgery, the combination of (1) all stroke and death from randomization to randomization plus 30 days and (2) ipsilateral ischemic stroke within 2 years of randomization. Results The trial was terminated early for futility. Two-year rates for the primary end point were 21.0% (95% CI, 12.8% to 29.2%; 20 events) for the surgical group and 22.7% (95% CI, 13.9% to 31.6%; 20 events) for the nonsurgical group (P=.78, Z test), a difference of 1.7% (95% CI, -10.4% to 13.8%). Thirty-day rates for ipsilateral ischemic stroke were 14.4% (14/97) in the surgical group and 2.0% (2/98) in the nonsurgical group, a difference of 12.4% (95% CI, 4.9% to 19.9%). Conclusion Among participants with recently symptomatic AICAO and hemodynamic cerebral ischemia, EC-IC bypass surgery plus medical therapy compared with medical therapy alone did not reduce the risk of recurrent ipsilateral ischemic stroke at 2 years.	[Powers, William J.] Univ N Carolina, Dept Neurol, Sch Med, Chapel Hill, NC 27599 USA; [Clarke, William R.] Univ Iowa, Coll Publ Hlth, Clin Trials Stat & Data Management Ctr, Iowa City, IA USA; [Grubb, Robert L., Jr.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO USA; [Videen, Tom O.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Derdeyn, Colin P.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Adams, Harold P., Jr.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Iowa; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Iowa	Powers, WJ (corresponding author), Univ N Carolina, Dept Neurol, Sch Med, Box 7025,Room 2131,170 Manning, Chapel Hill, NC 27599 USA.	powersw@neurology.unc.edu	Narayana, Shalini/F-3031-2010; Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028; Guzman, Raphael/0000-0001-9620-0581; Ponto, Laura/0000-0003-1197-6714; Jumaa, Mouhammad/0000-0002-7165-797X; Majid, Arshad/0000-0002-1144-039X; Derdeyn, Colin/0000-0002-5932-2683; Eidelberg, David/0000-0002-0854-864X; Malkoff, Marc/0000-0002-6665-3114	NIMH NIH HHS [K24 MH076955] Funding Source: Medline; NINDS NIH HHS [U01 NS042167, U01 NS041895, NS42157, R01 NS042157, NS39526, NS41895] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH076955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS039526, U01NS042167, U01NS041895, R01NS042157] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; DAY AL, 1986, SURG NEUROL, V26, P222, DOI 10.1016/0090-3019(86)90153-9; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Derdeyn CP, 1999, RADIOLOGY, V212, P499, DOI 10.1148/radiology.212.2.r99au27499; Derdeyn CP, 2000, J NUCL MED, V41, P800; Flaherty ML, 2004, STROKE, V35, pE349, DOI 10.1161/01.STR.0000135024.54608.3f; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; JET Study Group, 2002, SURG CEREB STROKE, V30, P434, DOI [DOI 10.2335/SCS.30.434, 10.2335/scs.30.434]; Lachin JM, 2005, STAT MED, V24, P2747, DOI 10.1002/sim.2151; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marquardt L, 2010, STROKE, V41, pE11, DOI 10.1161/STROKEAHA.109.561837; Ogasawara K, 2002, STROKE, V33, P1857, DOI 10.1161/01.STR.0000019511.81583.A8; Ogasawara Kuniaki, 2006, Nihon Rinsho, V64 Suppl 7, P524; Powers William J., 2003, Curr Treat Options Cardiovasc Med, V5, P501, DOI 10.1007/s11936-003-0039-3; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; SCHMIEDEK P, 1994, J NEUROSURG, V81, P236, DOI 10.3171/jns.1994.81.2.0236; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vilela MD, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E2; Wardlaw JM, 2000, STROKE, V31, P1133, DOI 10.1161/01.STR.31.5.1133; Williams LS, 1999, NEUROLOGY, V53, P1839, DOI 10.1212/WNL.53.8.1839; Williams LS, 1999, STROKE, V30, P1362, DOI 10.1161/01.STR.30.7.1362; Yamauchi H, 1999, J NUCL MED, V40, P1992; Yonas H, 1998, STROKE, V29, P1742; Zhang Y, 2010, CLIN TRIALS, V7, P209, DOI 10.1177/1740774510369686	28	429	473	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					1983	1992		10.1001/jama.2011.1610	http://dx.doi.org/10.1001/jama.2011.1610			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068990	Bronze, Green Accepted			2022-12-28	WOS:000296704300021
J	Chang, HJ; Liang, MH				Chang, Huan J.; Liang, Matthew H.			The Quiet Epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Liang, Matthew H.] Brigham & Womens Hosp, Rheumatol Sect, Boston VA Healthcare Syst, Rehabil Serv, Boston, MA 02115 USA; [Liang, Matthew H.] Brigham & Womens Hosp, Rheumatol Sect, Boston VA Healthcare Syst, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System		tina.chang@jama-archives.org						Lansdale TF, 2008, CLEV CLIN J MED, V75, P618, DOI 10.3949/ccjm.75.9.618	1	1	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1843	1844		10.1001/jama.2011.1587	http://dx.doi.org/10.1001/jama.2011.1587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045757				2022-12-28	WOS:000296376200001
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Online is not a private space	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2011	343								d7109	10.1136/bmj.d7109	http://dx.doi.org/10.1136/bmj.d7109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844QC	22049527				2022-12-28	WOS:000296761400005
J	Stott, R				Stott, Robin			PERSONAL VIEW Global health cannot be achieved without efforts to curb population growth	BRITISH MEDICAL JOURNAL			English	Editorial Material												stott@dircon.co.uk						[Anonymous], 2009, SPIRIT LEVEL; Commission on the Social Determinants of Health, 2008, CLOS GAP GEN HLTH EQ; *UN DAT, IR ISL REP OF; *UNFPA GUTTM I, 2009, ADD IT COSTS BEN INV; *UNICEF, EQ ACC ED; United Nations Development Programme, HUM DEV REP 2009	6	0	0	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 31	2011	343								d7003	10.1136/bmj.d7003	http://dx.doi.org/10.1136/bmj.d7003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844PP	22042756				2022-12-28	WOS:000296759900014
J	Somalwar, AM; Bhagat, JP; Rathi, CD				Somalwar, Ashutosh M.; Bhagat, Jitendra P.; Rathi, Chetan D.			I wonder what the mobile mass is?	LANCET			English	Editorial Material							WANDERING SPLEEN		[Somalwar, Ashutosh M.; Bhagat, Jitendra P.; Rathi, Chetan D.] Govt Med Coll & Hosp, Dept Internal Med, Nagpur 440003, Maharashtra, India		Somalwar, AM (corresponding author), Govt Med Coll & Hosp, Dept Internal Med, Nagpur 440003, Maharashtra, India.	amsomalwar@gmail.com						Abell I, 1933, ANN SURG, V98, P722, DOI 10.1097/00000658-193310000-00020; DeJohn Lucas, 2008, Radiol Case Rep, V3, P229, DOI 10.2484/rcr.v3i4.229; Kenningham R, 2002, J ROY SOC MED, V95, P460, DOI 10.1258/jrsm.95.9.460; Soleimani M, 2007, SURG TODAY, V37, P261, DOI 10.1007/s00595-006-3389-0	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 29	2011	378	9802					1604	1604		10.1016/S0140-6736(11)61183-5	http://dx.doi.org/10.1016/S0140-6736(11)61183-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844SL	22035554				2022-12-28	WOS:000296767500026
J	O'Brien, LE; Soliman, SS; Li, XH; Bilder, D				O'Brien, Lucy Erin; Soliman, Sarah S.; Li, Xinghua; Bilder, David			Altered Modes of Stem Cell Division Drive Adaptive Intestinal Growth	CELL			English	Article							BACTERIAL-INFECTION; TISSUE HOMEOSTASIS; DROSOPHILA MIDGUT; SELF-RENEWAL; INSULIN; PROLIFERATION; METABOLISM; PEPTIDES; GUT	Throughout life, adult organs continually adapt to variable environmental factors. Adaptive mechanisms must fundamentally differ from homeostatic maintenance, but little is known about how physiological factors elicit tissue remodeling. Here, we show that specialized stem cell responses underlie the adaptive resizing of a mature organ. In the adult Drosophila midgut, intestinal stem cells interpret a nutrient cue to "break homeostasis" and drive growth when food is abundant. Activated in part by niche production of insulin, stem cells direct a growth program through two altered modes of behavior: accelerated division rates and predominance of symmetric division fates. Together, these altered modes produce a net increase in total intestinal cells, which is reversed upon withdrawal of food. Thus, tissue renewal programs are not committed to maintain cellular equilibrium; stem cells can remodel organs in response to physiological triggers.	[O'Brien, Lucy Erin; Soliman, Sarah S.; Li, Xinghua; Bilder, David] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Bilder, D (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	bilder@berkeley.edu		Bilder, David/0000-0002-1842-4966	NIH [K01DK083505, R01GM068675, R01GM090150]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK083505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068675, R01GM084947, R01GM090150] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We appreciate generous gifts of reagents from the following: B. Ohlstein, B. Edgar, J. Veenstra, H. Stocker, E. Rulifson, L. Jones, T. Lee, and the Bloomington Drosophila Stock Center. We thank TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947) for fly stocks and S. Stowers and the Developmental Studies Hybridoma Bank for antibodies. We are particularly grateful to B. Ohlstein for technical advice and helpful discussions. We further thank J. Freimer for MATLAB coding and T. Nystul, S. Siegrist, J. Thaler, K. Siller, L. Skwarek, A. Wurmser, L. Jones, J. Schoenfeld, and I. Hariharan for invaluable comments. L.E.O. was a Genentech Foundation Fellow of the Life Sciences Research Foundation and is supported by NIH K01DK083505. This work was supported by NIH R01GM068675 and R01GM090150 to D.B.	Ambrosio F, 2009, AM J PHYS MED REHAB, V88, P145, DOI 10.1097/PHM.0b013e3181951fc5; Amcheslavsky A, 2009, CELL STEM CELL, V4, P49, DOI 10.1016/j.stem.2008.10.016; Apidianakis Y, 2009, P NATL ACAD SCI USA, V106, P20883, DOI 10.1073/pnas.0911797106; Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024; Biteau B, 2011, DEVELOPMENT, V138, P1045, DOI 10.1242/dev.056671; Biteau B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001159; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; BROWN HO, 1963, AM J PHYSIOL, V205, P868, DOI 10.1152/ajplegacy.1963.205.5.868; Buchon N, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-152; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; CAREY HV, 1990, AM J PHYSIOL, V259, pR385, DOI 10.1152/ajpregu.1990.259.2.R385; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chell JM, 2010, CELL, V143, P1161, DOI 10.1016/j.cell.2010.12.007; Drozdowski L, 2006, WORLD J GASTROENTERO, V12, P4614, DOI 10.3748/wjg.v12.i29.4614; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Dunel-Erb S, 2001, COMP BIOCHEM PHYS A, V129, P933, DOI 10.1016/S1095-6433(01)00360-9; HARRISON DA, 1993, CURR BIOL, V3, P424, DOI 10.1016/0960-9822(93)90349-S; Hsu HJ, 2008, DEV BIOL, V313, P700, DOI 10.1016/j.ydbio.2007.11.006; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Jiang HQ, 2011, CELL STEM CELL, V8, P84, DOI 10.1016/j.stem.2010.11.026; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Koury MJ, 2005, EXP HEMATOL, V33, P1263, DOI 10.1016/j.exphem.2005.06.031; LaFever L, 2005, SCIENCE, V309, P1071, DOI 10.1126/science.1111410; Lander AD, 2009, PLOS BIOL, V7, P84, DOI 10.1371/journal.pbio.1000015; Lee WC, 2009, DEVELOPMENT, V136, P2255, DOI 10.1242/dev.035196; Lin GN, 2008, NATURE, V455, P1119, DOI 10.1038/nature07329; Losick VP, 2011, DEV CELL, V21, P159, DOI 10.1016/j.devcel.2011.06.018; Mathur D, 2010, SCIENCE, V327, P210, DOI 10.1126/science.1181958; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; McLeod CJ, 2010, CURR BIOL, V20, P2100, DOI 10.1016/j.cub.2010.10.038; Meyers LA, 2002, TRENDS ECOL EVOL, V17, P551, DOI 10.1016/S0169-5347(02)02633-2; Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371; Miller A., 1950, BIOL DROSOPHILA, P420; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Ohlstein B, 2007, SCIENCE, V315, P988, DOI 10.1126/science.1136606; Pellettieri J, 2007, ANNU REV GENET, V41, P83, DOI 10.1146/annurev.genet.41.110306.130244; Piersma T, 1997, TRENDS ECOL EVOL, V12, P134, DOI 10.1016/S0169-5347(97)01003-3; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Secor SM, 1998, NATURE, V395, P659, DOI 10.1038/27131; Siegrist SE, 2010, CURR BIOL, V20, P643, DOI 10.1016/j.cub.2010.01.060; Simons BD, 2011, CELL, V145, P851, DOI 10.1016/j.cell.2011.05.033; Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867; Veenstra JA, 2008, CELL TISSUE RES, V334, P499, DOI 10.1007/s00441-008-0708-3; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; WINESETT DE, 1995, AM J PHYSIOL-GASTR L, V268, pG631, DOI 10.1152/ajpgi.1995.268.4.G631; Yu HH, 2009, NAT NEUROSCI, V12, P947, DOI 10.1038/nn.2345	48	283	285	0	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					603	614		10.1016/j.cell.2011.08.048	http://dx.doi.org/10.1016/j.cell.2011.08.048			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036568	Bronze, Green Accepted			2022-12-28	WOS:000296573700015
J	Tatem, AJ; Smith, DL; Gething, PW; Kabaria, CW; Snow, RW; Hay, SI				Tatem, A. J.; Smith, D. L.; Gething, P. W.; Kabaria, C. W.; Snow, R. W.; Hay, S., I			Ranking of elimination feasibility between malaria-endemic countries. (vol 376, pg 1579, 2010)	LANCET			English	Correction													Gething, Peter/GQR-1884-2022; Hay, Simon Iain/F-8967-2015; Smith, David L/L-8850-2013; Gething, Peter/ABD-2110-2020; Morote Robles, Juan/M-6914-2017	Gething, Peter/0000-0001-6759-5449; Hay, Simon Iain/0000-0002-0611-7272; Smith, David L/0000-0003-4367-3849; TOMBAL, Bertrand/0000-0002-0093-8408; Morote Robles, Juan/0000-0002-2168-323X	NCI NIH HHS [K24 CA121990] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3	1	115	120	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2011	377	9759					30	30						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709MQ	22093187	Green Accepted			2022-12-28	WOS:000286445200027
J	Huang, JF; Millis, JM; Mao, YL; Millis, MA; Sang, XT; Zhong, SX				Huang, Jiefu; Millis, J. Michael; Mao, Yilei; Millis, M. Andrew; Sang, Xinting; Zhong, Shouxian			A pilot programme of organ donation after cardiac death in China	LANCET			English	Article							DONOR LIVER-TRANSPLANTATION; HEART-BEATING DONORS; EXECUTED PRISONERS; OUTCOMES; POLICY	China's aims are to develop an ethical and sustainable organ transplantation system for the Chinese people and to be accepted as a responsible member of the international transplantation community. In 2007, China implemented the Regulation on Human Organ Transplantation, which was the first step towards the establishment of a voluntary organ donation system. Although progress has been made, several ethical and legal issues associated with transplantation in China remain, including the use of organs from executed prisoners, organ scarcity, the illegal organ trade, and transplantation tourism. In this Health Policy article we outline the standards used to define cardiac death in China and a legal and procedural framework for an organ donation system based on voluntary donation after cardiac death that adheres to both China's social and cultural principles and international transplantation standards.	[Huang, Jiefu; Mao, Yilei; Sang, Xinting; Zhong, Shouxian] Beijing Union Med Coll Hosp, Dept Liver Surg, Beijing 100730, Peoples R China; [Millis, J. Michael; Millis, M. Andrew] Univ Chicago, Sect Transplantat Liver Transplantat & Hepatobili, Chicago, IL 60637 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; University of Chicago	Huang, JF (corresponding author), Beijing Union Med Coll Hosp, Dept Liver Surg, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.	jeffrey1301@hotmail.com	Millis, Michael/K-5346-2019		China Medical Board [CMB 06-837]	China Medical Board	This work was supported by a China Medical Board grant (CMB 06-837). We thank ST Fan, Youmin Wu, Haibo Wang, Zhonghua Chen, Yongfeng Liu, Zhongyang Shen, Xiaoshun He, Jiahong Dong, and Jiye Zhu for their kindly contributions to this work.	Adcock L, 2010, AM J TRANSPLANT, V10, P364, DOI 10.1111/j.1600-6143.2009.02950.x; [Anonymous], 2009, TRANSPLANT P, V41, P23; Cameron JS, 1999, KIDNEY INT, V55, P724, DOI 10.1046/j.1523-1755.1999.00286.x; Chen Z., 2006, AM J TRANSPLANT S, V6, P437; Chinese Ministry of Health, REG HUM ORG TRANSPL; Chinese Ministry of Health, 2011, CHIN J TRANSPLANT, V5, P72; Cronin DC, 2001, NEW ENGL J MED, V344, P1633, DOI 10.1056/NEJM200105243442112; Hillman H, 2001, BRIT MED J, V323, P1254, DOI 10.1136/bmj.323.7323.1254; Huang J, 2007, ZHONGHUA WAI KE ZA Z, V45, P297; Huang JF, 2007, LIVER TRANSPLANT, V13, P193, DOI 10.1002/lt.21081; Huang JF, 2008, LANCET, V372, P1937, DOI 10.1016/S0140-6736(08)61359-8; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893; Liu J, 2009, CAIJING MAGAZIN 0831, P63; Minister of Public Security Bureau of Traffic Authority, REP 2009 NAT ROAD TR; Ministry of Health, 2006, CHIN HLTH STAT YB; Sanchez-Fructuoso AI, 2000, J AM SOC NEPHROL, V11, P350, DOI 10.1681/ASN.V112350; Shah SA, 2006, CAN J GASTROENTEROL, V20, P339, DOI 10.1155/2006/320530; Shan J, 2009, CHINA DAILY     0826, P3; Shang XM, 2010, LANCET, V376, P1033, DOI 10.1016/S0140-6736(10)60937-3; Standard for Brain Death Decision Drafting Group Ministry of Health, 2003, CHIN MED J, V83, P262; Tibell A, 2007, TRANSPLANTATION, V84, P292, DOI 10.1097/01.tp.0000275181.33071.07; [吴洪艳 Wu Hongyan], 2008, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V12, P6125; Yongfeng L., 2009, CHIN J TRANSPLANT, V3, P4; Yuan D, 2011, HEPATOB PANCREAT DIS, V10, P480, DOI 10.1016/S1499-3872(11)60082-9; Zhenyu M., 2009, CHIN J TRANSPLANT, V3, P273	25	92	124	2	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 3	2012	379	9818					862	865		10.1016/S0140-6736(11)61086-6	http://dx.doi.org/10.1016/S0140-6736(11)61086-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	901RB	22078722				2022-12-28	WOS:000300983400036
J	Almadi, MA; Barkun, A; Brophy, J				Almadi, Majid A.; Barkun, Alan; Brophy, James			Antiplatelet and Anticoagulant Therapy in Patients With Gastrointestinal Bleeding An 86-Year-Old Woman With Peptic Ulcer Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DOSE ASPIRIN; PROTON PUMP INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EXPERT CONSENSUS DOCUMENT; ATRIAL-FIBRILLATION; GASTRODUODENAL ULCERS; CARDIOVASCULAR EVENTS; COST-EFFECTIVENESS; PREDICTING STROKE; ISCHEMIC EVENTS	Bleeding in the upper gastrointestinal tract is a common medical problem, with an incidence of 48 to 160 cases per 1000 adults per year and a mortality rate of 5% to 14%. The risk of gastrointestinal bleeding is increased with the use of antiplatelet medications including aspirin and clopidogrel, as well as warfarin or a combination of these medications. The recurrence rate for bleeding in patients who continue to take aspirin after an episode of peptic ulcer disease-related bleeding can reach up to 300 cases per 1000 person-years and varies by age, sex, and the use of nonsteroidal anti-inflammatory medications. Using the case of Ms S, an 86-year-old woman who presented to the emergency department with an episode of nonvariceal upper gastrointestinal tract bleeding, we address the management of patients who are receiving antiplatelet or anticoagulation therapy who present with gastrointestinal bleeding, including when to restart antiplatelet or anticoagulation therapy, interventions to reduce the risk of bleeding recurrence, and the potential for drug interactions between clopidogrel and proton pump inhibitors. JAMA. 2011;306(21):2367-2374	[Almadi, Majid A.] King Saud Univ, King Khalid Univ Hosp, Dept Med, Div Gastroenterol, Riyadh, Saudi Arabia; [Barkun, Alan; Brophy, James] McGill Univ, Dept Med, Montreal, PQ, Canada; [Barkun, Alan; Brophy, James] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Barkun, Alan; Brophy, James] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada; [Barkun, Alan; Brophy, James] McGill Univ, Ctr Hlth, Montreal, PQ, Canada	King Saud University; King Khalid University Hospital; McGill University; McGill University; McGill University; McGill University	Barkun, A (corresponding author), Montreal Gen Hosp, 650 Cedar Ave,D7-148, Montreal, PQ H3G 1A4, Canada.	alan.barkun@muhc.mcgill.ca	brophy, james/H-6673-2019; Almadi, Majid A/K-7819-2017	brophy, james/0000-0001-8049-6875; Almadi, Majid A/0000-0001-9917-2758	Olympus Canada Inc; Cook Canada Inc.	Olympus Canada Inc; Cook Canada Inc.	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Barkun reports receiving consultancy fees from Olympus Canada Inc and Cook Canada Inc. No other disclosures were reported.	Abraham NS, 2010, AM J GASTROENTEROL, V105, P2533, DOI 10.1038/ajg.2010.445; Adamopoulos AB, 2009, J CARDIOVASC PHARM, V54, P163, DOI 10.1097/FJC.0b013e3181af6d9c; Arisawa T, 2007, INT J MOL MED, V20, P373; Atkins D, 2004, GROUP, V328, P1490; Baradarian R, 2004, AM J GASTROENTEROL, V99, P619, DOI 10.1111/j.1572-0241.2004.04073.x; Barkun A, 2004, AM J GASTROENTEROL, V99, P1238, DOI 10.1111/j.1572-0241.2004.30272.x; Barkun AN, 2010, ANN INTERN MED, V152, P101, DOI 10.7326/0003-4819-152-2-201001190-00009; Barkun AN, 2010, ANN INTERN MED, V152, P52, DOI 10.7326/0003-4819-152-1-201001050-00183; Berger PB, 2010, CIRCULATION, V121, P2575, DOI 10.1161/CIRCULATIONAHA.109.895342; Bhatt DL, 2008, J AM COLL CARDIOL, V52, P1502, DOI 10.1016/j.jacc.2008.08.002; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334; Blackburn DE, 2010, PHARMACOTHERAPY, V30, P985, DOI 10.1592/phco.30.10.985; Brandt JT, 2007, J THROMB HAEMOST, V5, P2429, DOI 10.1111/j.1538-7836.2007.02775.x; Burger W, 2005, J INTERN MED, V257, P399, DOI 10.1111/j.1365-2796.2005.01477.x; Cairns JA, 2011, CAN J CARDIOL, V27, P74, DOI 10.1016/j.cjca.2010.11.007; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; Charlot M, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2690; CHOUDARI CP, 1994, GUT, V35, P464, DOI 10.1136/gut.35.4.464; Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Cryer B, 2010, GASTROENTEROLOGY, V138, P30, DOI 10.1053/j.gastro.2009.11.032; Lima JPD, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-81; Lima JPD, 2010, ANN INTERN MED, V153, P413, DOI 10.7326/0003-4819-153-6-201009210-00011; DeEugenio D, 2007, PHARMACOTHERAPY, V27, P691, DOI 10.1592/phco.27.5.691; Delaney JA, 2007, CAN MED ASSOC J, V177, P347, DOI 10.1503/cmaj.070186; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289; Friberg L, 2010, EUR HEART J, V31, P967, DOI 10.1093/eurheartj/ehn599; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Rodriguez LAG, 2011, CIRCULATION, V123, P1108, DOI 10.1161/CIRCULATIONAHA.110.973008; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hallas J, 2006, BMJ-BRIT MED J, V333, P726, DOI 10.1136/bmj.38947.697558.AE; Hansen ML, 2010, ARCH INTERN MED, V170, P1433, DOI 10.1001/archinternmed.2010.271; Hearnshaw SA, 2011, GUT, V60, P1327, DOI 10.1136/gut.2010.228437; Hearnshaw SA, 2010, GUT, V59, P1022, DOI 10.1136/gut.2008.174599; Hernandez-Diaz S, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-22; Hsiao FY, 2009, CLIN THER, V31, P2038, DOI 10.1016/j.clinthera.2009.09.005; Hsu PI, 2011, GASTROENTEROLOGY, V140, P791, DOI 10.1053/j.gastro.2010.11.056; Huang ES, 2011, AM J MED, V124, P426, DOI 10.1016/j.amjmed.2010.12.022; Kim KA, 2008, CLIN PHARMACOL THER, V84, P236, DOI 10.1038/clpt.2008.20; Kwok CS, 2011, BONE, V48, P768, DOI 10.1016/j.bone.2010.12.015; Lai KC, 2002, NEW ENGL J MED, V346, P2033, DOI 10.1056/NEJMoa012877; Laine L, 2006, ALIMENT PHARM THER, V24, P897, DOI 10.1111/j.1365-2036.2006.03077.x; Lanas A, 2007, AM J GASTROENTEROL, V102, P507, DOI 10.1111/j.1572-0241.2006.01062.x; Lassen A, 2006, AM J GASTROENTEROL, V101, P945, DOI 10.1111/j.1572-0241.2006.00518.x; Lau JY, 2011, DIGESTION, V84, P102, DOI 10.1159/000323958; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; Lewis JD, 2002, AM J GASTROENTEROL, V97, P2540; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Lu CC, 2005, AM J GASTROENTEROL, V100, P1274, DOI 10.1111/j.1572-0241.2005.40852.x; Marcil V, 2010, J BIOL CHEM, V285, P40448, DOI 10.1074/jbc.M110.155358; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Ng FH, 2003, ALIMENT PHARM THER, V18, P443, DOI 10.1046/j.1365-2036.2003.01693.x; Ng FH, 2010, GASTROENTEROLOGY, V138, P82, DOI 10.1053/j.gastro.2009.09.063; O'Donoghue ML, 2009, LANCET, V374, P989, DOI 10.1016/S0140-6736(09)61525-7; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; Rostom A, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002296, DOI 10.1002/14651858.CD002296]; Saini SD, 2011, ALIMENT PHARM THER, V34, P243, DOI 10.1111/j.1365-2036.2011.04707.x; Serebruany VL, 2004, AM J HEMATOL, V75, P40, DOI 10.1002/ajh.10451; Shiotani A, 2010, J GASTROEN HEPATOL, V25, pS31, DOI 10.1111/j.1440-1746.2009.06212.x; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simon T, 2011, CIRCULATION, V123, P474, DOI 10.1161/CIRCULATIONAHA.110.965640; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Small DS, 2008, J CLIN PHARMACOL, V48, P475, DOI 10.1177/0091270008315310; Sung JJY, 2010, ANN INTERN MED, V152, P1, DOI 10.7326/0003-4819-152-1-201001050-00179; Taha AS, 2009, LANCET, V374, P119, DOI 10.1016/S0140-6736(09)61246-0; Takahashi M, 1997, BIOCHEM BIOPH RES CO, V234, P493, DOI 10.1006/bbrc.1997.5974; Targownik LE, 2006, CLIN GASTROENTEROL H, V4, P1459, DOI 10.1016/j.cgh.2006.08.018; US Food and Drug Administration, 2010, FDA DRUG SAF COMM RE; Usman MHU, 2009, AM J CARDIOL, V103, P1107, DOI 10.1016/j.amjcard.2009.01.003; van Leerdam ME, 2003, AM J GASTROENTEROL, V98, P1494, DOI 10.1016/S0002-9270(03)00299-5; van Walraven C, 2006, CHEST, V129, P1155, DOI 10.1378/chest.129.5.1155; Wann LS, 2011, J AM COLL CARDIOL, V57, P1330, DOI 10.1016/j.jacc.2011.01.010; WHITTLE BJR, 1981, PROSTAGLANDINS, V21, P113, DOI 10.1016/0090-6980(81)90126-X; Wiedermann CJ, 2008, THROMB RES, V122, pS13, DOI 10.1016/S0049-3848(08)70004-5; Wolf AT, 2007, AM J GASTROENTEROL, V102, P290, DOI 10.1111/j.1572-0241.2006.00969.x; Yeomans ND, 2005, ALIMENT PHARM THER, V22, P795, DOI 10.1111/j.1365-2036.2005.02649.x; Yeomans N, 2008, AM J GASTROENTEROL, V103, P2465, DOI 10.1111/j.1572-0241.2008.01995.x	79	16	17	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2011	306	21					2367	2374		10.1001/jama.2011.1653	http://dx.doi.org/10.1001/jama.2011.1653			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856YH	22045703				2022-12-28	WOS:000297680300022
J	Wachsman, ED; Lee, KT				Wachsman, Eric D.; Lee, Kang Taek			Lowering the Temperature of Solid Oxide Fuel Cells	SCIENCE			English	Review							HIGH-PERFORMANCE; BILAYER ELECTROLYTES; ANODE MATERIALS; ION CONDUCTORS; SOFC CATHODES; IT-SOFC; CONDUCTIVITY; CERIA; MICROSTRUCTURE; PEROVSKITES	Fuel cells are uniquely capable of overcoming combustion efficiency limitations (e. g., the Carnot cycle). However, the linking of fuel cells (an energy conversion device) and hydrogen (an energy carrier) has emphasized investment in proton-exchange membrane fuel cells as part of a larger hydrogen economy and thus relegated fuel cells to a future technology. In contrast, solid oxide fuel cells are capable of operating on conventional fuels (as well as hydrogen) today. The main issue for solid oxide fuel cells is high operating temperature (about 800 degrees C) and the resulting materials and cost limitations and operating complexities (e. g., thermal cycling). Recent solid oxide fuel cells results have demonstrated extremely high power densities of about 2 watts per square centimeter at 650 degrees C along with flexible fueling, thus enabling higher efficiency within the current fuel infrastructure. Newly developed, high-conductivity electrolytes and nanostructured electrode designs provide a path for further performance improvement at much lower temperatures, down to similar to 350 degrees C, thus providing opportunity to transform the way we convert and store energy.	[Wachsman, Eric D.; Lee, Kang Taek] Univ Maryland, Energy Res Ctr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Wachsman, ED (corresponding author), Univ Maryland, Energy Res Ctr, College Pk, MD 20742 USA.	ewach@umd.edu	Lee, Kang Taek/AHC-8558-2022					Ahn JS, 2009, FUEL CELLS, V9, P643, DOI 10.1002/fuce.200900005; Ahn JS, 2009, ELECTROCHEM COMMUN, V11, P1504, DOI 10.1016/j.elecom.2009.05.041; Andersson DA, 2006, P NATL ACAD SCI USA, V103, P3518, DOI 10.1073/pnas.0509537103; Armstrong EN, 2011, J ELECTROCHEM SOC, V158, pB492, DOI 10.1149/1.3555122; Boivin JC, 1998, CHEM MATER, V10, P2870, DOI 10.1021/cm980236q; Coocia L. G., 1996, APPL SURF SCI, V96-98, P795; deSouza S, 1997, SOLID STATE IONICS, V98, P57, DOI 10.1016/S0167-2738(96)00525-5; Duncan KL, 2011, J POWER SOURCES, V196, P2445, DOI 10.1016/j.jpowsour.2010.10.034; EG&G Technical Services Inc, 2004, FUEL CELL HDB; EGUCHI K, 1992, SOLID STATE IONICS, V52, P165, DOI 10.1016/0167-2738(92)90102-U; Flipsen SFJ, 2006, J POWER SOURCES, V162, P927, DOI 10.1016/j.jpowsour.2005.07.007; Fu QX, 2006, J ELECTROCHEM SOC, V153, pD74, DOI 10.1149/1.2170585; Gourba E, 2003, IONICS, V9, P15, DOI 10.1007/BF02376531; He HP, 2005, ELECTROCHEM SOLID ST, V8, pA279, DOI 10.1149/1.1896469; Huang H, 2007, J ELECTROCHEM SOC, V154, pB20, DOI 10.1149/1.2372592; Huang YH, 2006, SCIENCE, V312, P254, DOI 10.1126/science.1125877; Jung DW, 2010, ACTA MATER, V58, P355, DOI 10.1016/j.actamat.2009.08.072; Mogensen M, 1996, SOLID STATE IONICS, V86-8, P1151, DOI 10.1016/0167-2738(96)00280-9; National Renewable Energy Laboratory, 2010, NRELBK6A1048265; Omar S, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2794725; Park JY, 2006, IONICS, V12, P15, DOI 10.1007/s11581-006-0010-x; Park JY, 2005, J AM CERAM SOC, V88, P2402, DOI 10.1111/j.1551-2916.2005.00475.x; Schafer F., 2004, INTERNAL COMBUSTION, P22; Sholklapper TZ, 2007, NANO LETT, V7, P2136, DOI 10.1021/nl071007i; Smith JR, 2009, SOLID STATE IONICS, V180, P90, DOI 10.1016/j.ssi.2008.10.017; Song CS, 2002, CATAL TODAY, V77, P17, DOI 10.1016/S0920-5861(02)00231-6; Srinivasan Venkat, 2008, BATTERIES VEHICULAR; STEELE BCH, 1995, SOLID STATE IONICS, V75, P157, DOI 10.1016/0167-2738(94)00182-R; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Sun CW, 2007, J POWER SOURCES, V171, P247, DOI 10.1016/j.jpowsour.2007.06.086; TAKAHASHI T, 1977, J APPL ELECTROCHEM, V7, P299, DOI 10.1007/BF01059169; Virkar AV, 2000, SOLID STATE IONICS, V131, P189, DOI 10.1016/S0167-2738(00)00633-0; Vohs JM, 2009, ADV MATER, V21, P943, DOI 10.1002/adma.200802428; Wachsman ED, 2004, J EUR CERAM SOC, V24, P1281, DOI 10.1016/S0955-2219(03)00509-0; Wachsman ED, 1997, J ELECTROCHEM SOC, V144, P233, DOI 10.1149/1.1837390; Will J, 2000, SOLID STATE IONICS, V131, P79, DOI 10.1016/S0167-2738(00)00624-X; Wray P, 2010, AM CERAM SOC BULL, V89, P25; Zhan ZL, 2005, SCIENCE, V308, P844, DOI 10.1126/science.1109213; Zhi MJ, 2011, ENERG ENVIRON SCI, V4, P417, DOI 10.1039/c0ee00358a	39	1694	1727	70	2288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					935	939		10.1126/science.1204090	http://dx.doi.org/10.1126/science.1204090			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096189				2022-12-28	WOS:000297101800044
J	Cooper, WO; Habel, LA; Sox, CM; Chan, KA; Arbogast, PG; Cheetham, TC; Murray, KT; Quinn, VP; Stein, CM; Callahan, ST; Fireman, BH; Fish, FA; Kirshner, HS; O'Duffy, A; Connell, FA; Ray, WA				Cooper, William O.; Habel, Laurel A.; Sox, Colin M.; Chan, K. Arnold; Arbogast, Patrick G.; Cheetham, T. Craig; Murray, Katherine T.; Quinn, Virginia P.; Stein, C. Michael; Callahan, S. Todd; Fireman, Bruce H.; Fish, Frank A.; Kirshner, Howard S.; O'Duffy, Anne; Connell, Frederick A.; Ray, Wayne A.			ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; ACUTE MYOCARDIAL-INFARCTION; SUDDEN-DEATH; STIMULANT-DRUGS; CARDIAC SAFETY; ADOLESCENTS; STROKE; TRIALS; RISK	BACKGROUND Adverse-event reports from North America have raised concern that the use of drugs for attention deficit-hyperactivity disorder (ADHD) increases the risk of serious cardiovascular events. METHODS We conducted a retrospective cohort study with automated data from four health plans (Tennessee Medicaid, Washington State Medicaid, Kaiser Permanente California, and OptumInsight Epidemiology), with 1,200,438 children and young adults between the ages of 2 and 24 years and 2,579,104 person-years of follow-up, including 373,667 person-years of current use of ADHD drugs. We identified serious cardiovascular events (sudden cardiac death, acute myocardial infarction, and stroke) from health-plan data and vital records, with end points validated by medical-record review. We estimated the relative risk of end points among current users, as compared with non-users, with hazard ratios from Cox regression models. RESULTS Cohort members had 81 serious cardiovascular events (3.1 per 100,000 person-years). Current users of ADHD drugs were not at increased risk for serious cardiovascular events (adjusted hazard ratio, 0.75; 95% confidence interval [CI], 0.31 to 1.85). Risk was not increased for any of the individual end points, or for current users as compared with former users (adjusted hazard ratio, 0.70; 95% CI, 0.29 to 1.72). Alternative analyses addressing several study assumptions also showed no significant association between the use of an ADHD drug and the risk of a study end point. CONCLUSIONS This large study showed no evidence that current use of an ADHD drug was associated with an increased risk of serious cardiovascular events, although the upper limit of the 95% confidence interval indicated that a doubling of the risk could not be ruled out. However, the absolute magnitude of such an increased risk would be low. (Funded by the Agency for Healthcare Research and Quality and the Food and Drug Administration.)	[Cooper, William O.] Vanderbilt Univ, Div Gen Pediat, Nashville, TN USA; [Callahan, S. Todd] Vanderbilt Univ, Div Adolescent Med, Nashville, TN USA; [Fish, Frank A.] Vanderbilt Univ, Dept Pediat, Div Pediat Cardiol, Nashville, TN USA; [Arbogast, Patrick G.] Vanderbilt Univ, Dept Biostat, Nashville, TN USA; [Cooper, William O.; Ray, Wayne A.] Vanderbilt Univ, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN USA; [Murray, Katherine T.] Vanderbilt Univ, Div Cardiol, Nashville, TN 37232 USA; [Stein, C. Michael] Vanderbilt Univ, Div Rheumatol, Nashville, TN USA; [Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Nashville, TN USA; [Kirshner, Howard S.; O'Duffy, Anne] Vanderbilt Univ, Stroke Div, Dept Neurol, Nashville, TN USA; [Habel, Laurel A.; Fireman, Bruce H.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA; [Sox, Colin M.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA; [Sox, Colin M.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; [Chan, K. Arnold] OptumInsight Epidemiol, Waltham, MA USA; [Cheetham, T. Craig] Kaiser Permanente So Calif, Pharm Analyt Serv, Pasadena, CA USA; [Quinn, Virginia P.] Kaiser Permanente So Calif, Res & Evaluat Dept, Pasadena, CA USA; [Connell, Frederick A.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Kaiser Permanente; Harvard University; Harvard Medical School; Boston University; Optum; Kaiser Permanente; Kaiser Permanente; University of Washington; University of Washington Seattle	Cooper, WO (corresponding author), Suite 313,Oxford House,1313 21st Ave S, Nashville, TN 37232 USA.	william.cooper@vanderbilt.edu		Chan, Kinwei/0000-0001-8161-1986; Habel, Laurel/0000-0002-7230-587X; Sox, Colin/0000-0002-0249-9656	Agency for Healthcare Research and Quality and the Food and Drug Administration; Agency for Healthcare Research and Quality, Department of Health and Human Services [HHSA290-2005-0042, HHSA290-2005-0033]; FDA [223-2005-10100C, 223-2005-10012, 223-2005-10006C, 223-2005-10012C]; Developing Evidence to Inform Decisions about Effectiveness program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096844] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality and the Food and Drug Administration; Agency for Healthcare Research and Quality, Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA(United States Department of Health & Human Services); Developing Evidence to Inform Decisions about Effectiveness program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the Agency for Healthcare Research and Quality and the Food and Drug Administration.; Supported by contracts (HHSA290-2005-0042, to Vanderbilt University; and HHSA290-2005-0033, to Harvard Pilgrim Health Care Institute) from the Agency for Healthcare Research and Quality, Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness program; and by contracts (223-2005-10100C, to Vanderbilt University; 223-2005-10012, to Kaiser Permanente Northern California; 223-2005-10006C, to OptumInsight Epidemiology; and 223-2005-10012C, to Harvard Pilgrim Health Care Institute) from the FDA.	Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; BRODERICK J, 1993, J CHILD NEUROL, V8, P250, DOI 10.1177/088307389300800308; Brown RT, 2005, PEDIATRICS, V115, pE749, DOI 10.1542/peds.2004-2560; Buck ML, 2002, PEDIAT PHARM, V8, P1; Elia J, 1999, NEW ENGL J MED, V340, P780, DOI 10.1056/NEJM199903113401007; Epstein AE, 1996, J AM COLL CARDIOL, V27, P433, DOI 10.1016/0735-1097(95)00482-3; Food and Drug Administration, 2006, DRUG SAF RISK MAN AD; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; Gould MS, 2009, AM J PSYCHIAT, V166, P992, DOI 10.1176/appi.ajp.2009.09040472; Granger BB, 2005, LANCET, V366, P2005, DOI 10.1016/S0140-6736(05)67760-4; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; Liu LY, 1999, CEREBROVASC DIS, V9, P224, DOI 10.1159/000015960; Mahaffey KW, 2005, AM J CARDIOL, V95, P1404, DOI 10.1016/j.amjcard.2005.02.005; Mahle WT, 2007, J PEDIATR-US, V151, P150, DOI 10.1016/j.jpeds.2007.02.045; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; McCarthy S, 2009, DRUG SAFETY, V32, P1089, DOI 10.2165/11317630-000000000-00000; Nissen SE, 2006, NEW ENGL J MED, V354, P1445, DOI 10.1056/NEJMp068049; Perrin JM, 2008, PEDIATRICS, V122, P451, DOI 10.1542/peds.2008-1573; Rappley MD, 2005, NEW ENGL J MED, V352, P165, DOI 10.1056/NEJMcp032387; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Ray WA, 2010, ANN INTERN MED, V152, P337, DOI 10.7326/0003-4819-152-6-201003160-00003; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schelleman H, 2011, PEDIATRICS, V127, P1102, DOI 10.1542/peds.2010-3371; SCHOENBERG BS, 1978, NEUROLOGY, V28, P763, DOI 10.1212/WNL.28.8.763; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Vetter R, 2009, CIRCULATION, V120, pE55, DOI 10.1161/CIRCULATIONAHA.109.192623; Vetter VL, 2008, CIRCULATION, V117, P2407, DOI 10.1161/CIRCULATIONAHA.107.189473; Visser S. N., 2010, Morbidity and Mortality Weekly Report, V59, P1439; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563; Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1; Wilens TE, 2006, PEDIATRICS, V118, P1215, DOI 10.1542/peds.2006-0942; Winterstein AG, 2007, PEDIATRICS, V120, pE1494, DOI 10.1542/peds.2007-0675; Winterstein AG, 2009, PEDIATRICS, V124, pE75, DOI 10.1542/peds.2008-3138	38	264	266	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2011	365	20					1896	1904		10.1056/NEJMoa1110212	http://dx.doi.org/10.1056/NEJMoa1110212			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848HG	22043968	Green Accepted			2022-12-28	WOS:000297041900008
J	Lauer, MS				Lauer, Michael S.			Cardiovascular Science in the Service of National Strength	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYPERTENSION		NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lauer, MS (corresponding author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Room 8128, Bethesda, MD 20892 USA.	lauerm@nhlbi.nih.gov	Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				Cutler DM, 2006, NEW ENGL J MED, V355, P920, DOI 10.1056/NEJMsa054744; Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650; Frieden TR, 2011, NEW ENGL J MED, V365, DOI [10.1056/NEJMp1110421, 10.1056/NEJMP1110421]; Harismendy O, 2011, NATURE, V470, P264, DOI 10.1038/nature09753; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Lee TH, 2007, NEW ENGL J MED, V357, P1175, DOI 10.1056/NEJMp078102; Tricoci P, 2009, JAMA-J AM MED ASSOC, V301, P831, DOI 10.1001/jama.2009.205; Varmus H., 2009, ART POLITICS SCI; Victor RG, 2011, ARCH INTERN MED, V171, P342, DOI 10.1001/archinternmed.2010.390; 2011, CONSUM REP, V76, P26	10	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2145	2146		10.1001/jama.2011.1669	http://dx.doi.org/10.1001/jama.2011.1669			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22089722				2022-12-28	WOS:000297013000021
J	Heyland, DK				Heyland, Daren K.			Late initiation of parenteral nutrition reduced length of intensive care unit stay	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Queens Univ, Kingston, ON, Canada	Queens University - Canada	Heyland, DK (corresponding author), Queens Univ, Kingston, ON, Canada.		Van den Berghe, Greet/J-6788-2018; Casaer, Michael/Y-7131-2019	Van den Berghe, Greet/0000-0002-5320-1362; Casaer, Michael/0000-0002-7087-0795				Clinical Evaluation Research Unit; Kingston General Hospital, 2000, TRIAL SUPPL PAR NUTR; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; University Hospital Geneva, 2000, IMP SPN INF RAT DUR	3	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-11	10.7326/0003-4819-155-10-201111150-02011	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084358				2022-12-28	WOS:000208885300010
J	Smith, KR; McCracken, JP; Weber, MW; Hubbard, A; Jenny, A; Thompson, LM; Balmes, J; Diaz, A; Arana, B; Bruce, N				Smith, Kirk R.; McCracken, John P.; Weber, Martin W.; Hubbard, Alan; Jenny, Alisa; Thompson, Lisa M.; Balmes, John; Diaz, Anaite; Arana, Byron; Bruce, Nigel			Effect of reduction in household air pollution on childhood pneumonia in Guatemala (RESPIRE): a randomised controlled trial	LANCET			English	Article							SYNCYTIAL VIRUS-INFECTION; PARTICULATE MATTER; BIOMASS COMBUSTION; CARBON-MONOXIDE; SOLID-FUEL; INDOOR; CHILDREN; EXPOSURE; WOOD; PARTICLES	Background Pneumonia causes more child deaths than does any other disease. Observational studies have indicated that smoke from household solid fuel is a significant risk factor that affects about half the world's children. We investigated whether an intervention to lower indoor wood smoke emissions would reduce pneumonia in children. Methods We undertook a parallel randomised controlled trial in highland Guatemala, in a population using open indoor wood fires for cooking. We randomly assigned 534 households with a pregnant woman or young infant to receive a woodstove with chimney (n=269) or to remain as controls using open woodfires (n=265), by concealed permuted blocks of ten homes. Fieldworkers visited homes every week until children were aged 18 months to record the child's health status. Sick children with cough and fast breathing, or signs of severe illness were referred to study physicians, masked to intervention status, for clinical examination. The primary outcome was physician-diagnosed pneumonia, without use of a chest radiograph. Analysis was by intention to treat (ITT). Infant 48-h carbon monoxide measurements were used for exposure-response analysis after adjustment for covariates. This trial is registered, number ISRCTN29007941. Findings During 29 125 child-weeks of surveillance of 265 intervention and 253 control children, there were 124 physician-diagnosed pneumonia cases in intervention households and 139 in control households (rate ratio [RR] 0.84, 95% CI 0.63-1.13; p=0.257). After multiple imputation, there were 149 cases in intervention households and 180 in controls (0.78, 0.59-1.06, p=0.095; reduction 22%, 95% CI -6% to 41%). ITT analysis was undertaken for secondary outcomes: all and severe fieldworker-assessed pneumonia; severe (hypoxaemic) physician-diagnosed pneumonia; and radio logically confirmed, RSV-negative, and RSV-positive pneumonia, both total and severe. We recorded significant reductions in the intervention group for three severe outcomes-fieldworker-assessed, physician-diagnosed, and RSV-negative pneumonia-but not for others. We identified no adverse effects from the intervention. The chimney stove reduced exposure by 50% on average (from 2.2 to 1.1 ppm carbon monoxide), but exposure distributions for the two groups overlapped substantially. In exposure-response analysis, a 50% exposure reduction was significantly associated with physician-diagnosed pneumonia (RR 0.82, 0.70-0.98), the greater precision resulting from less exposure misclassification compared with use of stove type alone in ITT analysis. Interpretation In a population heavily exposed to wood smoke from cooking, a reduction in exposure achieved with chimney stoves did not significantly reduce physician-diagnosed pneumonia for children younger than 18 months. The significant reduction of a third in severe pneumonia, however, if confirmed, could have important implications for reduction of child mortality. The significant exposure-response associations contribute to causal inference and suggest that stove or fuel interventions producing lower average exposures than these chimney stoves might be needed to substantially reduce pneumonia in populations heavily exposed to biomass fuel air pollution.	[Smith, Kirk R.; McCracken, John P.; Hubbard, Alan; Jenny, Alisa; Thompson, Lisa M.; Balmes, John] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Thompson, Lisa M.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA; [Balmes, John] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [McCracken, John P.] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA; [McCracken, John P.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Weber, Martin W.] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; [Diaz, Anaite; Arana, Byron] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala; [Bruce, Nigel] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool L69 3BX, Merseyside, England	University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; University of Geneva; World Health Organization; Universidad del Valle de Guatemala; University of Liverpool	Smith, KR (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 747 Univ Hall, Berkeley, CA 94720 USA.	krksmith@berkeley.edu	Balmes, John/L-6281-2019; Weber, Martin/GPW-6095-2022; Thompson, Lisa M./H-2059-2019	Thompson, Lisa M./0000-0002-8001-2057	US National Institute of Environmental Health Sciences; WHO; National Institute of Environmental Health Sciences (NIEHS) [R01ES010178]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010178] Funding Source: NIH RePORTER	US National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); WHO(World Health Organization); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	US National Institute of Environmental Health Sciences and WHO.; We thank R Acevedo, M de Campo, T Cherian, M Gotway, S Gove, A Khalakdina, R Klein, L Muhe, K Mulholland, S Qazi, M Schei, and J Sterne for advice and assistance, and acknowledge the efforts of the project data safety monitoring board. We appreciate the assistance and cooperation of our field team and participants and the Guatemala Ministry of Health. The National Institute of Environmental Health Sciences provided funding through a grant (NIEHS #R01ES010178). WHO provided funding for the RSV testing through a Technical Services Agreement. MWW is an employee of WHO, but acted in an independent role as a member of the research team; the opinions expressed in this paper are his and do not necessarily represent the position of WHO.	Akunne AF, 2006, INT J HYG ENVIR HEAL, V209, P445, DOI 10.1016/j.ijheh.2006.04.009; Albalak R, 2001, ENVIRON SCI TECHNOL, V35, P2650, DOI 10.1021/es001940m; ANKER M, 1999, STANDARD VERBAL AUTO; [Anonymous], 1992, LANCET, V339, P396; Benguigui Y, 1997, INFECCIONES RESPIRAT; Boy E, 2002, ENVIRON HEALTH PERSP, V110, P109, DOI 10.1289/ehp.02110109; Boy E., 2000, ENERGY SUSTAIN DEV, V4, P23, DOI [10.1016/S0973-0826(08)60239-2, DOI 10.1016/S0973-0826(08)60239-2]; Bruce N, 2004, J EXPO ANAL ENV EPID, V14, pS26, DOI 10.1038/sj.jea.7500355; Bruce N, 1998, INT J EPIDEMIOL, V27, P454, DOI 10.1093/ije/27.3.454; Bruce N, 2007, B WORLD HEALTH ORGAN, V85, P535, DOI 10.2471/BLT.06.035832; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P853; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; Djelantik IGG, 2003, PEDIATR INFECT DIS J, V22, P150, DOI 10.1097/00006454-200302000-00012; Efron B, 1993, MONOGRAPHS STAT APPL, p[179, 372]; ENGLE PL, 1998, HUM ORGAN, V54, P522; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; Ezzati M, 2001, ENVIRON HEALTH PERSP, V109, P481, DOI 10.2307/3454706; Ezzati M, 2004, COMP QUANTIFICATION; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Lanata CF, 2004, INT J EPIDEMIOL, V33, P1362, DOI 10.1093/ije/dyh229; Lundborg M, 2007, ENVIRON RES, V104, P250, DOI 10.1016/j.envres.2007.01.002; McCracken JP, 2009, EPIDEMIOLOGY, V20, P127, DOI 10.1097/EDE.0b013e31818ef327; McCracken JP, 1998, ENVIRON INT, V24, P739, DOI 10.1016/S0160-4120(98)00062-2; Mishra V, 2005, POPUL ENVIRON, V26, P375, DOI 10.1007/s1111-005-0005-y; Mishra V, 2003, INT J EPIDEMIOL, V32, P847, DOI 10.1093/ije/dyg240; Mulholland EK, 2008, B WORLD HEALTH ORGAN, V86, P399, DOI 10.2471/BLT.07.044545; Naeher LP, 2000, INDOOR AIR, V10, P200; Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g; Naeher LP, 2000, J EXPO ANAL ENV EPID, V10, P544, DOI 10.1038/sj.jea.7500113; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Neufeld LM, 2004, REV PANAM SALUD PUBL, V15, P110, DOI 10.1590/S1020-49892004000200006; Northcross A, 2010, J ENVIRON MONITOR, V12, P873, DOI 10.1039/b916068j; Ogra P. L., 2004, PAEDIAT RESP REV SA, V5, P119; Romieu I, 2002, J OCCUP ENVIRON MED, V44, P640, DOI 10.1097/00043764-200207000-00010; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Saksena S, 2003, INDOOR AIR POLLUTION; Smith KR, 2010, J EXPO SCI ENV EPID, V20, P406, DOI 10.1038/jes.2009.30; Thompson L, 2008, THESIS U CALIFORNIA; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x; Weber MW, 1999, INT J EPIDEMIOL, V28, P157, DOI 10.1093/ije/28.1.157; WHO, 2005, AIR QUAL GUID GLOB U; WHO UNICEF, 1997, INT MAN CHILDH ILLN; World Health Organization, 2008, GLOB BURD DIS 2004 U; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhou HW, 2007, AM J RESP CELL MOL, V36, P460, DOI 10.1165/rcmb.2006-0293OC	49	368	379	4	120	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2011	378	9804					1717	1726		10.1016/S0140-6736(11)60921-5	http://dx.doi.org/10.1016/S0140-6736(11)60921-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846LB	22078686				2022-12-28	WOS:000296899800029
J	Hulme, M; O'Neill, SJ; Dessai, S				Hulme, Mike; O'Neill, Saffron J.; Dessai, Suraje			Is Weather Event Attribution Necessary for Adaptation Funding?	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; IMPACTS; SCIENCE; MODELS		[Hulme, Mike] Univ E Anglia, Sch Environm Sci, Sci Soc & Sustainabil Grp 3S, Norwich NR4 7TJ, Norfolk, England; [O'Neill, Saffron J.] Univ Melbourne, Dept Resource Management & Geog, Melbourne, Vic 3010, Australia; [Dessai, Suraje] Univ Exeter, Coll Life & Environm Sci, Exeter EX4 4RJ, Devon, England	University of East Anglia; University of Melbourne; University of Exeter	Hulme, M (corresponding author), Univ E Anglia, Sch Environm Sci, Sci Soc & Sustainabil Grp 3S, Norwich NR4 7TJ, Norfolk, England.	m.hulme@uea.ac.uk	Hulme, Mike/F-9012-2010; Dessai, Suraje/D-4219-2009	Hulme, Mike/0000-0002-1273-7662; Dessai, Suraje/0000-0002-7879-9364; O'Neill, Saffron/0000-0002-9062-6247				Annan JD, 2010, WIRES CLIM CHANGE, V1, P486, DOI 10.1002/wcc.47; [Anonymous], 2009, EOS T AM GEOPHYS UN, DOI [10.1029/2009EO130003, DOI 10.1029/2009EO130003]; [Anonymous], PILOT PROGRAM CLIMAT; Barnett J, 2002, CLIM POLICY, V2, P231, DOI 10.1016/S1469-3062(02)00023-2; Beck S, 2011, REG ENVIRON CHANGE, V11, P297, DOI 10.1007/s10113-010-0136-2; Frame DJ, 2011, GEOGR J, V177, P138, DOI 10.1111/j.1475-4959.2010.00385.x; Gillis J., 2011, NY TIMES        0216, pA4; Hegerl G, 2011, WIRES CLIM CHANGE, V2, P570, DOI 10.1002/wcc.121; Hoegh-Guldberg O, 2011, NAT CLIM CHANGE, V1, P72, DOI 10.1038/nclimate1107; Hof AF, 2011, ENVIRON SCI POLICY, V14, P615, DOI 10.1016/j.envsci.2011.05.006; Klein RJT, 2011, IDS BULL-I DEV STUD, V42, P15, DOI 10.1111/j.1759-5436.2011.00218.x; Klein RJT, 2009, ADAPTING TO CLIMATE CHANGE: THRESHOLDS, VALUES, GOVERNANCE, P465; Klein RJT, 2005, ENVIRON SCI POLICY, V8, P579, DOI 10.1016/j.envsci.2005.06.010; ORESKES N, 1994, SCIENCE, V263, P641, DOI 10.1126/science.263.5147.641; Pall P, 2011, NATURE, V470, P382, DOI 10.1038/nature09762; Pielke RA, 2007, PHILOS T R SOC A, V365, P2717, DOI 10.1098/rsta.2007.2086; Sarewitz D, 2004, ENVIRON SCI POLICY, V7, P385, DOI 10.1016/j.envsci.2004.06.001; Smith JB, 2011, CLIM POLICY, V11, P987, DOI 10.1080/14693062.2011.582385; Stirling A, 2010, NATURE, V468, P1029, DOI 10.1038/4681029a; Stone DA, 2005, CLIMATIC CHANGE, V71, P303, DOI 10.1007/s10584-005-6778-2; UNCC, 2010, CANC CLIM CHANG C NO	21	71	72	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2011	334	6057					764	765		10.1126/science.1211740	http://dx.doi.org/10.1126/science.1211740			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	845US	22076365				2022-12-28	WOS:000296849600031
J	Saltiel, AR				Saltiel, Alan R.			Derepressing Nuclear Receptors for Metabolic Adaptation	CELL			English	Editorial Material							PPAR-GAMMA; CO-REPRESSOR; PHOSPHORYLATION	NCoR is a corepressor of several transcription factors, including the PPAR family of nuclear receptors in fat and muscle. By specifically deleting NCoR in these tissues, Li et al. and Yamamoto et al. now uncover an important role for NCoR in regulating lipid homeostasis through the coordinated control of different nuclear receptors.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	saltiel@lsi.umich.edu	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Guan YF, 2005, NAT MED, V11, P861, DOI 10.1038/nm1278; Li PP, 2011, CELL, V147, P815, DOI 10.1016/j.cell.2011.09.050; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Yamamoto H, 2011, CELL, V147, P827, DOI 10.1016/j.cell.2011.10.017	10	4	4	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					717	718		10.1016/j.cell.2011.10.027	http://dx.doi.org/10.1016/j.cell.2011.10.027			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078871	Bronze			2022-12-28	WOS:000296902300005
J	Walker, AK; Jacobs, RL; Watts, JL; Rottiers, V; Jiang, K; Finnegan, DM; Shioda, T; Hansen, M; Yang, F; Niebergall, LJ; Vance, DE; Tzoneva, M; Hart, AC; Naar, AM				Walker, Amy K.; Jacobs, Rene L.; Watts, Jennifer L.; Rottiers, Veerle; Jiang, Karen; Finnegan, Deirdre M.; Shioda, Toshi; Hansen, Malene; Yang, Fajun; Niebergall, Lorissa J.; Vance, Dennis E.; Tzoneva, Monika; Hart, Anne C.; Naeaer, Anders M.			A Conserved SREBP-1/Phosphatidylcholine Feedback Circuit Regulates Lipogenesis in Metazoans	CELL			English	Article							PHOSPHATIDYLETHANOLAMINE-N-METHYLTRANSFERASE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE-ALPHA; ENDOPLASMIC-RETICULUM STRESS; NUCLEOTIDE-EXCHANGE PROTEIN; FATTY-ACID SYNTHESIS; PLASMA HIGH-DENSITY; CAENORHABDITIS-ELEGANS; HEPATIC STEATOSIS; LIVER-DISEASE; BREFELDIN-A	Sterol regulatory element-binding proteins (SREBPs) activate genes involved in the synthesis and trafficking of cholesterol and other lipids and are critical for maintaining lipid homeostasis. Aberrant SREBP activity, however, can contribute to obesity, fatty liver disease, and insulin resistance, hallmarks of metabolic syndrome. Our studies identify a conserved regulatory circuit in which SREBP-1 controls genes in the one-carbon cycle, which produces the methyl donor S-adenosylmethionine (SAMe). Methylation is critical for the synthesis of phosphatidylcholine (PC), a major membrane component, and we find that blocking SAMe or PC synthesis in C. elegans, mouse liver, and human cells causes elevated SREBP-1-dependent transcription and lipid droplet accumulation. Distinct from negative regulation of SREBP-2 by cholesterol, our data suggest a feedback mechanism whereby maturation of nuclear, transcriptionally active SREBP-1 is controlled by levels of PC. Thus, nutritional or genetic conditions limiting SAMe or PC production may activate SREBP-1, contributing to human metabolic disorders.	[Walker, Amy K.; Jiang, Karen; Finnegan, Deirdre M.; Shioda, Toshi; Yang, Fajun; Hart, Anne C.; Naeaer, Anders M.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Rottiers, Veerle; Yang, Fajun; Naeaer, Anders M.] Harvard Univ, Dept Cell Biol, Sch Med, Boston, MA 02115 USA; [Jacobs, Rene L.] Univ Alberta, Dept Agr Food & Nutr Sci, Ag Ctr D 1 32, Edmonton, AB T6G 2M7, Canada; [Watts, Jennifer L.; Tzoneva, Monika] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; [Hansen, Malene] Sanford Burnham Inst Med Res, La Jolla, CA 92037 USA; [Niebergall, Lorissa J.; Vance, Dennis E.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2M7, Canada	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Alberta; Washington State University; Sanford Burnham Prebys Medical Discovery Institute; University of Alberta	Walker, AK (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.	amy_walker@mac.com; naar@helix.mgh.harvard.edu	Watts, Jennifer/AAC-7425-2020	Watts, Jennifer/0000-0003-4349-0639; Jacobs, Rene/0000-0002-5525-1355	Claflin Distinguished Scholar Award [R01DK084352]; The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School; NIH [R01DK078332, R01GM071449, R01DK074114]; Canadian Institutes of Health Research [MOP 5182, 4487]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074114, R01DK078332, R01DK093623, R01DK084352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071449] Funding Source: NIH RePORTER	Claflin Distinguished Scholar Award; The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Keith Blackwell for advice on examining ER stress in C. elegans as well as members of the Naar lab and Drs. Nick Dyson, Johnathan Whetstine, Andrew Gladden, and Tom Rapoport for helpful discussions. We express our gratitude to Drs. Stefan Taubert and Raul Mostoslavsky for critical reading of the manuscript. We thank Dr. Michael Brown for the SRD13A, SCAP-deficient cells and Dr. Joachim Seemann for advice on S1P staining. We thank the Caenorhabditis Genetics Center for strains. Funding for A. K. W. was provided by the Claflin Distinguished Scholar Award and R01DK084352. Funding for A.M.N. was provided by The Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School and the following grants from NIH: R01DK078332 and R01GM071449. Funding for J.L.W. was provided by NIH grant R01DK074114. Funding for research in the D.E.V. and R.L.J. labs was from the Canadian Institutes of Health Research (MOP 5182 and 4487).	Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bartz R, 2008, EMBO J, V27, P948, DOI 10.1038/emboj.2008.36; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Brendza KM, 2007, BIOCHEM J, V404, P439, DOI 10.1042/BJ20061815; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Citterio C, 2008, P NATL ACAD SCI USA, V105, P2877, DOI 10.1073/pnas.0712224105; Colombo C, 1998, SEMIN LIVER DIS, V18, P227, DOI 10.1055/s-2007-1007159; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Ferre P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/j.1463-1326.2010.01275.x; Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968; Guo Y, 2008, NATURE, V453, P657, DOI 10.1038/nature06928; Hagen RM, 2010, FEBS LETT, V584, P2689, DOI 10.1016/j.febslet.2010.04.004; Hansen M, 2005, PLOS GENET, V1, P119, DOI 10.1371/journal.pgen.0010017; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Innis SM, 2007, AM J CLIN NUTR, V85, P702, DOI 10.1093/ajcn/85.3.702; Jacobs RL, 2008, J BIOL CHEM, V283, P2147, DOI 10.1074/jbc.M706628200; Jacobs RL, 2010, J BIOL CHEM, V285, P22403, DOI 10.1074/jbc.M110.108514; Jacobs RL, 2004, J BIOL CHEM, V279, P47402, DOI 10.1074/jbc.M404027200; Jacobs RL, 2005, J BIOL CHEM, V280, P28299, DOI 10.1074/jbc.M501971200; Kharbanda KK, 2009, SEMIN LIVER DIS, V29, P155, DOI 10.1055/s-0029-1214371; Larter CZ, 2008, J GASTROEN HEPATOL, V23, P1635, DOI 10.1111/j.1440-1746.2008.05543.x; Lev S, 2006, BIOCHEM SOC T, V34, P363, DOI 10.1042/BST0340363; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; Lim HY, 2011, GENE DEV, V25, P189, DOI 10.1101/gad.1992411; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Mato JM, 2005, HEPATOLOGY, V41, P976, DOI 10.1002/hep.20708; Mato JM, 2008, ANNU REV NUTR, V28, P273, DOI 10.1146/annurev.nutr.28.061807.155438; Osborne TF, 2009, GENE DEV, V23, P2578, DOI 10.1101/gad.1854309; Palavalli LH, 2006, BIOCHEMISTRY-US, V45, P6056, DOI 10.1021/bi060199d; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Song JN, 2005, FASEB J, V19, P1266, DOI 10.1096/fj.04-3580com; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Testerink N, 2009, J LIPID RES, V50, P2182, DOI 10.1194/jlr.M800660-JLR200; Vance DE, 2007, J BIOL CHEM, V282, P33237, DOI 10.1074/jbc.R700028200; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210; Watkins SM, 2003, J NUTR, V133, P3386, DOI 10.1093/jn/133.11.3386; Watts JL, 2006, DEV BIOL, V292, P381, DOI 10.1016/j.ydbio.2006.01.013; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zeisel SH, 2008, BRAIN RES, V1237, P5, DOI 10.1016/j.brainres.2008.08.059	55	264	284	1	45	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					840	852		10.1016/j.cell.2011.09.045	http://dx.doi.org/10.1016/j.cell.2011.09.045			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22035958	Bronze, Green Accepted			2022-12-28	WOS:000296902300017
J	Hakkinen, S; Rhines, PB; Worthen, DL				Haekkinen, Sirpa; Rhines, Peter B.; Worthen, Denise L.			Atmospheric Blocking and Atlantic Multidecadal Ocean Variability	SCIENCE			English	Article							NORTH-ATLANTIC; OSCILLATION; WINTER; HEMISPHERE; TIME	Atmospheric blocking over the northern North Atlantic, which involves isolation of large regions of air from the westerly circulation for 5 days or more, influences fundamentally the ocean circulation and upper ocean properties by affecting wind patterns. Winters with clusters of more frequent blocking between Greenland and western Europe correspond to a warmer, more saline subpolar ocean. The correspondence between blocked westerly winds and warm ocean holds in recent decadal episodes (especially 1996 to 2010). It also describes much longer time scale Atlantic multidecadal ocean variability (AMV), including the extreme pre-greenhouse-gas northern warming of the 1930s to 1960s. The space-time structure of the wind forcing associated with a blocked regime leads to weaker ocean gyres and weaker heat exchange, both of which contribute to the warm phase of AMV.	[Haekkinen, Sirpa; Worthen, Denise L.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Rhines, Peter B.] Univ Washington, Seattle, WA 98195 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Washington; University of Washington Seattle	Hakkinen, S (corresponding author), NASA, Goddard Space Flight Ctr, Code 615, Greenbelt, MD 20771 USA.	sirpa.hakkinen@nasa.gov	Hakkinen, Sirpa/E-1461-2012		NASA; Ocean Surface Topography (OST) Science Team; NASA through the OST Science Team	NASA(National Aeronautics & Space Administration (NASA)); Ocean Surface Topography (OST) Science Team; NASA through the OST Science Team	S.H. and D.L.W. were funded by NASA Headquarters Physical Oceanography Program and Ocean Surface Topography (OST) Science Team. P. B. R. is supported by NASA through the OST Science Team. We thank our reviewers for constructive criticism.	Barriopedro D, 2006, J CLIMATE, V19, P1042, DOI 10.1175/JCLI3678.1; Barsugli JJ, 1998, J ATMOS SCI, V55, P477, DOI 10.1175/1520-0469(1998)055<0477:TBEOAO>2.0.CO;2; Cassou C, 2004, J CLIMATE, V17, P1055, DOI 10.1175/1520-0442(2004)017<1055:NAWCRS>2.0.CO;2; Cattiaux J, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044613; Compo GP, 2011, Q J ROY METEOR SOC, V137, P1, DOI 10.1002/qj.776; Compo GP, 2006, B AM METEOROL SOC, V87, P175, DOI 10.1175/BAMS-87-2-175; Croci-Maspoli M, 2007, CLIM DYNAM, V29, P713, DOI 10.1007/s00382-007-0259-4; Croci-Maspoli M, 2009, MON WEATHER REV, V137, P664, DOI 10.1175/2008MWR2533.1; Delworth TL, 2000, CLIM DYNAM, V16, P661, DOI 10.1007/s003820000075; DESER C, 1993, J CLIMATE, V6, P1743, DOI 10.1175/1520-0442(1993)006<1743:SCVOTN>2.0.CO;2; Enfield DB, 2001, GEOPHYS RES LETT, V28, P2077, DOI 10.1029/2000GL012745; Hakkinen S, 2011, J GEOPHYS RES-OCEANS, V116, DOI 10.1029/2010JC006275; Hakkinen S, 2004, SCIENCE, V304, P555, DOI 10.1126/science.1094917; Hakkinen S, 2009, J GEOPHYS RES-OCEANS, V114, DOI 10.1029/2008JC004883; Hurrell JW, 2010, J MARINE SYST, V79, P231, DOI 10.1016/j.jmarsys.2009.11.002; Knight JR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026242; KUSHNIR Y, 1994, J CLIMATE, V7, P141, DOI 10.1175/1520-0442(1994)007<0141:IVINAS>2.0.CO;2; Miller L, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030862; Polyakov IV, 2010, CLIM DYNAM, V34, P439, DOI 10.1007/s00382-008-0522-3; Rimbu E., 2009, CLIM PAST DISCUSS, V5, P2411; Scherrer SC, 2006, INT J CLIMATOL, V26, P233, DOI 10.1002/joc.1250; Shabbar A, 2001, INT J CLIMATOL, V21, P355, DOI 10.1002/joc.612; Tibaldi S., 1990, TELLUS, V42A, P343, DOI [10.3402/tellusa.v42i3.11882, DOI 10.1034/J.1600-0870.1990.T01-2-00003.X, DOI 10.3402/TELLUSA.V42I3.11882]; Ting MF, 2009, J CLIMATE, V22, P1469, DOI 10.1175/2008JCLI2561.1; Trenberth KE, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026894; Woollings T, 2008, J ATMOS SCI, V65, P609, DOI 10.1175/2007JAS2347.1; Woollings T, 2010, J CLIMATE, V23, P1291, DOI 10.1175/2009JCLI3087.1	27	220	221	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2011	334	6056					655	659		10.1126/science.1205683	http://dx.doi.org/10.1126/science.1205683			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053046	Green Submitted			2022-12-28	WOS:000296494700051
J	Hsin, JP; Sheth, A; Manley, JL				Hsin, Jing-Ping; Sheth, Amit; Manley, James L.			RNAP II CTD Phosphorylated on Threonine-4 Is Required for Histone mRNA 3 ' End Processing	SCIENCE			English	Article							CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II; GENE-EXPRESSION; P-TEFB; TRANSCRIPTION; SERINE-7; ASF/SF2; EVENTS	The RNA polymerase II (RNAP II) largest subunit contains a C-terminal domain (CTD) with up to 52 Tyr(1)-Ser(2)-Pro(3)-Thr(4)-Ser(5)-Pro(6)-Ser(7) consensus repeats. Serines 2, 5, and 7 are known to be phosphorylated, and these modifications help to orchestrate the interplay between transcription and processing of messenger RNA (mRNA) precursors. Here, we provide evidence that phosphorylation of CTD Thr(4) residues is required specifically for histone mRNA 3' end processing, functioning to facilitate recruitment of 3' processing factors to histone genes. Like Ser(2), Thr(4) phosphorylation requires the CTD kinase CDK9 and is evolutionarily conserved from yeast to human. Our data thus illustrate how a CTD modification can play a highly specific role in facilitating efficient gene expression.	[Hsin, Jing-Ping; Sheth, Amit; Manley, James L.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu	Sheth, Amit/ABC-4600-2020	Sheth, Amit/0000-0002-0021-5293; Manley, James/0000-0002-8341-1459	NIH [R01 GM28983]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T. Kashima for plasmids and help with construction of the DT40-Rpb1 cell line, W. Marzluff for the SLBP antibody, Z. Dominski for the Lsm11 antibody, and Novus Biologicals for the P-Thr4 antibody. This work was supported by NIH grant R01 GM28983.	Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chapman RD, 2005, MOL CELL BIOL, V25, P7665, DOI 10.1128/MCB.25.17.7665-7674.2005; Chapman RD, 2007, SCIENCE, V318, P1780, DOI 10.1126/science.1145977; Chen CY, 1996, MOL CELL BIOL, V16, P6582; Egloff S, 2007, SCIENCE, V318, P1777, DOI 10.1126/science.1145989; Hirose Y, 2000, GENE DEV, V14, P1415; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Marzluff WF, 2008, NAT REV GENET, V9, P843, DOI 10.1038/nrg2438; Moore MJ, 2009, CELL, V136, P688, DOI 10.1016/j.cell.2009.02.001; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Rozenblatt-Rosen O, 2009, P NATL ACAD SCI USA, V106, P755, DOI 10.1073/pnas.0812023106; Sakurai H, 2002, GENES CELLS, V7, P273, DOI 10.1046/j.1365-2443.2002.00522.x; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Sullivan KD, 2009, RNA, V15, P459, DOI 10.1261/rna.1205409; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222	21	111	112	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					683	686		10.1126/science.1206034	http://dx.doi.org/10.1126/science.1206034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053051	Green Accepted			2022-12-28	WOS:000296494700058
J	Mottron, L				Mottron, Laurent			The power of autism	NATURE			English	Editorial Material									[Mottron, Laurent] Univ Montreal, Montreal, PQ H3C 3J7, Canada; [Mottron, Laurent] Hosp Riviere des Prairies, Autism Programme, Montreal, PQ H1E 1A4, Canada	Universite de Montreal	Mottron, L (corresponding author), Univ Montreal, Montreal, PQ H3C 3J7, Canada.	mottronl@uniserve.com		Mottron, Laurent/0000-0001-5668-5422				Dawson M, 2007, PSYCHOL SCI, V18, P657, DOI 10.1111/j.1467-9280.2007.01954.x; Gaffrey MS, 2007, NEUROPSYCHOLOGIA, V45, P1672, DOI 10.1016/j.neuropsychologia.2007.01.008; GERNSBACHER MA, 2007, OBSERVER, V20, P43; Heaton P, 2003, J CHILD PSYCHOL PSYC, V44, P543, DOI 10.1111/1469-7610.00143; Mottron L, 2009, PHILOS T R SOC B, V364, P1385, DOI 10.1098/rstb.2008.0333; Pellicano E, 2006, DEV PSYCHOPATHOL, V18, P77, DOI 10.1017/S0954579406060056; Perreault A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019519; Plaisted K, 1998, J CHILD PSYCHOL PSYC, V39, P765, DOI 10.1111/1469-7610.00375; Samson F, 2011, HUM BRAIN MAPP; Soulieres I, 2009, HUM BRAIN MAPP, V30, P4082, DOI 10.1002/hbm.20831	10	81	84	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					33	35		10.1038/479033a	http://dx.doi.org/10.1038/479033a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	840FA	22051659				2022-12-28	WOS:000296422600016
J	Watts, G				Watts, Geoff			MEDICAL TECHNOLOGY Lost in translation	BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH INNOVATION; AFRICA					geoff@scileg.freeserve.co.uk						Al-Bader S, 2010, BMC INT HEALTH HUM R, V10, DOI 10.1186/1472-698X-10-S1-S1; Nwaka S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000293; Shah R, 2010, BMC INT HEALTH HUM R, V10, DOI 10.1186/1472-698X-10-S1-S4; Simiyu K, 2010, SCIENCE, V330, P1483, DOI 10.1126/science.1195401	4	0	0	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2011	343								d7047	10.1136/bmj.d7047	http://dx.doi.org/10.1136/bmj.d7047			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QC	22049526				2022-12-28	WOS:000296761400008
J	Connolly, SJ; Eikelboom, JW; Ng, J; Hirsh, J; Yusuf, S; Pogue, J; de Caterina, R; Hohnloser, S; Hart, RG				Connolly, Stuart J.; Eikelboom, John W.; Ng, Jennifer; Hirsh, Jack; Yusuf, Salim; Pogue, Janice; de Caterina, Raffaele; Hohnloser, Stefan; Hart, Robert G.		ACTIVE Atrial Fibrillation	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable	ANNALS OF INTERNAL MEDICINE			English	Article							STROKE; PREVENTION; WARFARIN; ANTICOAGULATION; IRBESARTAN; TRIAL	Background: Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage. Objective: To quantify the net benefit of adding clopidogrel to aspirin therapy, accounting for differences in clinical significance between ischemic and hemorrhagic events. Design: Observational cohort study to assign the relative weighting of events and post hoc analysis of randomized trial data to assess net benefit of dual antiplatelet therapy in the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) clinical trials. Setting: Global randomized clinical trial. Patients: 10 041 patients with AF, 7554 of whom were not candidates for warfarin therapy. Measurements: Ischemic events (ischemic stroke or myocardial infarction) and hemorrhagic events (hemorrhagic stroke or subdural or extracranial bleeding), weighted by the hazard ratio for death (or death or disability) after an event relative to death (or death or disability) after ischemic stroke. The net clinical benefit of dual antiplatelet therapy in the ACTIVE A trial participants was defined as the sum of weighted event incidence with dual antiplatelet therapy subtracted from the sum of weighted event incidence on control treatment, expressed as ischemic stroke equivalents prevented per 100 patients years. Results: Adding clopidogrel to aspirin therapy prevented 0.57 ischemic stroke equivalent (95% Cl, -0.12 to 1.24) per 100 patient-years of treatment when weighted by hazard for death after ischemia or hemorrhage and 0.67 ischemic stroke equivalent (Cl, -0.03 to 1.18) when weighted by death or disability after ischemia or hemorrhage. Limitation: No attempt was made to relate deaths used for weighting to events; disability data were missing for more than one half of patients. Conclusion: Adding clopidogrel to aspirin therapy resulted in a modest net benefit among patients with AF for whom warfarin was unsuitable. The benefit would probably be clinically relevant for some patients, but estimates could not exclude the possibility of either no benefit or very small harm in this population. Primary Funding Source: Bristol-Myers Squibb and sanofi-aventis.	McMaster Univ, Hamilton, ON, Canada; Gabriele dAnnunzio Univ, I-66013 Chieti, Italy; Goethe Univ, Frankfurt, Germany	McMaster University; G d'Annunzio University of Chieti-Pescara; Goethe University Frankfurt	Connolly, SJ (corresponding author), Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	Stuart.Connolly@phri.ca	De Caterina, Raffaele/K-3857-2016; Eikelboom, John/AAG-6117-2019	De Caterina, Raffaele/0000-0003-1637-574X; Eikelboom, John/0000-0003-4126-1285; Yusuf, Salim/0000-0003-4776-5601	Bristol-Myers Squibb; sanofi-aventis	Bristol-Myers Squibb(Bristol-Myers Squibb); sanofi-aventis(Sanofi-Aventis)	Primary Funding Source: Bristol-Myers Squibb and sanofi-aventis.	Boysen G, 2009, LANCET NEUROL, V8, P507, DOI 10.1016/S1474-4422(09)70109-7; Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4; Connolly S, 2006, AM HEART J, V151, P1187, DOI 10.1016/j.ahj.2005.06.026; Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Efron B., 1994, MONOGRAPHS STAT APPL; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Go AS, 2009, NEW ENGL J MED, V360, P2127, DOI 10.1056/NEJMe0902676; Hart RG, 2009, STROKE, V40, P2607, DOI 10.1161/STROKEAHA.109.549428; Nemeth G, 2006, EUR SPINE J, V15, pS44, DOI 10.1007/s00586-005-1046-8; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678; Singer DE, 2009, ANN INTERN MED, V151, P297, DOI 10.7326/0003-4819-151-5-200909010-00003; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Verheugt FWA, 2009, LANCET, V374, P510, DOI 10.1016/S0140-6736(09)61471-9	17	108	111	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					579	U41		10.7326/0003-4819-155-9-201111010-00004	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041946				2022-12-28	WOS:000296612400002
J	Tilbrook, HE; Cox, H; Hewitt, CE; Kang'ombe, AR; Chuang, LH; Jayakody, S; Aplin, JD; Semlyen, A; Trewhela, A; Watt, I; Torgerson, DJ				Tilbrook, Helen E.; Cox, Helen; Hewitt, Catherine E.; Kang'ombe, Arthur Ricky; Chuang, Ling-Hsiang; Jayakody, Shalmini; Aplin, John D.; Semlyen, Anna; Trewhela, Alison; Watt, Ian; Torgerson, David J.			Yoga for Chronic Low Back Pain	ANNALS OF INTERNAL MEDICINE			English	Article							HATHA YOGA; EXERCISE; THERAPY; DISABILITY; TRIAL	Background: Previous studies indicate that yoga may be an effective treatment for chronic or recurrent low back pain. Objective: To compare the effectiveness of yoga and usual care for chronic or recurrent low back pain. Design: Parallel-group, randomized, controlled trial using computer-generated randomization conducted from April 2007 to March 2010. Outcomes were assessed by postal questionnaire. (International Standard Randomised Controlled Trial Number Register: ISRCTN 81079604) Setting: 13 non-National Health Service premises in the United Kingdom. Patients: 313 adults with chronic or recurrent low back pain. Intervention: Yoga (n = 156) or usual care (n = 157). All participants received a back pain education booklet. The intervention group was offered a 12-class, gradually progressing yoga program delivered by 12 teachers over 3 months. Measurements: Scores on the Roland-Morris Disability Questionnaire (RMDQ) at 3 (primary outcome), 6, and 12 (secondary outcomes) months; pain, pain self-efficacy, and general health measures at 3, 6, and 12 months (secondary outcomes). Results: 93 (60%) patients offered yoga attended at least 3 of the first 6 sessions and at least 3 other sessions. The yoga group had better back function at 3, 6, and 12 months than the usual care group. The adjusted mean RMDQ score was 2.17 points (95% Cl, 1.03 to 3.31 points) lower in the yoga group at 3 months, 1.48 points (Cl, 0.33 to 2.62 points) lower at 6 months, and 1.57 points (Cl, 0.42 to 2.71 points) lower at 12 months. The yoga and usual care groups had similar back pain and general health scores at 3, 6, and 12 months, and the yoga group had higher pain self-efficacy scores at 3 and 6 months but not at 12 months. Two of the 157 usual care participants and 12 of the 156 yoga participants reported adverse events, mostly increased pain. Limitation: There were missing data for the primary outcome (yoga group, n = 21; usual care group, n = 18) and differential missing data (more in the yoga group) for secondary outcomes. Conclusion: Offering a 12-week yoga program to adults with chronic or recurrent low back pain led to greater improvements in back function than did usual care. Primary Funding Source: Arthritis Research UK.	[Tilbrook, Helen E.] Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England; Univ Manchester, St Marys Hosp, Manchester M13 9WL, Lancs, England; Yoga York, York YO10 4BH, N Yorkshire, England; Walsingham Clin, SBRCP Yoga, Truro TR1 2RP, Cornwall, England	University of York - UK; University of Manchester	Tilbrook, HE (corresponding author), Univ York, Dept Hlth Sci, York Trials Unit, Lower Ground Floor,ARRC Bldg, York YO10 5DD, N Yorkshire, England.	helen.tilbrook@york.ac.uk	Torgerson, David/L-4566-2019; Aplin, John/AET-4363-2022	Torgerson, David/0000-0002-1667-4275; Aplin, John/0000-0001-8777-9261; Hewitt, Catherine Elizabeth/0000-0002-0415-3536	Arthritis Research UK	Arthritis Research UK(Versus Arthritis)	Primary Funding Source: Arthritis Research UK.	Balding DJ, 2004, APPL LONGITUDINAL AN; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Burton K, 2002, BACK BOOK; Cox Helen, 2010, Complement Ther Clin Pract, V16, P76, DOI 10.1016/j.ctcp.2009.09.010; Galantino ML, 2004, ALTERN THER HEALTH M, V10, P56; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Jacobs BP, 2004, ALTERN THER HEALTH M, V10, P80; Jenkinson C, 1997, J Health Serv Res Policy, V2, P14; Johnson RE, 2007, SPINE, V32, P1578, DOI 10.1097/BRS.0b013e318074f890; Lamb SE, 2010, LANCET, V375, P916, DOI 10.1016/S0140-6736(09)62164-4; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; Man MS, 2011, J CLIN EPIDEMIOL, V64, P1001, DOI 10.1016/j.jclinepi.2010.10.013; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; Nicholas MK, 1989, P ANN C BRIT PSYCH S; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; RUTA DA, 1994, SPINE, V19, P1887, DOI 10.1097/00007632-199409000-00004; Saper RB, 2009, ALTERN THER HEALTH M, V15, P18; Savigny P., 2009, LOND NATL COLLAB CEN; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Tekur P, 2008, J ALTERN COMPLEM MED, V14, P637, DOI 10.1089/acm.2007.0815; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Verbeke G, 2000, LINEAR MIXED MODELS; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Williams KA, 2005, PAIN, V115, P107, DOI 10.1016/j.pain.2005.02.016; Williams K, 2009, SPINE, V34, P2066, DOI 10.1097/BRS.0b013e3181b315cc	27	126	134	8	49	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					569	U32		10.7326/0003-4819-155-9-201111010-00003	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041945				2022-12-28	WOS:000296612400001
J	Tricoci, P; Huang, Z; Held, C; Moliterno, DJ; Armstrong, PW; Van de Werf, F; White, HD; Aylward, PE; Wallentin, L; Chen, E; Lokhnygina, Y; Pei, JL; Leonardi, S; Rorick, TL; Kilian, AM; Jennings, LHK; Ambrosio, G; Bode, C; Cequier, A; Cornel, JH; Diaz, R; Erkan, A; Huber, K; Hudson, MP; Jiang, LX; Jukema, JW; Lewis, BS; Lincoff, AM; Montalescot, G; Nicolau, JC; Ogawa, H; Pfisterer, M; Prieto, JC; Ruzyllo, W; Sinnaeve, PR; Storey, RF; Valgimigli, M; Whellan, DJ; Widimsky, P; Strony, J; Harrington, RA; Mahaffey, KW				Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Van de Werf, Frans; White, Harvey D.; Aylward, Philip E.; Wallentin, Lars; Chen, Edmond; Lokhnygina, Yuliya; Pei, Jinglan; Leonardi, Sergio; Rorick, Tyrus L.; Kilian, Ann M.; Jennings, Lisa H. K.; Ambrosio, Giuseppe; Bode, Christoph; Cequier, Angel; Cornel, Jan H.; Diaz, Rafael; Erkan, Aycan; Huber, Kurt; Hudson, Michael P.; Jiang, Lixin; Jukema, J. Wouter; Lewis, Basil S.; Lincoff, A. Michael; Montalescot, Gilles; Nicolau, Jose Carlos; Ogawa, Hisao; Pfisterer, Matthias; Carlos Prieto, Juan; Ruzyllo, Witold; Sinnaeve, Peter R.; Storey, Robert F.; Valgimigli, Marco; Whellan, David J.; Widimsky, Petr; Strony, John; Harrington, Robert A.; Mahaffey, Kenneth W.		TRACER Investigators	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCOPROTEIN IIB/IIIA INHIBITORS; DOUBLE-BLIND; ANTIPLATELET THERAPY; TASK-FORCE; PLACEBO; CLOPIDOGREL; SAFETY	BACKGROUND Vorapaxar is a new oral protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5010 vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P=0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. CONCLUSIONS In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.)	[Tricoci, Pierluigi] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Cardiol, Durham, NC 27705 USA; [Held, Claes; Wallentin, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Held, Claes; Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Moliterno, David J.] Univ Kentucky, Lexington, KY 40506 USA; [Armstrong, Paul W.] Univ Alberta, Canadian Virtual Coordinating Ctr Global Collabor, Edmonton, AB, Canada; [Van de Werf, Frans; Sinnaeve, Peter R.] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Van de Werf, Frans; Sinnaeve, Peter R.] Leuven Coordinating Ctr, Louvain, Belgium; [White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand; [Aylward, Philip E.] Flinders Med Ctr, Bedford Pk, SA, Australia; [Chen, Edmond; Pei, Jinglan; Kilian, Ann M.; Strony, John] Merck, Whitehouse Stn, NJ USA; [Jennings, Lisa H. K.] Univ Tennessee, CirQuest Labs, Memphis, TN USA; [Jennings, Lisa H. K.] Univ Tennessee, Dept Med, Memphis, TN 38104 USA; [Ambrosio, Giuseppe] Univ Perugia, Sch Med, I-06100 Perugia, Italy; [Bode, Christoph] Univ Hosp, Dept Internal Med Cardiol & Angiol 3, Freiburg, Germany; [Cequier, Angel] Univ Barcelona, Hosp Univ Bellvitge, Barcelona, Spain; [Cornel, Jan H.] Med Ctr Alkmaar, Alkmaar, Netherlands; [Diaz, Rafael] Estudios Clin Latino Amer, Rosario, Argentina; [Erkan, Aycan] Ufuk Univ, Dept Cardiol, Ankara, Turkey; [Huber, Kurt] Wilhelminen Hosp, Dept Med Cardiol & Emergency Med, Vienna, Austria; [Hudson, Michael P.] Henry Ford Hosp, Detroit, MI 48202 USA; [Jiang, Lixin] Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100730, Peoples R China; [Jiang, Lixin] Chinese Acad Med Sci, Fuwai Hosp, Beijing 100730, Peoples R China; [Jiang, Lixin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; [Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Lincoff, A. Michael] Cleveland Clin, Coordinating Ctr Clin Res, Cleveland, OH USA; [Montalescot, Gilles] Hop La Pitie Salpetriere, Inst Cardiol, Paris, France; [Nicolau, Jose Carlos] Univ Sao Paulo, Fac Med, Inst Coracao, Hosp Clin,Unidade Coronariopatia Aguda, Sao Paulo, Brazil; [Ogawa, Hisao] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto, Japan; [Pfisterer, Matthias] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland; [Carlos Prieto, Juan] Univ Chile, Clin Hosp, Cardiovasc Dept, Santiago, Chile; [Ruzyllo, Witold] Inst Cardiol, Dept Coronary Artery Dis & Cardiac Catheterizat L, Warsaw, Poland; [Storey, Robert F.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England; [Valgimigli, Marco] Univ Ferrara, Unita Operat Cardiol, I-44100 Ferrara, Italy; [Whellan, David J.] Thomas Jefferson Univ, Div Cardiol, Philadelphia, PA 19107 USA; [Widimsky, Petr] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic	Duke University; Uppsala University; Uppsala University; University of Kentucky; University of Alberta; KU Leuven; University Hospital Leuven; KU Leuven; Auckland City Hospital; Flinders Medical Centre; Merck & Company; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Perugia; University of Freiburg; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Medical Center Of Alkmaar; Ufuk University; Wilhelminenspital; Henry Ford Health System; Henry Ford Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Clalit Health Services; Carmel Medical Center; Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universidade de Sao Paulo; Kumamoto University; University of Basel; Universidad de Chile; Institute of Cardiology - Poland; University of Sheffield; University of Ferrara; Jefferson University; Charles University Prague; University Hospital Vinohrady	Tricoci, P (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, Div Cardiol, Rm 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.	pierluigi.tricoci@duke.edu	Aroney, Con/A-7672-2013; De+Servi, Stefano/AAT-2631-2021; Fernandez-Ortiz, Antonio/B-2227-2017; cornel, jan hein/Y-7065-2019; Linhart, Ales/O-2375-2017; Storey, Robert/AAA-6853-2019; Zemánek, David/O-1059-2017; Ambrosio, Giuseppe/C-6596-2013; Prunier, Fabrice/A-5210-2011; Widimsky, Petr/P-8088-2016; Held, Claes/AAA-3973-2021; Erkan, Aycan Fahri/AAN-5880-2021; YILDIRIR, Aylin/A-4947-2018; sinagra, gianfranco gs/P-7643-2014; Nicolau, Jose C/E-1487-2012; Motovska, Zuzana/J-1122-2016; Leonardi, Sergio/K-4334-2018; Jeger, Raban/ABG-1678-2021; Ferrari, Emile/R-2917-2016; corrada, elena/GZK-5818-2022; Urina-Triana, Miguel A/H-2605-2016; Ponikowski, Piotr/O-6454-2015; Leonardi, Sergio/AAK-1490-2020; Valgimigli, Marco/AAE-9103-2019; De Caterina, Raffaele/K-3857-2016; Verheugt, F.W.A./H-8105-2014; Jukema, J. Wouter/ABD-6503-2021	Aroney, Con/0000-0002-0908-7179; Fernandez-Ortiz, Antonio/0000-0002-3239-1910; cornel, jan hein/0000-0002-1006-2112; Linhart, Ales/0000-0002-3372-7850; Zemánek, David/0000-0001-7336-6116; Ambrosio, Giuseppe/0000-0002-9677-980X; Widimsky, Petr/0000-0001-5686-7752; Held, Claes/0000-0001-9402-7404; Erkan, Aycan Fahri/0000-0002-9469-7149; YILDIRIR, Aylin/0000-0001-8750-5287; Nicolau, Jose C/0000-0002-9680-3689; Motovska, Zuzana/0000-0002-5319-473X; Leonardi, Sergio/0000-0002-4800-6132; Jeger, Raban/0000-0003-1290-5491; corrada, elena/0000-0002-6200-5152; Urina-Triana, Miguel A/0000-0001-6003-4622; Ponikowski, Piotr/0000-0002-3391-7064; Leonardi, Sergio/0000-0002-4800-6132; Valgimigli, Marco/0000-0002-4353-7110; De Caterina, Raffaele/0000-0003-1637-574X; Jukema, J. Wouter/0000-0002-3246-8359; Jaramillo, Monica/0000-0003-0100-5682; Luz Leiria, Tiago Luiz/0000-0002-3905-102X; Gavina, Cristina/0000-0003-2553-8264; Dorr, Marcus/0000-0001-7471-475X; Storey, Robert/0000-0002-6677-6229; Airaksinen, Juhani/0000-0002-0193-568X; ELBAZ, Meyer/0000-0002-3520-7883; Van de Werf, Frans/0000-0001-9479-7767; Lopez-Palop, Ramon/0000-0003-4385-7939; Varenhorst, Christoph/0000-0002-8378-3869; Sanz-Girgas, Esther/0000-0001-7058-6711; moreu, jose/0000-0003-4020-0325; Brilakis, Emmanouil/0000-0001-9416-9701; Sinnaeve, Peter/0000-0003-4716-5892; Armstrong, Paul/0000-0002-0460-3445; GALINIER, Michel/0000-0003-1735-3390; Cequier, Angel/0000-0002-3230-0011; Baumbach, Andreas/0000-0001-7707-2254; Aylward, Philip/0000-0002-5358-8552	Merck	Merck(Merck & Company)	Supported by Merck.	Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819; Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189; Anderson JL, 2011, CIRCULATION, V123, pE627, DOI 10.1161/CIR.0b013e3182231fc2; Anderson JL, 2011, CIRCULATION, V123, pE426, DOI 10.1161/CIR.0b013e318212bb8b; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Califf RM, 2010, EUR HEART J, V31, P911, DOI 10.1093/eurheartj/ehp550; Chintala M, 2010, ARTERIOSCL THROM VAS, V30, P2143, DOI 10.1161/ATVBAHA.110.203414; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Giugliano RP, 2005, AM HEART J, V149, P994, DOI 10.1016/j.ahj.2005.03.029; Goto S, 2010, J ATHEROSCLER THROMB, V17, P156, DOI 10.5551/jat.3038; Harrington RA, 2009, AM HEART J, V158, P327, DOI 10.1016/j.ahj.2009.07.001; Mega JL, 2009, LANCET, V374, P29, DOI 10.1016/S0140-6736(09)60738-8; Morrow DA, 2009, AM HEART J, V158, P335, DOI 10.1016/j.ahj.2009.06.027; Oldgren J, 2011, EUR HEART J     0507; Park SJ, 2010, NEW ENGL J MED, V362, P1374, DOI 10.1056/NEJMoa1001266; Rao SV, 2007, EUR HEART J, V28, P1193, DOI 10.1093/eurheartj/ehm019; Shah R, 2009, AM HEART J, V157, P253, DOI 10.1016/j.ahj.2008.09.025; Shinohara Y, 2010, J STROKE CEREBR 1013; Stone GW, 2007, JAMA-J AM MED ASSOC, V297, P591, DOI 10.1001/jama.297.6.591; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Tricoci P, 2011, CIRC-CARDIOVASC QUAL, V4, P448, DOI 10.1161/CIRCOUTCOMES.110.960294; Valgimigli M., 2011, EUR SOC CARD ESC C P; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yamaguchi T, 2010, AM HEART J, V159, P932; Yusuf S, 2001, NEW ENGL J MED, V345, P494; 2001, N ENGL J MED, V345, P1506	28	588	609	0	138	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 5	2012	366	1					20	33		10.1056/NEJMoa1109719	http://dx.doi.org/10.1056/NEJMoa1109719			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XY	22077816	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000299968800004
J	Boden, WE; Probstfield, JL; Anderson, T; Chaitman, BR; Desvignes-Nickens, P; Koprowicz, K; McBride, R; Teo, K; Weintraub, W				Boden, William E.; Probstfield, Jeffrey L.; Anderson, Todd; Chaitman, Bernard R.; Desvignes-Nickens, Patrice; Koprowicz, Kent; McBride, Ruth; Teo, Koon; Weintraub, William		AIM-HIGH Investigators	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTENDED-RELEASE NIACIN; CORONARY-HEART-DISEASE; SECONDARY PREVENTION; ARTERIAL BIOLOGY; ATHEROSCLEROSIS; COMBINATION	BACKGROUND In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P = 0.79 by the log-rank test). CONCLUSIONS Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.)	[Koprowicz, Kent; McBride, Ruth] Axio Res, Seattle, WA 98121 USA; [Boden, William E.] SUNY Buffalo, Buffalo, NY 14260 USA; [Probstfield, Jeffrey L.] Univ Washington, Seattle, WA 98195 USA; [Anderson, Todd] Univ Calgary, Calgary, AB, Canada; [Anderson, Todd] Libin Cardiovasc Inst, Calgary, AB, Canada; [Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA; [Desvignes-Nickens, Patrice] NHLBI, NIH, Bethesda, MD 20892 USA; [Teo, Koon] McMaster Univ, Hamilton, ON, Canada; [Weintraub, William] Christiana Care Hlth Syst, Wilmington, DE USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Washington; University of Washington Seattle; University of Calgary; Libin Cardiovascular Institute Of Alberta; Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McMaster University; Christiana Care Health System	McBride, R (corresponding author), Axio Res, 2601 4th Ave,Suite 200, Seattle, WA 98121 USA.	ruthm@axioresearch.com	O'Brien, Kevin/CAH-4638-2022; Force, Rex W/K-4094-2012; O'Brien, Kevin Douglas/HDO-1461-2022	O'Brien, Kevin/0000-0002-2293-9196; O'Brien, Kevin Douglas/0000-0002-2293-9196; Guyton, John/0000-0003-0224-7923	National Heart, Lung, and Blood Institute; Abbott; Amylin; Genentech; Sanofi-Aventis; Eli Lilly; Merck; Oryx Pharmaceuticals; Pfizer; Roche; Novartis	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Abbott(Abbott Laboratories); Amylin; Genentech(Roche HoldingGenentech); Sanofi-Aventis(Sanofi-Aventis); Eli Lilly(Eli Lilly); Merck(Merck & Company); Oryx Pharmaceuticals; Pfizer(Pfizer); Roche(Roche Holding); Novartis(Novartis)	Supported by the National Heart, Lung, and Blood Institute and by an unrestricted grant from Abbott Laboratories. Abbott Laboratories donated the extended-release niacin, the matching placebo, and the ezetimibe; Merck donated the simvastatin. Neither of these companies had any role in the oversight or design of the study or in the analysis or interpretation of the data.; Dr. Boden reports receiving consulting fees from Abbott; Dr. Probstfield, receiving consulting fees from Amylin, Genentech, and Sanofi-Aventis and grant support through his institution from Abbott, Eli Lilly, and Sanofi-Aventis; Dr. Anderson, receiving consulting fees from Merck, lecture fees from Merck and Oryx Pharmaceuticals, and support through his institution from Merck for rounds speakers; Dr. Chaitman, receiving consulting fees from Merck, Pfizer, and Roche; Mr. Koprowicz, being employed by Axio Research; Ms. McBride, being employed by Axio Research; and Dr. Teo, receiving grant support through his institution from Novartis. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; Assmann G, 1996, ATHEROSCLEROSIS, V124, pS11, DOI 10.1016/0021-9150(96)05852-2; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Bruckert E, 2010, ATHEROSCLEROSIS, V210, P353, DOI 10.1016/j.atherosclerosis.2009.12.023; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Cannon CP, 2006, NEW ENGL J MED, V354, P778; Carlson LA, 1971, METABOLIC EFFECTS NI, P157; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASTELLI WP, 1988, CAN J CARDIOL, V4, pA5; Heart and Stroke Foundation of Canada, 2022, HLTH WEIGHT WAIST; Khot UN, 2003, JAMA-J AM MED ASSOC, V290, P898, DOI 10.1001/jama.290.7.898; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; McBride R, 2011, AM HEART J, V161, P538, DOI 10.1016/j.ahj.2010.12.007; Nichols GA, 2009, AM J CARDIOL, V104, P1689, DOI 10.1016/j.amjcard.2009.07.050; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Taylor AJ, 2005, CIRCULATION, V111, P1727; Taylor AJ, 2004, CIRCULATION, V110, P3512, DOI 10.1161/01.CIR.0000148955.19792.8D; Taylor AJ, 2006, CURR MED RES OPIN, V22, P2243, DOI 10.1185/030079906X148508; The AIM-HIGH Investigators, 2011, AM HEART J, V161, p471e2; Villines TC, 2010, J AM COLL CARDIOL, V55, P2721, DOI 10.1016/j.jacc.2010.03.017; Zhao XQ, 2011, JACC-CARDIOVASC IMAG, V4, P977, DOI 10.1016/j.jcmg.2011.06.013	23	1944	2033	2	124	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2255	2267		10.1056/NEJMoa1107579	http://dx.doi.org/10.1056/NEJMoa1107579			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861PN	22085343	Bronze			2022-12-28	WOS:000298031800006
J	Smillie, CS; Smith, MB; Friedman, J; Cordero, OX; David, LA; Alm, EJ				Smillie, Chris S.; Smith, Mark B.; Friedman, Jonathan; Cordero, Otto X.; David, Lawrence A.; Alm, Eric J.			Ecology drives a global network of gene exchange connecting the human microbiome	NATURE			English	Article							EVOLUTION; BACTERIA; PATHOGENESIS; GENOMES; SEARCH	Horizontal gene transfer (HGT), the acquisition of genetic material from non-parental lineages, is known to be important in bacterial evolution(1,2). In particular, HGT provides rapid access to genetic innovations, allowing traits such as virulence(3), antibiotic resistance(4) and xenobiotic metabolism(5) to spread through the human microbiome. Recent anecdotal studies providing snapshots of active gene flow on the human body have highlighted the need to determine the frequency of such recent transfers and the forces that govern these events(4,5). Here we report the discovery and characterization of a vast, human-associated network of gene exchange, large enough to directly compare the principal forces shaping HGT. We show that this network of 10,770 unique, recently transferred (more than 99% nucleotide identity) genes found in 2,235 full bacterial genomes, is shaped principally by ecology rather than geography or phylogeny, with most gene exchange occurring between isolates from ecologically similar, but geographically separated, environments. For example, we observe 25-fold more HGT between human-associated bacteria than among ecologically diverse non-human isolates (P = 3.0 x 10(-270)). We show that within the human microbiome this ecological architecture continues across multiple spatial scales, functional classes and ecological niches with transfer further enriched among bacteria that inhabit the same body site, have the same oxygen tolerance or have the same ability to cause disease. This structure offers a window into the molecular traits that define ecological niches, insight that we use to uncover sources of antibiotic resistance and identify genes associated with the pathology of meningitis and other diseases.	[Cordero, Otto X.; Alm, Eric J.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [Smillie, Chris S.; Friedman, Jonathan] MIT, Computat & Syst Biol Initiat, Cambridge, MA 02139 USA; [Smith, Mark B.] MIT, Microbiol Grad Program, Cambridge, MA 02139 USA; [David, Lawrence A.] Harvard Univ, Soc Fellows, Cambridge, MA 02138 USA; [Alm, Eric J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Alm, Eric J.] Broad Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Alm, EJ (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ejalm@mit.edu	David, Lawrence/B-1044-2010; Friedman, Jonathan/I-6930-2019; David, Lawrence Anthony/HCJ-0062-2022	David, Lawrence/0000-0002-3570-4767; Friedman, Jonathan/0000-0001-8476-8030; David, Lawrence Anthony/0000-0002-3570-4767; Smillie, Chris/0000-0002-7606-3433	National Science Foundation [0918333, 0936234]; Department of Energy's ENIGMA Scientific Focus Area; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Department of Energy's ENIGMA Scientific Focus Area; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by National Science Foundation awards 0918333 and 0936234 to E.J.A., and by the Department of Energy's ENIGMA Scientific Focus Area. This work is part of the National Institutes of Health Human Microbiome Project.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Boucher Y, 2011, MBIO, V2, DOI 10.1128/mBio.00335-10; Caro-Quintero A, 2011, ISME J, V5, P131, DOI 10.1038/ismej.2010.93; Chen J, 2009, SCIENCE, V323, P139, DOI 10.1126/science.1164783; Clatworthy AE, 2007, NAT CHEM BIOL, V3, P541, DOI 10.1038/nchembio.2007.24; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Hehemann JH, 2010, NATURE, V464, P908, DOI 10.1038/nature08937; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Kim KS, 2003, NAT REV NEUROSCI, V4, P376, DOI 10.1038/nrn1103; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2; Lawrence JG, 2003, MOL MICROBIOL, V50, P739, DOI 10.1046/j.1365-2958.2003.03778.x; Lester CH, 2006, ANTIMICROB AGENTS CH, V50, P596, DOI 10.1128/AAC.50.2.596-599.2006; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Liu B, 2009, NUCLEIC ACIDS RES, V37, pD443, DOI 10.1093/nar/gkn656; Markowitz VM, 2006, NUCLEIC ACIDS RES, V34, pD344, DOI 10.1093/nar/gkj024; Mazodier P., 2011, ANNU REV GENET, V25, P147; Ochman H, 1999, P NATL ACAD SCI USA, V96, P12638, DOI 10.1073/pnas.96.22.12638; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Thomas CM, 2005, NAT REV MICROBIOL, V3, P711, DOI 10.1038/nrmicro1234; Tuller T., 2011, NUCLEIC ACIDS RES, V39, P1; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xu J, 2007, PLOS BIOL, V5, P1574, DOI 10.1371/journal.pbio.0050156	29	525	554	11	329	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 8	2011	480	7376					241	244		10.1038/nature10571	http://dx.doi.org/10.1038/nature10571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857TR	22037308				2022-12-28	WOS:000297744200051
J	Nicholls, SJ; Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, RM; Libby, P; Raichlen, JS; Uno, K; Borgman, M; Wolski, K; Nissen, SE				Nicholls, Stephen J.; Ballantyne, Christie M.; Barter, Philip J.; Chapman, M. John; Erbel, Raimund M.; Libby, Peter; Raichlen, Joel S.; Uno, Kiyoko; Borgman, Marilyn; Wolski, Kathy; Nissen, Steven E.			Effect of Two Intensive Statin Regimens on Progression of Coronary Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVASCULAR ULTRASOUND; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; CHOLESTEROL; ROSUVASTATIN; ATORVASTATIN; EVENTS; PRAVASTATIN; PREVENTION; EFFICACY	Background Statins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration. Methods We performed serial intravascular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of treatment with either atorvastatin, 80 mg daily, or rosuvastatin, 40 mg daily, to compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis, as well as to assess their safety and side-effect profiles. Results After 104 weeks of therapy, the rosuvastatin group had lower levels of LDL cholesterol than the atorvastatin group (62.6 vs. 70.2 mg per deciliter [1.62 vs. 1.82 mmol per liter], P<0.001), and higher levels of high-density lipoprotein (HDL) cholesterol (50.4 vs. 48.6 mg per deciliter [1.30 vs. 1.26 mmol per liter], P=0.01). The primary efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval [CI], -1.19 to -0.63) with atorvastatin and by 1.22% (95% CI, -1.52 to -0.90) with rosuvastatin (P=0.17). The effect on the secondary efficacy end point, normalized total atheroma volume (TAV), was more favorable with rosuvastatin than with atorvastatin: -6.39 mm(3) (95% CI, -7.52 to -5.12), as compared with -4.42 mm(3) (95% CI, -5.98 to -3.26) (P = 0.01). Both agents induced regression in the majority of patients: 63.2% with atorvastatin and 68.5% with rosuvastatin for PAV (P = 0.07) and 64.7% and 71.3%, respectively, for TAV (P=0.02). Both agents had acceptable side-effect profiles, with a low incidence of laboratory abnormalities and cardiovascular events. Conclusions Maximal doses of rosuvastatin and atorvastatin resulted in significant regression of coronary atherosclerosis. Despite the lower level of LDL cholesterol and the higher level of HDL cholesterol achieved with rosuvastatin, a similar degree of regression of PAV was observed in the two treatment groups. (Funded by AstraZeneca Pharmaceuticals.)	[Nicholls, Stephen J.; Uno, Kiyoko; Nissen, Steven E.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA; [Nicholls, Stephen J.; Uno, Kiyoko] Cleveland Clin Coordinating Ctr Clin Res, Cleveland, OH USA; [Ballantyne, Christie M.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA; [Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA; [Barter, Philip J.] Heart Res Inst, Sydney, NSW, Australia; [Chapman, M. John] Hop Pitie, INSERM, Dyslipidemia & Atherosclerosis Res Unit, F-75651 Paris, France; [Erbel, Raimund M.] W German Heart Ctr Essen, Dept Cardiol, Essen, Germany; [Libby, Peter] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Raichlen, Joel S.] AstraZeneca, Wilmington, DE USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; University of Sydney; Heart Research Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Harvard University; Brigham & Women's Hospital; AstraZeneca	Nicholls, SJ (corresponding author), Cleveland Clin, Dept Cardiovasc Med, Mail Code JJ 65, Cleveland, OH 44195 USA.	nichols1@ccf.org	Libby, Peter/AAY-6404-2021; Koshelskaya, Olga/M-8197-2016; chapman, john/Y-2742-2019; Ballantyne, Christie/A-6599-2008	Libby, Peter/0000-0002-1502-502X; Koshelskaya, Olga/0000-0002-6679-1269; Ballantyne, Christie/0000-0002-6432-1730; Nicholls, Stephen/0000-0002-9668-4368	AstraZeneca; Roche; Esperion; Merck; Omthera; Sanofi-Aventis; Boehringer Ingelheim; Eli Lilly; Novartis; Anthera; LipoScience; Resverlogix; Abbott; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Kowa; Sanofi-Synthelabo; Takeda; Adnexus; Amarin; Amylin; Idera; CSL Behring; Pfizer; Heinz Nixdorf Foundation; German Research Foundation; Biotronik; Sanofi; Pronova; Sigma Tau; Karo Bio; Novo Nordisk	AstraZeneca(AstraZeneca); Roche(Roche Holding); Esperion; Merck(Merck & Company); Omthera; Sanofi-Aventis(Sanofi-Aventis); Boehringer Ingelheim(Boehringer Ingelheim); Eli Lilly(Eli Lilly); Novartis(Novartis); Anthera; LipoScience; Resverlogix; Abbott(Abbott Laboratories); Bristol-Myers Squibb(Bristol-Myers Squibb); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Kowa; Sanofi-Synthelabo; Takeda(Takeda Pharmaceutical Company Ltd); Adnexus; Amarin; Amylin; Idera; CSL Behring; Pfizer(Pfizer); Heinz Nixdorf Foundation; German Research Foundation(German Research Foundation (DFG)); Biotronik; Sanofi; Pronova; Sigma Tau; Karo Bio; Novo Nordisk(Novo Nordisk)	Supported by AstraZeneca.; Dr. Nicholls reports receiving consulting fees from Roche, Esperion, Merck, Omthera, Sanofi-Aventis, and Boehringer Ingelheim, serving as an unpaid consultant for Abbott, Pfizer, Lipo-Science, Novo Nordisk, AtheroNova, and CSL Behring, receiving grant support from Eli Lilly, AstraZeneca, Novartis, Anthera, LipoScience, Roche, and Resverlogix and lecture fees from AstraZeneca and Roche; Dr. Ballantyne, receiving grant support from Abbott, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, and Takeda, consulting fees and honoraria from Abbott, Adnexus, Amarin, Amylin, AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera, Kowa, Merck, Novartis, Omthera, Resverlogix, Roche, Sanofi-Synthelabo, and Takeda and lecture fees from Abbott, AstraZeneca, GlaxoSmithKline, and Merck; Dr. Barter, holding an advisory board position for AstraZeneca, Merck, Roche, CSL Behring, and Pfizer, receiving grant support from Merck, consulting fees from CSL Behring, and lecture fees from AstraZeneca, Kowa, Merck, Pfizer, and Roche; Dr. Chapman, receiving grant support from Merck and Kowa, consulting fees from Merck and Pfizer, and lectures fees from Merck and Kowa; Dr. Erbel, receiving grant support from the Heinz Nixdorf Foundation and the German Research Foundation and support for travel, accommodations, or meeting expenses from Biotronik, Sanofi, and Novartis; Dr. Libby, serving as an unpaid consultant for Novartis, Johnson & Johnson,. Amgen, and Roche, serving in unpaid leadership roles for clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Pronova, and Sigma Tau, and having previously received royalties from Roche for the patent on CD40L in cardiovascular risk stratification; Dr. Raichlen, being an employee of and owning stock in AstraZeneca; and Dr. Nissen, receiving consulting fees from Eli Lilly, grant funding from AstraZeneca, Pfizer, Novartis, Karo Bio, Novo Nordisk, Takeda, Resverlogix, and Omthera, and support for travel, accommodations, or meeting expenses from Novo Nordisk, Takeda, Karo Bio, Eli Lilly, Pfizer, Novartis, and Amgen. No other potential conflict of interest relevant to this article was reported.	Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Barter PJ, 2010, J LIPID RES, V51, P1546, DOI 10.1194/jlr.P002816; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Jones PH, 2003, AM J CARDIOL, V92, P152, DOI 10.1016/S0002-9149(03)00530-7; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Nicholls SJ, 2007, JAMA-J AM MED ASSOC, V297, P499, DOI 10.1001/jama.297.5.499; Nicholls SJ, 2006, NAT REV DRUG DISCOV, V5, P485, DOI 10.1038/nrd2040; Nicholls SJ, 2011, CURR MED RES OPIN, V27, P1119, DOI 10.1185/03007995.2011.570746; Nicholls SJ, 2010, AM J CARDIOL, V105, P69, DOI 10.1016/j.amjcard.2009.08.651; Nicholls SJ, 2010, J AM COLL CARDIOL, V55, P2399, DOI 10.1016/j.jacc.2010.02.026; Nissen SE, 2007, NEW ENGL J MED, V357, P835; Nissen SE, 2006, NEW ENGL J MED, V355, P638; Nissen SE, 2006, NEW ENGL J MED, V354, P1253, DOI 10.1056/NEJMoa054699; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1547, DOI 10.1001/jama.299.13.1547; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1561, DOI 10.1001/jama.299.13.1561; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1093/eurheartj/ehr158, 10.1016/j.atherosclerosis.2011.06.012]; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tardif JC, 2004, CIRCULATION, V110, P3372, DOI 10.1161/01.CIR.0000147777.12010.EF; Tardif JC, 2007, JAMA-J AM MED ASSOC, V297, P1675, DOI 10.1001/jama.297.15.jpc70004; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; von Birgelen C, 2003, CIRCULATION, V108, P2757, DOI 10.1161/01.CIR.0000103664.47406.49	31	574	620	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 1	2011	365	22					2078	2087		10.1056/NEJMoa1110874	http://dx.doi.org/10.1056/NEJMoa1110874			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854MO	22085316				2022-12-28	WOS:000297499000008
J	Lazcano-Ponce, E; Lorincz, AT; Cruz-Valdez, A; Salmeron, J; Uribe, P; Velasco-Mondragon, E; Nevarez, PH; Acosta, RD; Hernandez-Avila, M				Lazcano-Ponce, Eduardo; Lorincz, Attila Tibor; Cruz-Valdez, Aurelio; Salmeron, Jorge; Uribe, Patricia; Velasco-Mondragon, Eduardo; Hernandez Nevarez, Pilar; Diaz Acosta, Rodrigo; Hernandez-Avila, Mauricio			Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; CONVENTIONAL CYTOLOGY; PAP TEST; DNA; RISK	Background Vaginal self-sampling for human papillomavirus (HPV) DNA testing could increase rates of screening participation. In clinic-based settings, vaginal HPV testing is at least as sensitive as cytology for detecting cervical intraepithelial neoplasia (CIN) grade 2 or worse; however, effectiveness in home settings is unknown. We aimed to establish the relative sensitivity and positive predictive value for HPV screening of vaginal samples self-collected at home as compared with clinic-based cervical cytology. Methods We did a community-based, randomised equivalence trial in Mexican women of low socioeconomic status aged 25-65 years. Participants came from 540 medically underserved, predominantly rural communities in Morelos, Guerrero, and the state of Mexico. Our primary endpoint was CIN 2 or worse, detected by colposcopy. We used a computer-generated randomisation sequence to randomly allocate patients to HPV screening or cervical cytology. Eight community nurses who were masked to patient allocation received daily lists of the women's names and addresses, and did the assigned home visits. We referred women with positive results in either test to colposcopy. We did per-protocol and intention-to-screen analyses. This trial was registered with the Instituto Nacional de Salud Publica, Mexico, INSP number 590. Findings 12 330 women were randomly allocated to HPV screening and 12 731 to cervical cytology; 9202 women in the HPV screening group adhered to the protocol, as did 11 054 in the cervical cytology group. HPV prevalence was 9.8% (95% CI 9.1-10.4) and abnormal cytology rate was 0.38% (0.23-0.45). HPV testing identified 117.4 women with CIN 2 or worse per 10 000 (95.2-139.5) compared with 34.4 women with CIN 2 or worse per 10 000 (23.4-45.3) identified by cytology; the relative sensitivity of HPV testing was 3.4 times greater (2.4-4.9). Similarly, HPV testing detected 4.2 times (1.9-9.2) more invasive cancers than did cytology (30.4 per 10 000 [19.1-41.7] vs 7.2 per 10 000 [2.2-12.3]). The positive predictive value of HPV testing for CIN 2 or worse was 12.2% (9.9-14.5) compared with 90.5% (61.7-100) for cytology. Interpretation Despite the much lower positive predictive value for HPV testing of self-collected vaginal specimens compared with cytology, such testing might be preferred for detecting CIN 2 or worse in low-resource settings where restricted infrastructure reduces the effectiveness of cytology screening programmes. Because women at these sites will be screened only a few times in their lives, the high sensitivity of a HPV screen is of paramount importance.	[Lorincz, Attila Tibor] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, Barts & London Sch Med, London EC1M 6BQ, England; [Lazcano-Ponce, Eduardo; Cruz-Valdez, Aurelio; Hernandez Nevarez, Pilar; Diaz Acosta, Rodrigo] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca, Morelos, Mexico; [Salmeron, Jorge] Inst Mexicano Seguro Social, Unidad Invest Epidemiol, Cuernavaca, Morelos, Mexico; [Salmeron, Jorge] Inst Mexicano Seguro Social, Serv Salud, Cuernavaca, Morelos, Mexico; [Uribe, Patricia] Secretaria Salud Mexico, Ctr Nacl Equidad & Genero, Mexico City, DF, Mexico; [Hernandez-Avila, Mauricio] Secretaria Salud Mexico, Subsecretaria Prevenc & Promoc Salud, Mexico City, DF, Mexico; [Velasco-Mondragon, Eduardo] Morgan State Univ, Sch Community Hlth & Policy, Baltimore, MD 21239 USA	University of London; Queen Mary University London; Instituto Nacional de Salud Publica; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social; Morgan State University	Lorincz, AT (corresponding author), Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, Barts & London Sch Med, London EC1M 6BQ, England.	a.lorincz@qmul.ac.uk		Salmeron, Jorge/0000-0002-5113-299X	Instituto Nacional de Salud Publica; Health Ministry of Mexico; QiAGEN Corp; INSP; Oportunidades, Morelos State, Mexico	Instituto Nacional de Salud Publica; Health Ministry of Mexico; QiAGEN Corp; INSP; Oportunidades, Morelos State, Mexico	Instituto Nacional de Salud Publica, the Health Ministry of Mexico, QiAGEN Corp; INSP, the Health Ministry of Mexico, and QIAGEN Corp funded this study. Jack Cuzick and Peter Sasieni of the Wolfson Institute of Preventive Medicine, Queen Mary University of London provided valuable assistance with statistical issues. Enrique Carmona Balandrano and Mario Balbuena Basurto provided colposcopy and pathology expertise. Norma Beatriz Garcia Fuentes and Gregorio Vergara Cebria from Oportunidades, Morelos State, Mexico, supported this social programme. Betania Allen-Leigh provided support with scientific editing.	Agorastos T, 2005, INT J STD AIDS, V16, P727, DOI 10.1258/095646205774763225; Almonte M, 2007, INT J CANCER, V121, P796, DOI 10.1002/ijc.22757; Almonte M, 2010, SALUD PUBLICA MEXICO, V52, P544, DOI 10.1590/S0036-36342010000600010; Anttila A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1804; Arbyn M, 2009, LANCET ONCOL, V10, P935, DOI 10.1016/S1470-2045(09)70296-7; Arbyn M, 2006, VACCINE, V24, P78, DOI 10.1016/j.vaccine.2006.05.117; Arbyn M, 2009, INT J CANCER, V125, P2489, DOI 10.1002/ijc.24774; Baay M, 2004, SCAND J INFECT DIS, V36, P456, DOI 10.1080/00365540410020677; Baldwin S, 2005, GYNECOL ONCOL, V97, P612, DOI 10.1016/j.ygyno.2005.02.001; Bulkmans NWJ, 2007, LANCET, V370, P1764, DOI 10.1016/S0140-6736(07)61450-0; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019; Cuzick J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/ijc.21955; Denny L, 2010, JNCI-J NATL CANCER I, V102, P1557, DOI 10.1093/jnci/djq342; Dzuba IG, 2002, J WOMEN HEALTH GEN-B, V11, P265, DOI 10.1089/152460902753668466; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Grce M, 2008, EXPERT REV MOL DIAGN, V8, P599, DOI 10.1586/14737159.8.5.599; Kahn JA, 2005, J WOMENS HEALTH, V14, P650, DOI 10.1089/jwh.2005.14.650; Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016/S1470-2045(09)70156-1; Leinonen M, 2009, JNCI-J NATL CANCER I, V101, P1612, DOI 10.1093/jnci/djp367; Leroy JL, 2008, J NUTR, V138, P638, DOI 10.1093/jn/138.3.638; Lorincz A T, 1996, J Obstet Gynaecol Res, V22, P629; Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430; Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204; Parikh S, 2003, INT J CANCER, V105, P687, DOI 10.1002/ijc.11141; Pepe MS., 2003, STAT EVALUATION MEDI; Reid R, 1990, PREMALIGNANT LESIONS, V2, P87; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2; Salmeron J, 2003, CANCER CAUSE CONTROL, V14, P505, DOI 10.1023/A:1024806707399; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; United Mexican States-Ministry of Health, 1995, NOM014SSA21994 UN ME; WHO, 2011, PROJ MORT BURD DIS	31	160	169	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2011	378	9806					1868	1873		10.1016/S0140-6736(11)61522-5	http://dx.doi.org/10.1016/S0140-6736(11)61522-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857DQ	22051739				2022-12-28	WOS:000297695800031
J	Blumhagen, F; Zhu, PX; Shum, J; Scharer, YPZ; Yaksi, E; Deisseroth, K; Friedrich, RW				Blumhagen, Francisca; Zhu, Peixin; Shum, Jennifer; Schaerer, Yan-Ping Zhang; Yaksi, Emre; Deisseroth, Karl; Friedrich, Rainer W.			Neuronal filtering of multiplexed odour representations	NATURE			English	Article							ZEBRAFISH OLFACTORY-BULB; COINCIDENCE DETECTION; TRANSIENT DYNAMICS; PIRIFORM CORTEX; VISUAL-CORTEX; OSCILLATIONS; COMPUTATION; INHIBITION; CIRCUITS; SYSTEM	Neuronal activity patterns contain information in their temporal structure, indicating that information transfer between neurons may be optimized by temporal filtering. In the zebrafish olfactory bulb, subsets of output neurons ( mitral cells) engage in synchronized oscillations during odour responses, but information about odour identity is contained mostly in non-oscillatory firing rate patterns. Using optogenetic manipulations and odour stimulation, we found that firing rate responses of neurons in the posterior zone of the dorsal telencephalon (Dp), a target area homologous to olfactory cortex, were largely insensitive to oscillatory synchrony of mitral cells because passive membrane properties and synaptic currents act as low-pass filters. Nevertheless, synchrony influenced spike timing. Moreover, Dp neurons responded primarily during the decorrelated steady state of mitral cell activity patterns. Temporal filtering therefore tunes Dp neurons to components of mitral cell activity patterns that are particularly informative about precise odour identity. These results demonstrate how temporal filtering can extract specific information from multiplexed neuronal codes.	[Blumhagen, Francisca; Zhu, Peixin; Shum, Jennifer; Schaerer, Yan-Ping Zhang; Friedrich, Rainer W.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Yaksi, Emre] Neuroelect Res Flanders, B-3001 Louvain, Belgium; [Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Friedrich, Rainer W.] Univ Basel, CH-4003 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Stanford University; University of Basel	Friedrich, RW (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	Rainer.Friedrich@fmi.ch	Yaksi, Emre/A-3215-2019	Yaksi, Emre/0000-0003-3761-0235; Zhang, Yan-Ping/0000-0001-7602-4453; Friedrich, Rainer/0000-0001-9107-0482; Shum, Jennifer/0000-0002-1893-1538	Novartis Research Foundation; Max-Planck-Society; Swiss National Fonds (SNF); Deutsche Forschungsgemeinschaft (DFG); Human Frontier Science Program (HFSP); Whitaker Foundation	Novartis Research Foundation; Max-Planck-Society(Max Planck Society); Swiss National Fonds (SNF)(Swiss National Science Foundation (SNSF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Human Frontier Science Program (HFSP)(Human Frontier Science Program); Whitaker Foundation	This work was supported by the Novartis Research Foundation, the Max-Planck-Society, the Swiss National Fonds (SNF), the Deutsche Forschungsgemeinschaft (DFG), the Human Frontier Science Program (HFSP), and the Whitaker Foundation (J.S.). We are grateful to S.-i. Higashijima for vglut2a-GFP transgenic fish and thank T. Frank, A. Luthi, I. Namekawa and T. Oertner for comments on the manuscript.	Azouz R, 2003, NEURON, V37, P513, DOI 10.1016/S0896-6273(02)01186-8; Bathellier B, 2008, NEURON, V57, P586, DOI 10.1016/j.neuron.2008.02.011; Bhandawat V, 2007, NAT NEUROSCI, V10, P1474, DOI 10.1038/nn1976; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Bruno RM, 2006, SCIENCE, V312, P1622, DOI 10.1126/science.1124593; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cury KM, 2010, NEURON, V68, P570, DOI 10.1016/j.neuron.2010.09.040; Engeszer RE, 2007, ZEBRAFISH, V4, P21, DOI 10.1089/zeb.2006.9997; Franks KM, 2006, NEURON, V49, P357, DOI 10.1016/j.neuron.2005.12.026; Friedrich RW, 2004, NAT NEUROSCI, V7, P862, DOI 10.1038/nn1292; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; Friedrich RW, 2001, SCIENCE, V291, P889, DOI 10.1126/science.291.5505.889; Fries P, 2009, ANNU REV NEUROSCI, V32, P209, DOI 10.1146/annurev.neuro.051508.135603; Gawne TJ, 1996, J NEUROPHYSIOL, V76, P1356, DOI 10.1152/jn.1996.76.2.1356; Gerstner W, 1997, P NATL ACAD SCI USA, V94, P12740, DOI 10.1073/pnas.94.24.12740; Gollisch T, 2008, SCIENCE, V319, P1108, DOI 10.1126/science.1149639; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gutig R, 2006, NAT NEUROSCI, V9, P420, DOI 10.1038/nn1643; Higashijima S, 2003, J NEUROPHYSIOL, V90, P3986, DOI 10.1152/jn.00576.2003; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Hutcheon B, 2000, TRENDS NEUROSCI, V23, P216, DOI 10.1016/S0166-2236(00)01547-2; Jortner RA, 2007, J NEUROSCI, V27, P1659, DOI 10.1523/JNEUROSCI.4171-06.2007; Junek S, 2010, NEURON, V67, P872, DOI 10.1016/j.neuron.2010.08.005; KETCHUM KL, 1993, J NEUROSCI, V13, P3980; LAURENT G, 1994, J NEUROSCI, V14, P2993; Laurent G, 2002, NAT REV NEUROSCI, V3, P884, DOI 10.1038/nrn964; Luna VM, 2008, J NEUROSCI, V28, P8851, DOI 10.1523/JNEUROSCI.2385-08.2008; Maass W, 2002, NEURAL COMPUT, V14, P2531, DOI 10.1162/089976602760407955; MATHIESON WB, 1988, J COMP PHYSIOL A, V163, P489, DOI 10.1007/BF00604903; Mazor O, 2005, NEURON, V48, P661, DOI 10.1016/j.neuron.2005.09.032; Miyamichi K, 2011, NATURE, V472, P191, DOI 10.1038/nature09714; Miyasaka N, 2009, J NEUROSCI, V29, P4756, DOI 10.1523/JNEUROSCI.0118-09.2009; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Niessing J, 2010, NATURE, V465, P47, DOI 10.1038/nature08961; Perez-Orive J, 2004, J NEUROSCI, V24, P6037, DOI 10.1523/JNEUROSCI.1084-04.2004; Perez-Orive J, 2002, SCIENCE, V297, P359, DOI 10.1126/science.1070502; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Poo C, 2009, NEURON, V62, P850, DOI 10.1016/j.neuron.2009.05.022; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; Sato Y, 2005, J NEUROSCI, V25, P4889, DOI 10.1523/JNEUROSCI.0679-05.2005; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Spence R, 2008, BIOL REV, V83, P13, DOI 10.1111/j.1469-185X.2007.00030.x; Spors H, 2006, J NEUROSCI, V26, P1247, DOI 10.1523/JNEUROSCI.3100-05.2006; Stokes CCA, 2010, NEURON, V67, P452, DOI 10.1016/j.neuron.2010.06.029; Stopfer M, 2003, NEURON, V39, P991, DOI 10.1016/j.neuron.2003.08.011; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; Suter BA, 2010, FRONT NEURAL CIRCUIT, V4, P100, DOI DOI 10.3389/FNCIR.2010.00100; Tabor R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001416; Yaksi E, 2006, NAT METHODS, V3, P377, DOI 10.1038/NMETH874; Yaksi E, 2009, NAT NEUROSCI, V12, P474, DOI 10.1038/nn.2288; Zhu PX, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.021.2009	53	69	70	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 24	2011	479	7374					493	U215		10.1038/nature10633	http://dx.doi.org/10.1038/nature10633			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22080956				2022-12-28	WOS:000297285600042
J	Kastrati, A; Neumann, FJ; Schulz, S; Massberg, S; Byrne, RA; Ferenc, M; Laugwitz, KL; Pache, J; Ott, I; Hausleiter, J; Seyfarth, M; Gick, M; Antoniucci, D; Schomig, A; Berger, PB; Mehilli, J				Kastrati, Adnan; Neumann, Franz-Josef; Schulz, Stefanie; Massberg, Steffen; Byrne, Robert A.; Ferenc, Miroslaw; Laugwitz, Karl-Ludwig; Pache, Juergen; Ott, Ilka; Hausleiter, Joerg; Seyfarth, Melchior; Gick, Michael; Antoniucci, David; Schoemig, Albert; Berger, Peter B.; Mehilli, Julinda		ISAR-REACt 4 Trial Investigators	Abciximab and Heparin versus Bivalirudin for Non-ST-Elevation Myocardial Infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; UNFRACTIONATED HEPARIN; RANDOMIZED-TRIAL; CLINICAL-TRIALS; ELUTING STENTS; CLOPIDOGREL; PLATELET; PRETREATMENT; BLOCKADE; PCI	BACKGROUND The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). We compared the two treatments in this patient population. METHODS Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). The study tested the hypothesis that abciximab and heparin would be superior to bivalirudin with respect to the primary composite end point of death, large recurrent myocardial infarction, urgent target-vessel revascularization, or major bleeding within 30 days. Secondary end points included the composite of death, any recurrent myocardial infarction, or urgent target-vessel revascularization (efficacy end point) and major bleeding (safety end point) within 30 days. RESULTS The primary end point occurred in 10.9% of the patients in the abciximab group (94 patients) and in 11.0% in the bivalirudin group (95 patients) (relative risk with abciximab, 0.99; 95% confidence interval [CI], 0.74 to 1.32; P=0.94). Death, any recurrent myocardial infarction, or urgent target-vessel revascularization occurred in 12.8% of the patients in the abciximab group (110 patients) and in 13.4% in the bivalirudin group (115 patients) (relative risk, 0.96; 95% CI, 0.74 to 1.25; P = 0.76). Major bleeding occurred in 4.6% of the patients in the abciximab group (40 patients) as compared with 2.6% in the bivalirudin group (22 patients) (relative risk, 1.84; 95% CI, 1.10 to 3.07; P = 0.02). CONCLUSIONS Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non-ST-segment elevation myocardial infarction who were undergoing PCI. (Funded by Nycomed Pharma and others; ISAR-REACT 4 ClinicalTrials.gov number, NCT00373451.)	[Kastrati, Adnan; Schulz, Stefanie; Massberg, Steffen; Byrne, Robert A.; Pache, Juergen; Ott, Ilka; Hausleiter, Joerg; Schoemig, Albert; Mehilli, Julinda] Deutsch Herzzentrum Munich, D-80636 Munich, Germany; [Laugwitz, Karl-Ludwig; Schoemig, Albert] Tech Univ Munich, Med Klin Rechts Isar 1, Munich, Germany; [Neumann, Franz-Josef; Ferenc, Miroslaw; Gick, Michael] Herz Zentrum, Bad Krozingen, Germany; [Seyfarth, Melchior] HELIOS Klinikum Wuppertal, Wuppertal, Germany; [Seyfarth, Melchior] Univ Witten Herdecke, Witten, Germany; [Antoniucci, David] Careggi Hosp, Florence, Italy; [Berger, Peter B.] Geisinger Med Ctr, Danville, PA 17822 USA	German Heart Centre Munich; Technical University of Munich; Helios Kliniken; Witten Herdecke University; University of Florence; Azienda Ospedaliero Universitaria Careggi; Geisinger Medical Center	Kastrati, A (corresponding author), Deutsch Herzzentrum Munich, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	Massberg, Steffen/AAN-6054-2021; Hausleiter, Jörg/V-4206-2019; Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019; Schupke, Stefanie/G-8382-2016; Byrne, Robert/C-3902-2016	Schupke, Stefanie/0000-0002-0294-2283; Byrne, Robert/0000-0001-5224-6393; Kufner, Sebastian/0000-0002-8091-4552	Nycomed Pharma, Unterschleissheim, Germany; Deutsches Herzzentrum, Munich, Germany [KKF 04-06 [974404]]; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Eli Lilly; Abbott; Biotronik; Cordis; Medtronic; Medicines Company; Novartis; Sanofi-Aventis; Boston Scientific; Siemens Medical; Abiomed; Accumetrics; Boehringer-Ingelheim; Medicure; Ortho-McNeil; Corgenix/AspirinWorks; Haemoscope; Helena; Thrombovision; Terumo	Nycomed Pharma, Unterschleissheim, Germany; Deutsches Herzzentrum, Munich, Germany; AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Daiichi Sankyo/Eli Lilly(Daiichi Sankyo Company LimitedEli Lilly); Abbott(Abbott Laboratories); Biotronik; Cordis; Medtronic(Medtronic); Medicines Company; Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Boston Scientific(Boston Scientific); Siemens Medical; Abiomed; Accumetrics; Boehringer-Ingelheim(Boehringer Ingelheim); Medicure; Ortho-McNeil; Corgenix/AspirinWorks; Haemoscope; Helena; Thrombovision; Terumo	Supported in part by Nycomed Pharma, Unterschleissheim, Germany (former distributor of bivalirudin in Europe), and a grant (KKF 04-06 [974404]) from Deutsches Herzzentrum, Munich, Germany.; Dr. Kastrati reports receiving consulting fees from AstraZeneca, Bristol-Myers Squibb, and Daiichi Sankyo/Eli Lilly and lecture fees from Abbott, Biotronik, Cordis, and Medtronic; Dr. Neumann, receiving consulting fees and grant support from Daiichi Sankyo/Eli Lilly and lecture fees from AstraZeneca, Daiichi Sankyo/Eli Lilly, the Medicines Company, Novartis, and Sanofi-Aventis; Dr. Ferenc, receiving lecture fees from AstraZeneca, Biotronic, Boston Scientific, Cordis, and Daiichi Sankyo/Eli Lilly; Dr. Hausleiter, receiving grant support and lecture fees from Siemens Medical; Dr. Seyfarth, receiving consulting fees from Abiomed and Sanofi-Aventis and lecture fees from Daiichi Sankyo/Eli Lilly and Novartis; Dr. Antoniucci, holding board memberships with Cordis and CID and receiving consulting fees from Daiichi Sankyo/Eli Lilly and the Medicines Company; Dr. Berger, receiving consulting fees from Accumetrics, AstraZeneca, Boehringer-Ingelheim, Daiichi Sankyo/Eli Lilly, Medicure, and Ortho-McNeil and grant support from Accumetrics, AstraZeneca, Corgenix/AspirinWorks, Haemoscope, Helena, the Medicines Company, and Thrombovision; and Dr. Mehilli, receiving lecture fees from Abbott, Daiichi Sankyo/Eli Lilly, and Terumo. No other potential conflict of interest relevant to this article was reported.	Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Busch G, 2009, THROMB HAEMOSTASIS, V101, P340, DOI 10.1160/TH08-09-0582; Kastrati A, 2008, NEW ENGL J MED, V359, P983; Kastrati A, 2006, JAMA-J AM MED ASSOC, V295, P1531, DOI 10.1001/jama.295.13.joc60034; Kastrati A, 2004, NEW ENGL J MED, V350, P232, DOI 10.1056/NEJMoa031859; Kastrati A, 2008, NEW ENGL J MED, V359, P688, DOI 10.1056/NEJMoa0802944; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mehilli J, 2004, CIRCULATION, V110, P3627, DOI 10.1161/01.CIR.0000148956.93631.4D; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; Ndrepepa G, 2008, J AM COLL CARDIOL, V51, P690, DOI 10.1016/j.jacc.2007.10.040; Neumann FJ, 2001, J AM COLL CARDIOL, V37, P1323, DOI 10.1016/S0735-1097(01)01165-2; Neumann FJ, 1999, J AM COLL CARDIOL, V34, P1420, DOI 10.1016/S0735-1097(99)00350-2; Rajagopal V, 2006, AM HEART J, V152, P149, DOI 10.1016/j.ahj.2005.09.007; Sibbing D, 2008, EUR HEART J, V29, P1504, DOI 10.1093/eurheartj/ehn195; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Stone GW, 2007, LANCET, V369, P907, DOI 10.1016/S0140-6736(07)60450-4; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; Stone GW, 2011, LANCET, V377, P2193, DOI 10.1016/S0140-6736(11)60764-2; Wright RS, 2011, CIRCULATION, V123, P2022, DOI 10.1161/CIR.0b013e31820f2f3e; Wright RS, 2011, CIRCULATION, V123, pE625, DOI 10.1161/CIR.0b013e31822319d0; TIMI DEFINITIONS COM	23	213	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2011	365	21					1980	1989		10.1056/NEJMoa1109596	http://dx.doi.org/10.1056/NEJMoa1109596			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851PF	22077909				2022-12-28	WOS:000297282600008
J	Moussion, C; Girard, JP				Moussion, Christine; Girard, Jean-Philippe			Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules	NATURE			English	Article							VASCULAR ADDRESSIN EXPRESSION; SELECTIN LIGAND BIOSYNTHESIS; TUMOR-NECROSIS-FACTOR; CD8(+) T-CELLS; IN-VIVO; BONE-MARROW; TRAFFICKING; VESSELS; PROLIFERATION; MODULATION	While patrolling the body in search of foreign antigens, naive lymphocytes continuously circulate from the blood, through the lymph nodes, into the lymphatic vessels and back to the blood(1,2). This process, called lymphocyte recirculation, provides the body with effective immune surveillance for foreign invaders and for alterations to the body's own cells. However, the mechanisms that regulate lymphocyte recirculation during homeostasis remain incompletely characterized. Here we show that dendritic cells (DCs), which are well known for their role in antigen presentation to T lymphocytes(3), control the entry of naive lymphocytes to lymph nodes by modulating the phenotype of high endothelial venules (HEVs), which are blood vessels specialized in lymphocyte recruitment(2,4,5). We found that in vivo depletion of CD11c(+) DCs in adult mice over a 1-week period induces a reduction in the size and cellularity of the peripheral and mucosal lymph nodes. In the absence of DCs, the mature adult HEV phenotype reverts to an immature neonatal phenotype, and HEV-mediated lymphocyte recruitment to lymph nodes is inhibited. Co-culture experiments showed that the effect of DCs on HEV endothelial cells is direct and requires lymphotoxin-beta-receptor-dependent signalling. DCs express lymphotoxin, and DC-derived lymphotoxin is important for lymphocyte homing to lymph nodes in vivo. Together, our results reveal a previously unsuspected role for DCs in the regulation of lymphocyte recirculation during immune surveillance.	[Moussion, Christine; Girard, Jean-Philippe] CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; [Moussion, Christine; Girard, Jean-Philippe] Univ Toulouse, UPS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Girard, JP (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691	Ligue Nationale Contre le Cancer; Association pour la Recherche contre le Cancer (ARC) [8505]; French Ministry of Research; Fondation RITC	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Fondation RITC	We are grateful to S. Rosen, J. Lowe and J. Browning for the gift of antibodies, to H. Korner, T. Winkler, E. Donnadieu, M. Lipp, O. Lantz, B. Ryffel, L. Brault, S. A. Nedospasov and S. Jung for providing mice, to J. van Meerwijk for critical reading of the manuscript, and to N. Ortega, E. Bellard and F. El-Fahqui-Olive for help with immunohistochemistry, intravital microscopy and cell sorting, respectively. We thank the IPBS TRI imaging facility, A. Dujardin and the IPBS animal and transgenic facilities for help with animal experiments, and F. Viala for preparation of the figures. This work was supported by grants from the Ligue Nationale Contre le Cancer (Equipe labellisee Ligue 2009 to J.-P.G.) and the Association pour la Recherche contre le Cancer (ARC, equipment 8505). C. M. was supported by fellowships from the French Ministry of Research, the ARC and Fondation RITC.	Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Bajenoff M, 2003, J EXP MED, V198, P715, DOI 10.1084/jem.20030167; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Browning JL, 2005, IMMUNITY, V23, P539, DOI 10.1016/j.immuni.2005.10.002; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carriere V, 2005, CANCER RES, V65, P11639, DOI 10.1158/0008-5472.CAN-05-1190; Cayrol C, 2007, BLOOD, V109, P584, DOI 10.1182/blood-2006-03-012013; Chen Q, 2006, NAT IMMUNOL, V7, P1299, DOI 10.1038/ni1406; Flaishon L, 2008, BLOOD, V112, P5016, DOI 10.1182/blood-2007-12-129122; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; HENDRIKS HR, 1983, EUR J IMMUNOL, V13, P663, DOI 10.1002/eji.1830130811; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kawashima H, 2005, NAT IMMUNOL, V6, P1096, DOI 10.1038/ni1259; Korner H, 1997, EUR J IMMUNOL, V27, P2600, DOI 10.1002/eji.1830271020; Kuprash DV, 2002, MOL CELL BIOL, V22, P8626, DOI 10.1128/MCB.22.24.8626-8634.2002; Lacorre DA, 2004, BLOOD, V103, P4164, DOI 10.1182/blood-2003-10-3537; Liao S, 2006, J IMMUNOL, V177, P3369, DOI 10.4049/jimmunol.177.5.3369; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MEBIUS RE, 1993, J IMMUNOL, V151, P6769; Mebius RE, 1996, P NATL ACAD SCI USA, V93, P11019, DOI 10.1073/pnas.93.20.11019; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miyasaka M, 2004, NAT REV IMMUNOL, V4, P360, DOI 10.1038/nri1354; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Muniz LR, 2011, J IMMUNOL, V187, P828, DOI 10.4049/jimmunol.1004233; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Sapoznikov A, 2008, NAT IMMUNOL, V9, P388, DOI 10.1038/ni1571; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Swarte VVR, 1998, EUR J IMMUNOL, V28, P3040, DOI 10.1002/(SICI)1521-4141(199810)28:10<3040::AID-IMMU3040>3.0.CO;2-5; Uchimura K, 2005, NAT IMMUNOL, V6, P1105, DOI 10.1038/ni1258; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303; Webster B, 2006, J EXP MED, V203, P1903, DOI 10.1084/jem.20052272; Zaft T, 2005, J IMMUNOL, V175, P6428, DOI 10.4049/jimmunol.175.10.6428	37	208	211	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2011	479	7374					542	U273		10.1038/nature10540	http://dx.doi.org/10.1038/nature10540			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22080953				2022-12-28	WOS:000297285600054
J	Donner, SD; Kandlikar, M; Zerriffi, H				Donner, Simon D.; Kandlikar, Milind; Zerriffi, Hisham			Preparing to Manage Climate Change Financing	SCIENCE			English	Editorial Material									[Donner, Simon D.] Univ British Columbia, Dept Geog, Vancouver, BC V6T 1Z2, Canada; [Kandlikar, Milind; Zerriffi, Hisham] Univ British Columbia, Liu Inst Global Issues, Vancouver, BC V6T 1Z2, Canada; [Kandlikar, Milind] Univ British Columbia, Inst Resources Environm & Sustainabil, Vancouver, BC V6T 1Z2, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Donner, SD (corresponding author), Univ British Columbia, Dept Geog, Vancouver, BC V6T 1Z2, Canada.	simon.donner@ubc.ca		Zerriffi, Hisham/0000-0003-4890-2575				Agarwal Anil, 2011, HDB CLIMATE CHANGE I; Banerjee A., 2011, POOR EC; Cohen J, 2010, Q J ECON, V125, P1, DOI 10.1162/qjec.2010.125.1.1; Easterly W, 2009, J ECON LIT, V47, P373, DOI 10.1257/jel.47.2.373; Fleck RK, 2010, J DEV ECON, V91, P185, DOI 10.1016/j.jdeveco.2009.09.011; Parry M.L., 2009, ASSESSING COSTS ADAP; Sovacool BK, 2011, CLIM POLICY, V11, P1177, DOI 10.1080/14693062.2011.579315; Stirrat J, 2006, ANTHROPOL TODAY, V22, P11, DOI 10.1111/j.1467-8322.2006.00459.x; Svensson J, 2008, REINVENTING FOREIGN AID, P311; UNFCCC. 2011, 2010, P C PART ITS 16 SESS; United Nations Framework Convention on Climate Change (UNFCCC), 2011, REP TRANS COMM DES G; Wara M, 2007, NATURE, V445, P595, DOI 10.1038/445595a; World Resources Institute, 2011, SUMM DEV COUNTR FAST; [No title captured]; [No title captured]; [No title captured]; [No title captured]	17	32	32	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					908	909		10.1126/science.1211886	http://dx.doi.org/10.1126/science.1211886			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	849CA	22096175				2022-12-28	WOS:000297101800031
J	Freidin, E; Kacelnik, A				Freidin, Esteban; Kacelnik, Alex			Rational Choice, Context Dependence, and the Value of Information in European Starlings (Sturnus vulgaris)	SCIENCE			English	Article							PREFERENCE; MEMORY; REWARD; COSTS; LONG	Both human and nonhuman decision-makers can deviate from optimal choice by making context-dependent choices. Because ignoring context information can be beneficial, this is called a "less-is-more effect." The fact that organisms are so sensitive to the context is thus paradoxical and calls for the inclusion of an ecological perspective. In an experiment with starlings, adding cues that identified the context impaired performance in simultaneous prey choices but improved it in sequential prey encounters, in which subjects could reject opportunities in order to search instead in the background. Because sequential prey encounters are likely to be more frequent in nature, storing and using contextual information appears to be ecologically rational on balance by conditioning acceptance of each opportunity to the relative richness of the background, even if this causes context-dependent suboptimal preferences in (less-frequent) simultaneous choices. In ecologically relevant scenarios, more information seems to be more.	[Freidin, Esteban; Kacelnik, Alex] Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Kacelnik, A (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	alex.kacelnik@zoo.ox.ac.uk	Freidin, Esteban/AAE-7426-2020		European Union [E04D031814AR]; Overseas Research Student Scheme Award UK; UK Biotechnology and Biological Sciences Research Council [BB/G007144/1]; Biotechnology and Biological Sciences Research Council [BB/G007144/1] Funding Source: researchfish; BBSRC [BB/G007144/1] Funding Source: UKRI	European Union(European Commission); Overseas Research Student Scheme Award UK; UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This research was supported by the Programme Al beta an (the European Union program of High Level Scholarships for Latin America) scholarship E04D031814AR and Overseas Research Student Scheme Award UK to E. F., and UK Biotechnology and Biological Sciences Research Council grant BB/G007144/1 to A. K. The authors declare no competing financial interests or conflict of interest. E. F. performed the experiment and collected, processed, and analyzed the data. Both authors shared the experimental design and writing of the paper.	ARKES HR, 1985, ORGAN BEHAV HUM DEC, V35, P124, DOI 10.1016/0749-5978(85)90049-4; ARONSON E, 1961, J ABNORM SOC PSYCH, V63, P375, DOI 10.1037/h0046890; Aw JM, 2009, BEHAV PROCESS, V81, P333, DOI 10.1016/j.beproc.2008.09.002; BELKE TW, 1992, ANIM LEARN BEHAV, V20, P401, DOI 10.3758/BF03197963; Catania A.C., 1970, THEORY REINFORCEMENT, P1; CHARNOV EL, 1976, AM NAT, V110, P141, DOI 10.1086/283054; CHARNOV EL, 1976, THEOR POPUL BIOL, V9, P129, DOI 10.1016/0040-5809(76)90040-X; Clement TS, 2000, PSYCHON B REV, V7, P100, DOI 10.3758/BF03210727; Dukas R, 1999, J THEOR BIOL, V197, P41, DOI 10.1006/jtbi.1998.0856; Flaherty C.F., 1996, INCENTIVE RELATIVITY; Golstein D. G., 2008, HDB EXPT EC RESULTS, P987; HUBER J, 1982, J CONSUM RES, V9, P90, DOI 10.1086/208899; JOHNSTON TD, 1982, ADV STUD BEHAV, V12, P65, DOI 10.1016/S0065-3454(08)60046-7; Kacelnik A, 2002, ANIM BEHAV, V63, P245, DOI 10.1006/anbe.2001.1900; Mery F, 2005, SCIENCE, V308, P1148, DOI 10.1126/science.1111331; Pompilio L, 2006, SCIENCE, V311, P1613, DOI 10.1126/science.1123924; Pompilio L, 2005, ANIM BEHAV, V70, P571, DOI 10.1016/j.anbehav.2004.12.009; Pompilio L, 2010, P NATL ACAD SCI USA, V107, P508, DOI 10.1073/pnas.0907250107; ROBERTS S, 1981, J EXP PSYCHOL ANIM B, V7, P242, DOI 10.1037/0097-7403.7.3.242; Samuelson P. A., 2010, ECONOMICS; Schultz W, 2004, CURR OPIN NEUROBIOL, V14, P139, DOI 10.1016/j.conb.2004.03.017; Shapiro MS, 2008, J EXP PSYCHOL-ANIM B, V34, P75, DOI 10.1037/0097-7403.34.1.75; SIMONSON I, 1992, J MARKETING RES, V29, P281, DOI 10.2307/3172740; Stephens D.W., 1986, pi; Stephens DW, 2001, BEHAV ECOL, V12, P330, DOI 10.1093/beheco/12.3.330; Waite TA, 2001, BEHAV ECOL, V12, P318, DOI 10.1093/beheco/12.3.318	26	51	51	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2011	334	6058					1000	1002		10.1126/science.1209626	http://dx.doi.org/10.1126/science.1209626			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096203				2022-12-28	WOS:000297101800062
J	Lavine, M; Szuromi, P; Coontz, R				Lavine, Marc; Szuromi, Phillip; Coontz, Robert			Electricity Now and When INTRODUCTION	SCIENCE			English	Editorial Material																			0	3	3	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					921	921		10.1126/science.334.6058.921	http://dx.doi.org/10.1126/science.334.6058.921			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CA	22096184				2022-12-28	WOS:000297101800040
J	Schulman, S; Parpia, S; Stewart, C; Rudd-Scott, L; Julian, JA; Levine, M				Schulman, Sam; Parpia, Sameer; Stewart, Clare; Rudd-Scott, Lisa; Julian, Jim A.; Levine, Mark			Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; INTERVALS; THERAPY	Background: Guidelines recommend that patients receiving warfarin undergo international normalized ratio (INR) monitoring every 4 weeks. Objective: To investigate whether assessment of warfarin dosing every 12 weeks is as safe as assessment every 4 weeks. Design: Noninferiority randomized trial. The randomization schedule (in a 1: 1 ratio) was computer-generated, and allocation was concealed until the database was locked by using a centralized schedule. Patients, study and clinical personnel, adjudicators of clinical events, and the study statistician were blinded to treatment assignment. (ClinicalTrials.gov registration number: NCT00356759) Setting: Single center in Hamilton, Ontario, Canada. Patients: 250 patients receiving long-term warfarin therapy, whose dose was unchanged for at least 6 months; 226 completed the study. Intervention: Dosing assessment every 12 weeks (n = 124) compared with every 4 weeks (n = 126) for 12 months. Patients in the 12-week group were tested every 4 weeks; sham INRs within the target range were reported for two of the three 4-week periods. Measurements: Percentage of time in the therapeutic range (primary outcome) and number of extreme INRs, changes in maintenance dose, major bleeding events, objectively verified thromboembolism, and death (secondary outcomes). Results: The percentage of time in the therapeutic range was 74.1% (SD, 18.8%) in the 4-week group compared with 71.6% (SD, 20.0%) in the 12-week group (absolute difference, 2.5 percentage points [1-sided 97.5% upper confidence bound, 7.3 percentage points]; noninferiority P = 0.020 for a 7.5-percentage point margin). Fewer patients in the 12-week group than in the 4-week group had any dose changes (37.1% vs. 55.6%; absolute difference, 18.5 percentage points [95% CI, 6.1 to 30.0 percentage points]; P = 0.004). Secondary outcomes did not differ between groups. Limitations: Patients in the 12-week group had testing and contact with clinic staff every 4 weeks. The study was conducted at a single center and used surrogate outcomes. Conclusion: Assessment of warfarin dosing every 12 weeks seems to be safe and noninferior to assessment every 4 weeks. A comparison of INR testing, patient contact, and warfarin dose assessment every 12 weeks versus every 4 weeks is necessary before INR testing every 12 weeks can be routinely recommended for practice.	McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada; Ontario Clin Oncol Grp, Hamilton, ON, Canada	McMaster University	Schulman, S (corresponding author), Hamilton Hlth Sci Gen Hosp, Thrombosis Serv, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	schulms@mcmaster.ca	Schulman, Sam/I-7559-2019	Schulman, Sam/0000-0002-8512-9043	Physicians' Services Incorporated Foundation [06-21]	Physicians' Services Incorporated Foundation	Grant Support: By the Physicians' Services Incorporated Foundation (grant 06-21).	American Heart Association, 2009, HEART DIS STROK STAT; [Anonymous], 1998, BR J HAEMATOL, V101, P374; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Banet GA, 2003, CHEST, V123, P499, DOI 10.1378/chest.123.2.499; Lidstone V, 2000, CLIN LAB HAEMATOL, V22, P291, DOI 10.1046/j.1365-2257.2000.00315.x; Pengo V, 2003, AM J CLIN PATHOL, V120, P944, DOI 10.1309/U7164E0XH5UERKRV; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schulman S, 2010, J THROMB HAEMOST, V8, P2192, DOI 10.1111/j.1538-7836.2010.03989.x; Schulman S, 2010, THROMB RES, V125, P393, DOI 10.1016/j.thromres.2009.07.006; Schulman S, 2005, HAEMATOLOGICA, V90, P132; van Walraven C, 2009, J CLIN EPIDEMIOL, V62, P1306, DOI 10.1016/j.jclinepi.2009.01.015; Weitz JI, 2008, CHEST, V133, p234S, DOI 10.1378/chest.08-0673	13	69	72	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10					653	+		10.7326/0003-4819-155-10-201111150-00003	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EI	22084331				2022-12-28	WOS:000297108000001
J	Haddad, L				Haddad, Lawrence			Why India needs a national nutrition strategy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHILD UNDERNUTRITION; CONSEQUENCES; HEALTH; STATES; FOOD		Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England	University of Sussex	Haddad, L (corresponding author), Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England.	l.haddad@ids.ac.uk						[Anonymous], 2011, HINDU           0721; [Anonymous], 2003, 131 IFPRI; [Anonymous], 2005, PERF EV TARG PUBL DI; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Christiaensen L, 2010, 201036 WIDER; Haddad L, 2009, IDS BULL-I DEV STUD, V40, P1, DOI 10.1111/j.1759-5436.2009.00052.x; Hagen Zanker J., 2011, SYSTEMATIC REV IMPAC; Harriss J, 2009, IDS BULL-I DEV STUD, V40, P9, DOI 10.1111/j.1759-5436.2009.00053.x; Himaz R, 2009, IDS BULL-I DEV STUD, V40, P30, DOI 10.1111/j.1759-5436.2009.00056.x; Horton S., 2008, MALNUTRITION HUNGER; Indian Ministry of Health and Family Welfare, 2009, NAT FAM HLTH SURV 3; Int Mon Fund, 2011, WOR ECON OUTLOOK, P1; Kandpal E, WORLD DEV IN PRESS; Low JW, 2007, J NUTR, V137, P1320; Masset E, 2011, EFFECTIVENE IN PRESS; Mehrotra S, 2010, IND EC J, V58, P140; Menon P, 2009, IDS BULL-I DEV STUD, V40, P60, DOI 10.1111/j.1759-5436.2009.00060.x; Pattanayak SK, 2009, B WORLD HEALTH ORGAN, V87, P580, DOI 10.2471/BLT.08.057422; Ramalingaswami V, 1996, PROGR NATIONS; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; Rocha C, 2009, DEV POLICY REV, V27, P51, DOI 10.1111/j.1467-7679.2009.00435.x; Saxena NC, 2009, IDS BULL-I DEV STUD, V40, P45, DOI 10.1111/j.1759-5436.2009.00058.x; Singh A., 2008, DO SCH MEALS WORK TR; Subramanyam MA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000424; Thorat S, 2009, IDS BULL-I DEV STUD, V40, P25, DOI 10.1111/j.1759-5436.2009.00055.x; UNICEF, 1990, STRAT IMPR NUTR CHIL; Ved R., 2011, ASHA WHICH WAY FORWA; Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X; WHO/UNICEF-Joint Monitoring Program, 2010, PROGR SAN DRINK WAT; World Health Organization, 2000, HLTH SYST IMPR PERF	31	12	12	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2011	343								d6687	10.1136/bmj.d6687	http://dx.doi.org/10.1136/bmj.d6687			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NY	22080488				2022-12-28	WOS:000297059500010
J	James, S; Simmons, CP; James, AA				James, Stephanie; Simmons, Cameron P.; James, Anthony A.			Mosquito Trials	SCIENCE			English	Editorial Material							TRANSMISSION		[James, Stephanie] Fdn NIH, Bethesda, MD 20814 USA; [Simmons, Cameron P.] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Wellcome Trust Major Overseas Program, Ho Chi Minh City, Vietnam; [James, Anthony A.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; [James, Anthony A.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	National Institutes of Health (NIH) - USA; University of Oxford; University of California System; University of California Irvine; University of California System; University of California Irvine	James, S (corresponding author), Fdn NIH, Bethesda, MD 20814 USA.	sjames@fnih.org; csimmons@oucru.org; aajames@uci.edu	Simmons, Cameron P/ABA-3896-2021	Simmons, Cameron P/0000-0002-9039-7392; James, Anthony/0000-0001-5577-3308				Halstead SB, 2008, ANNU REV ENTOMOL, V53, P273, DOI 10.1146/annurev.ento.53.103106.093326; Harris AF, 2011, NAT BIOTECHNOL, V29, P1034, DOI 10.1038/nbt.2019; Hoffmann AA, 2011, NATURE, V476, P454, DOI 10.1038/nature10356; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; Sinkins SP, 2006, NAT REV GENET, V7, P427, DOI 10.1038/nrg1870; Subbaraman N, 2011, NAT BIOTECHNOL, V29, P9, DOI 10.1038/nbt0111-9a	6	22	22	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					771	772		10.1126/science.1213798	http://dx.doi.org/10.1126/science.1213798			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	845US	22076370				2022-12-28	WOS:000296849600036
J	Pearlman, SM; Serber, Z; Ferrell, JE				Pearlman, Samuel M.; Serber, Zach; Ferrell, James E., Jr.			A Mechanism for the Evolution of Phosphorylation Sites	CELL			English	Article							MULTIPLE SEQUENCE ALIGNMENT; ISOCITRATE DEHYDROGENASE; PROTEIN FUNCTION; HUMAN GENOME; MAP KINASE; LIFE; TREE; SPECIFICITY; ACTIVATION; PREDICTION	Protein phosphorylation provides a mechanism for the rapid, reversible control of protein function. Phosphorylation adds negative charge to amino acid side chains, and negatively charged amino acids (Asp/Glu) can sometimes mimic the phosphorylated state of a protein. Using a comparative genomics approach, we show that nature also employs this trick in reverse by evolving serine, threonine, and tyrosine phosphorylation sites from Asp/Glu residues. Structures of three proteins where phosphosites evolved from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the relevant acidic residues are present in salt bridges with conserved basic residues, and that phosphorylation has the potential to conditionally restore the salt bridges. The evolution of phosphorylation sites from glutamate and aspartate provides a rationale for why phosphorylation sometimes activates proteins, and helps explain the origins of this important and complex process.	[Pearlman, Samuel M.; Serber, Zach; Ferrell, James E., Jr.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Pearlman, Samuel M.] Stanford Univ, Sch Med, Biomed Informat Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA.	james.ferrell@stanford.edu			National Institutes of Health [R01 GM046383, T15 LM007033]; Arnold Beckman Foundation; NIH [P41 RR001081]; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007033] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Arnold Beckman Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Kurt Thorn, Peter Chien, Michael Reese, Arend Sidow, Serafim Batzoglou, Rob Tibshirani, Bill Weis, the participants of the 2011 Evolution of Protein Phosphorylation Keystone Meeting, our colleagues in the Stanford Department of Chemical and Systems Biology, and members of the Ferrell lab for many helpful comments. This work was supported by grants from the National Institutes of Health (R01 GM046383 and T15 LM007033) and the Arnold Beckman Foundation. Molecular graphics images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH P41 RR001081).	Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dayhoff M., 1978, ATLAS PROTEIN SEQUEN; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Essoussi N, 2008, BIOINFORMATION, V2, P452; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Holt LJ, 2009, SCIENCE, V325, P1682, DOI 10.1126/science.1172867; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; Jorgensen R, 2006, BIOCHEM SOC T, V34, P1; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Kurmangaliyev YZ, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-8; Laub MT, 2007, ANNU REV GENET, V41, P121, DOI 10.1146/annurev.genet.41.042007.170548; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moses AM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r23; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Pace NR, 2009, MICROBIOL MOL BIOL R, V73, P565, DOI 10.1128/MMBR.00033-09; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Schoeffler AJ, 2008, Q REV BIOPHYS, V41, P41, DOI 10.1017/S003358350800468X; Serber Z, 2007, CELL, V128, P441, DOI 10.1016/j.cell.2007.01.018; Strickfaden SC, 2007, CELL, V128, P519, DOI 10.1016/j.cell.2006.12.032; Taylor JW, 2006, MYCOLOGIA, V98, P838, DOI 10.3852/mycologia.98.6.838; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Tjong H, 2007, NUCLEIC ACIDS RES, V35, pW357, DOI 10.1093/nar/gkm231; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang ZH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000526	46	151	151	0	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 11	2011	147	4					934	946		10.1016/j.cell.2011.08.052	http://dx.doi.org/10.1016/j.cell.2011.08.052			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078888	Green Accepted, Bronze			2022-12-28	WOS:000296902300024
J	Stella, N				Stella, Nephi			Anatomy of Prostaglandin Signals	SCIENCE			English	Editorial Material							MICROGLIAL ACTIVATION; RECEPTORS; BLOCKADE; DISEASE; BRAIN		Univ Washington, Dept Pharmacol Psychiat & Behav Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stella, N (corresponding author), Univ Washington, Dept Pharmacol Psychiat & Behav Sci, Seattle, WA 98195 USA.	nstella@u.washington.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014486, R01DA026430] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA026430, R01 DA014486] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	13	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2011	334	6057					768	769		10.1126/science.1215389	http://dx.doi.org/10.1126/science.1215389			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	845US	22076368	Green Accepted			2022-12-28	WOS:000296849600034
J	de Souza, RKM; Martins, RT; da Rocha, SFB; Sato, HK; Kowacs, PA				Martinez de Souza, Ricardo Krause; Martins, Rodrigo Tomazini; Blattes da Rocha, Samanta Fabricio; Sato, Henry Koiti; Kowacs, Pedro Andre			Never too old	LANCET			English	Editorial Material							HYDROCEPHALUS; PRESSURE; DEMENTIA		[Martinez de Souza, Ricardo Krause; Martins, Rodrigo Tomazini; Sato, Henry Koiti; Kowacs, Pedro Andre] Inst Neurol Curitaba, Neurol Unit, BR-80210310 Curitiba, Brazil; [Blattes da Rocha, Samanta Fabricio] Inst Neurol Curitaba, Neuropsychol Unit, BR-80210310 Curitiba, Brazil		Kowacs, PA (corresponding author), Inst Neurol Curitaba, Serv Neurol, Rua Jeremias Maciel Perretto 300, BR-80210310 Curitiba, Brazil.	pkowacs@gmail.com	Paay, Jeni/M-6073-2018; Kowacs, Pedro André/AAL-8473-2021	Paay, Jeni/0000-0001-8328-6662; Rocha, Samanta Fabricio Blattes da/0000-0003-2231-8637; Tomazini Martins, Rodrigo/0000-0002-6415-0310				ADAMS RD, 1965, NEW ENGL J MED, V273, P117, DOI 10.1056/NEJM196507152730301; Lindau ST, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c810; Marmarou A, 2005, NEUROSURGERY, V57, P17, DOI 10.1227/01.NEU.0000168184.01002.60; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; McMurtray A, 2006, DEMENT GERIATR COGN, V21, P59, DOI 10.1159/000089546	5	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 5	2011	378	9803					1676	1676		10.1016/S0140-6736(11)61225-7	http://dx.doi.org/10.1016/S0140-6736(11)61225-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844ST	22055042				2022-12-28	WOS:000296768300033
J	Gatesman, ML; Smith, TJ				Gatesman, Mandy L.; Smith, Thomas J.			The Shortage of Essential Chemotherapy Drugs in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gatesman, Mandy L.] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA; [Smith, Thomas J.] Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Med, Baltimore, MD USA	Virginia Commonwealth University; Johns Hopkins University; Johns Hopkins Medicine	Gatesman, ML (corresponding author), Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA.			Smith, Thomas/0000-0003-3040-6434				Food and Drug Administration, CURR DRUG SHORT; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; Neubauer MA, 2010, J ONCOL PRACT, V6, P12, DOI 10.1200/JOP.091058; Twombly R, 2004, J NATL CANCER I, V96, P1268, DOI 10.1093/jnci/96.17.1268	5	85	86	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1653	1655		10.1056/NEJMp1109772	http://dx.doi.org/10.1056/NEJMp1109772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	840FL	22040130				2022-12-28	WOS:000296424200001
J	Jilek, C; Tzeis, S; Vrazic, H; Semmler, V; Andrikopoulos, G; Reents, T; Fichtner, S; Ammar, S; Rassias, I; Theodorakis, G; Weber, S; Hessling, G; Deisenhofer, I; Kolb, C				Jilek, Clemens; Tzeis, Stylianos; Vrazic, Hrvoje; Semmler, Verena; Andrikopoulos, Georgios; Reents, Tilko; Fichtner, Stephanie; Ammar, Sonia; Rassias, Ioannis; Theodorakis, Georgios; Weber, Stefan; Hessling, Gabriele; Deisenhofer, Isabel; Kolb, Christof			Safety of Screening Procedures With Hand-Held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices A Cross-sectional Analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVERTER-DEFIBRILLATORS; ELECTROMAGNETIC-INTERFERENCE; PERMANENT PACEMAKERS; MEDIA PLAYERS; TELEMETRY	Background: Case reports suggest that the hand-held metal detectors used for security screening generate electromagnetic fields that may interfere with pacemaker and implantable cardioverter-defibrillator (ICD) function. Objective: To assess changes in function of pacemakers and ICDs after exposure to hand-held metal detectors. Design: Cross-sectional study. Setting: Two medical centers in Europe. Patients: 388 patients (209 with pacemakers and 179 with ICDs) presenting for routine follow-up of device function between September 2009 and December 2010. Measurements: Abnormalities on electrocardiography suggestive of rhythm device malfunction (pacing inhibition, loss of capture, inappropriate mode switch, ventricular oversensing, and spontaneous reprogramming) after 30 seconds of exposure to 2 widely used hand-held metal detectors with a maximal electromagnetic flux density of 6.3 mu T. Results: No change in device function, including pacing or sensing abnormalities or device reprogramming, was observed in any patient. Limitations: The study included a convenience sample of patients, and the number of different device models tested was small. Testing was conducted in 2 clinic settings. Conclusion: Hand-held metal detectors did not affect the function of pacemakers or ICDs in this sample. The use of hand-held metal detectors for security screening is probably safe for patients with pacemakers and ICDs, but these findings require confirmation. Primary Funding Source: None.	[Jilek, Clemens] Deutsch Herzzentrum Munich, D-80636 Munich, Germany; Tech Univ Munich, Fac Med, Med Klin Klinikum Rechts Isar 1, Munich, Germany; Henry Dunant Hosp, Athens 11526, Greece; Univ Hosp Dubrava, Zagreb 10000, Croatia; Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany	German Heart Centre Munich; Technical University of Munich; Henry Dunant Hospital; University of Regensburg	Jilek, C (corresponding author), Deutsch Herzzentrum Munich, Lazarettstr 36, D-80636 Munich, Germany.	research@jilek.de	Vrazic, Hrvoje/F-6450-2012	Vrazic, Hrvoje/0000-0001-8151-9899; Deisenhofer, Isabel/0000-0001-5826-6846; Jilek, Clemens/0000-0001-9558-6240	European Heart Rhythm Association	European Heart Rhythm Association	Dr. Vrazic was supported by an educational fellowship of the European Heart Rhythm Association.	Burlington B, 1998, IMPORTANT INFORM ANT; Chiladakis JA, 2001, EUR HEART J, V22, P1337, DOI 10.1053/euhj.2000.2516; COPPERMAN Y, 1988, PACE, V11, P1386, DOI 10.1111/j.1540-8159.1988.tb04985.x; Kolb C, 2004, PACE, V27, P221, DOI 10.1111/j.1540-8159.2004.00414.x; Kolb C, 2003, J AM COLL CARDIOL, V41, P2054, DOI 10.1016/S0735-1097(03)00424-8; Kolb C, 2001, PACE, V24, P465, DOI 10.1046/j.1460-9592.2001.00465.x; Mugica J, 2000, PACE, V23, P333, DOI 10.1111/j.1540-8159.2000.tb06758.x; Pinski SL, 2002, PACE, V25, P1496, DOI 10.1046/j.1460-9592.2002.01496.x; Pinski SL, 2002, PACE, V25, P1367, DOI 10.1046/j.1460-9592.2002.01367.x; Rickli H, 2003, PACE, V26, P1494, DOI 10.1046/j.1460-9592.2003.t01-1-00216.x; Santucci PA, 1998, NEW ENGL J MED, V339, P1371, DOI 10.1056/NEJM199811053391905; Shah AJ, 2010, PACE, V33, P712, DOI [10.1111/J.1540-8159.2009.02672.X, 10.1111/j.1540-8159.2009.02672.x]; Thaker JP, 2008, HEART RHYTHM, V5, P538, DOI 10.1016/j.hrthm.2008.01.028; The European Society of Cardiology Guidelines for the diagnosis and management of syncope reviewed by Angel Moya, 2009, EUR HEART J, V30, P2539; Trigano A, 2005, HEART RHYTHM, V2, P837, DOI 10.1016/j.hrthm.2005.03.011; Webster G, 2008, HEART RHYTHM, V5, P545, DOI 10.1016/j.hrthm.2008.02.033	16	19	19	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					587	U53		10.7326/0003-4819-155-9-201111010-00005	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041947				2022-12-28	WOS:000296612400003
J	Trompouki, E; Bowman, TV; Lawton, LN; Fan, ZP; Wu, DC; DiBiase, A; Martin, CS; Cech, JN; Sessa, AK; Leblanc, JL; Li, PL; Durand, EM; Mosimann, C; Heffner, GC; Daley, GQ; Paulson, RF; Young, RA; Zon, LI				Trompouki, Eirini; Bowman, Teresa V.; Lawton, Lee N.; Fan, Zi Peng; Wu, Dai-Chen; DiBiase, Anthony; Martin, Corey S.; Cech, Jennifer N.; Sessa, Anna K.; Leblanc, Jocelyn L.; Li, Pulin; Durand, Ellen M.; Mosimann, Christian; Heffner, Garrett C.; Daley, George Q.; Paulson, Robert F.; Young, Richard A.; Zon, Leonard I.			Lineage Regulators Direct BMP and Wnt Pathways to Cell-Specific Programs during Differentiation and Regeneration	CELL			English	Article							EMBRYONIC STEM-CELLS; UCSC GENOME BROWSER; TRANSCRIPTION FACTORS; BETA-CATENIN; MEGAKARYOCYTIC DIFFERENTIATION; HEMATOPOIETIC PROGENITORS; SIGNALING PATHWAYS; GENE ACTIVATION; GAMMA-CATENIN; PROTEIN	BMP and Wnt signaling pathways control essential cellular responses through activation of the transcription factors SMAD (BMP) and TCF (Wnt). Here, we show that regeneration of hematopoietic lineages following acute injury depends on the activation of each of these signaling pathways to induce expression of key blood genes. Both SMAD1 and TCF7L2 co-occupy sites with master regulators adjacent to hematopoietic genes. In addition, both SMAD1 and TCF7L2 follow the binding of the predominant lineage regulator during differentiation from multipotent hematopoietic progenitor cells to erythroid cells. Furthermore, induction of the myeloid lineage regulator C/EBP alpha in erythroid cells shifts binding of SMAD1 to sites newly occupied by C/EBP alpha, whereas expression of the erythroid regulator GATA1 directs SMAD1 loss on nonerythroid targets. We conclude that the regenerative response mediated by BMP and Wnt signaling pathways is coupled with the lineage master regulators to control the gene programs defining cellular identity.	[Trompouki, Eirini; Bowman, Teresa V.; DiBiase, Anthony; Martin, Corey S.; Cech, Jennifer N.; Sessa, Anna K.; Leblanc, Jocelyn L.; Li, Pulin; Durand, Ellen M.; Mosimann, Christian; Zon, Leonard I.] Harvard Univ, Sch Med, Stem Cell Program, Boston, MA 02115 USA; [Trompouki, Eirini; Bowman, Teresa V.; DiBiase, Anthony; Martin, Corey S.; Cech, Jennifer N.; Sessa, Anna K.; Leblanc, Jocelyn L.; Li, Pulin; Durand, Ellen M.; Mosimann, Christian; Zon, Leonard I.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston,Harvard Stem Cell Inst, Boston, MA 02115 USA; [Trompouki, Eirini; Bowman, Teresa V.; DiBiase, Anthony; Martin, Corey S.; Cech, Jennifer N.; Sessa, Anna K.; Leblanc, Jocelyn L.; Li, Pulin; Durand, Ellen M.; Mosimann, Christian; Zon, Leonard I.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Lawton, Lee N.; Fan, Zi Peng; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Wu, Dai-Chen; Paulson, Robert F.] Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA; [Wu, Dai-Chen; Paulson, Robert F.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Heffner, Garrett C.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Heffner, Garrett C.; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Heffner, Garrett C.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Fan, Zi Peng] MIT, Computat & Syst Biol Program, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Zon, LI (corresponding author), Harvard Univ, Sch Med, Stem Cell Program, Boston, MA 02115 USA.	zon@enders.tch.harvard.edu	Trompouki, Eirini/AAX-9539-2020; cheng, yong/I-4270-2012	Trompouki, Eirini/0000-0002-7242-8810; Li, Pulin/0000-0002-8525-4936; /0000-0001-8855-8647; Mosimann, Christian/0000-0002-0749-2576	NIH [P50-NS40828, NIH-P30-HD18655, 5PO1HL32262-29, 5R01HL048801-18, 1R01DK080040-01, R01-HG002668, K01 DK085270-02, U01 HL100001, 1 RC2HL102815, T32HL007623]; ROFAR; HHMI; EMBO; Jane Coffin Childs Memorial Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623, F32HL082448, P01HL032262, R01HL048801, U01HL100001, RC2HL102815] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK085270, R01DK080040, P30DK056465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040828] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ROFAR; HHMI(Howard Hughes Medical Institute); EMBO(European Molecular Biology Organization (EMBO)); Jane Coffin Childs Memorial Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to acknowledge A. Mullen and D. Orlando for helpful discussions and sharing critical insights prior to publication and G. Frampton for analytical advice and development of the ChIP-seq analysis platform. We thank F. Rentzsch and M. Hammerschmidt for the Hs: BMP zebrafish line, J. Tucker and M. Mullins for the Hs: Chordin zebrafish line, and T. Schlaeger for the GATA2 expression plasmid. We are grateful to X. Bai and R. White for critical reviews of the manuscript and O. Tamplin for computational advice. The Whitehead Genome Technology Core was instrumental in timely data production and analysis support, especially S. Gupta. Microarray studies were performed by the Molecular Genetics Core Facility at Children's Hospital Boston, supported by NIH-P50-NS40828 and NIH-P30-HD18655. This work was supported by NIH # 5PO1HL32262-29 and # 5R01HL048801-18 (to L.I.Z), NIH 1R01DK080040-01 (to R. F. P.), R01-HG002668 (to R. A. Y.), NIH K01 DK085270-02 (to T. V. B.), NIH U01 HL100001, NIH 1 RC2HL102815, and ROFAR (to G. Q. D.), NIH T32HL007623 (to G. C. H.), HHMI (to L.I.Z. and G. Q. D.), and EMBO fellowship and Jane Coffin Childs Memorial Fund (to E. T.). L.I.Z. is a founder and stock holder of Fate, Inc. and a scientific advisor for Stemgent. G. Q. D. is a member of the Scientific Advisory Boards of MPM Capital, Inc., Epizyme, Inc., and iPierian, Inc.	Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bresnick EH, 2010, J BIOL CHEM, V285, P31087, DOI 10.1074/jbc.R110.159079; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Cantor AB, 2005, INT J HEMATOL, V81, P378, DOI 10.1532/IJH97.04180; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng X, 2008, DEVELOPMENT, V135, P3447, DOI 10.1242/dev.025916; Cheng Y, 2009, GENOME RES, V19, P2172, DOI 10.1101/gr.098921.109; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Detmer K, 2002, CYTOKINE, V17, P36, DOI 10.1006/cyto.2001.0984; Fuchs O, 2002, BLOOD CELL MOL DIS, V28, P221, DOI 10.1006/bcmd.2002.0487; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006; Ide Y, 2004, BLOOD, V104, P4097, DOI 10.1182/blood-2004-04-1476; Jeannet G, 2008, BLOOD, V111, P142, DOI 10.1182/blood-2007-07-102558; Jeanpierre S, 2008, BLOOD, V112, P3154, DOI 10.1182/blood-2008-03-145326; Koch U, 2008, BLOOD, V111, P160, DOI 10.1182/blood-2007-07-099754; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Larsson J, 2005, ONCOGENE, V24, P5676, DOI 10.1038/sj.onc.1208920; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lengerke C, 2008, CELL STEM CELL, V2, P72, DOI 10.1016/j.stem.2007.10.022; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; McReynolds LJ, 2007, BLOOD, V110, P3881, DOI 10.1182/blood-2007-04-085753; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Raney BJ, 2011, NUCLEIC ACIDS RES, V39, pD871, DOI 10.1093/nar/gkq1017; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961; Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Singbrant S, 2010, BLOOD, V115, P4689, DOI 10.1182/blood-2009-05-220988; Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111; Staal FJT, 2010, J CELL BIOCHEM, V109, P844, DOI 10.1002/jcb.22467; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Tran HT, 2010, P NATL ACAD SCI USA, V107, P16160, DOI 10.1073/pnas.1007725107; Traver D, 2004, BLOOD, V104, P1298, DOI 10.1182/blood-2004-01-0100; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsiftsoglou AS, 2009, IUBMB LIFE, V61, P800, DOI 10.1002/iub.226; Tucker JA, 2008, DEV CELL, V14, P108, DOI 10.1016/j.devcel.2007.11.004; Verzi MP, 2010, P NATL ACAD SCI USA, V107, P15157, DOI 10.1073/pnas.1003822107; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Weidinger G, 2005, CURR BIOL, V15, P489, DOI 10.1016/j.cub.2005.01.041; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, P1; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002	60	218	227	1	38	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 28	2011	147	3					577	589		10.1016/j.cell.2011.09.044	http://dx.doi.org/10.1016/j.cell.2011.09.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036566	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000296573700013
J	Jit, M; Stagg, HR; Aldridge, RW; White, PJ; Abubakar, I				Jit, Mark; Stagg, Helen R.; Aldridge, Robert W.; White, Peter J.; Abubakar, Ibrahim		Find Treat Evaluation Team	Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-STATUS; EPIDEMIOLOGY	Objective To assess the cost effectiveness of the Find and Treat service for diagnosing and managing hard to reach individuals with active tuberculosis. Design Economic evaluation using a discrete, multiple age cohort, compartmental model of treated and untreated cases of active tuberculosis. Setting London, United Kingdom. Population Hard to reach individuals with active pulmonary tuberculosis screened or managed by the Find and Treat service (48 mobile screening unit cases, 188 cases referred for case management support, and 180 cases referred for loss to follow-up), and 252 passively presenting controls from London's enhanced tuberculosis surveillance system. Main outcome measures Incremental costs, quality adjusted life years (QALYs), and cost effectiveness ratios for the Find and Treat service. Results The model estimated that, on average, the Find and Treat service identifies 16 and manages 123 active cases of tuberculosis each year in hard to reach groups in London. The service has a net cost of 1.4 pound million/year and, under conservative assumptions, gains 220 QALYs. The incremental cost effectiveness ratio was 6400- pound 10 pound 000/QALY gained (about (sic)7300-(sic)11 000 or $10 000-$16 000 in September 2011). The two Find and Treat components were also cost effective, even in unfavourable scenarios (mobile screening unit (for undiagnosed cases), 18000- pound 26 pound 000/QALY gained; case management support team, 4100- pound 6800 pound/QALY gained). Conclusions Both the screening and case management components of the Find and Treat service are likely to be cost effective in London. The cost effectiveness of the mobile screening unit in particular could be even greater than estimated, in view of the secondary effects of infection transmission and development of antibiotic resistance.	[Abubakar, Ibrahim] Hlth Protect Agcy, TB Sect, London NW9 5EQ, England; [Aldridge, Robert W.] Royal Free Hosp, Univ Coll London, Res Dept Infect & Populat Hlth, Ctr Infect Dis Epidemiol, London NW3 2QG, England; [White, Peter J.] Imperial Coll Sch Publ Hlth, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, Modelling & Econ Unit, London, England; [Abubakar, Ibrahim] Univ E Anglia, Norwich Med Sch, TB Sect, Norwich NR4 7TJ, Norfolk, England; [White, Peter J.] Hlth Protect Agcy, Modelling & Econ Unit, London NW9 5EQ, England	Health Protection Agency; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London; University of East Anglia; Health Protection Agency	Abubakar, I (corresponding author), Hlth Protect Agcy, TB Sect, London NW9 5EQ, England.	ibrahim.abubakar@hpa.org.uk	Jit, Mark/HDM-7797-2022	Aldridge, Robert/0000-0003-0542-0816; Abubakar, Ibrahim/0000-0002-0370-1430; Jit, Mark/0000-0001-6658-8255; Stagg, Helen/0000-0003-4022-3447	English Department of Health [0150305]; Medical Research Council; National Institute for Health Research; Medical Research Council [G0600719B] Funding Source: researchfish; National Institute for Health Research [ACF-2009-18-028] Funding Source: researchfish	English Department of Health; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by a grant from the English Department of Health (policy research programme grant reference number 0150305). PJW was partly funded by centre funding from the Medical Research Council. IA and HS are partly funded by the National Institute for Health Research. The authors' work was independent of the funders, who had no role in the study design, analysis of data, writing of the manuscript, or decision to submit for publication.	Anderson C, 2010, J EPIDEMIOL COMMUN H, V64, P373, DOI 10.1136/jech.2009.094375; Anderson SR, 2007, THORAX, V62, P162, DOI 10.1136/thx.2006.058313; [Anonymous], 1974, Bull World Health Organ, V51, P473; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Corbett EL, 2010, LANCET, V376, P1244, DOI 10.1016/S0140-6736(10)61425-0; Crampin AC, 2009, INT J TUBERC LUNG D, V13, P153; Crofts JP, 2008, PUBLIC HEALTH, V122, P1302, DOI 10.1016/j.puhe.2008.04.011; Curtis L., 2010, UNIT COSTS HLTH SOCI; de Vries G, 2007, AM J RESP CRIT CARE, V176, P201, DOI 10.1164/rccm.200612-1877OC; *DEP HLTH, 2011, NHS REF COSTS 2008 2; Dewilde S, 2004, MED DECIS MAKING, V24, P486, DOI 10.1177/0272989X04268953; Getahun H, 2010, LANCET, V376, P1205, DOI 10.1016/S0140-6736(10)61503-6; Guo N, 2008, VALUE HEALTH, V11, P1154, DOI 10.1111/j.1524-4733.2008.00355.x; Health Protection Agency, 2010, TUB UK ANN REP TUB S; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; Kruijshaar ME, 2010, INT J TUBERC LUNG D, V14, P296; Love J, 2009, INT J TUBERC LUNG D, V13, P201; Mangura BT, 1999, LANCET, V353, P319, DOI 10.1016/S0140-6736(98)10144-7; *NAT COLL CTR CHRO, 2006, TUB CLIN DIAGN MAN T; National Institute for Health and Clinical Excellence, 2008, GUID METH TECHN APPR; Neely F, 2010, J PUBLIC HEALTH-UK, V32, P44, DOI 10.1093/pubmed/fdp056; QUABECK L, 2009, COMP ANAL TUBERCULOS; Story A, 2007, THORAX, V62, P667, DOI 10.1136/thx.2006.065409; TOMAN K, 2004, TOMANS TUBERCULOSIS, P66; White VLC, 2000, THORAX, V55, P962, DOI 10.1136/thorax.55.11.962; Zumla A, 2011, LANCET, V377, P10, DOI 10.1016/S0140-6736(10)62176-9	26	70	70	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2011	343								d5376	10.1136/bmj.d5376	http://dx.doi.org/10.1136/bmj.d5376			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822VI	22067473	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000295077500013
J	Crosnier, C; Bustamante, LY; Bartholdson, SJ; Bei, AK; Theron, M; Uchikawa, M; Mboup, S; Ndir, O; Kwiatkowski, DP; Duraisingh, MT; Rayner, JC; Wright, GJ				Crosnier, Cecile; Bustamante, Leyla Y.; Bartholdson, S. Josefin; Bei, Amy K.; Theron, Michel; Uchikawa, Makoto; Mboup, Souleymane; Ndir, Omar; Kwiatkowski, Dominic P.; Duraisingh, Manoj T.; Rayner, Julian C.; Wright, Gavin J.			Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum	NATURE			English	Article							GENOME-WIDE; ASSOCIATION ANALYSIS; INTERACTION NETWORK; GENETIC-ANALYSIS; MALARIA; SELECTION; MOLECULE; HOMOLOG; LIGAND; CELLS	Erythrocyte invasion by Plasmodium falciparum is central to the pathogenesis of malaria. Invasion requires a series of extracellular recognition events between erythrocyte receptors and ligands on the merozoite, the invasive form of the parasite. None of the few known receptor-ligand interactions involved(1-4) are required in all parasite strains, indicating that the parasite is able to access multiple redundant invasion pathways(5). Here, we show that we have identified a receptor-ligand pair that is essential for erythrocyte invasion in all tested P. falciparum strains. By systematically screening a library of erythrocyte proteins, we have found that the Ok blood group antigen, basigin, is a receptor for PfRh5, a parasite ligand that is essential for blood stage growth(6). Erythrocyte invasion was potently inhibited by soluble basigin or by basigin knockdown, and invasion could be completely blocked using low concentrations of anti-basigin antibodies; importantly, these effects were observed across all laboratory-adapted and field strains tested. Furthermore, Ok(a-) erythrocytes, which express a basigin variant that has a weaker binding affinity for PfRh5, had reduced invasion efficiencies. Our discovery of a cross-strain dependency on a single extracellular receptor-ligand pair for erythrocyte invasion by P. falciparum provides a focus for new anti-malarial therapies.	[Crosnier, Cecile; Bartholdson, S. Josefin; Wright, Gavin J.] Wellcome Trust Sanger Inst, Cell Surface Signalling Lab, Cambridge CB10 1HH, England; [Bustamante, Leyla Y.; Theron, Michel; Kwiatkowski, Dominic P.; Rayner, Julian C.; Wright, Gavin J.] Wellcome Trust Sanger Inst, Malaria Programme, Cambridge CB10 1SA, England; [Bei, Amy K.; Duraisingh, Manoj T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Uchikawa, Makoto] Tokyo Red Cross Blood Ctr, Tokyo 1358639, Japan; [Mboup, Souleymane; Ndir, Omar] Cheikh Anta Diop Univ, La Dantec Hosp, Lab Bacteriol & Virol, Dakar, Senegal; [Mboup, Souleymane; Ndir, Omar] Cheikh Anta Diop Univ, Parasitol Lab, Dakar, Senegal; [Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	Wellcome Trust Sanger Institute; Wellcome Trust Sanger Institute; Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar; University Cheikh Anta Diop Dakar; University of Oxford; Wellcome Centre for Human Genetics	Wright, GJ (corresponding author), Wellcome Trust Sanger Inst, Cell Surface Signalling Lab, Cambridge CB10 1HH, England.	jr9@sanger.ac.uk; gw2@sanger.ac.uk	Theron, Michel/E-2067-2012	Rayner, Julian/0000-0002-9835-1014; Kwiatkowski, Dominic/0000-0002-5023-0176; Theron, Michel/0000-0002-5781-1985; Wright, Gavin/0000-0003-0537-0863; Bartholdson Scott, Sara Josefin/0000-0003-3380-4446	Wellcome Trust [077108, 089084]; National Institutes of Health [R01AI057919]; Center for Disease Control [R36 CK000119-01]; Epidemiology of Infectious Disease and Biodefense Training Grant [2T32 AI007535-12]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057919, T32AI007535] Funding Source: NIH RePORTER; Medical Research Council [G0600718B, G19/9] Funding Source: researchfish; MRC [G19/9] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Disease Control; Epidemiology of Infectious Disease and Biodefense Training Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to the Ok<SUP>a-</SUP> blood donors. We thank V. Horejsi for monoclonal antibodies and D. Ahr for technical assistance. This work was supported by the Wellcome Trust grant numbers 077108 (G.J.W.) and 089084 (J.C.R.) and National Institutes of Health R01AI057919 (M. T. D.). A. K. B. is supported by a Center for Disease Control grant R36 CK000119-01 and an Epidemiology of Infectious Disease and Biodefense Training Grant 2T32 AI007535-12.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; ANSTEE DJ, 1990, J IMMUNOGENET, V17, P219; Baum J, 2009, INT J PARASITOL, V39, P371, DOI 10.1016/j.ijpara.2008.10.006; Bei AK, 2010, J INFECT DIS, V202, P1722, DOI 10.1086/657157; Bushell KM, 2008, GENOME RES, V18, P622, DOI 10.1101/gr.7187808; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Crosnier C, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-76; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; Guo HM, 1997, J BIOL CHEM, V272, P24; Hayton K, 2008, CELL HOST MICROBE, V4, P40, DOI 10.1016/j.chom.2008.06.001; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Iyer J, 2007, MOL MICROBIOL, V65, P231, DOI 10.1111/j.1365-2958.2007.05791.x; Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Martin S, 2010, MOL CELL PROTEOMICS, V9, P2654, DOI 10.1074/mcp.M110.004119; Mayer DCG, 2009, P NATL ACAD SCI USA, V106, P5348, DOI 10.1073/pnas.0900878106; Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171; Pasini EM, 2006, BLOOD, V108, P791, DOI 10.1182/blood-2005-11-007799; Rodriguez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003300; Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250; Schlegel J, 2009, J MOL BIOL, V391, P518, DOI 10.1016/j.jmb.2009.05.080; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; Snounou G, 1998, PARASITOL TODAY, V14, P462, DOI 10.1016/S0169-4758(98)01340-4; Sollner C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r99; Spring FA, 1997, EUR J IMMUNOL, V27, P891, DOI 10.1002/eji.1830270414; Teo YY, 2010, NAT REV GENET, V11, P149, DOI 10.1038/nrg2731; Tham WH, 2010, P NATL ACAD SCI USA, V107, P17327, DOI 10.1073/pnas.1008151107; Theron M, 2010, CYTOM PART A, V77A, P1067, DOI 10.1002/cyto.a.20972; vanderMerwe PA, 1996, CURR OPIN IMMUNOL, V8, P257, DOI 10.1016/S0952-7915(96)80065-3; WILLIAMS BP, 1988, IMMUNOGENETICS, V27, P322, DOI 10.1007/BF00395127; Wright GJ, 2009, MOL BIOSYST, V5, P1405, DOI [10.1039/B903580J, 10.1039/b903580j]; Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200	32	425	432	0	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					534	U158		10.1038/nature10606	http://dx.doi.org/10.1038/nature10606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22080952	Green Accepted			2022-12-28	WOS:000298318000063
J	Price, CTD; Al-Quadan, T; Santic, M; Rosenshine, I; Abu Kwaik, Y				Price, Christopher T. D.; Al-Quadan, Tasneem; Santic, Marina; Rosenshine, Ilan; Abu Kwaik, Yousef			Host Proteasomal Degradation Generates Amino Acids Essential for Intracellular Bacterial Growth	SCIENCE			English	Article							LEGIONELLA-PNEUMOPHILA; CLASS-I; MACROPHAGES; DIFFERENTIATION; EXPLOITATION; REPLICATION; PROTEIN	Legionella pneumophila proliferates in environmental amoeba and human cells within the Legionella-containing vacuole (LCV). The exported AnkB F-box effector of L. pneumophila is anchored into the LCV membrane by host-mediated farnesylation. Here, we report that host proteasomal degradation of Lys(48)-linked polyubiquitinated proteins, assembled on the LCV by AnkB, generates amino acids required for intracellular bacterial proliferation. The severe defect of the ankB null mutant in proliferation within amoeba and human cells is rescued by supplementation of a mixture of amino acids or cysteine, serine, pyruvate, or citrate, similar to rescue by genetic complementation. Defect of the ankB mutant in intrapulmonary proliferation in mice is rescued upon injection of a mixture of amino acids or cysteine. Therefore, Legionella promotes eukaryotic proteasomal degradation to generate amino acids needed as carbon and energy sources for bacterial proliferation within evolutionarily distant hosts.	[Price, Christopher T. D.; Al-Quadan, Tasneem; Abu Kwaik, Yousef] Univ Louisville, Coll Med, Dept Microbiol & Immunol, Louisville, KY 40202 USA; [Santic, Marina] Univ Rijeka, Dept Microbiol & Parasitol, Rijeka 51000, Croatia; [Rosenshine, Ilan] Hebrew Univ Jerusalem, Sch Med, Dept Microbiol & Mol Genet, IL-91120 Jerusalem, Israel	University of Louisville; University of Rijeka; Hebrew University of Jerusalem	Abu Kwaik, Y (corresponding author), Univ Louisville, Coll Med, Dept Microbiol & Immunol, Louisville, KY 40202 USA.	abukwaik@louisville.edu	Santic, Marina/N-6796-2018; Abu Kwaik, Yousef/A-2802-2012; Santic, Marina/AAB-3137-2019	Santic, Marina/0000-0003-4138-3581; Santic, Marina/0000-0003-4138-3581; Abu Kwaik, Yousef/0000-0002-2119-2078	Public Health Service, National Institute of Allergy and Infectious Diseases [R01AI43965, R01AI069321]; commonwealth of Kentucky Research Challenge Trust; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043965, R01AI069321] Funding Source: NIH RePORTER	Public Health Service, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)United States Public Health Service); commonwealth of Kentucky Research Challenge Trust; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank C. Sasakawa for the generous gift of providing all the ubiquitin mutant plasmid DNA and J. Cox at the University of Utah Metabolomics Core Facility for the free amino acids analyses. Y.A.K. is supported by Public Health Service awards R01AI43965 and R01AI069321 from National Institute of Allergy and Infectious Diseases and by the commonwealth of Kentucky Research Challenge Trust Fund.	Al-Khodor S, 2008, MOL MICROBIOL, V70, P908, DOI 10.1111/j.1365-2958.2008.06453.x; Al-Quadan T, 2011, TRENDS MICROBIOL, V19, P573, DOI 10.1016/j.tim.2011.08.003; Al-Quadan T, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00023; Appelberg R, 2006, J LEUKOCYTE BIOL, V79, P1117, DOI 10.1189/jlb.0206079; Ashida H, 2010, NAT CELL BIOL, V12, P66, DOI 10.1038/ncb2006; Dalebroux ZD, 2009, MOL MICROBIOL, V71, P640, DOI 10.1111/j.1365-2958.2008.06555.x; DebRoy S, 2006, P NATL ACAD SCI USA, V103, P19146, DOI 10.1073/pnas.0608279103; Dorer MS, 2006, PLOS PATHOG, V2, P315, DOI 10.1371/journal.ppat.0020034; Eylert E, 2010, J BIOL CHEM, V285, P22232, DOI 10.1074/jbc.M110.128678; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; Gallastegui N, 2010, TRENDS BIOCHEM SCI, V35, P634, DOI 10.1016/j.tibs.2010.05.005; Isberg RR, 2009, NAT REV MICROBIOL, V7, P12, DOI 10.1038/nrmicro1967; Lomma M, 2010, CELL MICROBIOL, V12, P1272, DOI 10.1111/j.1462-5822.2010.01467.x; Luo ZQ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00031; Molmeret M, 2005, APPL ENVIRON MICROB, V71, P20, DOI 10.1128/AEM.71.1.20-28.2005; Price CT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000704; Price CTD, 2010, J EXP MED, V207, P1712, DOI 10.1084/jem.20100771; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rohmer L, 2011, TRENDS MICROBIOL, V19, P341, DOI 10.1016/j.tim.2011.04.003; Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200; Sauer JD, 2005, P NATL ACAD SCI USA, V102, P9924, DOI 10.1073/pnas.0502767102; Wieland H, 2005, MOL MICROBIOL, V55, P1528, DOI 10.1111/j.1365-2958.2005.04490.x	22	146	148	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	2011	334	6062					1553	1557		10.1126/science.1212868	http://dx.doi.org/10.1126/science.1212868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	862LE	22096100				2022-12-28	WOS:000298091400053
J	Vogels, TP; Sprekeler, H; Zenke, F; Clopath, C; Gerstner, W				Vogels, T. P.; Sprekeler, H.; Zenke, F.; Clopath, C.; Gerstner, W.			Inhibitory Plasticity Balances Excitation and Inhibition in Sensory Pathways and Memory Networks	SCIENCE			English	Article							NEURONAL NETWORKS; AUDITORY-CORTEX; SPIKING; PROPAGATION; POPULATION; DYNAMICS; STATE	Cortical neurons receive balanced excitatory and inhibitory synaptic currents. Such a balance could be established and maintained in an experience-dependent manner by synaptic plasticity at inhibitory synapses. We show that this mechanism provides an explanation for the sparse firing patterns observed in response to natural stimuli and fits well with a recently observed interaction of excitatory and inhibitory receptive field plasticity. The introduction of inhibitory plasticity in suitable recurrent networks provides a homeostatic mechanism that leads to asynchronous irregular network states. Further, it can accommodate synaptic memories with activity patterns that become indiscernible from the background state but can be reactivated by external stimuli. Our results suggest an essential role of inhibitory plasticity in the formation and maintenance of functional cortical circuitry.	[Vogels, T. P.; Sprekeler, H.; Zenke, F.; Clopath, C.; Gerstner, W.] Ecole Polytech Fed Lausanne, Sch Comp & Commun Sci, CH-1015 Lausanne Epfl, Switzerland; [Vogels, T. P.; Sprekeler, H.; Zenke, F.; Clopath, C.; Gerstner, W.] Ecole Polytech Fed Lausanne, Brain Mind Inst, CH-1015 Lausanne Epfl, Switzerland; [Clopath, C.] Univ Paris 05, CNRS, UMR 8119, F-75270 Paris 06, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Vogels, TP (corresponding author), Ecole Polytech Fed Lausanne, Sch Comp & Commun Sci, CH-1015 Lausanne Epfl, Switzerland.	tim.vogels@epfl.ch	Sprekeler, Henning/B-8779-2012	Sprekeler, Henning/0000-0003-0690-3553	Swiss National Science Foundation [200020 13287]; CRSIK0 [122697]; European Community [268436, 243914, 237955]; French National Science [ANR-08-SYSC-005]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); CRSIK0; European Community(European Commission); French National Science	Research was supported by Swiss National Science Foundation grant no. 200020 13287 (Coding Characteristics) and CRSIK0 122697 (Sinergia). Additionally, T. P. V. was supported by the European Community's Seventh Framework Marie Curie International Reintegration grant no. 268436, and H. S. and F.Z. by the European Community's Seventh Framework Program under grant agreement no. 243914 (BRAIN-I-NETS) and 237955 (FACETS-ITN), respectively. C. C. received additional support from a French National Science grant ANR-08-SYSC-005. Thanks to G. Hennequin and A. Woodruff for helpful discussions.	AITKIN LM, 1970, J NEUROPHYSIOL, V33, P421, DOI 10.1152/jn.1970.33.3.421; Amit DJ, 1997, CEREB CORTEX, V7, P237, DOI 10.1093/cercor/7.3.237; Balena T, 2011, INHIBITORY SYNAPTIC PLASTICITY, P137, DOI 10.1007/978-1-4419-6978-1_10; Beck J, 2011, NEURAL COMPUT, V23, P1484, DOI 10.1162/NECO_a_00125; Brunel N, 2000, J COMPUT NEUROSCI, V8, P183, DOI 10.1023/A:1008925309027; Cafaro J, 2010, NATURE, V468, P964, DOI 10.1038/nature09570; Crochet S, 2011, NEURON, V69, P1160, DOI 10.1016/j.neuron.2011.02.022; de la Rocha J, 2008, J NEUROSCI, V28, P9151, DOI 10.1523/JNEUROSCI.1789-08.2008; DeWeese MR, 2003, J NEUROSCI, V23, P7940; Froemke RC, 2007, NATURE, V450, P425, DOI 10.1038/nature06289; GERSTNER W, 1993, BIOL CYBERN, V69, P503, DOI 10.1007/BF00199450; Gerstner W, 2000, NEURAL COMPUT, V12, P43, DOI 10.1162/089976600300015899; Hartmann K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002979; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hromadka T, 2008, PLOS BIOL, V6, P124, DOI 10.1371/journal.pbio.0060016; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kumar A, 2010, NAT REV NEUROSCI, V11, P615, DOI 10.1038/nrn2886; Murphy BK, 2009, NEURON, V61, P635, DOI 10.1016/j.neuron.2009.02.005; Okun M, 2008, NAT NEUROSCI, V11, P535, DOI 10.1038/nn.2105; Renart A, 2007, NEURAL COMPUT, V19, P1, DOI 10.1162/neco.2007.19.1.1; Renart A, 2010, SCIENCE, V327, P587, DOI 10.1126/science.1179850; Series P, 2004, NAT NEUROSCI, V7, P1129, DOI 10.1038/nn1321; Shu YS, 2003, NATURE, V423, P288, DOI 10.1038/nature01616; TSODYKS MV, 1995, NETWORK-COMP NEURAL, V6, P111, DOI 10.1088/0954-898X/6/2/001; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724; Vogels TP, 2009, NAT NEUROSCI, V12, P483, DOI 10.1038/nn.2276; Vogels TP, 2005, J NEUROSCI, V25, P10786, DOI 10.1523/JNEUROSCI.3508-05.2005; VOLKOV IO, 1991, NEUROSCIENCE, V43, P307, DOI 10.1016/0306-4522(91)90295-Y; Wehr M, 2003, NATURE, V426, P442, DOI 10.1038/nature02116; Woodin MA, 2003, NEURON, V39, P807, DOI 10.1016/S0896-6273(03)00507-5; Yao HS, 2007, NAT NEUROSCI, V10, P772, DOI 10.1038/nn1895	31	349	354	2	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	2011	334	6062					1569	1573		10.1126/science.1211095	http://dx.doi.org/10.1126/science.1211095			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	862LE	22075724	Green Submitted			2022-12-28	WOS:000298091400057
J	Higham, T; Compton, T; Stringer, C; Jacobi, R; Shapiro, B; Trinkaus, E; Chandler, B; Groning, F; Collins, C; Hillson, S; O'Higgins, P; FitzGerald, C; Fagan, M				Higham, Tom; Compton, Tim; Stringer, Chris; Jacobi, Roger; Shapiro, Beth; Trinkaus, Erik; Chandler, Barry; Groening, Flora; Collins, Chris; Hillson, Simon; O'Higgins, Paul; FitzGerald, Charles; Fagan, Michael			The earliest evidence for anatomically modern humans in northwestern Europe	NATURE			English	Article							OXFORD AMS SYSTEM; RADIOCARBON-DATES; BONE; AGE; ANCIENT; MIDDLE	The earliest anatomically modern humans in Europe are thought to have appeared around 43,000-42,000 calendar years before present (43-42 kyr cal BP), by association with Aurignacian sites and lithic assemblages assumed to have been made by modern humans rather than by Neanderthals. However, the actual physical evidence for modern humans is extremely rare, and direct dates reach no farther back than about 41-39 kyr cal BP, leaving a gap. Here we show, using stratigraphic, chronological and archaeological data, that a fragment of human maxilla from the Kent's Cavern site, UK, dates to the earlier period. The maxilla (KC4), which was excavated in 1927, was initially diagnosed as Upper Palaeolithic modern human(1). In 1989, it was directly radiocarbon dated by accelerator mass spectrometry to 36.4-34.7 kyr cal BP2. Using a Bayesian analysis of new ultrafiltered bone collagen dates in an ordered stratigraphic sequence at the site, we show that this date is a considerable underestimate. Instead, KC4 dates to 44.2-41.5 kyr cal BP. This makes it older than any other equivalently dated modern human specimen and directly contemporary with the latest European Neanderthals, thus making its taxonomic attribution crucial. We also show that in 13 dental traits KC4 possesses modern human rather than Neanderthal characteristics; three other traits show Neanderthal affinities and a further seven are ambiguous. KC4 therefore represents the oldest known anatomically modern human fossil in northwestern Europe, fills a key gap between the earliest dated Aurignacian remains and the earliest human skeletal remains, and demonstrates the wide and rapid dispersal of early modern humans across Europe more than 40 kyr ago.	[Higham, Tom] Univ Oxford, Res Lab Archaeol & Hist Art, Oxford Radiocarbon Accelerator Unit, Oxford OX1 3QY, England; [Compton, Tim; Stringer, Chris; Jacobi, Roger; Collins, Chris] Nat Hist Museum, London SW7 5BD, England; [Jacobi, Roger] British Museum, Dept Prehist & Europe, Quaternary Sect, London N1 5QJ, England; [Shapiro, Beth] Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; [Trinkaus, Erik] Washington Univ, Dept Anthropol, St Louis, MO 63130 USA; [Chandler, Barry] Torquay Museum, Torquay TQ1 1HG, Devon, England; [Groening, Flora; Fagan, Michael] Univ Hull, Dept Engn, Kingston Upon Hull HU6 7RX, Yorks, England; [Hillson, Simon] UCL, Inst Archaeol, London WC1H 0PY, England; [O'Higgins, Paul] Univ York, Hull York Med Sch, Ctr Anat & Human Sci, York YO10 5DD, N Yorkshire, England; [FitzGerald, Charles] McMaster Univ, Dept Anthropol, Hamilton, ON L8S 4L9, Canada	University of Oxford; Natural History Museum London; Natural History Museum London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Washington University (WUSTL); University of Hull; University of London; University College London; University of Hull; University of York - UK; McMaster University	Higham, T (corresponding author), Univ Oxford, Res Lab Archaeol & Hist Art, Oxford Radiocarbon Accelerator Unit, S Parks Rd, Oxford OX1 3QY, England.	thomas.higham@rlaha.ox.ac.uk; c.stringer@nhm.ac.uk	Higham, Tom/Y-2707-2019; Gröning, Flora/C-2220-2012	Higham, Tom/0000-0002-5949-598X; Gröning, Flora/0000-0002-8127-4112; Shapiro, Beth/0000-0002-2733-7776; O'Higgins, Paul/0000-0002-9797-0809	NERC [NE/D014077/1]; Leverhulme Trust; NERC [NE/E015905/1] Funding Source: UKRI; Natural Environment Research Council [NE/E015905/1, NE/D014077/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Leverhulme Trust(Leverhulme Trust); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank R. Kruszynski for allowing us access to fossils and casts in his care and for his help. S. Taft performed CT scans of the specimens, N. Curtis created a preliminary CT-based model and R. Abel provided CT scans of comparative specimens. We thank M. Bradtmoller of NESPOS for his assistance. H. Liversidge provided specimens of modern teeth. S. Bello helped with the Alicona microscope. A. Coppa made available dental morphological data for upper canines, and R. L. Tompkins donated X-ray photographs of fossil dentitions. M. Skinner, P. Gunz, M. Richards, A. Olejniczak and J.-J. Hublin advised on investigative approaches to the study of the specimen. H. Taylor photographed KC4. We are grateful to the following people for making available CT scans of fossils from Neanderthal sites for viewing on the NESPOS database: R. Macchiarelli and J. F. Tournepiche (La Chaise de Vouthon), R. Macchiarelli and D. Berthet (La Quina), B. Illerhaus (Le Moustier) and P. Semal (Spy). Funding was provided by the Leverhulme Trust and the NERC. We thank all staff at the Oxford Radiocarbon Accelerator Unit. Funding was provided for T. H. through the NERC (grant NE/D014077/1). C. S. and T. H. are Members, and T. C. is an Associate Member, of the Ancient Human Occupation of Britain project, funded by the Leverhulme Trust.	Akimova E, 2010, ARCHAEOMETRY, V52, P1122, DOI 10.1111/j.1475-4754.2010.00532.x; Andersen KK, 2006, QUATERNARY SCI REV, V25, P3246, DOI 10.1016/j.quascirev.2006.08.002; BROWN TA, 1988, RADIOCARBON, V30, P171, DOI 10.1017/S0033822200044118; Dowie H. G., 1927, 95 M BRIT ASS ADV SC, P303; Flas D., 2008, ANTHR PRAEHISTORICA, V119, P5; Green RE, 2010, SCIENCE, V328, P710, DOI 10.1126/science.1188021; HEDGES REM, 1989, ARCHAEOMETRY, V31, P207, DOI 10.1111/j.1475-4754.1989.tb01015.x; Henry-Gambier Dominique, 2008, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V20, P79; Higham TFG, 2007, ARCHAEOMETRY, V49, pS1, DOI 10.1111/j.1475-4754.2007.00363.x; Higham TFG, 2006, RADIOCARBON, V48, P179, DOI 10.1017/S0033822200066388; Jacobi R., 2007, P PREHIST SOC, V73, P229, DOI [10.1017/s0079497x0000009, DOI 10.1017/S0079497X0000009, DOI 10.1017/S0079497X00000098, 10.1017/S0079497X00000098]; Jacobi RM, 2006, J QUATERNARY SCI, V21, P557, DOI 10.1002/jqs.1037; Keith A., 1927, T P TORQUAY NATURAL, V5, P1; Lundberg J, 2007, GEOSPHERE, V3, P199, DOI 10.1130/GES00085.1; Prat S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020834; Ramsey CB, 2001, RADIOCARBON, V43, P355; Reimer PJ, 2009, RADIOCARBON, V51, P1111, DOI 10.1017/S0033822200034202; Soficaru A, 2007, CURR ANTHROPOL, V48, P611, DOI 10.1086/519915; Soficaru A, 2006, P NATL ACAD SCI USA, V103, P17196, DOI 10.1073/pnas.0608443103; Svensson EM, 2007, ANIM GENET, V38, P378, DOI 10.1111/j.1365-2052.2007.01620.x; Trinkaus E, 2003, P NATL ACAD SCI USA, V100, P11231, DOI 10.1073/pnas.2035108100; Trinkaus E, 2007, P NATL ACAD SCI USA, V104, P7367, DOI 10.1073/pnas.0702214104; Weninger B, 2008, J HUM EVOL, V55, P772, DOI 10.1016/j.jhevol.2008.08.017; Wild EM, 2005, NATURE, V435, P332, DOI 10.1038/nature03585; Zilhao J, 1999, J WORLD PREHIST, V13, P1, DOI 10.1023/A:1022348410845	25	194	201	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2011	479	7374					521	524		10.1038/nature10484	http://dx.doi.org/10.1038/nature10484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	851QI	22048314				2022-12-28	WOS:000297285600049
J	Keszthelyi, LP				Keszthelyi, Laszlo P.			PLANETARY SCIENCE Europa awakening	NATURE			English	Editorial Material							CHAOS		US Geol Survey, Astrogeol Sci Ctr, Flagstaff, AZ 86001 USA	United States Department of the Interior; United States Geological Survey	Keszthelyi, LP (corresponding author), US Geol Survey, Astrogeol Sci Ctr, Flagstaff, AZ 86001 USA.	laz@usgs.gov						Bjornsson H, 2003, GLOBAL PLANET CHANGE, V35, P255, DOI 10.1016/S0921-8181(02)00130-3; Committee on the Planetary Science Decadal Survey Space Studies Board National Research Council, 2011, VIS VOYAG PLAN SCI D; Greenberg R, 1999, ICARUS, V141, P263, DOI 10.1006/icar.1999.6187; Hoppa GV, 1999, SCIENCE, V285, P1899, DOI 10.1126/science.285.5435.1899; McKinnon WB, 1999, GEOPHYS RES LETT, V26, P951, DOI 10.1029/1999GL900125; National Research Council, 2003, NEW FRONT SOL SYST I; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Phillips CB, 2000, J GEOPHYS RES-PLANET, V105, P22579, DOI 10.1029/1999JE001139; Schmidt BE, 2011, NATURE, V479, P502, DOI 10.1038/nature10608; Turtle EP, 2001, SCIENCE, V294, P1326, DOI 10.1126/science.1062492; Zahnle K, 2003, ICARUS, V163, P263, DOI 10.1016/S0019-1035(03)00048-4	11	5	5	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2011	479	7374					485	485		10.1038/nature10701	http://dx.doi.org/10.1038/nature10701			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22089137	Bronze			2022-12-28	WOS:000297285600040
J	Schmidt, BE; Blankenship, DD; Patterson, GW; Schenk, PM				Schmidt, B. E.; Blankenship, D. D.; Patterson, G. W.; Schenk, P. M.			Active formation of 'chaos terrain' over shallow subsurface water on Europa	NATURE			English	Article							LIQUID WATER; ICE-SHELF; ICELAND; OCEAN; MODEL	Europa, the innermost icy satellite of Jupiter, has a tortured young surface(1-4) and sustains a liquid water ocean(1-6) below an ice shell of highly debated thickness(1-5,7-10). Quasi-circular areas of ice disruption called chaos terrains are unique to Europa, and both their formation and the ice-shell thickness depend on Europa's thermal state(1-5,7-17). No model so far has been able to explain why features such as Conamara Chaos stand above surrounding terrain and contain matrix domes(10,18). Melt-through of a thin ( few-kilometre) shell(3,7,8) is thermodynamically improbable and cannot raise the ice(10,18). The buoyancy of material rising as either plumes of warm, pure ice called diapirs(1,9-15) or convective cells(16,17) in a thick (> 10 kilometres) shell is insufficient to produce the observed chaos heights, and no single plume can create matrix domes(10,18). Here we report an analysis of archival data from Europa, guided by processes observed within Earth's subglacial volcanoes and ice shelves. The data suggest that chaos terrains form above liquid water lenses perched within the ice shell as shallow as 3 kilometres. Our results suggest that ice-water interactions and freeze-out give rise to the diverse morphologies and topography of chaos terrains. The sunken topography of Thera Macula indicates that Europa is actively resurfacing over a lens comparable in volume to the Great Lakes in North America.	[Schmidt, B. E.; Blankenship, D. D.] Univ Texas Austin, Inst Geophys, John A & Katherine G Jackson Sch Geosci, Austin, TX 78758 USA; [Patterson, G. W.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; [Schenk, P. M.] Lunar & Planetary Inst, Houston, TX 77058 USA	University of Texas System; University of Texas Austin; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Schmidt, BE (corresponding author), Univ Texas Austin, Inst Geophys, John A & Katherine G Jackson Sch Geosci, JJ Pickle Res Campus,Bldg 196 ROC,10100 Burnet Rd, Austin, TX 78758 USA.	britneys@ig.utexas.edu	Patterson, Gerald W/E-7699-2015	Patterson, Gerald W/0000-0003-4787-3899; Schmidt, Britney Elyce/0000-0001-7376-8510	Vetlesen Foundation; Institute for Geophysics of the Jackson School of Geosciences, University of Texas at Austin (UTIG); NASA; NSF	Vetlesen Foundation; Institute for Geophysics of the Jackson School of Geosciences, University of Texas at Austin (UTIG); NASA(National Aeronautics & Space Administration (NASA)); NSF(National Science Foundation (NSF))	We thank D. Young, K. Soderlund, A. Barr, J. Greenbaum, J. Leisner and D. MacAyeal for comments and discussions on the development of these concepts. B. E. S. was supported by a fellowship from the Vetlesen Foundation and the Institute for Geophysics of the Jackson School of Geosciences, University of Texas at Austin (UTIG). D. D. B. was supported by NASA, NSF and UTIG. NASA supported the work of G. W. P. and P. M. S.	Bjornsson H, 2003, GLOBAL PLANET CHANGE, V35, P255, DOI 10.1016/S0921-8181(02)00130-3; Blankenship D.D., 2009, EUROPA, P631, DOI [10.2307/j.ctt1xp3wdw.33, DOI 10.2307/J.CTT1XP3WDW.33]; Carlson RW, 2002, ICARUS, V157, P456, DOI 10.1006/icar.2002.6858; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; Collins G.C., 2009, EUROPA, P259; Collins GC, 2000, J GEOPHYS RES-PLANET, V105, P1709, DOI 10.1029/1999JE001143; Figueredo PH, 2004, ICARUS, V167, P287, DOI 10.1016/j.icarus.2003.09.016; Gaidos EJ, 2000, NATURE, V405, P637, DOI 10.1038/35015170; Greenberg R, 1999, ICARUS, V141, P263, DOI 10.1006/icar.1999.6187; Gudmundsson MT, 2004, B VOLCANOL, V66, P46, DOI 10.1007/s00445-003-0295-9; Guttenberg N, 2011, ANN GLACIOL, V52, P51, DOI 10.3189/172756411799096178; Han LJ, 2010, ICARUS, V207, P834, DOI 10.1016/j.icarus.2009.12.028; Head JW, 1999, J GEOPHYS RES-PLANET, V104, P27143, DOI 10.1029/1999JE001062; Kivelson MG, 2000, SCIENCE, V289, P1340, DOI 10.1126/science.289.5483.1340; KOVACS A, 1975, J GEOPHYS RES, V80, P1957, DOI 10.1029/JC080i015p01957; MacAyeal DR, 2003, J GLACIOL, V49, P22, DOI 10.3189/172756503781830863; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; McKinnon WB, 1999, GEOPHYS RES LETT, V26, P951, DOI 10.1029/1999GL900125; Mevel L, 2007, PLANET SPACE SCI, V55, P915, DOI 10.1016/j.pss.2006.12.001; NYE JF, 1980, ANN GLACIOL, V1, P49; O'Brien DP, 2002, ICARUS, V156, P152, DOI 10.1006/icar.2001.6777; Pappalardo RT, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019202; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Rathbun JA, 1998, GEOPHYS RES LETT, V25, P4157, DOI 10.1029/1998GL900135; Scambos T, 2009, EARTH PLANET SC LETT, V280, P51, DOI 10.1016/j.epsl.2008.12.027; Schenk PM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019978; Sotin C, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013844; Spaun NA, 1998, GEOPHYS RES LETT, V25, P4277, DOI 10.1029/1998GL900176; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0	30	170	171	1	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 24	2011	479	7374					502	505		10.1038/nature10608	http://dx.doi.org/10.1038/nature10608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22089135				2022-12-28	WOS:000297285600044
J	Feachem, RGA				Feachem, Richard G. A.			The Global Fund: getting the reforms right	LANCET			English	Editorial Material									[Feachem, Richard G. A.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94105 USA; [Feachem, Richard G. A.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley	Feachem, RGA (corresponding author), Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94105 USA.	FeachemR@globalhealth.ucsf.edu						[African Leaders Malaria Alliance Evidence to Policy Initiative linton Health Access Initiative], 2011, MAINT GAINS MAL CONT; [Anonymous], 2011, LANCET, V378, P1198, DOI 10.1016/S0140-6736(11)61526-2; High-Level Independent Review Panel on Fiduciary Controls and Oversight Mechanisms of the Global Fund to Fight AIDS, 2011, TURN PAG EM SUST; Mahgoub A., 2010, CASH DELIVERY NEW AP; The Global Fund to Fight AIDS, 2011, 24 BOARD M GEN SWITZ	5	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	2011	378	9805					1764	+		10.1016/S0140-6736(11)61747-9	http://dx.doi.org/10.1016/S0140-6736(11)61747-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851IS	22098844				2022-12-28	WOS:000297262300009
J	Ferraccioli, F; Finn, CA; Jordan, TA; Bell, RE; Anderson, LM; Damaske, D				Ferraccioli, Fausto; Finn, Carol A.; Jordan, Tom A.; Bell, Robin E.; Anderson, Lester M.; Damaske, Detlef			East Antarctic rifting triggers uplift of the Gamburtsev Mountains	NATURE			English	Article							TRANSANTARCTIC MOUNTAINS; SUBGLACIAL MOUNTAINS; CRUSTAL; STRENGTH; SOUTHERN; DELAMINATION; DEFORMATION; LITHOSPHERE; INTRAPLATE; EVOLUTION	The Gamburtsev Subglacial Mountains are the least understood tectonic feature on Earth, because they are completely hidden beneath the East Antarctic Ice Sheet. Their high elevation and youthful Alpine topography, combined with their location on the East Antarctic craton, creates a paradox that has puzzled researchers since the mountains were discovered in 1958(1). The preservation of Alpine topography in the Gamburtsevs(2) may reflect extremely low long-term erosion rates beneath the ice sheet(3), but the mountains' origin remains problematic. Here we present the first comprehensive view of the crustal architecture and uplift mechanisms for the Gamburtsevs, derived from radar, gravity and magnetic data. The geophysical data define a 2,500-km-long rift system in East Antarctica surrounding the Gamburtsevs, and a thick crustal root(4) beneath the range. We propose that the root formed during the Proterozoic assembly of interior East Antarctica (possibly about 1 Gyr ago), was preserved as in some old orogens(5,6) and was rejuvenated during much later Permian (roughly 250 Myr ago) and Cretaceous (roughly 100 Myr ago) rifting. Much like East Africa(7), the interior of East Antarctica is a mosaic of Precambrian provinces affected by rifting processes. Our models show that the combination of rift-flank uplift, root buoyancy and the isostatic response to fluvial and glacial erosion explains the high elevation and relief of the Gamburtsevs. The evolution of the Gamburtsevs demonstrates that rifting and preserved orogenic roots can produce broad regions of high topography in continental interiors without significantly modifying the underlying Precambrian lithosphere.	[Ferraccioli, Fausto; Jordan, Tom A.; Anderson, Lester M.] British Antarctic Survey, Cambridge CB3 0ET, England; [Finn, Carol A.] US Geol Survey, Denver, CO 80225 USA; [Bell, Robin E.] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; [Damaske, Detlef] Bundesanstalt Geowissensch & Rohstoffe, D-30655 Hannover, Germany	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; United States Department of the Interior; United States Geological Survey; Columbia University	Ferraccioli, F (corresponding author), British Antarctic Survey, Madingley Rd, Cambridge CB3 0ET, England.	ffe@bas.ac.uk		Ferraccioli, Fausto/0000-0002-9347-4736; Jordan, Tom/0000-0003-2780-1986	AGAP International Polar Year; Federal Institute for Geosciences and Resources; Australian Antarctic Division; Natural Environment Research Council [bas0100026] Funding Source: researchfish; NERC [bas0100026] Funding Source: UKRI	AGAP International Polar Year; Federal Institute for Geosciences and Resources; Australian Antarctic Division; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We acknowledge the seven nations involved in the AGAP International Polar Year effort for their major logistical, financial and intellectual support. The US Antarctic Program of the National Science Foundation provided support for the logistics, the development of the instrumentation and data analysis. The Natural Environment Research Council/British Antarctic Survey provided support for deep-field operations, data collection and analysis. The Federal Institute for Geosciences and Resources provided financial support. The Australian Antarctic Division provided support at the AGAP North field camp; the Chinese Antarctic programme and the Alfred Wegner Institute also assisted. We thank all the AGAP project members involved, and in particular M. Studinger, N. Frearson and C. Robinson. C. Ebinger provided an early review and P. Molnar provided discussions. S. Golynsky provided geophysical data over adjacent regions and related discussions. We thank C. Braitenberg for assistance with Lithoflex and R. Buck for providing 2D flexural modelling code. J. J. Veevers provided a review.	Audet P, 2011, NAT GEOSCI, V4, P184, DOI 10.1038/NGEO1080; Avigad D, 2009, TECTONOPHYSICS, V477, P217, DOI 10.1016/j.tecto.2009.04.018; Bo S, 2009, NATURE, V459, P690, DOI 10.1038/nature08024; Boger SD, 2002, EARTH PLANET SC LETT, V195, P195, DOI 10.1016/S0012-821X(01)00587-8; Braitenberg C, 2002, EARTH PLANET SC LETT, V202, P387, DOI 10.1016/S0012-821X(02)00793-8; Burov E, 1998, EARTH PLANET SC LETT, V164, P205, DOI 10.1016/S0012-821X(98)00205-2; Cooper GRJ, 2009, GEOPHYS PROSPECT, V57, P1067, DOI 10.1111/j.1365-2478.2009.00791.x; Cox SE, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL045106; Damm V., 2007, TERRA ANTARTICA, V14, P85; Ferraccioli F, 1998, GEOPHYS PROSPECT, V46, P177, DOI 10.1046/j.1365-2478.1998.00080.x; Fischer KM, 2002, NATURE, V417, P933, DOI 10.1038/nature00855; Fitzsimons ICW, 2003, GEOL SOC SPEC PUBL, P93, DOI 10.1144/GSL.SP.2003.206.01.07; Gimenez ME, 2009, INT J GEOPHYS, V2009, DOI 10.1155/2009/607458; Golynsky AV, 2002, TECTONOPHYSICS, V347, P109, DOI 10.1016/S0040-1951(01)00240-2; GOLYNSKY AV, 2001, BAS MISC, V10; Hansen SE, 2010, EARTH PLANET SC LETT, V300, P395, DOI 10.1016/j.epsl.2010.10.022; Hemant K, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003837; Jackson JA, 2004, GEOLOGY, V32, P625, DOI 10.1130/G20397.1; Johnson A, 1999, ANN GEOFIS, V42, P249; Journel A. G., 1978, MINING GEOSTATISTICS; KARNER GD, 1983, J GEOPHYS RES, V88, P449, DOI 10.1029/JB088iB12p10449; KU CC, 1983, GEOPHYSICS, V48, P754, DOI 10.1190/1.1441505; Leech ML, 2001, EARTH PLANET SC LETT, V185, P149, DOI 10.1016/S0012-821X(00)00374-5; Leitchenkov G.L, 2007, ANTARCTICA KEYSTONE; Levander A, 2011, NATURE, V472, P461, DOI 10.1038/nature10001; Lisker F., 2007, ANTARCTICA KEYSTONE, P1; Lythe MB, 2001, J GEOPHYS RES-SOL EA, V106, P11335, DOI 10.1029/2000JB900449; Maus S, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2008GC001949; MCKENZIE D, 2003, J GEOPHYS RES, V108; McLean MA, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB005650; Miller KG, 2005, SCIENCE, V310, P1293, DOI 10.1126/science.1116412; Muller RD, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001743; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; O'Neill C, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000784; Pail R, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL044906; PARKER RL, 1973, GEOPHYS J ROY ASTR S, V31, P447, DOI 10.1111/j.1365-246X.1973.tb06513.x; Perez-Gussinye M, 2005, NATURE, V436, P381, DOI 10.1038/nature03854; Petit C, 2000, J GEOPHYS RES-SOL EA, V105, P19151, DOI 10.1029/2000JB900101; Phillips G, 2009, TECTONOPHYSICS, V471, P216, DOI 10.1016/j.tecto.2009.02.012; Pilkington M, 2001, EXPLOR GEOPHYS, V32, P95; Popov S. V., 2007, ANTARCTICA AKEYSTONE; Reading AM, 2006, EARTH PLANET SC LETT, V244, P44, DOI 10.1016/j.epsl.2006.01.031; Ritzwoller MH, 2001, J GEOPHYS RES-SOL EA, V106, P30645, DOI 10.1029/2001JB000179; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Scarrow JH, 2002, J GEOL SOC LONDON, V159, P659, DOI 10.1144/0016-764901-147; Semprich J, 2010, INT J EARTH SCI, V99, P1487, DOI 10.1007/s00531-010-0557-7; Sleep NH, 2006, EARTH-SCI REV, V77, P231, DOI 10.1016/j.earscirev.2006.03.007; Sorokhtin O., 1959, B SOVIET ANTARCTIC E, V11, P9; Stern TA, 2005, GEOLOGY, V33, P221, DOI 10.1130/G21068.1; Studinger M, 2003, EARTH PLANET SC LETT, V216, P663, DOI 10.1016/S0012-821X(03)00548-X; TENBRINK U, 1992, J GEOPHYS RES-SOL EA, V97, P569, DOI 10.1029/91JB02231; Veevers JJ, 2008, SEDIMENT GEOL, V211, P12, DOI 10.1016/j.sedgeo.2008.08.003; Veevers JJ, 2009, GONDWANA RES, V16, P90, DOI 10.1016/j.gr.2009.02.007; VEEVERS JJ, 1994, GEOLOGY, V22, P593, DOI 10.1130/0091-7613(1994)022<0593:CFTGSM>2.3.CO;2; Watts A.B., 2001, ISOSTASY FLEXURE LIT; Wienecke S, 2007, GEOPHYS J INT, V169, P789, DOI 10.1111/j.1365-246X.2007.03396.x	56	161	162	4	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2011	479	7373					388	U139		10.1038/nature10566	http://dx.doi.org/10.1038/nature10566			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094700				2022-12-28	WOS:000297059700043
J	Traverse, JH; Henry, TD; Ellis, SG; Pepine, CJ; Willerson, JT; Zhao, DXM; Forder, JR; Byrne, BJ; Hatzopoulos, AK; Penn, MS; Perin, EC; Baran, KW; Chambers, J; Lambert, C; Raveendran, G; Simon, DI; Vaughan, DE; Simpson, LM; Gee, AP; Taylor, DA; Cogle, CR; Thomas, JD; Silva, GV; Jorgenson, BC; Olson, RE; Bowman, S; Francescon, J; Geither, C; Handberg, E; Smith, DX; Baraniuk, S; Piller, LB; Loghin, C; Aguilar, D; Richman, S; Zierold, C; Bettencourt, J; Sayre, SL; Vojvodic, RW; Skarlatos, SI; Gordon, DJ; Ebert, RF; Kwak, M; Moye, LA; Simari, RD				Traverse, Jay H.; Henry, Timothy D.; Ellis, Stephen G.; Pepine, Carl J.; Willerson, James T.; Zhao, David X. M.; Forder, John R.; Byrne, Barry J.; Hatzopoulos, Antonis K.; Penn, Marc S.; Perin, Emerson C.; Baran, Kenneth W.; Chambers, Jeffrey; Lambert, Charles; Raveendran, Ganesh; Simon, Daniel I.; Vaughan, Douglas E.; Simpson, Lara M.; Gee, Adrian P.; Taylor, Doris A.; Cogle, Christopher R.; Thomas, James D.; Silva, Guilherme V.; Jorgenson, Beth C.; Olson, Rachel E.; Bowman, Sherry; Francescon, Judy; Geither, Carrie; Handberg, Eileen; Smith, Deirdre X.; Baraniuk, Sarah; Piller, Linda B.; Loghin, Catalin; Aguilar, David; Richman, Sara; Zierold, Claudia; Bettencourt, Judy; Sayre, Shelly L.; Vojvodic, Rachel W.; Skarlatos, Sonia I.; Gordon, David J.; Ebert, Ray F.; Kwak, Minjung; Moye, Lemuel A.; Simari, Robert D.		Cardiovasc Cell Therapy Res Networ	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function The LateTIME Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOTHELIAL PROGENITOR CELLS; MESENCHYMAL STEM-CELLS; RESEARCH NETWORK CCTRN; CARDIAC REPAIR; DOUBLE-BLIND; EJECTION FRACTION; PILOT TRIAL; THERAPY; INFUSION; DETERMINANTS	Context Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuclear cells (BMCs) may improve left ventricular (LV) function when administered within the first week following myocardial infarction (MI). However, because a substantial number of patients may not present for early cell delivery, the efficacy of autologous BMC delivery 2 to 3 weeks post-MI warrants investigation. Objective To determine if intracoronary delivery of autologous BMCs improves global and regional LV function when delivered 2 to 3 weeks following first MI. Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial (LateTIME) of the National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network of 87 patients with significant LV dysfunction (LV ejection fraction [LVEF] <= 45%) following successful primary percutaneous coronary intervention (PCI) between July 8, 2008, and February 28, 2011. Interventions Intracoronary infusion of 150 x 10(6) autologous BMCs (total nucleated cells) or placebo (BMC: placebo, 2:1) was performed within 12 hours of bone marrow aspiration after local automated cell processing. Main Outcome Measures Changes in global (LVEF) and regional (wall motion) LV function in the infarct and border zone between baseline and 6 months, measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volumes and infarct size. Results A total of 87 patients were randomized (mean [SD] age, 57 [11] years; 83% men). Harvesting, processing, and intracoronary delivery of BMCs in this setting was feasible. Change between baseline and 6 months in the BMC group vs placebo for mean LVEF (48.7% to 49.2% vs 45.3% to 48.8%; between-group mean difference, -3.00; 95% CI, -7.05 to 0.95), wall motion in the infarct zone (6.2 to 6.5 mm vs 4.9 to 5.9 mm; between-group mean difference, -0.70; 95% CI, -2.78 to 1.34), and wall motion in the border zone (16.0 to 16.6 mm vs 16.1 to 19.3 mm; between-group mean difference, -2.60; 95% CI, -6.03 to 0.77) were not statistically significant. No significant change in LV volumes and infarct volumes was observed; both groups decreased by a similar amount at 6 months vs baseline. Conclusion Among patients with MI and LV dysfunction following reperfusion with PCI, intracoronary infusion of autologous BMCs vs intracoronary placebo infusion, 2 to 3 weeks after PCI, did not improve global or regional function at 6 months.	[Traverse, Jay H.; Henry, Timothy D.; Jorgenson, Beth C.; Olson, Rachel E.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA; [Traverse, Jay H.; Henry, Timothy D.; Raveendran, Ganesh; Taylor, Doris A.; Zierold, Claudia] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Ellis, Stephen G.; Thomas, James D.; Geither, Carrie] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Forder, John R.] Univ Florida, Coll Med, Dept Radiol, Gainesville, FL 32610 USA; [Willerson, James T.; Perin, Emerson C.; Silva, Guilherme V.; Smith, Deirdre X.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA; [Zhao, David X. M.; Hatzopoulos, Antonis K.; Bowman, Sherry; Francescon, Judy] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Penn, Marc S.] Summa Cardiovasc Inst, Akron, OH USA; [Baran, Kenneth W.] United Heart & Vasc Clin, St Paul, MN USA; [Chambers, Jeffrey] Mercy Hosp, Coon Rapids, MN USA; [Lambert, Charles] Florida Hosp Tampa, Pepin Heart Inst, Tampa, FL USA; [Simon, Daniel I.] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Vaughan, Douglas E.] Northwestern Univ, Chicago, IL 60611 USA; [Loghin, Catalin] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Simpson, Lara M.; Baraniuk, Sarah; Piller, Linda B.; Bettencourt, Judy; Sayre, Shelly L.; Vojvodic, Rachel W.; Moye, Lemuel A.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA; [Gee, Adrian P.; Aguilar, David; Richman, Sara] Baylor Coll Med, Houston, TX 77030 USA; [Skarlatos, Sonia I.; Gordon, David J.; Ebert, Ray F.; Kwak, Minjung] NHLBI, Bethesda, MD 20892 USA; [Simari, Robert D.] Mayo Clin, Rochester, MN USA	Minneapolis Heart Institute Foundation; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; State University System of Florida; University of Florida; Saint Lukes Episcopal Hospital; Texas Heart Institute; Vanderbilt University; Summa Health System; Adventist Health Services; AdventHealth; (AdventHealth) West Florida Division; West Florida Hospital; AdventHealth Tampa; Case Western Reserve University; Case Western Reserve University Hospital; Northwestern University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic	Moye, LA (corresponding author), Univ Texas Houston, Sch Publ Hlth, 1200 Herman Pressler,Ste E815, Houston, TX 77030 USA.	lemmoye@msn.com	Hatzopoulos, Antonis/D-2049-2010; Hatzopoulos, Antonis/X-2043-2019; Cogle, Christopher/H-1746-2016; Aguilar, David/GZM-1928-2022; Raveendran, Ganesh/ABC-2669-2021; Loghin, Catalin/AAU-9519-2020	Hatzopoulos, Antonis/0000-0001-5610-0017; Cogle, Christopher/0000-0001-5422-6863; Aguilar, David/0000-0002-0916-2722; Byrne, Barry J./0000-0002-7302-1756; Handberg, Eileen/0000-0002-7805-9577	National Heart, Lung, and Blood Institute (NHLBI) [5 U01 HL087318-04, N01-HB-37164, HHSN268201000008C, N01-HB-37163, HHSN268201000007C]; Athersys; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL087318, UM1HL087318, R43HL037164] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Athersys; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Dr Penn reported being a consultant for Juventas Therapeutics and Aastrom Biosciences and receiving grant funding for his institution from Athersys. No other authors reported any financial disclosures.; This study was supported by the National Heart, Lung, and Blood Institute (NHLBI) under the cooperative agreement 5 U01 HL087318-04 and in part by the NHLBI contracts N01-HB-37164 and HHSN268201000008C to the Molecular and Cellular Therapeutics Facility, University of Minnesota, and N01-HB-37163 and HHSN268201000007C to the Cell Processing Facility, Baylor College of Medicine.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Cogle CR, 2009, CIRCULATION, V120, pS1132; Dobaczewski M, 2010, J MOL CELL CARDIOL, V48, P504, DOI 10.1016/j.yjmcc.2009.07.015; Frangogiannis NG, 2008, PHARMACOL RES, V58, P88, DOI 10.1016/j.phrs.2008.06.007; Gee AP, 2010, CYTOTHERAPY, V12, P684, DOI 10.3109/14653249.2010.487900; Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055; Higuchi T, 2008, CARDIOVASC RES, V78, P395, DOI 10.1093/cvr/cvn033; Hirsch A, 2011, EUR HEART J, V32, P1736, DOI 10.1093/eurheartj/ehq449; Huang Rong-chong, 2006, Zhonghua Yi Xue Za Zhi, V86, P1107; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Leone AM, 2005, EUR HEART J, V26, P1196, DOI 10.1093/eurheartj/ehi164; Lipinski MJ, 2007, J AM COLL CARDIOL, V50, P1761, DOI 10.1016/j.jacc.2007.07.041; Lunde K, 2006, NEW ENGL J MED, V355, P1199, DOI 10.1056/NEJMoa055706; Martin-Rendon E, 2008, EUR HEART J, V29, P1807, DOI 10.1093/eurheartj/ehn220; Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831; Miettinen JA, 2010, HEART, V96, P362, DOI 10.1136/hrt.2009.171694; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Perin EC, 2011, 2011 SCI SESS AM HEA; Roncalli J, 2011, EUR HEART J, V32, P1748, DOI 10.1093/eurheartj/ehq455; Schachinger V, 2008, CIRCULATION, V118, P1425, DOI 10.1161/CIRCULATIONAHA.108.777102; Schachinger V, 2006, EUR HEART J, V27, P2775, DOI 10.1093/eurheartj/ehl388; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Seeger FH, 2007, EUR HEART J, V28, P766, DOI 10.1093/eurheartj/ehl509; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Simari RD, 2010, J CARDIOVASC TRANSL, V3, P30, DOI 10.1007/s12265-009-9160-3; Tendera M, 2009, EUR HEART J, V30, P1313, DOI 10.1093/eurheartj/ehp073; Traverse JH, 2011, AM HEART J, V162, P671, DOI 10.1016/j.ahj.2011.06.019; Traverse JH, 2010, AM HEART J, V160, P428, DOI 10.1016/j.ahj.2010.06.009; Traverse JH, 2010, TEX HEART I J, V37, P412; Traverse JH, 2009, AM HEART J, V158, P356, DOI 10.1016/j.ahj.2009.06.009; van Beem Rachel T, 2008, EuroIntervention, V4, P133; Wang XY, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002814; Wohrle J, 2010, AM J CARDIOL, V105, P804, DOI 10.1016/j.amjcard.2009.10.060; WOJAKOWSKI W, LEUKEMIA, DOI DOI 10.1038/LEU2011.184; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326	38	298	308	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2011	306	19					2110	2119		10.1001/jama.2011.1670	http://dx.doi.org/10.1001/jama.2011.1670			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YU	22084195	Green Accepted, Bronze			2022-12-28	WOS:000297013000017
J	Gross, CP				Gross, Cary P.			Screening with low-dose computed tomography reduced lung cancer mortality in high-risk patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Gross, CP (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.							Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X; Marcus PM, 2000, J NATL CANCER I, V92, P1308, DOI 10.1093/jnci/92.16.1308; Nelson HD, 2009, ANN INTERN MED, V151, pW237, DOI DOI 10.7326/0003-4819-151-10-200911170-00009; Nelson HD, 2009, ANN INTERN MED, V151, P727, DOI 10.7326/0003-4819-151-10-200911170-00009	4	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-6	10.7326/0003-4819-155-10-201111150-02006	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084353				2022-12-28	WOS:000208885300005
J	Miller, FG; Pearson, SD				Miller, Franklin G.; Pearson, Steven D.			Linking Insurance Coverage for Innovative Invasive Procedures With Participation in Clinical Research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STENOSIS; STROKE		[Miller, Franklin G.; Pearson, Steven D.] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Miller, FG (corresponding author), NIH, Dept Bioeth, Ctr Clin, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	fmiller@nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bose A, 2007, STROKE, V38, P1531, DOI 10.1161/STROKEAHA.106.477711; Broderick JP, 2011, NEW ENGL J MED, V365, P1054, DOI 10.1056/NEJMe1108394; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Chimowitz MI, 2011, J STROKE CEREBROVASC, V20, P357, DOI 10.1016/j.jstrokecerebrovasdis.2011.05.001; Kolata G., 2011, NY TIMES, pA1; Miller FG, 2008, MED CARE, V46, P746, DOI 10.1097/MLR.0b013e3181789453; Miller FG, 2010, SPINE, V35, P2023, DOI 10.1097/BRS.0b013e3181ecd393; Tunis SR, 2006, HEALTH AFFAIR, V25, P1218, DOI 10.1377/hlthaff.25.5.1218; US Food and Drug Administration, HUM DEV EX	9	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2011	306	18					2024	2025		10.1001/jama.2011.1631	http://dx.doi.org/10.1001/jama.2011.1631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	843VT	22068996				2022-12-28	WOS:000296704300027
J	Basko, D				Basko, Denis			A Photothermoelectric Effect in Graphene	SCIENCE			English	Editorial Material									Univ Grenoble 1, CNRS, Lab Phys & Modelisat Milieux Condenses, UMR 5493, F-38042 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Basko, D (corresponding author), Univ Grenoble 1, CNRS, Lab Phys & Modelisat Milieux Condenses, UMR 5493, BP 166, F-38042 Grenoble, France.	denis.basko@grenoble.cnrs.fr						CUTLER M, 1969, PHYS REV, V181, P1336, DOI 10.1103/PhysRev.181.1336; Gabor NM, 2011, SCIENCE, V334, P648, DOI 10.1126/science.1211384; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Song J. C., 2011, NANO LETT, DOI [10.1021/nl202318u, DOI 10.1021/NL202318U]; Zuev YM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.096807	6	64	64	8	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					610	611		10.1126/science.1214560	http://dx.doi.org/10.1126/science.1214560			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053036	Green Submitted			2022-12-28	WOS:000296494700037
J	Zoncu, R; Bar-Peled, L; Efeyan, A; Wang, SY; Sancak, Y; Sabatini, DM				Zoncu, Roberto; Bar-Peled, Liron; Efeyan, Alejo; Wang, Shuyu; Sancak, Yasemin; Sabatini, David M.			mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase	SCIENCE			English	Article							V-ATPASE; RAG GTPASES; COMPLEX; TARGET; ACIDIFICATION; AVAILABILITY; TRANSPORTER; DROSOPHILA; PATHWAY; KINASE	The mTOR complex 1 (mTORC1) protein kinase is a master growth regulator that is stimulated by amino acids. Amino acids activate the Rag guanosine triphosphatases (GTPases), which promote the translocation of mTORC1 to the lysosomal surface, the site of mTORC1 activation. We found that the vacuolar H+-adenosine triphosphatase ATPase (v-ATPase) is necessary for amino acids to activate mTORC1. The v-ATPase engages in extensive amino acid-sensitive interactions with the Ragulator, a scaffolding complex that anchors the Rag GTPases to the lysosome. In a cell-free system, ATP hydrolysis by the v-ATPase was necessary for amino acids to regulate the v-ATPase-Ragulator interaction and promote mTORC1 translocation. Results obtained in vitro and in human cells suggest that amino acid signaling begins within the lysosomal lumen. These results identify the v-ATPase as a component of the mTOR pathway and delineate a lysosome-associated machinery for amino acid sensing.	[Zoncu, Roberto; Bar-Peled, Liron; Efeyan, Alejo; Wang, Shuyu; Sancak, Yasemin; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Zoncu, Roberto; Bar-Peled, Liron; Efeyan, Alejo; Wang, Shuyu; Sancak, Yasemin; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Zoncu, Roberto; Bar-Peled, Liron; Efeyan, Alejo; Wang, Shuyu; Sancak, Yasemin; Sabatini, David M.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Zoncu, Roberto; Sabatini, David M.] Broad Inst, Cambridge, MA 02142 USA; [Sabatini, David M.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Sabatini, DM (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Efeyan, Alejo/J-8197-2016; Wang, shuyu/GZM-3462-2022	Efeyan, Alejo/0000-0002-3806-6799; 	National Institutes of Health [CA103866, AI47389]; Department of Defense [W81XWH-07-0448]; W.M. Keck Foundation; LAM Foundation; Jane Coffin Childs Memorial Fund for Medical Research; Human Frontier Science Program; Medical Scientist Training Program; NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047389, R01AI047389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); W.M. Keck Foundation(W.M. Keck Foundation); LAM Foundation; Jane Coffin Childs Memorial Fund for Medical Research; Human Frontier Science Program(Human Frontier Science Program); Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Sabatini Lab as well as R. Perera for helpful suggestions, E. Spooner for the mass spectrometric analysis, and J. De Brabander (University of Texas Southwestern) for salicylihalamide A. Supported by grants from the National Institutes of Health (CA103866 and AI47389) and Department of Defense (W81XWH-07-0448) to D. M. S., awards from the W.M. Keck Foundation and LAM Foundation to D. M. S., and fellowship support from the Jane Coffin Childs Memorial Fund for Medical Research and the LAM Foundation to R.Z., from the Human Frontier Science Program to A. E., and from the Medical Scientist Training Program to S. W. D. M. S. is an investigator of the Howard Hughes Medical Institute.	Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bond S, 2008, J BIOL CHEM, V283, P36513, DOI 10.1074/jbc.M805232200; Bowman BJ, 2006, J BIOL CHEM, V281, P31885, DOI 10.1074/jbc.M605532200; Boyd MR, 2001, J PHARMACOL EXP THER, V297, P114; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; REEVES JP, 1979, J BIOL CHEM, V254, P8914; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Steinberg BE, 2010, J CELL BIOL, V189, P1171, DOI 10.1083/jcb.200911083; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Wu BQ, 2006, J CELL BIOL, V173, P327, DOI 10.1083/jcb.200602089; Xie XS, 2004, J BIOL CHEM, V279, P19755, DOI 10.1074/jbc.M313796200; Yan Y, 2009, DEV CELL, V17, P387, DOI 10.1016/j.devcel.2009.07.001; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	25	1082	1108	13	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					678	683		10.1126/science.1207056	http://dx.doi.org/10.1126/science.1207056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053050	Green Accepted, Green Submitted			2022-12-28	WOS:000296494700057
J	McMurray, JJV; Smith, GL				McMurray, John J. V.; Smith, Godfrey L.			Calcium Handling in the Failing Heart and SUMO - Weighing the Evidence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GENE-TRANSFER; FAILURE; SERCA2A		[McMurray, John J. V.; Smith, Godfrey L.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland	University of Glasgow	McMurray, JJV (corresponding author), Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Jessup M, 2011, CIRCULATION, V124, P304, DOI 10.1161/CIRCULATIONAHA.111.022889; Kawase Y, 2008, J AM COLL CARDIOL, V51, P1112, DOI 10.1016/j.jacc.2007.12.014; Kho C, 2011, NATURE, V477, P601, DOI 10.1038/nature10407; Wang J, 2011, WIRES SYST BIOL MED, V3, P446, DOI 10.1002/wsbm.130	6	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1738	1739		10.1056/NEJMcibr1110758	http://dx.doi.org/10.1056/NEJMcibr1110758			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047567				2022-12-28	WOS:000296424200016
J	O'Reilly, T				O'Reilly, Tim			Steve Jobs (1955-2011) OBITUARY	NATURE			English	Biographical-Item									OReilly Media, Sebastopol, CA 95472 USA		O'Reilly, T (corresponding author), OReilly Media, Sebastopol, CA 95472 USA.	timoreilly@gmail.com							0	2	2	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2011	479	7371					42	42		10.1038/479042a	http://dx.doi.org/10.1038/479042a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051667	Bronze			2022-12-28	WOS:000296422600023
J	Zoltowski, BD; Vaidya, AT; Top, D; Widom, J; Young, MW; Crane, BR				Zoltowski, Brian D.; Vaidya, Anand T.; Top, Deniz; Widom, Joanne; Young, Michael W.; Crane, Brian R.			Structure of full-length Drosophila cryptochrome	NATURE			English	Article							BLUE-LIGHT PHOTORECEPTOR; 6-4 PHOTOLYASE; CRYSTAL-STRUCTURE; FLAVIN COFACTOR; CIRCADIAN CLOCK; MECHANISM; MELANOGASTER; DEGRADATION; TERMINUS; TIMELESS	The cryptochrome/photolyase (CRY/PL) family of photoreceptors mediates adaptive responses to ultraviolet and blue light exposure in all kingdoms of life(1-5). Whereas PLs function predominantly in DNA repair of cyclobutane pyrimidine dimers (CPDs) and 6-4 photolesions caused by ultraviolet radiation, CRYs transduce signals important for growth, development, magnetosensitivity and circadian clocks(1-5). Despite these diverse functions, PLs/CRYs preserve a common structural fold, a dependence on flavin adenine dinucleotide (FAD) and an internal photoactivation mechanism(3,6). However, members of the CRY/PL family differ in the substrates recognized (protein or DNA), photochemical reactions catalysed and involvement of an antenna cofactor. It is largely unknown how the animal CRYs that regulate circadian rhythms act on their substrates. CRYs contain a variable carboxy-terminal tail that appends the conserved PL homology domain (PHD) and is important for function(7-12). Here, we report a 2.3-angstrom resolution crystal structure of Drosophila CRY with an intact C terminus. The C-terminal helix docks in the analogous groove that binds DNA substrates in PLs. Conserved Trp 536 juts into the CRY catalytic centre to mimic PL recognition of DNA photolesions. The FAD anionic semiquinone found in the crystals assumes a conformation to facilitate restructuring of the tail helix. These results help reconcile the diverse functions of the CRY/PL family by demonstrating how conserved protein architecture and photochemistry can be elaborated into a range of light-driven functions.	[Zoltowski, Brian D.; Vaidya, Anand T.; Widom, Joanne; Crane, Brian R.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [Top, Deniz; Young, Michael W.] Rockefeller Univ, Genet Lab, New York, NY 10065 USA	Cornell University; Rockefeller University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.	bc69@cornell.edu	, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Vaidya, Anand/0000-0002-5812-5266; Top, Deniz/0000-0002-1042-8460	NIH [GM079679, GM054339]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079679, R01GM054339, R37GM054339] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by NIH Grant GM079679 to B. R. C. and GM054339 to M.W.Y. We thank the NE-CAT at the Advanced Photon Source of Argonne Laboratories for access to data collection facilities. We are indebted to C. Kemp for insect cell expression of dCRY and C. Manahan, X. Xu and W. Horne for their help with the ITC experiments.	Berndt A, 2007, J BIOL CHEM, V282, P13011, DOI 10.1074/jbc.M608872200; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Dissel S, 2004, NAT NEUROSCI, V7, P834, DOI 10.1038/nn1285; Fogle KJ, 2011, SCIENCE, V331, P1409, DOI 10.1126/science.1199702; Gegear RJ, 2008, NATURE, V454, P1014, DOI 10.1038/nature07183; Gegear RJ, 2010, NATURE, V463, P804, DOI 10.1038/nature08719; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hemsley MJ, 2007, BIOCHEM BIOPH RES CO, V355, P531, DOI 10.1016/j.bbrc.2007.01.189; Hitomi K, 2009, P NATL ACAD SCI USA, V106, P6962, DOI 10.1073/pnas.0809180106; Hoang N, 2008, PLOS BIOL, V6, P1559, DOI 10.1371/journal.pbio.0060160; Kao YT, 2008, J AM CHEM SOC, V130, P7695, DOI 10.1021/ja801152h; Koh K, 2006, SCIENCE, V312, P1809, DOI 10.1126/science.1124951; Maul MJ, 2008, ANGEW CHEM INT EDIT, V47, P10076, DOI 10.1002/anie.200804268; Ozturk N, 2008, J BIOL CHEM, V283, P3256, DOI 10.1074/jbc.M708612200; Ozturk N, 2011, P NATL ACAD SCI USA, V108, P516, DOI 10.1073/pnas.1017093108; Partch CL, 2005, PHOTOCHEM PHOTOBIOL, V81, P1291, DOI 10.1562/2005-07-08-IR-607; Partch CL, 2005, BIOCHEMISTRY-US, V44, P3795, DOI 10.1021/bi047545g; Peschel N, 2009, CURR BIOL, V19, P241, DOI 10.1016/j.cub.2008.12.042; Rohr AK, 2010, ANGEW CHEM INT EDIT, V49, P2324, DOI 10.1002/anie.200907143; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Schleicher E, 2007, J BIOL CHEM, V282, P4738, DOI 10.1074/jbc.M604734200; Senda T, 2009, ANTIOXID REDOX SIGN, V11, P1741, DOI 10.1089/ARS.2008.2348; Tang CHA, 2010, NEURON, V66, P378, DOI 10.1016/j.neuron.2010.04.015; van der Schalie EA, 2007, MOL CELL BIOL, V27, P2120, DOI 10.1128/MCB.01638-06; vanVickle-Chavez SJ, 2007, J BIOL CHEM, V282, P10561, DOI 10.1074/jbc.M609314200; Yoshii T, 2009, PLOS BIOL, V7, P813, DOI 10.1371/journal.pbio.1000086; Yuan Q, 2007, MOL BIOL EVOL, V24, P948, DOI 10.1093/molbev/msm011	31	116	122	2	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	2011	480	7377					396	U156		10.1038/nature10618	http://dx.doi.org/10.1038/nature10618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PZ	22080955	Green Accepted			2022-12-28	WOS:000298033000058
J	Grijalva, CG; Chen, L; Delzell, E; Baddley, JW; Beukelman, T; Winthrop, KL; Griffin, MR; Herrinton, LJ; Liu, LY; Ouellet-Hellstrom, R; Patkar, NM; Solomon, DH; Lewis, JD; Xie, FL; Saag, KG; Curtis, JR				Grijalva, Carlos G.; Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Winthrop, Kevin L.; Griffin, Marie R.; Herrinton, Lisa J.; Liu, Liyan; Ouellet-Hellstrom, Rita; Patkar, Nivedita M.; Solomon, Daniel H.; Lewis, James D.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.			Initiation of Tumor Necrosis Factor-alpha Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODIFYING ANTIRHEUMATIC DRUGS; SERIOUS BACTERIAL-INFECTIONS; RHEUMATOID-ARTHRITIS; OPPORTUNISTIC INFECTIONS; BRITISH-SOCIETY; THERAPY; METAANALYSIS; SAFETY; ASSOCIATION; INFLIXIMAB	Context Although tumor necrosis factor (TNF)-alpha antagonists are increasingly used in place of nonbiologic comparator medications, their safety profile remains incomplete. Objectives To determine whether initiation of TNF-alpha antagonists compared with nonbiologic comparators is associated with an increased risk of serious infections requiring hospitalization. Design, Setting, and Patients Within a US multi-institutional collaboration, we assembled retrospective cohorts (1998-2007) of patients with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Permanente Northern California, New Jersey and Pennsylvania Pharmaceutical Assistance programs, Tennessee Medicaid, and national Medicaid/Medicare. TNF-alpha antagonists and nonbiologic regimens were compared in disease-specific propensity score (PS)-matched cohorts using Cox regression models with nonbiologics as the reference. Baseline glucocorticoid use was evaluated as a separate covariate. Main Outcome Measure Infections requiring hospitalization (serious infections) during the first 12 months after initiation of TNF-alpha antagonists or nonbiologic regimens. Results Study cohorts included 10 484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha antagonists and comparator medications. Overall, we identified 1172 serious infections, most of which (53%) were pneumonia and skin and soft tissue infections. Among patients with RA, serious infection hospitalization rates were 8.16 (TNF-alpha antagonists) and 7.78 (comparator regimens) per 100 person-years (adjusted hazard ratio [aHR], 1.05 [95% CI, 0.91-1.21]). Among patients with IBD, rates were 10.91 (TNF-alpha antagonists) and 9.60 (comparator) per 100 person-years (aHR, 1.10 [95% CI, 0.83-1.46]). Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antagonists) and 5.37 (comparator) per 100 person-years (aHR, 1.05 [95% CI, 0.76-1.45]). Among patients with RA, infliximab was associated with a significant increase in serious infections compared with etanercept (aHR, 1.26 [95% CI, 1.07-1.47]) and adalimumab (aHR, 1.23 [95% CI, 1.02-1.48]). Baseline glucocorticoid use was associated with a dose-dependent increase in infections. Conclusion Among patients with autoimmune diseases, compared with treatment with nonbiologic regimens, initiation of TNF-alpha antagonists was not associated with an increased risk of hospitalizations for serious infections. JAMA. 2011;306(21):2331-2339 Published online November 6, 2011. doi:10.1001/jama.2011.1692	[Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, Nashville, TN 37212 USA; [Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Patkar, Nivedita M.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA; [Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA; [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Herrinton, Lisa J.; Liu, Liyan] Kaiser Permanente No Calif, Oakland, CA USA; [Ouellet-Hellstrom, Rita] US FDA, Silver Spring, MD USA; [Solomon, Daniel H.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Solomon, Daniel H.] Harvard Univ, Boston, MA 02115 USA; [Lewis, James D.] Univ Penn, Dept Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Lewis, James D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Vanderbilt University; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; Oregon Health & Science University; Kaiser Permanente; US Food & Drug Administration (FDA); Harvard University; Brigham & Women's Hospital; Harvard University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Grijalva, CG (corresponding author), Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, 1500 21st Ave S,Ste 2600, Nashville, TN 37212 USA.	carlos.grijalva@vanderbilt.edu		Beukelman, Timothy/0000-0001-9463-6306; Grijalva, Carlos/0000-0002-2329-7797	Amgen; Genentech; Centocor; Procter Gamble; Abbott; Eli Lilly; Bristol-Myers Squibb; Takeda; Shire; Pfizer; Roche/Genentech; UCB biopharma; CORRONA; Crescendo; Food and Drug Administration (FDA); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality (AHRQ) [U18 HS17919, R01HS018517]; National Institutes of Health (NIH) [AR053351]; NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2 RR025776-03]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [5P60AR56116]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018517, U18HS017919] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR053351, P60AR056116] Funding Source: NIH RePORTER	Amgen(Amgen); Genentech(Roche HoldingGenentech); Centocor; Procter Gamble(Procter & Gamble); Abbott(Abbott Laboratories); Eli Lilly(Eli Lilly); Bristol-Myers Squibb(Bristol-Myers Squibb); Takeda(Takeda Pharmaceutical Company Ltd); Shire; Pfizer(Pfizer); Roche/Genentech(Roche HoldingGenentech); UCB biopharma; CORRONA; Crescendo(European Commission); Food and Drug Administration (FDA)(United States Department of Health & Human Services); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Delzell reported receiving research support from Amgen. Dr Baddley reported consulting for Abbott and Merck. Dr Herrinton reported receiving research support from Genentech, Centocor, and Procter & Gamble. Dr Solomon reported receiving research support from Amgen, Abbott, Eli Lilly, and Bristol-Myers Squibb. Dr Lewis reported consulting for Genentech, Abbott, CORRONA (Consortium of Rheumatology Researchers of North America Inc), Millennium Pharmaceuticals, Elan, AstraZeneca, Procter & Gamble, GlaxoSmithKline, Alios Therapeutics, Roche, and Amgen; he also reported receiving research support from Centocor, Takeda, and Shire, and consultant honoraria from Amgen and Pfizer. Dr Winthrop reported receiving consultant fees from Genentech and Abbott, research support from Pfizer, and speakers honoraria from Amgen and Pfizer. Dr Saag reported receiving research support from Amgen, Genentech, and Pfizer. Dr Curtis reported receiving consultant fees and research grants from Roche/Genentech, UCB biopharma, Centocor, CORRONA, Amgen, Pfizer, Bristol-Myers Squibb, Crescendo, and Abbott. Other authors reported no conflicts.; This work was supported by the Food and Drug Administration (FDA), US Department of Health and Human Services (DHHS), and the Agency for Healthcare Research and Quality (AHRQ) grant U18 HS17919. Dr Curtis receives support from the National Institutes of Health (NIH; AR053351) and AHRQ (R01HS018517). Dr Beukelman was supported by NIH grant 5KL2 RR025776-03 via the University of Alabama at Birmingham Center for Clinical and Translational Science. Drs Grijalva and Griffin receive support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant 5P60AR56116.	Askling J, 2007, ANN RHEUM DIS, V66, P1339, DOI 10.1136/ard.2006.062760; Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637; Bernatsky S, 2010, J RHEUMATOL, V37, P928, DOI 10.3899/jrheum.091107; Bijlsma JWJ, 2003, ANN RHEUM DIS, V62, P1033, DOI 10.1136/ard.62.11.1033; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Buttgereit F, 2002, ANN RHEUM DIS, V61, P718, DOI 10.1136/ard.61.8.718; Curtis JR, 2007, ARTHRIT RHEUM-ARTHR, V57, P343, DOI 10.1002/art.22544; Curtis JR, 2007, ARTHRITIS RHEUM, V56, P4226, DOI 10.1002/art.23050; Curtis JR, 2007, ARTHRITIS RHEUM-US, V56, P1125, DOI 10.1002/art.22504; Curtis JR, 2011, ANN RHEUM DIS, V70, P1401, DOI 10.1136/ard.2010.146365; Dixon WG, 2007, ARTHRITIS RHEUM, V56, P2896, DOI 10.1002/art.22808; Dixon WG, 2006, ARTHRITIS RHEUM-US, V54, P2368, DOI 10.1002/art.21978; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2294, DOI 10.1002/art.10529; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Fouque-Aubert A, 2010, ANN RHEUM DIS, V69, P1756, DOI 10.1136/ard.2008.098822; Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002; Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242; Greenberg JD, 2010, ANN RHEUM DIS, V69, P380, DOI 10.1136/ard.2008.089276; Grijalva CG, 2008, RHEUMATOLOGY, V47, P1061, DOI 10.1093/rheumatology/ken193; Grijalva CG, 2008, PHARMACOEPIDEM DR S, V17, P890, DOI 10.1002/pds.1625; Grijalva CG, 2010, RHEUMATOLOGY, V49, P82, DOI 10.1093/rheumatology/kep325; Herrinton LJ, 2011, PHARMACOEPIDEM DR S, V20, P1199, DOI 10.1002/pds.2196; Hsieh FY, 2000, CONTROL CLIN TRIALS, V21, P552, DOI 10.1016/S0197-2456(00)00104-5; Hudson M, 2010, ARTHRIT CARE RES, V62, P805, DOI 10.1002/acr.20124; Lane MA, 2011, MEDICINE, V90, P139, DOI 10.1097/MD.0b013e318211106a; Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386; Patkar NM, 2009, J CLIN EPIDEMIOL, V62, P321, DOI 10.1016/j.jclinepi.2008.06.006; Peyrin-Biroulet L, 2008, CLIN GASTROENTEROL H, V6, P644, DOI 10.1016/j.cgh.2008.03.014; Rassen JA, 2010, MED CARE, V48, pS83, DOI 10.1097/MLR.0b013e3181d59541; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Rigby WFC, 2007, NAT CLIN PRACT RHEUM, V3, P227, DOI 10.1038/ncprheum0438; Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721; Schmajuk G, 2011, JAMA-J AM MED ASSOC, V305, P480, DOI 10.1001/jama.2011.67; Schneeweiss S, 2009, ALIMENT PHARM THER, V30, P253, DOI 10.1111/j.1365-2036.2009.04037.x; Schneeweiss S, 2007, ARTHRITIS RHEUM-US, V56, P1754, DOI 10.1002/art.22600; Schneeweiss S, 2007, J CLIN EPIDEMIOL, V60, P397, DOI 10.1016/j.jclinepi.2006.07.011; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Solomon DH, 2008, ARTHRITIS RHEUM-US, V58, P919, DOI 10.1002/art.23396; Solomon DH, 2006, ARTHRITIS RHEUM-US, V54, P3790, DOI 10.1002/art.22255; Solomon DH, 2011, JAMA-J AM MED ASSOC, V305, P2525, DOI 10.1001/jama.2011.878; STUCK AE, 1989, REV INFECT DIS, V11, P954; Ting G, 2005, J RHEUMATOL, V32, P1679; Westhovens R, 2006, ARTHRITIS RHEUM-US, V54, P1075, DOI 10.1002/art.21734; Wolfe F, 2006, ARTHRITIS RHEUM-US, V54, P628, DOI 10.1002/art.21568; Yu O, 2011, EPIDEMIOL INFECT, V139, P1296, DOI 10.1017/S0950268810002529	49	264	274	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2011	306	21					2331	2339		10.1001/jama.2011.1692	http://dx.doi.org/10.1001/jama.2011.1692			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856YH	22056398	Green Accepted, Bronze			2022-12-28	WOS:000297680300018
J	Li, HB; Henning, T				Li, Hua-bai; Henning, Thomas			The alignment of molecular cloud magnetic fields with the spiral arms in M33	NATURE			English	Article							INSTABILITY; HERSCHEL; GAS	The formation of molecular clouds, which serve as stellar nurseries in galaxies, is poorly understood. A class of cloud formation models suggests that a large-scale galactic magnetic field is irrelevant at the scale of individual clouds, because the turbulence and rotation of a cloud may randomize the orientation of its magnetic field(1,2). Alternatively, galactic fields could be strong enough to impose their direction upon individual clouds(3,4), thereby regulating cloud accumulation and fragmentation(5), and affecting the rate and efficiency of star formation(6). Our location in the disk of the Galaxy makes an assessment of the situation difficult. Here we report observations of the magnetic field orientation of six giant molecular cloud complexes in the nearby, almost face-on, galaxy M33. The fields are aligned with the spiral arms, suggesting that the large-scale field in M33 anchors the clouds.	[Li, Hua-bai; Henning, Thomas] Max Planck Inst Astron, D-69117 Heidelberg, Germany	Max Planck Society	Li, HB (corresponding author), Max Planck Inst Astron, Konigstuhl 17, D-69117 Heidelberg, Germany.	li@mpia.de	Henning, Thomas K/O-4372-2018	Henning, Thomas K/0000-0002-1493-300X	Max-Planck-Institut fur Astronomie and Harvard-Smithsonian Center for Astrophysics; Smithsonian Institution; Academia Sinica	Max-Planck-Institut fur Astronomie and Harvard-Smithsonian Center for Astrophysics; Smithsonian Institution(Smithsonian Institution); Academia Sinica(Academia Sinica - Taiwan)	We thank E. Rosolowsky, R. Shetty, T. K. Sridharan, M. Houde, S. Paine, H.-H. Wang, A. Karim, S. Ragan, K. Smith, P. Boley and T. Wufor comments. We appreciate the help of D. Marrone, G. Petitpas and R. Rao with the observations. We are grateful for the Herschel maps of M33 offered by C. Kramer. This research is supported by the Max-Planck-Institut fur Astronomie and Harvard-Smithsonian Center for Astrophysics. The Submillimeter Array is a joint project between the Smithsonian Astrophysical Observatory and the Academia Sinica Institute of Astronomy and Astrophysics and is funded by the Smithsonian Institution and the Academia Sinica.	CHANDRASEKHAR S, 1953, ASTROPHYS J, V118, P113, DOI 10.1086/145731; Crutcher R., 2005, MAGNETIZED PLASMA GA, P103; Dobbs CL, 2008, MON NOT R ASTRON SOC, V391, P844, DOI 10.1111/j.1365-2966.2008.13939.x; Falceta-Goncalves D, 2008, ASTROPHYS J, V679, P537, DOI 10.1086/587479; FIELD GB, 1969, ASTROPHYS J, V155, pL149, DOI 10.1086/180324; Frick P, 2001, MON NOT R ASTRON SOC, V327, P1145, DOI 10.1046/j.1365-8711.2001.04812.x; GOLDREICH P, 1981, ASTROPHYS J, V243, pL75, DOI 10.1086/183446; Greaves JS, 1999, ASTROPHYS J, V512, pL139, DOI 10.1086/311888; Han JL, 2007, ASTRON ASTROPHYS, V464, P609, DOI 10.1051/0004-6361:20065801; Heyer M, 2008, ASTROPHYS J, V680, P420, DOI 10.1086/587510; Ho PTP, 2004, ASTROPHYS J, V616, pL1, DOI 10.1086/423245; Kim CG, 2008, ASTROPHYS J, V681, P1148, DOI 10.1086/588752; Kim M, 2002, ASTRON J, V123, P244, DOI 10.1086/324639; Kramer C, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014613; Kwak K, 2009, ASTROPHYS J, V699, P1775, DOI 10.1088/0004-637X/699/2/1775; Li H, 2006, ASTROPHYS J, V648, P340, DOI 10.1086/505858; Li HB, 2011, MON NOT R ASTRON SOC, V411, P2067, DOI 10.1111/j.1365-2966.2010.17839.x; Li HB, 2009, ASTROPHYS J, V704, P891, DOI 10.1088/0004-637X/704/2/891; Men'shchikov A, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014668; Mouschovias TC, 2009, MON NOT R ASTRON SOC, V397, P14, DOI 10.1111/j.1365-2966.2009.14472.x; PASSOT T, 1995, ASTROPHYS J, V455, P536, DOI 10.1086/176603; Price DJ, 2008, MON NOT R ASTRON SOC, V385, P1820, DOI 10.1111/j.1365-2966.2008.12976.x; ROGSTAD DH, 1976, ASTROPHYS J, V204, P703, DOI 10.1086/154219; Rosolowsky E, 2003, ASTROPHYS J, V599, P258, DOI 10.1086/379166; SANDAGE A, 1980, ASTROPHYS J, V236, pL1, DOI 10.1086/183186; Shetty R, 2006, ASTROPHYS J, V647, P997, DOI 10.1086/505594; Shukurov A., 1999, DYNAMIC INTERSTELLAR, P66; Tabatabaei FS, 2008, ASTRON ASTROPHYS, V490, P1005, DOI 10.1051/0004-6361:200810590; Wilson CD, 1997, ASTROPHYS J, V483, P210, DOI 10.1086/304216	30	50	50	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 24	2011	479	7374					499	501		10.1038/nature10551	http://dx.doi.org/10.1038/nature10551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	851QI	22089133	Green Submitted			2022-12-28	WOS:000297285600043
J	Giocomo, LM; Hussaini, SA; Zheng, F; Kandel, ER; Moser, MB; Moser, EI				Giocomo, Lisa M.; Hussaini, Syed A.; Zheng, Fan; Kandel, Eric R.; Moser, May-Britt; Moser, Edvard I.			Grid Cells Use HCN1 Channels for Spatial Scaling	CELL			English	Article							MEDIAL ENTORHINAL CORTEX; CA1 PYRAMIDAL NEURONS; STELLATE CELLS; LAYER-II; DISTAL DENDRITES; PATH-INTEGRATION; PLACE CELLS; H-CURRENT; THETA; REPRESENTATION	Entorhinal grid cells have periodic, hexagonally patterned firing locations that scale up progressively along the dorsal-ventral axis of medial entorhinal cortex. This topographic expansion corresponds with parallel changes in cellular properties dependent on the hyperpolarization-activated cation current (Ih), which is conducted by hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. To test the hypothesis that grid scale is determined by Ih, we recorded grid cells in mice with forebrain-specific knockout of HCN1. We find that, although the dorsal-ventral gradient of the grid pattern was preserved in HCN1 knockout mice, the size and spacing of the grid fields, as well as the period of the accompanying theta modulation, was expanded at all dorsal-ventral levels. There was no change in theta modulation of simultaneously recorded entorhinal interneurons. These observations raise the possibility that, during self-motion-based navigation, Ih contributes to the gain of the transformation from movement signals to spatial firing fields.	[Giocomo, Lisa M.; Zheng, Fan; Moser, May-Britt; Moser, Edvard I.] Norwegian Univ Sci & Technol, Kavli Inst Syst Neurosci, N-7030 Trondheim, Norway; [Giocomo, Lisa M.; Zheng, Fan; Moser, May-Britt; Moser, Edvard I.] Norwegian Univ Sci & Technol, Ctr Biol Memory, N-7030 Trondheim, Norway; [Hussaini, Syed A.; Kandel, Eric R.] Columbia Univ, Dept Neurosci, Kavli Inst Brain Sci, New York, NY 10032 USA; [Hussaini, Syed A.; Kandel, Eric R.] Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Columbia University; Columbia University; Howard Hughes Medical Institute	Giocomo, LM (corresponding author), Norwegian Univ Sci & Technol, Kavli Inst Syst Neurosci, N-7030 Trondheim, Norway.	lisa.m.giocomo@ntnu.no; edvard.moser@ntnu.no	Hussaini, Abid/AAZ-2418-2020	Hussaini, S. Abid/0000-0002-3921-9021; Giocomo, Lisa/0000-0003-0416-2528	European Commission; European Research Council; NIH [MH080745]; Howard Hughes Medical Institute; Kavli Foundation; Norwegian Research Council; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH080745] Funding Source: NIH RePORTER	European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Kavli Foundation; Norwegian Research Council(Research Council of NorwayEuropean Commission); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank R. Skjerpeng for programming; O. Salvesen for statistical advice; A. M. Amundsga rd, I. Hammer, K. Haugen, and H. Waade for technical assistance; and M. E. Hasselmo, T. Solstad, and J.F. Storm for helpful discussion and/or comments on the manuscript. This work was supported by a Marie Curie Fellowship to L. M. G. from the European Commission; an Advanced Investigator Grant to E. I. M. from the European Research Council; an NIH grant MH080745 to S. A. H. and E. R. K.; the Howard Hughes Medical Institute (E. R. K.); the Kavli Foundation (M.-B. M. and E. I. M.); and a Centre of Excellence grant from the Norwegian Research Council (M.-B. M. and E. I. M.).	Blair HT, 2008, HIPPOCAMPUS, V18, P1239, DOI 10.1002/hipo.20509; Boccara CN, 2010, NAT NEUROSCI, V13, P987, DOI 10.1038/nn.2602; Boehlen A, 2010, J NEUROSCI, V30, P4585, DOI 10.1523/JNEUROSCI.4939-09.2010; Brun VH, 2008, HIPPOCAMPUS, V18, P1200, DOI 10.1002/hipo.20504; Burgess N, 2007, HIPPOCAMPUS, V17, P801, DOI 10.1002/hipo.20327; Burgess N, 2008, HIPPOCAMPUS, V18, P1157, DOI 10.1002/hipo.20518; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Dodson PD, 2011, J PHYSIOL-LONDON, V589, P2993, DOI 10.1113/jphysiol.2011.205021; Doeller CF, 2010, NATURE, V463, P657, DOI 10.1038/nature08704; Fuhs MC, 2006, J NEUROSCI, V26, P4266, DOI 10.1523/JNEUROSCI.4353-05.2006; Fyhn M, 2004, SCIENCE, V305, P1258, DOI 10.1126/science.1099901; Fyhn M, 2007, NATURE, V446, P190, DOI 10.1038/nature05601; Fyhn M, 2008, HIPPOCAMPUS, V18, P1230, DOI 10.1002/hipo.20472; Garden DLF, 2008, NEURON, V60, P875, DOI 10.1016/j.neuron.2008.10.044; Giocomo LM, 2008, J NEUROSCI, V28, P9414, DOI 10.1523/JNEUROSCI.3196-08.2008; Giocomo LM, 2007, SCIENCE, V315, P1719, DOI 10.1126/science.1139207; Giocomo LM, 2009, J NEUROSCI, V29, P7625, DOI 10.1523/JNEUROSCI.0609-09.2009; Giocomo LM, 2008, HIPPOCAMPUS, V18, P1186, DOI 10.1002/hipo.20501; Hafting T, 2005, NATURE, V436, P801, DOI 10.1038/nature03721; Heys JG, 2010, J NEUROPHYSIOL, V104, P258, DOI 10.1152/jn.00492.2009; Hu H, 2002, J PHYSIOL-LONDON, V545, P783, DOI 10.1113/jphysiol.2002.029249; Hu H, 2009, J NEUROSCI, V29, P14472, DOI 10.1523/JNEUROSCI.0187-09.2009; Hussaini SA, 2011, NEURON, V72, P643, DOI 10.1016/j.neuron.2011.09.007; Jeewajee A, 2008, HIPPOCAMPUS, V18, P1175, DOI 10.1002/hipo.20510; Kispersky T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013697; Kjonigsen Lisa J, 2011, Front Neuroinform, V5, P2, DOI 10.3389/fninf.2011.00002; Langston RF, 2010, SCIENCE, V328, P1576, DOI 10.1126/science.1188210; Maurer AP, 2005, HIPPOCAMPUS, V15, P841, DOI 10.1002/hipo.20114; McNaughton BL, 2006, NAT REV NEUROSCI, V7, P663, DOI 10.1038/nrn1932; Navratilova Z, 2011, HIPPOCAMPUS IN PRESS; Nolan MF, 2007, J NEUROSCI, V27, P12440, DOI 10.1523/JNEUROSCI.2358-07.2007; Nolan MF, 2004, CELL, V119, P719, DOI 10.1016/S0092-8674(04)01055-4; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; O'Keefe J, 2005, HIPPOCAMPUS, V15, P853, DOI 10.1002/hipo.20115; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Sargolini F, 2006, SCIENCE, V312, P758, DOI 10.1126/science.1125572; Schmitzer-Torbert N, 2005, NEUROSCIENCE, V131, P1, DOI 10.1016/j.neuroscience.2004.09.066; Solstad T, 2008, SCIENCE, V322, P1865, DOI 10.1126/science.1166466; Tsay D, 2007, NEURON, V56, P1076, DOI 10.1016/j.neuron.2007.11.015; Yartsev MM, 2011, NATURE, V479, P103, DOI 10.1038/nature10583; Zilli EA, 2010, J NEUROSCI, V30, P13850, DOI 10.1523/JNEUROSCI.0547-10.2010	42	107	107	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 23	2011	147	5					1159	1170		10.1016/j.cell.2011.08.051	http://dx.doi.org/10.1016/j.cell.2011.08.051			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852SA	22100643	Bronze			2022-12-28	WOS:000297376600025
J	Katikireddi, SV; Higgins, M; Bond, L; Bonell, C; Macintyre, S				Katikireddi, Srinivasa Vittal; Higgins, Martin; Bond, Lyndal; Bonell, Chris; Macintyre, Sally			How evidence based is English public health policy?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Katikireddi, Srinivasa Vittal; Bond, Lyndal; Macintyre, Sally] MRC, Chief Scientist Off, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; [Higgins, Martin] NHS Lothian, Publ Hlth & Hlth Policy, Edinburgh, Midlothian, Scotland; [Bonell, Chris] Univ London London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1E 7HT, England	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of London; London School of Hygiene & Tropical Medicine	Katikireddi, SV (corresponding author), MRC, Chief Scientist Off, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	vkatikireddi@sphsu.mrc.ac.uk	Macintyre, Sally/P-6246-2014	BOND, LYNDAL/0000-0003-1693-5508; Katikireddi, Srinivasa/0000-0001-6593-9092	MRC [MC_U130059821, MC_U130085862, MC_U130059812] Funding Source: UKRI; Medical Research Council [MC_U130059821, MC_U130085862, MC_U130059812] Funding Source: Medline; Chief Scientist Office [SPHSU1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chief Scientist Office		Craig P, USING NATURAL EXPT E; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Davis P, 1996, SOC SCI MED, V43, P865, DOI 10.1016/0277-9536(96)00130-X; Department of Health, 2010, EQ EXC LIB NHS; Healthy People 2020, 2010, FDN HLTH MEAS REP HE; House of Commons Health Committee, 2009, HLTH IN REP SESS 200, V1; Lansley A., 2010, SECRETARY STATE HEAL; Macintyre S, 2003, BRIT MED J, V326, P5, DOI 10.1136/bmj.326.7379.5; Macintyre S, 2011, J EPIDEMIOL COMMUN H, V65, P564, DOI 10.1136/jech.2010.124198; Parsons W., 2002, PUBLIC POLICY ADMIN, V17, P43, DOI DOI 10.1177/095207670201700304; Radaelli C. M., 1995, J EUR PUBLIC POLICY, V2, P159, DOI [10.1080/13501769508406981, DOI 10.1080/13501769508406981]; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; Tannahill A, 2008, HEALTH PROMOT INT, V23, P380, DOI 10.1093/heapro/dan032	13	39	39	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2011	343								d7310	10.1136/bmj.d7310	http://dx.doi.org/10.1136/bmj.d7310			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	875FU	22096256	Green Accepted			2022-12-28	WOS:000299016600008
J	Schonbauer, C; Distler, J; Jahrling, N; Radolf, M; Dodt, HU; Frasch, M; Schnorrer, F				Schoenbauer, Cornelia; Distler, Jutta; Jaehrling, Nina; Radolf, Martin; Dodt, Hans-Ulrich; Frasch, Manfred; Schnorrer, Frank			Spalt mediates an evolutionarily conserved switch to fibrillar muscle fate in insects	NATURE			English	Article							FLIGHT-MUSCLE; DROSOPHILA EMBRYO; GENETIC-ANALYSIS; PROTEIN; EXPRESSION; MYOGENESIS; SALL1; ACTIN	Flying insects oscillate their wings at high frequencies of up to 1,000 Hz(1,2) and produce large mechanical forces of 80 W per kilogram of muscle(3). They utilize a pair of perpendicularly oriented indirect flight muscles that contain fibrillar, stretch-activated myofibres. In contrast, all other, more slowly contracting, insect body muscles have a tubular muscle morphology(4). Here we identify the transcription factor Spalt major (Salm) as a master regulator of fibrillar flight muscle fate in Drosophila. salm is necessary and sufficient to induce fibrillar muscle fate. salm switches the entire transcriptional program from tubular to fibrillar fate by regulating the expression and splicing of key sarcomeric components specific to each muscle type. Spalt function is conserved in insects evolutionarily separated by 280 million years. We propose that Spalt proteins switch myofibres from tubular to fibrillar fate during development, a function potentially conserved in the vertebrate heart-a stretch-activated muscle sharing features with insect flight muscle.	[Schoenbauer, Cornelia; Schnorrer, Frank] Max Planck Inst Biochem, D-82152 Martinsried, Germany; [Distler, Jutta; Frasch, Manfred] Univ Erlangen Nurnberg, Dept Biol, Dev Biol Div, D-91058 Erlangen, Germany; [Jaehrling, Nina; Dodt, Hans-Ulrich] Vienna Univ Technol, FKE, Dept Bioelect, A-1040 Vienna, Austria; [Jaehrling, Nina; Dodt, Hans-Ulrich] Med Univ Vienna, Ctr Brain Res, A-1090 Vienna, Austria; [Radolf, Martin] IMP, A-1030 Vienna, Austria	Max Planck Society; University of Erlangen Nuremberg; Technische Universitat Wien; Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Schnorrer, F (corresponding author), Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	schnorrer@biochem.mpg.de	Frasch, Manfred/H-7002-2013; Schnorrer, Frank/AIE-3578-2022	Frasch, Manfred/0000-0003-1373-9798; Schnorrer, Frank/0000-0002-9518-7263	Max-Planck-Society; Human Frontier Science Programme; Austrian Academy of Sciences; DFG	Max-Planck-Society(Max Planck SocietyFoundation CELLEX); Human Frontier Science Programme(Human Frontier Science Program); Austrian Academy of Sciences; DFG(German Research Foundation (DFG))	We thank M. Affolter, D. Baumer, M. Beckerle, B. Bullard, E. Chen, K. Clark, C. Desplan, K. Jagla, A. Lalouette, J. Posakony, D. Reiff, J. Saide, S. Sprecher, R. Schuh, G. Tanentzapf, J. Vigoreaux, K. VijayRaghavan, the Bloomington and the VDRC stock centres for fly stocks, antibodies and insect species. We are grateful to B. Dickson, I. Hein, M. Klingler and M. Sixt for discussions, and to R. Fassler for support and discussions. We thank A. Kaya-Copur, H. Knaut, M. Spletter and N. Vogt for critical comments on the manuscript. This work was supported by the Max-Planck-Society, a Career Development Award by the Human Frontier Science Programme to F. S., a Doc-fForte predoctoral fellowship from the Austrian Academy of Sciences to C. S., and DFG grants to M.F.	Agianian B, 2004, EMBO J, V23, P772, DOI 10.1038/sj.emboj.7600097; Anant S, 1998, DEVELOPMENT, V125, P1361; Arredondo JJ, 2001, J BIOL CHEM, V276, P8278, DOI 10.1074/jbc.M009302200; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; Bernard F, 2003, DEV BIOL, V260, P391, DOI 10.1016/S0012-1606(03)00255-0; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3; de Celis JF, 2009, INT J DEV BIOL, V53, P1385, DOI 10.1387/ijdb.072408jd; Dickinson M, 2006, CURR BIOL, V16, pR309, DOI 10.1016/j.cub.2006.03.087; Dudley R, 2000, BIOMECHANICS INSECT, P36; DUDLEY R, 2000, BIOMECHANICS INSECT, P75; Dutta D, 2004, DEVELOPMENT, V131, P3761, DOI 10.1242/dev.01249; Fernandes JJ, 1996, DEV BIOL, V176, P166, DOI 10.1006/dbio.1996.0125; Franch-Marro X, 2002, DEV BIOL, V250, P374, DOI 10.1006/dbio.2002.0799; Grieder NC, 2009, DEV BIOL, V329, P315, DOI 10.1016/j.ydbio.2009.03.006; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; Klein Thomas, 2008, V420, P253, DOI 10.1007/978-1-59745-583-1_15; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lehmann FO, 1997, J EXP BIOL, V200, P1133; Manisastry SM, 2009, EXP CELL RES, V315, P2126, DOI 10.1016/j.yexcr.2009.02.006; Maqbool T, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000122; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; Newsome TP, 2000, DEVELOPMENT, V127, P851; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; Nongthomba U, 2001, J MUSCLE RES CELL M, V22, P111, DOI 10.1023/A:1010308326890; Parrish M, 2004, MOL CELL BIOL, V24, P7102, DOI 10.1128/MCB.24.16.7102-7112.2004; Patel SR, 2005, J MUSCLE RES CELL M, V26, P213, DOI 10.1007/s10974-005-9012-y; Qiu F, 2005, J CELL SCI, V118, P1527, DOI 10.1242/jcs.02281; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; Rebeiz M, 2002, P NATL ACAD SCI USA, V99, P9888, DOI 10.1073/pnas.152320899; Reedy MC, 2000, J CELL BIOL, V151, P1483, DOI 10.1083/jcb.151.7.1483; Savard J, 2006, GENOME RES, V16, P1334, DOI 10.1101/gr.5204306; Schnorrer F, 2010, NATURE, V464, P287, DOI 10.1038/nature08799; Shiels HA, 2008, J EXP BIOL, V211, P2005, DOI 10.1242/jeb.003145; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; Surka WS, 2001, AM J MED GENET, V102, P250, DOI 10.1002/1096-8628(20010815)102:3<250::AID-AJMG1479>3.0.CO;2-Q; Tomoyasu Y, 2004, DEV GENES EVOL, V214, P575, DOI 10.1007/s00427-004-0434-0	37	72	73	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2011	479	7373					406	U160		10.1038/nature10559	http://dx.doi.org/10.1038/nature10559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	848OA	22094701				2022-12-28	WOS:000297059700047
J	Murff, HJ				Murff, Harvey J.			Review: Cholecalciferol (vitamin D-3) reduces mortality in adults; other forms of vitamin D do not	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vanderbilt Univ, Nashville, TN 37235 USA	Vanderbilt University	Murff, HJ (corresponding author), Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.							Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Houghton LA, 2006, AM J CLIN NUTR, V84, P694, DOI 10.1093/ajcn/84.4.694; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704	3	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-4	10.7326/0003-4819-155-10-201111150-02004	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084351				2022-12-28	WOS:000208885300003
J	Zanoni, I; Ostuni, R; Marek, LR; Barresi, S; Barbalat, R; Barton, GM; Granucci, F; Kagan, JC				Zanoni, Ivan; Ostuni, Renato; Marek, Lorri R.; Barresi, Simona; Barbalat, Roman; Barton, Gregory M.; Granucci, Francesca; Kagan, Jonathan C.			CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4	CELL			English	Article							DENDRITIC CELLS; LIPOPOLYSACCHARIDE; INNATE; TLR4; INDUCTION; CAPTURE; KINASE; MICE; SYK; TOLL-LIKE-RECEPTOR-4	The transport of Toll-like Receptors (TLRs) to various organelles has emerged as an essential means by which innate immunity is regulated. While most of our knowledge is restricted to regulators that promote the transport of newly synthesized receptors, the regulators that control TLR transport after microbial detection remain unknown. Here, we report that the plasma membrane localized Pattern Recognition Receptor (PRR) CD14 is required for the microbe-induced endocytosis of TLR4. In dendritic cells, this CD14-dependent endocytosis pathway is upregulated upon exposure to inflammatory mediators. We identify the tyrosine kinase Syk and its downstream effector PLC gamma 2 as important regulators of TLR4 endocytosis and signaling. These data establish that upon microbial detection, an upstream PRR (CD14) controls the trafficking and signaling functions of a downstream PRR (TLR4). This innate immune trafficking cascade illustrates how pathogen detection systems operate to induce both membrane transport and signal transduction.	[Zanoni, Ivan; Marek, Lorri R.; Kagan, Jonathan C.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Zanoni, Ivan; Marek, Lorri R.; Kagan, Jonathan C.] Childrens Hosp, Div Gastroenterol, Boston, MA 02115 USA; [Zanoni, Ivan; Ostuni, Renato; Barresi, Simona; Granucci, Francesca] Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; [Barbalat, Roman; Barton, Gregory M.] Univ Calif Berkeley, Div Immunol & Pathogenesis, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Milano-Bicocca; University of California System; University of California Berkeley	Granucci, F (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	francesca.granucci@unimib.it; jonathan.kagan@childrens.harvard.edu	GRANUCCI, Francesca/K-6150-2019; Ostuni, Renato/AAB-8832-2022	Ostuni, Renato/0000-0003-0460-3426; granucci, francesca/0000-0002-7046-4914; Zanoni, Ivan/0000-0002-3423-7474; Barton, Gregory/0000-0002-3793-0100	Harvard Digestive Diseases Center [P30 DK34854]; NIAID [5R00AI072955]; European Union [HEALTH-F4-2008-202156, HEALTH-F4-2008-201842]; Associazione Italiana per la Ricerca sul Cancro; Italian Ministry of Education and Research; Fondazione Cariplo [n.2010-0678]; EMBO; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R00AI072955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	Harvard Digestive Diseases Center; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); European Union(European Commission); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Education and Research(Ministry of Education, Universities and Research (MIUR)); Fondazione Cariplo(Fondazione Cariplo); EMBO(European Molecular Biology Organization (EMBO)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank the members of our lab for helpful discussions. This work was supported by the Harvard Digestive Diseases Center P30 DK34854 (J.K.), and grants from NIAID 5R00AI072955 (J.K.), European Union FP7 Program TOLERAGE: HEALTH-F4-2008-202156 and ENCITE: HEALTH-F4-2008-201842 (F. G.), Associazione Italiana per la Ricerca sul Cancro, and Italian Ministry of Education and Research (F. G.), Fondazione Cariplo (grant n.2010-0678, I.Z.). I.Z. was the recipient of an EMBO fellowship.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Barbalat R, 2009, NAT IMMUNOL, V10, P1200, DOI 10.1038/ni.1792; Barton GM, 2009, NAT REV IMMUNOL, V9, P535, DOI 10.1038/nri2587; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Chu CL, 2008, EUR J IMMUNOL, V38, P166, DOI 10.1002/eji.200737600; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Depoil D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.263pt1; Dietrich N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010250; Dixit E, 2010, CELL, V141, P668, DOI 10.1016/j.cell.2010.04.018; Drutman SB, 2010, J IMMUNOL, V185, P2140, DOI 10.4049/jimmunol.1000642; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirotani T, 2005, BIOCHEM BIOPH RES CO, V328, P383, DOI 10.1016/j.bbrc.2004.12.184; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hoshino K, 1999, J IMMUNOL, V162, P3749; Husebye H, 2006, EMBO J, V25, P683, DOI 10.1038/sj.emboj.7600991; Ip WKE, 2009, IMMUNOL REV, V230, P9, DOI 10.1111/j.1600-065X.2009.00789.x; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Latz E, 2003, J ENDOTOXIN RES, V9, P375, DOI 10.1179/096805103225003303; Lowell CA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002352; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Motshwene PG, 2009, J BIOL CHEM, V284, P25404, DOI 10.1074/jbc.M109.022392; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Perera PY, 1997, J IMMUNOL, V158, P4422; Platt CD, 2010, P NATL ACAD SCI USA, V107, P4287, DOI 10.1073/pnas.0910609107; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Takahashi K, 2007, J EXP MED, V204, P2963, DOI 10.1084/jem.20071132; Tanimura N, 2008, BIOCHEM BIOPH RES CO, V368, P94, DOI 10.1016/j.bbrc.2008.01.061; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118; Zaru R, 2007, NAT IMMUNOL, V8, P1227, DOI 10.1038/ni1517	44	591	603	1	86	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 11	2011	147	4					868	880		10.1016/j.cell.2011.09.051	http://dx.doi.org/10.1016/j.cell.2011.09.051			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	846LM	22078883	Bronze, Green Accepted			2022-12-28	WOS:000296902300019
J	Heyman, SRG; Vervloessem, D				Heyman, Stijn R. G.; Vervloessem, Dirk			Bryant's and Stabler's Signs after a Difficult Delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Heyman, Stijn R. G.; Vervloessem, Dirk] ZNA Queen Paola Childrens Hosp, Antwerp, Belgium		Heyman, SRG (corresponding author), ZNA Queen Paola Childrens Hosp, Antwerp, Belgium.	dirk.vervloessem@zna.be							0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2011	365	19					1824	1824		10.1056/NEJMicm1104679	http://dx.doi.org/10.1056/NEJMicm1104679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844QQ	22070479				2022-12-28	WOS:000296762800011
J	Kudernac, T; Ruangsupapichat, N; Parschau, M; Macia, B; Katsonis, N; Harutyunyan, SR; Ernst, KH; Feringa, BL				Kudernac, Tibor; Ruangsupapichat, Nopporn; Parschau, Manfred; Macia, Beatriz; Katsonis, Nathalie; Harutyunyan, Syuzanna R.; Ernst, Karl-Heinz; Feringa, Ben L.			Electrically driven directional motion of a four-wheeled molecule on a metal surface	NATURE			English	Article							SINGLE-MOLECULE; SCALE; ADSORPTION; MACHINES; DYNAMICS; CU(111); MOTORS; WORK	Propelling single molecules in a controlled manner along an unmodified surface remains extremely challenging because it requires molecules that can use light, chemical or electrical energy to modulate their interaction with the surface in a way that generates motion. Nature's motor proteins(1,2) have mastered the art of converting conformational changes into directed motion, and have inspired the design of artificial systems(3) such as DNA walkers(4,5) and light-and redox-driven molecular motors(6-11). But although controlled movement of single molecules along a surface has been reported(12-16), the molecules in these examples act as passive elements that either diffuse along a preferential direction with equal probability for forward and backward movement or are dragged by an STM tip. Here we present a molecule with four functional units-our previously reported rotary motors(6,8,17)-that undergo continuous and defined conformational changes upon sequential electronic and vibrational excitation. Scanning tunnelling microscopy confirms that activation of the conformational changes of the rotors through inelastic electron tunnelling propels the molecule unidirectionally across a Cu(111) surface. The system can be adapted to follow either linear or random surface trajectories or to remain stationary, by tuning the chirality of the individual motor units. Our design provides a starting point for the exploration of more sophisticated molecular mechanical systems with directionally controlled motion.	[Kudernac, Tibor; Macia, Beatriz; Katsonis, Nathalie; Harutyunyan, Syuzanna R.; Feringa, Ben L.] Univ Groningen, Stratingh Inst Chem, Ctr Syst Chem, NL-9747 AG Groningen, Netherlands; [Kudernac, Tibor; Ruangsupapichat, Nopporn; Katsonis, Nathalie; Feringa, Ben L.] Univ Groningen, Zernike Inst Adv Mat, NL-9747 AG Groningen, Netherlands; [Parschau, Manfred; Ernst, Karl-Heinz] Empa, Swiss Fed Labs Mat Sci & Technol, Nanoscale Mat Sci, CH-8600 Dubendorf, Switzerland; [Ernst, Karl-Heinz] Univ Zurich, Dept Chem, CH-8057 Zurich, Switzerland	University of Groningen; University of Groningen; Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA); University of Zurich	Harutyunyan, SR (corresponding author), Univ Groningen, Stratingh Inst Chem, Ctr Syst Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	s.harutyunyan@rug.nl; karl-heinz.ernst@empa.ch; b.l.feringa@rug.nl	Ernst, Karl-Heinz/GZA-3468-2022; Institute, Zernike/W-7033-2019; Ernst, Karl-Heinz/O-6128-2015; Feringa, Ben L./C-1665-2013	Ernst, Karl-Heinz/0000-0002-2077-4922; Macia, Beatriz/0000-0001-5148-0516	Netherlands Organization for Scientific Research (NWO-CW); Swiss Secretary for Education and Research; Swiss National Science Foundation; European Research Council (ERC) [227897]	Netherlands Organization for Scientific Research (NWO-CW)(Netherlands Organization for Scientific Research (NWO)); Swiss Secretary for Education and Research; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council (ERC)(European Research Council (ERC)European Commission)	This research was supported by the Netherlands Organization for Scientific Research (NWO-CW) (B. L. F. and T. K. through a VENI grant), the Swiss Secretary for Education and Research and the Swiss National Science Foundation (K.-H. E. and M. P.), and the European Research Council (ERC advanced grant 227897 to B.L.F.).	Alemani M, 2008, J PHYS CHEM C, V112, P10509, DOI 10.1021/jp711134p; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Browne WR, 2006, NAT NANOTECHNOL, V1, P25, DOI 10.1038/nnano.2006.45; Chiaravalloti F, 2007, NAT MATER, V6, P30, DOI 10.1038/nmat1802; Eelkema R, 2006, NATURE, V440, P163, DOI 10.1038/440163a; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Green JE, 2007, NATURE, V445, P414, DOI 10.1038/nature05462; Grill L, 2007, NAT NANOTECHNOL, V2, P95, DOI 10.1038/nnano.2006.210; Gu HZ, 2010, NATURE, V465, P202, DOI 10.1038/nature09026; Henzl J, 2010, PHYS CHEM CHEM PHYS, V12, P6035, DOI 10.1039/b924488c; Iancu V, 2006, NANO LETT, V6, P820, DOI 10.1021/nl0601886; Ismagilov RF, 2002, ANGEW CHEM INT EDIT, V41, P652, DOI 10.1002/1521-3773(20020215)41:4<652::AID-ANIE652>3.0.CO;2-U; Kay ER, 2007, ANGEW CHEM INT EDIT, V46, P72, DOI 10.1002/anie.200504313; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Lastapis M, 2005, SCIENCE, V308, P1000, DOI 10.1126/science.1108048; Lukas S, 2001, J CHEM PHYS, V114, P10123, DOI 10.1063/1.1370936; Lund K, 2010, NATURE, V465, P206, DOI 10.1038/nature09012; Parschau M, 2011, J AM CHEM SOC, V133, P5689, DOI 10.1021/ja200143z; Parschau M, 2009, ANGEW CHEM INT EDIT, V48, P4065, DOI 10.1002/anie.200805740; Qiu XH, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.196806; Sainoo Y, 2003, SURF SCI, V536, pL403, DOI 10.1016/S0039-6028(03)00564-8; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Seideman T, 2003, J PHYS-CONDENS MAT, V15, pR521, DOI 10.1088/0953-8984/15/14/201; Shirai Y, 2005, NANO LETT, V5, P2330, DOI 10.1021/nl051915k; Ueba H, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.041403; van Delden RA, 2005, NATURE, V437, P1337, DOI 10.1038/nature04127; van den Heuvel MGL, 2007, SCIENCE, V317, P333, DOI 10.1126/science.1139570; Wong KL, 2007, SCIENCE, V315, P1391, DOI 10.1126/science.1135302	29	536	547	23	620	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2011	479	7372					208	211		10.1038/nature10587	http://dx.doi.org/10.1038/nature10587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861PD	22071765				2022-12-28	WOS:000298030800037
J	Ohlemuller, R				Ohlemueller, Ralf			Running Out of Climate Space	SCIENCE			English	Editorial Material							BIOGEOGRAPHY; EVOLUTION; ECOLOGY; RISK		[Ohlemueller, Ralf] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; [Ohlemueller, Ralf] Univ Durham, IHRR, Durham DH1 3LE, England	Durham University; Durham University	Ohlemuller, R (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.	ralf.ohlemuller@durham.ac.uk		Ohlemuller, Ralf/0000-0001-9102-6481				Ackerly DD, 2010, DIVERS DISTRIB, V16, P476, DOI 10.1111/j.1472-4642.2010.00654.x; Anderson BJ, 2009, P ROY SOC B-BIOL SCI, V276, P1415, DOI 10.1098/rspb.2008.1681; Burrows MT, 2011, SCIENCE, V334, P652, DOI 10.1126/science.1210288; Dormann CF, 2010, BIOL LETTERS, V6, P229, DOI 10.1098/rsbl.2009.0688; Loarie SR, 2009, NATURE, V462, P1052, DOI 10.1038/nature08649; Mokany K, 2011, ECOL LETT, V14, P1043, DOI 10.1111/j.1461-0248.2011.01675.x; Ohlemuller R, 2008, BIOL LETTERS, V4, P568, DOI 10.1098/rsbl.2008.0097; Ohlemuller R, 2006, GLOBAL ECOL BIOGEOGR, V15, P395, DOI 10.1111/j.1466-822X.2006.00245.x; Pagel J, 2012, GLOBAL ECOL BIOGEOGR, V21, P293, DOI 10.1111/j.1466-8238.2011.00663.x; Ricklefs RE, 2011, PHILOS T R SOC B, V366, P2438, DOI 10.1098/rstb.2011.0066; Sandel B, 2011, SCIENCE, V334, P660, DOI 10.1126/science.1210173; Smith SA, 2009, P ROY SOC B-BIOL SCI, V276, P4345, DOI 10.1098/rspb.2009.1176; Wiens JA, 2011, BIOL CONSERV, V144, P2119, DOI 10.1016/j.biocon.2011.05.002; Wiens JJ, 2010, ECOL LETT, V13, P1310, DOI 10.1111/j.1461-0248.2010.01515.x; Williams JW, 2007, P NATL ACAD SCI USA, V104, P5738, DOI 10.1073/pnas.0606292104	15	20	21	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					613	614		10.1126/science.1214215	http://dx.doi.org/10.1126/science.1214215			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053039				2022-12-28	WOS:000296494700040
J	Daniels, RJ; Carson, LD				Daniels, Ronald J.; Carson, Lindsey D.			Academic Medical Centers-Organizational Integration and Discipline Through Contractual and Firm Models	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Daniels, Ronald J.] Johns Hopkins Univ, Baltimore, MD 21218 USA; [Carson, Lindsey D.] Univ Toronto, Toronto, ON, Canada	Johns Hopkins University; University of Toronto	Daniels, RJ (corresponding author), Johns Hopkins Univ, 3400 N Charles St,242 Garland Hall, Baltimore, MD 21218 USA.	president@jhu.edu						Dzau VJ, 2010, LANCET, V375, P949, DOI 10.1016/S0140-6736(09)61082-5; Macher JT, 2008, BUS POLIT, V10, DOI 10.2202/1469-3569.1210; Pizzo PA, 2008, ACAD MED, V83, P867, DOI 10.1097/ACM.0b013e318181d880; Pomeroy C, 2008, ACAD MED, V83, P809, DOI 10.1097/ACM.0b013e318181d147; Wartman SA, 2008, ACAD MED, V83, P797, DOI 10.1097/ACM.0b013e318181cf8c	5	4	4	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1912	1913		10.1001/jama.2011.1606	http://dx.doi.org/10.1001/jama.2011.1606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045769				2022-12-28	WOS:000296376200026
J	Hof, C; Araujo, MB; Jetz, W; Rahbek, C				Hof, Christian; Araujo, Miguel B.; Jetz, Walter; Rahbek, Carsten			Additive threats from pathogens, climate and land-use change for global amphibian diversity	NATURE			English	Article							SPECIES DISTRIBUTION MODELS; POPULATION DECLINES; SAMPLE-SIZE; CONSERVATION; DISEASE; EXTINCTION; ECOLOGY; FUTURE; WORLDS; DISTRIBUTIONS	Amphibian population declines far exceed those of other vertebrate groups, with 30% of all species listed as threatened by the International Union for Conservation of Nature(1-3). The causes of these declines are a matter of continued research, but probably include climate change, land-use change and spread of the pathogenic fungal disease chytridiomycosis(1,4,5). Here we assess the spatial distribution and interactions of these primary threats in relation to the global distribution of amphibian species. We show that the greatest proportions of species negatively affected by climate change are projected to be found in Africa, parts of northern South America and the Andes. Regions with the highest projected impact of land-use and climate change coincide, but there is little spatial overlap with regions highly threatened by the fungal disease. Overall, the areas harbouring the richest amphibian faunas are disproportionately more affected by one or multiple threat factors than areas with low richness. Amphibian declines are likely to accelerate in the twenty-first century, because multiple drivers of extinction could jeopardize their populations more than previous, mono-causal, assessments have suggested.	[Hof, Christian; Araujo, Miguel B.; Rahbek, Carsten] Univ Copenhagen, Dept Biol, Ctr Macroecol Evolut & Climate, DK-2100 Copenhagen O, Denmark; [Hof, Christian; Araujo, Miguel B.] CSIC, Natl Museum Nat Sci, Dept Biodivers & Evolutionary Biol, E-28006 Madrid, Spain; [Araujo, Miguel B.] Univ Evora, CIBIO, Rui Nabeiro Biodivers Chair, P-7000 Evora, Portugal; [Jetz, Walter] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	University of Copenhagen; Consejo Superior de Investigaciones Cientificas (CSIC); University of Evora; Yale University	Hof, C (corresponding author), Univ Copenhagen, Dept Biol, Ctr Macroecol Evolut & Climate, Univ Pk 15, DK-2100 Copenhagen O, Denmark.	christian.hof@senckenberg.de	Jetz, Walter/ABF-1517-2020; Rahbek, Carsten/L-1129-2013; Hof, Christian/J-8888-2014; Rahbek, Carsten/D-9372-2013; Araújo, Miguel B/B-6117-2008	Rahbek, Carsten/0000-0003-4585-0300; Hof, Christian/0000-0002-7763-1885; Araújo, Miguel B/0000-0002-5107-7265; Jetz, Walter/0000-0002-1971-7277	Danish National Research Foundation; Portuguese Foundation for Science and Technology [PTDC/AAC-AMB/98163/2008]; NSF [DBI 0960550, DEB 1026764]; Direct For Biological Sciences [1026764] Funding Source: National Science Foundation	Danish National Research Foundation(Danmarks Grundforskningsfond); Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); NSF(National Science Foundation (NSF)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We are grateful to D. Rodder, S. Lotters and J. Kielgast for the provision of data and B. dendrobatidis modelling results. We thank C. Graham, R. Colwell, N. Sanders, H. H. Bruun and S. Fritz for comments on previous versions of the manuscript. Special thanks to T. Rangel for technical and statistical support. C. H., M. B. A. and C. R. acknowledge the Danish National Research Foundation for support to the Center for Macroecology, Evolution and Climate; research by M. B. A. was funded by the Portuguese Foundation for Science and Technology (PTDC/AAC-AMB/98163/2008); W. J. acknowledges support from NSF grants DBI 0960550 and DEB 1026764.	Alcamo J., 1998, GLOBAL CHANGE SCENAR, P3; [Anonymous], 2005, EC HUM WELL BEING SY; [Anonymous], 2009, BIOENSEMBLES SOFTWAR; Araujo MB, 2006, J BIOGEOGR, V33, P1712, DOI 10.1111/j.1365-2699.2006.01482.x; Araujo MB, 2005, GLOBAL ECOL BIOGEOGR, V14, P529, DOI 10.1111/j.1466-822x.2005.00182.x; Araujo MB, 2005, GLOBAL CHANGE BIOL, V11, P1504, DOI 10.1111/j.1365-2486.2005.01000.x; Araujo MB, 2008, ECOGRAPHY, V31, P8, DOI 10.1111/j.2007.0906-7590.05318.x; Araujo MB, 2007, TRENDS ECOL EVOL, V22, P42, DOI 10.1016/j.tree.2006.09.010; Araujo MB, 2011, ECOL LETT, V14, P484, DOI 10.1111/j.1461-0248.2011.01610.x; Ashcroft MB, 2010, J BIOGEOGR, V37, P1407, DOI 10.1111/j.1365-2699.2010.02300.x; Beaumont LJ, 2011, P NATL ACAD SCI USA, V108, P2306, DOI 10.1073/pnas.1007217108; Becker CG, 2011, P NATL ACAD SCI USA, V108, P9893, DOI 10.1073/pnas.1014497108; Becker CG, 2007, SCIENCE, V318, P1775, DOI 10.1126/science.1149374; Beebee TJC, 2005, BIOL CONSERV, V125, P271, DOI 10.1016/j.biocon.2005.04.009; Bielby J, 2008, CONSERV LETT, V1, P82, DOI 10.1111/j.1755-263X.2008.00015.x; Blaustein AR, 2002, ECOL LETT, V5, P597, DOI 10.1046/j.1461-0248.2002.00352.x; Bosch J, 2007, P ROY SOC B-BIOL SCI, V274, P253, DOI 10.1098/rspb.2006.3713; Carey C, 2003, DIVERS DISTRIB, V9, P111, DOI 10.1046/j.1472-4642.2003.00011.x; Daszak P, 2003, DIVERS DISTRIB, V9, P141, DOI 10.1046/j.1472-4642.2003.00016.x; Diniz JAF, 2009, ECOGRAPHY, V32, P897, DOI 10.1111/j.1600-0587.2009.06196.x; Farber O, 2003, ECOL MODEL, V160, P115, DOI 10.1016/S0304-3800(02)00327-7; Hof C, 2011, GLOBAL CHANGE BIOL, V17, P2987, DOI 10.1111/j.1365-2486.2011.02418.x; Hof C, 2010, ECOGRAPHY, V33, P242, DOI 10.1111/j.1600-0587.2010.06309.x; Houlahan JE, 2000, NATURE, V404, P752, DOI 10.1038/35008052; Hurlbert AH, 2007, P NATL ACAD SCI USA, V104, P13384, DOI 10.1073/pnas.0704469104; IPCC, 2007, CONTR WORK GROUP 1 4; IPCC, 2000, SPEC REP EM SCEN PRE; IUCN, 2008, AN AMPH 2008 IUCN RE; IUCN Conservation International and Nature Serve, 2004, GLOB AMPH ASS; Jetz W, 2007, PLOS BIOL, V5, P1211, DOI 10.1371/journal.pbio.0050157; Kilpatrick AM, 2010, TRENDS ECOL EVOL, V25, P109, DOI 10.1016/j.tree.2009.07.011; Lawler JJ, 2010, CONSERV BIOL, V24, P38, DOI 10.1111/j.1523-1739.2009.01403.x; Lips KR, 2008, PLOS BIOL, V6, P441, DOI 10.1371/journal.pbio.0060072; McPherson JM, 2004, J APPL ECOL, V41, P811, DOI 10.1111/j.0021-8901.2004.00943.x; Meehl GA, 2007, B AM METEOROL SOC, V88, P1383, DOI 10.1175/BAMS-88-9-1383; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING SC; Nenzen HK, 2011, ECOL MODEL, V222, P3346, DOI 10.1016/j.ecolmodel.2011.07.011; Pearson RG, 2006, J BIOGEOGR, V33, P1704, DOI 10.1111/j.1365-2699.2006.01460.x; Phillimore AB, 2010, P NATL ACAD SCI USA, V107, P8292, DOI 10.1073/pnas.0913792107; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Phillips SJ, 2008, ECOGRAPHY, V31, P161, DOI 10.1111/j.0906-7590.2008.5203.x; Pounds JA, 2006, NATURE, V439, P161, DOI 10.1038/nature04246; Rodder D, 2010, DIS AQUAT ORGAN, V92, P201, DOI 10.3354/dao02197; Rohr JR, 2008, P NATL ACAD SCI USA, V105, P17436, DOI 10.1073/pnas.0806368105; Smith MA, 2005, ECOGRAPHY, V28, P110; Sodhi NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001636; Stockwell DRB, 2002, ECOL MODEL, V148, P1, DOI 10.1016/S0304-3800(01)00388-X; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; van Vuuren DP, 2006, ECOL SOC, V11; Wake DB, 2008, P NATL ACAD SCI USA, V105, P11466, DOI 10.1073/pnas.0801921105; Wisz MS, 2008, DIVERS DISTRIB, V14, P763, DOI 10.1111/j.1472-4642.2008.00482.x	51	397	421	11	448	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					516	U137		10.1038/nature10650	http://dx.doi.org/10.1038/nature10650			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22089134				2022-12-28	WOS:000298318000059
J	Nair, H; Brooks, WA; Katz, M; Roca, A; Berkley, JA; Madhi, SA; Simmerman, JM; Gordon, A; Sato, M; Howie, S; Krishnan, A; Ope, M; Lindblade, KA; Carosone-Link, P; Lucero, M; Ochieng, W; Kamimoto, L; Dueger, E; Bhat, N; Vong, S; Theodoratou, E; Chittaganpitch, M; Chimah, O; Balmaseda, A; Buchy, P; Harris, E; Evans, V; Katayose, M; Gaur, B; O'Callaghan-Gordo, C; Goswami, D; Arvelo, W; Venter, M; Briese, T; Tokarz, R; Widdowson, MA; Mounts, AW; Breiman, RF; Feikin, DR; Klugman, KP; Olsen, SJ; Gessner, BD; Wright, PF; Rudan, I; Broor, S; Simoes, EAF; Campbell, H				Nair, Harish; Brooks, W. Abdullah; Katz, Mark; Roca, Anna; Berkley, James A.; Madhi, Shabir A.; Simmerman, James Mark; Gordon, Aubree; Sato, Masatoki; Howie, Stephen; Krishnan, Anand; Ope, Maurice; Lindblade, Kim A.; Carosone-Link, Phyllis; Lucero, Marilla; Ochieng, Walter; Kamimoto, Laurie; Dueger, Erica; Bhat, Niranjan; Vong, Sirenda; Theodoratou, Evropi; Chittaganpitch, Malinee; Chimah, Osaretin; Balmaseda, Angel; Buchy, Philippe; Harris, Eva; Evans, Valerie; Katayose, Masahiko; Gaur, Bharti; O'Callaghan-Gordo, Cristina; Goswami, Doli; Arvelo, Wences; Venter, Marietjie; Briese, Thomas; Tokarz, Rafal; Widdowson, Marc-Alain; Mounts, Anthony W.; Breiman, Robert F.; Feikin, Daniel R.; Klugman, Keith P.; Olsen, Sonja J.; Gessner, Bradford D.; Wright, Peter F.; Rudan, Igor; Broor, Shobha; Simoes, Eric A. F.; Campbell, Harry			Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis	LANCET			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIAL VIRUS; HUMAN METAPNEUMOVIRUS; TRACT INFECTIONS; VIRAL ETIOLOGY; UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL PNEUMONIA; CHILDHOOD PNEUMONIA	Background The global burden of disease attributable to seasonal influenza virus in children is unknown. We aimed to estimate the global incidence of and mortality from lower respiratory infections associated with influenza in children younger than 5 years. Methods We estimated the incidence of influenza episodes, influenza-associated acute lower respiratory infections (ALRI), and influenza-associated severe ALRI in children younger than 5 years, stratified by age, with data from a systematic review of studies published between Jan 1, 1995, and Oct 31, 2010, and 16 unpublished population-based studies. We applied these incidence estimates to global population estimates for 2008 to calculate estimates for that year. We estimated possible bounds for influenza-associated ALRI mortality by combining incidence estimates with case fatality ratios from hospital-based reports and identifying studies with population-based data for influenza seasonality and monthly ALRI mortality. Findings We identified 43 suitable studies, with data for around 8 million children. We estimated that, in 2008, 90 million (95% CI 49-162 million) new cases of influenza (data from nine studies), 20 million (13-32 million) cases of influenza-associated ALRI (13% of all cases of paediatric ALRI; data from six studies), and 1 million (1-2 million) cases of influenza-associated severe ALRI (7% of cases of all severe paediatric ALRI; data from 39 studies) occurred worldwide in children younger than 5 years. We estimated there were 28 000-111 500 deaths in children younger than 5 years attributable to influenza-associated ALRI in 2008, with 99% of these deaths occurring in developing countries. Incidence and mortality varied substantially from year to year in any one setting. Interpretation Influenza is a common pathogen identified in children with ALRI and results in a substantial burden on health services worldwide. Sufficient data to precisely estimate the role of influenza in childhood mortality from ALRI are not available.	[Nair, Harish] Univ Edinburgh, Ctr Populat Hlth Sci, Sch Med, Global Hlth Acad, Edinburgh EH8 9AG, Midlothian, Scotland; [Nair, Harish] Publ Hlth Fdn India, New Delhi, India; [Brooks, W. Abdullah; Goswami, Doli] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; [Katz, Mark; Breiman, Robert F.; Feikin, Daniel R.] Kenya Govt Med Res Ctr, Nairobi, Kenya; [Katz, Mark; Breiman, Robert F.; Feikin, Daniel R.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya; [Roca, Anna; O'Callaghan-Gordo, Cristina] Univ Barcelona, Ctr Int Hlth Res CRESIB, Hosp Clin, IDIBAPS, Barcelona, Spain; [Berkley, James A.] Ctr Geog Med Res Coast, Kilin, Kenya; [Berkley, James A.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England; [Madhi, Shabir A.] Univ Witwatersrand, Med Res Council, Resp & Meningeal Pathogens Res Unit, ZA-2050 Johannesburg, South Africa; [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, ZA-2050 Johannesburg, South Africa; [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, ZA-2050 Johannesburg, South Africa; [Simmerman, James Mark; Olsen, Sonja J.] US Ctr Dis Control & Prevent Thailand, Div & Int Emerging Infect Program, MOPH Collaborat, Nonthaburi, Thailand; [Gordon, Aubree; Harris, Eva] Univ Calif Berkeley, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA; [Gordon, Aubree] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; [Sato, Masatoki] Fukushima Med Univ, Dept Paediat, Sch Med, Fukushima, Japan; [Howie, Stephen; Chimah, Osaretin] Med Res Council UK Labs, Banjul, Gambia; [Krishnan, Anand; Gaur, Bharti] All India Inst Med Sci, New Delhi, India; [Lindblade, Kim A.; Arvelo, Wences] Ctr Dis Control & Prevent, Global Dis Detect Program, Reg Off Cent Amer & Panama, Guatemala City, Guatemala; [Carosone-Link, Phyllis; Simoes, Eric A. F.] Univ Colorado, Denver, CO 80202 USA; [Lindblade, Kim A.; Simoes, Eric A. F.] Childrens Hosp, Denver, CO 80218 USA; [Ochieng, Walter] Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi, Kenya; [Kamimoto, Laurie; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Dueger, Erica] Global Dis Detect & Response Ctr, Naval Med Res Unit 3, Cairo, Egypt; [Bhat, Niranjan] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA; [Chittaganpitch, Malinee] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand; [Chimah, Osaretin] Med Ctr, Asaba, Delta State, Nigeria; [Katayose, Masahiko] Soma Gen Hosp, Dept Paediat, Soma, Japan; [Venter, Marietjie] Natl Inst Communicable Dis, Resp Virus Unit, Natl Inflenza Ctr, Natl Hlth Lab Serv, Johannesburg, South Africa; [Venter, Marietjie] Univ Pretoria, Resp & Zoonot Virus Programme, Dept Med Virol, ZA-0002 Pretoria, South Africa; [Briese, Thomas; Tokarz, Rafal] Columbia Univ, Ctr Infect & Immun, Mailman Sch Publ Hlth, New York, NY USA; [Mounts, Anthony W.] World Hlth Org, Global Influenza Program, Geneva, Switzerland; [Klugman, Keith P.] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Klugman, Keith P.] Emory Univ, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA; [Gessner, Bradford D.] Agence Med Prevent, Paris, France; [Wright, Peter F.] Dartmouth Med Sch, Div Infect Dis & Int Hlth, Lebanon, NH USA; [Rudan, Igor] Univ Split, Croatian Ctr Global Hlth, Fac Med, Split, Croatia; [Simoes, Eric A. F.] Univ Padjadjaram, Bandung, Indonesia	University of Edinburgh; Public Health Foundation of India; International Centre for Diarrhoeal Disease Research (ICDDR); Kenya Medical Research Institute; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Oxford; South African Medical Research Council; University of Witwatersrand; University of Witwatersrand; National Research Foundation - South Africa; University of Witwatersrand; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Fukushima Medical University; University of London; London School of Hygiene & Tropical Medicine; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Colorado System; University of Colorado Denver; Children's Hospital Colorado; Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; Naval Medical Research Center (NMRC); Naval Medical Research Unit - No. 3 (NAMRU-3); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Ministry of Public Health - Thailand; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Pretoria; Columbia University; World Health Organization; Emory University; Rollins School Public Health; Emory University; Agence de Medecine Preventive; Dartmouth College; University of Split; Universitas Padjadjaran	Nair, H (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Sch Med, Global Hlth Acad, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	harish.nair@ed.ac.uk; harry.campbell@ed.ac.uk	Campbell, Harry/E-2959-2010; Theodoratou, Evropi/C-3430-2014; Krishnan, Anand/D-8537-2012; Broor, Shobha/AAX-4163-2021; Brooks, W. Abdullah/AAD-3876-2021; Venter, Marietjie/P-9604-2016; Rudan, Igor/I-1467-2012; Gordon, Aubree/X-1113-2019; Nair, Harish/E-7431-2010	Campbell, Harry/0000-0002-6169-6262; Theodoratou, Evropi/0000-0001-5887-9132; Krishnan, Anand/0000-0002-9173-7811; Broor, Shobha/0000-0001-9679-4180; Brooks, W. Abdullah/0000-0001-9871-5546; Venter, Marietjie/0000-0003-2696-824X; Rudan, Igor/0000-0001-6993-6884; Gordon, Aubree/0000-0002-9352-7877; Nair, Harish/0000-0002-9432-9100; Widdowson, Marc-Alain/0000-0002-0682-6933; O'Callaghan-Gordo, Cristina/0000-0002-4229-2991; Lindblade, Kim/0000-0002-5593-0470; Berkley, James/0000-0002-1236-849X; BUCHY, Philippe/0000-0003-1372-3008	WHO [HQGIP1002906]; Bill & Melinda Gates Foundation [51285]; Wyeth; Pfizer; GSK; Sanofi Pasteur; GlaxoSmithKline; Merck; MedImmune; Roche; Aventis Pasteur; Evans-Powderject; US Centers for Disease Control and Prevention (CDC); Indian Council of Medical Research; Medical Research Council [MC_UP_A900_1124, MC_U190088478] Funding Source: researchfish; MRC [MC_U190088478, MC_UP_A900_1124] Funding Source: UKRI	WHO(World Health Organization); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Wyeth(Wyeth); Pfizer(Pfizer); GSK(GlaxoSmithKline); Sanofi Pasteur; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); MedImmune(AstraZenecaMedimmune); Roche(Roche Holding); Aventis Pasteur; Evans-Powderject; US Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Indian Council of Medical Research(Indian Council of Medical Research (ICMR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	WHO; Bill & Melinda Gates Foundation.; SAM has received research funding from Wyeth for the Soweto study that contributed to the data. He has received consultancy from Pfizer, GSK, and Novartis and speaker fees from Pfizer and GSK. However, no honoraria were received for work included in this study. BDG has received consultancy from WHO and a travel grant from Sanofi Pasteur to attend a conference on influenza in 2010. He is employed by Agence de Medecine Preventive, which has received funding from WHO, Pfizer, GlaxoSmithKline, and Merck. In 2010, the Agence de Medecine Preventive was hired by Sanofi Pasteur to organize a conference on influenza. However, no grants or honoraria were received for work included in this study. EAFS has received speaker fees and consultancy from MedImmune and research grants from Roche and MedImmune. However, no grants or honoraria were received for work included in this study. NB is employed by Johns Hopkins University which has received funding from Aventis Pasteur and Evans-Powderject. All other authors declare that they have no conflicts of interest.; Financial support for this work was provided by WHO Global Influenza Program (grant number HQGIP1002906) and the Bill & Melinda Gates Foundation (grant number 51285). The study in Ballabgarh, India, received financial support from US Centers for Disease Control and Prevention (CDC) and Indian Council of Medical Research. This work was done as part of the wider programme of the Child Health Epidemiology Working Group (CHERG) to establish the major causes of global childhood disease burden. Walter Ochieng sadly died suddenly and unexpectedly while this paper was being prepared for publication. We would like to acknowledge his important contribution to this study and his role in strengthening influenza surveillance in Kenya. We thank Johannes Forster (Department of Paediatrics, St Josefskrankenhaus Freiburg and University of Freiburg, Freiburg, Germany), Gabriele Ihorst (Clinical Trials Center, University Medical Centre Freiburg, Freiburg, Germany), Terho Heikkinen (Turku University Hospital, Turku, Finland), Alex Ezeh, Samuel Oti, and Catherine Kyobutungi (African Population and Health Research Centre, Nairobi, Kenya), and the Influenza Emerging Infections Program Network, USA for providing additional data from their published papers; Vivek Gupta and Sanjay K Rai (Comprehensive Rural Health Services Project, Ballabgarh and All India Institute of Medical Sciences, New Delhi, India); Samander Kaushik and Yashpal Singh (Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India); National Institute of Virology, Pune, India; Wallace D Bulimo (National Influenza Centre, Nairobi, Kenya); Respiratory and Zoonosis group, Department of Medical Virology, University of Pretoria, South Africa; D James Nokes (KEMRI, Kilifi, Kenya); Locadiah Kuwanda (Chris Hani Baragwanath Hospital, Johannesburg, South Africa); Pedro L Alonso, Ll Quinto, Q Bassat (CRESIB, Hospital Clinic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain and Centro de Investigacao em Saude da Manhica, Ministerio de Saude, Maputo, Mozambique); Jens Levy (Influenza Division and International Emerging Infections Program, US CDC-Thailand MOPH Collaboration, Nonthaburi, Thailand); Alejandra Estevez, Fabiola Moscoso, and Jennifer Gray (Centro de Estudios en Salud, Universidad del Valle de Guatemala); Lissette Reyes, Juan Carlos Moir (Ministerio de Salud Publica y Asistencia Social, Guatemala); Alicia M Fry (Influenza Division, CDC, Atlanta, USA); Hanna Nohynek, Taneli Puumalainen and Petri Ruutu (National Institute for Health and Welfare, Finland); Leilani Nillos (Research Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa, Philippines) and ARIVAC consortium; Ian Lipkin (University of Columbia, New York); Gerard Morris (University Witwatersrand, South Africa); Grant Mackenzie, Readon Ideh, Bernard Ebruke, Claire Oluwalana (MRC, Gambia) and the Gambia Severe Pneumonia Studies Group; Karen Fowler (University of Alabama at Birmingham, Birmingham, AL, USA); Katherine O'Brien (Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA) for their assistance; Jian Shayne F Zhang (Centre for Population Health Sciences, The University of Edinburgh, UK) for doing the literature search in Chinese language databases; Carolyn B Bridges (Influenza Division, National Center for Immunizations and Respiratory Disease, CDC, Atlanta, GA, USA) for critically reviewing the manuscript and providing helpful comments.; The findings and conclusions in this report are those of the authors and do not necessarily represent he views of the US CDC or WHO.	ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; AIIMS, 53 AIIMS ANN REP 200; Ajayi-Obe EK, 2008, EPIDEMIOL INFECT, V136, P1046, DOI 10.1017/S0950268807009557; Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; [Anonymous], COMMUN DIS INTELL S2; Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675; Bigogo G, 2010, INT J INFECT DIS, V14, pE967, DOI 10.1016/j.ijid.2010.05.016; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bourgeois FT, 2006, PEDIATRICS, V118, pE1, DOI 10.1542/peds.2005-2248; Brooks WA, 2010, PEDIATR INFECT DIS J, V29, P216, DOI 10.1097/INF.0b013e3181bc23fd; Broor S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000491; Bueving HJ, 2005, REV MED VIROL, V15, P383, DOI 10.1002/rmv.477; Chiu SS, 2009, CLIN INFECT DIS, V49, P1016, DOI 10.1086/605570; Coelho MC, 2007, BRAZ J INFECT DIS, V11, P220, DOI 10.1590/S1413-86702007000200010; Coffin SE, 2007, PEDIATRICS, V119, P740, DOI 10.1542/peds.2006-2679; D'Onise K, 2008, MED J AUSTRALIA, V188, P510, DOI 10.5694/j.1326-5377.2008.tb01763.x; Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ESPY MJ, 1986, J CLIN MICROBIOL, V24, P677, DOI 10.1128/JCM.24.4.677-679.1986; Forster J, 2004, EUR J PEDIATR, V163, P709, DOI 10.1007/s00431-004-1523-9; Foulongne V, 2006, PEDIATR INFECT DIS J, V25, P354, DOI 10.1097/01.inf.0000207480.55201.f6; Global Burden of Disease Study, 2009, GLOB BURD D IN PRESS; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149, DOI 10.1093/oxfordjournals.epirev.a036050; Grijalva CG, 2007, EPIDEMIOL INFECT, V135, P951, DOI 10.1017/S095026880600762X; Grijalva CG, 2007, PEDIATRICS, V119, pE6, DOI 10.1542/peds.2006-1694; Grijalva CG, 2006, EMERG INFECT DIS, V12, P103; Hamelin ME, 2004, CLIN INFECT DIS, V38, P983, DOI 10.1086/382536; Hasan K, 2006, SCAND J INFECT DIS, V38, P690, DOI 10.1080/00365540600606473; Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527; Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48; ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143; Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Ji W, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-82; Johnson AWBR, 2008, J NATL MED ASSOC, V100, P370, DOI 10.1016/S0027-9684(15)31269-4; Johnson BF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007671; Karaivanova G M, 1995, Afr J Med Med Sci, V24, P1; Klugman KP, 2009, VACCINE, V27, pC9, DOI 10.1016/j.vaccine.2009.06.007; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Kwong KL, 2009, J PAEDIATR CHILD H, V45, P660, DOI 10.1111/j.1440-1754.2009.01591.x; Lankinen KS, 1997, AM J TROP MED HYG, V56, P211, DOI 10.4269/ajtmh.1997.56.211; Madhi SA, 2007, PEDIATR INFECT DIS J, V26, P693, DOI 10.1097/INF.0b013e3180621192; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; McCullers JA, 2010, J INFECT DIS, V202, P1287, DOI 10.1086/656333; Milne Bronwyn G, 2004, Commun Dis Intell Q Rep, V28, P504; Montes A, 2005, VACCINE, V23, P4302, DOI 10.1016/j.vaccine.2005.04.006; Moore DL, 2006, PEDIATRICS, V118, pE610, DOI 10.1542/peds.2005-2744; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020; Nelson Edmund A. S., 2007, Hong Kong Medical Journal, V13, P114; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Nicholson KG, 2006, VACCINE, V24, P102, DOI 10.1016/j.vaccine.2005.02.004; Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019; Nokes DJ, 2009, CLIN INFECT DIS, V49, P1341, DOI 10.1086/606055; Nongkynrih Baridalyne, 2003, Indian Pediatr, V40, P766; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; O'Brien KL, 2000, CLIN INFECT DIS, V30, P784, DOI 10.1086/313772; O'Callaghan-Gordo C, 2011, PEDIATR INFECT DIS J, V30, P39, DOI 10.1097/INF.0b013e3181f232fe; Ortiz JR, 2009, EMERG INFECT DIS, V15, P1271, DOI 10.3201/eid1508.081422; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Rawlinson WD, 2004, J MED VIROL, V74, P127, DOI 10.1002/jmv.20155; Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8; Rojo JC, 2006, PEDIATR INFECT DIS J, V25, P596, DOI 10.1097/01.inf.0000220208.59965.95; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Sam IC, 2010, INT J INFECT DIS, V14, pE36, DOI 10.1016/j.ijid.2009.10.005; Schrag SJ, 2006, PEDIATR INFECT DIS J, V25, P395, DOI 10.1097/01.inf.0000214988.81379.71; Simmerman JM, 2008, INFLUENZA OTHER RESP, V2, P81, DOI 10.1111/j.1750-2659.2008.00045.x; Singeton RJ, 2010, J MED VIROL, V82, P1282, DOI 10.1002/jmv.21790; Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998; Straliotto SM, 2004, MEM I OSWALDO CRUZ, V99, P883, DOI 10.1590/S0074-02762004000800017; Sutanto A, 2002, AM J TROP MED HYG, V66, P175, DOI 10.4269/ajtmh.2002.66.175; SUTMOLLER F, 1995, CLIN INFECT DIS, V20, P854, DOI 10.1093/clinids/20.4.854; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; UNICEF, 2009, STAT WORLDS CHIDR SP; Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4; Weber MW, 2002, B WORLD HEALTH ORGAN, V80, P562; Weigl JAI, 2005, KLIN PADIATR, V217, P259, DOI 10.1055/s-2004-820352; WHO, 1985, CAS MAN AC RESP INF; Wolf DG, 2006, PEDIATR INFECT DIS J, V25, P320, DOI 10.1097/01.inf.0000207395.80657.cf; World Health Organization, 2008, GLOB BURD DIS 2004 U; World Health Organization, 1991, TECHN BAS WHO REC MA; Ye Y, 2009, AM J TROP MED HYG, V81, P770, DOI 10.4269/ajtmh.2009.09-0070; Yoo Y, 2007, CLIN VACCINE IMMUNOL, V14, P1050, DOI 10.1128/CVI.00465-06; Yoshida LM, 2010, PEDIATR INFECT DIS J, V29, P75, DOI 10.1097/INF.0b013e3181af61e9; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	89	610	638	8	107	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2011	378	9807					1917	1930		10.1016/S0140-6736(11)61051-9	http://dx.doi.org/10.1016/S0140-6736(11)61051-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22078723				2022-12-28	WOS:000298136200026
J	Rini, BI; Escudier, B; Tomczak, P; Kaprin, A; Szczylik, C; Hutson, TE; Michaelson, MD; Gorbunova, VA; Gore, ME; Rusakov, IG; Negrier, S; Ou, YC; Castellano, D; Lim, HY; Uemura, H; Tarazi, J; Cella, D; Chen, C; Rosbrook, B; Kim, S; Motzer, RJ				Rini, Brian I.; Escudier, Bernard; Tomczak, Piotr; Kaprin, Andrey; Szczylik, Cezary; Hutson, Thomas E.; Michaelson, M. Dror; Gorbunova, Vera A.; Gore, Martin E.; Rusakov, Igor G.; Negrier, Sylvie; Ou, Yen-Chuan; Castellano, Daniel; Lim, Ho Yeong; Uemura, Hirotsugu; Tarazi, Jamal; Cella, David; Chen, Connie; Rosbrook, Brad; Kim, Sinil; Motzer, Robert J.			Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial	LANCET			English	Article							DOUBLE-BLIND; SUNITINIB; EFFICACY; SU11248; CANCER	Background The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer. Methods We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1: 1) to either axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). Axitinib dose increases to 7 mg and then to 10 mg, twice daily, were allowed for those patients without hypertension or adverse reactions above grade 2. Participants were not masked to study treatment. The primary endpoint was progression-free survival (PFS) and was assessed by a masked, independent radiology review and analysed by intention to treat. This trial was registered on ClinicalTrials.gov, number NCT00678392. Findings A total of 723 patients were enrolled and randomly assigned to receive axitinib (n=361) or sorafenib (n=362). The median PFS was 6.7 months with axitinib compared to 4.7 months with sorafenib (hazard ratio 0.665; 95% CI 0.544-0.812; one-sided p<0.0001). Treatment was discontinued because of toxic effects in 14 (4%) of 359 patients treated with axitinib and 29 (8%) of 355 patients treated with sorafenib. The most common adverse events were diarrhoea, hypertension, and fatigue in the axitinib arm, and diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia in the sorafenib arm. Interpretation Axitinib resulted in significantly longer PFS compared with sorafenib. Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma.	[Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA; [Escudier, Bernard] Inst Gustave Roussy, Serv Immunotherapie, Villejuif, France; [Tomczak, Piotr] Uniwersytet Med, Klin Onkol, Poznan, Poland; [Kaprin, Andrey] Russian Res Ctr Roentgenol & Radiol, Moscow, Russia; [Szczylik, Cezary] Cent Clin Hosp, Mil Med Inst, Klin Onkol, Warsaw, Poland; [Hutson, Thomas E.] Baylor Sammons Texas Oncol Phys Assoc, Sammons Canc Ctr, Dallas, TX USA; [Michaelson, M. Dror] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Gorbunova, Vera A.] State Inst Natl Canc Res Ctr, Dept Chemotherapy, Moscow, Russia; [Gore, Martin E.] Royal Marsden Hosp, London SW3 6JJ, England; [Rusakov, Igor G.] Hertzen Res Inst Oncol, Moscow, Russia; [Ou, Yen-Chuan] Taichung Vet Gen Hosp, Dept Surg 160, Taichung, Taiwan; [Castellano, Daniel] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain; [Lim, Ho Yeong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Uemura, Hirotsugu] Kinki Univ Hosp, Dept Urol, Osaka, Japan; [Tarazi, Jamal; Rosbrook, Brad; Kim, Sinil] Pfizer Inc, Clin Oncol, San Diego, CA USA; [Cella, David] Northwestern Univ, Chicago, IL 60611 USA; [Chen, Connie] Pfizer Inc, Global Outcomes Res, New York, NY USA; [Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Cleveland Clinic Foundation; UNICANCER; Gustave Roussy; Military Medical Institute; Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center; Harvard University; Massachusetts General Hospital; Royal Marsden NHS Foundation Trust; Taichung Veterans General Hospital; Hospital Universitario 12 de Octubre; Sungkyunkwan University (SKKU); Samsung Medical Center; Kindai University (Kinki University); Pfizer; Northwestern University; Pfizer; Memorial Sloan Kettering Cancer Center	Rini, BI (corresponding author), Cleveland Clin, Taussig Canc Inst, Main Campus,Mail Code R35,9500 Euclid Ave, Cleveland, OH 44195 USA.	rinib2@ccf.org	Hutson, Thomas/AAS-9639-2020; Toon, Christopher W/G-3610-2012; Kaprin, A.D/K-1445-2014	Hutson, Thomas/0000-0002-4529-4212; Szczylik, Cezary/0000-0002-2524-2810; Motzer, Robert/0000-0001-6925-2327; Kaprin, A.D/0000-0001-8784-8415; Michaelson, Dror/0000-0001-9249-6338	Pfizer Inc.; Pfizer; AVEO; Bayer; Genentech; GlaxoSmithKline	Pfizer Inc.(Pfizer); Pfizer(Pfizer); AVEO; Bayer(Bayer AG); Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline)	Pfizer Inc.; BIR has served as a consultant for and received research funding from Pfizer. DCe has served as a consultant for and received research funding from Pfizer. MEG has served on the speakers' bureau and as an adviser for Bayer and Pfizer. TEH has served as a consultant for and received honoraria and research funding from AVEO, Bayer, Genentech, GlaxoSmithKline, and Pfizer. RJM has served as a consultant for Pfizer. SN has served as a consultant for Pfizer and Roche, and has received honoraria from Novartis and Pfizer and research funding from GlaxoSmithKline. BE has received honoraria from AVEO, Bayer, GlaxoSmithKline, Novartis, and Pfizer. CS has served on an advisory board for Pfizer. JT, CC, BR, and SK are employed by and own stock in Pfizer. AK, DCa, VG, IR, HYL, YCO, HU, MDM, and PT declare that they have no conflicts of interest.	Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Alexandre I, 2009, J CLIN ONCOL, V27, P472, DOI 10.1200/JCO.2008.20.1087; Cella D, 2007, VALUE HEALTH, V10, P285, DOI 10.1111/j.1524-4733.2007.00183.x; Cella David, 2006, J Support Oncol, V4, P191; Di Lorenzo G, 2009, J CLIN ONCOL, V27, P4469, DOI 10.1200/JCO.2009.22.6480; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Escudier B, 2009, J CLIN ONCOL, V27, P4068, DOI 10.1200/JCO.2008.20.5476; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Flaherty KT, 2007, CLIN CANCER RES, V13, p747S, DOI 10.1158/1078-0432.CCR-06-2063; Garcia JA, 2010, CANCER-AM CANCER SOC, V116, P5383, DOI 10.1002/cncr.25327; Gore ME, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.4609; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; International Agency for Research on Cancer, GLOBOCAN PROJ CANC I; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Motzer RJ, 2004, J CLIN ONCOL, V22, P454, DOI 10.1200/JCO.2004.06.132; Motzer RJ, 2011, J CLIN ONCOL, V29; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Rini B, 2005, J CLIN ONCOL, V23, p380S; Rini BI, 2011, CLIN CANCER RES, V17, P3841, DOI 10.1158/1078-0432.CCR-10-2806; Rini BI, 2009, J CLIN ONCOL, V27, P4462, DOI 10.1200/JCO.2008.21.7034; Rini BI, 2009, J CLIN ONCOL, V27, P3225, DOI 10.1200/JCO.2008.19.9836; Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/S1470-2045(07)70285-1; Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P741, DOI [10.1517/13543784.17.5.741, 10.1517/13543784.17.5.741 ]; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tomita Y, 2010, ANN ONCOL S8, V21; Ueda T, 2010, INT J UROL, V17, P811, DOI 10.1111/j.1442-2042.2010.02604.x	31	1407	1446	1	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 3	2011	378	9807					1931	1939		10.1016/S0140-6736(11)61613-9	http://dx.doi.org/10.1016/S0140-6736(11)61613-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	863AW	22056247				2022-12-28	WOS:000298136200027
J	Blumberg, JM				Blumberg, Jeremy M.			The Perfect Match	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Kidney Transplant Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Blumberg, JM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Kidney Transplant Program, Los Angeles, CA 90095 USA.	jblumberg@mednet.ucla.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2011	306	20					2197	2198		10.1001/jama.2011.1710	http://dx.doi.org/10.1001/jama.2011.1710			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851GD	22110096				2022-12-28	WOS:000297255500001
J	Arthur, R; Diamond, J				Arthur, Ronan; Diamond, Jared			Understanding Tribal Fates	SCIENCE			English	Editorial Material									[Arthur, Ronan; Diamond, Jared] Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Arthur, R (corresponding author), Univ Calif Los Angeles, Dept Geog, Los Angeles, CA 90095 USA.			Arthur, Ronan/0000-0001-8513-8348				Bailey Garrick Alan, 1986, HIST NAVAJOS RESERVA; Champagne Duane, 2010, NOTES CTR TURTLE ISL; *HARV PROJ AM IND, 2008, STAT NAT NAT COND US; Iverson Peter, 2002, DINE HIST NAVAJOS; Jorgensen Miriam, 2007, REBUILDING NATIVE NA; Kroeber T., 1961, ISHI 2 WORLDS BIOGRA; Kuegler S., 2009, JAGERIN GEJAGTE; Lewis M. P., 2009, ETHNOLOGUE LANGUAGES; McPherson, 2001, NO NAVAJO FRONTIER 1; Nielsen M. O., 2005, NAVAJO NATION PEACEM; Rosser E., 2011, ENVIRON LAW, V40, P437; TOWNER RH, 1996, ARCHAEOLOGY NAVAJO O; Warburton M, 2005, ETHNOHISTORY, V52, P533, DOI 10.1215/00141801-52-3-533	13	3	3	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2011	334	6058					911	912		10.1126/science.1213787	http://dx.doi.org/10.1126/science.1213787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	849CA	22096177				2022-12-28	WOS:000297101800033
J	Cronin, AJ				Cronin, Antonia J.			Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							DONORS		[Cronin, Antonia J.] Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England; [Cronin, Antonia J.] Kings Coll London, MRC Ctr Transplantat, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Cronin, AJ (corresponding author), Guys & St Thomas NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.	antonia.cronin@kcl.ac.uk			MRC [G0600698] Funding Source: UKRI; Medical Research Council [G0600698] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		British Transplantation Society/The Renal Association, 2011, UK GUID LIV DON KIDN; CRONIN AJ, 2011, ORGAN TRANSPLANTATIO; Franklin PM, 2003, TRANSPLANTATION, V76, P1247, DOI 10.1097/01.TP.0000087833.48999.3D; *NHS BLOOD TRANSPL, STAT; Nuffield Council on Bioethics, 2011, HUM BOD DON MED RES; Organ Donation Taskforce, 2008, ORG TRANSPL; SELLS RA, 1986, BRIT MED J, V293, P257; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601	8	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2011	343								d7140	10.1136/bmj.d7140	http://dx.doi.org/10.1136/bmj.d7140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854LU	22089241				2022-12-28	WOS:000297497000004
J	Howell, J				Howell, Joel			Review: Several instruments are accurate for evaluating patient capacity for medical treatment decision-making	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Michigan, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Howell, J (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.			Zembrzuska, Hanna/0000-0002-8066-7379				JOURDAN JB, 1991, PSYCHOSOMATICS, V32, P413, DOI 10.1016/S0033-3182(91)72043-4	1	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-12	10.7326/0003-4819-155-10-201111150-02012	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084359				2022-12-28	WOS:000208885300011
J	Deer, B				Deer, Brian			MORE SECRETS OF THE MMR SCARE Pathology reports solve "new bowel disease" riddle	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RETRACTED ARTICLE. SEE; AUTISTIC ENTEROCOLITIS; NONSPECIFIC COLITIS; BIOPSY DIAGNOSIS; DISORDERS; CHILDREN; VACCINE											BARTRAM CI, 1994, BAILLIERE CLIN GASTR, V8, P101, DOI 10.1016/S0950-3528(06)80021-7; BEATTIE RM, 1995, ARCH DIS CHILD, V73, P354, DOI 10.1136/adc.73.4.354; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Carpenter HA, 2000, AM J GASTROENTEROL, V95, P878; Davies SE, 2010, BMJ; Deer B, TABULATION PATHOLOGY; Deer Brian, 2011, BMJ, V342, pc5347, DOI 10.1136/bmj.c5347; Deer B, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1127; Dhillon A, 2007, HISTOPATHOLOGY, V50, P794, DOI 10.1111/j.1365-2559.2007.02668.x; Eisenberg RL, 2003, GASTROINTESTINAL PAT; Fiocchi C, 2003, INFLAMMATORY BOWEL D; Godlee Fiona, 2011, BMJ, V342, pc7452, DOI 10.1136/bmj.c7452; Jenkins D, 1997, J CLIN PATHOL, V50, P93, DOI 10.1136/jcp.50.2.93; LEVINE DS, 1989, AM J SURG PATHOL, V13, P966, DOI 10.1097/00000478-198911000-00008; MacDonald TT, 2007, HISTOPATHOLOGY, V50, P371, DOI 10.1111/j.1365-2559.2007.02606.x; Mantzaris GJ, 2005, ANN GASTROENTEROL, V18, P116; Molavi DW., 2008, PRACTICE SURG PATHOL; Montgomery EA, 2006, BIOPSY INT, P1; Murch S, 1998, LANCET, V351, P908, DOI 10.1016/S0140-6736(05)70323-8; Paski SC, 2007, AM J GASTROENTEROL, V102, P2294, DOI 10.1111/j.1572-0241.2007.01389.x; Tsang P, 1999, AM J SURG PATHOL, V23, P423, DOI 10.1097/00000478-199904000-00006; Villanacci V, 2007, DIGEST DIS SCI, V52, P321, DOI 10.1007/s10620-006-9476-7; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wakefield AJ, 1998, LANCET, V351, P908, DOI 10.1016/S0140-6736(05)70322-6; Wakefield AJ, 2000, AM J GASTROENTEROL, V95, P2285; Wakefield AJ, 1999, DEV DISORDERS CHILDR; Wakefield Andrew Jeremy, 2010, DETERMINATION SERIOU; Walker-Smith JA, 1983, PRACTICAL PAEDIAT GA; WILLIAMS CB, 1994, BAILLIERE CLIN GASTR, V8, P121, DOI 10.1016/S0950-3528(06)80022-9	29	6	6	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2011	343								d6823	10.1136/bmj.d6823	http://dx.doi.org/10.1136/bmj.d6823			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NP	22077090	Bronze			2022-12-28	WOS:000297058600011
J	Pugliese, F; Pagliuca, V				Pugliese, Fabrizio; Pagliuca, Valentino			Metastasis of Renal-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pugliese, Fabrizio] Clin Hosp, Foligno, Italy; [Pagliuca, Valentino] Villa Fiorita Med Ctr, Perugia, Italy		Pugliese, F (corresponding author), Clin Hosp, Foligno, Italy.	fapukr@yahoo.it							0	1	1	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					E38	E38		10.1056/NEJMicm1101091	http://dx.doi.org/10.1056/NEJMicm1101091			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840FL	22047584				2022-12-28	WOS:000296424200012
J	Chen, WY; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC				Chen, Wendy Y.; Rosner, Bernard; Hankinson, Susan E.; Colditz, Graham A.; Willett, Walter C.			Moderate Alcohol Consumption During Adult Life, Drinking Patterns, and Breast Cancer Risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGESTERONE-RECEPTOR STATUS; POSTMENOPAUSAL WOMEN; PROSPECTIVE COHORT; ESTROGEN; DISEASE; HEALTH; AGE; PREMENOPAUSAL; ASSOCIATION; NUTRITION	Context Multiple studies have linked alcohol consumption to breast cancer risk, but the risk of lower levels of consumption has not been well quantified. In addition, the role of drinking patterns (ie, frequency of drinking and "binge" drinking) and consumption at different times of adult life are not well understood. Objective To evaluate the association of breast cancer with alcohol consumption during adult life, including quantity, frequency, and age at consumption. Design, Setting, and Participants Prospective observational study of 105 986 women enrolled in the Nurses' Health Study followed up from 1980 until 2008 with an early adult alcohol assessment and 8 updated alcohol assessments. Main Outcome Measures Relative risks of developing invasive breast cancer. Results During 2.4 million person-years of follow-up, 7690 cases of invasive breast cancer were diagnosed. Increasing alcohol consumption was associated with increased breast cancer risk that was statistically significant at levels as low as 5.0 to 9.9 g per day, equivalent to 3 to 6 drinks per week (relative risk, 1.15; 95% CI, 1.06-1.24; 333 cases/100 000 person-years). Binge drinking, but not frequency of drinking, was associated with breast cancer risk after controlling for cumulative alcohol intake. Alcohol intake both earlier and later in adult life was independently associated with risk. Conclusions Low levels of alcohol consumption were associated with a small increase in breast cancer risk, with the most consistent measure being cumulative alcohol intake throughout adult life. Alcohol intake both earlier and later in adult life was independently associated with risk. JAMA. 2011; 306(17): 1884-1890	[Chen, Wendy Y.; Rosner, Bernard; Hankinson, Susan E.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; [Chen, Wendy Y.; Rosner, Bernard; Hankinson, Susan E.; Willett, Walter C.] Harvard Univ, Sch Med, Boston, MA USA; [Colditz, Graham A.] Washington Univ, Sch Med, Dept Surg, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; [Chen, Wendy Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hankinson, Susan E.; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Hankinson, Susan E.] Univ Massachusetts, Div Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Siteman Cancer Center; Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Massachusetts System; University of Massachusetts Amherst	Chen, WY (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	wendy.chen@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	National Institutes of Health [P01 CA87969]; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work reported herein was supported by the National Institutes of Health (grant P01 CA87969).	Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Colditz GA, 2000, AM J EPIDEMIOL, V152, P950, DOI 10.1093/aje/152.10.950; Colditz GA, 2004, JNCI-J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025; Deandrea S, 2008, CANCER EPIDEM BIOMAR, V17, P2025, DOI 10.1158/1055-9965.EPI-08-0157; Dorgan JF, 2001, JNCI-J NATL CANCER I, V93, P710, DOI 10.1093/jnci/93.9.710; Dumeaux V, 2004, CANCER EPIDEM BIOMAR, V13, P1302; Ellison RC, 2001, AM J EPIDEMIOL, V154, P740, DOI 10.1093/aje/154.8.740; Enger SM, 1999, BRIT J CANCER, V79, P1308, DOI 10.1038/sj.bjc.6690210; Fan SJ, 2000, CANCER RES, V60, P5635; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; Horn-Ross PL, 2004, CANCER EPIDEM BIOMAR, V13, P405; Kinney AY, 2000, CANCER CAUSE CONTROL, V11, P345, DOI 10.1023/A:1008973709917; Lew JQ, 2009, AM J EPIDEMIOL, V170, P308, DOI 10.1093/aje/kwp120; Li CI, 2010, J NATL CANCER I, V102, P1422, DOI 10.1093/jnci/djq316; Li CI, 2003, CANCER EPIDEM BIOMAR, V12, P1061; Li Y, 2009, EUR J CANCER, V45, P843, DOI 10.1016/j.ejca.2008.11.001; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; Mattisson I, 2004, INT J CANCER, V110, P589, DOI 10.1002/ijc.20166; McDonald JA, 2004, CANCER EPIDEM BIOMAR, V13, P2106; MIDANIK LT, 1994, AM J PUBLIC HEALTH, V84, P1218, DOI 10.2105/AJPH.84.8.1218; Morch LS, 2007, EUR J PUBLIC HEALTH, V17, P624, DOI 10.1093/eurpub/ckm036; Onland-Moret NC, 2005, J CLIN ENDOCR METAB, V90, P1414, DOI 10.1210/jc.2004-0614; Purohit V, 2000, ALCOHOL, V22, P123, DOI 10.1016/S0741-8329(00)00124-5; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; Rinaldi S, 2006, CANCER CAUSE CONTROL, V17, P1033, DOI 10.1007/s10552-006-0041-7; Rohan TE, 2000, CANCER CAUSE CONTROL, V11, P239, DOI 10.1023/A:1008933824645; Ronksley PE, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d671; Rosner BA, 1996, STAT MED, V15, P293, DOI 10.1002/(SICI)1097-0258(19960215)15:3<293::AID-SIM166>3.0.CO;2-E; Sarkola T, 2001, J CLIN ENDOCR METAB, V86, P1981, DOI 10.1210/jc.86.5.1981; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Suzuki R, 2005, JNCI-J NATL CANCER I, V97, P1601, DOI 10.1093/jnci/dji341; Suzuki R, 2010, INT J CANCER, V127, P685, DOI 10.1002/ijc.25079; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Terry MB, 2006, ANN EPIDEMIOL, V16, P230, DOI 10.1016/j.annepidem.2005.06.048; Tjonneland A, 2004, J NUTR, V134, P173, DOI 10.1093/jn/134.1.173; Tjonneland A, 2003, CANCER CAUSE CONTROL, V14, P277, DOI 10.1023/A:1023640720385; Tjonneland A, 2007, CANCER CAUSE CONTROL, V18, P361, DOI 10.1007/s10552-006-0112-9; *USDA, 1997, USDA NUTR DAT STAND	44	278	290	1	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1884	1890		10.1001/jama.2011.1590	http://dx.doi.org/10.1001/jama.2011.1590			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045766	Green Accepted, Bronze			2022-12-28	WOS:000296376200022
J	Oricchio, E; Nanjangud, G; Wolfe, AL; Schatz, JH; Mavrakis, KJ; Jiang, M; Liu, XP; Bruno, J; Heguy, A; Olshen, AB; Socci, ND; Teruya-Feldstein, J; Weis-Garcia, F; Tam, W; Shaknovich, R; Melnick, A; Himanen, JP; Chaganti, RSK; Wendel, HG				Oricchio, Elisa; Nanjangud, Gouri; Wolfe, Andrew L.; Schatz, Jonathan H.; Mavrakis, Konstantinos J.; Jiang, Man; Liu, Xiaoping; Bruno, Joanne; Heguy, Adriana; Olshen, Adam B.; Socci, Nicholas D.; Teruya-Feldstein, Julie; Weis-Garcia, Frances; Tam, Wayne; Shaknovich, Rita; Melnick, Ari; Himanen, Juha P.; Chaganti, R. S. K.; Wendel, Hans-Guido			The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma	CELL			English	Article							NF-KAPPA-B; NON-HODGKIN-LYMPHOMA; SOMATIC MUTATIONS; P53 RESTORATION; TNFAIP3 A20; CELL; GENE; DELETIONS; INTERFERENCE; INACTIVATION	Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiological function in brain development, a soluble splice variant of EPHA7 (EPHA7 TR) interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7(TR) protein produces antitumor effects against xenografted human lymphomas. Further, by fusing EPHA7(TR) to the anti-CD20 antibody (rituximab) we can directly target this tumor suppressor to lymphomas in vivo. Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7 TR as tumor suppressor with immediate therapeutic potential.	[Oricchio, Elisa; Wolfe, Andrew L.; Schatz, Jonathan H.; Mavrakis, Konstantinos J.; Jiang, Man; Liu, Xiaoping; Wendel, Hans-Guido] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Nanjangud, Gouri; Chaganti, R. S. K.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA; [Wolfe, Andrew L.] Weill Cornell Grad Sch Med Sci, New York, NY 10065 USA; [Schatz, Jonathan H.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Schatz, Jonathan H.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA; [Bruno, Joanne] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY 10065 USA; [Heguy, Adriana] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Olshen, Adam B.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Socci, Nicholas D.] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA; [Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Weis-Garcia, Frances] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10065 USA; [Tam, Wayne] Weill Cornell Grad Sch Med Sci, Dept Pathol & Lab Med, New York, NY 10065 USA; [Shaknovich, Rita; Melnick, Ari] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY 10065 USA; [Himanen, Juha P.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Cornell University; Memorial Sloan Kettering Cancer Center	Wendel, HG (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.	wendelh@mskcc.org	Heguy, Adriana/GPP-3907-2022; Melnick, Ari/AAA-5763-2020	Schatz, Jonathan/0000-0003-1842-228X; Oricchio, Elisa/0000-0002-1690-0447; Wolfe, Andrew/0000-0003-0418-716X	NCI [R01-CA142798-01, R01 CA104348]; AIDS Malignancy Consortium (AMC); Leukemia Research Foundation; Louis V. Gerstner Foundation; WLBH Foundation; Society of MSKCC; Starr Cancer Consortium [I4-A410]; NIH MSTP [GM07739, NIH-K08 CA127353]; ASCO Cancer Foundation; LLS TRP; LLS SCOR [S 7032-04]; LLS scholar; Burroughs Wellcome Clinical Translational Scientist; Cancer Center [P30-CA008748]; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [K08CA127353, R01CA142798, P30CA008748, R01CA104348] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIDS Malignancy Consortium (AMC); Leukemia Research Foundation; Louis V. Gerstner Foundation; WLBH Foundation; Society of MSKCC; Starr Cancer Consortium; NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ASCO Cancer Foundation; LLS TRP; LLS SCOR; LLS scholar; Burroughs Wellcome Clinical Translational Scientist; Cancer Center; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L. Pasqualucci, E. Papapetrou, S. L. Morrison, and M. Teitell for reagents; several MSK core facilities, including the Research Animal Facility, A. Viale of the Genomics Core, Elisa deStanchina of the Antitumor Assessment Core, A. Lash of the Computational Biology Core, Katy Huberman of the Geoffrey Beene Translational Oncology Core Facility, Aleksey V. Kamenshchikov of the Monoclonal Antibody Core Facility, and Irina Linkov of the Pathology Core. This work is supported by grants from the NCI (R01-CA142798-01), a P30 supplemental award from the NCI and the AIDS Malignancy Consortium (AMC) (H.G.-W.), the Leukemia Research Foundation (H.G.-W.), the Louis V. Gerstner Foundation (H.G.-W.), the WLBH Foundation (H.G.-W.), the Society of MSKCC (H.G.-W.), the Starr Cancer Consortium grant I4-A410 (H.G.-W. and J.H.), NIH MSTP grant GM07739 (J.B.), NIH-K08 CA127353 (R. S), the ASCO Cancer Foundation (J.H. S.), LLS TRP (R. S.), LLS SCOR S 7032-04 (A. M.), NCI R01 CA104348 (A. M.) LLS scholar (A. M.), Burroughs Wellcome Clinical Translational Scientist (A. M.), Cancer Center Support Grant P30-CA008748 (F. W.-G.) and a SCOR grant from The Leukemia and Lymphoma Society (R. S. K. C.).	Barr PM, 2008, CURR OPIN ONCOL, V20, P502, DOI 10.1097/CCO.0b013e32830b61ac; Bende RJ, 2007, LEUKEMIA, V21, P18, DOI 10.1038/sj.leu.2404426; Bidere N, 2009, NATURE, V458, P92, DOI 10.1038/nature07613; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Chin L, 2008, NATURE, V452, P553, DOI 10.1038/nature06914; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Dawson DW, 2007, ONCOGENE, V26, P4243, DOI 10.1038/sj.onc.1210211; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; Heyer J, 2010, NAT REV CANCER, V10, P470, DOI 10.1038/nrc2877; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Kuang SQ, 2010, BLOOD, V115, P2412, DOI 10.1182/blood-2009-05-222208; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Maloney David G, 2003, Curr Hematol Rep, V2, P13; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; McBride KM, 2008, J EXP MED, V205, P2585, DOI 10.1084/jem.20081319; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Nanjangud G, 2007, CYTOGENET GENOME RES, V118, P337, DOI 10.1159/000108318; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; OFFIT K, 1993, BLOOD, V82, P2157; Oricchio E, 2010, DIS MODEL MECH, V3, P701, DOI 10.1242/dmm.006296; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Relander T, 2010, J CLIN ONCOL, V28, P2902, DOI 10.1200/JCO.2009.26.1693; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Seiradake E, 2010, NAT STRUCT MOL BIOL, V17, P398, DOI 10.1038/nsmb.1782; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; Velculescu VE, 2008, CARCINOGENESIS, V29, P1087, DOI 10.1093/carcin/bgn096; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Viardot A, 2002, J CLIN ONCOL, V20, P4523, DOI 10.1200/JCO.2002.12.006; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	48	132	148	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 28	2011	147	3					554	564		10.1016/j.cell.2011.09.035	http://dx.doi.org/10.1016/j.cell.2011.09.035			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	842EH	22036564	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000296573700011
J	Katsnelson, A				Katsnelson, Alla			WHY FAKE IT?	NATURE			English	News Item							ADVANCED PARKINSONS-DISEASE; PHASE-I TRIAL; DOUBLE-BLIND; SHAM-SURGERY; NEUROTROPHIC FACTOR; GENE-THERAPY; OPEN-LABEL; TRANSPLANTATION; TOLERABILITY; DELIVERY											de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Gross RE, 2011, LANCET NEUROL, V10, P509, DOI 10.1016/S1474-4422(11)70097-7; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kim SYH, 2005, ARCH NEUROL-CHICAGO, V62, P1357, DOI 10.1001/archneur.62.9.1357; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Marks WJ, 2010, LANCET NEUROL, V9, P1164, DOI 10.1016/S1474-4422(10)70254-4; McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Politis M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000976; Stover NP, 2008, NEUROTHERAPEUTICS, V5, P252, DOI 10.1016/j.nurt.2008.02.006	15	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	2011	476	7359					142	144		10.1038/476142a	http://dx.doi.org/10.1038/476142a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805MU	22103003	Bronze			2022-12-28	WOS:000293731900012
